Authors,Title,Year,Source title,Volume,Issue,Art. No.,Page start,Page end,Page count,Cited by,DOI,Link,Affiliations,Authors with affiliations,Abstract,Author Keywords,References,Document Type,Source,EID
"Rubattu S., Pagliaro B., Pierelli G., Santolamazza C., Di Castro S., Mennuni S., Volpe M.","Pathogenesis of target organ damage in hypertension: Role of mitochondrial oxidative stress",2015,"International Journal of Molecular Sciences","16","1",,"823","839",,,10.3390/ijms16010823,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920156971&partnerID=40&md5=f0c2614c883da8bdfa3c25e0aa2521a9","Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, Ospedale S. AndreaRome, Italy; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) NeuromedPozzilli, Italy","Rubattu, S., Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, Ospedale S. AndreaRome, Italy, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) NeuromedPozzilli, Italy; Pagliaro, B., Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, Ospedale S. AndreaRome, Italy; Pierelli, G., Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, Ospedale S. AndreaRome, Italy; Santolamazza, C., Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, Ospedale S. AndreaRome, Italy; Di Castro, S., Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) NeuromedPozzilli, Italy; Mennuni, S., Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, Ospedale S. AndreaRome, Italy; Volpe, M., Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, Ospedale S. AndreaRome, Italy, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) NeuromedPozzilli, Italy","Hypertension causes target organ damage (TOD) that involves vasculature, heart, brain and kidneys. Complex biochemical, hormonal and hemodynamic mechanisms are involved in the pathogenesis of TOD. Common to all these processes is an increased bioavailability of reactive oxygen species (ROS). Both in vitro and in vivo studies explored the role of mitochondrial oxidative stress as a mechanism involved in the pathogenesis of TOD in hypertension, especially focusing on atherosclerosis, heart disease, renal failure, cerebrovascular disease. Both dysfunction of mitochondrial proteins, such as uncoupling protein-2 (UCP2), superoxide dismutase (SOD) 2, peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α), calcium channels, and the interaction between mitochondria and other sources of ROS, such as NADPH oxidase, play an important role in the development of endothelial dysfunction, cardiac hypertrophy, renal and cerebral damage in hypertension. Commonly used anti-hypertensive drugs have shown protective effects against mitochondrial-dependent oxidative stress. Notably, few mitochondrial proteins can be considered therapeutic targets on their own. In fact, antioxidant therapies specifically targeted at mitochondria represent promising strategies to reduce mitochondrial dysfunction and related hypertensive TOD. In the present article, we discuss the role of mitochondrial oxidative stress as a contributing factor to hypertensive TOD development. We also provide an overview of mitochondria-based treatment strategies that may reveal useful to prevent TOD and reduce its progression. © 2014 by the authors; licensee MDPI, Basel, Switzerland.","Hypertension; Mitochondrial dysfunction; Oxidative stress; Target organ damage","Kearney, P., Whelton, M., Reynolds, K., Muntner, P., He, J., Global burden of hypertension analysis of worldwide data (2005) Lancet, 365, pp. 217-223; Karpha, M., Lip, G.V., The pathophysiology of target organ damage in hypertension (2006) Minerva Cardioangiol, 54, pp. 417-429; Ezzati, M., Lopez, A.D., Rodgers, A., Vandernhoorn, S., Murray, C.J., Selected major risk factors and global and regional burden of disease (2002) Lancet, 360, pp. 1347-1360; Dawood, T., Schilaich, M.P., Mediators of target organ damage in hypertension: Focus on obesity associated factors and inflammation (2009) Minerva Cardioangiol, 57, pp. 687-703; Perlini, S., Grassi, G., Hypertension-related target organ damage: Is it a continuum (2013) J. Hypertens, 31, pp. 1083-1085; Nadar, S.K., Tayebjee, M.H., Messerli, F., Lip, G.Y., Target organ damage in hypertension: Pathophysiology and implications for drug theraphy (2006) Curr. Pharm. Des, 12, pp. 1581-1592; Laurent, S., Alivon, M., Beaussier, H., Boutouyrie, P., Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects (2012) Ann. Med, 44, pp. S93-S97; Matsui, Y., Ishikawa, J., Shibasaki, S., Shimada, K., Kario, K., Association between home arterial stiffness index and target organ damage in hypertension: Comparison with pulse wave velocity and augmentation index (2011) Atherosclerosis, 219, pp. 637-642; Garcia-Garcia, A., Gomez-Marcos, M.A., Recio-Rodriguez, J.I., Patino-Alonso, M.C., Rodriguez-Sanchez, E., Agudo-Conde, C., García-Ortiz, L., Office and 24-h heart rate and target organ damage in hypertensive patients (2012) BMC Cardiovasc. Disord, 12, p. 19; Grassi, G., Sympathetic neural activity in hypertension and related diseases (2010) Am. J. Hypertens, 23, pp. 1052-1060; Falcao-Pires, I., Palladini, G., Goncalves, N., Van Der Velden, J., Moreira-Goncalves, D., Miranda-Silva, D., Salinaro, F., Perlini, S., Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload (2011) Basic. Res. Cardiol, 106, pp. 801-814; Tozzi, R., Palladini, G., Fallarini, S., Nano, R., Gatti, C., Presotto, C., Schiavone, A., Fogari, R., Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy (2007) Am. J. Hypertens, 20, pp. 663-669; Lee, M.Y., Griendling, K.K., Redox signaling, vascular function, and hypertension (2008) Antioxid. Redox Signal, 10, pp. 1045-1059; Schiffrin, E.L., Touyz, R.M., From bedside to bench to bedside: Role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension (2004) Am. J. Physiol. Heart Circ. Physiol, 287, pp. H435-H446; Dikalov, S., Cross talk between mitochondria and NADPH oxidases (2011) Free Radic. Biol. Med, 51, pp. 1289-1301; Schulz, E., Wenzel, P., Münzel, T., Daiber, A., Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress (2014) Antioxid. Redox Signal, 20, pp. 308-324; Yu, E., Mercer, J., Bennett, M., Mitochondria in vascular disease (2012) Cardiovasc. Res, 95, pp. 173-182; Turrens, J.F., Mitochondrial formation of reactive oxygen species (2003) J. Physiol, 552, pp. 335-344; Case, A.J., Li, S., Basu, U., Tian, J., Zimmerman, M.C., Mitochondrial-localized NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons (2013) Am. J. Physiol. Heart Circ. Physiol, 305, pp. H19-H28; Kuroda, J., Ago, T., Matsushima, S., Zhai, P., Schneider, M.D., Sadoshima, J., NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart (2010) Proc. Natl. Acad. Sci. USA, 107, pp. 15565-15570; Block, K., Gorin, Y., Abboud, H.E., Subcellular localization of Nox4 and regulation in diabetes (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 14385-14390; Puddu, P., Puddu, G.M., Galletti, L., Cravero, E., Muscari, A., Mitochondrial dysfunction as an initiating event in atherogenesis: A plausible hypothesis (2005) Cardiology, 103, pp. 137-141; Dikalov, S.L., Ungvari, Z., Role of mitochondrial oxidative stress in hypertension (2013) Am. J. Physiol. Heart Circ. Physiol, 305, pp. H1417-H1427; De Cavanagh, E.M., Toblli, J.E., Ferder, L., Piotrkowski, B., Stella, I., Fraga, C.G., Inserra, F., Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats (2005) Cell. Mol. Biol, 51, pp. 573-578; Ross, R., Cell biology of atherosclerosis (1995) Annu. Rev. Physiol, 57, pp. 791-804; Chen, J., Mehta, J.L., Haider, N., Zhang, X., Narula, J., Li, D., Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells (2004) Circ. Res, 94, pp. 370-376; Ballinger, S.W., Patterson, C., Yan, C.N., Doan, R., Burow, D.L., Young, C.G., Yakes, F.M., Freeman, B.A., Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells (2000) Circ. Res, 86, pp. 960-966; Choi, H., Tostes, R.C., Webb, R.C., Mitochondrial aldehyde dehydrogenase prevents ROS-induced vascular contraction in angiotensin-II hypertensive mice (2011) J. Am. Soc. Hypertens, 5, pp. 154-160; Dikalova, A.E., Bikineyeva, A.T., Budzyn, K., Nazarewicz, R.R., McCann, L., Lewis, W., Harrison, D.G., Dikalov, S.I., Therapeutic targeting of mitochondrial superoxide in hypertension (2010) Circ. Res, 107, pp. 106-116; Doughan, A.K., Harrison, D.G., Dikalov, S.I., Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: Linking mitochondrial oxidative damage and vascular endothelial dysfunction (2008) Circ. Res, 102, pp. 488-496; Mehta, P.K., Griendling, K.K., Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system (2007) Am. J. Physiol. Cell. Physiol, 292, pp. C82-C97; Dikalov, S.I., Nazarewicz, R.R., Bikineyeva, A., Hilenski, L., Lassègue, B., Griendling, K.K., Harrison, D.G., Dikalova, A.E., Nox2 induced production of mitochondrial superoxide in Ang-II mediated endothelial oxidative stress and hypertension (2014) Antioxid. Redox Signal, 20, pp. 281-294; Ma, S., Wang, Q., Zhang, Y., Yang, D., Li, D., Tang, B., Yang, Y., Transgenic overexpression of uncoupling protein-2 attenuates salt-induced vascular dysfunction by inhibition of oxidative stress (2014) Am. J. Hypertens, 27, pp. 345-354; Tian, X.Y., Wong, W.T., Xu, A., Lu, Y., Zhang, Y., Wang, L., Cheang, W.S., Huang, Y., Uncoupling protein-2 protects endothelial function in diet-induced obese mice (2010) Circ. Res, 110, pp. 1211-1216; Liu, L., Liu, J., Tian, X.Y., Wong, W.T., Lau, C.W., Xu, G., Ng, C.F., Huang, Y., Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress (2014) Antioxid. Redox Signal, 21, pp. 1571-1581; Langlois, M., Duprez, D., Delanghe, J., De Buyzere, M., Clement, D.L., Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis (2001) Circulation, 103, pp. 1863-1868; Cooper, G.T., Cardiocyte adaptation to chronically altered load (1987) Annu. Rev. Physiol, 49, pp. 501-518; Bernardo, B.D., Weeks, K.L., Pretorious, L., McMullen, J.R., Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies (2010) Pharmacol. Ther, 128, pp. 191-227; Dale Abel, E., Doenst, T., Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy (2011) Cardiovasc. Res, 90, pp. 234-242; Takimoto, E., Kass, D.A., Role of oxidative stress in cardiac hypertrophy and remodeling (2006) Hypertension, 49, pp. 241-248; Arany, Z., Novikov, M., Chin, S., Ma, Y., Rosenzweig, A., Spiegelman, B.M., Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 10086-10091; Sirker, A., Zhang, M., Murdoch, C., Shah, A.M., Involvement of NADPH oxidases in cardiac remodelling and heart failure (2007) Am. J. Nephrol, 27, pp. 649-660; Xiao, L., Pimentel, D.R., Wang, J., Singh, K., Colucci, W.S., Sawyer, D.B., Role of reactive oxygen species and NAD(P)H oxidase in α(1)-adrenoceptor signaling in adult rat cardiac myocytes (2002) Am. J. Physiol. Cell. Physiol, 282, pp. C926-C934; Minhas, K.M., Saraiva, R.M., Schuleri, K.H., Lehrke, S., Zheng, M., Saliaris, A.P., Berry, C.E., Li, D., Xanthine oxido reductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy (2006) Circ. Res, 98, pp. 271-279; Takimoto, E., Champion, H.C., Li, M., Ren, S., Rodriguez, E.R., Tavazzi, B., Lazzarino, G., Paolocci, N., Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load (2005) J. Clin. Investig, 11 (5), pp. 1221-1231; Aon, M.A., Cortassa, S., O’Rourke, B., B. ROS balance: A unifying hypothesis (2010) Biochim. Biophys. Acta, 1797, pp. 865-877; Murphy, M.P., How mitochondria produce reactive oxygen species (2009) Biochem. J, 417, pp. 1-13; Doenst, T., Pytel, G., Schrepper, A., Amorim, P., Färber, G., Shingu, Y., Mohr, F.W., Schwarzer, M., Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload (2010) Cardiovasc. Res, 86, pp. 461-470; Bugger, H., Schwarzer, M., Chen, D., Schrepper, A., Amorim, P.A., Schoepe, M., Nguyen, T.D., Mohr, F.W., Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure (2010) Cardiovasc. Res, 85, pp. 376-384; Kohlhaas, M., Liu, T., Knopp, A., Zeller, T., Ong, M.F., Böhm, M., O’Rourke, B., Maack, C., Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes (2010) Circulation, 121, pp. 1606-1613; Csonka, C., Pataki, T., Kovacs, P., Müller, S.L., Schroeter, M.L., Tosaki, A., Blasig, I.E., Effects of oxidative stress on the expression of antioxidative defense enzymes in spontaneously hypertensive rat hearts (2000) Free Radic. Biol. Med, 29, pp. 612-619; Dai, F., Johnson, S.C., Villarin, J.J., Chin, M.T., Nieves-Cintrón, M., Chen, T., Marcinek, D.J., Dorn, G.W., Mitochondrial oxidative stress mediates angiotensin II—Induced cardiac hypertrophy and Gαq overexpression—Induced heart failure (2011) Circ. Res, 108, pp. 837-846; Dai, F., Chen, T., Szeto, H., Nieves-Cintrón, M., Kutyavin, V., Santana, L.F., Rabinovitch, P.S., Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy (2011) J. Am. Coll. Cardiol, 58, pp. 73-82; Graham, D., Huynh, N.N., Hamilton, C.A., Beattie, E., Smith, R.A., Cochemé, H.M., Murphy, M.P., Dominiczak, A.F., Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy (2009) Hypertension, 54, pp. 322-328; Udani, S., Lazich, I., Bakris, G.L., Epidemiology of hypertensive kidney disease (2011) Nat. Rev. Nephrol, 7, pp. 11-21; Mennuni, S., Rubattu, S., Pierelli, G., Tocci, G., Fofi, C., Volpe, M., Hypertension and kidneys: Unraveling complex molecular mechanisms underlying hypertensive renal damage (2014) J. Hum. Hypertens, 28, pp. 74-79; Epstein, F.H., Oxygen and renal metabolism (1997) Kidney Int, 51, pp. 381-385; Che, R., Yuan, Y., Huang, S., Zhang, A., Mitochondrial dysfunction in the pathophysiology of renal diseases (2014) Am. J. Physiol. Renal Physiol, 306, pp. F367-F378; Araujo, M., Wilcox, C.S., Oxidative stress in hypertension: Role of the kidney (2014) Antioxid. Redox Signal, 20, pp. 74-101; De Cavanagh, E.M., Toblli, J.E., Ferder, L., Piotrkowski, B., Stella, I., Inserra, F., Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine (2006) Am. J. Physiol. Regul. Integr. Comp. Physiol, 290, pp. R1616-R1625; Laursen, J.B., Rajagopalan, S., Galis, Z., Tarpey, M., Freeman, B.A., Harrison, D.G., Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension (1997) Circulation, 95, pp. 588-593; Ying, W.Z., Sanders, P.W., Cytochrome c mediates apoptosis in hypertensive nephrosclerosis in Dahl/Rapp rats (2001) Kidney Int, 59, pp. 662-672; Di Castro, S., Scarpino, S., Marchitti, S., Bianchi, F., Stanzione, R., Cotugno, M., Sironi, L., Ruco, L., Differential modulation of uncoupling protein-2 in kidneys of stroke-prone spontaneously hypertensive rats under high-salt/low-potassium diet (2013) Hypertension, 61, pp. 534-541; Jin, K., Vaziri, N.D., Salt-sensitive hypertension in mitochondrial superoxide dismutase deficiency is associated with intra-renal oxidative stress and inflammation (2014) Clin. Exp. Nephrol, 18, pp. 445-452; Ohtsuki, T., Matsumoto, M., Suzuki, K., Taniguchi, N., Kamada, T., Mitochondrial lipid peroxidation and superoxide dismutase in rat hypertensive target organs (1995) Am. J. Physiol, 268, pp. H1418-H1421; Patten, D.A., Germain, M., Kelly, M.A., Slack, R.S., Reactive oxygen species: Stuck in the middle of neurodegeneration (2010) J. Alzheimers Dis, 20, pp. S357-S367; Keane, P.C., Kurzawa, M., Blain, P.G., Morris, C.M., Mitochondrial dysfunction in Parkinson’s disease (2011) Parkinsons Dis, 2011, p. 716871; Paglieri, C., Bisbocci, D., Caserta, M., Rabbia, F., Bertello, C., Canadè, A., Veglio, F., Hypertension and cognitive function (2008) Clin. Exp. Hypertens, 30, pp. 701-710; Lopez-Campistrous, A., Hao, L., Xiang, W., Ton, D., Semchuk, P., Sander, J., Ellison, M.J., Fernandez-Patron, C., Mitochondrial dysfunction in the hypertensive rat brain: Respiratory complexes exhibit assembly defects in hypertension (2008) Hypertension, 51, pp. 412-419; Brandt, U., Energy converting NADH:Quinone oxidoreductase (complex I) (2006) Annu. Rev. Biochem, 75, pp. 69-92; Galkin, A., Dröse, S., Brandt, U., The proton pumping stoichiometry of purified mitochondrial complex I reconstituted into proteoliposome (2006) Biochim. Biophys. Acta, 1757, pp. 1575-1581; Hunte, C., Zickermann, V., Brandt, U., Functional modules and structural basis of conformational coupling in mitochondrial complex I (2010) Science, 329, pp. 448-451; Nicholls, D.G., Mitochondrial membrane potential and aging (2004) Aging Cell, 3, pp. 35-40; Calderón-Cortés, E., Cortés-Rojo, C., Clemente-Guerrero, M., Manzo-Avalos, S., Villalobos-Molina, R., Boldogh, I., Saavedra-Molina, A., Changes in mitochondrial functionality and calcium uptake in hypertensive rats as a function of age (2008) Mitochondrion, 8, pp. 262-272; Aguilera-Aguirre, L., González-Hernández, J.C., Pérez-Vázquez, V., Ramírez, J., Clemente-Guerrero, M., Villalobos-Molina, R., Saavedra-Molina, A., Role of intramitochondrial nitric oxide in rat heart and kidney during hypertension (2002) Mitochondrion, 1, pp. 413-423; Saavedra-Molina, A., Ramírez-Emiliano, J., Clemente-Guerrero, M., Pérez-Vázquez, V., Aguilera-Aguirre, L., González-Hernández, J.C., Mitochondrial nitric oxide inhibits ATP synthesis. Effect of free calcium in rat heart (2003) Amino Acids, 24, pp. 95-102; Xu, X., Zhao, L., Hu, X., Zhang, P., Wessale, J., Bache, R., Chen, Y., Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction (2010) Nucleosides Nucleotides Nucleic Acids, 29, pp. 306-313; Finckenberg, P., Eriksson, O., Baumann, M., Merasto, S., Lalowski, M.M., Levijoki, J., Haasio, K., Luft, F.C., Caloric restriction ameliorates angiotensin II-induced mitochondrial remodeling and cardiac hypertrophy (2012) Hypertension, 59, pp. 76-84; O’Brien, D., Chunduri, P., Iyer, A., Brown, L., L-Carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats (2010) Basic Clin. Pharmacol. Toxicol, 106, pp. 296-301; Frei, B., Birlouez-Aragon, I., Lykkesfeldt, J., Authors’ perspective: What is the optimum intake of vitamin C in humans? (2012) Crit. Rev. Food Sci. Nutr, 52, pp. 815-829; Cook, N.R., Albert, C.M., Gaziano, J.M., Zaharris, E., Macfadyen, J., Danielson, E., Buring, J.E., Manson, J.E., A randomized factorial trial of vitamins C and E and β carotene in the secondary prevention of cardiovascular events in women: Results from the Women’s Antioxidant Cardiovascular Study (2007) Arch. Intern. Med, 167, pp. 1610-1618; Sesso, H.D., Buring, J.E., Christen, W.G., Kurth, T., Belanger, C., Macfadyen, J., Bubes, V., Gaziano, J.M., Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians’ Health Study II randomized controlled trial (2008) JAMA, 300, pp. 2123-2133; Podmore, I.D., Griffiths, H.R., Herbert, K.E., Mistry, N., Mistry, P., Lunec, J., Vitamin C exhibits pro-oxidant properties (1998) Nature, 392, p. 559; Michels, A.J., Frei, B., Myths, artifacts, and fatal flaws: Identifying limitations and opportunities in vitamin C research (2013) Nutrients, 5, pp. 5161-5192; Michels, A.J., Hagen, T.M., Frei, B., Human genetic variation influences vitamin C homeostasis by altering vitamin C transport and antioxidant enzyme function (2013) Annu. Rev. Nutr, 33, pp. 45-70; Wilson, T.W., Alonso-Galicia, M., Roman, R.J., Effects of lipid-lowering agents in the Dahl salt-sensitive rat (1998) Hypertension, 31, pp. 225-231; Wassmann, S., Laufs, U., Muller, K., Konkol, C., Ahlbory, K., Baumer, A.T., Linz, W., Nickenig, G., Cellular antioxidant effects of atorvastatin in vitro and in vivo (2002) Arterioscler. Thromb. Vasc. Biol, 22, pp. 300-305; Vecchione, C., Brandes, R.P., Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice (2002) Circ. Res, 91, pp. 173-179; Raij, L., Workshop: Hypertension and cardiovascular risk factors: Role of the angiotensin II-nitric oxide interaction (2001) Hypertension, 37, pp. 767-773; Opie, L.H., Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension (2001) Lancet, 358, pp. 1829-1831; De Cavanagh, E.M., Inserra, F., Ferder, L., Fraga, C.G., Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues (2000) Am. J. Physiol. Regul. Integr. Comp. Physiol, 278, pp. R572-R577; Murphy, M.P., Targeting lipophilic cations to mitochondria (2008) Biochim. Biophys. Acta, 1777, pp. 1028-1031; James, A.M., Cocheme, H.M., Smith, R.A.J., Murphy, M.P., Interactions of mitochondrial-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species: Implications for the use of exogenous ubiquinones as therapies and experimental tools (2005) J. Biol. Chem, 280, pp. 21295-21312; Ross, M.F., Prime, T.A., Abakumova, I., James, A.M., Porteous, C.M., Smith, R.A., Murphy, M.P., Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells (2008) Biochem. J, 411, pp. 633-645; McLachlanm, J., Beattie, E., Murphy, M.P., Koh-Tan, C.H., Olson, E., Beattie, W., Dominiczak, A.F., Graham, D., Combined therapeutic benefit of mitochondria targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function (2014) J. Hypertens, 32, pp. 555-564; Li, M., Georgakopoulos, D., Lu, G., Hester, L., Kass, D.A., Hasday, J., Wang, Y., P38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart (2005) Circulation, 111, pp. 2494-2502; See, F., Thomas, W., Way, K., Tzanidis, A., Kompa, A., Lewis, D., Itescu, S., Krum, H., P38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat (2004) J. Am. Coll. Cardiol, 44, pp. 1679-1689; Date, M., Morita, T., Yamashita, N., Nishida, K., Yamaguchi, O., Higuchi, Y., Hirotani, S., Tada, M., The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model (2002) J. Am. Coll. Cardiol, 39, pp. 907-912; Subramanian, S., Kalyanaraman, B., Migrino, R.Q., Mitochondrially targeted antioxidants for the treatment of cardiovascular diseases (2010) Recent Pat. Cardiovasc. Drug Discov, 5, pp. 54-65; Szeto, H.H., Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury (2008) Antioxid. Redox Signal, 10, pp. 601-619; Zhao, K., Zhao, G.M., Wu, D., Soong, Y., Birk, A.V., Schiller, P.W., Szeto, H.H., Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury (2004) J. Biol. Chem, 279, pp. 34682-34690; Watanabe, T., Yuki, S., Egawa, M., Nishi, H., Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions (1994) J. Pharmacol. Exp. Ther, 268, pp. 1597-1604; Tsujimoto, I., Hikoso, S., Yamaguchi, O., Kashiwase, K., Nakai, A., Takeda, T., Watanabe, T., Nishida, K., The antioxidant Edaravone attenuates pressure overload induced left ventricular hypertrophy (2005) Hypertension, 45, pp. 921-926",Review,Scopus,2-s2.0-84920156971
"Scandroglio A.M., Finco G., Pieri M., Ascari R., Calabro M.G., Taddeo D., Isella F., Franco A., Musu M., Landoni G., Alfieri O., Zangrillo A.","Cardiac surgery in 260 octogenarians: A case series",2015,"BMC Anesthesiology","15","1", 15,"","",,,10.1186/1471-2253-15-15,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924176736&partnerID=40&md5=26b497ad3c1fe38619a83abc192277b2","Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy; Department of Medical Sciences M. Aresu, Cagliari UniversityCagliari, Italy; Department of Cardiac Surgery, IRCCS San Raffaele Scientific InstituteMilan, Italy; Vita-Salute San Raffaele UniversityMilan, Italy","Scandroglio, A.M., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy; Finco, G., Department of Medical Sciences M. Aresu, Cagliari UniversityCagliari, Italy; Pieri, M., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy; Ascari, R., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy; Calabrò, M.G., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy; Taddeo, D., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy; Isella, F., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy; Franco, A., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy; Musu, M., Department of Medical Sciences M. Aresu, Cagliari UniversityCagliari, Italy; Landoni, G., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy, Vita-Salute San Raffaele UniversityMilan, Italy; Alfieri, O., Department of Cardiac Surgery, IRCCS San Raffaele Scientific InstituteMilan, Italy, Vita-Salute San Raffaele UniversityMilan, Italy; Zangrillo, A., Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60Milan, Italy, Vita-Salute San Raffaele UniversityMilan, Italy","Background: The elderly undergo cardiac surgery more and more frequently, often present multiple comorbidities, assume chronic therapies, and present a unique physiology. Aim of our study was to analyze the experience of a referral cardiac surgery center with all types of cardiac surgery interventions performed in patients ≥80 years old over a six years' period. Methods: A retrospective observational study performed in a university hospital. 260 patients were included in the study (3.5% of the patients undergoing cardiac surgery in the study period). Results: Mean age was 82 ± 1.8 years. Eighty-five percent of patients underwent elective surgery, 15% unplanned surgery and 4.2% redo surgery. Intervention for aortic valve pathology and coronary artery bypass grafting were performed in 51% and 46% of the patients, respectively. Interventions involving the mitral valve were the 26% of the total, those on the tricuspid valve were 13% and those on the ascending aortic arch the 9.6%. Postoperative low output syndrome was identified in 44 patients (17%). Mortality was 3.9% and most of the patients (91%) were discharged from hospital in good clinical conditions. Hospital mortality was lower in planned vs unplanned surgery: 3.8% vs 14% respectively. Chronic obstructive pulmonary disease (OR 9.106, CI 2.275 - 36.450) was the unique independent predictor of mortality. Conclusions: Clinicians should be aware that cardiac surgery can be safely performed at all ages, that risk stratification is mandatory and that hemodynamic treatment to avoid complications is expected. © Scandroglio et al.","Anesthesia; Cardiac surgery; Complications; Intensive care; Mortality; Octogenarian","Oskvig, R.M., Special problems in the elderly (1999) Chest, 115, pp. 158S-164S; Geokas, M.C., Lakatta, E.G., Makinodan, T., Timiras, P.S., The aging process (1990) Ann Intern Med, 113, pp. 455-466; Wk, F., Schaff, H.V., O'Brian, P.C., Orszulak, T.A., Naessens, J.M., Tajik, A.J., Cardiac outcome in the octogenarian: perioperative outcome and clinical follow-up (1991) J Am Coll Cardiol, 18 (1), pp. 29-35; Edmunds, L.H., Stephenson, L.W., Edie, R.N., Ratcliffe, M.B., Open-heart surgery in octogenarians (1988) N Engl J Med, 319, pp. 131-136; Song, H.K., Diggs, B.S., Slater, M.S., Guyton, S.W., Ungerleider, R.M., Welke, K.F., Improved quality and cost-effectiveness of coronary artery bypass grafting in the United States from 1988-2005 (2009) J Thorac Cardiovasc Surg, 137, pp. 65-69; Universal definition of myocardial infarction (2007) Circulation, 116, pp. 2634-2653; Prondzinsky, R., Unverzagt, S., Russ, M., Lemm, H., Swyter, M., Wegener, N., Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP shock trial (2012) Shock, 37 (4), pp. 378-384; Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group (2004) Crit Care, 8 (4), pp. R204-R212; Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine (1976) Nephron, 16, pp. 31-41; Ranucci, M., Castelvecchio, S., Conte, M., Megliola, G., Speziale, G., Fiore, F., The easier, the better: age, creatinine, ejection fraction score for operative mortality risk stratification in a series of 29,659 patients undergoing elective cardiac surgery (2011) J Thorac Cardiovasc Surg, 142 (3), pp. 581-586; http://www.sts.org/sites/default/files/documents/pdf/guidelines/BloodConservationUpdate0311.pdfBridges, C.R., Edwards, F.H., Peterson, E.D., Coombs, L.P., Ferguson, T.B., Cardiac surgery in nonagenarians and centenarians (2003) J Am Coll Surg, 197 (3), pp. 347-356; Biancari, F., Schifano, P., Pighi, M., Vasques, F., Juvonen, T., Vinco, G., Pooled estimates of immediate and late outcome of mitral valve surgery in octogenarians: a meta-analysis and meta-regression (2013) J Cardiothorac Vasc Anesth, 27 (2), pp. 213-219; A decade of change: risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999 - a report from the STS National Database Committee and the Duke Clinical Research Institute (2002) Ann Thorac Surg, 73 (2), pp. 480-489; Paparella, D., Brister, S.J., Buchanan, M.R., Coagulation disorders of cardiopulmonary bypass: a review (2004) Intensive Care Med, 30 (10), pp. 1873-1881; Warren, O.J., Smith, A.J., Alexiou, C., Rogers, P.L., Jawad, N., Vincent, C., The inflammatory response to cardiopulmonary bypass: part 1-mechanisms of pathogenesis (2009) J Cardiothorac Vasc Anesth, 23 (2), pp. 223-231; Zangrillo, A., Crescenzi, G., Landoni, G., Leoni, A., Marino, G., Calabrò, M.G., Off-pump coronary artery bypass grafting reduces postoperative neurologic complications compared to CPB (2005) J Cardiothorac Vasc Anesth, 19 (2), pp. 193-196; Hemmerling, T.M., Romano, G., Terrasini, N., Noiseux, N., Anesthesia for off-pump coronary artery bypass surgery (2013) Ann Card Anaesh, 16 (1), pp. 28-39; Abdel-Wahab, M., Zahn, R., Horack, M., Gerckens, U., Schuler, G., Sievert, H., Transcatheter aortic valve implantation in patients with and without concomitant coronary artery disease: comparison of characteristics and early outcome in the German multicenter TAVI registry (2012) Clin Res Cardiol, 101 (12), pp. 973-981; Blackman, D.J., Baxter, P.D., Gale, C.P., Moat, N.E., Maccarthy, P.A., Hildick-Smith, D., Do outcomes from transcatheter aortic valve implantation vary according to access route and valve type? The UK TAVI Registry (2014) J Interv Cardiol, 27 (1), pp. 86-95; Wenaweser, P., Stortecky, S., Heg, D., Tueller, D., Nietlispach, F., Falk, V., Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry (2014) EuroIntervention, , In press; Alfieri, O., Pozzoli, A., Mitral valve surgery in octogenarians: insights and perspectives (2013) J Cardiothorac Vasc Anesth, 27 (2), pp. 201-202; Zangrillo, A., Sparicio, D., Crivellari, M., Aletti, G., Bove, T., Mamo, D., Low perioperative mortality for cardiac surgery in octogenarians (2004) Minerva Anestesiol, 70 (10), pp. 717-723; Landoni, G., Gonfalini, M., Zangrillo, A., Safety of cardiac surgery in octogenarians and nonagenarians (2008) J Cardiothorac Vasc Anesth, 22 (4), pp. 646-647; Bignami, E., Biondi-Zoccai, G., Landoni, G., Fochi, O., Testa, V., Shaiban, I., Volatile anesthetics reduce mortality in cardiac surgery (2009) J Cardiothorac Vasc Anesth, 23 (5), pp. 594-599; Olper, L., Cabrini, L., Landoni, G., Rossodivita, A., Nobile, L., Monti, G., Non-invasive ventilation after cardiac surgery outside the intensive care unit (2011) Minerva Anestesiol, 77 (1), pp. 40-45; Gjeilo, K.H., Wahba, A., Klepstad, P., Lydersen, S., Stenseth, R., Survival and quality of life in an elderly cardiac surgery population: 5-year follow-up (2013) Eur J Cardiothorac Surg Eur J Cardiothorac Surg, 44 (3), pp. e182-e188; Khan, D., Mukherjee, S., Sarkar, S., Kumar, V., Charles, E.V., Cardiac surgery in octogenarians (2012) J Indian Med Assoc, 110 (9), pp. 662-663; Deschka, H., Schreier, R., El-Ayoubi, L., Erler, S., Müller, D., Alken, A., Prolonged intensive care treatment of octogenarians after cardiac surgery: a reasonable economic burden? (2013) Interact Cardiovasc Thorac Surg, 17 (3), pp. 501-506; Mézière, A., Paillaud, E., Plaud, B., Anesthesia in the elderly (2013) Presse Med, 42 (2), pp. 197-201",Article,Scopus,2-s2.0-84924176736
"Boissier F., Razazi K., Thille A.W., Roche-Campo F., Leon R., Vivier E., Brochard L., Brun-Buisson C., Mekontso Dessap A.","Echocardiographic detection of transpulmonary bubble transit during acute respiratory distress syndrome",2015,"Annals of Intensive Care","5","1",,"1","9",,,10.1186/s13613-015-0046-z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927134676&partnerID=40&md5=6fec13a6912436e880c38b4f164339a4","AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France; INSERM, Unité U955 (IMRB), 8 rue du Général SarrailCréteil, France; Faculté de Médecine, Université Paris Est Créteil, 8, rue du Général SarrailCréteil, France; CHU de Poitiers, Réanimation médicale, Poitiers, France; INSERM CIC 1402 (équipe 5 ALIVE), Université de Poitiers, 2 Rue de la MilétriePoitiers, France; Servei de Medicina Intensiva, Hospital Verge de la Cinta, Carrer de les Esplanetes, 14Tortosa, Tarragona, Spain; Centre Hospitalier Intercommunal de Créteil, Réanimation polyvalente, 40 avenue de VerdunCréteil, France; Centre Hospitalier Saint Luc Saint Joseph, Réanimation Polyvalente, 20, quai Claude BernardLyon, France; Saint Michael’s Hospital, 30 Bond StreetToronto, ON, Canada","Boissier, F., AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France, INSERM, Unité U955 (IMRB), 8 rue du Général SarrailCréteil, France, Faculté de Médecine, Université Paris Est Créteil, 8, rue du Général SarrailCréteil, France; Razazi, K., AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France; Thille, A.W., AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France, CHU de Poitiers, Réanimation médicale, Poitiers, France; INSERM CIC 1402 (équipe 5 ALIVE), Université de Poitiers, 2 Rue de la MilétriePoitiers, France; Roche-Campo, F., AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France, Servei de Medicina Intensiva, Hospital Verge de la Cinta, Carrer de les Esplanetes, 14Tortosa, Tarragona, Spain; Leon, R., AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France, Centre Hospitalier Intercommunal de Créteil, Réanimation polyvalente, 40 avenue de VerdunCréteil, France; Vivier, E., AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France, Centre Hospitalier Saint Luc Saint Joseph, Réanimation Polyvalente, 20, quai Claude BernardLyon, France; Brochard, L., Saint Michael’s Hospital, 30 Bond StreetToronto, ON, Canada; Brun-Buisson, C., AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France, INSERM, Unité U955 (IMRB), 8 rue du Général SarrailCréteil, France, Faculté de Médecine, Université Paris Est Créteil, 8, rue du Général SarrailCréteil, France; Mekontso Dessap, A., AP-HP, Hôpital Henri Mondor, DHU A-TVB, Service de Réanimation Médicale, Groupe de recherche CARMAS, 51 Av Mal de Lattre de TassignyCréteil, France, INSERM, Unité U955 (IMRB), 8 rue du Général SarrailCréteil, France, Faculté de Médecine, Université Paris Est Créteil, 8, rue du Général SarrailCréteil, France","Background: Transpulmonary bubble transit (TPBT) detected with contrast echocardiography is reported as a sign of intrapulmonary shunt during cirrhosis or exercise in healthy humans. However, its physiological meaning is not clear during acute respiratory distress syndrome (ARDS). Our aim was to determine the prevalence, significance, and prognosis of TPBT detection during ARDS.Methods: This was a prospective observational study in an academic medical intensive care unit in France. Two hundred and sixteen consecutive patients with moderate-to-severe ARDS underwent transesophageal echocardiography with modified gelatine contrast. Moderate-to-large TPBT was defined as right-to-left passage of at least ten bubbles through a pulmonary vein more than three cardiac cycles after complete opacification of the right atrium. Patients with intra-cardiac shunt through patent foramen ovale were excluded.Conclusions: Moderate-to-large TPBT was detected with contrast echocardiography in 26% of patients with ARDS. This finding was associated with a hyperdynamic and septic state, but did not influence oxygenation.Results: The prevalence of moderate-to-large TPBT was 26% (including 42 patients with moderate and 15 with large TPBT). Patients with moderate-to-large TPBT had higher values of cardiac index and heart rate as compared to those without TPBT. There was no significant difference in PaO<inf>2</inf>/FIO<inf>2</inf> ratio between groups, and TPBT was not influenced by end-expiratory positive pressure level in 93% of tested patients. Prevalence of septic shock was higher in the group with moderate-to-large TPBT. Patients with moderate-to-large TPBT had fewer ventilator-free days and intensive care unit-free days within the first 28 days, and higher in-hospital mortality as compared to others. © 2015, Boissier et al.; licensee Springer.","Acute respiratory distress syndrome; Echocardiography; Shunt","Kelman, G.R., Nunn, J.F., Prys-Roberts, C., Greenbaum, R., The influence of cardiac output on arterial oxygenation: a theoretical study (1967) Br J Anaesth, 39 (6), pp. 450-458. , COI: 1:STN:280:DyaF2s7nsFaksA%3D%3D, PID: 6027953; Mekontso Dessap, A., Boissier, F., Leon, R., Carreira, S., Campo, F.R., Lemaire, F., Prevalence and prognosis of shunting across patent foramen ovale during acute respiratory distress syndrome (2010) Crit Care Med, 38 (9), pp. 1786-1792. , PID: 20601861; Dantzker, D.R., Brook, C.J., Dehart, P., Lynch, J.P., Weg, J.G., Ventilation-perfusion distributions in the adult respiratory distress syndrome (1979) Am Rev Respir Dis, 120 (5), pp. 1039-1052. , COI: 1:STN:280:DyaL3c%2FmtlaqsA%3D%3D, PID: 389116; Matamis, D., Lemaire, F., Harf, A., Teisseire, B., Brun-Buisson, C., Redistribution of pulmonary blood flow induced by positive end-expiratory pressure and dopamine infusion in acute respiratory failure (1984) Am Rev Respir Dis, 129 (1), pp. 39-44. , COI: 1:STN:280:DyaL2c7lt1SqtQ%3D%3D, PID: 6367569; Ralph, D.D., Robertson, H.T., Weaver, L.J., Hlastala, M.P., Carrico, C.J., Hudson, L.D., Distribution of ventilation and perfusion during positive end-expiratory pressure in the adult respiratory distress syndrome (1985) Am Rev Respir Dis, 131 (1), pp. 54-60. , COI: 1:STN:280:DyaL2M%2FpsFaltA%3D%3D, PID: 3881062; Riley, R.L., Cournand, A., Ideal alveolar air and the analysis of ventilation-perfusion relationships in the lungs (1949) J Appl Physiol, 1 (12), pp. 825-847. , COI: 1:STN:280:DyaH1M%2FkslSmtw%3D%3D, PID: 18145478; Wagner, P.D., Saltzman, H.A., West, J.B., Measurement of continuous distributions of ventilation-perfusion ratios: theory (1974) J Appl Physiol, 36 (5), pp. 588-599. , COI: 1:CAS:528:DyaE2cXktFWntLk%3D, PID: 4826323; Cressoni, M., Caironi, P., Polli, F., Carlesso, E., Chiumello, D., Cadringher, P., Anatomical and functional intrapulmonary shunt in acute respiratory distress syndrome (2008) Crit Care Med, 36 (3), pp. 669-675. , PID: 18091555; Laurie, S.S., Yang, X., Elliott, J.E., Beasley, K.M., Lovering, A.T., Hypoxia-induced intrapulmonary arteriovenous shunting at rest in healthy humans (2010) J Appl Physiol (1985), 109 (4), pp. 1072-1079; Lovering, A.T., Romer, L.M., Haverkamp, H.C., Pegelow, D.F., Hokanson, J.S., Eldridge, M.W., Intrapulmonary shunting and pulmonary gas exchange during normoxic and hypoxic exercise in healthy humans (2008) J Appl Physiol (1985), 104 (5), pp. 1418-1425; Vedrinne, J.M., Duperret, S., Bizollon, T., Magnin, C., Motin, J., Trepo, C., Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease (1997) Chest, 111 (5), pp. 1236-1240. , COI: 1:STN:280:DyaK2s3ptlKrsw%3D%3D, PID: 9149575; Boissier, F., Katsahian, S., Razazi, K., Thille, A.W., Roche-Campo, F., Leon, R., Prevalence and prognosis of cor pulmonale during protective ventilation for acute respiratory distress syndrome (2013) Intensive Care Med, 39 (10), pp. 1725-1733. , PID: 23673401; Ranieri, V.M., Rubenfeld, G.D., Thompson, B.T., Ferguson, N.D., Caldwell, E., Fan, E., Acute respiratory distress syndrome: the Berlin definition (2012) JAMA, 307 (23), pp. 2526-2533. , PID: 22797452; Mercat, A., Richard, J.C., Vielle, B., Jaber, S., Osman, D., Diehl, J.L., Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial (2008) JAMA, 299 (6), pp. 646-655. , COI: 1:CAS:528:DC%2BD1cXhvFensLY%3D, PID: 18270353; Mekontso Dessap, A., Charron, C., Devaquet, J., Aboab, J., Jardin, F., Brochard, L., Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome (2009) Intensive Care Med, 35 (11), pp. 1850-1858. , PID: 19652953; Trachsel, D., McCrindle, B.W., Nakagawa, S., Bohn, D., Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure (2005) Am J Respir Crit Care Med, 172 (2), pp. 206-211. , PID: 15817802; Mayo, P.H., Beaulieu, Y., Doelken, P., Feller-Kopman, D., Harrod, C., Kaplan, A., American college of chest physicians/La Societe de reanimation de langue Francaise statement on competence in critical care ultrasonography (2009) Chest, 135 (4), pp. 1050-1060. , PID: 19188546; Vieillard-Baron, A., Charron, C., Chergui, K., Peyrouset, O., Jardin, F., Bedside echocardiographic evaluation of hemodynamics in sepsis: is a qualitative evaluation sufficient? (2006) Intensive Care Med, 32 (10), pp. 1547-1552. , PID: 16855828; Jardin, F., Dubourg, O., Bourdarias, J.P., Echocardiographic pattern of acute cor pulmonale (1997) Chest, 111 (1), pp. 209-217. , COI: 1:STN:280:DyaK2s7kvFaisw%3D%3D, PID: 8996019; Fischer, C.H., Campos, O., Fernandes, W.B., Kondo, M., Souza, F.L., De Andrade, J.L., Role of contrast-enhanced transesophageal echocardiography for detection of and scoring intrapulmonary vascular dilatation (2010) Echocardiography, 27 (10), pp. 1233-1237. , PID: 20584052; Siostrzonek, P., Zangeneh, M., Gossinger, H., Lang, W., Rosenmayr, G., Heinz, G., Comparison of transesophageal and transthoracic contrast echocardiography for detection of a patent foramen ovale (1991) Am J Cardiol, 68 (11), pp. 1247-1249. , COI: 1:STN:280:DyaK38%2FlvVOiuw%3D%3D, PID: 1951092; Tan, H.C., Fung, K.C., Kritharides, L., Agitated colloid is superior to saline and equivalent to levovist in enhancing tricuspid regurgitation Doppler envelope and in the opacification of right heart chambers: a quantitative, qualitative, and cost-effectiveness study (2002) J Am Soc Echocardiogr, 15 (4), pp. 309-315. , PID: 11944007; Nemec, J.J., Marwick, T.H., Lorig, R.J., Davison, M.B., Chimowitz, M.I., Litowitz, H., Comparison of transcranial Doppler ultrasound and transesophageal contrast echocardiography in the detection of interatrial right-to-left shunts (1991) Am J Cardiol, 68 (15), pp. 1498-1502. , COI: 1:STN:280:DyaK38%2FotFKgsg%3D%3D, PID: 1746433; Butler, B.D., Hills, B.A., The lung as a filter for microbubbles (1979) J Appl Physiol Respir Environ Exerc Physiol, 47 (3), pp. 537-543. , COI: 1:STN:280:DyaL3c%2FpsVWgsg%3D%3D, PID: 533747; Horner, S., Ni, X.S., Weihs, W., Harb, S., Augustin, M., Duft, M., Simultaneous bilateral contrast transcranial doppler monitoring in patients with intracardiac and intrapulmonary shunts (1997) J Neurol Sci, 150 (1), pp. 49-57. , COI: 1:STN:280:DyaK2svgsFyisQ%3D%3D, PID: 9260857; Tomashefski, J.F., Jr., Davies, P., Boggis, C., Greene, R., Zapol, W.M., Reid, L.M., The pulmonary vascular lesions of the adult respiratory distress syndrome (1983) Am J Pathol, 112 (1), pp. 112-126. , PID: 6859225; Myers, T.P., Myers, P.R., Adams, H.R., Parker, J.L., Enhanced prostanoid-mediated vasorelaxation in pulmonary arteries isolated during experimental endotoxemia (1999) Shock, 11 (6), pp. 436-442. , COI: 1:STN:280:DyaK1MzhsVOgsQ%3D%3D, PID: 10454834; Spohr, F., Cornelissen, A.J., Busch, C., Gebhard, M.M., Motsch, J., Martin, E.O., Role of endogenous nitric oxide in endotoxin-induced alteration of hypoxic pulmonary vasoconstriction in mice (2005) Am J Physiol Heart Circ Physiol, 289 (2), pp. H823-H831. , PID: 15778287; Stickland, M.K., Welsh, R.C., Haykowsky, M.J., Petersen, S.R., Anderson, W.D., Taylor, D.A., Intra-pulmonary shunt and pulmonary gas exchange during exercise in humans (2004) J Physiol, 561, pp. 321-329. , COI: 1:CAS:528:DC%2BD2cXhtVehu7%2FN, PID: 15388775; Lovering, A.T., Riemer, R.K., Thebaud, B., Intrapulmonary arteriovenous anastomoses: physiol, pathophysiol both? (2013) Ann Am Thorac Soc, 10 (5), pp. 504-508. , PID: 24161053; Rodriguez-Roisin, R., Krowka, M.J., Hepatopulmonary syndrome–a liver-induced lung vascular disorder (2008) N Engl J Med, 358 (22), pp. 2378-2387. , COI: 1:CAS:528:DC%2BD1cXmsVKgtbk%3D, PID: 18509123; Lindstedt, S.L., Pulmonary transit time and diffusing capacity in mammals (1984) Am J Physiol, 246 (3 Pt 2), pp. R384-R388. , COI: 1:STN:280:DyaL2c7ltFaqtQ%3D%3D, PID: 6703093; Freden, F., Cigarini, I., Mannting, F., Hagberg, A., Lemaire, F., Hedenstierna, G., Dependence of shunt on cardiac output in unilobar oleic acid edema: distribution of ventilation and perfusion (1993) Intensive Care Med, 19 (4), pp. 185-190. , COI: 1:STN:280:DyaK3sznsFWhtQ%3D%3D, PID: 8366225; Bryan, T.L., van Diepen, S., Bhutani, M., Shanks, M., Welsh, R.C., Stickland, M.K., The effects of dobutamine and dopamine on intrapulmonary shunt and gas exchange in healthy humans (2012) J Appl Physiol (1985), 113 (4), pp. 541-548. , COI: 1:CAS:528:DC%2BC38XhtlOmsb%2FI; Lemaire, F., Gastine, H., Regnier, B., Teisseire, B., Rapin, M., Perfusion changes modify intrapulmonary shunting in patients with adult respiratory distress syndrome (1978) Am Rev Respir Dis, Suppl, pp. 117-144; Lynch, J.P., Mhyre, J.G., Dantzker, D.R., Influence of cardiac output on intrapulmonary shunt (1979) J Appl Physiol Respir Environ Exerc Physiol, 46 (2), pp. 315-321. , COI: 1:STN:280:DyaE1M7jtVWgsA%3D%3D, PID: 422447; Payen, D.M., Carli, P.A., Brun-Buisson, C.J., Huet, Y.J., Teisseire, B.P., Chiron-Payen, B., Lower body positive pressure vs. dopamine during PEEP in humans (1985) J Appl Physiol (1985), 58 (1), pp. 77-82. , COI: 1:STN:280:DyaL2M7gsVGrug%3D%3D; Glazier, J.B., Hughes, J.M., Maloney, J.E., West, J.B., Measurements of capillary dimensions and blood volume in rapidly frozen lungs (1969) J Appl Physiol, 26 (1), pp. 65-76. , COI: 1:STN:280:DyaF1M%2FovVGhuw%3D%3D, PID: 5762878; Fougeres, E., Teboul, J.L., Richard, C., Osman, D., Chemla, D., Monnet, X., Hemodynamic impact of a positive end-expiratory pressure setting in acute respiratory distress syndrome: importance of the volume status (2010) Crit Care Med, 38 (3), pp. 802-807. , PID: 19926983; Warrell, D.A., Evans, J.W., Clarke, R.O., Kingaby, G.P., West, J.B., Pattern of filling in the pulmonary capillary bed (1972) J Appl Physiol, 32 (3), pp. 346-356. , COI: 1:STN:280:DyaE387isFegsA%3D%3D, PID: 5010044; Pfeiffer, B., Hachenberg, T., Wendt, M., Marshall, B., Mechanical ventilation with permissive hypercapnia increases intrapulmonary shunt in septic and nonseptic patients with acute respiratory distress syndrome (2002) Crit Care Med, 30 (2), pp. 285-289. , PID: 11889294; Aboab, J., Jonson, B., Kouatchet, A., Taille, S., Niklason, L., Brochard, L., Effect of inspired oxygen fraction on alveolar derecruitment in acute respiratory distress syndrome (2006) Intensive Care Med, 32 (12), pp. 1979-1986. , PID: 17019545; Permutt, S.W.R., Brower, R.G., How changes in pleural and alveolar pressure cause changes in afterload and preload (1989) Marcel Dekker, editor, pp. 243-250. , Heart-lung interaction in Health and Disease, New York:; McCabe, W.R., Jackson, GC Gram negative bacteriemia: etiology and ecology (1962) Arch Intern Med, 110 (6), pp. 847-855",Article,Scopus,2-s2.0-84927134676
"Juhl K.S., Bendstrup E., Rasmussen F., Hilberg O.","Emphysema mimicking interstitial lung disease: Two case reports",2015,"Respiratory Medicine Case Reports","15",,,"24","26",,,10.1016/j.rmcr.2014.12.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927727753&partnerID=40&md5=0b51e7a2c94eb59b0e3c20411fd31296","Dpt. Respiratory Medicine and Allergology, Aarhus University HospitalAarhus, Denmark; Department of Radiology, Aarhus University HospitalAarhus, Denmark","Juhl, K.S., Dpt. Respiratory Medicine and Allergology, Aarhus University HospitalAarhus, Denmark; Bendstrup, E., Dpt. Respiratory Medicine and Allergology, Aarhus University HospitalAarhus, Denmark; Rasmussen, F., Department of Radiology, Aarhus University HospitalAarhus, Denmark; Hilberg, O., Dpt. Respiratory Medicine and Allergology, Aarhus University HospitalAarhus, Denmark","Honeycombing in general is a sign of severe end-stage fibrosis. Here we present two cases, where the combination of emphysema, acute inflammation and pulmonary embolism gave an appearance of honeycombing seen in pulmonary fibrosis. HRCT interpretation in the evaluation of acutely ill patients with pulmonary infection is a challenge. Our case reports emphasize the importance of a multidisciplinary approach, when it comes to patients with suspected complicated pulmonary diseases. At the same time they give very realistic examples of the challenges found in diagnosing patients with simultaneous acute and chronic pulmonary diseases. © 2015 The Authors.","Emphysema; Honeycombing; HRCT; Interstitial; Mimicking; Pulmonary embolism","American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus classification of the idiopathic interstitial pneumonias (2002) Am J Respir Crit Care Med, 165, pp. 277-304; Hansell, D.M., Bankier, A.A., MacMahon, H., McLoud, T.C., Müller, N.L., Remy, J., Fleischner Society: glossary of terms for thoracic imaging (2008) Radiology, 246, pp. 697-722; Wright, J.L., Tazelaar, H.D., Churg, A., Fibrosis with emphysema (2011) Histopathology, 58, pp. 517-524; Elicker, B., Pereira, C.A.C., Webb, R., Leslie, K.O., High-resolution computed tomography patterns of diffuse interstitial lung disease with clinical and pathological correlation (2008) JBras Pneumol, 34, pp. 715-744; Morgenthau, A.S., Padilla, M.L., Spectrum of fibrosing diffuse parenchymal lung diseases (2009) Mt Sinai J Med, 76, pp. 2-23; Johkoh, T., Müller, N.L., Ichikado, K., Suga, M., Ando, M., Yoshinaga, T., Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients (2000) Radiology, 216, pp. 773-780; Hunninghake, G.W., Lynch, D.A., Galvin, J.R., Gross, B.H., Müller, N., Schwartz, D.A., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia (2003) Chest, 124, pp. 1215-1223; Hunninghake, G.W., Zimmerman, M.B., Schwartz, D.A., King, T.E., Lynch, J., Hegele, R., Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis (2001) Am J Respir Crit Care Med, 164, pp. 193-196; Flaherty, K.R., Thwaite, E.L., Kazerooni, E.A., Gross, B.H., Toews, G.B., Colby, T.V., Radiological versus histological diagnosis in UIP and NSIP: survival implications (2003) Thorax, 58, pp. 143-148; Hartman, T.E., Swensen, S.J., Hansell, D.M., Colby, T.V., Myers, J.L., Tazelaar, H.D., Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT (2000) Radiology, 217, pp. 701-705; MacDonald, S.L., Rubens, M.B., Hansell, D.M., Copley, S.J., Desai, S.R., du Bois, R.M., Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT (2001) Radiology, 221, pp. 600-605; Akira, M., Inoue, Y., Kitaichi, M., Yamamoto, S., Arai, T., Toyokawa, K., Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: thin-section CT findings (2009) Radiology, 251, pp. 271-279",Article,Scopus,2-s2.0-84927727753
"Peter W.L.St., Yusuf A.A., Do T., Lowe K.A., Liu J., Nieman K.M., Bradbury B.D., Collins A.J.","Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: A retrospective cohort study",2015,"BMC Nephrology","16","1",,"","",,,10.1186/s12882-015-0030-8,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927775476&partnerID=40&md5=8c4df0d9f1294763bf6681d0404fb0e8","Chronic Disease Research Group, Minneapolis Medical Research FoundationMinneapolis, MN, United States; University of Minnesota, College of PharmacyMinneapolis, MN, United States; Center for Observational Research, Amgen Inc.Thousand Oaks, CA, United States","Peter, W.L.St., Chronic Disease Research Group, Minneapolis Medical Research FoundationMinneapolis, MN, United States, University of Minnesota, College of PharmacyMinneapolis, MN, United States; Yusuf, A.A., Chronic Disease Research Group, Minneapolis Medical Research FoundationMinneapolis, MN, United States, University of Minnesota, College of PharmacyMinneapolis, MN, United States; Do, T., Center for Observational Research, Amgen Inc.Thousand Oaks, CA, United States; Lowe, K.A., Center for Observational Research, Amgen Inc.Thousand Oaks, CA, United States; Liu, J., Chronic Disease Research Group, Minneapolis Medical Research FoundationMinneapolis, MN, United States; Nieman, K.M., Chronic Disease Research Group, Minneapolis Medical Research FoundationMinneapolis, MN, United States; Bradbury, B.D., Center for Observational Research, Amgen Inc.Thousand Oaks, CA, United States; Collins, A.J., Chronic Disease Research Group, Minneapolis Medical Research FoundationMinneapolis, MN, United States, University of Minnesota, College of PharmacyMinneapolis, MN, United States","Background: Cinacalcet reduces parathyroid hormone (PTH) levels in patients receiving hemodialysis, but no non-experimental studies have evaluated the association between changes in PTH levels following cinacalcet initiation and clinical outcomes. We assessed whether short-term change in PTH levels after first cinacalcet prescription could serve as a surrogate marker for improvements in longer-term clinical outcomes. Methods: United States Renal Data System data were linked with data from a large dialysis organization. We created a point prevalent cohort of adult hemodialysis patients with Medicare as primary payer who initiated cinacalcet November 1, 2004-February 1, 2007, and were on cinacalcet for ≥ 40 days. We grouped patients into quartiles of PTH change after first cinacalcet prescription. We used Cox proportional hazard modeling to evaluate associations between short-term PTH change and time to first composite event (hospitalization for cardiovascular events or mortality) within 1 year. Overall models and models stratified by baseline PTH levels were adjusted for several patient-related factors. Results: For 2485 of 3467 included patients (72%), PTH levels decreased after first cinacalcet prescription; for 982 (28%), levels increased or were unchanged. Several characteristics differed between PTH change groups, including age and mineral-and-bone-disorder laboratory values. In adjusted models, we did not identify an association between greater short-term PTH reduction and lower composite event rates within 1 year, overall or in models stratified by baseline PTH levels. Conclusions: Short-term change in PTH levels after first cinacalcet prescription does not appear to be a useful surrogate for longer-term improvements in cardiovascular or survival risk. © 2015 St. Peter et al.; licensee BioMed Central.","Cinacalcet; Hemodialysis; Parathyroid hormone; Secondary hyperparathyroidism","Block, G.A., Martin, K.J., De Francisco, A.L., Turner, S.A., Avram, M.M., Suranyi, M.G., Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis (2004) N Engl J Med, 350, pp. 1516-1525; Moe, S.M., Cunningham, J., Bommer, J., Adler, S., Rosansky, S.J., Urena-Torres, P., Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl (2005) Nephrol Dial Transplant, 20, pp. 2186-2193; Lindberg, J.S., Culleton, B., Wong, G., Borah, M.F., Clark, R.V., Shapiro, W.B., Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study (2005) J Am Soc Nephrol, 16, pp. 800-807; St Peter, W.L., Li, Q., Liu, J., Persky, M., Nieman, K., Arko, C., Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006 (2009) Clin J Am Soc Nephrol, 4, pp. 354-360; Danese, M.D., Belozeroff, V., Smirnakis, K., Rothman, K.J., Consistent control of mineral and bone disorder in incident hemodialysis patients (2008) Clin J Am Soc Nephrol, 3, pp. 1423-1429; Kalantar-Zadeh, K., Kuwae, N., Regidor, D.L., Kovesdy, C.P., Kilpatrick, R.D., Shinaberger, C.S., Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients (2006) Kidney Int, 70, pp. 771-780; Tentori, F., Wang, M., Bieber, B.A., Karaboyas, A., Li, Y., Jacobson, S.H., Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study (2015) Clin J Am Soc Nephrol, 10, pp. 98-109; Block, G.A., Kilpatrick, R.D., Lowe, K.A., Wang, W., Danese, M.D., CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis (2013) Clin J Am Soc Nephrol, 8, pp. 2132-2140; Department of Health and Human Services, Centers for Medicare and Medicaid: Federal Register, (2014) Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule - 42 CFR Parts 405, 411, 413 and 414, , http://www.gpo.gov/fdsys/pkg/FR-2014-11-06/pdf/2014-26182.pdf, Available at Accessed January 23, 2015; Block, G.A., Zaun, D., Smits, G., Persky, M., Brillhart, S., Nieman, K., Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients (2010) Kidney Int, 78, pp. 578-589; Padhi, D., Harris, R., Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride (2009) Clin Pharmacokinet, 48, pp. 303-311; Goodman, W.G., Hladik, G.A., Turner, S.A., Blaisdell, P.W., Goodkin, D.A., Liu, W., The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism (2002) J Am Soc Nephrol, 13, pp. 1017-1024; U.S. Renal Data System, USRDS 2013 Annual Data Report (2013) Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, , 2013 Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Kilpatrick, R.D., Newsome, B.B., Zaun, D., Liu, J., Solid, C.A., Nieman, K., Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients (2013) Am J Nephrol, 37, pp. 389-398; Gincherman, Y., Moloney, K., McKee, C., Coyne, D.W., Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients (2010) Hemodial Int, 14, pp. 68-72; Gardham, C., Stevens, P.E., Delaney, M.P., LeRoux, M., Coleman, A., Lamb, E.J., Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis (2010) Clin J Am Soc Nephrol, 5, pp. 1261-1267; Chertow, G.M., Block, G.A., Correa-Rotter, R., Drueke, T.B., Floege, J., Goodman, W.G., Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis (2012) N Engl J Med, 367, pp. 2482-2494",Article,Scopus,2-s2.0-84927775476
"Assaad-Khalil S.H., Najem R., Sison J., Kitchlew A.R., Cho B., Ueng K.-C., Ditommaso S., Shete A.","Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups",2015,"Vascular Health and Risk Management","11",,,"71","78",,,10.2147/VHRM.S76599,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921860898&partnerID=40&md5=77e86d5df324f0abd15038b1f481e877","Department of Diabetology, Lipidology and Metabolism, Alexandria UniversityAlexandria, Egypt; Lebanese University HospitalBeirut, Lebanon; Medical Center ManilaManila, Philippines; Pakistan Institute of Medical SciencesIslamabad, Pakistan; Seoul National University College of MedicineSeoul, South Korea; Chung Shan Medical University HospitalTaichung City, Taiwan; Novartis Pharma AGAGBasel, Switzerland","Assaad-Khalil, S.H., Department of Diabetology, Lipidology and Metabolism, Alexandria UniversityAlexandria, Egypt; Najem, R., Lebanese University HospitalBeirut, Lebanon; Sison, J., Medical Center ManilaManila, Philippines; Kitchlew, A.R., Pakistan Institute of Medical SciencesIslamabad, Pakistan; Cho, B., Seoul National University College of MedicineSeoul, South Korea; Ueng, K.-C., Chung Shan Medical University HospitalTaichung City, Taiwan; Ditommaso, S., Novartis Pharma AGAGBasel, Switzerland; Shete, A., Novartis Pharma AGAGBasel, Switzerland","Background: The clinical EXCITE (EXperienCe of amlodIpine and valsarTan in hypErtension) study reported clinically relevant blood pressure (BP) reductions across all doses of amlodipine/valsartan (Aml/Val) and Aml/Val/hydrochlorothiazide (HCT) single-pill combinations. The study prospectively observed a multiethnic population of hypertensive patients for 26 weeks who were treated according to routine clinical practice. Here, we present the results in high-risk subgroups including the elderly, obese patients, and patients with diabetes or isolated systolic hypertension. In addition, we present a post hoc analysis as per prior antihypertensive monotherapy and dual therapy. Methods: Patients prescribed Aml/Val or Aml/Val/HCT were assessed in this 26±8 week, noninterventional, multicenter study across 13 countries in the Middle East and Asia. Changes in mean sitting systolic BP, mean sitting diastolic BP, and overall safety were assessed. Results: Of a total of 9,794 patients analyzed, 8,603 and 1,191 patients were prescribed Aml/Val and Aml/Val/HCT, respectively. Among these, 15.5% were elderly, 32.5% were obese, 31.3% had diabetes, and 9.8% had isolated systolic hypertension. Both Aml/Val and Aml/Val/HCT single-pill combinations, respectively, were associated with clinically relevant and significant mean sitting systolic/diastolic BP reductions across all subgroups: elderly patients (−32.2/−14.3 mmHg and −38.5/−16.5 mmHg), obese patients (−32.2/−17.9 mmHg and −38.5/−18.4 mmHg), diabetic patients (−30.3/−16.1 mmHg and −34.4/−16.6 mmHg), and patients with isolated systolic hypertension (−25.5/−4.1 mmHg and −30.2/−5.9 mmHg). Incremental BP reductions with Aml/Val or Aml/Val/HCT single-pill combinations were also observed in patients receiving prior monotherapy or dual therapy for hypertension. Overall, both Aml/Val and Aml/Val/HCT were generally well tolerated. Conclusion: This large, multiethnic study supports the evidence that Aml/Val and Aml/Val/HCT single-pill combinations are effective in diverse and clinically important subgroups of patients with hypertension. © 2015 Assaad-Khalil et al.","Amlodipine; Hydrochlorothiazide; Real world; Single-pill combinations; Valsartan","Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J., Global burden of hypertension: Analysis of worldwide data (2005) Lancet, 365, pp. 217-223; Chow, C.K., Teo, K.K., Rangarajan, S., Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries (2013) JAMA, 310, pp. 959-968; Gradman, A.H., Managing high-risk patients with hypertension: Focus on the renin-angiotensin system (2004) J Clin Hypertens (Greenwich), 6, pp. 501-508; Mancia, G., Fagard, R., Narkiewicz, K., ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) J Hypertens. 2013;31, pp. 1281-1357; Bramlage, P., Pittrow, D., Wittchen, H.U., Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled (2004) Am J Hypertens, 17, pp. 904-910; Eguchi, K., Pickering, T.G., Kario, K., Why is blood pressure so hard to control in patients with type 2 diabetes? (2007) J Cardiometab Syndr, 2, pp. 114-118; Stokes, G.S., Management of hypertension in the elderly patient (2009) Clin Interv Aging, 4, pp. 379-389; Chobanian, A.V., Bakris, G.L., Black, H.R., Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (2003) Hypertension, 42, pp. 1206-1252; Duprez, D., Treatment of isolated systolic hypertension in the elderly (2012) Expert Rev Cardiovasc Ther, 10, pp. 1367-1373; Kidambi, S., Kotchen, T.A., Treatment of hypertension in obese patients (2013) Am J Cardiovasc Drugs, 13, pp. 163-175; Mallat, S.G., Itani, H.S., Tanios, B.Y., Current perspectives on combination therapy in the management of hypertension (2013) Integr Blood Press Control, 6, pp. 69-78; Chiang, C.E., Wang, T.D., Li, Y.H., Guidelines of the Taiwan Society of Cardiology for the management of hypertension (2010) J Formos Med Assoc, 109, pp. 740-773; Chung, N., Baek, S., Chen, M.F., Expert recommendations on the challenges of hypertension in Asia (2008) Int J Clin Pract, 62, pp. 1306-1312; Fujita, T., Wu, Z., Park, J.-B., Chen, M.-F., Briefings on JHS, CHS, KHS and THS guidelines and their difference from JNC VII and ESC/ESH (2006) Int J Clin Pract, 60, pp. 3-6; Sison, J., Assaad-Khalil, S.H., Najem, R., Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: The EXCITE study (2014) Curr Med Res Opin, 30, pp. 1937-1945; Pistrosch, F., Natali, A., Hanefeld, M., Is hyperglycemia a cardiovascular risk factor? (2011) Diabetes Care, 34, pp. S128-S131; Stearne, M.R., Palmer, S.L., Hammersley, M.S., Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group (1998) BMJ, 317, pp. 703-713; Singer, G.M., Setaro, J.F., Secondary hypertension: Obesity and the metabolic syndrome (2008) J Clin Hypertens (Greenwich), 10, pp. 567-574; Landsberg, L., Aronne, L.J., Beilin, L.J., Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment – a position paper of the The Obesity Society and The American Society of Hypertension (2013) Obesity (Silver Spring), 21, pp. 8-24; Chobanian, A.V., Bakris, G.L., Black, H.R., The Seventh Report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report (2003) JAMA, 289, pp. 2560-2572; Weber, M.A., Schiffrin, E.L., White, W.B., Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension (2014) J Clin Hypertens (Greenwich), 16, pp. 14-26; Izzo, J.L., Jr., Levy, D., Black, H.R., Clinical Advisory Statement. Importance of systolic blood pressure in older Americans (2000) Hypertension, 35, pp. 1021-1024; Calhoun, D.A., Lacourciere, Y., Crikelair, N., Jia, Y., Glazer, R.D., Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension (2013) Curr Med Res Opin, 29, pp. 901-910; Smith, T.R., Philipp, T., Vaisse, B., Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: Subgroup analyses of 2 randomized, placebo-controlled studies (2007) J Clin Hypertens (Greenwich), 9, pp. 355-364; Flack, J.M., Calhoun, D.A., Satlin, L., Barbier, M., Hilkert, R., Brunel, P., Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: The EX-STAND study (2009) J Hum Hypertens, 23, pp. 479-489; Allemann, Y., Fraile, B., Lambert, M., Barbier, M., Ferber, P., Izzo, J.L., Jr., Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The Exforge in Failure after Single Therapy (EX-FAST) study (2008) J Clin Hypertens (Greenwich), 10, pp. 185-194; Destro, M., Luckow, A., Samson, M., Kandra, A., Brunel, P., Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: A randomized, double-blind, multicenter study: The EX-EFFeCTS Study (2008) J am Soc Hypertens, 2, pp. 294-302; Calhoun, D.A., Crikelair, N.A., Yen, J., Glazer, R.D., Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety (2009) Adv Ther, 26, pp. 1012-1023; Poldermans, D., Glazes, R., Kargiannis, S., Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension (2007) Clin Ther, 29, pp. 279-289; Eckert, S., Freytag, S.B., Muller, A., Klebs, S.H., Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors (2013) Blood Press, 22, pp. 11-21; Kizilirmak, P., Berktas, M., Yalcin, M.R., Boyaci, B., Efficacy and safety of valsartan and amlodipine single-pill combination in hypertensive patients (PEAK study) (2013) Turk Kardiyol Dern Ars, 41, pp. 406-417; Hu, D., Liu, L., Li, W., Efficacy and safety of valsartan/amlodipine single-pill Combination in 11,422 Chinese patients with hypertension: An observational study (2014) Adv Ther, 31, pp. 762-775; Dusing, R., Optimizing blood pressure control through the use of fixed combinations (2010) Vasc Health Risk Manag, 6, pp. 321-325",Article,Scopus,2-s2.0-84921860898
"Carstensen H.G., Larsen L.H., Hassager C., Kofoed K.F., Jensen J.S., Mogelvang R.","Association of ischemic heart disease to global and regional longitudinal strain in asymptomatic aortic stenosis",2015,"International Journal of Cardiovascular Imaging","31","3",,"485","495",,,10.1007/s10554-014-0572-z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925446992&partnerID=40&md5=177147281ba83bb17a602bdf2a5debd0","Department of Cardiology, Gentofte Hospital, University Hospital of Copenhagen, Niels Andersens Vej 65Copenhagen, Denmark; Department of Cardiology, Rigshospitalet, University Hospital of CopenhagenCopenhagen, Denmark; Department of Radiology, Rigshospitalet, University Hospital of CopenhagenCopenhagen, Denmark","Carstensen, H.G., Department of Cardiology, Gentofte Hospital, University Hospital of Copenhagen, Niels Andersens Vej 65Copenhagen, Denmark; Larsen, L.H., Department of Cardiology, Rigshospitalet, University Hospital of CopenhagenCopenhagen, Denmark; Hassager, C., Department of Cardiology, Rigshospitalet, University Hospital of CopenhagenCopenhagen, Denmark; Kofoed, K.F., Department of Radiology, Rigshospitalet, University Hospital of CopenhagenCopenhagen, Denmark; Jensen, J.S., Department of Cardiology, Gentofte Hospital, University Hospital of Copenhagen, Niels Andersens Vej 65Copenhagen, Denmark; Mogelvang, R., Department of Cardiology, Rigshospitalet, University Hospital of CopenhagenCopenhagen, Denmark","Longitudinal deformation has been shown to deteriorate with progressive aortic stenosis as well as ischemic heart disease. Despite that both conditions share risk factors and are often coexisting, studies have not assessed the influence on longitudinal deformation for both conditions simultaneously. Thus the purpose of this study was to evaluate the association between subclinical ischemic heart disease and global and regional longitudinal strain in asymptomatic patients with significant aortic stenosis. Prevalent patients with a diagnosis of aortic stenosis at six hospitals in the Greater Copenhagen area were screened for inclusion. A total of 104 asymptomatic patients with moderate-severe aortic stenosis (aortic valve area ≤1.5 cm2) fulfilled study criteria and underwent advanced echocardiographic analysis and coronary angiography by multi-detector computed tomography. Angiography revealed coronary stenosis &gt;50 % in 31 % (n = 32). All regional longitudinal strain measures (apical, mid and basal longitudinal strain) were significant predictors of significant coronary stenosis (&gt;70 % stenosis), but only apical and mid longitudinal strain were significant predictors in multivariable analyses independent of aortic valve area, stroke volume index, pro-BNP, valvulo-arterial impedance, body mass index and heart rate. In linear regression models with both aortic valve area and significant coronary stenosis, apical (p &lt; 0.001) and mid (p &lt; 0.01) longitudinal strain were associated to significant coronary stenosis but not aortic valve area. Conversely, basal longitudinal strain was significantly associated to aortic valve area (p = 0.001), but not to significant coronary stenosis. Subclinical coronary artery disease is frequent in moderate and severe aortic stenosis, and should be suspected when regional longitudinal dysfunction is predominant in the apical and mid ventricular segments. © 2014, Springer Science+Business Media Dordrecht.","Asymptomatic aortic stenosis; Deformation; Ischemic heart disease; Regional longitudinal strain","Stewart, B.F., Siscovick, D., Lind, B.K., clinical factors associated with calcific aortic valve disease (1997) J Am Coll Cardiol, 29, pp. 630-634. , COI: 1:STN:280:DyaK2s3hsVGhsQ%3D%3D, PID: 9060903; Morrison, G.W., Thomas, R.D., Grimmer, S.F., Silverton, P.N., Smith, D.R., Incidence of coronary artery disease in patients with valvular heart disease (1980) Br Heart J, 44, pp. 630-637. , COI: 1:STN:280:DyaL3M7htVWntA%3D%3D, PID: 7459146; Ramsdale, D.R., Bennett, D.H., Bray, C.L., Ward, C., Beton, D.C., Faragher, E.B., Angina, coronary risk factors and coronary artery disease in patients with valvular disease. A prospective study (1984) Eur Heart J, 5, pp. 716-726. , COI: 1:STN:280:DyaL2M%2FltFeqsQ%3D%3D, PID: 6499859; Bourantas, C.V., Zhang, Y.-J., Garg, S., Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials (2014) Heart heartjnl–2013–305180; Hou, Z., Lu, B., Gao, Y., Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients (2012) JACC Cardiovasc Imaging, 5, pp. 990-999. , PID: 23058065; Arad, Y., Spadaro, L.A., Goodman, K., Newstein, D., Guerci, A.D., Prediction of coronary events with electron beam computed tomography (2000) J Am Coll Cardiol, 36, pp. 1253-1260. , COI: 1:STN:280:DC%2BD3cvnslWisg%3D%3D, PID: 11028480; Biering-Sorensen, T., Hoffmann, S., Mogelvang, R., Myocardial strain analysis by 2-dimensional speckle tracking echocardiography improves diagnostics of coronary artery stenosis in stable angina pectoris (2014) Circ Cardiovasc Imaging, 7, pp. 58-65. , PID: 24186963; Choi, J.-O., Cho, S.W., Song, Y.B., Longitudinal 2D strain at rest predicts the presence of left main and three vessel coronary artery disease in patients without regional wall motion abnormality (2009) Eur J Echocardiogr, 10, pp. 695-701. , PID: 19401300; Attias, D., Macron, L., Dreyfus, J., Relationship between longitudinal strain and symptomatic status in aortic stenosis (2013) J Am Soc Echocardiogr, 26, pp. 868-874. , PID: 23768690; Ng, A.C.T., Delgado, V., Bertini, M., Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: a two-dimensional speckle tracking analysis (2011) Eur Heart J, 32, pp. 1542-1550. , PID: 21447510; Larsen, L.H., Kofoed, K.F., Carstensen, H.G., Aortic valve area assessed with 320-detector computed tomography: comparison with transthoracic echocardiography (2014) Int J Cardiovasc Imaging, 30, pp. 165-173. , PID: 24126620; Lang, R.M., Bierig, M., Devereux, R.B., Recommendations for chamber quantification (2006) Eur J Echocardiogr, 7, pp. 79-108. , PID: 16458610; Baumgartner, H., Hung, J., Bermejo, J., Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice (2009) J Am Soc Echocardiogr, 22, pp. 1-23. , PID: 19130998; Raff, G.L., Abidov, A., Achenbach, S., SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography (2009) J Cardiovasc Comput Tomogr, 3, pp. 122-136. , PID: 19272853; Austen, W.G., Edwards, J.E., Frye, R.L., A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease, council on cardiovascular surgery. American Heart Association (1975) Circulation, 51, pp. 5-40; Go, A.S., Mozaffarian, D., Roger, V.L., Heart disease and stroke statistics—2013 update. A report from the American Heart Association (2013) Circulation, 127, pp. e6-e245; Gaziano, T.A., Bitton, A., Anand, S., Abrahams-Gessel, S., Murphy, A., Growing epidemic of coronary heart disease in low- and middle-income countries (2010) Curr Probl Cardiol, 35, pp. 72-115. , PID: 20109979; Greenbaum, R.A., Ho, S.Y., Gibson, D.G., Becker, A.E., Anderson, R.H., Left ventricular fibre architecture in man (1981) Br Heart J, 45, pp. 248-263. , COI: 1:STN:280:DyaL3M7jtl2nsw%3D%3D, PID: 7008815; Reimer, K.A., Lowe, J.E., Rasmussen, M.M., Jennings, R.B., The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs (1977) Circulation, 56, pp. 786-794. , COI: 1:STN:280:DyaE1c%2Fit1yjtQ%3D%3D, PID: 912839; Dunn, R.B., Griggs, D.M., Transmural gradients in ventricular tissue metabolites produced by stopping coronary blood flow in the dog (1975) Circ Res, 37, pp. 438-445. , COI: 1:CAS:528:DyaE2MXlslKitbc%3D, PID: 1182935; Algranati, D., Kassab, G.S., Lanir, Y., Why is the subendocardium more vulnerable to ischemia? A new paradigm (2011) AJP Heart Circ Physiol, 300, pp. H1090-H1100. , COI: 1:CAS:528:DC%2BC3MXjs1GqsL8%3D; Dellsperger, K.C., Marcus, M.L., The effects of pressure-induced cardiac hypertrophy on the functional capacity of the coronary circulation (1988) Am J Hypertens, 1, pp. 200-207. , COI: 1:STN:280:DyaL1c3ptlOrtw%3D%3D, PID: 2969742; Mahmod, M., Francis, J.M., Pal, N., Myocardial perfusion and oxygenation are impaired during stress in severe aortic stenosis and correlate with impaired energetics and subclinical left ventricular dysfunction (2014) J Cardiovasc Magn Reson, 16, p. 29. , PID: 24779370; Hoffmann, S., Mogelvang, R., Sogaard, P., Tissue Doppler echocardiography reveals impaired cardiac function in patients with reversible ischaemia (2011) Eur J Echocardiogr, 12, pp. 628-634. , PID: 21757478; Bruch, C., Stypmann, J., Grude, M., Gradaus, R., Breithardt, G., Wichter, T., Tissue Doppler imaging in patients with moderate to severe aortic valve stenosis: clinical usefulness and diagnostic accuracy (2004) Am Heart J, 148, pp. 696-702. , PID: 15459603; MacGregor, D.C., Covell, J.W., Mahler, F., Dilley, R.B., Ross, J., Jr., Relations between afterload, stroke volume, and descending limb of Starling’s curve (1974) Am J Physiol, 227, pp. 884-890. , COI: 1:STN:280:DyaE2M%2Flt1ClsA%3D%3D, PID: 4279559; Ersbøll, M., Valeur, N., Mogensen, U.M., Relationship between left ventricular longitudinal deformation and clinical heart failure during admission for acute myocardial infarction: a two-dimensional speckle-tracking study (2012) J Am Soc Echocardiogr, 25, pp. 1280-1289. , PID: 23072712; Gjesdal, O., Helle-Valle, T., Hopp, E., Noninvasive separation of large, medium, and small myocardial infarcts in survivors of reperfused ST-elevation myocardial infarction a comprehensive tissue doppler and speckle-tracking echocardiography study (2008) Circ Cardiovasc Imaging, 1, pp. 189-196. , PID: 19808542; Morris, D.A., Otani, K., Bekfani, T., Multidirectional global left ventricular systolic function in normal subjects and patients with hypertension: multicenter evaluation (2014) J Am Soc Echocardiogr, 27, pp. 493-500. , PID: 24582162; Lafitte, S., Perlant, M., Reant, P., Impact of impaired myocardial deformations on exercise tolerance and prognosis in patients with asymptomatic aortic stenosis (2009) Eur J Echocardiogr, 10, pp. 414-419. , PID: 18996958; Baltabaeva, A., Marciniak, M., Bijnens, B., Regional left ventricular deformation and geometry analysis provides insights in myocardial remodelling in mild to moderate hypertension (2008) Eur J Echocardiogr, 9, pp. 501-508. , PID: 17905662; Richand, V., Lafitte, S., Reant, P., An ultrasound speckle tracking (two-dimensional strain) analysis of myocardial deformation in professional soccer players compared with healthy subjects and hypertrophic cardiomyopathy (2007) Am J Cardiol, 100, pp. 128-132. , PID: 17599454; Serri, K., Reant, P., Lafitte, M., Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy (2006) J Am Coll Cardiol, 47, pp. 1175-1181. , PID: 16545649; Phelan, D., Collier, P., Thavendiranathan, P., Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis (2012) Heart, 98, pp. 1442-1448. , PID: 22865865; Heng, M.K., Janz, R.F., Jobin, J., Estimation of regional stress in the left ventricular septum and free wall: an echocardiographic study suggesting a mechanism for asymmetric septal hypertrophy (1985) Am Heart J, 110, pp. 84-90. , COI: 1:STN:280:DyaL2M3kvVWgsg%3D%3D, PID: 3160227; Basford, J.R., The law of laplace and its relevance to contemporary medicine and rehabilitation (2002) Arch Phys Med Rehabil, 83, pp. 1165-1170. , PID: 12161841; Weidemann, F., Herrmann, S., Störk, S., Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis (2009) Circulation, 120, pp. 577-584. , COI: 1:CAS:528:DC%2BD1MXpsFylu7w%3D, PID: 19652094; Chow, B.W., Freeman, M.R., Bowen, J.M., Ontario multidetector computed tomographic coronary angiography study: field evaluation of diagnostic accuracy (2011) Arch Intern Med, 171, pp. 1021-1029. , PID: 21403014; Larsen, L.H., Kofoed, K.F., Dalsgaard, M., Assessment of coronary artery disease using coronary computed tomography angiography in patients with aortic valve stenosis referred for surgical aortic valve replacement (2013) Int J Cardiol, 168, pp. 126-131. , PID: 23073274; Utsunomiya, H., Yamamoto, H., Kitagawa, T., Incremental prognostic value of cardiac computed tomography angiography in asymptomatic aortic stenosis: significance of aortic valve calcium score (2013) Int J Cardiol, 168, pp. 5205-5211. , PID: 23978365; Herzog, B.A., Wyss, C.A., Husmann, L., First head-to-head comparison of effective radiation dose from low-dose 64-slice CT with prospective ECG-triggering versus invasive coronary angiography (2009) Heart, 95, pp. 1656-1661. , COI: 1:STN:280:DC%2BD1Mnlt1Cksw%3D%3D, PID: 19581273",Article,Scopus,2-s2.0-84925446992
"Edelman M.J., Tan M.T., Fidler M.J., Sanborn R.E., Otterson G., Sequist L.V., Evans T.L., Schneider B.J., Keresztes R., Rogers J.S., De Mayolo J.A., Feliciano J., Yang Y., Medeiros M., Zaknoen S.L.","Randomized, double-blind, placebo-controlled, multicenter phase ii study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer",2015,"Journal of Clinical Oncology","33","2",,"189","194",,,10.1200/JCO.2014.55.5789,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920938211&partnerID=40&md5=4218c13e8e322b494fa7ceee91e2fbbb","Greenebaum Cancer Center, University of Maryland, 22 South Greene StBaltimore, MD, United States; Georgetown UniversityWashington, DC, United States; Rush University Medical CenterChicago, IL, United States; Providence Portland Medical CenterPortland, OR, United States; Ohio State University Comprehensive Cancer CenterColumbus, OH, United States; Massachusetts General Hospital Cancer CenterBoston, MA, United States; University of PennsylvaniaPhiladelphia, PA, United States; Weill Cornell Medical CollegeNew York City, United States; State University of New York Stony BrookStony Brook, NY, United States; West Virginia University School of MedicineMorgantown, WV, United States; Mercy Research InstituteMiami, FL, United States; TragaraSan Diego, CA, United States","Edelman, M.J., Greenebaum Cancer Center, University of Maryland, 22 South Greene StBaltimore, MD, United States; Tan, M.T., Georgetown UniversityWashington, DC, United States; Fidler, M.J., Rush University Medical CenterChicago, IL, United States; Sanborn, R.E., Providence Portland Medical CenterPortland, OR, United States; Otterson, G., Ohio State University Comprehensive Cancer CenterColumbus, OH, United States; Sequist, L.V., Massachusetts General Hospital Cancer CenterBoston, MA, United States; Evans, T.L., University of PennsylvaniaPhiladelphia, PA, United States; Schneider, B.J., Weill Cornell Medical CollegeNew York City, United States; Keresztes, R., State University of New York Stony BrookStony Brook, NY, United States; Rogers, J.S., West Virginia University School of MedicineMorgantown, WV, United States; De Mayolo, J.A., Mercy Research InstituteMiami, FL, United States; Feliciano, J., Greenebaum Cancer Center, University of Maryland, 22 South Greene StBaltimore, MD, United States; Yang, Y., Greenebaum Cancer Center, University of Maryland, 22 South Greene StBaltimore, MD, United States; Medeiros, M., Greenebaum Cancer Center, University of Maryland, 22 South Greene StBaltimore, MD, United States; Zaknoen, S.L., TragaraSan Diego, CA, United States","Purpose Overexpression of COX-2 correlates with advanced stage and worse outcomes in non-small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2). Exploratory analyses of studies that used COX-2 inhibitors have demonstrated potentially superior outcome in patients in whom the urinary metabolite of PGE2 (PGE-M) is suppressed. We hypothesized that patients with disease defined by PGE-M suppression would benefit from the addition of apricoxib to second-line docetaxel or pemetrexed. Patients and Methods Patients with NSCLC who had disease progression after one line of platinum-based therapy, performance status of 0 to 2, and normal organ function were potentially eligible. Only patients with a 50% decrease in urinary PGE-M after 5 days of treatment with apricoxib could enroll. Docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days per the investigator was administered with apricoxib or placebo 400 mg once per day. The primary end point was progression-free survival (PFS). Exploratory analysis was performed regarding baseline urinary PGE-M and outcomes. Results In all, 101 patients completed screening, and 72 of the 80 who demonstrated 50% suppression were randomly assigned to apricoxib or placebo. Toxicity was similar between the arms. No improvement in PFS was seen with apricoxib versus placebo. The median PFS for the control arm was 97 days (95% CI, 52 to 193 days) versus 85 days (95% CI, 67 to 142 days) for the experimental arm (P =.91). Conclusion Apricoxib did not improve PFS, despite biomarker-driven patient selection. © 2014 by American Society of Clinical Oncology.Copyright © 2015 American Society of Clinical Oncology.",,"Altorki, N.K., Port, J.L., Zhang, F., Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer (2005) Clin Cancer Res, 11, pp. 4191-4197; Edelman, M.J., Watson, D., Wang, X., Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203 (2008) J Clin Oncol, 26, pp. 848-855; Fidler, M.J., Argiris, A., Patel, J.D., The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib (2008) Clin Cancer Res, 14, pp. 2088-2094; Fabi, A., Metro, G., Papaldo, P., Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: Results of a phase II study with biomarker evaluation (2008) Cancer Chemother Pharmacol, 62, pp. 717-725; Rini, B.I., Weinberg, V., Dunlap, S., Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma (2006) Cancer, 106, pp. 566-575; Murphey, L.J., Williams, M.K., Sanchez, S.C., Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: Determination of cyclooxygenasespecific PGE2 synthesis in healthy humans and those with lung cancer (2004) Anal Biochem, 334, pp. 266-275; Csiki, I., Morrow, J.D., Sandler, A., Targeting cyclooygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel (2005) Clin Cancer Res, 11, pp. 6634-6640; Rao, P.N., Grover, R.K., Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer (2009) IDrugs, 12, pp. 711-722; Howe, L.R., Subbaramaiah, K., Brown, A.M., Cyclooxygenase-2: A target for the prevention and treatment of breast cancer (2001) Endocr Relat Cancer, 8, pp. 97-114; Midgley, R.S., McConkey, C.C., Johnstone, E.C., Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: Final results of the VICTOR trial (2010) J Clin Oncol, 28, pp. 4575-4580; Reckamp, K., Gitlitz, B., Chen, L.C., Biomarkerbased phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer (2011) Cancer, 117, pp. 809-818; Gitlitz, B.J., Bernstein, E., Santos, E.S., A randomized, placebo-controlled, multicenter, biomarkerselected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer (2014) J Thorac Oncol, 9, pp. 577-582; Groen, H.J., Sietsma, H., Vincent, A., Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-smallcell lung cancer: The NVALT-4 study (2011) J Clin Oncol, 29, pp. 4320-4326",Article,Scopus,2-s2.0-84920938211
"Mackey J.R., Ramos-Vazquez M., Lipatov O., McCarthy N., Krasnozhon D., Semiglazov V., Manikhas A., Gelmon K.A., Konecny G.E., Webster M., Hegg R., Verma S., Gorbunova V., Gerges D.A., Thireau F., Fung H., Simms L., Buyse M., Ibrahim A., Martin M.","Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer",2015,"Journal of Clinical Oncology","33","2",,"141","148",,1,10.1200/JCO.2014.57.1513,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920919864&partnerID=40&md5=0a4b49c8f95f1884273f2bc3c343676b","Department of Medical Oncology, University of Alberta, Cross Cancer Institute, 11560 University AveEdmonton, AB, Canada; Translational Research in OncologyEdmonton, AB, Canada; Tom Baker Cancer CentreCalgary, AB, Canada; British Columbia Cancer AgencyVancouver, BC, Canada; Sunnybrook Health Sciences CenterToronto, ON, Canada; Eli LillyToronto, ON, Canada; Centro Oncológico de Galicia 'José Antonio Quiroga y Piñeiro'A Coruña, Spain; Instituto de Investigación Sanitaria Gregorio Marañon, Universidad ComplutenseMadrid, Spain; Republican Clinical Oncology Dispensary, Bashkortostan Republic Ministry of HealthUfa, Russian Federation; Leningrad Regional Oncology DispensaryLeningrad, Russian Federation; Institute of Oncology N.N. PetrovSt-Petersburg, Russian Federation; City Clinical Oncology DispensarySt-Petersburg, Russian Federation; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesMoscow, Russian Federation; ICON Cancer Care WesleyBrisbane, QLD, Australia; University of California Los AngelesLos Angeles, CA, United States; Hospital Pérola Byigton, Centro de Referência da Saúde da MulherSao Paulo, Brazil; Middle East Institute of HealthBsalim, Lebanon; International Drug Development InstituteLouvain-la-Neuve, Belgium; ImClone SystemsBridgewater, NJ, United States","Mackey, J.R., Department of Medical Oncology, University of Alberta, Cross Cancer Institute, 11560 University AveEdmonton, AB, Canada; Ramos-Vazquez, M., Centro Oncológico de Galicia 'José Antonio Quiroga y Piñeiro'A Coruña, Spain; Lipatov, O., Republican Clinical Oncology Dispensary, Bashkortostan Republic Ministry of HealthUfa, Russian Federation; McCarthy, N., ICON Cancer Care WesleyBrisbane, QLD, Australia; Krasnozhon, D., Leningrad Regional Oncology DispensaryLeningrad, Russian Federation; Semiglazov, V., Institute of Oncology N.N. PetrovSt-Petersburg, Russian Federation; Manikhas, A., City Clinical Oncology DispensarySt-Petersburg, Russian Federation; Gelmon, K.A., British Columbia Cancer AgencyVancouver, BC, Canada; Konecny, G.E., University of California Los AngelesLos Angeles, CA, United States; Webster, M., Tom Baker Cancer CentreCalgary, AB, Canada; Hegg, R., Hospital Pérola Byigton, Centro de Referência da Saúde da MulherSao Paulo, Brazil; Verma, S., Sunnybrook Health Sciences CenterToronto, ON, Canada; Gorbunova, V., N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesMoscow, Russian Federation; Gerges, D.A., Middle East Institute of HealthBsalim, Lebanon; Thireau, F., Translational Research in OncologyEdmonton, AB, Canada; Fung, H., Translational Research in OncologyEdmonton, AB, Canada; Simms, L., Eli LillyToronto, ON, Canada; Buyse, M., International Drug Development InstituteLouvain-la-Neuve, Belgium; Ibrahim, A., ImClone SystemsBridgewater, NJ, United States; Martin, M., Instituto de Investigación Sanitaria Gregorio Marañon, Universidad ComplutenseMadrid, Spain","Purpose: Currently, antiangiogenic strategies in metastatic breast cancer have demonstrated modest improvements in progression-free survival (PFS) but not improved quality or duration of survival, warranting evaluation of new agents in a placebo-controlled setting. Ramucirumab is a human immunoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks ligand-stimulated activation. The ROSE/TRIO-012 trial evaluated ramucirumab with docetaxel in unresectable, locally recurrent, or metastatic breast cancer. Patients and Methods: In this double-blind, placebo-controlled, randomized, multinational phase III trial, 1,144 patients with human epidermal growth factor receptor 2 (HER2) -negative breast cancer who had not received cytotoxic chemotherapy in the advanced setting were randomly assigned at a two-to-one ratio to receive docetaxel 75 mg/m2 plus ramucirumab 10 mg/kg or docetaxel 75 mg/m2 plus placebo once every 3 weeks. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria. Patients were stratified by previous taxane therapy, visceral metastasis, hormone receptor status, and geographic region. An independent data monitoring committee oversaw the trial. The primary end point was investigator-assessed PFS. Results: Median PFS in patients treated with ramucirumab plus docetaxel was 9.5 months, compared with 8.2 months in patients who received placebo plus docetaxel (hazard ratio [HR], 0.88; P = .077). Median overall survival was 27.3 months in patients who received ramucirumab plus docetaxel, compared with 27.2 months in patients who received placebo plus docetaxel (HR, 1.01; P = .915). Toxicities seen at significantly higher rates in patients receiving ramucirumab included fatigue, hypertension, febrile neutropenia, palmar-plantar erythrodysesthesia syndrome, and stomatitis. Conclusion: Addition of ramucirumab to docetaxel in HER2-negative advanced breast cancer did not meaningfully improve important clinical outcomes. © 2014 by American Society of Clinical Oncology.",,"Jitawatanarat, P., Wee, W., Update on antiangiogenic therapy in colorectal cancer: Aflibercept and regorafenib (2013) J Gastrointest Oncol, 4, pp. 231-238; Ainsworth, N.L., Lee, J.S., Eisen, T., Impact of anti-angiogenic treatments on metastatic renal cell carcinoma (2009) Expert Rev Anticancer Ther, 9, pp. 1793-1805; Choueiri, T.K., Duh, M.S., Clement, J., Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: Effectiveness, safety and treatment patterns in clinical practice-based on medical chart review (2010) BJU Int, 105, pp. 1247-1254; Tewari, K.S., Sill, M.W., Long, H.J., III, Improved survival with bevacizumab in advanced cervical cancer (2014) N Engl J Med, 370, pp. 734-743; Aghajanian, C., Blank, S.V., Goff, B.A., OCEANS: A randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer (2012) J Clin Oncol, 30, pp. 2039-2045; O'Malley, D.M., Richardson, D.L., Rheaume, P.S., Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer (2011) Gynecol Oncol, 121, pp. 269-272; Perren, T.J., Swart, A.M., Pfisterer, J., A phase 3 trial of bevacizumab in ovarian cancer (2011) N Engl J Med, 365, pp. 2484-2496; Lilly, E., Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival: Ramucirumab Improved Survival in Second-line Study of Patients with Non-small Cell Lung Cancer, , https://investor.lilly.com/releasedetail.cfm?ReleaseID_826569; Lee, C.B., Socinski, M.A., Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: A review of recent clinical trials (2007) Rev Recent Clin Trials, 2, pp. 117-120; MacKey, J.R., Kerbel, R.S., Gelmon, K.A., Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials (2012) Cancer Treat Rev, 38, pp. 673-688; Belugali Nataraj, N., Salimath, B.P., Crosstalk between VEGF and novel angiogenic protein regulates tumor angiogenesis and contributes to aggressiveness of breast carcinoma (2013) Cell Signal, 25, pp. 277-294; Garon, E.B., Cao, D., Alexandris, E., A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): Treatment rationale and study design (2012) Clin Lung Cancer, 13, pp. 505-509; Ghosh, S., Sullivan, C.A., Zerkowski, M.P., High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer (2008) Hum Pathol, 39, pp. 1835-1843; Meunier-Carpentier, S., Dales, J.P., Djemli, A., Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma (2005) Int J Oncol, 26, pp. 977-984; Krupitskaya, Y., Wakelee, H.A., Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer (2009) Curr Opin Investig Drugs, 10, pp. 597-605; Fuchs, C.S., Tomasek, J., Yong, C.J., Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial (2014) Lancet, 383, pp. 31-39; Spratlin, J.L., Cohen, R.B., Eadens, M., Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 (2010) J Clin Oncol, 28, pp. 780-787; National Cancer Institute, Cancer Therapy Evaluation Program, , http://ctep.cancer.gov; Therasse, P., Arbuck, S.G., Eisenhauer, E.A., New guidelines to evaluate the response to treatment in solid tumors (2000) J Natl Cancer Inst, 92, pp. 205-216; Brady, M.J., Cella, D.F., Mo, F., Reliability and validity of the Functional Assessment of Cancer-Breast quality of life instrument (1997) J Clin Oncol, 15, pp. 974-986; Ramucirumab in Combination with Paclitaxel Improves Overall Survival in Second Line Treatment for Metastatic Gastric Cancer: The Phase III RAINBOW Study Met Primary Endpoint, , http://www.esmo.org/Oncology-News/Ramucirumab-in-Combination-With-Paclitaxel-Improves-Overall-Survival-in-Second-Line-Treatment-for-Metastatic-Gastric-Cancer; Wilke, H., Van Cutsem, E., Cheul Oh, S., RAINBOW: A global, phase III, randomized, doubleblind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4TIE-JVBE) (2014) J Clin Oncol, 32. , (abstr LBA7); Cameron, D., Brown, J., Dent, R., Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial (2013) Lancet Oncol, 14, pp. 933-942; Slamon, D.J., Swain, S.M., Buyse, M., Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, nodepositive or high risk node-negative breast cancer (2013) Presented at the 36th Annual San Antonio Breast Cancer Symposium, , San Antonio, TX, December 10-14; Bear, H.D., Tang, G., Rastogi, P., Bevacizumab added to neoadjuvant chemotherapy for breast cancer (2012) N Engl J Med, 366, pp. 310-320; Gerber, B., Loibl, S., Eidtmann, H., Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers: Results from the Geparquinto study (GBG 44) (2013) Ann Oncol, 24, pp. 2978-2984; Von Minckwitz, G., Eidtmann, H., Rezai, M., Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer (2012) N Engl J Med, 366, pp. 299-309; Andres, A.C., Djonov, V., The mammary gland vasculature revisited (2010) J Mammary Gland Biol Neoplasia, 15, pp. 319-328; Lindholm, E.M., Krohn, M., Iadevaia, S., Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations (2014) Clin Cancer Res, 20, pp. 404-412; Chen, X., Iliopoulos, D., Zhang, Q., XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway (2014) Nature, 508, pp. 103-107; Giuliano, S., Pages, G., Mechanisms of resistance to anti-angiogenesis therapies (2013) Biochimie, 95, pp. 1110-1119",Article,Scopus,2-s2.0-84920919864
"Burchard E.G.","Medical research: Missing patients",2014,"Nature","513","7518",,"301","302",,,10.1038/513301a,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84907775411&partnerID=40&md5=503d7095b1dd900f2b03a78750c59ff5","University of CaliforniaSan Francisco, United States","Burchard, E.G., University of CaliforniaSan Francisco, United States",[No abstract available],,"Moorman, J.E., (2012) National Surveillance of Asthma: United States, 2001-2010, , National Center for Health Statistics; Aizer, A.A., (2014) Cancer, 120, pp. 1532-1539; Durazzo, T.S., Frencher, S., Gusberg, R., (2013) JAMA Surg., 148, pp. 617-623; Currie, G.P., Lee, D.K., Lipworth, B.J., (2006) Drug Saf., 29, pp. 647-656; Burchard, E.G., (1999) Am. J. Respir. Crit. Care Med., 160, pp. 919-922; Naqvi, M., (2007) J. Asthma, 44, pp. 639-648; Ginther, D.K., (2011) Science, 333, pp. 1015-1019; Chen, M.S., Jr., Lara, P.N., Dang, J.H., Paterniti, D.A., Kelly, K., (2014) Cancer, 120, pp. 1091-1096",Note,Scopus,2-s2.0-84907775411
"Imai K., Maeda T., Sayama Y., Osa M., Mikita K., Kurane I., Miyahira Y., Kawana A., Miura S.","Chronic Chagas disease with advanced cardiac complications in Japan: Case report and literature review",2015,"Parasitology International","64","5",,"240","242",,,10.1016/j.parint.2015.02.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924601241&partnerID=40&md5=959f9009f5de2367bc5314e9c217d808","Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical CollegeSaitama, Japan; Infectious Disease Research Department, Central Blood Institute, Japanese Red Cross SocietyTokyo, Japan; National Institute of Infectious DiseasesTokyo, Japan; Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical CollegeSaitama, Japan","Imai, K., Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical CollegeSaitama, Japan; Maeda, T., Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical CollegeSaitama, Japan; Sayama, Y., Infectious Disease Research Department, Central Blood Institute, Japanese Red Cross SocietyTokyo, Japan; Osa, M., Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical CollegeSaitama, Japan; Mikita, K., Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical CollegeSaitama, Japan; Kurane, I., National Institute of Infectious DiseasesTokyo, Japan; Miyahira, Y., Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical CollegeSaitama, Japan; Kawana, A., Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical CollegeSaitama, Japan; Miura, S., Infectious Disease Research Department, Central Blood Institute, Japanese Red Cross SocietyTokyo, Japan","Due to the unprecedented recent increases in global migration, Chagas disease has become a global health threat and its epidemiology has drastically changed. Here we describe the first case in Japan of benznidazole treatment for chronic Chagas disease characterized by advanced cardiac complications. A 55-year-old Japanese-Brazilian woman who had previously presented with chronic heart failure was diagnosed as having Chagas disease and treated with benznidazole to prevent aggravation of her cardiac complications. However, benznidazole administration was stopped on day 56 due to severe drug-induced peripheral neuritis. Sixteen months later, her serologic test for Trypanosoma cruzi is still positive and she is being followed regularly by cardiology. Despite an estimated prevalence of over 4000 cases in Japan, only a few cases of Chagas disease have been reported. A Medline search revealed only 7 cases identified between 1995 and 2014 in Japan: in 6 cases, complications of chronic Chagas disease were apparent at the time of presentation, and sudden death occurred in 2 of these cases due to cardiac complications. This clinical case and literature review re-emphasize the urgent need to establish a surveillance network and improve the diagnostic methods and treatment framework for Chagas disease in Japan. © 2015 Elsevier Ireland Ltd.","Benznidazole; Chronic Chagas cardiomyopathy; Migrant; Peripheral neuritis; Trypanosoma cruzi","Schmunis, G.A., Epidemiology of Chagas disease in non-endemic countries: the role of international migration (2007) Mem Inst Oswaldo Cruz, 102, pp. 75-85; Chagas disease: control and elimination (2009) A62/17. 62nd World Health Assembly, , http://apps.who.int/gb/ebwha/pdf_files/A62/A62_17-en.pdf, [Geneva, Available from: ]; Muñoz, J., Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain) (2009) Acta Trop, 111, pp. 51-55. , [2009]; Marcon, G.E., Andrade, P.D., de Albuquerque, D.M., Wanderley Jda, S., de Almeida, E.A., Guariento, M.E., Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies (2002) Diagn Microbiol Infect Dis, 43, pp. 39-43; Ueno, Y., Nakamura, Y., Takahashi, M., Inoue, T., Endo, S., Kinoshita, M., A highly suspected case of chronic Chagas' heart disease diagnosed in Japan (1995) Jpn Circ J, 59, pp. 219-223; Araki, T., Miki, C., Yoshiyama, S., Toiyama, Y., Sakamoto, N., Kusunoki, M., Total proctocolectomy and ileal J-pouch anal anastomosis for chagasic megacolon with fecaloma: report of a case (2006) Surg Today, 36, pp. 277-279; Satoh, F., Tachibana, H., Hasegawa, I., Osawa, M., Sudden death caused by chronic Chagas disease in a non-endemic country: autopsy report (2010) Pathol Int, 60, pp. 235-240; Imai, K., Maeda, T., Sayama, Y., Mikita, K., Fujikura, Y., Misawa, K., Mother-to-child transmission of congenital Chagas disease, Japan (2014) Emerg Infect Dis, 20, pp. 146-148; Nishimura, A., An autopsy case of sudden death due to Chagas' disease (1997) Nihon Hoigaku Zasshi, 51, pp. 39-43; Takeno, M., Chronic Chagas' heart disease in a Japanese-Brazilian traveler. A case report (1999) Jpn Heart J, 40, pp. 375-382; Sabino, E.C., Ribeiro, A.L., Salemi, V.M., Ianni, B.M., Nastari, L., Fernandes, F., Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors (2013) Circulation, 127, pp. 1105-1115; Rassi, A., Rassi, A., Little, W.C., Chagas' heart disease (2000) Clin Cardiol, 23, pp. 883-889; Bern, C., Montgomery, S.P., Herwaldt, B.L., Rassi, A., Marin-Neto, J.A., Dantas, R.O., Evaluation and treatment of Chagas disease in the United States: a systematic review (2007) JAMA, 298, pp. 2171-2181; Marin-Neto, J.A., Cunha-Neto, E., Maciel, B.C., Simões, M.V., Pathogenesis of chronic Chagas heart disease (2007) Circulation, 115, pp. 1109-1123; Viotti, R., Vigliano, C., Lococo, B., Bertocchi, G., Petti, M., Alvarez, M.G., Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial (2006) Ann Intern Med, 144, pp. 724-734; Cancado, J.R., Long term evaluation of etiological treatment of Chagas disease with benznidazole (2002) Rev Inst Med Trop Sao Paulo, 44, pp. 29-37",Article,Scopus,2-s2.0-84924601241
"Sergueeva A.I., Miasnikova G.Y., Polyakova L.A., Nouraie M., Prchal J.T., Gordeuk V.R.","Complications in children and adolescents with Chuvash polycythemia",2015,"Blood","125","2",,"414","415",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921044634&partnerID=40&md5=86958243b29677b7aa447b77f5c54fed","Cheboksary Children's HospitalCheboksary, Russian Federation; Chuvash Republic Clinical Hospital, No. 1Cheboksary, Russian Federation; Center for Sickle Cell Disease, Howard UniversityWashington, DC, United States; Department of Internal Medicine, University of Utah, VA Medical CenterSalt Lake City, UT, United States; Department of Medicine, University of Illinois at ChicagoChicago, United States; Sickle Cell Center (M/C 712), Clinical Sciences Building, 820 South Wood StChicago, IL, United States","Sergueeva, A.I., Cheboksary Children's HospitalCheboksary, Russian Federation; Miasnikova, G.Y., Chuvash Republic Clinical Hospital, No. 1Cheboksary, Russian Federation; Polyakova, L.A., Chuvash Republic Clinical Hospital, No. 1Cheboksary, Russian Federation; Nouraie, M., Center for Sickle Cell Disease, Howard UniversityWashington, DC, United States; Prchal, J.T., Department of Internal Medicine, University of Utah, VA Medical CenterSalt Lake City, UT, United States; Gordeuk, V.R., Department of Medicine, University of Illinois at ChicagoChicago, United States, Sickle Cell Center (M/C 712), Clinical Sciences Building, 820 South Wood StChicago, IL, United States",[No abstract available],,"Polyakova, L.A., Familial erythrocytosis among inhabitants of the Chuvash ASSR (1974) Problemi Gematologii I Perelivaniya Krovi, 10, pp. 30-36; Ang, S.O., Chen, H., Hirota, K., Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia (2002) Nat Genet, 32 (4), pp. 614-621; Russell, R.C., Sufan, R.I., Zhou, B., Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia (2011) Nat Med, 17 (7), pp. 845-853; Gordeuk, V.R., Sergueeva, A.I., Miasnikova, G.Y., Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors (2004) Blood, 103 (10), pp. 3924-3932; Sable, C.A., Aliyu, Z.Y., Dham, N., Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia) (2012) Haematologica, 97 (2), pp. 193-200; Polyakova, L.A., (1977) Familial-Hereditary Erythrocytosis, , Cheboksary, Russia: Faculty of Medicine, Chuvash State University; Gordeuk, V.R., Prchal, J.T., Vascular complications in Chuvash polycythemia (2006) Semin Thromb Hemost, 32 (3), pp. 289-294",Article,Scopus,2-s2.0-84921044634
"Romano M., Cianci E., Simiele F., Recchiuti A.","Lipoxins and aspirin-triggered lipoxins in resolution of inflammation",2015,"European Journal of Pharmacology","760",,,"49","63",,,10.1016/j.ejphar.2015.03.083,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928580559&partnerID=40&md5=69da086a27878a296f3bd24dff10c9dd","Department of Medical, Oral and Biotechnological Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Medicine and Aging Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy","Romano, M., Department of Medical, Oral and Biotechnological Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy, Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Cianci, E., Medicine and Aging Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy, Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Simiele, F., Department of Medical, Oral and Biotechnological Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy, Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy; Recchiuti, A., Department of Medical, Oral and Biotechnological Sciences, G. DAnnunzio University of Chieti-PescaraChieti, Italy, Center of Excellence on Aging, G. DAnnunzio University of Chieti-PescaraChieti, Italy","The resolution of the inflammatory response is highly regulated by the timely biosynthesis of a number of endogenous lipid mediators. Among these, lipoxins (LX) and their 15-epimers, aspirin triggered lipoxins (ATL) derived by the lipoxygenase (LO) route of arachidonic acid metabolism. In particular, they are formed and released by cells expressing 5-, 12- and 15-LO such as leukocytes, platelets, vascular endothelium and epithelium, alone or during transcellular interactions. ATL biosynthesis requires cyclooxygenase-2 acetylation by aspirin. LX and ATL exert potent bioactions on leukocytes, vascular and epithelial cells to stop inflammation and promote resolution. They have shown to be beneficial in a broad spectrum of preclinical models of disease as well as in some clinical trials. Counter-regulatory signaling by LXA<inf>4</inf> and 15-epi-LXA<inf>4</inf> follows the activation of a G protein-coupled receptor, termed ALX/FPR2, which is emerging as a key anti-inflammatory receptor. © 2015 Elsevier B.V. All rights reserved.","Efferocytosis; Inflammation; Lipoxin; Lipoxygenase; microRNA; Polymorphysm; Promoter; Receptor; Resolution","Abdelmoaty, S., Wigerblad, G., Bas, D.B., Codeluppi, S., Fernandez-Zafra, T., El, E.-A., Moustafa, S., Svensson, C.I.E., Spinal actions of Lipoxin A4 and 17(R)-Resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release (2013) PLoS One, 8, p. e75543; Al-Alawi, M., Buchanan, P., Verriere, V., Higgins, G., McCabe, O., Costello, R.W., McNally, P., Harvey, B.J., Physiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epithelium (2014) Physiol. Rep., 2, p. e12093; Aliberti, J., Hieny, S., Reis Sousa E, C., Serhan, C.N., Sher, A., Lipoxin-mediated inhibition of IL-12 production by DCs: A mechanism for regulation of microbial immunity (2002) Nat Immunol., 3, pp. 76-82; Aliberti, J., Serhan, C., Sher, A., Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection (2002) J. Exp. Med., 196, pp. 1253-1262; Ariel, A., Chiang, N., Arita, M., Petasis, N.A., Serhan, C.N., Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells (2003) J. Immunol., 170, pp. 6266-6272; Ariel, A., Fredman, G., Sun, Y.-P., Kantarci, A., Van Dyke, T.E., Luster, A.D., Serhan, C.N., Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression (2006) Nat. Immunol., 7, pp. 1209-1216; Badr, K.F., Deboer, D.K., Schwartzberg, M., Serhan, C.N., Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: Evidence for competition at a common receptor (1989) Proc. Natl. Acad. Sci. USA, 86, pp. 3438-3442; Bafica, A., Scanga, C.A., Serhan, C., Machado, F., White, S., Sher, A., Aliberti, J., Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production (2005) J. Clinic.Investig., 115, pp. 1601-1606; Baker, N., Omeara, S.J., Scannell, M., Maderna, P., Godson, C., Lipoxin A4: Anti-inflammatory and anti-angiogenic impact on endothelial cells (2009) J. Immunol., 182, pp. 3819-3826; Bandeira-Melo, C., Serra, M.F., Diaz, B.L., Cordeiro, R.S., Silva, P.M., Lenzi, H.L., Bakhle, Y.S., Martins, M.A., Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: Relationship with concurrent eosinophilia (2000) J. Immunol., 164, pp. 1029-1036; Bannenberg, G.L., Aliberti, J., Hong, S., Sher, A., Serhan, C., Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis (2004) J. Exp. Med., 199, pp. 515-523; Bannenberg, G.L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K.H., Hong, S., Serhan, C.N., Molecular circuits of resolution: Formation and actions of resolvins and protectins (2005) J. Immunol., 174, pp. 4345-4355; Barnig, C., Cernadas, M., Dutile, S., Liu, X., Perrella, M.A., Kazani, S., Wechsler, M.E., Levy, B.D., Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma (2013) Sci. Transl. Med., 5, p. 174ra126; Biteman, B., Hassan, I.R., Walker, E., Leedom, A.J., Dunn, M., Seta, F., Laniado-Schwartzman, M., Gronert, K., Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing (2007) FASEB J., 21, pp. 2257-2266; Bonnans, C., Fukunaga, K., Levy, M.A., Levy, B.D., Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury (2006) Am. J. Pathol., 168, pp. 1064-1072; Borgeson, E., Docherty, N.G., Murphy, M., Rodgers, K., Ryan, A., Osullivan, T.P., Guiry, P.J., Godson, C., Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis (2011) FASEB J., 25, pp. 2967-2979; Borgeson, E., Godson, C., Resolution of inflammation: Therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications (2012) Front. Immunol., 3, p. 318; Borgeson, E., Lonn, J., Bergstrom, I., Brodin, V.P., Ramstrom, S., Nayeri, F., Sarndahl, E., Bengtsson, T., Lipoxin A(4) inhibits Porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression (2011) Infect. Immun., 79, pp. 1489-1497; Borgeson, E., McGillicuddy, F.C., Harford, K.A., Corrigan, N., Higgins, D.F., Maderna, P., Roche, H.M., Godson, C., Lipoxin A4 attenuates adipose inflammation (2012) FASEB J., 26, pp. 4287-4294; Brady, H.R., Persson, U., Ballermann, B.J., Brenner, B.M., Serhan, C.N., Leukotrienes stimulate neutrophil adhesion to mesangial cells: Modulation with lipoxins (1990) Am. J. Physiol., 259, pp. F809-815; Brancaleone, V., Gobbetti, T., Cenac, N., Le Faouder, P., Colom, B., Flower, R.J., Vergnolle, N., Perretti, M., A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation (2013) Blood, 122, pp. 608-617; Brennan, E.P., Nolan, K.A., Borgeson, E., Gough, O.S., McEvoy, C.M., Docherty, N.G., Higgins, D.F., Godson, C., Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFbetaR1 (2013) J. Am. Soc. Nephrol., 24, pp. 627-637; Brezinski, D.A., Nesto, R.W., Serhan, C.N., Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy (1992) Circulation, 86, pp. 56-63; Brezinski, D.A., Serhan, C.N., Characterization of lipoxins by combined gas chromatography and electron-capture negative ion chemical ionization mass spectrometry: Formation of lipoxin A4 by stimulated human whole blood (1991) Biol. Mass Spectrom., 20, pp. 45-52; Brezinski, M.E., Gimbrone, Jr.M.A., Nicolaou, K.C., Serhan, C.N., Lipoxins stimulate prostacyclin generation by human endothelial cells (1989) FEBS Lett., 245, pp. 167-172; Buchanan, P.J., McNally, P., Harvey, B.J., Urbach, V., Lipoxin A4-mediated KATP potassium channel activation results in cystic fibrosis airway epithelial repair (2013) Am. J. Physiol. Lung Cell. Mol. Physiol., 305, pp. L193-201; Carlo, T., Kalwa, H., Levy, B.D., 15-Epi-lipoxin A4 inhibits human neutrophil superoxide anion generation by regulating polyisoprenyl diphosphate phosphatase 1 (2013) FASEB J., 27, pp. 2733-2741; Celik, G.E., Erkekol, F.O., Misirligil, Z., Melli, M., Lipoxin A4 levels in asthma: Relation with disease severity and aspirin sensitivity (2007) Clin. Exp. Allergy, 37, pp. 1494-1501; Cezar-De-Mello, P.F., Nascimento-Silva, V., Villela, C.G., Fierro, I.M., Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly (2006) Oncogene, 25, pp. 122-129; Cezar-De-Mello, P.F., Vieira, A.M., Nascimento-Silva, V., Villela, C.G., Barja-Fidalgo, C., Fierro, I.M., ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor (2008) Br. J. Pharmacol., 153, pp. 956-965; Chan, M.M., Moore, A.R., Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production (2010) J. Immunol, 184, pp. 6418-6426; Chen, M., Divangahi, M., Gan, H., Shin, D.S., Hong, S., Lee, D.M., Serhan, C.N., Remold, H.G., Lipid mediators in innate immunity against tuberculosis: Opposing roles of PGE2 and LXA4 in the induction of macrophage death (2008) J. Exp. Med., 205, pp. 2791-2801; Chen, X.Q., Wu, S.H., Zhou, Y., Tang, Y.R., Involvement of K+ channel-dependant pathways in lipoxin A4-induced protective effects on hypoxia/reoxygenation injury of cardiomyocytes (2013) Prostaglandins Leuk. Essent. Fatty Acids, 88, pp. 391-397; Chen, X.Q., Wu, S.H., Zhou, Y., Tang, Y.R., Lipoxin A4-induced heme oxygenase-1 protects cardiomyocytes against hypoxia/reoxygenation injury via p38 MAPK activation and Nrf2/ARE complex (2013) PLoS One, 8, p. e67120; Chen, Y., Hao, H., He, S., Cai, L., Li, Y., Hu, S., Ye, D., Chen, X., Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: The role of antiangiogenesis (2010) Mol. Cancer Ther., 9, pp. 2164-2174; Chiang, N., Bermudez, E.A., Ridker, P.M., Hurwitz, S., Serhan, C.N., Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial (2004) Proc. Natl. Acad. Sci. USA, 101, pp. 15178-15183; Chiang, N., Gronert, K., Clish, C.B., Obrien, J.A., Freeman, M.W., Serhan, C.N., Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion (1999) J. Clin. Investig., 104, pp. 309-316; Chiang, N., Hurwitz, S., Ridker, P.M., Serhan, C.N., Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: A randomized human trial (2006) Arterioscler. Thromb. Vasc. Biol., 26, pp. e14-17; Chiang, N., Takano, T., Arita, M., Watanabe, S., Serhan, C.N., A novel rat lipoxin A4 receptor that is conserved in structure and function (2003) Br. J. Pharmacol., 139, pp. 89-98; Christie, P.E., Spur, B.W., Lee, T.H., The effects of lipoxin A4 on airway responses in asthmatic subjects (1992) Am. Rev. Respir. Dis., 145, pp. 1281-1284; Cilloniz, C., Pantin-Jackwood, M.J., Ni, C., Goodman, A.G., Peng, X., Proll, S.C., Carter, V.S., Katze, M.G., Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection (2010) J. Virol., 84, pp. 7613-7624; Claria, J., Lee, M.H., Serhan, C.N., Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation (1996) Mol. Med., 2, pp. 583-596; Claria, J., Serhan, C.N., Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions (1995) Proc. Natl. Acad. Sci. USA, 92, pp. 9475-9479; Clish, C.B., Levy, B.D., Chiang, N., Tai, H.H., Serhan, C.N., Oxidoreductases in lipoxin A4 metabolic inactivation: A novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation (2000) J. Biol. Chem., 275, pp. 25372-25380; Clish, C.B., Obrien, J.A., Gronert, K., Stahl, G.L., Petasis, N.A., Serhan, C.N., Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo (1999) Proc. Natl. Acad. Sci. USA, 96, pp. 8247-8252; Colgan, S.P., Serhan, C.N., Parkos, C.A., Delp-Archer, C., Madara, J.L., Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers (1993) J. Clin. Investig., 92, pp. 75-82; Conte, F.P., Menezes-De-Lima, Jr.O., Verri, Jr.W.A., Cunha, F.Q., Penido, C., Henriques, M.G., Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects (2010) Br. J. Pharmacol., 161, pp. 911-924; Cooray, S.N., Gobbetti, T., Montero-Melendez, T., McArthur, S., Thompson, D., Clark, A.J.L., Flower, R.J., Perretti, M., Ligand-specific conformational change of the G-protein coupled receptor ALX/FPR2 determines proresolving functional responses (2013) Proc. Natl. Acad. Sci. USA, 110, pp. 18232-18237; Dalli, J., Colas, R.A., Serhan, C.N., Novel n-3 immunoresolvents: Structures and actions (2013) Sci. Rep., 3, p. 1940; Dalli, J., Winkler, J.W., Colas, R.A., Arnardottir, H., Cheng, C.Y., Chiang, N., Petasis, N.A., Serhan, C.N., Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents (2013) Chem. Biol., 20, pp. 188-201; Das, U.N., Arachidonic acid and lipoxin A4 as possible endogenous anti-diabetic molecules (2013) Prostaglandins Leukot. Essent. Fatty Acids, 88, pp. 201-210; Das, U.N., Lipoxins, resolvins, and protectins in the prevention and treatment of diabetic macular edema and retinopathy (2013) Nutrition, 29, pp. 1-7; Deng, X., Ueda, H., Su, S.B., Gong, W., Dunlop, N.M., Gao, J.L., Murphy, P.M., Wang, J.M., A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R (1999) Blood, 94, pp. 1165-1173; Devchand, P.R., Arita, M., Hong, S., Bannenberg, G., Moussignac, R.L., Gronert, K., Serhan, C.N., Human ALX receptor regulates neutrophil recruitment in transgenic mice: Roles in inflammation and host defense (2003) FASEB J., 17, pp. 652-659; Devchand, P.R., Schmidt, B.A., Primo, V.C., Zhang, Q.-Y., Arnaout, M.A., Serhan, C.N., Nikolic, B., A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils (2005) FASEB J., 19, pp. 203-210; Duffy, C.D., Maderna, P., McCarthy, C., Loscher, C.E., Godson, C., Guiry, P., Synthesis and biological evaluation of pyridine-containing lipoxin A4 analogues (2010) Chem. Med. Chem., 5, pp. 517-522; Dufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H.B., Gray, M., Dacquisto, F., Flower, R.J., Anti-inflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation (2010) J. Immunol., 184, pp. 2611-2619; Dunn, H.C., Ager, R.R., Baglietto-Vargas, D., Cheng, D., Kitazawa, M., Cribbs, D.H., Medeiros, R., Restoration of Lipoxin A4 Signaling Reduces Alzheimers Disease-Like Pathology in the 3xTg-AD Mouse Model (2015) J. Alzheimers Dis., 43, pp. 893-903; Edenius, C., Haeggstrom, J., Lindgren, J.A., Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions (1988) Biochem. Biophys. Res. Commun., 157, pp. 801-807; Edenius, C., Kumlin, M., Bjork, T., Anggard, A., Lindgren, J.A., Lipoxin formation in human nasal polyps and bronchial tissue (1990) FEBS Lett., 272, pp. 25-28; Eke Gungor, H., Tahan, F., Gokahmetoglu, S., Saraymen, B., Decreased levels of lipoxin A4 and annexin A1 in wheezy infants (2014) Int. Arch. Allergy Immunol., 163, pp. 193-197; El Kebir, D., Jozsef, L., Pan, W., Wang, L., Petasis, N.A., Serhan, C.N., Filep, J.G., 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury (2009) Am. J. Respir. Crit. Care Med., 180, pp. 311-319; Fierro, I.M., Colgan, S.P., Bernasconi, G., Petasis, N.A., Clish, C.B., Arita, M., Serhan, C.N., Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: Comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells (2003) J. Immunol., 170, pp. 2688-2694; Fierro, I.M., Kutok, J.L., Serhan, C.N., Novel lipid mediator regulators of endothelial cell proliferation and migration: Aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4) (2002) J. Pharmacol. Exp. Ther., 300, pp. 385-392; Fiore, S., Ryeom, S.W., Weller, P.F., Serhan, C.N., Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils (1992) J. Biol. Chem., 267, pp. 16168-16176; Fiore, S., Serhan, C.N., Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils (1990) J. Exp. Med., 172, pp. 1451-1457; Fiore, S., Serhan, C.N., Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: Inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction (1995) Biochemistry, 34, pp. 16678-16686; Fiorucci, S., De Lima, Jr.O.M., Mencarelli, A., Palazzetti, B., Distrutti, E., McKnight, W., Dicay, M., Wallace, J.L., Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage (2002) Gastroenterology, 123, pp. 1598-1606; Fiorucci, S., Distrutti, E., De Lima, O.M., Romano, M., Mencarelli, A., Barbanti, M., Palazzini, E., Wallace, J.L., Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin (2003) FASEB J., 17, pp. 1171-1173; Fiorucci, S., Santucci, L., Wallace, J.L., Sardina, M., Romano, M., Del Soldato, P., Morelli, A., Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa (2003) Proc. Natl. Acad. Sci. USA, 100, pp. 10937-10941; Fiorucci, S., Wallace, J.L., Mencarelli, A., Distrutti, E., Rizzo, G., Farneti, S., Morelli, A., Parkinson, J.F., A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction (2004) Proc. Natl. Acad. Sci. USA, 101, pp. 15736-15741; Gangemi, S., Luciotti, G., D'Urbano, E., Mallamace, A., Santoro, D., Bellinghieri, G., Davi, G., Romano, M., Physical exercise increases urinary excretion of lipoxin A4 and related compounds (2003) J. Appl. Physiol. (1985), 94, pp. 2237-2240; Gangemi, S., Patella, V., Cianci, E., Saitta, S., Lattanzio, S., Florio, G., Romano, M., Ultrarush venom immunotherapy and the lipoxin a4 inflammation resolution pathway (2012) Ann. Allergy Asthma Immunol., 109, pp. 226-227; Genis, P., Jett, M., Bernton, E.W., Boyle, T., Gelbard, H.A., Dzenko, K., Keane, R.W., Volsky, D.J., Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: Implications for the neuropathogenesis of HIV disease (1992) J. Exp. Med., 176, pp. 1703-1718; Gewirtz, A.T., Collier-Hyams, L.S., Young, A.N., Kucharzik, T., Guilford, W.J., Parkinson, J.F., Williams, I.R., Madara, J.L., Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis (2002) J. Immunol., 168, pp. 5260-5267; Gewirtz, A.T., Fokin, V.V., Petasis, N.A., Serhan, C.N., Madara, J.L., LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation (1999) Am. J. Physiol., 276, pp. C988-994; Gil-Villa, A.M., Norling, L.V., Serhan, C.N., Cordero, D., Rojas, M., Cadavid, A., Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma (2012) Prostaglandins Leukot. Essent. Fatty Acids, 87, pp. 127-134; Gobbetti, T., Coldewey, S.M., Chen, J., McArthur, S., Le Faouder, P., Cenac, N., Flower, R.J., Perretti, M., Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis (2014) Proc. Natl. Acad. Sci. USA, 111, pp. 18685-18690; Godson, C., Mitchell, S., Harvey, K., Petasis, N.A., Hogg, N., Brady, H.R., Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages (2000) J. Immunol., 164, pp. 1663-1667; Goh, J., Baird, A.W., Okeane, C., Watson, R.W., Cottell, D., Bernasconi, G., Petasis, N.A., Mac Mathuna, P., Lipoxin A(4) and aspirin-triggered 15-epi-lipoxin A(4) antagonize TNF-alpha-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-alpha-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo (2001) J. Immunol., 167, pp. 2772-2780; Gronert, K., Maheshwari, N., Khan, N., Hassan, I.R., Dunn, M., Laniado Schwartzman, M., A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense (2005) J. Biol. Chem., 280, pp. 15267-15278; Grumbach, Y., Quynh, N.V., Chiron, R., Urbach, V., LXA4 stimulates ZO-1 expression and transepithelial electrical resistance in human airway epithelial (16HBE14o-) cells (2009) Am. J. Physiol. Lung Cell. Mol. Physiol., 296, pp. L101-108; Guilford, W.J., Bauman, J.G., Skuballa, W., Bauer, S., Wei, G.P., Davey, D., Schaefer, C., Parkinson, J.F., Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo (2004) J. Med. Chem., 47, pp. 2157-2165; Guilherme, R.F., Xisto, D.G., Kunkel, S.L., Freire-De-Lima, C.G., Rocco, P.R., Neves, J.S., Fierro, I.M., Benjamim, C.F., Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog (2013) Am. J. Respir. Cell Mol. Biol., 49, pp. 1029-1037; Gutierrez, A.D., Sathyanarayana, P., Konduru, S., Ye, Y., Birnbaum, Y., Bajaj, M., The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes (2012) Atherosclerosis, 223, pp. 204-208; Hao, H., Liu, M., Wu, P., Cai, L., Tang, K., Yi, P., Li, Y., Ye, D., Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment (2011) Cancer Lett., 309, pp. 85-94; Hashimoto, A., Hayashi, I., Murakami, Y., Sato, Y., Kitasato, H., Matsushita, R., Iizuka, N., Endo, H., Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis (2007) J. Rheumatol., 34, pp. 2144-2153; Higgins, G., Buchanan, P., Perriere, M., Al-Alawi, M., Costello, R.W., Verriere, V., McNally, P., Urbach, V., Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis (2014) Am. J. Respir. Cell Mol. Biol., 51, pp. 178-190; Ho, K.J., Spite, M., Owens, C.D., Lancero, H., Kroemer, A.H., Pande, R., Creager, M.A., Conte, M.S., Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis (2010) Am. J. Pathol., 177, pp. 2116-2123; Hu, S., Mao-Ying, Q.L., Wang, J., Wang, Z.F., Mi, W.L., Wang, X.W., Jiang, J.W., Wang, Y.Q., Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines (2012) J. Neuroinflammation, p. 278; Janakiram, N.B., Mohammed, A., Rao, C.V., Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer (2011) Cancer Metastasis Rev., 30, pp. 507-523; Jin, H., Li, Y.H., Xu, J.S., Guo, G.Q., Chen, D.L., Bo, Y., Lipoxin A4 analog attenuates morphine antinociceptive tolerance, withdrawal-induced hyperalgesia, and glial reaction and cytokine expression in the spinal cord of rat (2012) Neuroscience, 208, pp. 1-10; Jin, S.W., Zhang, L., Lian, Q.Q., Liu, D., Wu, P., Yao, S.L., Ye, D.Y., Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: The role of heme oxygenase-1 (2007) Anesth. Analg., 104, pp. 369-377; Jin, W., Jia, Y., Huang, L., Wang, T., Wang, H., Dong, Y., Zhang, H., Lv, P., Lipoxin A4 methyl ester ameliorates cognitive deficits induced by chronic cerebral hypoperfusion through activating ERK/Nrf2 signaling pathway in rats (2014) Pharmacol. Biochem. Behav., 124, pp. 145-152; Jin, Y., Arita, M., Zhang, Q., Saban, D.R., Chauhan, S.K., Chiang, N., Serhan, C.N., Dana, R., Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators (2009) Investig. Ophthalmol. Vis. Sci., 50, pp. 4743-4752; Jozsef, L., Zouki, C., Petasis, N.A., Serhan, C.N., Filep, J.G., Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes (2002) Proc. Natl. Acad. Sci. USA, 99, pp. 13266-13271; Kakazu, A., He, J., Kenchegowda, S., Bazan, H.E., Lipoxin A(4) inhibits platelet-activating factor inflammatory response and stimulates corneal wound healing of injuries that compromise the stroma (2012) Exp. Eye Res., 103, pp. 9-16; Karp, C.L., Flick, L.M., Park, K.W., Softic, S., Greer, T.M., Keledjian, R., Yang, R., Petasis, N.A., Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway (2004) Nat. Immunol., 5, pp. 388-392; Kieran, N.E., Doran, P.P., Connolly, S.B., Greenan, M.C., Higgins, D.F., Leonard, M., Godson, C., Brady, H.R., Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog (2003) Kidney Int., 64, pp. 480-492; Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., Serhan, C.N., Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs (2012) Am. J. Pathol., 180, pp. 2018-2027; Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C.H., Yang, R., Petasis, N.A., Serhan, C.N., Resolvin D1 binds human phagocytes with evidence for proresolving receptors (2010) Proc. Natl. Acad. Sci. USA, 107, pp. 1660-1665; Kumar, R., Clerc, A.C., Gori, I., Russell, R., Pellegrini, C., Govender, L., Wyss, J.C., Canny, G.O., Lipoxin A(4) prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E(2) production and estrogen signaling (2014) PLoS One, 9, p. e89742; Kure, I., Nishiumi, S., Nishitani, Y., Tanoue, T., Ishida, T., Mizuno, M., Fujita, T., Yoshida, M., Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation (2010) J. Pharmacol. Exp. Ther., 332, pp. 541-548; Le, Y., Gong, W., Tiffany, H.L., Tumanov, A., Nedospasov, S., Shen, W., Dunlop, N.M., Wang, J.M., Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1 (2001) J. Neurosci., 21, p. RC123; Leedom, A.J., Sullivan, A.B., Dong, B., Lau, D., Gronert, K., Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury (2010) Am. J. Pathol., 176, pp. 74-84; Leibovich, S.J., Ross, R., The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum (1975) Am. J. Pathol., 78, pp. 71-100; Leonard, M.O., Hannan, K., Burne, M.J., Lappin, D.W., Doran, P., Coleman, P., Stenson, C., Brady, H.R., 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure (2002) J. Am. Soc. Nephrol., 13, pp. 1657-1662; Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., Serhan, C.N., Lipid mediator class switching during acute inflammation: Signals in resolution (2001) Nat. Immunol., 2, pp. 612-619; Levy, B.D., De Sanctis, G.T., Devchand, P.R., Kim, E., Ackerman, K., Schmidt, B.A., Szczeklik, W., Serhan, C.N., Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4) (2002) Nat. Med., 8, pp. 1018-1023; Levy, B.D., Fokin, V.V., Clark, J.M., Wakelam, M.J., Petasis, N.A., Serhan, C.N., Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: A 'stop' signaling switch for aspirin-triggered lipoxin A4 (1999) FASEB J., 13, pp. 903-911; Levy, B.D., Lukacs, N.W., Berlin, A.A., Schmidt, B., Guilford, W.J., Serhan, C.N., Parkinson, J.F., Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism (2007) FASEB J., 21, pp. 3877-3884; Levy, B.D., Romano, M., Chapman, H.A., Reilly, J.J., Drazen, J., Serhan, C.N., Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins (1993) J. Clin. Investig., 92, pp. 1572-1579; Levy, B.D., Zhang, Q.Y., Bonnans, C., Primo, V., Reilly, J.J., Perkins, D.L., Liang, Y., Serhan, C.N., The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection (2011) Prostaglandins Leukot. Essent. Fatty Acids, 84, pp. 43-50; Li, Q., Tian, Y., Wang, Z.F., Liu, S.B., Mi, W.L., Ma, H.J., Wu, G.C., Wang, Y.Q., Involvement of the spinal NALP1 inflammasome in neuropathic pain and aspirin-triggered-15-epi-lipoxin A4 induced analgesia (2013) Neuroscience, 254, pp. 230-240; Lucas, T., Waisman, A., Ranjan, R., Roes, J., Krieg, T., Muller, W., Roers, A., Eming, S.A., Differential roles of macrophages in diverse phases of skin repair (2010) J. Immunol., 184, pp. 3964-3977; Luo, C.L., Li, Q.Q., Chen, X.P., Zhang, X.M., Li, L.L., Li, B.X., Zhao, Z.Q., Tao, L.Y., Lipoxin A4 attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury (2013) Brain Res., 1502, pp. 1-10; Maddox, J.F., Colgan, S.P., Clish, C.B., Petasis, N.A., Fokin, V.V., Serhan, C.N., Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: Design of stable lipoxin B4 analogs with increased biologic activity (1998) FASEB J., 12, pp. 487-494; Maddox, J.F., Hachicha, M., Takano, T., Petasis, N.A., Fokin, V.V., Serhan, C.N., Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor (1997) J. Biol. Chem., 272, pp. 6972-6978; Maddox, J.F., Serhan, C.N., Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: Selective inactivation by dehydrogenation and reduction (1996) J. Exp. Med., 183, pp. 137-146; Majno, G., Joris, I., (2004) Cells, Tissues, and Disease: Principles of General Pathology: Principles of General Pathology, , Oxford University Press USA; Maldonado-Perez, D., Golightly, E., Denison, F.C., Jabbour, H.N., Norman, J.E., A role for lipoxin A4 as anti-inflammatory and proresolution mediator in human parturition (2011) FASEB J., 25, pp. 569-575; Martins, V., Valenca, S.S., Farias-Filho, F.A., Molinaro, R., Simoes, R.L., Ferreira, T.P., Silva P M, E., Benjamim, C.F., ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis (2009) J. Immunol., 182, pp. 5374-5381; Mattoscio, D., Evangelista, V., De Cristofaro, R., Recchiuti, A., Pandolfi, A., Di Silvestre, S., Manarini, S., Romano, M., Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response (2010) FASEB J., 24, pp. 3970-3980; McMahon, B., Mitchell, D., Shattock, R., Martin, F., Brady, H.R., Godson, C., Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation (2002) FASEB J., 16, pp. 1817-1819; McMahon, B., Stenson, C., McPhillips, F., Fanning, A., Brady, H.R., Godson, C., Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors (2000) J. Biol. Chem., 275, pp. 27566-27575; Medeiros, R., Kitazawa, M., Passos, G.F., Baglietto-Vargas, D., Cheng, D., Cribbs, D.H., Laferla, F.M., Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice (2013) Am. J. Pathol., 182, pp. 1780-1789; Medeiros, R., Rodrigues, G.B., Figueiredo, C.P., Rodrigues, E.B., Grumman, Jr.A., Menezes-De-Lima, Jr.O., Passos, G.F., Calixto, J.B., Molecular mechanisms of topical anti-inflammatory effects of lipoxin A(4) in endotoxin-induced uveitis (2008) Mol. Pharmacol., 74, pp. 154-161; Merched, A.J., Ko, K., Gotlinger, K.H., Serhan, C.N., Chan, L., Atherosclerosis: Evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators (2008) FASEB J., 22, pp. 3595-3606; Mitchell, D., Omeara, S.J., Gaffney, A., Crean, J.K.G., Kinsella, B.T., Godson, C., The Lipoxin A4 Receptor Is Coupled to SHP-2 Activation: Implications for regulation of receptor tyrosine kinases (2007) J. Biol. Chem., 282, pp. 15606-15618; Mitchell, D., Rodgers, K., Hanly, J., McMahon, B., Brady, H.R., Martin, F., Godson, C., Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells (2004) Am. J. Pathol., 164, pp. 937-946; Molina-Berrios, A., Campos-Estrada, C., Henriquez, N., Faundez, M., Torres, G., Castillo, C., Escanilla, S., Maya, J.D., Protective role of acetylsalicylic acid in experimental Trypanosoma cruzi infection: Evidence of a 15-epi-lipoxin A(4)-mediated effect (2013) PLoS Negl. Trop. Dis., 7, p. e2173; Morris, T., Stables, M., Hobbs, A., De Souza, P., Colville-Nash, P., Warner, T., Newson, J., Gilroy, D.W., Effects of low-dose aspirin on acute inflammatory responses in humans (2009) J. Immunol., 183, pp. 2089-2096; Munger, K.A., Montero, A., Fukunaga, M., Uda, S., Yura, T., Imai, E., Kaneda, Y., Badr, K.F., Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis (1999) Proc. Natl. Acad. Sci. USA, 96, pp. 13375-13380; Murphy, P.M., Ozcelik, T., Kenney, R.T., Tiffany, H.L., McDermott, D., Francke, U., A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family (1992) J. Biol. Chem., 267, pp. 7637-7643; Nascimento-Silva, V., Arruda, M.A., Barja-Fidalgo, C., Fierro, I.M., Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: A novel antioxidative mechanism (2007) Thromb. Haemost., 97, pp. 88-98; Nascimento-Silva, V., Arruda, M.A., Barja-Fidalgo, C., Villela, C.G., Fierro, I.M., Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells (2005) Am. J. Physiol. Cell Physiol., 289, pp. C557-563; Nathan, C., Ding, A., Nonresolving inflammation (2010) Cell, 140, pp. 871-882; Norling, L.V., Spite, M., Yang, R., Flower, R.J., Perretti, M., Serhan, C.N., Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing (2011) J. Immunol., 186, pp. 5543-5547; Norris, P.C., Gosselin, D., Reichart, D., Glass, C.K., Dennis, E.A., Phospholipase A2 regulates eicosanoid class switching during inflammasome activation (2014) Proc. Natl. Acad. Sci. USA, 111, pp. 12746-12751; O'Sullivan, T.P., Vallin, K.S., Shah, S.T., Fakhry, J., Maderna, P., Scannell, M., Sampaio, A.L., Guiry, P.J., Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities (2007) J. Med. Chem., 50, pp. 5894-5902; Ono, E., Dutile, S., Kazani, S., Wechsler, M.E., Yang, J., Hammock, B.D., Douda, D.N., Levy, B.D., Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma (2014) Am. J. Respir. Crit. Care Med., 190, pp. 886-897; Ortiz-Munoz, G., Mallavia, B., Bins, A., Headley, M., Krummel, M.F., Looney, M.R., Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice (2014) Blood, 124, pp. 2625-2634; Papayianni, A., Serhan, C.N., Brady, H.R., Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells (1996) J. Immunol., 156, pp. 2264-2272; Papayianni, A., Serhan, C.N., Phillips, M.L., Rennke, H.G., Brady, H.R., Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis (1995) Kidney Int., 47, pp. 1295-1302; Park, S.W., Lee, E.H., Lee, E.J., Kim, H.J., Bae, D.J., Han, S., Kim, D., Park, C.S., Apolipoprotein A1 potentiates lipoxin A4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium (2013) Clin. Exp. Allergy, 43, pp. 914-927; Paul-Clark, M.J., Van Cao, T., Moradi-Bidhendi, N., Cooper, D., Gilroy, D.W., 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation (2004) J. Exp. Med., 200, pp. 69-78; Perretti, M., Chiang, N., La, M., Fierro, I.M., Marullo, S., Getting, S.J., Solito, E., Serhan, C.N., Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor (2002) Nat. Med., 8, pp. 1296-1302; Peskar, B.M., Ehrlich, K., Schuligoi, R., Peskar, B.A., Role of lipoxygenases and lipoxin A(4)/annexin-1 receptor in gastric protection induced by 20% ethanol or sodium salicylate in rats (2009) Pharmacology, 84, pp. 310-313; Peskar, B.M., Ehrlich, K., Schuligoi, R., Peskar, B.A., Role of lipoxygenases and the lipoxin A(4)/annexin 1 receptor in ischemia-reperfusion-induced gastric mucosal damage in rats (2009) Pharmacology, 84, pp. 294-299; Petri, M.H., Laguna-Fernandez, A., Tseng, C.N., Hedin, U., Perretti, M., Back, M., Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation (2014) Int. J. Cardiol., 179, pp. 370-372; Pierdomenico, A.M., Recchiuti, A., Simiele, F., Codagnone, M., Mari, V.C., Davi, G., Romano, M., MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages (2015) J. Biol. Chem., 290, pp. 3592-3600; Planaguma, A., Kazani, S., Marigowda, G., Haworth, O., Mariani, T.J., Israel, E., Bleecker, E.R., Levy, B.D., Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma (2008) Am. J. Respir. Crit. Care Med., 178, pp. 574-582; Pouliot, M., Clish, C.B., Petasis, N.A., Van Dyke, T.E., Serhan, C.N., Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: A role for cyclooxygenase-2 and lipoxins in periodontal disease (2000) Biochemistry, 39, pp. 4761-4768; Prescott, D., McKay, D.M., Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production (2011) Am. J. Physiol. Gastrointest. Liver Physiol., 301, pp. G487-497; Ramon, S., Bancos, S., Serhan, C.N., Phipps, R.P., Lipoxin A modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism (2013) Eur. J. Immunol., 44, pp. 357-369; Ramstedt, U., Ng, J., Wigzell, H., Serhan, C.N., Samuelsson, B., Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: Effects on intracellular cAMP and target cell binding (1985) J. Immunol., 135, pp. 3434-3438; Ramstedt, U., Serhan, C.N., Nicolaou, K.C., Webber, S.E., Wigzell, H., Samuelsson, B., Lipoxin A-induced inhibition of human natural killer cell cytotoxicity: Studies on stereospecificity of inhibition and mode of action (1987) J. Immunol., 138, pp. 266-270; Reina-Couto, M., Carvalho, J., Valente, M.J., Vale, L., Afonso, J., Carvalho, F., Bettencourt, P., Albino-Teixeira, A., Impaired resolution of inflammation in human chronic heart failure (2014) Eur. J. Clin. Investig., 44, pp. 527-538; Renda, G., Zurro, M., Romano, M., De Caterina, R., Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. Nonselective COX-2 inhibitors (2010) Br. J. Clin. Pharmacol., 69, pp. 303-306; Ringholz, F.C., Buchanan, P.J., Clarke, D.T., Millar, R.G., McDermott, M., Linnane, B., Harvey, B.J., Urbach, V., Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis (2014) Eur. Respir. J., 44, pp. 394-404; Rodgers, K., McMahon, B., Mitchell, D., Sadlier, D., Godson, C., Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells (2005) Am. J. Pathol., 167, pp. 683-694; Romano, M., Lipid mediators: Lipoxin and aspirin-triggered 15-epi-lipoxins (2006) Inflamm. Allergy Drug Targets, 5, pp. 81-90; Romano, M., Chen, X.S., Takahashi, Y., Yamamoto, S., Funk, C.D., Serhan, C.N., Lipoxin synthase activity of human platelet 12-lipoxygenase (1993) Biochem. J., 296, pp. 127-133; Romano, M., Maddox, J.F., Serhan, C.N., Activation of human monocytes and the acute monocytic leukemia cell line (THP-1) by lipoxins involves unique signaling pathways for lipoxin A4 versus lipoxin B4: Evidence for differential Ca2+ mobilization (1996) J. Immunol., 157, pp. 2149-2154; Romano, M., Recchia, I., Recchiuti, A., Lipoxin receptors (2007) ScientificWorldJournal, 7, pp. 1393-1412; Romano, M., Serhan, C.N., Lipoxin generation by permeabilized human platelets (1992) Biochemistry, 31, pp. 8269-8277; Russell, R., Gori, I., Pellegrini, C., Kumar, R., Achtari, C., Canny, G.O., Lipoxin A4 is a novel estrogen receptor modulator (2011) FASEB J., 25, pp. 4326-4337; Sanak, M., Levy, B.D., Clish, C.B., Chiang, N., Gronert, K., Mastalerz, L., Serhan, C.N., Szczeklik, A., Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics (2000) Eur. Respir. J., 16, pp. 44-49; Scalia, R., Gefen, J., Petasis, N.A., Serhan, C.N., Lefer, A.M., Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: Role of P-selectin (1997) Proc. Natl. Acad. Sci. USA, 94, pp. 9967-9972; Schottelius, A.J., Giesen, C., Asadullah, K., Fierro, I.M., Colgan, S.P., Bauman, J., Guilford, W., Parkinson, J.F., An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile (2002) J. Immunol., 169, pp. 7063-7070; Schwab, J.M., Chiang, N., Arita, M., Serhan, C.N., Resolvin E1 and protectin D1 activate inflammation-resolution programmes (2007) Nature, 447, pp. 869-874; Serhan, C.N., A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: Missing links to resolution (2004) Histochem. Cell Biol., 122, pp. 305-321; Serhan, C.N., Chiang, N., Resolution phase lipid mediators of inflammation: Agonists of resolution (2013) Curr. Opin. Pharmacol., 13, pp. 632-640; Serhan, C.N., Chiang, N., Van Dyke, T.E., Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators (2008) Nat. Rev. Immunol., 8, pp. 349-361; Serhan, C.N., Clish, C.B., Brannon, J., Colgan, S.P., Chiang, N., Gronert, K., Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing (2000) J. Exp. Med., 192, pp. 1197-1204; Serhan, C.N., Hamberg, M., Samuelsson, B., Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes (1984) Proc. Natl. Acad. Sci. USA, 81, pp. 5335-5339; Serhan, C.N., Hamberg, M., Samuelsson, B., Trihydroxytetraenes: A novel series of compounds formed from arachidonic acid in human leukocytes (1984) Biochem. Biophys. Res. Commun., 118, pp. 943-949; Serhan, C.N., Hamberg, M., Samuelsson, B., Morris, J., Wishka, D.G., On the stereochemistry and biosynthesis of lipoxin B (1986) Proc. Natl. Acad. Sci. USA, 83, pp. 1983-1987; Serhan, C.N., Hirsch, U., Palmblad, J., Samuelsson, B., Formation of lipoxin A by granulocytes from eosinophilic donors (1987) FEBS Lett., 217, pp. 242-246; Serhan, C.N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S.P., Van Dyke, T.E., Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators (2003) J. Immunol., 171, pp. 6856-6865; Serhan, C.N., Maddox, J.F., Petasis, N.A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H.R., Colgan, S.P., Madara, J.L., Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils (1995) Biochemistry, 34, pp. 14609-14615; Serhan, C.N., Savill, J., Resolution of inflammation: The beginning programs the end (2005) Nat. Immunol., 6, pp. 1191-1197; Sheppard, K.A., Greenberg, S.M., Funk, C.D., Romano, M., Serhan, C.N., Lipoxin generation by human megakaryocyte-induced 12-lipoxygenase (1992) Biochim. Biophys. Acta, 1133, pp. 223-234; Shryock, N., McBerry, C., Salazar Gonzalez, R.M., Janes, S., Costa, F.T., Aliberti, J., Lipoxin A(4) and 15-epi-lipoxin A(4) protect against experimental cerebral malaria by inhibiting IL-12/IFN-gamma in the brain (2013) PLoS One, 8, p. e61882; Simiele, F., Recchiuti, A., Mattoscio, D., De Luca, A., Cianci, E., Franchi, S., Gatta, V., Romano, M., Transcriptional regulation of the human FPR2/ALX gene: Evidence of a heritable genetic variant that impairs promoter activity (2012) FASEB J., 26, pp. 1323-1333; Sodin-Semrl, S., Taddeo, B., Tseng, D., Varga, J., Fiore, S., Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases (2000) J. Immunol., 164, pp. 2660-2666; Souza, M.C., Padua, T.A., Torres, N.D., Souza Costa, M.F., Candea, A.P., Maramaldo, T., Seito, L.N., Henriques, M.G., Lipoxin A4 attenuates endothelial dysfunction during experimental cerebral malaria (2015) Int. Immunopharmacol., 24, pp. 400-407; Soyombo, O., Spur, B.W., Lee, T.H., Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-l-methionyl-l-leucyl-l-phenylalanine (1994) Allergy, 49, pp. 230-234; Sun, Y.P., Tjonahen, E., Keledjian, R., Zhu, M., Yang, R., Recchiuti, A., Pillai, P.S., Serhan, C.N., Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs (2009) Prostaglandins Leukot. Essent. Fatty Acids, 81, pp. 357-366; Svensson, C.I., Zattoni, M., Serhan, C.N., Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing (2007) J. Exp. Med., 204, pp. 245-252; Takano, T., Fiore, S., Maddox, J.F., Brady, H.R., Petasis, N.A., Serhan, C.N., Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors (1997) J. Exp. Med., 185, pp. 1693-1704; Titos, E., Chiang, N., Serhan, C.N., Romano, M., Gaya, J., Pueyo, G., Claria, J., Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4) (1999) Am. J. Physiol., 277, pp. C870-877; Tobin, D.M., Roca, F.J., Oh, S.F., McFarland, R., Vickery, T.W., Ray, J.P., Ko, D.C., Ramakrishnan, L., Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections (2012) Cell, 148, pp. 434-446; Ueda, T., Fukunaga, K., Seki, H., Miyata, J., Arita, M., Miyasho, T., Obata, T., Takeda, J., Combination therapy of 15-epi-lipoxin A4 with antibiotics protects mice from Escherichia coli-induced sepsis∗ (2014) Crit. Care Med., 42, pp. e288-295; Verriere, V., Higgins, G., Al-Alawi, M., Costello, R.W., McNally, P., Chiron, R., Harvey, B.J., Urbach, V., Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia (2012) PLoS One, 7, p. e37746; Vong, L., Ferraz, J.G., Dufton, N., Panaccione, R., Beck, P.L., Sherman, P.M., Perretti, M., Wallace, J.L., Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis (2012) PLoS One, 7, p. e39244; Waechter, V., Schmid, M., Herova, M., Weber, A., Gunther, V., Marti-Jaun, J., Wust, S., Hersberger, M., Characterization of the promoter and the transcriptional regulation of the lipoxin A4 receptor (FPR2/ALX) gene in human monocytes and macrophages (2012) J. Immunol., 188, pp. 1856-1867; Walker, J., Dichter, E., Lacorte, G., Kerner, D., Spur, B., Rodriguez, A., Yin, K., Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis (2011) Shock, 36, pp. 410-416; Wang, Q., Lian, Q.Q., Li, R., Ying, B.Y., He, Q., Chen, F., Zheng, X., Jin, S.W., Lipoxin A(4) activates alveolar epithelial sodium channel, Na,K-ATPase, and increases alveolar fluid clearance (2013) Am. J. Respir. Cell Mol. Biol., 48, pp. 610-618; Wang, Z.F., Li, Q., Liu, S.B., Mi, W.L., Hu, S., Zhao, J., Tian, Y., Wu, G.C., Aspirin-triggered Lipoxin A4 attenuates mechanical allodynia in association with inhibiting spinal JAK2/STAT3 signaling in neuropathic pain in rats (2014) Neuroscience, 273, pp. 65-78; Winkler, J.W., Uddin, J., Serhan, C.N., Petasis, N.A., Stereocontrolled total synthesis of the potent anti-inflammatory and pro-resolving lipid mediator resolvin D3 and its aspirin-triggered 17R-epimer (2013) Org. Lett., 15, pp. 1424-1427; Wu, H., Yang, J., Su, E.M., Li, L., Zhao, C., Yang, X., Gao, Z., Su, X., Lipoxin A4 and platelet activating factor are involved in E. Coli or LPS-induced lung inflammation in CFTR-deficient mice (2014) PLoS One, 9, p. e93003; Wu, J., Wang, A., Min, Z., Xiong, Y., Yan, Q., Zhang, J., Xu, J., Zhang, S., Lipoxin A4 inhibits the production of proinflammatory cytokines induced by beta-amyloid in vitro and in vivo (2011) Biochem. Biophys. Res. Commun., 408, pp. 382-387; Wu, L., Miao, S., Zou, L.B., Wu, P., Hao, H., Tang, K., Zeng, P., Ye, D.Y., Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury (2012) J. Mol. Neurosci., 48, pp. 185-200; Wu, R., Zhou, W., Chen, S., Shi, Y., Su, L., Zhu, M., Chen, Q., Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway (2014) Br. J. Pharmacol., 171, pp. 4927-4940; Wu, S.H., Liu, B., Dong, L., Wu, H.J., NF-kappaB is involved in inhibition of lipoxin A4 on dermal inflammation and hyperplasia induced by mezerein (2010) Exp. Dermatol., 19, pp. e286-288; Wu, S.H., Wu, X.H., Lu, C., Dong, L., Chen, Z.Q., Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor (2006) Am. J. Respir. Cell Mol. Biol., 34, pp. 65-72; Wu, S.H., Wu, X.H., Lu, C., Dong, L., Zhou, G.P., Chen, Z.Q., Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells (2006) Kidney Int., 69, pp. 248-256; Xiong, J., Zeng, P., Ye, D., Lipoxins: A novel regulator in embryo implantation (2011) ScientificWorldJournal, 11, pp. 235-241; Xu, Z., Zhao, F., Lin, F., Chen, J., Huang, Y., Lipoxin A4 inhibits the development of endometriosis in mice: The role of anti-inflammation and anti-angiogenesis (2012) Am. J. Reprod. Immunol., 67, pp. 491-497; Yamaguchi, H., Higashi, N., Mita, H., Ono, E., Komase, Y., Nakagawa, T., Miyazawa, T., Taniguchi, M., Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma (2011) Clin. Exp. Allergy, 41, pp. 1711-1718; Yang, F., Xie, J., Wang, W., Xie, Y., Sun, H., Jin, Y., Xu, D., Zhou, M., Regional arterial infusion with lipoxin A4 attenuates experimental severe acute pancreatitis (2014) PLoS One, 9, p. e108525; Yang, J., Eiserich, J.P., Cross, C.E., Morrissey, B.M., Hammock, B.D., Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients (2012) Free Radic. Biol. Med., 53, pp. 160-171; Ye, R.D., Boulay, F., Wang, J.M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C.N., Murphy, P.M., International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family (2009) Pharmacol. Rev., 61, pp. 119-161; Zhang, B., Jia, H., Liu, J., Yang, Z., Jiang, T., Tang, K., Li, D., Huang, B., Depletion of regulatory T cells facilitates growth of established tumors: A mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4 (2010) J. Immunol., 185, pp. 7199-7206; Zhang, L., Zhang, X., Wu, P., Li, H., Jin, S., Zhou, X., Li, Y., Wan, J., BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis (2008) Inflamm. Res., 57, pp. 157-162; Zhou, H.Y., Hao, J.L., Bi, M.M., Wang, S., Zhang, H., Zhang, W.S., Molecular mechanism of the inhibition effect of Lipoxin A4 on corneal dissolving pathology process (2013) Int. J. Ophthalmol., 6, pp. 39-43; Zhou, M., Chen, B., Sun, H., Deng, Z., Andersson, R., Zhang, Q., The protective effects of Lipoxin A4 during the early phase of severe acute pancreatitis in rats (2011) Scand. J. Gastroenterol., 46, pp. 211-219; Zhou, X.L., Yang, Q.S., Ni, S.Z., Tu, X.P., Zhao, Y., Xu, B., Pan, Z.Q., Shen, J., Protective effects of lipoxin A4 in testis injury following testicular torsion and detorsion in rats (2014) Mediat. Inflamm., 2014, p. 898056",Review,Scopus,2-s2.0-84928580559
"Sarigiannis D.A., Karakitsios S.P., Kermenidou M.V.","Health impact and monetary cost of exposure to particulate matter emitted from biomass burning in large cities",2015,"Science of the Total Environment","524-525",,,"319","330",,,10.1016/j.scitotenv.2015.02.108,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928150284&partnerID=40&md5=759d3a00de61092c516d50f1bd45c699","Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering LaboratoryThessaloniki, Greece; Centre for Research and Technology Hellas (CE.R.T.H.)Thessaloniki, Greece","Sarigiannis, D.A., Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering LaboratoryThessaloniki, Greece, Centre for Research and Technology Hellas (CE.R.T.H.)Thessaloniki, Greece; Karakitsios, S.P., Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering LaboratoryThessaloniki, Greece, Centre for Research and Technology Hellas (CE.R.T.H.)Thessaloniki, Greece; Kermenidou, M.V., Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering LaboratoryThessaloniki, Greece","The study deals with the assessment of health impact and the respective economic cost attributed to particulate matter (PM) emitted into the atmosphere from biomass burning for space heating, focusing on the differences between the warm and cold seasons in 2011-2012 and 2012-2013 in Thessaloniki (Greece). Health impact was assessed based on estimated exposure levels and the use of established WHO concentration-response functions (CRFs) for all-cause mortality, infant mortality, new chronic bronchitis cases, respiratory and cardiac hospital admissions. Monetary cost was based on the valuation of the willingness-to-pay/accept (WTP/WTA), to avoid or compensate for the loss of welfare associated with illness.Results showed that long term mortality during the 2012-2013 winter increased by 200 excess deaths in a city of almost 900,000 inhabitants or 3540. years of life lost, corresponding to an economic cost of almost 200-250m€. New chronic bronchitis cases dominate morbidity estimates (490 additional new cases corresponding to a monetary cost of 30m€). Estimated health and monetary impacts are more severe during the cold season, despite its smaller duration (4. months). Considering that the increased ambient air concentrations (and the integral of outdoor/indoor exposure) are explained by shifting from oil to biomass for domestic heating purposes, several alternative scenarios were evaluated. Policy scenario analysis revealed that significant public health and monetary benefits (up to 2b€ in avoided mortality and 130m€ in avoided illness) might be obtained by limiting the biomass share in the domestic heat energy mix. Fiscal policy affecting fuels/technologies used for domestic heating needs to be reconsidered urgently, since the net tax loss from avoided oil taxation due to reduced consumption was further compounded by the public health cost of increased mid-term morbidity and mortality. © 2015 Elsevier B.V.","Biomass burning; Health impact; Monetary valuation; Morbidity; Mortality","Adler, N.E., Newman, K., Socioeconomic Disparities In Health: Pathways And Policies (2002) Health Aff., 21, pp. 60-76; Alberini, A., Hunt, A., Markandya, A., Willingness to pay to reduce mortality risks: Evidence from a three-country contingent valuation study (2006) Environ. Resour. Econ., 33, pp. 251-264; (2004) Health impact assessment of air pollution and communication: Third Year Report, 2002-2003 (Apheis-3), , http://www.apheis.org/ApheisNewCityReports1.PDF/index.html; Arcus-Arth Broadwin, R., Lam, R., Impacts of socioeconomic factors on residential indoor air quality and human health (2001) Environ. Toxicol. Hum. Health, 2; Barregard, L., Sällsten, G., Gustafson, P., Andersson, L., Johansson, L., Basu, S., Stigendal, L., Experimental exposure to woodsmoke particles in healthy humans: effects on markers of inflammation, coagulation, and lipid peroxidation (2006) Inhal. Toxicol., 18, pp. 845-853; Behera, D., Balamugesh, T., Indoor air pollution as a risk factor for lung cancer in women (2005) J. Assoc. Physicians India, 53, pp. 190-192; Berkowicz, R., Ketzel, M., Jensen, S.S., Hvidberg, M., Raaschou-Nielsen, O., Evaluation and application of OSPM for traffic pollution assessment for a large number of street locations (2008) Environ. Model. Softw., 23, pp. 296-303; Boman, B.C., Forsberg, A.B., Järvholm, B.G., Adverse health effects from ambient air pollution in relation to residential wood combustion in modern society (2003) Scand. J. Work Environ. Health, 29, pp. 251-260; Boman, C., Forsberg, B., Sandström, T., Shedding new light on wood smoke: a risk factor for respiratory health (2006) Eur. Respir. J., 27, pp. 446-447; Brook, R.D., Cardiovascular effects of air pollution (2008) Clin. Sci., 115, pp. 175-187; Daigler, G.E., Markello, S.J., Cummings, K.M., The effect of indoor air pollutants on otitis media and asthma in children (1991) Laryngoscope, 101, pp. 293-296; Desaigues, B., Ami, D., Bartczak, A., Braun-Kohlová, M., Chilton, S., Czajkowski, M., Farreras, V., Urban, J., Economic valuation of air pollution mortality: a 9-country contingent valuation survey of value of a life year (VOLY) (2011) Ecol. Indic., 11, pp. 902-910; Diette, G.B., Accinelli, R.A., Balmes, J.R., Buist, A.S., Checkley, W., Garbe, P., Hansel, N.N., Kiley, J.P., Obstructive lung disease and exposure to burning biomass fuel in the indoor environment (2012) Glob. Health, 7, pp. 265-270; Population data, , http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home, (Accessed on:); Forastiere, F., Stafoggia, M., Tasco, C., Picciotto, S., Agabiti, N., Cesaroni, G., Perucci, C.A., Socioeconomic status, particulate air pollution, and daily mortality: differential exposure or differential susceptibility (2007) Am. J. Ind. Med., 50, pp. 208-216; Guillén, M.D., Ibargoitia, M.L., (1999) J. Agric. Food Chem., 47, pp. 4126-4136; Haluza, D., Kaiser, A., Moshammer, H., Flandorfer, C., Kundi, M., Neuberger, M., Estimated health impact of a shift from light fuel to residential wood-burning in Upper Austria (2012) J. Expo. Sci. Environ. Epidemiol., 22, pp. 339-343; Hänninen, O.O., Lebret, E., Ilacqua, V., Katsouyanni, K., Künzli, N., Srám, R.J., Jantunen, M., Infiltration of ambient PM2.5 and levels of indoor generated non-ETS PM2.5 in residences of four European cities (2004) Atmos. Environ., 38, pp. 6411-6423; Happo, M.S., Uski, O., Jalava, P.I., Kelz, J., Brunner, T., Hakulinen, P., Mäki-Paakkanen, J., Hirvonen, M.R., Pulmonary inflammation and tissue damage in the mouse lung after exposure to PM samples from biomass heating appliances of old and modern technologies (2013) Sci. Total Environ., 443, pp. 256-266; Hays, M.D., Geron, C.D., Linna, K.J., Smith, N.D., Schauer, J.J., Speciation of gas-phase and fine particle emissions from burning of foliar fuels (2002) Environ. Sci. Technol., 36, pp. 2281-2295; Hernández-Garduño, E., Brauer, M., Pérez-Neria, J., Vedal, S., (2004) Int. J. Tuberc. Lung Dis., 8, pp. 377-383; Hoek, G., Pattenden, S., Willers, S., Antova, T., Fabianova, E., Braun-Fahrlander, C., Forastiere, F., Fletcher, T., PM10, and children's respiratory symptoms and lung function in the PATY study (2012) Eur. Respir. J., 40, pp. 538-547; Hoek, G., Krishnan, R., Beelen, R., Peters, A., Ostro, B., Brunekreef, B., Kaufman, J., Long-term air pollution exposure and cardio-respiratory mortality: a review (2013) Environ. Heal., 12, p. 43; Holland, M., Hunt, A., Hurley, F., Watkiss, P., Methodology for carrying out the cost-benefit analysis for CAFE. Consultation-Issue 3-July 2004 (2004) Report to DG Environment of the European Commission, , http://europa.eu.int/comm/environment/air/cafe/activities/cba.htm, AEA Technology Environment, UK; Honicky, R.E., Osborne Iii, J.S., Akpom, C.A., Symptoms of respiratory illness in young children and the use of wood-burning stoves for indoor heating (1985) Pediatrics, 75, pp. 587-593; Hurley, F., Hunt, A., Cowie, H., Holland, M., Miller, B., Pye, S., Watkiss, P., (2005) Methodology for the cost-benefit analysis for CAFE: volume 2: health impact assessment, , IOM, Edinburg, IOM (Ed.); (2012) World Economic Outlook, , http://www.imf.org/external/pubs/ft/weo/2012/01/pdf/text.pdf, World Economic and Financial Surveys, Washington, DC, U.S.A; (2013) Equating the Excise Duty Rates on Heating and Diesel Oil, , http://www.iobe.gr/docs/research/RES_04_10092013PRE_GR.pdf, Foundation for economic and industrial research; (2011) Final Report on Risk Functions Used in the Case Studies, , http://www.heimtsa.eu/Results/Deliverables/tabid/2937/Default.asp, IOM, Edinburg, IOM (Ed.); Johnston, F.H., Hanigan, I.C., Henderson, S.B., Morgan, G.G., Evaluation of interventions to reduce air pollution from biomass smoke on mortality in Launceston, Australia: retrospective analysis of daily mortality, 1994-2007 (2013) BMJ, 346; Khalil, M.A.K., Rasmussen, R.A., Tracers of wood smoke (2003) Atmos. Environ., 37, pp. 1211-1222; Koenig, J.Q., Larson, T.V., Hanley, Q.S., Rebolledo, V., Dumler, K., Checkoway, H., Wang, S.Z., Pierson, W.E., Pulmonary function changes in children associated with fine particulate matter (1993) Environ. Res., 63, pp. 26-38; Koenig, J.Q., Mar, T.F., Allen, R.W., Jansen, K., Lumley, T., Sullivan, J.H., Trenga, C.A., Liu, L.J.S., Pulmonary effects of indoor- and outdoor-generated particles in children with asthma (2005) Environ. Health Perspect., 113, pp. 499-503; Krupnick, A.J., Cropper, M.L., The effect of information on health risk valuations (1992) J. Risk Uncertain., 5, pp. 29-48; Le Tertre, A., Medina, S., Samoli, E., Forsberg, B., Michelozzi, P., Boumghar, A., Vonk, J.M., Katsouyanni, K., Short-term effects of particulate air pollution on cardiovascular diseases in eight European cities (2002) J. Epidemiol. Community Health, 56, pp. 773-779; Leaderer, B.P., Naeher, L., Jankun, T., Balenger, K., Holford, T.R., Toth, C., Sullivan, J., Koutrakis, P., Indoor, outdoor, and regional summer and winter concentrations of PM10, PM2.5, SO4(2-), H+, NH4+, NO3-, NH3, and nitrous acid in homes with and without kerosene space heaters (1999) Environ. Health Perspect., 107, pp. 223-231; Lee, K., Yanagisawa, Y., Spengler, J.D., Billick, I.H., Classification of house characteristics based on indoor nitrogen dioxide concentrations (1995) Environ. Int., 21, pp. 277-282; Naeher, L.P., Brauer, M., Lipsett, M., Zelikoff, J.T., Simpson, C.D., Koenig, J.Q., Smith, K.R., Woodsmoke health effects: a review (2007) Inhal. Toxicol., 19, pp. 67-106; Navrud, S., Valuing health impacts from air pollution in Europe (2001) Environ. Resour. Econ., 20, pp. 305-329; Neidell, M.J., Air pollution, health, and socio-economic status: the effect of outdoor air quality on childhood asthma (2004) J. Health Econ., 23, pp. 1209-1236; Noonan, C.W., Balmes, J.R., Biomass smoke exposures: health outcomes measures and study design (2010) Inhal. Toxicol., 22, pp. 108-112; Norris, G., YoungPong, S.N., Koenig, J.Q., Larson, T.V., Sheppard, L., Stout, J.W., An association between fine particles and asthma emergency department visits for children in Seattle (1999) Environ. Health Perspect., 107, pp. 489-493; Nussbaumer, T., Czasch, C., Klippel, N., Johansson, L., Tullin, T., (2008) Particulate Emissions from Biomass Combustion in IEA Countries, , www.verenum.ch, Swiss Federal Office of Energy (SFOE), Zürich, Switzerland, International Energy Agency (IEA) Bioenergy SFOoES (Ed.); (2011) Oracle Crystal Ball Fusion Edition, version 11.0; Ortiz, R.A., Hunt, A., da Motta, R.S., MacKnight, V., Morbidity costs associated with ambient air pollution exposure in Sao Paulo, Brazil (2011) Atmos. Pollut. Res., 2, pp. 520-529; Ostro, B.D., Lipsett, M.J., Wiener, M.B., Selner, J.C., Asthmatic responses to airborne acid aerosols (1991) Am. J. Public Health, 81, pp. 694-702; Ott, W.R., Concepts of human exposure to air pollution (1982) Environ. Int., 7, pp. 179-196; Özkaynak, H., Xue, J., Weker, R., Butler, D., Koutrakis, P., Spengler, J., The particle TEAM (PTEAM) study: analysis of the data (1996) Technical report, 3. , U.S. Environmental Protection Agency, Research Triangle Park, NC; (2000) Guide to Your Child's Allergies and Asthma, , Villard Books, New York, Villard Books (Ed.); Pope, C.A., Burnett, R.T., Thun, M.J., Calle, E.E., Krewski, D., Ito, K., Thurston, G.D., Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution (2002) J. Am. Med. Assoc., 287, pp. 1132-1141; Roman, H.A., Hammitt, J.K., Walsh, T.L., Stieb, D.M., Expert elicitation of the value per statistical life in an air pollution context (2012) Risk Anal., 32, pp. 2133-2151; Sarigiannis, D.A., Soulakellis, N., Schäfer, K., Tombrou, M., Sifakis, N.I., Assimakopoulos, D., Lointier, M., Saisana, M., ICAROS: an integrated computational environment for the assimilation of environmental data and models for urban and regional air quality (2002) Water Air Soil Pollut. Focus, 2, pp. 641-654; Sarigiannis, D.A., Soulakellis, N.A., Sifakis, N.I., Information fusion for computational assessment of air quality and health effects (2004) Photogramm. Eng. Remote. Sens., 70, pp. 235-245; Sarigiannis, D., Gotti, A., Karakitsios, S., Kontoroupis, P., Nikolaki, S., Intera platform: a tool for mechanistic risk assessment of indoor air pollutants (2012) Epidemiology, 23; Sarigiannis, D.A., Karakitsios, S.P., Kermenidou, M., Nikolaki, S., Zikopoulos, D., Semelidis, S., Papagiannakis, A., Tzimou, R., Total exposure to airborne particulate matter in cities: the effect of biomass combustion (2014) Sci. Total Environ., 493, pp. 795-805; Sarigiannis, D.A., Karakitsios, S.P., Zikopoulos, D., Nikolaki, S., Kermenidou, M., Lung cancer risk from PAHs emitted from biomass combustion (2015) Environ. Res., 137, pp. 147-156; Schikowski, T., Mills, I.C., Anderson, H.R., Cohen, A., Hansell, A., Kauffmann, F., Kramer, U., Kunzli, N., Ambient air pollution: a cause of COPD? (2014) Eur. Respir. J., 43, pp. 250-263; Schindler, C., Keidel, D., Gerbase, M.W., Zemp, E., Bettschart, R., Brandli, O., Brutsche, M.H., The SAPALDIA, Team, Improvements in PM10 exposure and reduced rates of respiratory symptoms in a cohort of Swiss adults (SAPALDIA) (2009) Am. J. Respir. Crit. Care Med., 179, pp. 579-587; Scire, J., Robe, F.R., Fernau, M.E., Yamartino, R.J., (2000) A User's Guide for the CALMET Meteorological Model (Version 5), , Earth Tech Inc., Concord; Scire, J., Strimaitis, D.G., Yamartino, R.J., (2000) A User's Guide for the CALPUFF Dispersion Model (Version 5), , Earth Tech Inc., Concord; Sheppard, L., Levy, D., Norris, G., Larson, T.V., Koenig, J.Q., Effects of ambient air pollution on nonelderly asthma hospital admissions in Seattle, Washington, 1987-1994 (1999) Epidemiology, 10, pp. 23-30; (2011) Monetary Values for Health End-points Used in the HEIMTSA/INTARESE Common Case Study, , http://www.heimtsa.eu/Results/Deliverables/tabid/2937/language/en-GB/Default.aspx, UBath, Bath, UK, UBath (Ed.); (2006) Bulletin of Housing Statistics for Europe and North America, , http://www.unece.org/hlm/prgm/hsstat/Bulletin_06.htm; (2004) Joint Task Force on the Health Aspects of Air Pollution - Modelling and Assessment of the Health Impact of Particulate Matter and Ozone, Geneva; Watkiss, P., Hunt, A., Projection of economic impacts of climate change in sectors of Europe based on bottom up analysis: human health (2012) Clim. Chang., 112, pp. 101-126; (2004) Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors, Geneva; Health aspects of air pollution - answers to follow-up questions from CAFE (2004) Report on a WHO Working Group Meeting, Bonn, Germany; (2004) Meta-analysis of Time-series Studies and Panel Studies of Particulate Matter (PM) and Ozone (O3), Copenhagen, Denmark; Outdoor air pollution - assessing the environmental burden of disease at national and local levels (2004) Environmental Burden of Disease Series, No. 5, Geneva; Particulate matter air pollution: how it harms health (2005) Fact Sheet EURO/04/05, , WΗΟ, Berlin, Copenhagen, Rome; (2006) Health Risks of Particulate Matter From Long-range Transboundary Air Pollution, Copenhagen, Denmark; Health Relevance of Particulate Matter From Various Sources (2007) Report on a WHO workshop Bonn, Germany 26-27 March 2007, , WHO (Ed.); (2008) The Global Burden of Disease, , (Geneva), WHO (Ed.); Health risks of air pollution in Europe - HRAPIE project (2013) Recommendations for Concentration-Response Functions for Cost-Benefit Analysis of Particulate Matter, Ozone and Nitrogen Dioxide, , WHO Regional Office for Europe, Copenhagen, Denmark; Global Health Observatory, , http://apps.who.int/gho/data/node.main.692?lang=en, (Accessed on:); WHO methods for life expectancy and healthy life expectancy (2014) Global Health Estimates Technical Paper WHO/HIS/HSI/GHE/2014.5, Geneva, Switzerland, , http://www.who.int/healthinfo/statistics/LT_method.pdf, Systems DoHSaI (Ed.); Woodruff, T.J., Grillo, J., Schoendorf, K.C., The relationship between selected causes of postneonatal infant mortality and particulate air pollution in the United States (1997) Environ. Health Perspect., 105, pp. 608-612; Yu, O., Sheppard, L., Lumley, T., Koenig, J.Q., Shapiro, G.G., Effects of ambient air pollution on symptoms of asthma in Seattle-area children enrolled in the CAMP study (2000) Environ. Health Perspect., 108, pp. 1209-1214",Article,Scopus,2-s2.0-84928150284
"Kumar P., Kim K.-H., Deep A.","Recent advancements in sensing techniques based on functional materials for organophosphate pesticides",2015,"Biosensors and Bioelectronics","70",,,"469","481",,,10.1016/j.bios.2015.03.066,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926436285&partnerID=40&md5=e9395a4725f1031261273042aaf681c3","Department of Civil and Environmental Engineering, Hanyang University, 222 Wangsimni-RoSeoul, South Korea; Academy of Scientific and Innovative Research, CSIR-CSIO, Sector 30CChandigarh, India","Kumar, P., Department of Civil and Environmental Engineering, Hanyang University, 222 Wangsimni-RoSeoul, South Korea; Kim, K.-H., Department of Civil and Environmental Engineering, Hanyang University, 222 Wangsimni-RoSeoul, South Korea; Deep, A., Academy of Scientific and Innovative Research, CSIR-CSIO, Sector 30CChandigarh, India","The use of organophosphate pesticides (OPs) for pest control in agriculture has caused serious environmental problems throughout the world. OPs are highly toxic with the potential to cause neurological disorders in humans. As the application of OPs has greatly increased in various agriculture activities, it has become imperative to accurately monitor their concentration levels for the protection of ecological systems and food supplies. Although there are many conventional methods available for the detection of OPs, the development of portable sensors is necessary to facilitate routine analysis with more convenience. Some of these potent alternative techniques based on functional materials include fluorescence nanomaterials based sensors, molecular imprinted (MIP) sensors, electrochemical sensors, and biosensors. This review explores the basic features of these sensing approaches through evaluation of their performance. The discussion is extended further to describe the challenges and opportunities for these unique sensing techniques. © 2015 Elsevier B.V.","Health issues; Monitoring techniques; Organophosphate; Pesticides; Sensing","Aktar, M.W., Sengupta, D., Chowdhury, A., (2009) Interdiscip. Toxicol., 2 (1), pp. 1-12; Alexander, C., Andersson, H.K.S., Andersson, L.I., Ansell, R.J., Kirsch, N., Nicholls, I.A., O'Mahony, W.M.J., (2006) J. Mol. Recognit., 19 (2), p. 106; Amaya-Chavez, A., Martanez-Tabche, L., Lopez-Lopez, E., (2006) Chemosphere, 63 (7), p. 1124; Bassi, A.S., Flickinger, M.C., (2009) ""Biosensors, Environmental,"" Encyclopedia of Industrial Biotechnology, , John Wiley & Sons, Inc; Barreto, A.S., Silva, R.L.D., Silva, S.C., (2010) J. Sep. Sci., 33 (23-24), pp. 3811-3816; Baker, P.A., Goltz, M.N., Schrand, A.M., Yoon do, Y., Kim, D.S., (2014) Biosens. Bioelectron., 61 (2014), pp. 119-123; Brun, E.M., Garces-Garcia, M., Puchades, R., Maquieira, A., (2005) J. Agric. Food Chem., 53, pp. 9352-9360; Boro, R.C., Kaushal, J., Nangia, Y., Wangoo, N., Bhasin, A., Suri, C.R., (2011) Analyst, 136, pp. 2125-2130; Burn Worth, M., Rowan, S.J., Weder, C., (2007) Chemistry, 13 (28), pp. 7828-7836; Cao, X., Mello, S.V., Leblanc, R.M., Rastogi, V.K., Cheng, T.C., DeFrank, J.J., (2004) Colloids Surf. A, 250, pp. 349-356; Campanella, L., Achilli, M., Sammartino, P.M., Tomassetti, M., (1991) Bioelectrochem. Bioenerg., 26, pp. 237-249; Choong, C.L., Bendall, J.S., Milne, W.I., (2009) Biosens. Bioelectron., 25 (3), pp. 652-656; Cho, Y.A., Lee, V., Park, E.Y., Lee, Y.T., Bruce, D.H., Chang, A.K., Jae, K.L., (2002) Bull. Korean Chem. Soc., 23, pp. 481-487; Costa, L.G., (2006) Clin. Chim. Acta, 366 (1-2), pp. 1-13; Chauhan, N., Pundir, C.S., (2011) Anal. Chim. Acta, 701, p. 66; Defrank, J.J., Cheng, T.C., (1991) J. Bacteriol., pp. 1938-1943; Dale, T.J., Rebek, J., (2006) J. Am. Chem. Soc., 128 (14), pp. 4500-4501; De Marcos, S., Callizo, E., Mateos, E., Galban, J., (2014) Talanta, 122, pp. 251-256; Delattre, F., Cazier, F., Cazier, F., Tine, A., (2009) Curr. Anal. Chem., 5, pp. 48-52; Deep, A., Bhardwaj, S.K., Paul, A.K., Kim, K.H., Kumar, P., (2015) Biosens. Bioelectron., 65, pp. 226-231; Deo, R.P., Wang, J., Block, I., Mulchandanic, A., Joshi, K.A., Trojanowicz, M., Scholz, F., Lin, Y., (2005) Anal. Chim. Acta, 530 (2), pp. 185-189; Diaz-Diaz, G., Blanco-Lopez, M.C., Lopo-Orddieres, M.J., Tunon-Blanco, P., (2009) Electroanalysis, pp. 1348-1353; Du, D., Chen, S., Song, D., Li, H., Chen, X., (2008) Biosens. Bioelectron., 24, pp. 475-479; Dhull, V., Dilbaghi, N., Hooda, V., (2014) Int. J. Pharm. Pharm. Sci.; Eddleston, M., Buckley, N.A., Eyer, P., Dawson, A.H., (2008) Lancet, 37, pp. 597-607; Fukuto, T.R., (1990) Environ. Health Perspect., 87, pp. 245-254; Fukuto, T.R., (1990) Environ. Health Perspect., 87, p. 245; Ge, X., Asiri, A.M., Du, D., Wen, W., Wang, S., Lin, Y., (2014) Trac-Trend Anal. Chem., 58, p. 31; Gong, J., Miao, X., Zhou, T., Zhou, T., Zhang, L., (2011) Talanta, 85 (3), pp. 1344-1349; Gong, J., Miao, X., Wan, H., Song, D., (2014) Sens. Actuat B-Chem., 162 (1), pp. 341-347; Goel, P., (2013) Afr. J. Biotechnol. Special Rev. Issue, 12 (52), pp. 7158-7167; Grieshaber, D., MacKenzie, R., Varas, J., Reimhult, E., (2008) Sensors, 8 (3), p. 1400; Hayes, W.J., Laws, E.R., (1991) Handbook of Pesticide Toxicology, , Academic Press, Inc, San Diego; Hoskin, G.C.F., Rajan, S.K., David, R., Walker, E.J., (1993) Chem. Biol. Interact., 87 (1-3), pp. 109-116; Huo, D., Li, Q., Zhang, Y., Hou, C., Le, Y., (2014) Sens. Actuat B-Chem., 199 (2014), pp. 410-417; Hu, S.Q., Xie, J.W., Xu, Q.H., Rong, K.T., Shen, G.L., Yu, R.Q., (2003) Talanta, 61 (6), pp. 769-777; Jurewicz, J., Hanke, W., (2008) Int. J. Occup. Med. Environ. Health, 21 (2), p. 121; Jin, M., Shao, H., Jin, F., Gui, W., Shi, X., Wang, J., Zhu, G., (2012) J. Food Sci., 77, pp. T99-T104; Ji, X., Zheng, J., Xu, J., Xu, J., Rastogi, V.K., Cheng, T.C., DeFrank, J.J., Leblanc, R.M., (2005) J. Phys. Chem. B, 109 (9), pp. 3793-3799; Kaur, J., Singh, V.K., Boro, R., Thampi, R.K., Raje, M., Varshney, G.C., Suri, C.R., (2007) Environ. Sci. Technol., 41, pp. 5028-5036; Kazemi, M., Tahmasbi, A.M., Valizadeh, R., (2012) Agric. Sci. Res. J., 2, pp. 512-522; Kojima, H., Takeuchi, S., Nagai, T., (2010) J. Health Sci., 56 (4), pp. 374-386; Knapton, D., Burnworth, M., Rowan, S.J., (2006) Angew. Chem. Int. Edit. 2006, 45 (35), pp. 5825-5829; Kumar, P., Deep, A., Kim, H.K., Brown, C.J.R., (2015) Prog. Poly. Sci; Kumar, P., Bansal, V., Deep, A., Kim, H.K., (2015) J. Por. Mater.; Kumar, P., Paul, A.K., Deep, A., (2014) Anal. Methods, 6, p. 1094095; Kumar, P., Paul, A.K., Deep, A., (2014) Micropor. Mesopor. Mater., 195, pp. 60-66; Kumar, P., Kumar, P., Deep, A., Bharadwaj, L.M., (2012) Adv. Mat., 488, pp. 1543-1546; Kumar, M.A., Chouhan, R.S., Thakur, M.S., Amita Rani, B.E., Karanth, N.G., (2006) Anal. Chim. Acta, 560 (1-2), pp. 30-34; Kolosova, A.Y., Park, J.H., Eremin, S.A., Kang, S.J., Chung, D., (2003) J. Agric. Food Chem., 51, pp. 1107-1114; Kong, Y., Zhang, Q., Zhang, W., Gee, S.J., Li, P., (2010) J. Agric. Food Chem., 58, pp. 8189-8195; Kwong, T.C., (2002) Ther. Drug Monit., 24 (1), pp. 144-149; Liang, H., Song, D., Gong, J., (2014) Biosens. Bioelectron., 53, pp. 363-369; Li, Y., Bai, Y., Han, G., Li, M., (2013) Sens. Actuat B-Chem., 185, pp. 706-712; Lisa, M., Chouhan, R.S., Vinayaka, A.C., Manonmani, H.K., Thakur, M.S., (2009) Biosens. Bioelectron., 25, pp. 224-227; Liu, G., Song, D., Chen, F., (2013) Talanta, 104, pp. 103-108; Liu, G., Lin, Y., (2006) Anal. Chem., 78, pp. 835-843; Liu, S., Yuan, L., Yue, X., Zheng, Z., Tang, Z., (2008) Adv. Powder Technol., 19, pp. 419-441; Liu, Y., Wang, C., Gui, W., Bi, J., Jin, M., Zhu, G., (2009) Ecotoxicol. Environ. Saf, 72, pp. 1673-1679; Liu, G., Lin, Y., (2005) Anal. Chem., 77, pp. 5894-5901; Ma, L.Y., Wang, H.Y., Xie, H., Xu, L.X., (2004) Spectrochim. Acta A Mol. Biomol. Spectrosc., 60, p. 1865; Mulchandani, A., Chen, W., Mulchandani, P., Wang, J., Rogers, K.R., (2001) Biosens. Bioelectron., 16 (4-5), pp. 225-230; Mulbry, W.W., Karns, S.J., Kearney, C.P., Nelson, O.J., Mcdaniel, S.C., Wild, R.J., (1986) Appl. Environ. Microbiol., 51, pp. 926-930; Obare, S.O., De, C., Guo, W., Haywood, T.L., Samuels, T.A., Adams, C.P., Masika, N.O., Jaffrezic-Renault, N., (2010) Sensors, 1 (2), pp. 60-74; Palchetti, I., Laschi, S., Mascini, M., (2009) Biosensors and Biodetection, 504, p. 115. , Humana Press; Philip, J.Y.N., Mosha, D.M.S., (2012) Tanzan. J. Sci., 38 (3), pp. 72-83; Roger, K.R., Cao, C.J., Valdes, J.J., Eldedri, M.E., (1991) Appl. Toxcol., 16, pp. 810-820; Sassolas, A., Simon, B.P., Marty, J.L., (2012) Am. J. Anal. Chem., 3, pp. 210-232; Simonian, A.L., Grimsley, J.K., Flounders, A.W., Schoeniger, J.S., Cheng, T.C., DeFrank, J.J., Wild, J.R., (2001) Analytica Chimica Acta, 442 (1), pp. 15-23; Sullivan, J.J., Chen, Y.G., Goh, K.S., (2007) J. Agric. Food Chem, 55 (16), pp. 6407-6416; Salmain, M., Fischer-Durand, N., Pradier, C.M., (2008) Anal. Biochem., 373 (2008), pp. 61-70; Shim, J.Y., Kim, Y.A., Lee, Y.T., Hammock, B.D., Lee, H.S., (2010) J. Agric. Food Chem., 58, pp. 5241-5247; Soltaninejad, K., Abdollahi, M., (2009) Med. Sci. Monit., 15 (3), p. RA75; Smith, A.G., Gangolli, S.D., (2002) Food Chem. Toxicol, 40 (6), pp. 767-779; Tang, S.J., Zhang, M., Cheng, C.G., Lu, Y.T., (2008) J. Immuno. Immunochem., 29, pp. 356-369; Tang, B., Zhang, J.E., Zang, L.G., Zhang, Y.Z., Li, X.Y., Zhou, L., (2005) J. Chromatogr. Sci., 43 (7), pp. 337-341; Tahara, M., Kubota, R., Nakazawa, H., (2005) Water Res., 39 (20), pp. 5112-5118; Thakur, S., Venkateswar Reddy, M., Siddavattam, D., Paul, A.K., (2012) Sens. Actuat B-Chem., 163 (1), pp. 153-158; Thakur, S., Kumar, P., Venkateswar Reddy, M., Siddavattamc, D., Paul, A.K., (2013) Sens. Actuat B-Chem., 178, pp. 458-464; Trojanowicz, M., (2014) Electrochem. Commun., 38, pp. 47-52; http://www.epa.gov/opp00001/factsheets/opworkers.htm, (OPs) (accessed on December 30, 2014a)http://www.epa.gov/%20opp00001/cumulative/rra-op/pr.htm, (accessed on December 30, 2014b)Vasapollo, G., Sole, R.D., Mergola, L., Lazzoi, M.R., Scardino, A., Scorrano, S., Mele, G., (2011) Int. J. Mol. Sci., 12 (9), p. 5908; Van Houten, K.A., Heath, D.C., Pilato, R.S., (1998) J. Am. Chem. Soc., 120, pp. 12359-12360; Vadgama, P., Crump, P.W., (1992) Analyst, 117 (11), pp. 1657-1670; Wang, R., Wang, Z., Yang, H., Wang, Y., (2012) J. Sci. Food Agric., 92, pp. 1253-1260; Wang, J., Timchalk, C., Lin, Y., (2008) Environ. Sci. Technol., 42 (7), pp. 2688-2693; Wang, Y., Zhang, S., Du, D., Shao, Y., Li, Z., Wang, J., Engelhard, M.H., Lin, Y., (2011) J. Mater. Chem., 21, pp. 5319-5325; Wang, J., Timchalk, C., Lin, Y., (2008) Environ. Sci. Technol, 42, pp. 2688-2693; Wang, X., Lu, X., Chen, J., (2014) Trac-Trend Anal. Chem., 2, pp. 25-32; Watanabe, H., Satake, A., Kido, Y., Tsuji, A., (2002) Analyst, 127 (1), pp. 98-103; Wen, L.L., Wang, F., Leng, X.K., Wang, C.G., Wang, L.Y., Gong, J.M., Li, D.F., (2010) Cryst. Growth Des., 10 (7), p. 2835; Wen, L.L., Wang, F., Leng, X.K., Wang, F., Leng, X.K., Wang, C.G., Wang, L.Y., Li, D.F., (2010) Cryst. Growth Des., 10 (7), p. 2835; Wu, J., Fu, X., Xie, C., Fang, W., Gao, S., (2011) Sens. Actuat B-Chem., 160 (1), pp. 511-516; Xue, R., Kang, T.F., Lu, L.P., Cheng, S.Y., (2013) Anal. Lett., 46 (1), pp. 131-141; Xie, C., Gao, S., Guo, Q., Xu, K., (2010) Microchim. Acta, 169 (1-2), pp. 145-152; Xu, M.-L., Liu, J.-B., Lu, J., (2014) Appl. Spectrosc. Rev., 49 (2), pp. 97-120; Yang, Y., Tu, H., Zhang, A., Du, D., Lin, Y., (2012) J. Mater. Chem., 22, pp. 4977-4981; Zhao, Y., Zhang, W., Lin, Y., Du, D., (2013) Nanoscale, 5, pp. 1121-1126; Zhao, Y., Ma, Y., Li, H., Wang, L., (2011) Anal. Chem., 84 (1), pp. 386-395; Zhao, X., Hwang, H.M., (2009) Arch. Environ. Contam. Toxicol., 56 (4), pp. 646-653; Zhang, K., Qingsong, M., Guan, G., Liu, B., Wang, S., Zhang, Z., (2010) Anal. Chem., 82 (22), pp. 9579-9586; Zhang, W., Tang, Y., Du, D., Smith, J., Timchalk, C., Liu, D., Lin, Y., (2013) Talanta, 114, pp. 261-267; Zhang, X., Wang, H., Yang, C., Du, D., Lin, Y., (2013) Biosens. Bioelectron., 41, pp. 669-674; Zhang, W., Asiri, A.M., Liu, D., Du, D., Lin, Y., (2014) TrAC Trends Anal. Chem., 54, pp. 1-10; Zhu, W., Liu, W., Li, T., Yue, X., Liu, T., Zhang, W., Yu, S., Wang, J., (2014) Electrochim. Acta, 146, pp. 419-428",Review,Scopus,2-s2.0-84926436285
"Avitabile C.M., Goldberg D.J., Zemel B.S., Brodsky J.L., Dodds K., Hayden-Rush C., Whitehead K.K., Goldmuntz E., Rychik J., Leonard M.B.","Deficits in bone density and structure in children and young adults following Fontan palliation",2015,"Bone","77",,,"12","16",,,10.1016/j.bone.2015.04.012,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928248647&partnerID=40&md5=7e9aba51afbebdfbde6634737e43f41c","Division of Cardiology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States; Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States; Mid-Hudson Medical Group, 30 Columbia StreetPoughkeepsie, NY, United States; Division of Nephrology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States; St. Christopher's Hospital for Children, 160 East Erie AvenuePhiladelphia, PA, United States","Avitabile, C.M., Division of Cardiology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States, St. Christopher's Hospital for Children, 160 East Erie AvenuePhiladelphia, PA, United States; Goldberg, D.J., Division of Cardiology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States; Zemel, B.S., Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States, Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States; Brodsky, J.L., Mid-Hudson Medical Group, 30 Columbia StreetPoughkeepsie, NY, United States; Dodds, K., Division of Cardiology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States; Hayden-Rush, C., Division of Cardiology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States; Whitehead, K.K., Division of Cardiology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States; Goldmuntz, E., Division of Cardiology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States; Rychik, J., Division of Cardiology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States; Leonard, M.B., Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States, Division of Nephrology, Children's Hospital of Philadelphia, 34 and Civic Center BoulevardPhiladelphia, PA, United States, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, 415 Curie BoulevardPhiladelphia, PA, United States","Background: Survival of patients with congenital heart disease has improved such that there are now more adults than children living with these conditions. Complex single ventricle congenital heart disease requiring Fontan palliation is associated with multiple risk factors for impaired bone accrual. Bone density and structure have not been characterized in these patients. Methods: Tibia peripheral quantitative computed tomography (pQCT) was used to assess trabecular and cortical volumetric bone mineral density (vBMD), cortical dimensions, and calf muscle area in 43 Fontan participants (5-33. years old), a median of 10. years following Fontan palliation. pQCT outcomes were converted to sex- and race-specific Z-scores relative to age based on >. 700 healthy reference participants. Cortical dimensions and muscle area were further adjusted for tibia length. Results: Height Z-scores were lower in Fontan compared to reference participants (mean. ±. SD: -. 0.29. ±. 1.00 vs. 0.25. ±. 0.93, p. <. 0.001); BMI Z-scores were similar (0.16. ±. 0.88 vs. 0.35. ±. 1.02, p. =. 0.1). Fontan participants had lower trabecular vBMD Z-scores (-. 0.85. ±. 0.96 vs. 0.01. ±. 1.02, p. <. 0.001); cortical vBMD Z-scores were similar (-. 0.17. ±. 0.98 vs. 0.00. ±. 1.00, p. =. 0.27). Cortical dimensions were reduced with lower cortical area (-. 0.59. ±. 0.84 vs. 0.00. ±. 0.88, p. <. 0.001) and periosteal circumference (-. 0.50. ±. 0.82 vs. 0.00. ±. 0.84, p. <. 0.001) Z-scores, compared to reference participants. Calf muscle area Z-scores were lower in the Fontan participants (-. 0.45. ±. 0.98 vs. 0.00. ±. 0.96, p. =. 0.003) and lower calf muscle area Z-scores were associated with smaller periosteal circumference Z-scores (R. =. 0.62, p. <. 0.001). Musculoskeletal deficits were not associated with age, Fontan characteristics, parathyroid hormone or vitamin D levels. Conclusions: Children and young adults demonstrate low trabecular vBMD, cortical structure and muscle area following Fontan. Muscle deficits were associated with smaller periosteal dimensions. Future studies should determine the fracture implications of these deficits and identify interventions to promote musculoskeletal development. © 2015.","Bone mineral density; Congenital heart disease; Fontan; Muscle; Peripheral quantitative computed tomography","Rogers, L.S., Glatz, A.C., Ravishankar, C., Spray, T.L., Nicolson, S.C., Rychik, J., 18years of the Fontan operation at a single institution: results from 771 consecutive patients (2012) J Am Coll Cardiol, 60, pp. 1018-1025; O'Brien, J.E., Marshall, J.A., Young, A.R., Handley, K.M., Lofland, G.K., The nonfenestrated extracardiac Fontan procedure: a cohort of 145 patients (2010) Ann Thorac Surg, 89, pp. 1815-1820; Tweddell, J.S., Nersesian, M., Mussatto, K.A., Nugent, M., Simpson, P., Mitchell, M.E., Fontan palliation in the modern era: factors impacting mortality and morbidity (2009) Ann Thorac Surg, 88, pp. 1291-1299; Hirsch, J.C., Goldberg, C., Bove, E.L., Salehian, S., Lee, T., Ohye, R.G., Fontan operation in the current era: a 15-year single institution experience (2008) Ann Surg, 248, pp. 402-410; Khairy, P., Fernandes, S.M., Mayer, J.E., Treidman, J.K., Walsh, E.P., Lock, J.E., Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery (2008) Circulation, 117, pp. 85-92; Marelli, A., Gilboa, S., Devine, O., Kucik, J., Ionescu-Ittu, R., Oster, M., Estimating the congenital heart disease population in the United States in 2010-what are the numbers? (2012) J Am Coll Cardiol, 59, pp. E787-E787; Longmuir, P.E., Russell, J.L., Corey, M., Faulkner, G., McCrindle, B.W., Factors associated with the physical activity level of children who have the Fontan procedure (2011) Am Heart J, 161, pp. 411-417; McCrindle, B.W., Williams, R.V., Mital, S., Clark, B.J., Russell, J.L., Klein, G., Physical activity levels in children and adolescents are reduced after the Fontan procedure, independent of exercise capacity, and are associated with lower perceived general health (2007) Arch Dis Child, 92, pp. 509-514; Goldberg, D.J., Dodds, K., Avitabile, C.M., Glatz, A.C., Brodsky, J.L., Semeao, E.J., Children with protein-losing enteropathy after the fontan operation are at risk for abnormal bone mineral density (2012) Pediatr Cardiol, 33, pp. 1264-1268; Vogt, K.N., Manlhiot, C., Van Arsdell, G., Russell, J.L., Mital, S., McCrindle, B.W., Somatic growth in children with single ventricle physiology impact of physiologic state (2007) J Am Coll Cardiol, 50, pp. 1876-1883; Cohen, M.I., Bush, D.M., Ferry, R.J., Spray, T.L., Moshang, T., Wernovsky, G., Somatic growth failure after the Fontan operation (2000) Cardiol Young, 10, pp. 447-457; Cohen, M.S., Zak, V., Atz, A.M., Printz, B.F., Pinto, N., Lambert, L., Anthropometric measures after Fontan procedure: implications for suboptimal functional outcome (2010) Am Heart J, 160, pp. 1092-1098. , [8 e1]; Ovroutski, S., Ewert, P., Alexi-Meskishvili, V., Stiller, B., Nurnberg, J.H., Abdul-Khalia, H., Comparison of somatic development and status of conduit after extracardiac Fontan operation in young and older children (2004) Eur J Cardiothorac Surg, 26, pp. 1073-1079; Witzel, C., Sreeram, N., Coburger, S., Schickendantz, S., Brockmeier, K., Schoenau, E., Outcome of muscle and bone development in congenital heart disease (2006) Eur J Pediatr, 165, pp. 168-174; Avitabile, C.M., Leonard, M.B., Zemel, B.S., Brodsky, J.L., Lee, D., Dodds, K., Lean mass deficits, vitamin D status, and exercise capacity in children and young adults after Fontan palliation (2014) Heart, , [Published Online First [27 June 2014]]; Wetzsteon, R., Zemel, B.S., Shults, J., Howard, K.M., Kibe, L.W., Leonard, M.B., Mechanical loads and cortical bone geometry in healthy children and young adults (2011) Bone, 48, pp. 1103-1108; Leonard, M.B., Elmi, A., Mostoufi-Moab, S., Shults, J., Burnham, J.M., Thayu, M., Effects of sex, race, and puberty on cortical bone and the functional muscle bone unit in children, adolescents, and young adults (2010) J Clin Endocrinol Metab, 95, pp. 1681-1689; Liu, D., Manske, S.L., Kontulainen, S.A., Tang, C., Guy, P., Oxland, T.R., Tibial geometry is associated with failure load ex vivo: a MRI, pQCT and DXA study (2007) Osteoporos Int, 18, pp. 991-997; Zemel, B.S., Leonard, M.B., Kelly, A., Lappe, J.M., Gilsanz, V., Oberfield, S., Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children (2010) J Clin Endocrinol Metab, 95, pp. 1265-1273; Mostoufi-Moab, S., Ginsberg, J.P., Bunin, N., Zemel, B.S., Shults, J., Thayu, M., Body composition abnormalities in long-term survivors of pediatric hematopoietic stem cell transplantation (2012) J Pediatr, 160, pp. 122-128; Baker, J.F., Davis, M., Alexander, R., Zemel, B.S., Moustoufi-Moab, S., Shults, J., Associations between body composition and bone density and structure in men and women across the adult age spectrum (2013) Bone, 53, pp. 34-41; Mostoufi-Moab, S., Brodsky, J., Isaacoff, E.J., Tsampalieros, A., Ginsberg, J.P., Zemel, B., Longitudinal assessment of bone density and structure in childhood survivors of acute lymphoblastic leukemia without cranial radiation (2012) J Clin Endocrinol Metab, 97, pp. 3584-3592; Terpstra, A.M., Kalkwarf, H.J., Shults, J., Zemel, B.S., Wetzsteon, R.J., Foster, B.J., Bone density and cortical structure after pediatric renal transplantation (2012) J Am Soc Nephrol, 23, pp. 715-726; Tsampalieros, A., Kalkwarf, H.J., Wetzsteon, R.J., Shults, J., Zemel, B.S., Foster, B.J., Changes in bone structure and the muscle-bone unit in children with chronic kidney disease (2013) Kidney Int, 83, pp. 495-502; Morris, M., Udry, J.R., Validation of a self-administered instrument to assess stage of adolescent development (1980) J Youth Adolesc, 9, pp. 271-280; Saenger, A.K., Laha, T.J., Bremner, D.E., Sadrzadeh, S.M., Quantification of serum 25-hydroxyvitamin D(2) and D(3) using HPLC-tandem mass spectrometry and examination of reference intervals for diagnosis of vitamin D deficiency (2006) Am J Clin Pathol, 125, pp. 914-920; Ky, B., Shults, J., Keane, M.G., Sutton, M.S., Wolf, M., Feldman, H.I., FGF23 modifies the relationship between vitamin D and cardiac remodeling (2013) Circ Heart Fail, 6, pp. 817-824; Ogden, C.L., Kuczmarski, R.J., Flegal, K.M., Mei, Z., Guo, S., Wei, R., Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version (2002) Pediatrics, 109, pp. 45-60; Cole, T.J., The LMS, method for constructing normalized growth standards (1990) Eur J Clin Nutr, 44, pp. 45-60; Tsampalieros, A., Lam, C.K., Spencer, J.C., Thayu, M., Shults, J., Zemel, B.S., Long-term inflammation and glucocorticoid therapy impair skeletal modeling during growth in childhood Crohn disease (2013) J Clin Endocrinol Metab, 98, pp. 3438-3445; Ross, A.C., The 2011 report on dietary reference intakes for calcium and vitamin D (2011) Public Health Nutr, 14, pp. 938-939; Mostoufi-Moab, S., Ginsberg, J.P., Bunin, N., Zemel, B., Shults, J., Leonard, M.B., Bone density and structure in long-term survivors of pediatric allogeneic hematopoietic stem cell transplantation (2012) J Bone Miner Res, 27, pp. 760-769; Dubner, S.E., Shults, J., Baldassano, R.N., Zemel, B.S., Thayu, M., Burnham, J.M., Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease (2009) Gastroenterology, 136, pp. 123-130; Burnham, J.M., Shults, J., Dubner, S.E., Sembhi, H., Zemel, B.S., Leonard, M.B., Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits (2008) Arthritis Rheum, 58, pp. 2518-2527; Ashe, M.C., Khan, K.M., Kontulainen, S.A., Guy, P., Liu, D., Beck, T.J., Accuracy of pQCT for evaluating the aged human radius: an ashing, histomorphometry and failure load investigation (2006) Osteoporos Int, 17, pp. 1241-1251; Bechtold, S., Putzker, S., Birnbaum, J., Schwarz, H.P., Netz, H., Dalla, P.R., Impaired bone geometry after heart and heart-lung transplantation in childhood (2010) Transplantation, 90, pp. 1006-1010; Burnham, J.M., Shults, J., Sembhi, H., Zemel, B.S., Leonard, M.B., The dysfunctional muscle-bone unit in juvenile idiopathic arthritis (2006) J Musculoskelet Neuronal Interact, 6, pp. 351-352; Pfister, R., Michels, G., Sharp, S.J., Luben, R., Wareham, N.J., Khaw, K.-T., Low bone mineral density predicts incident heart failure in men and women (2014) J Am Coll Cardiol, 2, pp. 380-389; Lee, A.M., Morrison, J.L., Botting, K.J., Shandala, T., Xian, C.J., Effects of maternal hypoxia during pregnancy on bone development in offspring: a guinea pig model (2014) Int J Endocrinol, , [Published Online First [14 May 2014]]",Article,Scopus,2-s2.0-84928248647
"Nguyen M.M., Gianneschi N.C., Christman K.L.","Developing injectable nanomaterials to repair the heart",2015,"Current Opinion in Biotechnology","34",,,"225","231",,,10.1016/j.copbio.2015.03.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926651838&partnerID=40&md5=e0334fcfa432e8f1a0e37a9e910ef76e","Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of CaliforniaSan Diego, United States; Department of Chemistry and Biochemistry, University of CaliforniaSan Diego, United States","Nguyen, M.M., Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of CaliforniaSan Diego, United States; Gianneschi, N.C., Department of Chemistry and Biochemistry, University of CaliforniaSan Diego, United States; Christman, K.L., Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of CaliforniaSan Diego, United States","Injectable nanomaterials have been designed for the treatment of myocardial infarction, particularly during the acute stages of inflammation and injury. Among these strategies, injectable nanofibrous hydrogel networks or nanoparticle complexes may be delivered alone or with a therapeutic to improve heart function. Intramyocardial delivery of these materials localizes treatments to the site of injury. As an alternative, nanoparticles may be delivered intravenously, which provides the ultimate minimally invasive approach. These systems take advantage of the leaky vasculature after myocardial infarction, and may be designed to specifically target the injured region. The translational applicability of both intramyocardial and intravenous applications may provide safe and effective solutions upon optimizing the timing of the treatments and biodistribution. © 2015 Elsevier Ltd.",,"Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., Bravata, D.M., Fox, C.S., Heart disease and stroke statistics-2013 update: a report from the american heart association (2013) Circulation, 127, pp. e6-e245; Dobaczewski, M., Gonzalez-Quesada, C., Frangogiannis, N.G., The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction (2010) J Mol Cell Cardiol, 48, pp. 504-511; Sutton, M.G.S., Sharpe, N., Left ventricular remodeling after myocardial infarction-pathophysiology and therapy (2000) Circulation, 101, pp. 2981-2988; Vanhoutte, D., Schellings, M., Pinto, Y., Heymans, S., Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window (2006) Cardiovasc Res, 69, pp. 604-613; Nelson, D.M., Ma, Z., Fujimoto, K.L., Hashizume, R., Wagner, W.R., Intra-myocardial biomaterial injection therapy in the treatment of heart failure: materials, outcomes and challenges (2011) Acta Biomater, 7 (1), pp. 1-15; Johnson, T.D., Christman, K.L., Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction (2013) Exp Opin Drug Deliv, 10, pp. 59-72; van der Laan, A.M., Nahrendorf, M., Piek, J.J., Healing and adverse remodelling after acute myocardial infarction: role of the cellular immune response (2012) Heart, 98 (18), pp. 1384-1390; Ungerleider, J.L., Christman, K.L., Concise review: injectable biomaterials for the treatment of myocardial infarction and peripheral artery disease: translational challenges and progress (2014) Stem Cells Transl Med, 3, pp. 1090-1099; Frangogiannis, N.G., Smith, C.W., Entman, M.L., The inflammatory response in myocardial infarction (2002) Cardiovasc Res, 53, pp. 31-47; Galaup, A., Gomez, E., Souktani, R., Durand, M., Cazes, A., Monnot, C., Teillon, J., Briois, G., Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4 (2012) Circulation, 125, pp. 140-149; Leor, J., Tuvia, S., Guetta, V., Manczur, F., Castel, D., Willenz, U., Petneházy, Ö., Konen, E., Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in swine (2009) J Am Coll Cardiol, 54, pp. 1014-1023; Frey, N., Linke, A., Süselbeck, T., Müller-Ehmsen, J., Vermeersch, P., Schoors, D., Rosenberg, M., Leor, J., Intracoronary delivery of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after st-elevation myocardial infarction: a first-in-man study (2014) Circ Cardiovascr Intervent; Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C., Factors affecting the clearance and biodistribution of polymeric nanoparticles (2008) Mol Pharm, 5, pp. 505-515; Clares, B., Ruiz, M.A., Gallardo, V., Arias, J.L., Drug delivery to inflammation based on nanoparticles surface decorated with biomolecules (2012) Curr Med Chem, 19, pp. 3203-3211; Tous, E., Purcell, B., Ifkovits, J.L., Burdick, J.A., Injectable acellular hydrogels for cardiac repair (2011) J Cardiovasc Transl Res, 4, pp. 528-542; Rane, A.A., Christman, K.L., Biomaterials for the treatment of myocardial infarction (2011) J Am Coll Cardiol, 58, pp. 2615-2629; Rane, A.A., Chuang, J.S., Shah, A., Hu, D.P., Dalton, N.D., Gu, Y., Peterson, K.L., Christman, K.L., Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction (2011) PLoS ONE, 6, p. e21571; McGarvey, J.R., Pettaway, S., Shuman, J.A., Novack, C.P., Zellars, K.N., Freels, P.D., Echols, R.L., Spinale, F.G., Targeted injection of a biocomposite material alters macrophage and fibroblast phenotype and function following myocardial infarction: relation to left ventricular remodeling (2014) J Pharm Exp Therap, 350, pp. 701-709; Kharaziha, M., Nikkhah, M., Shin, S.R., Annabi, N., Masoumi, N., Gaharwar, A.K., Camci-Unal, G., Khademhosseini, A., PGS:gelatin nanofibrous scaffolds with tunable mechanical and structural properties for engineering cardiac tissues (2013) Biomaterials, 34, pp. 6355-6366; Venugopal, J., Rajeswari, R., Shayanti, M., Sridhar, R., Sundarrajan, S., Balamurugan, R., Ramakrishna, S., Xylan polysaccharides fabricated into nanofibrous substrate for myocardial infarction (2013) Mater Sci Eng - C Mater Biol Appl, 33, pp. 1325-1331; Bhaarathy, V., Venugopal, J., Gandhimathi, C., Ponpandian, N., Mangalaraj, D., Ramakrishna, S., Biologically improved nanofibrous scaffolds for cardiac tissue engineering (2014) Mater Sci Eng - C Mater Biol Appl, 44, pp. 268-277; Lin, Y.D., Ko, M.C., Wu, S.T., Li, S.F., Hu, J.F., Lai, Y.J., Harn, H.I.C., Yeh, H.I., A nanopatterned cell-seeded cardiac patch prevents electro-uncoupling and improves the therapeutic efficacy of cardiac repair (2014) Biomater Sci, 2 (4), pp. 567-580; Davis, M.E., Motion, J.P.M., Narmoneva, D.A., Takahashi, T., Hakuno, D., Kamm, R.D., Zhang, S.G., Lee, R.T., Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells (2005) Circulation, 111, pp. 442-450; Lin, Y.-D., Yeh, M.-L., Yang, Y.-J., Tsai, D.-C., Chu, T.-Y., Shih, Y.-Y., Chang, M.-Y., Chen, T.-Y., Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs (2010) Circulation, 122 (11), pp. S132-S141; Davis, M.E., Hsieh, P.C.H., Takahashi, T., Song, Q., Zhang, S., Kamm, R.D., Grodzinsky, A.J., Lee, R.T., Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction (2006) Proc Natl Acad Sci, 103, pp. 8155-8160; Lin, Y.-D., Luo, C.-Y., Hu, Y.-N., Yeh, M.-L., Hsueh, Y.-C., Chang, M.-Y., Tsai, D.-C., Wei, E.I.H., Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair (2012) Sci Transl Med, 4. , 146ra109; Guo, H., Cui, G., Yang, J., Wang, C., Zhu, J., Zhang, L., Jiang, J., Shao, S., Sustained delivery of VEGF from designer self-assembling peptides improves cardiac function after myocardial infarction (2012) Biochem Biophys Res Commun, 424, pp. 105-111; Singelyn, J.M., DeQuach, J.A., Seif-Naraghi, S.B., Littlefield, R.B., Schup-Magoffin, P.J., Christman, K.L., Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering (2009) Biomaterials, 30, pp. 5409-5416; Singelyn, J.M., Sundaramurthy, P., Johnson, T.D., Schup-Magoffin, P.J., Hu, D.P., Faulk, D.M., Wang, J., Salvatore, M., Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction (2012) J Amer College Cardiol, 59, pp. 751-763; Seif-Naraghi, S.B., Horn, D., Schup-Magoffin, P.J., Christman, K.L., Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor (2012) Acta Biomater, 8, pp. 3695-3703; Seif-Naraghi, S.B., Singelyn, J.M., Salvatore, M.A., Osborn, K.G., Wang, J.J., Sampat, U., Kwan, O.L., Schup-Magoffin, P.J., Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction (2013) Sci Transl Med, 5. , 173ra25; Sonya Sonnenberg, A.A.R., Liu, C.J., Rao, N., Bajaj, V., Zhang, S., Braden, R., Schup-Magoffin, P.J., Christman, K.L., Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative lv remodeling post-myocardial infarction (2015) Biomaterials, 45, pp. 56-63; Bastings, M.M.C., Koudstaal, S., Kieltyka, R.E., Nakano, Y., Pape, A.C.H., Feyen, D.A.M., van Slochteren, F.J., Meijer, E.W., A fast pH-switchable and self-healing supramolecular hydrogel carrier for guided, local catheter injection in the infarcted myocardium (2014) Adv Healthc Mater, 3, pp. 70-78; Paul, A., Hasan, A., Al Kindi, H., Gaharwar, A.K., Rao, V.T.S., Nikkhah, M., Shin, S.R., Khademhosseini, A., Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair (2014) Acs Nano, 8, pp. 8050-8062; Lu, Z.-X., Mao, L.-L., Lian, F., He, J., Zhang, W.-T., Dai, C.-Y., Xue, S., Zhu, H.-S., Cardioprotective activity of placental growth factor in a rat model of acute myocardial infarction: nanoparticle-based delivery versus direct myocardial injection (2014) Bmc Cardiovasc Disorders, 14; Chang, M.Y., Yang, Y.J., Chang, C.H., Tang, A.C.L., Liao, W.Y., Cheng, F.Y., Yeh, C.S., Hsieh, P.C.H., Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction (2013) J Control Release, 170, pp. 287-294; Paulis, L.E., Geelen, T., Kuhlmann, M.T., Coolen, B.F., Schaefers, M., Nicolay, K., Strijkers, G.J., Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for mri-monitored drug delivery (2012) J Control Release, 162, pp. 276-285; Scott, R.C., Rosano, J.M., Ivanov, Z., Wang, B., Chong, P.L.-G., Issekutz, A.C., Crabbe, D.L., Kiani, M.F., Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function (2009) Faseb J, 23, pp. 3361-3367; Swyer, T.W., Strom, J., Larson, D.F., Nanoparticle oxygen delivery to the ischemic heart (2014) Perfusion, 29, pp. 539-543; Ko, Y.T., Hartner, W.C., Kale, A., Torchilin, V.P., Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide (2009) Gene Therapy, 16, pp. 52-59; Dvir, T., Bauer, M., Schroeder, A., Tsui, J.H., Anderson, D.G., Langer, R., Liao, R., Kohane, D.S., Nanoparticles targeting the infarcted heart (2011) Nano Letters, 11, pp. 4411-4414; Won, Y.W., McGinn, A.N., Lee, M., Bull, D.A., Kim, S.W., Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier (2013) Mol Pharm, 10, pp. 378-385; Kanki, S., Jaalouk, D.E., Lee, S., Yu, A.Y., Gannon, J., Lee, R.T., Identification of targeting peptides for ischemic myocardium by in vivo phage display (2011) J Mol Cell Cardiol, 50, pp. 841-848; Dasari, M., Lee, S., Sy, J., Kim, D., Lee, S., Brown, M., Davis, M., Hoechst, -I.R., An imaging agent that detects necrotic tissue in vivo by binding extracellular DNA (2010) Org Lett, 12, pp. 3300-3303; Khan, R.S., Martinez, M.D., Sy, J.C., Pendergrass, K.D., Che, P.-, Brown, M.E., Cabigas, E.B., Davis, M.E., Targeting extracellular DNA to deliver IGF-1 to the injured heart (2014) Scientific Reports, 4, pp. 1-7; Eifler, A., Thaxton, C.S., Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study (2011) Biomedical Nanotechnology, 726, pp. 325-338. , Humana Press",Review,Scopus,2-s2.0-84926651838
"Chui K.T., Tsang K.F., Wu C.K., Hung F.H., Chi H.R., Chung H.S.-H., Man K.F., Ko K.T.","Cardiovascular diseases identification using electrocardiogram health identifier based on multiple criteria decision making",2015,"Expert Systems with Applications","42","13",,"5684","5695",,,10.1016/j.eswa.2015.01.059,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926627777&partnerID=40&md5=135d3a3d47ec94e3c35818fe56f0c611","Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong","Chui, K.T., Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong; Tsang, K.F., Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong; Wu, C.K., Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong; Hung, F.H., Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong; Chi, H.R., Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong; Chung, H.S.-H., Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong; Man, K.F., Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong; Ko, K.T., Department of Electronic Engineering, City University of Hong KongHong Kong, Hong Kong","Cardiovascular diseases can wreak havoc on human beings and lead to 30% of global death annually. The World Health Organization has always highlighted that there is a severe shortage of medical personnel, especially cardiologists, in most of the countries. In this paper, an electrocardiogram health identifier (ECGHI) has been proposed and developed for swift identification of heart diseases. The ECGHI has been applied to four most common types of cardiovascular diseases, namely Myocardial Infarction, Dysrhythmia, Bundle Branch Block and Heart Failure since these four types of cardiovascular diseases contribute to 25% of the overall population suffering from heart diseases. In the investigation of ECGHI, the binary classifier (BC) and multi-class classifier (MCC) are designed and analyzed. The MCC features a multi-class support vector machine (SVM) to diagnose the exact type of cardiovascular disease. The BC features a two-class SVM to identify healthiness of heart accurately. In this paper, the following indicators have been investigated, namely the overall accuracy, specificity, sensitivity, the dimensionality of feature vector, the total training and testing time of ECGHI and a newly defined confidence index. These six criteria form the basis to derive an analytic hierarchy process (AHP) to facilitate the multiple criteria decision making (MCDM) for the optimal evaluation of hyperplanes. Four kernels have been analyzed from which both the BC and MCC are evaluated and analyzed. The optimized ECGHI using BC yields an AHP Performance Score of 0.079 with score components (overall accuracy, specificity, sensitivity, average confidence index, dimensionality, total time for training and testing time) of 0.982, 0.978, 0.986, 0.608, 6, and 5.77 s respectively. Likewise, the optimized ECGHI using MCC yields an AHP Performance Score of 0.093 with score components of 0.882, 0.89, 0.874, 0.504, 9, and 7.32 s respectively. The BC is employed as a supplement of the MCC to achieve a further improvement in all six criteria. Such a novel process of identification and detection with high accuracy is referred as the MCC-BC scheme. The developed ECGHI (MCC) may identify the FOUR most common and important cardiovascular diseases simultaneously (with BC supplementing the MCC to achieve a high accuracy). Such simultaneous identification of cardiovascular diseases is the first of its kind in this research area, so no comparison can be made. The MCC-BC scheme will pave the way for speedy and accurate identification and detection of heart disease. The instant response of the ECGHI minimizes the probability of death from Myocardial Infarction, Bundle Branch Block, Dysrhythmia, and Heart Failure. © 2015 Published by Elsevier Ltd.","Cardiovascular diseases; Electrocardiogram; Feature vector; Multiple criteria decision making; Support vector machine","Alonso, J.A., Lamata, M.T., Consistency in the analytic hierarchy process: A new approach (2006) International Journal of Uncertainty, Fuzziness and Knowledge-Based Systems, 14 (4), pp. 445-459; Behar, J., Oster, J., Li, Q., Clifford, G.D., ECG signal quality during arrhythmia and its application to false alarm reduction (2013) IEEE Transactions on Biomedical Engineering, 60 (6), pp. 1660-1666; Bishop, C.M., Pattern recognition and machine learning (2006) Sparse Kernel Machines, pp. 325-343. , M. Jordan, J. Kleinberg, B. Schölkopf, Springer Singapore; Chan, A.D.C., Hamdy, M.M., Badre, A., Badee, V., Wavelet distance measure for person identification using electrocardiograms (2008) IEEE Transactions on Instrumentation and Measurement, 57 (2), pp. 248-253; Chen, T., Mazomenos, E.B., Maharatna, K., Dasmahapatra, S., Niranjan, M., Design of a low-power on-body ECG classifier for remote cardiovascular monitoring systems (2013) IEEE Journal of Emerging and Selected Topics in Circuits and Systems, 3 (1), pp. 77-85; Fong, E., Chung, W.Y., Mobile cloud-computing-based healthcare service by noncontact ECG monitoring (2013) Sensors, 13, pp. 16451-16473; Gao, J., Agrafioti, F., Mohammadzad, H., Hatzinakos, D., ECG for blind identity verification in distributed systems (2011) IEEE International Conference on Acoustics, Speech, and Signal Processing, pp. 1916-1919; Han, J.G., Pauwels, E.J., Zeeuw, P.M.D., With, P.H.N., Employing a RGB-D sensor for real-time tracking of humans across multiple re-entries in a smart environment (2012) IEEE Transactions on Consumer Electronics, 58 (2), pp. 255-263; Homaeinezhad, M.R., Atyabi, S.A., Tavakkoli, E., Toosi, H.N., Ghaffari, A., Ebrahimpour, R., ECG arrhythmia recognition via a neuro-SVM-KNN hybrid classifier with virtual QRS image-based geometrical features (2012) Expert Systems with Applications, 39 (2), pp. 2047-2058; Hsu, C.W., Lin, C.J., A comparison of methods for multiclass support vector machine (2002) IEEE Transactions on Neural Network, 13 (2), pp. 415-425; Jiang, W., Kong, S.G., Block-based neural networks for personalized ECG signal classification (2007) IEEE Transactions on Neural Networks, 18 (6), pp. 1750-1761; Kleiger, R.E., Miller, J.P., Bigger, J.T., Moss, A.J., Decreased heart rate variability and its association with increased mortality after acute myocardial infarction (1987) The American Journal of Cardiology, 59 (4), pp. 256-262; Köksalan, M., Vallenius, J., Zionts, S., Multiple criteria decision making: From early history to the 21st century (2011) MCDM Developments in the 1990s and beyond (Pp. 43-62), , World Scientific Singapore; Li, Q., Rajagopalan, C., Clifford, G.D., Ventricular fibrillation and tachycardia classification using a machine learning approach (2014) IEEE Transactions on Biomedical Engineering, 61 (6), pp. 1607-1613; Luna, A.B.D., (2012) Clinical Electrocardiography: A Textbook, , Wiley-Blackwell Oxford, UK; McLachlan, G.J., Do, K.A., Ambroise, C., Analyzing microarray gene expression data (2004) Supervised Classification of Tissue Samples (Pp. 221-251), , John Wiley & Sons Inc New Jersey; Melgani, F., Bazi, Y., Classification of electrocardiogram signals with support vector machines and particle swarm optimization (2008) IEEE Transactions on Information Technology in Biomedicine, 12 (5), pp. 667-677; Odinaka, I., Lai, P.H., Kaplan, A.D., O'Sullivan, J.A., Sirevaag, E.J., Rohrbaugh, J.W., ECG biometric recognition: A comparative analysis (2012) IEEE Transactions on Information Forensics and Security, 7 (6), pp. 1812-1824; PhysioBank ATM, , http://physionet.org/cgi-bin/atm/ATM, (accessed on 5 Jul 2014); Physionet MIT-BIH Arrhythmia Database, , http://www.physionet.org/physiobank/database/mitdb/, (accessed on 5 Jul 2014); Ravanshad, N., Rezaee-Dehsorkh, H., Lotfi, R., Lian, Y., Level-crossing based QRS-detection algorithm for wearable ECG sensors (2014) IEEE Journal of Biomedical and Health Informatics, 18 (1), pp. 183-192; Ron, K., A study of cross-validation and bootstrap for accuracy estimation and model selection (1995) IJCAI'95 Proceedings of the 14th International Joint Conference on Artificial Intelligence, 2, pp. 1137-1143; Safie, S.I., Soraghan, J.J., Petropoulakis, L., Electrocardiogram (ECG) biometric authentication using pulse active ratio (PAR) (2011) IEEE Transactions on Information Forensics and Security, 6 (4), pp. 1315-1322; Seymour, G., (1993) Predictive Inference: An Introduction, , Chapman and Hall Press New York; Shen, C.-P., Kao, W.-C., Yang, Y.-Y., Hsu, M.-C., Wu, Y.-T., Lai, F., Detection of cardiac arrhythmia in electrocardiogram using adaptive feature extraction and modified support vector machines (2012) Expert Systems with Applications, 39 (9), pp. 7845-7852; Sufi, F., Fang, Q., Khalil, I., Mahmoud, S.S., Compressed ECG biometric: A fast, secured and efficient method for identification of CVD patient (2011) Journal of Medical Systems, 35 (6), pp. 1349-1358; Task Shifting Global Recommendations and Guidelines, , http://www.who.int/healthsystems/TTR-TaskShifting.pdf, (accessed on 20 Sep 2014); Texas Arrhythmia Institute: Ventricular Tachyarrhythmias, , http://www.physionet.org/physiobank/database/mitdb/, (accessed on 5 Jul 2014); Tompkins, W.J., Biomedical digital signal processing C-language examples and laboratory experiments for the IBM®PC (2000) ECG QRS Detection (Pp. 236-264), , Prentice Hall New Jersey; (2013) UNFPA State of World Population, , http://www.unfpa.org/swp#ref, (accessed on 20 Sep 2014); Vázquez-Seisdedos, C.R., Neto, J.E., Reyes, E.J.M., Klautau, A., Oliveira, C.L.D., New approach for T-wave end detection on electrocardiogram: Performance in noisy conditions (2011) BioMedical Engineering Online, 10 (77), pp. 1-11; Venkatesh, N., Javaraman, S., Human electrocardiogram for biometrics using DTW and FLDS (2010) 20th International Conference on Pattern Recognition, pp. 3838-3841; Wasan, P.S., Uttamchandani, M., Moochhala, S., Yap, V.B., Yap, P.H., Application of statistics and machine learning for risk stratification of heritable cardiac arrhythmias (2013) Expert Systems with Applications, 40 (7), pp. 2476-2486; (2013) World Health Statistics, , http://www.who.int/gho/publications/world_health_statistics/2013/en/, (accessed on 20 Sep 2014); Zhao, Z., Yang, L., Chen, D., Luo, Y., A human ECG identification system based on ensemble empirical mode decomposition (2013) Sensors, 13 (5), pp. 6832-6864",Article,Scopus,2-s2.0-84926627777
"Chen C.-Y., Harrison T., Heathcock J.","Infants with complex congenital heart diseases show poor short-term memory in the mobile paradigm at 3 months of age",2015,"Infant Behavior and Development","40",,,"12","19",,,10.1016/j.infbeh.2015.02.007,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928340741&partnerID=40&md5=e482f452e08537145d9a76f944db8b8a","The Ohio State University, Program in Heath and Rehabilitation Sciences, United States; Nationwide Children's Hospital, The Heart Center, United States; The Ohio State University, Division of Physical Therapy, 453W. 10th AvenueColumbus, OH, United States","Chen, C.-Y., The Ohio State University, Program in Heath and Rehabilitation Sciences, United States; Harrison, T., Nationwide Children's Hospital, The Heart Center, United States; Heathcock, J., The Ohio State University, Division of Physical Therapy, 453W. 10th AvenueColumbus, OH, United States","The purpose of this study was to examine learning, short-term memory and general development including cognitive, motor, and language domains in infants with Complex Congenital Heart Defects (CCDH). Ten infants with CCHD (4 males, 6 females) and 14 infants with typical development (TD) were examined at 3 months of age. The mobile paradigm, where an infant's leg is tethered to an overhead mobile, was used to evaluate learning and short-term memory. The Bayley Scales of Infant Development 3rd edition (Bayley-III) was used to evaluate general development in cognitive, motor, and language domains. Infants with CCHD and infants with TD both showed learning with significant increase in kicking rate (. p<. 0.001) across periods of the mobile paradigm, but only infants with TD demonstrated short-term memory (. p=. 0.017) in the mobile paradigm. There were no differences on cognitive, motor, and language development between infants with CCHD and infants with TD on the Bayley-III. Early assessment is necessary to guide targeted treatment in infants with CCHD. One-time assessment may fail to detect potential cognitive impairments during early infancy in infants with CCHD. Supportive intervention programs for infants with CCHD that focuses on enhancing short-term memory are recommended. © 2015 Elsevier Inc.","Complex congenital heart defects; Development; Learning; Motor; Short-term memory","Brosig, C.L., Mussatto, K.A., Kuhn, E.M., Tweddell, J.S., Neurodevelopmental outcome in preschool survivors of complex congenital heart disease: Implications for clinical practice (2007) Journal of Pediatric Health Care, 21 (1), pp. 3-12. , Matched; Clouchoux, C., du Plessis, A.J., Bouyssi-Kobar, M., Tworetzky, W., McElhinney, D.B., Brown, D.W., Delayed cortical development in fetuses with complex congenital heart disease (2012) Cerebral Cortex, , Matched; Connolly, B.H., McClune, N.O., Gatlin, R., Concurrent validity of the Bayley-III and the Peabody Developmental Motor Scale-2 (2012) Pediatric Physical Therapy, 24 (4), pp. 345-352. , Matched; Deroma, L., Bin, M., Tognin, V., Rosolen, V., Valent, F., Barbone, F., Interrater reliability of the Bayley III test in the Italian Northern-Adriatic Cohort II (2013) Epidemiologia & Prevenzione, 37 (4-5), pp. 297-302. , Matched; Feldman, R., Eidelman, A.I., Skin-to-skin contact (Kangaroo Care) accelerates autonomic and neurobehavioural maturation in preterm infants (2003) Developmental Medicine & Child Neurology, 45 (4), pp. 274-281. , Matched; Freed, D.H., Robertson, C.M., Sauve, R.S., Joffe, A.R., Rebeyka, I.M., Ross, D.B., Intermediate-term outcomes of the arterial switch operation for transposition of great arteries in neonates: Alive but well? (2006) The Journal of Thoracic and Cardiovascular Surgery, 132 (4), pp. 845-852. , Matched; Galantowicz, M., Cheatham, J.P., Phillips, A., Cua, C.L., Hoffman, T.M., Hill, S.L., Hybrid approach for hypoplastic left heart syndrome: Intermediate results after the learning curve (2008) The Annals of thoracic surgery, 85 (6), pp. 2063-2070. , discussion 2070-2061; Gekoski, M.J., Fagen, J.W., Pearlman, M.A., Early learning and memory in the preterm infant (1984) Infant Behavior and Development, 7, pp. 267-276. , Matched; Granberg, M., Rydberg, A., Fisher, A.G., Activities in daily living and schoolwork task performance in children with complex congenital heart disease (2008) Acta Paediatra, 97 (9), pp. 1270-1274. , Matched; Harrison, T.M., Brown, R.L., Autonomic nervous system function in infants with transposition of the great arteries (2012) Biological Research for Nursing, 14 (3), pp. 257-268. , Matched; Heathcock, J.C., Bhat, A.N., Lobo, M.A., Galloway, J.C., The performance of infants born preterm and full-term in the mobile paradigm: Learning and memory (2004) Physical Therapy, 84 (9), pp. 808-821. , Matched; Johnson, S., Moore, T., Marlow, N., Using the Bayley-III to assess neurodevelopmental delay: Which cut-off should be used? (2014) Pediatric Research, , Matched; Licht, D.J., Shera, D.M., Clancy, R.R., Wernovsky, G., Montenegro, L.M., Nicolson, S.C., Brain maturation is delayed in infants with complex congenital heart defects (2009) The Journal of Thoracic and Cardiovascular Surgery, 137 (3), pp. 529-536. , discussion 536-527; Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T.B., Flegal, K., Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2009) Circulation, 119 (3), pp. 480-486. , Matched; Lobo, M.A., Galloway, J.C., Assessment and stability of early learning abilities in preterm and full-term infants across the first two years of life (2013) Research in Developmental Disabilities, 34 (5), pp. 1721-1730. , Matched; Mahle, W.T., Tavani, F., Zimmerman, R.A., Nicolson, S.C., Galli, K.K., Gaynor, J.W., An MRI, study of neurological injury before and after congenital heart surgery (2002) Circulation, 106 (12), pp. I109-I114. , Matched; Marino, B.S., Lipkin, P.H., Newburger, J.W., Peacock, G., Gerdes, M., Gaynor, J.W., Neurodevelopmental outcomes in children with congenital heart disease: Evaluation and management: A scientific statement from the American Heart Association (2012) Circulation, 126 (9), pp. 1143-1172. , Matched; Olsen, C.M., Winder, D.G., Stimulus dynamics increase the self-administration of compound visual and auditory stimuli (2012) Neuroscience Letters, 511 (1), pp. 8-11. , Matched; Rajantie, I., Laurila, M., Pollari, K., Lonnqvist, T., Sarajuuri, A., Jokinen, E., Motor development of infants with univentricular heart at the ages of 16 and 52 weeks (2013) Pediatric Physical Therapy, 25 (4), pp. 444-450. , Matched; Rovee, C.K., Rovee, D.T., Conjugate reinforcement of infant exploratory behavior (1969) Journal of Experimental Child Psychology, 8 (1), pp. 33-39. , Matched; Snookes, S.H., Gunn, J.K., Eldridge, B.J., Donath, S.M., Hunt, R.W., Galea, M.P., A systematic review of motor and cognitive outcomes after early surgery for congenital heart disease (2010) Pediatrics, 125 (4), pp. e818-e827. , Matched; Tarullo, A.R., Balsam, P.D., Fifer, W.P., Sleep and Infant Learning (2011) Infant and Child Development, 20 (1), pp. 35-46. , Matched; Van Hus, J.W., Jeukens-Visser, M., Koldewijn, K., Van Sonderen, L., Kok, J.H., Nollet, F., Comparing two motor assessment tools to evaluate neurobehavioral intervention effects in infants with very low birth weight at 1 year (2013) Physical Therapy, 93 (11), pp. 1475-1483. , Matched; Visconti, K.J., Rimmer, D., Gauvreau, K., del Nido, P., Mayer, J.E., Hagino, I., Regional low-flow perfusion versus circulatory arrest in neonates: One-year neurodevelopmental outcome (2006) The Annals of Thoracic Surgery, 82 (6), pp. 2207-2211. , discussion 2211-2203; Walton, T., Thirkettle, M., Redgrave, P., Gurney, K.N., Stafford, T., The discovery of novel actions is affected by very brief reinforcement delays and reinforcement modality (2013) Journal of Motor Behavior, 45 (4), pp. 351-360. , Matched; Williams, D.L., Gelijns, A.C., Moskowitz, A.J., Weinberg, A.D., Ng, J.H., Crawford, E., Hypoplastic left heart syndrome: Valuing the survival (2000) The Journal of Thoracic and Cardiovascular Surgery, 119 (4), pp. 720-731. , Matched; Ykeda, D.S., Lorenzi-Filho, G., Lopes, A.A., Alves, R.S., Sleep in infants with congenital heart disease (2009) Clinics, 64 (12), pp. 1205-1210. , Matched",Article,Scopus,2-s2.0-84928340741
"Ezhov M.V., Safarova M.S., Afanasieva O.I., Kukharchuk V.V., Pokrovsky S.N.","Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting",2015,"Atherosclerosis","235","2",,"477","482",,5,10.1016/j.atherosclerosis.2014.05.944,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921509674&partnerID=40&md5=266491d01affadae7a462f353ec618e1","Atherosclerosis Department, Institute of Clinical Cardiology named after A.L. Myasnikov, Fed. State Inst. Rus. Cardiology Research and Prod. Complex of Min. of Health of the Russian Fed., 15A, 3rd Cherepkovskaya streetMoscow, Russian Federation; Laboratory of Atherosclerosis, Institute of Experimental Cardiology, Fed. State Inst. Rus. Cardiology Research and Prod. Complex of Min. of Health of the Russian Fed., 15A, 3rd Cherepkovskaya streetMoscow, Russian Federation","Ezhov, M.V., Atherosclerosis Department, Institute of Clinical Cardiology named after A.L. Myasnikov, Fed. State Inst. Rus. Cardiology Research and Prod. Complex of Min. of Health of the Russian Fed., 15A, 3rd Cherepkovskaya streetMoscow, Russian Federation; Safarova, M.S., Atherosclerosis Department, Institute of Clinical Cardiology named after A.L. Myasnikov, Fed. State Inst. Rus. Cardiology Research and Prod. Complex of Min. of Health of the Russian Fed., 15A, 3rd Cherepkovskaya streetMoscow, Russian Federation; Afanasieva, O.I., Laboratory of Atherosclerosis, Institute of Experimental Cardiology, Fed. State Inst. Rus. Cardiology Research and Prod. Complex of Min. of Health of the Russian Fed., 15A, 3rd Cherepkovskaya streetMoscow, Russian Federation; Kukharchuk, V.V., Atherosclerosis Department, Institute of Clinical Cardiology named after A.L. Myasnikov, Fed. State Inst. Rus. Cardiology Research and Prod. Complex of Min. of Health of the Russian Fed., 15A, 3rd Cherepkovskaya streetMoscow, Russian Federation; Pokrovsky, S.N., Laboratory of Atherosclerosis, Institute of Experimental Cardiology, Fed. State Inst. Rus. Cardiology Research and Prod. Complex of Min. of Health of the Russian Fed., 15A, 3rd Cherepkovskaya streetMoscow, Russian Federation","Objective: To evaluate the relationships of lipoprotein(a) (Lp(a)) concentration and apolipoprotein(a) (apo(a)) phenotype to major adverse cardiovascular events after coronary artery bypass grafting (CABG) in long-term follow-up. Methods: This single-center study included 356 patients with stable coronary heart disease (CHD) who underwent successful CABG. At baseline, we assessed the patient's risk factor profile for atherosclerosis, Lp(a) concentration and apo(a) phenotype. The primary endpoint was the composite of cardiovascular death and non-fatal myocardial infarction (MI). The secondary endpoint also included hospitalization for recurrent or unstable angina and repeat revascularization. Results: Over a mean of 8.5±3.5 years (range 0.9-15.0 years), the primary and secondary endpoints were registered in 46 (13%) and 107 (30%) patients, respectively. Patients with Lp(a) ≥30mg/dL were at significantly greater risk for the primary endpoint (hazard ratio (HR) 2.98, 95% confidence interval (CI) 1.76-5.03, p<0.001) and secondary endpoint (HR 3.47, 95% CI 2.48-4.85, p<0.001) than patients with Lp(a) values <30mg/dL. The low molecular-weight apo(a) phenotype was also associated with higher risk of both primary and secondary endpoints (3.57 (1.87-6.82) and 3.05 (2.00-4.62), respectively; p<0.001 for both), regardless of conventional risk factors and statins use. Conclusion: In stable CHD patients Lp(a) concentration and low molecular-weight apo(a) phenotype are independently associated with three-fold increase in risk of major adverse cardiovascular events within 15 years after CABG. Lp(a) levels may provide an additional information for postoperative cardiovascular risk assessment. © 2014 Elsevier Ireland Ltd.","Apo(a) phenotype; Apolipoprotein(a); Coronary artery bypass grafting; Coronary heart disease; Lipoprotein(a); Long-term prognosis; Vein graft disease","Nordestgaard, B.G., Chapman, M.J., Ray, K., Borén, J., Andreotti, F., Watts, G.F., European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status (2010) Eur Heart J, 31, pp. 2844-2853; Erqou, S., Kaptoge, S., Perry, P.L., Di Angelantonio, E., Thompson, A., White, I.R., Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality (2009) JAMA, 302, pp. 412-423; Kamstrup, P.R., Tybjaerg-Hansen, A., Steffensen, R., Nordestgaard, B.G., Genetically elevated lipoprotein(a) and increased risk of myocardial infarction (2009) JAMA, 301, pp. 2331-2339; Berg, K., A new serum type system in men - the Lp(a) system (1963) Acta. Path. Microbiol. Scand, 59, pp. 369-382; MacLean, J.W., Tomlinson, J.E., Kuang, W.J., Eaton, D.L., Chen, E.Y., Fless, G.M., CDNA Sequence of human apolipoprotein(a) is homologous to plasminogen (1987) Nature, 330, pp. 132-137; Rath, M., Niendorf, A., Reblin, T., Dietel, M., Krebber, H.J., Beisiegel, U., Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients (1989) Arteriosclerosis, 9, pp. 579-592; Cushing, G.L., Gaubatz, J.W., Nava, M.L., Burdick, B.J., Bocan, T.M., Guyton, J.R., Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation (1989) Arteriosclerosis, 9, pp. 593-603; Utermann, G., Menzel, H., Kraft, H., Duba, H., Kemmler, H., Seitz, C., Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma (1987) J Clin Invest, 80, pp. 458-465; Hervio, L., Chapman, M.J., Thillet, J., Loyau, S., Angles-Cano, E., Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? (1993) Blood, 82, pp. 392-397; Erqou, S., Thompson, A., Di Angelantonio, E., Saleheen, D., Kaptoge, S., Marcovina, S., Danesh, J., Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants (2010) J Am Coll Cardiol, 55, pp. 2160-2167; Eritsland, J., Arnesen, H., Seljeflot, I., Abdelnoor, M., Grønseth, K., Berg, K., Malinow, M.R., Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting (1994) Am J Cardiol, 74, pp. 1099-1102; Skinner, J.S., Farrer, M., Albers, C.J., Piper, K., Neil, H.A., Adams, P.C., Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery (1997) Heart, 78, pp. 131-135; Lindén, T., Taddei-Peters, W., Wilhelmsen, L., Herlitz, J., Karlsson, T., Ullström, C., Wiklund, O., Serum lipids, lipoprotein(a) and apo(a) isoforms in patients withestablished coronary artery disease and their relation to disease andprognosis after coronary by-pass surgery (1998) Atherosclerosis, 137, pp. 175-186; Harris, M., Shammas, N.W., Jerin, M., Elevated levels of low-density lipoprotein cholesterol, homocysteine, and lipoprotein(a) are associated with the occurrence of symptomatic bypass graft disease 1 year following coronary artery bypass graft surgery (2004) Prev Cardiol, 7, pp. 106-108; Pokrovsky, S.N., Ezhov, M.V., Il'ina, L.N., Afanasieva, O.I., Sinitsyn, V.Y., Shiriaev, A.A., Akchurin, R.S., Association of lipoprotein(a) excess with early vein graft occlusions in patients undergoing coronary artery bypass surgery (2003) J Thorac Cardiovasc Surg, 126, pp. 1071-1075; Ezhov, M.V., Safarova, M.C., Afanas'eva, O.I., Il'ina, L.N., Liakishev, A.A., Pokrovski SN. [High level of lipoprotein (a) as a predictor of poor long-term prognosis after coronary artery bypass surgery] (2011) Kardiologiia, 51 (1), pp. 18-22. , [RUS]; Afanasieva, O.I., Adamova, I.Y., Benevolenskaya, G.F., Pokrovsky, S.N., Immuno-enzyme assay for lipoprotein(a) measurement (1995) Bull Experim Biol Med, 4, pp. 398-401. , [RUS]; Kraft, H.G., Dieplinger, H., Hoye, E., Utermann, G., Lp(a) phenotyping by immunoblotting with polyclonal and monoclonal antibodies (1988) Arteriosclerosis, 8, pp. 212-216; Berg, K., Dahlen, G., Christophersen, B., Cook, T., Kjekshus, J., Pedersen, T., Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study (1997) Clin Genet, 52, pp. 254-261; Glader, C.A., Birgander, L.S., Stenlund, H., Dahlén, G.H., Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden (2002) J Intern Med, 252, pp. 27-35; Nicholls, S.J., Tang, W.H., Scoffone, H., Brennan, D.M., Hartiala, J., Allayee, H., Hazen, S.L., Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy (2010) J Lipid Res, 51, pp. 3055-3061; Campeau, L., Enjalbert, M., Lespérance, J., Bourassa, M.G., Kwiterovich, P., Wacholder, S., Sniderman, A., The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery (1984) N Engl J Med, 311, pp. 1329-1332; Hoff, H.F., Beck, G.J., Skibinski, C.I., Jürgens, G., O'Neil, J., Kramer, J., Lytle, B., Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients (1988) Circulation, 77, pp. 1238-1244; Hueb, W., Lopes, N., Gersh, B.J., Soares, P.R., Ribeiro, E.E., Pereira, A.C., Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease (2010) Circulation, 122, pp. 949-957; Fukushima, Y., Ohmura, H., Mokuno, H., Kajimoto, K., Kasai, T., Hirayama, S., Non-high-density lipoprotein cholesterol is a practical predictor of long-term cardiac death after coronary artery bypass grafting (2012) Atherosclerosis, 221, pp. 206-211; Song, P., Seok, J.M., Kim, W.S., Lee, Y.T., Kim, D.K., Kim, G.M., Increased lipoprotein(a) is associated with polyvascular disease in patients undergoing coronary artery bypass graft (2011) Atherosclerosis, 219, pp. 285-290; Marcovina, S.M., Koschinsky, M.L., Albers, J.J., Skarlatos, S., Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions (2003) Clin Chem, 49, pp. 1785-1796; Sandholzer, C., Saha, M., Boerwinkle, E., Apo(a) isoforms predict risk for coronary heart disease. A study in six populations (1992) Arterioscler Thromb, 12, pp. 1214-1226; Kronenberg, F., Neyer, U., Lhotta, K., Trenkwalder, E., Auinger, M., Pribasnig, A., The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up (1999) J Am Soc Nephrol, 10, pp. 1027-1036; Kang, S., Liu, Y., Liu, X.B., Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials (2013) Clin Ther, 35, pp. 1125-1136; Ezhov, M.V., Il'ina, L.N., Safarova, M.S., Afanasieva, O.I., Adamova, I.Y., Atanesyan, R.V., Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins (2013) Atheroscler Suppl, 14, pp. 101-105",Article,Scopus,2-s2.0-84921509674
"Feng Y., Huang X., Sun H., Liu C., Zhang B., Zhang Z., Sharma Tengur V., Chen W., Wu T., Yuan J., Zhang X.","Framingham risk score modifies the effect of PM<inf>10</inf> on heart rate variability",2015,"Science of the Total Environment","523",,,"146","151",,,10.1016/j.scitotenv.2015.04.009,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926332767&partnerID=40&md5=994b002be718b16b13cbb721932f519a","Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China","Feng, Y., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Huang, X., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Sun, H., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Liu, C., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Zhang, B., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Zhang, Z., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Sharma Tengur, V., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Chen, W., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Wu, T., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Yuan, J., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China; Zhang, X., Department of Occupational and Environmental Health, Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China","Health conditions may greatly modify the association between particulate matter (PM) and heart rate variability (HRV), but whether the modification of PM effect by coronary artery disease (CAD) risk status depends on the PM levels remains unknown. We investigated the associations between personal exposures to PM with aerodynamic diameter of ≤10μm (PM<inf>10</inf>) and ≤2.5μm (PM<inf>2.5</inf>) and concurrent HRV, and whether the effect of PM on HRV was modified by Framingham risk score (FRS) in healthy subjects with different PM exposure levels. Personal exposures to PM<inf>10</inf> and PM<inf>2.5</inf> were measured for 24h in 152 volunteers of community residents who were free of cardiovascular disease in two cities (Zhuhai and Wuhan) that differ in air quality. Simultaneously, 24h HRV indices were obtained from 3-channel Holter monitor. FRS was calculated based on age, sex, lipid profiles, blood pressure, diabetes, and smoking status. Linear regression models were constructed after adjusting for potential confounders. We found significant decrease in total power (TP) and low power (LF) with increased PM<inf>10</inf> concentrations (P for trend<0.05) in the high PM levels city (Wuhan) and total population, but not in the low PM levels city (Zhuhai). We also observed significant modification of FRS on PM<inf>10</inf> effect in Wuhan. Interestingly, elevated PM<inf>10</inf> was associated in a greater decreased HRV in the low FRS subgroup, but not in the high FRS subgroup. However, we did not find any significant main effects of PM<inf>2.5</inf> or PM<inf>2.5</inf>-FRS interactions on HRV in city-specified or city-combined analyses. Overall, the findings indicate that individual coronary risk profiles may modulate the association between particulate air pollution and HRV in high PM exposure levels. © 2015 Elsevier B.V.","Framingham risk score; Heart rate variability; Particulate matter","Diagnosis and classification of diabetes mellitus (2012) Diabetes Care, 35, pp. S64-S71; Baccarelli, A., Cassano, P.A., Litonjua, A., Park, S.K., Suh, H., Sparrow, D., Cardiac autonomic dysfunction: effects from particulate air pollution and protection by dietary methyl nutrients and metabolic polymorphisms (2008) Circulation, 117, pp. 1802-1809; Brook, R.D., Franklin, B., Cascio, W., Hong, Y., Howard, G., Lipsett, M., Air pollution and cardiovascular disease: a statement for healthcare professionals from the expert panel on Population and Prevention Science of the American Heart Association (2004) Circulation, 109, pp. 2655-2671; Cavallari, J.M., Eisen, E.A., Chen, J.C., Fang, S.C., Dobson, C.B., Schwartz, J., Night heart rate variability and particulate exposures among boilermaker construction workers (2007) Environ. Health Perspect., 115, pp. 1046-1051; Chahine, T., Baccarelli, A., Litonjua, A., Wright, R.O., Suh, H., Gold, D.R., Particulate air pollution, oxidative stress genes, and heart rate variability in an elderly cohort (2007) Environ. Health Perspect., 115, pp. 1617-1622; Chen, J.C., Stone, P.H., Verrier, R.L., Nearing, B.D., MacCallum, G., Kim, J.Y., Personal coronary risk profiles modify autonomic nervous system responses to air pollution (2006) J. Occup. Environ. Med., 48, pp. 1133-1142; Chen, J.C., Cavallari, J.M., Stone, P.H., Christiani, D.C., Obesity is a modifier of autonomic cardiac responses to fine metal particulates (2007) Environ. Health Perspect., 115, pp. 1002-1006; Chen, R., Wang, X., Meng, X., Hua, J., Zhou, Z., Chen, B., Communicating air pollution-related health risks to the public: an application of the Air Quality Health Index in Shanghai, China (2013) Environ. Int., 51, pp. 168-173; Feng, Y., Sun, H., Song, Y., Bao, J., Huang, X., Ye, J., A community study of the effect of polycyclic aromatic hydrocarbon metabolites on heart rate variability based on the Framingham risk score (2014) Occup. Environ. Med., 71, pp. 338-345; Folino, A.F., Scapellato, M.L., Canova, C., Maestrelli, P., Bertorelli, G., Simonato, L., Individual exposure to particulate matter and the short-term arrhythmic and autonomic profiles in patients with myocardial infarction (2009) Eur. Heart J., 30, pp. 1614-1620; Ford, E.S., The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study (2004) Atherosclerosis, 173, pp. 309-314; Gold, D.R., Litonjua, A., Schwartz, J., Lovett, E., Larson, A., Nearing, B., Ambient pollution and heart rate variability (2000) Circulation, 101, pp. 1267-1273; Grundy, S.M., Pasternak, R., Greenland, P., Smith, S., Fuster, V., Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology (1999) Circulation, 100, pp. 1481-1492; Holguin, F., Tellez-Rojo, M.M., Hernandez, M., Cortez, M., Chow, J.C., Watson, J.G., Air pollution and heart rate variability among the elderly in Mexico City (2003) Epidemiology, 14, pp. 521-527; Huang, W., Zhu, T., Pan, X., Hu, M., Lu, S.E., Lin, Y., Air pollution and autonomic and vascular dysfunction in patients with cardiovascular disease: interactions of systemic inflammation, overweight, and gender (2012) Am. J. Epidemiol., 176, pp. 117-126; Jedrychowski, W.A., Perera, F.P., Maugeri, U., Spengler, J., Mroz, E., Flak, E., Prohypertensive effect of gestational personal exposure to fine particulate matter. Prospective cohort study in non-smoking and non-obese pregnant women (2012) Cardiovasc. Toxicol., 12, pp. 216-225; Jia, X., Song, X., Shima, M., Tamura, K., Deng, F., Guo, X., Effects of fine particulate on heart rate variability in Beijing: a panel study of healthy elderly subjects (2012) Int. Arch. Occup. Environ. Health, 85, pp. 97-107; Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men (2002) JAMA, 288, pp. 2709-2716; Li, L., Qian, J., Ou, C.Q., Zhou, Y.X., Guo, C., Guo, Y., Spatial and temporal analysis of Air Pollution Index and its timescale-dependent relationship with meteorological factors in Guangzhou, China, 2001-2011 (2014) Environ. Pollut., 190, pp. 75-81; Luttmann-Gibson, H., Suh, H.H., Coull, B.A., Dockery, D.W., Sarnat, S.E., Schwartz, J., Systemic inflammation, heart rate variability and air pollution in a cohort of senior adults (2010) Occup. Environ. Med., 67, pp. 625-630; Maestrelli, P., Canova, C., Scapellato, M.L., Visentin, A., Tessari, R., Bartolucci, G.B., Personal exposure to particulate matter is associated with worse health perception in adult asthma (2011) J. Investig. Allergol. Clin. Immunol., 21, pp. 120-128; Magari, S.R., Hauser, R., Schwartz, J., Williams, P.L., Smith, T.J., Christiani, D.C., Association of heart rate variability with occupational and environmental exposure to particulate air pollution (2001) Circulation, 104, pp. 986-991; Magari, S.R., Schwartz, J., Williams, P.L., Hauser, R., Smith, T.J., Christiani, D.C., The association of particulate air metal concentrations with heart rate variability (2002) Environ. Health Perspect., 110, pp. 875-880; Determination of atmospheric articles PM<inf>10</inf> and PM<inf>2.5</inf> in ambient air by gravimetric method (HJ 618-2011), , http://kjs.mep.gov.cn/hjbhbz/bzwb/dqhjbh/jcgfffbz/201109/t20110914_217272.htm, (accessed on July 24, 2014); Ambient air quality standards (GB 3095-2012), , http://kjs.mep.gov.cn/hjbhbz/bzwb/dqhjbh/dqhjzlbz/201203/t20120302_224165.htm, Available online:, (accessed on July 24, 2014); Air quality in 2013, , http://www.mep.gov.cn/zhxx/hjyw/201403/t20140326_269702.htm, Available online:, (accessed on June 14, 2014); Park, S.K., O'Neill, M.S., Vokonas, P.S., Sparrow, D., Schwartz, J., Effects of air pollution on heart rate variability: the VA normative aging study (2005) Environ. Health Perspect., 113, pp. 304-309; Park, S.K., Auchincloss, A.H., O'Neill, M.S., Prineas, R., Correa, J.C., Keeler, J., Particulate air pollution, metabolic syndrome, and heart rate variability: the Multi-Ethnic Study of Atherosclerosis (MESA) (2010) Environ. Health Perspect., 118, pp. 1406-1411; Pieters, N., Plusquin, M., Cox, B., Kicinski, M., Vangronsveld, J., Nawrot, T.S., An epidemiological appraisal of the association between heart rate variability and particulate air pollution: a meta-analysis (2012) Heart, 98, pp. 1127-1135; Pope, C.A., Hansen, M.L., Long, R.W., Nielsen, K.R., Eatough, N.L., Wilson, W.E., Ambient particulate air pollution, heart rate variability, and blood markers of inflammation in a panel of elderly subjects (2004) Environ. Health Perspect., 112, pp. 339-345; Qian, Z., He, Q., Lin, H.M., Kong, L., Liao, D., Dan, J., Association of daily cause-specific mortality with ambient particle air pollution in Wuhan, China (2007) Environ. Res., 105, pp. 380-389; Riediker, M., Cascio, W.E., Griggs, T.R., Herbst, M.C., Bromberg, P.A., Neas, L., Particulate matter exposure in cars is associated with cardiovascular effects in healthy young men (2004) Am. J. Respir. Crit. Care Med., 169, pp. 934-940; Sarnat, J.A., Koutrakis, P., Suh, H.H., Assessing the relationship between personal particulate and gaseous exposures of senior citizens living in Baltimore, MD (2000) J. Air Waste Manag. Assoc., 50, pp. 1184-1198; Schwartz, J., Park, S.K., O'Neill, M.S., Vokonas, P.S., Sparrow, D., Weiss, S., Glutathione-S-transferase M1, obesity, statins, and autonomic effects of particles: gene-by-drug-by-environment interaction (2005) Am. J. Respir. Crit. Care Med., 172, pp. 1529-1533; Report on the state of the environment in China 2006, , http://english.mep.gov.cn/down_load/Documents/200710/P020071023479580153243.pdf, Available online:, (accessed on June 10, 2014); Sullivan, J.H., Schreuder, A.B., Trenga, C.A., Liu, S.L., Larson, T.V., Koenig, J.Q., Association between short term exposure to fine particulate matter and heart rate variability in older subjects with and without heart disease (2005) Thorax, 60, pp. 462-466; Timonen, K.L., Vanninen, E., de Hartog, J., Ibald-Mulli, A., Brunekreef, B., Gold, D.R., Effects of ultrafine and fine particulate and gaseous air pollution on cardiac autonomic control in subjects with coronary artery disease: the ULTRA study (2006) J. Expo. Sci. Environ. Epidemiol., 16, pp. 332-341; Wannamethee, S.G., Shaper, A.G., Lennon, L., Morris, R.W., Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus (2005) Arch. Intern. Med., 165, pp. 2644-2650; Wheeler, A., Zanobetti, A., Gold, D.R., Schwartz, J., Stone, P., Suh, H.H., The relationship between ambient air pollution and heart rate variability differs for individuals with heart and pulmonary disease (2006) Environ. Health Perspect., 114, pp. 560-566; Whitsel, E.A., Quibrera, P.M., Christ, S.L., Liao, D., Prineas, R.J., Anderson, G.L., Heart rate variability, ambient particulate matter air pollution, and glucose homeostasis: the environmental epidemiology of arrhythmogenesis in the women's health initiative (2009) Am. J. Epidemiol., 169, pp. 693-703; Wilson, P.W., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B., Prediction of coronary heart disease using risk factor categories (1998) Circulation, 97, pp. 1837-1847; Environment and people's health in China (2001), , http://www.wpro.who.int/environmental_health/documents/docs/CHNEnvironmentalHealth.pdf, Available online:, (accessed on June 10, 2014); Wu, S., Deng, F., Niu, J., Huang, Q., Liu, Y., Guo, X., Association of heart rate variability in taxi drivers with marked changes in particulate air pollution in Beijing in 2008 (2010) Environ. Health Perspect., 118, pp. 87-91; Wu, S., Deng, F., Niu, J., Huang, Q., Liu, Y., Guo, X., Exposures to PM<inf>2.5</inf> components and heart rate variability in taxi drivers around the Beijing 2008 Olympic Games (2011) Sci. Total Environ., 409, pp. 2478-2485; Wu, S., Deng, F., Liu, Y., Shima, M., Niu, J., Huang, Q., Temperature, traffic-related air pollution, and heart rate variability in a panel of healthy adults (2013) Environ. Res., 120, pp. 82-89; Xiang, H., Mertz, K.J., Arena, V.C., Brink, L.L., Xu, X., Bi, Y., Estimation of short-term effects of air pollution on stroke hospital admissions in Wuhan, China (2013) PLoS One, 8, p. e61168",Article,Scopus,2-s2.0-84926332767
"Katakami N., Kaneto H., Matsuoka T.-A., Takahara M., Osonoi T., Saitou M., Kawai K., Ishibashi F., Kashiwagi A., Kawamori R., Shimomura I., Yamasaki Y.","Accumulation of oxidative stress-related gene polymorphisms and the risk of coronary heart disease events in patients with type 2 diabetes - An 8-year prospective study",2015,"Atherosclerosis","235","2",,"408","414",,,10.1016/j.atherosclerosis.2014.05.936,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921473820&partnerID=40&md5=cd07ea00a9655908c946009645c3ef6a","Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, Japan; Naka Memorial Clinic, Japan; Kawai Clinic, Japan; Ishibashi Clinic, Japan; Department of Medicine, Shiga University of Medical Science, Japan; Sportology Center, Juntendo University School of Medicine, Japan","Katakami, N., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan, Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, Japan; Kaneto, H., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Matsuoka, T.-A., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Takahara, M., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Osonoi, T., Naka Memorial Clinic, Japan; Saitou, M., Naka Memorial Clinic, Japan; Kawai, K., Kawai Clinic, Japan; Ishibashi, F., Ishibashi Clinic, Japan; Kashiwagi, A., Department of Medicine, Shiga University of Medical Science, Japan; Kawamori, R., Sportology Center, Juntendo University School of Medicine, Japan; Shimomura, I., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan; Yamasaki, Y., Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan","Objective: Oxidative stress, which is provoked in patients with diabetes, plays critical roles in the pathogenesis of coronary heart disease (CHD). We simultaneously determined 5 relatively common genetic variants related to oxidative stress and evaluated the combined effect on CHD. Methods: We enrolled 1977 Japanese type 2 diabetic subjects without history of CVD (males 66.1%, 59.5±10.0 years old), determined their genotypes regarding glutamate-cysteine ligase modifier subunit (GCLM) C-588T, manganese superoxide dismutase (SOD2) Val16Ala, endothelial nitric oxide synthase (NOS3) G894T, NAD(P)H oxidase p22phox (CYBA) C242T, and myeloperoxidase (MPO) G-463A polymorphisms, and prospectively evaluated the association between these polymorphisms and CHD events. Results: The median follow-up period was 7.5 years and there were 85 new CHD events. The single association analysis revealed that there were no statistically significant associations between each polymorphism and the prevalence of CHD. Interestingly, the risk of CHD event was higher with the increase of the total number of 10 concomitant unfavorable ""pro-oxidant alleles"" in each subject (p for trend=0.018, log-rank test). Especially, the carriers of <8 pro-oxidant alleles had a significantly increased risk as compared to the carriers of <8 pro-oxidant alleles, whether the other clinical variables were adjusted (HR 2.92 with 95%CI 1.50-5.67, p=0.002) or not (HR 2.89 with 95%CI 1.49-5.59, p=0.002). Conclusions: Accumulation of gene polymorphisms related to oxidative stress is likely associated with the development of CHD in patients with type 2 diabetes, suggesting that the combined information about these variants is useful to assess the risk of CHD. © 2014 Elsevier Ireland Ltd.","Atherosclerosis; Coronary heart disease; Diabetes; Oxidative stress; Polymorphism","Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H., Keen, H., Mortality and causes of death in the WHO multinational study of vascular disease in diabetes (2001) Diabetologia, 44 (Suppl.2), pp. S14-S21; Eckel, R.H., Kahn, R., Robertson, R.M., Rizza, R.A., Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association (2006) Circulation, 113, pp. 2943-2946; Khot, U.N., Khot, M.B., Bajzer, C.T., Sapp, S.K., Ohman, E.M., Brener, S.J., Prevalence of conventional risk factors in patients with coronary heart disease (2003) JAm Med Assoc, 290, pp. 898-904; Greenland, P., Knoll, M.D., Stamler, J., Neaton, J.D., Dyer, A.R., Garside, D.B., Major risk factors as antecedents of fatal and nonfatal coronary heart disease events (2003) JAm Med Assoc, 290, pp. 891-897; West, I.C., Radicals in oxidative stress in diabetes (2002) Diabet Med, 17, pp. 171-180; Meister, A., Anderson, M.E., Glutathione (1983) Annu Rev Biochem, 52, pp. 711-760; Minova, H.R., Mulcahy, R.T., An electrophile responsive element (EpRE) regulates gamma-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory subunit gene (1998) JBiol Chem, 273, pp. 14683-14689; Nakamura, S., Kugiyama, K., Sugiyama, S., Miyamoto, S., Koide, S., Fukushima, H., Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction (2002) Circulation, 105, pp. 2968-2973; Lebovitz, R.M., Zhang, H., Vogel, H., Cartwright, J., Dionne, L., Lu, N., Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice (1996) Proc Natl Acad Sci U S A, 93, pp. 9782-9787; Shimoda-Matsubayashi, S., Matsumine, H., Kobayashi, T., Nakagawa-Hattori, Y., Shimizu, Y., Mizuno, Y., Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease (1996) Biochem Biophys Res Commun, 226, pp. 561-565; Sutton, A., Khoury, H., Prip-Buus, C., Cepanec, C., Pessayre, D., Degoul, F., The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria (2003) Pharmacogenetics, 13, pp. 145-157; Shimoda-Matsubayashi, S., Hattori, T., Matsumine, H., Shinohara, A., Yoritaka, A., Mori, H., MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson' disease and control (1997) Neurology, 49, pp. 1257-1262; Tesauro, M., Thompson, W.C., Rogliani, P., Qi, L., Chaudhary, P.P., Moss, J., Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298 (2000) Proc Natl Acad Sci U S A, 97, pp. 2832-2835; Wang, X.L., Sim, A.S., Wang, M.X., Murrell, G.A., Trudinger, B., Wang, J., Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity (2000) FEBS Lett, 471, pp. 45-50; Veldman, B.A., Spiering, W., Doevendans, P.A., Vervoort, G., Kroon, A.A., de Leeuw, P.W., The Glu298Asp polymorphism of the NOS3 gene as a determinant of the baseline production of nitric oxide (2002) JHypertens, 20, pp. 2023-2027; Noiri, E., Satoh, H., Taguchi, J., Brodsky, S.V., Nakao, A., Ogawa, Y., Association of eNOS Glu298Asp polymorphism with end-stage renal disease (2002) Hypertension, 40, pp. 535-540; Azumi, H., Inoue, N., Takeshita, S., Rikitake, Y., Kawashima, S., Hayashi, Y., Expression of NADH/NADPH oxidase p22phox in human coronary arteries (1999) Circulation, 100, pp. 1494-1498; Guzik, T.J., West, N.E., Black, E., McDonald, D., Ratnatunga, C., Pillai, R., Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis (2000) Circulation, 102, pp. 1744-1747; Daugherty, A., Dunn, J.L., Rateri, D.L., Heinecke, J.W., Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions (1994) JClin Invest, 94, pp. 437-444; Reynolds, W.F., Chang, E., Douer, E., Ball, E.D., Kanda, V., An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia (1997) Blood, 90, pp. 2730-2737; Piedrafita, F.J., Molander, R.B., Vansant, G., Orlova, E.A., Pfhal, M., Reynolds, W.F., An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element (1996) JBiol Chem, 271, pp. 14412-14420; Katakami, N., Kume, S., Kaneto, H., Uzu, T., Kashiwagi, A., Yamasaki, Y., Association of myeloperoxidase G-463A gene polymorphism with diabetic nephropathy in Japanese type 2 diabetic subjects (2013) Endocr J, 60, pp. 457-471; Katakami, N., Kaneto, H., Matsuoka, T.A., Takahara, M., Imamura, K., Ishibashi, F., Accumulation of gene polymorphisms related to oxidative stress is associated with myocardial infarction in Japanese type 2 diabetic patients (2010) Atherosclerosis, 212, pp. 534-538; Yamada, Y., Izawa, H., Ichihara, S., Takatsu, F., Ishihara, H., Hirayama, H., Prediction of the risk of myocardial infarction from polymorphisms in candidate genes (2002) NEngl J Med, 347, pp. 1916-1923; Yang, Q., Khoury, M.J., Botto, L., Friedman, J.M., Flanders, W.D., Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes (2003) Am J Hum Genet, 72, pp. 636-649; Cam, S.F., Sekuri, C., Tengiz, I., Ecran, E., Sagcan, A., Akin, M., The G894T polymorphism on endothelial nitric oxide synthase gene is associated with premature coronary artery disease in a Turkish population (2005) Thromb Res, 116, pp. 278-292; Tamemoto, H., Ishikawa, S.E., Kawakami, M., Association of the Glu298Asp polymorphism of the eNOS gene with ischemic heart disease in Japanese diabetic subjects (2008) Diabetes Res Clin Pract, 80, pp. 275-279; Jaramillo, P.C., Munoz, M.A., Lanas, M.C., Lanas, Z.F., Salazar, L.A., Endothelial nitric oxide synthase G894T gene polymorphism in Chilean subjects with coronary artery disease and controls (2006) Clin Chim Acta, 371, pp. 102-106; Inoue, N., Kawashima, S., Kanazawa, K., Yamada, S., Akita, H., Yokoyama, M., Polymorphism of the NADH/NADPH oxidase p22phox gene in patients with coronary artery disease (1998) Circulation, 97, pp. 135-137; Soccio, M., Toniato, E., Evangelista, V., Carluccio, M., De Caterina, R., Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants (2005) Eur J Clin Invest, 35, pp. 305-314; Nikpoor, B., Turecki, G., Fournier, C., Theroux, P., Rouleau, G.A., Afunctional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians (2001) Am Heart J, 142, pp. 336-339; Makela, R., Loimaala, A., Nenonen, A., Mercuri, M., Vuori, I., Huhtala, H., The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes (2008) Clin Biochem, 41, pp. 532-553; Wainstein, R.V., Wainstein, M.V., Riberio, J.P., Dornelles, L.V., Tozzati, P., Ashton-Prolla, P., Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease (2010) Clin Biochem, 43, pp. 57-62; Fujimoto, H., Taguchi, J., Imai, Y., Ayabe, S., Hashimoto, H., Kobayashi, H., Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease (2008) Eur Heart J, 29, pp. 1267-1274; Dalager, S., Paaske, W.P., Kristensen, I.B., Laurberg, J.M., Falk, E., Artery-related differences in atherosclerosis expression. Implications for atherogenesis and dynamics in intima-media thickness (2007) Stroke, 38, pp. 2698-2705; Glagov, S., Zarins, C., Giddens, D.P., Ku, D.N., Hemodynamics and atherosclerosis: insights and perspectives gained from studies of human arteries (1988) Arch Pathol Lab Med, 112, pp. 1018-1031; Sone, H., Tanaka, S., Tanaka, S., Iimuro, S., Oida, K., Yamasaki, Y., Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS) (2011) JClin Endocrinol Metab, 96, pp. 3448-3456. , Japan Diabetes Complications Study Group; van der Heijden, A.A., Ortegon, M.M., Niessen, L.W., Nijpels, G., Dekker, J.M., Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions (2009) Diabetes Care, 32, pp. 2094-2098; Mulnier, H.E., Seaman, H.E., Raleigh, V.S., Soedamah-Muthu, S.S., Colhoun, H.M., Lawrenson, R.A., Risk of stroke in people with type 2 diabetes in the UK: a study using the general practice research database (2006) Diabetologia, 49, pp. 2859-2865; Sone, H., Mizuno, S., Fujii, H., Yoshimura, Y., Yamasaki, Y., Ishibashi, S., Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study (2005) Diabetes Care, 28, pp. 1463-1471; Sone, H., Ito, H., Ohashi, Y., Akanuma, Y., Yamada, N., Obesity and type 2 diabetes in Japanese patients (2003) Lancet, 361, p. 85",Article,Scopus,2-s2.0-84921473820
"Fandino-Vaquero R., Fernandez-Trasancos A., Alvarez E., Ahmad S., Batista-Oliveira A.L., Adrio B., Fernandez T.L., Gonzalez-Juanatey J.R., Eiras S.","Orosomucoid secretion levels by epicardial adipose tissue as possible indicator of endothelial dysfunction in diabetes mellitus or inflammation in coronary artery disease",2015,"Atherosclerosis","235","2",,"281","288",,2,10.1016/j.atherosclerosis.2014.05.921,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908217682&partnerID=40&md5=eb24b3d47bd7c395b0e0d3bfc78230f6","Department of Cardiology and Coronary Unit, Clinical Hospital of Santiago de Compostela, Spain; Health Research Institute, Spain; Department of Cardiac Surgery, Clinical Hospital of Santiago de Compostela, Spain","Fandiño-Vaquero, R., Department of Cardiology and Coronary Unit, Clinical Hospital of Santiago de Compostela, Spain; Fernández-Trasancos, A., Health Research Institute, Spain; Álvarez, E., Health Research Institute, Spain; Ahmad, S., Health Research Institute, Spain; Batista-Oliveira, A.L., Health Research Institute, Spain; Adrio, B., Department of Cardiac Surgery, Clinical Hospital of Santiago de Compostela, Spain; Fernández, T.L., Department of Cardiac Surgery, Clinical Hospital of Santiago de Compostela, Spain; González-Juanatey, J.R., Department of Cardiology and Coronary Unit, Clinical Hospital of Santiago de Compostela, Spain, Health Research Institute, Spain; Eiras, S., Health Research Institute, Spain","Objective: Type 2 diabetes mellitus (T2DM) is associated with fat and autonomic system dysfunction. Epicardial adipose tissue (EAT) plays an endocrine role over the heart. Since orosomucoid (ORM) has local actions around the coronaries, our aim was to assess the relationship between its secretion profile by EAT and its catecholaminergic regulation in patients with T2DM and coronary artery disease (CAD). Methods: We obtained EAT, subcutaneous adipose tissue (SAT) and plasma from 55 patients undergoing cardiac surgery. Fat explants were stimulated with isoproterenol (ISO) 1μM for 6h. After, the fat explants released-ORM and plasma levels were analyzed by ELISA. mRNA or protein expression was analyzed by real time PCR or western blot, respectively. The effects of ORM on endothelial cells were analyzed by impedance and wound healing assays. Results: We observed that EAT-released ORM levels were higher than SAT (328±185 vs 58±45ng/mL; p<0.001). Interestingly, EAT secretion was lower in patients with than those without T2DM (260±141 vs 370±194ng/mL; p<0.05) and this difference was enhanced after ISO stimulation (. p<0.01). However, plasma levels (412±119 vs 594±207μg/mL) and EAT-released ORM levels were higher in patients with than those without CAD (384±195 vs 279±159ng/mL; p<0.05). ISO stimulation, also reduced the EAT released-ORM levels in patients with CAD. On human endothelial cells, ORM induced an increase of healing and proliferation in a dose-dependent manner. Conclusion: EAT-released ORM levels in patients with T2DM or CAD and its regulation by catecholamines might be the mirror of local endothelium dysfunction or inflammatory process in different cardiovascular disorders. © 2014 Elsevier Ireland Ltd.","Epicardial adipose tissue; Orosomucoid; Type 2 diabetes mellitus","Iacobellis, G., Corradi, D., Sharma, A.M., Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart (2005) Nat Clin Pract Cardiovasc Med, 2, pp. 536-543; Sacks, H.S., Fain, J.N., Human epicardial adipose tissue: a review (2007) Am Heart J, 153, pp. 907-917; Gorter, P.M., de Vos, A.M., van der Graaf, Y., Stella, P.R., Doevendans, P.A., Meijs, M.F., Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography (2008) Am J Cardiol, 102, pp. 380-385; Iozzo, P., Myocardial, perivascular, and epicardial fat (2011) Diabetes Care, 34 (Suppl.2), pp. S371-S379; Shimabukuro, M., Hirata, Y., Tabata, M., Dagvasumberel, M., Sato, H., Kurobe, H., Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis (2013) Arterioscler Thromb Vasc Biol, 33, pp. 1077-1084; Mazurek, T., Zhang, L., Zalewski, A., Mannion, J.D., Diehl, J.T., Arafat, H., Human epicardial adipose tissue is a source of inflammatory mediators (2003) Circulation, 108, pp. 2460-2466; Silaghi, A., Achard, V., Paulmyer-Lacroix, O., Scridon, T., Tassistro, V., Duncea, I., Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status (2007) Am J Physiol Endocrinol Metab, 293, pp. E1443-E1450; Salgado-Somoza, A., Teijeira-Fernandez, E., Fernandez, A.L., Gonzalez-Juanatey, J.R., Eiras, S., Changes in lipid transport-involved proteins of epicardial adipose tissue associated with coronary artery disease (2012) Atherosclerosis, 224, pp. 492-499; Karastergiou, K., Evans, I., Ogston, N., Miheisi, N., Nair, D., Kaski, J.C., Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells (2010) Arterioscler Thromb Vasc Biol, 30, pp. 1340-1346; Wang, C.P., Hsu, H.L., Hung, W.C., Yu, T.H., Chen, Y.H., Chiu, C.A., Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis (2009) Clin Endocrinol (Oxf), 70, pp. 876-882; Galvez-Monton, C., Prat-Vidal, C., Roura, S., Farre, J., Soler-Botija, C., Llucia-Valldeperas, A., Transposition of a pericardial-derived vascular adipose flap for myocardial salvage after infarct (2011) Cardiovasc Res, 91, pp. 659-667; Gao, Y.J., Zeng, Z.H., Teoh, K., Sharma, A.M., Abouzahr, L., Cybulsky, I., Perivascular adipose tissue modulates vascular function in the human internal thoracic artery (2005) JThorac Cardiovasc Surg, 130, pp. 1130-1136; Greulich, S., Maxhera, B., Vandenplas, G., Herzfeld de Wiza, D., Smiris, K., Mueller, H., Secretory products from epicardial adipose tissue of patients with type 2 diabetes induce cardiomyocyte dysfunction (2012) Circulation, 126, pp. 2324-2334; Aksakal, E., Tanboga, I.H., Kurt, M., Predictors of coronary lesions complexity in patients with stable coronary artery disease (2013) Angiology, 64, p. 313; Costello, M.J., Gewurz, H., Siegel, J.N., Inhibition of neutrophil activation by alpha1-acid glycoprotein (1984) Clin Exp Immunol, 55, pp. 465-472; Sorensson, J., Matejka, G.L., Ohlson, M., Haraldsson, B., Human endothelial cells produce orosomucoid, an important component of the capillary barrier (1999) Am J Phys, 276, pp. H530-H534; Lee, Y.S., Choi, J.W., Hwang, I., Lee, J.W., Lee, J.H., Kim, A.Y., Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation (2010) JBiol Chem, 285, pp. 22174-22185; Teijeira-Fernandez, E., Eiras, S., Grigorian-Shamagian, L., Fernandez, A., Adrio, B., Gonzalez-Juanatey, J.R., Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension (2008) JHum Hypertens, 22, pp. 856-863; Teijeira-Fernandez, E., Eiras, S., Grigorian-Shamagian, L., Salgado-Somoza, A., Martinez-Comendador, J.M., Gonzalez-Juanatey, J.R., Diabetic and nondiabetic patients express similar adipose tissue adiponectin and leptin levels (2010) Int J Obes (Lond), 34, pp. 1200-1208; Eiras, S., Teijeira-Fernandez, E., Shamagian, L.G., Fernandez, A.L., Vazquez-Boquete, A., Gonzalez-Juanatey, J.R., Extension of coronary artery disease is associated with increased IL-6 and decreased adiponectin gene expression in epicardial adipose tissue (2008) Cytokine, 43, pp. 174-180; Catapano, A.L., Reiner, Z., De Backer, G., Graham, I., Taskinen, M.R., Wiklund, O., ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) Atherosclerosis, 217, pp. 3-46; Scriba, D., Aprath-Husmann, I., Blum, W.F., Hauner, H., Catecholamines suppress leptin release from invitro differentiated subcutaneous human adipocytes in primary culture via beta1- and beta2-adrenergic receptors (2000) Eur J Endocrinol, 143, pp. 439-445; Rodino-Janeiro, B.K., Gonzalez-Peteiro, M., Ucieda-Somoza, R., Gonzalez-Juanatey, J.R., Alvarez, E., Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy (2010) Diabetes Metab Res Rev, 26, pp. 550-558; Jiang, A., Gao, H., Kelley, M.R., Qiao, X., Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis invitro and invivo (2010) Vision Res, 51, pp. 93-100; Dessy, C., Balligand, J.L., Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives (2010) Adv Pharmacol, 59, pp. 135-163; Boncela, J., Smolarczyk, K., Wyroba, E., Cierniewski, C.S., Binding of PAI-1 to endothelial cells stimulated by thymosin beta4 and modulation of their fibrinolytic potential (2006) JBiol Chem, 281, pp. 1066-1072; Correale, M., Brunetti, N.D., De Gennaro, L., Di Biase, M., Acute phase proteins in atherosclerosis (acute coronary syndrome) (2008) Cardiovasc Hematol Agents Med Chem, 6, pp. 272-277; Agra, R.M., Teijeira-Fernandez, E., Pascual-Figal, D., Jesus, S.M., Fernandez-Trasancos, A., Sierra, J., Differential behavior between S100A9 and adiponectin in coronary artery disease. Plasma or epicardial fat (2014) Life Sci, 100, pp. 147-151; Alexopoulos, N., Katritsis, D., Raggi, P., Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis (2014) Atherosclerosis, 233, pp. 104-112; Ligresti, G., Aplin, A.C., Dunn, B.E., Morishita, A., Nicosia, R.F., The acute phase reactant orosomucoid-1 is a bimodal regulator of angiogenesis with time- and context-dependent inhibitory and stimulatory properties (2012) PLoS One, 7, p. e41387; Kuebler, J.F., Toth, B., Yokoyama, Y., Bland, K.I., Rue, L.W., Chaudry, I.H., Alpha1-acid-glycoprotein protects against trauma-hemorrhagic shock (2004) JSurg Res, 119, pp. 21-28; Hjalmarsson, C., Lidell, M.E., Haraldsson, B., Beneficial effects of orosomucoid on the glomerular barrier in puromycin aminonucleoside-induced nephrosis (2006) Nephrol Dial Transplant, 21, pp. 1223-1230; Gunnarsson, P., Levander, L., Pahlsson, P., Grenegard, M., Alpha(1)-acid glycoprotein (AGP)-induced platelet shape change involves the Rho/Rho kinase signalling pathway (2009) Thromb Haemost, 102, pp. 694-703; Manfrini, O., Pizzi, C., Trere, D., Fontana, F., Bugiardini, R., Parasympathetic failure and risk of subsequent coronary events in unstable angina and non-ST-segment elevation myocardial infarction (2003) Eur Heart J, 24, pp. 1560-1566; Licht, C.M., de Geus, E.J., Penninx, B.W., Dysregulation of the autonomic nervous system predicts the development of the metabolic syndrome (2013) JClin Endocrinol Metab, 98, pp. 2484-2493",Article,Scopus,2-s2.0-84908217682
"Dai J., Chen R., Meng X., Yang C., Zhao Z., Kan H.","Ambient air pollution, temperature and out-of-hospital coronary deaths in Shanghai, China",2015,"Environmental Pollution","203",,,"116","121",,,10.1016/j.envpol.2015.03.050,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927133231&partnerID=40&md5=640ba77a7c855784b6767db2d1c5af12","Shandong Provincial Environmental Monitoring Center StationJi'nan, China; School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China; Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP3), Fudan UniversityShanghai, China; Key Lab of Health Technology Assessment of the Ministry of Health, Fudan UniversityShanghai, China","Dai, J., Shandong Provincial Environmental Monitoring Center StationJi'nan, China; Chen, R., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China, Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP3), Fudan UniversityShanghai, China, Key Lab of Health Technology Assessment of the Ministry of Health, Fudan UniversityShanghai, China; Meng, X., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China; Yang, C., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China; Zhao, Z., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China; Kan, H., School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan UniversityShanghai, China, Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP3), Fudan UniversityShanghai, China, Key Lab of Health Technology Assessment of the Ministry of Health, Fudan UniversityShanghai, China","Few studies have evaluated the effects of ambient air pollution and temperature in triggering out-of-hospital coronary deaths (OHCDs) in China. We evaluated the associations of air pollution and temperature with daily OHCDs in Shanghai, China from 2006 to 2011. We applied an over-dispersed generalized additive model and a distributed lag nonlinear model to analyze the effects of air pollution and temperature, respectively. A 10 μg/m3 increase in the present-day PM<inf>10</inf>, PM<inf>2.5</inf>, SO<inf>2</inf>, NO<inf>2</inf> and CO were associated with increases in OHCD mortality of 0.49%, 0.68%, 0.88%, 1.60% and 0.08%, respectively. A 1 °C decrease below the minimum-mortality temperature corresponded to a 3.81% increase in OHCD mortality on lags days 0-21, and a 1 °C increase above minimum-mortality temperature corresponded to a 4.61% increase over lag days 0-3. No effects were found for in-hospital coronary deaths. This analysis suggests that air pollution, low temperature and high temperature may increase the risk of OHCDs. © 2015 Elsevier Ltd. All rights reserved.","Air pollution; Coronary heart disease; Out-of-hospital; Risk factors; Temperature","Baxter, L.K., Burke, J., Lunden, M., Turpin, B.J., Rich, D.Q., Thevenet-Morrison, K., Hodas, N., Okaynak, H., Influence of human activity patterns, particle composition, and residential air exchange rates on modeled distributions of PM2.5 exposure compared with central-site monitoring data (2013) J. Expo. Sci. Environ. Epidemiol., 23, pp. 241-247; Chen, R., Kan, H., Chen, B., Huang, W., Bai, Z., Song, G., Pan, G., Association of particulate air pollution with daily mortality: The China air pollution and health effects study (2012) Am. J. Epidemiol., 175, pp. 1173-1181; Chen, R.J., Li, T.T., Cai, J., Yan, M.L., Zhao, Z.H., Kan, H.D., Extreme temperatures and out-of-hospital coronary deaths in six large Chinese cities (2014) J. Epidemiol. Community Health, 68, pp. 1119-1124; Dennekamp, M., Akram, M., Abramson, M.J., Tonkin, A., Sim, M.R., Fridman, M., Erbas, B., Outdoor air pollution as a trigger for out-of-hospital cardiac arrests (2010) Epidemiology, 21, pp. 494-500; Dominici, F., Peng, R.D., Bell, M.L., Pham, L., McDermott, A., Zeger, S.L., Samet, J.M., Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases (2006) JAMA, 295, pp. 1127-1134; Engdahl, J., Holmberg, M., Karlson, B.W., Luepker, R., Herlitz, J., The epidemiology of out-of-hospital 'sudden' cardiac arrest (2002) Resuscitation, 52, pp. 235-245; Ensor, K.B., Raun, L.H., Persse, D., A case-crossover analysis of out-of-hospital cardiac arrest and air pollution (2013) Circulation, 127, pp. 1192-1199; Forastiere, F., Stafoggia, M., Picciotto, S., Bellander, T., D'Ippoliti, D., Lanki, T., Von Klot, S., Perucci, C.A., A case-crossover analysis of out-of-hospital coronary deaths and air pollution in Rome, Italy (2005) Am. J. Respir. Crit. Care Med., 172, pp. 1549-1555; Gasparrini, A., Distributed lag linear and non-linear models in R: The package dlnm (2011) J. Stat. Softw., 43, pp. 1-20; Goraya, T.Y., Jacobsen, S.J., Kottke, T.E., Frye, R.L., Weston, S.A., Roger, V.L., Coronary heart disease death and sudden cardiac death: A 20-year population-based study (2003) Am. J. Epidemiol., 157, pp. 763-770; Levy, D., Sheppard, L., Checkoway, H., Kaufman, J., Lumley, T., Koenig, J., Siscovick, D., A case-crossover analysis of particulate matter air pollution and out-of-hospital primary cardiac arrest (2001) Epidemiology, 12, pp. 193-199; Lozano, R., Naghavi, M., Foreman, K., Almazroa, M.A., Memish, Z.A., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010 (vol. 380, pg 2095, 2012) (2013) Lancet, 381. , 628-628; Ma, W., Chen, R., Kan, H., Temperature-related mortality in 17 large Chinese cities: How heat and cold affect mortality in China (2014) Environ. Res., 134, pp. 127-133; Peng, R.D., Dominici, F., Louis, T.A., Model choice in time series studies of air pollution and mortality (2006) J. Roy. Stat. Soc. A Stat., 169, pp. 179-203; Pope, C.A., Burnett, R.T., Turner, M.C., Cohen, A., Krewski, D., Jerrett, M., Gapstur, S.M., Thun, M.J., Lung Cancer and cardiovascular disease mortality associated with ambient air pollution and cigarette smoke: Shape of the exposure-response relationships (2011) Environ. Health Perspect., 119, pp. 1616-1621; Rosenthal, F.S., Carney, J.P., Inger, M.L., Out-of-hospital cardiac arrest and airborne fine particulate matter: A case-crossover analysis of emergency medical services data in Indianapolis, Indiana (2008) Environ. Health Perspect., 116, pp. 631-636; Rosenthal, F.S., Kuisma, M., Lanki, T., Hussein, T., Boyd, J., Halonen, J.I., Pekkanen, J., Association of ozone and particulate air pollution with out-of-hospital cardiac arrest in Helsinki, Finland: Evidence for two different etiologies (2013) J. Expo. Sci. Environ. Epidemiol., 23, pp. 281-288; Serinelli, M., Vigotti, M.A., Stafoggia, M., Berti, G., Bisanti, L., Mallone, S., Pacelli, B., Forastiere, F., Particulate matter and out-of-hospital coronary deaths in eight Italian cities (2010) Occup. Environ. Med., 67, pp. 301-306; Silverman, R.A., Ito, K., Freese, J., Kaufman, B.J., De Claro, D., Braun, J., Prezant, D.J., Association of ambient Fine particles with out-of-hospital cardiac arrests in New York City (2010) Am. J. Epidemiol., 172, pp. 917-923; Sullivan, J., Ishikawa, N., Sheppard, L., Siscovick, D., Checkoway, H., Kaufman, J., Exposure to ambient fine particulate matter and primary cardiac arrest among persons with and without clinically recognized heart disease (2003) Am. J. Epidemiol., 157, pp. 501-509; Teng, T.H.K., Williams, T.A., Bremner, A., Tohira, H., Franklin, P., Tonkin, A., Jacobs, I., Finn, J., A systematic review of air pollution and incidence of out-of-hospital cardiac arrest (2014) J. Epidemiol. Community Health, 68, pp. 37-43; Wichmann, J., Folke, F., Torp-Pedersen, C., Lippert, F., Ketzel, M., Ellermann, T., Loft, S., Out-of-hospital cardiac arrests and outdoor air pollution exposure in Copenhagen, Denmark (2013) PLoS One, 8, p. e53684; Zeka, A., Schwartz, J., Estimating the independent effects of multiple pollutants in the presence of measurement error: An application of a measurement-error-resistant technique (2004) Environ. Health Perspect., 112, pp. 1686-1690; Zhang, S., Sudden cardiac death in China (2009) Pacing Clin. Electrophysiol., 32, pp. 1159-1162; Zipes, D.P., Epidemiology and mechsanisms of sudden cardiac death (2005) Can. J. Cardiol., 21, pp. 37A-40A",Article,Scopus,2-s2.0-84927133231
"Lipinski M.J., Pendyala L.K., Torguson R., Chen F., Waksman R.","Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin",2015,"Atherosclerosis","235","2",,"295","298",,,10.1016/j.atherosclerosis.2014.05.919,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921442608&partnerID=40&md5=ac50f30e0a674418533d7cfb1f607aaa","Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States","Lipinski, M.J., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States; Pendyala, L.K., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States; Torguson, R., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States; Chen, F., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States; Waksman, R., Division of Cardiology, MedStar Washington Hospital CenterWashington, DC, United States","Objective: Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis. Therefore, we assessed the impact of metformin on stent thrombosis and major adverse cardiovascular events (MACE) in non-insulin-dependent diabetes mellitus (NIDDM) patients who receive drug-eluting stents (DES). Methods: We assessed the impact of metformin and stent type on stent thrombosis, MACE, and death in NIDDM patients following DES placement. Of the 1201 patients included, 74.8% received LES, 25.2% received paclitaxel-eluting stents (PES), and 55% were taking metformin. Results: There was no difference in stent thrombosis, regardless of stent type or metformin use. While Kaplan-Meier curves demonstrated reduced MACE (. p=0.007) and death (. p=0.006) with metformin use, multivariate analysis demonstrated that stent type and metformin use were not associated with outcome. Conclusion: In NIDDM patients, metformin use or stent type following DES placement did not increase stent thrombosis and MACE rates. © 2014 Elsevier Ireland Ltd.","Diabetes mellitus; Drug-eluting stents; Metformin; Outcomes; Percutaneous coronary intervention","Donahoe, S.M., Stewart, G.C., McCabe, C.H., Mohanavelu, S., Murphy, S.A., Cannon, C.P., Diabetes and mortality following acute coronary syndromes (2007) JAm Med Assoc, 298, pp. 765-775; Stettler, C., Allemann, S., Wandel, S., Kastrati, A., Morice, M.C., Schomig, A., Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis (2008) BMJ, 337, p. a1331; De Luca, G., Dirksen, M.T., Spaulding, C., Kelbaek, H., Schalij, M., Thuesen, L., Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention (2013) Am J Cardiol, 111, pp. 1295-1304; Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group (1998) Lancet, 352, pp. 854-865; Isoda, K., Young, J.L., Zirlik, A., MacFarlane, L.A., Tsuboi, N., Gerdes, N., Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells (2006) Arterioscler Thromb Vasc Biol, 26, pp. 611-617; Li, Y., Xu, S., Mihaylova, M.M., Zheng, B., Hou, X., Jiang, B., AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice (2011) Cell Metab, 13, pp. 376-388; Habib, A., Karmali, V., Polavarapu, R., Akahori, H., Nakano, M., Yazdani, S., Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation (2013) JAm Coll Cardiol, 61, pp. 971-980; Habib, A., Karmali, V., Polavarapu, R., Akahori, H., Pachura, K., Finn, A.V., Metformin impairs endothelialization after placement of newer generation drug eluting stents (2013) Atherosclerosis, 229, pp. 385-387; DeFronzo, R.A., Goodman, A.M., Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group (1995) NEngl J Med, 333, pp. 541-549; Huang, N.L., Chiang, S.H., Hsueh, C.H., Liang, Y.J., Chen, Y.J., Lai, L.P., Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation (2009) Int J Cardiol, 134, pp. 169-175; Ewart, M.A., Kennedy, S., AMPK and vasculoprotection (2011) Pharmacol Ther, 131, pp. 242-253; Barbash, I.M., Minha, S., Torguson, R., Ben-Dor, I., Badr, S., Loh, J.P., Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice (2014) JInvasive Cardiol, 26, pp. 154-160; Kim, W.J., Lee, S.W., Park, S.W., Kim, Y.H., Yun, S.C., Lee, J.Y., Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial (2011) Circulation, 124, pp. 886-892",Article,Scopus,2-s2.0-84921442608
"Bochaton T., Crola-Da-Silva C., Pillot B., Villedieu C., Ferreras L., Alam M.R., Thibault H., Strina M., Gharib A., Ovize M., Baetz D.","Inhibition of myocardial reperfusion injury by ischemic postconditioning requires sirtuin 3-mediated deacetylation of cyclophilin D",2015,"Journal of Molecular and Cellular Cardiology","84",,,"61","69",,,10.1016/j.yjmcc.2015.03.017,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928121207&partnerID=40&md5=4c23129df35f3ffd67cb88a9f69f9001","INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France; Hospices Civils de Lyon, Hôpital Louis Pradel, Service d'Explorations Fonctionnelles Cardiovasculaires and CIC de LyonLyon, France","Bochaton, T., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France, Hospices Civils de Lyon, Hôpital Louis Pradel, Service d'Explorations Fonctionnelles Cardiovasculaires and CIC de LyonLyon, France; Crola-Da-Silva, C., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France; Pillot, B., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France; Villedieu, C., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France; Ferreras, L., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France; Alam, M.R., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France; Thibault, H., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France, Hospices Civils de Lyon, Hôpital Louis Pradel, Service d'Explorations Fonctionnelles Cardiovasculaires and CIC de LyonLyon, France; Strina, M., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France; Gharib, A., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France; Ovize, M., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France, Hospices Civils de Lyon, Hôpital Louis Pradel, Service d'Explorations Fonctionnelles Cardiovasculaires and CIC de LyonLyon, France; Baetz, D., INSERM U1060, CarMeN Laboratory, Claude Bernard Lyon 1 UniversityLyon, France","Rationale. How ischemic postconditioning can inhibit opening of the mitochondrial permeability transition pore (PTP) and subsequent cardiac myocytes death at reperfusion remains unknown. Recent studies have suggested that de-acetylation of cyclophilin D (CyPD) by sirtuin 3 (SIRT3) can modulate its binding to the PTP. Objective: The aim of the present study was to examine whether ischemic postconditioning (PostC) might activate SIRT3 and consequently prevent lethal myocardial reperfusion injury through a deacetylation of CyPD.Methods and results. Using hypoxia-reoxygenation (H/R) in H9C2 cells, we showed that SIRT3 overexpression prevented CyPD acetylation, limited PTP opening and reduced cell death by 24%. In vitro modification of the CyPD acetylation status in MEFs by site-directed mutagenesis altered capacity of PTP opening by calcium. Calcium Retention Capacity (CRC) was significantly decreased with CyPD-KQ that mimics acetylated protein compared with CyPD WT (871±266 vs 1193±263nmolesCa2+/mg protein respectively). Cells expressing non-acetylable CyPD mutant (CyPD-KR) displayed 20% decrease in cell death compared to cells expressing CyPD WT after H/R. Correspondingly, in mice we showed that cardiac ischemic postconditioning could not reduce infarct size and CyPD acetylation in SIRT3 KO mice, and was unable to restore CRC in mitochondria as it is observed in WT mice.Conclusions. Our study suggests that the increased acetylation of CyPD following myocardial ischemia-reperfusion facilitates PTP opening and subsequent cell death. Therefore ischemic postconditioning might prevent lethal reperfusion injury through an increased SIRT3 activity and subsequent attenuation of CyPD acetylation at reperfusion. © 2015 Elsevier Ltd.","Cyclophilin D; Ischemia-reperfusion; Post-conditioning; Sirtuin 3; Survival","Burns, R.J., Gibbons, R.J., Yi, Q., Roberts, R.S., Miller, T.D., Schaer, G.L., The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis (2002) J Am Coll Cardiol, 39 (1), pp. 30-36. , Jan; Herlitz, J., Karlson, B.W., Hjalmarson, A., Ten year mortality in relation to original size of myocardial infarct: results from the Gothenburg metoprolol study (1994) Br Heart J, 71 (3), pp. 238-241. , Mar; Maroko, P.R., Libby, P., Ginks, W.R., Bloor, C.M., Shell, W.E., Sobel, B.E., Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis (1972) J Clin Invest, 51 (10), pp. 2710-2716. , Oct; Ginks, W.R., Sybers, H.D., Maroko, P.R., Covell, J.W., Sobel, B.E., Ross, J., Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1week after the coronary occlusion (1972) J Clin Invest, 51 (10), pp. 2717-2723. , Oct; Piper, H.M., Garcia-Dorado, D., Ovize, M., A fresh look at reperfusion injury (1998) Cardiovasc Res, 38 (2), pp. 291-300. , May; Griffiths, E.J., Halestrap, A.P., Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion (1995) Biochem J, 307, pp. 93-98. , Apr 1; Argaud, L., Gateau-Roesch, O., Raisky, O., Loufouat, J., Robert, D., Ovize, M., Postconditioning inhibits mitochondrial permeability transition (2005) Circulation, 111 (2), pp. 194-197. , Jan 18; Piot, C., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., Effect of cyclosporine on reperfusion injury in acute myocardial infarction (2008) N Engl J Med, 359 (5), pp. 473-481. , Jul 31; Di Lisa, F., Bernardi, P., A CaPful of mechanisms regulating the mitochondrial permeability transition (2009) J Mol Cell Cardiol, 46 (6), pp. 775-780. , Jun; Baines, C.P., Kaiser, R.A., Purcell, N.H., Blair, N.S., Osinska, H., Hambleton, M.A., Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death (2005) Nature, 434 (7033), pp. 658-662. , Mar 31; Hausenloy, D.J., Lim, S.Y., Ong, S.G., Davidson, S.M., Yellon, D.M., Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning (2010) Cardiovasc Res, 88 (1), pp. 67-74. , Oct 1; Rasola, A., Sciacovelli, M., Chiara, F., Pantic, B., Brusilow, W.S., Bernardi, P., Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition (2010) Proc Natl Acad Sci U S A, 107 (2), pp. 726-731. , Jan; Nguyen, T.T., Stevens, M.V., Kohr, M., Steenbergen, C., Sack, M.N., Murphy, E., Cysteine 203 of cyclophilin D is critical for cyclophilin D activation of the mitochondrial permeability transition pore (2011) J Biol Chem, 286 (46), pp. 40184-40192. , Nov; Alam, M.R., Baetz, D., Ovize, M., Cyclophilin D and myocardial ischemia-reperfusion injury: a fresh perspective (2015) J Mol Cell Cardiol, 78 C, pp. 80-89. , Jan; Hafner, A.V., Dai, J., Gomes, A.P., Xiao, C.Y., Palmeira, C.M., Rosenzweig, A., Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy (2011) Aging, 2 (12), pp. 914-923. , Dec; Shulga, N., Pastorino, J.G., Ethanol sensitizes mitochondria to the permeability transition by inhibiting deacetylation of cyclophilin-D mediated by sirtuin-3 (2010) J Cell Sci, 123, pp. 4117-4127. , Dec 1; Guarente, L., Sirtuins, aging, and metabolism (2011) Cold Spring Harb Symp Quant Biol, 76, pp. 81-90; Houtkooper, R.H., Pirinen, E., Auwerx, J., Sirtuins as regulators of metabolism and healthspan (2012) Nat Rev Mol Cell Biol, 13 (4), pp. 225-238. , Apr; Huang, J.Y., Hirschey, M.D., Shimazu, T., Ho, L., Verdin, E., Mitochondrial sirtuins (2010) Biochim Biophys Acta, 1804 (8), pp. 1645-1651. , Aug; Lombard, D.B., Alt, F.W., Cheng, H.L., Bunkenborg, J., Streeper, R.S., Mostoslavsky, R., Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation (2007) Mol Cell Biol, 27 (24), pp. 8807-8814. , Dec; Gomez, L., Paillard, M., Thibault, H., Derumeaux, G., Ovize, M., Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion (2008) Circulation, 117 (21), pp. 2761-2768. , May 27; Thibault, H., Gomez, L., Bergerot, C., Augeul, L., Scherrer-Crosbie, M., Ovize, M., Strain-rate imaging predicts the attenuation of left ventricular remodeling induced by ischemic postconditioning after myocardial infarction in mice (2011) Circ Cardiovasc Imaging, 4 (5), pp. 550-557. , Sep; Hescheler, J., Meyer, R., Plant, S., Krautwurst, D., Rosenthal, W., Schultz, G., Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart (1991) Circ Res, 69 (6), pp. 1476-1486. , Dec; North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M., Verdin, E., The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase (2003) Mol Cell, 11 (2), pp. 437-444. , Feb; Hirschey, M.D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D.B., SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation (2010) Nature, 464 (7285), pp. 121-125. , Mar 4; Jozefczuk, J., Drews, K., Adjaye, J., Preparation of mouse embryonic fibroblast cells suitable for culturing human embryonic and induced pluripotent stem cells (2012) J Vis Exp, 64; Teixeira, G., Abrial, M., Portier, K., Chiari, P., Couture-Lepetit, E., Tourneur, Y., Synergistic protective effect of cyclosporin A and rotenone against hypoxia-reoxygenation in cardiomyocytes (2012) J Mol Cell Cardiol, 56, pp. 55-62. , Mar; Heusch, G., Cardioprotection: chances and challenges of its translation to the clinic (2013) Lancet, 381 (9861), pp. 166-175. , Jan 12; Zeng, H., Li, L., Chen, J.X., Loss of sirt3 limits bone marrow cell-mediated angiogenesis and cardiac repair in post-myocardial infarction (2014) PLoS One, 9 (9); Porter, G.A., Urciuoli, W.R., Brookes, P.S., Nadtochiy, S.M., SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts (2014) Am J Physiol Heart Circ Physiol, 306 (12), pp. H1602-H1609. , Jun 15; Di Lisa, F., Menabo, R., Canton, M., Barile, M., Bernardi, P., Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart (2001) J Biol Chem, 276 (4), pp. 2571-2575. , Jan; Hill, B.G., Awe, S.O., Vladykovskaya, E., Ahmed, Y., Liu, S.Q., Bhatnagar, A., Myocardial ischaemia inhibits mitochondrial metabolism of 4-hydroxy-trans-2-nonenal (2009) Biochem J, 417 (2), pp. 513-524. , Jan 15; Fu, J., Jin, J., Cichewicz, R.H., Hageman, S.A., Ellis, T.K., Xiang, L., Trans-(-)-epsilon-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease (2012) J Biol Chem., 287 (29), pp. 24460-24472. , Jul; Chen, Y., Zhang, J., Lin, Y., Lei, Q., Guan, K.L., Zhao, S., Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS (2011) EMBO Rep, 12 (6), pp. 534-541. , Jun; Someya, S., Yu, W., Hallows, W.C., Xu, J., Vann, J.M., Leeuwenburgh, C., Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction (2010) Cell, 143 (5), pp. 802-812. , Nov 24; Qiu, X., Brown, K., Hirschey, M.D., Verdin, E., Chen, D., Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation (2010) Cell Metab, 12 (6), pp. 662-667. , Dec 1; Yu, W., Dittenhafer-Reed, K.E., Denu, J.M., SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status (2012) J Biol Chem, 287 (17), pp. 14078-14086. , Apr 20; Palacios, O.M., Carmona, J.J., Michan, S., Chen, K.Y., Manabe, Y., Ward, J.L., Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle (2009) Aging, 1 (9), pp. 771-783. , Sep; Paiva, M.A., Goncalves, L.M., Providencia, L.A., Davidson, S.M., Yellon, D.M., Mocanu, M.M., Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction (2010) Cardiovasc Drugs Ther, 24 (1), pp. 25-32. , Feb; Maksin-Matveev, A., Kanfi, Y., Hochhauser, E., Isak, A., Cohen, H.Y., Shainberg, A., Sirtuin 6 protects the heart from hypoxic damage (2015) Exp Cell Res, 330 (1), pp. 81-90. , Jan 1; Verma, M., Shulga, N., Pastorino, J.G., Sirtuin-4 modulates sensitivity to induction of the mitochondrial permeability transition pore (2013) Biochim Biophys Acta. 2012, 1827 (1), pp. 38-49",Article,Scopus,2-s2.0-84928121207
"Grubb D.R., Crook B., Ma Y., Luo J., Qian H.W., Gao X.-M., Kiriazis H., Du X.-J., Gregorevic P., Woodcock E.A.","The atypical 'b' splice variant of phospholipase Cβ1 promotes cardiac contractile dysfunction",2015,"Journal of Molecular and Cellular Cardiology","84",,,"95","103",,,10.1016/j.yjmcc.2015.04.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928724755&partnerID=40&md5=6efe54a0c6275da8692574dc87d94795","Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia","Grubb, D.R., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Crook, B., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Ma, Y., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Luo, J., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Qian, H.W., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Gao, X.-M., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Kiriazis, H., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Du, X.-J., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Gregorevic, P., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia; Woodcock, E.A., Baker IDI Heart and Diabetes Institute, 75 Commercial RoadMelbourne, VIC, Australia","The activity of the early signaling enzyme, phospholipase Cβ1b (PLCβ1b), is selectively elevated in diseased myocardium and activity increases with disease progression. We aimed to establish the contribution of heightened PLCβ1b activity to cardiac pathology. PLCβ1b, the alternative splice variant, PLCβ1a, and a blank virus were expressed in mouse hearts using adeno-associated viral vectors (rAAV6-FLAG-PLCβ1b, rAAV6-FLAG-PLCβ1a, or rAAV6-blank) delivered intravenously (IV). Following viral delivery, FLAG-PLCβ1b was expressed in all of the chambers of the mouse heart and was localized to the sarcolemma. Heightened PLCβ1b expression caused a rapid loss of contractility, 4-6weeks, that was fully reversed, within 5days, by inhibition of protein kinase Cα (PKCα). PLCβ1a did not localize to the sarcolemma and did not affect contractile function. Expression of PLCβ1b, but not PLCβ1a, caused downstream dephosphorylation of phospholamban and depletion of the Ca2+ stores of the sarcoplasmic reticulum. We conclude that heightened PLCβ1b activity observed in diseased myocardium contributes to pathology by PKCα-mediated contractile dysfunction. PLCβ1b is a cardiac-specific signaling system, and thus provides a potential therapeutic target for the development of well-tolerated inotropic agents for use in failing myocardium. © 2015.","AAV; Cardiac contractility; Gene therapy; Signaling pathways","Rauch, H., Motsch, J., Bottiger, B.W., Newer approaches to the pharmacological management of heart failure (2006) Curr Opin Anaesthesiol, 19, pp. 75-81; Sikkel, M.B., Hayward, C., MacLeod, K.T., Harding, S.E., Lyon, A.R., SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope (2014) Br J Pharmacol, 171, pp. 38-54; Fish, K.M., Ladage, D., Kawase, Y., Karakikes, I., Jeong, D., Ly, H., AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling (2013) Circ Heart Fail, 6, pp. 310-317; Hambleton, M., Hahn, H., Pleger, S.T., Kuhn, M.C., Klevitsky, R., Carr, A.N., Pharmacological- and gene therapy-based inhibition of protein kinase Cα/β enhances cardiac contractility and attenuates heart failure (2006) Circulation, 114, pp. 574-582; Smrcka, A.V., Hepler, J.R., Brown, K.O., Sternweis, P.C., Regulation of polyphosphoinositide-specific phospholipase C activity by purified Gq (1991) Science, 251, pp. 804-807; Streb, H., Bayerdorffer, E., Haase, W., Irvine, R.F., Schulz, I., Effect of inositol-1,4,5-trisphosphate on isolated subcellular fractions of rat pancreas (1984) J Membr Biol, 81, pp. 241-253; Asaoka, Y., Nakamura, S.-I., Yoshida, K., Nishizuka, Y., Protein kinase C, calcium and phospholipid degradation (1992) Trends Biochem Sci, 17, pp. 414-417; Waldron, R.T., Innamorati, G., Torres-Marquez, M.E., Sinnett-Smith, J., Rozengurt, E., Differential PKC-dependent and -independent PKD activation by G protein alpha subunits of the Gq family: selective stimulation of PKD Ser(748) autophosphorylation by Gαq (2012) Cell Signal, 24, pp. 914-921; Dietrich, A., Mederos y Schnitzler, M., Kalwa, H., Storch, U., Gudermann, T., Functional characterization and physiological relevance of the TRPC3/6/7 subfamily of cation channels (2005) Naunyn Schmiedebergs Arch Pharmacol, 371, pp. 257-265; Steinberg, S.F., Cardiac actions of protein kinase C isoforms (2012) Physiology, 27, pp. 130-139; Liu, Q., Molkentin, J.D., Protein kinase Cα as a heart failure therapeutic target (2011) J Mol Cell Cardiol, 51, pp. 474-478; Duquesnes, N., Lezoualc'h, F., Crozatier, B., PKC-δ and PKC-ε: foes of the same family or strangers? (2011) J Mol Cell Cardiol, 51, pp. 665-673; Palaniyandi, S.S., Sun, L., Ferreira, J.C.B., Mochly-Rosen, D., Protein kinase C in heart failure: a therapeutic target? (2009) Cardiovasc Res, 82, pp. 229-239; Arthur, J.F., Matkovich, S.J., Mitchell, C.J., Biden, T.J., Woodcock, E.A., Evidence for selective coupling of α<inf>1</inf>-adrenergic receptors to phospholipase C-β1 in rat neonatal cardiomyocytes (2001) J Biol Chem, 276, pp. 37341-37346; Otaegui, D., Querejeta, R., Arrieta, A., Lazkano, A., Bidaurrazaga, A., Arriandiaga, J.R., Phospholipase Cβ4 isozyme is expressed in human, rat, and murine heart left ventricles and in HL-1 cardiomyocytes (2010) Mol Cell Biochem, 337, pp. 167-173; Bahk, Y.Y., Lee, Y.H., Lee, T.G., Seo, J.K., Ryu, S.H., Suh, P.G., Two forms of phospholipase c-β1 generated by alternative splicing (1994) J Biol Chem, 269, pp. 8240-8245; Suh, P.G., Hwang, J.I., Ryu, S.H., Donowitz, M., Kim, J.H., The roles of PDZ-containing proteins in PLC-β-mediated signaling (2001) Biochem Biophys Res Commun, 288, pp. 1-7; Grubb, D.R., Iliades, P., Cooley, N., Yu, Y.L., Luo, J., Filtz, T.M., Phospholipase Cbeta1b associates with a Shank3 complex at the cardiac sarcolemma (2011) FASEB J, 25, pp. 1040-1047; Filtz, T.M., Grubb, D.R., McLeod-Dryden, T.J., Luo, J., Woodcock, E.A., Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase Cβ1b (2009) FASEB J, 23, pp. 3564-3570; Grubb, D.R., Vasilevski, O., Huynh, H., Woodcock, E.A., The extreme C-terminal region of phospholipase Cβ1 determines subcellular localization and function; the ""b"" splice variant mediates α<inf>1</inf>-adrenergic receptor responses in cardiomyocytes (2008) FASEB J, 22, pp. 2768-2774; Woodcock, E.A., Grubb, D.R., Filtz, T.M., Marasco, S., Luo, J., McLeod-Dryden, T.J., Selective activation of the ""b"" splice variant of phospholipase Cβ1 in chronically dilated human and mouse atria (2009) J Mol Cell Cardiol, 47, pp. 676-683; Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Meuse, L., Miller, D.G., Systemic delivery of genes to striated muscles using adeno-associated viral vectors (2004) Nat Med, 10, pp. 828-834; Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT-PCR (2001) Nucleic Acids Res, 29; McMullen, J.R., Amirahmadi, F., Woodcock, E.A., Schinke-Braun, M., Bouwman, R.D., Hewitt, K.A., Protective effects of exercise and phosphoinositide 3-kinase (p110 α) signaling in dilated and hypertrophic cardiomyopathy (2007) Proc Natl Acad Sci USA, 104, pp. 612-617; Kawahara, Y., Tanonaka, K., Daicho, T., Nawa, M., Oikawa, R., Nasa, Y., Preferable anesthetic conditions for echocardiographic determination of murine cardiac function (2005) J Pharmacol Sci, 99, pp. 95-104; Cooley, N., Ouyang, K., McMullen, J.R., Kiriazis, H., Sheikh, F., Wu, W., No contribution of IP<inf>3</inf>-R(2) to disease phenotype in models of dilated cardiomyopathy or pressure overload hypertrophy (2013) Circ Heart Fail, 6, pp. 318-325; Du, X.J., Autelitano, D.J., Dilley, R.J., Wang, B., Dart, A.M., Woodcock, E.A., β<inf>2</inf>-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis (2000) Circulation, 101, pp. 71-77; Kranias, E.G., Hajjar, R.J., Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome (2012) Circ Res, 110, pp. 1646-1660; Braz, J.C., Gregory, K., Pathak, A., Zhao, W., Sahin, B., Klevitsky, R., PKC-α regulates cardiac contractility and propensity toward heart failure (2004) Nat Med, 10, pp. 248-254; Hahn, H.S., Marreez, Y., Odley, A., Sterbling, A., Yussman, M.G., Hilty, K.C., Protein kinase Cα negatively regulates systolic and diastolic function in pathological hypertrophy (2003) Circ Res, 93, pp. 1111-1119; Oestreich, E.A., Malik, S., Goonasekera, S.A., Blaxall, B.C., Kelley, G.G., Dirksen, R.T., Epac and phospholipase Cepsilon regulate Ca2+ release in the heart by activation of protein kinase Cepsilon and calcium-calmodulin kinase II (2009) J Biol Chem, 284, pp. 1514-1522; Hoit, B.D., Left atrial size and function: role in prognosis (2014) J Am Coll Cardiol, 63, pp. 493-505; Wang, B.H., Du, X.J., Autelitano, D.J., Milano, C.A., Woodcock, E.A., Adverse effects of constitutively active α<inf>1B</inf>-adrenergic receptors after pressure overload in mouse hearts (2000) Am J Physiol, 279, pp. H1079-H1086; Byrne, M.J., Raman, J.S., Alferness, C.A., Esler, M.D., Kaye, D.M., Power, J.M., An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset (2002) J Card Fail, 8, pp. 108-115; Bavelloni, A., Dmitrienko, G.I., Goodfellow, V.J., Ghavami, A., Piazzi, M., Blalock, W., PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation (2015) J Cell Physiol, 230, pp. 587-594; Caricasole, A., Sala, C., Roncarati, R., Formenti, E., Terstappen, G.C., Cloning and characterization of the human phosphoinositide-specific phospholipase C-β1 (PLC β1) (2000) Biochim Biophys Acta Gene Structure and Expression, 1517, pp. 63-72; Kunkel, M.T., Garcia, E.L., Kajimoto, T., Hall, R.A., Newton, A.C., The protein scaffold NHERF-1 controls the amplitude and duration of localized protein kinase D activity (2009) J Biol Chem, 284, pp. 24653-24661; Dorn, G.W., Brown, J.H., Gq signaling in cardiac adaptation and maladaptation (1999) Trends Cardiovasc Med, 9, pp. 26-34; Mende, U., Kagen, A., Cohen, A., Aramburu, J., Schoen, F.J., Neer, E.J., Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways (1998) Proc Natl Acad Sci U S A, 95, pp. 13893-13898; Adams, J.W., Sakata, Y., Davis, M.G., Sah, V.P., Wang, Y., Liggett, S.B., Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure (1998) Proc Natl Acad Sci U S A, 95, pp. 10140-10145; Syed, F., Odley, A., Hahn, H.S., Brunskill, E.W., Lynch, R.A., Marreez, Y., Physiological growth synergizes with pathological genes in experimental cardiomyopathy (2004) Circ Res, 95, pp. 1200-1206; D'Angelo, D., Sakata, Y., Lorenz, J., Boivin, G., Walsh, R., Liggett, S., Transgenic Gaq overexpression induces cardiac contractile failure in mice (1997) Proc Natl Acad Sci U S A, 94, pp. 8121-8126; Fan, G., Jiang, Y.P., Lu, Z., Martin, D.W., Kelly, D.J., Zuckerman, J.M., A transgenic mouse model of heart failure using inducible Gαq (2005) J Biol Chem, 280, pp. 40337-40346; Yatani, A., Frank, K., Sako, H., Kranias, E.G., Dorn, G.W., Cardiac-specific overexpression of Gαq alters excitation-contraction coupling in isolated cardiac myocytes (1999) J Mol Cell Cardiol, 31, pp. 1327-1336; Grubb, D.R., Luo, J.T., Yu, Y.L., Woodcock, E.A., Scaffolding protein homer 1c mediates hypertrophic responses downstream of Gq in cardiomyocytes (2012) FASEB J, 26, pp. 596-603; Liu, Q., Chen, X., Macdonnell, S.M., Kranias, E.G., Lorenz, J.N., Leitges, M., Protein kinase Cα, but not PKCβ or PKCγ, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach (2009) Circ Res, 105, pp. 194-200; Florea, S., Anjak, A., Cai, W.F., Qian, J., Vafiadaki, E., Figueria, S., Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging (2012) Basic Res Cardiol, 107, p. 279; Takeishi, Y., Goto, K., Kubota, I., Role of diacylglycerol kinase in cellular regulatory processes: a new regulator for cardiomyocyte hypertrophy (2007) Pharmacol Ther, 115, pp. 352-359; Ladage, D., Tilemann, L., Ishikawa, K., Correll, R.N., Kawase, Y., Houser, S.R., Inhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury (2011) Circ Res, 109, pp. 1396-1400; Hambleton, M., York, A., Sargent, M.A., Kaiser, R.A., Lorenz, J.N., Robbins, J., Inducible and myocyte-specific inhibition of PKCα enhances cardiac contractility and protects against infarction-induced heart failure (2007) Am J Physiol Heart Circ Physiol, 293, pp. H3768-H3771; Zeng, L., Webster, S.V., Newton, P.M., The biology of protein kinase C (2012) Adv Exp Med Biol, 740, pp. 639-661; Mochly-Rosen, D., Das, K., Grimes, K.V., Protein kinase C, an elusive therapeutic target? (2012) Nat Rev Drug Discov, 11, pp. 937-957; Bahk, Y.Y., Song, H., Baek, S.H., Park, B.Y., Kim, H., Ryu, S.H., Localization of two forms of phospholipase C-β1, a and b, in C6Bu-1 cells (1998) Biochim Biophys Acta, 1389, pp. 76-80; Sheng, M., Kim, E., The Shank family of scaffold proteins (2000) J Cell Sci, 113, pp. 1851-1856",Article,Scopus,2-s2.0-84928724755
"To T., Zhu J., Villeneuve P.J., Simatovic J., Feldman L., Gao C., Williams D., Chen H., Weichenthal S., Wall C., Miller A.B.","Chronic disease prevalence in women and air pollution - A 30-year longitudinal cohort study",2015,"Environment International","80",,,"26","32",,,10.1016/j.envint.2015.03.017,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926381489&partnerID=40&md5=9eb21b1c39e6fc1953d10b2934073a89","Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada; Institute for Clinical Evaluative SciencesToronto, ON, Canada; Dalla Lana School of Public HealthToronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of TorontoToronto, ON, Canada; Department of Health Sciences, Carleton UniversityOttawa, ON, Canada; Public Health OntarioToronto, ON, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill UniversityMontreal, ON, Canada","To, T., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada, Institute for Clinical Evaluative SciencesToronto, ON, Canada, Dalla Lana School of Public HealthToronto, ON, Canada, Institute of Health Policy, Management and Evaluation, University of TorontoToronto, ON, Canada; Zhu, J., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada, Institute for Clinical Evaluative SciencesToronto, ON, Canada; Villeneuve, P.J., Department of Health Sciences, Carleton UniversityOttawa, ON, Canada; Simatovic, J., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada; Feldman, L., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada, Dalla Lana School of Public HealthToronto, ON, Canada; Gao, C., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada, Institute for Clinical Evaluative SciencesToronto, ON, Canada; Williams, D., Child Health Evaluative Sciences, The Hospital for Sick ChildrenToronto, ON, Canada; Chen, H., Institute for Clinical Evaluative SciencesToronto, ON, Canada, Dalla Lana School of Public HealthToronto, ON, Canada, Public Health OntarioToronto, ON, Canada; Weichenthal, S., Department of Epidemiology, Biostatistics and Occupational Health, McGill UniversityMontreal, ON, Canada; Wall, C., Dalla Lana School of Public HealthToronto, ON, Canada; Miller, A.B., Dalla Lana School of Public HealthToronto, ON, Canada","Background: Air pollution, such as fine particulate matter (PM<inf>2.5</inf>), can increase risk of adverse health events among people with heart disease, diabetes, asthma and chronic obstructive pulmonary disease (COPD) by aggravating these conditions. Identifying the influence of PM<inf>2.5</inf> on prevalence of these conditions may help target interventions to reduce disease morbidity among high-risk populations. Objectives: The objective of this study is to measure the association of exposure of PM<inf>2.5</inf> with prevalence risk of various chronic diseases among a longitudinal cohort of women. Methods: Women from Ontario who enrolled in the Canadian National Breast Screening Study (CNBSS) from 1980 to 1985 (n=29,549) were linked to provincial health administrative data from April 1, 1992 to March 31, 2013 to determine the prevalence of major chronic disease and conditions (heart disease, diabetes, asthma, COPD, acute myocardial infarction, angina, stroke and cancers). Exposure to PM<inf>2.5</inf> was measured using satellite data collected from January 1, 1998 to December 31, 2006 and assigned to resident postal-code at time of entry into study. Poisson regression models were used to describe the relationship between exposure to ambient PM<inf>2.5</inf> and chronic disease prevalence. Prevalence rate ratios (PRs) were estimated while adjusting for potential confounders: baseline age, smoking, BMI, marital status, education and occupation. Separate models were run for each chronic disease and condition. Results: Congestive heart failure (PR=1.31, 95% CI: 1.13, 1.51), diabetes (PR=1.28, 95% CI: 1.16, 1.41), ischemic heart disease (PR=1.22, 95% CI: 1.14, 1.30), and stroke (PR=1.21, 95% CI: 1.09, 1.35) showed over a 20% increase in PRs per 10μg/m3 increase in PM<inf>2.5</inf> after adjusting for risk factors. Risks were elevated in smokers and those with BMI greater than 30. Conclusions: This study estimated significant elevated prevalent rate ratios per unit increase in PM<inf>2.5</inf> in nine of the ten chronic diseases studied. © 2015 Elsevier Ltd.","Air pollution; Chronic disease prevalence; Environmental exposures","Brook, R., Franklin, B., Cascio, W., Hong, Y., Howard, G., Lipsett, M., Luepker, R., Tager, I., Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association (2004) Circulation, 109, pp. 2655-2671. , Association E.P.O.P.A.P.S.O.T.A.H; Brook, R., Cakmak, S., Turner, M., Brook, J., Crouse, D., Peters, P., van Donkelaar, A., Burnett, R., Long-term fine particulate matter exposure and mortality from diabetes in Canada (2013) Diabetes Care, 36, pp. 3313-3320; Chen, H., Burnett, R., Kwong, J., Villeneuve, P., Goldberg, M., Brook, R., van Donkelaar, A., Copes, R., Risk of incident diabetes in relation to long-term exposure to fine particulate matter in Ontario, Canada (2013) Environ. Health Perspect., 121, pp. 46-52. , (121:804-810); Chen, H., Burnett, R., Kwong, J., Villeneuve, P., Goldberg, M., Brook, R., van Donkelaar, A., Copes, R., Spatial association between ambient fine particulate matter and incident hypertension (2014) Circulation, 129, pp. 562-569; Coogan, P., White, L., Jerrett, M., Brook, R., Su, J., Seto, E., Burnett, R., Rosenberg, L., Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles (2012) Circ. Res., 125, pp. 767-772; Crouse, D., Peters, P., van Donkelaar, A., Goldberg, M., Villeneuve, P., Brion, O., Khan, S., Burnett, R., Risk of nonaccidental and cardiovascular mortality in relation to long-term exposure to low concentrations of fine particulate matter: a Canadian national-level cohort study (2012) Environ. Health Perspect., 121, pp. 46-52. , (120:708-714); EPA, U.S., (2008) Integrated Science Assessment for Oxides of Nitrogen - Health Criteria (Final Report), , U.S. Environmental Protection Agency, Washington, DC; EPA, U.S., (2009) Integrated Science Assessment for Particulate Matter (Final Report), , U.S. Environmental Protection Agency, Washington, DC; EPA, U.S., (2013) Integrated Science Assessment of Ozone and Related Photochemical Oxidants (Final Report), , U.S. Environmental Protection Agency, Washington, DC; Eze, I., Schaffner, E., Fischer, E., Schikowski, T., Adam, M., Imboden, M., Tsai, M., Probst-Hensch, N., Long-term air pollution exposure and diabetes in a population-based Swiss cohort (2014) Environ. Int., 70, pp. 95-105; Heinävaara, S., Sarkeala, T., Anttila, A., Overdiagnosis due to breast cancer screening: updated estimates of the Helsinki Service Study in Finland (2014) Br. J. Cancer, , (ahead of print); Hopman, W., Leroux, C., Berger, C., Joseph, L., Barr, S., Prior, J., Harrison, M.S.P., Group, C.R., Changes in body mass index in Canadians over a five-year period: results of a prospective, population based study (2007) BMC Public Health, p. 7; Johnson, D., Parker, J., Air pollution exposure and self-reported cardiovascular disease (2009) Environ. Res., 109, pp. 582-589; Koton, S., Molshatzki, N., Yuval Myers, V., Broday, D., Drory, Y., Steinberg, D., Gerber, Y., Cumulative exposure to particulate matter air pollution and long-term post-myocardial infarction outcomes (2013) Prev. Med., 57, pp. 339-344; Kramer, U., Herder, C., Sugiri, D., Strassburger, K., Schikowski, T., Ranft, U., Rathmann, W., Traffic-related air pollution and incident type 2 diabetes: results from the SALIA cohort study (2010) Environ. Health Perspect., 118, pp. 1273-1279; Miller, A.B., Baines, C.J., To, T., Wall, C., Canadian National Breast Screening Study 1. Breast cancer detection and death rates among women aged 40 to 49years (1992) CMAJ, 147, pp. 1458-1476; Miller, A.B., Baines, C.J., To, T., Wall, C., Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 50years (1996) CMAJ, 147, pp. 1477-1488; Njor, S., Olsen, A., Blichert-Toft, M., Schwartz, W., Vejborg, I., Lynge, E., Overdiagnosis in screening mammography in Denmark: population based cohort study (2013) BMJ, 346, p. f1064; Pearson, J., Bachireddy, C., Shyamprasad, S., Goldfine, A., Brownstein, J., Association between fine particulate matter and diabetes prevalence in the U.S. (2010) Diabetes Care, 33, pp. 2196-2201; Puett, R., Hart, J., Schwartz, J., Hu, F., Liese, A., Laden, F., Are particulate matter exposures associated with risk of type 2 diabetes? (2011) Environ. Health Perspect., 121, pp. 46-52. , (119:384-389); Royall, R., Model robust confidence intervals using maximum likelihood estimators (1986) Int. Stat. Rev., p. 54; Schikowski, T., Adam, M., Marcon, A., Cai, Y., Vierkötter, A., Carsin, A., Jacquemin, B., Künzli, N., Association of ambient air pollution with the prevalence and incidence of COPD (2014) Eur. Respir. J., 44, pp. 614-626; To, T., Feldman, L., Foty, R., Dell, S., Gershon, A., Zhu, J., Su, J., Licskai, C., Using the air quality health index to measure the impact of poor air quality on chronic diseases in Ontario: a population-based study. American Thoracic Society. Philadelphia (2013) Am. J. Respir. Crit. Care Med.; To, T., Shen, S., Atenafu, E.G., Guan, J., McLimont, S., Stocks, B., Licskai, C., The Air Quality Health Index and asthma morbidity: a population-based study (2013) Environ. Health Perspect., 121, pp. 46-52; van Donkelaar, A., Martin, R.V., Brauer, M., Kahn, R., Levy, R., Verduzco, C., Villeneuve, P.J., Global estimates of ambient fine particulate matter concentrations from satellite-based aerosol optical depth: development and application (2010) Environ. Health Perspect., 118, pp. 847-855; Zocchetti, C., Consonni, D., Bertazzi, P., Estimation of prevalence rate ratios from cross-sectional data (1995) Int. J. Epidemiol., 24, pp. 1064-1065; Zou, G., A modified Poisson regression approach to prospective studies with binary data (2004) Am. J. Epidemiol., 159, pp. 702-706",Article,Scopus,2-s2.0-84926381489
"Song J.L., Nigam P., Tektas S.S., Selva E.","MicroRNA regulation of Wnt signaling pathways in development and disease",2015,"Cellular Signalling","27","7",,"1380","1391",,,10.1016/j.cellsig.2015.03.018,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927613389&partnerID=40&md5=ab914979e6044c8e34792abbb06fc89a","Department of Biological Sciences, University of DelawareNewark, DE, United States","Song, J.L., Department of Biological Sciences, University of DelawareNewark, DE, United States; Nigam, P., Department of Biological Sciences, University of DelawareNewark, DE, United States; Tektas, S.S., Department of Biological Sciences, University of DelawareNewark, DE, United States; Selva, E., Department of Biological Sciences, University of DelawareNewark, DE, United States","Wnt signaling pathways and microRNAs (miRNAs) are critical regulators of development. Aberrant Wnt signaling pathways and miRNA levels lead to developmental defects and diverse human pathologies including but not limited to cancer. Wnt signaling pathways regulate a plethora of cellular processes during embryonic development and maintain homeostasis of adult tissues. A majority of Wnt signaling components are regulated by miRNAs which are small noncoding RNAs that are expressed in both animals and plants. In animal cells, miRNAs fine tune gene expression by pairing primarily to the 3'untranslated region of protein coding mRNAs to repress target mRNA translation and/or induce target degradation. miRNA-mediated regulation of signaling transduction pathways is important in modulating dose-sensitive response of cells to signaling molecules. This review discusses components of the Wnt signaling pathways that are regulated by miRNAs in the context of development and diseases. A fundamental understanding of miRNA functions in Wnt signaling transduction pathways may yield new insight into crosstalks of regulatory mechanisms essential for development and disease pathophysiology leading to novel therapeutics. © 2015 Elsevier Inc.","Cancer; Non-canonical Wnt signaling; Post-transcriptional regulation; Regulatory network; β-catenin","Clevers, H., (2006) Cell, 127 (3), pp. 469-480; Moon, R.T., Kohn, A.D., De Ferrari, G.V., Kaykas, A., (2004) Nat. Rev. Genet., 5 (9), pp. 691-701; Clevers, H., Nusse, R., (2012) Cell, 149 (6), pp. 1192-1205; MacDonald, B.T., Tamai, K., He, X., (2009) Dev. Cell, 17 (1), pp. 9-26. , (PMCID: 2861485); Kim, W., Kim, M., Jho, E.H., (2013) Biochem. J., 450 (1), pp. 9-21; Anastas, J.N., Moon, R.T., (2013) Nat. Rev. Cancer, 13 (1), pp. 11-26; Inui, M., Martello, G., Piccolo, S., (2010) Nat. Rev. Mol. Cell Biol., 11 (4), pp. 252-263; Schepeler, T., (2013) Crit. Rev. Oncog., 18 (4), pp. 357-371; Nusse, R., Varmus, H.E., (1982) Cell, 31 (1), pp. 99-109; Rijsewijk, F., van Deemter, L., Wagenaar, E., Sonnenberg, A., Nusse, R., (1987) EMBO J., 6 (1), pp. 127-131. , (PMCID: 553367); Tsukamoto, A.S., Grosschedl, R., Guzman, R.C., Parslow, T., Varmus, H.E., (1988) Cell, 55 (4), pp. 619-625; Sokol, S., Christian, J.L., Moon, R.T., Melton, D.A., (1991) Cell, 67 (4), pp. 741-752; Slusarski, D.C., Yang-Snyder, J., Busa, W.B., Moon, R.T., (1997) Dev. Biol., 182 (1), pp. 114-120; Teo, J.L., Kahn, M., (2010) Adv. Drug Deliv. Rev., 62 (12), pp. 1149-1155; Lin, C.L., Wang, J.Y., Huang, Y.T., Kuo, Y.H., Surendran, K., Wang, F.S., (2006) J. Am. Soc. Nephrol., 17 (10), pp. 2812-2820; Martin, B.L., Kimelman, D., (2012) Dev. Cell, 22 (1), pp. 223-232. , (PMCID: 3465166); Miki, T., Yasuda, S.Y., Kahn, M., (2011) Stem Cell Rev., 7 (4), pp. 836-846; Hikasa, H., Sokol, S.Y., (2013) Cold Spring Harb. Perspect. Biol., 5 (1), p. a007955. , (PMCID: 3579404); Lee, J.Y., Marston, D.J., Walston, T., Hardin, J., Halberstadt, A., Goldstein, B., (2006) Curr. Biol., 16 (20), pp. 1986-1997. , (PMCID: 2989422); Boras-Granic, K., Wysolmerski, J.J., (2008) Organogenesis, 4 (2), pp. 116-122. , (PMCID: 2634257); Gao, B., Yang, Y., (2013) Curr. Opin. Genet. Dev., 23 (4), pp. 438-444. , (PMCID: 3759593); Gessert, S., Kuhl, M., (2010) Circ. Res., 107 (2), pp. 186-199; Mulligan, K.A., Cheyette, B.N., (2012) J. Neuroimmune Pharmacol., 7 (4), pp. 774-787. , (PMCID: 3518582); Day, T.F., Yang, Y., (2008) J. Bone Joint Surg. Am., 90, pp. 19-24; Yost, C., Torres, M., Miller, J.R., Huang, E., Kimelman, D., Moon, R.T., (1996) Genes Dev., 10 (12), pp. 1443-1454; Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G.H., Tan, Y., (2002) Cell, 108 (6), pp. 837-847; Hart, M., Concordet, J.P., Lassot, I., Albert, I., del los Santos, R., Durand, H., (1999) Curr. Biol., 9 (4), pp. 207-210; Cadigan, K.M., Liu, Y.I., (2006) J. Cell Sci., 119, pp. 395-402; Gao, C., Chen, Y.G., (2010) Cell. Signal., 22 (5), pp. 717-727; Schwarz-Romond, T., Metcalfe, C., Bienz, M., (2007) J. Cell Sci., 120, pp. 2402-2412; Wong, H.C., Bourdelas, A., Krauss, A., Lee, H.J., Shao, Y., Wu, D., (2003) Mol. Cell, 12 (5), pp. 1251-1260; Logan, C.Y., Miller, J.R., Ferkowicz, M.J., McClay, D.R., (1999) Development, 126 (2), pp. 345-357; Weitzel, H.E., Illies, M.R., Byrum, C.A., Xu, R., Wikramanayake, A.H., Ettensohn, C.A., (2004) Development, 131 (12), pp. 2947-2956; Miyawaki, K., Yamamoto, M., Saito, K., Saito, S., Kobayashi, N., Matsuda, S., (2003) Dev. Growth Differ., 45 (2), pp. 121-128; Kawai, N., Iida, Y., Kumano, G., Nishida, H., (2007) Dev. Dyn., 236 (6), pp. 1570-1582; Larabell, C.A., Torres, M., Rowning, B.A., Yost, C., Miller, J.R., Wu, M., (1997) J. Cell Biol., 136 (5), pp. 1123-1136. , (PMCID: 2132470); Orsulic, S., Huber, O., Aberle, H., Arnold, S., Kemler, R., (1999) J. Cell Sci., 112, pp. 1237-1245; Heuberger, J., Birchmeier, W., (2010) Cold Spring Harb. Perspect. Biol., 2 (2), p. a002915. , (PMCID: 2828280); Heasman, J., Crawford, A., Goldstone, K., Garner-Hamrick, P., Gumbiner, B., McCrea, P., (1994) Cell, 79 (5), pp. 791-803; Fagotto, F., Funayama, N., Gluck, U., Gumbiner, B.M., (1996) J. Cell Biol., 132 (6), pp. 1105-1114. , (PMCID: 2120760); Wikramanayake, A.H., Huang, L., Klein, W.H., (1998) Proc. Natl. Acad. Sci. U. S. A., 95 (16), pp. 9343-9348. , (PMCID: 21340); Bovolenta, P., Esteve, P., Ruiz, J.M., Cisneros, E., Lopez-Rios, J., (2008) J. Cell Sci., 121, pp. 737-746; Glinka, A., Wu, W., Delius, H., Monaghan, A.P., Blumenstock, C., Niehrs, C., (1998) Nature, 391 (6665), pp. 357-362; Semenov, M., Tamia, K., He, X., (2005) J. Biol. Chem., 280, pp. 26770-26775; Wylie, C., Kofron, M., Payne, C., Anderson, R., Hosobuchi, M., Joseph, E., (1996) Development, 122 (10), pp. 2987-2996; Kelly, G.M., Erezyilmaz, D.F., Moon, R.T., (1995) Mech. Dev., 53 (2), pp. 261-273; Pelegri, F., Maischein, H.M., (1998) Mech. Dev., 77 (1), pp. 63-74; Imai, K., Takada, N., Satoh, N., Satou, Y., (2000) Development, 127 (14), pp. 3009-3020; Tada, M., Smith, J.C., (2000) Development, 127 (10), pp. 2227-2238; Wallingford, J.B., Rowning, B.A., Vogeli, K.M., Rothbacher, U., Fraser, S.E., Harland, R.M., (2000) Nature, 405 (6782), pp. 81-85; Heisenberg, C.P., Tada, M., Rauch, G.J., Saude, L., Concha, M.L., Geisler, R., (2000) Nature, 405 (6782), pp. 76-81; Kibar, Z., Vogan, K.J., Groulx, N., Justice, M.J., Underhill, D.A., Gros, P., (2001) Nat. Genet., 28 (3), pp. 251-255; Wang, J., Hamblet, N.S., Mark, S., Dickinson, M.E., Brinkman, B.C., Segil, N., (2006) Development, 133 (9), pp. 1767-1778. , (PMCID: 4158842); Merkel, C.E., Karner, C.M., Carroll, T.J., (2007) Pediatr. Nephrol., 22 (11), pp. 1825-1838; Matthews, H.K., Marchant, L., Carmona-Fontaine, C., Kuriyama, S., Larrain, J., Holt, M.R., (2008) Development, 135 (10), pp. 1771-1780; Wang, Y., Thekdi, N., Smallwood, P.M., Macke, J.P., Nathans, J., (2002) J. Neurosci., 22 (19), pp. 8563-8573; Lyuksyutova, A.I., Lu, C.C., Milanesio, N., King, L.A., Guo, N., Wang, Y., (2003) Science, 302 (5652), pp. 1984-1988; Range, R.C., Angerer, R.C., Angerer, L.M., (2013) PLoS Biol., 11 (1), p. e1001467. , (PMCID: 3545869); Jordan, B.K., Shen, J.H., Olaso, R., Ingraham, H.A., Vilain, E., (2003) Proc. Natl. Acad. Sci. U. S. A., 100 (19), pp. 10866-10871. , (PMCID: 196894); Byrum, C.A., Xu, R., Bince, J.M., McClay, D.R., Wikramanayake, A.H., (2009) Dev. Dyn., 238 (7), pp. 1649-1665. , (PMCID: 3057072); Kang, S., Bennett, C.N., Gerin, I., Rapp, L.A., Hankenson, K.D., Macdougald, O.A., (2007) J. Biol. Chem., 282 (19), pp. 14515-14524; Komiya, Y., Habas, R., (2008) Organogenesis, 4 (2), pp. 68-75. , (PMCID: 2634250); Sugimura, R., Li, L., (2010) Birth Defects Res. C Embryo Today, 90 (4), pp. 243-256; Habas, R., Kato, Y., He, X., (2001) Cell, 107 (7), pp. 843-854; Heng, Y.W., Koh, C.G., (2010) Int. J. Biochem. Cell Biol., 42 (10), pp. 1622-1633; Beane, W.S., Gross, J.M., McClay, D.R., (2006) Dev. Biol., 292 (1), pp. 213-225; Croce, J., Duloquin, L., Lhomond, G., McClay, D.R., Gache, C., (2006) Development, 133 (3), pp. 547-557; Tada, M., Concha, M.L., Heisenberg, C.P., (2002) Semin. Cell Dev. Biol., 13 (3), pp. 251-260; Kim, G.H., Han, J.K., (2005) Dev. Dyn., 232 (4), pp. 958-968; Mierke, C.T., (2013) Phys. Biol., 10 (6), p. 065005; Ahumada, A., Slusarski, D.C., Liu, X., Moon, R.T., Malbon, C.C., Wang, H.Y., (2002) Science, 298 (5600), pp. 2006-2010; Kohn, A.D., Moon, R.T., (2005) Cell Calcium, 38 (3-4), pp. 439-446; Ma, L., Wang, H.Y., (2007) J. Biol. Chem., 282 (39), pp. 28980-28990; Sheldahl, L.C., Slusarski, D.C., Pandur, P., Miller, J.R., Kuhl, M., Moon, R.T., (2003) J. Cell Biol., 161 (4), pp. 769-777. , (PMCID: 2199364); Rao, T.P., Kuhl, M., (2010) Circ. Res., 106 (12), pp. 1798-1806; De, A., (2011) Acta Biochim. Biophys. Sin. (Shanghai), 43 (10), pp. 745-756; Habas, R., Dawid, I.B., He, X., (2003) Genes Dev., 17 (2), pp. 295-309. , (PMCID: 195976); Schlessinger, K., McManus, E.J., Hall, A., (2007) J. Cell Biol., 178 (3), pp. 355-361. , (PMCID: 2064837); Schlessinger, K., Hall, A., Tolwinski, N., (2009) Genes Dev., 23 (3), pp. 265-277; Rao, A., Luo, C., Hogan, P.G., (1997) Annu. Rev. Immunol., 15, pp. 707-747; Minami, Y., Oishi, I., Endo, M., Nishita, M., (2010) Dev. Dyn., 239 (1), pp. 1-15; Green, J., Nusse, R., van Amerongen, R., (2014) Cold Spring Harb. Perspect. Biol., 6 (2); Yoshikawa, S., McKinnon, R.D., Kokel, M., Thomas, J.B., (2003) Nature, 422 (6932), pp. 583-588; Kim, G.H., Her, J.H., Han, J.K., (2008) J. Cell Biol., 182 (6), pp. 1073-1082. , (PMCID: 2542470); Lin, S., Baye, L.M., Westfall, T.A., Slusarski, D.C., (2010) J. Cell Biol., 190 (2), pp. 263-278. , (PMCID: 2930277); Liu, Y., Shi, J., Lu, C.C., Wang, Z.B., Lyuksyutova, A.I., Song, X.J., (2005) Nat. Neurosci., 8 (9), pp. 1151-1159; Keeble, T.R., Cooper, H.M., (2006) Int. J. Biochem. Cell Biol., 38 (12), pp. 2011-2017; Lu, W., Yamamoto, V., Ortega, B., Baltimore, D., (2004) Cell, 119 (1), pp. 97-108; Keeble, T.R., Halford, M.M., Seaman, C., Kee, N., Macheda, M., Anderson, R.B., (2006) J. Neurosci., 26 (21), pp. 5840-5848; Li, L., Hutchins, B.I., Kalil, K., (2009) J. Neurosci., 29 (18), pp. 5873-5883. , (PMCID: 2697037); Macheda, M.L., Sun, W.W., Kugathasan, K., Hogan, B.M., Bower, N.I., Halford, M.M., (2012) J. Biol. Chem., 287 (35), pp. 29312-29323. , (PMCID: 3436188); Habu, M., Koyama, H., Kishida, M., Kamino, M., Iijima, M., Fuchigami, T., (2014) J. Biochem., 156 (1), pp. 29-38; Nomi, M., Oishi, I., Kani, S., Suzuki, H., Matsuda, T., Yoda, A., (2001) Mol. Cell. Biol., 21 (24), pp. 8329-8335. , (PMCID: 99997); DeChiara, T.M., Kimble, R.B., Poueymirou, W.T., Rojas, J., Masiakowski, P., Valenzuela, D.M., (2000) Nat. Genet., 24 (3), pp. 271-274; Oldridge, M., Fortuna, A.M., Maringa, M., Propping, P., Mansour, S., Pollitt, C., (2000) Nat. Genet., 24 (3), pp. 275-278; Schwabe, G.C., Trepczik, B., Suring, K., Brieske, N., Tucker, A.S., Sharpe, P.T., (2004) Dev. Dyn., 229 (2), pp. 400-410; Baskar, S., Kwong, K.Y., Hofer, T., Levy, J.M., Kennedy, M.G., Lee, E., (2008) Clin. Cancer Res., 14 (2), pp. 396-404; Shabani, M., Asgarian-Omran, H., Vossough, P., Sharifian, R.A., Faranoush, M., Ghragozlou, S., (2008) Leuk. Lymphoma, 49 (7), pp. 1360-1367; Zhang, S., Chen, L., Cui, B., Chuang, H.Y., Yu, J., Wang-Rodriguez, J., (2012) PLoS ONE, 7 (3), p. e31127. , (PMCID: 3293865); Rabbani, H., Ostadkarampour, M., Danesh Manesh, A.H., Basiri, A., Jeddi-Tehrani, M., Forouzesh, F., (2010) Iran. Biomed. J., 14 (3), pp. 77-82. , (PMCID: 3904057); Wright, T.M., Brannon, A.R., Gordan, J.D., Mikels, A.J., Mitchell, C., Chen, S., (2009) Oncogene, 28 (27), pp. 2513-2523. , (PMCID: 2771692); Edris, B., Espinosa, I., Muhlenberg, T., Mikels, A., Lee, C.H., Steigen, S.E., (2012) J. Pathol., 227 (2), pp. 223-233. , (PMCID: 3992120); Kobayashi, M., Shibuya, Y., Takeuchi, J., Murata, M., Suzuki, H., Yokoo, S., (2009) Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 107 (3), pp. 398-406; Bicocca, V.T., Chang, B.H., Masouleh, B.K., Muschen, M., Loriaux, M.M., Druker, B.J., (2012) Cancer Cell, 22 (5), pp. 656-667. , (PMCID: 3500515); Rebagay, G., Yan, S., Liu, C., Cheung, N.K., (2012) Front Oncol., 2, p. 34. , (PMCID: 3356025); Axelrod, J.D., (2009) Semin. Cell Dev. Biol., 20 (8), pp. 964-971; Simons, M., Mlodzik, M., (2008) Annu. Rev. Genet., 42, pp. 517-540. , (PMCID: 2814158); Kikuchi, A., Yamamoto, H., Sato, A., Matsumoto, S., (2011) Int. Rev. Cell Mol. Biol., 291, pp. 21-71; Tanaka, K., Kitagawa, Y., Kadowaki, T., (2002) J. Biol. Chem., 277 (15), pp. 12816-12823; Burrus, L.W., McMahon, A.P., (1995) Exp. Cell Res., 220 (2), pp. 363-373; Janda, C.Y., Waghray, D., Levin, A.M., Thomas, C., Garcia, K.C., (2012) Science, 337 (6090), pp. 59-64. , (PMCID: 3577348); MacDonald, B.T., Hien, A., Zhang, X., Iranloye, O., Virshup, D.M., Waterman, M.L., (2014) J. Biol. Chem., 289 (26), pp. 18122-18136. , (PMCID: 4140276); Verras, M., Papandreou, I., Lim, A.L., Denko, N.C., (2008) Mol. Cell. Biol., 28 (23), pp. 7212-7224. , (PMCID: 2593368); Takada, R., Satomi, Y., Kurata, T., Ueno, N., Norioka, S., Kondoh, H., (2006) Dev. Cell, 11 (6), pp. 791-801; Zhai, L., Chaturvedi, D., Cumberledge, S., (2004) J. Biol. Chem., 279 (32), pp. 33220-33227; Ching, W., Hang, H.C., Nusse, R., (2008) J. Biol. Chem., 283 (25), pp. 17092-17098. , (PMCID: 2427328); Komekado, H., Yamamoto, H., Chiba, T., Kikuchi, A., (2007) Genes Cells, 12 (4), pp. 521-534; Willert, K., Brown, J.D., Danenberg, E., Duncan, A.W., Weissman, I.L., Reya, T., (2003) Nature, 423 (6938), pp. 448-452; Herr, P., Basler, K., (2012) Dev. Biol., 361 (2), pp. 392-402; Banziger, C., Soldini, D., Schutt, C., Zipperlen, P., Hausmann, G., Basler, K., (2006) Cell, 125 (3), pp. 509-522; Bartscherer, K., Pelte, N., Ingelfinger, D., Boutros, M., (2006) Cell, 125 (3), pp. 523-533; Goodman, R.M., Thombre, S., Firtina, Z., Gray, D., Betts, D., Roebuck, J., (2006) Development, 133 (24), pp. 4901-4911; Najdi, R., Proffitt, K., Sprowl, S., Kaur, S., Yu, J., Covey, T.M., (2012) Differentiation, 84 (2), pp. 203-213. , (PMCID: 4015730); Gross, J.C., Chaudhary, V., Bartscherer, K., Boutros, M., (2012) Nat. Cell Biol., 14 (10), pp. 1036-1045; Koles, K., Nunnari, J., Korkut, C., Barria, R., Brewer, C., Li, Y., (2012) J. Biol. Chem., 287 (20), pp. 16820-16834. , (PMCID: 3351299); Mulligan, K.A., Fuerer, C., Ching, W., Fish, M., Willert, K., Nusse, R., (2012) Proc. Natl. Acad. Sci. U. S. A., 109 (2), pp. 370-377. , (PMCID: 3258625); Neumann, S., Coudreuse, D.Y., van der Westhuyzen, D.R., Eckhardt, E.R., Korswagen, H.C., Schmitz, G., (2009) Traffic, 10 (3), pp. 334-343; Greco, V., Hannus, M., Eaton, S., (2001) Cell, 106 (5), pp. 633-645; Hsiung, F., Ramirez-Weber, F.A., Iwaki, D.D., Kornberg, T.B., (2005) Nature, 437 (7058), pp. 560-563; Korkut, C., Ataman, B., Ramachandran, P., Ashley, J., Barria, R., Gherbesi, N., (2009) Cell, 139 (2), pp. 393-404. , (PMCID: 2785045); Panakova, D., Sprong, H., Marois, E., Thiele, C., Eaton, S., (2005) Nature, 435 (7038), pp. 58-65; Grzeschik, K.H., Bornholdt, D., Oeffner, F., Konig, A., del Carmen, B.M., Enders, H., (2007) Nat. Genet., 39 (7), pp. 833-835; Wang, X., Reid Sutton, V., Omar Peraza-Llanes, J., Yu, Z., Rosetta, R., Kou, Y.C., (2007) Nat. Genet., 39 (7), pp. 836-838; Barrott, J.J., Cash, G.M., Smith, A.P., Barrow, J.R., Murtaugh, L.C., (2011) Proc. Natl. Acad. Sci. U. S. A., 108 (31), pp. 12752-12757. , (PMCID: 3150921); Biechele, S., Cox, B.J., Rossant, J., (2011) Dev. Biol., 355 (2), pp. 275-285; Cui, M., Siriwon, N., Li, E., Davidson, E.H., Peter, I.S., (2014) Proc. Natl. Acad. Sci. U. S. A., 111 (47), pp. E5029-E5038. , (PMCID: 4250154); Fu, J., Jiang, M., Mirando, A.J., Yu, H.M., Hsu, W., (2009) Proc. Natl. Acad. Sci. U. S. A., 106 (44), pp. 18598-18603. , (PMCID: 2773984); Carpenter, A.C., Rao, S., Wells, J.M., Campbell, K., Lang, R.A., (2010) Genesis, 48 (9), pp. 554-558. , (PMCID: 3689319); Voloshanenko, O., Erdmann, G., Dubash, T.D., Augustin, I., Metzig, M., Moffa, G., (2013) Nat. Commun., 4, p. 2610. , (PMCID: 3826636); Giraldez, A.J., Copley, R.R., Cohen, S.M., (2002) Dev. Cell, 2 (5), pp. 667-676; Zhang, X., Abreu, J.G., Yokota, C., MacDonald, B.T., Singh, S., Coburn, K.L., (2012) Cell, 149 (7), pp. 1565-1577. , (PMCID: 3383638); Zhang, X., Cheong, S.M., Amado, N.G., Reis, A.H., MacDonald, B.T., Zebisch, M., (2015) Dev. Cell, 32 (6), pp. 719-730; Kakugawa, S., Langton, P.F., Zebisch, M., Howell, S.A., Chang, T.H., Liu, Y., (2015) Nature, 519 (7542), pp. 187-192; Gerlitz, O., Nellen, D., Ottiger, M., Basler, K., (2002) Int. J. Dev. Biol., 46 (1), pp. 173-176; Flowers, G.P., Topczewska, J.M., Topczewski, J., (2012) Development, 139 (13), pp. 2416-2425. , (PMCID: 3367448); Petersen, C.P., Reddien, P.W., (2011) Science, 332 (6031), pp. 852-855. , (PMCID: 3320723); Nusse, R., (2015) Nature, 519 (7542), pp. 163-164; Teh, M.T., Blaydon, D., Ghali, L.R., Briggs, V., Edmunds, S., Pantazi, E., (2007) J. Cell Sci., 120, pp. 330-339; Onizuka, T., Yuasa, S., Kusumoto, D., Shimoji, K., Egashira, T., Ohno, Y., (2012) J. Mol. Cell. Cardiol., 52 (3), pp. 650-659; Karasawa, T., Yokokura, H., Kitajewski, J., Lombroso, P.J., (2002) J. Biol. Chem., 277 (40), pp. 37479-37486; Endo, Y., Beauchamp, E., Woods, D., Taylor, W.G., Toretsky, J.A., Uren, A., (2008) Mol. Cell. Biol., 28 (7), pp. 2368-2379. , (PMCID: 2268413); Galli, L.M., Munji, R.N., Chapman, S.C., Easton, A., Li, L., Onguka, O., (2014) Dev. Dyn., 243 (6), pp. 833-843. , (PMCID: 4031291); Varela-Nallar, L., Grabowski, C.P., Alfaro, I.E., Alvarez, A.R., Inestrosa, N.C., (2009) Neural Dev., 4, p. 41. , (PMCID: 2779803); Lyons, J.P., Mueller, U.W., Ji, H., Everett, C., Fang, X., Hsieh, J.C., (2004) Exp. Cell Res., 298 (2), pp. 369-387; Heinonen, K.M., Vanegas, J.R., Lew, D., Krosl, J., Perreault, C., (2011) PLoS ONE, 6 (4), p. e19279. , (PMCID: 3082562); Umbhauer, M., Djiane, A., Goisset, C., Penzo-Mendez, A., Riou, J.F., Boucaut, J.C., (2000) EMBO J., 19 (18), pp. 4944-4954. , (PMCID: 314225); Chen, W., ten Berge, D., Brown, J., Ahn, S., Hu, L.A., Miller, W.E., (2003) Science, 301 (5638), pp. 1391-1394; Robitaille, J., MacDonald, M.L., Kaykas, A., Sheldahl, L.C., Zeisler, J., Dube, M.P., (2002) Nat. Genet., 32 (2), pp. 326-330; Hering, H., Sheng, M., (2002) FEBS Lett., 521 (1-3), pp. 185-189; Medina, A., Reintsch, W., Steinbeisser, H., (2000) Mech. Dev., 92 (2), pp. 227-237; Le Grand, F., Jones, A.E., Seale, V., Scime, A., Rudnicki, M.A., (2009) Cell Stem Cell, 4 (6), pp. 535-547. , (PMCID: 2743383); De Calisto, J., Araya, C., Marchant, L., Riaz, C.F., Mayor, R., (2005) Development, 132 (11), pp. 2587-2597; Nalesso, G., Sherwood, J., Bertrand, J., Pap, T., Ramachandran, M., De Bari, C., (2011) J. Cell Biol., 193 (3), pp. 551-564. , (PMCID: 3087013); Schroeder, K.E., Condic, M.L., Eisenberg, L.M., Yost, H.J., (1999) Dev. Biol., 214 (2), pp. 288-297; Kuhl, M., Sheldahl, L.C., Malbon, C.C., Moon, R.T., (2000) J. Biol. Chem., 275 (17), pp. 12701-12711; Tao, Q., Yokota, C., Puck, H., Kofron, M., Birsoy, B., Yan, D., (2005) Cell, 120 (6), pp. 857-871; Slusarski, D.C., Corces, V.G., Moon, R.T., (1997) Nature, 390 (6658), pp. 410-413; Kestler, H.A., Kuhl, M., (2011) J. Cell Biol., 193 (3), pp. 431-433. , (PMCID: 3087014); Ishitani, T., Kishida, S., Hyodo-Miura, J., Ueno, N., Yasuda, J., Waterman, M., (2003) Mol. Cell. Biol., 23 (1), pp. 131-139. , (PMCID: 140665); Bartel, D.P., (2004) Cell, 116 (2), pp. 281-297; Lee, R.C., Feinbaum, R.L., Ambros, V., (1993) Cell, 75 (5), pp. 843-854; Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, J.C., Rougvie, A.E., (2000) Nature, 403 (6772), pp. 901-906; Bartel, D.P., (2009) Cell, 136 (2), pp. 215-233; Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., (2005) Nature, 433 (7027), pp. 769-773; Giraldez, A.J., Mishima, Y., Rihel, J., Grocock, R.J., Van Dongen, S., Inoue, K., (2006) Science, 312 (5770), pp. 75-79; Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., Rajewsky, N., (2008) Nature, 455 (7209), pp. 58-63; He, L., Hannon, G.J., (2004) Nat. Rev. Genet., 5 (7), pp. 522-531; Iorio, M.V., Croce, C.M., (2012) EMBO Mol. Med., 4 (3), pp. 143-159. , (PMCID: 3376845); Zhu, S., Pan, W., Qian, Y., (2013) J. Mol. Med. (Berl.), 91 (9), pp. 1039-1050; Bian, S., Sun, T., (2011) Mol. Neurobiol., 44 (3), pp. 359-373. , (PMCID: 3246283); Kim, V.N., Nam, J.W., (2006) Trends Genet., 22 (3), pp. 165-173; Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., (2005) Cancer Res., 65 (21), pp. 9628-9632; Han, J., Lee, Y., Yeom, K.H., Nam, J.W., Heo, I., Rhee, J.K., (2006) Cell, 125 (5), pp. 887-901; Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., (2003) Nature, 425 (6956), pp. 415-419; Lund, E., Dahlberg, J.E., (2006) Cold Spring Harb. Symp. Quant. Biol., 71, pp. 59-66; Zhang, H., Kolb, F.A., Brondani, V., Billy, E., Filipowicz, W., (2002) EMBO J., 21 (21), pp. 5875-5885; Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., Zamore, P.D., (2003) Cell, 115 (2), pp. 199-208; Khvorova, A., Reynolds, A., Jayasena, S.D., (2003) Cell, 115 (2), pp. 209-216; Okamura, K., Phillips, M.D., Tyler, D.M., Duan, H., Chou, Y.T., Lai, E.C., (2008) Nat. Struct. Mol. Biol., 15 (4), pp. 354-363. , (PMCID: 2698667); Ruby, J.G., Jan, C.H., Bartel, D.P., (2007) Nature, 448 (7149), pp. 83-86; Okamura, K., Hagen, J.W., Duan, H., Tyler, D.M., Lai, E.C., (2007) Cell, 130 (1), pp. 89-100; Berezikov, E., Chung, W.J., Willis, J., Cuppen, E., Lai, E.C., (2007) Mol. Cell, 28 (2), pp. 328-336. , (PMCID: 2763384); Kim, Y.K., Kim, V.N., (2007) EMBO J., 26 (3), pp. 775-783. , (PMCID: 1794378); Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P., Burge, C.B., (2003) Cell, 115 (7), pp. 787-798; Lewis, B.P., Burge, C.B., Bartel, D.P., (2005) Cell, 120 (1), pp. 15-20; Brennecke, J., Stark, A., Russell, R.B., Cohen, S.M., (2005) PLoS Biol., 3 (3), p. e85. , (PMCID: 1043860); Krek, A., Grun, D., Poy, M.N., Wolf, R., Rosenberg, L., Epstein, E.J., (2005) Nat. Genet., 37 (5), pp. 495-500; Lim, L.P., Lau, N.C., Weinstein, E.G., Abdelhakim, A., Yekta, S., Rhoades, M.W., (2003) Genes Dev., 17 (8), pp. 991-1008. , (PMCID: 196042); Lai, E.C., (2002) Nat. Genet., 30 (4), pp. 363-364; Grimson, A., Farh, K.K., Johnston, W.K., Garrett-Engele, P., Lim, L.P., Bartel, D.P., (2007) Mol. Cell, 27 (1), pp. 91-105; Xie, X., Lu, J., Kulbokas, E.J., Golub, T.R., Mootha, V., Lindblad-Toh, K., (2005) Nature, 434 (7031), pp. 338-345; Friedman, R.C., Farh, K.K., Burge, C.B., Bartel, D.P., (2009) Genome Res., 19 (1), pp. 92-105; Tay, Y., Zhang, J., Thomson, A.M., Lim, B., Rigoutsos, I., (2008) Nature, 455 (7216), pp. 1124-1128; Chekulaeva, M., Filipowicz, W., (2009) Curr. Opin. Cell Biol., 21 (3), pp. 452-460; Place, R.F., Li, L.C., Pookot, D., Noonan, E.J., Dahiya, R., (2008) Proc. Natl. Acad. Sci. U. S. A., 105 (5), pp. 1608-1613. , (PMCID: 2234192); Alvarez-Garcia, I., Miska, E.A., (2005) Development, 132 (21), pp. 4653-4662; Bushati, N., Cohen, S.M., (2007) Annu. Rev. Cell Dev. Biol., 23, pp. 175-205; Ambros, V., (2004) Nature, 431 (7006), pp. 350-355; Wienholds, E., Plasterk, R.H., (2005) FEBS Lett., 579 (26), pp. 5911-5922; Bernstein, E., Kim, S.Y., Carmell, M.A., Murchison, E.P., Alcorn, H., Li, M.Z., (2003) Nat. Genet., 35 (3), pp. 215-217; Giraldez, A.J., Cinalli, R.M., Glasner, M.E., Enright, A.J., Thomson, J.M., Baskerville, S., (2005) Science, 308 (5723), pp. 833-838; Song, J.L., Stoeckius, M., Maaskola, J., Friedlander, M., Stepicheva, N., Juliano, C., (2012) Dev. Biol., 362 (1), pp. 104-113. , (PMCID: 3254792); Ivey, K.N., Srivastava, D., (2010) Cell Stem Cell, 7 (1), pp. 36-41; Mukherji, S., Ebert, M.S., Zheng, G.X., Tsang, J.S., Sharp, P.A., van Oudenaarden, A., (2011) Nat. Genet., 43 (9), pp. 854-859. , (PMCID: 3163764); Jovanovic, M., Hengartner, M.O., (2006) Oncogene, 25 (46), pp. 6176-6187; Stark, A., Brennecke, J., Russell, R.B., Cohen, S.M., (2003) PLoS Biol., 1 (3), p. E60; Martello, G., Zacchigna, L., Inui, M., Montagner, M., Adorno, M., Mamidi, A., (2007) Nature, 449 (7159), pp. 183-188; Niehrs, C., (2004) Nat. Rev. Genet., 5 (6), pp. 425-434; Meng, F., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T., Patel, T., (2007) Gastroenterology, 133 (2), pp. 647-658. , (PMCID: 4285346); Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., (2008) Nature, 456 (7224), pp. 980-984; Fish, J.E., Santoro, M.M., Morton, S.U., Yu, S., Yeh, R.F., Wythe, J.D., (2008) Dev. Cell, 15 (2), pp. 272-284. , (PMCID: 2604134); Kuhnert, F., Mancuso, M.R., Hampton, J., Stankunas, K., Asano, T., Chen, C.Z., (2008) Development, 135 (24), pp. 3989-3993; Kim, N.H., Kim, H.S., Kim, N.G., Lee, I., Choi, H.S., Li, X.Y., (2011) Sci. Signal., 4 (197), p. ra71. , (PMCID: 3447368); Stepicheva, N., Nigam, P.A., Siddam, A., Peng, C.F., Song, J.L., (2015) Dev. Biol., (15). , http://dx.doi.org/10.106/j.ydbio.2015.01.008, 00016-0, (PMID: 261438), S0012-1606; Anton, R., Chatterjee, S.S., Simundza, J., Cowin, P., Dasgupta, R., (2011) PLoS ONE, 6 (10), p. e26257. , (PMCID: 3197157); Bianco, P., Riminucci, M., Gronthos, S., Robey, P.G., (2001) Stem Cells, 19 (3), pp. 180-192; Inose, H., Ochi, H., Kimura, A., Fujita, K., Xu, R., Sato, S., (2009) Proc. Natl. Acad. Sci. U. S. A., 106 (49), pp. 20794-20799. , (PMCID: 2791638); Kang, H., Hata, A., (2014) BMB Rep., , (PMID: 25341923); Lin, G.L., Hankenson, K.D., (2011) J. Cell. Biochem., 112 (12), pp. 3491-3501. , (PMCID: 3202082); Vimalraj, S., Selvamurugan, N., (2012) Curr. Issues Mol. Biol., 15 (1), pp. 7-18; Wang, T., Xu, Z., (2010) Biochem. Biophys. Res. Commun., 402 (2), pp. 186-189; Hu, W., Ye, Y., Zhang, W., Wang, J., Chen, A., Guo, F., (2013) Mol. Med. Rep., 7 (2), pp. 689-693; Chen, C., Peng, Y., Peng, J., Jiang, S., (2014) J. Mol. Endocrinol., 52 (3), pp. 311-320; Kapinas, K., Kessler, C., Ricks, T., Gronowicz, G., Delany, A.M., (2010) J. Biol. Chem., 285 (33), pp. 25221-25231. , (PMCID: 2919085); Zhang, J., Tu, Q., Bonewald, L.F., He, X., Stein, G., Lian, J., (2011) J. Bone Miner. Res., 26 (8), pp. 1953-1963. , (PMCID: 3810406); Zhang, W.B., Zhong, W.J., Wang, L., (2014) Bone, 58, pp. 59-66; Chen, H., Mo, D., Li, M., Zhang, Y., Chen, L., Zhang, X., (2014) Cell. Signal., 26 (11), pp. 2583-2589; Chen, H., Wang, S., Chen, L., Chen, Y., Wu, M., Zhang, Y., (2014) FEBS Lett., 588 (3), pp. 429-435; Wang, Q., Cai, J., Cai, X.H., Chen, L., (2013) PLoS ONE, 8 (9), p. e72266. , (PMCID: 3762871); Wu, T., Zhou, H., Hong, Y., Li, J., Jiang, X., Huang, H., (2012) J. Biol. Chem., 287 (10), pp. 7503-7511. , (PMCID: 3293535); Qin, L., Chen, Y., Niu, Y., Chen, W., Wang, Q., Xiao, S., (2010) BMC Genomics, 11, p. 320. , (PMCID: 2895628); Kennell, J.A., Gerin, I., MacDougald, O.A., Cadigan, K.M., (2008) Proc. Natl. Acad. Sci. U. S. A., 105 (40), pp. 15417-15422. , (PMCID: 2563117); Arfat, Y., Xiao, W.Z., Ahmad, M., Zhao, F., Li, D.J., Sun, Y.L., (2014) Curr. Med. Chem., 22 (6), pp. 748-758; Olson, E.N., (2006) Science, 313 (5795), pp. 1922-1927; Chen, J., Wang, D.Z., (2012) J. Mol. Cell. Cardiol., 52 (5), pp. 949-957. , (PMCID: 3721071); Zhao, Y., Ransom, J.F., Li, A., Vedantham, V., von Drehle, M., Muth, A.N., (2007) Cell, 129 (2), pp. 303-317; Rao, P.K., Toyama, Y., Chiang, H.R., Gupta, S., Bauer, M., Medvid, R., (2009) Circ. Res., 105 (6), pp. 585-594. , (PMCID: 2828903); Li, M., Hu, X., Zhu, J., Zhu, C., Zhu, S., Liu, X., (2014) Cell. Physiol. Biochem., 33 (6), pp. 1988-2002; Qin, D.N., Qian, L., Hu, D.L., Yu, Z.B., Han, S.P., Zhu, C., (2013) Cell Biochem. Biophys., 66 (3), pp. 709-722; Zhang, L.L., Liu, J.J., Liu, F., Liu, W.H., Wang, Y.S., Zhu, B., (2012) Biochem. Biophys. Res. Commun., 420 (4), pp. 875-881; Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond, S.M., (2006) Nat. Genet., 38 (2), pp. 228-233. , (PMCID: 2538576); Kwon, C., Han, Z., Olson, E.N., Srivastava, D., (2005) Proc. Natl. Acad. Sci. U. S. A., 102 (52), pp. 18986-18991; Lu, T.Y., Lin, B., Li, Y., Arora, A., Han, L., Cui, C., (2013) J. Mol. Cell. Cardiol., 63 C, pp. 146-154; Sun, E., Shi, Y., (2014) Exp. Neurol.; Follert, P., Cremer, H., Beclin, C., (2014) Front. Mol. Neurosci., 7, p. 5. , (PMCID: 3916726); Petri, R., Malmevik, J., Fasching, L., Akerblom, M., Jakobsson, J., (2014) Exp. Cell Res., 321 (1), pp. 84-89; Liu, Y., Huang, T., Zhao, X., Cheng, L., (2011) Biochem. Biophys. Res. Commun., 408 (2), pp. 259-264; Anderegg, A., Lin, H.P., Chen, J.A., Caronia-Brown, G., Cherepanova, N., Yun, B., (2013) PLoS Genet., 9 (12), p. e1003973. , (PMCID: 3861205); Wu, D., Raafat, A., Pak, E., Clemens, S., Murashov, A.K., (2012) Exp. Neurol., 233 (1), pp. 555-565. , (PMCID: 3268911); Wu, D., Murashov, A.K., (2013) Front. Mol. Neurosci., 6, p. 35. , (PMCID: 3807041); Kim, Y., Capel, B., (2006) Dev. Dyn., 235 (9), pp. 2292-2300; Bernard, P., Harley, V.R., (2007) Int. J. Biochem. Cell Biol., 39 (1), pp. 31-43; Pancratov, R., Peng, F., Smibert, P., Yang, S., Olson, E.R., Guha-Gilford, C., (2013) Development, 140 (14), pp. 2904-2916. , (PMCID: 3699279); Wang, Y., Huang, C., Reddy Chintagari, N., Bhaskaran, M., Weng, T., Guo, Y., (2013) Nucleic Acids Res., 41 (6), pp. 3833-3844. , (PMCID: 3616718); Ye, X., Hemida, M.G., Qiu, Y., Hanson, P.J., Zhang, H.M., Yang, D., (2013) Cell. Mol. Life Sci., 70 (23), pp. 4631-4644; Alexander, M.S., Kawahara, G., Motohashi, N., Casar, J.C., Eisenberg, I., Myers, J.A., (2013) Cell Death Differ., 20 (9), pp. 1194-1208. , (PMCID: 3741500); Slobodov, G., Feloney, M., Gran, C., Kyker, K.D., Hurst, R.E., Culkin, D.J., (2004) J. Urol., 171 (4), pp. 1554-1558; Sanchez Freire, V., Burkhard, F.C., Kessler, T.M., Kuhn, A., Draeger, A., Monastyrskaya, K., (2010) Am. J. Pathol., 176 (1), pp. 288-303. , (PMCID: 2797891); Monastyrskaya, K., Sanchez-Freire, V., Hashemi Gheinani, A., Klumpp, D.J., Babiychuk, E.B., Draeger, A., (2013) Am. J. Pathol., 182 (2), pp. 431-448; Hashemi Gheinani, A., Burkhard, F.C., Rehrauer, H., Aquino Fournier, C., Monastyrskaya, K., (2015) J. Biol. Chem., 290 (11), pp. 7067-7086; Simonson, M.S., (2007) Kidney Int., 71 (9), pp. 846-854; Mishra, R., Cool, B.L., Laderoute, K.R., Foretz, M., Viollet, B., Simonson, M.S., (2008) J. Biol. Chem., 283 (16), pp. 10461-10469; Mishra, R., Simonson, M.S., (2008) Arterioscler. Thromb. Vasc. Biol., 28 (3), pp. 541-547; Mu, J., Pang, Q., Guo, Y.H., Chen, J.G., Zeng, W., Huang, Y.J., (2013) PLoS ONE, 8 (3), p. e58622. , (PMCID: 3595285); Sun, X., He, Y., Huang, C., Ma, T.T., Li, J., (2013) Cell. Signal., 25 (12), pp. 2805-2811; Saydam, O., Shen, Y., Wurdinger, T., Senol, O., Boke, E., James, M.F., (2009) Mol. Cell. Biol., 29 (21), pp. 5923-5940. , (PMCID: 2772747); Goodenberger, M.L., Jenkins, R.B., (2012) Cancer Genet., 205 (12), pp. 613-621; Delic, S., Lottmann, N., Stelzl, A., Liesenberg, F., Wolter, M., Gotze, S., (2014) Neuro Oncol., 16 (2), pp. 179-190. , (PMCID: 3895379); Guo, M., Zhang, X., Wang, G., Sun, J., Jiang, Z., Khadarian, K., (2015) Cancer Lett., 360 (1), pp. 76-86; Yan, Z., Wang, J., Wang, C., Jiao, Y., Qi, W., Che, S., (2014) FEBS Lett., 588 (17), pp. 3038-3046; Chen, L., Zhang, A., Li, Y., Zhang, K., Han, L., Du, W., (2013) Cancer Lett., 329 (2), pp. 174-180; Li, Q., Shen, K., Zhao, Y., He, X., Ma, C., Wang, L., (2013) FEBS Lett., 587 (12), pp. 1742-1748; Li, Q., Shen, K., Zhao, Y., Ma, C., Liu, J., Ma, J., (2013) J. Transl. Med., 11, p. 302. , (PMCID: 4028874); Wang, X., Wang, K., Han, L., Zhang, A., Shi, Z., Zhang, K., (2013) Cancer Lett., 331 (2), pp. 211-219; Gokhale, A., Kunder, R., Goel, A., Sarin, R., Moiyadi, A., Shenoy, A., (2010) J. Cancer Res. Ther., 6 (4), pp. 521-529; http://www.cancer.org/acs/groups/content/documents/document/acspc-042280.pdf, Available from:Kim, N.H., Cha, Y.H., Kang, S.E., Lee, Y., Lee, I., Cha, S.Y., (2013) Cell Cycle, 12 (10), pp. 1578-1587. , (PMCID: 3680537); Zhang, H., Hao, Y., Yang, J., Zhou, Y., Li, J., Yin, S., (2011) Nat. Commun., 2, p. 554; Subramanian, M., Rao, S.R., Thacker, P., Chatterjee, S., Karunagaran, D., (2014) J. Cell. Biochem., 115 (11), pp. 1974-1984; Ke, T.W., Hsu, H.L., Wu, Y.H., Chen, W.T., Cheng, Y.W., Cheng, C.W., (2014) Dis. Markers, 2014, p. 617150. , (PMCID: 4004168); Strillacci, A., Valerii, M.C., Sansone, P., Caggiano, C., Sgromo, A., Vittori, L., (2013) J. Pathol., 229 (3), pp. 379-389; Tang, Q., Zou, Z., Zou, C., Zhang, Q., Huang, R., Guan, X., (2015) Tumour Biol., 36 (3), pp. 1701-1710; Yamada, N., Noguchi, S., Mori, T., Naoe, T., Maruo, K., Akao, Y., (2013) Cancer Lett., 335 (2), pp. 332-342; Nagel, R., le Sage, C., Diosdado, B., van der Waal, M., Oude Vrielink, J.A., Bolijn, A., (2008) Cancer Res., 68 (14), pp. 5795-5802; Ji, S., Ye, G., Zhang, J., Wang, L., Wang, T., Wang, Z., (2013) Gut, 62 (5), pp. 716-726. , (PMCID: 3618686); Yu, Y., Kanwar, S.S., Patel, B.B., Oh, P.S., Nautiyal, J., Sarkar, F.H., (2012) Carcinogenesis, 33 (1), pp. 68-76. , (PMCID: 3276336); Zhang, N., Li, X., Wu, C.W., Dong, Y., Cai, M., Mok, M.T., (2013) Oncogene, 32 (42), pp. 5078-5088; Xia, H., Ooi, L.L., Hui, K.M., (2012) PLoS ONE, 7 (9), p. e44206. , (PMCID: 3433464); Wang, X., Chen, J., Li, F., Lin, Y., Zhang, X., Lv, Z., (2012) Biochem. Biophys. Res. Commun., 428 (4), pp. 525-531; Gu, W., Li, X., Wang, J., (2014) Oncol. Rep., 31 (1), pp. 397-404; Xu, J., Zhu, X., Wu, L., Yang, R., Yang, Z., Wang, Q., (2012) Liver Int., 32 (5), pp. 752-760; Zhang, J.G., Shi, Y., Hong, D.F., Song, M., Huang, D., Wang, C.Y., (2015) Sci. Rep., 5, p. 8087; Wu, L., Cai, C., Wang, X., Liu, M., Li, X., Tang, H., (2011) FEBS Lett., 585 (9), pp. 1322-1330; Tang, J., Tao, Z.H., Wen, D., Wan, J.L., Liu, D.L., Zhang, S., (2014) Biochem. Biophys. Res. Commun., 447 (1), pp. 210-215; Tao, Z.H., Wan, J.L., Zeng, L.Y., Xie, L., Sun, H.C., Qin, L.X., (2013) J. Exp. Med., 210 (4), pp. 789-803. , (PMCID: 3620363); Law, P.T., Ching, A.K., Chan, A.W., Wong, Q.W., Wong, C.K., To, K.F., (2012) Carcinogenesis, 33 (6), pp. 1134-1141; Dearth, R.K., Cui, X., Kim, H.J., Kuiatse, I., Lawrence, N.A., Zhang, X., (2006) Mol. Cell. Biol., 26 (24), pp. 9302-9314. , (PMCID: 1698542); Longato, L., de la Monte, S., Kuzushita, N., Horimoto, M., Rogers, A.B., Slagle, B.L., (2009) Hepatology, 49 (6), pp. 1935-1943. , (PMCID: 2754284); Shen, G., Jia, H., Tai, Q., Li, Y., Chen, D., (2013) Carcinogenesis, 34 (1), pp. 211-219; Zhang, Y., Wei, W., Cheng, N., Wang, K., Li, B., Jiang, X., (2012) Hepatology, 56 (5), pp. 1631-1640; Xu, N., Shen, C., Luo, Y., Xia, L., Xue, F., Xia, Q., (2012) Biochem. Biophys. Res. Commun., 425 (2), pp. 468-472; Hua, H.W., Jiang, F., Huang, Q., Liao, Z., Ding, G., (2015) Oncotarget, 6 (6), pp. 3840-3847; Sachdeva, M., Mo, Y.Y., (2010) Cancer Res., 70 (1), pp. 378-387. , (PMCID: 2805032); Kim, S.J., Oh, J.S., Shin, J.Y., Lee, K.D., Sung, K.W., Nam, S.J., (2011) J. Control. Release, 155 (3), pp. 427-434; Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szasz, A.M., Wang, Z.C., (2009) Cell, 137 (6), pp. 1032-1046; Valastyan, S., Weinberg, R.A., (2010) Cell Cycle, 9 (11); Xi, S., Yang, M., Tao, Y., Xu, H., Shan, J., Inchauste, S., (2010) PLoS ONE, 5 (10), p. e13764. , (PMCID: 2966442); De Menna, M., D'Amato, V., Ferraro, A., Fusco, A., Di Lauro, R., Garbi, C., (2013) Oncogene, 32 (35), pp. 4110-4119; Cai, J., Guan, H., Fang, L., Yang, Y., Zhu, X., Yuan, J., (2013) J. Clin. Invest., 123 (2), pp. 566-579. , (PMCID: 3561816); Isobe, T., Hisamori, S., Hogan, D.J., Zabala, M., Hendrickson, D.G., Dalerba, P., (2014) Elife, 3. , (PMCID: 4235011); Weilbaecher, K.N., Guise, T.A., McCauley, L.K., (2011) Nat. Rev. Cancer, 11 (6), pp. 411-425. , (PMCID: 3666847); Hassan, M.Q., Gordon, J.A., Beloti, M.M., Croce, C.M., van Wijnen, A.J., Stein, J.L., (2010) Proc. Natl. Acad. Sci. U. S. A., 107 (46), pp. 19879-19884. , (PMCID: 2993380); Lian, J.B., Stein, G.S., van Wijnen, A.J., Stein, J.L., Hassan, M.Q., Gaur, T., (2012) Nat. Rev. Endocrinol., 8 (4), pp. 212-227. , (PMCID: 3589914); Li, Z., Hassan, M.Q., Volinia, S., van Wijnen, A.J., Stein, J.L., Croce, C.M., (2008) Proc. Natl. Acad. Sci. U. S. A., 105 (37), pp. 13906-13911. , (PMCID: 2544552); Hassan, M.Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J.A., (2012) J. Biol. Chem., 287 (50), pp. 42084-42092. , (PMCID: 3516754); Iliopoulos, D., Bimpaki, E.I., Nesterova, M., Stratakis, C.A., (2009) Cancer Res., 69 (8), pp. 3278-3282. , (PMCID: 3124768); Guo, Y., Ying, L., Tian, Y., Yang, P., Zhu, Y., Wang, Z., (2013) FEBS J., 280 (18), pp. 4531-4538; Hirata, H., Ueno, K., Shahryari, V., Tanaka, Y., Tabatabai, Z.L., Hinoda, Y., (2012) PLoS ONE, 7 (11), p. e51056. , (PMCID: 3511415); Ueno, K., Hirata, H., Majid, S., Yamamura, S., Shahryari, V., Tabatabai, Z.L., (2012) Mol. Cancer Ther., 11 (1), pp. 244-253. , (PMCID: 3940358); Hirata, H., Hinoda, Y., Ueno, K., Nakajima, K., Ishii, N., Dahiya, R., (2012) Carcinogenesis, 33 (3), pp. 501-508. , (PMCID: 3291860); Hirata, H., Hinoda, Y., Ueno, K., Shahryari, V., Tabatabai, Z.L., Dahiya, R., (2012) Carcinogenesis, 33 (1), pp. 41-48. , (PMCID: 3276333); Wang, Z., Humphries, B., Xiao, H., Jiang, Y., Yang, C., (2014) J. Biol. Chem., 289 (26), pp. 18373-18386. , (PMCID: 4140296); Zhang, J., Han, C., Wu, T., (2012) Gastroenterology, 143 (1). , 246-56.e8. (PMCID: 3668336); Aprelikova, O., Palla, J., Hibler, B., Yu, X., Greer, Y.E., Yi, M., (2013) Oncogene, 32 (27), pp. 3246-3253. , (PMCID: 3711253); Jia, Y., Yang, Y., Zhan, Q., Brock, M.V., Zheng, X., Yu, Y., (2012) J. Mol. Diagn., 14 (6), pp. 577-585; Zhang, Z., Liu, S., Shi, R., Zhao, G., (2011) Cancer Genet., 204 (9), pp. 486-491; Liu, Y., Yan, W., Zhang, W., Chen, L., You, G., Bao, Z., (2012) Oncol. Rep., 28 (3), pp. 1013-1021; Zhang, W., Shen, C., Li, C., Yang, G., Liu, H., Chen, X., (2015) Mol. Carcinog.; Zhang, P., Bill, K., Liu, J., Young, E., Peng, T., Bolshakov, S., (2012) Cancer Res., 72 (7), pp. 1751-1762. , (PMCID: 3319789); Jang, J.S., Jeon, H.S., Sun, Z., Aubry, M.C., Tang, H., Park, C.H., (2012) Clin. Cancer Res., 18 (13), pp. 3658-3667. , (PMCID: 3616503); Xia, H., Ng, S.S., Jiang, S., Cheung, W.K., Sze, J., Bian, X.W., (2010) Biochem. Biophys. Res. Commun., 39 (1), pp. 535-541; Cong, N., Du, P., Zhang, A., Shen, F., Su, J., Pu, P., (2013) Oncol. Rep., 29 (4), pp. 1579-1587; Zhang, X., Li, M., Zuo, K., Li, D., Ye, M., Ding, L., (2013) J. Clin. Endocrinol. Metab., 98 (8), pp. E1305-E1313; Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., (2008) Nat. Med., 14 (11), pp. 1271-1277; Liang, J., Li, Y., Daniels, G., Sfanos, K., De Marzo, A., Wei, J., (2015) Mol. Cancer Res.; Liu, H., Yin, J., Wang, H., Jiang, G., Deng, M., Zhang, G., (2015) Cell. Signal., 27 (3), pp. 510-518. , http://dx.doi.org/101016j.cellsig.2015.01.001; Zheng, C., Yinghao, S., Li, J., (2012) Med. Oncol., 29 (2), pp. 815-822; Hsieh, I.S., Chang, K.C., Tsai, Y.T., Ke, J.Y., Lu, P.J., Lee, K.H., (2013) Carcinogenesis, 34 (3), pp. 530-538; Xu, X., Gnatenko, D.V., Ju, J., Hitchcock, I.S., Martin, D.W., Zhu, W., (2012) Blood, 120 (17), pp. 3575-3585. , (PMCID: 3482865); Veronese, A., Visone, R., Consiglio, J., Acunzo, M., Lupini, L., Kim, T., (2011) Proc. Natl. Acad. Sci. U. S. A., 108 (12), pp. 4840-4845. , (PMCID: 3064338); Buechling, T., Chaudhary, V., Spirohn, K., Weiss, M., Boutros, M., (2011) EMBO Rep., 12 (12), pp. 1265-1272. , (PMCID: 3245698); Port, F., Hausmann, G., Basler, K., (2011) EMBO Rep., 12 (11), pp. 1144-1152. , (PMCID: 3207098); Fuerer, C., Habib, S.J., Nusse, R., (2010) Dev. Dyn., 239 (1), pp. 184-190. , (PMCID: 2846786); Belenkaya, T.Y., Wu, Y., Tang, X., Zhou, B., Cheng, L., Sharma, Y.V., (2008) Dev. Cell, 14 (1), pp. 120-131; Franch-Marro, X., Wendler, F., Guidato, S., Griffith, J., Baena-Lopez, A., Itasaki, N., (2008) Nat. Cell Biol., 10 (2), pp. 170-177; Port, F., Kuster, M., Herr, P., Furger, E., Banziger, C., Hausmann, G., (2008) Nat. Cell Biol., 10 (2), pp. 178-185; Yu, J., Chia, J., Canning, C.A., Jones, C.M., Bard, F.A., Virshup, D.M., (2014) Dev. Cell, 29 (3), pp. 277-291; Delling, U., Tureckova, J., Lim, H.W., De Windt, L.J., Rotwein, P., Molkentin, J.D., A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression (2000) Mol Cell Biol., 20 (17), pp. 6600-6611. , (PMCID: 86143)",Review,Scopus,2-s2.0-84927613389
"White M.P., Theodoris C.V., Liu L., Collins W.J., Blue K.W., Lee J.H., Meng X., Robbins R.C., Ivey K.N., Srivastava D.","NOTCH1 regulates matrix gla protein and calcification gene networks in human valve endothelium",2015,"Journal of Molecular and Cellular Cardiology","84",,,"13","23",,,10.1016/j.yjmcc.2015.04.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928104278&partnerID=40&md5=f93748a487f8199b55da13aed29e04ad","Gladstone Institute of Cardiovascular Disease, University of CaliforniaSan Francisco, United States; University of Colorado Denver School of MedicineAurora, CO, United States; Stanford Cardiovascular Institute, Stanford University School of MedicineStanford, CA, United States","White, M.P., Gladstone Institute of Cardiovascular Disease, University of CaliforniaSan Francisco, United States; Theodoris, C.V., Gladstone Institute of Cardiovascular Disease, University of CaliforniaSan Francisco, United States; Liu, L., Gladstone Institute of Cardiovascular Disease, University of CaliforniaSan Francisco, United States; Collins, W.J., Gladstone Institute of Cardiovascular Disease, University of CaliforniaSan Francisco, United States; Blue, K.W., Gladstone Institute of Cardiovascular Disease, University of CaliforniaSan Francisco, United States; Lee, J.H., University of Colorado Denver School of MedicineAurora, CO, United States; Meng, X., University of Colorado Denver School of MedicineAurora, CO, United States; Robbins, R.C., Stanford Cardiovascular Institute, Stanford University School of MedicineStanford, CA, United States; Ivey, K.N., Gladstone Institute of Cardiovascular Disease, University of CaliforniaSan Francisco, United States; Srivastava, D., Gladstone Institute of Cardiovascular Disease, University of CaliforniaSan Francisco, United States","Valvular and vascular calcification are common causes of cardiovascular morbidity and mortality. Developing effective treatments requires understanding the molecular underpinnings of these processes. Shear stress is thought to play a role in inhibiting calcification. Furthermore, NOTCH1 regulates vascular and valvular endothelium, and human mutations in NOTCH1 can cause calcific aortic valve disease. Here, we determined the genome-wide impact of altering shear stress and NOTCH signaling on human aortic valve endothelium. mRNA-sequencing of primary human aortic valve endothelial cells (HAVECs) with or without knockdown of NOTCH1, in the presence or absence of shear stress, revealed NOTCH1-dependency of the atherosclerosis-related gene connexin 40 (GJA5), and numerous repressors of endochondral ossification. Among these, matrix gla protein (MGP) is highly expressed in aortic valve and vasculature, and inhibits soft tissue calcification by sequestering bone morphogenetic proteins (BMPs). Altering NOTCH1 levels affected MGP mRNA and protein in HAVECs. Furthermore, shear stress activated NOTCH signaling and MGP in a NOTCH1-dependent manner. NOTCH1 positively regulated endothelial MGP in vivo through specific binding motifs upstream of MGP. Our studies suggest that shear stress activates NOTCH1 in primary human aortic valve endothelial cells leading to downregulation of osteoblast-like gene networks that play a role in tissue calcification. © 2015.","Matrix gla protein; NOTCH signaling; NOTCH1; Valve calcification; Valve endothelium","Bray, S.J., Notch signalling: a simple pathway becomes complex (2006) Nat Rev Mol Cell Biol, 7, pp. 678-689; de La Pompa, J.L., Notch signaling in cardiac development and disease (2009) Pediatr Cardiol, 30, pp. 643-650; Akat, K., Borggrefe, M., Kaden, J.J., Aortic valve calcification: basic science to clinical practice (2008) Heart, 95, pp. 616-623; Ge, G., Bone morphogenetic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis (2004) J Biol Chem, 279, pp. 41626-41633; Garg, V., Muth, A.N., Ransom, J.F., Schluterman, M.K., Barnes, R., King, I.N., Mutations in NOTCH1 cause aortic valve disease (2005) Nature, 437, pp. 270-274; Simmons, C.A., Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves (2005) Circ Res, 96, pp. 792-799; Zambon, A.C., Gaj, S., Ho, I., Hanspers, K., Vranizan, K., Evelo, C.T., GO-Elite: a flexible solution for pathway and ontology over-representation (2012) Bioinformatics, 28, pp. 2209-2210; Wamstad, J.A., Alexander, J.M., Truty, R.M., Shrikumar, A., Li, F., Eilertson, K.E., Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage (2012) Cell, 151, pp. 206-220; Salomonis, N., Hanspers, K., Zambon, A.C., Vranizan, K., Lawlor, S.C., Dahlquist, K.D., GenMAPP 2: new features and resources for pathway analysis (2007) BMC Bioinforma., 8, p. 217; Roberts, W.C., The congenitally bicuspid aortic valve. A study of 85 autopsy cases (1970) Am J Cardiol, 26, pp. 72-83; Otto, C.M., Lind, B.K., Kitzman, D.W., Gersh, B.J., Siscovick, D.S., Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly (1999) N Engl J Med, 341, pp. 142-147; Stewart, B.F., Siscovick, D., Lind, B.K., Gardin, J.M., Gottdiener, J.S., Smith, V.E., Clinical factors associated with calcific aortic valve disease. Cardiovascular health study (1997) J Am Coll Cardiol, 29, pp. 630-634; Bossé, Y., Mathieu, P., Pibarot, P., Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis (2008) J Am Coll Cardiol, 51, pp. 1327-1336; Butcher, J.T., Nerem, R.M., Valvular endothelial cells and the mechanoregulation of valvular pathology (2007) Philos Trans R Soc Lond B Biol Sci, 362, pp. 1445-1457; Weinberg, E.J., Mack, P.J., Schoen, F.J., García-Cardeña, G., Kaazempur Mofrad, M.R., Hemodynamic environments from opposing sides of human aortic valve leaflets evoke distinct endothelial phenotypes in vitro (2010) Cardiovasc Eng, 10, pp. 5-11; Schoen, F.J., Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering (2008) Circulation, 118, pp. 1864-1880; Yao, Y., Jumabay, M., Ly, A., Radparvar, M., Cubberly, M.R., Bostrom, K.I., A role for the endothelium in vascular calcification (2013) Circ Res, 113, pp. 495-504; Nus, M., Macgrogan, D., Martínez-Poveda, B., Benito, Y., Casanova, J.C., Fernández-Avilés, F., Diet-induced aortic valve disease in mice haploinsufficient for the notch pathway effector RBPJK/CSL (2011) Arterioscler Thromb Vasc Biol, pp. 1580-1588; Hofmann, J.J., Briot, A., Enciso, J., Zovein, A.C., Ren, S., Zhang, Z.W., Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome (2012) Development (Cambridge, England), 139, pp. 4449-4460; Theodoris, C.V., Li, M., White, M.P., Liu, L., He, D., Pollard, K.S., Bruneau, B.G., Srivastava, D., Human disease modeling reveals integrated transcriptional and epigenetic mechanisms of NOTCH1 haploinsufficiency (2015) Cell, 160, pp. 1072-1086; Luo, G., Ducy, P., McKee, M.D., Pinero, G.J., Loyer, E., Behringer, R.R., Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein (1997) Nature, 386, pp. 78-81; Langmead, B., Trapnell, C., Pop, M., Salzberg, S.L., Ultrafast and memory-efficient alignment of short DNA sequences to the human genome (2009) Genome Biol, 10; Roberts, A., Pimentel, H., Trapnell, C., Pachter, L., Identification of novel transcripts in annotated genomes using RNA-Seq (2011) Bioinformatics, 27, pp. 2325-2329; Neph, S., Kuehn, M.S., Reynolds, A.P., Haugen, E., Thurman, R.E., Johnson, A.K., BEDOPS: high-performance genomic feature operations (2012) Bioinformatics, 28, pp. 1919-1920; Kharchenko, P.V., Tolstorukov, M.Y., Park, P.J., Design and analysis of ChIP-seq experiments for DNA-binding proteins (2008) Nat Biotechnol, 26, pp. 1351-1359; Hubbard, T., Barker, D., Birney, E., Cameron, G., Chen, Y., Clark, L., The ensembl genome database project (2002) Nucleic Acids Res, 30, pp. 38-41; Dodou, E., Xu, S.-M., Black, B.L., Mef2c is activated directly by myogenic basic helix-loop-helix proteins during skeletal muscle development in vivo (2003) Mech Dev, 120, pp. 1021-1032; Holliday, C.J., Ankeny, R.F., Jo, H., Nerem, R.M., Discovery of shear- and side-specific mRNAs and miRNAs in human aortic valvular endothelial cells (2011) Am J Physiol Heart Circ Physiol, 301, pp. H856-H867; Ankeny, R.F., Thourani, V.H., Weiss, D., Vega, J.D., Taylor, W.R., Nerem, R.M., Preferential activation of SMAD1/5/8 on the fibrosa endothelium in calcified human aortic valves- association with low BMP antagonists and SMAD6 (2011) PLoS One, 6; An integrated encyclopedia of DNA elements in the human genome (2012) Nature, 489, pp. 57-74; Ernst, J., Kheradpour, P., Mikkelsen, T.S., Shoresh, N., Ward, L.D., Epstein, C.B., Mapping and analysis of chromatin state dynamics in nine human cell types (2011) Nature, 473, pp. 43-49; Buschmann, I., Pries, A., Styp-Rekowska, B., Hillmeister, P., Loufrani, L., Henrion, D., Pulsatile shear and Gja5 modulate arterial identity and remodeling events during flow-driven arteriogenesis (2010) Development (Cambridge, England), 137, pp. 2187-2196; Chadjichristos, C.E., Scheckenbach, K.E.L., van Veen, T.A.B., Richani Sarieddine, M.Z., de Wit, C., Yang, Z., Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion (2010) Circulation, 121, pp. 123-131; Yang, X., Meng, X., Su, X., Mauchley, D.C., Ao, L., Cleveland, J.C., Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase 1/2 (2009) J Thorac Cardiovasc Surg, 138, pp. 1008-1015; Tang, Z., Wang, A., Yuan, F., Yan, Z., Liu, B., Chu, J.S., Differentiation of multipotent vascular stem cells contributes to vascular diseases (2012) Nat Commun, 3, pp. 1-13; Shin, V., Zebboudj, A.F., Boström, K., Endothelial cells modulate osteogenesis in calcifying vascular cells (2004) J Vasc Res, 41, pp. 193-201; Butcher, J.T., Nerem, R.M., Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress (2006) Tissue Eng, 12, pp. 905-915; Murshed, M., Schinke, T., McKee, M.D., Karsenty, G., Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins (2004) J Cell Biol, 165, pp. 625-630; Danziger, J., Vitamin K-dependent proteins, warfarin, and vascular calcification (2008) Clin J Am Soc Nephrol, 3, pp. 1504-1510; Holden, R.M., Sanfilippo, A.S., Hopman, W.M., Zimmerman, D., Garland, J.S., Morton, A.R., Warfarin and aortic valve calcification in hemodialysis patients (2007) J Nephrol, 20, pp. 417-422; Geleijnse, J.M., Vermeer, C., Grobbee, D.E., Schurgers, L.J., Knapen, M.H.J., van der Meer, I.M., Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study (2004) J Nutr, 134, pp. 3100-3105; Shea, M.K., Holden, R.M., Vitamin K status and vascular calcification: evidence from observational and clinical studies (2012) Adv Nutr, 3, pp. 158-165; Delanaye, P., Krzesinski, J.-M., Warling, X., Moonen, M., Smelten, N., Médart, L., Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients (2014) BMC Nephrol, 15, p. 145",Article,Scopus,2-s2.0-84928104278
"Michos E.D., Misialek J.R., Selvin E., Folsom A.R., Pankow J.S., Post W.S., Lutsey P.L.","25-hydroxyvitamin D levels, vitamin D binding protein gene polymorphisms and incident coronary heart disease among whites and blacks: The ARIC study",2015,"Atherosclerosis","241","1",,"12","17",,,10.1016/j.atherosclerosis.2015.04.803,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928798984&partnerID=40&md5=c18659e035f46d645187ede4f9f323d8","Division of Cardiology, Johns Hopkins University School of Medicine, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States; Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States","Michos, E.D., Division of Cardiology, Johns Hopkins University School of Medicine, United States, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States; Misialek, J.R., Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States; Selvin, E., Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States; Folsom, A.R., Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States; Pankow, J.S., Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States; Post, W.S., Division of Cardiology, Johns Hopkins University School of Medicine, United States, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States; Lutsey, P.L., Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States","Background: In observational studies, low 25-hydroxyvitamin D (25(OH)D) has been associated with increased risk of coronary heart disease (CHD), and this association may vary by race. Racial differences in the frequency of vitamin D binding protein (DBP) single nucleotide polymorphisms (SNPs) might account for similar bioavailable vitamin D in blacks despite lower mean 25(OH)D. We hypothesized that the associations of low 25(OH)D with CHD risk would be stronger among whites and among persons with genotypes associated with higher DBP levels. Methods: We measured 25(OH)D by mass spectroscopy in 11,945 participants in the ARIC Study (baseline 1990-1992, mean age 57 years, 59% women, 24% black). Two DBP SNPs (rs7041; rs4588) were genotyped. We used adjusted Cox proportional hazards models to examine the association of 25(OH)D with adjudicated CHD events through December 2011. Results: Over a median of 20 years, there were 1230 incident CHD events. Whites in the lowest quintile of 25(OH)D (<17ng/ml) compared to the upper 4 quintiles had an increased risk of incident CHD (HR 1.28, 95% CI 1.05-1.56), but blacks did not (1.03, 0.82-1.28), after adjustment for demographics and behavioral/socioeconomic factors (p-interaction with race=0.22). Results among whites were no longer significant after further adjustment for potential mediators of this association (i.e. diabetes, hypertension). There was no statistically significant interaction of 25(OH)D with the DBP SNPs rs4588 (p=0.92) or rs7041 (p=0.87) in relation to CHD risk. Conclusions: Low 25(OH)D was associated with incident CHD in whites, but no interactions of 25(OH)D with key DBP genotypes was found. © 2015 Elsevier Ireland Ltd.","Coronary heart disease; Epidemiology; Race; Vitamin D; Vitamin D binding protein","Holick, M.F., Vitamin D deficiency (2007) N.Engl. J. Med., 357, pp. 266-281; Wang, L., Song, Y., Manson, J.E., Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies (2012) Circ. Cardiovasc Qual. Outcomes, 5, pp. 819-829; Wang, T.J., Pencina, M.J., Booth, S.L., Vitamin D deficiency and risk of cardiovascular disease (2008) Circulation, 117, pp. 503-511; Anderson, J.L., May, H.T., Horne, B.D., Relationship of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general health care population (2010) Am. J. Cardiol., 106, pp. 963-968; Fiscella, K., Franks, P., Vitamin D, race, and cardiovascular mortality: findings from a National US Sample (2010) Ann. Fam. Med., 8, pp. 11-18; Giovannucci, E., Liu, Y., Hollis, B.W., Rimm, E.B., 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study (2008) Arch. Intern. Med., 168, pp. 1174-1180; Robinson-Cohen, C., Hoofnagle, A.N., Ix, J.H., Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events (2013) JAMA, 310 (2), pp. 179-188; Lutsey, P.L., Michos, E.D., Vitamin D, calcium, and atherosclerotic risk - evidence from serum levels and supplementation studies (2013) Curr. Atheroscler. Rep., 15 (1), p. 293; Manson, J.E., Bassuk, S.S., Lee, I.M., The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease (2012) Contemp. Clin. Trials, 33 (1), pp. 159-171; Michos, E.D., Reis, J.P., Post, W.S., 25-hydroxyvitamin D deficiency is associated with fatal stroke among whites but not blacks: the nhanes-iii linked mortality files (2012) Nutrition, 28, pp. 367-371; Powe, C.E., Evans, M.K., Wenger, J., Vitamin D-binding protein and vitamin D status of black Americans and white Americans (2013) N.Engl. J. Med., 369, pp. 1991-2000; Bikle, D.D., Gee, E., Halloran, B., Kowalski, M.A., Ryzen, E., Haddad, J.G., Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein (1986) J.Clin. Endocrinol. Metab., 63, pp. 954-959; The, A.R.I.C., Investigators. The atherosclerosis risk in communities (aric) study: design and objectives. The aric investigators (1989) Am. J. Epidemiol., 129, pp. 687-702; Inker, L.A., Schmid, C.H., Tighiouart, H., Estimating glomerular filtration rate from serum creatinine and cystatin C (2012) N.Engl. J. Med., 367, pp. 20-29; White, A.D., Folsom, A.R., Chambless, L.E., Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience (1996) J.Clin. Epidemiol., 49, pp. 223-233; Musunuru, K., Lettre, G., Young, T., Candidate gene association resource (care): design, methods, and proof of concept (2010) Circ. Cardiovasc. Genet., 3, pp. 267-275; Keating, B.J., Tischfield, S., Murray, S.S., Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies (2008) PLoS One, 3 (10); Baecke, J.A., Burema, J., Frijters, J.E., Ashort questionnaire for the measurement of habitual physical activity in epidemiological studies (1982) Am. J. Clin. Nutr., 36, pp. 936-942; Shoben, A.B., Kestenbaum, B., Levin, G., Seasonal variation in 25-hydroxyvitamin D concentrations in the Cardiovascular Health Study (2011) Am. J. Epidemiol., 174 (12), pp. 1363-1372; Lutsey, P.L., Michos, E.D., Misialek, J.R., Race and vitamin D binding protein gene polymorphisms modify the association of 25-hydroxyvitamin D and incident heart failure: the Atherosclerosis Risk in Communities Study (ARIC) (2015) JACC Heart Fail, , Published online April 08, 2015; Go, A.S., Mozaffarian, D., Roger, V.L., Heart disease and stroke statistics-2014 update: a report from the American Heart Association (2014) Circulation, 129, pp. e28-292; Kunutsor, S., Apekey, T., Steur, M., Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants (2013) Eur. J. Epidemiol., 28, pp. 205-221; Li, Y.C., Kong, J., Wei, M., 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system (2002) J.Clin. Invest, 110 (2), pp. 229-238; Mitri, J., Pittas, A.G., Vitamin D and diabetes (2014) Endocrinol. Metab. Clin. North Am., 43 (1), pp. 205-232; Reis, J.P., Michos, E.D., Pankow, J.S., Selvin, E., Lutsey, P.L., Race, vitamin D binding protein gene polymorphisms, 25-hydroxyvitamin D, and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study (2015) Am. J. Clin. Nutr., , (in press); Schleithoff, S.S., Zittermann, A., Tenderich, G., Berthold, H.K., Stehle, P., Koerfer, R., Vitamin D supplementation improves cytopkine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial (2006) Am. J. Clin. Nutr., 83 (4), pp. 754-759; Oh, J., Weng, S., Felton, S.K., 1,25(OH)<inf>2</inf> vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus (2009) Circulation, 120, pp. 687-698; Schnatz, P.F., Manson, J.E., Vitamin D and cardiovascular disease: an appraisal of the evidence (2014) Clin. Chem., 60 (4), pp. 600-609; Harris, S.S., Vitamin D and African Americans (2006) J.Nutr., 136, pp. 1126-1129; Gutierrez, O.M., Farwell, W.R., Kermah, D., Taylor, E.N., Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey (2011) Osteoporos. Int., 22, pp. 1745-1753; Strawbridge, R.J., Deleskog, A., McLeod, O., Aserum 25-hydroxyvitamin D concentration-associated genetic variant in DHCR7 interacts with type 2 diabetes status to influence subclinical atherosclerosis (measured by carotid intima-media thickness) (2014) Diabetologia, 57 (6), pp. 1159-1172",Article,Scopus,2-s2.0-84928798984
"Hammer K.P., Ljubojevic S., Ripplinger C.M., Pieske B.M., Bers D.M.","Cardiac myocyte alternans in intact heart: Influence of cell-cell coupling and β-adrenergic stimulation",2015,"Journal of Molecular and Cellular Cardiology","84",,,"1","9",,,10.1016/j.yjmcc.2015.03.012,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926452629&partnerID=40&md5=fb9ff8aca77497e3478eb8aa6535cf18","Department of Pharmacology, University of California, Davis, GBSFDavis, CA, United States; Department of Cardiology, Medical University of Graz, Auenbruggerplatz 15Graz, Austria; Department of Cardiology, Charité - Medical University Berlin, Augustenburgerplatz 1Berlin, Germany; Department of Internal Medicine II, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11Regensburg, Germany","Hammer, K.P., Department of Pharmacology, University of California, Davis, GBSFDavis, CA, United States, Department of Internal Medicine II, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11Regensburg, Germany; Ljubojevic, S., Department of Cardiology, Medical University of Graz, Auenbruggerplatz 15Graz, Austria; Ripplinger, C.M., Department of Pharmacology, University of California, Davis, GBSFDavis, CA, United States; Pieske, B.M., Department of Cardiology, Medical University of Graz, Auenbruggerplatz 15Graz, Austria, Department of Cardiology, Charité - Medical University Berlin, Augustenburgerplatz 1Berlin, Germany; Bers, D.M., Department of Pharmacology, University of California, Davis, GBSFDavis, CA, United States","Background: Cardiac alternans are proarrhythmic and mechanistically link cardiac mechanical dysfunction and sudden cardiac death. Beat-to-beat alternans occur when beats with large Ca2+ transients and long action potential duration (APD) alternate with the converse. APD alternans are typically driven by Ca2+ alternans and sarcoplasmic reticulum (SR) Ca2+ release alternans. But the effect of intercellular communication via gap junctions (GJ) on alternans in the intact heart remains unknown. Objective: We assessed the effects of cell-to-cell coupling on local alternans in intact Langendorff-perfused mouse hearts, measuring single myocyte [Ca2+] alternans synchronization among neighboring cells, and effects of β-adrenergic receptor (β-AR) activation and reduced GJ coupling. Methods and results: Mouse hearts (C57BL/6) were retrogradely perfused and loaded with Fluo8-AM to record cardiac myocyte [Ca2+] in situ with confocal microscopy. Single cell resolution allowed analysis of alternans within the intact organ during alternans induction. Carbenoxolone (25μM), a GJ inhibitor, significantly increased the occurrence and amplitude of alternans in single cells within the intact heart. Alternans were concordant between neighboring cells throughout the field of view, except transiently during onset. β-AR stimulation only reduced Ca2+ alternans in tissue that had reduced GJ coupling, matching effects seen in isolated myocytes. Conclusions: Ca2+ alternans among neighboring myocytes is predominantly concordant, likely because of electrical coupling between cells. Consistent with this, partial GJ uncoupling increased propensity and amplitude of Ca2+ alternans, and made them more sensitive to reversal by β-AR activation, as in isolated myocytes. Electrical coupling between myocytes may thus limit the alternans initiation, but also allow alternans to be more stable once established. © 2015 Elsevier Ltd.","Alternans; Calcium; Whole heart; β-Adrenergic receptor activation","Diaz, M.E., O'Neill, S.C., Eisner, D.A., Sarcoplasmic reticulum calcium content fluctuation is the key to cardiac alternans (2004) Circ Res, 94, pp. 650-656; Tao, T., O'Neill, S.C., Diaz, M.E., Li, Y.T., Eisner, D.A., Zhang, H., Alternans of cardiac calcium cycling in a cluster of ryanodine receptors: a simulation study (2008) Am J Physiol Heart Circ Physiol, 295, pp. H598-H609; Huser, J., Wang, Y.G., Sheehan, K.A., Cifuentes, F., Lipsius, S.L., Blatter, L.A., Functional coupling between glycolysis and excitation-contraction coupling underlies alternans in cat heart cells (2000) J Physiol, 524, pp. 795-806; Diaz, M.E., Eisner, D.A., O'Neill, S.C., Depressed ryanodine receptor activity increases variability and duration of the systolic Ca2+ transient in rat ventricular myocytes (2002) Circ Res, 91, pp. 585-593; Wan, X.P., Laurita, K.R., Pruvot, E.J., Rosenbaum, D.S., Molecular correlates of repolarization alternans in cardiac myocytes (2005) J Mol Cell Cardiol, 39, pp. 419-428; Chudin, E., Goldhaber, J., Garfinkel, A., Weiss, J., Kogan, B., Intracellular Ca2+ dynamics and the stability of ventricular tachycardia (1999) Biophys J, 77, pp. 2930-2941; Qu, Z., Nivala, M., Weiss, J.N., Calcium alternans in cardiac myocytes: order from disorder (2013) J Mol Cell Cardiol, 58, pp. 100-109; Kockskamper, J., Blatter, L.A., Subcellular Ca2+ alternans represents a novel mechanism for the generation of arrhythmogenic Ca2+ waves in cat atrial myocytes (2002) J Physiol, 545, pp. 65-79; Flore, V., Claus, P., Symons, R., Smith, G.L., Sipido, K.R., Willems, R., Can body surface microvolt T-wave alternans distinguish concordant and discordant intracardiac alternans? (2013) Pacing Clin Electrophysiol, 36, pp. 1007-1016; Pastore, J.M., Girouard, S.D., Laurita, K.R., Akar, F.G., Rosenbaum, D.S., Mechanism linking T-wave alternans to the genesis of cardiac fibrillation (1999) Circulation, 99, pp. 1385-1394; Aistrup, G.L., Balke, C.W., Wasserstrom, J.A., Arrhythmia triggers in heart failure: the smoking gun of [Ca2+]<inf>i</inf> dysregulation (2011) Heart Rhythm, 8, pp. 1804-1808; Kapur, S., Aistrup, G.L., Sharma, R., Kelly, J.E., Arora, R., Zheng, J., Early development of intracellular calcium cycling defects in intact hearts of spontaneously hypertensive rats (2010) Am J Physiol Heart Circ Physiol, 299, pp. H1843-H1853; Verrier, R.L., Malik, M., Electrophysiology of T-wave alternans: mechanisms and pharmacologic influences (2013) J Electrocardiol, 46, pp. 580-584; Narayan, S.M., Bode, F., Karasik, P.L., Franz, M.R., Alternans of atrial action potentials during atrial flutter as a precursor to atrial fibrillation (2002) Circulation, 106, pp. 1968-1973; Picht, E., DeSantiago, J., Blatter, L.A., Bers, D.M., Cardiac alternans do not rely on diastolic sarcoplasmic reticulum calcium content fluctuations (2006) Circ Res, 99, pp. 740-748; Ramay, H.R., Liu, O.Z., Sobie, E.A., Recovery of cardiac calcium release is controlled by sarcoplasmic reticulum refilling and ryanodine receptor sensitivity (2011) Cardiovasc Res, 91, pp. 598-605; Bers, D.M., (2001) Excitation-contraction coupling and cardiac contractile force, , Kluwer Academic Press, Dordrecht, Netherlands; Wang, L., Myles, R.C., De Jesus, N.M., Ohlendorf, A.K., Bers, D.M., Ripplinger, C.M., Optical mapping of sarcoplasmic reticulum Ca2+ in the intact heart: ryanodine receptor refractoriness during alternans and fibrillation (2014) Circ Res, 114, pp. 1410-1421; Thimm, J., Mechler, A., Lin, H., Rhee, S., Lal, R., Calcium-dependent open/closed conformations and interfacial energy maps of reconstituted hemichannels (2005) J Biol Chem, 280, pp. 10646-10654; Spray, D.C., White, R.L., Mazet, F., Bennett, M.V., Regulation of gap junctional conductance (1985) Am J Physiol, 248, pp. H753-H764; Rohr, S., Role of gap junctions in the propagation of the cardiac action potential (2004) Cardiovasc Res, 62, pp. 309-322; Li, C., Meng, Q., Yu, X., Jing, X., Xu, P., Luo, D., Regulatory effect of connexin 43 on basal Ca2+ signaling in rat ventricular myocytes (2012) PLoS One, 7, p. e36165; Bers, D.M., Cardiac excitation-contraction coupling (2002) Nature, 415, pp. 198-205; Eisner, D., Bode, E., Venetucci, L., Trafford, A., Calcium flux balance in the heart (2013) J Mol Cell Cardiol, 58, pp. 110-117; Ogrodnik, J., Niggli, E., Increased Ca2+ leak and spatiotemporal coherence of Ca2+ release in cardiomyocytes during beta-adrenergic stimulation (2010) J Physiol, 588, pp. 225-242; Florea, S.M., Blatter, L.A., Regulation of cardiac alternans by β-adrenergic signaling pathways (2012) Am J Physiol Heart Circ Physiol, 303, pp. H1047-H1056; Ljubojevic, S., Walther, S., Asgarzoei, M., Sedej, S., Pieske, B., Kockskamper, J., In situ calibration of nucleoplasmic versus cytoplasmic Ca2+ concentration in adult cardiomyocytes (2011) Biophys J, 100, pp. 2356-2366; Euler, D.E., Cardiac alternans: mechanisms and pathophysiological significance (1999) Cardiovasc Res, 42, pp. 583-590; Aistrup, G.L., Kelly, J.E., Kapur, S., Kowalczyk, M., Sysman-Wolpin, I., Kadish, A.H., Pacing-induced heterogeneities in intracellular Ca2+ signaling, cardiac alternans, and ventricular arrhythmias in intact rat heart (2006) Circ Res, 99, pp. e65-e73; Wu, Y., Clusin, W.T., Calcium transient alternans in blood-perfused ischemic hearts: observations with fluorescent indicator fura red (1997) Am J Physiol, 273, pp. H2161-H2169; Shy, D., Gillet, L., Ogrodnik, J., Albesa, M., Verkerk, A.O., Wolswinkel, R., PDZ domain-binding motif regulates cardiomyocyte compartment-specific NaV1.5 channel expression and function (2014) Circulation, 130, pp. 147-160; Ng, G.A., Brack, K.E., Patel, V.H., Coote, J.H., Autonomic modulation of electrical restitution, alternans and ventricular fibrillation initiation in the isolated heart (2007) Cardiovasc Res, 73, pp. 750-760; Rudisuli, A., Weingart, R., Electrical properties of gap junction channels in guinea-pig ventricular cell pairs revealed by exposure to heptanol (1989) Pflugers Arch, 415, pp. 12-21; Maurer, P., Weingart, R., Cell pairs isolated from adult guinea pig and rat hearts: effects of [Ca2+]<inf>i</inf> on nexal membrane resistance (1987) Pflugers Arch, 409, pp. 394-402; Wier, W.G., ter Keurs, H.E., Marban, E., Gao, W.D., Balke, C.W., Ca2+ 'sparks' and waves in intact ventricular muscle resolved by confocal imaging (1997) Circ Res, 81, pp. 462-469; Popolo, A., Morello, S., Sorrentino, R., Pinto, A., Antiadrenergic effect of adenosine involves connexin 43 turn-over in H9c2 cells (2013) Eur J Pharmacol, 715, pp. 56-61; Johnstone, S.R., Billaud, M., Lohman, A.W., Taddeo, E.P., Isakson, B.E., Posttranslational modifications in connexins and pannexins (2012) J Membr Biol, 245, pp. 319-332; Campbell, A.S., Johnstone, S.R., Baillie, G.S., Smith, G., β-Adrenergic modulation of myocardial conduction velocity: connexins vs. sodium current (2014) J Mol Cell Cardiol, 77 C, pp. 147-154; Sato, D., Bartos, D.C., Ginsburg, K.S., Bers, D.M., Depolarization of cardiac membrane potential synchronizes calcium sparks and waves in tissue (2014) Biophys J, 107 (6), pp. 1313-1317; Hoeker, G.S., Hood, A.R., Katra, R.P., Poelzing, S., Pogwizd, S.M., Sex differences in β-adrenergic responsiveness of action potentials and intracellular calcium handling in isolated rabbit hearts (2014) PLoS One, 9, p. e111411; Stauffer, B.L., Sobus, R.D., Sucharov, C.C., Sex differences in cardiomyocyte connexin43 expression (2011) J Cardiovasc Pharmacol, 58, pp. 32-39; Jansen, J.A., Noorman, M., Musa, H., Stein, M., de Jong, S., van der Nagel, R., Reduced heterogeneous expression of Cx43 results in decreased Nav1.5 expression and reduced sodium current that accounts for arrhythmia vulnerability in conditional Cx43 knockout mice (2012) Heart Rhythm, 9, pp. 600-607; Agullo-Pascual, E., Delmar, M., The noncanonical functions of Cx43 in the heart (2012) J Membr Biol, 245, pp. 477-482; de Groot, J.R., Veenstra, T., Verkerk, A.O., Wilders, R., Smits, J.P., Wilms-Schopman, F.J., Conduction slowing by the gap junctional uncoupler carbenoxolone (2003) Cardiovasc Res, 60, pp. 288-297; Kojodjojo, P., Kanagaratnam, P., Segal, O.R., Hussain, W., Peters, N.S., The effects of carbenoxolone on human myocardial conduction: a tool to investigate the role of gap junctional uncoupling in human arrhythmogenesis (2006) J Am Coll Cardiol, 48, pp. 1242-1249; Myles, R.C., Wang, L., Kang, C., Bers, D.M., Ripplinger, C.M., Local β-adrenergic stimulation overcomes source-sink mismatch to generate focal arrhythmia (2012) Circ Res, 110, pp. 1454-1464; Howarth, F.C., Qureshi, M.A., Effects of carbenoxolone on heart rhythm, contractility and intracellular calcium in streptozotocin-induced diabetic rat (2006) Mol Cell Biochem, 289, pp. 21-29; Kjolbye, A.L., Dikshteyn, M., Eloff, B.C., Deschenes, I., Rosenbaum, D.S., Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans (2008) Am J Physiol Heart Circ Physiol, 294, pp. H41-H49; Jia, Z., Bien, H., Shiferaw, Y., Entcheva, E., Cardiac cellular coupling and the spread of early instabilities in intracellular Ca2+ (2012) Biophys J, 102, pp. 1294-1302; Sato, D., Bers, D.M., Shiferaw, Y., Formation of spatially discordant alternans due to fluctuations and diffusion of calcium (2013) PLoS One, 8, p. e85365; Gizzi, A., Cherry, E.M., Gilmour, R.F., Luther, S., Filippi, S., Fenton, F.H., Effects of pacing site and stimulation history on alternans dynamics and the development of complex spatiotemporal patterns in cardiac tissue (2013) Front Physiol, 4, p. 71; Watanabe, M.A., Koller, M.L., Mathematical analysis of dynamics of cardiac memory and accommodation: theory and experiment (2002) Am J Physiol Heart Circ Physiol, 282, pp. H1534-H1547; Kalb, S.S., Dobrovolny, H.M., Tolkacheva, E.G., Idriss, S.F., Krassowska, W., Gauthier, D.J., The restitution portrait: a new method for investigating rate-dependent restitution (2004) J Cardiovasc Electrophysiol, 15, pp. 698-709; Mironov, S., Jalife, J., Tolkacheva, E.G., Role of conduction velocity restitution and short-term memory in the development of action potential duration alternans in isolated rabbit hearts (2008) Circulation, 118, pp. 17-25; Stein, M., van Veen, T.A., Hauer, R.N., de Bakker, J.M., van Rijen, H.V., A 50% reduction of excitability but not of intercellular coupling affects conduction velocity restitution and activation delay in the mouse heart (2011) PLoS One, 6, p. e20310; Prosser, B.L., Ward, C.W., Lederer, W.J., X-ROS signaling: rapid mechano-chemo transduction in heart (2011) Science, 333, pp. 1440-1445; Jian, Z., Han, H., Zhang, T., Puglisi, J., Izu, L.T., Shaw, J.A., Mechanochemotransduction during cardiomyocyte contraction is mediated by localized nitric oxide signaling (2014) Sci Signal, 7, p. ra27; Fedorov, V.V., Lozinsky, I.T., Sosunov, E.A., Anyukhovsky, E.P., Rosen, M.R., Balke, C.W., Application of blebbistatin as an excitation-contraction uncoupler for electrophysiologic study of rat and rabbit hearts (2007) Heart Rhythm, 4, pp. 619-626; Lou, Q., Li, W., Efimov, I.R., The role of dynamic instability and wavelength in arrhythmia maintenance as revealed by panoramic imaging with blebbistatin vs. 2,3-butanedione monoxime (2012) Am J Physiol Heart Circ Physiol, 302, pp. H262-H269; Brack, K.E., Narang, R., Winter, J., Ng, G.A., The mechanical uncoupler blebbistatin is associated with significant electrophysiological effects in the isolated rabbit heart (2013) Exp Physiol, 98, pp. 1009-1027; Myles, R.C., Burton, F.L., Cobbe, S.M., Smith, G.L., Alternans of action potential duration and amplitude in rabbits with left ventricular dysfunction following myocardial infarction (2011) J Mol Cell Cardiol, 50, pp. 510-521; Miragoli, M., Gaudesius, G., Rohr, S., Electrotonic modulation of cardiac impulse conduction by myofibroblasts (2006) Circ Res, 98, pp. 801-810; Zlochiver, S., Munoz, V., Vikstrom, K.L., Taffet, S.M., Berenfeld, O., Jalife, J., Electrotonic myofibroblast-to-myocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers (2008) Biophys J, 95, pp. 4469-4480; Xie, Y., Garfinkel, A., Weiss, J.N., Qu, Z., Cardiac alternans induced by fibroblast-myocyte coupling: mechanistic insights from computational models (2009) Am J Physiol Heart Circ Physiol, 297, pp. H775-H784",Article,Scopus,2-s2.0-84926452629
"Chang K.-C., Lee A.-S., Chen W.-Y., Lin Y.-N., Hsu J.-F., Chan H.-C., Chang C.-M., Chang S.-S., Pan C.-C., Sawamura T., Chang C.-T., Su M.-J., Chen C.-H.","Increased LDL electronegativity in chronic kidney disease disrupts calcium homeostasis resulting in cardiac dysfunction",2015,"Journal of Molecular and Cellular Cardiology","84",,,"36","44",,,10.1016/j.yjmcc.2015.03.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928118417&partnerID=40&md5=bfcd555df3cbcbe921b318046002cb81","Division of Cardiology, China Medical University (CMU) HospitalTaichung, Taiwan; Graduate Institute of Clinical Medical Science, CMUTaichung, Taiwan; Department of Medicine, Mackay Medical CollegeNew Taipei, Taiwan; L5 Research Center, CMU Hospital, CMUTaichung, Taiwan; Center for Lipid Biosciences, Kaohsiung Medical University (KMU) Hospital, KMUKaohsiung, Taiwan; Department of Physiology, Shinshu University School of MedicineMatsumoto, Nagano, Japan; Division of Nephrology, CMU HospitalTaichung, Taiwan; Graduate Institute of Pharmacology, National Taiwan UniversityTaipei, Taiwan; Vascular and Medicinal Research, Texas Heart InstituteHouston, TX, United States; Department of Medicine, Baylor College of MedicineHouston, TX, United States; Center for Lipid and Glycomedicine Research, KMU Hospital, KMUKaohsiung, Taiwan","Chang, K.-C., Division of Cardiology, China Medical University (CMU) HospitalTaichung, Taiwan, Graduate Institute of Clinical Medical Science, CMUTaichung, Taiwan; Lee, A.-S., Department of Medicine, Mackay Medical CollegeNew Taipei, Taiwan, L5 Research Center, CMU Hospital, CMUTaichung, Taiwan; Chen, W.-Y., L5 Research Center, CMU Hospital, CMUTaichung, Taiwan; Lin, Y.-N., Division of Cardiology, China Medical University (CMU) HospitalTaichung, Taiwan; Hsu, J.-F., L5 Research Center, CMU Hospital, CMUTaichung, Taiwan; Chan, H.-C., L5 Research Center, CMU Hospital, CMUTaichung, Taiwan, Center for Lipid Biosciences, Kaohsiung Medical University (KMU) Hospital, KMUKaohsiung, Taiwan; Chang, C.-M., L5 Research Center, CMU Hospital, CMUTaichung, Taiwan; Chang, S.-S., Division of Cardiology, China Medical University (CMU) HospitalTaichung, Taiwan; Pan, C.-C., L5 Research Center, CMU Hospital, CMUTaichung, Taiwan; Sawamura, T., Department of Physiology, Shinshu University School of MedicineMatsumoto, Nagano, Japan; Chang, C.-T., Division of Nephrology, CMU HospitalTaichung, Taiwan; Su, M.-J., Graduate Institute of Pharmacology, National Taiwan UniversityTaipei, Taiwan; Chen, C.-H., L5 Research Center, CMU Hospital, CMUTaichung, Taiwan, Vascular and Medicinal Research, Texas Heart InstituteHouston, TX, United States, Department of Medicine, Baylor College of MedicineHouston, TX, United States, Center for Lipid and Glycomedicine Research, KMU Hospital, KMUKaohsiung, Taiwan","Chronic kidney disease (CKD), an independent risk factor for cardiovascular disease, is associated with abnormal lipoprotein metabolism. We examined whether electronegative low-density lipoprotein (LDL) is mechanistically linked to cardiac dysfunction in patients with early CKD. We compared echocardiographic parameters between patients with stage 2 CKD (n=88) and normal controls (n=89) and found that impaired relaxation was more common in CKD patients. Reduction in estimated glomerular filtration rate was an independent predictor of left ventricular relaxation dysfunction. We then examined cardiac function in a rat model of early CKD induced by unilateral nephrectomy (UNx) by analyzing pressure-volume loop data. The time constant of isovolumic pressure decay was longer and the maximal velocity of pressure fall was slower in UNx rats than in controls. When we investigated the mechanisms underlying relaxation dysfunction, we found that LDL from CKD patients and UNx rats was more electronegative than LDL from their respective controls and that LDL from UNx rats induced intracellular calcium overload in H9c2 cardiomyocytes in vitro. Furthermore, chronic administration of electronegative LDL, which signals through lectin-like oxidized LDL receptor-1 (LOX-1), induced relaxation dysfunction in wild-type but not LOX-1-/- mice. In in vitro and in vivo experiments, impaired cardiac relaxation was associated with increased calcium transient resulting from nitric oxide (NO)-dependent nitrosylation of SERCA2a due to increases in inducible NO synthase expression and endothelial NO synthase uncoupling. In conclusion, LDL becomes more electronegative in early CKD. This change disrupts SERCA2a-regulated calcium homeostasis, which may be the mechanism underlying cardiorenal syndrome. © 2015 Elsevier Ltd.","Cardiorenal syndrome; Lipoproteins; SERCA2a; Unilateral nephrectomy","Ronco, C., Haapio, M., House, A.A., Anavekar, N., Bellomo, R., Cardiorenal syndrome (2008) J Am Coll Cardiol, 52, pp. 1527-1539; Manjunath, G., Tighiouart, H., Coresh, J., Macleod, B., Salem, D.N., Griffith, J.L., Level of kidney function as a risk factor for cardiovascular outcomes in the elderly (2003) Kidney Int, 63, pp. 1121-1129; National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (2002) Am J Kidney Dis, 39, pp. S1-S266; Fried, L.F., Shlipak, M.G., Crump, C., Bleyer, A.J., Gottdiener, J.S., Kronmal, R.A., Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals (2003) J Am Coll Cardiol, 41, pp. 1364-1372; Patel, P.C., Ayers, C.R., Murphy, S.A., Peshock, R., Khera, A., de Lemos, J.A., Association of cystatin C with left ventricular structure and function: the Dallas Heart Study (2009) Circ Heart Fail, 2, pp. 98-104; Bock, J.S., Gottlieb, S.S., Cardiorenal syndrome: new perspectives (2010) Circulation, 121, pp. 2592-2600; Chan, D.T., Irish, A.B., Dogra, G.K., Watts, G.F., Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials (2008) Atherosclerosis, 196, pp. 823-834; Chen, C.H., Jiang, T., Yang, J.H., Jiang, W., Lu, J., Marathe, G.K., Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription (2003) Circulation, 107, pp. 2102-2108; Chen, H.H., Hosken, B.D., Huang, M., Gaubatz, J.W., Myers, C.L., Macfarlane, R.D., Electronegative LDLs from familial hypercholesterolemic patients are physicochemically heterogeneous but uniformly proapoptotic (2007) J Lipid Res, 48, pp. 177-184; Yang, C.Y., Raya, J.L., Chen, H.H., Chen, C.H., Abe, Y., Pownall, H.J., Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins (2003) Arterioscler Thromb Vasc Biol, 23, pp. 1083-1090; Lee, A.S., Chen, W.Y., Chan, H.C., Hsu, J.F., Shen, M.Y., Chang, C.M., Gender disparity in LDL-induced cardiovascular damage and the protective role of estrogens against electronegative LDL (2014) Cardiovasc Diabetol, 13, p. 64; Lu, J., Jiang, W., Yang, J.H., Chang, P.Y., Walterscheid, J.P., Chen, H.H., Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation (2008) Diabetes, 57, pp. 158-166; Chan, H.C., Ke, L.Y., Chu, C.S., Lee, A.S., Shen, M.Y., Cruz, M.A., Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation (2013) Blood, 122, pp. 3632-3641; Chang, P.Y., Chen, Y.J., Chang, F.H., Lu, J., Huang, W.H., Yang, T.C., Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction (2013) Cardiovasc Res, 99, pp. 137-145; Liang, H.Y., Cheng, W.C., Chang, K.C., Mechanisms of right atrial pacing inducing left atrial and left ventricular dysfunction evaluated by strain echocardiography (2010) Acta Cardiol Sin, 26, pp. 157-164; Zhang, X., Chen, C., A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy (2012) Endocrine, 41, pp. 398-409; Lokuta, A.J., Maertz, N.A., Meethal, S.V., Potter, K.T., Kamp, T.J., Valdivia, H.H., Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in human heart failure (2005) Circulation, 111, pp. 988-995; Karbach, S., Wenzel, P., Waisman, A., Munzel, T., Daiber, A., ENOS uncoupling in cardiovascular diseases-the role of oxidative stress and inflammation (2014) Curr Pharm Des, 20, pp. 3579-3594; Attman, P.O., Alaupovic, P., Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis (1991) Nephron, 57, pp. 401-410; Ke, L.Y., Engler, D.A., Lu, J., Matsunami, R.K., Chan, H.C., Wang, G.J., Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein (2011) Pure Appl Chem, 83, pp. 1731-1740; Gonen, B., Goldberg, A.P., Harter, H.R., Schonfeld, G., Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure (1985) Metabolism, 34, pp. 10-14; Batista, M.C., Welty, F.K., Diffenderfer, M.R., Sarnak, M.J., Schaefer, E.J., Lamon-Fava, S., Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome (2004) Metabolism, 53, pp. 1255-1261; Ke, L.Y., Stancel, N., Bair, H., Chen, C.H., The underlying chemistry of electronegative LDL's atherogenicity (2014) Curr Atheroscler Rep, 16, p. 428; Lee, A.S., Wang, G.J., Chan, H.C., Chen, F.Y., Chang, C.M., Yang, C.Y., Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines (2012) Apoptosis, 17, pp. 1009-1018; Martin, F.L., McKie, P.M., Cataliotti, A., Sangaralingham, S.J., Korinek, J., Huntley, B.K., Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection (2012) Am J Physiol Regul Integr Comp Physiol, 302, pp. R292-R299",Article,Scopus,2-s2.0-84928118417
"Stansfeld S.A., Shipley M.","Noise sensitivity and future risk of illness and mortality",2015,"Science of the Total Environment","520",,,"114","119",,,10.1016/j.scitotenv.2015.03.053,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925263188&partnerID=40&md5=904a9ecef4ad35a11a261a55965f6fa8","Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry,Queen Mary University of London, Charterhouse SquareLondon, United Kingdom; Department of Epidemiology and Public Health, University College London, 1-19 Torrington PlaceLondon, United Kingdom","Stansfeld, S.A., Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry,Queen Mary University of London, Charterhouse SquareLondon, United Kingdom; Shipley, M., Department of Epidemiology and Public Health, University College London, 1-19 Torrington PlaceLondon, United Kingdom","Aircraft and road traffic noise exposure increase the risk of cardiovascular disease (CVD). Noise annoyance is the most frequent response to environmental noise. Noise annoyance has been shown to modify the association of transport noise exposure on CVD and noise sensitivity moderates the annoyance response to noise. This study uses prospective data from phases 1, 3, 5, 7 and 9 in 3630 male and female civil servants from the UK Whitehall II Study to examine whether a single question on noise sensitivity measured by annoyance responses to noise in general predicts physical and mental ill-health and mortality. Non-fatal myocardial infarction and stroke morbidity over the follow-up were defined by MONICA criteria based on study ECGs, hospital records, hospital admission statistics or General Practitioner confirmation. Depressive symptoms were measured by the Center for Epidemiologic Studies Depression Scale (CES-D) and psychological distress by the General Health questionnaire (GHQ). There was no association between noise sensitivity and CVD morbidity or mortality except in people from lower employment grades where there was an association with angina. Noise sensitivity was a consistent predictor of depressive symptoms and psychological distress at phases 3, 5 and 7. High noise sensitivity scores at baseline predicted GHQ caseness at phase 3 adjusting for age, sex, employment grade, self-rated health and GHQ caseness at baseline (OR. = 1.56 95% CI 1.29-1.88). Noise sensitivity has been identified as a predictor of mental ill-health. More longitudinal research is needed including measures of noise exposure. © 2015.","Annoyance; Coronary heart disease; Depression; Mortality; Noise; Sensitivity","Babisch, W., Road traffic noise and cardiovascular risk (2008) Noise Health, 10, pp. 27-33; Babisch, W., Pershagen, G., Selander, J., Noise annoyance-a modifier of the association between noise level and cardiovascular health? (2013) Sci. Total Environ., pp. 50-57; Baliatsas, C., van Kamp, I., Hooiveld, M., Yzermans, J., Lebret, E., Comparing non-specific physical symptoms in environmentally sensitive patients: prevalence, duration, functional status and illness behavior (2014) J. Psychosom. Res., 76, pp. 405-413; Clark, C., Smuk, M., Stansfeld, S.A., van de Kerchove, R., Notley, H., What factors are associated with noise sensitivity in the UK population? (2014) Proceedings of Internoise 2014, Melbourne, Australia; Floud, S., Blangiardo, M., Clark, C., Exposure to aircraft and road traffic noise and associations with heart disease and stroke in six European countries: a cross-sectional study (2013) Environ. Heal., 12, p. 89; Fyhri, A., Klaeboe, R., Road traffic noise, sensitivity, annoyance and self-reported health-a structural equation model exercise (2009) Environ. Int., 35, pp. 91-97; Goldberg, D.P., (1972) The Detection of Psychiatric Illness by Questionnaire, , Oxford University Press, London; Hansell, A.L., Blangiardo, M., Fortunato, L., Aircraft noise and cardiovascular disease near London Heathrow Airport (2013) Br. Med. J., 347, p. f5432; Heinonen-Guzejev, M., Vuorinen, H.S., Mussalo-Rauhamaa, H., Genetic component of noise sensitivity (2005) Twin Res. Hum. Genet., 8, pp. 245-249; Heinonen-Guzejev, M., Vuorinen, H.S., Mussalo-Rauhamaa, H., The association of noise sensitivity with coronary heart and cardiovascular mortality among Finnish adults (2007) Sci. Total Environ., 372, pp. 406-412; Heinonen-Guzejev, M., Koskenvuo, M., Mussalo-Rauhamaa, H., Noise sensitivity and multiple chemical sensitivity scales: properties in a population based epidemiological study (2012) Noise Health, 14, pp. 215-223; Heinonen-Guzejev, M., Koskenvuo, M., Silventoinen, K., Noise sensitivity and disability retirement: a longitudinal twin study (2013) J. Occup. Environ. Med., 55, pp. 365-370; Hill, E.M., Billington, R., Krägeloh, C., Noise sensitivity and diminished health: testing moderators and mediators of the relationship (2014) Noise Health, 16, pp. 47-56; Huss, A., Spoerri, A., Egger, M., Röösli, M., for the Swiss National Cohort Study, Group, Aircraft noise, air pollution, and mortality from myocardial infarction (2010) Epidemiology, 21, pp. 829-836; Jarup, L., Babisch, W., Houthuijs, D., Hypertension and exposure to noise near airports: the HYENA study (2008) Environ. Health Perspect., 116, pp. 329-333; Job, R.F.S., Community response to noise: a review of factors influencing the relationship between noise exposure and reaction (1988) J. Acoust. Soc. Am., 83, pp. 991-1001; Job, R.F., Noise sensitivity as a factor influencing human reaction to noise (1999) Noise Health, 1, pp. 57-68; Kessler, R.C., Wittchen, H., Abelson, J.M., Methodological studies of the Composite International Diagnostic Interview (CIDI) in the US National Comorbidity Survey (NCS) (1998) Int. J. Methods Psychiatr. Res., 7, pp. 33-55; Marmot, M., Brunner, E., Cohort profile: the Whitehall II study (2005) Int. J. Epidemiol., 34, pp. 251-256; Miedema, H.M.E., Vos, H., Exposure-response relationships for transportation noise (1998) J. Acoust. Soc. Am., 104, pp. 3432-3445; Munzel, T., Gori, T., Babisch, W., Cardiovascular effects of environmental noise exposure (2014) Eur. Heart J., 356, pp. 829-836; Nordin, S., Neely, G., Olsson, D., Odor and noise intolerance in persons with self-reported electromagnetic hypersensitivity (2014) Int. J. Environ. Res. Public Health, 11, pp. 8794-8805; Osterberg, K., Persson, R., Karlson, B., Personality, mental distress, and subjective health complaints among persons with environmental annoyance (2007) Hum. Exp. Toxicol., 26, pp. 231-241; Palmquist, E., Claeson, A.S., Neely, G., Overlap in prevalence between various types of environmental intolerance (2014) Int. J. Hyg. Environ. Health, 217, pp. 427-434; Paunović, K., Jakovljević, B., Belojević, G., Predictors of noise annoyance in noisy and quiet urban streets (2009) Sci. Total Environ., 407, pp. 3707-3711; Persson, R., Björk, J., Ardö, J., Trait anxiety and modeled exposure as determinants of self-reported annoyance to sound, air pollution and other environmental factors in the home (2007) Int. Arch. Occup. Environ. Health, 81, pp. 179-191; Radloff, L.S., The CES-D scale: a self-report depression scale for research in the general population (1977) Appl. Psychol. Meas., 1, pp. 385-401; Rose, G.A., The diagnosis of ischaemic heart pain and intermittent claudication in field surveys (1962) Bull. World Health Organ., 27, pp. 645-658; Smith, A., The concept of noise sensitivity: implications for noise control (2003) Noise Health, 5, pp. 57-59; Sorensen, M., Hvidberg, M., Andersen, Z.J., Road traffic noise and stroke: a prospective cohort study (2011) Eur. Heart J., 32, pp. 737-744; Sorensen, M., Andersen, Z.J., Nordsborg, R.B., Road traffic noise and incident myocardial infarction: a prospective cohort study (2012) PLoS ONE, 7, p. e39283; Stansfeld, S.A., Noise, noise sensitivity and psychiatric-disorder - epidemiologic and psychophysiological studies (1992) Psychol. Med. Monogr. Suppl., 22; Stansfeld, S.A., Sharp, D., Gallacher, J., Road traffic noise, noise sensitivity and psychological disorder (1993) Psychol. Med., 23, pp. 977-985; Tarnopolsky, A., Watkins, G., Hand, D.J., Aircraft noise and mental health: I. Prevalence of individual symptoms (1980) Psychol. Med., 10, pp. 683-698; van Kamp, I., Job, R.F., Hatfield, J., The role of noise sensitivity in the noise-response relation: a comparison of three international airport studies (2004) J. Acoust. Soc. Am., 116, pp. 3471-3479",Article,Scopus,2-s2.0-84925263188
"Xie L., Yan W., Li J., Yu L., Wang J., Li G., Chen N., Steinman A.D.","Microcystin-RR exposure results in growth impairment by disrupting thyroid endocrine in zebrafish larvae",2015,"Aquatic Toxicology","164",,,"16","22",,,10.1016/j.aquatox.2015.04.014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927923518&partnerID=40&md5=69bb6b30bc9b0df7089ca530c254b9c6","State Key Laboratory of Lake Science and Environment, Nanjing Institute of Geography and Limnology, Chinese Academy of Sciences, 73 East Beijing RoadNanjing, China; Institute of Agricultural Quality Standards and Testing Technology, Hubei Academy of Agricultural SciencesWuhan, China; College of Fisheries, Huazhong Agricultural UniversityWuhan, China; Freshwater Aquaculture Collaborative Innovation Center of Hubei ProvinceWuhan, China; Robert B. Annis Water Resources Institute, Grand Valley State University, 740 West Shoreline DriveMuskegon, MI, United States","Xie, L., State Key Laboratory of Lake Science and Environment, Nanjing Institute of Geography and Limnology, Chinese Academy of Sciences, 73 East Beijing RoadNanjing, China; Yan, W., Institute of Agricultural Quality Standards and Testing Technology, Hubei Academy of Agricultural SciencesWuhan, China; Li, J., College of Fisheries, Huazhong Agricultural UniversityWuhan, China; Yu, L., College of Fisheries, Huazhong Agricultural UniversityWuhan, China; Wang, J., College of Fisheries, Huazhong Agricultural UniversityWuhan, China; Li, G., College of Fisheries, Huazhong Agricultural UniversityWuhan, China, Freshwater Aquaculture Collaborative Innovation Center of Hubei ProvinceWuhan, China; Chen, N., College of Fisheries, Huazhong Agricultural UniversityWuhan, China; Steinman, A.D., Robert B. Annis Water Resources Institute, Grand Valley State University, 740 West Shoreline DriveMuskegon, MI, United States","Recent studies have shown that cyanobacteria-derived microcystins (MCs) have the potential to disrupt endocrine systems. However, the effects of microcystin-RR (MC-RR) and their underlying mechanisms are poorly resolved in fish. In this study, MC-RR exposure through submersion caused serious developmental toxicity, such as growth delay and depressed heart rates in zebrafish larvae. We also detected decreased levels of thyroid hormones (THs), suggesting that MC-RR-triggered thyroid endocrine disruption might contribute to the growth impairment observed in developing zebrafish. To further our understanding of mechanisms of MC-RR-induced endocrine toxicity, quantitative real-time PCR (QPCR) analysis was performed on hypothalamic-pituitary-thyroid (HPT) axis related genes, i.e., corticotropin-releasing factor (CRF), thyroid-stimulating hormone (TSH), sodium/iodide symporter (NIS), thyroglobulin (TG), thyroid receptors (TRα and TRβ) and iodothyronine deiodinases (Dio1 and Dio2), of developing zebrafish embryos exposed to 0, 0.3, 1.0 or 3.0mgL-1 MC-RR until 96h post-fertilization. Our results showed that transcription pattern of HPT axis related genes were greatly changed by MC-RR exposure, except TG gene. Furthermore, western blot was used to validate the results of gene expression. The results showed protein synthesis of TG was not affected, while that of NIS was significantly up-regulated, which are in accordance with gene expression. The overall results indicated that exposure to MC-RR can induce developmental toxicity, which might be associated with thyroid endocrine disruption in developing zebrafish larvae. © 2015 Elsevier B.V..","Developing zebrafish; Growth impairment; Hypothalamic-pituitary-thyroid axis; MC-RR","Arukewe, A., Jenssen, B.M., Differential organ expression patterns of thyroid hormone receptor isoform genes in p,p'-DDE-treated adult male common frog, Rana temporaria (2005) Environ. Toxicol. Pharmacol., 20, pp. 485-492; Bury, N.R., Eddy, F.B., Codd, G.A., The effects of the cyanobacterium Microcystis aeruginosa, the cyanobacterial hepatotoxin microcystin-LR, and ammonia on growth rate and ionic regulation of brown trout (1995) J. Fish Biol., 46, pp. 1042-1054; Chen, J., Xie, P., Zhang, D., Ke, Z.X., Yang, H., In situ studies on the bioaccumulation of microcystins in the phytoplanktivorous silver carp (Hypophthalmichthys molitrix) stocked in Lake Taihu with dense toxic Microcystis blooms (2006) Aquaculture, 261, pp. 1026-1038; Chen, Q., Yu, L.Q., Yang, L., Zhou, B.S., Bioconcentration and metabolism of decabromodiphenyl ether (BDE-209) result in thyroid endocrine disruption in zebrafish larvae (2012) Aquat. Toxicol., 110, pp. 141-148; Crane, H.M., Pickford, D.B., Hutchinson, T.H., Brown, J.A., Developmental changes of thyroid hormones in the fathead minnow: Pimephales promelas (2004) Gen. Comp. Endocrinol., 139, pp. 55-60; Ding, W.X., Shen, H.M., Ong, C.N., Microcystic cyanobacteria extract induces cytoskeletal disruption and intracellular glutathione alteration in hepatocytes (2000) Environ. Health Perspect., 108, pp. 605-609; Ding, W.X., Shen, H.M., Ong, C.N., Critical role of reactive oxygen species formation in microcystin-induced cytoskeleton disruption in primary cultured hepatocytes (2001) J. Toxicol. Environ. Health, 64, pp. 507-519; De Groef, B., Van der Geyten, S., Darras, V.M., Kuhn, E.R., Role of corticotropin-releasing hormone as a thyrotropin-releasing factor in non-mammalian vertebrates (2006) Gen. Comp. Endocrinol., 146, pp. 62-68; Dohán, O., Carrasco, N., Advances in Na+/I- symporter (NIS) research in the thyroid and beyond (2003) Mol. Cell. Endocrinol., 213, pp. 59-70; Eriksson, J.E., Toivola, D., Meriluoto, J.A.O., Karaki, H., Han, Y., Hartshorne, D., Hepatocyte deformation induced by cyanobacterial toxins reflects inhibition of protein phosphatases (1990) Biochem. Biophys. Res. Commun., 173, pp. 1347-1353; Falconer, I.R., Yeung, D.S.K., Cytoskeletal changes in hepatocytes induced by Microcystis toxins and their relation to hyperphosphorylation of cell proteins (1992) Chem. Biol. Interact., 81, pp. 181-196; Fischer, W.J., Dietrich, D.R., Pathological and biochemical characterization of microcystins-induced hepatopancreas and kidney damage in carp (Cyprinus carpio) (2000) Toxicol. Appl. Pharmacol., 164, pp. 73-81; Gehringer, M.M., Microcystin-LR and okadaic acid-induced cellular effects: a dualistic response (2004) FEBS Lett., 557, pp. 1-8; Jia, X., Cai, C., Wang, J., Gao, N., Zhang, H., Endocrine-disrupting effects and reproductive toxicity of low dose MCLR on male frogs (Rana nigromaculata) in vivo (2014) Aquat. Toxicol., 13 (155), pp. 24-31; Kaasalainen, U., Fewer, D.P., Jokela, J., Wahlsten, M., Sivonen, K., Rikkinen, J., Cyanobacteria produce a high variety of hepatotoxic peptides in lichen symbiosis (2012) Proc. Natl. Acad. Sci. U. S. A., 109, pp. 5886-5891; Kawakami, Y., Shin, D.H., Kitano, T., Adachi, S., Yamauchi, K., Ohta, H., Transactivation activity of thyroid hormone receptors in fish (Conger myriaster) in response to thyroid hormones (2006) Comp. Biochem. Physiol., 144 B, pp. 503-509; Li, D.P., Xie, P., Zhang, X.Z., Changes in plasma thyroid hormones and cortisol levels in crucian carp (Carassius auratus) exposed to the extracted microcystins (2008) Chemosphere, 74, pp. 13-18; Li, G.Y., Chen, J., Xie, P., Jiang, Y., Wu, L.Y., Zhang, X.Z., Protein profiles in zebrafish (Danio rerio) embryos exposed to microcystin-LR (2011) Proteomics, 1, pp. 2003-2008; Li, G.Y., Xie, P., Fu, J., Hao, L., Xiong, Q., Li, H.Y., Microcystin-induced variations in transcription of GSTs in an omnivorous freshwater fish, goldfish (2008) Aquat. Toxicol., 88, pp. 75-80; Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method (2001) Methods, 25, pp. 402-408; Li, Z.H., Chen, L., Wu, Y.H., Li, P., Li, Y.F., Ni, Z.H., Effects of waterborne cadmium on thyroid hormone levels and related gene expression in Chinese rare minnow larvae (2014) Comp. Biochem. Physiol. C: Toxicol. Pharmacol., 161, pp. 53-57; Liu, Y.W., Chan, W.K., Thyroid hormones are important for embryonic to larval transitory phase in zebrafish (2002) Differentiation, 70, pp. 36-45; Manchado, M., Infante, C., Asensio, E., Planas, J.V., Canavate, J.P., Thyroid hormones down-regulate thyrotropin beta subunit and thyroglobulin during metamorphosis in the flatfish Senegalese sole (Solea senegalensis Kaup) (2008) Gen. Comp. Endocrinol., 155, pp. 447-455; Nagase, H., Nagasawa, Y., Tachida, Y., Sakakibara, S., Okutsu, J., Suematsu, N., Arita, S., Shimada, K., Deiodinase 2 upregulation demonstrated in osteoarthritis patients cartilage causes cartilage destruction in tissue-specific transgenic rats (2013) Osteoarthr. Cartilage, 21, pp. 514-523; Oberemm, A., Becker, J., Codd, G.A., Steinberg, C., Effects of cyanobacterial toxins and aqueous crude extracts of cyanobacteria on the development of fish and amphibians (1999) Environ. Toxicol., 14, pp. 77-88; Oberemm, A., Fastner, J., Steinberg, C.E.W., Effects of microcystin-LR and cyanobacterial crude extracts on embryolarval development of zebrafish (Danio rerio) (1997) Water Res., 31, pp. 2918-2921; Orozco, A., Villalobos, P., Valverde, R.C., Environmental salinity selectively modifies the outer-ring deiodinating activity of liver: kidney and gill in the rainbow trout (2002) Comp. Biochem. Physiol. A: Mol. Integr. Physiol., 131, pp. 387-395; Parng, C., Seng, W.L., Semino, C., McGrath, P., Zebrafish: a preclinical model for drug screening (2002) Assay Drug Dev. Technol., 1, pp. 41-48; Power, D.M., Elias, N.P., Richardson, S.J., Mendes, J., Soares, C.M., Santos, C.R., Evolution of the thyroid hormone-binding protein, transthyretin (2000) Gen. Comp. Endocrinol., 119, pp. 241-255; Qiao, Q., Liu, W., Wu, K., Song, T., Hu, J., Huang, X., Wen, J., Zhang, X., Female zebrafish (Danio rerio) are more vulnerable than males to microcystin-LR exposure, without exhibitingestrogenic effects (2013) Aquat. Toxicol., pp. 272-282; Qiu, T., Xie, P., Liu, Y., Li, G.Y., Hao, L., Experimental studies on the cardiotoxic effects of microcystins in rat: possibly a new contributing factor to circulatory insufficiency in human microcystin intoxication (2009) Toxicology, 257, pp. 86-94; Scholz, S., Zebrafish embryos as an alternative model for screening of druginduced organ toxicity (2013) Arch. Toxicol., 87, pp. 767-769; Shi, X., Liu, C., Wu, G., Zhou, B., Waterborne exposure to PFOS causes disruption of the hypothalamus-pituitary-thyroid axis in zebrafish larvae (2009) Chemosphere, 77, pp. 1010-1018; Van der Geyten, S., Toguyeni, A., Baroiller, J.F., Fauconneau, B., Fostier, A., Sanders, J.P., Visser, T.J., Darras, V.M., Hypothyroidism induces type I iodothyronine deiodinase expression in tilapia liver (2001) Gen. Comp. Endocrinol., 124, pp. 333-342; Wang, X., Ying, F., Chen, Y., Han, X., Microcystin (-LR) affects hormones level of male mice by damaging hypothalamic-pituitary system (2012) Toxicon, 59, pp. 205-214; Walpita, C.N., Van der Geyten, S., Rurangwa, E., Darras, V.M., The effect of 3,5,3 0-triiodothyronine supplementation on zebrafish (Danio rerio) embryonic development and expression of iodothyronine deiodinases and thyroid hormone receptors (2007) Gen. Comp. Endocrinol., 152, pp. 206-214; Xie, L.Q., Xie, P., Guo, L.G., Li, L., Yuichi, M., Park, H.D., Organ distribution and bioaccumulation of microcystins in freshwater fishes with different trophic levels from the eutrophic Lake Chaohu (2005) China Environ. Toxicol., 20, pp. 293-300; Yan, W., Zhou, Y., Yang, J., Li, S., Hu, D., Wang, J., Chen, J., Li, G., Waterborne exposure to microcystin-LR alters thyroid hormone levels and gene transcription in the hypothalamic-pituitary-thyroid axis in zebrafish larvae (2012) Chemosphere, 87, pp. 1301-1307; Yen, P.M., Chin, W.W., Molecular mechanisms of dominant negative activity by nuclear hormone receptors (1994) Mol. Endocrinol., 8, pp. 1450-1454; Yu, L., Chen, M., Liu, Y., Gui, W., Zhu, G., Thyroid endocrine disruption in zebrafish larvae following exposure to hexaconazole and tebuconazole (2013) Aquat. Toxicol., 15, pp. 35-42; Yu, L.Q., Deng, J., Shi, X.J., Liu, C.S., Yu, K., Zhou, B.S., Exposure to DE-71 alters thyroid hormone levels and gene transcription in the hypothalamic-pituitary-thyroid axis of zebrafish larvae (2010) Aquat. Toxicol., 97, pp. 226-233; Yu, L.Q., Lam, J.C.W., Guo, Y.Y., Wu, R.S.S., Lam, P.K.S., Zhou, B.S., Parental transfer of polybrominated diphenyl Ethers (PBDEs) and thyroid endocrine disruption in zebrafish (2011) Environ. Sci. Technol., 45, pp. 10652-10659; Zeng, C., Sun, H., Xie, P., Wang, J., Zhang, G., Chen, N., Yan, W., Li, G., The role of apoptosis in MCLR-induced developmental toxicity in zebrafish embryos (2014) Aquat. Toxicol., 149, pp. 25-32; Zhao, X., Wang, S., Li, D., You, H., Ren, X., Effects of perchlorate on BDE-47-induced alteration thyroid hormone and gene expression of the hypothalamus-pituitary-thyroid axis in zebrafish larvae (2013) Environ. Toxicol. Pharmacol., 36, pp. 1176-1185; Zhao, Y., Xie, L.Q., Yan, Y., Microcystin-LR impairs zebrafish reproduction by affecting oogenesis and endocrine system (2015) Chemosphere, 120, pp. 115-122; Zhang, X., Xie, P., Li, D., Shi, Z., Haematological and plasma biochemical responses of crucian carp (Carassius auratus) to intraperitoneal injection of extracted microcystins with the possible mechanisms of anemia (2008) Toxicon, 49, pp. 1150-1157",Article,Scopus,2-s2.0-84927923518
"Dupuis L.E., Berger M.G., Feldman S., Doucette L., Fowlkes V., Chakravarti S., Thibaudeau S., Alcala N.E., Bradshaw A.D., Kern C.B.","Lumican deficiency results in cardiomyocyte hypertrophy with altered collagen assembly",2015,"Journal of Molecular and Cellular Cardiology","84",,,"70","80",,,10.1016/j.yjmcc.2015.04.007,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928152361&partnerID=40&md5=9d75ae1bdcfe72031e540e4b4926a61b","Department of Regenerative Medicine and Cell Biology, Medical University of South CarolinaCharleston, SC, United States; Honors College, College of CharlestonCharleston, SC, United States; Department of Medicine, Johns Hopkins School of MedicineBaltimore, MD, United States; Gazes Cardiac Research Institute, Medical University of South CarolinaCharleston, SC, United States","Dupuis, L.E., Department of Regenerative Medicine and Cell Biology, Medical University of South CarolinaCharleston, SC, United States; Berger, M.G., Honors College, College of CharlestonCharleston, SC, United States; Feldman, S., Honors College, College of CharlestonCharleston, SC, United States; Doucette, L., Honors College, College of CharlestonCharleston, SC, United States; Fowlkes, V., Department of Regenerative Medicine and Cell Biology, Medical University of South CarolinaCharleston, SC, United States; Chakravarti, S., Department of Medicine, Johns Hopkins School of MedicineBaltimore, MD, United States; Thibaudeau, S., Department of Regenerative Medicine and Cell Biology, Medical University of South CarolinaCharleston, SC, United States; Alcala, N.E., Honors College, College of CharlestonCharleston, SC, United States; Bradshaw, A.D., Gazes Cardiac Research Institute, Medical University of South CarolinaCharleston, SC, United States; Kern, C.B., Department of Regenerative Medicine and Cell Biology, Medical University of South CarolinaCharleston, SC, United States","The ability of the heart to adapt to increased stress is dependent on the modification of its extracellular matrix (ECM) architecture that is established during postnatal development as cardiomyocytes differentiate, a process that is poorly understood. We hypothesized that the small leucine-rich proteoglycan (SLRP) lumican (LUM), which binds collagen and facilitates collagen assembly in other tissues, may play a critical role in establishing the postnatal murine myocardial ECM. Although previous studies suggest that LUM deficient mice (lum-/-) exhibit skin anomalies consistent with Ehlers-Danlos syndrome, lum-/- hearts have not been evaluated. These studies show that LUM was immunolocalized to non-cardiomyocytes of the cardiac ventricles and its expression increased throughout development. Lumican deficiency resulted in significant (50%) perinatal death and further examination of the lum-/- neonatal hearts revealed an increase in myocardial tissue without a significant increase in cell proliferation. However cardiomyocytes from surviving postnatal day 0 (P0), 1. month (1. mo) and adult (4. mo) lum-/- hearts were significantly larger than their wild type (WT) littermates. Immunohistochemistry revealed that the increased cardiomyocyte size in the lum-/- hearts correlated with alteration of the cardiomyocyte pericellular ECM components collagenα1(I) and the class I SLRP decorin (DCN). Western blot analysis demonstrated that the ratio of glycosaminoglycan (GAG) decorated DCN to core DCN was reduced in P0 and 1. mo lum-/- hearts. There was also a reduction in the β and γ forms of collagenα1(I) in lum-/- hearts. While the total insoluble collagen content was significantly reduced, the fibril size was increased in lum-/- hearts, indicating that LUM may play a role in collagen fiber stability and lateral fibril assembly. These results suggest that LUM controls cardiomyocyte growth by regulating the pericellular ECM and also indicates that LUM may coordinate multiple factors of collagen assembly in the murine heart. Further investigation into the role of LUM may yield novel therapeutic targets and/or biomarkers for patients with cardiovascular disease. © 2015 Elsevier Ltd.","Cardiomyocyte; Collagen; Decorin; Lumican; Myocardium; SLRP","Dorn, G.W., Robbins, J., Sugden, P.H., Phenotyping hypertrophy: eschew obfuscation (2003) Circ Res, 92, pp. 1171-1175; Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B., Castelli, W.P., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study (1990) N Engl J Med, 322, pp. 1561-1566; Evans, S.M., Yelon, D., Conlon, F.L., Kirby, M.L., Myocardial lineage development (2010) Circ Res, 107, pp. 1428-1444; Klug, M.G., Soonpaa, M.H., Koh, G.Y., Field, L.J., Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts (1996) J Clin Invest, 98, pp. 216-224; Goldsmith, E.C., Borg, T.K., The dynamic interaction of the extracellular matrix in cardiac remodeling (2002) J Card Fail, 8, pp. S314-S318; Terracio, L., Rubin, K., Gullberg, D., Balog, E., Carver, W., Jyring, R., Expression of collagen binding integrins during cardiac development and hypertrophy (1991) Circ Res, 68, pp. 734-744; Goldsmith, E.C., Bradshaw, A.D., Zile, M.R., Spinale, F.G., Myocardial fibroblast-matrix interactions and potential therapeutic targets (2014) J Mol Cell Cardiol, 70, pp. 92-99; Miller, A.D., Tyagi, S.C., Mutation in collagen gene induces cardiomyopathy in transgenic mice (2002) J Cell Biochem, 85, pp. 259-267; Callewaert, B., Malfait, F., Loeys, B., De Paepe, A., Ehlers-Danlos syndromes and Marfan syndrome (2008) Best Pract Res Clin Rheumatol, 22, pp. 165-189; Byers, P.H., Ehlers-Danlos syndrome: recent advances and current understanding of the clinical and genetic heterogeneity (1994) J Invest Dermatol, 103, pp. 47S-52S; Raff, M.L., Byers, P.H., Joint hypermobility syndromes (1996) Curr Opin Rheumatol, 8, pp. 459-466; Chakravarti, S., The cornea through the eyes of knockout mice (2001) Exp Eye Res, 73, pp. 411-419; Iozzo, R.V., Moscatello, D.K., McQuillan, D.J., Eichstetter, I., Decorin is a biological ligand for the epidermal growth factor receptor (1999) J Biol Chem, 274, pp. 4489-4492; Tingbo, M.G., Pedersen, M.E., Kolset, S.O., Enersen, G., Hannesson, K.O., Lumican is a major small leucine-rich proteoglycan (SLRP) in Atlantic cod (Gadus morhua L.) skeletal muscle (2012) Glycoconj J, 29, pp. 13-23; Jepsen, K.J., Wu, F., Peragallo, J.H., Paul, J., Roberts, L., Ezura, Y., A syndrome of joint laxity and impaired tendon integrity in lumican- and fibromodulin-deficient mice (2002) J Biol Chem, 277, pp. 35532-35540; Chakravarti, S., Zhang, G., Chervoneva, I., Roberts, L., Birk, D.E., Collagen fibril assembly during postnatal development and dysfunctional regulation in the lumican-deficient murine cornea (2006) Dev Dyn, 235, pp. 2493-2506; Beecher, N., Chakravarti, S., Joyce, S., Meek, K.M., Quantock, A.J., Neonatal development of the corneal stroma in wild-type and lumican-null mice (2006) Invest Ophthalmol Vis Sci, 47, pp. 146-150; Chakravarti, S., Magnuson, T., Lass, J.H., Jepsen, K.J., LaMantia, C., Carroll, H., Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican (1998) J Cell Biol, 141, pp. 1277-1286; Kern, C.B., Norris, R.A., Thompson, R.P., Argraves, W.S., Fairey, S.E., Reyes, L., Versican proteolysis mediates myocardial regression during outflow tract development (2007) Dev Dyn, 236, pp. 671-683; Dupuis, L.E., McCulloch, D.R., McGarity, J.D., Bahan, A., Wessels, A., Weber, D., Altered versican cleavage in ADAMTS5 deficient mice; a novel etiology of myxomatous valve disease (2011) Dev Biol, 357, pp. 152-164; Bradshaw, A.D., Reed, M.J., Sage, E.H., SPARC-null mice exhibit accelerated cutaneous wound closure (2002) J Histochem Cytochem, 50, pp. 1-10; Ieda, M., Tsuchihashi, T., Ivey, K.N., Ross, R.S., Hong, T.T., Shaw, R.M., Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling (2009) Dev Cell, 16, pp. 233-244; Li, Y., Liu, Y., Xia, W., Lei, D., Voorhees, J.J., Fisher, G.J., Age-dependent alterations of decorin glycosaminoglycans in human skin (2013) Sci Rep, 3, p. 2422; Engebretsen, K.V., Waehre, A., Bjornstad, J.L., Skrbic, B., Sjaastad, I., Behmen, D., Decorin, lumican, and their GAG chain-synthesizing enzymes are regulated in myocardial remodeling and reverse remodeling in the mouse (2013) J Appl Physiol, 114, pp. 988-997; Carrino, D.A., Sorrell, J.M., Caplan, A.I., Age-related changes in the proteoglycans of human skin (2000) Arch Biochem Biophys, 373, pp. 91-101; Chen, S., Birk, D.E., The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly (2013) FEBS J, 280, pp. 2120-2137; Moreth, K., Iozzo, R.V., Schaefer, L., Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation (2012) Cell Cycle, 11, pp. 2084-2091; Iozzo, R.V., Karamanos, N., Proteoglycans in health and disease: emerging concepts and future directions (2010) FEBS J, 277, p. 3863; Kalamajski, S., Oldberg, A., The role of small leucine-rich proteoglycans in collagen fibrillogenesis (2010) Matrix Biol, 29, pp. 248-253; Banerjee, I., Yekkala, K., Borg, T.K., Baudino, T.A., Dynamic interactions between myocytes, fibroblasts, and extracellular matrix (2006) Ann N Y Acad Sci, 1080, pp. 76-84; Lajiness, J.D., Conway, S.J., Origin, development, and differentiation of cardiac fibroblasts (2014) J Mol Cell Cardiol, 70, pp. 2-8; Chakravarti, S., Functions of lumican and fibromodulin: lessons from knockout mice (2002) Glycoconj J, 19, pp. 287-293; Ezura, Y., Chakravarti, S., Oldberg, A., Chervoneva, I., Birk, D.E., Differential expression of lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons (2000) J Cell Biol, 151, pp. 779-788; Keene, D.R., San Antonio, J.D., Mayne, R., McQuillan, D.J., Sarris, G., Santoro, S.A., Decorin binds near the C terminus of type I collagen (2000) J Biol Chem, 275, pp. 21801-21804; Kalamajski, S., Liu, C., Tillgren, V., Rubin, K., Oldberg, A., Rai, J., Increased C-telopeptide cross-linking of tendon type I collagen in fibromodulin-deficient mice (2014) J Biol Chem, 289, pp. 18873-18879; Gotte, M., Kresse, H., Defective glycosaminoglycan substitution of decorin in a patient with progeroid syndrome is a direct consequence of two point mutations in the galactosyltransferase I (beta4GalT-7) gene (2005) Biochem Genet, 43, pp. 65-77; Liu, C.Y., Birk, D.E., Hassell, J.R., Kane, B., Kao, W.W., Keratocan-deficient mice display alterations in corneal structure (2003) J Biol Chem, 278, pp. 21672-21677; Henninger, H.B., Maas, S.A., Underwood, C.J., Whitaker, R.T., Weiss, J.A., Spatial distribution and orientation of dermatan sulfate in human medial collateral ligament (2007) J Struct Biol, 158, pp. 33-45; Lewis, P.N., Pinali, C., Young, R.D., Meek, K.M., Quantock, A.J., Knupp, C., Structural interactions between collagen and proteoglycans are elucidated by three-dimensional electron tomography of bovine cornea (2010) Structure, 18, pp. 239-245; Waehre, A., Vistnes, M., Sjaastad, I., Nygard, S., Husberg, C., Lunde, I.G., Chemokines regulate small leucine-rich proteoglycans in the extracellular matrix of the pressure-overloaded right ventricle (2012) J Appl Physiol, 112, pp. 1372-1382; Carrino, D.A., Onnerfjord, P., Sandy, J.D., Cs-Szabo, G., Scott, P.G., Sorrell, J.M., Age-related changes in the proteoglycans of human skin. Specific cleavage of decorin to yield a major catabolic fragment in adult skin (2003) J Biol Chem, 278, pp. 17566-17572; Imai, K., Hiramatsu, A., Fukushima, D., Pierschbacher, M.D., Okada, Y., Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release (1997) Biochem J, 322, pp. 809-814; Svensson, L., Heinegard, D., Oldberg, A., Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5 (1995) J Biol Chem, 270, pp. 20712-20716; Schonherr, E., Broszat, M., Brandan, E., Bruckner, P., Kresse, H., Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen (1998) Arch Biochem Biophys, 355, pp. 241-248; Engebretsen, K.V., Lunde, I.G., Strand, M.E., Waehre, A., Sjaastad, I., Marstein, H.S., Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli (2013) FEBS J, 280, pp. 2382-2398; Waehre, A., Halvorsen, B., Yndestad, A., Husberg, C., Sjaastad, I., Nygard, S., Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload (2011) PLoS One, 6; Nikitovic, D., Katonis, P., Tsatsakis, A., Karamanos, N.K., Tzanakakis, G.N., Lumican, a small leucine-rich proteoglycan (2008) IUBMB Life, 60, pp. 818-823; Iozzo, R.V., Schaefer, L., Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans (2010) FEBS J, 277, pp. 3864-3875",Article,Scopus,2-s2.0-84928152361
"Cao G., Ying P., Yan B., Xue W., Li K., Shi A., Sun T., Yan J., Hu X.","Pharmacokinetics, safety, and tolerability of single and multiple-doses of pinocembrin injection administered intravenously in healthy subjects",2015,"Journal of Ethnopharmacology","168",,,"31","36",,,10.1016/j.jep.2015.03.041,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927517593&partnerID=40&md5=84cceeecd2f609c61479454851109c15","Department of Clinical Pharmacology, Beijing HospitalBeijing, China; School of Pharmaceutical Sciences, Shandong UniversityJinan, Shandong, China; Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Shijiazhuang, China","Cao, G., Department of Clinical Pharmacology, Beijing HospitalBeijing, China; Ying, P., Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Shijiazhuang, China; Yan, B., Department of Clinical Pharmacology, Beijing HospitalBeijing, China; Xue, W., Department of Clinical Pharmacology, Beijing HospitalBeijing, China; Li, K., Department of Clinical Pharmacology, Beijing HospitalBeijing, China; Shi, A., Department of Clinical Pharmacology, Beijing HospitalBeijing, China; Sun, T., School of Pharmaceutical Sciences, Shandong UniversityJinan, Shandong, China; Yan, J., Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Shijiazhuang, China; Hu, X., Department of Clinical Pharmacology, Beijing HospitalBeijing, China","Ethnopharmacological relevance Pinocembrin is the most abundant flavonoid in propolis. Preclinical studies have suggested that pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro. To investigate the safety, tolerability and pharmacokinetics of a new neuroprotective agent, pinocembrin. Materials and method A double-blind, placebo-controlled, randomized study was carried out in 58 healthy subjects. Single ascending doses of pinocembrin (20-150 mg) were evaluated in 5 cohorts. Multi-dose was studied at pinocembrin 60 mg. Results Pinocembrin was well tolerated. No serious adverse events occurred. No subjects were discontinued because of a treatment emergent AE. Treatment related adverse event was acute urticaria. Two subjects in 150 mg cohort developed grade II urticaria during the study. One subject discontinued after 3 days at 60 mg bid because of diarrhea. In the single-dose study, the mean peak plasma pinocembrin concentration was obtained at the end of the 30-min infusion. The C<inf>max</inf> ranged from 0.28 μg mL-1 to 2.46 μg mL-1. AUC <inf>(0,∞)</inf> ranged from 10.34 μg mL-1 min to 89.34 μg mL-1 min. The T<inf>1/2</inf> was similar across 5 dose groups, ranging from 40 to 55 min. Both urinary and feces excretion levels of pinocembrin were extremely low and similar among each dose groups, with mean values ranging from 0.07% to 0.17% and 0.94% to 1.94% of the administered dose, respectively. Linear increases in C<inf>max</inf> and AUC<inf>(0,∞)</inf> were observed. The pharmacokinetics of pinocembrin in multiple-dose was similar to those observed in the single-dose study, with no evidence of accumulation. Both urinary and feces excretion levels of pinocembrin were extremely low. Conclusions Pinocembrin displayed linear plasma pharmacokinetics over the dose range, 20-150 mg and was well tolerated up to 120 mg day-1 when administered intravenously to healthy adults. No major safety concerns were identified that would preclude further clinical development of pinocembrin injection. © 2015 Elsevier Ireland Ltd.","Pharmacokinetics; Phase I; Pinocembrin; Safety; Tolerability","Ahn, M.R., Kunimasa, K., Kumazawa, S., Nakayama, T., Kaji, K., Uto, Y., Hori, H., Ohta, T., Correlation between antiangiogenic activity and antioxidant activity of various components from propolis (2009) Mol. Nutr. Food Res., 53, pp. 643-651; Gao, M., Liu, R., Zhu, S.Y., Du, G.H., Acute neurovascular unit protective action of pinocembrin against permanent cerebral ischemia in rats (2008) J. Asian Nat. Prod. Res., 10, pp. 551-558; Jantan, I., Raweh, S.M., Sirat, H.M., Jamil, S., Mohd Yasin, Y.H., Jalil, J., Jamal, J.A., Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation (2008) Phytomedicine, 15, pp. 306-309; Kapoor, S., Comment on isolation and identification of compounds from Penthorum chinense Pursh with antioxidant and antihepatocarcinoma properties: Pinocembrin and its rapidly emerging neuroprotective effects (2013) J. Agric. Food. Chem., 61, p. 1416; Liu, R., Gao, M., Yang, Z.H., Du, G.H., Pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro (2008) Brain Res., 1216, pp. 104-115; Paintz, M., Metzner, J., On the local anaesthetic action of propolis and some of its constituents (1979) Pharmazie, 34, pp. 839-841; Rasul, A., Millimouno, F.M., Ali Eltayb, W., Ali, M., Li, J., Li, X., Pinocembrin: A novel natural compound with versatile pharmacological and biological activities (2013) BioMed Res. Int., 2013, p. 379850; Santos, A.C., Uyemura, S.A., Lopes, J.L., Bazon, J.N., Mingatto, F.E., Curti, C., Effect of naturally occurring flavonoids on lipid peroxidation and membrane permeability transition in mitochondria (1998) Free Radic. Biol. Med., 24, pp. 1455-1461; Shi, L.L., Qiang, G.F., Gao, M., Zhang, H.A., Chen, B.N., Yu, X.Y., Xuan, Z.H., Du, G.H., Effect of pinocembrin on brain mitochondrial respiratory function (2011) Acta Pharm. Sin., 46, pp. 642-649; Soromou, L.W., Chu, X., Jiang, L., Wei, M., Huo, M., Chen, N., Guan, S., Deng, X., In vitro and in vivo protection provided by pinocembrin against lipopolysaccharide-induced inflammatory responses (2012) Int. Immunopharmacol., 14, pp. 66-74; Wang, S.B., Pang, X.B., Gao, M., Fang, L.H., Du, G.H., Pinocembrin protects rats against cerebral ischemic damage through soluble epoxide hydrolase and epoxyeicosatrienoic acids (2013) Chin. J. Nat. Med., 11, pp. 207-213; Wu, C.X., Liu, R., Gao, M., Zhao, G., Wu, S., Wu, C.F., Du, G.H., Pinocembrin protects brain against ischemia/reperfusion injury by attenuating endoplasmic reticulum stress induced apoptosis (2013) Neurosci. Lett., 546, pp. 57-62; Yang, Z., Liu, R., Li, X., Tian, S., Liu, Q., Du, G., Development and validation of a high-performance liquid chromatographic method for determination of pinocembrin in rat plasma: Application to pharmacokinetic study (2009) J. Pharm. Biomed. Anal., 49, pp. 1277-1281; Yu, Y.S., Hsu, C.L., Yen, G.C., Anti-inflammatory effects of the roots of Alpinia pricei Hayata and its phenolic compounds (2009) J. Agric. Food Chem., 57, pp. 7673-7680; http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/gclp.pdf",Article,Scopus,2-s2.0-84927517593
"Xu R.-X., Zhang Y., Li X.-L., Li S., Guo Y.-L., Dong Q., Liu G., Li J.-J.","Relationship between plasma phospholipase A<inf>2</inf> concentrations and lipoprotein subfractions in patients with stable coronary artery disease",2015,"Clinica Chimica Acta","446",,,"195","200",,,10.1016/j.cca.2015.04.032,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928804760&partnerID=40&md5=1defb3b0184d237b3da156b7b038371e","Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China","Xu, R.-X., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Zhang, Y., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Li, X.-L., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Li, S., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Guo, Y.-L., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Dong, Q., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Liu, G., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China; Li, J.-J., Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China","Background: Both increased lipoprotein-associated phospholipase A<inf>2</inf> (Lp-PLA<inf>2</inf>) concentrations and atherogenic lipoprotein subfractions have been shown to reflect unfavourable cardiovascular risk. However, the correlation between Lp-PLA<inf>2</inf> and lipoprotein subfractions in patients with coronary artery disease (CAD) has not been assessed yet. Methods: A total of 324 consecutive subjects who were not treated with lipid-lowering drugs were enrolled (angiographically proven CAD: n=253; non-CAD: n=71). Plasma Lp-PLA<inf>2</inf> concentrations were measured using ELISA. The low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions were determined by Lipoprint System. Results: Plasma Lp-PLA<inf>2</inf> concentrations were higher in patients with CAD compared with those without CAD (153.61±78.73 vs. 131.41±65.49ng/ml, p=0.028). The univariable correlation analysis revealed that Lp-PLA<inf>2</inf> concentrations were positively correlated with the cholesterol concentrations of each LDL subfractions and the intermediate as well as small HDL subfractions, while negatively linked with the LDL particle size and large HDL-cholesterol (HDL-C) concentrations in CAD group. However, no similar results were observed in the non-CAD group. Furthermore, multivariable regression analysis was performed in patients with CAD and showed that plasma Lp-PLA<inf>2</inf> concentrations were independently correlated with the cholesterol concentrations of each LDL subfractions [large LDL-cholesterol (LDL-C): β=0.263, p<0.001; intermediate LDL-C: β=0.327, p<0.001; small LDL-C: β=0.135, p=0.033] and small HDL-C (β=0.133, p=0.034). Conclusion: Lp-PLA<inf>2</inf> concentrations were positively associated with all LDL subfractions and small HDL subfraction, suggesting an interaction between Lp-PLA<inf>2</inf> and lipoprotein subfraction phenotypes in the status of CAD. © 2015 Elsevier B.V.","Coronary artery disease; High-density lipoprotein subfraction; Lipoprotein associated phospholipase A<inf>2</inf>; Low-density lipoprotein subfraction","Cai, A., Zheng, D., Qiu, R., Mai, W., Zhou, Y., Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment (2013) Dis Markers, 34, pp. 323-331; Rosenson, R.S., Stafforini, D.M., Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2 (2012) J Lipid Res, 53, pp. 1767-1782; Tselepis, A.D., Dentan, C., Karabina, S.A., Chapman, M.J., Ninio, E., PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme (1995) Arterioscler Thromb Vasc Biol, 15, pp. 1764-1773; Stafforini, D.M., Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2) (2009) Cardiovasc Drugs Ther, 23, pp. 73-83; MacPhee, C.H., Moores, K.E., Boyd, H.F., Dhanak, D., Ife, R.J., Leach, C.A., Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor (1999) Biochem J, 338, pp. 479-487; Goncalves, I., Edsfeldt, A., Ko, N.Y., Grufman, H., Berg, K., Björkbacka, H., Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation (2012) Arterioscler Thromb Vasc Biol, 32, pp. 1505-1512; Mangili, A., Ahmad, R., Wolfert, R.L., Kuvin, J., Polak, J.F., Karas, R.H., Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients (2014) Clin Infect Dis, 58, pp. 893-900; Stafforini, D.M., McIntyre, T.M., Carter, M.E., Prescott, S.M., Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor (1987) J Biol Chem, 262, pp. 4215-4222; Noto, H., Chitkara, P., Raskin, P., The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes (2006) J Diabetes Complicat, 20, pp. 343-348; Feng, L.M., Feng, G.F., Chen, Y., Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adult serum (2014) Lipids Health Dis, 13, p. 6; Gregson, J., Stirnadel-Farrant, H.A., Doobaree, I.U., Koro, C., Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature (2012) Atherosclerosis, 225, pp. 11-21; Irving, B.A., Nair, K.S., Srinivasan, M., Effects of insulin sensitivity, body composition, and fitness on lipoprotein particle sizes and concentrations determined by nuclear magnetic resonance (2011) J Clin Endocrinol Metab, 96, pp. E713-E718; Superko, H.R., Pendyala, L., Williams, P.T., Momary, K.M., King, S.B., Garrett, B.C., High-density lipoprotein subclasses and their relationship to cardiovascular disease (2012) J Clin Lipidol, 6, pp. 496-523; Goliasch, G., Oravec, S., Blessberger, H., Dostal, E., Hoke, M., Wojta, J., Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (</=40years of age) (2012) Eur J Clin Invest, 42, pp. 631-636; Gazi, I., Lourida, E.S., Filippatos, T., Tsimihodimos, V., Elisaf, M., Tselepis, A.D., Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma (2005) Clin Chem, 51, pp. 2264-2273; Sanchez-Quesada, J.L., Vinagre, I., De Juan-Franco, E., Vinagre, I., De Juan-Franco, E., Sánchez-Hernández, J., Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes (2013) Cardiovasc Diabetol, 12, p. 112; Christogiannis, L.G., Kostapanos, M.S., Tellis, C.C., Milionis, H.J., Tselepis, A.D., Elisaf, M.S., Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension (2013) J Hum Hypertens, 27, pp. 44-50; Banuls, C., Bellod, L., Jove, A., Martínez-Triguero, M.L., Víctor, V.M., Rocha, M.M., Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type (2012) Clin Chim Acta Int J Clin Chem, 413, pp. 251-257; Kolodgie, F.D., Burke, A.P., Skorija, K.S., Ladich, E., Kutys, R., Makuria, A.T., Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis (2006) Arterioscler Thromb Vasc Biol, 26, pp. 2523-2529; Khuseyinova, N., Imhof, A., Rothenbacher, D., Trischler, G., Kuelb, S., Scharnagl, H., Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis (2005) Atherosclerosis, 182, pp. 181-188; Lp, P.L.A.S.C., Thompson, A., Gao, P., Orfei, L., Watson, S., Di Angelantonio, E., Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies (2010) Lancet, 375, pp. 1536-1544; Constantinides, A., van Pelt, L.J., van Leeuwen, J.J., de Vries, R., Tio, R.A., van der Horst, I.C., Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes (2011) Eur J Clin Investig, 41, pp. 820-827; Dohi, T., Miyauchi, K., Ohkawa, R., Nakamura, K., Thuboi, S., Ogita, M., Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography (2012) Ann Clin Biochem, 49, pp. 527-533; Robins, S.J., Collins, D., Nelson, J.J., Bloomfield, H.E., Asztalos, B.F., Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial (2008) Arterioscler Thromb Vasc Biol, 28, pp. 1172-1178; Jabor, B., Choi, H., Ruel, I., Hafiane, A., Mourad, W., Genest, J., Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol (2013) Can J Cardiol, 29, pp. 1679-1686; Miklishanskaia, S.V., Vlasik, T.N., Kheimets, G.I., Kaznacheeva, E.I., Liakishev, A.A., Kukharchuk, V.V., Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease (2013) Kardiologiia, 53, pp. 4-11; Chae, J.S., Kim, O.Y., Paik, J.K., Kang, R., Seo, W.J., Jeong, T.S., Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome (2011) Atherosclerosis, 218, pp. 499-506; Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (2002) Circulation, 106, pp. 3143-3421; El Harchaoui, K., van der Steeg, W.A., Stroes, E.S., Kuivenhoven, J.A., Otvos, J.D., Wareham, N.J., Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study (2007) J Am Coll Cardiol, 49, pp. 547-553; Lepedda, A.J., Nieddu, G., Zinellu, E., De Muro, P., Piredda, F., Guarino, A., Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker (2013) Oxid Med Cell Longev, 2013, p. 385214; Barylski, M., Toth, P.P., Nikolic, D., Banach, M., Rizzo, M., Montalto, G., Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality (2014) Best Pract Res Clin Endocrinol Metab, 28, pp. 453-461; Kypreos, K.E., Gkizas, S., Rallidis, L.S., Karagiannides, I., HDL particle functionality as a primary pharmacological target for HDL-based therapies (2013) Biochem Pharmacol, 85, pp. 1575-1578; Tian, L., Long, S., Li, C., Liu, Y., Chen, Y., Zeng, Z., High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes (2012) Lipids Health Dis, 11, p. 54",Article,Scopus,2-s2.0-84928804760
"Stoekenbroek R.M., Rensing K.L., Bernelot Moens S.J., Nieuwdorp M., DeVries J.H., Zwinderman A.H., Stroes E.S., Currie C.J., Hutten B.A.","High daily insulin exposure in patients with type 2 diabetes isassociated with increased risk of cardiovascular events",2015,"Atherosclerosis","240","2",,"318","323",,1,10.1016/j.atherosclerosis.2015.03.040,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926512788&partnerID=40&md5=0df1a4afb74819a8e90db5d583f783a8","Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Academic Medical Centre, Department of Internal MedicineAmsterdam, Netherlands; Academic Medical Centre, Department of Clinical Epidemiology, Biostatistics and BioinformaticsAmsterdam, Netherlands; School of Medicine, Cardiff University, Department of MedicineCardiff, United Kingdom","Stoekenbroek, R.M., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Rensing, K.L., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Bernelot Moens, S.J., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Nieuwdorp, M., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; DeVries, J.H., Academic Medical Centre, Department of Internal MedicineAmsterdam, Netherlands; Zwinderman, A.H., Academic Medical Centre, Department of Clinical Epidemiology, Biostatistics and BioinformaticsAmsterdam, Netherlands; Stroes, E.S., Academic Medical Centre, Department of Vascular MedicineAmsterdam, Netherlands; Currie, C.J., School of Medicine, Cardiff University, Department of MedicineCardiff, United Kingdom; Hutten, B.A., Academic Medical Centre, Department of Clinical Epidemiology, Biostatistics and BioinformaticsAmsterdam, Netherlands","Aims: Intensive glucose control, often involving insulin treatment, failed to improve cardiovascular outcomes in several clinical trials. Observational studies reported an association between insulin use and cardiovascular disease (CVD) risk. It has therefore been suggested that insulin adversely affects CVD risk. To investigate the feasibility of this hypothesis, we studied the association between insulin dose and CVD risk in type 2 diabetes. Methods: A case-control study was conducted of new users of oral antidiabetics who were prescribed insulin, using the Dutch Pharmo database. Cases were hospitalized for a cardiovascular event (CVE) and matched 1:2 to patients who were not hospitalized for a CVE, by sex, age, duration of diabetes and type of oral antidiabetic. Patients were divided into tertiles according to mean daily insulin dose. Conditional logistic regression analyses were used to explore the association between insulin exposure and CVE risk. Results: We included 836 patients (517 (62%) male, mean age 66 years). After adjusting for available potential confounders, including HbA1c and triglycerides, insulin exposure was positively related to CVE risk (odds ratios for high (≥53.0 U/day) and intermediate (24.3-52.9 U/day) vs. low exposure (≤24.2 U/day): 3.00 [95% confidence interval (CI) 1.70 to 5.28] and 2.03 [95% CI 1.17 to 3.52]. Conclusion: Our findings are in line with the suggestion that high-dose insulin therapy adversely affects CVD risk, but need to be interpreted with caution due to the observational nature of the study. The role of particularly high-dose insulin in the progression of CVD warrants further investigation. © 2015 Elsevier Ireland Ltd.","Cardiovascular disease; Diabetes; Insulin therapy","Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction (1998) N.Engl. J. Med., 339, pp. 229-234; Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F.L., Powe, N.R., Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus (2004) Ann. Intern. Med., 141, pp. 421-431; Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C., Bigger, J.T., Buse, J.B., Effects of intensive glucose lowering in type 2 diabetes (2008) N.Engl. J. Med., 358, pp. 2545-2559; Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes (2008) N.Engl. J. Med., 358, pp. 2560-2572; Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., Glucose control and vascular complications in veterans with type 2 diabetes (2009) N.Engl. J. Med., 360, pp. 129-139; Gerstein, H.C., Bosch, J., Dagenais, G.R., Diaz, R., Jung, H., Maggioni, A.P., Basal insulin and cardiovascular and other outcomes in dysglycemia (2012) N.Engl. J. Med., 367, pp. 319-328; Riddle, M.C., Ambrosius, W.T., Brillon, D.J., Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial (2010) Diabetes Care, 33, pp. 983-990; Bonds, D.E., Miller, M.E., Bergenstal, R.M., The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study (2010) BMJ, 340. , b4909-b4909; Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes (2008) N.Engl. J. Med., 359, pp. 1577-1589; Hoebers, L.P., Claessen, B.E., Woudstra, P., DeVries, J.H., Wykrzykowska, J.J., Vis, M.M., Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus (2014) Eurointervention, 10, pp. 90-96; Anselmino, M., Ohrvik, J., Malmberg, K., Standl, E., Ryden, L., Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the euro heart survey on diabetes and the Heart (2008) Eur. Heart J., 29, pp. 177-184; Smooke, S., Horwich, T.B., Fonarow, G.C., Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (2005) Am. Heart J., 149, pp. 168-174; Margolis, D.J., Hoffstad, O., Strom, B.L., Association between serious ischemic cardiac outcomes and medications used to treat diabetes (2008) Pharmacoepidemiol. Drug Saf., 17, pp. 753-759; Colayco, D.C., Niu, F., McCombs, J.S., Cheetham, T.C., A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study (2011) Diabetes Care, 34, pp. 77-83; Gamble, J.M., Simpson, S.H., Eurich, D.T., Majumdar, S.R., Johnson, J.A., Insulin use and increased risk of mortality in type 2 diabetes: a cohort study (2010) Diabetes Obes. Metab., 12, pp. 47-53; Currie, C.J., Peters, J.R., Tynan, A., Evans, M., Heine, R.J., Bracco, O.L., Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study (2010) Lancet, 375, pp. 481-489; Rensing, K.L., Reuwer, A.Q., Arsenault, B.J., von der Thusen, J.H., Hoekstra, J.B., Kastelein, J.J., Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? (2011) Diabetes Obes. Metab., 13, pp. 1073-1087; Park, Y.M., Kashyap, R., Major, A., Silverstein, R.L., Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis (2012) Lab. Invest., 92, pp. 1171-1180; Muntoni, S., Muntoni, S., Draznin, B., Effects of chronic hyperinsulinemia in insulin-resistant patients (2008) Curr. Diabetes Rep., 8, pp. 233-238; Chaudhuri, A., Dandona, P., Fonseca, V., Cardiovascular benefits of exogenous insulin (2012) J.Clin. Endocrinol. Metab., 97, pp. 3079-3091; Paneni, F., Beckman, J.A., Creager, M.A., Cosentino, F., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I (2013) Eur. Heart J., 34, pp. 2436-2443; El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P.L., Roeder, R.G., Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia (2008) J.Exp. Med., 205, pp. 2409-2417; Eeg-Olofsson, K., Cederholm, J., Nilsson, P.M., New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR) (2010) J.Intern. Med., 268, pp. 471-482; Zoungas, S., Chalmers, J., Ninomiya, T., Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds (2012) Diabetologia, 55, pp. 636-643; Turnbull, F.M., Abraira, C., Anderson, R.J., Byington, R.P., Chalmers, J.P., Duckworth, W.C., Intensive glucose control and macrovascular outcomes in type 2 diabetes (2009) Diabetologia, 52, pp. 2288-2298; Kramer, C.K., Zinman, B., Retnakaran, R., Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis (2013) Lancet Diabetes Endocrinol., 1, pp. 28-34; Hemmingsen, B., Christensen, L.L., Wetterslev, J., Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses (2012) BMJ, 344; Goudswaard, A.N., Furlong, N.J., Valk, G.D., Stolk, R.P., Rutten, G.E.H.M., Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus (2004) Cochrane Database Syst. Rev., (4); Kooy, A., De Jager, J., Lehert, P., Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus (2009) Arch. Intern. Med., 169, pp. 616-625; Executive summary: standards of medical care in diabetes-2014 (2014) Diabetes Care, 37 (SUPPL.1), pp. S5-S13",Article,Scopus,2-s2.0-84926512788
"D'Ovidio F., d'Errico A., Scarinzi C., Costa G.","Increased incidence of coronary heart disease associated with ""double burden"" in a cohort of Italian women",2015,"Social Science and Medicine","135",,,"40","46",,,10.1016/j.socscimed.2015.04.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928750246&partnerID=40&md5=5b1cf516322a3c678f6b704414e111f1","Department of Neuroscience, University of Turin, Italy; Department of Epidemiology, ASL TO3Piedmont Region, Italy; Department of Environmental and Health, ARPA Piedmont, Italy; Department of Clinical and Biological Sciences, University of Turin, Italy","D'Ovidio, F., Department of Neuroscience, University of Turin, Italy; d'Errico, A., Department of Epidemiology, ASL TO3Piedmont Region, Italy; Scarinzi, C., Department of Environmental and Health, ARPA Piedmont, Italy; Costa, G., Department of Clinical and Biological Sciences, University of Turin, Italy","Objective of this study was to assess the risk of coronary heart disease (CHD) associated with the combination of employment status and child care among women of working age, also examining the sex of the offspring. Only two previous studies investigated the effect of double burden on CHD, observing an increased risk among employed women with high domestic burden or providing child care, although the relative risks were marginally or not significant.The study population was composed of all women 25-50 years old at 2001 census, living in Turin in families composed only by individuals or couples, with or without children (N=109,358). Subjects were followed up during 2002-2010 for CHD incidence and mortality through record-linkage of the cohort with the local archives of mortality and hospital admissions. CHD risk was estimated by multivariate Poisson regression models.Among employed women, CHD risk increased significantly by 29% for each child in the household (IRR=1.29) and by 39% for each son (IRR=1.39), whereas no association with the presence of children was found among non-employed women or among employed women with daughters. When categorized, the presence of two or more sons significantly increased CHD risk among employed women (IRR=2.23), compared to those without children.The study found a significant increase in CHD risk associated with the presence of two or more sons in the household, but not daughters, among employed women. This is a new finding, which should be confirmed in other studies, conducted also in countries where the division of domestic duties between males and females is more balanced, such as the European Nordic countries. © 2015 Elsevier Ltd.","Children; Coronary heart disease; Double burden; Employment; Epidemiology; Women","Anxo, D., Mencarini, L., Paihlé, A., Solaz, A., Tanturri, M.L., Flood, L., Gender differences in time-use over the life-course. A comparative analysis of France, Italy, Sweden and the United States (2011) Femminist Econ., 17, pp. 59-195; Brisson, C., Laflamme, N., Moisan, J., Milot, A., Mâsse, B., Vézina, M., Effect of family responsibility and job strain on ambulatory blood pressure among white-collar women (1999) Psychosom. Med., 61, pp. 205-213; Catov, J.M., Newman, A.B., Sutton-Tyrrell, K., Harris, T.B., Tylavsky, F., Visser, M., Ayonayon, H.N., Ness, R.B., Parity and cardiovascular disease risk among older women: how do pregnancy complications mediate the association? (2008) Ann. Epidemiol., 18, pp. 873-879; Cavallo, F., Giacchi, M., Vieno, A., Galeone, D., Tomba, A., Lamberti, A., Nardone, P., Andreozzi, S., (2013) Studio HBSC-italia (Health Behaviour in School-aged Children), , rapporto sui dati 2010, Rapporti ISTISAN 13/5, Roma; Cesarini, D., Lindqvist, E., Wallace, B., Maternal longevity and the sex of offspring in pre-industrial Sweden (2007) Ann. Hum. Biol., 34, pp. 535-546; De Kleijn, M.J.J., Van der Schouw, Y.T., Van der Graaf, Y., Reproductive history and cardiovascular disease risk in postmenopausal women. A review of the literature (1999) Maturitas, 33, pp. 7-36; Eller, N.H., Kristiansen, J., Hansen, A.M., Long-term effects of psychosocial factors of home and work on biomarkers of stress (2011) Int. J. Psychophysiol., 79, pp. 195-202; Francavilla, F., Gianelli, G.C., Mangiavacchi, L., Piccoli, L., Unpaid family work in Europe: gender and country differences (2013) Gender and the European Labor Market, pp. 53-72. , Routledge, Abingdon, F. Bettio, J. Plantenga, M. Smith (Eds.); Gershuny, J., (2000) Changing Times: Work and Leisure in Post-industrial Society, , Oxford University Press, Oxford; Gove, W.R., Gender differences in mental and physical illness: the effects of fixed roles and nurturant roles (1984) Soc. Sci. Med., 19, pp. 77-91; Grzywacz, J.G., Marks, N.F., Reconceptualizing the work-family interface: an ecological perspective on the correlates of positive and negative spillover between work and family (2000) J.Occup. Health Psychol., 5, pp. 111-126; Hardy, R., Lawlor, D.A., Black, S., Wadsworth, M.E.J., Kuh, D., Number of children and coronary heart disease risk factors in men and women from a British birth cohort (2007) Int. J. Gynecol. Obstet., 114, pp. 721-730; Haynes, S.G., Feinleib, M., Women, work and coronary heart disease: prospective findings from the Framingham heart study (1980) Am. J. Public Health, 70, pp. 133-141; Helle, S., Lummaa, V., Jokela, J., Sons reduced maternal longevity in preindustrial humans (2002) Science, 296, p. 1085; Hindmarsh, P.C., Geary, M.P., Rodeck, C.H., Kingdom, J.C.P., Cole, T.J., Intrauterine growth and its relationship to shape at birth (2002) Pediatr. Res., 52, pp. 263-268; Hurt, L.S., Ronsmans, C., Quigley, M., Does the number of sons born affect long-term mortality of parents? A cohort study in rural Bangladesh (2006) Proc. R. Soc. B: Biol. Sci., 273, pp. 149-155; (2013) Occupati e disoccupati. Dati ricostruiti dal 1977, , Statistiche Report, Roma; (2013) Rapporto Bes 2013. Il benessere equo e sostenibile in Italia, , CSR, Roma; Jasienska, G., Nenko, I., Jasienski, M., Daughters increase longevity of fathers, but daughters and sons equally reduce longevity of mothers (2006) Am. J. Hum. Biol., 18, pp. 422-425; Jaumotte, F., (2003) Female Labour Force Participation: Past Trends and Main Determinants in OECD Countries, p. 67. , OECD Economics Department Working Papers. N. 376; Karasek, R.A., Job demands, job decision latitude, and mental strain: implications for job redesign (1979) Adm. Sci. Q., 24, pp. 285-308; Kivimäki, M., Nyberg, S.T., Batty, G.D., Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data (2012) Lancet, 27, pp. 1491-1497; Krantz, G., Ostergren, P., Double exposure. The combined impact of domestic responsibilities and job strain on common symptoms in employed Swedish women (2001) Eur. J. Public Health, 11, pp. 413-419; Krantz, G., Berntsson, L., Lundberg, U., Total workload, work stress and perceived symptoms in Swedish male and female white-collar employees (2005) Eur. J. Public Health, 15, pp. 209-214; Lahelma, E., Arber, S., Kivelä, K., Roos, E., Multiple roles and health among British and Finnish women: the influence of socioeconomic circumstances (2002) Soc. Sci. Med., 54 (5), pp. 727-740; Lawlor, D.A., Emberson, J.R., Ebrahim, S., Whincup, P.H., Goya Wannamethee, S., Walker, M., Smith, G.D., Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? (2003) Circulation, 11, pp. 1260-1264; Lee, S., Colditz, G., Berkman, L., Kawachi, I., Caregiving to children and grandchildren and risk of coronary heart disease in women (2003) Am. J. Public Health, 93, pp. 1939-1944; Maršál, K., Persson, P.H., Larsen, T., Lilja, H., Selbing, A., Sultan, B., Intrauterine growth curves based on ultrasonically estimated foetal weights (1996) Acta Paediatr., 85, pp. 843-848; McLanahan, S., Adams, J., Parenthood and psychological well-being (1987) Annu. Rev. Sociol., 13, pp. 237-257; Mencarini, L., Soddisfazione e uso del tempo nelle coppie italiane (2012) Uso del tempo e ruoli di genere. Tra lavoro e famiglia nel ciclo di vita, pp. 41-64. , Istat, Roma, 2012, M.C. Romano, L. Mencarini, M.L. Tanturri (Eds.); Moen, P., Dempster-McClain, D., Williams, R.M., Successful Aging: a life-course perspective on women's multiple roles and health (1992) Am. J. Sociol., 97, pp. 1612-1638; Ness, R.B., Schotland, H.M., Flegal, K.M., Shofer, F.S., Reproductive history and coronary heart disease risk in women (1994) Epidemiol. Rev., 16 (2), pp. 298-314; Netterstrøm, B., Kristensenb, T.S., Sjølc, A., Psychological job demands increase the risk of ischaemic heart disease: a 14-year cohort study of employed Danish men (2006) Eur. J. Cardiovasc. Prev. Rehabil., 13, pp. 414-420; How's Life? 2013. Measuring Well-being (2013) Gender Differences in Well-Being: Can Women and Men Have It All?, pp. 103-141. , (chapter 4), OECD Publishing; Parikh, N.I., Cnattingius, S., Dickman, P.W., Mittleman, M.A., Ludvigsson, J.F., Ingelsson, E., Parity and risk of later-life maternal cardiovascular disease (2010) Am. Heart J., 159 (2), pp. 215-221; Romano, M.C., Generazioni a confronto: un approccio triangolare allo studio del lavoro familiare (2012) Uso del tempo e ruoli di genere. Tra lavoro e famiglia nel ciclo di vita, pp. 65-94. , Istat, Roma, M.C. Romano, L. Mencarini, M.L. Tanturri (Eds.); Rosengren, A., Thelle, D.S., Köster, M., Rosén, M., .Changing sex ratio in acute coronary heart disease: data from Swedish national registers 1984-99 (2003) J.Intern. Med., 253, pp. 301-310; Ross, C.E., Mirowsky, J., Goldsteen, K., The impact of the family on health: the decade in review (1990) J.Marriage Fam., 52, pp. 1059-1078; Sieber, S.D., Toward a theory of role accumulation (1974) Am. Sociol. Rev., 39, pp. 357-378; Siegrist, J., Adverse health effects of high-effort/low-reward conditions (1996) J.Occup. Health Psychol., 1, pp. 27-41; Siegrist, J., Effort-reward imbalance at work and cardiovascular diseases (2010) Int. J. Occup. Environ. Health, 23, pp. 279-285; Silventoinen, K., Pankow, J., Jousilahti, P., Hu, G., Tuomilehto, J., Educational inequalities in the metabolic syndrome and coronary heart disease among middle-aged men and women (2005) Int. J. Epidemiol., 34, pp. 327-334; Tamimi, R.M., Lagiou, P., Mucci, L.A., Hsieh, C.C., Adami, H.O., Trichopoulos, D., Average energy intake among pregnant women carrying a boy compared with a girl (2003) Br. Med. J., 7 (326), p. 1245; Thoits, P.A., Multiple identities and psychological well Being: a reformulation and test of the social isolation hypothesis (1983) Am. Sociol. Rev., 48, pp. 174-187; Väänänen, A., Kevin, M.V., Ala-Mursula, L., Pentti, J., Kivimäki, M., Vahtera, J., The double burden of and negative spillover between paid and domestic work: associations with health among men and women (2004) Women Health, 40, pp. 1-17; Van de Putte, B., Matthijs, K., Vlietinck, R., Asocial component in the negative effect of sons on maternal longevity in pre-industrial humans (2004) J.Biosoc. Sci., 36, pp. 289-297; Waldron, I., Jacobs, J.A., Effects of multiple roles on women's health-evidence from a national longitudinal study (1989) Women Health, 15, pp. 3-19; Waldron, I., Weiss, C.C., Hughes, M.E., Interacting effects of multiple roles on women's health (1998) J.Health Soc. Behav., 39, pp. 216-236; Zimmerman, M.K., Hartley, W.S., High blood pressure among employed women: a multi-factor discriminant analysis (1982) J.Health Soc. Behav., 23, pp. 205-220",Article,Scopus,2-s2.0-84928750246
"Wang X., Cao C., Huan H., Zhang L., Mu X., Gao Q., Dong X., Gao S., Liu X.","Isolation, identification, and pathogenicity of O142 avian pathogenic Escherichia coli causing black proventriculus and septicemia in broiler breeders",2015,"Infection, Genetics and Evolution","32",,,"23","29",,,10.1016/j.meegid.2015.02.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924132863&partnerID=40&md5=3cf31faf1b9bfc331445f14076f56a05","Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China; Huaiyin Normal University School of Life Science, China","Wang, X., Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China; Cao, C., Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China; Huan, H., Huaiyin Normal University School of Life Science, China; Zhang, L., Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China; Mu, X., Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China; Gao, Q., Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China; Dong, X., Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China; Gao, S., Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China; Liu, X., Jiangsu Co-Innovation Center for the Prevention, Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou/College of Veterinary Medicine, Yangzhou University, China","Avian colibacillosis, characterized by black proventriculus and caused by avian pathogenic Escherichia coli (APEC) with an uncommon O142 serogroup, was diagnosed in young broiler breeders. Colonization and persistence assays performed in 7-day-old broilers showed that the bacterial load of the APEC 4d/9-1 O142 proventricular isolate in the lung was about 10-fold higher than that of the APEC 4d/9-1 O142 heart blood isolate (P&lt;0.01), and about 100-fold higher in the heart blood, livers, spleens, kidneys, and proventriculi of inoculated broilers (P&lt;0.001). When 32 common virulence genes of APEC were tested, the two isolates had nearly identical profiles, except that only the APEC 4d/9-1 O142 proventricular isolate carried the feoB gene. Furthermore, 100% mortality was observed in both 1-day-old Arbor Acres (AA) broilers and 1-day-old specific-pathogen-free (SPF) chickens inoculated with 106 colony-forming units of the APEC 4d/9-1 O142 proventricular isolate. However, black proventriculus was only observed in the dead AA broilers, consistent with the clinical occurrence of the disease. This implies that the black proventriculi seen in the dead birds, caused by the APEC 4d/9-1 O142 proventricular isolate, was breed-specific. Both the APEC 4d/9-1 O142 proventricular and heart blood isolates belong to phylogroup B2. However, the former was assigned to ST131 and the latter to ST2704 with multilocus sequence typing, demonstrating the genetic heterogeneity of these two bacterial isolates, although they were derived from the same dead broiler. These results suggest that the O142 APEC isolate was the main pathogenic agent for black proventriculi in 7-day-old broiler breeders. © 2015 Elsevier B.V.","Avian pathogenic escherichia coli; Black proventriculus; Heart blood isolate; Proventricular isolate; Virulence","Andrews, S.C., Robinson, A.K., Rodriguez-Quinones, F., Bacterial iron homeostasis (2003) FEMS Microbiol. Rev., 27, pp. 215-237; Ask, B., van der Waaij, E.H., Stegeman, J.A., van Arendonk, J.A.M., Genetic variation among broiler genotypes in susceptibility to colibacillosis (2006) Poult. Sci., 85, pp. 415-421; Barnes, H.J., Nolan, L.K., Vaillancourt, J.F., (2008) Colibacillosis. In Diseases of Poultry, , Blackwell Publishing, Ames; Bockemühl, J., Fricke, G., Seeliger, H.P., Enteritis due to Escherichia coli O142:K86:H34 in a ward of premature infants. With a discussion on the problem of pathogenicity of ""enteropathogenic serogroups of E. coli"" (author's transl). Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale (1979) Reihe A Med. Mikrobiol Parasitol., 243, pp. 197-206; Doyle, M.P., Erickson, M.C., Reducing the carriage of foodborne pathogens in livestock and poultry (2006) Poult. Sci., 85, pp. 960-973; Engvall, A., May organically farmed animals pose a risk for Campylobacter infections in humans? (2001) Acta. Vet. Scand., 95, pp. 85-87; Ewers, C., Li, G., Wilking, H., Kiessling, S., Alt, K., Antao, E.M., Laturnus, C., Wieler, L.H., Avian pathogenic, uropathogenic, and newborn meningitis-causing Escherichia coli: how closely related are they? (2007) Int. J. Med. Microbiol., 297, pp. 163-176; Gao, Q., Xu, H., Wang, X., Zhang, D., Ye, Z., Gao, S., Liu, X., RfaH promotes the ability of the avian pathogenic Escherichia coli O2 strain E058 to cause avian colibacillosis (2013) J. Bacteriol., 195, pp. 2474-2480; Gao, S., Liu, X., Zhang, R., Jiao, X., Wen, Q., Wu, C.X., The isolation and identification of pathogenic Escherichia coli isolates of chicken origin from some regions in China (1999) Acta Vet. Zootechnica Sin., 30, pp. 164-171; Hantke, K., Is the bacterial ferrous iron transporter FeoB a living fossil? (2003) Trends Microbiol., 11, pp. 192-195; Johnson, J.R., Johnston, B., Clabots, C., Kuskowski, M.A., Castanheira, M., Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States (2010) Clin. Infect. Dis., 51, pp. 286-294; Johnson, J.R., Stell, A.L., Scheutz, F., O'Bryan, T.T., Russo, T.A., Carlino, U.B., Fasching, C., Gaastra, W., Analysis of the F antigen-specific papA alleles of extraintestinal pathogenic Escherichia coli using a novel multiplex PCR-based assay (2000) Infect. Immun., 68, pp. 1587-1599; Kammler, M., Schon, C., Hantke, K., Characterization of the ferrous iron uptake system of Escherichia coli (1993) J. Bacteriol., 175, pp. 6212-6219; Kohler, C.D., Dobrindt, U., What defines extraintestinal pathogenic Escherichia coli? (2011) Int. J. Med. Microbiol., 301, pp. 642-647; Li, G., Ewers, C., Laturnus, C., Diehl, I., Alt, K., Dai, J., Antao, E.M., Wieler, L.H., Characterization of a yjjQ mutant of avian pathogenic Escherichia coli (APEC) (2008) Microbiology, 154, pp. 1082-1093; Mu, X., Huan, H., Xu, H., Gao, Q., Xiong, L., Gao, R., Gao, S., Liu, X., The transfer-messenger RNA-small protein B system plays a role in avian pathogenic Escherichia coli pathogenicity (2013) J. Bacteriol., 195, pp. 5064-5071; Nakamura, K., Maeda, M., Imada, Y., Imada, T., Sato, K., Pathology of spontaneous colibacillosis in a broiler flock (1985) Vet. Pathol., 22, pp. 592-597; Rodriguez-Siek, K.E., Giddings, C.W., Doetkott, C., Johnson, T.J., Nolan, L.K., Characterizing the APEC pathotype (2005) Vet. Res., 36, pp. 241-256; Rosario, C.C., Lopez, A.C., Tellez, I.G., Navarro, O.A., Anderson, R.C., Eslava, C.C., Serotyping and virulence genes detection in Escherichia coli isolated from fertile and infertile eggs, dead-in-shell embryos, and chickens with yolk sac infection (2004) Avian Dis., 48, pp. 791-802; Sabri, M., Caza, M., Proulx, J., Lymberopoulos, M.H., Bree, A., Moulin-Schouleur, M., Curtiss, R., Dozois, C.M., Contribution of the SitABCD, MntH, and FeoB metal transporters to the virulence of avian pathogenic Escherichia coli O78 strain chi 7122 (2008) Infect. Immun., 76, pp. 601-611; Wirth, T., Falush, D., Lan, R., Colles, F., Mensa, P., Wieler, L.H., Karch, H., Achtman, M., Sex and virulence in Escherichia coli: an evolutionary perspective (2006) Mol. Microbiol., 60, pp. 1136-1151; Zhao, S.H., Maurer, J.J., Hubert, S., De Villena, J.F., McDermott, P.F., Meng, J.H., Ayers, S., White, D.G., Antimicrobial susceptibility and molecular characterization of avian pathogenic Escherichia coli isolates (2005) Vet. Microbiol., 107, pp. 215-224",Article,Scopus,2-s2.0-84924132863
"Raggi P.","Left ventricular size as a predictor of vascular events",2015,"Atherosclerosis","240","2",,"398","399",,,10.1016/j.atherosclerosis.2015.04.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927722528&partnerID=40&md5=9342567d42e26ccf58e6de6e16292f80","Mazankowski Alberta Heart Institute, Division of Cardiology and Department of Medicine, University of Alberta, 8440-112 Street,Suite 4A7.050Edmonton, AB, Canada","Raggi, P., Mazankowski Alberta Heart Institute, Division of Cardiology and Department of Medicine, University of Alberta, 8440-112 Street,Suite 4A7.050Edmonton, AB, Canada",[No abstract available],"Coronary artery calcium; Coronary artery disease; Hypertrophy; Left ventricular size; Stroke","Dykun, I., Geisel, M.H., Kalsch, H., Association of computed tomography-derived left ventricular size with major cardiovascular events in the general population: the Heinz Nixdorf Recall Study (2015) Atherosclerosis, 240 (1), pp. 46-52; Levy, D., Garrison, R.J., Savage, D.D., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study (1990) N.Engl. J. Med., 322, pp. 1561-1566; Bluemke, D.A., Kronmal, R.A., Lima, J.A.C., The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA Study (2008) J.Am. Coll. Cardiol., 52, pp. 2148-2155; Levy, D., Garrison, R.J., Savage, D.D., Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study (1989) Ann. Intern. Med., 110, pp. 101-107; Dykun, I., Mahabadi, A.A., Lehmann, N., Left ventricle size quantification using non-contrast enhanced cardiac computed tomography - association with cardiovascular risk factors and coronary artery calcium score in the general population: the Heinz Nixdorf Recall study (2014) Acta Radiol., , pii: 0284185114542996. (Epub ahead of print) J 17; Poulikakos, D., Ross, L., Recio-Mayoral, A., Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease (2014) Eur. Heart J. Cardiovasc. Imaging, 15 (1), pp. 56-61; Dervisoglu, E., Kozdag, G., Etiler, N., Kalender, B., Association of glomerular filtration rate and inflammation with left ventricular hypertrophy in chronic kidney disease patients (2012) Hippokratia, 16 (2), pp. 137-142; McMaster, W., Kirabo, A., Madhur, M.S., Harrison, D.G., Inflammation, immunity and hypertensive end-organ damage (2015) Circ. Res., 116, pp. 1022-1033; Andersen, L.B., Przybyl, L., Haase, N., Vitamin D depletion aggravates hypertension and target-organ damage (2015) J.Am. Heart Assoc., 4 (2). , pii: e001417 J 28; Kestenbaum, B., Katz, R., de Boer, I., Vitamin D, parathyroid hormone, and cardiovascular events among older adults (2011) J.Am. Coll. Cardiol., (14), pp. 1433-1441; Deo, R., Katz, R., Shlipak, M.G., Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study (2011) Hypertension, 58 (6), pp. 1021-1028; Choi, T., Ahmadi, N., Sourayanezhad, S., Relation of vascular stiffness with epicardial and pericardial adipose tissues, and coronary atherosclerosis (2013) Atherosclerosis, 229 (1), pp. 118-123; Nasir, K., Katz, R., Mao, S., Comparison of left ventricular size by computed tomography with magnetic resonance imaging measures of left ventricle mass and volumes: the multi-ethnic study of atherosclerosis (2008) J.Cardiovasc. Comput. Tomogr., 2, pp. 141-148; Alexopoulos, N., Katritsis, D., Raggi, P., Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis (2014) Atherosclerosis, 233, pp. 104-112; Ding, J., Hsu, F.C., Harris, T.B., The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA) (2009) Am. J. Clin. Nutr., 90, pp. 499-504; Mahabadi, A.A., Berg, M.H., Lehmann, N., Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study (2013) J.Am. Coll. Cardiol., 61, pp. 1388-1395",Note,Scopus,2-s2.0-84927722528
"McDonald K., Ledwidge M., Gallagher J., Watson C.","Biomarker testing and pre-emptive therapy in preventing heart failure",2015,"Current Cardiovascular Risk Reports","9","6",,"","",6,,10.1007/s12170-015-0456-3,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928317765&partnerID=40&md5=76d3c8cf22db1debf2e1b51a38ac1bf2","St Vincent’s University Hospital, Elm ParkDublin 4, Ireland; University College DublinDublin, Ireland","McDonald, K., St Vincent’s University Hospital, Elm ParkDublin 4, Ireland, University College DublinDublin, Ireland; Ledwidge, M., St Vincent’s University Hospital, Elm ParkDublin 4, Ireland; Gallagher, J., St Vincent’s University Hospital, Elm ParkDublin 4, Ireland; Watson, C., St Vincent’s University Hospital, Elm ParkDublin 4, Ireland, University College DublinDublin, Ireland","In an attempt to reduce the heart failure epidemic, screening and prevention will become an increasing focus of management in the wider at-risk population. Refining risk prediction through the use of biomarkers in isolation or in combination is emerging as a critical step in this process. The utility of biomarkers to identify disease manifestations before the onset of symptoms and detrimental myocardial damage is proving to be valuable. In addition, biomarkers that predict the likelihood and rate of disease progression over time will help streamline and focus clinical efforts and therapeutic strategies. Importantly, several recent early intervention studies using biomarker strategies are promising and indicate that not only can new-onset heart failure be reduced but also the development of other cardiovascular conditions. © 2015, Springer Science+Business Media New York.","Biomarkers; Cardiovascular disease prediction and prevention; Heart failure","Van Heerebeek, L., Borbély, A., Niessen, H.W., Myocardial structure and function differ in systolic and diastolic heart failure (2006) Circulation, 113, pp. 1966-1973. , PID: 16618817; Westermann, D., Lindner, D., Kasner, M., Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction (2011) Circ Heart Fail, 4, pp. 44-52. , PID: 21075869; Wang, T.J., Larson, M.G., Levy, D.E., Plasma natriuretic peptide levels and the risk of cardiovascular events and death (2004) N Engl J Med, 350, pp. 655-663. , COI: 1:CAS:528:DC%2BD2cXhtFCrtrg%3D, PID: 14960742; Vellaichamy, E., Kaur, K., Pandey, K., Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A (2007) Peptides, 28 (4), pp. 893-899. , COI: 1:CAS:528:DC%2BD2sXislGqt70%3D, PID: 17267074; Phelan D, Watson CJ, Martos R, et al. Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One. 2012;7(11)Murtagh, G., Dawkins, I.R., O’Connell, R., Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction (2012) Eur J Heart Fail, 14, pp. 480-486. , COI: 1:CAS:528:DC%2BC38XmsFaru74%3D, PID: 22416086; McGrady, M., Reid, C.M., Shiel, L., NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction; results of the SCReening Evaluation of the Evolution of New Heart Failure study(SCREEN-HF) (2013) Int J Cardiol, 169, pp. 133-138. , PID: 24080362; Nadir, M.A., Gandy, S., Ireland, S., An increased B-type natriuretic peptide in the absence of a cardiac abnormality identifies those in whose left ventricular mass will increase over time (2015) JACC Heart Fail, 3 (1), pp. 87-93. , PID: 25454393; Seliger S, de Lemos J, Neeland I, et al. Older adults, “malignant” left ventricular hypertrophy and associated cardiac specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure—JACC Heart Failure 2015 (in press)Wang, T.J., Wollert, K.C., Larson, M.G., Prognostic utility of novel biomarkers of cardiovascular stress (2012) Framingham Heart Study Circ, 126, pp. 1596-1604. , COI: 1:CAS:528:DC%2BC38XhsVWmsLbN, This important paper highlights that the value of measuring cardiovascular stress biomarkers in adding prognostic value to standard risk factors for predicting death, overall cardiovascular events, and heart failure; Saunders, J.T., Nambi, V., de Lemos, J.A., Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study (2011) Circulation, 123, pp. 1367-1376. , COI: 1:CAS:528:DC%2BC3MXkt1Ghsrs%3D, PID: 21422391; Nadir, M.A., Rekhraj, S., Wei, L., Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease (2012) J Am Coll Cardiol, 60, pp. 960-968. , PID: 22921971; de Lemos, J.A., Drazner, M.H., Omland, T., Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population (2010) JAMA, 304, pp. 2503-2512. , PID: 21139111; de Filippi, C.R., de Lemos, J.A., Christenson, R.H., Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults (2010) JAMA, 304, pp. 2494-2502; Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction (2002) Circulation, 106, pp. 2961-2966. , COI: 1:CAS:528:DC%2BD38XovVeltrY%3D, PID: 12460879; Sanada, S., Hakuno, D., Higgins, L.J., IL-33 and ST2 comprise acritical biomechanically induced and cardioprotective signaling system (2007) J Clin Invest, 117, pp. 1538-1549. , COI: 1:CAS:528:DC%2BD2sXmsVWkur4%3D, PID: 17492053; Hughes, M.F., Appelbaum, S., Havulinna, A.S., ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality (2014) Heart, 100, pp. 1715-1721. , PID: 25080471; Chen, L.Q., de Lemos, J.A., Das, S.R., Ayers, C.R., Rohatgi, A., Soluble ST2 is associated with all cause and cardiovascular mortality in a population based cohort (2013) Dallas Heart Study Clin Chem, 59, pp. 536-546. , COI: 1:CAS:528:DC%2BC3sXjvFOgsr4%3D; Lok, D.J., Van Der Meer, P., de la Porte, P.W., Prognostic value of galectin-3, a novel marker of fibrosis in patients with chronic heart failure (2010) Clin Res Cardiol, 99, pp. 323-328. , COI: 1:CAS:528:DC%2BC3cXlt1Wqs74%3D, PID: 20130888; Ho, J.E., Liu, C., Lyass, A., Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community (2012) J Am Coll Cardiol, 60, pp. 1249-1256. , COI: 1:CAS:528:DC%2BC38XhsVCjsb3O, PID: 22939561; Browers, F.P., van Gilst, W.H., Dammen, K., Clinical risk stratification optimises value of biomarkers to predict new-onset heart failure in a community based cohort (2014) Circ Heart Fail, 7, pp. 723-731. , This is an important paper highlighting a multi-marker approach to risk stratify patients in the prediction of new onset heart failure; Neeland, I.J., Drazner, M.H., Berry, J.D., Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population (2013) J Am Coll Cardiol, 61 (2), pp. 187-195. , COI: 1:CAS:528:DC%2BC38XhvFWhu7zI, PID: 23219305; Neuhold, S., Resl, M., Huelsmann, M., Repeat measurements of glycated haemoglobin A and N-terminal pro-B-type natriurietic peptide: divergent behaviour in diabetes mellitus (2011) Eur J Clin Investig, 41 (12), pp. 1292-1298. , COI: 1:CAS:528:DC%2BC38Xos1eisA%3D%3D; Wang, T.J., Gona, P., Larson, M.G., Multiple biomarkers for the prediction of first major cardiovascular events and death (2006) N Engl J Med, 355, pp. 2631-2639. , COI: 1:CAS:528:DC%2BD28XhtlGhtLvJ, PID: 17182988; McMurray, J.J., CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin angiotensin aldosterone system the cornerstone of therapy for systolic heart failure (2011) Eur J Heart Fail, 13, pp. 929-936. , COI: 1:CAS:528:DC%2BC3MXhtVyhu73I, PID: 21816763; Minguet, L., Sutton, G., Ferrero, C., Gomez, T., Bramlage P.LCZ 696: a new paradigm for the treatment of heart failure? (2015) Expert Opin Pharmacother, 16, pp. 435-446. , COI: 1:CAS:528:DC%2BC2MXhsF2msbY%3D, PID: 25597387; Ledwidge, M., Gallagher, J., Conlon, C., Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial (2013) JAMA, 310 (1), pp. 66-74. , COI: 1:CAS:528:DC%2BC3sXht1ajtrzI, PID: 23821090, This study provides the first evidence that natriuretic peptide screening and collaborative of patients at risk of heart failure can reduce the combined rates of left ventricular systolic dysfunction, diastolic dysfunction, and heart failure; Huelsmann, M., Neuhold, S., Resl, M., PONTIAC (NT-proBNP selected PreventiOn of cardiac eveNts in a population of diabetic patients without a history of Cardiac disease): a prospective randomized controlled trial (2013) J Am Coll Cardiol, 62, pp. 1365-1372. , PID: 23810874; Madamanchi, C., Alhosaini, H., Sumida, A., Runge, M.S., Obesity and natriuretic peptides, BNP and NT-proBNP: mechanism and diagnostic implications for heart failure (2014) Int J Cardiol, 17, pp. 611-617; Davis, M.E., Richards, M., Nicholls, G., Yandle, T.G., Frampton, C.M., Troughton, R.W., (2006) Introduction of metoprolol increases plasma B-type natriuretic peptides in mild stable heart failure, 113, pp. 977-985",Review,Scopus,2-s2.0-84928317765
"Weitkunat R., Lee P.N., Baker G., Sponsiello-Wang Z., Gonzalez-Zuloeta Ladd A.M., Ludicke F.","A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product",2015,"Regulatory Toxicology and Pharmacology","72","1",,"87","93",,,10.1016/j.yrtph.2015.03.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926143038&partnerID=40&md5=f3bbb6aa319090bed2b6a0c720dd485e","Philip Morris International Research and Development, Quai Jeanrenaud 5Neuchâtel, Switzerland; P N Lee Statistics and Computing Ltd, 17 Cedar RoadSutton, Surrey, United Kingdom","Weitkunat, R., Philip Morris International Research and Development, Quai Jeanrenaud 5Neuchâtel, Switzerland; Lee, P.N., P N Lee Statistics and Computing Ltd, 17 Cedar RoadSutton, Surrey, United Kingdom; Baker, G., Philip Morris International Research and Development, Quai Jeanrenaud 5Neuchâtel, Switzerland; Sponsiello-Wang, Z., Philip Morris International Research and Development, Quai Jeanrenaud 5Neuchâtel, Switzerland; González-Zuloeta Ladd, A.M., Philip Morris International Research and Development, Quai Jeanrenaud 5Neuchâtel, Switzerland; Lüdicke, F., Philip Morris International Research and Development, Quai Jeanrenaud 5Neuchâtel, Switzerland","Based on the Food and Drug Administration's Modified Risk Tobacco Product (MRTP) Application draft guideline, Philip Morris International (PMI) has developed a Population Health Impact Model to estimate the reduction in the number of deaths over a period following the introduction of an MRTP. Such a model is necessary to assess the effect that its introduction would have on population health, given the lack of epidemiological data available prior to marketing authorization on any risks from MRTPs. The model is based on publicly available data on smoking prevalence and on the relationships between smoking-related disease-specific mortality and various aspects of the smoking of conventional cigarettes (CCs), together with an estimate of exposure from the MRTP relative to that from CCs, and allows the exploration of possible scenarios regarding the effect of MRTP introduction on the prevalence of CC and MRTP use, individually and in combination. By comparing mortality attributable in a scenario where the MRTP is introduced with one where it is not, the model can estimate the mortality attributable to CCs and the MRTP, as well as the reduction in the deaths attributable to the introduction of the MRTP. © 2015 The Authors.","Attributable risk; Harm reduction; Modeling; Modified Risk Tobacco Product; Smoking","Ezzati, M., Lopez, A.D., Estimates of global mortality attributable to smoking in 2000 (2003) Lancet, 362, pp. 847-852; (2012) Modified Risk Tobacco Product Applications (Draft Guidance), , http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297751.pdf, FDA Center for Tobacco Products, Silver Spring, <; Forey, B., Lee, P., Estimation of sex-specific smoking statistics by standardized age groups and time periods (2002) Supplement 1 to International Smoking Statistics, A Collection of Historical Data From 30 Economically Developed Countries, , http://www.pnlee.co.uk/Reports.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, (second ed.) <; Forey, B., Hamling, J., Lee, P., Wald, N., (2002) International Smoking Statistics. A Collection of Historical Data From 30 Economically Developed Countries, , http://www.pnlee.co.uk/ISS2.htm, Wolfson Institute of Preventive Medicine and Oxford University Press, London and Oxford, <; Forey, B., Hamling, J., Hamling, J., Thornton, A., Lee, P., (2006) International Smoking Statistics. A Collection of Worldwide Historical Data, , www.pnlee.co.uk/iss.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, <>; Forey, B., Hamling, J., Hamling, J., Lee, P., Estimation of sex-specific smoking statistics by standardized age groups and time periods (2007) Supplement 1 to International Smoking Statistics, A Collection of Historical Data From 30 Economically Developed Countries, , www.pnlee.co.uk/iss.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, (web edition); Forey, B.A., Thornton, A.J., Lee, P.N., Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema (2011) BMC Pulm. Med., 11, p. 36; Fry, J.S., Lee, P.N., Forey, B.A., Coombs, K.J., Dose-response relationship of lung cancer to amount smoked, duration and age starting (2013) World J. Meta-Anal., 1, pp. 57-77; Fry, J.S., Lee, P.N., Forey, B.A., Coombs, K.J., How rapidly does the excess risk of lung cancer decline following quitting smoking? a quantitative review using the negative exponential model (2013) Regul. Toxicol. Pharmacol., 67, pp. 13-26; Lee, P.N., (1995) Studying the Relationship of Smoking to Lung Cancer Using the Multistage Model of Carcinogenesis. A review, , www.pnlee.co.uk/Reports.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, <; Lee, P.N., Forey, B.A., Fry, J.S., Hamling, J.S., Hamling, J.F., Sanders, E.B., Carchman, R.A., Does use of flue-cured rather than blended cigarettes affect international variation in mortality from lung cancer and COPD (2009) Inhalation Toxicol., 21, pp. 404-430. , www.pnlee.co.uk/Reports.htm, Supplementary material available at <; Lee, P.N., Forey, B.A., Coombs, K.J., Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer (2012) BMC Cancer, 12, p. 385; Lee, P.N., Fry, J.S., Hamling, J.S., Using the negative exponential distribution to quantitatively review the evidence on how rapidly the excess risk of ischaemic heart disease declines following quitting smoking (2012) Regul. Toxicol. Pharmacol., 64, pp. 51-67; Lee, P., Forey, B., Thornton, A., (2013) Epidemiological Evidence on Environmental Tobacco Smoke and COPD. A Review with Meta-Analyses, , www.pnlee.co.uk/Reports.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, <; Lee, P.N., Forey, B.A., Hamling, J.S., (2013) Epidemiological Evidence on Environmental Tobacco Smoke and Heart Disease, , http://www.pnlee.co.uk/Reports.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, <; Lee, P.N., Forey, B.A., Hamling, J.S., (2013) Epidemiological Evidence on Environmental Tobacco Smoke and Lung Cancer, , http://www.pnlee.co.uk/Reports.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, <; Lee, P.N., Forey, B.A., Hamling, J.S., (2013) ETS and Heart Disease Meta-Analyses, , http://www.pnlee.co.uk/Reports.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, <; Lee, P.N., Forey, B.A., Hamling, J.S., (2013) ETS and Lung Cancer Meta-Analyses, , http://www.pnlee.co.uk/Reports.htm, P N Lee Statistics and Computing Ltd., Sutton, Surrey, <; Lee, P.N., Forey, B.A., Hamling, J.S., Thornton, A.J., Epidemiological evidence on environmental tobacco smoke and stroke - a review with meta-analyses (2013), http://www.pnlee.co.uk/reports.htmLee, P.N., Fry, J.S., Forey, B.A., Estimating the decline in excess risk of chronic obstructive pulmonary disease following quitting smoking - a systematic review based on the negative exponential model (2014) Regul. Toxicol. Pharmacol., 68, pp. 231-239; Lee, P.N., Fry, J.S., Thornton, A., Estimating the decline in excess risk of cerebrovascular disease following quitting smoking - a systematic review based on the negative exponential model (2014) Regul. Toxicol. Pharmacol., 68, pp. 85-95; Peto, R., Lopez, A.D., Boreham, J., Thun, M., Heath, C., (1994) Mortality From Smoking in Developed Countries 1950-2000, , Oxford University Press; (2010), http://esa.un.org/wpp/index.htm, (updated 28th June 2011). World Population Prospects, the 2010 Revision. (<>)",Article,Scopus,2-s2.0-84926143038
"Thomas D.M., Divakaran S., Villines T.C., Nasir K., Shah N.R., Slim A.M., Blankstein R., Cheezum M.K.","Management of Coronary Artery Calcium and Coronary CTA Findings",2015,"Current Cardiovascular Imaging Reports","8","6",,"","",14,,10.1007/s12410-015-9334-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928803831&partnerID=40&md5=36147c3fee69406de00c8dd0046c8d18","Department of Medicine (Cardiology Service), San Antonio Military Medical CenterSan Antonio, TX, United States; Department of Medicine, Brigham and Women’s Hospital and Harvard Medical SchoolBoston, MA, United States; Department of Medicine (Cardiology Service), Walter Reed National Military Medical CenterBethesda, MD, United States; Center for Prevention and Wellness Research, Baptist Health Medical GroupMiami Beach, FL, United States; Noninvasive Cardiovascular Imaging Program, Departments of Medicine (Cardiovascular Division) and Radiology, Brigham and Women’s HospitalBoston, MA, United States; Non-invasive Cardiovascular Imaging Program, Brigham and Women’s Hospital, 75 Francis StBoston, MA, United States","Thomas, D.M., Department of Medicine (Cardiology Service), San Antonio Military Medical CenterSan Antonio, TX, United States; Divakaran, S., Department of Medicine, Brigham and Women’s Hospital and Harvard Medical SchoolBoston, MA, United States; Villines, T.C., Department of Medicine (Cardiology Service), Walter Reed National Military Medical CenterBethesda, MD, United States; Nasir, K., Center for Prevention and Wellness Research, Baptist Health Medical GroupMiami Beach, FL, United States; Shah, N.R., Noninvasive Cardiovascular Imaging Program, Departments of Medicine (Cardiovascular Division) and Radiology, Brigham and Women’s HospitalBoston, MA, United States; Slim, A.M., Department of Medicine (Cardiology Service), San Antonio Military Medical CenterSan Antonio, TX, United States; Blankstein, R., Noninvasive Cardiovascular Imaging Program, Departments of Medicine (Cardiovascular Division) and Radiology, Brigham and Women’s HospitalBoston, MA, United States; Cheezum, M.K., Noninvasive Cardiovascular Imaging Program, Departments of Medicine (Cardiovascular Division) and Radiology, Brigham and Women’s HospitalBoston, MA, United States, Non-invasive Cardiovascular Imaging Program, Brigham and Women’s Hospital, 75 Francis StBoston, MA, United States","Coronary artery calcium (CAC) testing and coronary computed tomography angiography (CTA) have significant data supporting their ability to identify coronary artery disease (CAD) and classify patient risk for atherosclerotic cardiovascular disease (ASCVD). Evidence regarding CAC use for screening has established an excellent prognosis in patients with no detectable CAC, and the ability to risk re-classify the majority of asymptomatic patients considered intermediate risk by traditional risk scores. While data regarding the ideal management of CAC findings are limited, evidence supports statin consideration in patients with CAC > 0 and individualized aspirin therapy accounting for CAD risk factors, CAC severity, and factors which increase a patient’s risk of bleeding. In patients with stable or acute symptoms undergoing coronary CTA, a normal CTA predicts excellent prognosis, allowing reassurance and disposition without further testing. When CTA identifies nonobstructive CAD (<50 % stenosis), observational data support consideration of statin use/intensification in patients with extensive plaque (at least four coronary segments involved) and patients with high-risk plaque features. In patients with both nonobstructive and obstructive CAD, multiple studies have now demonstrated an ability of CTA to guide management and improve CAD risk factor control. Still, significant under-treatment of cardiovascular risk factors and high-risk image findings remain, among concerns that CTA may increase invasive angiography and revascularization. To fully realize the impact of atherosclerosis imaging for ASCVD prevention, patient engagement in lifestyle changes and the modification of ASCVD risk factors remain the foundation of care. This review provides an overview of available data and recommendations in the management of CAC and CTA findings. © 2015, The Author(s).","Acute coronary syndrome; atherosclerosis; Cardiovascular disease; Chest pain; Coronary artery calcium; Coronary CTA; High risk plaque; Ischemic heart disease; Major adverse cardiac events; Management; Prognosis","Xu, J., Kochanek, K.D., Murphy, S.L., (2012) NCHS Data Brief; Crescioni M, Gorina Y, Bilheimer L, Gillum RF. Trends in health status and health care use among older men. Natl Health Stat Report. 2010;(24):1–18Bavry, A.A., Kumbhani, D.J., Rassi, A.N., Bhatt, D.L., Askari, A.T., Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials (2006) J Am Coll Cardiol, 48 (7), pp. 1319-1325. , PID: 1701078; Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials (2010) Lancet, 376 (9753), pp. 1670-1681. , COI: 1:STN:280:DC%2BC3cbmvVGmsQ%3D%3D, PID: 2106780; Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R., Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (2002) Lancet, 360 (9349), pp. 1903-1913. , PID: 1249325; Schoenborn CA1, Heyman KM. Health characteristics of adults aged 55 years and over: United States, 2004-2007. Natl Health Stat Report. 2009;(16):1–31http://www.cdc.gov/nchs/hdi.htm, Centers for Disease Control and Prevention. National Center for Health Statistics. National Health Interview Survey. Chronic conditions, ages 18+: US, 1998-2012. Accessed 26 Nov 2014Nasir, K., Blaha, M.J., Short and lifetime cardiovascular risk estimates: same wine, different bottles. Do we have the COURAGE to abandon risk scores? (2014) J Nuclear Cardiol : Off Publ Am Soc Nuclear Cardiol, 21 (1), pp. 46-49; Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology (2013) Eur Heart J, 34 (38), pp. 2949-3003. , PID: 23996286, Current recommendations from the European Society of Cardiology for the management of stable coronary artery disease; Agatston, A.S., Janowitz, W.R., Hildner, F.J., Zusmer, N.R., Viamonte, M., Jr., Detrano, R., Quantification of coronary artery calcium using ultrafast computed tomography (1990) J Am Coll Cardiol, 15 (4), pp. 827-832. , COI: 1:STN:280:DyaK3c7ntFelug%3D%3D, PID: 240776; McClelland, R.L., Chung, H., Detrano, R., Post, W., Kronmal, R.A., Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA) (2006) Circulation, 113 (1), pp. 30-37. , PID: 1636519; http://www.hps.org/documents/radiationrisk.pdf, Radiation Risk in Perspective. Health Physics Society. August 2004. Accessed January 15, 2015Oudkerk, M., Stillman, A.E., Halliburton, S.S., Kalender, W.A., Mohlenkamp, S., McCollough, C.H., Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging (2008) Eur Radiol, 18 (12), pp. 2785-2807. , PID: 1865115; Horton, K.M., Post, W.S., Blumenthal, R.S., Fishman, E.K., Prevalence of significant noncardiac findings on electron-beam computed tomography coronary artery calcium screening examinations (2002) Circulation, 106 (5), pp. 532-534. , PID: 1214753; Gibson, A.O., Blaha, M.J., Arnan, M.K., Sacco, R.L., Szklo, M., Herrington, D.M., Coronary artery calcium and incident cerebrovascular events in an asymptomatic cohort: the MESA study (2014) J Am Coll Cardiol Img, 7 (11), pp. 1108-1115; Kavousi, M., Elias-Smale, S., Rutten, J.H., Leening, M.J., Vliegenthart, R., Verwoert, G.C., Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study (2012) Ann Intern Med, 156 (6), pp. 438-444. , PID: 2243167; Nasir, K., Shaw, L.J., Budoff, M.J., Ridker, P.M., Pena, J.M., Coronary artery calcium scanning should be used for primary prevention: pros and cons (2012) J Am Coll Cardiol Img, 5 (1), pp. 111-118; Silverman, M.G., Blaha, M.J., Krumholz, H.M., Budoff, M.J., Blankstein, R., Sibley, C.T., Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis (2014) Eur Heart J, 35 (33), pp. 2232-2241. , COI: 1:CAS:528:DC%2BC2cXhslCht7nM, PID: 2436691; Sarwar, A., Shaw, L.J., Shapiro, M.D., Blankstein, R., Hoffmann, U., Cury, R.C., Diagnostic and prognostic value of absence of coronary artery calcification (2009) J Am Coll Cardiol Img, 2 (6), pp. 675-688; Joshi, P.H., Blaha, M.J., Budoff, M.J., Miedema, M., McClelland, R., Lima, J., The ten year prognostic value of zero and minimal coronary artery calcium: the Multi-Ethnic Study of Atherosclerosis (MESA) (2014) Circulation, 130; Earls, J.P., Woodard, P.K., Abbara, S., Akers, S.R., Araoz, P.A., Cummings, K., ACR appropriateness criteria asymptomatic patient at risk for coronary artery disease (2014) J Am Coll Radiol : JACR, 11 (1), pp. 12-19. , PID: 2431623; Taylor, A.J., Cerqueira, M., Hodgson, J.M., Mark, D., Min, J., O’Gara, P., ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance (2010) J Cardiovasc Comput Tomogr, 4 (6). , PID: 21232696, Multisocietal appropriate use criteria for the use of cardiac computed tomography; Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) (2012) Eur Heart J, 33 (13), pp. 1635-1701. , COI: 1:CAS:528:DC%2BC38XhtVeitr3P, PID: 2255521; Greenland, P., Alpert, J.S., Beller, G.A., Benjamin, E.J., Budoff, M.J., Fayad, Z.A., ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2010) Circulation, 122 (25), pp. 584-636. , PID: 21098428, Prior guidelines from the ACC/AHA provided a IIa recommendation for the use of coronary artery calcium (CAC) scoring in patients at intermediate risk by Framingham risk score; Goff, D.C., Jr., Lloyd-Jones, D.M., Bennett, G., Coady, S., D’Agostino, R.B., Sr., Gibbons, R., ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2013) Circulation, , Updated guidelines from the ACC/AHA for the assessment of cardiovascular risk provide a IIb indication for coronary artery calcium scoring in select patients; Divakaran, S., Cheezum, M.K., Hulten, E.A., Bittencourt, M.S., Silverman, M.G., Nasir, K., Use of cardiac CT and calcium scoring for detecting coronary plaque: implications on prognosis and patient management (2014) Br J Radiol, , PID: 2549481; Pursnani, A., Mayrhofer, T., Ferencik, M., Hoffmann, U., The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography (2014) Atherosclerosis, 237 (1), pp. 314-318. , COI: 1:CAS:528:DC%2BC2cXhs1KgurzN, PID: 2529996; Appelros, P., Stegmayr, B., Terent, A., Sex differences in stroke epidemiology: a systematic review (2009) Stroke J Cerebral Circ, 40 (4), pp. 1082-1090; DeFilippis, A.P., Young, R., Carrubba, C.J., McEvoy, J.W., Budoff, M.J., Blumenthal, R.S., An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort (2015) Ann Intern Med, 162 (4), pp. 266-275. , PID: 2568616; Arad, Y., Spadaro, L.A., Roth, M., Newstein, D., Guerci, A.D., Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis heart study randomized clinical trial (2005) J Am Coll Cardiol, 46 (1), pp. 166-172. , COI: 1:CAS:528:DC%2BD2MXlvVenurs%3D, PID: 1599265; Rozanski, A., Gransar, H., Shaw, L.J., Kim, J., Miranda-Peats, L., Wong, N.D., Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial (2011) J Am Coll Cardiol, 57 (15), pp. 1622-1632. , COI: 1:CAS:528:DC%2BC3MXmsVClu7c%3D, PID: 2143975; Miedema, M.D., Duprez, D.A., Misialek, J.R., Blaha, M.J., Nasir, K., Silverman, M.G., Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis (2014) Circ Cardiovasc Qual Outcomes, 7 (3), pp. 453-460. , PID: 2480347; Blaha, M.J., Budoff, M.J., DeFilippis, A.P., Blankstein, R., Rivera, J.J., Agatston, A., Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study (2011) Lancet, 378 (9792), pp. 684-692. , COI: 1:CAS:528:DC%2BC3MXhtVGmtrzF, PID: 2185648; Depta, J.P., Bhatt, D.L., Should patients stop taking aspirin for primary prevention? (2015) Cleve Clin J Med, 82, pp. 91-96; Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials (2009) Lancet, 373 (9678), pp. 1849-1860. , PID: 19482214, Large meta-analysis incorporating 6 major trials of 95,000 individuals demonstrating aspirin provides no benefit in the combined outcome of cardiovascular death compared to no aspirin among patients who were generally low risk for CVD; Nasir, K., Blankstein, R., Disparities between ideal cardiovascular health metrics and subclinical atherosclerotic burden: more than meets the eye (2015) Circulation Cardiovascular imaging, 8 (1), pp. 4-6; Cheezum, M.K., Hulten, E.A., Fischer, C., Smith, R.M., Slim, A.M., Villines, T.C., Prognostic value of coronary CT angiography (2012) Cardiol Clin, 30 (1), pp. 77-91. , PID: 2230495; Abbara, S., Arbab-Zadeh, A., Callister, T.Q., Desai, M.Y., Mamuya, W., Thomson, L., SCCT guidelines for performance of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee (2009) J Cardiovasc Comput Tomogr, 3 (3), pp. 190-204. , PID: 1940987; Budoff, M.J., Achenbach, S., Berman, D.S., Fayad, Z.A., Poon, M., Taylor, A.J., Task force 13: training in advanced cardiovascular imaging (computed tomography) (2008) J Cardiovasc Comput Tomogr, 2 (2), pp. 130-135. , PID: 1908393; Leipsic, J., Abbara, S., Achenbach, S., Cury, R., Earls, J.P., Mancini, G.J., SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee (2014) J Cardiovasc Comput Tomogr, 8 (5), pp. 342-358. , PID: 2530104; Otsuka, K., Fukuda, S., Tanaka, A., Nakanishi, K., Taguchi, H., Yoshikawa, J., Napkin-ring sign on coronary CT angiography for the prediction of acute coronary syndrome (2013) J Am Coll Cardiol Img, 6 (4), pp. 448-457; Leber, A.W., Knez, A., von Ziegler, F., Becker, A., Nikolaou, K., Paul, S., Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound (2005) J Am Coll Cardiol, 46 (1), pp. 147-154. , PID: 1599264; Ambrose, J.A., Tannenbaum, M.A., Alexopoulos, D., Hjemdahl-Monsen, C.E., Leavy, J., Weiss, M., Angiographic progression of coronary artery disease and the development of myocardial infarction (1988) J Am Coll Cardiol, 12 (1), pp. 56-62. , COI: 1:STN:280:DyaL1c3ksVahtg%3D%3D, PID: 337921; Motoyama, S., Sarai, M., Harigaya, H., Anno, H., Inoue, K., Hara, T., Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome (2009) J Am Coll Cardiol, 54 (1), pp. 49-57. , PID: 19555840, Followed 1,059 patients after coronary CTA demonstrating patients with high risk plaque features (positive remodeling/low attenuation plaque) were at increased risk for acute coronary syndrome in 27 month follow-up; Pundziute, G., Schuijf, J.D., Jukema, J.W., Decramer, I., Sarno, G., Vanhoenacker, P.K., Head-to-head comparison of coronary plaque evaluation between multislice computed tomography and intravascular ultrasound radiofrequency data analysis (2008) J Am Coll Cardiol Intv, 1 (2), pp. 176-182; Stone, G.W., Maehara, A., Lansky, A.J., de Bruyne, B., Cristea, E., Mintz, G.S., A prospective natural-history study of coronary atherosclerosis (2011) N Engl J Med, 364 (3), pp. 226-235. , COI: 1:CAS:528:DC%2BC3MXhtVGhtLw%3D, PID: 2124731; Blankstein, R., Di Carli, M.F., Integration of coronary anatomy and myocardial perfusion imaging (2010) Nat Rev Cardiol, 7 (4), pp. 226-236. , PID: 20212502, Summary of evidence demonstrating that half of patients with obstructive CAD on coronary CTA will have no demonstrable ischemia on stress perfusion imaging; Hulten, E., Goehler, A., Bittencourt, M.S., Bamberg, F., Schlett, C.L., Truong, Q.A., Cost and resource utilization associated with use of computed tomography to evaluate chest pain in the emergency department: the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) study (2013) Circ Cardiovasc Qual Outcomes, 6 (5), pp. 514-524. , PID: 2402169; Raff, G.L., Radiation dose from coronary CT angiography: five years of progress (2010) J Cardiovasc Comput Tomogr, 4 (6), pp. 365-374. , PID: 2113006; Cho, I., Chang, H.J., Sung, J.M., Pencina, M.J., Lin, F.Y., Dunning, A.M., Coronary computed tomographic angiography and risk of all-cause mortality and nonfatal myocardial infarction in subjects without chest pain syndrome from the CONFIRM Registry (coronary CT angiography evaluation for clinical outcomes: an international multicenter registry) (2012) Circulation, 126 (3), pp. 304-313. , PID: 2268511; Patel, M.R., Bailey, S.R., Bonow, R.O., Chambers, C.E., Chan, P.S., Dehmer, G.J., ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons (2012) J Am Coll Cardiol, 59 (22), pp. 1995-2027. , PID: 22578925, Multisocietal guideline recommendations for the use of diagnostic invasive angiography after coronary CTA; Min, J.K., Berman, D.S., Dunning, A., Achenbach, S., Al-Mallah, M., Budoff, M.J., All-cause mortality benefit of coronary revascularization vs. medical therapy in patients without known coronary artery disease undergoing coronary computed tomographic angiography: results from CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: an InteRnational Multicenter Registry) (2012) Eur Heart J, 33 (24), pp. 3088-3097. , COI: 1:CAS:528:DC%2BC38XhvVKgs73E, PID: 2304819; Muhlestein, J.B., Lappe, D.L., Lima, J.A., Rosen, B.D., May, H.T., Knight, S., Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial (2014) JAMA : J Am Med Assoc, 312 (21), pp. 2234-2243. , COI: 1:CAS:528:DC%2BC2MXisFyiur4%3D, Randomized controlled trial demonstrating screening coronary CTA in asymptomatic diabetics had no reduction in major cardiovascular events at 4 years compared to standard care without coronary CTA; Skinner, J.S., Smeeth, L., Kendall, J.M., Adams, P.C., Timmis, A., NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin (2010) Heart, 96 (12), pp. 974-978. , PID: 2053867; Cheezum, M.K., Hulten, E.A., Smith, R.M., Taylor, A.J., Kircher, J., Surry, L., Changes in preventive medical therapies and CV risk factors after CT angiography (2013) J Am Coll Cardiol Img, 6 (5), pp. 574-581; Uretsky, S., Rozanski, A., Supariwala, A., Thotakura, G., Kanneganti, S., Satyanarayana, N., Clinical outcomes following a strategy of optimized medical management and selective “downstream” procedures following coronary computed tomography angiography (2013) Int J Cardiol, 165 (3), pp. 468-473. , PID: 2196807; Hulten, E., Bittencourt, M.S., Singh, A., O’Leary, D., Christman, M.P., Osmani, W., Coronary artery disease detected by coronary CT angiography is associated with intensification of preventive medical therapy and lower LDL cholesterol (2014) Circ Cardiovasc Imaging, , Observational study provided first demonstration that statin therapy in patients with extensive nonobstructive CAD (segment involvement score > 4) was associated with improved mortality relative to no statin use; Bittencourt, M.S., Hulten, E., Ghoshhajra, B., O’Leary, D., Christman, M.P., Montana, P., Prognostic value of nonobstructive and obstructive coronary artery disease detected by coronary computed tomography angiography to identify cardiovascular events (2014) Circ Cardiovasc Imaging, 7 (2), pp. 282-291. , PID: 2455043; Hachamovitch, R., Nutter, B., Hlatky, M.A., Shaw, L.J., Ridner, M.L., Dorbala, S., Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease) (2012) J Am Coll Cardiol, 59 (5), pp. 462-474. , PID: 22281249, Prospective, multicenter, observational registry of over 3,000 patients undergoing coronary CTA, SPECT, or PET that demonstrated significant undertreatment of patients with high risk imaging findings; Nicholls, S.J., Tuzcu, E.M., Sipahi, I., Grasso, A.W., Schoenhagen, P., Hu, T., Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis (2007) JAMA, 297 (5), pp. 499-508. , COI: 1:CAS:528:DC%2BD2sXhs1Wis7k%3D, PID: 1728470; Ray, K.K., Cannon, C.P., The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes (2005) J Am Coll Cardiol, 46 (8), pp. 1425-1433. , COI: 1:CAS:528:DC%2BD2MXhtFWht7zE, PID: 1622616; Komukai, K., Kubo, T., Kitabata, H., Matsuo, Y., Ozaki, Y., Takarada, S., Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: The EASY-FIT Study (2014) J Am Coll Cardiol, 64 (21), pp. 2207-2217. , COI: 1:CAS:528:DC%2BC2cXhvF2htLfJ, PID: 2545675; Nakazato, R., Gransar, H., Berman, D.S., Cheng, V.Y., Lin, F.Y., Achenbach, S., Statins use and coronary artery plaque composition: results from the International Multicenter CONFIRM Registry (2012) Atherosclerosis, 225 (1), pp. 148-153. , COI: 1:CAS:528:DC%2BC38XhtlGqu7%2FN, PID: 2298140; Andreini, D., Pontone, G., Mushtaq, S., Bartorelli, A.L., Bertella, E., Antonioli, L., A long-term prognostic value of coronary CT angiography in suspected coronary artery disease (2012) J Am Coll Cardiol Img, 5 (7), pp. 690-701; Wolk, M.J., Bailey, S.R., Doherty, J.U., Douglas, P.S., Hendel, R.C., Kramer, C.M., ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons (2014) J Am Coll Cardiol, 63 (4), pp. 380-406. , PID: 24355759, Multisocietal guideline recommendations for testing following coronary CTA; Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey, D.E., Jr., 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) Circulation, 127 (23), pp. 663-828. , PID: 2363012; Hulten, E., Bittencourt, M.S., Singh, A., O’Leary, D., Christman, M.P., Osmani, W., Coronary artery disease detected by coronary computed tomographic angiography is associated with intensification of preventive medical therapy and lower low-density lipoprotein cholesterol (2014) Circ Cardiovasc Imaging, 7 (4), pp. 629-638. , PID: 2490635; Nakazato, R., Arsanjani, R., Achenbach, S., Gransar, H., Cheng, V.Y., Dunning, A., Age-related risk of major adverse cardiac event risk and coronary artery disease extent and severity by coronary CT angiography: results from 15 187 patients from the International Multisite CONFIRM Study (2014) Eur Heart J Cardiovasc Imaging, 15 (5), pp. 586-594. , PID: 2471431; Hulten, E., Pickett, C., Bittencourt, M.S., Villines, T.C., Petrillo, S., Di Carli, M.F., Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials (2013) J Am Coll Cardiol, 61 (8), pp. 880-892. , PID: 2339506; Cheezum, M.K., Bittencourt, M.S., Hulten, E.A., Scirica, B.M., Villines, T.C., Blankstein, R., Coronary computed tomographic angiography in the emergency room: state of the art (2014) Expert Rev Cardiovasc Ther, 12 (2), pp. 241-253. , COI: 1:CAS:528:DC%2BC2cXht1Omu7w%3D, PID: 2441734; Hoffmann, U., Bamberg, F., Chae, C.U., Nichols, J.H., Rogers, I.S., Seneviratne, S.K., Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial (2009) J Am Coll Cardiol, 53 (18), pp. 1642-1650. , PID: 1940633; Puchner, S.B., Liu, T., Mayrhofer, T., Truong, Q.A., Lee, H., Fleg, J.L., High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial (2014) J Am Coll Cardiol, 64 (7), pp. 684-692. , PID: 2512530; O’Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E., Jr., Chung, M.K., de Lemos, J.A., ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) Circulation, 127 (4), pp. 529-555. , PID: 2324730; Fihn, S.D., Gardin, J.M., Abrams, J., Berra, K., Blankenship, J.C., Dallas, A.P., 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons (2012) Circulation, 126 (25), pp. 354-471. , PID: 2316621; Farkouh, M.E., Domanski, M., Sleeper, L.A., Siami, F.S., Dangas, G., Mack, M., Strategies for multivessel revascularization in patients with diabetes (2012) N Engl J Med, 367 (25), pp. 2375-2384. , COI: 1:CAS:528:DC%2BC38XhvVyrsr3O, PID: 2312132; Boden, W.E., O’Rourke, R.A., Teo, K.K., Hartigan, P.M., Maron, D.J., Kostuk, W.J., Optimal medical therapy with or without PCI for stable coronary disease (2007) N Engl J Med, 356 (15), pp. 1503-1516. , COI: 1:CAS:528:DC%2BD2sXkt1Sjsbc%3D, PID: 1738712; Frye, R.L., August, P., Brooks, M.M., Hardison, R.M., Kelsey, S.F., MacGregor, J.M., A randomized trial of therapies for type 2 diabetes and coronary artery disease (2009) N Engl J Med, 360 (24), pp. 2503-2515. , COI: 1:CAS:528:DC%2BD1MXntVKqtrw%3D, PID: 1950264; Shaw, L.J., Berman, D.S., Maron, D.J., Mancini, G.B., Hayes, S.W., Hartigan, P.M., Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy (2008) Circulation, 117 (10), pp. 1283-1291. , PID: 1826814; De Bruyne, B., Fearon, W.F., Pijls, N.H., Barbato, E., Tonino, P., Piroth, Z., Fractional flow reserve-guided PCI for stable coronary artery disease (2014) N Engl J Med, 371 (13), pp. 1208-1217. , PID: 2517628; Fearon, W.F., Bornschein, B., Tonino, P.A., Gothe, R.M., Bruyne, B.D., Pijls, N.H., Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease (2010) Circulation, 122 (24), pp. 2545-2550. , PID: 2112697; Shaw, L.J., Hausleiter, J., Achenbach, S., Al-Mallah, M., Berman, D.S., Budoff, M.J., Coronary computed tomographic angiography as a gatekeeper to invasive diagnostic and surgical procedures: results from the multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: an International Multicenter) registry (2012) J Am Coll Cardiol, 60 (20), pp. 2103-2114. , PID: 2308378; Douglas, P.S., Hoffmann, U., Lee, K.L., Mark, D.B., Al-Khalidi, H.R., Anstrom, K., PROspective multicenter imaging study for evaluation of chest pain: rationale and design of the PROMISE trial (2014) Am Heart J, 167 (6). , PID: 2489052; https://clinicaltrials.gov/ct2/show/NCT01471522, Clinicaltrials.gov. International study of comparative health effectiveness with medical and invasive approaches. [Accessed 11 February 2015Min, J.K., Hachamovitch, R., Rozanski, A., Shaw, L.J., Berman, D.S., Gibbons, R., Clinical benefits of noninvasive testing: coronary computed tomography angiography as a test case (2010) J Am Coll Cardiol Img, 3 (3), pp. 305-315; Shreibati, J.B., Baker, L.C., Hlatky, M.A., Association of coronary CT angiography or stress testing with subsequent utilization and spending among Medicare beneficiaries (2011) JAMA : J Am Med Assoc, 306 (19), pp. 2128-2136. , COI: 1:CAS:528:DC%2BC3MXhs1Sis73",Review,Scopus,2-s2.0-84928803831
"Mackey R.H., McTigue K.M., Chang Y.F., Barinas-Mitchell E., Evans R.W., Tinker L.F., Lewis C.E., Manson J.E., Stefanick M.L., Howard B.V., Phillips L.S., Liu S., Kulick D., Kuller L.H.","Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study",2015,"BBA Clinical","3",,,"243","250",,,10.1016/j.bbacli.2015.03.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925066477&partnerID=40&md5=71597769fbfee024ec0e6307a992edc2","Department of Epidemiology, University of PittsburghPittsburgh, PA, United States; Department of Medicine, University of PittsburghPittsburgh, PA, United States; Department of Neurological Surgery, University of PittsburghPittsburgh, PA, United States; Department of Public Health Sciences, Fred Hutchinson Cancer Research CenterSeattle, WA, United States; Department of Medicine, University of Alabama at Birmingham, United States; Brigham and Women's Hospital, Harvard Medical SchoolBoston, MA, United States; Stanford Prevention Research Center, Department of Medicine, Stanford UniversityStanford, CA, United States; Medstar Health Research InstituteHyattsville, MD, United States; Clinical Studies Center, Atlanta VA Medical CenterDecatur, GA, United States; Division of Endocrinology, Emory University School of MedicineAtlanta, GA, United States; Department of Epidemiology, Brown UniversityProvidence, RI, United States; Mayo Clinic ArizonaPhoenix, AZ, United States","Mackey, R.H., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States; McTigue, K.M., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States, Department of Medicine, University of PittsburghPittsburgh, PA, United States; Chang, Y.F., Department of Neurological Surgery, University of PittsburghPittsburgh, PA, United States; Barinas-Mitchell, E., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States; Evans, R.W., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States; Tinker, L.F., Department of Public Health Sciences, Fred Hutchinson Cancer Research CenterSeattle, WA, United States; Lewis, C.E., Department of Medicine, University of Alabama at Birmingham, United States; Manson, J.E., Brigham and Women's Hospital, Harvard Medical SchoolBoston, MA, United States; Stefanick, M.L., Stanford Prevention Research Center, Department of Medicine, Stanford UniversityStanford, CA, United States; Howard, B.V., Medstar Health Research InstituteHyattsville, MD, United States; Phillips, L.S., Clinical Studies Center, Atlanta VA Medical CenterDecatur, GA, United States, Mayo Clinic ArizonaPhoenix, AZ, United States; Liu, S., Division of Endocrinology, Emory University School of MedicineAtlanta, GA, United States; Kulick, D., Department of Epidemiology, Brown UniversityProvidence, RI, United States; Kuller, L.H., Department of Epidemiology, University of PittsburghPittsburgh, PA, United States","Background: We hypothesized that higher concentrations of LDL particles (LDL-P) and leptin, and lower concentrations of HDL particles (HDL-P), and total and high molecular weight (HMW) adiponectin, would predict incident coronary heart disease (CHD) among severely obese postmenopausal women. Methods: In a case-cohort study nested in the Women's Health Initiative Observational Study, we sampled 677 of the 1852 white or black women with body mass index (BMI) ≥40kg/m2 and no prevalent cardiovascular disease (CVD), including all 124 cases of incident CHD over mean 5.0year follow-up. Biomarkers were assayed on stored blood samples. Results: In multivariable-adjusted weighted Cox models, higher baseline levels of total and small LDL-P, and lower levels of total and medium HDL-P, and smaller mean HDL-P size were significantly associated with incident CHD. In contrast, large HDL-P levels were inversely associated with CHD only for women without diabetes, and higher total and HMW adiponectin levels and lower leptin levels were associated with CHD only for women with diabetes. Higher total LDL-P and lower HDL-P were associated with CHD risk independently of confounders including CV risk factors and other lipoprotein measures, with adjusted HR (95% CIs) of 1.55 (1.28, 1.88) and 0.70 (0.57, 0.85), respectively, and similar results for medium HDL-P. Conclusions: Higher CHD risk among severely obese postmenopausal women is strongly associated with modifiable concentrations of LDL-P and HDL-P, independent of diabetes, smoking, hypertension, physical activity, BMI and waist circumference. General significance: Severely obese postmenopausal women should be considered high risk candidates for lipid lowering therapy. © 2015 The Authors.","Adiponectin; Coronary heart disease; Extreme obesity; Lipoproteins; Postmenopausal women; Severe obesity","Poirier, P., Alpert, M.A., Fleisher, L.A., Thompson, P.D., Sugerman, H.J., Burke, L.E., Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association (2009) Circulation, 120 (1), pp. 86-95; Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 (2012) JAMA, 307 (5), pp. 491-497; McTigue, K.M., Chang, Y.F., Eaton, C., Garcia, L., Johnson, K.C., Lewis, C.E., Severe obesity, heart disease, and death among white, African American, and Hispanic postmenopausal women (2014) Obesity (Silver Spring), 22 (3), pp. 801-810; Sjostrom, L., Peltonen, M., Jacobson, P., Sjostrom, C.D., Karason, K., Wedel, H., Bariatric surgery and long-term cardiovascular events (2012) JAMA, 307 (1), pp. 56-65; McTigue, K.M., Mackey, R.H., Kuller, L.H., Cardiovascular complications of extreme obesity in women (2011) Curr. Cardiovasc. Risk Rep., 5, pp. 246-252; Sattar, N., Wannamethee, G., Sarwar, N., Chernova, J., Lawlor, D.A., Kelly, A., Leptin and coronary heart disease: prospective study and systematic review (2009) J. Am. Coll. Cardiol., 53 (2), pp. 167-175; Sook Lee, E., Park, S.S., Kim, E., Sook Yoon, Y., Ahn, H.Y., Park, C.Y., Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis (2013) Int. J. Epidemiol., 42 (4), pp. 1029-1039; Lawlor, D.A., Davey, S.G., Ebrahim, S., Thompson, C., Sattar, N., Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women (2005) J. Clin. Endocrinol. Metab., 90 (10), pp. 5677-5683; Sattar, N., Watt, P., Cherry, L., Ebrahim, S., Davey, S.G., Lawlor, D.A., High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study (2008) J. Clin. Endocrinol. Metab., 93 (5), pp. 1846-1849; Herder, C., Peltonen, M., Svensson, P.A., Carstensen, M., Jacobson, P., Roden, M., Adiponectin and bariatric surgery: associations with diabetes and cardiovascular disease in the Swedish Obese Subjects Study (2014) Diabetes Care, 37 (5), pp. 1401-1409; Mackey, R.H., Greenland, P., Goff, D.C., Lloyd-Jones, D., Sibley, C.T., Mora, S., High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-ethnic Study of Atherosclerosis) (2012) J. Am. Coll. Cardiol., 60 (6), pp. 508-516; Parish, S., Offer, A., Clarke, R., Hopewell, J.C., Hill, M.R., Otvos, J.D., Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study (2012) Circulation, 125 (20), pp. 2469-2478; Kuller, L.H., Grandits, G., Cohen, J.D., Neaton, J.D., Prineas, R., Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome (2007) Atherosclerosis, 195 (1), pp. 122-128; Mora, S., Glynn, R.J., Ridker, P.M., High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy (2013) Circulation, 128 (11), pp. 1189-1197; Otvos, J.D., Mora, S., Shalaurova, I., Greenland, P., Mackey, R.H., Goff, D.C., Clinical implications of discordance between low-density lipoprotein cholesterol and particle number (2011) J. Clin. Lipidol., 5 (2), pp. 105-113; Mora, S., Buring, J.E., Ridker, P.M., Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events (2014) Circulation, 129 (5), pp. 553-561; Mackey, R.H., Kuller, L.H., Sutton-Tyrrell, K., Evans, R.W., Holubkov, R., Matthews, K.A., Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study (2005) Arch. Intern. Med., 165 (5), pp. 510-515; Chandra, A., Neeland, I.J., Das, S.R., Khera, A., Turer, A.T., Ayers, C.R., Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study) (2015) Am. J. Cardiol., 115 (7), pp. 890-894; El Harchaoui, K., van der Steeg, W.A., Stroes, E.S., Kuivenhoven, J.A., Otvos, J.D., Wareham, N.J., Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study (2007) J. Am. Coll. Cardiol., 49 (5), pp. 547-553; Mora, S., Szklo, M., Otvos, J.D., Greenland, P., Psaty, B.M., Goff, D.C., LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-ethnic Study of Atherosclerosis (MESA) (2007) Atherosclerosis, 192 (1), pp. 211-217; El Harchaoui, K., Arsenault, B.J., Franssen, R., Despres, J.P., Hovingh, G.K., Stroes, E.S., High-density lipoprotein particle size and concentration and coronary risk (2009) Ann. Intern. Med., 150 (2), pp. 84-93; van der Steeg, W.A., Holme, I., Boekholdt, S.M., Larsen, M.L., Lindahl, C., Stroes, E.S., High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies (2008) J. Am. Coll. Cardiol., 51 (6), pp. 634-642; Anderson, G.L., Manson, J., Wallace, R., Lund, B., Hall, D., Davis, S., Implementation of the Women's Health Initiative study design (2003) Ann. Epidemiol., 13 (9), pp. S5-S17; Barlow, W.E., Ichikawa, L., Rosner, D., Izumi, S., Analysis of case-cohort designs (1999) J. Clin. Epidemiol., 52 (12), pp. 1165-1172; Curb, J.D., McTiernan, A., Heckbert, S.R., Kooperberg, C., Stanford, J., Nevitt, M., Outcomes ascertainment and adjudication methods in the Women's Health Initiative (2003) Ann. Epidemiol., 13 (9), pp. S122-S128; Go, A.S., Bauman, M.A., Coleman King, S.M., Fonarow, G.C., Lawrence, W., Williams, K.A., An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention (2014) J. Am. Coll. Cardiol., 63 (12), pp. 1230-1238; (2) Classification and diagnosis of diabetes (2015) Diabetes Care, 38, pp. S8-S16; Jeyarajah, E.J., Cromwell, W.C., Otvos, J.D., Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy (2006) Clin. Lab. Med., 26 (4), pp. 847-870; Mackey, R.H., Mora, S., Bertoni, A.G., Wassel, C.L., Carnethon, M.R., Sibley, C.T., Lipoprotein particles and incident type 2 diabetes in the Multi-ethnic Study of Atherosclerosis (2015) Diabetes Care, , [Epub ahead of print]; Mora, S., Otvos, J.D., Rifai, N., Rosenson, R.S., Buring, J.E., Ridker, P.M., Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women (2009) Circulation, 119 (7), pp. 931-939; Kontush, A., Chapman, M.J., Why is HDL functionally deficient in type 2 diabetes? (2008) Curr. Diab. Rep., 8 (1), pp. 51-59; Camont, L., Chapman, M.J., Kontush, A., Biological activities of HDL subpopulations and their relevance to cardiovascular disease (2011) Trends Mol. Med., 17 (10), pp. 594-603; von Eynatten, M., Hamann, A., Twardella, D., Nawroth, P.P., Brenner, H., Rothenbacher, D., Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease (2008) Eur. Heart J., 29 (10), pp. 1307-1315; Wannamethee, S.G., Welsh, P., Whincup, P.H., Sawar, N., Thomas, M.C., Gudnarsson, V., High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? (2011) Eur. J. Cardiovasc. Prev. Rehabil., 18 (1), pp. 65-71; Kizer, J.R., Benkeser, D., Arnold, A.M., Mukamal, K.J., Ix, J.H., Zieman, S.J., Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study (2012) Circulation, 126 (25), pp. 2951-2961; Kizer, J.R., Benkeser, D., Arnold, A.M., Djousse, L., Zieman, S.J., Mukamal, K.J., Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults (2013) J. Clin. Endocrinol. Metab., 98 (1), pp. 255-263; Tsukamoto, O., Fujita, M., Kato, M., Yamazaki, S., Asano, Y., Ogai, A., Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure (2009) J. Am. Coll. Cardiol., 53 (22), pp. 2070-2077; Piemonti, L., Calori, G., Mercalli, A., Lattuada, G., Monti, P., Garancini, M.P., Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality (2003) Diabetes Care, 26 (10), pp. 2883-2889; Allison, M.A., Bluemke, D.A., McClelland, R., Cushman, M., Criqui, M.H., Polak, J.F., Relation of leptin to left ventricular hypertrophy (from the Multi-ethnic Study of Atherosclerosis) (2013) Am. J. Cardiol., 112 (5), pp. 726-730; Mackey, R.H., Belle, S.H., Courcoulas, A.P., Dakin, G.F., Deveney, C.W., Flum, D.R., Distribution of 10-year and lifetime predicted risk for cardiovascular disease prior to surgery in the longitudinal assessment of bariatric surgery-2 study (2012) Am. J. Cardiol., 60 (6), pp. 508-516; Davidson, M.H., Ballantyne, C.M., Jacobson, T.A., Bittner, V.A., Braun, L.T., Brown, A.S., Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists (2011) J. Clin. Lipidol., 5 (5), pp. 338-367; McTigue, K., Larson, J.C., Valoski, A., Burke, G., Kotchen, J., Lewis, C.E., Mortality and cardiac and vascular outcomes in extremely obese women (2006) JAMA, 296 (1), pp. 79-86; Livingston, E.H., Chandalia, M., Abate, N., Do current body mass index criteria for obesity surgery reflect cardiovascular risk? (2007) Surg. Obes. Relat. Dis., 3 (6), pp. 577-585; Matthews, K.A., Crawford, S.L., Chae, C.U., Everson-Rose, S.A., Sowers, M.F., Sternfeld, B., Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? (2009) J. Am. Coll. Cardiol., 54 (25), pp. 2366-2373; Kuller, L.H., Pettee Gabriel, K.K., Kinzel, L.S., Underwood, D.A., Conroy, M.B., Chang, Y., The Women on the Move Through Activity and Nutrition (WOMAN) study: final 48-month results (2012) Obesity (Silver Spring), 20 (3), pp. 636-643; Rosenson, R.S., Otvos, J.D., Hsia, J., Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study (2009) Diabetes Care, 32 (6), pp. 1087-1091; Mora, S., Glynn, R.J., Hsia, J., MacFadyen, J.G., Genest, J., Ridker, P.M., Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials (2010) Circulation, 121 (9), pp. 1069-1077",Article,Scopus,2-s2.0-84925066477
"Li H.-X., Lu X.-J., Li C.-H., Chen J.","Molecular characterization of the liver-expressed antimicrobial peptide 2 (LEAP-2) in a teleost fish, Plecoglossus altivelis: Antimicrobial activity and molecular mechanism",2015,"Molecular Immunology","65","2",,"406","415",,,10.1016/j.molimm.2015.02.022,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924627674&partnerID=40&md5=8e6d25825b5ac22fb5fea71b8a354376","Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Ningbo UniversityNingbo, China; The Donghai Sea Collaborative Innovation Center for Industrial Upgrading Mariculture, Ningbo UniversityNingbo, China","Li, H.-X., Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Ningbo UniversityNingbo, China, The Donghai Sea Collaborative Innovation Center for Industrial Upgrading Mariculture, Ningbo UniversityNingbo, China; Lu, X.-J., Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Ningbo UniversityNingbo, China; Li, C.-H., Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Ningbo UniversityNingbo, China; Chen, J., Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Ningbo UniversityNingbo, China, The Donghai Sea Collaborative Innovation Center for Industrial Upgrading Mariculture, Ningbo UniversityNingbo, China","Liver-expressed antimicrobial peptide 2 (LEAP-2) is widespread in fish and plays an important role in the host's innate immune system. In this study, full-length cDNA for LEAP-2 (PaLEAP-2) gene was cloned and sequenced from ayu, Plecoglossus altivelis. PaLEAP-2 mRNA was detected in a wide range of tissues, with the highest level of transcripts found in the liver. Upon induction by Vibrio anguillarum, its expression significantly increased in the liver, kidney, spleen, gill, and heart, but decreased in the intestine. The PaLEAP-2 mature peptide was chemically synthesized; it exhibited selective antimicrobial activity against various bacteria in vitro. PaLEAP-2 at high concentration reduced the bacterial load and improved the survival rate of V. anguillarum-infected ayu. Moreover, it inhibited the expression of mRNAs for TNF-α and IL-1β in V. anguillarum-infected ayu, both at high and low concentrations. PaLEAP-2 induced hydrolysis of the pET-22b plasmid DNA and bacterium genomic DNA. These results suggest that PaLEAP-2 plays a role in ayu immune responses against bacterial infection. © 2015 Elsevier Ltd.","Antimicrobial activity; Bacterial load; Gene expression; Liver-expressed antimicrobial peptide 2; Survival rate","Bao, B., Peatman, E., Xu, P., Li, P., Zeng, H., He, C., Liu, Z., The catfish liver-expressed antimicrobial peptide 2 (LEAP-2) gene is expressed in a wide range of tissues and developmentally regulated (2006) Mol. Immunol., 43, pp. 367-377; Cuesta, A., Meseguer, J., Esteban, M.A., The antimicrobial peptide hepcidin exerts an important role in the innate immunity against bacteria in the bony fish gilthead seabream (2008) Mol. Immunol., 45, pp. 2333-2342; Chang, C.I., Zhang, Y.A., Zou, J., Nie, P., Secombes, C.J., Two cathelicidin genes are present in both rainbow trout (Oncorhynchus mykiss) and Atlantic salmon (Salmo salar) (2006) Antimicrob. Agents Chemother., 50, pp. 185-195; Costanzo, S.D., Murby, J., Bates, J., Ecosystem response to antibiotics entering the aquatic environment (2005) Mar. Pollut. Bull., 51, pp. 218-223; Dinarello, C., The IL-1 family and inflammatory diseases (2002) Clin. Exp. Rheumatol., 20, pp. S1-S13; Ganz, T., Hepcidin-a regulator of intestinal iron absorption and iron recycling by macrophages (2005) Best. Pract. Res. Clin. Haematol., 18, pp. 171-182; Gao, P., Mao, D., Luo, Y., Wang, L., Xu, B., Xu, L., Occurrence of sulfonamide and tetracycline-resistant bacteria and resistance genes in aquaculture environment (2012) Water Res., 46, pp. 2355-2364; Hahn, T., Schulz, R., Indirect effects of antibiotics in the aquatic environment: a laboratory study on detritivore food selection behavior (2007) Hum. Ecol. Risk Assess., 13, pp. 535-542; Haney, E.F., Petersen, A.P., Lau, C.K., Jing, W., Storey, D.G., Vogel, H.J., Mechanism of action of puroindoline derived tryptophan-rich antimicrobial peptides (2013) BBA - Biomembranes, 1828, pp. 1802-1813; Henriques, S.T., Tan, C.C., Craik, D.J., Clark, R.J., Structural and functional analysis of human liver-expressed antimicrobial peptide 2 (2010) ChemBioChem, 11, pp. 2148-2157; Hocquellet, A., Odaert, B., Cabanne, C., Noubhani, A., Dieryck, W., Joucla, G., Le Senechal, C., Costaglioli, P., Structure-activity relationship of human liver-expressed antimicrobial peptide 2 (2010) Peptides, 31, pp. 58-66; Howard, A., Townes, C., Milona, P., Nile, C.J., Michailidis, G., Hall, J., Expression and functional analyses of liver expressed antimicrobial peptide-2 (LEAP-2) variant forms in human tissues (2010) Cell. Immunol., 261, pp. 128-133; Hsu, C.H., Chen, C., Jou, M.L., Lee, A.Y.L., Lin, Y.C., Yu, Y.P., Huang, W.T., Wu, S.H., Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA (2005) Nucleic Acids Res., 33, pp. 4053-4064; Jenssen, H., Hamill, P., Hancock, R.E., Peptide antimicrobial agents (2006) Clin. Microbiol. Rev., 19, pp. 491-511; Kümmerer, K., Antibiotics in the aquatic environment - a review-part I (2009) Chemosphere, 75, pp. 417-434; Kopp, E.B., Medzhitov, R., PERSPECTIVE: infection and inflammation in somatic maintenance, growth and longevity (2009) Evol. Appl., 2, pp. 132-141; Krause, A., Neitz, S., Mägert, H.J., Schulz, A., Forssmann, W.G., LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity (2000) FEBS Lett., 480, pp. 147-150; Krause, A., Sillard, R., Kleemeier, B., Kluver, E., Maronde, E., Conejo-Garcia, J.R., Forssmann, W.G., Wattler, F., Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver (2003) Protein Sci., 12, pp. 143-152; Lai, Y., Gallo, R.L., AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense (2009) Trends. Immunol., 30, pp. 131-141; Li, C.H., Chen, J., Shi, Y.H., Li, M.Y., Characterization of Listonella anguillarum as the aetiological agent of vibriosis occurred in cultured ayu (Plecoglossus altivelis) in Ninghai county, China (2009) Acta Microbiol. Sin., 49, pp. 931-937; Li, H.X., Lu, X.J., Li, C.H., Chen, J., Molecular characterization and functional analysis of two distinct liver-expressed antimicrobial peptide 2 (LEAP-2) genes in large yellow croaker (Larimichthys crocea) (2014) Fish Shellfish Immunol., 38, pp. 330-339; Liang, T., Ji, W., Zhang, G.R., Wei, K.J., Feng, K., Wang, W.M., Zou, G.W., Molecular cloning and expression analysis of liver-expressed antimicrobial peptide 1 (LEAP-1) and LEAP-2 genes in the blunt snout bream (Megalobrama amblycephala) (2013) Fish Shellfish Immunol., 35, pp. 553-563; Liu, F., Li, J.L., Yue, G.H., Fu, J.J., Zhou, Z.F., Molecular cloning and expression analysis of the liver-expressed antimicrobial peptide 2 (LEAP-2) gene in grass carp (2010) Vet. Immunol. Immunopathol., 133, pp. 133-143; Liu, T., Gao, Y., Wang, R., Xu, T., Characterization, evolution and functional analysis of the liver-expressed antimicrobial peptide 2 (LEAP-2) gene in miiuy croaker (2014) Fish Shellfish Immunol., 41, pp. 191-199; Lu, X.J., Chen, Q., Yang, G.J., Chen, J., The TNFα converting enzyme (TACE) from ayu (Plecoglossus altivelis) exhibits TNFα shedding activity (2015) Mol. Immunol., 63, pp. 497-504; Masso-Silva, J., Diamond, G., Macias-Rodriguez, M., Ascencio, F., Genomic organization and tissue-specific expression of hepcidin in the pacific mutton hamlet, Alphestes immaculatus (Breder, 1936) (2011) Fish Shellfish Immunol., 31, pp. 1297-1302; Marguti, I., Control of immunopathology during Plasmodium infection by hepcidin (2012) Med. Hypotheses, 78, pp. 250-253; Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization (2004) Science, 306, pp. 2090-2093; Nguyen, L.T., Haney, E.F., Vogel, H.J., The expanding scope of antimicrobial peptide structures and their modes of action (2011) Trends Biotechnol., 29, pp. 464-472; Nicolas, G., Viatte, L., Bennoun, M., Beaumont, C., Kahn, A., Hepcidin, a new iron regulatory peptide (2002) Blood Cells Mol. Dis., 29, pp. 327-335; Poisa-Beiro, L., Dios, S., Montes, A., Aranguren, R., Figueras, A., Nodavirus increases the expression of Mx and inflammatory cytokines in fish brain (2008) Mol. Immunol., 45, pp. 218-225; Rajanbabu, V., Chen, J.Y., Antiviral function of tilapia hepcidin 1-5 and its modulation of immune-related gene expressions against infectious pancreatic necrosis virus (IPNV) in Chinook salmon embryo (CHSE)-214 cells (2011) Fish Shellfish Immunol., 30, pp. 39-44; Ren, G., Shen, W., Li, W., Zhu, Y., Molecular characterization and expression pattern of a liver-expressed antimicrobial peptide 2 (LEAP-2) gene in yellow catfish (Pelteobagrus fulvidraco) (2014) J. Aquac. Res. Dev., 5, p. 2; Rodríguez, I., Novoa, B., Figueras, A., Immune response of zebrafish (Danio rerio) against a newly isolated bacterial pathogen Aeromonas hydrophila (2008) Fish Shellfish Immunol., 25, pp. 239-249; Shata, M.T.M., Abdel-Hameed, E.A., Hetta, H.F., Sherman, K.E., Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2) (2013) J. Clin. Pathol., 66, pp. 967-975; Shike, H., Lauth, X., Westerman, M.E., Ostland, V.E., Carlberg, J.M., Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge (2002) Eur. J. Biochem., 269, pp. 2232-2237; Steckbeck, J.D., Deslouches, B., Montelaro, R.C., Antimicrobial peptides: new drugs for bad bugs? (2014) Expert. Opin. Biol. Ther., 14, pp. 11-14; Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., Kumar, S., MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods (2011) Mol. Biol. Evol., 28, pp. 2731-2739; Townes, C.L., Michailidis, G., Hall, J., The interaction of the antimicrobial peptide cLEAP-2 and the bacterial membrane (2009) Biochem. Biophys. Res. Commun., 387, pp. 500-503; Yang, G., Guo, H., Li, H., Shan, S., Zhang, X., Rombout, J.H., An, L., Molecular characterization of LEAP-2 cDNA in common carp (Cyprinus carpio) and the differential expression upon a Vibrio anguillarum stimulus; indications for a significant immune role in skin (2014) Fish Shellfish Immunol., 37, pp. 22-29; Yonezawa, A., Sugiura, Y., Tachyplesin I as a model peptide for antiparallel beta-sheet DNA binding motif (1992) Nucleic. Acids. Symp. Ser., 27, pp. 161-162; Zhang, Y.A., Zou, J., Chang, C.I., Secombes, C.J., Discovery and characterization of two types of liver-expressed antimicrobial peptide 2 (LEAP-2) genes in rainbow trout (2004) Vet. Immunol. Immunopathol., 101, pp. 259-269; Zhang, M., Li, M.F., Sun, L., NKLP27: a teleost NK-lysin peptide that modulates immune response, induces degradation of bacterial DNA, and inhibits bacterial and viral infection (2014) PLoS ONE, 9, p. e106543; Zhou, J.G., Wei, J.G., Xu, D., Cui, H.C., Yan, Y., Molecular cloning and characterization of two novel hepcidins from orange-spotted grouper, Epinephelus coioides (2011) Fish Shellfish Immunol., 30, pp. 559-568",Article,Scopus,2-s2.0-84924627674
"Harrison J.L., Whitaker J., Chubb H., Williams S.E., Wright M., Razavi R.S., O'Neill M.D.","Advances in CMR of Post-ablation Atrial Injury",2015,"Current Cardiovascular Imaging Reports","8","6",,"","",8,,10.1007/s12410-015-9336-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928797676&partnerID=40&md5=6634d74cbbe9d55e1908814092592c65","Division of Imaging Sciences and Biomedical Engineering, King’s College LondonLondon, United Kingdom","Harrison, J.L., Division of Imaging Sciences and Biomedical Engineering, King’s College LondonLondon, United Kingdom; Whitaker, J., Division of Imaging Sciences and Biomedical Engineering, King’s College LondonLondon, United Kingdom; Chubb, H., Division of Imaging Sciences and Biomedical Engineering, King’s College LondonLondon, United Kingdom; Williams, S.E., Division of Imaging Sciences and Biomedical Engineering, King’s College LondonLondon, United Kingdom; Wright, M., Division of Imaging Sciences and Biomedical Engineering, King’s College LondonLondon, United Kingdom; Razavi, R.S., Division of Imaging Sciences and Biomedical Engineering, King’s College LondonLondon, United Kingdom; O’Neill, M.D., Division of Imaging Sciences and Biomedical Engineering, King’s College LondonLondon, United Kingdom","Technical advancements in cardiac magnetic resonance (CMR) imaging over the past two decades have allowed clinically useful imaging of the thin atrial wall for the first time. During this period, there has been a parallel increase in the use of catheter ablation to treat atrial fibrillation (AF). These developments have led to new indications for and increasing use of CMR in the assessment of pre- and post-ablation atrial structure and function and their potential link to arrhythmia substrate. This review focuses on the role of CMR in the assessment of acute and chronic post-ablation atrial tissue characterisation and its potential use in the treatment of atrial arrhythmias. © 2015, Springer Science+Business Media New York.","Ablation; Atrial fibrillation; Cardiac magnetic resonance","Lardo, A.C., Mcveigh, E.R., Jumrussirikul, P., Berger, R.D., Calkins, H., Halperin, H.R., Visualization and temporal/spatial characterization of cardiac radiofrequency ablation lesions using magnetic resonance imaging (2000) Circulation, 102, pp. 698-705. , COI: 1:STN:280:DC%2BD3cvhtV2ntw%3D%3D, PID: 10931812; Dickfeld, T., Kato, R., Zviman, M., Lai, S., Meininger, G., Lardo, A.C., Characterization of radiofrequency ablation lesions with gadolinium-enhanced cardiovascular magnetic resonance imaging (2006) J Am Coll Cardiol, 47, pp. 370-378. , PID: 16412863; Dickfeld, T., Kato, R., Zviman, M., Nazarian, S., Dong, J., Ashikaga, H., Characterization of acute and subacute radiofrequency ablation lesions with nonenhanced magnetic resonance imaging (2007) Heart Rhythm, 4, pp. 208-214. , PID: 17275759; Vergara, G.R., Vijayakumar, S., Kholmovski, E.G., Blauer, J.J.E.E., Guttman, M.A., Gloschat, C., Real-time MRI guided radiofrequency atrial ablation and visualization of lesion formation at 3-tesla. Hear Rhythm (2011) Elsevier Inc., 8, pp. 295-303; Nordbeck, P., Hiller, K.-H., Fidler, F., Warmuth, M., Burkard, N., Nahrendorf, M., Feasibility of contrast-enhanced and nonenhanced MRI for intraprocedural and postprocedural lesion visualization in interventional electrophysiology: animal studies and early delineation of isthmus ablation lesions in patients with typical atrial flutter (2011) Circ Cardiovasc Imaging, 4, pp. 282-294. , PID: 21415125; Ranjan, R., Kholmovski, E.G., Blauer, J., Vijayakumar, S., Volland, N.A., Salama, M.E., Identification and acute targeting of gaps in atrial ablation lesion sets using a real-time magnetic resonance imaging system (2012) Circ Arrhythm Electrophysiol, 5, pp. 1130-1135. , PID: 23071143, A study demonstrating the ability of real time magnetic resonance imaging to guide radiofrequency ablation. This study provides compelling experimental evidence justifying the trial of real time CMR in human studies, which are currently underway; Harrison, J.L., Jensen, H.K., Peel, S.A., Chiribiri, A., Grøndal, A.K., Bloch, L., Cardiac magnetic resonance and electroanatomical mapping of acute and chronic atrial ablation injury: a histological validation study (2014) Eur Heart J, 35, pp. 1486-1495. , PID: 24419806, The first correlation of magnetic resonance imaging data with a comprehensive histopathological tissue assessment in a bovine model. This work identified the role of T2 weighted imaging and LGE in the quantitative assessment of acute and chronic atrial scar; Peters, D.C., Wylie, J.V., Hauser, T.H., Nezafat, R., Han, Y., Woo, J.J., Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study. JACC Cardiovasc Imaging (2009) Elsevier Inc., 2, pp. 308-316; Peters, D.C., Wylie, J.V., Hauser, T.H., Kissinger, K.V., Josephson, M.E., (2007) Manning WJ. Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement mr imaging: methods: results: conclusion, p. 243; Knowles, B.R., Caulfield, D., Cooklin, M., Rinaldi, C.A., Gill, J., Bostock, J., 3-D visualization of acute RF ablation lesions using MRI for the simultaneous determination of the patterns of necrosis and edema (2010) IEEE Trans Biomed Eng, 57, pp. 1467-1475. , PID: 20172807; Arujuna, A., Karim, R., Caulfield, D., Knowles, B., Rhode, K., Schaeffter, T., Acute pulmonary vein isolation is achieved by a combination of reversible and irreversible atrial injury after catheter ablation: evidence from magnetic resonance imaging (2012) Circ Arrhythm Electrophysiol, 5, pp. 691-700. , PID: 22652692; Badger, T.J., Daccarett, M., Akoum, N.W., Adjei-Poku, Y.A., Burgon, N.S., Haslam, T.S., Evaluation of left atrial lesions after initial and repeat atrial fibrillation ablation: lessons learned from delayed-enhancement MRI in repeat ablation procedures (2010) Circ Arrhythm Electrophysiol, 3, pp. 249-259. , PID: 20335558; Badger, T.J., Oakes, R.S., Daccarett, M., Burgon, N.S., Akoum, N., Fish, E.N., Temporal left atrial lesion formation after ablation of atrial fibrillation. HRTHM (2009) Heart Rhythm Society, 6, pp. 161-168; McGann, C.J., Kholmovski, E.G., Oakes, R.S., Blauer, J.J.E., Daccarett, M., Segerson, N., New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation (2008) J Am Coll Cardiol, 52, pp. 1263-1271. , PID: 18926331; Bisbal, F., Guiu, E., Cabanas-Grandío, P., Berruezo, A., Prat-Gonzalez, S., Vidal, B., CMR-guided approach to localize and ablate gaps in repeat AF ablation procedure (2014) JACC Cardiovasc Imaging, 7, pp. 653-663. , PID: 24813966, This study raises the novel possibility of purely CMR guided ablation of atrial fibrillation. If successfully reproduced, the results suggest the prospect of a purely imaging guided approach to the ablation of atrial fibrillation; Khurram, I.M., Beinart, R., Zipunnikov, V., Dewire, J., Yarmohammadi, H., Sasaki, T., Magnetic resonance image intensity ratio, a normalized measure to enable interpatient comparability of left atrial fibrosis. Heart Rhythm (2014) Elsevier, 11, pp. 85-92; Oakes, R.S., Badger, T.J., Kholmovski, E.G., Akoum, N., Burgon, N.S., Fish, E.N., Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation (2009) Circulation, 119, pp. 1758-1767. , PID: 19307477; Badger, T.J., Adjei-Poku, Y.A., Burgon, N.S., Kalvaitis, S., Shaaban, A., Sommers, D.N., Initial experience of assessing esophageal tissue injury and recovery using delayed-enhancement MRI after atrial fibrillation ablation (2009) Circ Arrhythm Electrophysiol, 2, pp. 620-625. , PID: 20009076; Mcgann, C., Kholmovski, E., Blauer, J., Vijayakumar, S., Haslam, T., Cates, J., Dark regions of no-reflow on late gadolinium enhancement magnetic resonance imaging result in scar formation after atrial fibrillation ablation (2011) J Am Coll Cardiol. Elsevier Inc., 58, pp. 177-185; Spragg, D.D., Khurram, I., Zimmerman, S.L., Yarmohammadi, H., Barcelon, B., Needleman, M., Initial experience with magnetic resonance imaging of atrial scar and co-registration with electroanatomic voltage mapping during atrial fibrillation: success and limitations (2012) Hear Rhythm, 9, pp. 2003-2009; Sohns, C., Karim, R., Harrison, J., Arujuna, A., Linton, N., Sennett, R., Quantitative magnetic resonance imaging analysis of the relationship between contact force and left atrial scar formation after catheter ablation of atrial fibrillation (2014) J Cardiovasc Electrophysiol, 25, pp. 138-145; Badger, T.J., Oakes, R.S., Daccarett, M., Burgon, N.S., Akoum, N., Fish, E.N., Temporal left atrial lesion formation after ablation of atrial fibrillation. Heart Rhythm (2009) Heart Rhythm Society, 6, pp. 161-168; Sohns, C., Karim, R., Harrison, J., Arujuna, A., Linton, N., Sennett, R., Quantitative magnetic resonance imaging analysis of the relationship between contact force and left atrial scar formation after catheter ablation of atrial fibrillation (2013) J Cardiovasc Electrophysiol, pp. 138-145; Segerson, N.M., Daccarett, M., Badger, T.J., Shabaan, A., Akoum, N.W., Fish, E.N., Magnetic resonance imaging-confirmed ablative debulking of the left atrial posterior wall and septum for treatment of persistent atrial fibrillation: rationale and initial experience (2010) J Cardiovasc Electrophysiol, 21, pp. 126-132. , PID: 19804549; Akoum, N.W., Daccarett, M., McGann, C., Segerson, N., Vergara, G.R., Kuppahally, S., Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach (2011) J Cardiovasc Electrophysiol, 22, pp. 16-22. , PID: 20807271; Judd, R.M., Lugo-Olivieri, C.H., Arai, M., Kondo, T., Croisille, P., Lima, J.A.C., Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts (1995) Circulation, 92, pp. 1902-1910. , COI: 1:STN:280:DyaK2MvgtFentQ%3D%3D, PID: 7671375; Malcolme-Lawes, L.C., Juli, C., Karim, R., Bai, W., Quest, R., Lim, P.B., Automated analysis of atrial late gadolinium enhancement imaging that correlates with endocardial voltage and clinical outcomes: a 2-center study (2013) Heart Rhythm, 10, pp. 1184-1191. , COI: 1:STN:280:DC%2BC3snkslyhsg%3D%3D, PID: 23685170; Harrison, J.L., Sohns, C., Linton, N.W., Karim, R., Williams, S.E., Rhode, K.S., Repeat left atrial catheter ablation: cardiac magnetic resonance prediction of endocardial voltage and gaps in ablation lesion sets (2015) Circ Arrhythm Electrophysiol; Hunter, R.J., Jones, D.A., Boubertakh, R., Malcolme-Lawes, L.C., Kanagaratnam, P., Juli, C.F., Diagnostic accuracy of cardiac magnetic resonance imaging in the detection and characterization of left atrial catheter ablation lesions: a multicenter experience (2013) J Cardiovasc Electrophysiol, 24, pp. 396-403. , PID: 23293924, This study demonstrates that when examining CMR imaging taken post ablation, LGE scar imaging is not yet accurate enough to reliably identify ablation lesions or determine their distribution. This important study from two centres of excellence raises a note of caution in the interpretation of the growing body of work reporting increasingly accurate scar identification using CMR",Review,Scopus,2-s2.0-84928797676
"Tweet M.S., Arruda-Olson A.M., Anavekar N.S., Pellikka P.A.","Stress Echocardiography: What Is New and How Does It Compare with Myocardial Perfusion Imaging and Other Modalities?",2015,"Current Cardiology Reports","17","6",,"","",10,,10.1007/s11886-015-0600-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928625600&partnerID=40&md5=d571c2d47469c116d5293a9220f01599","Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 1st Street SWRochester, MN, United States","Tweet, M.S., Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 1st Street SWRochester, MN, United States; Arruda-Olson, A.M., Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 1st Street SWRochester, MN, United States; Anavekar, N.S., Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 1st Street SWRochester, MN, United States; Pellikka, P.A., Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 1st Street SWRochester, MN, United States","Cardiovascular disease is a leading cause of morbidity and mortality, and noninvasive strategies to diagnose and risk stratify patients remain paramount in the evaluative process. Stress echocardiography is a well-established, versatile, real-time imaging modality with advantages including lack of radiation exposure, portability, and affordability. Innovative techniques in stress echocardiography include myocardial contrast echocardiography, deformation imaging, three-dimensional (3D) echocardiography, and assessment of coronary flow reserve. Myocardial perfusion imaging with single-photon emission computed tomography (SPECT) or positron emission tomography (PET) are imaging alternatives, and stress cardiac magnetic resonance imaging and coronary computed tomography (CT) angiography, including CT perfusion imaging, are emerging as newer approaches. This review will discuss recent and upcoming developments in the field of stress testing, with an emphasis on stress echocardiography while highlighting comparisons with other modalities. © 2015, Springer Science+Business Media New York.","Cardiac magnetic resonance imaging; Coronary computed tomography angiography; Dobutamine echocardiography; Exercise echocardiography; Myocardial perfusion imaging; Positron emission tomography; Single-photon emission computed tomography; Stress testing","Go, A., Mozaffarian, D., Roger, V., Benajmin, E., Berry, J., ObotAHASCaSSSe. Heart disease and stroke statistics—2013 update: a report from the American Heart Association (2013) Circulation, 127, pp. e6-e245. , PID: 23239837; Picano, E., Pellikka, P.A., Stress echo applications beyond coronary artery disease (2014) Eur Heart J, 35 (16), pp. 1033-1040. , PID: 24126880, This article describes the application of stress echocardiography to a wide spectrum of cardiovascular diseases; Wolk, M.J., Bailey, S.R., Doherty, J.U., Douglas, P.S., Hendel, R.C., Kramer, C.M., ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease a Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons (2014) J Am Coll Cardiol, 63 (4), pp. 380-406. , PID: 24355759, These appropriate use criteria outline the current expert recommendations regarding the appropriateness of stress testing for specific clinical scenarios and serves as a helpful guide for determining the most appropriate approach to a patient being considered for stress imaging; Pellikka, P.A., Nagueh, S.F., Elhendy, A.A., Kuehl, C.A., Sawada, S.G., American society of echocardiography recommendations for performance, interpretation, and application of stress echocardiography (2007) J Am Soc Echocardiogr, 20 (9), pp. 1021-1041. , PID: 17765820; Gibbons, R.J., Balady, G.J., Timothy Bricker, J., Chaitman, B.R., Fletcher, G.F., Froelicher, V.F., ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American college of cardiology/American heart association task force on practice guidelines (committee to update the 1997 exercise testing guidelines) (2002) J Am Coll Cardiol, 40 (8), pp. 1531-1540. , PID: 12392846; Einstein, A.J., Berman, D.S., Min, J.K., Hendel, R.C., Gerber, T.C., Carr, J.J., Patient-centered imaging: shared decision making for cardiac imaging procedures with exposure to ionizing radiation (2014) J Am Coll Cardiol, 63 (15), pp. 1480-1489. , PID: 24530677, This article brings attention to the patient education and consent which should be obtained prior to performing noninvasive imaging involving radiation; Murín, P., Mitro, P., Valocik, G., Spurný, P., Global myocardial contractile reserve assessed by high-dose dobutamine stress echocardiography predicts response to the cardiac resynchronization therapy (2014) Echocardiography, , PID: 25059770; Fihn, S.D., Gardin, J.M., Abrams, J., Berra, K., Blankenship, J.C., Dallas, A.P., 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons (2012) J Am Coll Cardiol, 60 (24), pp. 2564-2603; Fine, N.M., Pellikka, P.A., Scott, C.G., Gharacholou, S.M., McCully, R.B., Characteristics and outcomes of patients who achieve high workload (≥10 metabolic equivalents) during treadmill exercise echocardiography (2013) Mayo Clin Proc, 88 (12), pp. 1408-1419. , PID: 24290114, This study provides helpful prognostic information about patients who undergo exercise echocardiography and achieve a high workload; Ling, L.H., Christian, T.F., Mulvagh, S.L., Klarich, K.W., Hauser, M.F., Nishimura, R.A., Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography (2006) Am Heart J, 151 (4), pp. 882-889. , PID: 16569554; Bonow, R.O., Maurer, G., Lee, K.L., Holly, T.A., Binkley, P.F., Desvigne-Nickens, P., Myocardial viability and survival in ischemic left ventricular dysfunction (2011) N Engl J Med, 364 (17), pp. 1617-1625. , COI: 1:CAS:528:DC%2BC3MXlsFeltrw%3D, PID: 21463153; Panza, J.A., Holly, T.A., Asch, F.M., She, L., Pellikka, P.A., Velazquez, E.J., Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction (2013) J Am Coll Cardiol, 61 (18), pp. 1860-1870. , PID: 23500234; Plana, J., Galderisi, M., Barac, A., Ewer, M., Ky, B., Scherrer-Crosbie, M., Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging (2014) Eur Heart J Cardiovasc Imaging, 15 (10), pp. 1063-1093. , PID: 25239940, This important and recent document delineates specific cardiac imaging recommendations for cancer therapy patients; Ishii, K., Imai, M., Suyama, T., Maenaka, M., Nagai, T., Kawanami, M., Exercise-induced post-ischemic left ventricular delayed relaxation or diastolic stunning: is it a reliable marker in detecting coronary artery disease? (2009) J Am Coll Cardiol, 53 (8), pp. 698-705. , PID: 19232903; Elliott, P.M., Anastasakis, A., Borger, M.A., Borggrefe, M., Cecchi, F., Charron, P., ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 2014;39 (2014) This expert consensus outlines recommendations regarding cardiac imaging and management of hypertrophic cardiomyopathy patients; Peteiro, J., Bouzas-Mosquera, A., Fernandez, X., Monserrat, L., Pazos, P., Estevez-Loureiro, R., Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy (2012) J Am Soc Echocardiogr, 25 (2), pp. 182-189. , PID: 22137254; Nishimura, R.A., Otto, C.M., Bonow, R.O., Carabello, B.A., Erwin Iii, J.P., Guyton, R.A., 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) J Thorac Cardiovasc Surg, 148 (1), pp. e1-e132. , PID: 24939033, This pertinent document guides the diagnosis and treatment of valvular disease; it also highlights appropriateness of stress imaging when relevant; Clavel, M.-A., Fuchs, C., Burwash, I.G., Mundigler, G., Dumesnil, J.G., Baumgartner, H., Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS study (2008) Circulation, 118, pp. S234-S242. , PID: 18824760; Monin, J.-L., Quéré, J.-P., Monchi, M., Petit, H., Baleynaud, S., Chauvel, C., Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics (2003) Circulation, 108 (3), pp. 319-324. , PID: 12835219; Clavel, M.-A., Ennezat, P.V., Maréchaux, S., Dumesnil, J.G., Capoulade, R., Hachicha, Z., Stress echocardiography to assess stenosis severity and predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis and preserved LVEF (2013) JACC Cardiovasc Imaging, 6 (2), pp. 175-183. , PID: 23489531; Grimaldi, A., Olivotto, I., Figini, F., Pappalardo, F., Capritti, E., Ammirati E (2012) Dynamic assessment of ‘valvular reserve capacity’ in patients with rheumatic mitral stenosis, p. 6; Magne, J., Donal, E., Mahjoub, H., Miltner, B., Dulgheru, R., Thebault, C., Impact of exercise pulmonary hypertension on postoperative outcome in primary mitral regurgitation (2014) Heart; Senior, R., Moreo, A., Gaibazzi, N., Agati, L., Tiemann, K., Shivalkar, B., Comparison of sulfur hexafluoride microbubble (SonoVue)-enhanced myocardial contrast echocardiography with gated single-photon emission computed tomography for detection of significant coronary artery disease: a large European multicenter study (2013) J Am Coll Cardiol, 62 (15), pp. 1353-1361. , COI: 1:CAS:528:DC%2BC3sXhsFCisb%2FN, PID: 23770168; Chen J-h (2013) The value of quantitative real-time myocardial contrast echocardiography for detection of angiographically significant coronary artery disease, 36 (8), pp. 468-474; Jayaweera, A.R., Wei, K., Coggins, M., Bin, J.P., Goodman, C., Kaul, S., Role of capillaries in determining CBF reserve: new insights using myocardial contrast echocardiography (1999) Am J Physiol Heart Circ Physiol, 277 (6), pp. H2363-H2372. , COI: 1:CAS:528:DC%2BD3cXps1Wg; Shah, B.N., Chahal, N.S., Bhattacharyya, S., Li, W., Roussin, I., Khattar, R.S., The feasibility and clinical utility of myocardial contrast echocardiography in clinical practice: results from the incorporation of myocardial perfusion assessment into clinical testing with stress echocardiography study (2014) J Am Soc Echocardiogr, 27 (5), pp. 520-530. , PID: 24637056; Yu, Y., Villarraga, H., Saleh, H., Cha, S., Pellikka, P., Can ischemia and dyssynchrony be detected during early stages of dobutamine stress echocardiography by 2-dimensional speckle tracking echocardiography? (2013) Int J Cardiovasc Imaging, 29 (1), pp. 95-102. , PID: 22628053; Ng, A.C.T., Sitges, M., Pham, P.N., Tran, D.T., Delgado, V., Bertini, M., Incremental value of 2-dimensional speckle tracking strain imaging to wall motion analysis for detection of coronary artery disease in patients undergoing dobutamine stress echocardiography (2009) Am Heart J, 158 (5), pp. 836-844. , PID: 19853706; Yamada, A., Luis, S.A., Sathianathan, D., Khandheria, B.K., Cafaro, J., Hamilton-Craig, C.R., Reproducibility of regional and global longitudinal strains derived from two-dimensional speckle-tracking and Doppler tissue imaging between expert and novice readers during quantitative dobutamine stress echocardiography (2014) J Am Soc Echocardiogr, 27 (8), pp. 880-887. , PID: 24891261; Casas Rojo, E., Fernández-Golfín, C., Zamorano J (2013) Hybrid imaging with coronary tomography and 3D speckle-tracking stress echocardiography fusion; Jasaityte, R., Heyde, B., Ferferieva, V., Amundsen, B., Barbosa, D., Loeckx, D., Comparison of a new methodology for the assessment of 3D myocardial strain from volumetric ultrasound with 2D speckle tracking (2012) Int J Cardiovasc Imaging, 28 (5), pp. 1049-1060. , PID: 21847561; Seo, Y., Ishizu, T., Enomoto, Y., Sugimori, H., Yamamoto, M., Machino, T., Validation of 3-dimensional speckle tracking imaging to quantify regional myocardial deformation (2009) Circ Cardiovasc Imaging, 2 (6), pp. 451-459. , PID: 19920043; Badano, L.P., Muraru, D., Rigo, F., Del Mestre, L., Ermacora, D., Gianfagna, P., High volume-rate three-dimensional stress echocardiography to assess inducible myocardial ischemia: a feasibility study (2010) J Am Soc Echocardiogr, 23 (6), pp. 628-635. , PID: 20434877; Johri, A.M., Chitty, D.W., Hua, L., Marincheva, G., Picard, M.H., Assessment of image quality in real time three-dimensional dobutamine stress echocardiography: an integrated 2D/3D approach (2014) Echocardiography; Cortigiani, L., Rigo, F., Gherardi, S., Bovenzi, F., Molinaro, S., Picano, E., Coronary flow reserve during dipyridamole stress echocardiography predicts mortality (2012) JACC Cardiovasc Imaging, 5 (11), pp. 1079-1085. , PID: 23153906; Gaibazzi, N., Rigo, F., Lorenzoni, V., Molinaro, S., Bartolomucci, F., Reverberi, C., Comparative prediction of cardiac events by wall motion, wall motion plus coronary flow reserve, or myocardial perfusion analysis: a multicenter study of contrast stress echocardiography (2013) JACC Cardiovasc Imaging, 6 (1), pp. 1-12. , PID: 23219414; Weyman, A.E., More may not always be better (2013) JACC Cardiovasc Imaging, 6 (1), pp. 13-15. , PID: 23219413; Cerqueira, M., Allman, K., Ficaro, E., Hansen, C., Nichols, K., Thompson, R., Recommendations for reducing radiation exposure in myocardial perfusion imaging (2010) J Nucl Cardiol, 17 (4), p. 709. , PID: 20503120; Ketelsen, D., Buchgeister, M., Korn, A., Fenchel, M., Schmidt, B., Flohr, T.G., High-pitch computed tomography coronary angiography—a new dose-saving algorithm: estimation of radiation exposure (2012) Radiol Res Pract; Miller, T.D., Askew, J.W., Anavekar, N.S., Noninvasive stress testing for coronary artery disease (2014) Cardiol Clin, 32 (3), pp. 387-404. , PID: 25091965; Sharir, T., Slomka, P., Berman, D., Solid-State SPECT technology: fast and furious (2010) J Nucl Cardiol, 17 (5), pp. 890-896. , PID: 20740337; Miller, T.D., Askew, J.W., O'Connor, M.K., New toys for nuclear cardiologists (2011) Circ Cardiovasc Imaging, 4 (1), pp. 5-7. , PID: 21245363; Rahmim, A., Zaidi, H., PET versus SPECT: strengths, limitations and challenges (2008) Nucl Med Commun, 29 (3), pp. 193-207. , PID: 18349789; Chow, B.J.W., Dorbala, S., Di Carli, M.F., Merhige, M.E., Williams, B.A., Veledar, E., Prognostic value of PET myocardial perfusion imaging in obese patients (2014) JACC Cardiovasc Imaging, 7 (3), pp. 278-287. , PID: 24560212; Flachskampf, F.A., Dilsizian, V., Leaning heavily on PET myocardial perfusion for prognosis (2014) JACC Cardiovasc Imaging, 7 (3), pp. 288-291. , PID: 24651101; Sogbein, O.O., Pelletier-Galarneau, M., Schindler, T.H., Wei, L., Wells, R.G., Ruddy, T.D., New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease (2014) BioMed Res Int, 2014, p. 25; Berman, D.S., Maddahi, J., Tamarappoo, B.K., Czernin, J., Taillefer, R., Udelson, J.E., Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography (2013) J Am Coll Cardiol, 61 (4), pp. 469-477. , COI: 1:CAS:528:DC%2BC38XhvFWhu7jL, PID: 23265345; Shaw, L.J., Berman, D.S., Picard, M.H., Friedrich, M.G., Kwong, R.Y., Stone, G.W., Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging (2014) JACC Cardiovasc Imaging, 7 (6), pp. 593-604. , PID: 24925328, This document attempts to unify the multi-modality definitions of ischemia; Douglas, P.S., Hoffman, U., Patel, M.R., Mark, D.B., Al-Khalidi, H.R., Cavanaugh, B., Outcomes of anatomic versus functional testing for coronary artery disease (2015) N Engl J Med, 372, pp. 1291-1300; Shaw, L., Iskandrian, A.E., Prognostic value of gated myocardial perfusion SPECT (2004) J Nucl Cardiol, 11 (2), pp. 171-185. , PID: 15052249; Hachamovitch, R., Hayes, S.W., Friedman, J.D., Cohen, I., Berman, D.S., Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography (2003) Circulation, 107 (23), pp. 2900-2907. , PID: 12771008; https://ischemiatrial.org, ISCHEMIA Study. Accessed 12 Nov 2014Arruda-Olson, A.M., Juracan, E.M., Mahoney, D.W., McCully, R.B., Roger, V.L., Pellikka, P.A., Prognostic value of exercise echocardiographyin 5,798 patients: is there a gender difference? (2002) J Am Coll Cardiol, 39 (4), pp. 625-631. , PID: 11849861; Shaw, L., Vasey, C., Sawada, S., Rimmerman, C., Marwick, T., Impact of gender on risk stratification by exercise and dobutamine stress echocardiography: long-term mortality in 4234 women and 6898 men (2005) Eur Heart J, 26 (5), pp. 447-456. , PID: 15687253; McCully, R.B., Roger, V.L., Mahoney, D.W., Burger, K.N., Click, R.L., Seward, J.B., Outcome after abnormal exercise echocardiography for patients with good exercise capacity: prognostic importance of the extent and severity of exercise-related left ventricular dysfunction (2002) J Am Coll Cardiol, 39 (8), pp. 1345-1352. , PID: 11955853; Gharacholou, S.M., Scott, C.G., Takahashi, P.Y., Nkomo, V.T., McCully, R.B., Fine, N.M., Ventricular diastolic function and long-term outcomes in patients with normal exercise echocardiographic findings (2013) Am J Cardiol, 112 (2), pp. 200-207. , PID: 23611754; From, A.M., Kane, G., Bruce, C., Pellikka, P.A., Scott, C., McCully, R.B., Characteristics and outcomes of patients with abnormal stress echocardiograms and angiographically mild coronary artery disease (<50 % stenoses) or normal coronary arteries (2010) J Am Soc Echocardiogr, 23 (2), pp. 207-214. , PID: 20152703; Metz, L.D., Beattie, M., Hom, R., Redberg, R.F., Grady, D., Fleischmann, K.E., The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis (2007) J Am Coll Cardiol, 49 (2), pp. 227-237. , PID: 17222734; Finn, J.P., Nael, K., Deshpande, V., Ratib, O., Laub, G., Cardiac MR imaging: state of the technology (2006) Radiology, 241 (2), pp. 338-354. , PID: 17057063; Kato, S., Kitagawa, K., Ishida, N., Ishida, M., Nagata, M., Ichikawa, Y., Assessment of coronary artery disease using magnetic resonance coronary angiography: a National Multicenter Trial (2010) J Am Coll Cardiol, 56 (12), pp. 983-991. , PID: 20828652; Rajiah, P., Bolen, M.A., Cardiovascular MR imaging at 3 T: opportunities, challenges, and solutions (2014) RadioGraphics, 34 (6), pp. 1612-1635. , PID: 25310420; Pflugi, S., Roujol, S., Akçakaya, M., Kawaji, K., Foppa, M., Heydari, B., Accelerated cardiac MR stress perfusion with radial sampling after physical exercise with an MR-compatible supine bicycle ergometer (2014) Magn Reson Med; Greenwood, J.P., Motwani, M., Maredia, N., Brown, J.M., Everett, C.C., Nixon, J., Comparison of cardiovascular magnetic resonance and single-photon emission computed tomography in women with suspected coronary artery disease from the clinical evaluation of magnetic resonance imaging in coronary heart disease (CE-MARC) trial (2014) Circulation, 129 (10), pp. 1129-1138. , PID: 24357404; Leipsic, J., Abbara, S., Achenbach, S., Cury, R., Earls, J.P., Mancini, G.B.J., SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee (2014) J Cardiovasc Comput Tomogr, 8 (5), pp. 342-358. , PID: 25301040, Description of diagnostic criteria and findings that are reported on coronary CT angiography; Budoff, M.J., Dowe, D., Jollis, J.G., Gitter, M., Sutherland, J., Halamert, E., Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial (2008) J Am Coll Cardiol, 52 (21), pp. 1724-1732. , PID: 19007693; Rochitte, C.E., George, R.T., Chen, M.Y., Arbab-Zadeh, A., Dewey, M., Miller, J.M., Computed tomography angiography and perfusion to assess coronary artery stenosis causing perfusion defects by single photon emission computed tomography: the CORE320 study (2014) Eur Heart J, 35 (17), pp. 1120-1130. , PID: 24255127; George, R.T., Mehra, V.C., Chen, M.Y., Kitagawa, K., Arbab-Zadeh, A., Miller, J.M., Myocardial CT perfusion imaging and SPECT for the diagnosis of coronary artery disease: a head-to-head comparison from the CORE320 multicenter diagnostic performance study (2014) Radiology, 272 (2), pp. 407-416. , PID: 24865312; Rossi, A., Dharampal, A., Wragg, A., Davies, L., van Geuns, R., Anagnostopoulos, C., Diagnostic performance of hyperaemic myocardial blood flow index obtained by dynamic computed tomography: does it predict functionally significant coronary lesions? (2014) Eur Heart J Cardiovasc Imaging, 15 (1), pp. 85-94. , PID: 23935153; Loewe, C., Stadler, A., Computed tomography assessment of hemodynamic significance of coronary artery disease: CT perfusion, contrast gradients by coronary CTA, and fractional flow reserve review.[Review] (2014) J Thorac Imaging, 29 (3), pp. 163-172. , PID: 24576836; Renker, M., Schoepf, U.J., Wang, R., Meinel, F.G., Rier, J.D., Bayer Ii, R.R., Comparison of diagnostic value of a novel noninvasive coronary computed tomography angiography method versus standard coronary angiography for assessing fractional flow reserve (2014) Am J Cardiol, 114 (9), pp. 1303-1308. , PID: 25205628",Review,Scopus,2-s2.0-84928625600
"Azucena H., Rios E., Pena R.D., Diaz J.","Design and implementation of a simple portable biomedical electronic device to diagnose cardiac arrhythmias",2015,"Sensing and Bio-Sensing Research","4",,,"1","10",,,10.1016/j.sbsr.2015.01.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923379425&partnerID=40&md5=c3df15a4fbcec2ea2ac01aa41d0b0512","Facultad de Ciencias de la Electrónica, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, Av. San Claudio y 18 Sur Colonia Jardines de San ManuelPuebla Pue, Mexico; Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, Av. San Claudio y 18 Sur Colonia Jardines de San ManuelPuebla Pue, Mexico","Azucena, H., Facultad de Ciencias de la Electrónica, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, Av. San Claudio y 18 Sur Colonia Jardines de San ManuelPuebla Pue, Mexico; Ríos, E., Facultad de Ciencias de la Electrónica, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, Av. San Claudio y 18 Sur Colonia Jardines de San ManuelPuebla Pue, Mexico; Peña, R.D., Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, Av. San Claudio y 18 Sur Colonia Jardines de San ManuelPuebla Pue, Mexico; Díaz, J., Facultad de Ciencias de la Electrónica, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, Av. San Claudio y 18 Sur Colonia Jardines de San ManuelPuebla Pue, Mexico","This paper presents the development of a simple portable biomedical electronic device to detect cardiac arrhythmias in humans. It identifies three main parts: an electrocardiograph, a device for data communication and a personal computer with software for diagnosis. The system performs automatic diagnosis of cardiac arrhythmias by comparing the patient's electrocardiogram with those contained in a database stored in a personal computer. The biomedical device performance is satisfactory and it demonstrated its usefulness even in the absence of medical specialist in cardiology. © 2015 The Authors.","Bioelectric signals; Cardiac arrhythmias; Cardiology software; Electrocardiograph; Heart diseases automatic diagnosis; USB","Guadalajara, J.F., (1997) Cardiología, , Méndez editores, México; Aminoff, M.J., (2012) Electrodiagnosis in Clinical Neurology, , Elsevier Saunders, USA; Constant, J., (2002) Learning Electrocardiography: A Complete Course, , Parthenon Publishing, USA; Iturralde, P., (2002) Arritmias Cardiacas, , McGraw-Hill, México; Coughlin, R., Driscoll, F., (1987) Operational Amplifiers and Linear Integrated Circuits, , Prentice-Hall Inc., USA; (1979), Newnes-Butterworths, London, UKHayt, W., Kemmerly, J., Durbin, S., (2007) Engineering Circuit Analysis, , McGraw-Hill Companies Inc., USA; (2004), PIC18F2455/2550/4455/4550 Data Sheet, Microchip Technology Inc., USAAxelson, J., (2009) USB Complete: The Developer's Guide, , Lakeview Research LLC, USA; Bishop, R., (2006) Labview 8, , National Instruments, Pearson, USA",Article,Scopus,2-s2.0-84923379425
"Krarup N.T., Borglykke A., Allin K.H., Sandholt C.H., Justesen J.M., Andersson E.A., Grarup N., Jorgensen T., Pedersen O., Hansen T.","A genetic risk score of 45 coronary artery disease risk variants associates with increased risk of myocardial infarction in 6041 danish individuals",2015,"Atherosclerosis","240","2",,"305","310",,,10.1016/j.atherosclerosis.2015.03.022,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926455477&partnerID=40&md5=cb3ff36fa3e0179efbfbafc329567885","The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Research Center for Prevention and Health, Glostrup University HospitalGlostrup, Denmark; Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Faculty of Medicine, University of AalborgAalborg, Denmark; Faculty of Health Sciences, University of Southern DenmarkOdense, Denmark","Krarup, N.T., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Borglykke, A., Research Center for Prevention and Health, Glostrup University HospitalGlostrup, Denmark; Allin, K.H., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Sandholt, C.H., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Justesen, J.M., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Andersson, E.A., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Grarup, N., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Jørgensen, T., Research Center for Prevention and Health, Glostrup University HospitalGlostrup, Denmark, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark, Faculty of Medicine, University of AalborgAalborg, Denmark; Pedersen, O., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark; Hansen, T., The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagen, Denmark, Faculty of Health Sciences, University of Southern DenmarkOdense, Denmark","Background: In Europeans, 45 genetic risk variants for coronary artery disease (CAD) have been identified in genome-wide association studies. We constructed a genetic risk score (GRS) of these variants to estimate the effect on incidence and clinical predictability of myocardial infarction (MI) and CAD. Methods: Genotype was available from 6041 Danes. An unweighted GRS was constructed by making a summated score of the 45 known genetic CAD risk variants. Registries provided information (mean follow-up=11.6 years) on CAD (n=374) and MI (n=124) events. Cox proportional hazard estimates with age as time scale was adjusted for sex, BMI, type 2 diabetes mellitus and smoking status. Analyses were also stratified either by sex or median age (below or above 45 years of age). We estimated GRS contribution to MI prediction by assessing net reclassification index (NRI) and integrated discrimination improvement (IDI) added to the European SCORE for 10-year MI risk prediction. Results: The GRS associated significantly with risk of incident MI (allele-dependent hazard ratio (95%CI): 1.06 (1.02-1.11), p=0.01) but not with CAD (p=0.39). Stratification revealed association of GRS with MI in men (1.06 (1.01-1.12), p=0.02) and in individuals above the median of 45.11 years of age (1.06 (1.00-1.12), p=0.03). There was no interaction between GRS and gender (p=0.90) or age (p=0.83). The GRS improved neither NRI nor IDI. Conclusion: The GRS of 45 GWAS identified risk variants increase the risk of MI in a Danish cohort. The GRS did not improve NRI or IDI beyond the performance of conventional European SCORE risk factors. © 2015 Elsevier Ireland Ltd.","Coronary artery disease; Genetic risk score; Myocardial infarction; Single-nucleotide polymorphism","Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030 (2006) PLoS Med., 3, p. e442; Conroy, R.M., Pyorala, K., Fitzgerald, A.P., Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project (2003) Eur. Heart J., 24, pp. 987-1003; Hawe, E., Talmud, P.J., Miller, G.J., Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study (2003) Ann. Hum. Genet., 67, pp. 97-106; Fischer, M., Broeckel, U., Holmer, S., Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction (2005) Circulation, 111, pp. 855-862; Zdravkovic, S., Wienke, A., Pedersen, N.L., Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins (2002) J.Intern. Med., 252, pp. 247-254; C Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls (2007) Nature, 447, pp. 661-678; McPherson, R., Pertsemlidis, A., Kavaslar, N., Acommon allele on chromosome 9 associated with coronary heart disease (2007) Science, 316, pp. 1488-1491; Helgadottir, A., Thorleifsson, G., Manolescu, A., Acommon variant on chromosome 9p21 affects the risk of myocardial infarction (2007) Science, 316, pp. 1491-1493; Samani, N.J., Erdmann, J., Hall, A.S., Genomewide association analysis of coronary artery disease (2007) N.Engl. J. Med., 357, pp. 443-453; Erdmann, J., Grosshennig, A., Braund, P.S., New susceptibility locus for coronary artery disease on chromosome 3q22.3 (2009) Nat. Genet., 41, pp. 280-282; Myocardial Infarction Genetics, C., Kathiresan, S., Voight, B.F., Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants (2009) Nat. Genet., 41, pp. 334-341; Schunkert, H., Konig, I.R., Kathiresan, S., Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease (2011) Nat. Genet., 43, pp. 333-338; Wild, P.S., Zeller, T., Schillert, A., Agenome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease (2011) Circ. Cardiovasc. Genet., 4, pp. 403-412; Reilly, M.P., Li, M., He, J., Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies (2011) Lancet, 377, pp. 383-392; Davies, R.W., Wells, G.A., Stewart, A.F., Agenome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex (2012) Circ. Cardiovasc. Genet., 5, pp. 217-225; Consortium, C.D., Deloukas, P., Kanoni, S., Large-scale association analysis identifies new risk loci for coronary artery disease (2013) Nat. Genet., 45, pp. 25-33; Vaarhorst, A.A., Lu, Y., Heijmans, B.T., Literature-based genetic risk scores for coronary heart disease: the Cardiovascular Registry Maastricht (CAREMA) prospective cohort study (2012) Circ. Cardiovasc. Genet., 5, pp. 202-209; Hughes, M.F., Saarela, O., Stritzke, J., Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts (2012) PloS One, 7, p. e40922; Tikkanen, E., Havulinna, A.S., Palotie, A., Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease (2013) Arterioscler. Thrombosis Vasc. Biol., 33, pp. 2261-2266; Glumer, C., Jorgensen, T., Borch-Johnsen, K., Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study (2003) Diabetes Care, 26, pp. 2335-2340; Jorgensen, T., Borch-Johnsen, K., Thomsen, T.F., Arandomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (2003) Eur. J. Cardiovasc Prev. Rehabil., 10, pp. 377-386; Andersen, T.F., Madsen, M., Jorgensen, J., The Danish National Hospital Register. A valuable source of data for modern health sciences (1999) Dan. Med. Bull., 46, pp. 263-268; Juel, K., Helweg-Larsen, K., The Danish registers of causes of death (1999) Dan. Med. Bull., 46, pp. 354-357; Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge (1972) Clin. Chem., 18, pp. 499-502; Varbo, A., Benn, M., Tybjaerg-Hansen, A., Remnant cholesterol as a causal risk factor for ischemic heart disease (2013) J.Am. Coll. Cardiol., 61, pp. 427-436; Johnson, A.D., Handsaker, R.E., Pulit, S.L., SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap (2008) Bioinformatics, 24, pp. 2938-2939; Hivert, M.F., Jablonski, K.A., Perreault, L., Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program (2011) Diabetes, 60, pp. 1340-1348; Liu, M., Kapadia, A.S., Etzel, C.J., Evaluating a new risk Marker's predictive contribution in survival models (2010) J.Stat. Theory Pract., 4, pp. 845-855; Pencina, M.J., D'Agostino, R.B., D'Agostino, R.B., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond (2008) Stat. Med., 27, pp. 157-172. , discussion 207-112; Manolio, T.A., Collins, F.S., Cox, N.J., Finding the missing heritability of complex diseases (2009) Nature, 461, pp. 747-753; Kitsios, G.D., Dahabreh, I.J., Trikalinos, T.A., Heterogeneity of the phenotypic definition of coronary artery disease and its impact on genetic association studies (2011) Circ. Cardiovasc. Genet., 4, pp. 58-67; de Miguel-Yanes, J.M., Shrader, P., Pencina, M.J., Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms (2011) Diabetes care, 34, pp. 121-125; Ganna, A., Magnusson, P.K., Pedersen, N.L., (2013) Multilocus Genetic Risk Scores for Coronary Heart Disease Prediction, Arteriosclerosis, Thrombosis, and Vascular Biology; Kilpelainen, T.O., Qi, L., Brage, S., Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children (2011) PLoS Med., 8, p. e1001116; Qi, Q., Chu, A.Y., Kang, J.H., Sugar-sweetened beverages and genetic risk of obesity (2012) N.Engl. J. Med., 367, pp. 1387-1396; Madsen, M., Davidsen, M., Rasmussen, S., The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry (2003) J.Clin. Epidemiol., 56, pp. 124-130; Lidegaard, O., Vestergaard, C.H., Hammerum, M.S., Quality monitoring based on data from the Danish National Patient Registry (2009) Ugeskr. Laeger, 171, pp. 412-415; Dudbridge, F., Power and predictive accuracy of polygenic risk scores (2013) PLoS Genet., 9, p. e1003348; Chatterjee, N., Wheeler, B., Sampson, J., Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies (2013) Nat. Genet., 45, pp. 400-405. , 405e401-403; Soininen, P., Kangas, A.J., Wurtz, P., High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism (2009) Analyst, 134, pp. 1781-1785; Cohen, J.C., Boerwinkle, E., Mosley, T.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease (2006) N.Engl. J. Med., 354, pp. 1264-1272",Article,Scopus,2-s2.0-84926455477
"Lee J.M., Park K.W., Koo B.-K., Kim H.-S.","Stenting of Coronary Bifurcation Lesions: a Literature and Technical Review",2015,"Current Cardiology Reports","17","6",,"","",15,,10.1007/s11886-015-0595-7,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928808051&partnerID=40&md5=28bb0633916c6e443d6c540331a0f282","Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, 101 DaeHak-RoJongRo-Gu, Seoul, South Korea; Institute of Aging, Seoul National UniversitySeoul, South Korea","Lee, J.M., Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, 101 DaeHak-RoJongRo-Gu, Seoul, South Korea; Park, K.W., Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, 101 DaeHak-RoJongRo-Gu, Seoul, South Korea; Koo, B.-K., Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, 101 DaeHak-RoJongRo-Gu, Seoul, South Korea, Institute of Aging, Seoul National UniversitySeoul, South Korea; Kim, H.-S., Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, 101 DaeHak-RoJongRo-Gu, Seoul, South Korea","Newer generation drug-eluting stents have improved outcomes in various subsets of coronary lesions including bifurcation lesions. This article reviews the current literature on various issues in bifurcation percutaneous coronary intervention (PCI). Generally, the provisional approach of placing one stent in the main vessel is the preferred first-line treatment for most bifurcation lesions. However, some lesions require 2-stenting. It is unknown whether 2nd-generation DES have improved outcomes with 2-stenting. The use of fractional flow reserve (FFR) for the assessment of functional significance of the jailed side branch can help avoid unnecessary stenting in complex lesions. Skilled techniques in every step of the 2-stenting process and meticulous use of imaging techniques including IVUS or OCT are warranted to obtain optimal angiographic and clinical results. Dedicated bifurcation stents are feasible treatment options and may change future concepts in bifurcation PCI, although larger trials with control groups are required in order to widely apply these techniques into daily routine practice. © 2015, Springer Science+Business Media New York.","Bifurcation; Coronary bifurcation; Drug-eluting stent; Fractional flow reserve; Percutaneous coronary intervention; Provisional stenting; Systemic 2-stenting","Steigen, T.K., Maeng, M., Wiseth, R., Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic Bifurcation Study (2006) Circulation, 114, pp. 1955-1961. , PID: 17060387; Latib, A., Colombo, A., Bifurcation disease: what do we know, what should we do? (2008) JACC Cardiovasc Interv, 1, pp. 218-226. , PID: 19463303, This review article provides a comprehensive insights about bifurcation PCI; Colombo, A., Bramucci, E., Sacca, S., Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study (2009) Circulation, 119, pp. 71-78. , PID: 19103990; Colombo, A., Moses, J.W., Morice, M.C., Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions (2004) Circulation, 109, pp. 1244-1249. , PID: 14981005; Ferenc, M., Gick, M., Kienzle, R.P., Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions (2008) Eur Heart J, 29, pp. 2859-2867. , PID: 18845665; Hildick-Smith, D., de Belder, A.J., Cooter, N., Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies (2010) Circulation, 121, pp. 1235-1243. , COI: 1:CAS:528:DC%2BC3cXlt1OqtLk%3D, PID: 20194880; Maeng, M., Holm, N.R., Erglis, A., Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results (2013) J Am Coll Cardiol, 62, pp. 30-34. , PID: 23644088; Pan, M., de Lezo, J.S., Medina, A., Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy (2004) Am Heart J, 148, pp. 857-864. , COI: 1:CAS:528:DC%2BD2cXpt1arsbY%3D, PID: 15523318; Song, Y.B., Hahn, J.Y., Yang, J.H., Differential prognostic impact of treatment strategy among patients with left main versus non-left main bifurcation lesions undergoing percutaneous coronary intervention: results from the COBIS (Coronary Bifurcation Stenting) Registry II (2014) JACC Cardiovasc Interv, 7, pp. 255-263. , PID: 24529936; Behan, M.W., Holm, N.R., Curzen, N.P., Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study (2011) Circ Cardiovasc Interv, 4, pp. 57-64. , PID: 21205942; Zhang, F., Dong, L., Ge, J., Simple versus complex stenting strategy for coronary artery bifurcation lesions in the drug-eluting stent era: a meta-analysis of randomised trials (2009) Heart, 95, pp. 1676-1681. , COI: 1:STN:280:DC%2BD1Mnlt1KmsA%3D%3D, PID: 19643768; Zimarino, M., Corazzini, A., Ricci, F., Di Nicola, M., De Caterina, R., Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational studies (2013) JACC Cardiovasc Interv, 6, pp. 687-695. , PID: 23769650; Gao, X.F., Zhang, Y.J., Tian, N.L., Stenting strategy for coronary artery bifurcation with drug-eluting stents: a meta-analysis of nine randomised trials and systematic review (2014) EuroIntervention, 10, pp. 561-569. , PID: 24970736; Windecker, S., Kolh, P., Alfonso, F., 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) (2014) Eur Heart J, 35, pp. 2541-2619. , PID: 25173339; Levine, G.N., Bates, E.R., Blankenship, J.C., 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions (2011) J Am Coll Cardiol, 58, pp. 44-122. , PID: 22070834; Palmerini, T., Biondi-Zoccai, G., Della Riva, D., Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis (2013) J Am Coll Cardiol, 62, pp. 496-504. , COI: 1:CAS:528:DC%2BC3sXht1Wru7jM, PID: 23747778; Palmerini, T., Biondi-Zoccai, G., Della Riva, D., Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis (2014) J Am Coll Cardiol, 63, pp. 299-307. , COI: 1:CAS:528:DC%2BC2cXhsV2iu7o%3D, PID: 24211507; Kang, S.H., Park, K.W., Kang, D.Y., Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis (2014) Eur Heart J, 35, pp. 1147-1158. , COI: 1:CAS:528:DC%2BC2cXnsVegsr4%3D, PID: 24459196; Burzotta, F., Trani, C., Todaro, D., Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach (2011) JACC Cardiovasc Interv, 4, pp. 327-335. , PID: 21435612; Pan, M., Medina, A., Suarez de Lezo, J., Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting (2012) Catheter Cardiovasc Interv, 80, pp. 1165-1170. , PID: 22511299; Ormiston, J.A., Webster, M.W., El Jack, S., Drug-eluting stents for coronary bifurcations: bench testing of provisional side-branch strategies (2006) Catheter Cardiovasc Interv, 67, pp. 49-55. , PID: 16003787; Mortier, P., Van Loo, D., De Beule, M., Comparison of drug-eluting stent cell size using micro-CT: important data for bifurcation stent selection (2008) EuroIntervention, 4, pp. 391-396. , PID: 19110814; Basalus, M.W., van Houwelingen, K.G., Ankone, M.J., Feijen, J., von Birgelen, C., Micro-computed tomographic assessment following extremely oversized partial postdilatation of drug-eluting stents (2010) EuroIntervention, 6, pp. 141-148. , PID: 20542810; Foin, N., Alegria-Barrero, E., Torii, R., Crush, culotte, T and protrusion: which 2-stent technique for treatment of true bifurcation lesions?—insights from in vitro experiments and micro-computed tomography (2013) Circ J, 77, pp. 73-80. , PID: 23006784; Basalus, M.W., Ankone, M.J., van Houwelingen, G.K., de Man, F.H., von Birgelen, C., Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy (2009) EuroIntervention, 5, pp. 157-165. , PID: 19577998; Foin, N., Sen, S., Allegria, E., Maximal expansion capacity with current DES platforms: a critical factor for stent selection in the treatment of left main bifurcations? (2013) EuroIntervention, 8, pp. 1315-1325. , PID: 23086760; Toledano Delgado, F.J., Alvarez-Ossorio, M.P., Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent (2014) Catheter Cardiovasc Interv, 84 (5), pp. 720-726; Yazdani, S.K., Nakano, M., Otsuka, F., Kolodgie, F.D., Virmani, R., Atheroma and coronary bifurcations: before and after stenting (2010) EuroIntervention, 6, pp. 24-30. , PID: 21930487; Burzotta, F., Mortier, P., Trani, C., Characteristics of drug-eluting stent platforms potentially influencing bifurcated lesion provisional stenting procedure (2014) EuroIntervention, 10, pp. 124-132. , PID: 24832640; Yoshimura, T., Tanaka, A., Mori, N., Difference of neointimal growth patterns in bifurcation lesions among four kinds of drug-eluting stents: an optical coherence tomographic study (2014) Catheter Cardiovasc Interv, 84 (5), pp. 742-749. , PID: 24497273; Garg, S., Wykrzykowska, J., Serruys, P.W., The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer (2011) EuroIntervention, 6, pp. 928-935. , PID: 21330239; Diletti, R., Garcia-Garcia, H.M., Bourantas, C.V., Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial (2013) Heart, 99, pp. 1267-1274. , COI: 1:CAS:528:DC%2BC3sXhs1Slsr7M, PID: 23800571; Dzavik, V., Kaul, U., Guagliumi, G., Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study (2013) Catheter Cardiovasc Interv, 82, pp. 163-172. , PID: 23225766; Chen, S.L., Santoso, T., Zhang, J.J., A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial (2011) J Am Coll Cardiol, 57, pp. 914-920. , PID: 21329837; Ruiz-Salmeron, R.J., Valenzuela, L.F., Perez, I., Approach to coronary bifurcation lesions using the everolimus-eluting stent: comparison between a simple strategy and a complex strategy with T-stenting (2013) Rev Esp Cardiol, 66, pp. 636-643. , PID: 24776332; Indulis Kumsars, M.N., Andrejs, E., Kari, K., Christiansen, E.H., Michael, M., Andis, D., Vytautas, A., Christian Juhl, T., Markku Ea, Hannu R, Per T (2013) Anne K,Tuija, , http://clinicaltrialresults.org/Slides/TCT_2013/Kumsars_Nordic-Baltic_Bifurcation_Study_IV.ppt, Pål G, Ole F, Fredrik C, Juha H, Svend Eggert J, Thomas E, Holm NR, Lassen JF, Leif T. Randomized comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch, TCT presentation:; Moussa, I.D., Coronary artery bifurcation interventions: the disconnect between randomized clinical trials and patient centered decision-making (2011) Catheter Cardiovasc Interv, 77, pp. 537-545. , PID: 21351230, This review provides valuable insight regarding pitfalls of currently available evidences and practical considerations in real-world practice; Hahn, J.-Y., Song, Y.B., Yang, J.H., TCT-689 Impact of final kissing ballooning on stent expansion, apposition, and neointimal hyperplasia in coronary bifurcation lesions treated with 1-stent technique (2012) J Am Coll Cardiol, 60 (17_S), p. 200; Koo, B.K., De Bruyne, B., FFR in bifurcation stenting: what have we learned? (2010) EuroIntervention, 6, pp. 94-98. , PID: 21930499, This review article provides comprehensive insights about FFR for evaluation and management of bifurcation lesions; Park, S.J., Kim, Y.H., Park, D.W., Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis (2009) Circ Cardiovasc Interv, 2, pp. 167-177. , PID: 20031713; Kim, J.S., Hong, M.K., Ko, Y.G., Impact of intravascular ultrasound guidance on long-term clinical outcomes in patients treated with drug-eluting stent for bifurcation lesions: data from a Korean multicenter bifurcation registry (2011) Am Heart J, 161, pp. 180-187. , COI: 1:CAS:528:DC%2BC3cXhsFyksrvF, PID: 21167352; Zhang, Y., Farooq, V., Garcia-Garcia, H.M., Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients (2012) EuroIntervention, 8, pp. 855-865. , PID: 23171805; Hahn, J.Y., Chun, W.J., Kim, J.H., Predictors and outcomes of side branch occlusion after main vessel stenting in coronary bifurcation lesions: results from the COBIS II Registry (COronary BIfurcation Stenting) (2013) J Am Coll Cardiol, 62, pp. 1654-1659. , PID: 23954335; Rahman, S., Leesar, T., Cilingiroglu, M., Impact of kissing balloon inflation on the main vessel stent volume, area, and symmetry after side-branch dilation in patients with coronary bifurcation lesions: a serial volumetric intravascular ultrasound study (2013) JACC Cardiovasc Interv, 6, pp. 923-931. , PID: 23954062; Hariki, H., Shinke, T., Otake, H., Potential benefit of final kissing balloon inflation after single stenting for the treatment of bifurcation lesions—insights from optical coherence tomography observations (2013) Circ J, 77, pp. 1193-1201. , PID: 23446003; Chen, S.L., Xu, B., Han, Y.L., Comparison of double kissing crush versus culotte stenting for unprotected distal left main bifurcation lesions: results from a multicenter, randomized, prospective DKCRUSH-III study (2013) J Am Coll Cardiol, 61, pp. 1482-1488. , PID: 23490040; Chen, S.L., Zhang, J.J., Ye, F., Study comparing the double kissing (DK) crush with classical crush for the treatment of coronary bifurcation lesions: the DKCRUSH-1 Bifurcation Study with drug-eluting stents (2008) Eur J Clin Investig, 38, pp. 361-371. , COI: 1:STN:280:DC%2BD1czis1Oqtg%3D%3D; Kervinen, K., Niemela, M., Romppanen, H., Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results (2013) JACC Cardiovasc Interv, 6, pp. 1160-1165. , PID: 24262616; Sgueglia, G.A., Chevalier, B., Kissing balloon inflation in percutaneous coronary interventions (2012) JACC Cardiovasc Interv, 5, pp. 803-811. , PID: 22917451, This review provides detailed literature review and practical guide regarding kissing balloon inflation which is essential component of bifurcation PCI; Chen, S.L., Ye, F., Zhang, J.J., Intravascular ultrasound-guided systematic two-stent techniques for coronary bifurcation lesions and reduced late stent thrombosis (2013) Catheter Cardiovasc Interv, 81, pp. 456-463. , PID: 22899562; Morlacchi, S., Chiastra, C., Cutri, E., Stent deformation, physical stress, and drug elution obtained with provisional stenting, conventional culotte and Tryton-based culotte to treat bifurcations: a virtual simulation study (2014) EuroIntervention, 9, pp. 1441-1453. , PID: 24755384; Naganuma, T., Latib, A., Basavarajaiah, S., The long-term clinical outcome of T-stenting and small protrusion technique for coronary bifurcation lesions (2013) JACC Cardiovasc Interv, 6, pp. 554-561. , PID: 23683737; Burzotta, F., De Vita, M., Sgueglia, G., Todaro, D., Trani, C., How to solve difficult side branch access? (2010) EuroIntervention, 6, pp. 72-80. , PID: 21930495; Alegria-Barrero, E., Foin, N., Chan, P.H., Optical coherence tomography for guidance of distal cell recrossing in bifurcation stenting: choosing the right cell matters (2012) EuroIntervention, 8, pp. 205-213. , PID: 22581489; Foin, N., Torii, R., Alegria, E., Location of side branch access critically affects results in bifurcation stenting: insights from bench modeling and computational flow simulation (2013) Int J Cardiol, 168, pp. 3623-3628. , COI: 1:STN:280:DC%2BC3snnslCquw%3D%3D, PID: 23714592; Ormiston, J.A., Webster, M.W., Webber, B., Stewart, J.T., Ruygrok, P.N., Hatrick, R.I., The ""crush"" technique for coronary artery bifurcation stenting: insights from micro-computed tomographic imaging of bench deployments (2008) JACC Cardiovasc Interv, 1, pp. 351-357. , PID: 19463329; Murasato, Y., Impact of three-dimensional characteristics of the left main coronary artery bifurcation on outcome of crush stenting (2007) Catheter Cardiovasc Interv, 69, pp. 248-256. , PID: 17211894; Dzavik, V., Kharbanda, R., Ivanov, J., Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: importance of the bifurcation angle (2006) Am Heart J, 152, pp. 762-769. , PID: 16996856; Hoye, A., Iakovou, I., Ge, L., Long-term outcomes after stenting of bifurcation lesions with the ""crush"" technique: predictors of an adverse outcome (2006) J Am Coll Cardiol, 47, pp. 1949-1958. , PID: 16697310; Adriaenssens, T., Byrne, R.A., Dibra, A., Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes (2008) Eur Heart J, 29, pp. 2868-2876. , PID: 19001472; Ormiston, J.A., Webster, M.W., Ruygrok, P.N., Stewart, J.T., White, H.D., Scott, D.S., Stent deformation following simulated side-branch dilatation: a comparison of five stent designs (1999) Catheter Cardiovasc Interv, 47, pp. 258-264. , COI: 1:STN:280:DyaK1MzgtlSjuw%3D%3D, PID: 10376516; Kawasaki, T., Koga, H., Serikawa, T., Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion (2009) Catheter Cardiovasc Interv, 73, pp. 205-211. , PID: 19085915; Koo, B.K., Kang, H.J., Youn, T.J., Physiologic assessment of jailed side branch lesions using fractional flow reserve (2005) J Am Coll Cardiol, 46, pp. 633-637. , PID: 16098427; Koo, B.K., Park, K.W., Kang, H.J., Physiological evaluation of the provisional side-branch intervention strategy for bifurcation lesions using fractional flow reserve (2008) Eur Heart J, 29, pp. 726-732. , PID: 18308689; Kumsars, I., Narbute, I., Thuesen, L., Side branch fractional flow reserve measurements after main vessel stenting: a Nordic-Baltic Bifurcation Study III substudy (2012) EuroIntervention, 7, pp. 1155-1161. , PID: 22334314; Chen, S.L., Ye, F., Zhang, J.J., (2015) Randomized Comparison of FFR-Guided and Angiography-Guided Provisional Stenting of True Coronary Bifurcation Lesions: The DKCRUSH-VI (Double Kissing Crush Versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions, , Trial, JACC Cardiovasc Interv:; Stankovic, G., Lefevre, T., Chieffo, A., Consensus from the 7th European Bifurcation Club meeting (2013) EuroIntervention, 9, pp. 36-45. , PID: 23552575; Latib, A., Colombo, A., Sangiorgi, G.M., Bifurcation stenting: current strategies and new devices (2009) Heart, 95, pp. 495-504. , COI: 1:STN:280:DC%2BD1M7ntF2mtQ%3D%3D, PID: 18812408, This comprehensive review provides detailed information regarding the dedicated bifurcation stents; Pillai, A.A., Jayaraman, B., Dedicated bifurcation stents (2012) Indian Heart J, 64, pp. 187-195. , PID: 22572498; Grundeken, M.J., Asgedom, S., Damman, P., Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies (2013) EuroIntervention, 9, pp. 195-203. , PID: 23360690; Buysschaert, I., Dubois, C.L., Dens, J., Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study (2013) EuroIntervention, 9, pp. 573-581. , PID: 24058075",Review,Scopus,2-s2.0-84928808051
"Zaccardi F., Pitocco D., Willeit P., Laukkanen J.A.","Efficacy and safety of P2Y<inf>12</inf> inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials",2015,"Atherosclerosis","240","2",,"439","445",,,10.1016/j.atherosclerosis.2015.04.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928015933&partnerID=40&md5=bf82a9ac4667757ff8b55314b7e3a37f","Institute of Internal Medicine and Diabetes Care Unit, Catholic University School of MedicineRome, Italy; Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Institute of Public Health and Clinical Nutrition, University of Eastern FinlandKuopio, Finland","Zaccardi, F., Institute of Internal Medicine and Diabetes Care Unit, Catholic University School of MedicineRome, Italy, Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Pitocco, D., Institute of Internal Medicine and Diabetes Care Unit, Catholic University School of MedicineRome, Italy; Willeit, P., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Laukkanen, J.A., Institute of Public Health and Clinical Nutrition, University of Eastern FinlandKuopio, Finland","Objective: The efficacy of antiplatelet drugs may differ in specific patient subgroups. We aimed to assess the efficacy and safety of the P2Y<inf>12</inf> inhibitors clopidogrel, ticlopidine, prasugrel, ticagrelor, and cangrelor according to diabetes status, age, gender, body mass index, and body weight. Methods: Randomized clinical trials (RCTs) of P2Y<inf>12</inf> inhibitors reporting information on cardiovascular disease (defined as myocardial infarction, stroke, or cardiovascular death) and bleeding (defined as any bleeding) events among the subgroups diabetes and non-diabetes, age ≥65 and <65 year-old, men and women, body mass index ≥30 and <30kg/m2, and body weight ≥60 and <60kg, were identified in Medline, Embase, Web of Science, and Cochrane Library on August 31st, 2014. For each inhibitor, random-effects meta-analyses were used to estimate the ratio of relative risks (rRR) for cardiovascular and bleeding events among patient subgroups. Results: Twenty distinct RCTs (233285 participants, 21323 cardiovascular and 5183 bleeding events) were identified. Cardiovascular risk reduction with clopidogrel did not significantly differ according to diabetes (rRR: 1.04; 95% CI: 0.95 to 1.13; p=0.395), age (0.98; 0.88 to 1.09; p=0.347), gender (0.97; 0.90 to 1.04; p=0.382), or body mass index (1.11, 0.95 to 1.31; p=0.191). Results for other inhibitors were comparable, although available data were sparse. Limited data on bleeding events were available. Conclusion: Data from RCTs did not show a different cardiovascular efficacy of clopidogrel in diabetes mellitus and other clinically relevant subgroups. Limited information was available on the efficacy and safety of other P2Y<inf>12</inf> inhibitors in specific subgroups. © 2015 Elsevier Ireland Ltd.","Antiplatelet resistance; Clopidogrel; Diabetes; Meta-analysis; P2Y<inf>12</inf> inhibitors; Thienopyridines","Patrono, C., Rocca, B., Drug insight: aspirin resistance-fact or fashion? (2007) Nat. Clin. Pract. Cardiovasc. Med., 4, pp. 42-50; Pulcinelli, F.M., Biasucci, L.M., Riondino, S., COX-1 sensitivity and TXA2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment (2009) Eur. Heart J., 30, pp. 1279-1286; Evangelista, V., De Berardis, G., Totani, L., Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin (2007) J.Thromb. Haemost., 5, pp. 2197-2203; Belch, J., MacCuish, A., Campbell, I., Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease (2008) BMJ, 337, pp. 1030-1036; Ogawa, H., Nakayama, M., Morimoto, T., Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A randomized controlled trial (2008) JAMA, 300, pp. 2134-2141; De Berardis, G., Sacco, M., Strippoli, G.F.M., Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials (2009) BMJ, 339. , b4531; Pignone, M.J., Alberts, M.J., Colwell, J.A., Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation (2010) Circulation, 121, pp. 2694-2701; Wang, T.H., Bhatt, D.L., Topol, E.J., Aspirin and clopidogrel resistance: an emerging clinical entity (2006) Eur. Heart J., 27, pp. 647-654; Angiolillo, D.J., Suryadevara, S., Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus (2009) Best Pract. Res. Clin. Endocrinol. Metab., 23, pp. 375-388; Siller-Matula, J.M., Trenk, D., Schrör, K., Response variability to P2Y<inf>12</inf> receptor inhibitors: expectations and reality (2013) JACC Cardiovasc. Interv., 6, pp. 1111-1128; Gagne, J.J., Bykov, K., Choudhry, N.K., Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison (2013) BMJ, 347. , f5307; Siller-Matula, J.M., Jilma, B., Why have studies of tailored anti-platelet therapy failed so far? (2013) Thromb. Haemost., 110, pp. 628-631; Calvin, A.D., Aggarwal, N.R., Murad, M.H., Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes (2009) Diabetes Care, 32, pp. 2300-2306; Moher, D., Liberati, A., Tetzlaff, J., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009) PLoS Med., 6. , PRISMA Group, e1000097; Higgins, J.P.T., Altman, D.G., Sterne, J.A.C., Assessing risk of bias in included studies (2011) Cochrane Handbook for Systematic Reviews of Interventions, , Cochrane Collaboration, J.P.T. Higgins, S. Green (Eds.); Altman, D.G., Bland, J.M., Interaction revisited: the difference between two estimates (2003) BMJ, 326, p. 219; Egger, M., Davey Smith, G., Schneider, M., Bias in meta-analysis detected by a simple, graphical test (1997) BMJ, 315, pp. 629-634; Connolly, S.J., Pogue, J., Hart, R.G., Effect of clopidogrel added to aspirin in patients with atrial fibrillation (2009) N.Engl. J. Med., 360, pp. 2066-2078. , ACTIVE Investigators; Arandomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) (1996) Lancet, 348, pp. 1329-1339; Bhatt, D.L., Marso, S.P., Hirsch, A.T., Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus (2002) Am. J. Cardiol., 90, pp. 625-628; Wang, Y., Wang, Y., Zhao, X., Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (2013) N.Engl. J. Med., 369, pp. 11-19. , CHANCE Investigators; Bhatt, D.L., Fox, K.A., Hacke, W., Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events (2006) N.Engl. J. Med., 354, pp. 1706-1717. , CHARISMA Investigators; Dasgupta, A., Steinhubl, S.R., Bhatt, D.L., Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial) (2009) Am. J. Cardiol., 103, pp. 1359-1363. , CHARISMA Investigators; Berger, J.S., Bhatt, D.L., Cannon, C.P., The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis (2009) J.Am. Coll. Cardiol., 54, pp. 1935-1945; Sabatine, M.S., Cannon, C.P., Gibson, C.M., Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation (2005) N.Engl. J. Med., 352, pp. 1179-1189. , CLARITY-TIMI 28 Investigators; Chen, Z.M., Jiang, L.X., Chen, Y.P., COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial (2005) Lancet, 366, pp. 1607-1621; Steinhubl, S.R., Berger, P.B., Mann, J.T., Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (2002) JAMA, 288, pp. 2411-2420. , CREDO Investigators; Yusuf, S., Zhao, F., Mehta, S.R., Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (2001) N.Engl. J. Med., 345, pp. 494-502; Mehta, S.R., Bassand, J.P., Chrolavicius, S., Dose comparisons of clopidogrel and aspirin in acute coronary syndromes (2010) N.Engl. J. Med., 363, pp. 930-942. , CURRENT-OASIS 7 Investigators; Sacco, R.L., Diener, H.C., Yusuf, S., Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke (2008) N.Engl. J. Med., 359, pp. 1238-1251. , PRoFESS Study Group; Benavente, O.R., Hart, R.G., McClure, L.A., Effects of clopidogrel added to aspirin in patients with recent lacunar stroke (2012) N.Engl. J. Med., 367, pp. 817-825. , SPS3 Investigators; Gent, M., Blakely, J.A., Easton, J.D., The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke (1989) Lancet, 1, pp. 1215-1220; Valentine, N., Van de Laar, F.A., van Driel, M.L., Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus (2012) Cochrane Database Syst. Rev., 11. , CD005449; Hass, W.K., Easton, J.D., Adams, H.P., Arandomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group (1989) N.Engl. J. Med., 321, pp. 501-507; Montalescot, G., Bolognese, L., Dudek, D., Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes (2013) N.Engl. J. Med., 369, pp. 999-1010. , ACCOAST Investigators; Roe, M.T., Armstrong, P.W., Fox, K.A., Prasugrel versus clopidogrel for acute coronary syndromes without revascularization (2012) N.Engl. J. Med., 367, pp. 1297-1309. , TRILOGY ACS Investigators; Wiviott, S.D., Braunwald, E., McCabe, C.H., Prasugrel versus clopidogrel in patients with acute coronary syndromes (2007) N.Engl. J. Med., 357, pp. 2001-2015. , TRITON-TIMI 38 Investigators; Wiviott, S.D., Braunwald, E., Angiolillo, D.J., Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 (2008) Circulation, 118, pp. 1626-1636. , TRITON-TIMI 38 Investigators; Wallentin, L., Becker, R.C., Budaj, A., Ticagrelor versus clopidogrel in patients with acute coronary syndromes (2009) N.Engl. J. Med., 361, pp. 1045-1057. , PLATO Investigators; James, S., Angiolillo, D.J., Cornel, J.H., Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial (2010) Eur. Heart J., 31, pp. 3006-3016; Husted, S., James, S., Becker, R.C., Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial (2012) Circ. Cardiovasc. Qual. Outcomes, 5, pp. 680-688. , PLATO Study Group; Harrington, R.A., Stone, G.W., McNulty, S., Platelet inhibition with cangrelor in patients undergoing PCI (2009) N.Engl. J. Med., 361, pp. 2318-2329; Bhatt, D.L., Stone, G.W., Mahaffey, K.W., Effect of platelet inhibition with cangrelor during PCI on ischemic events (2013) N.Engl. J. Med., 368, pp. 1303-1313. , CHAMPION PHOENIX Investigators; Bhatt, D.L., Lincoff, A.M., Gibson, C.M., Intravenous platelet blockade with cangrelor during PCI (2009) N.Engl. J. Med., 361, pp. 2330-2341. , CHAMPION PLATFORM Investigators; Andersson, C., Lyngbæk, S., Nguyen, C.D., Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes (2012) JAMA, 308, pp. 882-889; Jochmann, N., Stangl, K., Garbe, E., Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases (2005) Eur. Heart J., 26, pp. 1585-1595; Breet, N.J., van Donkersgoed, H.E., van Werkum, J.W., Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? (2011) Neth. Heart J., 19, pp. 279-284; Hochholzer, W., Trenk, D., Fromm, M.F., Impact of cytochrome P450 2C19 loss of function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement (2010) J.Am. Coll. Cardiol., 55, pp. 2427-2434; Rydén, L., Grant, P.J., Anker, S.D., ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) (2013) Eur. Heart J., 34, pp. 3035-3087",Article,Scopus,2-s2.0-84928015933
"Zhang Y.-J., Ma N., Su F., Liu H., Mei J.","Increased TRPM6 expression in atrial fibrillation patients contribute to atrial fibrosis",2015,"Experimental and Molecular Pathology","98","3",,"486","490",,,10.1016/j.yexmp.2015.03.025,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926378480&partnerID=40&md5=a4d9d2671c5c3d09d9bbe0ba6f52b590","Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong UniversityShanghai, China","Zhang, Y.-J., Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong UniversityShanghai, China; Ma, N., Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong UniversityShanghai, China; Su, F., Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong UniversityShanghai, China; Liu, H., Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong UniversityShanghai, China; Mei, J., Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong UniversityShanghai, China","Background: Transient receptor potential (TRP) family plays important roles in cardiovascular system. We investigated the relationship between transient receptor potential channel subfamily M6 (TRPM6) and atrial fibrosis in rheumatic heart disease patients with atrial fibrillation (AF). Methods: The right atrial tissue samples were obtained from 64 patients with rheumatic heart diseases who underwent heart valve replacement surgery, and composed of 34 sinus rhythm (SR) patients and 30 AF patients. Hematoxylin and Eosin (HE) staining was used to observe cross-sectional area (CSA) of myocardial cell. Masson staining and measurement of connective tissue growth factor (CTGF), transforming growth factor beta 1 (TGF-β 1), and collagen type I/III (Collagen I/III) were performed to determine atrial fibrosis. The mRNA and protein levels of TRPM6 were detected by real-time quantitative polymerase chain reaction (RT-PCR) and western blotting, respectively. Results: Marked increases were observed in CSA of myocardial cell and myocardial collagen volume fraction in AF group compared with the SR group (all P< 0.05). The mRNA levels of myocardial fibrosis markers (CTGF, TGF-beta 1, Collagen I/III) in AF group increased significantly compared to the SR group (all P< 0.05). TRPM6 mRNA and protein levels in AF group were elevated markedly in comparison with SR group (P< 0.01). Conclusion: These findings revealed that increased TRPM6 mRNA and protein levels may contribute to atrial fibrosis, and suggested that TRPM6 might be involved in AF development by promoting fibrogenesis. © 2015 Elsevier Inc.","Atrial fibrillation; Atrial fibrosis; MRNA level; Myocardial fibrosis markers; Protein level; Rheumatic heart disease; Sinus rhythm; Transient receptor potential channel subfamily M6; Transient receptor potential family","Adapala, R.K., TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals (2013) J. Mol. Cell. Cardiol., 54, pp. 45-52; Bennett, J.A., Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease (2002) Heart Lung, 31, pp. 262-270; Bodding, M., TRPM6: a Janus-like protein (2007) Handb. Exp. Pharmacol., pp. 299-311; Burstein, B., Nattel, S., Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation (2008) J. Am. Coll. Cardiol., 51, pp. 802-809; Chen, M.M., CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis (2000) J. Mol. Cell. Cardiol., 32, pp. 1805-1819; Chubanov, V., Essential role for TRPM6 in epithelial magnesium transport and body magnesium homeostasis (2005) Pflugers Arch., 451, pp. 228-234; Chugh, S.S., Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study (2014) Circulation, 129, pp. 837-847; Chugh, S.S., Global burden of atrial fibrillation in developed and developing nations (2014) Glob. Heart, 9, pp. 113-119; Chujo, S., Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model (2005) J. Cell. Physiol., 203, pp. 447-456; Davis, J., A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo (2012) Dev. Cell, 23, pp. 705-715; Du, J., TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation (2010) Circ. Res., 106, pp. 992-1003; Fonfria, E., Tissue distribution profiles of the human TRPM cation channel family (2006) J. Recept. Signal Transduct. Res., 26, pp. 159-178; Glas, J., IRGM variants and susceptibility to inflammatory bowel disease in the German population (2013) PLoS One, 8, p. e54338; Go, A.S., Heart disease and stroke statistics-2014 update: a report from the American Heart Association (2014) Circulation, 129, pp. e28-e292; Gwanyanya, A., Magnesium-inhibited, TRPM6/7-like channel in cardiac myocytes: permeation of divalent cations and pH-mediated regulation (2004) J. Physiol., 559, pp. 761-776; Harada, M., Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation (2012) Circulation, 126, pp. 2051-2064; Ihn, H., Pathogenesis of fibrosis: role of TGF-beta and CTGF (2002) Curr. Opin. Rheumatol., 14, pp. 681-685; Iwasaki, Y.K., Atrial fibrillation pathophysiology: implications for management (2011) Circulation, 124, pp. 2264-2274; Latorre, R., Structure-functional intimacies of transient receptor potential channels (2009) Q. Rev. Biophys., 42, pp. 201-246; Lin, Y.Z., Relationship between atrial fibroblast proliferation/fibrosis and atrial fibrillation in patients with rheumatic heart disease (2009) Zhonghua Xin Xue Guan Bing Za Zhi, 37, pp. 813-817; Lofsjogard, J., Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure (2014) Scand. Cardiovasc. J., 48, pp. 299-303; Lopez, B., Circulating biomarkers of collagen metabolism in cardiac diseases (2010) Circulation, 121, pp. 1645-1654; Magnani, J.W., Atrial fibrillation: current knowledge and future directions in epidemiology and genomics (2011) Circulation, 124, pp. 1982-1993; Oliveira, M., Acute vagal modulation of electrophysiology of the atrial and pulmonary veins increases vulnerability to atrial fibrillation (2011) Exp. Physiol., 96, pp. 125-133; Pedersen, S.F., TRP channels: an overview (2005) Cell Calcium, 38, pp. 233-252; Querejeta, R., Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis (2004) Circulation, 110, pp. 1263-1268; Reiffel, J.A., Atrial fibrillation and stroke: epidemiology (2014) Am. J. Med., 127, pp. e15-e16; Rondon, L.J., Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine (2008) Am. J. Physiol. Regul. Integr. Comp. Physiol., 294, pp. R2001-R2007; Schlingmann, K.P., Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family (2002) Nat. Genet., 31, pp. 166-170; Schlingmann, K.P., TRPM6 and TRPM7-gatekeepers of human magnesium metabolism (2007) Biochim. Biophys. Acta, 1772, pp. 813-821; Schotten, U., Pathophysiological mechanisms of atrial fibrillation: a translational appraisal (2011) Physiol. Rev., 91, pp. 265-325; Song, M.Y., Yuan, J.X., Introduction to TRP channels: structure, function, and regulation (2010) Adv. Exp. Med. Biol., 661, pp. 99-108; Sontia, B., Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium (2008) Hypertension, 51, pp. 915-921; Swartz, M.F., Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation (2012) J. Am. Coll. Cardiol., 60, pp. 1799-1806; Thodeti, C.K., A TRP to cardiac fibroblast differentiation (2013) Channels (Austin), 7, pp. 211-214; Tucker, N.R., Ellinor, P.T., Emerging directions in the genetics of atrial fibrillation (2014) Circ. Res., 114, pp. 1469-1482; Venkatachalam, K., Montell, C., TRP channels (2007) Annu. Rev. Biochem., 76, pp. 387-417; Vennekens, R., Emerging concepts for the role of TRP channels in the cardiovascular system (2011) J. Physiol., 589, pp. 1527-1534; Verrecchia, F., Mauviel, A., Transforming growth factor-beta and fibrosis (2007) World J. Gastroenterol., 13, pp. 3056-3062; Xiao, J., The genetics of atrial fibrillation: from the bench to the bedside (2011) Annu. Rev. Genomics Hum. Genet., 12, pp. 73-96; Xie, J., (2011) Regulation of Channel Enzymes and Their Contribution to Cardiac Fibrosis; Yue, L., Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation (2011) Cardiovasc. Res., 89, pp. 744-753; Zhang, Y.H., Evidence for functional expression of TRPM7 channels in human atrial myocytes (2012) Basic Res. Cardiol., 107, p. 282; Zhang, Y.H., Functional transient receptor potential canonical type 1 channels in human atrial myocytes (2013) Pflugers Arch., 465, pp. 1439-1449; Zhang, Z., The TRPM6 kinase domain determines the Mg.ATP sensitivity of TRPM7/M6 heteromeric ion channels (2014) J. Biol. Chem., 289, pp. 5217-5227",Article,Scopus,2-s2.0-84926378480
"Morishita M., Thompson K.C., Brook R.D.","Understanding Air Pollution and Cardiovascular Diseases: Is It Preventable?",2015,"Current Cardiovascular Risk Reports","9","6",,"","",9,,10.1007/s12170-015-0458-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928618220&partnerID=40&md5=1d9c875e764b65373d8782f1db9fa25e","School of Public Health, University of MichiganAnn Arbor, MI, United States; Division of Cardiovascular Medicine, University of MichiganAnn Arbor, MI, United States","Morishita, M., School of Public Health, University of MichiganAnn Arbor, MI, United States; Thompson, K.C., School of Public Health, University of MichiganAnn Arbor, MI, United States; Brook, R.D., Division of Cardiovascular Medicine, University of MichiganAnn Arbor, MI, United States","Fine particulate matter (<2.5 μm, PM<inf>2.5</inf>) air pollution is a leading risk factor for morbidity and mortality worldwide. The largest portion of adverse health effects is from cardiovascular diseases. In North America, PM<inf>2.5</inf> concentrations have shown a steady decline over the past several decades; however, the opposite trend has occurred throughout much of the developing world whereby daily concentrations commonly reach extraordinarily high levels. While air quality regulations can reduce air pollution at a societal level, what individuals can do to reduce their personal exposures remains an active field of investigation. Here, we review the emerging evidence that several interventions (e.g., air filters) and/or behavioral changes can lower PM pollution exposure and as such, may be capable of mitigating the ensuing adverse cardiovascular health consequences. Air pollution remains a worldwide epidemic and a multi-tiered prevention strategy is required in order to optimally protect global public health. © 2015, Springer Science+Business Media New York.","Air pollution; Cardiovascular disease risks; Interventions","Brook, R.D., Franklin, B., Cascio, W., Hong, Y., Howard, G., Lipsett, M., Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association (2004) Circulation, 109, pp. 2655-2671. , PID: 15173049; Brook, R.D., Rajagopalan, S., Pope, C.A., III, Brook, J.R., Bhatnagar, A., Diez-Roux, A., Particulate matter air pollution and cardiovascular disease. An update to the scientific statement from the American Heart Association (2010) Circulation, 121, pp. 2331-2378. , COI: 1:CAS:528:DC%2BC3cXmslGmu78%3D, PID: 20458016; Newby, D.E., Mannucci, P.M., Tell, G.S., Baccarelli, A.A., Brook, R.D., Donaldson, K., Expert position paper on air pollution and cardiovascular disease (2015) Eur Heart J, 36, pp. 83-93. , PID: 25492627, This is the latest updated review of the cardiovascular health effects of air pollution; Mustafic, H., Jabre, P., Caussin, C., Murad, M.H., Escolano, S., Tafflet, M., Main air pollutants and myocardial infarction: a systematic review and meta-analysis (2012) JAMA, 307, pp. 713-721. , COI: 1:CAS:528:DC%2BC38XisVCntLk%3D, PID: 22337682; Yu, X.B., Su, J.W., Li, X.Y., Chen, G., Short-term effects of particulate matter on stroke attack: meta-regression and meta-analyses (2014) PLoS One, 9. , PID: 24802512; Shah, A.S., Langrish, J.P., Nair, H., McAllister, D.A., Hunter, A.L., Donaldson, K., Global association of air pollution and heart failure: a systematic review and meta-analysis (2013) Lancet, 382, pp. 1039-1048. , COI: 1:CAS:528:DC%2BC3sXhtFShs7fO, PID: 23849322; Crouse, D.L., Peters, P.A., van Donkelaar, A., Goldberg, M.S., Villeneuve, P.J., Brion, O., Risk of nonaccidental and cardiovascular mortality in relation to long-term exposure to low concentrations of fine particulate matter: a Canadian national-level cohort study (2012) Environ Health Perspect, 120, pp. 708-714. , PID: 22313724; Hoek, G., Krishnan, R.M., Beelen, R., Peters, A., Ostro, B., Brunekreef, B., Long-term air pollution exposure and cardio-respiratory mortality: a review (2013) Environ Health, 12, p. 43. , COI: 1:CAS:528:DC%2BC3sXhtVWksbfM, PID: 23714370; Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) Lancet, 380, pp. 2224-2260. , PID: 23245609; Van Donkelaar, A., Martin, R.V., Brauer, M., Boys, B.L., Use of satellite observations for long-term exposure assessment of global concentrations of fine particulate matter (2015) Environ Health Perspect, 123, pp. 135-143. , PID: 25343779; Zhao, X., Sun, Z., Ruan, Y., Yan, J., Mukherjee, B., Yang, F., Personal black carbon exposure influences ambulatory blood pressure. Air pollution and cardiometabolic disease (AIRCMND-China) study (2014) Hypertension, 63, pp. 871-877. , COI: 1:CAS:528:DC%2BC2cXktFeksrs%3D, PID: 24420543; Rajagopalan, S., Brook, R.D., The indoor-outdoor air-pollution continuum and the burden of cardiovascular disease: An opporutnity for improving global health (2012) Glob Heart, 7, pp. 207-213. , PID: 23181202; Smith, K.R., Peel, J.L., Mind the gap (2010) Environ Health Perspect, 118, pp. 1643-1645. , COI: 1:CAS:528:DC%2BC3MXovVykuw%3D%3D, PID: 20729177; Balakrishnan, K., Ramaswamy, P., Sambandam, S., Thangavel, G., Ghosh, S., Johnson, P., Air pollution from household solid fuel combustion in India: an overview of exposure and health related information to inform health research priorities (2011) Glob Health Action, p. 4; Clancy, L., Goodman, P., Sinclair, H., Dockery, D.W., Effect of air-pollution control on death rates in Dublin, Ireland: an intervention study (2002) Lancet, 360, pp. 1210-1214. , PID: 12401247; Pope, C.A., III, Schwartz, J., Ransom, M.R., Daily mortality and PM<inf>10</inf> pollution in Utah Valley (1992) Arch Environ Health, 47, pp. 211-217. , PID: 1596104; Hedley, A.J., Wong, C.M., Thach, T.Q., Ma, S., Lam, T.H., Andderson, H.R., Cardiorespiratory and all-cause mortality after restrictions on sulphur content of fuel in Hong Kong: an intervention study (2002) Lancet, 360, pp. 1646-1652. , PID: 12457788; Pope, C.A., III, Rodemund, D.L., Gee, M.M., Mortality effects of a copper smelter strike and reduced ambient sulfate particulate matter air pollution (2007) Environ Health Perspect, 115, pp. 679-683. , COI: 1:CAS:528:DC%2BD2sXmt1Sks7w%3D, PID: 17520052; http://www.epa.gov/air/criteria.html, Accessed 21 Feb 2015http://epa.gov/airtrends/aqtrends.html, Accessed 21 Feb 2015Laden, F., Schwartz, J., Speizer, F.E., Dockery, D.W., Reduction in fine particulate air pollution and mortality. Extended follow-up of the Harvard Six Cities Study (2006) Am J Respir Crit Care Med, 173, pp. 667-672. , COI: 1:CAS:528:DC%2BD28XmslSrurk%3D, PID: 16424447; Lepeule, J., Laden, F., Dockery, D., Schwartz, J., Chronic exposure to fine particles and mortality: an extended follow-up of the Harvard Six Cities Study from 1974 to 2009 (2012) Environ Health Perspect, 120, pp. 965-970. , PID: 22456598; Pope, C.A., III, Ezzati, M., Dockery, D.W., Fine-particulate air pollution and life expectancy in the Unites States (2009) N Engl J Med, 360, pp. 376-386. , COI: 1:CAS:528:DC%2BD1MXhtVSltr8%3D, PID: 19164188; Correia, A.W., Pope, C.A., III, Dockery, D.W., Wang, Y., Ezzati, M., Dominici, F., Effect of air pollution control on life expectancy in the United States. An analysis of 545 U.S. counties for the period from 2000 to 2007 (2013) Epidemiology, 24, pp. 23-31. , PID: 23211349; Rich, D.Q., Kipen, H.M., Huang, W., Wang, G., Wang, Y., Zhu, P., Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults (2012) JAMA, 307, pp. 2068-2078. , COI: 1:CAS:528:DC%2BC38Xnt1yjsL0%3D, PID: 22665106, This study demonstrates that policy efforts to reduce ambient air pollutants at a city-wide scale can rapidly improve markers of cardiovascular health; Giles, L.V., Barn, P., Kunzli, N., Romieu, I., Mittleman, M.A., van Eeden, S., From good intentions to proven interventions: effectiveness of actions to reduce the health impacts of air pollution (2011) Environ Health Perspect, 119, pp. 29-36. , COI: 1:CAS:528:DC%2BC3MXhvVaht7s%3D, PID: 20729178; Henderson, D.E., Milford, J.B., Miller, S.L., Prescribed burns and wildfires in Colorado: impacts of mitigation measures on indoor air particulate matter (2005) J Air Waste Manag Assoc, 55, pp. 1516-1526. , COI: 1:CAS:528:DC%2BD2MXhtF2nurrL, PID: 16295277; Barn, P., Larson, T., Noullett, M., Kennedy, S., Copes, R., Brauer, M., Infiltration of forest fire and residential wood smoke: an evaluation of air cleaner effectiveness (2008) J Expo Sci Environ Epidemiol, 18, pp. 503-511. , COI: 1:CAS:528:DC%2BD1cXhtVSitbbJ, PID: 18059421; Bräuner, E.V., Forchhammer, L., Møller, P., Barregard, L., Gunnarsen, L., Afshari, A., Indoor particles affect vascular function in the aged: an air filtration-based intervention study (2008) Am J Respir Crit Care Med, 177, pp. 419-425. , PID: 17932377; Allen, R.W., Carlsten, C., Karlen, B., Leckie, S., van Eeden, S., Vedal, S., An air filter intervention study of endothelial function among healthy adults in a woodsmoke-impacted community (2011) Am J Respir Crit Care Med, 183, pp. 1222-1230. , PID: 21257787, This study shows that an indoor air filter can improve endothelial function within a few days; Lin, L.Y., Chen, H.W., Su, T.L., Hong, G.B., Huang, L.C., Chuang, K.J., The effects of indoor particle exposure on blood pressure and heart rate among young adults: an air filtration-based intervention study (2011) Atmos Environ, 45, pp. 5540-5544. , COI: 1:CAS:528:DC%2BC3MXhtVWjsbnM; Weichenthal, S., Mallach, G., Kulka, R., Black, A., Wheeler, A., You, H., A randomized double‐blind crossover study of indoor air filtration and acute changes in cardiorespiratory health in a First Nations community (2013) Indoor Air, 3, pp. 175-184; Karottki, D.G., Spilak, M., Frederiksen, M., Gunnarsen, L., Brauner, E.V., Kolarik, B., An indoor air filtration study in homes of elderly: cardiovascular and respiratory effects of exposure to particulate matter (2013) Environ Health, 12, p. 116. , PID: 24373585; Lin, L.Y., Lin, C.Y., Lin, Y.C., Chuang, K.J., The effects of indoor particles on blood pressure and heart rate among young adults in Taipei, Taiwan (2009) Indoor Air, 19, pp. 482-488. , PID: 19682103; Lin, L.Y., Chuang, H.C., Liu, I.J., Chen, H.W., Chuang, K.J., Reducing indoor air pollution by air conditioning is associated with improvements in cardiovascular health among the general population (2013) Sci Total Environ, 463, pp. 176-181. , PID: 23803502, This study shows that closing windows and using air conditioning can lower blood pressure among people living in a highly-polluted city; Chuang, H.C., Lin, L.Y., Hsu, Y.W., Ma, C.M., Chuang, K.J., In-car particles and cardiovascular health: an air conditioning-based intervention study (2013) Sci Total Environ, 452, pp. 309-313. , PID: 23523729; Bell, M.L., Ebisu, K., Peng, R.D., Dominici, F., Adverse health effects of particulate air pollution: modification by air conditioning (2009) Epidemiology, 20, pp. 682-686. , PID: 19535984; Vedal, S., Does air conditioning modify the health effects of exposure to outdoor air pollution? (2009) Epidemiology, 20, pp. 687-688. , PID: 19680037; Langrish, J.P., Li, X., Wang, S., Lee, M.M., Barnes, G.D., Miller, M.R., Reducing personal exposure to particulate air pollution improves cardiovascular health in patients with coronary heart disease (2012) Environ Health Perspect, 120, pp. 367-372. , COI: 1:CAS:528:DC%2BC38XltFKgu7k%3D, PID: 22389220, This study shows that wearing a facemask can prevent myocardial ischemia and lead to lower blood pressure levels during walking in a highly-polluted city; Langrish, J.P., Mills, N.L., Chan, J.K., Leseman, D.L., Aitken, R.J., Fokkens, P.H., Beneficial cardiovascular effects of reducing exposure to particulate air pollution with a simple facemask (2009) Part Fibre Toxicol, 6, p. 8. , PID: 19284642; Laumbach, R.J., Kipen, H.M., Ko, S., Kelly-McNeil, K., Cepeda, C., Pettit, A., A controlled trial of acute effects of human exposure to traffic particles on pulmonary oxidative stress and heart rate variability (2014) Part Fibre Toxicol, 11, p. 45. , PID: 25361615; Pui, D.Y., Qi, C., Stanley, N., Oberdörster, G., Maynard, A., Recirculating air filtration significantly reduces exposure to airborne nanoparticles (2008) Environ Health Perspect, 116, pp. 863-866. , PID: 18629306; Lucking, A.J., Lundbäck, M., Barath, S.L., Mills, N.L., Sidhu, M.K., Langrish, J.P., Particle traps prevent adverse vascular and prothrombotic effects of diesel engine exhaust inhalation in men (2011) Circulation, 123, pp. 1721-1728. , COI: 1:CAS:528:DC%2BC3MXltFyhsrg%3D, PID: 21482966, This study provides strong evidence that it is the particulate matter portion of air pollution that plays a role in causing endothelial dysfunction and adverse cardiovascular responses. Diesel particle traps are able to reduce particulate exposures and mitigate the harmful effects if exposures; Muala, A., Sehlstedt, M., Bion, A., Osterlund, C., Bosson, J.A., Behndig, A.F., Assessment of the capacity of vehicle cabin air inlet filters to reduce diesel exhaust-induced symptoms in human volunteers (2014) Environ Health, 13, p. 16. , PID: 24621126; Clark, M.L., Bachand, A.M., Heiderscheidt, J.M., Yoder, S.A., Luna, B., Volckens, J., Impact of a cleaner‐burning cookstove intervention on blood pressure in Nicaraguan women (2013) Indoor Air, 23, pp. 105-114. , COI: 1:STN:280:DC%2BC38bgtl2ltg%3D%3D, PID: 22913364; McCracken, J., Smith, K.R., Stone, P., Díaz, A., Arana, B., Schwartz, J., Intervention to lower household wood smoke exposure in Guatemala reduces ST-segment depression on electrocardiograms (2011) Environ Health Perspect, 119, pp. 1562-1568. , PID: 21669557; McCracken, J.P., Smith, K.R., Díaz, A., Mittleman, M.A., Schwartz, J., Chimney stove intervention to reduce long-term wood smoke exposure lowers blood pressure among Guatemalan women (2007) Environ Health Perspect, 115, pp. 996-1001. , PID: 17637912; Lissåker, C., Talbott, E.O., Kan, H., Xu, X., Status and determinants of individual actions to reduce health impacts of air pollution in U.S. adults (2014) Arch Environ Occup Health; Brook, R.D., Bard, R.L., Burnett, R.T., Shin, H.H., Vette, A., Croghan, C., Differences in blood pressure and vascular responses associated with ambient fine particulate matter exposures measured at the personal versus community level (2011) Occup Environ Med, 68, pp. 224-230. , PID: 20935292",Review,Scopus,2-s2.0-84928618220
"Abnousi F., Yong C.M., Fearon W., Banerjee D.","The Evolution of Temporary Percutaneous Mechanical Circulatory Support Devices: a Review of the Options and Evidence in Cardiogenic Shock",2015,"Current Cardiology Reports","17","6",,"","",7,,10.1007/s11886-015-0594-8,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928330007&partnerID=40&md5=fd7ae120cc9754990ae4a53c24fad236","Stanford University Medical Center, 300 Pasteur DriveStanford, CA, United States","Abnousi, F., Stanford University Medical Center, 300 Pasteur DriveStanford, CA, United States; Yong, C.M., Stanford University Medical Center, 300 Pasteur DriveStanford, CA, United States; Fearon, W., Stanford University Medical Center, 300 Pasteur DriveStanford, CA, United States; Banerjee, D., Stanford University Medical Center, 300 Pasteur DriveStanford, CA, United States","Temporary percutaneous mechanical circulatory support (MCS) devices were introduced in the 1960s and have developed into a diverse portfolio of options currently available for left, right, and biventricular support. Patients undergoing high-risk percutaneous coronary interventions (PCI), patients with acute myocardial infarction (AMI), and patients with cardiogenic shock in particular may benefit from these options. In this review, we will discuss the currently available devices and the evidence supporting their use in cardiogenic shock. © 2015, Springer Science+Business Media New York.","Percutaneous mechanical circulatory support; Ventricular assist device","Naidu, S.S., Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support (2011) Circulation, 123 (5), pp. 533-543. , PID: 21300961; Maini, B., Gregory, D., Scotti, D.J., Buyantseva, L., Percutaneous cardiac assist devices compared with surgical hemodynamic support alternatives: cost-effectiveness in the emergent setting (2014) Catheter Cardiovasc Interv, 83 (6), pp. 183-192. , PID: 24130115; Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Benjamin, E.J., Berry, J.D., Borden, W.B., Heart disease and stroke statistics—2012 update: a report from the American Heart Association (2012) Circulation, 125, pp. 2-220. , PID: 22179539; Awad, H.H., Anderson, F.A., Jr., Gore, J.M., Goodman, S.G., Goldberg, R.J., Cardiogenic shock complicating acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (2012) Am Heart J, 163, pp. 963-971. , PID: 22709748; Zeymer, U., Bauer, T., Hamm, C., Zahn, R., Weidinger, F., Seabra-Gomes, R., Use and impact of intra-aortic balloon pump on mortality in patients with acute myocardial infarction complicated by cardiogenic shock: results of the Euro Heart Survey on PCI (2011) EuroIntervention, 7, pp. 437-441. , PID: 21764661; Goldberg, R.J., Spencer, F.A., Gore, J.M., Lessard, D., Yarzebski, J., Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective (2009) Circulation, 119, pp. 1211-1219. , PID: 19237658; Lindholm, M.G., Kïber, L., Boesgaard, S., Torp-Pedersen, C., Aldershvile, J., Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development (2003) Eur Heart J, 24, pp. 258-265. , COI: 1:STN:280:DC%2BD3s%2FnvFyktw%3D%3D, PID: 12590903; Hochman, J.S., Buller, C.E., Sleeper, L.A., Boland, J., Dzavik, V., Sanborn, T.A., Cardiogenic shock complicating acute myocardial infarction—etiologies, management and outcome: a report from the SHOCK trial registry (2000) J Am Coll Cardiol, 36, pp. 1063-1070. , COI: 1:STN:280:DC%2BD3cvlvV2ksw%3D%3D, PID: 10985706; Werdan, K., Gielen, S., Ebelt, H., Hochman, J.S., Mechanical circulatory support in cardiogenic shock (2014) Eur Heart J, 35 (3), pp. 156-167. , COI: 1:CAS:528:DC%2BC2cXhtVOmt7Y%3D, PID: 24014384; Scheidt, S., Wilner, G., Mueller, H., Summers, D., Lesch, M., Wolff, G., Intra-aortic balloon counterpulsation in cardiogenic shock: report of a co-operative clinical trial (1973) N Engl J Med, 288, pp. 979-984. , COI: 1:STN:280:DyaE3s7ltlGgsQ%3D%3D, PID: 4696253; Ouweneel, D.M., Henriques, J.P., Percutaneous cardiac support devices for cardiogenic shock: current indications and recommendations (2012) Heart, 98 (16), pp. 1246-1254. , COI: 1:CAS:528:DC%2BC38XhtlOgur7N, PID: 22826561; Hatch, J., Baklanov, D., Percutaneous hemodynamic support in PCI (2014) Curr Treat Options Cardiovasc Med, 16, p. 293. , PID: 24522337; Ho, K.W., Dzavik, V., Haemodynamic support devices for complex and high-risk percutaneous coronary intervention (2011) Interv Cardiol, 6 (1), pp. 17-24; Thiele, H., Zeymer, U., Neumann, F.J., Intraaortic balloon support for myocardial infarction with cardiogenic shock (2012) N Engl J Med, 367, p. 1287. , COI: 1:CAS:528:DC%2BC38XhsFWksL3M, PID: 22920912; Thiele, H., Zeymer, U., Neumann, F.J., Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial (2013) Lancet, 382, p. 1638. , PID: 24011548, This is a major trial of IABP in cardiogenic shock; Chen, E.W., Canto, J.G., Parsons, L.S., Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock (2003) Circulation, 108, p. 951. , PID: 12912817; Sjauw, K.D., Engström, A.E., Vis, M.M., A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? (2009) Eur Heart J, 30, p. 459. , PID: 19168529; Gibbon, J.H., Jr., The development of the heart-lung apparatus (1978) Am J Surg, 135, pp. 608-619. , PID: 347960; Kawashima, D., Gojo, S., Nishimura, T., Itoda, Y., Kitahori, K., Motomura, N., Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation (2011) ASAIO J, 57, pp. 169-176. , PID: 21317769; Sheu, J.J., Tsai, T.H., Lee, F.Y., Fang, H.Y., Sun, C.K., Leu, S., Early extracorporeal membrane oxygenator- assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock (2010) Crit Care Med, 38, pp. 1810-1817. , COI: 1:CAS:528:DC%2BC3cXhtVGmtrzM, PID: 20543669; Cheng, J.M., den Uil, C.A., Hoeks, S.E., Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials (2009) Eur Heart J, 30 (17), pp. 2102-2108. , PID: 19617601; Thiele, H., Sick, P., Boudriot, E., Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock (2005) Eur Heart J, 26 (13), pp. 1276-1283. , PID: 15734771; Burkhoff, D., O’Neill, W., Brunckhorst, C., Feasibility study of the use of the TandemHeart percutaneous ventricular assist device for treatment of cardiogenic shock (2006) Catheter Cardiovasc Interv, 68 (2), pp. 211-217. , PID: 16819767; Seyfarth, M., Sibbing, D., Bauer, I., A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction (2008) J Am Coll Cardiol, 52 (19), pp. 1584-1588. , PID: 19007597; Kar, B., Gregoric, I.D., Basra, S.S., Idelchik, G.M., Loyalka, P., The percutaneous ventricular assist device in severe refractory cardiogenic shock (2011) J Am Coll Cardiol, 57, pp. 688-696. , PID: 20950980; Henriques, J.P., Remmelink, M., Baan, J., Jr., Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5 (2006) Am J Cardiol, 97, p. 990; Dixon, S.R., Henriques, J.P., Mauri, L., A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (the PROTECT I Trial): initial U.S. experience (2009) JACC Cardiovasc Interv, 2, p. 91; O’Neill, W.W., Kleiman, N.S., Moses, J., Henriques, J.P., Dixon, S., Massaro, J., A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study (2012) Circulation, 126 (14), pp. 1717-1727. , PID: 22935569, This is a major trial of Impella versus IABP",Review,Scopus,2-s2.0-84928330007
"Lee M.S., Kong J.","Achieving Safe Femoral Arterial Access",2015,"Current Cardiology Reports","17","6",,"","",8,,10.1007/s11886-015-0596-6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928591699&partnerID=40&md5=e6433a60c0b71773871ec1d0c1ec9997","Division of Cardiology, UCLA Medical Center, 100 Medical Plaza, Suite 630Los Angeles, CA, United States","Lee, M.S., Division of Cardiology, UCLA Medical Center, 100 Medical Plaza, Suite 630Los Angeles, CA, United States; Kong, J., Division of Cardiology, UCLA Medical Center, 100 Medical Plaza, Suite 630Los Angeles, CA, United States","Percutaneous coronary intervention can lead to vascular access complications that prolong patient hospital stay and costs as well as increase patient morbidity and mortality. Given its ease of use and familiarity, transfemoral access is still the preferred method of approach by many operators. The transfemoral approach is used when large bore access is required or if transradial access is not feasible due to variations in the anatomy of the upper extremity artery. The use of fluoroscopy, ultrasonography, and femoral angiography can help the operator obtain proper arteriotomy of the common femoral artery. Measures to decrease vascular access complications include proper technique, optimal pharmacotherapy, and avoiding the use of arterial sheaths >6 Fr. Optimal pharmacotherapy includes the use of bivalirudin and weight-based unfractionated heparin to avoid supratherapeutic activated clotting times, and to avoid glycoprotein IIb/IIIa inhibitors. When used appropriately, vascular closure devices can decrease the risk of bleeding complications. Randomized trials are needed to confirm these recommendations. © 2015, Springer Science+Business Media New York.","Bleeding; Vascular access; Vascular complications","Verheugt, F.W., Steinhubl, S.R., Hamon, M., Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention (2011) JACC Interv, 4, pp. 191-197. , This study evaluates the frequency and associated mortality of both access and nonaccess site bleeding after percutaneous coronary intervention. It also compares the effectiveness and safety of different antithrombotic therapies in this setting; Brueck, M., Bandorski, D., Kramer, W., Wieczorek, M., Höltgen, R., Tillmanns, H., A randomized comparison of transradial versus transfemoral approach for coronary angiography and angioplasty (2009) JACC Cardiovasc Interv, 2 (11), pp. 1047-1054. , PID: 19926042; Kugelmass, A.D., Cohen, D.J., Brown, P.P., Simon, A.W., Becker, E.R., Culler, S.D., Hospital resources consumed in treating complications associated with percutaneous coronary interventions (2006) Am J Cardiol, 97, pp. 322-327. , PID: 16442389; Rao, S.V., Jollis, J.G., Harrington, R.A., Granger, C.B., Newby, L.K., Armstrong, P.W., Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes (2004) JAMA, 292, pp. 1555-1562. , COI: 1:CAS:528:DC%2BD2cXot1aks7Y%3D, PID: 15467057; Yang, X., Alexander, K.P., Chen, A.Y., Roe, M.T., Brindis, R.G., Rao, S.V., The implications of blood transfusions for patients with non-ST segment elevation acute coronary syndromes: results from the crusade national quality improvement initiative (2005) J Am Coll Cardiol, 46, pp. 1490-1495. , PID: 16226173; Manoukian, S., Feit, F., Mehran, R., Voeltz, M.D., Ebrahimi, R., Hamon, M., Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial (2007) J Am Coll Cardiol, 49, pp. 1362-1368. , PID: 17394970; Farouque, H.M.O., Tremmel, J.A., Shabari, F.R., Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices (2005) J Am Coll Cardiol, 45, pp. 363-368. , COI: 1:CAS:528:DC%2BD2MXoslChtw%3D%3D, PID: 15680713; Ellis, S.G., Bhatt, D., Kapadia, S., Lee, D., Yen, M., Whitlow, P.L., Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention (2006) Catheter Cardiovasc Interv, 67, pp. 541-545. , PID: 16547938; Resnic, F.S., Arora, N., Matheny, M., Reynolds, M.R., A cost-minimization analysis of the Angio-Seal vascular closure device following percutaneous coronary intervention (2007) Am J Cardiol, 99, pp. 766-770. , PID: 17350361; Eikelboom, J.W., Mehta, S.R., Anand, S.S., Xie, C., Fox, K.A., Yusuf, S., Adverse impact of bleeding on prognosis in patients with acute coronary syndromes (2006) Circulation, 114, pp. 774-782. , PID: 16908769; Pinto, D.S., Stone, G.W., Shi, C., Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes (2008) J Am Coll Cardiol, 52, pp. 1758-1768. , COI: 1:CAS:528:DC%2BD1cXhsVWht7jL, PID: 19022155; Ndrepepa, G., Berger, P.B., Mehilli, J., Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point (2008) J Am Coll Cardiol, 51, pp. 690-697. , PID: 18279731; Spencer, F.A., Moscucci, M., Granger, C.B., Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? (2007) Circulation, 116, pp. 2793-2801. , PID: 18025530; Nikolsky, E., Aymong, E.D., Halkin, A., Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial (2004) J Am Coll Cardiol, 44, pp. 547-553. , PID: 15358018; Twomley, K.M., Rao, S.V., Becker, R.C., Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions (2006) J Thromb Thrombolysis, 21, pp. 167-174. , PID: 16622613; Cooper, C.J., El-Shiekh, R.A., Cohen, D.J., Effect of transradial access on quality of life and cost of cardiac catheterization: a randomized comparison (1999) Am Heart J, 138, pp. 430-436. , COI: 1:STN:280:DyaK1MzpslyqsA%3D%3D, PID: 10467191; Jolly, S.S., Cairns, J., Niemela, K., Steg, P.G., Natarajan, M.K., Cheema, A.N., Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial (2013) JACC Interv, 6, pp. 258-266; Rapoport, S., Sniderman, K.W., Morse, S.S., Proto, M.H., Ross, G.R., Pseudoaneurysm: a complication of faulty technique in femoral arterial puncture (1985) Radiology, 154, pp. 529-530. , COI: 1:STN:280:DyaL2M%2FovFekug%3D%3D, PID: 3966139; Garrett, P.D., Eckart, R.E., Bauch, T.D., Thompson, C.M., Stajduhar, K.C., Fluoroscopic localization of the femoral head as a landmark for common femoral artery cannulation (2005) Catheter Cardiovasc Interv, 65, pp. 205-207. , PID: 15900552; Schnyder, G., Sawhney, N., Whisenant, B., Tsimikas, S., Turi, Z.G., Common femoral artery anatomy is influenced by demographics and comorbidities: implications for cardiac and peripheral invasive studies (2001) Catheter Cardiovasc Interv, 53, pp. 289-295. , COI: 1:STN:280:DC%2BD3MvgsF2gtA%3D%3D, PID: 11458402; Fitts, J., Ver, L.P., Hofmaster, P., Malenka, D., Fluoroscopy-guided femoral artery puncture reduces the risk of PCI-related vascular complications (2008) J Interv Cardiol, 21, pp. 273-278. , PID: 18341522; Turi, Z.G., Optimizing vascular access: routine femoral angiography keeps the vascular complication away (2005) Catheter Cardiovasc Interv, 65, pp. 203-204. , PID: 15895408; Turi, Z.G., Fluoroscopy guided vascular access: asking the right question, but getting the wrong answer? (2009) Catheter Cardiovasc Interv, 74, pp. 540-542. , PID: 19780060; Baim, S.D., Percutaneous approach, including trans-septal and apical puncture (2000) Grossman’s cardiac catheterization, angiography, and intervention, pp. 69-100. , Baim SD, Grossman W, (eds), Lippincott Williams and Wilkins, Philadelphia:; Abu-Fadel, M.S., Sparling, J.M., Zacharias, S.J., Fluoroscopy vs. traditional guided femoral arterial access and the use of closure devices: a randomized controlled trial (2009) Catheter Cardiovasc Interv, 74, pp. 533-539. , PID: 19626694; Jacobi, J., Schussler, J.M., Johnson, K.B., Routine femoral head fluoroscopy to reduce complications in coronary catheterization (2009) Proc (Bayl Univ Med Cent), 22, pp. 7-8; Huggins, C.E., Gillespie, M.J., Tan, W.A., A prospective randomized clinical trial of the use of fluoroscopy in obtaining femoral arterial access (2009) J Invasive Cardiol, 21, pp. 105-109. , PID: 19258640; Ahmed, B., Piper, W.D., Malenka, D., Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the Northern New England Percutaneous Coronary Intervention Registry (2009) Circ Cardiovasc Interv, 2, pp. 423-429. , PID: 20031752; Gabriel, M., Pawlaczyk, K., Waliszewski, K., Krasinski, Z., Majewski, W., Location of femoral artery puncture site and the risk of postcatheterization pseudoaneurysm formation (2007) Int J Cardiol, 120, pp. 167-171. , PID: 17250906; Seto, A.H., Abu-Fadel, M.S., Sparling, J.M., Real-time ultrasound guidance facilitates femoral arterial access and reduces vascular complications: FAUST (Femoral Arterial Access with Ultrasound Trial) (2010) JACC Cardiovasc Interv, 3, pp. 751-758. , PID: 20650437; Ben-Dor, I., Maluenda, G., Mahmoudi, M., Torguson, R., Xue, Z., Bernardo, N., A novel, minimally invasive access technique versus standard 18-gauge needle set for femoral access (2012) Catheter Cardiovasc Interv, 79, pp. 1180-1185. , PID: 22334384, This study examines the differences in access site complications using the Micropunture 21 gauge (G) needle vs. the standard 18G needle in patients undergoing percutaneous coronary intervention via the femoral approach; Muller, D.W., Shamir, K.J., Ellis, S.G., Topol, E.J., Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures (1992) Am J Cardiol, 69, pp. 63-68. , COI: 1:STN:280:DyaK387gvFajtQ%3D%3D, PID: 1729869; Trimarchi, S., Smith, D.E., Share, D., Jani, S.M., O’Donnell, M., McNamara, R., Retroperitoneal hematoma after percutaneous coronary intervention: prevalence, risk factors, management, outcomes, and predictors of mortality: a report from the BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) registry (2010) JACC Cardiovasc Interv, 3, pp. 845-850. , PID: 20723857; Sanborn, T.A., Ebrahimi, R., Manoukian, S.V., McLaurin, B.T., Cox, D.A., Feit, F., Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial (2010) Circ Cardiovasc Interv, 3, pp. 57-62. , COI: 1:CAS:528:DC%2BC3cXjt1Gmt74%3D, PID: 20118151; Sherev, D.A., Shaw, R.E., Brent, B.N., Angiographic predictors of femoral access site complications: implication for planned percutaneous coronary intervention (2005) Catheter Cardiovasc Interv, 65, pp. 196-202. , PID: 15895402; Turi, Z.G., Ooze you lose: II, are we really getting better all the time? (2002) Catheter Cardiovasc Interv, 57, pp. 484-485. , PID: 12455082; Sittig, K.M., Rohr, M.S., McDonald, J.C., Abdominal wall, umbilicus, peritonium, mesenteries, omentum, and retroperitonium (2001) Sabistan textbook of surgery, pp. 769-773. , Townsend CM, Buachamp RO, Evers BM, Mattay KL, (eds), W.B. Saunders, Philadelphia:; Altin, R.S., Flicker, S., Naidech, H.J., Pseudoaneurysm and arteriovenous fistula after femoral artery catheterization: association with low femoral punctures (1988) Am J Roentgenol, 152, p. 629; Kim, D., Orron, D.E., Skillman, J.J., Role of superficial femoral artery puncture in the development of pseudoaneurysm and arteriovenous fistula complicating percutaneous transfemoral cardiac catheterization (1992) Cathet Cardiovasc Diagn, 25, pp. 91-97. , COI: 1:STN:280:DyaK387otlWktw%3D%3D, PID: 1544161; Patel, M.R., Jneid, H., Derdeyn, C.P., Klein, L.W., Levine, G.N., Lookstein, R.A., Arteriotomy closure devices for cardiovascular procedures: a scientific statement from the American Heart Association (2010) Circulation, 122, pp. 1882-1893. , PID: 20921445; Doyle, B.J., Ting, H.H., Bell, M.R., Lennon, R.J., Mathew, V., Singh, M., Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005 (2008) J Am Coll Cardiol Intv, 1, pp. 202-209; Applegate, R.J., Sacrinty, M.T., Kutcher, M.A., Kahl, F.R., Gandhi, S.K., Santos, R.M., Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007 (2008) J Am Coll Cardiol Intv, 1, pp. 317-326; Metz, D., Meyer, P., Touati, C., Comparison of 6F with 7F and 8F guiding catheters for elective coronary angioplasty: results of a prospective, multicenter, randomized trial (1997) Am Heart J, 134, pp. 131-137. , COI: 1:STN:280:DyaK2svhtVSkuw%3D%3D, PID: 9266794; Dehmer, G.J., Weaver, D., Roe, M.T., Milford-Beland, S., Fitzgerald, S., Hermann, A., A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011 (2012) J Am Coll Cardiol, 60, pp. 2017-2031. , PID: 23083784; Lincoff, A.M., Bittl, J.A., Harrington, R.A., Feit, F., Kleiman, N.S., Jackman, J.D., Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial (2003) JAMA, 289, pp. 853-863. , COI: 1:CAS:528:DC%2BD3sXht1Ohu7Y%3D, PID: 12588269; Stone, G.W., McLaurin, B.T., Cox, D.A., Bivalirudin for patients with acute coronary syndromes (2006) N Engl J Med, 355, pp. 2203-2216. , COI: 1:CAS:528:DC%2BD28Xht1Chsb3L, PID: 17124018; Stone, G.W., Witzennbichler, B., Guagliumi, G., Bivalirudin during primary PCI in acute myocardial infarction (2008) N Engl J Med, 358, pp. 2218-2230. , COI: 1:CAS:528:DC%2BD1cXmt1Gju7Y%3D, PID: 18499566; Kastrati, A., Neumann, F.J., Schulz, S., Massberg, S., Byrne, R.A., Ferenc, M., (2011) N Engl J Med, 365, pp. 1980-1989. , PID: 22077909, This study compares the combination of glycoprotein IIb/IIIa inhibitors and heparin with bivalirudin treatments specifically in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention; Marso, S.P., Amin, A.P., House, J.A., Kennedy, K.F., Spertus, J.A., Rao, S.V., Association between bleeding events and in-hospital mortality after percutaneous coronary intervention (2010) JAMA, 303, pp. 2156-2164. , COI: 1:CAS:528:DC%2BC3cXntVaitrs%3D, PID: 20516416; Rassen, J.A., Mittleman, M.A., Glynn, R.J., Alan Brookhart, M., Schneeweiss, S., (2010) Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention, 31, pp. 561-572; Bertrand, O.F., Jolly, S.S., Rao, S.V., Patel, T., Belle, L., Bernat, I., Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention (2012) Am J Cardiol, 110, pp. 599-606. , COI: 1:CAS:528:DC%2BC38XntVSktbs%3D, PID: 22591669; Alexander, K.P., Chen, A.Y., Roe, M.T., Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes (2005) JAMA, 294, pp. 3108-3116. , COI: 1:CAS:528:DC%2BD28Xmtl2l, PID: 16380591; Levine, G.N., Bates, E.R., Blankenship, J.C., 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions (2011) Circulation, 124, pp. 2574-2609. , PID: 22064598; Brener, S.J., Moliterno, D.J., Lincoff, A.M., Steinhubl, S.R., Wolski, K.E., Topol, E.J., Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention (2004) Circulation, 110, pp. 994-998. , PID: 15302778; Stabile, E., Nammas, W., Salemme, L., The CIAO (Coronary Interventions Antiplatelet-based Only) study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention (2008) J Am Coll Cardiol, 52, pp. 1293-1298. , PID: 18929239; Lee, M.S., Oyama, J., Iqbal, Z., Tarantini, G., Low-dose heparin for elective percutaneous coronary intervention (2014) J Interv Cardiol, 27, pp. 58-62. , PID: 24152197; Kastrati, A., Mehilli, J., Neumann, F.J., Dotzer, F., ten Berg, J., Bollwein, H., Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial (2006) JAMA, 295, pp. 1531-1538. , COI: 1:CAS:528:DC%2BD28Xjt12isbc%3D, PID: 16533938; O’Gara, P.T., Kushner, F.G., Ascheim, D.D., 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2012) J Am Coll Cardiol, 61, pp. 1-26; Steinhubl, S.R., Berger, P.B., Mann, J.T., 3rd, Fry, E.T., DeLago, A., Wilmer, C., Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (2002) JAMA, 288, pp. 2411-2420. , COI: 1:CAS:528:DC%2BD38XoslOksL0%3D, PID: 12435254; Wallentin, L., Becker, R.C., Budaj, A., Ticagrelor vs clopidogrel in patients with acute coronary syndromes (2009) N Engl J Med, 361, pp. 1045-1057. , COI: 1:CAS:528:DC%2BD1MXhtFaltL%2FJ, PID: 19717846; Wiviott, S.D., Braunwald, E., McCabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Prasugrel versus clopidogrel in patients with acute coronary syndromes (2007) N Engl J Med, 357, pp. 2001-2015. , COI: 1:CAS:528:DC%2BD2sXhtlWis7rN, PID: 17982182; Blankenship, J.C., Balog, C., Sapp, S.K., Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials (2002) Catheter Cardiovasc Interv, 57, pp. 476-483. , PID: 12455081; Subherwal, S., Bach, R.G., Chen, A.Y., Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction (2009) Circulation, 119, pp. 1873-1882. , PID: 19332461; Büchler, J.R., Ribeiro, E.E., Falcão, J.L., Randomized trial of 5 versus 7 French guiding catheters for transfemoral percutaneous coronary stent implantation (2008) J Interv Cardiol, 21, pp. 50-55. , PID: 18093100; Gallo, R., Steinhubl, S.R., White, H.D., Montalescot, G., Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial (2009) Catheter Cardiovasc Interv, 73, pp. 319-325. , PID: 19213086; Nikolsky, E., Mehran, R., Halkin, A., Aymong, E.D., Mintz, G.S., Lasic, Z., Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis (2004) J Am Coll Cardiol, 44, pp. 1200-1209. , PID: 15364320; Arora, N., Matheny, M.E., Sepke, C., Resnic, F.S., A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices (2007) Am Heart J, 153, pp. 606-611. , PID: 17383300; Vaitkus, P.T., A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention (2004) J Invasive Cardiol, 16, pp. 243-246. , PID: 15152128; Applegate, R.J., Sacrinty, M., Kutcher, M.A., Vascular complications with newer generations of angioseal vascular closure devices (2006) J Interv Cardiol, 19, pp. 67-74. , PID: 16483343; Balzer, J.O., Scheinert, D., Diebold, T., Haufe, M., Vogl, T.J., Biamino, G., Postinterventional transcutaneous suture of femoral artery access sites in patients with peripheral arterial occlusive disease: a study of 930 patients (2001) Catheter Cardiovasc Interv, 53, pp. 174-181. , COI: 1:STN:280:DC%2BD3Mzhtl2rsQ%3D%3D, PID: 11387600; Warren, B.S., Warren, S.G., Miller, S.D., Predictors of complications and learning curve using the Angio-Seal closure device following interventional and diagnostic catheterization (1999) Catheter Cardiovasc Interv, 48, pp. 162-166. , COI: 1:STN:280:DyaK1MvjvVeisg%3D%3D, PID: 10506771; Bangalore, S., Arora, N., Resnic, F.S., Vascular closure device failure: frequency and implications: a propensity-matched analysis (2009) Circ Cardiovasc Interv, 2, pp. 549-556. , PID: 20031773",Review,Scopus,2-s2.0-84928591699
"Cainzos-Achirica M., Eissler K., Blaha M.J., Blumenthal R.S., Martin S.S.","Tools for cardiovascular risk assessment in clinical practice",2015,"Current Cardiovascular Risk Reports","9","6",,"","",12,,10.1007/s12170-015-0455-4,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928341072&partnerID=40&md5=1a87044b91bff1f51a572c98476402ee","Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins UniversityBaltimore, MD, United States; Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Johns Hopkins Medical Institutions, Carnegie 568ABaltimore, MD, United States","Cainzos-Achirica, M., Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins UniversityBaltimore, MD, United States, Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Johns Hopkins Medical Institutions, Carnegie 568ABaltimore, MD, United States; Eissler, K., Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Johns Hopkins Medical Institutions, Carnegie 568ABaltimore, MD, United States; Blaha, M.J., Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins UniversityBaltimore, MD, United States, Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Johns Hopkins Medical Institutions, Carnegie 568ABaltimore, MD, United States; Blumenthal, R.S., Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Johns Hopkins Medical Institutions, Carnegie 568ABaltimore, MD, United States; Martin, S.S., Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins UniversityBaltimore, MD, United States, Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Johns Hopkins Medical Institutions, Carnegie 568ABaltimore, MD, United States","Precise risk stratification of atherosclerotic cardiovascular disease guides best management and therefore is a public health priority. In addition to risk estimation using traditional risk factors, tools such as coronary artery calcium, high-sensitivity C-reactive protein, ankle-brachial index and carotid imaging, and clinical features such as family history of premature coronary heart disease may offer opportunities for a more personalized risk assessment. In this review, we discuss the strengths and limitations of each of these tools, focusing on the evidence provided by the latest studies relevant to the field. Among them, coronary artery calcium currently stands out as the most powerful tool for cardiovascular risk assessment, as recognized by the 2013 ACC/AHA Risk Assessment Guideline. Recent studies have expanded our knowledge regarding its value for improving the detection of both low and high absolute risk within clinically relevant subgroups, as well as for cost-effectively guiding preventive therapy allocation. © 2015, Springer Science+Business Media New York.","Absolute cardiovascular risk; Ankle-brachial index; Atherosclerosis; Cardiovascular disease; Carotid intima-media thickness; Carotid plaque; Coronary artery calcium; Family history; High-sensitivity C-reactive protein; Prevention; Risk assessment; Risk management; Risk scores; Serum biomarkers; Traditional risk factors","Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Heart disease and stroke statistics—2014 update: a report from the American Heart Association (2014) Circulation, 129, pp. e28-e292. , PID: 24352519; http://www.who.int/gho/publications/world_health_statistics/en/, World Health Organization. Global Health Observatory. World Health Statistics 2014. Available at Accessed January 6, 2015Gupta, A., Wang, Y., Spertus, J.A., Geda, M., Lorenze, N., Nkonde-Price, C., Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010 (2014) J Am Coll Cardiol, 64 (4), pp. 337-345. , PID: 25060366, This study showed that acute myocardial infarction hospitalization rates in young adults have not declined over the past decade in the US; Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (2004) Lancet, 364 (9438), pp. 937-952. , PID: 15364185; Libby, P., Mechanisms of acute coronary syndromes and their implications for therapy (2013) N Engl J Med, 368 (21), pp. 2004-2013. , COI: 1:CAS:528:DC%2BC3sXhtVOqtrfE, PID: 23697515; Erbel, R., Budoff, M., Improvement of cardiovascular risk prediction using coronary imaging: subclinical atherosclerosis: the memory of lifetime risk factor exposure (2012) Eur Heart J, 33 (10), pp. 1201-1133. , PID: 22547221, This review addressed the role of subclinical atherosclerosis as the vascular memory of lifetime exposure to risk factors, and of CAC, an atherosclerosis-imaging technique, as a tool for a more accurate risk prediction; McEvoy, J.W., Diamond, G.A., Detrano, R.C., Kaul, S., Blaha, M.J., Blumenthal, R.S., Risk and the physics of clinical prediction (2014) Am J Cardiol, 113 (8), pp. 1429-1435. , PID: 24581923, This review addressed the inherent limitations of the risk score-based approach for predicting an individual’s cardiovascular risk; Akosah, K.O., Schaper, A., Cogbill, C., Schoenfeld, P., Preventing myocardial infarction in the young adult in the first place: how do the national cholesterol education panel III guidelines perform? (2003) J Am Coll Cardiol, 41, pp. 1475-1479. , PID: 12742284; Lakoski, S.G., Greenland, P., Wong, N.D., Schreiner, P.J., Herrington, D.M., Kronmal, R.A., Coronary artery calcium scores and risk for cardiovascular events in women classified as ""low risk"" based on Framingham risk score: the Multi-Ethnic Study of Atherosclerosis (MESA) (2007) Arch Intern Med, 167, pp. 2437-2442. , PID: 18071165; Michos, E.D., Nasir, K., Braunstein, J.B., Rumberger, J.A., Budoff, M.J., Post, W.S., Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women (2006) Atherosclerosis, 184, pp. 201-206. , COI: 1:CAS:528:DC%2BD2MXht1Olu7jJ, PID: 15907856; Ford, E.S., Giles, W.H., Mokdad, A.H., The distribution of 10-year risk for coronary heart disease among US adults: findings from the national health and nutrition examination survey III (2004) J Am Coll Cardiol, 43 (10), pp. 1791-1796. , PID: 15145101; Ford, E.S., Will, J.C., Mercado, C.I., Loustalot, F., Trends in predicted risk for atherosclerotic cardiovascular disease using the pooled cohort risk equations among US adults from 1999 to 2012 (2014) JAMA Intern Med; Pencina, M.J., Navar-Boggan, A.M., D’Agostino, R.B., Sr., Williams, K., Neely, B., Sniderman, A.D., Application of new cholesterol guidelines to a population-based sample (2014) N Engl J Med, 370 (15), pp. 1422-1431. , COI: 1:CAS:528:DC%2BC2cXmsVWrurc%3D, PID: 24645848, This study used NHANES to calculate the number of US adults who would be considered eligible for statin therapy according to the 2013 ACC/AHA guidelines; Goff, D.C., Jr., Lloyd-Jones, D.M., Bennett, G., Coady, S., D’Agostino, R.B., Sr., Gibbons, R., 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) J Am Coll Cardiol, 63, pp. 2935-2959. , PID: 24239921, The 2013 ACC/AHA cardiovascular risk assessment guidelines; Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) J Am Coll Cardiol, 63 (25 Pt B), pp. 2889-2934. , PID: 24239923, The 2013 ACC/AHA treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk guidelines; Eckel, R.H., Jakicic, J.M., Ard, J.D., de Jesus, J.M., Houston Miller, N., Hubbard, V.S., 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) J Am Coll Cardiol, 63, pp. 2960-2984. , PID: 24239922; Jensen, M.D., Ryan, D.H., Apovian, C.M., Ard, J.D., Comuzzie, A.G., Donato, K.A., 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society (2014) J Am Coll Cardiol, 63, pp. 2985-3023. , PID: 24239920; Ridker, P.M., Cook, N.R., Statins: new American guidelines for prevention of cardiovascular disease (2013) Lancet, 382 (9907), pp. 1762-1765. , PID: 24268611, This study found that the implementation of the 2013 ACC/AHA risk assessment guidelines in modern cohorts resulted in a risk overestimation of up to 150%; Goff, D.C., Lloyd-Jones, D.M., Bennett, G., Gibbons, R., Greenland, P., Lackland, D.T., ACC/AHA guideline on the assessment of cardiovascular risk (2013) Risk Assessment Full Work Group Report, , http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437741.48606.98/suppl/DC1; Cook, N.R., Ridker, P.M., Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women’s health study (2014) JAMA Intern Med, 174 (12), pp. 1964-1971. , PID: 25285455, This study found that differences in statin use, revascularizations or underascertainment of events did not fully explain the discrepancy between observed rates of ASCVD in the WHS and those predicted by the 2013 ACC/AHA risk estimator; Karmali, K.N., Goff, D.C., Jr., Ning, H., Lloyd-Jones, D.M., A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease (2014) J Am Coll Cardiol, 64 (10), pp. 959-968. , PID: 25190228, This study addressed potential explanations for the risk overestimation resulting from the implementation of the 2013 ACC/AHA risk estimator in modern cohorts; Miedema, M.D., Lopez, F.L., Blaha, M.J., Virani, S.S., Coresh, J., Ballantyne, C.M., Eligibility for statin therapy according to new cholesterol guidelines and prevalent Use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort (2015) JAMA Intern Med, 175 (1), pp. 138-140. , PID: 25401375; Lloyd-Jones, D.M., Goff, D., Stone, N.J., Statins, risk assessment, and the new American prevention guidelines (2014) Lancet, 383 (9917), pp. 600-602. , COI: 1:CAS:528:DC%2BC3sXhvFyru7vI, PID: 24315619; Martin, S.S., Blumenthal, R.S., Concepts and controversies: the 2013 American College of Cardiology/American Heart Association Risk Assessment and Cholesterol Treatment Guidelines (2014) Ann Intern Med, 160 (5), pp. 356-358. , PID: 24473832, This editorial comment discussed the key controversies of the 2013 ACC/AHA risk assessment guidelines, and provided recommendations regarding the key features that should be addressed in the patient-physician discussion; Blaha, M.J., Dardari, Z.A., Blumenthal, R.S., Martin, S.S., Nasir, K., Al-Mallah, M.H., The new ""intermediate risk"" group: a comparative analysis of the new 2013 ACC/AHA risk assessment guidelines versus prior guidelines in men (2014) Atherosclerosis, 237 (1), pp. 1-4. , COI: 1:CAS:528:DC%2BC2cXhsVaktLnJ, PID: 25173946, This study showed how, compared with previous versions, the 2013 ACC/AHA guidelines produce an abridged, more temporary and lower risk ""intermediate risk"" group, and addressed its implications regarding the use of personalized risk assessment tools; (1995) J Am Coll Cardiol, 1996 (27), pp. 957-1047; Dhiman, P., Kai, J., Horsfall, L., Walters, K., Qureshi, N., Availability and quality of coronary heart disease family history in primary care medical records: implications for cardiovascular risk assessment (2014) PLoS One, 9, p. e81998. , PID: 24416135; Anderson, T.J., Grégoire, J., Hegele, R.A., Couture, P., Mancini, G.B., McPherson, R., 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult (2013) Can J Cardiol, 29, pp. 151-167. , PID: 23351925; Jacobson, T.A., Lipoprotein(a), cardiovascular disease, and contemporary management (2013) Mayo Clin Proc, 88, pp. 1294-1311. , COI: 1:CAS:528:DC%2BC3sXhslaitrzE, PID: 24182706; Williamson, C., Jeemon, P., Hastie, C.E., McCallum, L., Muir, S., Dawson, J., Family history of premature cardiovascular disease: blood pressure control and long-term mortality outcomes in hypertensive patients (2014) Eur Heart J, 35, pp. 563-570. , PID: 24344191; Pandey, A.K., Pandey, S., Blaha, M.J., Agatston, A., Feldman, T., Ozner, M., Family history of coronary heart disease and markers of subclinical cardiovascular disease: where do we stand? (2013) Atherosclerosis, 228, pp. 285-294. , COI: 1:CAS:528:DC%2BC3sXlsFelu7k%3D, PID: 23578356; Nasir, K., Budoff, M.J., Wong, N.D., Scheuner, M., Herrington, D., Arnett, D.K., Family history of premature coronary heart disease and coronary artery calcification: multi-ethnic study of atherosclerosis (MESA) (2007) Circulation, 116, pp. 619-626. , PID: 17646582; Wilkins, J.T., Gidding, S., Liu, K., Ning, H., Polak, J.F., Lloyd-Jones, D.M., Associations between a parental history of premature cardiovascular disease and carotid intima-media thickness: the coronary artery risk development in young adults (CARDIA) study (2014) Eur J Prev Cardiol, 21, pp. 601-607. , PID: 23027592; Pandey, A.K., Blaha, M.J., Sharma, K., Rivera, J., Budoff, M.J., Blankstein, R., Family history of coronary heart disease and the incidence and progression of coronary artery calcification: multi-ethnic study of atherosclerosis (MESA) (2014) Atherosclerosis, 232, pp. 369-376. , COI: 1:CAS:528:DC%2BC2cXhsVyrtLo%3D, PID: 24468150; Cohen, R., Budoff, M., McClelland, R.L., Sillau, S., Burke, G., Blaha, M., Significance of a positive family history for coronary heart disease in patients with a zero coronary artery calcium score (from the multi-ethnic study of atherosclerosis) (2014) Am J Cardiol, 114, pp. 1210-1214. , PID: 25152422; Agatston, A.S., Janowitz, W.R., Hildner, F.J., Zusmer, N.R., Viamonte, M., Jr., Detrano, R., Quantification of coronary artery calcium using ultrafast computed tomography (1990) J Am Coll Cardiol, 15 (4), pp. 827-832. , COI: 1:STN:280:DyaK3c7ntFelug%3D%3D, PID: 2407762; Rumberger, J.A., Simons, D.B., Fitzpatrick, L.A., Sheedy, P.F., Schwartz, R.S., Coronary artery calcium area by electron beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study (1995) Circulation, 92 (8), pp. 2157-2162. , COI: 1:STN:280:DyaK28%2FhslaqsA%3D%3D, PID: 7554196; Guerci, A.D., Spadaro, L.A., Popma, J.J., Goodman, K.J., Brundage, B.H., Budoff, M., Relation of coronary calcium score by electron beam computed tomography to arteriographic findings in asymptomatic and symptomatic adults (1997) Am J Cardiol, 79 (2), pp. 128-133. , COI: 1:STN:280:DyaK2szjs1aitw%3D%3D, PID: 9193010; Tinana, A., Mintz, G.S., Weissman, N.J., Volumetric intravascular ultrasound quantification of the amount of atherosclerosis and calcium in nonstenotic arterial segments (2002) Am J Cardiol, 89 (6), pp. 757-760. , PID: 11897220; Detrano, R., Guerci, A.D., Carr, J.J., Bild, D.E., Burke, G., Folsom, A.R., Coronary calcium as a predictor of coronary events in four racial or ethnic groups (2008) N Engl J Med, 358 (13), pp. 1336-1345. , COI: 1:CAS:528:DC%2BD1cXjvFCgsrk%3D, PID: 18367736; Greenland, P., More evidence for coronary calcium as a measure of cardiovascular risk: has anything changed? (2014) JAMA, 311 (3), pp. 247-248. , COI: 1:CAS:528:DC%2BC2cXisVGisrg%3D, PID: 24247361; Yeboah, J., McClelland, R.L., Polonsky, T.S., Burke, G.L., Sibley, C.T., O’Leary, D., Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals (2012) JAMA, 308 (8), pp. 788-795. , COI: 1:CAS:528:DC%2BC38XhsVyjtr3O, PID: 22910756, This study found that combining CAC with the FRS risk factors provided a superior discrimination and risk reclassification than adding CIMT, ABI, brachial flow-mediated dilation, hsCRP or family history of coronary heart disease; Kavousi, M., Elias-Smale, S., Rutten, J.H., Leening, M.J., Vliegenthart, R., Verwoert, G.C., Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study (2012) Ann Intern Med, 156 (6), pp. 438-444. , PID: 22431676, This study found that among 12 novel risk assessment tools including atherosclerosis-imaging techniques, serum biomarkers and other tests, adding CAC to the FRS risk factors resulted in the greatest improvement in risk prediction; Rana, J.S., Gransar, H., Wong, N.D., Shaw, L., Pencina, M., Nasir, K., Comparative value of coronary artery calcium and multiple blood biomarkers for prognostication of cardiovascular events (2012) Am J Cardiol, 109 (10), pp. 1449-1453. , COI: 1:CAS:528:DC%2BC38Xktleqtrs%3D, PID: 22425333, This study found that the addition of CAC but not biomarkers (neither individually nor combined in a multiple biomarker panel) substantially improved risk reclassification for future CVD events beyond traditional risk factors; Erbel, R., Möhlenkamp, S., Moebus, S., Schmermund, A., Lehmann, N., Stang, A., Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf recall study (2010) J Am Coll Cardiol, 56 (17), pp. 1397-1406. , PID: 20946997, This study showed that in subjects considered at intermediate risk by the FRS, CAC scoring resulted in a high risk reclassification rate; Peters, S.A.E., den Ruijter, H.M., Bots, M.L., Moons, K.G., Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review (2012) Heart, 98 (3), pp. 177-184. , PID: 22095617, This systematic review provided high-quality evidence regarding the added value of CAC as a tool for further cardiovascular risk assessment beyond traditional risk factors; Silverman, M.G., Blaha, M.J., Krumholz, H.M., Budoff, M.J., Blankstein, R., Sibley, C.T., Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the multi-ethnic study of atherosclerosis (2014) Eur Heart J, 35 (33), pp. 2232-2241. , COI: 1:CAS:528:DC%2BC2cXhslCht7nM, PID: 24366919, This study showed how among individuals without traditional risk factors, a high CAC score is associated with high event rates, whereas the absence of CAC even among subjects with a high traditional risk factor burden is associated with low event rates; Martin, S.S., Blaha, M.J., Blankstein, R., Agatston, A., Rivera, J.J., Virani, S.S., Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis (2014) Circulation, 129 (1), pp. 77-86. , COI: 1:CAS:528:DC%2BC2cXktFCiug%3D%3D, PID: 24141324, This study found that among individuals without lipid abnormalities or with low levels of LDL-C, a high CAC score is associated with high CVD event rates, whereas CAC = 0 is associated with low event rates even among subjects with several lipid abnormalities or high levels of LDL-C; Gibson, A.O., Blaha, M.J., Arnan, M.K., Sacco, R.L., Szklo, M., Herrington, D.M., Coronary artery calcium and incident cerebrovascular events in an asymptomatic cohort: the MESA study (2014) JACC Cardiovasc Imaging, 7 (11), pp. 1108-1115. , PID: 25459592; Pletcher, M.J., Pignone, M., Earnshaw, S., McDade, C., Phillips, K.A., Auer, R., Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis (2014) Circ Cardiovasc Qual Outcomes, 7 (2), pp. 276-284. , PID: 24619318, This study found CAC testing to be a cost-effective strategy for cardiovascular risk assessment and statin therapy allocation in intermediate risk patients; Miedema, M.D., Duprez, D.A., Misialek, J.R., Blaha, M.J., Nasir, K., Silverman, M.G., Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis (2014) Circ Cardiovasc Qual Outcomes, 7 (3), pp. 453-460. , PID: 24803472; Bittencourt, M.S., Blaha, M.J., Blankstein, R., Budoff, M., Vargas, J.D., Blumenthal, R.S., Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis) (2014) J Am Coll Cardiol, 63 (5), pp. 434-443. , PID: 24161320; Sarwar, A., Shaw, L.J., Shapiro, M.D., Blankstein, R., Hoffman, U., Cury, R.C., Diagnostic and prognostic value of absence of coronary artery calcification (2009) JACC Cardiovasc Imaging, 2 (6), pp. 675-688. , PID: 19520336; Brodov, Y., Gransar, H., Rozanski, A., Hayes, S.W., Friedman, J.D., Thomson, L.E., Extensive thoracic aortic calcification is an independent predictor of development of coronary artery calcium among individuals with coronary artery calcium score of zero (2015) Atherosclerosis, 238 (1), pp. 4-8. , COI: 1:CAS:528:DC%2BC2cXhvVGgur%2FN, PID: 25461732; Al Rifai, M., Cainzos-Achirica, M., Blaha, M.J., Establishing the warranty of a coronary artery calcium score of zero (2015) Atherosclerosis, 238 (1), pp. 1-3. , COI: 1:CAS:528:DC%2BC2cXhvVGgurjJ, PID: 25461731; Silverman, M.G., Harkness, J.R., Blankstein, R., Budoff, M.J., Agatston, A.S., Carr, J.J., Baseline subclinical atherosclerosis burden and distribution are associated with frequency and mode of future coronary revascularization: multi-ethnic study of atherosclerosis (2014) JACC Cardiovasc Imaging, 7 (5), pp. 476-486. , PID: 24831208, This study showed that regional distribution of CAC predicted the need for coronary revascularization independently of baseline CAC burden; Criqui, M.H., Denenberg, J.O., Ix, J.H., McClelland, R.L., Wassel, C.L., Rifkin, D.E., Calcium density of coronary artery plaque and risk of incident cardiovascular events (2014) JAMA, 311 (3), pp. 271-278. , COI: 1:CAS:528:DC%2BC2cXitlKgsr8%3D, PID: 24247483, This study found CAC density to be significantly and inversely associated with CHD and CVD risk, at any level of CAC volume; McEvoy, J.W., Blaha, M.J., Coronary artery calcium testing: exploring the need for a randomized trial (2014) Circ Cardiovasc Imaging, 7 (4), pp. 578-580. , PID: 25027452; Cho, I., Suh, J.W., Chang, H.J., Kim, K.I., Jeon, E.J., Choi, S.I., Prevalence and prognostic implication of non-calcified plaque in asymptomatic population with coronary artery calcium score of zero (2013) Korean Circ J, 43 (3), pp. 154-160. , COI: 1:CAS:528:DC%2BC3sXnsVWktbc%3D, PID: 23613691; Shreibati, J.B., Baker, L.C., McConnell, M.V., Hlatky, M.A., Outcomes after coronary artery calcium and other cardiovascular biomarker testing among asymptomatic medicare beneficiaries (2014) Circ Cardiovasc Imaging, 7 (4), pp. 655-662. , PID: 24777939, This study found, among asymptomatic Medicare beneficiaries, CAC testing to be associated with increased use of cardiac tests and procedures, and with higher spending, as well as with improved clinical outcomes, compared with hs-CRP testing; Pepys, M.B., Hirschfield, G.M., C-reactive protein: a critical update (2003) J Clin Invest, 111, pp. 1805-1812. , COI: 1:CAS:528:DC%2BD3sXkvV2ktb0%3D, PID: 12813013; Kuller, L.H., Tracy, R.P., Shaten, J., Meilahn, E.N., Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study multiple risk factor intervention trial (1996) Am J Epidemiol, 144, pp. 537-547. , COI: 1:STN:280:DyaK28zptVGhtQ%3D%3D, PID: 8797513; Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men (1997) N Engl J Med, 336, pp. 973-979. , COI: 1:CAS:528:DyaK2sXisFOrtL0%3D, PID: 9077376; Amrock, S.M., Weitzman, M., Effect of increased leptin and C-reactive protein levels on mortality: results from the National Health and Nutrition Examination Survey (2014) Atherosclerosis, 236 (1), pp. 1-6. , COI: 1:CAS:528:DC%2BC2cXht1Grt77K, PID: 24998933; Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M., Jr., Kastelein, J.J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (2008) N Engl J Med, 359 (21), pp. 2195-2207. , COI: 1:CAS:528:DC%2BD1cXhtl2gurnL, PID: 18997196; Yousuf, O., Mohanty, B.D., Martin, S.S., Joshi, P.H., Blaha, M.J., Nasir, K., High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? (2013) J Am Coll Cardiol, 62 (5), pp. 397-408. , COI: 1:CAS:528:DC%2BC3sXhtFCqsbfK, PID: 23727085, This review found that currently available evidence does not support the use of hsCRP neither as a tool for routine cardiovascular risk assessment nor for the allocation of statin therapy in clinical practice; Blaha, M.J., Budoff, M.J., DeFilippis, A.P., Blankstein, R., Rivera, J.J., Agatston, A., Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study (2011) Lancet, 378 (9792), pp. 684-692. , COI: 1:CAS:528:DC%2BC3MXhtVGmtrzF, PID: 21856482; Kaptoge, S., Di Angelantonio, E., Pennells, L., Wood, A.M., White, I.R., Gao, P., C-reactive protein, fibrinogen, and cardiovascular disease prediction (2012) N Engl J Med, 367 (14), pp. 1310-1320. , PID: 23034020; Bower, J.K., Lazo, M., Juraschek, S.P., Selvin, E., Within-person variability in high-sensitivity C-reactive protein (2012) Arch Intern Med, 172 (19), pp. 1519-1521. , COI: 1:CAS:528:DC%2BC38XhslygurvM, PID: 22945505; Anderson, T.J., Gerhard, M.D., Meredith, I.T., Charbonneau, F., Delagrange, D., Creager, M.A., Systemic nature of endothelial dysfunction in atherosclerosis (1995) Am J Cardiol, 75 (6), pp. 71B-74. , COI: 1:CAS:528:DyaK2MXkslGltLs%3D, PID: 7863979; Xu, D., Zou, L., Xing, Y., Hou, L., Wei, Y., Zhang, J., Diagnostic value of ankle-brachial index in peripheral arterial disease: a meta-analysis (2013) Can J Cardiol, 29 (4), pp. 492-498. , PID: 22926041; Resnick, H.E., Lindsay, R.S., McDermott, M.M., Devereux, R.B., Jones, K.L., Fabsitz, R.R., Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the strong heart study (2004) Circulation, 109 (6), pp. 733-739. , PID: 14970108; Fan, H., Hu, X., Yu, W., Cao, H., Wang, J., Li, J., Low ankle-brachial index and risk of stroke (2013) Atherosclerosis, 229 (2), pp. 317-323. , COI: 1:CAS:528:DC%2BC3sXhtFCktLjN, PID: 23880182; Doobay, A.V., Anand, S.S., Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review (2005) Arterioscler, Thromb, Vasc Biol, 25 (7), pp. 1463-1469. , COI: 1:CAS:528:DC%2BD2MXltlSit7k%3D; Pande, R.L., Perlstein, T.S., Beckman, J.A., Creager, M.A., Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004 (2011) Circulation, 124, pp. 17-23. , PID: 21690489; Lin, J.S., Olson, C.M., Johnson, E.S., Whitlock, E.P., The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force (2013) Ann Intern Med, 159 (5), pp. 333-341. , PID: 24026319, This systematic review found that currently available evidence is insufficient to assess the balance of harms and benefits of CVD risk assessment using the ABI; Moyer, V.A., US Preventive Services Task Force Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: US Preventive Services Task Force recommendation statement (2013) Ann Intern Med, 159, pp. 342-348. , PID: 24026320; Davies, J.H., Kenkre, J., Williams, E.M., Current utility of the ankle-brachial index (ABI) in general practice: implications for its use in cardiovascular disease screening (2014) BMC Fam Pract, 15, p. 69. , PID: 24742018; Lorenz, M.W., Markus, H.S., Bots, M.L., Rosvall, M., Sitzer, M., Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis (2007) Circulation, 115, pp. 459-467. , PID: 17242284; Baldassarre, D., Veglia, F., Hamsten, A., Humphries, S.E., Rauramaa, R., de Faire, U., Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study (2013) Arterioscler, Thromb, Vasc Biol, 33 (9), pp. 2273-2279. , COI: 1:CAS:528:DC%2BC3sXht1Oqtr7N; Folsom, A.R., Kronmal, R.A., Detrano, R.C., O’Leary, D.H., Bild, D.E., Bluemke, D.A., Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA) (2008) Arch Intern Med, 168 (12), pp. 1333-1339. , PID: 18574091; Polak, J.F., Pencina, M.J., Pencina, K.M., O’Donnell, C.J., Wolf, P.A., D’Agostino, R.B., Sr., Carotid-wall intima-media thickness and cardiovascular events (2011) N Engl J Med, 365 (3), pp. 213-221. , COI: 1:CAS:528:DC%2BC3MXptlGqs7g%3D, PID: 21774709; Den Ruijter, H.M., Peters, S.A., Anderson, T.J., Britton, A.R., Dekker, J.M., Eijkemans, M.J., Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis (2012) JAMA, 308 (8), pp. 796-803. , This meta-analysis found that the addition of common CIMT measurements to the FRS resulted in a modest improvement in CVD risk prediction, unlikely to have clinical relevance; Zavodni, A.E., Wasserman, B.A., McClelland, R.L., Gomes, A.S., Folsom, A.R., Polak, J.F., Carotid artery plaque morphology and composition in relation to incident cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA) (2014) Radiology, 271 (2), pp. 381-389. , PID: 24592924, This study found carotid plaque morphology, composition and remodeling (assessed using MRI) to improve cardiovascular risk predictions when added to traditional risk factors; Belcaro, G., Nicolaides, A.N., Ramaswami, G., Cesarone, M.R., De Sanctis, M., Incandela, L., Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study(1)) (2001) Atherosclerosis, 156, pp. 379-387. , COI: 1:CAS:528:DC%2BD3MXktVKqtb8%3D, PID: 11395035; Irie, Y., Katakami, N., Kaneto, H., Takahara, M., Nishio, M., Kasami, R., The utility of ultrasonic tissue characterization of carotid plaque in the prediction of cardiovascular events in diabetic patients (2013) Atherosclerosis, 230 (2), pp. 399-405. , COI: 1:CAS:528:DC%2BC3sXhsFentbbJ, PID: 24075774; Stein, J.H., Korcarz, C.E., Hurst, R.T., Lonn, E., Kendall, C.B., Mohler, E.R., Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine (2008) J Am Soc Echocardiogr, 21 (2), pp. 93-111. , PID: 18261694; Gardin, J.M., Bartz, T.M., Polak, J.F., O’Leary, D.H., Wong, N.D., What do carotid intima-media thickness and plaque add to the prediction of stroke and cardiovascular disease risk in older adults? The cardiovascular health study (2014) J Am Soc Echocardiogr, 27 (9), pp. 998-1005. , PID: 25172401; Greenland, P., Alpert, J.S., Beller, G.A., Benjamin, E.J., Budoff, M.J., Fayad, Z.A., 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2010) J Am Coll Cardiol, 56 (25), pp. e50-e103. , PID: 21144964; Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) Eur Heart J, 33 (13), pp. 1635-1701. , COI: 1:CAS:528:DC%2BC38XhtVeitr3P, PID: 22555213; Muhlestein, J.B., Lappé, D.L., Lima, J.A., Rosen, B.D., May, H.T., Knight, S., Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial (2014) JAMA, 312 (21), pp. 2234-2243. , COI: 1:CAS:528:DC%2BC2MXisFyiur4%3D, PID: 25402757; Shechter, M., Issachar, A., Marai, I., Koren-Morag, N., Freinark, D., Shahar, Y., Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease (2009) Int J Cardiol, 134 (1), pp. 52-58. , PID: 18479768; Vlachopoulos, C., Aznaouridis, K., Stefanadis, C., Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis (2010) J Am Coll Cardiol, 55 (13), pp. 1318-1327. , PID: 20338492; Sniderman, A.D., Islam, S., Yusuf, S., McQueen, M.J., Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study (2012) Atherosclerosis, 225 (2), pp. 444-449. , COI: 1:CAS:528:DC%2BC38XhsFWit7zI, PID: 23068583; Mora, S., Buring, J.E., Ridker, P.M., Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events (2014) Circulation, 129 (5), pp. 553-561. , COI: 1:CAS:528:DC%2BC2cXitFSqtrk%3D, PID: 24345402, This study found that discordance in lipid levels is a common phenomenon which may result in risk under- or overestimation; Martin, S.S., Michos, E.D., Are we moving towards concordance on the principle that lipid discordance matters? (2014) Circulation, 129 (5), pp. 539-541. , PID: 24345401; Tonelli, M., Muntner, P., Lloyd, A., Manns, B.J., Klarenbach, S., Pannu, N., Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study (2012) Lancet, 380 (9844), pp. 807-814. , PID: 22717317; Foster, M.C., Rawlings, A.M., Marrett, E., Neff, D., Grams, M.E., Kasiske, B.L., Potential effects of reclassifying CKD as a coronary heart disease risk equivalent in the US population (2014) Am J Kidney Dis, 63 (5), pp. 753-760. , PID: 24369751; Baigent, C., Landray, M.J., Reith, C., Emberson, J., Wheeler, D.C., Tomson, C., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial (2011) Lancet, 377 (9784), pp. 2181-2192. , COI: 1:CAS:528:DC%2BC3MXotVejsb0%3D, PID: 21663949; Blaha, M.J., Feldman, D.I., Nasir, K., Coronary artery calcium and physical fitness—the two best predictors of long-term survival (2014) Atherosclerosis, 234 (1), pp. 93-94. , COI: 1:CAS:528:DC%2BC2cXmtVCiurw%3D, PID: 24632043, This editorial comment addressed the potential value of cardiorespiratory fitness measurements in risk prediction beyond the information provided by CAC scoring",Review,Scopus,2-s2.0-84928341072
"Riachi L.G., De Maria C.A.B.","Peppermint antioxidants revisited",2015,"Food Chemistry","176",,,"72","81",,,10.1016/j.foodchem.2014.12.028,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84919808075&partnerID=40&md5=20075b81dbf4a7ef6bd0c69088e2147e","Food and Nutrition Program (PPGAN), Federal University of Rio de Janeiro State (UNIRIO), Pasteur Avenue, 296Urca, Rio de Janeiro, Brazil; Collective Health Department, Biomedical Institute, Federal University of Rio de Janeiro State (UNIRIO), Frei Caneca Street, 94Rio de Janeiro, Brazil","Riachi, L.G., Food and Nutrition Program (PPGAN), Federal University of Rio de Janeiro State (UNIRIO), Pasteur Avenue, 296Urca, Rio de Janeiro, Brazil; De Maria, C.A.B., Food and Nutrition Program (PPGAN), Federal University of Rio de Janeiro State (UNIRIO), Pasteur Avenue, 296Urca, Rio de Janeiro, Brazil, Collective Health Department, Biomedical Institute, Federal University of Rio de Janeiro State (UNIRIO), Frei Caneca Street, 94Rio de Janeiro, Brazil","This review discusses the relationship between the chemical composition and antioxidant property of peppermint tisane and essential oil. Phenolic acids (e.g. rosmarinic and caffeic acids), flavones (e.g. luteolin derivatives) and flavanones (e.g. eriocitrin derivatives) are possibly the major infusion antioxidants. Vitamin antioxidants (e.g. ascorbic acid and carotenoids) are minor contributors to the overall antioxidant potential. Unsaturated terpenes having a cyclohexadiene structure (e.g. terpinene) and minor cyclic oxygenated terpenes (e.g. thymol), may contribute to antioxidant potential whilst acyclic unsaturated oxygenated monoterpenes (e.g. linalool) may act as pro-oxidants in essential oil. Findings on the antioxidant potential of major cyclic oxygenated terpenes (menthol and menthone) are conflicting. Antioxidant behaviour of aqueous/organic solvent extracts and essential oil as well as the effect of environmental stresses on essential oil and phenolic composition are briefly discussed. ©2014 Elsevier Ltd. All rights reserved.","Antioxidant; Essential oil; Infusion; Peppermint; Phenolics; Terpenes","Alam, M.S., Roy, P.K., Miah, A.R., Mollick, S.H., Khan, M.R., Mahmud, M.C., Efficacy of Peppermint oil in diarrhea predominant IBS - A double blind randomized placebo - Controlled study (2013) Mymensingh Medical Journal, 22, pp. 27-30; Amorati, R., Foti, M.C., Valgimigli, L., Antioxidant activity of essential oils (2013) Journal of Agricultural and Food Chemistry, 61, pp. 10835-10847; Amorati, R., Foti, M.C., Oxidative stability and antioxidant properties of essential oils (2012) Essential Oils As Natural Food Additives, pp. 75-95. , L. Valgimigli, Nova Science Publishers New York; Ayyobi, H., Peyvast, G.A., Olfati, J.A., Effect of drying methods on essential oil yield, total phenol content and antioxidant capacity of peppermint and dill (2014) Ratarstvo i Povrtarstvo, 51 (1), pp. 18-22; Areias, F.M., Valentao, P., Andrade, P.B., Ferreres, F., Seabra, R.M., Phenolic fingerprint of peppermint leaves (2001) Food Chemistry, 73, pp. 307-311; Ballester, A.R., Teresa Lafuente, M., González-Candelas, L., Citrus phenylpropanoids and defence against pathogens. Part II: Gene expression and metabolite accumulation in the response of fruits to Penicillium digitatum infection (2013) Food Chemistry, 136 (1), pp. 285-291; Barja, G., The mitochondrial free radical theory of aging (2014) Progress in Molecular Biology and Translational Science, 127, pp. 1-27; Behn, H., Albert, A., Marx, F., Noga, G., Ulbrich, A., Ultraviolet-B and photosynthetically active radiation interactively affect yield and pattern of monoterpenes in leaves of peppermint (Mentha × piperita L.) (2010) Journal of Agricultural and Food Chemistry, 58, pp. 7361-7367; Brieger, K., Schiavone, S., Miller, Jr.F.J., Krause, K.H., Reactive oxygen species: From health to disease (2012) Swiss Medical Weekly, 142, p. 13659; Canistro, D., Boccia, C., Falconi, R., Bonamassa, B., Valgimigli, L., Vivarelli, F., Redox-based flagging of the global network of oxidative stress greatly promotes longevity (2014) The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences; Capecka, E., Mareczek, A., Leja, M., Antioxidant activity of fresh and dry herbs of some Lamiaceae species (2005) Food Chemistry, 93 (2), pp. 223-226; Chan, E.W.C., Lim, Y.Y., Chong, K.L., Tan, J.B.L., Wong, S.K., Antioxidant properties of tropical and temperate herbal teas (2010) Journal of Food Composition and Analysis, 23, pp. 185-189; Chen, M.Z., Trinnaman, L., Bardsley, K., St Hilaire, C.J., Da Costa, N.C., Volatile compounds and sensory analysis of both harvests of double-cut Yakima peppermint (Mentha piperita L.) (2011) Journal of Food Science, 76 (7), pp. 1032-1038; Clark, R.J., Menary, R.C., The effect of two harvests per year on the yield and composition of Tasmanian peppermint oil (Mentha piperita L.) (2006) Journal of the Science of Food and Agriculture, 35, pp. 1191-1195; Court, W.A., Roy, R.C., Pocs, R., Effects of harvest date on the yield and quality of the essential oil of peppermint (1993) Canadian Journal of Plant Science, 73, pp. 815-824; Dambrauskiene, E., Viskelas, P., Karleliene, R., Productivity and biochemical composition of Mentha piperita L. of different origin (2008) Biologija, 54 (2), pp. 105-107; Dehghan, G., Khoshkam, Z., Tin (II)-quercetin complex: Synthesis, spectral characterisation and antioxidant activity (2012) Food Chemistry, 131 (2), pp. 422-426; Derwich, E., Chabir, R., Taouil, R., Senhaji, O., In-vitro antioxidant activity and CG/MS studies on the leaves of Mentha piperita (Lamiaceae) from Morocco (2011) International Journal of Pharmaceutical Sciences and Drug Research, 3 (2), pp. 130-136; Dolzhenko, Y., Bertea, C.M., Occhipinti, A., Bossi, S., Maffei, M.E., UV-B modulates the interplay between terpenoids and flavonoids in peppermint (Mentha x piperita L.) (2010) Journal of Photochemistry and Photobiology B: Biology, 100, pp. 67-75; Duband, F., Carnat, A.P., Carnat, A., Petitjean-Frevtet, C., Clair, C., Lamaison, J.L., Composition aromatique et polyphénoliques de lÍinfusé de Menthe, Mentha × piperita L. (1992) Annales Pharmaceutiques Françaises, 50 (3), pp. 146-155; El-Hassani, F.Z., Amraoui, M.B., Zinedini, A., Aissam, H., Alaoui, S.M., Merzouki, M., Changes in leaf phenols and other physiological parameters of peppermint in response to olive mill wastewater application (2009) International Journal of Agriculture & Biology, 11 (4), pp. 413-418; (2010) FAOSTAT: Data on Peppermint Yield and Production by Continent, , http://faostat.fao.org/site/339/default.aspx.%20Accessed%20in%2020.10.2012, FAO/UN (Food and Agriculture Organization of the United Nations; Farnad, N., Heidari, R., Aslanipour, B., Phenolic composition and comparison of antioxidant activity of alcoholic extracts of peppermint (Mentha piperita) (2014) Food Measure, 8, pp. 113-121; Fecka, I., Turek, S., Determination of water soluble polyphenolic compounds in commercial herbal teas from Lamiaceae: Peppermint, melissa, and sage (2007) Journal of Agricultural and Food Chemistry, 55, pp. 10908-10917; Fecka, I., Raj, D., Krauze-Baranowska, M., Quantitative determination of four water-soluble compounds in herbal drugs from Lamiaceae using different chromatographic techniques (2007) Chromatographia, 66, pp. 87-93; Fletcher, R.S., Slimmon, T., Kott, L.S., Environmental factors affecting the accumulation of rosmarinic acid in spearmint (Mentha spicata L.) and peppermint (Mentha piperita L.) (2010) The Open Agricultural Journal, 4, pp. 10-16; Gao, B., Lu, Y., Qin, F., Chen, P., Shi, H., Charles, D., Differentiating organic from conventional peppermints using chromatographic and flow injection mass spectrometric (FIMS) fingerprints (2012) Journal of Agricultural and Food Chemistry, 60, pp. 11987-11994; Gharib, F., Silva, J., Composition, total phenolic content and antioxidant activity of the essential oil of four Lamiaceae herbs (2013) Medicinal and Aromatic Plant Science and Biotechnology, 7 (1), pp. 19-27; González-Burgos, E., Gómez-Serranillos, M.P., Terpene compounds in nature: A review of their potential antioxidant activity (2012) Current Medicinal Chemistry, 19, pp. 5319-5341; Gordon, M.H., The mechanism of antioxidant action in vitro (1990) Food Antioxidants, p. 1e18. , B.J.F. Hudson, Elsevier Applied Science London, UK; Gorjanovic, S., Komes, D., Pastor, F.T., Belščak-Cvitanovicí, A., Pezo, L., Hečimovicí, I., Antioxidant capacity of teas and herbal infusions polarographic assessment (2012) Journal of Agricultural and Food Chemistry, 60, pp. 9573-9580; Grulíova, D., Labun, P., Sersen, F., Salamon, I., Seasonal variation in DPPH scavenging activity of Mentha × piperita (2012) Advances in Environmental Biology, 6 (4), pp. 1477-1480; Guedon, D.J., Pasquier, B.P., Analysis and distribution of flavonoid glycosides and rosmarinic acid in 40 Mentha piperita clones (1994) Journal of Agricultural and Food Chemistry, 42, pp. 679-684; Güntert, M., Flavor chemistry of peppermint oil (Mentha piperita L.) (2001) Compounds in Foods: Chemistry and Sensory Properties, pp. 119-137. , G.R. Takeoka, M. Güntert, K.H. Engel, American Chemical Society Washington, DC; Hadjmohammadi, M., Karimiyan, H., Sharifi, V., Hollow fibre-based liquid phase microextraction combined with high-performance liquid chromatography for the analysis of flavonoids in Echinophora platyloba DC and Mentha piperita (2013) Food Chemistry, 141, pp. 731-735; Jin, C.J., Yu, S.H., Wang, X.-M., Woo, S.J., Park, H.J., Lee, H.C., The effect of lithospermic acid, an antioxidant, on development of diabetic retinopathy in spontaneously obese diabetic rats (2014) PLoS One, 9 (6), p. 98232; Kapp, K., Hakala, A.E., Anne Orav, A., Pohjala, L., Vuorela, P., Püssa, T., Commercial peppermint (Mentha × piperita L.) teas: Antichlamydial effect and polyphenolic composition (2013) Food Research International, 53 (2), pp. 758-766; Karthikkumar, V., Sivagami, G., Viswanathan, P., Nalini, N., Rosmarinic acid inhibits DMH-induced cell proliferation in experimental rats (2014) Journal of Basic and Clinical Physiology and Pharmacology; Khanna, R., Macdonald, J.K., Levesque, B.G., Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis (2014) Journal of Clinical Gastroenterology, 48, pp. 505-512; Kizil, S., Haşimi, N., Tolan, V., Kilinç, E., Yüksel, U., Mineral content, essential oil components and biological activity of two Mentha species (M. Piperita L., M. Spicata L.) (2010) Turkish Journal of Field Crops, 15, pp. 148-153; Kratchanova, M., Denev, P., Ciz, M., Lojek, A., Mihailov, A., Evaluation of antioxidant activity of medicinal plants containing polyphenol compounds. Comparison of two extraction systems (2010) Acta Biochimica Polonica, 57 (2), pp. 229-234; Krzyzanowska, J., Janda, B., Pecio, L., Stochmal, A., Oleszek, W., Czubacka, A., Determination of polyphenols in Mentha longifolia and M. Piperita field-grown and in vitro plant samples using UPLC-TQ-MS (2011) Journal of AOAC International, 94 (1), pp. 43-50; Lawrence, B.M., (2006) Mint: The Genus Mentha, , 1st. ed. CRC Press Boca Raton, FL; Lee, J., Caffeic acid derivatives in dried Lamiaceae and Echinacea purpurea products (2010) Journal of Functional Foods, 2, pp. 158-162; Lee, S.J., Umano, K., Shibamoto, T., Lee, K.G., Identification of volatile components in basil (Ocimum basilicum L.) and thyme leaves (Thymus vulgaris L.) and their antioxidant properties (2005) Food Chemistry, 91, pp. 131-137; Lembo, S., Balato, A., Di Caprio, R., Cirillo, T., Giannini, V., Gasparri, F., The modulatory effect of ellagic acid and rosmarinic acid on ultraviolet-B-induced cytokine/chemokine gene expression in skin keratinocyte (HaCaT) cells (2014) BioMed Research International, 2014, p. 346793; Loranty, A., Rembiałkowska, E., Rosa, E.A.S., Bennett, R.N., Identification, quantification and availability of carotenoids and chlorophylls in fruit, herb and medicinal teas (2010) Journal of Food Composition and Analysis, 23, pp. 411-432; Lv, J., Huang, H., Yua, L., Whent, M., Niu, Y., Shi, H., Phenolic composition and nutraceutical properties of organic and conventional cinnamon and peppermint (2012) Food Chemistry, 132, pp. 1442-1450; Maffei, M., Canova, D., Bertea, C.M., Scannerini, S., UV-A effects on photomorphogenesis and essential oil composition in Mentha piperita (1999) Journal of Photochemistry and Photobiology, B: Biology, 5, pp. 105-110; McKay, L.D., Blumberg, B.J., A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L.) (2006) Phytotherapy Research, 20, pp. 619-633; Mekinic, I.G., Skroza, D., Ljubenkov, I., Simat, V., Mozina, S.S., Katalinic, V., In vitro antioxidant and antibacterial activity of Lamiaceae phenolic extracts: A correlation study (2014) Food Technology and Biotechnology, 52 (1), pp. 119-127; Mimica-Dukic, N., Bozin, B., Sokovic, M., Mihajlovic, B., Matavulj, M., Antimicrobial and antioxidant activities of three Mentha species essential oils (2003) Planta Medica, 69 (5), pp. 413-419; Oh, J., Jo, H., Cho, A.R., Kim, S.J., Han, J., Antioxidant and antimicrobial activities of various leafy herbal teas (2013) Food Control, 31, pp. 403-409; Orav, A., Kann, J., Determination of peppermint and orange aroma compounds in food and beverages (2001) Proceedings of the Estonian Academy of Sciences. Chemistry, 50, pp. 217-225; Park, C.M., Song, Y.-S., Luteolin and luteolin-7-O-glucoside inhibit lipopolysaccharide-induced inflammatory responses through modulation of NF-κB/AP-1/PI3K-Akt signaling cascades in RAW 264.7 cells (2013) Nutrition Research and Practice, 7 (6), pp. 423-429; Park, S.-H., Ozden, O., Jiang, H., Cha, Y.I., Pennington, J.D., Aykin-Burns, N., Sirt3, mitochondrial ROS, ageing, and carcinogenesis (2011) International Journal of Molecular Sciences, 12 (9), pp. 6226-6239; Pérez, M.G.F., Rocha-Guzmán, N.E., Mercado-Silva, E., Loarca-Piña, G., Reynoso-Camacho, R., Effect of chemical elicitors on peppermint (Mentha piperita) plants and their impact on the metabolite profile and antioxidant capacity of resulting infusions (2014) Food Chemistry, 156, pp. 273-278; Pérez-Jiménez, J., Neveu, V., Vos, F., Scalbert, A., Identification of the 100 richest dietary sources of polyphenols: An application of the Phenol-Explorer database (2010) European Journal of Clinical Nutrition, 64, pp. 112-S120; Pinheiro Fernandes, F.D., Fontenele Menezes, A.P., De Sousa Neves, J.C., Fonteles, A.A., Da Silva, A.T.A., Caffeic acid protects mice from memory deficits induced by focal cerebral ischemia (2014) Behavioural Pharmacology, 25 (7), pp. 637-647; Politeo, O., Jukié, M., Milos, M., Chemical composition and antioxidant activity of essential oils of twelve spice plants (2006) Croatia Chemica Acta, 79 (4), pp. 545-552; Pramila, D.M., Xavier, R., Marimuthu, K., Kathiresan, S., Khoo, M.L., Senthilkumar, M., Phytochemical analysis and antimicrobial potential of methanolic leaf extract of peppermint (Mentha piperita: Lamiaceae) (2012) Journal of Medicinal Plants Research, 6 (2), pp. 331-335; Ramkissoon, J.S., Mahomoodally, M.F., Ahmed, N., Subratty, A.H., Relationship between total phenolic content, antioxidant potential and antiglycation abilities of common culinary herbs and spices (2012) Journal of Medicinal Food, 15 (12), pp. 1116-1123; Rastogi, H., Jana, S., Evaluation of inhibitory effects of caffeic acid and quercetin on human liver cytochrome P450 activities (2014) Phytotherapy Research: PTR; Riachi, L.G., Abi-Zaid, I.E., Moreira, R.F.A., De Maria, C.A.B., Volatile composition of peppermint (Mentha piperita L.) commercial teas through solid phase extraction (2012) Archivos Latinoamericanos de Nutrición, 62 (4), pp. 389-392; Rohloff, J., Dragland, S., Mordal, R., Iversen, T.-H., Effect of harvest time and drying method on biomass production, essential oil yield, and quality of peppermint (Mentha × piperita L.) (2005) Journal of Agricultural and Food Chemistry, 53, pp. 4143-4148; Ruberto, G., Baratta, M.T., Antioxidant activity of selected essential oil components in two lipid model systems (2000) Food Chemistry, 69, pp. 167-174; Schmidt, E., Bail, S., Buchbauer, G., Stoilova, I., Atanasova, T., Stoyanova, A., Krastanov, A., Jirovetz, L., Chemical composition, olfactory evaluation and antioxidant effects of essential oil from Mentha × piperita (2009) Natural Product Communications, 4 (8), pp. 1107-1112; Sharafi, S.M., Rasooli, I., Owlia, P., Taqhiadeh, M., Astaneh, S.D.A., Protective effects of bioactive phytochemicals from Mentha piperita with multiple health potentials (2010) Pharmacognosy Magazine, 6 (23), pp. 147-153; Song, Y.S., Park, C.M., Luteolin and luteolin-7-O-glucoside strengthen antioxidative potential through the modulation of Nrf2/MAPK mediated HO-1 signaling cascade in RAW 264.7 cells (2014) Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 65, pp. 70-75; Tahirovic, I., Kozljak, M., Toromanovic, J., Copra-Janicijevie, A., Klepo, L., Topcagic, A., Total phenolic content and antioxidant capacity in infusion of various teas (2014) Bulletin of Chemists and Technologists of Bosnia and Herzegovina, 42, pp. 51-55; Tsai, M.-L., Wu, C.-T., Lin, T.-F., Lin, W.-C., Huang, Y.-C., Yang, C.-H., Chemical composition and biological properties of essential oils of two mint species (2013) Tropical Journal of Pharmaceutical Research, 12 (4), pp. 577-582; Verma, R.S., Pandey, V., Padalia, R.C., Saikia, D., Krishna, B., Chemical composition and antimicrobial potential of aqueous distillate volatiles of indian peppermint (Mentha piperita) and spearmint (Mentha spicata) (2011) Journal of Herbs, Spices & Medicinal Plants, 17 (3), pp. 258-267; Voirin, B., Saunois, A., Bayet, C., Free flavonoid aglycones from Mentha × piperita: Developmental, chemotaxonomical and physiological aspects (1994) Biochemical, Systematics and Ecology, 22 (1), pp. 95-99; Wang, D., Fan, G., Wang, Y., Liu, H., Wang, B., Dong, J., Vascular reactivity screen of Chinese medicine danhong injection identifies danshensu as a no-independent but PGI2-mediated relaxation factor (2013) Journal of Cardiovascular Pharmacology, 62 (5), pp. 457-465; Wang, Y., Liu, J., Chen, F., Zhao, G., Effects of molecular structure of polyphenols on their noncovalent interactions with oat β-glucan (2013) Journal of Agricultural and Food Chemistry, 61 (19), pp. 4533-4538; Wei, A., Shibamoto, T., Antioxidant activities and volatile constituents of various essential oils (2007) Journal of Agricultural and Food Chemistry, 55 (5), pp. 1737-1742; Zheljazkov, V.D., Cantrell, C.L., Astatkie, T., Ebelhar, M.W., Peppermint productivity and oil composition as a function of nitrogen, growth stage, and harvest time (2010) Agronomy Journal, 102 (1), pp. 124-128; Zheng, W., Wang, S.Y., Antioxidant activity and phenolic compounds in selected herbs (2001) Journal of Agricultural and Food Chemistry, 49 (11), pp. 5165-5170",Review,Scopus,2-s2.0-84919808075
"Jugdaohsingh R., Watson A.I.E., Pedro L.D., Powell J.J.","The decrease in silicon concentration of the connective tissues with age in rats is a marker of connective tissue turnover",2015,"Bone","75",,,"40","48",,,10.1016/j.bone.2015.02.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923134020&partnerID=40&md5=593774804b4e790ddc6f1a335478e59d","MRC Human Nutrition Research, Elsie Widdowson LaboratoryCambridge, United Kingdom; School of Sport and Exercise Health Sciences, Loughborough UniversityLoughborough, United Kingdom","Jugdaohsingh, R., MRC Human Nutrition Research, Elsie Widdowson LaboratoryCambridge, United Kingdom; Watson, A.I.E., MRC Human Nutrition Research, Elsie Widdowson LaboratoryCambridge, United Kingdom, School of Sport and Exercise Health Sciences, Loughborough UniversityLoughborough, United Kingdom; Pedro, L.D., MRC Human Nutrition Research, Elsie Widdowson LaboratoryCambridge, United Kingdom; Powell, J.J., MRC Human Nutrition Research, Elsie Widdowson LaboratoryCambridge, United Kingdom","Silicon may be important for bone and connective tissue health. Higher concentrations of silicon are suggested to be associated with bone and the connective tissues, compared with the non-connective soft tissues. Moreover, in connective tissues it has been suggested that silicon levels may decrease with age based upon analyses of human aorta. These claims, however, have not been tested under controlled conditions. Here connective and non-connective tissues were collected and analysed for silicon levels from female Sprague-Dawley rats of different ages (namely, 3, 5, 8, 12, 26 and 43. weeks; n = 8-10 per age group), all maintained on the same feed source and drinking water, and kept in the same environment from weaning to adulthood. Tissues (696 samples) were digested in nitric acid and analysed by inductively coupled plasma optical emission spectrometry for total silicon content. Fasting serum samples were also collected, diluted and analysed for silicon. Higher concentrations of silicon (up to 50-fold) were found associated with bone and the connective tissues compared with the non-connective tissues. Although total silicon content increased with age in all tissues, the highest connective tissue silicon concentrations (up to 9.98. μg/g wet weight) were found in young weanling rats, decreasing thereafter with age (by 2-6 fold). Fasting serum silicon concentrations reflected the pattern of connective tissue silicon concentrations and, both measures, when compared to collagen data from a prior experiment in Sprague-Dawley rats, mirrored type I collagen turnover with age. Our findings confirm the link between silicon and connective tissues and would imply that young growing rats have proportionally higher requirements for dietary silicon than mature adults, for bone and connective tissue development, although this was not formally investigated here. However, estimation of total body silicon content suggested that actual Si requirements may be substantially lower than previously estimated which could explain why absolute silicon deficiency is difficult to achieve but, when it is achieved in young growing animals, it results in stunted growth and abnormal development of bone and other connective tissues. © 2015.","Collagen; Connective tissues; Growth & development; Silicon requirement; Silicon status; Whole body Si content","Nielsen, F.H., Nutritional requirements for boron, silicon, vanadium, nickel, and arsenic: current knowledge and speculation (1991) FASEB J, 5, pp. 2661-2667; Nielsen, F.H., Update on the possible nutritional importance of silicon (2014) J Trace Elem Med Biol, 28, pp. 379-382; Jugdaohsingh, R., Silicon and bone health (2007) J Nutr Health Aging, 11, pp. 99-110; Carlisle, E.M., Silicon: an essential element for the chick (1972) Science, 178, pp. 619-621; Schwarz, K., Milne, D.B., Growth-promoting effects of silicon in rats (1972) Nature, 239, pp. 333-334; Elliot, M.A., Edwards, H.M., Effect of dietary silicon on growth and skeletal development in chickens (1991) J Nutr, 121, pp. 201-207; Elliot, M.A., Edwards, H.M., Some effects of dietary aluminium and silicon on broiler chickens (1991) Poult Sci, 70, pp. 1390-1402; KayongoMale, H., Jia, X.J., Silicon bioavailability studies in young rats and turkeys fed semipurified diets-a comparative study (1999) Biol Trace Elem Res, 67, pp. 173-186; Seaborn, C.D., Nielsen, F.H., Dietary silicon affects acid and alkaline phosphatase and 45Ca uptake in bone of rats (1994) J Trace Elem Exp Med, 7, pp. 1-11; Seaborn, C.D., Nielsen, F.H., Effect of germanium and silicon on bone mineralisation (1994) Biol Trace Elem Res, 42, pp. 151-164; Seaborn, C.D., Nielsen, F.H., High dietary aluminum affects the response of rats to silicon deprivation (1994) Biol Trace Elem Res, 41, pp. 295-304; Seaborn, C.D., Nielsen, F.H., Dietary silicon and arginine affect mineral element composition of rat femur and vertebra (2002) Biol Trace Elem Res, 89, pp. 239-250; Seaborn, C.D., Nielsen, F.H., Silicon deprivation decreases collagen formation in wounds and bone, and ornithine transaminase enzyme activity in liver (2002) Biol Trace Elem Res, 89, pp. 251-261; Nielsen, F.H., Poellot, R., Dietary silicon affects bone turnover differently in ovariectomised and sham-operated growing rats (2004) J Trace Elem Exp Med, 17, pp. 137-149; Merkley, J.W., Miller, E.R., The effects of sodium-fluoride and sodium-silicate on growth and bone strength of broilers (1983) Poult Sci, 62, pp. 798-804; Jugdaohsingh, R., Calomme, M.R., Robinson, K., Nielsen, F., Anderson, S.H.C., D'Hease, P., Increased longitudinal growth in rats on a silicon-depleted diet (2008) Bone, 43, pp. 596-606; Ratcliffe, S., (2011) Identification of a silicon-responsive gene in the mammalian genome, , PhD Thesis, University of Cambridge; Jugdaohsingh, R., Tucker, K.L., Qiao, N., Cupples, L.A., Kiel, D.P., Powell, J.J., Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort (2004) J Bone Miner Res, 19, pp. 297-307; Macdonald, H.M., Hardcastle, A.E., Jugdaohsingh, R., Reid, D.M., Powell, J.J., Dietary silicon interacts with oestrogen to influence bone health: evidence from the Aberdeen Prospective Osteoporosis Screening Study (2012) Bone, 50, pp. 681-687; Jugdaohsingh, R., Kinrade, S.D., Powell, J.J., Is there a biochemical role for silicon? (2008) Metal Ions in Biology and Medicine Vol X, pp. 45-55. , John Libbey Eurotext, Paris; Domingo, J.L., Gomez, M., Colomina, M.T., Oral silicon supplementation: an effective therapy for preventing oral aluminium absorption and retention in mammals (2010) Nutr Rev, 69, pp. 41-51; Jugdaohsingh, R., Reffitt, D.M., Oldham, C., Day, J.P., Fifield, L.K., Thompson, R.P.H., Oligomeric but not monomeric silica prevents aluminium absorption in man (2000) Am J Clin Nutr, 71, pp. 944-949; Birchall, J.D., The essentiality of silicon in biology (1995) Chem Soc Rev; Reffitt, D.M., Ogston, N., Jugdaohsingh, R., Cheung, H.F.J., Evans, B.A.J., Thompson, R.P.H., Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro (2003) Bone, 32 (2), pp. 127-135; Carlisle, E.M., Silicon as an essential trace element in animal nutrition (1986) Silicon Biochemistry, Ciba Foundation Symposium 121, pp. 123-139. , John Wiley and Sons Ltd, Chichester; Schwarz, K., A bound form of silicon in glycosaminoglycans and polyuronides (1973) Proc Natl Acad Sci U S A, 70 (5), pp. 1608-1612; Loeper, J., Loeper, J., Fragny, M., The physiological role of the silicon and its antiatheromatous action (1978) Biochemistry of silicon and related problems, pp. 281-296. , Plenum Press, New York, G. Bendz, I. Lindqvist (Eds.); Adler, A.J., Etzion, Z., Berlyne, G.M., Uptake, distribution, and excretion of 31silicon in normal rats (1986) Am J Physiol, 251, pp. E670-E673; Berlyne, G.M., Shainkin-Kestenbaum, R., Yagil, R., Alfassi, Z., Kushelevsky, A., Etzion, Z., Distribution of 31silicon-labeled silicic acid in the rat (1986) Biol Trace Elem Res, 10, pp. 159-162; Charnot, Y., Pérès, G., Change in the absorption and tissue metabolism of silicon in relation to age, sex and various endocrine glands (1971) Lyon Med, 13, p. 85; Van Dyck, K., Robberecht, H., Van Cauwenbergh, R., Van Vlaslaer, V., Deelstra, H., Indication of silicon essentiality in humans. Serum concentrations in Belgian children and adults, including pregnant women (2000) Biol Trace Elem Res, 77, pp. 25-32; Jugdaohsingh, R., Anderson, S.H.C., Lakasing, L., Sripanyakorn, S., Ratcliffe, S., Powell, J.J., Serum silicon concentrations in pregnant women and newborn babies (2013) Br J Nutr, 110, pp. 2004-2010; Burden, T.R., Powell, J.J., Thompson, R.P.H., Optimal accuracy, precision and sensitivity of inductive coupled plasma optical emission spectrometry: bioanalysis of aluminium (1995) J Anal Atom Spectrom, 10, pp. 259-266; Sripanyakorn, S., Jugdaohsingh, R., Elliott, H., Walker, C., Mehta, P., Shoukru, S., The silicon content of beer and its bioavailability in healthy volunteers (2004) Bri J Nutr, 91 (3), pp. 403-409; Publication number 600R94906 (1994) Physiological parameter values for PBPK models, , http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=9100K030.txt; Argent, N.B., Liles, J., Rodham, D., Clayton, C.B., Wilkinson, R., Baylis, P.H., A new method for measuring the blood volume of the rat using 113mIndium as a tracer (1994) Lab Anim, 28, pp. 172-175; Probst, R.J., Lim, J.M., Bird, D.N., Pole, G.L., Sato, A.K., Claybaugh, J.R., Gender differences in the blood volume of conscious Sprague-Dawley rats (2006) J Am Assoc Lab Anim Sci, 45, pp. 49-52; Aleman, C.L., Mas, R.M., Rodeiro, I., Noa, M., Hernandez, C., Menlmdez, R., Reference database of the main physiological parameters in Sprague-Dawley rats from 6 to 32months (1998) Lab Anim, 32, pp. 457-466; Matsumura, Y., Kuro, T., Kobayashi, Y., Konishi, F., Takaoka, M., Wessale, J.L., Exagerated vascular and renal pathology in Endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension (2000) Circulation, 102, pp. 2765-2773; Tillery, S.I., Lehnert, B.E., Age-bodyweight relationships to lung growth in the F344 rat as indexed by lung weight measurements (1986) Lab Anim, 20, pp. 189-194; Cantini, C., Kieffer, P., Corman, B., Liminana, P., Atkinson, J., Lartaud-Idjouadiene, I., Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats (2001) Hypertension, 38, pp. 943-948; Looker, T., Berry, C.L., The growth and development of the rat aorta II. Changes in nucleic acid and scleroprotein content (1972) J Anat, 113, pp. 17-34; Powell, J.J., Ainley, C.C., Harvey, R.S.J., Mason, I.M., Kendall, M.D., Sankey, E.A., Characterisation of inorganic microparticles in pigment cells of human gut associated lymphoid tissue (1996) Gut, 38, pp. 390-395; Jugdaohsingh, R., Watson, A.I.E., Bhattacharya, P., van Lenthe, G.H., Powell, J.J., Positive association between serum silicon levels and bone mineral density in female rats following oral silicon supplementation with monomethylsilanetriol (2015) Osteoporos Int, , 9th January [Published online: Epub ahead of print]; Jugdaohsingh, R., Pedro, L.D., Watson, A., Powell, J.J., Silicon and boron differ in their localisation and loading in bone (2015) Bone Reports, 1, pp. 9-15; Jugdaohsingh, R., Anderson, S.H.C., Tucker, K.L., Elliott, H., Kiel, D.P., Thompson, R.P.H., Dietary silicon intake and absorption (2002) Am J Clin Nutr, 75, pp. 887-893; Emsley, J., (1998) The element, , Clarendon Press, Oxford; Pruksa, S., Siripinyanond, A., Powell, J.J., Jugdaohsingh, R., A silicon balance study in human volunteers; a study to establish the variance in silicon excretion versus intake (2014) Nutr Metab (Lond), 11 (1), p. 4; Mecham, R.P., Methods in elastic tissue biology: elastin isolation and purification (2008) Methods, 45, pp. 32-41; Wagenseil, J.E., Mecham, R.P., Vascular extracellular matrix and arterial mechanics (2009) Physiol Rev, 89, pp. 957-989; Flanagan, B., Nichols, G., Bone matrix turnover and balance in vitro. II. Effects of ageing (1969) J Clin Invest, 48, pp. 607-612; Isaksson, H., Harjula, T., Koistinen, A., Livarinen, J., Seppanen, K., Arokoski, J.P., Collagen and mineral deposition in rabbit cortical bone during maturation and growth: effects on tissue properties (2010) J Orthop Res, 28, pp. 1626-1633; Turunen, M.J., Saarakkala, S., Helminen, H.J., Jurvelin, J.S., Isaksson, H., Age-related changes in organisation and content of collagen matrix in rabbit cortical bone (2012) J Orthop Res, 30, pp. 435-442; Kinrade, S.D., Deguns, E.W., Gillson, A.-M.E., Knight, C.T.G., Complexes of pentaoxo and hexaoxo silicon with furanoidic vicinal cis-diols in aqueous solution (2003) Dalton Trans; Kinrade, S.D., Hamilton, R.J., Schach, A.S., Knight, C.T.G., Aqueous hypervalent siliconcomplexes with aliphatic sugar acids (2001) J Chem Soc Dalton Trans, pp. 961-963V; Kinrade, S.D., Schach, A.S., Hamilton, R.J., Knight, C.T.G., NMR evidence of pentaoxo organosilicon complexes in dilute neutral aqueous silicate solutions (2001) J Chem Soc Chem Commun, pp. 1564-1565; Kinrade, S.D., Del Nin, J.W., Schach, A.S., Sloan, T.A., Wilson, K.L., Knight, C.T.G., Stable five- and six-coordinated silicate anions in aqueous solution (1999) Science, 285, pp. 1542-1545; Pfleiderer, B., Garrido, L., Migration and accumulation of silicone in the liver of women with silicone gel-filled breast implants (1995) Magn Reson Med, 33, pp. 8-17; Yu, T., Hubbard, D., Ray, A., Ghandehari, H., In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics (2012) J Control Release, 163, pp. 46-54; Stanca, L., Petrache, S.N., Serban, A.I., Staicu, A.C., Sima, C., Munteanu, M.C., Interaction of silicon-based quantum dots with gibel carp liver: oxidation and structural modifications (2013) Nanoscale Res Lett, 8, p. 254; Sripanyakorn, S., Jugdaohsingh, R., Dissayabutr, W., Anderson, S.H.C., Thompson, R.P.T., Powell, J.J., The comparative absorption of silicon from different foods and food supplements (2009) Br J Nutr, 102, pp. 825-834; Mehard, C.W., Volcani, B.E., Similarity in uptake and retention of trace amounts of 31 silicon and 68 germanium in rat tissues and cell organelles (1975) Bioinorg Chem, 5, pp. 107-124",Article,Scopus,2-s2.0-84923134020
"Trezza B.M., Apolinario D., de Oliveira R.S., Busse A.L., Goncalves F.L.T., Saldiva P.H.N., Jacob-Filho W.","Environmental heat exposure and cognitive performance in older adults: a controlled trial",2015,"Age","37","3",,"","",10,,10.1007/s11357-015-9783-z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928815163&partnerID=40&md5=ad6b7e8e05bc8cc0917cfc6e2164f89c","Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, Av. Dr. Eneas de Carvalho Aguiar, 155, 8° Andar, Bloco 3São Paulo, SP, Brazil; Institute of Astronomy, Geophysics, and Atmospheric Sciences, University of São PauloSão Paulo, Brazil; Department of Pathology, College of Medicine, University of São PauloSão Paulo, SP, Brazil","Trezza, B.M., Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, Av. Dr. Eneas de Carvalho Aguiar, 155, 8° Andar, Bloco 3São Paulo, SP, Brazil; Apolinario, D., Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, Av. Dr. Eneas de Carvalho Aguiar, 155, 8° Andar, Bloco 3São Paulo, SP, Brazil; de Oliveira, R.S., Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, Av. Dr. Eneas de Carvalho Aguiar, 155, 8° Andar, Bloco 3São Paulo, SP, Brazil; Busse, A.L., Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, Av. Dr. Eneas de Carvalho Aguiar, 155, 8° Andar, Bloco 3São Paulo, SP, Brazil; Gonçalves, F.L.T., Institute of Astronomy, Geophysics, and Atmospheric Sciences, University of São PauloSão Paulo, Brazil; Saldiva, P.H.N., Department of Pathology, College of Medicine, University of São PauloSão Paulo, SP, Brazil; Jacob-Filho, W., Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School, Av. Dr. Eneas de Carvalho Aguiar, 155, 8° Andar, Bloco 3São Paulo, SP, Brazil","Thermal stress has a negative effect on the cognitive performance of military personnel and industry workers exposed to extreme environments. However, no studies have investigated the effects of environmental thermal stress on the cognitive functions of older adults. We carried out a controlled trial with 68 healthy older adults (mean age 73.3 years, 69 % female), each of whom has been assessed twice on the same day with selected tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB). Repeated sessions were conducted with air temperatures set at 24 °C and 32 °C in a balanced order. Our primary analyses did not show significant differences when comparing the cognitive performance of the total sample under the two experimental temperatures. However, interaction analysis has shown that humidity levels modify the effect of temperature on cognitive outcomes. The subgroup exposed to relative humidity greater than the median value (57.8 %) presented worse cognitive performance in the heat session when compared to the control session. Reported exercising frequency explained individual vulnerability to heat stress. Volunteers with lower levels of physical activity (<4 times per week) were more likely to present worsened cognitive performance under heat stress. In a fully adjusted linear regression model, the performance under heat stress remained associated with relative humidity (β = −0.21; p = 0.007) and frequency of exercising (β = 0.18; p = 0.020). Our results indicate that heat stress may have detrimental effects on the cognitive functioning of some subgroups of older adults and under particular circumstances. Further research is needed for exploring a variety of potentially influential factors. © 2015, American Aging Association.","Aged; Cognitive manifestations; Environmental exposure; Heat stress; Hot temperature; Neuropsychological test","Blatteis, C.M., Age-dependent changes in temperature regulation (2012) Gerontology, 58 (4), pp. 289-295. , PID: 2208583; Campbell, G.C., Norman, J.M., (1998) An introduction to environmental biophysics, , Springer-Verlag, New York; Drag, L.L., Bieliauskas, L.A., Contemporary review 2009: cognitive aging (2010) J Geriatr Psychiatry Neurol, 23 (2), pp. 75-93. , PID: 2010106; Falleti, M.G., Maruff, P., Collie, A., Darby, D.G., Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals (2006) J Clin Exp Neuropsychol, 28 (7), pp. 1095-1112. , PID: 1684023; Folstein, M.F., Folstein, S.E., McHuch, P.R., Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician (1975) J Psychiatr Res, 12 (3), pp. 189-198. , COI: 1:STN:280:DyaE28%2FntFKjtw%3D%3D, PID: 120220; Gaoua, N., Cognitive function in hot environments: a question of methodology (2010) Scand J Med Sci Sports, 20, pp. 60-70. , PID: 2102919; Gaoua, N., Racinais, S., Grantham, J., Alterations in cognitive performance during passive hyperthermia are task dependent (2011) Int J Hyperth, 27 (1), pp. 1-9; Gaoua, N., Grantham, J., Racinais, S., Massioui, F.E., Sensory displeasure reduces complex cognitive performance in the heat (2012) J Environ Psychol, 32, pp. 158-163; Guergova, S., Dufour, A., Thermal sensitivity in the elderly: a review (2011) Ageing Res Rev, 10, pp. 80-92. , PID: 2068526; Hancock, P.A., Ross, J.M., Szalma, J.L., A meta-analysis of performance response under thermal stressors (2007) Hum Factors, 49 (5), pp. 851-877. , COI: 1:STN:280:DC%2BD2srpsVKisw%3D%3D, PID: 1791560; Hocking, C., Silberstein, R.B., Lau, W.M., Stough, C., Roberts, W., Evaluation of cognitive performance in the heat by functional brain imaging and psychometric testing (2001) Comp Biochem Physiol A Mol Integr Physiol, 128, pp. 719-734. , COI: 1:STN:280:DC%2BD3MvkslKjsQ%3D%3D, PID: 1128231; Holowatz, L.A., Kenney, W.L., Peripheral mechanisms of thermoregulatory control of skin blood flow in aged humans (2010) J Appl Physiol, 109, pp. 1538-1544. , PID: 2041342; Inoue, Y., Kuwahara, T., Araki, T., Maturation and aging-related changes in heat loss effector function (2004) J Physiol Anthropol Appl Hum Sci, 23, pp. 289-294; International Organization for Standardization. ISO 9241 Ergonomic requirements for office work with visual display terminals (VDTs). Part 6: guidance on the work environmentIPCC, Stocker, T.F., Qin, D., Plattner, G.-K., Tignor, M., Allen, S.K., Boschung, J., Midgley, P.M., Summary for policymakers (2013) Contribution of Working Group I to the Fifth Assessment Report of the Intergovernmental Panel on Climate Change, , (eds), University Press, Cambridge; Jager, C.A., Milwain, E., Budge, M., Early detection of isolated memory deficits in the elderly: the need for more sensitive neuropsychological tests (2002) Psychol Med, 32 (3), pp. 483-491. , PID: 1198999; Jones, R.N., Fong, T.G., Metzger, E., TulebaevS, Y.F.M., Alsop, D.C., Marcantonio, E.R., Cupples, L.A., Inouye, S.K., Aging, brain disease and reserve: implications for delirium (2010) Am J Geriatr Psychiatr, 18 (2), pp. 117-127; Kenney, W.L., Munce, T.A., Invited review: aging and human temperature regulation (2003) J Appl Physiol, 95, pp. 2598-2603. , PID: 1460016; Lowe, C., Rabbitt, P., Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues (1998) Neuropsychologia, 36 (9), pp. 915-923. , COI: 1:STN:280:DyaK1cvhtFSrsg%3D%3D, PID: 974036; Mavrogianni, A., Wilkinson, P., Davies, M., Biddulph, P., Oikonomou, E., Building characteristics as determinants of propensity to high indoor summer temperatures in London dwellings (2012) Build Environ, 55, pp. 117-130; Minson, C.T., Wladkowski, S.L., Cardell, A.F., Pawelczyk, J.A., Kenney, W.L., Age alters the cardiovascular response to direct passive heating (1998) J Appl Physiol, 84, pp. 1323-1332. , COI: 1:STN:280:DyaK1c7ot1eltw%3D%3D, PID: 951620; Missenard, F.A., (1933) Etude physiologique et technique de la ventilation. Encyclopédie industrielle et commerciale, , Eyrolles, Paris; Moyen, N.E., Ellis, C.L., Ciccone, A.B., Thurston, T.S., Cochrane, K.C., Brown, L.E., Coburn, J.W., Judelson, D.A., Increasing relative humidity impacts low-intensity exercise in the heat (2014) Aviat Space Environ Med, 85 (2), pp. 112-119. , PID: 2459715; Nedel, A.S., Gonçalves, F.L.T., Cardoso, M.R.A., Evaluation of thermal simulation of households in the metropolitan region of São Paulo, Brazil (2009) Ecotoxicology, 18 (8), pp. 1143-1149. , COI: 1:CAS:528:DC%2BD1MXhtFegurnN, PID: 1959095; Pilcher, J.J., Nadler, E., Busch, C., Effects of hot and cold temperature exposure on performance: a meta-analytic review (2002) Ergonomics, 45, pp. 682-698. , PID: 1243785; Racinais, S., Gaoua, N., Grantham, J., Hyperthermia impairs short-term memory and peripheral motor drive transmission (2008) J Physiol, 586 (19), pp. 4751-4762. , COI: 1:CAS:528:DC%2BD1cXht12iu7vK, PID: 1870357; Radakovic, S.S., Maric, J., Surbatovic, M., Radjen, S., Stefanova, E., Stankovic, N., Filipovic, N., Effects of acclimation on cognitive performance in soldiers during exertional heat stress (2007) Mil Med, 172, pp. 133-136. , PID: 1735776; Simmons, S.E., Saxby, B.K., McGlone, F.P., Jones, D.A., The effect of passive heating and head cooling on perception, cardiovascular function and cognitive performance in the heat (2008) Eur J Appl Physiol, 104 (2), pp. 271-280. , PID: 1821452; Stern, Y., What is cognitive reserve? Theory and research application of the reserve concept (2002) J Int Neuropsychol Soc, 8, pp. 448-460. , PID: 1193970; Sun, G., Qian, S., Jiang, Q., Liu, K., Li, B., Li, M., Zhao, L., Liu, Y., Hyperthermia-induced disruption of functional connectivity in the human brain network (2013) PLoS One, 8 (4), p. 61157. , COI: 1:CAS:528:DC%2BC3sXmtlSmtbc%3D, PID: 2359341; Tong, S., Mackenzie, J., Pitman, A.J., FitzGerald, G., Nicholls, N., Selvey, L., Global climate change: time to mainstream health risks and their prevention on the medical research and policy agenda (2008) Intern Med J, 38 (6), pp. 445-447. , COI: 1:STN:280:DC%2BD1cvktV2kug%3D%3D, PID: 1861390; United Nations Population Fund (UNFPA) and HelpAge International (2012) Ageing in the twenty-first century: a celebration and a challenge - executive summarWunderlich, C.A., The course of the temperature in disease: a guide to clinical thermometry (1869) Am J Med Sci, 57, pp. 425-447; Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., Leirer, V.O., Development and validation of a geriatric depression screening scale: a preliminary report (1983) J Psychiatr Res, 17 (1), pp. 37-49. , COI: 1:STN:280:DyaL3s3ktFentA%3D%3",Article,Scopus,2-s2.0-84928815163
"Fergus I.V., Connell K.L., Ferdinand K.C.","A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk",2015,"Current Cardiology Reports","17","6",,"","",6,,10.1007/s11886-015-0592-x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928346266&partnerID=40&md5=e606cba02ec6487a779c9a28dd07687e","Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030New York, NY, United States; The University of the West Indies, Cave Hill CampusSt. Michael, Barbados; Tulane University School of Medicine, 1430 Tulane Avenue, #8548New Orleans, LA, United States","Fergus, I.V., Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030New York, NY, United States; Connell, K.L., The University of the West Indies, Cave Hill CampusSt. Michael, Barbados; Ferdinand, K.C., Tulane University School of Medicine, 1430 Tulane Avenue, #8548New Orleans, LA, United States","Cardiometabolic risk describes a collection of risk factors, with a likely underlying pathophysiology, resulting in accelerated atherosclerosis and the terminal cardiovascular events of myocardial infarction and stroke. Beta-blockers, which are divided as vasodilators or non-vasodilators, are used in the treatment of hypertension and other cardiovascular diseases. Vasodilators have been shown to be of particular benefit in both blood pressure control and other cardiometabolic components with limited disturbance in metabolic parameters. Nebivolol, a third-generation beta-blocker (BB), acts by increasing nitric oxide (NO) bioavailability. This property may be especially important in NO-deficient population, such as black people, in regulating both blood pressure control and glucose homeostasis. © 2015, Springer Science+Business Media New York.","Beta-blockers; Cardiometabolic risk; Nitric oxide; Vasodilators","Brunzell, J.D., Davidson, M., Furberg, C.D., Lipoprotein management in patients with cardiometabolic risk: Consensus Conference report from the American Diabetes Association and the American College of Cardiology Foundation (2008) J Am Coll Cardiol, 51 (15), pp. 1512-1524. , PID: 18402913; Lichtenstein, H., Loria, C.M., Millen, B.E., Houston Miller, N., Nonas, C.A., Eckel, R.H., AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report (2013) Circulation, 2013, pp. 2-40; Ayers, K., Byrne, L.M., DeMatteo, A., (2012), This study describes the differences in metabolic and anti-inflammatory of a vasodilating (nebivolol) and non- vasodilating (metoprolol) drugs, It highlights the unique property of nebivolol as a vasodilating BB via NO mediated mechanisms:Taylor, A.A., Bakris, G.L., The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome (2010) Am J Med, 123 (7), pp. 21-26. , COI: 1:CAS:528:DC%2BC3cXhtVKksr%2FM, PID: 20609696; Fares H, Lavie C, Ventura, HO. Vasodilating versus first generation beta blockade for the treatment of cardiovascular conditions. Postgrad Med. 2012; 124(2)Merchant, N., Searles, C.D., Pandian, A., Rahman, S.T., Ferdinand, K.C., Umpierrez, G.E., Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance and endothelial function (2009) J Clin Hypertens, 11 (12), pp. 721-725; Frishman, W.H., Saunders, E.B., Adrenergic blockers (2011) J Clin Hypertens, 13, pp. 649-653. , COI: 1:CAS:528:DC%2BC3MXhsVWjsL3J; Prichard, B.N.C., Gillam, P.M.S., Use of propranolol (Inderal) in the treatment of hypertension (1964) Br Med J, 2, pp. 725-727; Murray, D.R., Prabhu, S.D., Chandrasekar, B., Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression (2000) Circulation, 101, p. 2338. , COI: 1:CAS:528:DC%2BD3cXktVGgtrs%3D, PID: 10821806; Toblli, J.E., Digenarro, F., Giani, J.F., Dominici, F.P., Nebivolol: impact on cardiac and endothelial and clinical utility (2012) Vasc Health and Risk Manag, pp. 151-160; DeNicolantonio, J.J., Lavie, C.J., Fares, H., Menezes, A., O’Keefe, J.H., Meta analysis of carvedilol vs B 1 selective beta blockers (atenolol, bisoprolol, metoprolol and nebivolol) (2013) Am J Cardiol, 111, pp. 765-769. , This analysis is a major comparison of the traditional non- vasodilating BB (bisoprolol and metoprolol) with the vasodilating BB nebivolol; Van Veldhuisen, D.J., Cohen-Solal, A., Böhm, M., Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure) (2009) J Am Coll Cardiol, 53, p. 2150. , PID: 19497441; Hjalmarson, A., Goldstein, S., Fagerberg, B., Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group (2000) JAMA, 283, p. 1295. , COI: 1:CAS:528:DC%2BD3cXitVCktbk%3D, PID: 10714728; Bakris, G.L., Fonseca, V., Katholi, R.E., McGill, J.B., Messerli, F.H., Phillips, R.A., Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial (2004) JAMA, 292, pp. 2227-2236. , COI: 1:CAS:528:DC%2BD2cXpslyqtL8%3D, PID: 15536109; Remme, W.J., Torp-Pedersen, C., Cleland, J.G., Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET (2007) J Am Coll Cardiol, 49, p. 963. , COI: 1:CAS:528:DC%2BD2sXisVCgtb8%3D, PID: 17336720; Yancy, C.W., ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) JACC, 62 (16), pp. 147-239. , PID: 23747642; Gilbert, E.M., Anderson, J.L., Deitchman, D., Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo (1990) Am J Med, 88, p. 223. , COI: 1:STN:280:DyaK3c7nvVWgtA%3D%3D, PID: 1968710; Eichhorn, E.J., McGhie, A.L., Bedotto, J.B., Effects of bucindolol on neurohormonal activation in congestive heart failure (1991) Am J Cardiol, 67, p. 67. , COI: 1:STN:280:DyaK3M%2Fps1OhtA%3D%3D, PID: 1670902; A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure (2001) N Engl J Med, 344, pp. 1659-1667; Lechat, P., Escolano, S., Golmard, J.L., Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS) (1997) Circulation, 96, p. 2197. , COI: 1:CAS:528:DyaK2sXmvVKrsrg%3D, PID: 9337190; Fonseca, V., Sharma, P.P., Shah, M., Deedwania, P., Risk of new-onset diabetes mellitus associated with -blocker treatment for hypertension (2011) Curr Med Res Opin, 27, pp. 799-807. , PID: 21306286; Peter, P., Martin, U., Sharma, A., Dunne, F., Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension (2006) J Clin Pharm Ther, 31, pp. 153-159. , COI: 1:CAS:528:DC%2BD2sXitVCqtbo%3D, PID: 16635049; Probstfield, J.L., Applegate, W.B., Borhani, N.O., Curb, J.D., Cutler, J.A., Davis, B.R., The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group (1989) Clin Exp Hypertens A, 11 (5-6), pp. 973-989. , COI: 1:STN:280:DyaK3c%2FgtlyntQ%3D%3D, PID: 2676266; Giles, T.D., Sander, G.E., Nossaman, B.D., Kadowitz, P.J., Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelium-derived hyperpolarizing factors and prostaglandins (2012) J Clin Hypertens, 14 (4), pp. 198-205. , COI: 1:CAS:528:DC%2BC38XotlCns7g%3D; Kandavar, R., Higashi, W.C., Blackstock, C., Vaughn, C., Sukhanov, S., The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension (2011) Am Soc Hypertens, 5 (3), pp. 161-165. , COI: 1:CAS:528:DC%2BC3MXnvVegsrw%3D; Rizos, C.V., Elisaf, M.S., Antihypertensive drugs and glucose metabolism (2014) World J Cardiol, 6 (7), pp. 517-530. , PID: 25068013; Gilbert, E.M., Abraham, W.T., Olsen, S., Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart (1996) Circulation, 94, p. 2817. , COI: 1:CAS:528:DyaK2sXlsVShug%3D%3D, PID: 8941107; Ladage, D., Reidenbach, C., Rieckeheer, E., Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age (2010) J Cardiovasc Pharmacol, 56, pp. 275-281. , COI: 1:CAS:528:DC%2BC3cXhtFKmurzK, PID: 20571428; Martsevich, S.Y., Kutishenko, N.P., Deev, A.D., Oganov, R.G., Shalnova, S.A., Comparison of antihypertensive and metabolic effects of carvedilol and metoprolol in hypertensive patients with overweight and obesity (2010) Camellia Trial J Hyper, 28, p. 560; Deedwania P, Shea J, Chen W, Brener L. Effects of nebivolol on blood pressure and glucose parameters on hypertensive patients with prediabetes. J Clin Hypertens. 2013;15(4):270–8. This seminal paper highlights the positive effects of the unique NO mediated vasodilating beta blocker nebivolol on insulin resistance and blood pressureMerchant, N., Rahman, S.T., Ferdinand, K.C., Haque, T., Umpierrez, G.E., Khan, B.V., Effects of nebivolol in obese African American patients with hypertension NOAAH: markers of inflammation and obesity in response to exercise induced stress (2011) J Human Hypertens, 25, pp. 196-202. , COI: 1:CAS:528:DC%2BC3MXhs1yls7s%3D; Mancia, G., ESH/ESC guidelines for the management of arterial hypertension—the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) J Hypertens, 31 (7), pp. 1281-1357. , COI: 1:CAS:528:DC%2BC3sXhtVyksb%2FJ, PID: 23817082; Frishman, W.H., Sica, D.A., b-Adrenergic blockers (2008) Hypertension primer, 4th ed.: the essentials of high blood pressure, pp. 446-450. , Izzo JL, Sica D, Black HR, (eds), Wolters Kluwer ⁄ Lippincott Williams & Wilkins, Philadelphia:; Saunders, E., Smith, W.B., DeSalvo, K.B., The efficacy and tolerability of nebivolol in hypertensive African American patients (2007) J Clin Hypertens (Greenwich), 9, pp. 866-875. , COI: 1:CAS:528:DC%2BD2sXhsVSkurjO; Hall, W.D., Clark, L.T., Wenger, N.K., The metabolic syndrome in African Americans: a review (2003) Ethn Dis, 13 (4), pp. 414-428. , PID: 14632261; Torre, JJ and AACE Hypertension Task Force Members. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of Hypertension. AACE Hypertension Guidelines. Endocr Pract. 2006;12(2)James, P., Oparil, S., 2014 evidence-based guideline for the management of high blood pressure in adults—report from the panel members appointed to JNC8 (2014) JAMA, 311, pp. 507-520. , COI: 1:CAS:528:DC%2BC2cXis1aktr8%3D, PID: 24352797; Krakoff, L.R., Gillespie, R.L., Ferdinand, K.C., Fergus, I.V., Recommendations from the JNC 8 panel members raise concerns for elderly black and female populations (2014) J Am Coll Cardiol, 64, pp. 394-402; Williams, B., Lacy, P.S., Thom, S.M., Cruickshank, K., Stanton, A., Collier, D., Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outomes; principal results of the Conduit Artery Function Evaluation (CAFÉ) study (2006) Circulation, 113 (9), pp. 1213-1225. , COI: 1:CAS:528:DC%2BD28XhvVektrg%3D, PID: 16476843; Landsberg L, Aronne LJ, Beilin LJ, Igel LI, Lloyd-Jones D, Sowers J. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. J Clin Hypertens. 2013;15(1):14–33. This report highlights the unifying pathophysiology of traditional markers of the MetS in obesity and gives guidelines on the management of hypertension in obesityWright, J.T., Jr., Harris-Haywood, S., Pressel, S., Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2008) Arch Intern Med, 168 (2), pp. 207-217. , COI: 1:CAS:528:DC%2BD1cXitFKgtrc%3D, PID: 18227370",Review,Scopus,2-s2.0-84928346266
"Sikand G., Kris-Etherton P., Boulos N.M.","Impact of Functional Foods on Prevention of Cardiovascular Disease and Diabetes",2015,"Current Cardiology Reports","17","6",,"","",16,,10.1007/s11886-015-0593-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928321636&partnerID=40&md5=7e986e41cf0810f49dc7408455bbb3b5","Department of Medicine/Cardiology Division, University of California Irvine School of Medicine, 101 City Drive South, City Tower, Suite 400Orange, CA, United States; Department of Nutritional Sciences, Penn State University, 319 Chandlee LabUniversity Park, PA, United States; Heart Disease Prevention Program, Division of Cardiology, C240 Medical Sciences, University of CaliforniaIrvine, CA, United States","Sikand, G., Department of Medicine/Cardiology Division, University of California Irvine School of Medicine, 101 City Drive South, City Tower, Suite 400Orange, CA, United States; Kris-Etherton, P., Department of Nutritional Sciences, Penn State University, 319 Chandlee LabUniversity Park, PA, United States; Boulos, N.M., Heart Disease Prevention Program, Division of Cardiology, C240 Medical Sciences, University of CaliforniaIrvine, CA, United States","A healthy dietary pattern is a cornerstone for the prevention and treatment of cardiovascular disease (CVD) and type 2 diabetes (T2DM). Compelling scientific evidence has shown many health effects of individual foods (including herbs and spices), beverages, and their constituent nutrients and bioactive components on risk of chronic disease and associated risk factors. The focus of functional foods research that is reviewed herein has been on assessing the health effects and underlying mechanisms of action of fruits and vegetables, whole grains, dairy products including fermented products, legumes, nuts, green tea, spices, olive oil, seafood, red wine, herbs, and spices. The unique health benefits of these functional foods have been the basis for recommending their inclusion in a healthy dietary pattern. A better understanding of strategies for optimally including functional foods in a healthy dietary pattern will confer greater benefits on the prevention and treatment of CVD and T2DM. © 2015, Springer Science+Business Media New York.","Cardiovascular disease prevention; Functional foods; Type 2 diabetes prevention","http://www.who.int/mediacentre/factsheets/fs312/en/, World Health Organization Media Center Website. Access date November 21 2014Chen, G., Wang, H., Zhang, X., Yang, S., Nutraceuticals and functional foods in the management of hyperlipidemia (2014) Crit Rev Food Sci Nutr, 54, pp. 1180-1201. , COI: 1:CAS:528:DC%2BC3sXot1CgtLw%3D, PID: 24499150; Oh, Y.S., Jun, H.S., Role of bioactive food components in diabetes prevention: effects on beta-cell function and preservation (2014) Nutrit Metabol Insights, 7, pp. 51-59; Position of the Academy of Nutrition and Dietetics: Functional Foods J Acad Nutr Diet 2013;113:1096–1103. This position paper provides a definition of functional foods and the regulatory overview that requires significant substantiation of functional foodsMirmiran, P., Bahadoran, Z., Azizi, F., Functional foods-based diets a novel dietary approach for management of type 2 diabetes and its complications: a review (2014) World J Diab, 5 (3), pp. 267-281. , This review article provides a comprehensive review of the prevention of diabetes with functional foods based diets; Functional Foods. http;//www.foodinsight.org/Content/3842/Final%20Functional%20Foods%20Backgrounder.pdf (2015) Accessed February, p. 2. , www.foodinsight.org/Content/3842/Final%20Functional%20Foods%20Backgrounder.pdf; Ross, S., Functional foods: the food and drug administration perspective (2000) Am J Clin Nutr, 71 (6), pp. 1735-1738. , COI: 1:CAS:528:DC%2BD3cXjvFGnt7g%3D, PID: 10837331; http://www.gao.gov/new.items/rc00156.pdf, US General Accounting Office. Food safety: Improvements needed in over-seeing the safety of dietary supplements and “functional foods”. Published July 2000. Accessed February 2 2015http://www.fda.gov/Food/LabelingNutrition/LabelClaims/ucm111447.htm.Published, US Food and Drug Administration Claims that can be made for conventional foods and dietary supplements. September 2003. Accessed February 2 2015http://www.registrarcorp.com/contact/regulatory_updates.jsp?lang, Food and Drug Administration. Guidance for industry: A food labeling guide. = en&func = 1 Access date February 2 2015Borneo, R., Leon, A.E., Whole grain cereals: functional components and health benefits (2012) Food Funct, 3, pp. 110-119. , COI: 1:CAS:528:DC%2BC38XhslaltLc%3D, PID: 22134555; Ye, E.Q., Chacko, S.A., Chou, E.L., Kugizaski, M., Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease and weight gain (2012) J Nutr, 142, pp. 1304-1313. , COI: 1:CAS:528:DC%2BC38XpsFWmur0%3D, PID: 22649266; Okarter, N., Liu, R.H., Health benefits of whole grain phytochemicals (2010) Crit Rev Good Sci Nutr, 50, pp. 120-193. , COI: 1:CAS:528:DC%2BC3cXjsFeitbs%3D; Anderson, A., Tengblad, S., Karlstrom, B., Kamal-Eldin, A., Whole grain foods do not affect insulin sensitivity or markers of lipid peroxidations and inflammation in healthy, moderately overweight subjects (2007) J Nutr, 137, pp. 1401-1407; Martinez, I.M., Lattimer, J.M., Hubach, K.L., Case, J.A., Gut microbiome composition is linked to whole grain induced immunological improvements (2013) ISME J, 7, pp. 269-280. , COI: 1:CAS:528:DC%2BC3sXhsVansL0%3D, PID: 23038174; Cho, S., Lu, Q., Fahey, G.C., Klurfeld, D.M., Consumption of cereal fiber, mixtures of whole grains and bran, and whole grains and risk reduction in type 2 diabetes, obesity, and cardiovascular disease (2013) Am J Clin Nutr, 98, pp. 594-619. , COI: 1:CAS:528:DC%2BC3sXhtFyntrzN, PID: 23803885; http://www.cnpp.usda.gov/Publications/DietaryGuidelines/2010/DGAC/Report/D-3-FattyAcidsCholesterol.pdf, Accessed February 2 2015He, M., Van Dam, R.N., Rimm, E., Hu, F.B., Whole-grain, cereal fiber, bran, and germ intake and the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus (2010) Circulation, 121, pp. 2162-2168. , PID: 20458012; Toh, J.Y., Tan, V.M., Lim, P.C., Lim, S.T., Chong, M.F., Flavonoids from fruit and vegetables: a focus on cardiovascular risk factors (2013) Curr Atheroscler Rep, 15 (12), p. 368. , COI: 1:STN:280:DC%2BC2c%2FlvFCktg%3D%3D, PID: 24091782; Chawla, R., Patil, G.R., Soluble dietary fiber (2010) Compr Rev Food Sci Food Saf, 9 (2), pp. 178-196. , COI: 1:CAS:528:DC%2BC3cXnt1KitL4%3D; Raninen, K., Lappi, J., Mykkanen, H., Poutanen, K., Dietary fiber type reflects physiological functionality: comparison of grain fiber, inulin and polydextrose (2011) Nutr Rev, 60 (1), pp. 9-21; Viuda-martos, M., Sanchez-zapata, E., Sayas-barberá, E., Sendra, E., Pérez-Álvarez, J.A., Fernández-lópez, J., Tomato and tomato byproducts. Human health benefits of lycopene and its application to meat products: a review (2014) Crit Rev Food Sci Nutr, 54 (8), pp. 1032-1049. , COI: 1:CAS:528:DC%2BC3sXltVGjs7g%3D, PID: 24499120; Muller, F.O., Re: The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives (2011) Cardiovasc J Afr, 22 (1), p. 37. , COI: 1:STN:280:DC%2BC3M7nt1Cjsw%3D%3D, PID: 21298205; Takahashi, K., Kamada, C., Yoshimura, C., Okumura, R., Effects of total and green vegetable intakes on glycated hemoglobin A1c and triglycerides in elderly patients with type 2 diabetes mellitus: the Japanese Elderly Intervention Trial (2012) Geriatr Gerontol Int, 12, pp. 50-58. , PID: 22435940; Hegde, S.V., Adhikari, P.M.N., D’Souza, V., Effect of daily supplementation of fruits on oxidative stress indices and glycemic status in type 2 diabetes mellitus (2013) Complem Ther Clin Pract, 19, pp. 97-100; Tanaka, S., Yoshimura, Y., Kawasaki, R., Kamada, C., Fruit intake and incident diabetic retinopathy with type 2 diabetes (2013) Epidemiology, 24, pp. 204-211. , PID: 23348071; Chan, H.T., Yiu, K.H., Wong, C.Y., Li, S.W., Increased dietary fruit intake was associated with lower burden of carotid atherosclerosis in Chinese patients with type 2 diabetes mellitus (2013) Diabet Med, 30, pp. 100-108. , COI: 1:CAS:528:DC%2BC3sXjt1Sru78%3D, PID: 22913415; Yang, J., Xiao, Y.Y., Grape phytochemicals and associated health benefits (2013) Crit Rev Food Sci Nutr, 53 (11), pp. 1202-1225. , COI: 1:CAS:528:DC%2BC3sXhsVCitrbI, PID: 24007424; Stowe, C.B., The effects of pomegranate juice consumption on blood pressure and cardiovascular health (2011) Complement Ther Clin Pract, 17 (2), pp. 113-115. , PID: 21457902; Ismail, T., Sestilli, P., Akhtar, S., Pomogranate peel and fruit extracts: a review of potential anti-inflammatory and anti-infective effects (2012) J Ethnopharmacol, 143 (2), pp. 397-405. , COI: 1:CAS:528:DC%2BC38XhtFeitbnP, PID: 22820239; Bondonno, C.P., Yang, X., Croft, K.D., Flavonoid rich apples and nitrate-rich spinach augment nitric oxide status and improve endothelial function in healthy men and women: a randomized controlled trial (2012) Free Radic Ciol Med, 52 (1), pp. 95-102. , COI: 1:CAS:528:DC%2BC38XitlylsQ%3D%3D; Sirtori, C.R., Galli, C., Anderson, J.W., Arnoldi, A., Nutritional and neutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins (2009) Atherosclerosis, 203 (1), pp. 8-17. , COI: 1:CAS:528:DC%2BD1MXis1Cjs7g%3D, PID: 18687434; Flight, I., Clifton, P., Cereal grains and legumes in the prevention of coronary heart dz & stroke: a review of the literature (2006) Eur J Clin Nutr, 60, pp. 1145-1159. , COI: 1:CAS:528:DC%2BD28XhtVWqsLfL, PID: 16670693; Duranti, M., Grain legume proteins and nutraceutical properties (2006) Fitoterapia, 77, pp. 67-82. , COI: 1:CAS:528:DC%2BD28XhtlKmur0%3D, PID: 16406359; Barrett, M.I., Udani, J.K., A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clincal studies on weight loss and glycemic control (2011) Nutr J, 10, p. 24. , PID: 21414227; Yao, Y., Cheng, X.Z., Wang, L.X., Wang, S.H., Major phenolic compounds, antioxidant capacity and antidiabetic potential of rice bean (Vigna umbellata L.) in China (2012) In J Mol Sci, 13, pp. 2707-2716. , COI: 1:CAS:528:DC%2BC38Xjs12qsrs%3D; Helmstadter, A., Beans and diabetes: Phenolus vulgaris preparation as antihypertensive agents (2010) J Med Food, 13, pp. 251-254. , PID: 20132042; Preuss, H.G., Bean amylase inhibitor and other carbohydrate absorption blockers effects on diabesity and general health (2009) J Am Coll Nutr, 28, pp. 266-276. , COI: 1:CAS:528:DC%2BC3cXhtVWmt7o%3D, PID: 20150600; Thompson, S.V., Winham, D.M., Hutchins, A.M., Bean and rice meals reduce postprandial glycemic responses in adults with type 2 diabetes: a crossover study (2012) Nutr J, 11, p. 23. , PID: 22494488; Weisse, K., Brandsch, C., Zernsdorf, B., Nembongwe, G., Lupin protein compared to casein lowers the LDL-Cholesterol:HDL-Cholesterol ratio of hypercholesterolemic adults (2010) Eur J Nutr, 49 (2), pp. 65-71. , COI: 1:CAS:528:DC%2BC3cXhslOnsL4%3D, PID: 19680704; Gilbert, E.R., Liu, D., Anti-diabetic functions of soy isoflavone genistein: mechanism underlying its effects on pancreatic beta-cell function (2013) Food Fnct, 4, pp. 200-212. , COI: 1:CAS:528:DC%2BC3sXhvVCitb4%3D; Anderson, J.W., Bush, H.M., Soy protein effects on serum lipoproteins: a quality assessment and meta analysis of randomized, controlled studies (2011) J Am Coll Nutr, 30, pp. 79-91. , COI: 1:CAS:528:DC%2BC3MXhtVaksLvF, PID: 21730216; Azadbakht, L., Shakerhosseini, R., Atabak, S., Jamshidian, M., Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type 2 diabetes with nephropathy (2003) Eur J Clin Nutr, 57, pp. 1292-1294. , COI: 1:CAS:528:DC%2BD3sXnsVOqu7g%3D, PID: 14506491; Bhathena, S.J., Velasquez, M.T., Beneficial role of dietary phytoestrogens in obesity and diabetes (2002) Am J Clin Nutr, 76, pp. 1191-1201. , COI: 1:CAS:528:DC%2BD38Xpt1emtrs%3D, PID: 12450882; Yang, B., Chen, Y., Xu, T., Yu, Y., Systematic review and meta-analysis of soy products consumption in patients with type 2 diabetes mellitus (2011) Asia Pac J Clin Nutr, 20, pp. 593-602. , COI: 1:CAS:528:DC%2BC38XhtVyrt74%3D, PID: 22094845; Ronis, M.J., Chen, Y., Badeaus, J., Badger, T.M., Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR and SREBP signaling (2009) J Nutr, 139, pp. 1431-1438. , COI: 1:CAS:528:DC%2BD1MXhtlWrt7rN, PID: 19515742; Liu, C.F., Pan, T.M., Beneficial Effects of Bioactive Peptides derived from Soybean on Human Health and Their Production by Genetic Engineering (2011) Soybean and health, pp. 311-329; Anderson, J.W., Bush, H.M., Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies (2011) J Am Coll Nutr, 30, pp. 79-291; Harland, J.I., Haffner, T.A., Systematic review, meta-analysis and regression of randomized controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol (2008) Atherosclerosis, 200, pp. 13-27. , COI: 1:CAS:528:DC%2BD1cXhtVensb7I, PID: 18534601; Afshin, A., Micha, R., Khatibzadeh, S., Mozaffarian, D., Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis (2014) Am J Clin Nutr, 100, pp. 278-288. , COI: 1:CAS:528:DC%2BC2cXhtFWht7bP, PID: 24898241; Kendall, C.W., Esfahani, A., Truan, J., Srichaikul, K., Health benefits of nuts in prevention and management of diabetes (2010) Asia Pac J Clin Nutr, 19, pp. 110-116. , COI: 1:CAS:528:DC%2BC3cXkvVCntbw%3D, PID: 20199995; Ross, E., Nuts and novel biomarkers of cardiovascular disease (2009) Am J Clin Nutr, 89, pp. 1649-1656; Jenkins, D.J., Hu, F.B., Tapsell, L.C., Josse, A.R., Possible benefits of nuts in type 2 diabetes (2008) J Nutr, 138, pp. 1752-1756. , COI: 1:CAS:528:DC%2BD1cXhtVyksrvL, PID: 18716181; Li, T.Y., Brennan, A.M., Wedick, N.M., Mantzoros, C., Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes (2009) J Nutr, 139, pp. 1333-1338. , COI: 1:CAS:528:DC%2BD1MXhtlWrt7zI, PID: 19420347; Tey, S.L., Brown, R., Gray, A., Chisholm, A., Nuts improve diet quality compared to other energy dense snacks while maintaining body weight (2011) J Nutr Metab, 2011, p. 357350. , PID: 21845219; Mattes, R.D., Dreher, M.L., Nuts and healthy body weight maintenance mechanisms (2010) Asia Pac J Clin Nutr, 19, pp. 137-141. , PID: 20199999; Mantzoros, C.S., Williams, C.J., Manson, J.E., Meigs, J.B., Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women (2006) Am J Clin Nutr, 84, pp. 328-335. , COI: 1:CAS:528:DC%2BD28XosVehs7s%3D, PID: 16895879; Jiang, R., Jacobs, D.R., Mayer-Davis, E., Szklo, M., Nut and seed consumption and inflammatory markers in the multi-ethnic study of atherosclerosis (2006) Am J Epidemiol, 163, pp. 222-231. , PID: 16357111; Ross, E., Nuts and novel biomarkers of cardiovascular disease (2009) Am J Clin Nutr, 89, pp. 1649-1656; Bao, U., Han, J., Hu, F.G., Stampfer, M., Willett, W., Fuchs, C.S., Association of nut consumption with total and cause specific mortality (2013) N Engl J Med, 369, pp. 2001-2011. , COI: 1:CAS:528:DC%2BC3sXhvVCjtb%2FP, PID: 24256379, In two major cohort studies (Nurses’ Health Study and the Health Professionals Follow-up Study), the frequency of nut consumption was inversely associated with total and cause-specific mortality in a dose-dependent manner. Nut consumption (seven or more times per week) resulted in a 20 % lower death rate; Wang ZM, Zhou B, Wang YS, Gong Q et al. Black and green tea consumption and the risk of coronary artery disease: a meta-analysis. Am J Clin Nutr. 93 (3):506–515Jiao, H., Hu, G., Gu, D., Ni, X., (2014) Having a Promising Efficacy on Type II diabetes, , It’s definitely a green tea time, Curr Med Chem:; Takahashi, M., Miyashita, M., Suzuki, K., Acute ingestion of catechin-rich green tea improves postprandial glucose status and increases serum thioredoxin concentrations in postmenopausal women (2014) Br J Nutr, pp. 1-9; Zuo, X., Tian, C., Zhao, N., Ren, W., Tea polyphenols alleviate high fat and high glucose-induced endothelial hyper permeability by attenuating ROS production via NADPH oxidase pathway (2014) BMC Res Notes, 7, p. 120. , PID: 24580748; Grassi, D., Desideri, G., Ferri, C., Protective effects of dark chocolate on endothelial function and diabetes (2013) Curr Opin Clin Nutr Metab Care, 16 (6), pp. 662-668. , COI: 1:CAS:528:DC%2BC3sXhs1WlsbnP, PID: 24100673; Katz, D.L., Doughty, K., Ali, A., Cocoa and chocolate in human health and disease (2011) Antioxid Redox Signal, 15 (10), pp. 2779-2811. , COI: 1:CAS:528:DC%2BC3MXht12qsrnE, PID: 21470061; Buitrago-Lopez, A., Sanderson, J., Johnson, L., Warnakula, S., Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis (2011) BMJ, 343, p. 4488. , PID: 21875885; Messerli, F.H., Chocolate consumption, cognitive function, and nobel laureates (2012) N Engl J Med, 367, pp. 1562-1564. , COI: 1:CAS:528:DC%2BC38XhsFGqsrjL, PID: 23050509; Fernández-Murga, L., Tarín, J.J., García-Perez, M.A., Cano, A., The impact of chocolate on cardiovascular health (2011) Maturitas, 69, pp. 312-321. , PID: 21665390; Eilat-adar, S., Sinai, T., Yosefy, C., Henkin, Y., Nutritional recommendations for cardiovascular disease prevention (2013) Nutrients, 5 (9), pp. 3646-3683. , PID: 24067391; Kwon MJ, Song YS, Choi MS, Park S et al. Cholesteryl ester transfer protein activity and atherogenic parametes in rabbits supplemented with cholesterol and garlic powder. Life Sci. 72(26):2953–2964Khoo, Y.S., Aziz, Z., Garlic supplementation and serum cholesterol: a meta-analysis (2009) J Clin Pharm Ther, 34, pp. 133-145. , COI: 1:STN:280:DC%2BD1M7nsF2ktQ%3D%3D, PID: 19250134; Ackermann, R.T., Mulrow, C.D., Ramirez, G., Gardner, C.D., Garlic shows promise for improving some cardiovascular risk factors (2001) Arch Intern Med, 161, pp. 813-824. , COI: 1:STN:280:DC%2BD3M3mtVeltw%3D%3D, PID: 11268223; Zeb, I., Ahmadi, N., Nasir, K., Kadakia, J., Larijani, V.N., Flores, F., Aged garlic extract and coenzyme Q10 have favorable effect on inflammatory markers and coronary atherosclerosis progression: a randomized clinical trial (2012) J Cardiovasc Dis Res, 3 (3), pp. 185-190. , PID: 22923934; Qin, B., Panickar, K.S., Anderson, R.A., Cinnamon: potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes (2010) J Diabetes Sci Technol, 4 (3), pp. 685-693. , PID: 20513336; Crawford, P., Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial (2009) J Am Board Fam Med, 22 (5), pp. 507-512. , PID: 19734396; https://naturalmedicines.therapeuticresearch.com, Natural Standard. Accessed September 29, 2014Smith, J.D., Clinard, V.B., Natural products for the management of type 2 diabetes mellitus and comorbid conditions (2014) J Am Pharm Assoc, 54 (5), pp. 304-320; Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis (2014) Phytother Res, 28 (5), pp. 633-642. , COI: 1:CAS:528:DC%2BC2cXmvVyqs74%3D, PID: 23922235; Neelakantan, N., Narayanan, M., de Souza, R.J., Effect of fenugreek (Trigonella foenum-graecum L) intake on glycemia: a meta-analysis of clinical trials (2014) Nutr J, 13, p. 7. , PID: 24438170; Liu, Y., Kakani, R., Nair, M.G., Compounds in functional food fenugreek spice exhibit anti-inflammatory and antioxidant activities (2012) Food Chem, 3, pp. 1187-1192; Mandegary, A., Pournamdari, M., Sharififar, F., Pournourmohammadi, S., Fardiar, R., Shooli, S., Alkaloid and flavonoid rich fractions of fenugreek seeds (Trigonella foenum-graecum L.) with antinociceptive and anti-inflammatory effects (2012) Food Chem Toxicol, 50 (7), pp. 2503-2507. , COI: 1:CAS:528:DC%2BC38XosVehsbs%3D, PID: 22542922; Elwood, P., Pickering, J., Givens, D.I., Gallacher, J., The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence (2010) Lipids, 45 (10), pp. 925-939. , COI: 1:CAS:528:DC%2BC3cXht1GjtLrM, PID: 20397059; Soedamah-Muthu, S.S., Ding, E.L., Al-Delaimy, W.K., Hu, F.B., Engberink, M.F., Willett, W.C., Milk and dairy consumption and incidence of cardiovascular diseases and all-cause mortality: dose–response meta-analysis of prospective cohort studies (2011) Am J Clin Nutri, 93 (1), pp. 158-171. , COI: 1:CAS:528:DC%2BC3MXls1CrsA%3D%3D; Sonestedt, E., Wirfält, E., Wallström, P., Gullberg, B., Orho-Melander, M., Hedblad, B., Dairy products and its association with incidence of cardiovascular disease: the Malmö diet and cancer cohort (2011) Eur J Epidemiol, 26 (8), pp. 609-618. , COI: 1:CAS:528:DC%2BC3MXhtFGit7bI, PID: 21660519; Patterson, E., Larsson, S.C., Wolk, A., Åkesson, A., Association between dairy food consumption and risk of myocardial infarction in women differs by type of dairy food (2013) J Nutri, 143 (1), pp. 74-79. , COI: 1:CAS:528:DC%2BC3sXhs1Ghug%3D%3D; de Oliveira Otto, M.C., Nettleton, J.A., Lemaitre, R.N., Steffen, L.M., Kromhout, D., Rich, S.S., Biomarkers of dairy fatty acids and risk of cardiovascular disease in the multi-ethnic study of atherosclerosis (2013) J Am Heart Assoc, 2 (4), p. 000092. , PID: 23868191; Mann, G.V., Spoerry, A., Studies of a surfactant and cholesteremia in the Maasai (1974) Am J Clin Nutri, 27 (5), pp. 464-469. , COI: 1:CAS:528:DyaE2cXhsVCmurY%3D; de Roos, N.M., Schouten, G., Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels (1999) Eur J Clin Nutr, 53 (4), pp. 277-280. , PID: 10334653; Lewis, S.J., Burmeister, S., A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids (2005) Eur J Clin Nutr, 59 (6), pp. 776-780. , COI: 1:CAS:528:DC%2BD2MXks12ktb4%3D, PID: 15841092; Simons, L.A., Amansec, S.G., Conway, P., Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol (2006) Nutr Metab Cardiovasc Dis, 16 (8), pp. 531-535. , PID: 17126768; Ataie-Jafari, A., Larijani, B., Alavi Majd, H., Tahbaz, F., Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects (2009) Ann Nutr Metab, 54 (1), pp. 22-27. , COI: 1:CAS:528:DC%2BD1MXltVekuro%3D, PID: 19229114; Xiao, J.Z., Kondo, S., Takahashi, N., Miyaji, K., Oshida, K., Hiramatsu, A., Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers (2003) J Dairy Sci, 86 (7), pp. 2452-2461. , COI: 1:CAS:528:DC%2BD3sXltlSrtbg%3D, PID: 12906063; Anderson, J.W., Effect of fermented milk (yogurt) containing lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans (1999) J Am Coll Nutr, 18 (1), pp. 43-50. , COI: 1:STN:280:DyaK1M7msV2rsw%3D%3D, PID: 10067658; Guo, Z., Liu, X.M., Zhang, Q.X., Shen, Z., Tian, F.W., Zhang, H., Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials (2011) Nutr Metab Cardiovasc Dis, 21 (11), pp. 844-850. , COI: 1:CAS:528:DC%2BC3MXhtlejsbzM, PID: 21930366; Agerholm, L., Bell, M.L., The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies (2000) Eur J Clin Nutr, 54 (11), p. 856; DiRienzo, D.B., Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets (2014) Nutr Rev, 72 (1), pp. 18-29. , PID: 24330093; Jakobsen, M.U., O’Reilly, E.J., Heitmann, B.L., Pereira, M.A., Bälter, K., Fraser, G.E., Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies (2009) Am J Clin Nutr, 89 (5), pp. 1425-1432. , COI: 1:CAS:528:DC%2BD1MXlt1Ort7o%3D, PID: 19211817, Results from 11 American and European cohort pooled studies (with 344,696 participants) demonstrated that replacing saturated fatty acids with polyunsaturated fatty acids rather than monounsaturated fatty acids or dietary carbohydrate prevents CHD; Mente, A., de Koning, L., Shannon, H.S., Anand, S.S., A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease (2009) Arch Intern Med, 169 (7), pp. 659-669. , COI: 1:CAS:528:DC%2BD1MXltFert70%3D, PID: 19364995; Skeaff, C.M., Miller, J., Dietary fat and coronary heart disease: summary of evidence from prospective cohort and randomised controlled trials (2009) Ann Nutri Metab, 55 (1-3), pp. 173-201. , COI: 1:CAS:528:DC%2BD1MXhtFaksL3P; Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., Ward, H.A., Johnson, L., Association of dietary, circulating, and supplement fatty acids with coronary risk a systematic review and meta-analysis (2014) Ann Intern Med, 160 (6), pp. 398-406. , PID: 24723079; Schwingshackl, L., Hoffmann, G., Monounsaturated fatty acids and risk of cardiovascular disease: synopsis of the evidence available from systematic reviews and meta-analyses (2012) Nutrients, 4 (12), pp. 1989-2007. , COI: 1:CAS:528:DC%2BC3sXjsFSkug%3D%3D, PID: 23363996; Guasch-Ferre, M., Hu, F., Martinez-Gonzalez, M., Fito, M., Bullo, M., Estruch, R., Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED study (2014) BMC Med, 12 (1), p. 78. , PID: 24886626, In this study, for every 10 g/day increase in extra-virgin olive oil consumed, risk of cardiovascular disease and mortality decreased by 10 % and 7 %, respectively; Buckland, G., Mayén, A.L., Agudo, A., Travier, N., Navarro, C., Huerta, J.M., Olive oil intake and mortality within the Spanish population (EPIC-Spain) (2012) Am J Clin Nutr, 96 (1), pp. 142-149. , COI: 1:CAS:528:DC%2BC38XpsVyktrc%3D, PID: 22648725; Samieri, C., Feart, C., Proust-Lima, C., Peuchant, E., Tzourio, C., Stapf, C., Olive oil consumption, plasma oleic acid, and stroke incidence: the Three-City Study (2011) Neurology, 77 (5), pp. 418-425. , COI: 1:CAS:528:DC%2BC3MXpslKgs7c%3D, PID: 21676914; Martínez-González, M.A., Dominguez, L.J., Delgado-Rodríguez, M., Olive oil consumption and risk of CHD and/or stroke: a meta-analysis of case–control, cohort and intervention studies (2014) Br J Nutr, 112 (2), pp. 248-259. , PID: 24775425; Schwingshackl, L., Hoffmann, G., Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies (2014) Lipids Health Dis, 13 (1), p. 154. , PID: 25274026; Di Castelnuovo, A., Rotondo, S., Iacoviello, L., Donati, M.B., de Gaetano, G., Meta-analysis of wine and beer consumption in relation to vascular risk (2002) Circulation, 105 (24), pp. 2836-2844. , PID: 12070110; Li, H., Förstermann, U., Red wine and cardiovascular health (2012) Circ Res, 111 (8), pp. 959-961. , COI: 1:CAS:528:DC%2BC38XhsVWmtrfL, PID: 22955729; Chiva-Blanch, G., Urpi-Sarda, M., Ros, E., Arranz, S., Valderas-Martínez, P., Casas, R., Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication (2012) Circ Res, 111 (8), pp. 1065-1068. , COI: 1:CAS:528:DC%2BC38XhsVWmt77F, PID: 22955728; Krnic, M., Modun, D., Budimir, D., Gunjaca, G., Jajic, I., Vukovic, J., Comparison of acute effects of red wine, beer and vodka against hyperoxia-induced oxidative stress and increase in arterial stiffness in healthy humans (2011) Atherosclerosis, 218 (2), pp. 530-535. , COI: 1:CAS:528:DC%2BC3MXht1GrsbvF, PID: 21803358; Costanzo, S., Di Castelnuovo, A., Donati, M., Iacoviello, L., de Gaetano, G., Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis (2011) Eur J Epidemiol, 26 (11), pp. 833-850. , PID: 22076059; Bang, H.O., Dyerberg, J., Sinclair, H.M., The composition of the Eskimo food in north western Greenland (1980) Am J Clin Nutr, 33 (12), pp. 2657-2661. , COI: 1:CAS:528:DyaL3MXhsValsg%3D%3D, PID: 7435433; Mozaffarian, D., Rimm, E.B., Fish intake, contaminants, and human health: evaluating the risks and the benefits (2006) JAMA, 296 (15), pp. 1885-1899. , COI: 1:CAS:528:DC%2BD28XhtFWmt7%2FF, PID: 17047219; Mozaffarian, D., Lemaitre, R.N., King, I.B., Song, X., Huang, H., Sacks, F.M., Plasma phospholipid long-chain ω-3 fatty acids and total and cause-specific mortality in older adults a cohort study (2013) Ann Intern Med, 158 (7), pp. 515-525. , PID: 23546563; Wu, J.H.Y., Lemaitre, R.N., King, I.B., Song, X., Sacks, F.M., Rimm, E.B., Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study (2012) Circulation, 125 (9), pp. 1084-1093. , COI: 1:CAS:528:DC%2BC38Xjt1Gnu70%3D, PID: 22282329; Djoussé, L., Akinkuolie, A.O., Wu, J.H.Y., Ding, E.L., Gaziano, J.M., Fish consumption, omega-3 fatty acids and risk of heart failure: a meta-analysis (2012) Clin Nutr, 31 (6), pp. 846-853. , PID: 22682084; Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione (2002) Circulation, 105 (16), pp. 1897-1903. , COI: 1:CAS:528:DC%2BD38XktFajtbc%3D, PID: 11997274; Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis (2007) Lancet, 369 (9567), pp. 1090-1098. , COI: 1:CAS:528:DC%2BD2sXjs1Ohtro%3D, PID: 17398308; Harris, W.S., Are n-3 fatty acids still cardioprotective? (2013) Curr Opin Clin Nutr Metab Care, 16 (2), pp. 141-149. , COI: 1:CAS:528:DC%2BC3sXit1egtb8%3D, PID: 23196817; (2010) USDA H. dietary guidelines for Americans 2010, , US Government Printing Office, Washington, DC:; Spencer, J.P.E., Gozier, A., Flavonoids and related compounds (2012) Bioavaialability and function. oxidative stress and disease, vol 30, , Paker L, Cardenas H, (eds), CRG Press, Boca Raton:; Del Rio, D., Rodriguez-Mateos, A., Spencer, J.P., Tognolini M,Borges G, Crozier A. Dietary polyphenolics in Human Health: Atructures Bioavailabity and Evidence of Protective Effects against Chronic Diseases. 2013 Antioxidants and Redox Signaling 18, 14, pp. 1818-1892; Reedy, J., Krebs-Smith, S.M., Miler, P.E., Liese, A., Higher diet quality is associated with decreased risk of all-cause. Cardiovascular disease, and cancer mortality among older adults (2014) J Nutr, 144, pp. 881-889. , COI: 1:CAS:528:DC%2BC2cXovFGmsrw%3D, PID: 24572039; http://www.health.gov/dietaryguidelines/, 2015 Dietary Guidelines for Americans Committee Reportwww.athero.org, Grundy SM, Arai H, Barter P, Bersot TP et al. 2013. An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia (accessed September 20, 2014)http://content.onlinejacc.org/article.aspx?doi, Eckel et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation published online November 12 2013. 201310.1161/01.cir.0000437740.48606.d1. = Accessed February 2 2015Jacobson, T.A., Ito, M.K., Maki, K.C., Orringer, C.E., Bays, H.E., Jones, P.H., National lipid association recommendations for patient-centered management of dyslipidemia: part 1—executive summary (2014) J Clin Lipidol, 8, pp. 473-488. , PID: 25234560; Evert, A.B., Boucher, J.L., Cypress, M., Dunbar, S.A., Franz, M.J., Nutrition therapy recommendations for the management of adults with diabetes (2014) Diab Care, 37, pp. 120-143; Jensen, M.D., Ryan, D.H., Apovian, C.M., Jamy, D., AHA/ACC/TOS Guideline for the management of overweight and obesity in adults. Circulation. 2013: published online before print November 12, 2013 (2013) 10.1161/01.cir.0000437739.71477.ee, , 01.cir.0000437739.71477.ee",Review,Scopus,2-s2.0-84928321636
"Agewall S.","How to save six million people per year",2015,"Atherosclerosis","240","2",,"387","388",,,10.1016/j.atherosclerosis.2015.04.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927537766&partnerID=40&md5=c300ca243a71fbaec3415d5c0ce1bfea","Department of Cardiology, Oslo University Hospital Ullevål, Institute of Clinical SciencesOslo, Norway","Agewall, S., Department of Cardiology, Oslo University Hospital Ullevål, Institute of Clinical SciencesOslo, Norway",[No abstract available],"Cardiovascular risk score; Risk factors; Sick leave; Smoking","Chen, W.C., Yun, M., Fernandez, C., Li, S., Sun, D., Lai, C.C., Hua, Y., Berenson, G.S., Secondhand smoke exposure is associated with increased carotid artery intima-media thickness: the Bogalusa heart study (2015) Atherosclerosis, , in press; West, H.W., Juonala, M., Gall, S.L., Kähönen, M., Laitinen, T., Taittonen, L., Viikari, J.S., Magnussen, C.G., Exposure to parental smoking in childhood is associated with increased risk of carotid atherosclerotic plaque in adulthood: the cardiovascular risk in young Finns study (2015) Circulation, 131, pp. 1239-1246; Juonala, M., Magnussen, C.G., Venn, A., Gall, S., Kähönen, M., Laitinen, T., Taittonen, L., Raitakari, O.T., Parental smoking in childhood and brachial artery flow-mediated dilatation in young adults: the cardiovascular risk in Young Finns study and the childhood determinants of adult health study (2012) Arterioscler. Thromb. Vasc. Biol., 32, pp. 1024-1031. , Children of parents that smoke have increased risk of developing carotid atherosclerotic plaque in adulthood. However, parents who exercise good smoking hygiene can lessen their child's risk of developing plaque; Gall, S., Huynh, Q.L., Magnussen, C.G., Juonala, M., Viikari, J.S., Kahonen, M., Dwyer, T., Venn, A., Exposure to parental smoking in childhood or adolescence is associated with increased carotid intima-media thickness in young adults (2014) Eur. Heart J., 35, pp. 2484-2491; Lorenz, M.W., Polak, J.F., Kavousi, M., Mathiesen, E.B., Völzke, H., Tuomainen, T.P., Sander, D., Fagerberg, B., Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data (2012) Lancet, 379, pp. 2053-2062; Glantz, S.A., Parmley, W.W., Passive smoking and heart disease: epidemiology, physiology, and biochemistry (1991) Circulation, 83, pp. 1-12; He, J., Vupputuri, S., Allen, K., Prerost, M.R., Hughes, J., Whelton, P.K., Passive smoking and the risk of coronary heart disease - a meta-analysis of epidemiologic studies (1999) N.Engl. J. Med., 340, pp. 920-926; Barnoya, J., Glantz, S.A., Cardiovascular effects of secondhand smoke: nearly as large as smoking (2005) Circulation, 111, pp. 2684-2698; Agüero, F., Dégano, I.R., Subirana, I., Grau, M., Zamora, A., Sala, J., Ramos, R., Elosua, R., Impact of a partial smoke-free legislation on myocardial infarction incidence, mortality and case-fatality in a population-based registry: the REGICOR Study (2013) PLoS One, 8 (1), p. e53722; WHO Fact Sheet, p. 339. , http://www.who.int/mediacentre/factsheets/fs339; Lundborg, P., Does smoking increase sick leave? Evidence using register data on Swedish workers (2007) Tob. Control, 16, pp. 114-118; Braunwald, E., Cardiovascular pharmacology: a look back and a glimpse into the future (2015) Eur. Heart J. Cardiovasc. Pharmacother., 1, pp. 7-9",Note,Scopus,2-s2.0-84927537766
"Mehta N.K., Abraham W.T., Maytin M.","ICD and CRT Use in Ischemic Heart Disease in Women",2015,"Current Atherosclerosis Reports","17","6",,"","",7,,10.1007/s11883-015-0512-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928812594&partnerID=40&md5=1266430f71294ef0cc48451d97c1bb4e","Division of Cardiovascular Medicine, The Ohio State University Wexner Medical CenterColumbus, OH, United States; Division of Cardiovascular Medicine, 473 West 12th Avenue, Room 110PColumbus, OH, United States; Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 70 Francis Street, Shapiro CenterBoston, MA, United States","Mehta, N.K., Division of Cardiovascular Medicine, The Ohio State University Wexner Medical CenterColumbus, OH, United States; Abraham, W.T., Division of Cardiovascular Medicine, 473 West 12th Avenue, Room 110PColumbus, OH, United States; Maytin, M., Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 70 Francis Street, Shapiro CenterBoston, MA, United States","Although the role of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) in improving outcomes in ischemic cardiomyopathy (ICM) has been described, the data regarding gender-based survival outcomes are limited. There is a higher preponderance of non-ischemic cardiomyopathy (NICM) in women, and most of the ICM literature is derived from sub-study analysis. This review summarizes the current body of literature on prognosis, pathophysiology, and the present clinical practice for device implantation in women with ICM. © 2015, Springer Science+Business Media New York.","Cardiac resynchronization therapy; Gender differences; Implantable cardioverter defibrillator; Ischemic cardiomyopathy","Abraham, W.T., Fisher, W.G., Smith, A.L., Cardiac resynchronization in chronic heart failure (2002) N Engl J Med, 346, pp. 1845-1853. , PID: 12063368; Cazeau, S., Leclercq, C., Lavergne, T., Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay (2001) N Engl J Med, 344, pp. 873-880. , COI: 1:STN:280:DC%2BD3M7nsV2ltw%3D%3D, PID: 11259720; Linde, C., Abraham, W.T., Gold, M.R., St John Sutton, M., Ghio, S., Daubert, C., Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms (2008) J Am Coll Cardiol, 52, pp. 1834-1843. , PID: 19038680; Moss, A.J., Hall, W.J., Cannom, D.S., Cardiac-resynchronization therapy for the prevention of heart-failure events (2009) N Engl J Med, 361, pp. 1329-1338. , PID: 19723701; Stellbrink, C., Breithardt, O.A., Franke, A., Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances (2001) J Am Coll Cardiol, 38, pp. 1957-1965. , COI: 1:STN:280:DC%2BD3MnptVeiug%3D%3D, PID: 11738300; Tracy, C.M., Epstein, A.E., Darbar, D., 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2012) J Am Coll Cardiol, 60, pp. 1297-1313. , PID: 22975230; Young, J.B., Abraham, W.T., Smith, A.L., Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial (2003) JAMA, 289, pp. 2685-2694. , PID: 12771115; Moss, A.J., Zareba, W., Hall, W.J., Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (2002) N Engl J Med, 346, pp. 877-883. , PID: 11907286; Haigney, M.C., Zareba, W., Nasir, J.M., Gender differences and risk of ventricular tachycardia or ventricular fibrillation (2009) Heart Rhythm, 6, pp. 180-186. , PID: 19187907; Ghanbari, H., Dalloul, G., Hasan, R., Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials (2009) Arch Intern Med, 169, pp. 1500-1506. , PID: 19752408; Arshad, A., Moss, A.J., Foster, E., Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial (2011) J Am Coll Cardiol, 57, pp. 813-820. , PID: 21310317; Cheng, A., Gold, M.R., Waggoner, A.D., Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial (2012) Heart Rhythm, 9, pp. 736-741. , PID: 22182496, This study studied 846 patients from the SMART-AV trial to assess gender responses to CRT. The investigators reported that women had a better reponse to CRT demonstrated by improvement in LV volumes at 6 months. They ascribe this result to greater degrees of biventricular pacing in women who had a higher incidence of LBBB at baseline. Additionally, women tended to respond more favorably with AV optimization strategies using programmed device algorithm or via echocardiography; Mooyaart, E.A., Marsan, N.A., van Bommel, R.J., Comparison of long-term survival of men versus women with heart failure treated with cardiac resynchronization therapy (2011) Am J Cardiol, 108, pp. 63-68. , PID: 21529733; Xu, Y.Z., Friedman, P.A., Webster, T., Cardiac resynchronization therapy: do women benefit more than men? (2012) J Cardiovasc Electrophysiol, 23, pp. 172-178. , PID: 21914024; Curtis, L.H., Al-Khatib, S.M., Shea, A.M., Hammill, B.G., Hernandez, A.F., Schulman, K.A., Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death (2007) JAMA, 298, pp. 1517-1524. , COI: 1:CAS:528:DC%2BD2sXhtFeitrrJ, PID: 17911496; Hsing, J.M., Selzman, K.A., Leclercq, C., Paced left ventricular QRS width and ECG parameters predict outcomes after cardiac resynchronization therapy: PROSPECT-ECG substudy (2011) Circ Arrhythm Electrophysiol, 4, pp. 851-857. , PID: 21956038; Ypenburg, C., van Bommel, R.J., Borleffs, C.J., Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up (2009) J Am Coll Cardiol, 53, pp. 483-490. , PID: 19195605; Russo, A.M., Poole, J.E., Mark, D.B., Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial (2008) J Cardiovasc Electrophysiol, 19, pp. 720-724. , PID: 18373605; Albert, C.M., Quigg, R., Saba, S., Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy (2008) Am Heart J, 156, pp. 367-372. , PID: 18657670; Zareba, W., Moss, A.J., Jackson Hall, W., Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction (2005) J Cardiovasc Electrophysiol, 16, pp. 1265-1270. , PID: 16403053; Bardy, G.H., Lee, K.L., Mark, D.B., Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (2005) N Engl J Med, 352, pp. 225-237. , COI: 1:CAS:528:DC%2BD2MXmslShtw%3D%3D, PID: 15659722; Jamerson, D., McNitt, S., Polonsky, S., Zareba, W., Moss, A., Tompkins, C., Early procedure-related adverse events by gender in MADIT-CRT (2014) J Cardiovasc Electrophysiol, 25, pp. 985-989. , PID: 24758374, This study concluded that women had a better response to CRT-D. However, they had a higher incidence of complications notably pneumothorax/hemothorax within 30 days of device implantation. Low body mass index correlated with incidence of this complication in men and women. In addition, elevated blood urea nitrogen and creatinine levels correlated with device related complications in women; Wilcox, J.E., Fonarow, G.C., Zhang, Y., Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF (2014) Circ Heart Fail, 7, pp. 146-153. , PID: 24178311, This trial evaluated the effect of ICD and CRT in over 9000 patients in the outpatient setting from the IMPROVE-HF cohort. They demonstrated that regardless of gender, men and women derived similar benefit from CRT-D and CRT-P devices at 24 months. They concluded that gender modification should not be a factor for outpatient referral for device consideration; Henyan, N.N., White, C.M., Gillespie, E.L., Smith, K., Coleman, C.I., Kluger, J., The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death (2006) J Intern Med, 260, pp. 467-473. , COI: 1:STN:280:DC%2BD28ngvVenuw%3D%3D, PID: 17040253; Santangeli, P., Di Biase, L., Dello Russo, A., Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators (2010) Ann Intern Med, 153, pp. 592-599. , PID: 21041579; Kannel, W.B., Wilson, P.W., D’Agostino, R.B., Cobb, J., Sudden coronary death in women (1998) Am Heart J, 136, pp. 205-212. , COI: 1:STN:280:DyaK1czmvVekug%3D%3D, PID: 9704680; Lampert, R., McPherson, C.A., Clancy, J.F., Caulin-Glaser, T.L., Rosenfeld, L.E., Batsford, W.P., Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators (2004) J Am Coll Cardiol, 43, pp. 2293-2299. , PID: 15193696; Bhavnani, S.P., Pavuluri, V., Coleman, C.I., The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study (2013) Pacing Clin Electrophysiol, 36, pp. 878-884. , PID: 23614760, This propensity matched study indicated that 291 women had similar mortality to 291 men, but were less likely to receive ICD therapy. The investigators concluded that woman had a lower incidence of arrhythmic mortality; Russo, A.M., Stamato, N.J., Lehmann, M.H., Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial (2004) J Cardiovasc Electrophysiol, 15, pp. 993-998. , PID: 15363069; Liu, X.K., Katchman, A., Drici, M.D., Gender difference in the cycle length-dependent QT and potassium currents in rabbits (1998) J Pharmacol Exp Ther, 285, pp. 672-679. , COI: 1:CAS:528:DyaK1cXjtF2gu7s%3D, PID: 9580612; Wei, S.K., McCurley, J.M., Hanlon, S.U., Haigney, M.C., Gender differences in Na/Ca exchanger current and beta-adrenergic responsiveness in heart failure in pig myocytes (2007) Ann N Y Acad Sci, 1099, pp. 183-189. , COI: 1:CAS:528:DC%2BD2sXlt1Glu78%3D, PID: 17446456; Kwon, D.H., Hachamovitch, R., Adeniyi, A., Myocardial scar burden predicts survival benefit with implantable cardioverter defibrillator implantation in patients with severe ischaemic cardiomyopathy: influence of gender (2014) Heart, 100, pp. 206-213. , PID: 24186562, This retrospective observational study over 5.8 year follow up period showed that myocardial scar burden predicted a higher mortality in patients with ischemic cardiomyopathy with EF <40%. Men with higher scar burden were more likely to have survival benefit from ICD therapy, while the inverse relationship was seen in women. Given this finding, they suggested that higher scar burden in men led to more arrhythmic events, while it led to more heart failure related events in women; Dash, R., Frank, K.F., Carr, A.N., Moravec, C.S., Kranias, E.G., Gender influences on sarcoplasmic reticulum Ca2 + −handling in failing human myocardium (2001) J Mol Cell Cardiol, 33, pp. 1345-1353. , COI: 1:CAS:528:DC%2BD3MXkvVOktrw%3D, PID: 11437540; Hara, M., Danilo, P., Jr., Rosen, M.R., Effects of gonadal steroids on ventricular repolarization and on the response to E4031 (1998) J Pharmacol Exp Ther, 285, pp. 1068-1072. , COI: 1:CAS:528:DyaK1cXjvFCrsr0%3D, PID: 9618409; Nakagawa, M., Ooie, T., Ou, B., Gender differences in autonomic modulation of ventricular repolarization in humans (2005) J Cardiovasc Electrophysiol, 16, pp. 278-284. , PID: 15817086; Song, M., Helguera, G., Eghbali, M., Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones (2001) J Biol Chem, 276, pp. 31883-31890. , COI: 1:CAS:528:DC%2BD3MXms1Smsb0%3D, PID: 11427525; Vizgirda, V.M., Wahler, G.M., Sondgeroth, K.L., Ziolo, M.T., Schwertz, D.W., Mechanisms of sex differences in rat cardiac myocyte response to beta-adrenergic stimulation (2002) Am J Physiol Heart Circ Physiol, 282, pp. 256-263. , COI: 1:CAS:528:DC%2BD38XlsVOmug%3D%3D, PID: 11748070; Lund, L.H., Mancini, D., Heart failure in women (2004) Med Clin N Am, 88, pp. 1321-1345. , PID: 15331319; Zabarovskaja, S., Gadler, F., Braunschweig, F., Women have better long-term prognosis than men after cardiac resynchronization therapy (2012) Europace, 14, pp. 1148-1155. , PID: 22399204; Woo, G.W., Petersen-Stejskal, S., Johnson, J.W., Conti, J.B., Aranda, J.A., Jr., Curtis, A.B., Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study (2005) J Interv Card Electrophysiol, 12, pp. 107-113. , PID: 15744462; Ghali, J.K., Krause-Steinrauf, H.J., Adams, K.F., Gender differences in advanced heart failure: insights from the BEST study (2003) J Am Coll Cardiol, 42, pp. 2128-2134. , PID: 14680739; Zardkoohi, O., Nandigam, V., Murray, L., The impact of age and gender on cardiac resynchronization therapy outcome (2007) Pacing Clin Electrophysiol, 30, pp. 1344-1348. , PID: 17976097; Cipriani, M., Landolina, M., Oliva, F., (2014) et al, , Women with nonischemic cardiomyopathy have a favorable prognosis and a better left ventricular remodeling than men after cardiac resynchronization therapy, J Cardiovasc Med (Hagerstown:; Daubert, J.P., Zareba, W., Hall, W.J., Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients (2006) J Am Coll Cardiol, 47, pp. 98-107. , PID: 16386671; Villareal, R.P., Woodruff, A.L., Massumi, A., Gender and cardiac arrhythmias (2001) Tex Heart Inst J, 28, pp. 265-275. , COI: 1:STN:280:DC%2BD38%2FkvFOjug%3D%3D, PID: 11777151; Nemati, M., Doyle, J.T., McCaughan, D., Dunn, R.A., Pipberger, H.V., The orthogonal electrocardiogram in normal women. Implications of sex differences in diagnostic electrocariodgraphy (1978) Am Heart J, 95, pp. 12-21. , COI: 1:STN:280:DyaE1c%2FnvVSrug%3D%3D, PID: 145801; Strauss, D.G., Selvester, R.H., Wagner, G.S., Defining left bundle branch block in the era of cardiac resynchronization therapy (2011) Am J Cardiol, 107, pp. 927-934. , PID: 21376930; Zusterzeel, R., Curtis, J.P., Canos, D.A., Sex-specific mortality risk by QRS morphology and duration in patients receiving CRT: results from the NCDR (2014) J Am Coll Cardiol, 64, pp. 887-894. , PID: 25169173, This study from the National Cardiovascular Data Registry looked at gender differences in mortality following CRT-D therapy in over 31000 patients with upto 5 years follow up. They reported no gender difference in the non-LBBB cohort. For patients with LBBB, women benefited more than men. Longer QRS duration with LBBB predicted for improved survival in all patients; Loring, Z., Canos, D.A., Selzman, K., Left bundle branch block predicts better survival in women than men receiving cardiac resynchronization therapy: Long-term follow-up of approximately 145,000 patients (2013) JACC Heart Fail, 1, pp. 237-244. , PID: 24621876, This Medicare record based study with over 144000 patients with upto 90 months follow up data concluded that LBBB diagnoses was associated with improved survival in women compared to men with CRT-D. The investigators suggested that LBBB may have different prognostic significance, or higher positive rates in men; Zareba, W., Klein, H., Cygankiewicz, I., Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) (2011) Circulation, 123, pp. 1061-1072. , PID: 21357819; Strauss, D.G., Loring, Z., Selvester, R.H., Right, but not left, bundle branch block is associated with large anteroseptal scar (2013) J Am Coll Cardiol, 62, pp. 959-967. , PID: 23707313; Daugherty, S.L., Peterson, P.N., Wang, Y., Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria? (2009) Am Heart J, 158, pp. 224-229. , PID: 19619698; Gauri, A.J., Davis, A., Hong, T., Burke, M.C., Knight, B.P., Disparities in the use of primary prevention and defibrillator therapy among blacks and women (2006) Am J Med, 119, pp. 17-21; Horton, H.L., Marinchak, R.A., Rials, S.J., Kowey, P.R., Gender differences in device therapy for malignant ventricular arrhythmias (1995) Arch Intern Med, 155, pp. 2342-2345. , COI: 1:STN:280:DyaK28%2FnsVahsg%3D%3D, PID: 7487260; Yarnoz, M.J., Curtis, A.B., Sex-based differences in cardiac resynchronization therapy and implantable cardioverter defibrillator therapies: effectiveness and use (2006) Cardiol Rev, 14, pp. 292-298. , PID: 17053376; Hsich, E.M., Pina, I.L., Heart failure in women: a need for prospective data (2009) J Am Coll Cardiol, 54, pp. 491-498. , PID: 19643307; Peterson, P.N., Daugherty, S.L., Wang, Y., Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy (2009) Circulation, 119, pp. 1078-1084. , PID: 19221223",Review,Scopus,2-s2.0-84928812594
"Rashid S., Ahmad M., Zafar M., Sultana S., Ayub M., Khan M.A., Yaseen G.","Ethnobotanical survey of medicinally important shrubs and trees of Himalayan region of Azad Jammu and Kashmir, Pakistan",2015,"Journal of Ethnopharmacology","166",, 9402,"340","351",,,10.1016/j.jep.2015.03.042,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926289485&partnerID=40&md5=27a41ddff17f7567db72926e69390749","Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan","Rashid, S., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Ahmad, M., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Zafar, M., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Sultana, S., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Ayub, M., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Khan, M.A., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Yaseen, G., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan","Abstract Ethnopharmacological relevance Present study was commenced with an aim to document the indigenous knowledge of medicinally important shrubs and trees of Himalayan region of Azad Jammu and Kashmir, Pakistan. This is the first contribution to the quantitative ethnobotany of this region, as no reported data focusing on shrubs and trees from the area have been published. Study reported the ethnobotanical significance of medicinal plants for the treatment of various diseases. Method Study was conducted during 2012-2014 following standard ethnobotanical methods. The ethnomedicinal data was collected through informed consent semi- structured interviews of 160 key informants. Documented data was analyzed by using quantitative indices of informant consensus factor (ICF), fidelity level (FL), use value (UV) and relative frequency citation (RFC). Results A total of 73 shrub and tree species belonging to 56 genera and 37 families were reported to be used ethnomedicinally for the treatment of various ailments. Medicinal plant diversity showed that Rosaceae was dominating family with (9 spp.) followed by Moraceae (7 spp.), Euphorbiaceae, Mimosaceae, Pinaceae, Rhamnaceae (4 spp. each), Oleaceae (3 spp.), Apocynaceae, Caesalpinaceae, Ebenaceae, Fagaceae, Lythraceae, Papilionaceae, Acanthaceae, Verbenaceae (2 spp. each) while remaining 22 families were represented by one species each. Leaves (23%) were highly utilized plant parts, followed by fruits (22%), bark (18%), seeds (10%), roots (9%), flowers (8%), whole plant and aerial parts (4% each) and stem (2%). Modes of preparation fall into 14 categories including powder (33 reports) followed by decoction (29 reports), paste (22 reports), juice (18 reports), infusion (12 reports), raw (8 reports), extract and latex (5 reports each), gum and oil (4 reports each), fresh part and pulp (2 reports each), chewed and cooked (1 report each). The highest FIC was recorded for Gastro-intestinal disorders (0.58) followed by nail, skin and hair disorders (0.44). Maximum fidelity level (FL=100%) was expressed by Abies pindrow, Adhatoda vasica, Bauhinia variegata and Cedrela serrata. Based on use value Juglans regia (0.88) was found most significant species followed by Acacia nilotica (0.83), Phyllanthus emblica (0.81), Pinus roxburghii (0.75) and Punica granatum (0.71). Conclusion The area has a rich diversity of medicinally important shrub and tree species. The tradition of using plants for medicinal purposes is still alive in the local community but recently this tradition is gradually declining in new generation. Therefore awareness is needed to be raised among the local people on sustainable use and conservation of local flora. © 2015 Elsevier Ireland Ltd. All rights reserved.","Azad Jammu and Kashmir Pakistan; Ethnobotany; Himalayan region; Medicinal plants","Abbasi, A.M., Khan, M.A., Khan, N., Shah, M.H., Ethnobotanical survey of medicinally important wild edible fruits species used by tribal communities of Lesser Himalayas-Pakistan (2013) J. Ethnopharmacol., 148 (2), pp. 528-536; Abebe, D., Ayehu, A., (1993) Medicinal Plants and Enigmatic Health Practices of Northern Ethiopia, , B.S.P.E Addis Ababa, Ethiopia; Abu-Irmaileh, B.E., Afifi, F.U., Herbal medicine in Jordan with special emphasis on commonly used herbs (2003) J. Ethnopharmacol., 89, pp. 193-197; Ahmad, I., Ahmad, M.S.A., Hussain, M., Hameed, M., Ashraf, M.Y., Koukab, S., Spatio-temporal effects on species classification of medicinal plants in Soone valley of Pakistan (2009) Int. J. Agric. Biol., 11 (1), pp. 64-68; Ahmad, I., Ahmad, M.S.A., Hussain, M., Ashraf, M., Ashraf, M.Y., Hameed, M., Spatiotemporal aspects of plant community structure in open scrub rangelands of sub-mountainous Himalayan plateaus (2010) Pak. J. Bot., 42 (5), pp. 3431-3440; Ahmad, M., Sultana, S., Fazl-I-Hadi, S., Hadda, T.B., Rashid, S., Zafar, M., Yaseen, G., An ethnobotanical study of medicinal plants in high mountainous region of Chail valley (District Swat-Pakistan) (2014) J. Ethnobiol. Ethnomed., 10 (1), p. 36; Ajaib, M., Khan, Z.H., Khan, N., Wahab, M., Ethnobotanical studies on useful shrubs of district Kotli, Azad Jammu and Kashmir (2010) Pak. J. Bot., 42, pp. 1407-1415; Ajk Cdp, (2005) Azad Jammu and Kashmir Community Development Programme, , Azad Government of the State of Jammu and Kashmir Muzaffarabad; Akerele, O., Medicinal plants and primary healthcares: An agenda for action (1988) Fitoterapia, 59, pp. 355-363; Akerreta, S., Cavero, R.Y., Calvo, M.I., First comprehensive contribution to medical ethnobotany of Western Pyrenees (2007) J. Ethnobiol. Ethnomed., 3, p. 26; Alam, N., Shinwari, Z.K., Ilyas, M., Ullah, Z., Indigenous knowledge of medicinal plants of Chagharzai Valley, District Buner, Pakistan (2011) Pak. J. Bot., 43, pp. 773-780; Alexiades, M.N., (1996) Selected Guidelines for Ethnobotanical Research: A Field Manual, , The New York Botanical Garden Bronx, New York; Ali, S.I., Qaiser, M., (1995) Flora of Pakistan, , Botany Department,Universityof Karachi Karachi-Pakistan; Andrade-Cetto, A., Ethnobotanical study of the medicinal plants from Tlanchinol, Hidalgo, Mexico (2009) J. Ethnopharmacol., 122, pp. 163-171; Anonymous, (2006) Azad Jammu and Kashmir at a Glance, , Plan House, Azad Government of the State of Jammu and Kashmir Muzaffarabad; Arellanes, A.J., Meckes, M., Ramirez, R., Torres, J., Luna-Herrera, J., Activity against multidrug-resistant Mycobacterium tuberculosis in Mexican plants used to treat respiratory diseases (2003) Phytother. Res., 17, pp. 903-908; Bano, A., Ahmad, M., Zafar, M., Sultana, S., Rashid, S., Khan, M.A., Ethnomedicinal knowledge of the most commonly used plants from Deosai Plateau, Western Himalayas, Gilgit Baltistan, Pakistan (2014) J. Ethnopharmacol., 155 (2), pp. 1046-1052; Bibi, T., Ahmad, M., Tareen, R.B., Tareen, N.M., Jabeen, R., Rehman, S.U., Sultana, S., Yaseen, G., Ethnobotany of medicinal plants in district Mastung of Balochistan province-Pakistan (2014) J. Ethnopharmacol., 157, pp. 79-89; Cakilcioglu, U., Khatun, S., Turkoglu, I., Hayta, S., Ethnopharmacological survey of medicinal plants in Maden (Elazig-Turkey) (2011) J. Ethnopharmacol., 137, pp. 469-486; Cakilcioglu, U., Turkoglu, I., An ethnobotanical surveyof medicinal plants in Sivrice (ElazIʇ-Turkey) (2010) J. Ethnopharmacol., 132, pp. 165-175; Calixto, J.B., Twenty five years of research on medicinal plants in Latin America: a personal review (2005) J. Ethnopharmacol., 100, pp. 131-134; Cotton, C.M., (1996) Ethnobotany Principles and Applications, , John Wiley and Sons Chichester, New York; Dar, M.E.I., Ethnobotanical uses of plants of Lawat District Muzaffarabad, Azad Jammu and Kashmir (2003) Asian J. Plant Sci., 2, pp. 680-682; Dhar, U., Rawal, R.S., Upresti, J., Setting priorities for conservation of medicinal plants - a case study in Indian Himalaya (2000) Biol. Conserv., 95, pp. 57-65; Friedman, J., Yaniv, Z., Dafni, A., Palewitch, D., A preliminary classification of the healing potential of medicinal plants, based on the rational analysis of an ethnopharmacological field survey among Bedouins in Negev Desert, Israel (1986) J. Ethnopharmacol., 16, pp. 275-287; Ghimire, S.K., Gimenez, O., Pradel, R., Mckey, D., Aumeeruddy-Thomas, Y., Demographic variation and population viability in a threatened Himalayan medicinal and aromatic herb Nardostachys grandiflora: matrix modelling of harvesting effects in two contrasting habitats (2008) J. Appl. Ecol., 45, pp. 41-51; Ghorbani, A., Studies on pharmaceutical ethnobotany in the region of Turkmen Sahra, north of Iran: Part 1: General results (2005) J. Ethnopharmacol., 102 (1), pp. 58-68; Giday, M., Asfaw, Z., Elmqvist, T., Woldu, Z., An ethnobotanical study of medicinal plants used by the Zay people in Ethiopia (2003) J. Ethnopharmacol., 85, pp. 43-52; Giday, M., Asfaw, Z., Woldu, Z., Medicinal plants of the Meinit ethnic group of Ethiopia: an ethnobotanical study (2009) J. Ethnopharmacol., 124, pp. 513-521; Govaerts, R., How many species of seed plant are there? (2001) Taxon, 50, pp. 1085-1090; Hayta, S., Polat, R., Selvi, S., Traditional uses of medicinal plants in ElazIʇ (Turkey) (2014) J. Ethnopharmacol., 154, pp. 613-623; Heinrich, M., Ethnobotany and its role in drug development (2000) Phytother. Res., 14, pp. 479-488; Heinrich, M., Edwards, S., Moerman, D.E., Leonti, M., Ethnopharmacological field studies: a critical assessment of their conceptual basis and methods (2009) J. Ethnopharmacol., 124, pp. 1-17; Hill, A.F., (1952) Economic Botany, , McGraw-Hill Book Company, INC. Tokyo; Hoareau, L., Dasilva, E.J., Medicinal plants: a re-emerging health aid (1999) Electron. J. Biotechnol., 2, pp. 56-70; Hussain, F., Khaliq, A., Ethnobotanical studies on some plants of Dabargai Hills, Swat (1996) Proceedings of 1st Training Workshop on Ethnobotany and its Application to Conservation, pp. 207-215. , NARC, Islamabad; Joshi, A.R., Joshi, K., Indigenous knowledge and uses of medicinal plants by local communities of the Kali Gandaki Watershed Area, Nepal (2000) J. Ethnopharmacol., 73 (1), pp. 175-183; Kaya, G., Discussion of P&P model used for estimating option value of forest ecosystems as medicinal plant resources (2006) J. BartIn Fac. For., 8, pp. 23-32; Kayani, S., Ahmad, M., Zafar, M., Sultana, S., Khan, M.P.Z., Ashraf, M.A., Yaseen, G., Ethnobotanical uses of medicinal plants for respiratory disorders among the inhabitants of Gallies-Abbottabad, Northern Pakistan (2014) J. Ethnopharmacol., 156, pp. 47-60; Khan, A.U., History of decline and present status of natural tropical thorn forest in Punjab (1994) Biol. Conserv., 67, pp. 205-210; Kloutusos, G., Balatsouras, D.G., Kaberos, A.C., Kandiloros, D., Ferekidis, E., Economou, C., Upper airway edema resulting from use of Ecballium elaterium (2001) Laryngoscope, 111, pp. 1652-1655; Lee, S., Xiao, C., Pei, S., Ethnobotanical survey of medicinal plants at periodic markets of Honghe Prefecture in Yunnan Province, SW China (2008) J. Ethnopharmacol., 117 (2), pp. 362-377; Mahmood, A., Mahmood, A., Malik, R.N., Indigenous knowledge of medicinal plants from Leepa valley, Azad Jammu and Kashmir, Pakistan (2012) J. Ethnopharmacol., 143 (1), pp. 338-346; Mahmood, A., Mahmood, A., Tabassum, A., Ethnomedicinal survey of plants from District Sialkot, Pakistan (2011) J. Appl. Pharmacol., 2, pp. 212-220; Malik, F., Hussain, S., Dil, A.S., Hannan, A., Gilani, A.H., Islamic Republic of Pakistan (Chapter 22) (2005) WHO Global Atlas of Traditional, Complementary and Alternative Medicine (Mapvolume), pp. 165-169. , C.K. Ong, G. Bodeker, C. Grundy, G. Burford, K. Shein, World Health Organization Geneva; Mann, A., Amupitan, J.O., Oyewale, A.O., Okogun, J.I., Ibrahim, K., Oladosu, P., Lawson, L., Nnamdi, A., Evaluation of in vitro antimycobacterial activity of Nigerian plants used for treatment of respiratory diseases (2008) Afr. J. Biotechnol., 7 (11), pp. 1630-1636; Maregesi, S.M., Ngassapa, O.D., Pieters, L., Vlietinck, A.J., Ethnopharmacological survey of the Bunda district, Tanzania: plants used to treat infectious diseases (2007) J. Ethnopharmacol., 113, pp. 457-470; Martin, G.J., (1995) Ethnobotany: A Methods Manual, , Chapman and Hall London, UK; Martin, G.J., (2004) Ethnobotany: A Methods Manual, , Earths can Publications Ltd. London; Mittermeier, R.A., Gil, P.R., Hoffmann, M., Pilgrim, J., Brooks, T., Mittermeier, C.G., Lamoreux, J., Da Fonseca, G.A.B., Hotspots revised: earth's biologically richest and most threatened terrestrial ecoregions (2005) Conserv. Int., 4, pp. 1-392. , http://www.biodiversityhotspots.org; Nunkoo, D.H., Mahomoodally, M.F., Ethnopharmacological survey of native remedies commonly used against infectious diseases in the tropical island of Mauritius (2012) J. Ethnopharmacol., 143, pp. 548-564; Pardo-De-Santayana, M., Tardo, J., Blanco, E., Carvalho, A.M., Lastra, J.J., Miguel, S.E., Morales, R., Traditional knowledge of wild edible plants used in the northwest of the Iberian Peninsula (Spain and Portugal): a comparative study (2007) J. Ethnobiol. Ethnomed., 3, p. 27; Pfeiffer, J.M., Butz, R.J., Assessing cultural and ecological variation in ethnobiological research: the importance of gender (2005) J. Ethnopharmacol., 25, pp. 240-278; Poonam, K., Singh, G.S., Ethnobotanical study of medicinal plants used by the Taungya community in Terai Arc Landscape, India (2009) J. Ethnopharmacol., 123, pp. 167-176; Qureshi, R.A., Ghufran, M.A., Gilani, S.A., Ethnobotanical studies of selected medicinal plants of Sudhan Gali and Ganga Chotti Hills, district Bagh, Azad Kashmir (2007) Pak. J. Bot., 39, pp. 2275-2283; Reddy, K.N., Reddy, C.S., Trimurthulu, G., Ethnobotanical survey on respiratory disorders in Eastern Ghats of Andhra Pradesh, India (2006) Ethnobot. Leafl., 10, pp. 139-148; Rokaya, M.B., Münzbergova, Z., Timsina, B., Ethnobotanical study of medicinal plants from the Humla district of Western Nepal (2010) J. Ethnopharmacol., 130, pp. 485-504; Saghir, I.A., Awan, A.A., Majid, S., Khan, M.A., Qureshi, S.J., Ethnobotanical studies of Chikar and its allied area of District Muzaffarabad (2001) J. Biol. Sci., 1, pp. 1165-1170; Savikin, K., Zdunic, G., Menkovic, N., Zivkovic, J., Cujic, N., Terescenko, M., Bigovic, D., Ethnobotanical study on traditional use of medicinal plants in south-western Serbia, Zlatibor district (2013) J. Ethnopharmacol., 146 (3), pp. 803-810; Schippmann, U., Leaman, D.J., Cunningham, A.B., Impact of cultivation and gathering of medicinal plants on biodiversity: global trends and issues. In: Proceedings of the Biodiversity and the Ecosystem Approach in Agriculture, Forestry and Fisheries (2002) Ninth Regular Session of the Commission on Genetic Resources for Food and Agriculture, pp. 143-167. , FAO, Rome, Italy; Shahzad, K.R., Qureshi, R.A., Common Ethnomedicinal uses of plants in Jatlan Area District Mirpur, Azad Jammu and Kashmir, Pakistan (2001) Hamdard Med., 44 (3), pp. 42-45; Shil, S., Choudhury, M.D., Das, S., Indigenous knowledge of medicinal plants used by the Reang tribe of Tripura state of India (2014) J. Ethnopharmacol., 152, pp. 135-141; Shinwari, Z.K., The ethnobotany in Pakistan: sustainable and participatory approach (1996) Proceedings of 1st Traing Workshop on Ethnobotany and its Application to Conservation, pp. 14-25. , NARC, Islamabad; Shrivastava, S., Kanungo, V.K., Ethnobotanical survey of Surguja District with special reference to plants used by uraon tribe in treatment of respiratory diseases (2013) Int. J. Herb. Med., 1 (3), pp. 131-134; Singh, A., Singh, P.K., An ethnobotanical study of medicinal plants in Chandauli District of Uttar Pradesh, India (2009) J. Ethnopharmacol., 121 (2), pp. 324-329; Srithi, K., Balslevb, H., Wangpakapattanawonga, P., Srisangac, P., Trisonthia, C., Medicinal plant knowledge and its erosion among the Mien (Yao) in northern Thailand (2009) J. Ethnopharmacol., 123, pp. 335-342; Ssegawa, P., Kasenene, J.M., Medicinal plant diversity and uses in the Sango bay area, Southern Uganda (2007) J. Ethnopharmacol., 113, pp. 521-540; Sulaiman, S.F., Zahariluddin, A.S.M., Noor, S.S.M., Antituberculosis potential of some ethnobotanically selected Malaysian plants (2011) J. Ethnopharmacol., 133, pp. 1021-1026; Teklehaymanot, T., Giday, M., Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, northwestern Ethiopia (2007) J. Ethnobiol. Ethnomed., 3, p. 12; Trotter, R.T., Logan, M.H., Informant consensus: a new approach for identifying potentially effective medicinal plants (1986) Plants in Indigenous Medicine and Diet, Behavioural Approaches, pp. 91-112. , N.L. Etkin, Redgrave Publishing Company Bedford Hills, New York; Upadhyay, B., Singh, K.P., Kumar, A., Ethno-veterinary uses and informants consensus factor of medicinal plants of Sariska region, Rajasthan, India (2011) J. Ethnopharmacol., 133, pp. 14-25; Vendruscolo, G.S., Mentz, L.A., Ethnobotanical survey of the medicinal plants used by the community of Ponta Grossa neighborhood, Porto Alegre, Rio Grande do Sul, Brazil (2006) Iheringia Ser. Bot., 61 (12), pp. 83-103; Vitalini, S., Iriti, M., Puricelli, C., Ciuchi, D., Segale, A., Fico, G., Traditional knowledge on medicinal and food plants used in Val San Giacomo (Sondrio, Italy) - an alpine ethnobotanical study (2013) J. Ethnopharmacol., 145, pp. 517-529; WHO, (2002) Traditional Medicine: Growing Needs and Potentials, , Geneva; York, T., Dewet, H., Vuuren, S.F., Plants used for treating respiratory infections in rural Maputaland, KwaZulu-Natal, South Africa (2011) J. Ethnopharmacol., 135, pp. 696-710",Article,Scopus,2-s2.0-84926289485
"Seki A., Nishii K., Hagiwara N.","Gap junctional regulation of pressure, fluid force, and electrical fields in the epigenetics of cardiac morphogenesis and remodeling",2015,"Life Sciences","129",,,"27","34",,,10.1016/j.lfs.2014.10.022,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928255047&partnerID=40&md5=70a6edf88e07f40fbd8dc82fc82c3531","Department of Cardiology, Support Center for Women Health Care Professionals and Researchers, Tokyo Women's Medical University, 8-1 Kawada-choShinjuku-ku, Tokyo, Japan; Support Center for Women Health Care Professionals and Researchers, Tokyo Women's Medical University, 8-1 Kawada-choShinjuku-ku, Tokyo, Japan; Department of Anatomy and Neurobiology, National Defense Medical College, 3-2 NamikiTokorozawa, Saitama, Japan","Seki, A., Department of Cardiology, Support Center for Women Health Care Professionals and Researchers, Tokyo Women's Medical University, 8-1 Kawada-choShinjuku-ku, Tokyo, Japan, Support Center for Women Health Care Professionals and Researchers, Tokyo Women's Medical University, 8-1 Kawada-choShinjuku-ku, Tokyo, Japan; Nishii, K., Department of Anatomy and Neurobiology, National Defense Medical College, 3-2 NamikiTokorozawa, Saitama, Japan; Hagiwara, N., Department of Cardiology, Support Center for Women Health Care Professionals and Researchers, Tokyo Women's Medical University, 8-1 Kawada-choShinjuku-ku, Tokyo, Japan","Epigenetic factors of pressure load, fluid force, and electrical fields that occur during cardiac contraction affect cardiac development, morphology, function, and pathogenesis. These factors are orchestrated by intercellular communication mediated by gap junctions, which synchronize action potentials and second messengers. Misregulation of the gap junction protein connexin (Cx) alters cardiogenesis, and can be a pathogenic factor causing cardiac conduction disturbance, fatal arrhythmia, and cardiac remodeling in disease states such as hypertension and ischemia. Changes in Cx expression can occur even when the DNA sequence of the Cx gene itself is unaltered. Posttranslational modifications might reduce arrhythmogenic substrates, improve cardiac function, and promote remodeling in a diseased heart. In this review, we discuss the epigenetic features of gap junctions that regulate cardiac morphology and remodeling. We further discuss potential clinical applications of current knowledge of the structure and function of gap junctions. © 2014 Elsevier Inc. All rights reserved.","Gap junction; Heart; Morphogenesis; Remodeling","Alcoléa, S., Théveniau-Ruissy, M., Jarry-Guichard, T., Marics, I., Tzouanacou, E., Chauvin, J.P., Briand, J.P., Gros, D.B., Downregulation of connexin 45 gene products during mouse heart development (1999) Circ. Res., 84, pp. 1365-1379; Auman, H.J., Coleman, H., Riley, H.E., Olale, F., Tsai, H.J., Yelon, D., Functional modulation of cardiac form through regionally confined cell shape changes (2007) PLoS Biol., 5, p. e53; Banjo, T., Grajcarek, J., Yoshino, D., Osada, H., Miyasaka, K.Y., Kida, Y.S., Ueki, Y., Ogura, T., Haemodynamically dependent valvulogenesis of zebrafish heart is mediated by flow-dependent expression of miR-21 (2013) Nat. Commun., 4, p. 1978; Bartman, T., Walsh, E.C., Wen, K.K., McKane, M., Ren, J., Alexander, J., Rubenstein, P.A., Stainier, D.Y., Early myocardial function affects endocardial cushion development in zebrafish (2004) PLoS Biol., 2, p. E129; Beauchamp, P., Choby, C., Desplantez, T., De Peyer, K., Green, K., Yamada, K.A., Weingart, R., Kléber, A.G., Electrical propagation in synthetic ventricular myocyte strands from germline connexin43 knockout mice (2004) Circ. Res., 95, pp. 170-178; Bentrop, D., Beyermann, M., Wissmann, R., Fakler, B., NMR structure of the ""ball-and-chain"" domain of KCNMB2, the beta 2-subunit of large conductance Ca2 +- and voltage-activated potassium channels (2001) J. Biol. Chem., 276, pp. 42116-42121; Berdougo, E., Coleman, H., Lee, D.H., Stainier, D.Y.R., Yelon, D., Mutation of weak atrium/atrial myosin heavy chain disrupts atrial function and influences ventricular morphogenesis in zebrafish (2003) Development, 130, pp. 6121-6129; Bruce, A.F., Rothery, S., Dupont, E., Severs, N.J., Gap junction remodelling in human heart failure is associated with increased interaction of connexin43 with ZO-1 (2008) Cardiovasc. Res., 77, pp. 757-765; Bukauskas, F.F., Peracchia, C., Two distinct gating mechanisms in gap junction channels: CO<inf>2</inf>-sensitive and voltage-sensitive (1997) Biophys. J., 72, pp. 2137-2142; Burt, J.M., Spray, D.C., Volatile anesthetics block intercellular communication between neonatal rat myocardial cells (1989) Circ. Res., 65, pp. 829-837; Chi, N.C., Bussen, M., Brand-Arzamendi, K., Ding, C., Olgin, J.E., Shaw, R.M., Martin, G.R., Stainier, D.Y.R., Cardiac conduction is required to preserve cardiac chamber morphology (2010) Proc. Natl. Acad. Sci. U. S. A., 107, pp. 14662-14667; Cho, C.H., Kim, S.S., Jeong, M.J., Lee, C.O., Shin, H.S., The Na+-Ca2 + exchanger is essential for embryonic heart development in mice (2000) Mol. Cells, 10, pp. 712-722; Christ, G.J., Spektor, M., Brink, P.R., Barr, L., Further evidence for the selective disruption of intercellular communication by heptanol (1999) Am. J. Physiol., 276, pp. H1911-H1917; Dhein, S., Peptides acting at gap junctions (2002) Peptides, 23, pp. 1701-1709; Dhein, S., Larsen, B.D., Petersen, J.S., Mohr, F.W., Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern (2003) Cell Commun. Adhes., 10, pp. 371-378; Duffy, H.S., Ashton, A.W., O'Donnell, P., Coombs, W., Taffet, S.M., Delmar, M., Spray, D.C., Regulation of connexin43 protein complexes by intracellular acidification (2004) Circ. Res., 94, pp. 215-222; Duffy, H.S., Sorgen, P.L., Girvin, M.E., O'Donnell, P., Coombs, W., Taffet, S.M., Delmar, M., Spray, D.C., PH-dependent intramolecular binding and structure involving Cx43 cytoplasmic domains (2002) J. Biol. Chem., 277, pp. 36706-36714; Dupont, E., Matsushita, T., Kaba, R.A., Vozzi, C., Coppen, S.R., Khan, N., Kaprielian, R., Severs, N.J., Altered connexin expression in human congestive heart failure (2001) J. Mol. Cell. Cardiol., 33, pp. 359-371; Eckardt, D., Theis, M., Degen, J., Ott, T., Van Rijen, H.V.M., Kirchhoff, S., Kim, J.S., Willecke, K., Functional role of connexin43 gap junction channels in adult mouse heart assessed by inducible gene deletion (2004) J. Mol. Cell. Cardiol., 36, pp. 101-110; Ek-Vitorin, J.F., Calero, G., Morley, G.E., Coombs, W., Taffet, S.M., Delmar, M., PH regulation of connexin43: Molecular analysis of the gating particle (1996) Biophys. J., 71, pp. 1273-1284; Ek-Vitorin, J.F., King, T.J., Heyman, N.S., Lampe, P.D., Burt, J.M., Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation (2006) Circ. Res., 98, pp. 1498-1505; Emdad, L., Uzzaman, M., Takagishi, Y., Honjo, H., Uchida, T., Severs, N.J., Kodama, I., Murata, Y., Gap junction remodeling in hypertrophied left ventricles of aortic-banded rats: Prevention by angiotensin II type 1 receptor blockade (2001) J. Mol. Cell. Cardiol., 33, pp. 219-231; Fananapazir, L., Cannon, R.O., III, Tripodi, D., Panza, J.A., Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy (1992) Circulation, 85, pp. 2149-2161; Fleishman, S.J., Unger, V.M., Yeager, M., Ben-Tal, N., A Calpha model for the transmembrane alpha helices of gap junction intercellular channels (2004) Mol. Cell, 15, pp. 879-888; Freund, J.B., Goetz, J.G., Hill, K.L., Vermot, J., Fluid flows and forces in development: Functions, features and biophysical principles (2012) Development, 139, pp. 1229-1245; Funck, R.C., Koelsch, S., Waldhans, S., Prinz, H., Grimm, W., Moosdorf, R., Maisch, B., Marked improvement in left ventricular function and significant reverse left ventricular remodeling within 3 months of cardiac resynchronization therapy in patients with dilated cardiomyopathy (2005) Pacing Clin. Electrophysiol., 28 (SUPPL. 1), pp. S5-S7; Garcia-Dorado, D., Inserte, J., Ruiz-Meana, M., Gonzalez, M.A., Solares, J., Julia, M., Barrabes, J.A., Soler-Soler, J., Gap junction uncoupler heptanol prevents cell-to-cell progression of hypercontracture and limits necrosis during myocardial reperfusion (1997) Circulation, 96, pp. 3579-3586; Goodenough, D.A., Paul, D.L., Beyond the gap: Functions of unpaired connexon channels (2003) Nat. Rev. Mol. Cell Biol., 4, pp. 285-294; Granados-Riveron, J.T., Brook, J.D., The impact of mechanical forces in heart morphogenesis (2012) Circ. Cardiovasc. Genet., 5, pp. 132-142; Gros, D., Théveniau-Ruissy, M., Bernard, M., Calmels, T., Kober, F., Söhl, G., Willecke, K., Mangoni, M.E., Connexin 30 is expressed in the mouse sino-atrial node and modulates heart rate (2010) Cardiovasc. Res., 85, pp. 45-55; Gu, H., Smith, F.C., Taffet, S.M., Delmar, M., High incidence of cardiac malformations in connexin40-deficient mice (2003) Circ. Res., 93, pp. 201-206; Gutstein, D.E., Morley, G.E., Tamaddon, H., Vaidya, D., Schneider, M.D., Chen, J., Chien, K.R., Fishman, G.I., Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43 (2001) Circ. Res., 88, pp. 333-339; Gysembergh, A., Kloner, R.A., Przyklenk, K., Pretreatment with the gap junction uncoupler heptanol does not limit infarct size in rabbit heart (2001) Cardiovasc. Pathol., 10, pp. 13-17; Haugan, K., Marcussen, N., Kjolbye, A.L., Nielsen, M.S., Hennan, J.K., Petersen, J.S., Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction (2006) J. Cardiovasc. Pharmacol., 47, pp. 236-242; Hawat, G., Benderdour, M., Rousseau, G., Baroudi, G., Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury (2010) Pflugers Arch., 460, pp. 583-592; Heisenberg, C.P., Bellaïche, Y., Forces in tissue morphogenesis and patterning (2013) Cell, 153, pp. 948-962; Hennan, J.K., Swillo, R.E., Morgan, G.A., Keith, Jr.J.C., Schaub, R.G., Smith, R.P., Feldman, H.S., Crandall, D.L., Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs (2006) J. Pharmacol. Exp. Ther., 317, pp. 236-243; Homma, N., Alvarado, J.L., Coombs, W., Stergiopoulos, K., Taffet, S.M., Lau, A.F., Delmar, M., A particle-receptor model for the insulin-induced closure of connexin43 channels (1998) Circ. Res., 83, pp. 27-32; Hove, J.R., Koster, R.W., Forouhar, A.S., Acevedo-Bolton, G., Fraser, S.E., Gharib, M., Intracardiac fluid forces are an essential epigenetic factor for embryonic cardiogenesis (2003) Nature, 421, pp. 172-177; Huang, C., Sheikh, F., Hollander, M., Cai, C., Becker, D., Chu, P.H., Evans, S., Chen, J., Embryonic atrial function is essential for mouse embryogenesis, cardiac morphogenesis and angiogenesis (2003) Development, 130, pp. 6111-6119; Hunter, A.W., Barker, R.J., Zhu, C., Gourdie, R.G., Zonula occludens-1 alters connexin43 gap junction size and organization by influencing channel accretion (2005) Mol. Biol. Cell, 16, pp. 5686-5698; Jaffe, L.F., Nuccitelli, R., Electrical controls of development (1977) Annu. Rev. Biophys. Bioeng., 6, pp. 445-476; Jansen, J.A., Noorman, M., Musa, H., Stein, M., De Jong, S., Van Der Nagel, R., Hund, T.J., Van Rijen, H.V., Reduced heterogeneous expression of Cx43 results in decreased Nav1.5 expression and reduced sodium current that accounts for arrhythmia vulnerability in conditional Cx43 knockout mice (2012) Heart Rhythm., 9, pp. 600-607; Joshi-Mukherjee, R., Coombs, W., Musa, H., Oxford, E., Taffet, S., Delmar, M., Characterization of the molecular phenotype of two arrhythmogenic right ventricular cardiomyopathy (ARVC)-related plakophilin-2 (PKP2) mutations (2008) Heart Rhythm., 5, pp. 1715-1723; Kajimoto, K., Imai, T., Minami, Y., Kasanuki, H., Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline (2010) Am. J. Cardiol., 106, pp. 1307-1312; Kirchhoff, S., Kim, J.S., Hagendorff, A., Thönnissen, E., Krüger, O., Lamers, W.H., Willecke, K., Abnormal cardiac conduction and morphogenesis in connexin40 and connexin43 double-deficient mice (2000) Circ. Res., 87, pp. 399-405; Kirchhoff, S., Nelles, E., Hagendorff, A., Krüger, O., Traub, O., Willecke, K., Reduced cardiac conduction velocity and predisposition to arrhythmias in connexin40-deficient mice (1998) Curr. Biol., 8, pp. 299-302; Kjolbye, A.L., Haugan, K., Hennan, J.K., Petersen, J.S., Pharmacological modulation of gap junction function with the novel compound rotigaptide: A promising new principle for prevention of arrhythmias (2007) Basic Clin. Pharmacol. Toxicol., 101, pp. 215-230; Kjolbye, A.L., Knudsen, C.B., Jepsen, T., Larsen, B.D., Petersen, J.S., Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH<inf>2</inf> (ZP123): In vivo and in vitro studies (2003) J. Pharmacol. Exp. Ther., 306, pp. 1191-1199; Kobertz, W.R., Miller, C., K+ channels lacking the 'tetramerization' domain: Implications for pore structure (1999) Nat. Struct. Biol., 6, pp. 1122-1125; Kostin, S., Dammer, S., Hein, S., Klovekorn, W.P., Bauer, E.P., Schaper, J., Connexin 43 expression and distribution in compensated and decompensated cardiac hypertrophy in patients with aortic stenosis (2004) Cardiovasc. Res., 62, pp. 426-436; Kostin, S., Rieger, M., Dammer, S., Hein, S., Richter, M., Klovekorn, W.P., Bauer, E.P., Schaper, J., Gap junction remodeling and altered connexin43 expression in the failing human heart (2003) Mol. Cell. Biochem., 242, pp. 135-144; Koushik, S.V., Wang, J., Rogers, R., Moskophidis, D., Lambert, N.A., Creazzo, T.L., Conway, S.J., Targeted inactivation of the sodium-calcium exchanger (Ncx1) results in the lack of a heartbeat and abnormal myofibrillar organization (2001) FASEB J., 15, pp. 1209-1211; Krüger, O., Plum, A., Kim, J.S., Winterhager, E., Maxeiner, S., Hallas, G., Kirchhoff, S., Willecke, K., Defective vascular development in connexin 45-deficient mice (2000) Development, 127, pp. 4179-4193; Kretz, M., Eckardt, D., Krüger, O., Kim, J.S., Maurer, J., Theis, M., Van Rijen, H.V., Willecke, K., Normal embryonic development and cardiac morphogenesis in mice with Wnt1-Cre-mediated deletion of connexin43 (2006) Genesis, 44, pp. 269-276; Kreuzberg, M.M., Schrickel, J.W., Ghanem, A., Kim, J.S., Degen, J., Janssen-Bienhold, U., Lewalter, T., Willecke, K., Connexin30.2 containing gap junction channels decelerate impulse propagation through the atrioventricular node (2006) Proc. Natl. Acad. Sci. U. S. A., 103, pp. 5959-5964; Kreuzberg, M.M., Sohl, G., Kim, J.S., Verselis, V.K., Willecke, K., Bukauskas, F.F., Functional properties of mouse connexin30.2 expressed in the conduction system of the heart (2005) Circ. Res., 96, pp. 1169-1177; Kronengold, J., Trexler, E.B., Bukauskas, F.F., Bargiello, T.A., Verselis, V.K., Single-channel SCAM identifies pore-lining residues in the first extracellular loop and first transmembrane domains of Cx46 hemichannels (2003) J. Gen. Physiol., 122, pp. 389-405; Kumai, M., Nishii, K., Nakamura, K., Takeda, N., Suzuki, M., Shibata, Y., Loss of connexin45 causes a cushion defect in early cardiogenesis (2000) Development, 127, pp. 3501-3512; Kumar, N.M., Gilula, N.B., The gap junction communication channel (1996) Cell, 84, pp. 381-388; Lin, X., Liu, N., Lu, J., Zhang, J., Anumonwo, J.M., Isom, L.L., Fishman, G.I., Delmar, M., Subcellular heterogeneity of sodium current properties in adult cardiac ventricular myocytes (2011) Heart Rhythm., 8, pp. 1923-1930; Lo, C.W., Waldo, K.L., Kirby, M.L., Gap junction communication and the modulation of cardiac neural crest cells (1999) Trends Cardiovasc. Med., 9, pp. 63-69; Luther, P.W., Peng, H.B., Lin, J.J.C., Changes in cell shape and actin distribution induced by constant electric fields (1983) Nature, 303, pp. 61-64; Maass, K., Chase, S.E., Lin, X., Delmar, M., Cx43 CT domain influences infarct size and susceptibility to ventricular tachyarrhythmias in acute myocardial infarction (2009) Cardiovasc. Res., 84, pp. 361-367; Maeda, S., Nakagawa, S., Suga, M., Yamashita, E., Oshima, A., Fujiyoshi, Y., Tsukihara, T., Structure of the connexin 26 gap junction channel at 3.5 Å resolution (2009) Nature, 458, pp. 597-602; Malhotra, J.D., Thyagarajan, V., Chen, C., Isom, L.L., Tyrosine-phosphorylated and nonphosphorylated sodium channel beta1 subunits are differentially localized in cardiac myocytes (2004) J. Biol. Chem., 279, pp. 40748-40754; Maron, M.S., Olivotto, I., Betocchi, S., Casey, S.A., Lesser, J.R., Losi, M.A., Cecchi, F., Maron, B.J., Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy (2003) N. Engl. J. Med., 348, pp. 295-303; Matsushita, T., Oyamada, M., Fujimoto, K., Yasuda, Y., Masuda, S., Wada, Y., Oka, T., Takamatsu, T., Remodeling of cell-cell and cell-extracellular matrix interactions at the border zone of rat myocardial infarcts (1999) Circ. Res., 85, pp. 1046-1055; Morley, G.E., Taffet, S.M., Delmar, M., Intramolecular interactions mediate pH regulation of connexin43 channels (1996) Biophys. J., 70, pp. 1294-1302; Murry, C.E., Jennings, R.B., Reimer, K.A., Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium (1986) Circulation, 74, pp. 1124-1136; Naitoh, K., Yano, T., Miura, T., Itoh, T., Miki, T., Tanno, M., Sato, T., Shimamoto, K., Roles of Cx43-associated protein kinases in suppression of gap junction-mediated chemical coupling by ischemic preconditioning (2009) Am. J. Physiol. Heart Circ. Physiol., 296, pp. H396-H403; Nattel, S., Maguy, A., Le Bouter, S., Yeh, Y.H., Arrhythmogenic ion-channel remodeling in the heart: Heart failure, myocardial infarction, and atrial fibrillation (2007) Physiol. Rev., 87, pp. 425-456; Nerem, R.M., Harrison, D.G., Taylor, W.R., Alexander, R.W., Hemodynamics and vascular endothelial biology (1993) J. Cardiovasc. Pharmacol., 21 (SUPPL. 1), pp. S6-10; Nishii, K., Kumai, M., Egashira, K., Miwa, T., Hashizume, K., Miyano, Y., Shibata, Y., Mice lacking connexin45 conditionally in cardiac myocytes display embryonic lethality similar to that of germline knockout mice without endocardial cushion defect (2003) Cell Commun. Adhes., 10, pp. 365-369; Nishii, K., Kumai, M., Shibata, Y., Regulation of the epithelial-mesenchymal transformation through gap junction channels in heart development (2001) Trends Cardiovasc. Med., 11, pp. 213-218; Nishii, K., Morimoto, S., Minakami, R., Miyano, Y., Hashizume, K., Ohta, M., Zhan, D.Y., Shibata, Y., Targeted disruption of the cardiac troponin T gene causes sarcomere disassembly and defects in heartbeat within the early mouse embryo (2008) Dev. Biol., 322, pp. 65-73; Nishii, K., Shibata, Y., Mode and determination of the initial contraction stage in the mouse embryo heart (2006) Anat. Embryol. (Berl.), 211, pp. 95-100; Nishii, K., Shibata, Y., Kobayashi, Y., Connexin mutant embryonic stem cells and human diseases. World J (2014) Stem Cells, 6, pp. 571-578; Noma, A., Tsuboi, N., Dependence of junctional conductance on proton, calcium and magnesium ions in cardiac paired cells of guinea-pig (1987) J. Physiol., 382, pp. 193-211; Noorman, M., Van Der Heyden, M.A.G., Van Veen, T.A.B., Cox, M.G.P.J., Hauer, R.N.W., De Bakker, J.M.T., Van Rijen, H.V.M., Cardiac cell-cell junctions in health and disease: Electrical versus mechanical coupling (2009) J. Mol. Cell. Cardiol., 47, pp. 23-31; Nunn, R.S., Macke, T.J., Olson, A.J., Yeager, M., Transmembrane alpha-helices in the gap junction membrane channel: Systematic search of packing models based on the pair potential function (2001) Microsc. Res. Tech., 52, pp. 344-351; O'Quinn, M.P., Palatinus, J.A., Harris, B.S., Hewett, K.W., Gourdie, R.G., A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury (2011) Circ. Res., 108, pp. 704-715; Panza, J.A., Petrone, R.K., Fananapazir, L., Maron, B.J., Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy (1992) J. Am. Coll. Cardiol., 19, pp. 91-99; Patrick, D.M., Montgomery, R.L., Qi, X., Obad, S., Kauppinen, S., Hill, J.A., Van Rooij, E., Olson, E.N., Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice (2010) J. Clin. Invest., 120, pp. 3912-3916; Peracchia, C., Chemical gating of gap junction channels; Roles of calcium, pH and calmodulin (2004) Biochim. Biophys. Acta, 1662, pp. 61-80; Peters, N.S., Coromilas, J., Severs, N.J., Wit, A.L., Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia (1997) Circulation, 95, pp. 988-996; Petrich, B.G., Gong, X., Lerner, D.L., Wang, X., Brown, J.H., Saffitz, J.E., Wang, Y., C-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes (2002) Circ. Res., 91, pp. 640-647; Pfeffer, J.M., Pfeffer, M.A., Braunwald, E., Influence of chronic captopril therapy on the infarcted left ventricle of the rat (1985) Circ. Res., 57, pp. 84-95; Reaume, A.G., De Sousa, P.A., Kulkarni, S., Langille, B.L., Zhu, D., Davies, T.C., Juneja, S.C., Rossant, J., Cardiac malformation in neonatal mice lacking connexin43 (1995) Science, 267, pp. 1831-1834; Reuter, H., Henderson, S.A., Han, T., Ross, R.S., Goldhaber, J.I., Philipson, K.D., The Na+-Ca2 + exchanger is essential for the action of cardiac glycosides (2002) Circ. Res., 90, pp. 305-308; Ruiz-Meana, M., Garcia-Dorado, D., Hofstaetter, B., Piper, H.M., Soler-Soler, J., Propagation of cardiomyocyte hypercontracture by passage of Na(+) through gap junctions (1999) Circ. Res., 85, pp. 280-287; Saffitz, J.E., Kleber, A.G., Effects of mechanical forces and mediators of hypertrophy on remodeling of gap junctions in the heart (2004) Circ. Res., 94, pp. 585-591; Sankova, B., Benes, Jr.J., Krejci, E., Dupays, L., Theveniau-Ruissy, M., Miquerol, L., Sedmera, D., The effect of connexin40 deficiency on ventricular conduction system function during development (2012) Cardiovasc. Res., 95, pp. 469-479; Schwanke, U., Konietzka, I., Duschin, A., Li, X., Schulz, R., Heusch, G., No ischemic preconditioning in heterozygous connexin43-deficient mice (2002) Am. J. Physiol. Heart Circ. Physiol., 283, pp. H1740-H1742; Sehnert, A.J., Huq, A., Weinstein, B.M., Walker, C., Fishman, M., Stainier, D.Y., Cardiac troponin T is essential in sarcomere assembly and cardiac contractility (2002) Nat. Genet., 31, pp. 106-110; Seki, A., Duffy, H.S., Coombs, W., Spray, D.C., Taffet, S.M., Delmar, M., Modifications in the biophysical properties of connexin43 channels by a peptide of the cytoplasmic loop region (2004) Circ. Res., 95, pp. e22-e28; Severs, N.J., Bruce, A.F., Dupont, E., Rothery, S., Remodelling of gap junctions and connexin expression in diseased myocardium (2008) Cardiovasc. Res., 80, pp. 9-19; Severs, N.J., Coppen, S.R., Dupont, E., Yeh, H.I., Ko, Y.S., Matsushita, T., Gap junction alterations in human cardiac disease (2004) Cardiovasc. Res., 62, pp. 368-377; Shibayama, J., Lewandowski, R., Kieken, F., Coombs, W., Shah, S., Sorgen, P.L., Taffet, S.M., Delmar, M., Identification of a novel peptide that interferes with the chemical regulation of connexin43 (2006) Circ. Res., 98, pp. 1365-1372; Shiroshita-Takeshita, A., Sakabe, M., Haugan, K., Hennan, J.K., Nattel, S., Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs (2007) Circulation, 115, pp. 310-318; Shyu, K.G., Chen, C.C., Wang, B.W., Kuan, P., Angiotensin II receptor antagonist blocks the expression of connexin43 induced by cyclical mechanical stretch in cultured neonatal rat cardiac myocytes (2001) J. Mol. Cell. Cardiol., 33, pp. 691-698; Simon, A.M., Goodenough, D.A., Paul, D.L., Mice lacking connexin40 have cardiac conduction abnormalities characteristic of atrioventricular block and bundle branch block (1998) Curr. Biol., 8, pp. 295-298; Skerrett, I.M., Aronowitz, J., Shin, J.H., Cymes, G., Kasperek, E., Cao, F.L., Nicholson, B.J., Identification of amino acid residues lining the pore of a gap junction channel (2002) J. Cell Biol., 159, pp. 349-360; Skyschally, A., Walter, B., Schultz Hansen, R., Heusch, G., The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs (2013) Naunyn Schmiedeberg's Arch. Pharmacol., 386, pp. 383-391; Slough, J., Cooney, L., Brueckner, M., Monocilia in the embryonic mouse heart suggest a direct role for cilia in cardiac morphogenesis (2008) Dev. Dyn., 237, pp. 2304-2314; Solan, J.L., Lampe, P.D., Connexin43 phosphorylation: Structural changes and biological effects (2009) Biochem. J., 419, pp. 261-272; Sorgen, P.L., Duffy, H.S., Spray, D.C., Delmar, M., PH-dependent dimerization of the carboxyl terminal domain of Cx43 (2004) Biophys. J., 87, pp. 574-581; Taber, L.A., Mechanical aspects of cardiac development (1998) Prog. Biophys. Mol. Biol., 69, pp. 237-255; Takahashi, M., Ishida, T., Traub, O., Corson, M.A., Berk, B.C., Mechanotransduction in endothelial cells: Temporal signaling events in response to shear stress (1997) J. Vasc. Res., 34, pp. 212-219; Topper, J.N., Gimbrone, Jr.M.A., Blood flow and vascular gene expression: Fluid shear stress as a modulator of endothelial phenotype (1999) Mol. Med. Today, 5, pp. 40-46; Toyofuku, T., Yabuki, M., Otsu, K., Kuzuya, T., Hori, M., Tada, M., Direct association of the gap junction protein connexin-43 with ZO-1 in cardiac myocytes (1998) J. Biol. Chem., 273, pp. 12725-12731; Unger, V.M., Kumar, N.M., Gilula, N.B., Yeager, M., Three-dimensional structure of a recombinant gap junction membrane channel (1999) Science, 283, pp. 1176-1180; Unwin, P.N., Ennis, P.D., Calcium-mediated changes in gap junction structure: Evidence from the low angle X-ray pattern (1983) J. Cell Biol., 97, pp. 1459-1466; Van Der Heiden, K., Groenendijk, B.C.W., Hierck, B.P., Hogers, B., Koerten, H.K., Mommaas, A.M., Gittenberger-De Groot, A.C., Poelmann, R.E., Monocilia on chicken embryonic endocardium in low shear stress areas (2006) Dev. Dyn., 235, pp. 19-28; Wakimoto, K., Kobayashi, K., Kuro, O.M., Yao, A., Iwamoto, T., Yanaka, N., Kita, S., Azuma, S., Targeted disruption of Na+/Ca2 + exchanger gene leads to cardiomyocyte apoptosis and defects in heartbeat (2000) J. Biol. Chem., 275, pp. 36991-36998; Wang, Y., Hill, J.A., Electrophysiological remodeling in heart failure (2010) J. Mol. Cell. Cardiol., 48, pp. 619-632; Weingart, R., Bukauskas, F.F., Long-chain n-alkanols and arachidonic acid interfere with the Vm-sensitive gating mechanism of gap junction channels (1998) Pflugers Arch., 435, pp. 310-319; Weng, S., Lauven, M., Schaefer, T., Polontchouk, L., Grover, R., Dhein, S., Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation (2002) FASEB J., 16, pp. 1114-1116; Xing, D., Kjolbye, A.L., Nielsen, M.S., Petersen, J.S., Harlow, K.W., Holstein-Rathlou, N.H., Martins, J.B., ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs (2003) J. Cardiovasc. Electrophysiol., 14, pp. 510-520; Yamada, K.A., Rogers, J.G., Sundset, R., Steinberg, T.H., Saffitz, J.E., Up-regulation of connexin45 in heart failure (2003) J. Cardiovasc. Electrophysiol., 14, pp. 1205-1212; Yao, J.A., Hussain, W., Patel, P., Peters, N.S., Boyden, P.A., Wit, A.L., Remodeling of gap junctional channel function in epicardial border zone of healing canine infarcts (2003) Circ. Res., 92, pp. 437-443; Yeager, M., Structure of cardiac gap junction intercellular channels (1998) J. Struct. Biol., 121, pp. 231-245; Yoshida, M., Ohkusa, T., Nakashima, T., Takanari, H., Yano, M., Takemura, G., Honjo, H., Matsuzaki, M., Alterations in adhesion junction precede gap junction remodelling during the development of heart failure in cardiomyopathic hamsters (2011) Cardiovasc. Res., 92, pp. 95-105; Zagotta, W.N., Hoshi, T., Aldrich, R.W., Restoration of inactivation in mutants of Shaker potassium channels by a peptide derived from ShB (1990) Science, 250, pp. 568-571; Zhang, X.S., Xiang, B.R., Discontinued drugs in 2008: Cardiovascular drugs (2009) Expert Opin. Investig. Drugs, 18, pp. 875-885; Zhou, X.W., Pfahnl, A., Werner, R., Hudder, A., Llanes, A., Luebke, A., Dahl, G., Identification of a pore lining segment in gap junction hemichannels (1997) Biophys. J., 72, pp. 1946-1953",Review,Scopus,2-s2.0-84928255047
"Trattner S., Becker W., Wretling S., Ohrvik V., Mattisson I.","Fatty acid composition of Swedish bakery products, with emphasis on trans-fatty acids",2015,"Food Chemistry","175",,,"423","430",,,10.1016/j.foodchem.2014.11.145,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84917708552&partnerID=40&md5=5174ecc5cd29d19d721014a02636cb86","National Food Agency, Box 622Uppsala, Sweden; Department of Food Science, Uppsala BioCenter, Swedish University of Agricultural Sciences, P.O. Box 7051Uppsala, Sweden","Trattner, S., National Food Agency, Box 622Uppsala, Sweden, Department of Food Science, Uppsala BioCenter, Swedish University of Agricultural Sciences, P.O. Box 7051Uppsala, Sweden; Becker, W., National Food Agency, Box 622Uppsala, Sweden; Wretling, S., National Food Agency, Box 622Uppsala, Sweden; Öhrvik, V., National Food Agency, Box 622Uppsala, Sweden; Mattisson, I., National Food Agency, Box 622Uppsala, Sweden","Trans-fatty acids (TFA) have been associated with increased risk of coronary heart disease, by affecting blood lipids and inflammation factors. Current nutrition recommendations emphasise a limitation of dietary TFA intake. The aim of this study was to investigate fatty acid composition in sweet bakery products, with emphasis on TFA, on the Swedish market and compare fatty acid composition over time. Products were sampled in 2001, 2006 and 2007 and analysed for fatty acid composition by using GC. Mean TFA levels were 0.7% in 2007 and 5.9% in 2001 of total fatty acids. In 1995-97, mean TFA level was 14.3%. In 2007, 3 of 41 products had TFA levels above 2% of total fatty acids. TFA content had decreased in this product category, while the proportion of saturated (SFA) and polyunsaturated (PUFA) fatty acids had increased, mostly through increased levels of 16:0 and 18:2 n-6, respectively. The total fat content remained largely unchanged. © 2014 The Authors.","Bakery products; Cakes; Cookies; Fat content; Trans fatty acids","Rendahl Mikkelsen, A., Bysted, A., Langkilde, S., (2011) Trans Fatty Acids in Selected Products - Projekt 2009-20-64-00151 (in Danish), , Danmarks Tekniske Universitet Fødevareinstituttet; Aro, A., Amaral, E., Kesteloot, H., Rimestad, A., Thamm, M., Van Poppel, G., Trans fatty acids in French fries, soups, and snacks from 14 european countries: The TRANSFAIR study (1998) Journal of Food Composition and Analysis, 11, pp. 170-177; Aro, A., Van Amelsvoort, J., Becker, W., Van Erp-Baart, M.-A., Kafatos, A., Leth, T., Trans fatty acids in dietary fats and oils from 14 European countries: The TRANSFAIR study (1998) Journal of Food Composition and Analysis, 11, pp. 137-149; Ascherio, A., Hennekens, C.H., Buring, J.E., Master, C., Stampfer, M.J., Willett, W.C., Trans-fatty acids intake and risk of myocardial infarction (1994) Circulation, 89, pp. 94-101; Becker, W., (1998) Fatty Acid Composition of Foods on the Swedish Market - The TRANSFAIR Study in Sweden, , NFA Report 14; Becker, W., Haglund, M., Wretling, S., (2008) Fett Och Fettsyror i Den Svenska Kosten - Analyser Av Matkorgar Inköpta 2005, , NFA Report 17 (in Swedish); Brouwer, I.A., Wanders, A.J., Katan, M.B., Trans fatty acids and cardiovascular health: Research completed? (2013) European Journal of Clinical Nutrition, 67 (5), pp. 541-547; Chardigny, J.M., Destaillats, F., Malpuech-Brugere, C., Moulin, J., Bauman, D.E., Lock, A.L., Do trans fatty acids from industrially produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results of the trans Fatty Acids Collaboration (TRANSFACT) study (2008) American Journal of Clinical Nutrition, 87 (3), pp. 558-566; (2011) Nutrient Analysis Survey of Biscuits, Buns, Cakes and Pastries - Summary Report, , http://www.dh.gov.uk/publications, Department of Health. (2011) Prepared by the Diet and Nutrition Surveys Team, Health Improvement and Protection Directorate. August United Kingdom; Regulation (EU) No 1169/2011 of the European parliament and of the council of 25 October 2011on the provision of food information to consumers (2011) Official Journal of the European Union, , European Union; FAO, Fats and fatty acids in human nutrition Report and expert consultation (2010) Food and Nutrition Paper, 91. , Food and Agriculture Organization of the United Nations; Folch, J., Lees, M., Solane-Stanley, G.H., A simple method for the isolation and purification of total lipids from animal tissues (1957) Journal of Biological Chemistry, 226, pp. 497-509; Helldán, A., Kosonen, M., Tapanainen, H., The national FINDIET 2012 Survey (2013) Finnish, Summary, Figures and Tables in English, , Helsinki; Helsedirektoratet, (2012) Utviklingen i Norsk Kosthold, , Matforsyningsstatistikk og Forbruksundersøkelser Oslo; Hulshof, K.F.A.M., Van Erp-Baart, M.A., Anttolainen, M., Becker, W., Church, S.M., Intake of fatty acids in Western Europe with emphasis on trans fatty acids: The TRANSFAIR study (1999) European Journal of Clinical Nutrition, 53, pp. 143-157; Jakobsen, M.U., Overvad, K., Dyerberg, J., Heitmann, B.L., Intake of ruminant trans fatty acids and risk of coronary heart disease (2008) International Journal of Epidemiology, 37, pp. 173-182; Krettek, A., Thorpenberg, S., Bondjers, G., Trans fatty acids and health: A review of health hazards and existing legislation (2008) Policy Department Economic and Scientific Policy, 19; Kuhnt, K., Baehr, M., Rohrer, C., Jahreis, G., Trans fatty acid isomers and the trans-9/trans-11 index in fat containing foods (2011) European Journal of Lipid Science and Technology, 113, pp. 1281-1292; Laake, I., Pedersen, J.I., Selmer, R., Kirkhus, B., Lindman, A.S., Tverdal, A., A prospective study of intake of trans-fatty acids from ruminant fat, partially hydrogenated vegetable oils, and marine oils and mortality from CVD (2011) British Journal of Nutrition, 108 (4), pp. 1-12; Lindmark-Månsson, H., Fonden, R., Pettersson, H.-E., Composition of Swedish dairy milk (2003) International Dairy Journal, 13, pp. 409-425; Mattisson, I., Gard, C., Staffas, A., Åstrand, C., Ready-made sauces, gluten-free products and Aloe Vera (In Swedish) (2009) NFA Report 13; Mozaffarian, D., Katan, M.B., Ascherio, A., Stampfer, M.J., Willett, W.C., Trans fatty acids and cardiovascular disease (2006) New England Journal of Medicine, 354 (15), pp. 1601-1613; NFA, (2012) Market Basket 2010 - Chemical Analysis, Exposure Estimation and Health-related Assessment of Nutrients and Toxic Compounds in Swedish Food Baskets, , Rapport 7-2012. Uppsala, Sweden: National Food Agency; NMKL, Determination of fat by SBR in meat and meat products (1989) Nordic Committee on Food Analysis, , NMKL 131. Oslo, Norway: Norwegian Veterinary Institute; NNR, (2014) Nordic Nutrition Recommendations 2012 - Integrating Nutrition and Physical Activity (5th Ed.), , Nord 2014:002. Copenhagen: Nordic Council of Ministers; Nuernberg, K., Dannenberger, D., Nuernberg, G., Endera, K., Voigta, J., Scollan, N.D., Effect of a grass-based and a concentrate feeding system on meat quality characteristics and fatty acid composition of longissimus muscle in different cattle breeds (2005) Livestock Production Science, 94, pp. 137-147; Pedersen A. ., N., Fagt, S., Velsing Groth, M., Dietary habits of Danes 2003-2008 (2010) Main Results (In Danish). Copenhagen: DTU Fødevareinstituttet; Pietinen, P., Ascherio, A., Korhonen, P., Hartman, A.M., Willett, W.C., Albanes, D., Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men: The alpha-tocopherol, beta-carotene cancer prevention study (1997) American Journal of Epidemiology, 145 (10), pp. 876-886; Richter, E.K., Albash Shawish, K., Scheeder, M.R.L., Colombani, P.C., Trans fatty acid content of selected Swiss foods: The TransSwissPilot study (2009) Journal of Food Composition and Analysis, 22, pp. 479-484; Stender, S., Asturp, A., Dyerberg, J., What went in when trans went out? (2009) The New England Journal of Medicine, 361 (3), pp. 314-316; Thorgeirsdottir, H., Valgeirsdottir, H., Gunnarsdottir, I., National dietary survey of the Icelandic nutrition council 2010-2011 (2011) Main Findings, , Directorate of Health, Icelandic Food and Veterinary Authority and Unit for Nutrition Research, University of Iceland; Torelm, I., More sugar - Less trans fat in coffee bread (In Swedish) (2004) Vår Föda, 56, pp. 26-29; Van Erp-Baart, M.A., Couet, C., Cuadrado, C., Kafatos, A., Stanley, J., Van Poppel, G., Trans fatty acids in bakery products from 14 European countries: The TRANSFAIR study (1998) Journal of Food Composition and Analysis, 11, pp. 161-169; Van Rossum, C.T.M., Fransen, H.P., Verkaik-Kloosterman, J., Buurma-Rethans, E.J.M., Ocké, M., (2011) Dutch National Food Consumption Survey 2007-2010. Diet of Children and Adults Aged 7 to 69 Years, , Report number: 350050006/2011. National Institute for Public Health and the Environment, The Netherlands; Wagner, K.H., Plasser, E., Proell, C., Kanzler, S., Comprehensive studies on the trans fatty acid content of Austrian foods: Convenience products, fast food and fats (2008) Food Chemistry, 108, pp. 1054-1060; Wallin, L., Wretling, S., Mattisson, I., (2009) Trans Fatty Acids in Cookies/biscuits and Crisps - Labelling and Content (in Swedish), , NFA Report 18; Wang, Y., Jacome-Sosa, M., Proctor, S.D., The role of ruminant trans fat as a potential nutraceutical in the prevention of cardiovascular disease (2012) Food Research International, 46, pp. 460-468; Willett, W., Mozaffarian, D., Ruminant or industrial sources of trans fatty acids: Public health issue or food label skirmish? (2008) American Journal of Clinical Nutrition, 87, pp. 515-516; Willett, W.C., Stampfer, M.J., Manson, J.E., Colditz, G.A., Speizer, F.E., Rosner, B.A., Intake of trans fatty acids and risk of coronary heart disease among women (1993) The Lancet, 341, pp. 581-585",Article,Scopus,2-s2.0-84917708552
"Dobbins R., Byerly R., Gaddy R., Gao F., Mahar K., Napolitano A., Ambery P., Le Monnier De Gouville A.-C.","GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial",2015,"European Journal of Pharmacology","755",,,"95","101",,,10.1016/j.ejphar.2015.03.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925448638&partnerID=40&md5=1ae31ea943ce98c39c425cd7b47e5b15","GlaxoSmithKline, Drug DiscoveryResearch Triangle Park, NC, United States; GlaxoSmithKline, Quantitative SciencesUpper Merion, PA, United States; GlaxoSmithKline, Immuno-Inflammation Therapeutic AreaStevenage, United Kingdom; Department of Endocrinology and Diabetes, Addenbrooke's HospitalCambridge, United Kingdom; GlaxoSmithKline, Drug Discovery, Laboratoire GSK, 27av du QuebecLes Ulis cedex, France","Dobbins, R., GlaxoSmithKline, Drug DiscoveryResearch Triangle Park, NC, United States; Byerly, R., GlaxoSmithKline, Drug DiscoveryResearch Triangle Park, NC, United States; Gaddy, R., GlaxoSmithKline, Drug DiscoveryResearch Triangle Park, NC, United States; Gao, F., GlaxoSmithKline, Quantitative SciencesUpper Merion, PA, United States; Mahar, K., GlaxoSmithKline, Quantitative SciencesUpper Merion, PA, United States; Napolitano, A., GlaxoSmithKline, Immuno-Inflammation Therapeutic AreaStevenage, United Kingdom; Ambery, P., Department of Endocrinology and Diabetes, Addenbrooke's HospitalCambridge, United Kingdom; Le Monnier De Gouville, A.-C., GlaxoSmithKline, Drug Discovery, Laboratoire GSK, 27av du QuebecLes Ulis cedex, France","This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone. Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor unblinded), placebo-controlled, parallel group trial. Participants received placebo for two weeks before being randomised (2:2:2:2:1:1) to receive doses of GSK256073 5 mg twice-daily (BID), 10 mg once-daily (QD), 25 mg BID, 50 mg QD or placebo BID or QD in addition to their current metformin treatment. The primary efficacy endpoint was change from baseline in glycosylated haemoglobin (HbA1c) at week 12. The safety profile of GSK256073 did not significantly differ from that of placebo. Decreases from baseline in HbA1c were observed in all treatment groups but were not statistically significant compared to placebo; at week 12 a maximum decrease of 0.30% from placebo was reached in the GSK256073 50 mg QD group. On day 2, GSK256073 significantly decreased non-esterified fatty acid (NEFA) (0-12 h) concentrations but pharmacological activity was lost (5 mg BID, 10 mg QD, 25 mg BID) or reduced (50 mg QD) at week 6. Drug exposure demonstrated 2-fold accumulation over 6 weeks. The primary efficacy objective of the study was not met. GSK256073 did not improve HbA1c concentrations at week 12. Despite sustained drug exposure, the ability of the HCA2 agonist to suppress plasma NEFA concentrations waned over time and targeted effects on glucose oxidation and insulin sensitivity subsided. © 2015 Elsevier B.V. All rights reserved.","GSK 256073; HbA1c; Non Esterified Fatty Acid(NEFA)-Hydroxy-carboxylicacidreceptor2(HCA2); Type 2diabetes","Bajaj, M., Suraamornkul, S., Romanelli, A., Cline, G.W., Mandarino, L.J., Shulman, G.I., Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients (2005) Diabetes, 54, pp. 3148-3153; Baldeweg, S.E., Golay, A., Natali, A., Balkau, B., Del Prato, S., Coppack, S.W., Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans (2000) Eur. J. Clin. Investig., 30, pp. 45-52; Dobbins, R.L., Shearn, S.P., Byerly, R.L., Gao, F.F., Mahar, K.M., Napolitano, A., GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus (2013) Diab. Obes. Metab., 15, pp. 1013-1021; Garg, A., Grundy, S.M., Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus (1990) J. Am. Med. Assoc., 264, pp. 723-726; Girousse, A., Tavernier, G., Valle, C., Moro, C., Mejhert, N., Dinel, A.-L., Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass (2013) PLoS Biol., 11, p. e1001485. , 10.1371/journal.pbio.1001485; Grundy, S.M., Vega, G.L., McGovern, M.E., Tulloch, B.R., Kendall, D.M., Fitz-Patrick, D., Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial (2002) Arch. Intern. Med., 162, pp. 1568-1576; Lauring, B., Taggart, A.K., Tata, J.R., Dunbar, R., Caro, L., Cheng, K., Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression (2012) Sci. Transl. Med., 4. , 148ra115; Lavezzari, M., Milanesi, G., Oggioni, E., Pamparana, F., Results of a phase IV study carried out with Acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia (1989) J. Int. Med. Res., 17, p. 373380; Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homoeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man (1985) Diabetologia, 28, pp. 412-419; McGarry, J.D., Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes (2002) Diabetes, 51, pp. 7-18; Mohan, V., Yang, W., Son, H.Y., Xu, L., Noble, L., Landon, R.B., Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea (2009) Diab. Res. Clin. Pract., 83, pp. 106-116; Paolisso, G., Tataranni, P.A., Foley, J.E., Bogardus, C., Howard, B.V., Ravussin, E., A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM (1995) Diabetologia, 38, pp. 1213-1217; Randle, P.J., Garland, P.B., Hales, C.N., Newholme, E.A., The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus (1963) Lancet, 1, pp. 785-789; Reaven, G.M., Hollenbeck, C., Jeng, C.Y., Wu, M.S., Chen, Y.D., Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM (1988) Diabetes, 37, pp. 1020-1024; Roden, M., Stingl, H., Chandramouli, V., Schumann, W.C., Hofer, A., Landau, B.R., Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans (2000) Diabetes, 49, pp. 701-707; Saloranta, C., Groop, L., Ekstrand, A., Franssila-Kallunki, A., Eriksson, J., Taskinen, M.R., Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes (1993) Diab. Med., 10, pp. 950-957; Saloranta, C., Taskinen, M.R., Widen, E., Harkonen, M., Melander, A., Groop, L., Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM (1993) Diabetes, 42, pp. 1559-1566; Santomauro Atmg, B.G., Silva, M.E.R., Rocha, D.M., Santos, R.F., Ursich, M.J.M., Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non diabetic subjects (1999) Diabetes, 48, pp. 1836-1841; Shulman, G.I., Cellular mechanism of insulin resistance (2000) J. Clin. Investig., 106, pp. 171-176; Vaag, A.A., Beck-Nielsen, H., Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus (1992) Acta Endocrinol., 127, pp. 344-350; Vosper, H., Niacin: A re-emerging pharmaceutical for the treatment of dyslipidaemia (2009) Br. J. Pharmacol., 158, pp. 429-441; Worm, D., Henricksen, J.E., Vaag, A., Thye-Rønn, P., Melander, A., Beck-Nieldsen, H., Pronounced blood glucose-lowering effect of the antilipolytic drug Acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period (1994) J. Clin. Endocrinol. Metab., 78, pp. 717-721",Article,Scopus,2-s2.0-84925448638
"Rehman K., Mashwani Z.-U.-R., Khan M.A., Ullah Z., Chaudhary H.J.","An ethno botanical perspective of traditional medicinal plants from the Khattak tribe of Chonthra Karak, Pakistan",2015,"Journal of Ethnopharmacology","165",,,"251","259",,,10.1016/j.jep.2015.02.035,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925445849&partnerID=40&md5=e7f099e31c7a27e6265a3eb34a667677","Department of Plant Sciences, Quaid.-i-Azam UniversityIslamabad, Pakistan; Department of Botany, PMAS Arid Agriculture UniversityRawalpindi, Pakistan; Department of Biotechnology, Quaid.-i-.Azam UniversityIslamabad, Pakistan; Centre of Plant Sciences and Biodiversity, University of Swat, Pakistan","Rehman, K., Department of Plant Sciences, Quaid.-i-Azam UniversityIslamabad, Pakistan; Mashwani, Z.-U.-R., Department of Botany, PMAS Arid Agriculture UniversityRawalpindi, Pakistan; Khan, M.A., Department of Biotechnology, Quaid.-i-.Azam UniversityIslamabad, Pakistan; Ullah, Z., Centre of Plant Sciences and Biodiversity, University of Swat, Pakistan; Chaudhary, H.J., Department of Plant Sciences, Quaid.-i-Azam UniversityIslamabad, Pakistan","Ethno pharmacological relevance The present study was carried out with an aim to gather, evaluate and analyze the ethno botanical information of medicinal uses of the plant species possessed by the native Khattak tribe of the Chonthra, district Karak Pakistan. The region with poor documentation of traditional knowledge, preserving the local traditional knowledge, reporting new as well as rarely reported medicinal properties of medicinal plants, to be tested experimentally for validation. Material and method The medicinal uses of existing plant species were documented by oral communication with 103 people, all over above 60 years of age, born and residing in Chonthra. Information was gathered by semi-structured interviews with further analysis by indices like Relative frequency citation RFC and Medicinal use value MUV. Results The study resulted with medicinal information on 66 plants species belonging to 34 families (using against 58 health related problems with 83 different preparations mainly administered orally and topical). The dominant families include Brasicaceae and Limiaceae. Withania coagulans and Pegnum harmala were the plant species quoted 100% by the informants with RFC values 1 each. The MUV were scattered between 1.24 and 0.03. The highest MUV were W. coagulans 1.24, Pegnum harmala 1.18, Fagonia cretica 1.14. This study for the first time include Nepeta lagopsis to the ethnobotanical wealth. Conclusions This study was an extension to the ethnobotanical research conducted in Khyber Pakhtunkhwa (KPK) Pakistan. The target area being small and less number of plants with limited traditional knowledge can serve basis for further work focusing on rarely or non- reported plant species of pharmacological and phytochemical importance with active metabolite capable of broadening the sources of new drugs. © 2015 Elsevier Ireland Ltd. All rights reserved.","Chonthra; Ethnobotany; Karak; Khattak tribe; Medicinal plants; Traditional use","Abbasi, A., Dastagir, G., Hussain, F., Sanaullah, P., Ethnobotany and marketing of crude drug plants in district Haripur, Pakistan (2005) Pak. J. Plant Sci., 11, pp. 103-114; Abbasi, A.M., Khan, M.A., Ahmad, M., Zafar, M., Khan, H., Muhammad, N., Sultana, S., Medicinal plants used for the treatment of jaundice and hepatitis based on socio-economic documentation (2009) Afr. J. Biotechnol., 8; Ahmad, S.S., Husain, S.Z., Ethno medicinal survey of plants from salt range (Kallar Kahar) of Pakistan (2008) Pak. J. Bot., 40, pp. 1005-1011; Ali, H., Qaiser, M., The ethnobotany of Chitral valley, Pakistan with particular reference to medicinal plants (2009) Pak. J. Bot., 41, pp. 2009-2041; Badshah, L., Hussain, F., Mohammad, Z., Floristic and ethno ecological studies on some plants of Pirghar Hills South Waziristan, Pakistan (1996) Pak. J. Plant Sci., 2, pp. 167-177; Badshah, L., Hussain, F., Sher, Z., Floristic inventory, ecological characteristics and biological spectrum of rangeland, district Tank, Pakistan (2013) Pak. J. Bot., 45, pp. 1159-1168; Bibi, T., Ahmad, M., Tareen, R.B., Tareen, N.M., Jabeen, R., Rehman, S.-U., Sultana, S., Yaseen, G., Ethnobotany of medicinal plants in district Mastung of Balochistan province-Pakistan (2014) J. Ethnopharmacol., 157, pp. 79-89; Chaturvedi, V., (1994) Diseases in Tribal Women and Comparative Study for Their Medical Treatment, , M.L.V. Tribal Research Institute Udaipur, India (Project Report); Cox, P.A., Balick, M.J., The ethnobotanical approach to drug discovery (1994) Sci. Am., 270, pp. 60-65; Dastagir, G., Abbasi, A., Folk medicines used for the treatment of jaundice in district Haripur, Pakistan (2004) Pak. J. Plant Sci., 10, pp. 119-123; Fabricant, D.S., Farnsworth, N.R., The value of plants used in traditional medicine for drug discovery (2001) Environ. Health Perspect., 109, p. 69; Farnsworth, N.R., Screening plants for new medicines (1988) Biodiversity, 3, pp. 81-99; Farnsworth, N.R., Akerele, O., Bingel, A.S., Soejarto, D.D., Guo, Z., Medicinal plants in therapy (1985) Bull. World Health Org., 63, p. 965; Ghimire, S.K., Gimenez, O., Pradel, R., McKey, D., Aumeeruddythomas, Y., Demographic variation and population viability in a threatened Himalayan medicinal and aromatic herb Nardostachys grandiflora: Matrix modelling of harvesting effects in two contrasting habitats (2008) J. Appl. Ecol., 45, pp. 41-51; Giday, M., Asfaw, Z., Elmqvist, T., Woldu, Z., An ethnobotanical study of medicinal plants used by the Zay people in Ethiopia (2003) J. Ethnopharmacol., 85, pp. 43-52; Goleniowski, M.E., Bongiovanni, G., Palacio, L., Nuñez, C., Cantero, J., Medicinal plants from the ""sierra de Comechingones"", Argentina (2006) J. Ethnopharmacol., 107, pp. 324-341; Gulshan, A.B., Dasti, A.A., Hussain, S., Atta, M.I., Amin-Ud-Din, M., (2006) Indigenous Uses of Medicinal Plants in Rural Areas of Dera Ghazi Khan, , Punjab, Pakistan; Hamayun, M., Ethnobotanical studies of some useful shrubs and trees of District Buner, NWFP, Pakistan (2003) Ethnobot. Leafl., 12; Hamayun, M., Ethnobotanical profile of Utror and Gabral valleys, district Swat, Pakistan (2005) Ethnobot. Leafl., 9; Hamayun, M., Khan, A., Afzal, S., Khan, M.A., Study on traditional knowledge and utility of medicinal herbs of district Buner, NWFP, Pakistan (2006) Indian J. Trad. Knowl., 5, pp. 407-412; Haq, I., Hussain, Z., Medicinal plants of Palandri district Poonch (AJK) (1995) Pak. J. Plant Sci., 1, pp. 115-126; Haq, I., Rehman, M., Medicinal plants of upper Swat (NWFP) Pakistan (1990) Hamdard Med., 33, pp. 51-68; Haq, I., Shah, M., Medicinal plants of Peshawar district,(NWFP) Pakistan (1986) Hamdard Med., 29, pp. 73-87; Hussain, K., Shahazad, A., Zia-Ul-Hussnain, S., An ethnobotanical survey of important wild medicinal plants of Hattar district Haripur, Pakistan (2008) Ethnobot. Leafl., 5; Hussain, M., Palynological and ethnobotanical studies of Chrysanthemum leucanthemum L., from Gallies (Abbottabad), Pakistan (2003) Hamdard Med., 45, pp. 13-14; Hussain, M., Shah, G.M., Khan, M.A., Traditional medicinal and economic uses of Gymnosperms of Kaghan valley, Pakistan (2006) Ethnobot. Leafl., 7; Inam, B., Sultana, K., Qureshi, R., Malik, S., A checklist of plants of Bhogarmang, Siran Valley, NWFP, Pakistan (2000) Hamdard Med., 43, pp. 62-76; Khan, M., Hussain, F., Musharaf, S., Ethnobotanical profile of Tehsil Takht-e-Nasratti, District Karak, Pakistan (2013) J. Med. Plants Res., 7, pp. 1636-1651; Khan, M.A., Khan, S.A., Qureshi, M.A., Ahmed, G., Khan, M.A., Hussain, M., Ghulam, G.M., Ethnobotany of some useful plants of Poonch valley Azad Kashmir (2011) J. Med. Plants Res., 5, pp. 6140-6151; Khan, S.W., Khatoon, S., Ethnobotanical studies on some useful herbs of Haramosh and Bugrote valleys in Gilgit, northern areas of Pakistan (2008) Pak. J. Bot., 40, p. 43; Konno, B., (2004) Integration of Traditional Medicine with Modern Medicine, pp. 3-9. , EHNRI, AddisAbaba; Mahmood, A., Malik, R.N., Shinwari, Z.K., Mahmood, A., Ethnobotanical survey of plants from Nelum, Azad Jammu and Kashmir, Pakistan (2011) Pak. J. Bot., 43, pp. 105-110; Organization, W.H., (2003) WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants, , World Health Organization Geneva; Qasim, M., Gulzar, S., Ma, K., Halophytes as medicinal plants (2011) Proceedings of the NAM Meeting, , Denizli, Turkey; Qureshi, R.A., Ghufran, M.A., Gilani, S.A., Yousaf, Z., Abbas, G., Batool, A., Indigenous medicinal plants used by local women in southern Himalayan regions of Pakistan (2009) Pak. J. Bot., 41, pp. 19-25; Saqib, Z., Sultan, A., Ethnobotany of Palas valley, Pakistan (2005) Ethnobot. Leafl., 28; Shah, G.M., Khan, M.A., Common medicinal folk recipes of Siran Valley, Mansehra, Pakistan (2006) Ethnobot. Leafl., 5; Shinwari, M.I., Khan, M.A., Folk use of medicinal herbs of Margalla hills national park, Islamabad (2000) J. Ethnopharmacol., 69, pp. 45-56; Srithi, K., Balslev, H., Wangpakapattanawong, P., Srisanga, P., Trisonthi, C., Medicinal plant knowledge and its erosion among the Mien (Yao) in Northern Thailand (2009) J. Ethnopharmacol., 123, pp. 335-342; Tardío, J., Pardo-De-Santayana, M., Cultural importance indices: A comparative analysis based on the useful wild plants of Southern Cantabria (Northern Spain) 1 (2008) Econ. Bot., 62, pp. 24-39; Ul Haq, I., Hussain, M., Medicinal plants of Mansehra (1993) Hamdard Med., 36, pp. 63-100; Upadhyay, B., Parveen, Dhaker, A.K., Kumar, A., Ethnomedicinal and ethnopharmaco-statistical studies of Eastern Rajasthan, India (2010) J. Ethnopharmacol., 4 (129), pp. 64-86; Zabihullah, Q., Rashid, A., Akhtar, N., Ethnobotanical survey in kot Manzaray Baba valley Malakand agency, Pakistan (2006) Pak. J. Plant Sci., 12, pp. 115-121; Zhang, X., (2002) WHO Traditional Medicine Strategy 2002-2005, , World Health Organization Geneva 11",Article,Scopus,2-s2.0-84925445849
"Zhang X., Xu Y., Liu D., Geng J., Chen S., Jiang Z., Fu Q., Sun K.","A modified multiplex ligation-dependent probe amplification method for the detection of 22q11.2 copy number variations in patients with congenital heart disease",2015,"BMC Genomics","16","1", 364,"","",,,10.1186/s12864-015-1590-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928882752&partnerID=40&md5=0e5a334935043c10998f42e7b0808f0c","Shanghai Jiao Tong University School of Medicine, Department of Laboratory Medicine, Shanghai Children's Medical CenterShanghai, China; Shanghai Jiao Tong University School of Medicine, Department of Pediatric Cardiology, Xinhua HospitalShanghai, China; Genesky Diagnostics (Suzhou) IncSuzhou, China","Zhang, X., Shanghai Jiao Tong University School of Medicine, Department of Laboratory Medicine, Shanghai Children's Medical CenterShanghai, China; Xu, Y., Shanghai Jiao Tong University School of Medicine, Department of Pediatric Cardiology, Xinhua HospitalShanghai, China; Liu, D., Genesky Diagnostics (Suzhou) IncSuzhou, China; Geng, J., Shanghai Jiao Tong University School of Medicine, Department of Laboratory Medicine, Shanghai Children's Medical CenterShanghai, China; Chen, S., Shanghai Jiao Tong University School of Medicine, Department of Pediatric Cardiology, Xinhua HospitalShanghai, China; Jiang, Z., Genesky Diagnostics (Suzhou) IncSuzhou, China; Fu, Q., Shanghai Jiao Tong University School of Medicine, Department of Laboratory Medicine, Shanghai Children's Medical CenterShanghai, China; Sun, K., Shanghai Jiao Tong University School of Medicine, Department of Pediatric Cardiology, Xinhua HospitalShanghai, China","Background: Copy number variations (CNVs) of chromosomal region 22q11.2 are associated with a subset of patients with congenital heart disease (CHD). Accurate and efficient detection of CNV is important for genetic analysis of CHD. The aim of the study was to introduce a novel approach named CNVplex®, a high-throughput analysis technique designed for efficient detection of chromosomal CNVs, and to explore the prevalence of sub-chromosomal imbalances in 22q11.2 loci in patients with CHD from a single institute. Results: We developed a novel technique, CNVplex®, for high-throughput detection of sub-chromosomal copy number aberrations. Modified from the multiplex ligation-dependent probe amplification (MLPA) method, it introduced a lengthening ligation system and four universal primer sets, which simplified the synthesis of probes and significantly improved the flexibility of the experiment. We used 110 samples, which were extensively characterized with chromosomal microarray analysis and MLPA, to validate the performance of the newly developed method. Furthermore, CNVplex® was used to screen for sub-chromosomal imbalances in 22q11.2 loci in 818 CHD patients consecutively enrolled from Shanghai Children's Medical Center. In the methodology development phase, CNVplex® detected all copy number aberrations that were previously identified with both chromosomal microarray analysis and MLPA, demonstrating 100% sensitivity and specificity. In the validation phase, 22q11.2 deletion and 22q11.2 duplication were detected in 39 and 1 of 818 patients with CHD by CNVplex®, respectively. Our data demonstrated that the frequency of 22q11.2 deletion varied among sub-groups of CHD patients. Notably, 22q11.2 deletion was more commonly observed in cases with conotruncal defect (CTD) than in cases with non-CTD (P < 0.001). With higher resolution and more probes against selected chromosomal loci, CNVplex® also identified several individuals with small CNVs and alterations in other chromosomes. Conclusions: CNVplex® is sensitive and specific in its detection of CNVs, and it is an alternative to MLPA for batch screening of pathogenetic CNVs in known genomic loci. © 2015 Zhang et al.","22q11.2 deletion; Congenital heart disease; Copy number variation; Multiplex ligation-dependent probe amplification","Yoon, S., Xuan, Z., Makarov, V., Ye, K., Sebat, J., Sensitive and accurate detection of copy number variants using read depth of coverage (2009) Genome Res, 19 (9), pp. 1586-1592; Tang, Y.-C., Amon, A., Gene copy-number alterations: a cost-benefit analysis (2013) Cell, 152 (3), pp. 394-405; Lindsay, E.A., Chromosomal microdeletions: dissecting del22q11 syndrome (2001) Nat Rev Genet, 2 (11), pp. 858-868; Ryan, A.K., Goodship, J.A., Wilson, D.I., Philip, N., Levy, A., Seidel, H., Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study (1997) J Med Genet, 34 (10), pp. 798-804; Beauchesne, L.M., Warnes, C.A., Connolly, H.M., Ammash, N.M., Grogan, M., Jalal, S.M., Prevalence and clinical manifestations of 22q11.2 microdeletion in adults with selected conotruncal anomalies (2005) J Am Coll Cardiol, 45 (4), pp. 595-598; Anilkumar, A., Kappanayil, M., Nampoothiri, S., Thampi, M.V., Vasudevan, D.M., Kumar, R.K., Screening for TBX1 Gene in Children With or Without Microdeletion of Chromosome 22q11 and Conotruncal Defect (2012) Lab Med, 43 (2), pp. 11-13; Fanciulli, M., Petretto, E., Aitman, T.J., Gene copy number variation and common human disease (2010) Clin Genet, 77 (3), pp. 201-213; http://biotech.geneskies.com/index_EN.html, Genesky BiotechnologiesSchouten, J.P., McElgunn, C.J., Waaijer, R., Zwijnenburg, D., Diepvens, F., Pals, G., Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification (2002) Nucleic Acids Res, 30 (12), p. e57; Du, R., Lu, C., Jiang, Z., Li, S., Ma, R., An, H., Efficient typing of copy number variations in a segmental duplication-mediated rearrangement hotspot using multiplex competitive amplification (2012) J Hum Genet, 57 (8), pp. 545-551; Portnoi, M.F., Microduplication 22q11.2: a new chromosomal syndrome (2009) Eur J Med Genet, 52 (2-3), pp. 88-93; Wincent, J., Bruno, D.L., Bon, B.W., Bremer, A., Stewart, H., Bongers, E.M., Sixteen New Cases Contributing to the Characterization of Patients with Distal 22q11.2 Microduplications (2010) Mol Syndromol, 1 (5), pp. 246-254; Momma, K., Cardiovascular anomalies associated with chromosome 22q11.2 deletion syndrome (2010) Am J Cardiol, 105 (11), pp. 1617-1624; Agergaard, P., Olesen, C., Ostergaard, J.R., Christiansen, M., Sorensen, K.M., The prevalence of chromosome 22q11.2 deletions in 2,478 children with cardiovascular malformations. A population-based study (2012) Am J Med Genet A, 158A (3), pp. 498-508; Kobrynski, L.J.S.K., Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes (2007) The Lancet, 370 (9596), pp. 1443-1452; Wozniak, A., Wolnik-Brzozowska, D., Wisniewska, M., Glazar, R., Materna-Kiryluk, A., Moszura, T., Frequency of 22q11.2 microdeletion in children with congenital heart defects in western poland (2010) BMC Pediatr, 10, p. 88; Sorensen, K.M., El-Segaier, M., Fernlund, E., Errami, A., Bouvagnet, P., Nehme, N., Screening of congenital heart disease patients using multiplex ligation-dependent probe amplification: early diagnosis of syndromic patients (2012) Am J Med Genet A, 158A (4), pp. 720-725; Derbent, M., Yilmaz, Z., Baltaci, V., Saygili, A., Varan, B., Tokel, K., Chromosome 22q11.2 deletion and phenotypic features in 30 patients with conotruncal heart defects (2003) Am J Med Genet A, 116A (2), pp. 129-135; Fernandez, L., Lapunzina, P., Pajares, I.L., Palomares, M., Martinez, I., Fernandez, B., Unrelated chromosomal anomalies found in patients with suspected 22q11.2 deletion (2008) Am J Med Genet A, 146A (9), pp. 1134-1141; Rauch, A., Zink, S., Zweier, C., Thiel, C.T., Koch, A., Rauch, R., Systematic assessment of atypical deletions reveals genotype-phenotype correlation in 22q11.2 (2005) J Med Genet, 42 (11), pp. 871-876; Xu, H., Poh, W.-T., Sim, X., Ong, R.T.-H., Suo, C., Tay, W.-T., SgD-CNV, a database for common and rare copy number variants in three Asian populations (2011) Hum Mutat, 32 (12), pp. 1341-1349; Jalali, G.R., Vorstman, J.A., Errami, A., Vijzelaar, R., Biegel, J., Shaikh, T., Detailed analysis of 22q11.2 with a high density MLPA probe set (2008) Hum Mutat, 29 (3), pp. 433-440",Article,Scopus,2-s2.0-84928882752
"Colbert R.W., Holley C.T., Stone L.H., Crampton M., Adabag S., Garcia S., Iaizzo P.A., Ward H.B., Kelly R.F., McFalls E.O.","The Recovery of Hibernating Hearts Lies on a Spectrum: from Bears in Nature to Patients with Coronary Artery Disease",2015,"Journal of Cardiovascular Translational Research",,,,"","",9,,10.1007/s12265-015-9625-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928969599&partnerID=40&md5=dad187bde6411728491f8360151e3ad7","Cardiology Division, VA Medical Center, University of MinnesotaMinneapolis, MN, United States; Department of Cardiothoracic Surgery, University of MinnesotaMinneapolis, MN, United States; Department of Surgery, University of MinnesotaMinneapolis, MN, United States; Department of Integrative Biology and Physiology, University of MinnesotaMinneapolis, MN, United States; The Institute for Engineering in Medicine, University of MinnesotaMinneapolis, MN, United States; Cardiology (111C), VA Medical Center, 1 Veterans DriveMinneapolis, MN, United States","Colbert, R.W., Cardiology Division, VA Medical Center, University of MinnesotaMinneapolis, MN, United States; Holley, C.T., Department of Cardiothoracic Surgery, University of MinnesotaMinneapolis, MN, United States; Stone, L.H., Department of Cardiothoracic Surgery, University of MinnesotaMinneapolis, MN, United States; Crampton, M., Department of Cardiothoracic Surgery, University of MinnesotaMinneapolis, MN, United States; Adabag, S., Cardiology Division, VA Medical Center, University of MinnesotaMinneapolis, MN, United States; Garcia, S., Cardiology Division, VA Medical Center, University of MinnesotaMinneapolis, MN, United States; Iaizzo, P.A., Department of Surgery, University of MinnesotaMinneapolis, MN, United States, Department of Integrative Biology and Physiology, University of MinnesotaMinneapolis, MN, United States, The Institute for Engineering in Medicine, University of MinnesotaMinneapolis, MN, United States; Ward, H.B., Department of Cardiothoracic Surgery, University of MinnesotaMinneapolis, MN, United States; Kelly, R.F., Department of Cardiothoracic Surgery, University of MinnesotaMinneapolis, MN, United States; McFalls, E.O., Cardiology Division, VA Medical Center, University of MinnesotaMinneapolis, MN, United States, Cardiology (111C), VA Medical Center, 1 Veterans DriveMinneapolis, MN, United States","Clinicians often use the term “hibernating myocardium” in reference to patients with ischemic heart disease and decreased function within viable myocardial regions. Because the term is a descriptor of nature’s process of torpor, we provide a comparison of the adaptations observed in both conditions. In nature, hearts from hibernating animals undergo a shift in substrate preference in favor of fatty acids, while preserving glucose uptake and glycogen. Expression of electron transport chain proteins in mitochondria is decreased while antioxidant proteins including uncoupling protein-2 are increased. Similarly, hibernating hearts from patients have a comparable metabolic signature, with increased glucose uptake and glycogen accumulation and decreased oxygen consumption. In contrast to nature however, patients with hibernating hearts are at increased risk for arrhythmias, and contractility does not fully recover following revascularization. Clearly, additional interventions need to be advanced in patients with coronary artery disease and hibernating myocardium to prevent refractory heart failure. © 2015 Springer Science+Business Media New York (outside the USA)","Antioxidant; Coronary artery disease; Glycogen; Heart failure; Hibernating myocardium; Metabolism; Mitochondria; Revascularization; Torpor; Uncoupling protein",,Article in Press,Scopus,2-s2.0-84928969599
"Henninger C., Huelsenbeck S., Wenzel P., Brand M., Huelsenbeck J., Schad A., Fritz G.","Chronic heart damage following doxorubicin treatment is alleviated by lovastatin",2015,"Pharmacological Research","91",,,"1","10",,,10.1016/j.phrs.2014.11.003,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84915795118&partnerID=40&md5=913232ed1f795cb77c6e7cfc91e5d40f","Institute of Toxicology, Heinrich Heine University Düsseldorf, Universitätsstrasse 1Dusseldorf, Germany; Institute of Toxicology, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67, Germany; Department of Medicine 2 and Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67Mainz, Germany; Institute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67Mainz, Germany","Henninger, C., Institute of Toxicology, Heinrich Heine University Düsseldorf, Universitätsstrasse 1Dusseldorf, Germany; Huelsenbeck, S., Institute of Toxicology, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67, Germany; Wenzel, P., Department of Medicine 2 and Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67Mainz, Germany; Brand, M., Department of Medicine 2 and Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67Mainz, Germany; Huelsenbeck, J., Institute of Toxicology, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67, Germany; Schad, A., Institute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67Mainz, Germany; Fritz, G., Institute of Toxicology, Heinrich Heine University Düsseldorf, Universitätsstrasse 1Dusseldorf, Germany, Institute of Toxicology, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67, Germany","The anticancer efficacy of anthracyclines is limited by cumulative dose-dependent early and delayed cardiotoxicity resulting in congestive heart failure. Mechanisms responsible for anthracycline-induced heart damage are controversially discussed and effective preventive measures are preferable. Here, we analyzed the influence of the lipid lowering drug lovastatin on anthracycline-induced late cardiotoxicity three month after treatment of C57BL/6 mice with five low doses of doxorubicin (5 × 3 mg/kg BW; i.p.). Doxorubicin increased the cardiac mRNA levels of BNP, IL-6 and CTGF, while the expression of ANP remained unchanged. Lovastatin counteracted these persisting cardiac stress responses evoked by the anthracycline. Doxorubicin-induced fibrotic alterations were neither detected by histochemical collagen staining of heart sections nor by analysis of the mRNA expression of collagens. Extensive qRT-PCR-array based analyses revealed a large increase in the mRNA level of heat shock protein Hspa1b in doxorubicin-treated mice, which was mitigated by lovastatin co-treatment. Electron microscopy together with qPCR-based analysis of mitochondrial DNA content indicate that lovastatin attenuates doxorubicin-stimulated hyperproliferation of mitochondria. This was not paralleled by increased expression of oxidative stress responsive genes or senescence-associated proteins. Echocardiographic analyses disclosed that lovastatin protects from the doxorubicin-induced decrease in the left ventricular posterior wall diameter (LVPWD), while constrictions in fractional shortening (FS) and ejection fraction (EF) evoked by doxorubicin were not amended by the statin. Taken together, the data suggest beneficial effects of lovastatin against doxorubicin-induced delayed cardiotoxicity. Clinical studies are preferable to scrutinize the usefulness of statins for the prevention of anthracycline-induced late cardiotoxicity. © 2014 Elsevier Ltd. All rights reserved.","Anthracyclines; Chronic cardiotoxicity; Doxorubicin; Mitochondrial hyperproliferation; Rho GTPases; Statins","Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity (2004) Pharmacol Rev, 56, pp. 185-229; Kremer, L.C., Van Dalen, E.C., Offringa, M., Ottenkamp, J., Voute, P.A., Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study (2001) J Clin Oncol, 19, pp. 191-196; Van Dalen, E.C., Van Der Pal, H.J., Kok, W.E., Caron, H.N., Kremer, L.C., Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study (2006) Eur J Cancer, 42, pp. 3191-3198; Ferreira, A.L., Matsubara, L.S., Matsubara, B.B., Anthracycline-induced cardiotoxicity (2008) Cardiovasc Hematol Agents Med Chem, 6, pp. 278-281; Lyu, Y.L., Kerrigan, J.E., Lin, C.P., Azarova, A.M., Tsai, Y.C., Ban, Y., Topoisomerase IIbeta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane (2007) Cancer Res, 67, pp. 8839-8846; Fogli, S., Nieri, P., Breschi, M.C., The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage (2004) FASEB J, 18, pp. 664-675; Weinstein, D.M., Mihm, M.J., Bauer, J.A., Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice (2000) J Pharmacol Exp Ther, 294, pp. 396-401; Cole, M.P., Chaiswing, L., Oberley, T.D., Edelmann, S.E., Piascik, M.T., Lin, S.M., The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity (2006) Cardiovasc Res, 69, pp. 186-197; Chaiswing, L., Cole, M.P., Ittarat, W., Szweda, L.I., St Clair, D.K., Oberley, T.D., Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute adriamycin-induced mitochondrial toxicity (2005) Mol Cancer Ther, 4, pp. 1056-1064; Pacher, P., Liaudet, L., Bai, P., Mabley, J.G., Kaminski, P.M., Virag, L., Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction (2003) Circulation, 107, pp. 896-904; Gianni, L., Herman, E.H., Lipshultz, S.E., Minotti, G., Sarvazyan, N., Sawyer, D.B., Anthracycline cardiotoxicity: From bench to bedside (2008) J Clin Oncol, 26, pp. 3777-3784; Hasinoff, B.B., Herman, E.H., Dexrazoxane: How it works in cardiac and tumor cells. Is it a prodrug or is it a drug? (2007) Cardiovasc Toxicol, 7, pp. 140-144; Yan, T., Deng, S., Metzger, A., Godtel-Armbrust, U., Porter, A.C., Wojnowski, L., Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin (2009) Mol Cancer Ther, 8, pp. 1075-1085; Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R., Gersl, V., Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron (2009) Pharmacol Rep, 61, pp. 154-171; Classen, S., Olland, S., Berger, J.M., Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 (2003) Proc Natl Acad Sci U S A, 100, pp. 10629-10634; Willmore, E., Errington, F., Tilby, M.J., Austin, C.A., Formation and longevity of idarubicin-induced DNA topoisomerase ii cleavable complexes in k562 human leukaemia cells (2002) Biochem Pharmacol, 63, pp. 1807-1815; Marty, M., Espie, M., Llombart, A., Monnier, A., Rapoport, B.L., Stahalova, V., Multicenter randomized phase iii study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy (2006) Ann Oncol, 17, pp. 614-622; Hofland, K.F., Thougaard, A.V., Sehested, M., Jensen, P.B., Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin (2005) Clin Cancer Res, 11, pp. 3915-3924; Salzer, W.L., Devidas, M., Carroll, W.L., Winick, N., Pullen, J., Hunger, S.P., Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the children's oncology group (2010) Leukemia, 24, pp. 355-370; Tebbi, C.K., London, W.B., Friedman, D., Villaluna, D., De Alarcon, P.A., Constine, L.S., Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease (2007) J Clin Oncol, 25, pp. 493-500; Zhou, Q., Liao, J.K., Pleiotropic effects of statins - Basic research and clinical perspectives (2010) Circ J, 74, pp. 818-826; Liao, J.K., Laufs, U., Pleiotropic effects of statins (2005) Annu Rev Pharmacol Toxicol, 45, pp. 89-118; Fritz, G., Targeting the mevalonate pathway for improved anticancer therapy (2009) Curr Cancer Drug Targets, 9, pp. 626-638; Hall, A., Rho GTPases and the actin cytoskeleton (1998) Science, 279, pp. 509-514; Jaffe, A.B., Hall, A., Rho gtpases in transformation and metastasis (2002) Adv Cancer Res, 84, pp. 57-80; Vega, F.M., Ridley, A.J., Rho GTPases in cancer cell biology (2008) FEBS Lett, 582, pp. 2093-2101; Cafforio, P., Dammacco, F., Gernone, A., Silvestris, F., Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells (2005) Carcinogenesis, 26, pp. 883-891; Agarwal, B., Bhendwal, S., Halmos, B., Moss, S.F., Ramey, W.G., Holt, P.R., Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells (1999) Clin Cancer Res, 5, pp. 2223-2229; Rao, S., Lowe, M., Herliczek, T.W., Keyomarsi, K., Lovastatin mediated g1 arrest in normal and tumor breast cells is through inhibition of cdk2 activity and redistribution of p21 and p27, independent of p53 (1998) Oncogene, 17, pp. 2393-2402; Feleszko, W., Mlynarczuk, I., Olszewska, D., Jalili, A., Grzela, T., Lasek, W., Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism (2002) Int J Cancer, 100, pp. 111-118; Feleszko, W., Jakobisiak, M., Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells (2000) Clin Cancer Res, 6, pp. 1198-1199; Dimitroulakos, J., Nohynek, D., Backway, K.L., Hedley, D.W., Yeger, H., Freedman, M.H., Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach (1999) Blood, 93, pp. 1308-1318; Dimitroulakos, J., Ye, L.Y., Benzaquen, M., Moore, M.J., Kamel-Reid, S., Freedman, M.H., Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications (2001) Clin Cancer Res, 7, pp. 158-167; Damrot, J., Nuebel, T., Epe, B., Roos, W.P., Kaina, B., Fritz, G., Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide (2006) Br J Pharmacol, 149, pp. 988-997; Nuebel, T., Damrot, J., Roos, W.P., Kaina, B., Fritz, G., Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks (2006) Clin Cancer Res, 12, pp. 933-939; Mahmoudi, M., Gorenne, I., Mercer, J., Figg, N., Littlewood, T., Bennett, M., Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells (2008) Circ Res, 103, pp. 717-725; Haydont, V., Bourgier, C., Pocard, M., Lusinchi, A., Aigueperse, J., Mathe, D., Pravastatin inhibits the rho/ccn2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats (2007) Clin Cancer Res, 13, pp. 5331-5340; Haydont, V., Bourgier, C., Vozenin-Brotons, M.C., Rho/rock pathway as a molecular target for modulation of intestinal radiation-induced toxicity (2007) Br J Radiol, 80, pp. 32-40; Huelsenbeck, J., Henninger, C., Schad, A., Lackner, K.J., Kaina, B., Fritz, G., Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity (2011) Cell Death Dis, 2, p. 190; Riad, A., Bien, S., Westermann, D., Becher, P.M., Loya, K., Landmesser, U., Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice (2009) Cancer Res, 69, pp. 695-699; Yoshida, M., Shiojima, I., Ikeda, H., Komuro, I., Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-atm-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of rac1 activity (2009) J Mol Cell Cardiol, 47, pp. 698-705; Henninger, C., Huelsenbeck, J., Huelsenbeck, S., Grosch, S., Schad, A., Lackner, K.J., The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity (2012) Toxicol Appl Pharmacol, 261, pp. 66-73; Rashid, M., Tawara, S., Fukumoto, Y., Seto, M., Yano, K., Shimokawa, H., Importance of rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors (2009) Circ J, 73, pp. 361-370; Ma, J., Wang, Y., Zheng, D., Wei, M., Xu, H., Peng, T., Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways (2013) Cardiovasc Res, 97, pp. 77-87; Feleszko, W., Mlynarczuk, I., Balkowiec-Iskra, E.Z., Czajka, A., Switaj, T., Stoklosa, T., Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice (2000) Clin Cancer Res, 6, pp. 2044-2052; Huelsenbeck, S.C., Schorr, A., Roos, W.P., Huelsenbeck, J., Henninger, C., Kaina, B., Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase ii poisons (2012) J Biol Chem, 287, pp. 38590-38599; Gewirtz, D.A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin (1999) Biochem Pharmacol, 57, pp. 727-741; Carvalho, F.S., Burgeiro, A., Garcia, R., Moreno, A.J., Carvalho, R.A., Oliveira, P.J., Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy (2014) Med Res Rev, 34, pp. 106-135; De Beer, E.L., Bottone, A.E., Voest, E.E., Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: A review (2001) Eur J Pharmacol, 415, pp. 1-11; Kou, J., Song, M., Pattanayak, A., Lim, J.E., Yang, J., Cao, D., Combined treatment of abeta immunization with statin in a mouse model of Alzheimer's disease (2012) J Neuroimmunol, 244, pp. 70-83; Jawien, J., Nastalek, P., Korbut, R., Mouse models of experimental atherosclerosis (2004) J Physiol Pharmacol, 55, pp. 503-517; Fritz, G., Henninger, C., Huelsenbeck, J., Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents (2011) Br Med Bull, 97, pp. 17-26; Marechal, X., Montaigne, D., Marciniak, C., Marchetti, P., Hassoun, S.M., Beauvillain, J.C., Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics (2011) Clin Sci (Lond), 121, pp. 405-413; Olive, P.L., Detection of DNA damage in individual cells by analysis of histone h2ax phosphorylation (2004) Methods Cell Biol, 75, pp. 355-373; Eppstein, D.A., Kurahara, C.G., Bruno, N.A., Terrell, T.G., Prevention of doxorubicin-induced hematotoxicity in mice by interleukin 1 (1989) Cancer Res, 49, pp. 3955-3960; Montaigne, D., Marechal, X., Preau, S., Baccouch, R., Modine, T., Fayad, G., Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium (2011) Mitochondrion, 11, pp. 22-26; Maron, D.J., Fazio, S., Linton, M.F., Current perspectives on statins (2000) Circulation, 101, pp. 207-213; Merx, M.W., Liehn, E.A., Janssens, U., Lutticken, R., Schrader, J., Hanrath, P., HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis (2004) Circulation, 109, pp. 2560-2565; Ludman, A., Venugopal, V., Yellon, D.M., Hausenloy, D.J., Statins and cardioprotection - More than just lipid lowering (2009) Pharmacol Ther, 122, pp. 30-43; Ostrau, C., Hulsenbeck, J., Herzog, M., Schad, A., Torzewski, M., Lackner, K.J., Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo (2009) Radiother Oncol, 92, pp. 492-499; Monceau, V., Pasinetti, N., Schupp, C., Pouzoulet, F., Opolon, P., Vozenin, M.C., Modulation of the rho/rock pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity (2010) Curr Drug Targets, 11, pp. 1395-1404; Wang, J., Boerma, M., Fu, Q., Kulkarni, A., Fink, L.M., Hauer-Jensen, M., Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein c-independent mechanism (2007) Int J Radiat Oncol Biol Phys, 68, pp. 1483-1490; Porter, K.E., Turner, N.A., Statins and myocardial remodelling: Cell and molecular pathways (2011) Expert Rev Mol Med, 13, p. 22; Hermida, N., Markl, A., Hamelet, J., Van Assche, T., Vanderper, A., Herijgers, P., HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through amp-activated protein kinase activation in a mouse model of metabolic syndrome (2013) Cardiovasc Res, 99, pp. 44-54; Silver, J.T., Noble, E.G., Regulation of survival gene hsp70 (2012) Cell Stress Chaperones, 17, pp. 1-9; Daugaard, M., Rohde, M., Jaattela, M., The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions (2007) FEBS Lett, 581, pp. 3702-3710; Kluza, J., Marchetti, P., Gallego, M.A., Lancel, S., Fournier, C., Loyens, A., Mitochondrial proliferation during apoptosis induced by anticancer agents: Effects of doxorubicin and mitoxantrone on cancer and cardiac cells (2004) Oncogene, 23, pp. 7018-7030; Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.S., Lyu, Y.L., Liu, L.F., Identification of the molecular basis of doxorubicin-induced cardiotoxicity (2012) Nat Med, 18, pp. 1639-1642; Menna, P., Salvatorelli, E., Minotti, G., Doxorubicin degradation in cardiomyocytes (2007) J Pharmacol Exp Ther, 322, pp. 408-419; Menna, P., Salvatorelli, E., Minotti, G., Anthracycline degradation in cardiomyocytes: A journey to oxidative survival (2009) Chem Res Toxicol, 23, pp. 6-10; Woodbine, L., Brunton, H., Goodarzi, A.A., Shibata, A., Jeggo, P.A., Endogenously induced DNA double strand breaks arise in heterochromatic DNA regions and require ataxia telangiectasia mutated and artemis for their repair (2011) Nucleic Acids Res, 39, pp. 6986-6997; Colavitti, R., Finkel, T., Reactive oxygen species as mediators of cellular senescence (2005) IUBMB Life, 57, pp. 277-281; Shioi, T., Inuzuka, Y., Aging as a substrate of heart failure (2012) J Cardiol, 60, pp. 423-428; Cho, S.J., Kim, J.S., Kim, J.M., Lee, J.Y., Jung, H.C., Song, I.S., Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice (2008) Int J Cancer, 123, pp. 951-957; Seicean, S., Seicean, A., Plana, J.C., Budd, G.T., Marwick, T.H., Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: An observational clinical cohort study (2012) J Am Coll Cardiol, 60, pp. 2384-2390",Article,Scopus,2-s2.0-84915795118
"De Gobbi J.I.F., Omoto A.C.M., Siqueira T.F., Matsubara L.S., Roscani M.G., Matsubara B.B.","Antidepressant treatment decreases daily salt intake and prevents heart dysfunction following subchronic aortic regurgitation in rats",2015,"Physiology and Behavior","144",,,"124","128",,,10.1016/j.physbeh.2015.02.037,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925355904&partnerID=40&md5=4d45f7e01cc192013cc3da9a930a2ccc","Department of Physiology, Institute of Bioscience, UNESP-Botucatu, Brazil; Department of Internal Medicine, Botucatu Medical School, UNESP, Brazil","De Gobbi, J.I.F., Department of Physiology, Institute of Bioscience, UNESP-Botucatu, Brazil; Omoto, A.C.M., Department of Physiology, Institute of Bioscience, UNESP-Botucatu, Brazil; Siqueira, T.F., Department of Physiology, Institute of Bioscience, UNESP-Botucatu, Brazil; Matsubara, L.S., Department of Internal Medicine, Botucatu Medical School, UNESP, Brazil; Roscani, M.G., Department of Internal Medicine, Botucatu Medical School, UNESP, Brazil; Matsubara, B.B., Department of Internal Medicine, Botucatu Medical School, UNESP, Brazil","Depression is a predictor of poor prognosis in patients with heart failure. Selective serotonin (5-HT) reuptake inhibitors (SSRIs) may improve these outcomes. Left ventricular volume overload induced hypertrophy that is associated with aortic regurgitation (AR) leads to ventricular dysfunction and heart failure. The aim of this study was to verify the effects of the SSRI paroxetine on cardiac function, as well as on fluid intake and excretion, in subchronic AR. Male Wistar rats (260 to 280. g) received sham (SH) surgery or AR induced by retrograde puncture of the aortic valve leaflets. The presence of AR was confirmed by echocardiography (ECHO) exams. Four weeks after AR surgery, subcutaneous injections of paroxetine (PAR: 10. mg/kg 3 times in a week) or saline were administered. The rats were randomly divided into the following 4 groups and treated for 4 weeks: AR-PAR, ARsaline, SH-PAR and SH-saline. At the end of the treatment period, fractional shortening was preserved in AR-PAR, compared to AR-saline (46.6. ±. 2.7% vs 38.3. ±. 2.2%, respectively). Daily 0.3 M NaCl intake was reduced in PAR-treated rats. Natriuresis was increased in weeks 2-3 after PAR treatment. Our results suggest that augmentation of central 5-HT neurotransmission has a beneficial effect on cardiovascular remodeling following volume overload. The mechanisms underlying this effect are unknown. © 2015 The Authors.","Antidepressants; Aortic regurgitation; Serotonin; Sodium intake; Systolic function; Volume overload","Tarasoutchi, F., Grinberg, M., Spina, G.S., Sampaio, R.O., Cardoso, L.F., Rossi, E.G., Pomerantzeff, P., Ramires, J.A., Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology (2003) J. Am. Coll. Cardiol., 41 (8), pp. 1316-1324; Maganti, K., Rigolin, V.H., Sarano, M.E., Bonow, R.O., Valvular heart disease: diagnosis and management (2010) Mayo Clin. Proc., 85 (5), pp. 483-500; Grippo, A.J., Johnson, A.K., Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models (2009) Stress, 12, pp. 1-21; Penninx, B.W., Beekman, A.T., Honig, A., Deeg, D.J., Schoevers, R.A., van Eijk, J.T., van Tilburg, W., Depression and cardiac mortality: results from a community-based longitudinal study (2001) Arch. Gen. Psychiatry, 58 (3), pp. 221-227; van der Kooy, K., van Hout, H., Marwijk, H., Marten, H., Stehouwer, C., Beekman, A., Depression and the risk for cardiovascular diseases: systematic review and meta analysis (2007) Int. J. Geriatr. Psychiatry, 22 (7), pp. 613-626; Somberg, T.C., Arora, R.R., Depression and heart disease: therapeutic implications (2008) Cardiology, 111 (2), pp. 75-81; Grippo, A.J., Beltz, T.G., Weiss, R.M., Johnson, A.K., The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia (2006) Biol. Psychiatry, 59 (4), pp. 309-316; Roose, S.P., Laghrissi-Thode, F., Kennedy, J.S., Nelson, J.C., Bigger, J.T., Pollock, B.G., Gaffney, A., Gergel, I., Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease (1998) JAMA, 279 (4), pp. 287-291. , (28); Tucker, P., Adamson, P., Miranda, R., Scarborough, A., Williams, D., Groff, J., McLean, H., Paroxetine increases heart rate variability in panic disorder (1997) J. Clin. Psychopharmacol., 17 (5), p. 3; Urzedo-Rodrigues, L.S., Ferreira, H.S., Almeida, D.O., Medeiros, J.P., Batista, A., de Castro e Silva, E., Fregoneze, J.B., Blockade of 5-HT3 receptors at septal area increase blood pressure in unanaesthetized rats (2011) Auton. Neurosci., 159 (1-2), pp. 51-61; Beich, K.R., Yancy, C., The heart failure and sodium restriction controversy: challenging conventional practice (2008) Nutr. Clin. Pract., 23, pp. 477-486; Neily, J.B., Toto, K.H., Gardner, E.B., Rame, J.E., Yancy, C.W., Sheffield, M.A., Dries, D.L., Drazner, M.H., Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure (2002) Am. Heart. J., 143, pp. 29-33; Lima, H.R., Cavalcante-Lima, H.R., Cedraz-Mercez, P.L., Costa-E-Sousa, R.H., Olivares, E.L., Badauê-Passos, D., Medeiros, M.A., Reis, L.C., Brain serotonin depletion enhances the sodium appetite induced by sodium depletion or beta-adrenergic stimulation (2004) An. Acad. Bras. Cienc., 76, pp. 85-92; Azmitia, E.C., Segal, M., An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat (1978) J. Comp. Neurol., 179, pp. 641-646; Cavalcante-Lima, H.R., Badauê-Passos, D., de-Lucca, W., Lima, H.R., Costa-e-Sousa, R.H., Olivares, E.L., Cedraz-Mercez, P.L., Reis, L.C., Chronic excitotoxic lesion of the dorsal raphe nucleus induces sodium appetite (2005) Braz. J. Med. Biol. Res., 38, pp. 1669-1675; Arsenault, M., Plante, E., Drolet, M.C., Couet, J., Experimental aortic regurgitation in rats under echocardiographic guidance (2002) J. Heart Valve Dis., 11, pp. 128-134; Plante, E., Couet, J., Gaudreau, M., Dumas, M.P., Drolet, M.C., Arsenault, M., Left ventricular response to sustained volume overload from chronic aortic valve regurgitation in rats (2003) J. Card. Fail., 9, pp. 128-140; Sanh, D.J., DeMaria, A., Kisslo, J., Weyman, A.E., The Committee on M-mode standardization of the American Society of Ecocardiography (1978) Recommendations regarding quantitation in Mmode echocardiography: results of a survey of echocardiographic measurements. Circ, 58, pp. 1072-1083; Reis, L.C., Ramalho, M.J., Antunes-Rodrigues, J., Effect of central administration ofserotoninergic agonists on electrolyte excretion control (1991) Braz. J. Med. Biol. Res., 24, pp. 633-641; Golding, M., Kotlyar, M., Carson, S.W., Hoyler, S., Lazarus, C., Davidson, C., Guzzo, J., Garbutt, J.C., Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses (2005) Psychopharmacology, 182, pp. 321-326; McFarlane, A., Kamath, M.V., Fallen, E.L., Malcolm, V., Cherian, F., Norman, G., Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction (2001) Am. Heart J., 142 (4), pp. 617-623; Taylor, C.B., Youngblood, M.E., Catellier, D., Veith, R.C., Carney, R.M., Burg, M.M., Kaufmann, P.G., ENRICHD, Investigators, Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction (2005) Arch. Gen. Psychiatry., 62, pp. 792-798; Lederbogen, F., Gernoth, C., Weber, B., Colla, M., Kniest, A., Heuser, I., Deuschle, M., Antidepressive treatment with amitriptyline and paroxetine: comparable effects on heart rate variability (2001) J. Clin. Psychopharmacol., 21, pp. 238-239; Licht, C.M., de Geus, E.J., van Dyck, R., Penninx BW, B.W., Association between anxiety disorders and heart rate variability in The Netherlands Study of Depression and Anxiety (NESDA) (2009) Psychosom. Med., 71, pp. 508-518",Article,Scopus,2-s2.0-84925355904
"Liang S., Figtree G., Aiqun M., Ping Z.","GAPDH-knockdown reduce rotenone-induced H9C2 cells death via autophagy and anti-oxidative stress pathway",2015,"Toxicology Letters","234","3",,"162","171",,,10.1016/j.toxlet.2015.02.017,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924034044&partnerID=40&md5=44b8b5be02b51d7eabba801a7a2107d9","Department of Cardiology, The Second Affiliated Hospital of Wenzhou Medical UniversityWenzhou, Zhejiang Province, China; Department of Geriatrics and Neurology, The Second Affiliated Hospital, Wenzhou Medical UniversityWenzhou, Zhejiang, China; North Shore Heart Research Group, Kolling Institute of Medical Research, University of SydneySydney, Australia; Department of Cardiology, Royal North Shore HospitalSydney, Australia; Department of Cardiovascular Medicine, First Affiliated Hospital of Medical College of Xi'an Jiaotong UniversityXi'an, Shaanxi Province, China","Liang, S., Department of Cardiology, The Second Affiliated Hospital of Wenzhou Medical UniversityWenzhou, Zhejiang Province, China; Figtree, G., North Shore Heart Research Group, Kolling Institute of Medical Research, University of SydneySydney, Australia, Department of Cardiology, Royal North Shore HospitalSydney, Australia; Aiqun, M., Department of Cardiovascular Medicine, First Affiliated Hospital of Medical College of Xi'an Jiaotong UniversityXi'an, Shaanxi Province, China; Ping, Z., Department of Geriatrics and Neurology, The Second Affiliated Hospital, Wenzhou Medical UniversityWenzhou, Zhejiang, China","Background: GAPDH, well known for its house-keeping functions, has also been shown to be involved in cell injury, apoptosis and death under conditions of stress such as starvation, chemical injury and oxidative stress. This study examines the effect of GAPDH knockdown on cell injury in response to Rotenone. Methods: GAPDH was knocked down in H9C2 cardiomyoblasts using siRNA prior to exposure to rotenone (0. nM, 20. nM, 40. nM and 80. nM). Autophagy was detected by western blot for autophagy proteins (Beclin-1, Atg5, LC-3A/B and p62) and MDC staining for acidic substances. Pro-apoptosis protein and flow cytometry were used to assess cell apoptosis and death and intracellular ATP relative concentration was measured. Oxidant stress was assessed by measuring DCFH-DA, TBARS, GSH and SOD. Results: In this study, GAPDH-knockdown enhanced autophagy in rotenone-induced H9C2 cells, decreased oxidant stress and increased antioxidant pathways; and reduced cell apoptosis and death. Furthermore, GAPDH-knockdown preserved cell energy. Conclusion: siRNA-mediated GAPDH knockdown reduced rotenone-induced H9C2 cell death occurring via autophagy and anti-oxidative stress pathway. This study enriches the understanding of GAPDH pathophysiology role, and provides potential new therapeutic targets for cardiac disease states characterized by oxidative stress. © 2015 Elsevier Ireland Ltd.","Autophagy; Cell injury; GAPDH; H9C2 cell; Oxidative stress; Rotenone","Annangi, B., Bach, J., Vales, G., Rubio, L., Marcos, R., Hernández, A., Long-term exposures to low doses of cobalt nanoparticles induce cell transformation enhanced by oxidative damage (2014) Nanotoxicology; Baek, D., Jin, Y., Jeong, J.C., Lee, H.J., Moon, H., Lee, J., Shin, D., Yun, D.J., Suppression of reactive oxygen species by glyceraldehyde-3-phosphate dehydrogenase (2008) Phytochemistry, 69 (2), pp. 333-338; Colell, A., Ricci, J.E., Tait, S., Milasta, S., Maurer, U., Bouchier-Hayes, L., Fitzgerald, P., Green, D.R., GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation (2007) Cell, 129 (5), pp. 9839-9897; Donati, A., Cavallini, G., Paradiso, C., Vittorini, S., Pollera, M., Gori, Z., Bergamini, E., Age-related changes in the autophagic proteolysis of rat isolated liver cells: effects of antiaging dietary restrictions (2001) J. Gerontol A Biol. Sci. Med. Sci., 56 (9), pp. B375-B383; Eruslanov, E., Kusmartsev, S., Identification of ROS using oxidized DCFDA and flow-cytometry (2010) Methods Mol. Biol., 594, pp. 57-72; Gurusamy, N., Lekli, I., Gorbunov, N.V., Gherghiceanu, M., Popescu, L.M., Das, D.K., Cardioprotection by adaptation to ischaemia augments autophagy in association with BAG-1 protein (2009) J. Cell Mol. Med., 13 (2), pp. 373-387; Huang, J., Hao, L., Xiong, N., Cao, X., Liang, Z., Sun, S., Wang, T., Involvement of glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell apoptosis: relevance to protein misfolding and aggregation (2009) Brain Res., 1279, pp. 1-8; Jacquin, M.A., Chiche, J., Zunino, B., Bénéteau, M., Meynet, O., Pradelli, L.A., Marchetti, S., Ricci, J.E., GAPDH binds to active Akt leading to Bcl-xL increase and escape from caspase-independent cell death (2013) Cell Death Differ., 20 (8), pp. 1043-1054; Janko, C., Munoz, L., Chaurio, R., Maueröder, C., Berens, C., Lauber, K., Herrmann, M., Navigation to the graveyard-induction of various pathways of necrosis and their classification by flow cytometry (2013) Methods Mol. Biol., 1004, pp. 3-15; Krishnan, K., Ker, J.E., Mohammed, S.M., Nadarajah, V.D., Identification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a binding protein for a 68-kDa Bacillus thuringiensis parasporal protein cytotoxic against leukaemic cells (2010) J. Biomed. Sci., 17, p. 86; Lee, S.Y., Kim, J.H., Jung, H., Chi, S.W., Chung, S.J., Lee, C.K., Park, B.C., Park, S.G., Glyceraldehyde-3-phosphate, a glycolytic intermediate, prevents cells from apoptosis by lowering S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase (2012) J. Microbiol. Biotechnol., 22 (4), pp. 571-573; Mader, B.J., Pivtoraiko, V.N., Flippo, H.M., Klocke, B.J., Roth, K.A., Mangieri, L.R., Shacka, J.J., Rotenone inhibits autophagic flux prior to inducing cell death (2012) ACS Chem. Neurosci., 3 (12), pp. 1063-1072; Matsui, Y., Takagi, H., Qu, X., Abdellatif, M., Sakoda, H., Asano, T., Levine, B., Sadoshima, J., Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy (2007) Circ. Res., 100 (6), pp. 914-922; Martin, K.R., Barrett, J.C., Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity (2002) Hum. Exp. Toxicol., 21 (2), pp. 71-75; Mizushima, N., Levine, B., Cuervo, A.M., Klionsky, D.J., Autophagy fights disease through cellular self-digestion (2008) Nature, 451 (7182), pp. 1069-1075; Nakajima, H., Amano, W., Fukuhara, A., Kubo, T., Misaki, S., Azuma, Y.T., Inui, T., Takeuchi, T., An aggregate-prone mutant of human glyceraldehyde-3-phosphate dehydrogenase augments oxidative stress-induced cell death in SH-SY5Y cells (2009) Biochem. Biophys. Res. Commun., 390 (3), pp. 1066-1071; Nakamura, T., Lipton, S.A., According to GOSPEL: filling in the GAP (DH) of NO-mediated neurotoxicity (2009) Neuron, 63 (1), pp. 3-6; Ong, S.B., Gustafsson, A.B., New roles for mitochondria in cell death in the reperfused myocardium (2012) Cardiovasc. Res., 94 (2), pp. 190-196; Pierce, A., Mirzaei, H., Muller, F., De Waal, E., Taylor, A.B., Leonard, S., Van Remmen, H., Chaudhuri, A., GAPDH is conformationally and functionally altered in association with oxidative stress in mouse models of amyotrophic lateral sclerosis (2008) J. Mol. Biol., 382 (5), pp. 1195-1210; Sen, N., Hara, M.R., Kornberg, M.D., Cascio, M.B., Bae, B.I., Shahani, N., Thomas, B., Sawa, A., Nitric oxide-induced nuclea GAPDH activates p300/CBP and mediates apoptosis (2008) Nat. Cell Biol., 10 (7), pp. 866-873; Sen, N., Hara, M.R., Ahmad, A.S., Cascio, M.B., Kamiya, A., Ehmsen, J.T., Agrawal, N., Sawa, A., GOSPEL: a neuroprotective protein that binds to GAPDH upon s-nitrosylation (2009) Neuron, 63 (1), pp. 81-91; Tang, D., Kang, R., Livesey, K.M., Kroemer, G., Billiar, T.R., Van Houten, B., Zeh, H.J., III, Lotze, M.T., High-mobility group box 1 is essential for mitochondrial quality control (2011) Cell Metab., 13 (6), pp. 701-711; Tarze, A., Deniaud, A., Le Bras, M., Maillier, E., Molle, D., Larochette, N., Zamzami, N., Brenner, C., GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization (2007) Oncogene, 26 (18), pp. 2606-2620; Tiwari, R.V., Parajuli, P., Sylvester, P.W., γ-Tocotrienol-induced autophagy in malignant mammary cancer cells (2014) Exp. Biol. Med. (Maywood), 239 (1), pp. 33-44; Tristan, C., Shahani, N., Sedlak, T.W., Sawa, A., The diverse functions of GAPDH: views from different subcellular compartments (2011) Cell Signal., 23 (2), pp. 317-323; Xiong, N., Xiong, J., Jia, M., Liu, L., Zhang, X., Chen, Z., Huang, J., Wang, T., The role of autophagy in Parkinson's disease: rotenone-based modeling (2013) Behav. Brain Funct., 9, p. 13; You, B., Huang, S., Qin, Q., Yi, B., Yuan, Y., Xu, Z., Sun, J., Glyceraldehyde-3-phosphate dehydrogenase interacts with proapoptotic kinase mst1 to promote cardiomyocyte apoptosis (2013) PLoS One, 8 (3), p. e58697; Yu, W.H., Dorado, B., Figueroa, H.Y., Wang, L., Planel, E., Cookson, M.R., Clark, L.N., Duff, K.E., Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein (2009) Am. J. Pathol., 175 (2), pp. 736-747; Zhai, D., Li, S., Wang, M., Chin, K., Liu, F., Disruption of the GluR2/GAPDH complex protects against ischemia-induced neuronal damage (2013) Neurobiol. Dis., 54, pp. 392-403; Zorov, D.B., Filburn, C.R., Klotz, L.O., Zweier, J.L., Sollott, S.J., Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes (2000) J. Exp. Med., 192 (7), pp. 1001-1014",Article,Scopus,2-s2.0-84924034044
"Lipes M.A., Galderisi A.","Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes",2015,"Current Diabetes Reports","15","5",,"","",9,,10.1007/s11892-015-0598-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925954822&partnerID=40&md5=acd4b4214be5228d96158b040f2011fe","Joslin Diabetes Center, Harvard Medical School, 1 Joslin Place, Rm. 373Boston, MA, United States; Department of Woman’s and Child’s Health, University of Padua, Via Giustiniani, 3Padova, Italy","Lipes, M.A., Joslin Diabetes Center, Harvard Medical School, 1 Joslin Place, Rm. 373Boston, MA, United States; Galderisi, A., Joslin Diabetes Center, Harvard Medical School, 1 Joslin Place, Rm. 373Boston, MA, United States, Department of Woman’s and Child’s Health, University of Padua, Via Giustiniani, 3Padova, Italy","Patients with type 1 diabetes (T1D) suffer excess mortality from cardiovascular disease (CVD) that has persisted despite substantial reductions in microvascular complications. Although T1D and type 2 diabetes (T2D) are etiologically distinct, it has generally been assumed that CVD in T1D is “the same disease” as that found in T2D. Here, we review the most recent epidemiological and clinical studies on heart disease in T1D, highlighting differences between CVD in T1D and T2D. In addition, we discuss experimental and clinical evidence for a post-myocardial infarction (MI) autoimmune heart syndrome in T1D, including the development of diagnostic assays which we believe can, for the first time, differentiate between heart disease in T1D and T2D. We postulate that a clinically unrecognized form of chronic myocardial inflammation (“myocarditis”) triggered by MI contributes to the poor CVD outcomes in T1D. These findings provide a conceptual shift in our understanding of CVD in T1D and have important diagnostic and therapeutic implications. © 2015, The Author(s).","Autoimmunity; Cardiomyopathy; Cardiovascular disease; Heart failure; Immune tolerance; Myocardial infarction; Myocarditis; Type 1 diabetes","Authors Task Force, M., Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) (2013) Eur Heart J, 34, pp. 3035-3087; Harding, J.L., Shaw, J.E., Peeters, A., Guiver, T., Davidson, S., Magliano, D.J., Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997-2010 (2014) Diabetes Care, 37, pp. 2579-2586. , PID: 24947787; Laing, S.P., Swerdlow, A.J., Slater, S.D., Burden, A.C., Morris, A., Waugh, N.R., Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes (2003) Diabetologia, 46, pp. 760-765. , COI: 1:STN:280:DC%2BD3szgslWjsg%3D%3D, PID: 12774166; Lind M, Svensson AM, Kosiborod M, Gudbjornsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–82. This large population-based study was the first to show excess mortality due to CVD, even in T1D patients achieving on-target glycemic controlNathan, D.M., Cleary, P.A., Backlund, J.Y., Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes (2005) N Engl J Med, 353, pp. 2643-2653. , PID: 16371630; Nathan, D.M., Bayless, M., Cleary, P., Genuth, S., Lachin, J.M., Orchard, T.J., Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions (2013) Diabetes, 62, pp. 3976-3986. , COI: 1:CAS:528:DC%2BC3sXhvV2itL3F, PID: 24264395; Eckel, R.H., Eisenbarth, G.S., Autoimmune diabetes inflames the heart (2012) Sci Transl Med, 4, p. 138. , PID: 22700952; Libby, P., Nathan, D.M., Abraham, K., Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on cardiovascular complications of type 1 diabetes mellitus (2005) Circulation, 111, pp. 3489-3493. , PID: 15983263; de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014;130:1110–30. The most comprehensive and up-to-date review on the risk factors for CVD in T1DLibby, P., Inflammation in atherosclerosis (2002) Nature, 420, pp. 868-874. , COI: 1:CAS:528:DC%2BD38XpsFygtb8%3D, PID: 12490960; Ross, R., Atherosclerosis—an inflammatory disease (1999) N Engl J Med, 340, pp. 115-126. , COI: 1:STN:280:DyaK1M%2FptFSqtQ%3D%3D, PID: 9887164; Gottumukkala, R.V., Lv, H., Cornivelli, L., Wagers, A.J., Kwong, R.Y., Bronson, R., Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes (2012) Sci Transl Med, 4, p. 138. , PID: 22700956, The first demonstration that acute MI induces chronic myocardial autoimmunity in a humanized mouse model and patients with T1D. Shows for the first time how immune profiling can distinguish between CVD in T1D and T2D; Lv, H., Havari, E., Pinto, S., Gottumukkala, R.V., Cornivelli, L., Raddassi, K., Impaired thymic tolerance to alpha-myosin directs autoimmunity to the heart in mice and humans (2011) J Clin Invest, 121, pp. 1561-1573. , COI: 1:CAS:528:DC%2BC3MXksFahsLo%3D, PID: 21436590, This manuscript is the first demonstration of impaired central tolerance mechanisms in the pathogenesis of inflammatory heart disease (myocarditis) in mice and humans; Lv, H., Lipes, M.A., Role of impaired central tolerance to alpha-myosin in inflammatory heart disease (2012) Trends Cardiovasc Med, 22, pp. 113-117. , COI: 1:CAS:528:DC%2BC38XhsFSlsLrM, PID: 22902177; Taylor, J.A., Havari, E., McInerney, M.F., Bronson, R., Wucherpfennig, K.W., Lipes, M.A., A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8 (2004) J Immunol, 172, pp. 2651-2658. , COI: 1:CAS:528:DC%2BD2cXpslajtQ%3D%3D, PID: 14764740; Deckert, T., Poulsen, J.E., Larsen, M., Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications (1978) Diabetologia, 14, pp. 363-370. , COI: 1:STN:280:DyaE1c3hsFGnsA%3D%3D, PID: 669100; Secrest, A.M., Becker, D.J., Kelsey, S.F., Laporte, R.E., Orchard, T.J., Characterizing sudden death and dead-in-bed syndrome in type 1 diabetes: analysis from two childhood-onset type 1 diabetes registries (2011) Diabet Med, 28, pp. 293-300. , COI: 1:STN:280:DC%2BC3M7otlOkug%3D%3D, PID: 21309837; Secrest, A.M., Becker, D.J., Kelsey, S.F., Laporte, R.E., Orchard, T.J., Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes (2010) Diabetes, 59, pp. 3216-3222. , COI: 1:CAS:528:DC%2BC3MXlsVaktg%3D%3D, PID: 20739685; Soedamah-Muthu, S.S., Fuller, J.H., Mulnier, H.E., Raleigh, V.S., Lawrenson, R.A., Colhoun, H.M., High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database (2006) Diabetes Care, 29, pp. 798-804. , PID: 16567818; Hamman, R.F., Mortality risk in long-standing type 1 diabetes: hope and concern (2010) Diabetes, 59, pp. 2997-2998. , COI: 1:CAS:528:DC%2BC3MXlsVantQ%3D%3D, PID: 21115783; Pambianco, G., Costacou, T., Ellis, D., Becker, D.J., Klein, R., Orchard, T.J., The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience (2006) Diabetes, 55, pp. 1463-1469. , COI: 1:CAS:528:DC%2BD28XksFahtbY%3D, PID: 16644706; Marfella, R., Esposito, K., Giunta, R., Coppola, G., De Angelis, L., Farzati, B., Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia (2000) Circulation, 101, pp. 2247-2251. , COI: 1:CAS:528:DC%2BD3cXjvFSrt7c%3D, PID: 10811590; Livingstone, S.J., Looker, H.C., Hothersall, E.J., Wild, S.H., Lindsay, R.S., Chalmers, J., Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study (2012) PLoS Med, 9, p. 1001321. , PID: 23055834; Harjutsalo, V., Sjoberg, L., Tuomilehto, J., Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study (2008) Lancet, 371, pp. 1777-1782. , PID: 18502302; Skrivarhaug, T., Bangstad, H.J., Stene, L.C., Sandvik, L., Hanssen, K.F., Joner, G., Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway (2006) Diabetologia, 49, pp. 298-305. , COI: 1:STN:280:DC%2BD28%2FmvF2rtQ%3D%3D, PID: 16365724; Lind, M., Bounias, I., Olsson, M., Gudbjornsdottir, S., Svensson, A.M., Rosengren, A., Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study (2011) Lancet, 378, pp. 140-146. , PID: 21705065, This is the first study to show that heart failure is a major complication of T1D, occuring in relatively young patients and correlating with poor glycemic control; Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., Third universal definition of myocardial infarction (2012) Circulation, 126, pp. 2020-2035. , PID: 22923432; American Diabetes Association Clinical Practice Recommendations, Diagnosis and classification of diabetes mellitus (2013) Diabetes Care, 36, pp. 67-74; Retnakaran, R., Zinman, B., Type 1 diabetes, hyperglycaemia, and the heart (2008) Lancet, 371, pp. 1790-1799. , COI: 1:CAS:528:DC%2BD1cXmt1Ontr0%3D, PID: 18502304; Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease (2011) Nat Rev Immunol, 11, pp. 98-107. , COI: 1:CAS:528:DC%2BC3MXlsFehtQ%3D%3D, PID: 21233852; Grundy, S.M., Benjamin, I.J., Burke, G.L., Chait, A., Eckel, R.H., Howard, B.V., Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association (1999) Circulation, 100, pp. 1134-1146. , COI: 1:STN:280:DyaK1Mvgs1KjsA%3D%3D, PID: 10477542; Stadinski, B., Kappler, J., Eisenbarth, G.S., Molecular targeting of islet autoantigens (2010) Immunity, 32, pp. 446-456. , COI: 1:CAS:528:DC%2BC3cXlslSjurc%3D, PID: 20412755; Atkinson, M.A., Eisenbarth, G.S., Michels, A.W., Type 1 diabetes (2014) Lancet, 383, pp. 69-82. , PID: 23890997; Gale, E.A., The rise of childhood type 1 diabetes in the 20th century (2002) Diabetes, 51, pp. 3353-3361. , COI: 1:CAS:528:DC%2BD38Xptl2ntbw%3D, PID: 12453886; Atkinson, M.A., The pathogenesis and natural history of type 1 diabetes (2012) Cold Spring Harb Perspect Med, 2, pp. 1-18; Ziegler, A.G., Nepom, G.T., Prediction and pathogenesis in type 1 diabetes (2010) Immunity, 32, pp. 468-478. , COI: 1:CAS:528:DC%2BC3cXlslSju78%3D, PID: 20412757; Bingley, P.J., Christie, M.R., Bonifacio, E., Bonfanti, R., Shattock, M., Fonte, M.T., Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives (1994) Diabetes, 43, pp. 1304-1310. , COI: 1:STN:280:DyaK2M%2FhtFSksA%3D%3D, PID: 7926304; Verge, C.F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Jackson, R.A., Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies (1996) Diabetes, 45, pp. 926-933. , COI: 1:CAS:528:DyaK28Xkt1Wqs70%3D, PID: 8666144; Todd, J.A., Etiology of type 1 diabetes (2010) Immunity, 32, pp. 457-467. , COI: 1:CAS:528:DC%2BC3cXlslSju74%3D, PID: 20412756; Elliott, J.F., Liu, J., Yuan, Z.N., Bautista-Lopez, N., Wallbank, S.L., Suzuki, K., Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD mice (2003) Proc Natl Acad Sci U S A, 100, pp. 13447-13452. , COI: 1:CAS:528:DC%2BD3sXptFOitr4%3D, PID: 14570980; Verge, C.F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Chase, H.P., Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes (1996) J Autoimmun, 9, pp. 379-383. , COI: 1:STN:280:DyaK28vhtlyguw%3D%3D, PID: 8816974; Ziegler, A.G., Herskowitz, R.D., Jackson, R.A., Soeldner, J.S., Eisenbarth, G.S., Predicting type I diabetes (1990) Diabetes Care, 13, pp. 762-765. , COI: 1:STN:280:DyaK3czltlSmsw%3D%3D, PID: 2201499; Klein, L., Kyewski, B., Allen, P.M., Hogquist, K.A., Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see) (2014) Nat Rev Immunol, 14, pp. 377-391. , COI: 1:CAS:528:DC%2BC2cXotV2jt7o%3D, PID: 24830344; Pugliese, A., Zeller, M., Fernandez, A., Zalcberg, L.J., Bartlett, R.J., Ricordi C,  The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes (1997) Nat Genet, 15, pp. 293-297; Jaeckel, E., Lipes, M.A., Von Boehmer, H., Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes (2004) Nat Immunol, 5, pp. 1028-1035. , COI: 1:CAS:528:DC%2BD2cXnvFCgs7o%3D, PID: 15378058; Dressler, W., A post-myocardial infarction syndrome; preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis (1956) J Am Med Assoc, 160, pp. 1379-1383. , COI: 1:STN:280:DyaG28%2FlvV2itw%3D%3D, PID: 13306560; Mann, D.L., Activation of inflammatory mediators in heart failure (2004) Heart failure, a companion to Braunwald’s Heart Disease, pp. 159-180. , Mann DL, (ed), Saunders, Philadelphia:; Matzinger, P., An innate sense of danger (1998) Semin Immunol, 10, pp. 399-415. , COI: 1:STN:280:DyaK1M%2FksVOktQ%3D%3D, PID: 9840976; Entman, M.L., Michael, L., Rossen, R.D., Dreyer, W.J., Anderson, D.C., Taylor, A.A., Inflammation in the course of early myocardial ischemia (1991) FASEB J, 5, pp. 2529-2537. , COI: 1:CAS:528:DyaK3MXlsFKjuro%3D, PID: 1868978; Frangogiannis, N.G., The inflammatory response in myocardial injury, repair, and remodelling (2014) Nat Rev Cardiol, 11, pp. 255-265. , COI: 1:CAS:528:DC%2BC2cXkvF2mu70%3D, PID: 24663091; Nahrendorf, M., Pittet, M.J., Swirski, F.K., Monocytes: protagonists of infarct inflammation and repair after myocardial infarction (2010) Circulation, 121, pp. 2437-2445. , PID: 20530020; Bugger, H., Abel, E.D., Rodent models of diabetic cardiomyopathy (2009) Dis Models Mech, 2, pp. 454-466. , COI: 1:CAS:528:DC%2BD1MXhtlKqtb7F; Frangogiannis, N.G., The immune system and cardiac repair (2008) Pharmacol Res, 58, pp. 88-111; Bottazzo, G.F., Florin-Christensen, A., Doniach, D., Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies (1974) Lancet, 2, pp. 1279-1283. , COI: 1:STN:280:DyaE2M%2FksVCgsA%3D%3D, PID: 4139522; Pietropaolo, M., Towns, R., Eisenbarth, G.S., Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes (2012) Cold Spring Harb Perspect Med, 2, pp. 1-18; Lappe, J.M., Pelfrey, C.M., Tang, W.H., Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy (2008) J Card Fail, 14, pp. 521-530. , COI: 1:CAS:528:DC%2BD1cXpsVaksrY%3D, PID: 18672201; Galon, J., Pages, F., Marincola, F.M., Angell, H.K., Thurin, M., Lugli, A., Cancer classification using the Immunoscore: a worldwide task force (2012) J Transl Med, 10, p. 205. , PID: 23034130; Hundley, W.G., Bluemke, D.A., Finn, J.P., Flamm, S.D., Fogel, M.A., Friedrich, M.G., ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents (2010) Circulation, 121, pp. 2462-2508. , PID: 20479157; Kwong, R.Y., Sattar, H., Wu, H., Vorobiof, G., Gandla, V., Steel, K., Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction (2008) Circulation, 118, pp. 1011-1020. , PID: 18725488; Wu, E., Ortiz, J.T., Tejedor, P., Lee, D.C., Bucciarelli-Ducci, C., Kansal, P., Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study (2008) Heart, 94, pp. 730-736. , COI: 1:STN:280:DC%2BD1czhsFOqsA%3D%3D, PID: 18070953; Friedrich, M.G., Sechtem, U., Schulz-Menger, J., Holmvang, G., Alakija, P., Cooper, L.T., Cardiovascular magnetic resonance in myocarditis: a JACC White Paper (2009) J Am Coll Cardiol, 53, pp. 1475-1487. , PID: 19389557; Turkbey, E.B., Backlund, J.Y., Genuth, S., Jain, A., Miao, C., Cleary, P.A., Myocardial structure, function, and scar in patients with type 1 diabetes mellitus (2011) Circulation, 124, pp. 1737-1746. , PID: 21947298, This study from the DCCT/EDIC study group was the first to use CMR to study cardiac stucture and function in a large well phenotyped T1D population. They showed a relationship between poor glycemic control and aberrent LV function and also that only half of CMR-defined myocardial scars were in an ischemic distribution pattern, with a very low concordance between scar and clinical MI; Cooper, L.T., Jr., Myocarditis (2009) N Engl J Med, 360, pp. 1526-1538. , COI: 1:CAS:528:DC%2BD1MXltlSru7k%3D, PID: 19357408; Roberts, R., DeMello, V., Sobel, B.E., Deleterious effects of methylprednisolone in patients with myocardial infarction (1976) Circulation, 53, pp. 204-206. , COI: 1:STN:280:DyaE287jvVCrug%3D%3D, PID: 1253361; Eisenbarth, G.S., Type I diabetes mellitus. A chronic autoimmune disease (1986) N Engl J Med, 314, pp. 1360-1368. , COI: 1:STN:280:DyaL283gtlCrsw%3D%3D, PID: 3517648",Review,Scopus,2-s2.0-84925954822
"Pan H.-C., Sheu W.H.-H., Lee W.-J., Lee W.-L., Liao Y.-C., Wang K.-Y., Lee I.-T., Wang J.-S., Liang K.-W.","Coronary severity score and C-reactive protein predict major adverse cardiovascular events in patients with stable coronary artery disease (from the Taichung CAD study)",2015,"Clinica Chimica Acta","445",,,"93","100",,,10.1016/j.cca.2015.03.029,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925967621&partnerID=40&md5=14684b0e0a49459e490cbc953705c671","Cardiovascular Center, Taichung Veterans General HospitalTaichung, Taiwan; School of Medicine, National Yang Ming UniversityTaipei, Taiwan; School of Medicine, National Defense Medical CenterTaipei, Taiwan; Division of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General HospitalTaichung, Taiwan; Institute of Biomedical Sciences, National Chung Hsing UniversityTaichung, Taiwan; Department of Medical Research, Taichung Veterans General HospitalTaichung, Taiwan; Tunghai UniversityTaichung, Taiwan; Taichung Tzu Chi HospitalTaichung, Taiwan; School of Medicine, Tzu Chi UniversityHualien, Taiwan; Department of Medicine, China Medical UniversityTaichung, Taiwan; Department of Medicine, Chung Shan Medical UniversityTaichung, Taiwan","Pan, H.-C., Cardiovascular Center, Taichung Veterans General HospitalTaichung, Taiwan, School of Medicine, National Yang Ming UniversityTaipei, Taiwan, School of Medicine, National Defense Medical CenterTaipei, Taiwan; Sheu, W.H.-H., School of Medicine, National Yang Ming UniversityTaipei, Taiwan, School of Medicine, National Defense Medical CenterTaipei, Taiwan, Division of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General HospitalTaichung, Taiwan, Institute of Biomedical Sciences, National Chung Hsing UniversityTaichung, Taiwan; Lee, W.-J., Department of Medical Research, Taichung Veterans General HospitalTaichung, Taiwan, Tunghai UniversityTaichung, Taiwan; Lee, W.-L., Cardiovascular Center, Taichung Veterans General HospitalTaichung, Taiwan, School of Medicine, National Yang Ming UniversityTaipei, Taiwan; Liao, Y.-C., Cardiovascular Center, Taichung Veterans General HospitalTaichung, Taiwan, School of Medicine, National Yang Ming UniversityTaipei, Taiwan, Taichung Tzu Chi HospitalTaichung, Taiwan, School of Medicine, Tzu Chi UniversityHualien, Taiwan; Wang, K.-Y., Cardiovascular Center, Taichung Veterans General HospitalTaichung, Taiwan, School of Medicine, National Yang Ming UniversityTaipei, Taiwan, School of Medicine, National Defense Medical CenterTaipei, Taiwan, Department of Medicine, China Medical UniversityTaichung, Taiwan, Department of Medicine, Chung Shan Medical UniversityTaichung, Taiwan; Lee, I.-T., School of Medicine, National Yang Ming UniversityTaipei, Taiwan, Division of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General HospitalTaichung, Taiwan, Department of Medicine, Chung Shan Medical UniversityTaichung, Taiwan; Wang, J.-S., School of Medicine, National Yang Ming UniversityTaipei, Taiwan, Division of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General HospitalTaichung, Taiwan; Liang, K.-W., Cardiovascular Center, Taichung Veterans General HospitalTaichung, Taiwan, School of Medicine, National Yang Ming UniversityTaipei, Taiwan, Department of Medicine, China Medical UniversityTaichung, Taiwan","Background: Whether angiographic coronary severity really predicts future major adverse cardiovascular events (MACEs) in patients with coronary artery disease (CAD) is uncertain. Few studies have compared the efficacy of SYNTAX, Gensini and Jeopardy scores in predicting MACE in stable CAD. Methods: We collected data of MACE, including all-cause mortality, all strokes, new myocardial infarction and unplanned repeat revascularization, in subjects with stable CAD from our catheterization databank. Coronary severity was graded with SYNTAX, Gensini and Jeopardy scoring systems. Results: During a median follow-up period of 42. months, 39 out of the 181 subjects developed at least 1 MACE. Those with MACE had a significantly higher baseline high sensitivity C-reactive protein (hs-CRP) (p = 0.025). Multivariate analysis showed that coronary severity score, hs-CRP and diabetes mellitus were significant predictors for MACE. Kaplan-Meier estimates showed a significant difference in MACE-free rates between SYNTAX binary scores (≥ 15 vs < 15, p = 0.043), Gensini binary scores (≥ 36 vs < 36, p = 0.048) and Jeopardy binary scores (≥ 4 vs < 4, p = 0.001). Conclusion: Coronary severity score, hs-CRP and diabetes mellitus independently predicted MACE in patients with stable CAD. The Jeopardy score is simple to calculate and as effective for predicting MACE in stable CAD as the complex SYNTAX score. © 2015 Elsevier B.V.","Coronary artery disease (CAD); Diabetes mellitus; Gensini score; High-sensitivity C-reactive protein (hs-CRP); Jeopardy score; SYNTAX score","Califf, R.M., Phillips, H.R., Hindman, M.C., Prognostic value of a coronary artery jeopardy score (1985) J Am Coll Cardiol, 5, pp. 1055-1063; Serruys, P.W., Morice, M.C., Kappetein, A.P., Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease (2009) N Engl J Med, 360, pp. 961-972; Gensini, G.G., A more meaningful scoring system for determining the severity of coronary heart disease (1983) Am J Cardiol, 51, p. 606; Neeland, I.J., Patel, R.S., Eshtehardi, P., Coronary angiographic scoring systems: an evaluation of their equivalence and validity (2012) Am Heart J, 164, pp. 547-552; Califf, R.M., Armstrong, P.W., Carver, J.R., D'Agostino, R.B., Strauss, W.E., 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management (1996) J Am Coll Cardiol, 27, pp. 1007-1019; Ndrepepa, G., Tada, T., Fusaro, M., Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease (2012) Clin Res Cardiol, 101, pp. 1003-1011; Goto, K., Lansky, A.J., Fahy, M., Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy (2010) Circulation, 121, pp. 853-862; Little, W.C., Constantinescu, M., Applegate, R.J., Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? (1988) Circulation, 78, pp. 1157-1166; Ambrose, J.A., Tannenbaum, M.A., Alexopoulos, D., Angiographic progression of coronary artery disease and the development of myocardial infarction (1988) J Am Coll Cardiol, 12, pp. 56-62; Libby, P., Mechanisms of acute coronary syndromes (2013) N Engl J Med, 369, pp. 883-884; Little, W.C., Downes, T.R., Applegate, R.J., The underlying coronary lesion in myocardial infarction: implications for coronary angiography (1991) Clin Cardiol, 14, pp. 868-874; Sianos, G., Morel, M.A., Kappetein, A.P., The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease (2005) EuroIntervention, 1, pp. 219-227; Serruys, P.W., Onuma, Y., Garg, S., 5-Year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions (2010) J Am Coll Cardiol, 55, pp. 1093-1101; Capodanno, D., Di Salvo, M.E., Cincotta, G., Miano, M., Tamburino, C., Tamburino, C., Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease (2009) Circ Cardiovasc Interv, 2, pp. 302-308; Frey, N., Dietz, A., Kurowski, V., Angiographic correlates of a positive troponin T test in patients with unstable angina (2001) Crit Care Med, 29, pp. 1130-1136; Liang, K.W., Sheu, W.H., Lee, W.L., Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand (2006) Can J Cardiol, 22, pp. 691-696; Ridker, P.M., Buring, J.E., Shih, J., Matias, M., Hennekens, C.H., Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women (1998) Circulation, 98, pp. 731-733; Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men (1997) N Engl J Med, 336, pp. 973-979; Liuzzo, G., Biasucci, L.M., Gallimore, J.R., The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina (1994) N Engl J Med, 331, pp. 417-424; Morrow, D.A., Rifai, N., Antman, E.M., C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction (1998) J Am Coll Cardiol, 31, pp. 1460-1465; Sabatine, M.S., Morrow, D.A., Jablonski, K.A., Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease (2007) Circulation, 115, pp. 1528-1536; Ndrepepa, G., Braun, S., Tada, T., Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy (2014) Cardiovasc Revasc Med, 15, pp. 131-136; Libby, P., Tabas, I., Fredman, G., Fisher, E.A., Inflammation and its resolution as determinants of acute coronary syndromes (2014) Circ Res, 114, pp. 1867-1879; Mohr, F.W., Morice, M.C., Kappetein, A.P., Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial (2013) Lancet, 381, pp. 629-638; Liang, K.W., Lee, W.J., Lee, W.L., Chen, Y.T., Ting, C.T., Sheu, W.H., Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels (2008) Clin Chim Acta, 388, pp. 41-45; Liang, K.W., Tsai, I.C., Lee, W.J., MRI measured epicardial adipose tissue thickness at the right AV groove differentiates inflammatory status in obese men with metabolic syndrome (2012) Obesity (Silver Spring), 20, pp. 525-532; Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge (1972) Clin Chem, 18, pp. 499-502; Liao, Y.C., Liang, K.W., Lee, W.J., Leptin to adiponectin ratio as a useful predictor for cardiac syndrome X (2013) Biomarkers, 18, pp. 44-50; Kaptoge, S., Di Angelantonio, E., Pennells, L., C-reactive protein, fibrinogen, and cardiovascular disease prediction (2012) N Engl J Med, 367, pp. 1310-1320; Brooks, M.M., Jones, R.H., Bach, R.G., Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators (2000) Circulation, 101, pp. 2682-2689; Lenzen, M., Ryden, L., Ohrvik, J., Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart (2006) Eur Heart J, 27, pp. 2969-2974",Article,Scopus,2-s2.0-84925967621
"Cabrera-Bueno F., Medina-Palomo C., Ruiz-Salas A., Flores A., Rodriguez-Losada N., Barrera A., Jimenez-Navarro M., Alzueta J.","Serum levels of interleukin-2 predict the recurrence of atrial fibrillation after pulmonary vein ablation",2015,"Cytokine","73","1",,"74","78",,,10.1016/j.cyto.2015.01.026,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924075148&partnerID=40&md5=ecd20c3ad70054920d6e1b38b550c2c7","UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain","Cabrera-Bueno, F., UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain; Medina-Palomo, C., UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain; Ruiz-Salas, A., UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain; Flores, A., UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain; Rodríguez-Losada, N., UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain; Barrera, A., UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain; Jiménez-Navarro, M., UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain; Alzueta, J., UGC del Corazón, Servicio de Cardiología, Universidad de Málaga, Hospital Clínico Universitario Virgen de la Victoria de Málaga, IMIBA (Instituto de Investigación Biomédica de Málaga), Spain","Aims: Interleukin-2 has a significant antitumor activity in some types of cancer, and has been associated with the development of atrial fibrillation (AF). In addition, IL-2 serum levels in recent onset AF have been related with pharmaceutical cardioversion outcomes. We evaluated the hypothesis that a relationship exists between inflammation and the outcome of catheter ablation of AF. Methods: We studied 44 patients with paroxysmal AF who underwent catheter ablation. Patients with structural heart disease, coronary artery or valve disease, active inflammatory disease, known or suspected neoplasm, endocrinopathies, or exposure to anti-inflammatory drugs were excluded. All study participants underwent evaluation with a standardized protocol, including echocardiography, and cytokine levels of interleukin-2, interleukin-4, interleukin-6, interleukin-10, tumour necrosis factor-alpha, and gamma-interferon determination before procedure. Clinical and electrocardiographic follow-up were performed with Holter-ECG at 3, 6 and 12. months in order to know if sinus rhythm was maintained. Results: After catheter ablation of the 44 patients included (53. ±. 10. years, 27.3% female), all patients returned to sinus rhythm. During the first year of follow-up seven patients (15.9%) experienced recurrence of AF. The demographics, clinical and echocardiographic features, and pharmacological treatments of these patients were similar to those who maintained sinus rhythm. The only independent factor predictive of recurrence of AF was an elevated level of IL-2 (OR 1.18, 95% CI 1.12-1.38). Conclusions: High serum levels of interleukin-2, a pro-inflammatory non-vascular cytokine, are associated with the recurrence of AF in patients undergoing catheter ablation. © 2015 Elsevier Ltd.","Atrial fibrillation; Catheter ablation; Cytokine; Inflammation; Interleukin 2","Patel, P., Dokainish, H., Tsai, P., Lakkis, N.J., Update on the association of inflammation and atrial fibrillation (2010) Cardiovasc Electrophysiol, 21, pp. 1064-1070; Kaski, J.C., Arrebila-Moreno, A.L., Inflammation and thrombosis in atrial fibrilation (2011) Rev Esp Cardiol, 64, pp. 551-553; Olejniczak, K., Kasprzak, A., Biological properties of interleukin 2 and its role in pathogenesis of selected diseases - a review (2008) Med Sci Monit, 14, pp. RA179-RA189; Guglin, M., Aljayeh, M., Saiyad, S., Ali, R., Curtis, A.B., Introducing a new entity: chemotherapy-induced arrhythmia (2009) Europace, 11, pp. 1579-1586; Guo, Y., Lip, G.Y.H., Apostolakis, S., Inflammation in atrial fibrillation (2012) JACC, 60, pp. 2263-2270; Dutcher, J.P., Fisher, R.I., Weiss, G., Aronson, F., Margolin, K., Louie, A., Outpatient subcutaneous interleukin-2 and interferon-alpha for metastático renal cell cancer: five years-year-follow-up of the Cytokine Working Group Study (1997) Cancer J Sci Am, 3, pp. 157-162; Rizos, I., Tsiodras, S., Rigopoulos, A.G., Dragomanivits, S., Kalogeropoulos, A.S., Papathanasiou, S., Interleukin-2 serum levels variations in recent honest atrial fibrillation are related with cardioversion outcome (2007) Cytokine, 40, pp. 157-164; Hak, L., Mysliwska, J., Wieckiewicz, J., Szyndler, K., Siebert, J., Rogowski, J., Interleukin-2 as a predictor or early postoperative atrial fibrillation alter cardiopulmonary bypass graft (CABG) (2009) J Interferon Citokine Res, 29, pp. 327-332; Fuster, V., Ryden, L.E., Cannom, D.S., Crijns, H.J., Curtis, A.B., Ellenbogen, K.A., ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (2006) J Am Coll Cardiol, 48, pp. 854-906; Marcus, G.M., Smith, L.M., Ordovas, K., Scheinman, M.M., Kim, A.M., Badhwar, N., (2010) Heart Rhythm, 7 (2), pp. 149-154; Hof, I., Arbab-Zadeh, A., Dong, J., Scherr, D., Chilukuri, K., Calkins, H., Validation of a simplified method to determine left atrial volume by computed tomography in patients with atrial fibrillation (2008) Am J Cardiol, 102 (11), pp. 1567-1570; Takagi, Y., Ehara, S., Okuyama, T., Shirai, N., Yamashita, H., Sugioka, K., Comparison of determinations of left atrial volume by the biplane area-length and Simpson's methods using 64-slice computed tomography (2009) J Cardiol, 53 (2), pp. 257-264; Watson, T., Shantsila, E., Lip, G.Y., Mechanisms of thrombogenesis in atrial fibrillation: Virchow's trial revisited (2009) Lancet, 373, pp. 155-166; Patel, P., Dokainish, H., Tsai, P., Lakkis, N., Update on the association of inflammation and atrial fibrillation (2010) J Cardiovasc Electrophysiol, 21, pp. 1064-1970; Friedrichs, K., Klinke, A., Baldus, S., Inflammatory pathways underlying atrial fibrillation (2011) Trend Molec Med, 17, pp. 556-563; Devaraj, S., Singh, U., Jialal, I., The evolving role of C-reactive proteína in atherothrombosis (2009) Clin Chem, 55, pp. 229-238; Rizos, I., Rigopoulos, A.G., Kalogeropoulos, A.S., Tsiodras, S., Dragomanovits, S., Sakadakis, E.A., Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive proteína in cardioversion and long term recurrence (2010) J Hum Hypertens, 24, pp. 447-457; Youssef, G., Links, M., The prevention and Management of cardiovascular complications of chemotherapy in patients with cancer (2005) Am J Cardiovasc Drugs, 5, pp. 223-243; Lee, R.E., Lotze, M.T., Skibber, J.M., Tucker, E., Bonow, R.O., Ognibene, F.P., Cardiorespiratory effects of immunotherapy with interleukin-2 (1989) J Clin Oncol, 7, pp. 7-20",Article,Scopus,2-s2.0-84924075148
"Li X., Sundquist J., Hamano T., Zoller B., Sundquist K.","Neighbourhood Deprivation, Individual-Level and Familial-Level Socio-demographic Factors and Risk of Congenital Heart Disease: A Nationwide Study from Sweden",2015,"International Journal of Behavioral Medicine",,,,"","",9,,10.1007/s12529-015-9488-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928673989&partnerID=40&md5=3aeda5f9eb6f30f7284aad9978c98b86","Center for Primary Health Care Research, Lund University/Region Skåne CRC, Building 28, Floor 11, Jan Waldenströms gata 35, Skåne University HospitalMalmö, Sweden; Stanford Prevention Research Center, Stanford University School of MedicineStanford, CA, United States; Centre for Community-based Health Research and Education (COHRE), Organization for the Promotion of Project Research, Shimane UniversityIzumo, Japan","Li, X., Center for Primary Health Care Research, Lund University/Region Skåne CRC, Building 28, Floor 11, Jan Waldenströms gata 35, Skåne University HospitalMalmö, Sweden; Sundquist, J., Center for Primary Health Care Research, Lund University/Region Skåne CRC, Building 28, Floor 11, Jan Waldenströms gata 35, Skåne University HospitalMalmö, Sweden, Stanford Prevention Research Center, Stanford University School of MedicineStanford, CA, United States; Hamano, T., Centre for Community-based Health Research and Education (COHRE), Organization for the Promotion of Project Research, Shimane UniversityIzumo, Japan; Zöller, B., Center for Primary Health Care Research, Lund University/Region Skåne CRC, Building 28, Floor 11, Jan Waldenströms gata 35, Skåne University HospitalMalmö, Sweden; Sundquist, K., Center for Primary Health Care Research, Lund University/Region Skåne CRC, Building 28, Floor 11, Jan Waldenströms gata 35, Skåne University HospitalMalmö, Sweden, Stanford Prevention Research Center, Stanford University School of MedicineStanford, CA, United States","Objectives: The purpose of the study is to examine whether there is an association between neighbourhood deprivation and incidence of congenital heart disease (CHD), after accounting for family- and individual-level potential confounders. Methods: All children aged 0 to 11 years and living in Sweden (n = 748,951) were followed between January 1, 2000 and December 31, 2010. Data were analysed by multilevel logistic regression, with family- and individual-level characteristics at the first level and level of neighbourhood deprivation at the second level. Results: During the study period, among a total of 748,951 children, 1499 (0.2 %) were hospitalised with CHD. Age-adjusted cumulative hospitalisation rates for CHD increased with increasing level of neighbourhood deprivation. In the study population, 1.8 per 1000 and 2.2 per 1000 children in the least and most deprived neighbourhoods, respectively, were hospitalised with CHD. The incidence of hospitalisation for CHD increased with increasing neighbourhood-level deprivation across all family and individual-level socio-demographic categories. The odds ratio (OR) for hospitalisation for CHD for those living in high-deprivation neighbourhoods versus those living in low-deprivation neighbourhoods was 1.23 (95 % confidence interval (CI) = 1.04–1.46). In the full model, which took account for age, paternal and maternal individual-level socio-economic characteristics, comorbidities (e.g. maternal type 2 diabetes, OR = 3.03; maternal hypertension, OR = 2.01), and family history of CHD (OR = 3.27), the odds of CHD were slightly attenuated but did not remain significant in the most deprived neighbourhoods (OR = 1.20, 95 % CI = 0.99–1.45, p = 0.057). Conclusions: This study is the largest so far on neighbourhood influences on CHD, and the results suggest that deprived neighbourhoods have higher rates of CHD, which represents important clinical knowledge. However, the association does not seem to be independent of individual- and family-level characteristics. © 2015 International Society of Behavioral Medicine","Congenital heart disease; Incidence; Multilevel modelling; Neighbourhood-level deprivation; Socio-demographic factors",,Article in Press,Scopus,2-s2.0-84928673989
"Holmer M., Sandberg F., Solem K., Grigonyte E., Olde B., Sornmo L.","Extracting a cardiac signal from the extracorporeal pressure sensors of a hemodialysis machine",2015,"IEEE Transactions on Biomedical Engineering","62","5", 6998042,"1305","1315",,,10.1109/TBME.2014.2385964,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928628544&partnerID=40&md5=448b11975818383ca3bdad78953367d0","Department of Biomedical Engineering, Center of Integrative Electrocardiology (CIEL), Sweden; Gambro Lundia ABLund SE-221 00, Sweden; Department OfBiomedical Engineering and Center of Integrative Electrocardiology (CIEL), Lund University, Sweden","Holmer, M., Department of Biomedical Engineering, Center of Integrative Electrocardiology (CIEL), Sweden; Sandberg, F., Department of Biomedical Engineering, Center of Integrative Electrocardiology (CIEL), Sweden; Solem, K., Gambro Lundia ABLund SE-221 00, Sweden; Grigonyte, E., Gambro Lundia ABLund SE-221 00, Sweden; Olde, B., Department OfBiomedical Engineering and Center of Integrative Electrocardiology (CIEL), Lund University, Sweden; Sornmo, L., Department of Biomedical Engineering, Center of Integrative Electrocardiology (CIEL), Sweden","Although patients undergoing hemodialysis treatment often suffer from cardiovascular disease, monitoring of cardiac rhythm is not performed on a routine basis. Without requiring any extra sensor, this study proposes a method for extracting a cardiac signal from the built-in extracorporeal venous pressure sensor of the hemodialysis machine. The extraction is challenged by the fact that the cardiac component is much weaker than the pressure component caused by the peristaltic blood pump. To further complicate the extraction problem, the cardiac component is difficult to separate when the pump and heart rates coincide. The proposed method estimates a cardiac signal by subtracting an iteratively refined blood pump model signal from the signal measured at the extracorporeal venous pressure sensor. The method was developed based on simulated pressure signals, and evaluated on clinical pressure signals acquired during hemodialysis treatment. The heart rate estimated from the clinical pressure signal was compared to that derived from a photoplethysmographic reference signal, resulting in a difference of 0.07 \pm 0.84 beats/min. The accuracy of the heartbeat occurrence times was studied for different strengths of the cardiac component, using both clinical and simulated signals. The results suggest that the accuracy is sufficient for analysis of heart rate and certain arrhythmias. © 1964-2012 IEEE.","blood access pressure simulator; cardiac pressure signal; extracorporeal pressure sensors; fistula; Heart rate; hemodialysis","Patient mortality and survival (1996) Amer. J. Kidney Dis, 28, pp. 79-92. , US Renal Data System; Burton, J.O., Hemodialysis-induced left ventricular dysfunction is associated with an increase in ventricular arrhythmia (2008) Renal Failure, 30, pp. 701-709; Selby, N.M., McIntyre, C.W., The acute cardiac effects of dialysis (2007) Semin. Dial, 20, pp. 220-228; Sornmo, L., Noninvasive techniques for prevention of intradialytic hypotension (2012) IEEE Rev. Biomed. Eng, 5 (1), pp. 45-59. , Jul; Tateno, K., Glass, L., Automatic detection of atrial fibrillation using the coefficient of variation and density histograms of RR and deltaRR intervals (2001) Med. Biol. Eng. Comput, 39, pp. 664-671; Dash, S., Automatic real time detection of atrial fibrillation (2009) Ann. Biomed. Eng, 37, pp. 1701-1709; Huang, C., A novel method for detection of the transition between atrial fibrillation and sinus rhythm (2010) IEEE Trans. Biomed. Eng, 58 (4), pp. 1113-1119. , Apr; Moissl, U., Continuous observation and analysis of heart rate during hemodialysis treatment (1999) Proc. Eur. Med. Biol. Eng. Conf, 37, pp. S558-S559; Moissl, U., Heart rate monitoring during hemodialysis treatment (2002) Proc. Eur. Med. Biol. Eng. Conf, 3, pp. 584-585; Polaschegg, H.-D., Method formeasuring and indicating in liquid systems of medical devices, and device for carrying out this method (1993) Eur Patent 0, 330, p. 761. , Sep. 8; Hertz, T., Method and arrangement for detecting the condition of a blood vessel access (2000) U.S Patent 6, 90, p. 048. , Jul. 18; Polaschegg, H.D., Venous needle dislodgement: The pitfalls of venous pressure measurement and possible alternatives, a review (2010) J. Ren. Care, 36, pp. 41-48; Segelmark, M., Successful detection of venous needle dislodgement using extracted heart pulses obtained from venous pressure monitoring (2010) Proc. Amer. Soc. Nephrol. Kidney, 21, p. 241A; Lazaro, J., Pulse rate variability analysis for discrimination of sleepapnea-related decreases in the amplitude fluctuations of pulse photoplethysmographic signal in children (2014) IEEE J. Biomed. Health Inform, 18 (1), pp. 240-246. , Jan; Allen, J., Photoplethysmography and its application in clinical physiological measurement (2007) Physiol. Meas, 28, pp. R1-R39; Holmer, M., Determining heart activity present in the pressure sensors of a dialysis machine (2013) Comput. Cardiol, 40, pp. 217-220; Madsen, H., (2008) Time Series Analysis, , London, U.K Chapman&Hall/CRC; Sornmo, L., Laguna, P., (2005) Bioelectrical Signal Processing in Cardiac and Neurological Applications, , Amsterdam, The Netherlands Elsevier; Mateo, J., Laguna, P., Improved heart rate variability signal analysis from the beat occurrence times according to the IPFM model (2000) IEEE Trans. Biomed. Eng, 47 (8), pp. 997-1009. , Aug; Merri, M., Sampling frequency of the electrocardiogram for spectral analysis of the heart rate variability (1990) IEEE Trans. Biomed. Eng, 37 (1), pp. 99-106. , Jan; Woody, C.D., Characterization of an adaptive filter for the analysis of variable latency neuroelectric signals (1967) Med. Biol. Eng, 5, pp. 539-553; Cabasson, A., Meste, O., Time delay estimation:Anewinsight into the Woody's method (2008) IEEE Signal Proc. Lett, 15 (12), pp. 573-576. , Dec. 01; Abe, S., Electrocardiographic abnormalities in patients receiving hemodialysis (1996) Amer. Heart J, 131, pp. 1137-1144; Santoro, A., Electrophysiological response to dialysis: The role of dialysate potassium content and profiling (2005) Contrib. Nephrol, 149, pp. 295-305; Solem, K., Prediction of intradialytic hypotension using photoplethysmography (2010) IEEE Trans. Biomed. Eng, 57 (7), pp. 1611-1619. , Jul",Article,Scopus,2-s2.0-84928628544
"Yap S.-C.","Atrial fibrillation and stroke after atrial septal defect closure. Is earlier closure warranted?",2015,"Heart","101","9",,"661","662",,,10.1136/heartjnl-2015-307554,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927638395&partnerID=40&md5=489c7606cedc0ff2374e796fce443e67","Department of Cardiology, Erasmus Medical Centre, P.O. Box 204Rotterdam, Netherlands","Yap, S.-C., Department of Cardiology, Erasmus Medical Centre, P.O. Box 204Rotterdam, Netherlands",[No abstract available],,"Bouchardy, J., Therrien, J., Pilote, L., Atrial arrhythmias in adults with congenital heart disease (2009) Circulation, 120, pp. 1679-1686; Attie, F., Rosas, M., Granados, N., Surgical treatment for secundum atrial septal defects in patients >40 years old: A randomized clinical trial (2001) J Am Coll Cardiol, 38, pp. 2035-2042; Gatzoulis, M.A., Freeman, M.A., Siu, S.C., Atrial arrhythmia after surgical closure of atrial septal defects in adults (1999) N Engl J Med, 340, pp. 839-846; Murphy, J.G., Gersh, B.J., McGoon, M.D., Long-term outcome after surgical repair of isolated atrial septal defect: Follow-up at 27 to 32 years (1990) N Engl J Med, 323, pp. 1645-1650; Roos-Hesselink, J.W., Meijboom, F.J., Spitaels, S.E., Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age: A prospective follow-up study of 21-33 years (2003) Eur Heart J, 24, pp. 190-197; Opotowsky, A.R., Landzberg, M.J., Kimmel, S.E., Percutaneous closure of patent foramen ovale and atrial septal defect in adults: The impact of clinical variables and hospital procedure volume on in-hospital adverse events (2009) Am Heart J, 157, pp. 867-874; Silversides, C.K., Haberer, K., Siu, S.C., Predictors of atrial arrhythmias after device closure of secundum type atrial septal defects in adults (2008) Am J Cardiol, 101, pp. 683-687; Vecht, J.A., Saso, S., Rao, C., Atrial septal defect closure is associated with a reduced prevalence of atrial tachyarrhythmia in the short to medium term: A systematic review and meta-analysis (2010) Heart, 96, pp. 1789-1797; Nyboe, C., Olsen, M.S., Nielsen-Kudsk, J.E., Atrial fibrillation and stroke in adult patients with atrial septal defect and the long-term effect of closure (2015) Heart, 101, pp. 706-711",Editorial,Scopus,2-s2.0-84927638395
"Punzi L., Lapadula G., Mathieu A.","Efficacy and safety of certolizumab pegol in rheumatoid arthritis: Meeting rheumatologists' requirements in routine clinical practice",2014,"BioDrugs","28","1", 40259,"25","37",,,10.1007/s40259-013-0065-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927656702&partnerID=40&md5=fb4d8776b73e3b8bee8bf41e9eebb200","Rheumatology Unit, Department of Medicine DIMED, University of PadovaPadua, Italy; Rheumatology Unit of Interdisciplinary Department of Medicine (DIM), University of BariBari, Italy; Rheumatology Unit, Department of Medical Sciences, University of CagliariCagliari, Italy","Punzi, L., Rheumatology Unit, Department of Medicine DIMED, University of PadovaPadua, Italy; Lapadula, G., Rheumatology Unit of Interdisciplinary Department of Medicine (DIM), University of BariBari, Italy; Mathieu, A., Rheumatology Unit, Department of Medical Sciences, University of CagliariCagliari, Italy","Abstract Certolizumab pegol, a pegylated Fab′ anti-tumour necrosis factor (TNF)-α agent, has shown efficacy in patients with rheumatoid arthritis (RA) unresponsive to previous treatment. In key randomised controlled trials involving patients with moderate to severe RA and an inadequate response to methotrexate or one or more disease-modifying antirheumatic drug (DMARD), the efficacy of certolizumab pegol, as monotherapy or with methotrexate, was similar to that reported in other anti-TNF clinical studies, with 60 % or fewer of patients achieving American College of Rheumatology 20 % improvement in RA. Rapid clinical response was also seen, with significant differences evident at week 1, and efficacy maintained at study end and in open-label extensions. Adding certolizumab pegol to non-biological DMARDs is efficacious in other RA populations. In the CERTAIN study, certolizumab increased remission rates, prevented disease worsening and improved work productivity and daily activity in patients with low to moderate RA. In the REALISTIC study, rapid and consistent clinical responses were observed in a diverse group of anti-TNF-eligible RA patients representing those seen in clinical practice. In the RAPID studies, rapid and sustained reduction in RA signs and symptoms, inhibition of structural joint damage progression, and improved physical function were seen with certolizumab pegol plus methotrexate versus methotrexate alone in RA patients with an incomplete response to methotrexate. Certolizumab pegol was generally well-tolerated in clinical trials, although long-term observational data are not yet available. Current data suggest that certolizumab pegol suits a 'treat to target' approach, providing rapid and sustained improvements in RA signs and symptoms, and beneficial effects on workplace and home productivity in patients with RA. © Springer International Publishing Switzerland 2014.",,"Firestein, G.S., Evolving concepts of rheumatoid arthritis (2003) Nature, 423 (6937), pp. 356-361. , 1:CAS:528:DC%2BD3sXjs1ynu7c%3D 12748655; Symmons, D., Turner, G., Webb, R., Asten, P., Barrett, E., Lunt, M., The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century (2002) Rheumatology, 41 (7), pp. 793-800. , 1:STN:280:DC%2BD38zltlSrsA%3D%3D 12096230; McInnes, I.B., Schett, G., Cytokines in the pathogenesis of rheumatoid arthritis (2007) Nature Rev Immunol, 7 (6), pp. 429-442. , 1:CAS:528:DC%2BD2sXls1Kgt74%3D; European Medicines Agency, (2009) Assessment report for Cimzia, , http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001037/WC500069735.pdf, London: European Medicines Agency; Accessed 28 Oct 2011; UCB Pharma SA, Cimzia 200 mg solution for injection (certolizumab pegol) (2012) Summary of product characteristics, , http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf, Braine l'Alleud: UCB Pharma SA; Accessed 5 Sep 2012; Fleischmann, R., Vencovsky, J., Van Vollenhoven, R.F., Borenstein, D., Box, J., Coteur, G., Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study (2009) Ann Rheum Dis, 68 (6), pp. 805-811. , 2674555 1:CAS:528:DC%2BD1MXotVCjtLs%3D 19015206; Keystone, E., Heijde, D., Mason, D., Jr., Landewe, R., Vollenhoven, R.V., Combe, B., Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (2008) Arthritis Rheum, 58 (11), pp. 3319-3329. , 1:CAS:528:DC%2BD1cXhsV2hs7nM 18975346; Smolen, J.S., Emery, P., Ferraccioli, G.F., Samborski, W., Berenbaum, F., Davies, O., Efficacy and safety of certolizumab pegol after incomplete response to DMARDs in RA patients with low moderate disease activity: results from CERTAIN, a phase IIIb study [abstract no. THU0244] (2011) Ann Rheum Dis, 70, p. 259; Smolen, J., Landewe, R.B., Mease, P., Brzezicki, J., Mason, D., Luijtens, K., Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial (2009) Ann Rheum Dis, 68 (6), pp. 797-804. , 2674556 1:CAS:528:DC%2BD1MXotVCjtLo%3D 19015207; Choy, E., McKenna, F., Vencovsky, J., Valente, R., Goel, N., Vanlunen, B., Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX (2012) Rheumatology, 51 (7), pp. 1226-1234. , 1:CAS:528:DC%2BC38XpsVait7k%3D 22344576; Weinblatt, M.E., Fleischmann, R., Huizinga, T.W., Emery, P., Pope, J., Massarotti, E., Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study (2012) Rheumatology, 51, pp. 2204-2214. , 1:CAS:528:DC%2BC38XhvVSqurnP 22923753; Felson, D.T., Anderson, J.J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis (1995) Arthritis Rheum, 38 (6), pp. 727-735. , 1:STN:280:DyaK2M3pvVSmtA%3D%3D 7779114; Aletaha, D., Nell, V.P., Stamm, T., Uffmann, M., Pflugbeil, S., Machold, K., Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score (2005) Arthritis Res Ther, 7 (4), pp. R796-R806. , 1175030 1:CAS:528:DC%2BD2MXkt1CjsLY%3D 15987481; Horton, S., Walsh, C., Emery, P., Certolizumab pegol for the treatment of rheumatoid arthritis (2012) Expert Opin Biol Ther, 12 (2), pp. 235-249. , 1:CAS:528:DC%2BC38XntFKguw%3D%3D 22165979; Van Der Heijde, D.M., Radiographic imaging: the 'gold standard' for assessment of disease progression in rheumatoid arthritis (2000) Rheumatology, 39, pp. 9-16. , 11001374; Keystone, E.C., Curtis, J.R., Fleischmann, R.M., Furst, D.E., Khanna, D., Smolen, J.S., Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial (2011) J Rheumatol, 38 (6), pp. 990-996. , 21362764; Schiff, M., Keystone, E., Kvien, T.K., Curtis, J.R., Emery, P., Luijtens, K., DAS28(ESR) response at week 12 is predictive of long-term disease activity in rheumatoid arthritis patients treated with certolizumab pegol (2009) Ann Rheum Dis, 2009 (68), p. 543; Van Der Heijde, D., Keystone, E.C., Curtis, J.R., Landewe, R.B., Schiff, M.H., Khanna, D., Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 Trial (2012) J Rheumatol, 39 (7), pp. 1326-1333. , 22589265; Strand, V., Smolen, J.S., Van Vollenhoven, R.F., Mease, P., Burmester, G.R., Hiepe, F., Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial (2011) Ann Rheum Dis, 70 (6), pp. 996-1002. , 3086050 1:CAS:528:DC%2BC3MXotFyks7s%3D 21415050; Strand, V., Mease, P., Burmester, G.R., Nikai, E., Coteur, G., Van Vollenhoven, R., Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial (2009) Arthritis Res Ther, 11 (6), p. 170. , 3003523 19909548; Tack, B.B., Self-reported fatigue in rheumatoid arthritis. A pilot study (1990) Arthritis Care Res, 3 (3), pp. 154-157. , 1:STN:280:DyaK3M7jslOhsw%3D%3D 2285754; Ware, J.E., Jr., (2012) SF-36 Health Survey Update, , http://www.sf-36.org/tools/sf36.shtml, Accessed 25 Jan 2012; Kavanaugh, A., Smolen, J.S., Emery, P., Purcaru, O., Keystone, E., Richard, L., Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis (2009) Arthritis Rheum, 61 (11), pp. 1592-1600. , 1:CAS:528:DC%2BD1MXhsFenur7N 19877104; Osterhaus, J.T., Purcaru, O., Richard, L., Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific work productivity survey (WPS-RA) (2009) Arthritis Res Ther, 11 (3), p. 73. , 2714119 19457255; Keystone, E.C., Combe, B., Smolen, J., Strand, V., Goel, N., Van Vollenhoven, R., Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial (2012) Rheumatology, 51 (9), pp. 1628-1638. , 1:CAS:528:DC%2BC38Xht1Gjt7vJ 22596211; Smolen, J.S., Van Vollenhoven, R.F., Kavanaugh, A., Goel, N., Fichtner, A., Strand, V., Efficacy and safety of certolimab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the RAPID 2 study [abstract] (2010) Arthritis Rheum, 62, p. 1806; Fleischmann, R., Choy, E.H., Van Vollenhoven, R., Safety, efficacy and sustained improvements in household productivity and daily activities with certolizumab pegol (CZP) monotherapy over two years in patients with active rheumatoid arthritis [abstract] (2010) Arthritis Rheum, 62, p. 765; Yamamoto, K., Takeuchi, T., Yamanak, H., Ishiguro, N., Tanaka, Y., Eguchi, K., Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis [abstract] (2011) Arthritis Rheum, 63, p. 1220; Sokka, T., Pincus, T., Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission (2003) J Rheumatol, 30 (6), pp. 1138-1146. , 12784382; Pope, J., Fleischmann, R., Dougados, M., Bingham, C.O., Massarotti, E., Wollenhaupt, J., Rapid reductions in fatigue and sleep problems and correlation with improvements in patient-reported outcomes in patients with active RA treated with certolizumab pegol in the REALISTIC 12-week phase IIIb randomised controlled study [abstract no. 4491] (2011) Value Health, 14 (7), p. 313; Genovese, M.C., Rubbert-Roth, A., Smolen, J.S., Kremer, J., Khraishi, M., Gomez-Reino, J., Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure (2013) J Rheumatol, 40 (4), pp. 768-780. , 1:CAS:528:DC%2BC3sXhtV2mtbjJ 23457383; Singh, J.A., Wells, G.A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L., Macdonald, J.K., Adverse effects of biologics: a network meta-analysis and Cochrane overview (2011) Cochrane Database Syst Rev, (2); Canadian Agency for Drugs and Technologies in Health, (2011) CADTH therapeutic review: clinical and economic overview: biological response modifier agents for adults with rheumatoid arthritis;, , http://www.cadth.ca/media/pdf/TR_RA_Clinical_and_Economic_Overview_e.pdf, Accessed 5 Sep 2012; Mariette, X., Bertin, P., Arendt, C., Terpstra, I., VanLunen, B., De Longueville, M., Pooled analysis of the risk of serious infections and opportunistic infections in clinical trials of certolizumab pegol for rheumatoid arthritis [poster no. 213]. (2012) Rheumatology, 51; Lopez-Olivo, M.A., Tayar, J.H., Martinez-Lopez, J.A., Pollono, E.N., Cueto, J.P., Gonzales-Crespo, M.R., Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis (2012) JAMA, 308 (9), pp. 898-908. , 1:CAS:528:DC%2BC38XhsFamtb3J 22948700; Vassilopoulos, D., Apostolopoulou, A., Hadziyannis, E., Papatheodoridis, G.V., Manolakopoulos, S., Koskinas, J., Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection (2010) Ann Rheum Dis, 69 (7), pp. 1352-1355. , 1:CAS:528:DC%2BC3cXhtVSlur7P 20472596; Ramos-Casals, M., Therapy: are TNF blockers safe for patients with hepatitis B virus infection? (2010) Nat Rev Rheumatol, 6 (11), pp. 618-620. , 1:CAS:528:DC%2BC3cXhtlGkt7nK 21037559; Schoels, M., Knevel, R., Aletaha, D., Bijlsma, J.W., Breedveld, F.C., Boumpas, D.T., Evidence for treating rheumatoid arthritis to target: results of a systematic literature search (2010) Ann Rheum Dis, 69 (4), pp. 638-643. , 3015093 20237123; Goekoop-Ruiterman, Y.P., De Vries-Bouwstra, J.K., Allaart, C.F., Van Zeben, D., Kerstens, P.J., Hazes, J.M., Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial (2007) Ann Intern Med, 146 (6), pp. 406-415. , 17371885; Grigor, C., Capell, H., Stirling, A., McMahon, A.D., Lock, P., Vallance, R., Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial (2004) Lancet, 364 (9430), pp. 263-269. , 15262104; Smolen, J.S., Landewe, R., Breedveld, F.C., Dougados, M., Emery, P., Gaujoux-Viala, C., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010) Ann Rheum Dis, 69 (6), pp. 964-975. , 2935329 1:CAS:528:DC%2BC3cXos1GiurY%3D 20444750; Goekoop-Ruiterman, Y.P., De Vries-Bouwstra, J.K., Kerstens, P.J., Nielen, M.M., Vos, K., Van Schaardenburg, D., DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis (2010) Ann Rheum Dis, 69 (1), pp. 65-69. , 1:STN:280:DC%2BD1MfhsFWitg%3D%3D 19155234; Smolen, J.S., Han, C., Van Der Heijde, D.M., Emery, P., Bathon, J.M., Keystone, E., Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade (2009) Ann Rheum Dis, 68 (6), pp. 823-827. , 1:CAS:528:DC%2BD1MXotVCjtLk%3D 18593759; Verstappen, S.M., Jacobs, J.W., Van Der Veen, M.J., Heurkens, A.H., Schenk, Y., Ter Borg, E.J., Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) (2007) Ann Rheum Dis, 66 (11), pp. 1443-1449. , 2111604 1:CAS:528:DC%2BD2sXhtlGrt7fE 17519278; Aletaha, D., Funovits, J., Keystone, E.C., Smolen, J.S., Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients (2007) Arthritis Rheum, 56 (10), pp. 3226-3235. , 1:CAS:528:DC%2BD2sXht12rtLnN 17907167; Gulfe, A., Kristensen, L.E., Geborek, P., Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden (2009) J Rheumatol, 36 (3), pp. 517-521. , 19208596; Lacroix, B.D., Lovern, M.R., Stockis, A., Sargentini-Maier, M.L., Karlsson, M.O., Friberg, L.E., A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis (2009) Clin Pharmacol Ther, 86 (4), pp. 387-395. , 1:CAS:528:DC%2BD1MXhtFCgtL7P 19626001; Curtis, J.R., Luijtens, K., Kavanaugh, A., Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year (2012) Arthritis Care Res, 64 (5), pp. 658-667. , 1:CAS:528:DC%2BC38XpsFOmu7s%3D; Scott, D.L., Wolfe, F., Huizinga, T.W., Rheumatoid arthritis (2010) Lancet, 376 (9746), pp. 1094-1108. , 20870100; Breedveld, F.C., Combe, B., Understanding emerging treatment paradigms in rheumatoid arthritis (2011) Arthritis Res Ther, 13, p. 3. , 3123964 21624182; Buch, M.H., Bingham, S.J., Bryer, D., Emery, P., Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders (2007) Rheumatology, 46 (7), pp. 1153-1156. , 1:CAS:528:DC%2BD2sXosVSjtrk%3D 17478470; Kavanaugh, A., Rheumatoid arthritis: guidelines for RA therapy-avoiding hamartia (2010) Nat Rev Rheumatol, 6 (9), pp. 505-506. , 20808307",Article,Scopus,2-s2.0-84927656702
"Dykun I., Geisel M.H., Kalsch H., Lehmann N., Bauer M., Moebus S., Jockel K.-H., Mohlenkamp S., Erbel R., Mahabadi A.A.","Association of computed tomography-derived left ventricular size with major cardiovascular events in the general population: The Heinz Nixdorf recall study",2015,"Atherosclerosis","240","1",,"46e52","",,1,10.1016/j.atherosclerosis.2015.02.050,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924068842&partnerID=40&md5=91ffc22341bfde24a04e59f484ac29ba","West German Heart and Vascular Center, Department of Cardiology, Germany; Institute of Medical Informatics Biometry, and Epidemiology, University of Duisburg-EssenEssen, Germany; Krankenhaus Bethanien, Department of CardiologyMoers, Germany","Dykun, I., West German Heart and Vascular Center, Department of Cardiology, Germany; Geisel, M.H., Institute of Medical Informatics Biometry, and Epidemiology, University of Duisburg-EssenEssen, Germany; Kälsch, H., West German Heart and Vascular Center, Department of Cardiology, Germany; Lehmann, N., Institute of Medical Informatics Biometry, and Epidemiology, University of Duisburg-EssenEssen, Germany; Bauer, M., West German Heart and Vascular Center, Department of Cardiology, Germany; Moebus, S., Institute of Medical Informatics Biometry, and Epidemiology, University of Duisburg-EssenEssen, Germany; Jöckel, K.-H., Institute of Medical Informatics Biometry, and Epidemiology, University of Duisburg-EssenEssen, Germany; Möhlenkamp, S., Krankenhaus Bethanien, Department of CardiologyMoers, Germany; Erbel, R., West German Heart and Vascular Center, Department of Cardiology, Germany; Mahabadi, A.A., West German Heart and Vascular Center, Department of Cardiology, Germany","To investigate the relationship between LV size as determined by non-contrast enhanced cardiac CT with incident cardiovascular disease in the general population free of clinical cardiovascular disease. Methods: LV axial area was quantified from non-contrast CT in axial, end-diastolic images at a mid-ventricular slice in participants from the population-based Heinz Nixdorf recall study, free of cardiovascular disease (n=3926, 59±8years, 53%female). LV size index (LVI) was defined as the quotient of LV area and body surface area. Major CV events (coronary events, stroke, CV death) were assessed during follow-up. Association of LVI with events was assessed using Cox regression analysis in unadjusted and multivariable adjusted models. Results: During 8.0±1.5years of follow-up, 219 subjects developed a major CV event. Those with events had larger LVI at baseline (2258±352 vs. 2149±276mm2/m2, p&lt;0.0001). In univariate analysis, increase of LVI by 1 standard deviation was associated with 40% higher risk of events (HR(95%CI):1.41(1.26-1.59), p&lt;0.0001). Associations remained statistically significant after adjustment for CV risk factors (1.24(1.10-1.40), p=0.0007) and when further adjusting for CAC (1.21(1.07-1.37), p=0.003). There was a trend towards stronger association for subjects with low CAC-score (CAC&lt;100:1.41(1.16-1.71), p=0.0005, CAC≥100:1.24(1.06-1.44), p=0.006) in univariate analysis which persisted after multivariable adjustment (CAC&lt;100: 1.41(1.14-1.73), p=0.001, CAC≥100: 1.12(0.96-1.31), p=0.16). Conclusion: CT-derived LV size is associated with incident major CV events independent of traditional risk factors and CAC-score in a population-based cohort and may improve the prediction of hard events especially in subjects with low CAC-scores. © 2015 Elsevier Ireland Ltd.","Computed tomography; Coronary artery calcification; Epidemiology; Heinz Nixdorf recall study; Left ventricle; Prevention","Barbieri, A., Bursi, F., Mantovani, F., Prognostic impact of left ventricular mass severity according to the classification proposed by the american society of echocardiography/European association of echocardiography (2011) J.Am. Soc. Echocardiogr., 24, pp. 1383-1391; Bluemke, D.A., Kronmal, R.A., Lima, J.A.C., The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA study (2008) J.Am. Coll. Cardiol., 52, pp. 2148-2155; Levy, D., Garrison, R.J., Savage, D.D., Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The framingham heart study (1989) Ann. Intern Med., 110, pp. 101-107; Levy, D., Garrison, R.J., Savage, D.D., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study (1990) N.Engl. J. Med., 322, pp. 1561-1566; Gardin, J.M., McClelland, R., Kitzman, D., M-mode echocardiographic predictors of six- to seven year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the cardiovascular health study) (2001) Am. J. Cardiol., 87, pp. 1051-1057; Mazza, A., Tikhonoff, V., Casiglia, E., Predictors of congestive heart failure mortality in elderly people from the general population (2005) Int. Heart J., 46, pp. 419-431; Tsang, T.S., Barnes, M.E., Gersh, B.J., Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography (2003) J.Am. Coll. Cardiol., 42, pp. 1199-1205; Schlosser, T., Mohrs, O.K., Magedanz, A., Assessment of left ventricular function and mass in patients undergoing computed tomography coronary angiography using 64-detectorrow CT: comparison to magnetic resonance imaging (2007) Acta Radiol., 48, pp. 30-35; Maffei, E., Messalli, G., Martini, C., Left and right ventricle assessment with cardiac CT: validation study vs. Cardiac MR (2012) Eur. Radiol., 22, pp. 1041-1049; Schlett, C.L., Kwait, D.C., Mahabadi, A.A., Simple area-based measurement for multidetector computed tomography to predict left ventricular size (2010) Eur. Radiol., 20, pp. 1590-1596; Nasir, K., Katz, R., Mao, S., Comparison of left ventricular size by computed tomography with magnetic resonance imaging measures of left ventricle mass and volumes: the multi-ethnic study of atherosclerosis (2008) J.Cardiovasc Comput Tomogr., 2, pp. 141-148; Dykun, I., Mahabadi, A.A., Lehmann, N., Left ventricle size quantification using non-contrast enhanced cardiac computed tomography - association with cardiovascular risk factors and coronary artery calcium score in the general population: the Heinz Nixdorf recall study (2014) Acta Radiol., , pii: 0284185114542996. [Epub ahead of print]; Rubens, M., The chest X-ray in adult heart disease (1996) Diseases of the Heart, pp. 253-283. , Saunders, London, D. Julian, A.J. Camm, K.M. Fox, R.J.C. Hall, P.A. Poole-Wilson (Eds.); Erbel, R., Mohlenkamp, S., Moebus, S., Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf recall study (2010) J.Am. Coll. Cardiol., 56, pp. 1397-1406; Schmermund, A., Mohlenkamp, S., Stang, A., Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf recall study. Risk factors, evaluation of coronary calcium and lifestyle (2002) Am. Heart J., 144, pp. 212-218; Schmermund, A., Lehmann, N., Bielak, L.F., Comparison of subclinical coronary atherosclerosis and risk factors in unselected populations in Germany and US-America (2007) Atherosclerosis, 195, pp. 207-216; Moebus, S., Stang, A., Mohlenkamp, S., Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort-results of the Heinz Nixdorf recall study (2009) Diabetologia, 52, pp. 81-89; Jockel, K.H., Lehmann, N., Jaeger, B.R., Smoking cessation and subclinical atherosclerosis-results from the Heinz Nixdorf recall study (2009) Atherosclerosis, 203, pp. 221-227; Agatston, A.S., Janowitz, W.R., Hildner, F.J., Quantification of coronary artery calcium using ultrafast computed tomography (1990) J.Am. Coll. Cardiol., 15, pp. 827-832; Newson, R.B., Comparing the predictive powers of survival models using Harrell's C or Somers' D (2010) Stata J., 3, pp. 339-358; Chambless, L.E., Cummiskey, C.P., Cui, G., Several methods to assess improvement in risk prediction models: extension to survival analysis (2011) Statistics Med., 30, pp. 22-38; Kannel, W.B., Gordon, T., Castelli, W.P., Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study (1970) Ann. Intern Med., 72, pp. 813-822; Reichek, N., Devereux, R.B., Left ventricular hypertrophy: relation of anatomic, echocardiographic and electrocardiographic findings (1981) Circulation, 63, pp. 1391-1398; Devereux, R.B., Casale, P.N., Eisenberg, R.R., Electrocardiographic detection of left ventricular hypertrophy using echocardiographic determinants of left ventricular mass as the reference standard (1984) J.Am. Coil Cardiol., 3, pp. 82-87; Levy, D., Labib, S.B., Anderson, K.M., Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy (1990) Circulation, 81, pp. 815-820; Bauml, M.A., Underwood, D.A., Left ventricular hypertrophy: an overlooked cardiovascular risk factor (2010) Cleve Clin. J. Med., 77, pp. 381-387; Levy, D., Garrison, R.J., Savage, D.D., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study (1990) N.Engl. J. Med., 322, pp. 1561-1566; Grothues, F., Smith, G.C., Moon, J.C., Comparison of inter study reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy (2002) Am. J. Cardiol., 90, pp. 29-34; Butler, S.P., McKay, E., Paszkowski, A.L., Reproducibility study of left ventricular measurements with breath-hold cine MRI using a semiautomated volumetric image analysis program (1998) J.Magn. Reson Imaging, 8, pp. 467-472; Bottini, P.B., Carr, A.A., Prisant, L.M., Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient (1995) Am. J. Hypertens., 8, pp. 221-228; Woo, P., Mao, S., Wang, S., Left ventricular size determined by electron beam computed tomography predicts significant coronary artery disease and events (1997) Am. J. Cardiol., 79, pp. 1236-1238",Article,Scopus,2-s2.0-84924068842
"Burdick J., Berridge B., Coatney R.","Strain echocardiography combined with pharmacological stress test for early detection of anthracycline induced cardiomyopathy",2015,"Journal of Pharmacological and Toxicological Methods","73",,,"15","20",,,10.1016/j.vascn.2015.02.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924190157&partnerID=40&md5=ad9627ceee8a1726bd34c399064eb243","Laboratory Animal Sciences, GlaxoSmithKline, 709 Swedeland Rd, UMW 2630King of Prussia, PA, United States; Safety Assessment, GlaxoSmithKline, 5 Moore Drive, 9.3011E, RTPNC, United States","Burdick, J., Laboratory Animal Sciences, GlaxoSmithKline, 709 Swedeland Rd, UMW 2630King of Prussia, PA, United States; Berridge, B., Safety Assessment, GlaxoSmithKline, 5 Moore Drive, 9.3011E, RTPNC, United States; Coatney, R., Laboratory Animal Sciences, GlaxoSmithKline, 709 Swedeland Rd, UMW 2630King of Prussia, PA, United States","Introduction: Advances in echocardiography, including 2-D speckle tracking to quantitate myocardial strain and strain rate, have improved myocardial functional and mechanical evaluation and may provide a more sensitive assessment of cardiac functional and mechanical changes. Additionally, evaluating myocardial performance induced by a pharmacologic stress test (dobutamine infusion) may further improve the evaluation of potential changes in cardiac function. This study evaluates the use of 2-D speckle tracking strain echocardiography (2DSE) combined with a dobutamine stress test to detect doxorubicin induced cardiomyopathy in the rat. Methods: Rats were dosed once per week with 2. mg/kg doxorubicin for 6. weeks. Echocardiography was performed weekly at rest and during dobutamine infusion (20. mcg/kg/min IV). Results: Throughout the study there were no differences between control and doxorubicin treated groups at rest for radial strain, circumferential strain, fractional shortening (FS), or heart rate (HR). During dobutamine infusion, radial strain, circumferential strain, FS, and HR similarly increased significantly in both the control and doxorubicin treated groups at weeks 0, 1, and 2. At week 3 there was a significant attenuation of the increase in radial strain in the doxorubicin treated group, and at weeks 4 and 6 there was significant attenuation in radial strain and circumferential strain. No significant differences were detected in FS or HR between the two groups at any time points. Histology of the left ventricle at week 7 showed mild changes (mild cardiomyocyte vacuolation with minimal inflammation and no fibrosis) in the doxorubicin treated animals as compared to the control animals, which were consistent with mild doxorubicin induced injury. Discussion: These data suggest that 2 D speckle tracking strain echocardiography combined with dobutamine stress test can detect early changes in myocardial function and may be useful tools in early detection of drug-induced cardiac dysfunction. © 2015 Elsevier Inc.","2-D speckle; Cardiomyopathy; Cardiotoxicity; Dobutamine stress; Doxorubicin; Echocardiography; Methods; Strain","Armstrong, W.F., Pellikka, P.A., Ryan, T., Crouse, L., Zoghbi, W.A., Stress echocardiography: Recommendations for the performance and interpretation of stress echocardiography (1998) Journal of the American Society of Echocardiography, 11 (1), pp. 97-104; Bachner-Hinenzon, N., Ertracht, O., Leitman, M., Vered, Z., Shimoni, S., Beeri, R., Layer-specific strain analysis by speckle tracking echocardiography reveals differences in left ventricular function between rats and humans (2010) American Journal of Physiology - Heart and Circulatory Physiology, 299, pp. H664-H672; Bristow, M.R., Lopez, M.B., Mason, J.W., Billingham, M.E., Winchester, M.A., Efficacy and cost of cardiac monitoring in patients receiving doxorubicin (1982) Cancer, 50 (1), pp. 32-41; Christian, J.B., Finkle, J.K., Ky, B., Douglas, P.S., Gutstein, D.E., Hockings, P.D., Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction (2012) American Heart Journal, 164 (6), pp. 846-855; Chugun, A., Uchide, T., Temma, K., Kennedy, R.H., Klimberg, S.V., Hara, Y., Doxorubicin affects the cardiac muscarinic system in the rat (2001) Journal of Veterinary Medical Science, 63, pp. 1315-1322; Civelli, M., Cardinale, D., Martinoni, A., Lamantia, G., Colombo, N., Colombo, A., Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity (2006) International Journal of Cardiology, 111 (1), pp. 120-126; De Wolf, D., Suys, B., Maurus, R., Benoit, Y., Verhaaren, H., Matthijs, D., Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors (1996) Pediatric Research, 39, pp. 504-512; French, K.J., Coatney, R.W., Renninger, J.P., Hu, C.X., Gales, T.L., Zhao, S., Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity (2010) Toxicologic Pathology, 38, pp. 691-702; Geyer, H., Caracciolo, G., Abe, H., Wilansky, S., Carerj, S., Gentile, F., Assessment of myocardial mechanics using speckle tracking echocardiography: Fundamentals and clinical applications (2010) Journal of the American Society of Echocardiography, 23 (4), pp. 351-369; Hamada, H., Ohkubo, T., Maeda, M., Ogawa, S., Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer (2006) Pediatrics International, 48 (3), pp. 313-320; Heimdal, A., Stoylen, A., Torp, H., Skjaerpe, T., Real time strain rate imaging of the left ventricle by ultrasound (1998) Journal of the American Society of Echocardiography, 11, pp. 1013-1019; Herman, E.H., el-Hage, A.N., Ferrans, V.J., Ardalan, B., Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats (1985) Toxicology and Applied Pharmacology, 78 (2), pp. 202-214; Jiji, R.S., Kramer, C.M., Salerno, M., Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs (2012) Journal of Nuclear Cardiology, 19 (2), pp. 377-388; Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates? (2004) Nature Reviews Drug Discovery, 8, pp. 711-715; Kusunose, K., Penn, M.S., Zhang, Y., Cheng, Y., Thomas, J.D., Marwick, T.H., How similar are the mice to men? Between-species comparison of left ventricular mechanics using strain imaging (2012) PLoS One, 7 (6), p. e40061; Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology (2005) Journal of the American Society of Echocardiography, 18, pp. 1440-1463; Leitman, M., Lysyansky, P., Sidenko, S., Shir, V., Peleg, E., Binenbaum, M., Two-dimensional strain-A novel software for real-time quantitative echocardiographic assessment of myocardial function (2004) Journal of the American Society of Echocardiography, 17, pp. 1021-1029; Liu, J., Rigel, D.F., Echocardiographic examination in rats and mice (2009) Methods in Molecular Biology, 573, pp. 139-155; Migrino, R.Q., Aggarwal, D., Konorev, E., Brahmbhatt, T., Bright, M., Kalyanaraman, B., Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography (2008) Ultrasound in Medicine and Biology, 34, pp. 208-214; Migrino, R.Q., Zhu, X., Pajewski, N., Brahmbhatt, T., Hoffmann, R., Zhao, M., Assessment of segmental myocardial viability using regional 2-dimensional strain echocardiography (2007) Journal of the American Society of Echocardiography, 20, pp. 342-351; Moreno, L., Pearson, A.D., How can attrition rates be reduced in cancer drug discovery? (2013) Expert Opinion Drug Discovery, 4, pp. 363-368; Nesbitt, G.C., Mankad, S., Oh, J.K., Strain imaging in echocardiography: Methods and clinical applications (2009) International Journal of Cardiovascular Imaging, 25, pp. 9-22; Olson, H.M., Capen, C.C., Chronic cardiotoxicity of doxorubicin (adriamycin) in the rat: Morphologic and biochemical investigations (1978) Toxicology and Applied Pharmacology, 44, pp. 605-616; Pellikka, P.A., Roger, V.L., Oh, J.K., Miller, F.A., Seward, J.B., Tajik, A.J., Stress echocardiography. Part II. Dobutamine stress echocardiography: Techniques, implementation, clinical applications, and correlations (1995) Mayo Clinic Proceedings, 70, pp. 16-27; Piegari, E., Di Salvo, G., Castaldi, B., Vitelli, M.R., Rodolico, G., Golino, P., Myocardial strain analysis in a doxorubicin-induced cardiomyopathy model (2008) Ultrasound in Medicine and Biology, 34, pp. 370-378; Plante, E., Lachance, D., Drolet, M.C., Roussel, E., Couet, J., Arsenault, M., Dobutamine stress echocardiography in healthy adult male rats (2005) Cardiovascular Ultrasound, 3, p. 34; Schwarz, E.R., Pollick, C., Dow, J., Patterson, M., Birnbaum, Y., Kloner, R.A., A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography (1998) Cardiovascular Research, 39, pp. 216-223; Takemura, G., Fujiwara, H., Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management (2007) Progress in Cardiovascular Diseases, 9, pp. 330-352; Teske, A.J., DeBoeck, B.W.L., Melamn, P.G., Sieswerda, G.T., Doevendans, P.A., Cramer, M.J.M., Echocardiographic quantification of myocardial function using tissue deformation imaging, a guide to image acquisition and analysis using tissue Doppler and speckle tracking (2007) Cardiovascular Ultrasound, 5 (27). , http://www.cardiovascularultrasound.com/content/5/1/27; Thavendiranathan, P., Poulin, F., Lim, K.D., Plana, J.C., Woo, A., Marwick, T.H., Use of myocardial strain imaging for the early detection of cardiotoxicity in patients during and after cancer chemotherapy (2014) Journal of the American College of Cardiology, 63, pp. 2751-2768; Tontodonati, M., Fasdelli, N., Repeto, P., Dorigatti, R., Characterisation of rodent dobutamine echocardiography for preclinical safety pharmacology assessment (2011) Journal of Pharmacological and Toxicological Methods, 64 (2), pp. 2120-2126; Villarraga, H.R., Herrmann, J., Nkomo, V.T., Cardio-oncology: Role of echocardiography (2014) Echocardiography in Clinical Practice and Research, 57 (1), pp. 10-18; Volkova, M., Russell, R., Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment (2011) Current Cardiology Reviews, 7 (4), pp. 214-220; Watson, L.E., Sheth, M., Denyer, R.F., Dostal, D.E., Baseline echocardiographic values for adult male rats (2004) Journal of the American Society of Echocardiography, 17, pp. 161-167",Article,Scopus,2-s2.0-84924190157
"Grimaldi-Bensouda L., Alperovitch A., Aubrun E., Danchin N., Rossignol M., Abenhaim L., Richette P., Fromage P., Furber A., Mery D., El Jabali A., Banos J.-L., Tarabbia P., Sedighian S., Lallemant R., Kadri A., Ovize M., Saint-Mezard G., Brandstatt P., Koujan B., Amonchot A., Gouvion T., Ouanes K., Cottin Y., Zaouali H., Dormagen V., Afif Z., Godenir J.P., Alary J.P., Pierrard B., Imianitoff M., Bessede G., Vaquette B., Martelet M., Mouallem J., Sader R., Gorka H., Rosak P., Viallet M., Mokaddem J., Brefort G., Dahmani N., Nallet O., Guillot P., Leclercq F., Jamon Y., Tcheng E., Dibon O., Chaib A., Lozinguez O., Steg G., Delarche N., Boureux C., Merle E., Boukhsibi F., Rivet C.M., Broin P., Boulain L., Ferron B., Hajmoussa E., Pradies F., Destrac S., Prouteau N., Heiligenstein D., Galinier M., Banayan J., Goburdhun C., Craciun A.D., Zylberberg M., Gueranger P.","Impact of allopurinol on risk of myocardial infarction",2015,"Annals of the Rheumatic Diseases","74","5",,"836","842",,2,10.1136/annrheumdis-2012-202972,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926685553&partnerID=40&md5=87b2c4901cd8ecf9c1e96517d48fdf45","LA-SERParis, France; Conservatoire National des Arts and MétiersParis, France; INSERM/Pasteur InstituteParis, France; Inserm U708-NeuroepidemiologyBordeaux, France; Université Bordeaux-SegalenBordeaux, France; Coronary Disease Unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de ParisParis, France; LA-SER, Centre for Risk ResearchMontreal, Canada; Department of Epidemiology and Biostatistics, McGill UniversityMontreal, Canada; Department of Epidemiology, London School of Hygiene and Tropical MedicineLondon, United Kingdom; LA-SER Europe Ltd.London, United Kingdom; Université Paris 7, UFR Médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, 2, rue Ambroise ParéParis, Cedex 10, France; Inserm U1132, Hôpital LariboisièreParis, Cedex 10, France; CHI d'Annemasse, France; CHU d'Angers, France; Hôpital Joseph Imbert, France; Centre Hospitalier Louis Pasteur, France; Clinique Lafourcade, France; Clinique Paulmy, France; Centre Hospitalier de Béziers, France; Centre Hospitalier du Duchenne, France; Centre Hospitalier Pierre Oudot, France; Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, France; Centre Médical de Cambo les Bains, France; Centre Château Le Moine, France; Centre Hospitalier Châteauroux, France; CHU Gabriel-Montpied, France; Groupe Hospitalier du Centre Alsace, France; Centre Hospitalier de Crest, France; Hôpital du Bocage, France; Centre Hospitalier de la Dracénie, France; Hôpital Simone Veil, France; Centre Hospitalier de Firminy, France; Hôpital Marie Madeleine, France; CHI Fréjus Saint-Raphaël, France; Centre Hospitalier de Villefranche sur Saône, France; Centre Hospitalier de Grasse, France; Centre Hospitalier de Guéret, France; Centre Hospitalier Saint-Louis, France; Centre Hospitalier de Langres, France; Centre Hospitalier de Laon, France; Centre Hospitalier du Mans, France; Centre Hospitalier Emile Roux, France; Centre Hospitalier du Nord Mayenne, France; CHI du Sud Aveyron de Millau, France; Clinique Kennedy, France; CHI Le Raincy-Montfermeil, France; Clinique du Millénaire, France; Hôpital Arnaud de Villeneuve, France; Nîmes, France; Centre Hospitalier Louis Giorgi, France; Hôpital La Source, France; Hôpital Européen Georges Pompidou, France; Clinique Bizet, France; Hôpital Bichat, France; Centre Hospitalier François Mitterrand, France; Hôpital Saint-Jean, France; Centre de Réadaptation et de Convalescence Cardiocéan, France; Hôpital Départemental Stell, France; Centre Hospitalier de Rumilly, France; CHI de Sallanches, France; Centre Hospitalier de Salon de Provence, France; Centre Hospitalier Gaston Ramon, France; Centre Hospitalier de Saint-Amand, France; Clinique La Pinède, France; CHI du Val d'Ariège, France; Hôpitaux du Léman, France; CHU Toulouse Hôpital Rangueil, France; Hôpital Trousseau, France; Centre Hospitalier de Tulle, France; Centre Hospitalier de Valence, France; Centre Hospitalier La Chartreuse, France","Grimaldi-Bensouda, L., LA-SERParis, France, Conservatoire National des Arts and MétiersParis, France, INSERM/Pasteur InstituteParis, France; Alpérovitch, A., Inserm U708-NeuroepidemiologyBordeaux, France, Université Bordeaux-SegalenBordeaux, France; Aubrun, E., LA-SERParis, France; Danchin, N., Coronary Disease Unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de ParisParis, France; Rossignol, M., LA-SER, Centre for Risk ResearchMontreal, Canada, Department of Epidemiology and Biostatistics, McGill UniversityMontreal, Canada; Abenhaim, L., Department of Epidemiology, London School of Hygiene and Tropical MedicineLondon, United Kingdom, LA-SER Europe Ltd.London, United Kingdom; Richette, P., Université Paris 7, UFR Médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, 2, rue Ambroise ParéParis, Cedex 10, France, Inserm U1132, Hôpital LariboisièreParis, Cedex 10, France; Fromage, P., CHI d'Annemasse, France; Furber, A., CHU d'Angers, France; Mery, D., Hôpital Joseph Imbert, France; El Jabali, A., Centre Hospitalier Louis Pasteur, France; Banos, J.-L., Clinique Lafourcade, France; Tarabbia, P., Clinique Paulmy, France; Sedighian, S., Centre Hospitalier de Béziers, France; Lallemant, R., Centre Hospitalier du Duchenne, France; Kadri, A., Centre Hospitalier Pierre Oudot, France; Ovize, M., Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, France; Saint-Mézard, G., Centre Médical de Cambo les Bains, France; Brandstatt, P., Centre Château Le Moine, France; Koujan, B., Centre Hospitalier Châteauroux, France; Amonchot, A., CHU Gabriel-Montpied, France; Gouvion, T., Groupe Hospitalier du Centre Alsace, France; Ouanes, K., Centre Hospitalier de Crest, France; Cottin, Y., Hôpital du Bocage, France; Zaouali, H., Centre Hospitalier de la Dracénie, France; Dormagen, V., Hôpital Simone Veil, France; Afif, Z., Centre Hospitalier de Firminy, France; Godenir, J.P., Hôpital Marie Madeleine, France; Alary, J.P., CHI Fréjus Saint-Raphaël, France; Pierrard, B., Centre Hospitalier de Villefranche sur Saône, France; Imianitoff, M., Centre Hospitalier de Grasse, France; Bessede, G., Centre Hospitalier de Guéret, France; Vaquette, B., Centre Hospitalier Saint-Louis, France; Martelet, M., Centre Hospitalier de Langres, France; Mouallem, J., Centre Hospitalier de Langres, France; Sader, R., Centre Hospitalier de Laon, France; Gorka, H., Centre Hospitalier Louis Pasteur, France; Rosak, P., Centre Hospitalier du Mans, France; Viallet, M., Centre Hospitalier Emile Roux, France; Mokaddem, J., Centre Hospitalier du Nord Mayenne, France; Brefort, G., CHI du Sud Aveyron de Millau, France; Dahmani, N., Clinique Kennedy, France; Nallet, O., CHI Le Raincy-Montfermeil, France; Guillot, P., Clinique du Millénaire, France; Leclercq, F., Hôpital Arnaud de Villeneuve, France; Jamon, Y., Nîmes, France; Tcheng, E., Centre Hospitalier Louis Giorgi, France; Dibon, O., Hôpital La Source, France; Chaib, A., Hôpital Européen Georges Pompidou, France; Lozinguez, O., Clinique Bizet, France; Steg, G., Hôpital Bichat, France; Delarche, N., Centre Hospitalier François Mitterrand, France; Boureux, C., Hôpital Saint-Jean, France; Merle, E., Centre de Réadaptation et de Convalescence Cardiocéan, France; Boukhsibi, F., Hôpital Départemental Stell, France; Rivet, C.M., Centre Hospitalier de Rumilly, France; Broin, P., CHI de Sallanches, France; Boulain, L., Centre Hospitalier de Salon de Provence, France; Ferron, B., Centre Hospitalier Gaston Ramon, France; Hajmoussa, E., Centre Hospitalier de Saint-Amand, France; Pradies, F., Clinique La Pinède, France; Destrac, S., CHI du Val d'Ariège, France; Prouteau, N., CHI du Val d'Ariège, France; Heiligenstein, D., Hôpitaux du Léman, France; Galinier, M., CHU Toulouse Hôpital Rangueil, France; Banayan, J., Hôpital Trousseau, France; Goburdhun, C., Centre Hospitalier de Tulle, France; Craciun, A.D., Centre Hospitalier de Valence, France; Zylberberg, M., Centre Hospitalier La Chartreuse, France; Guéranger, P., Centre Hospitalier La Chartreuse, France","Background: Gout therapy includes xanthine oxidase inhibitors (XOI) and colchicine, which have both been associated with decreased cardiovascular risk. However, their effects on major cardiac events, such as myocardial infarction (MI), need to be investigated further. Objectives: To investigate whether XOIs and colchicine are associated with decreased risk of MI. Methods: This case-control study compared patients with first-ever MI and matched controls. Cases were recruited from the Pharmacoepidemiological General Research on MI registry. Controls were selected from a referent population (n=8444) from general practice settings. Results: The study sample consisted of 2277 MI patients and 4849 matched controls. Use of allopurinol was reported by 3.1% of cases and 3.8 of controls, and 1.1% of cases and controls used colchicine. The adjusted OR (95% CI) for MI with allopurinol use was 0.80 (0.59 to 1.09). When using less stringent matching criteria that allowed for inclusion of 2593 cases and 5185 controls, the adjusted OR was 0.73 (0.54 to 0.99). Similar results were found on analysis by sex and hypertension status. Colchicine used was not associated with a decreased risk of MI (aOR=1.17 (0.70 to 1.93)). Conclusions: Allopurinol may be associated with a reduced risk of MI. No decreased risk of MI was found in colchicine users. Besides its urate-lowering property, allopurinol might have a cardioprotective effect.",,"Richette, P., Bardin, T., (2010) Gout. Lancet, 375, pp. 318-328; Roddy, E., Doherty, M., Epidemiology of gout (2010) Arthritis Res Ther, 12, p. 223; Zhu, Y., Pandya, B.J., Choi, H.K., Comorbidities of gout and Hyperuricemia in the US general population: NHANES 2007-2008 (2011) Am J Med, 125, pp. 679-687. , e1; Feig, D.I., Kang, D.H., Johnson, R.J., Uric acid and cardiovascular risk (2008) N Engl J Med, 359, pp. 1811-1821; Gagliardi, A.C., Miname, M.H., Santos, R.D., Uric acid: A marker of increased cardiovascular risk (2009) Atherosclerosis, 202, pp. 11-17; Krishnan, E., Baker, J.F., Furst, D.E., Gout and the risk of acute myocardial infarction (2006) Arthritis Rheum, 54, pp. 2688-2696; Baker, J.F., Schumacher, H.R., Krishnan, E., Serum uric acid level and risk for peripheral arterial disease: Analysis of data from the multiple risk factor intervention trial (2007) Angiology, 58, pp. 450-457; Krishnan, E., Pandya, B.J., Lingala, B., Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction (2012) Arthritis Res Ther, 14, p. R10; Krishnan, E., Svendsen, K., Neaton, J.D., Long-term cardiovascular mortality among middle-aged men with gout (2008) Arch Intern Med, 168, pp. 1104-1110; Choi, H.K., Curhan, G., Independent impact of gout on mortality and risk for coronary heart disease (2007) Circulation, 116, pp. 894-900; Neogi, T., George, J., Rekhraj, S., Are either or both Hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal (2012) Arthritis Rheum, 64, pp. 327-338; Dalbeth, N., So, A., Hyperuricaemia and gout: State of the art and future perspectives (2010) Ann Rheum Dis, 69, pp. 1738-1743; Lyngdoh, T., Marques-Vidal, P., Paccaud, F., Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based colaus study (2011) PLoS ONE, 6; Perez-Ruiz, F., Martinez-Indart, L., Carmona, L., Tophaceous gout and high level of Hyperuricaemia are both associated with increased risk of mortality in patients with gout (2014) Ann Rheum Dis, 73, pp. 177-182; Jordan, K.M., Cameron, J.S., Snaith, M., British society for rheumatology and British health professionals in rheumatology guideline for the management of gout (2007) Rheumatology (Oxford), 46, pp. 1372-1374; Zhang, W., Doherty, M., Bardin, T., EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT) (2006) Ann Rheum Dis, 65, pp. 1312-1324; Richette, P., Bardin, T., Colchicine for the treatment of gout (2010) Expert Opin Pharmacother, 11, pp. 2933-2938; Crittenden, D.B., Lehmann, R.A., Schneck, L., Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout (2012) J Rheumatol, 39, pp. 1458-1464; Grimaldi-Bensouda, L., Rossignol, M., Danchin, N., Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs (2011) Heart, 97, pp. 1834-1840; Grimaldi-Bensouda, L., Rossignol, M., Aubrun, E., Agreement between patients' self-report and physicians' prescriptions on cardiovascular drug exposure: The PGRx database experience (2010) Pharmacoepidemiol Drug Saf, 19, pp. 591-595; Grimaldi-Bensouda, L., Rossignol, M., Aubrun, E., Agreement between patients' self-report and physicians' prescriptions on nonsteroidal anti-inflammatory drugs and other drugs used in musculoskeletal disorders: The international pharmacoepidemiologic general research eXtension database (2012) Pharmacoepidemiol Drug Saf, 21, pp. 753-759; Luk, A.J., Levin, G.P., Moore, E.E., Allopurinol and mortality in Hyperuricaemic patients (2009) Rheumatology (Oxford), 48, pp. 804-806; Higgins, P., Dawson, J., Lees, K.R., Xanthine oxidase inhibition for the treatment of cardiovascular disease: A systematic review and meta-analysis (2012) Cardiovasc Ther, 30, pp. 217-226; Noman, A., Ang, D.S., Ogston, S., Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomised, placebo controlled crossover trial (2010) Lancet, 375, pp. 2161-2167; Kelkar, A., Kuo, A., Frishman, W.H., Allopurinol as a cardiovascular drug (2011) Cardiol Rev, 19, pp. 265-271; Thanassoulis, G., Brophy, J.M., Richard, H., Gout, allopurinol use, and heart failure outcomes (2010) Arch Intern Med, 170, pp. 1358-1364; Feig, D.I., Soletsky, B., Johnson, R.J., Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial (2008) JAMA, 300, pp. 924-932; Harzand, A., Tamariz, L., Hare, J.M., Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition (2012) Congest Heart Fail, 18, pp. 179-182; Athyros, V.G., Elisaf, M., Papageorgiou, A.A., Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study (2004) Am J Kidney Dis, 43, pp. 589-599; Hoieggen, A., Alderman, M.H., Kjeldsen, S.E., The impact of serum uric acid on cardiovascular outcomes in the LIFE study (2004) Kidney Int, 65, pp. 1041-1049; George, J., Carr, E., Davies, J., High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid (2006) Circulation, 114, pp. 2508-2516; Ogino, K., Kato, M., Furuse, Y., Uric acid-lowering treatment with benzbromarone in patients with heart failure: A double-blind placebo-controlled crossover preliminary study (2010) Circ Heart Fail, 3, pp. 73-81; Annemans, L., Spaepen, E., Gaskin, M., Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000-2005 (2008) Ann Rheum Dis, 67, pp. 960-966; Mikuls, T.R., Farrar, J.T., Bilker, W.B., Gout epidemiology: Results from the UK general practice research database, 1990-1999 (2005) Ann Rheum Dis, 64, pp. 267-272; Mikuls, T.R., Farrar, J.T., Bilker, W.B., Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic Hyperuricaemia: Results from the UK general practice research database (GPRD) (2005) Rheumatology (Oxford), 44, pp. 1038-1042; Xu, X., Hu, X., Lu, Z., Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice (2008) J Card Fail, 14, pp. 746-753; Hou, M., Hu, Q., Chen, Y., Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure (2006) J Cardiovasc Pharmacol, 48, pp. 255-263; Becker, M.A., Schumacher, H.R., Jr., Wortmann, R.L., Febuxostat compared with allopurinol in patients with Hyperuricemia and gout (2005) N Engl J Med, 353, pp. 2450-2461; Becker, M.A., Schumacher, H.R., Espinoza, L.R., The urate-lowering efficacy and safety of febuxostat in the treatment of the Hyperuricemia of gout: The CONFIRMS trial (2010) Arthritis Res Ther, 12, p. R63; Grimaldi-Bensouda, L., Alperovitch, A., Besson, G., Guillain-barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses (2011) Am J Epidemiol, 174, pp. 326-335; Szwejkowski, B.R., Gandy, S.J., Rekhraj, S., Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy (2013) J Am Coll Cardiol, 62, pp. 2284-2293; Rekhraj, S., Gandy, S.J., Szwejkowski, B.R., High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease (2013) J Am Coll Cardiol, 61, pp. 926-932",Article,Scopus,2-s2.0-84926685553
"Yue M.S., Peterson R.E., Heideman W.","Dioxin inhibition of swim bladder development in zebrafish: Is it secondary to heart failure?",2015,"Aquatic Toxicology","162",,,"10","17",,,10.1016/j.aquatox.2015.02.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924308250&partnerID=40&md5=ce64e17e817877267ecf1de53c28548c","Molecular and Environmental Toxicology Center, University of Wisconsin, 1300 University AvenueMadison, WI, United States; Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, 777 Highland AvenueMadison, WI, United States","Yue, M.S., Molecular and Environmental Toxicology Center, University of Wisconsin, 1300 University AvenueMadison, WI, United States; Peterson, R.E., Molecular and Environmental Toxicology Center, University of Wisconsin, 1300 University AvenueMadison, WI, United States, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, 777 Highland AvenueMadison, WI, United States; Heideman, W., Molecular and Environmental Toxicology Center, University of Wisconsin, 1300 University AvenueMadison, WI, United States, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, 777 Highland AvenueMadison, WI, United States","The swim bladder is a gas-filled organ that is used for regulating buoyancy and is essential for survival in most teleost species. In zebrafish, swim bladder development begins during embryogenesis and inflation occurs within 5 days post fertilization (dpf). Embryos exposed to 2,3,7,8-tetrachlorodibenzo-. p-dioxin (TCDD) before 96. h post fertilization (hpf) developed swim bladders normally until the growth/elongation phase, at which point growth was arrested. It is known that TCDD exposure causes heart malformations that lead to heart failure in zebrafish larvae, and that blood circulation is a key factor in normal development of the swim bladder. The adverse effects of TCDD exposure on the heart occur during the same period of time that swim bladder development and growth occurs. Based on this coincident timing, and the dependence of swim bladder development on proper circulatory development, we hypothesized that the adverse effects of TCDD on swim bladder development were secondary to heart failure. We compared swim bladder development in TCDD-exposed embryos to: (1) silent heart morphants, which lack cardiac contractility, and (2) transiently transgenic cmlc2:caAHR-2AtRFP embryos, which mimic TCDD-induced heart failure via heart-specific, constitutive activation of AHR signaling. Both of these treatment groups, which were not exposed to TCDD, developed hypoplastic swim bladders of comparable size and morphology to those found in TCDD-exposed embryos. Furthermore, in all treatment groups swim bladder development was arrested during the growth/elongation phase. Together, these findings support a potential role for heart failure in the inhibition of swim bladder development caused by TCDD. © 2015 Elsevier B.V.","Aryl hydrocarbon receptor; Development; Heart failure; Swim bladder; TCDD; Zebrafish","Alexander, R.M., The energetics of vertical migration by fishes (1972) Symp. Soc. Exp. Biol., 26, pp. 273-294; Alexander, R.M., Buoyancy (1993) The Physiology of Fishes, pp. 75-97. , CRC Press, Boca Raton, D.H. Evans (Ed.); Antkiewicz, D.S., Burns, C.G., Carney, S.A., Peterson, R.E., Heideman, W., Heart malformation is an early response to TCDD in embryonic zebrafish (2005) Toxicol. Sci., 84, pp. 368-377; Antkiewicz, D.S., Peterson, R.E., Heideman, W., Blocking expression of AHR2 and ARNT1 in zebrafish larvae protects against cardiac toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (2006) Toxicol. Sci., 94, pp. 175-182; Belair, C.D., Peterson, R.E., Heideman, W., Disruption of erythropoiesis by dioxin in the zebrafish (2001) Dev. Dyn., 222, pp. 581-594; Carney, S.A., Chen, J., Burns, C.G., Xiong, K.M., Peterson, R.E., Heideman, W., Aryl hydrocarbon receptor activation produces heart-specific transcriptional and toxic responses in developing zebrafish (2006) Mol. Pharmacol., 70, pp. 549-561; Carney, S.A., Peterson, R.E., Heideman, W., 2,3,7,8-Tetrachlorodibenzo-p-dioxin activation of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator pathway causes developmental toxicity through a CYP1A-independent mechanism in zebrafish (2004) Mol. Pharmacol., 66, pp. 512-521; Denton, E.J., The buoyancy of fish and cephalopods (1961) Prog. Biophys. Biophys. Chem., 11, pp. 177-234; Elonen, G.E., Sphear, R.L., Holcombe, G.W., Johnson, R.D., Comparative toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin to seven freshwater species during early life-stage development (1998) Environ. Toxicol. Chem., 17, pp. 472-483; Evans, H.M., A contribution to the anatomy and physiology of the air-bladder and Weberian ossicles in cyprinidae (1925) Proc. R. Soc. Lond., Ser. B, 97, pp. 545-576; Finney, J.L., Robertson, G.N., McGee, C.A., Smith, F.M., Croll, R.P., Structure and autonomic innervation of the swim bladder in the zebrafish (Danio rerio) (2006) J. Comp. Neurol., 495, pp. 587-606; Goolish, E.M., Okutake, K., Lack of gas bladder inflation by the larvae of zebrafish in the absence of an air-water interface (1999) J. Fish Biol., 55, pp. 1054-1063; Hankinson, O., The aryl hydrocarbon receptor complex (1995) Annu. Rev. Pharmacol. Toxicol., 35, pp. 307-340; Henry, T.R., Spitsbergen, J.M., Hornung, M.W., Abnet, C.C., Peterson, R.E., Early life stage toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in zebrafish (Danio rerio) (1997) Toxicol. Appl. Pharmacol., 142, pp. 56-68; Jönsson, M.E., Kubota, A., Timme-Laragy, A.R., Woodin, B., Stegeman, J.J., Ahr2-dependence of PCB126 effects on the swim bladder in relation to expression of CYP1 and cox-2 genes in developing zebrafish (2012) Toxicol. Appl. Pharmacol., 265, pp. 166-174; King-Heiden, T.C., Mehta, V., Xiong, K.M., Lanham, K.A., Antkiewicz, D.S., Ganser, A., Heideman, W., Peterson, R.E., Reproductive and developmental toxicity of dioxin in fish (2012) Mol. Cell. Endocrinol., 354, pp. 121-138; King Heiden, T.C., Spitsbergen, J., Heideman, W., Peterson, R.E., Persistent adverse effects on health and reproduction caused by exposure of zebrafish to 2,3,7,8-tetrachlorodibenzo-p-dioxin during early development and gonad differentiation (2009) Toxicol. Sci., 109, pp. 75-87; Lanham, K.A., Peterson, R.E., Heideman, W., Sensitivity to dioxin decreases as zebrafish mature (2012) Toxicol. Sci., 127, pp. 360-370; Lanham, K.A., Plavicki, J., Peterson, R.E., Heideman, W., Cardiac myocyte-specific AHR activation phenocopies TCDD-induced toxicity in zebrafish (2014) Toxicol. Sci., 141, pp. 141-154; Mehta, V., Peterson, R.E., Heideman, W., 2,3,7,8-Tetrachlorodibenzo-p-dioxin exposure prevents cardiac valve formation in developing zebrafish (2008) Toxicol. Sci., 104, pp. 303-311; Nguyen, L.P., Bradfield, C.A., The search for endogenous activators of the aryl hydrocarbon receptor (2008) Chem. Res. Toxicol., 21, pp. 102-116; Ortiz-Delgado, J.B., Sarasquete, C., Toxicity, histopathological alterations and immunohistochemical CYP1A induction in the early life stages of the seabream, Sparus aurata, following waterborne exposure to B(a)P and TCDD (2004) J. Mol. Histol., 35, pp. 29-45; Peterson, R.E., Theobald, H.M., Kimmel, G.L., Developmental and reproductive toxicity of dioxins and related compounds: cross-species comparisons (1993) Crit. Rev. Toxicol., 23, pp. 283-335; Plavicki, J., Hofsteen, P., Peterson, R.E., Heideman, W., Dioxin inhibits zebrafish epicardium and proepicardium development (2013) Toxicol. Sci., 131, pp. 558-567; Prasch, A.L., Tanguay, R.L., Mehta, V., Heideman, W., Peterson, R.E., Identification of zebrafish ARNT1 homologs: 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in the developing zebrafish requires ARNT1 (2006) Mol. Pharmacol., 69, pp. 776-787; Prasch, A.L., Teraoka, H., Carney, S.A., Dong, W., Hiraga, T., Stegeman, J.J., Heideman, W., Peterson, R.E., Aryl hydrocarbon receptor 2 mediates 2,3,7,8-tetrachlorodibenzo-p-dioxin developmental toxicity in zebrafish (2003) Toxicol. Sci., 76, pp. 138-150; Robertson, G.N., McGee, C.A.S., Dumbarton, T.C., Croll, R.P., Smith, F.M., Development of the swimbladder and its innervation in the zebrafish, Danio rerio (2007) J. Morphol., 268, pp. 967-985; Schmidt, J.V., Bradfield, C.A., Ah receptor signaling pathways (1996) Annu. Rev. Cell Dev. Biol., 12, pp. 55-89; Sehnert, A.J., Huq, A., Weinstein, B.M., Walker, C., Fishman, M., Stainier, D.Y.R., Cardiac troponin T is essential in sarcomere assembly and cardiac contractility (2002) Nat. Genet., 31, pp. 106-110; Stainier, D.Y., Weinstein, B.M., Detrich, H.W., Zon, L.I., Fishman, M.C., Cloche an early acting zebrafish gene, is required by both the endothelial and hematopoietic lineages (1995) Development, 121, pp. 3141-3150; Tanguay, R.L., Andreasen, E.A., Walker, M.K., Peterson, R.E., Dioxin toxicity and aryl hydrocarbon receptor signaling in fish (2005) Dioxins and Health, pp. 603-628. , John Wiley & Sons, Inc., New York, A. Schecter, T.A. Gasiewicz (Eds.); Teraoka, H., Dong, W., Ogawa, S., Tsukiyama, S., Okuhara, Y., Niiyama, M., Ueno, N., Hiraga, T., 2,3,7,8-Tetrachlorodibenzo-p-dioxin toxicity in the zebrafish embryo: altered regional blood flow and impaired lower jaw development (2002) Toxicol. Sci., 65, pp. 192-199; Walker, M.K., Peterson, R.E., Aquatic toxicity of dioxins and related chemicals (1994) Dioxins and Health, pp. 347-387. , Plenum Press, New York, A. Schecter (Ed.); Westerfield, M., (2000) The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio), , University of Oregon Press, Eugene, OR; Winata, C.L., Korzh, S., Kondrychyn, I., Korzh, V., Gong, Z., The role of vasculature and blood circulation in zebrafish swimbladder development (2010) BMC Dev. Biol., 10, p. 3; Winata, C.L., Korzh, S., Kondrychyn, I., Zheng, W., Korzh, V., Gong, Z., Development of zebrafish swimbladder: the requirements of hedgehog signaling in specification and organization of the three tissue layers (2009) Dev. Biol., 331, pp. 222-236; Yin, A., Korzh, S., Winata, C.L., Korzh, V., Gong, Z., Wnt signaling is required for early development of zebrafish swimbladder (2011) PLoS One, 30, p. e18431; Zeddies, D.G., Fay, R.R., Development of the acoustically evoked behavioral response in zebrafish to pure tones (2005) J. Exp. Biol., 208, pp. 1363-1372",Article,Scopus,2-s2.0-84924308250
"Han X., Chen C., Cheng G., Xie C., Yang M., Shou X., Sun C.","Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients",2015,"Cytokine","73","1",,"176","180",,,10.1016/j.cyto.2015.02.019,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924338616&partnerID=40&md5=5e1d7b32ca3a498b0f1e6bf6af565020","Department of Cardiology, Shaanxi Provincial People's HospitalXi'an, Shaanxi, China; Department of Cardiovascular Medicine, The First Affiliated Hospital of Medical School, Xi'an Jiaotong University, China; Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, China","Han, X., Department of Cardiology, Shaanxi Provincial People's HospitalXi'an, Shaanxi, China; Chen, C., Department of Cardiovascular Medicine, The First Affiliated Hospital of Medical School, Xi'an Jiaotong University, China, Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, China; Cheng, G., Department of Cardiology, Shaanxi Provincial People's HospitalXi'an, Shaanxi, China; Xie, C., Department of Cardiology, Shaanxi Provincial People's HospitalXi'an, Shaanxi, China; Yang, M., Department of Cardiology, Shaanxi Provincial People's HospitalXi'an, Shaanxi, China; Shou, X., Department of Cardiology, Shaanxi Provincial People's HospitalXi'an, Shaanxi, China; Sun, C., Department of Cardiovascular Medicine, The First Affiliated Hospital of Medical School, Xi'an Jiaotong University, China","Background: Fibroblast growth factor 21 (FGF-21), a newly discovered adipokine, plays an important role in glucose and lipid metabolism and is associated with the development of metabolic disorders, such as obesity, and cardiovascular diseases. This study aimed to investigate the association of serum FGF-21 levels with the presence of atrial fibrillation (AF). Methods: Total 113 patients with AF and 60 healthy control subjects were enrolled. All AF cases were categorized into paroxysmal, persistent and permanent AF. Serum levels of FGF-21, high-sensitivity C-reactive protein (hs-CRP) and other routine biochemical parameters were measured. Results: Serum FGF-21 levels were significantly higher in AF patients than in controls (250.12. ±. 78.48 vs. 144.15. ±. 56.31. pg/mL, P<. 0.001), and hs-CRP levels were significantly higher in AF patients than in controls (2.36. ±. 1.10 vs. 1.24. ±. 0.82, P<. 0.05). In subgroup studies, patients with permanent AF had higher serum FGF-21 levels than those with persistent and paroxysmal AF. After the adjustment of the age, gender and body mass index, serum FGF-21 levels were positively correlated with left atrial diameter (LAD) (. P<. 0.01). A multivariate logistic regression analysis showed that FGF-21, LAD and hs-CRP were correlated with AF (. P<. 0.05). Conclusions: Our data demonstrate that serum FGF-21 levels are elevated in AF patients and associated with atrial remolding, independent of established risk factors such as C-reactive protein. © 2015 Elsevier Ltd.","Adipokine; Atrial fibrillation; Fibroblast growth factor 21; Obesity","Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., Heart disease and stroke statistics-2013 update: a report from the American Heart Association (2013) Circulation, 127, p. e6; Benjamin, E.J., Levy, D., Vaziri, S.M., D'Agostino, R.B., Belanger, A.J., Wolf, P.A., Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study (1994) JAMA, 271, pp. 840-844; Wang, T.J., Parise, H., Levy, D., D'Agostino, R.B., Wolf, P.A., Vasan, R.S., Obesity and the risk of new-onset atrial fibrillation (2004) JAMA, 292, pp. 2471-2477; Frost, L., Hune, L.J., Vestergaard, P., Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish diet, cancer, and health study (2005) Am J Med, 118, pp. 489-495; Al Chekakie, M.O., Welles, C.C., Metoyer, R., Ibrahim, A., Shapira, A.R., Cytron, J., Pericardial fat is independently associated with human atrial fibrillation (2010) J Am Coll Cardiol, 56, pp. 784-788; Wong, C.X., Abed, H.S., Molaee, P., Nelson, A.J., Brooks, A.G., Sharma, G., Pericardial fat is associated with atrial fibrillation severity and ablation outcome (2011) J Am Coll Cardiol, 57, pp. 1745-1751; Thanassoulis, G., Massaro, J.M., O'Donnell, C.J., Hoffmann, U., Levy, D., Ellinor, P.T., Pericardial fat is associated with prevalent atrial fibrillation the Framingham heart study (2010) Circulation: Arrhythmia Electrophysiol, 3, pp. 345-350; Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., FGF-21 as a novel metabolic regulator (2005) J Clin Invest, 115, pp. 1627-1635; Kharitonenkov, A., Wroblewski, V.J., Koester, A., Chen, Y.-F., Clutinger, C.K., Tigno, X.T., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 (2007) Endocrinology, 148, pp. 774-781; Dushay, J., Chui, P.C., Gopalakrishnan, G.S., Varela-Rey, M., Crawley, M., Fisher, F.M., Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease (2010) Gastroenterology, 139, pp. 456-463; Zhang, X., Yeung, D.C., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans (2008) Diabetes, 57, pp. 1246-1253; Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A., Folli, F., DeFronzo, R.A., Tripathy, D., Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance (2009) Diabetes Care, 32, pp. 1542-1546; Lin, Z., Wu, Z., Yin, X., Liu, Y., Yan, X., Lin, S., Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile (2010) PloS one, 5, p. e15534; Chow, W.S., Xu, A., Woo, Y.C., Tso, A.W., Cheung, S.C., Fong, C.H., Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors (2013) Arterioscler Throm Vas Biol, 33, pp. 2454-2459; Semba, R., Crasto, C., Strait, J., Sun, K., Schaumberg, D., Ferrucci, L., Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults (2012) J Hum Hypertens, 27, pp. 397-399; Lee, Y., Lim, S., Hong, E.S., Kim, J.H., Moon, M.K., Chun, E.J., Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status (2014) Clin Endocrinol (Oxf), 80, pp. 57-64; Fuster, V.R.L., Cannom, D.S., Crijns, H.J., Curtis, A.B., Ellenbogen, K.A., Halperin, J.L.L.H.J., ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society (2006) Circulation, 114, pp. e257-e354; Venteclef, N., Guglielmi, V., Balse, E., Gaborit, B., Cotillard, A., Atassi, F., Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines (2013) Europ Heart J, , eht099; Lin, Y.K., Chen, Y.C., Chen, J.H., Chen, S.A., Chen, Y.J., Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation (2012) Basic Res Cardiol, 107, p. 293; Tyynismaa, H., Raivio, T., Hakkarainen, A., Ortega-Alonso, A., Lundbom, N., Kaprio, J., Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins (2010) J Clin Endocrinol Metab, 96, pp. E351-E355; Yan, H., Xia, M., Chang, X., Xu, Q., Bian, H., Zeng, M., Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study (2011) PloS one, 6, p. e24895; Mutanen, A., Heikkilä, P., Lohi, J., Raivio, T., Jalanko, H., Pakarinen, M.P., Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure (2014) J Hepatol, 60, pp. 183-190; Li, H., Fang, Q., Gao, F., Fan, J., Zhou, J., Wang, X., Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride (2010) J Hepatol, 53, pp. 934-940; Shen, Y., Ma, X., Zhou, J., Pan, X., Hao, Y., Zhou, M., Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease (2013) Cardiovas Diabetol, 12, p. 124; Planavila, A., Redondo, I., Hondares, E., Vinciguerra, M., Munts, C., Iglesias, R., Fibroblast growth factor 21 protects against cardiac hypertrophy in mice (2013) Nat Commun, 4; Liu, S.Q., Roberts, D., Kharitonenkov, A., Zhang, B., Hanson, S.M., Li, Y.C., Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue (2013) Sci Rep, 3, p. 2767; Patel, V., Adya, R., Chen, J., Ramanjaneya, M., Bari, M.F., Bhudia, S.K., Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts (2014) PloS one, 9, p. e87102; Dostálová, I., Haluzikova, D., Haluzik, M., Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus (2009) Physiol Res, 58, pp. 1-7; Pinto, A., Tuttolomondo, A., Casuccio, A., Di Raimondo, D., Di Sciacca, R., Arnao, V., Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF) (2009) Clin Sci (Lond), 116, pp. 781-789; Marott, S.C., Nordestgaard, B.G., Zacho, J., Friberg, J., Jensen, G.B., Tybjærg-Hansen, A., Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population (2010) J Am Coll Cardiol, 56, pp. 789-795; Özcan, K.S., Güngör, B., Altay, S., Osmonov, D., Ekmekçi, A., Özpamuk, F., Increased level of resistin predicts development of atrial fibrillation (2014) J Cardiol, 63, pp. 308-312",Article,Scopus,2-s2.0-84924338616
"Gugliucci A., Caccavello R., Nassar H., Ahmad W.A., Sinnreich R., Kark J.D.","Low protective PON1 lactonase activity in an Arab population with high rates of coronary heart disease and diabetes",2015,"Clinica Chimica Acta","445",,,"41","47",,,10.1016/j.cca.2015.03.012,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925424571&partnerID=40&md5=673521885323515a8aa0f1d012ca96a2","Glycation Oxidation and Disease Laboratory, Department of Research, College of Osteopathic Medicine, Touro University CaliforniaVallejo, CA, United States; Dept of Cardiology, Hadassah Medical CenterEin Kerem, Jerusalem, Israel; St Joseph HospitalJerusalem, Israel; Hebrew University, Hadassah School of Public Health and Community MedicineEin Kerem, Jerusalem, Israel","Gugliucci, A., Glycation Oxidation and Disease Laboratory, Department of Research, College of Osteopathic Medicine, Touro University CaliforniaVallejo, CA, United States; Caccavello, R., Glycation Oxidation and Disease Laboratory, Department of Research, College of Osteopathic Medicine, Touro University CaliforniaVallejo, CA, United States; Nassar, H., Dept of Cardiology, Hadassah Medical CenterEin Kerem, Jerusalem, Israel, St Joseph HospitalJerusalem, Israel; Ahmad, W.A., Hebrew University, Hadassah School of Public Health and Community MedicineEin Kerem, Jerusalem, Israel; Sinnreich, R., Hebrew University, Hadassah School of Public Health and Community MedicineEin Kerem, Jerusalem, Israel; Kark, J.D., Hebrew University, Hadassah School of Public Health and Community MedicineEin Kerem, Jerusalem, Israel","Background: Recent studies showing that high density lipoproteins (HDL) can effect plaque regression indicate that recent trial failures do not exclude an atheroprotective role of HDL. Instead, they highlight differences between HDL function and measured HDL-cholesterol (HDL-C). PON1 is one key functional activity of HDL. Urban Palestinians have lower HDL-C and a higher incidence and mortality of coronary heart disease than those of Israelis. We hypothesized that the cardioprotective PON1 lactonase and arylesterase activities and PON1 functional genotype may differ between Palestinians and Israelis. Methods: We measured PON1 activities in a cross-sectional population-based study of Palestinian (n = 960) and Israeli (n = 694) residents in Jerusalem, 1654 participants in all. Results: Palestinians had high prevalences of obesity and diabetes and low mean concentrations of HDL-cholesterol (0.97mmol/l in men and 1.19mmol/l in women). Lactonase and arylesterase activities were lower by 10.8% (p=1.2*10-14) and 2.7% (p&lt;0.0005), respectively, in Palestinians as compared to Israelis. The functional genotype distribution, demonstrated by plotting paraoxonase vs lactonase activities, showed a modest between-group difference (p=0.024), with 12.1% RR in Palestinian Arabs vs 8.4% in Israeli Jews, but no overall difference in allele frequencies. Lactonase correlated inversely with age (Spearman's rho=-156), weakly with BMI (-059), positively with HDL-C (173) and non-HDL-C (103), but was not associated with triglycerides or fasting glucose. Palestinians showed consistently lower lactonase activity in logistic regression models adjusted for multiple covariates and for functional genotype (odds ratios of 1.81 and 1.98, respectively, for the lower fifth vs the upper 4 fifths of lactonase activity p&lt;0.0001). Conclusion: We showed a lower physiologically-significant lactonase PON1 activity in an Arab population, a finding consistent with the high cardiovascular and diabetes risk of Palestinians. © 2015 Elsevier B.V.","Cardiovascular risk; High-density lipoprotein; Jewish; Lactonase; Palestinians; PON1","Kark, J.D., Fink, R., Adler, B., Goldberger, N., Goldman, S., The incidence of coronary heart disease among Palestinians and Israelis in Jerusalem (2006) Int J Epidemiol, 35, pp. 448-457; Kark, J.D., Gordon, E.S., Haklai, Z., Coronary heart disease mortality among Arab and Jewish residents of Jerusalem (2000) Lancet, 356, pp. 1410-1411; Israel Ministry of Health (2005) The State of Health of the Arab Population 2004, , (Publication No. 226) (Hebrew); Kalter-Leibovici, O., Chetrit, A., Lubin, F., Atamna, A., Alpert, G., Ziv, A., Adult-onset diabetes among Arabs and Jews in Israel: a population-based study (2012) Diabet Med, 29, pp. 748-754; Abdul-Rahim, H.F., Husseini, A., Bjertness, E., Giacaman, R., Gordon, N.H., Jervell, J., The metabolic syndrome in the West Bank population: an urban-rural comparison (2001) Diabetes Care, 24, pp. 275-279; Voight, B.F., Peloso, G.M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M.K., Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study (2012) Lancet, 380, pp. 572-580; Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy (2011) N Engl J Med, 365, pp. 2255-2267; Kontush, A., HDL-mediated mechanisms of protection in cardiovascular disease (2014) Cardiovasc Res, 103, pp. 341-349; Mackness, B., Durrington, P.N., Abuashia, B., Boulton, A.J., Mackness, M.I., Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy (2000) Clin Sci, 98, pp. 355-363; Huang, Y., Wu, Z., Riwanto, M., Gao, S., Levison, B.S., Gu, X., Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex (2013) J Clin Invest, 123, pp. 3815-3828; Aviram, M., Vaya, J., Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion (2013) Curr Opin Lipidol, 24, pp. 339-344; Camps, J., Marsillach, J., Joven, J., The paraoxonases: role in human diseases and methodological difficulties in measurement (2009) Crit Rev Clin Lab Sci, 46, pp. 83-106; Bar-Rogovsky, H., Hugenmatter, A., Tawfik, D.S., The evolutionary origins of detoxifying enzymes: the mammalian serum paraoxonases (PONs) relate to bacterial homoserine lactonases (2013) J Biol Chem, 288, pp. 23914-23927; Mueller, R.F., Hornung, S., Furlong, C.E., Anderson, J., Giblett, E.R., Motulsky, A.G., Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies (1983) Am J Hum Genet, 35, pp. 393-408; Richter, R.J., Jarvik, G.P., Furlong, C.E., Paraoxonase 1 status as a risk factor for disease or exposure (2010) Adv Exp Med Biol, 660, pp. 29-35; Draganov, D.I., Lactonases with organophosphatase activity: structural and evolutionary perspectives (2010) Chem Biol Interact, 187, pp. 370-372; Rainwater, D.L., Rutherford, S., Dyer, T.D., Rainwater, E.D., Cole, S.A., Vandeberg, J.L., Determinants of variation in human serum paraoxonase activity (2009) Heredity, 102, pp. 147-154; Merom, D., Sinnreich, R., Aboudi, V., Kark, J.D., Nassar, H., Lifestyle physical activity among urban Palestinians and Israelis: a cross-sectional comparison in the Palestinian-Israeli Jerusalem risk factor study (2012) BMC Public Health, 12, p. 90; Kark, J.D., Nassar, H., Shaham, D., Sinnreich, R., Goldberger, N., Aboudi, V., Leukocyte telomere length and coronary artery calcification in Palestinians (2013) Atherosclerosis, 229, pp. 363-368; Gugliucci, A., Activation of paraoxonase 1 is associated with HDL remodeling ex vivo (2014) Clin Chim Acta, 429, pp. 38-45; Gugliucci, A., Caccavello, R., Kotani, K., Sakane, N., Kimura, S., Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess hdl function (2013) Clin Chim Acta, 415, pp. 162-168; Jabara, R., Namouz, S., Kark, J.D., Lotan, C., Risk characteristics of Arab and Jewish women with coronary heart disease in Jerusalem (2007) Isr Med Assoc J IMAJ, 9, pp. 316-320; Weiss, R., Nassar, H., Sinnreich, R., Kark, J.D., Differences in the triglyceride to HDL cholesterol ratio between Palestinian and Israeli adults (2015) PLoS One, 10 (1), p. e0116617; Tang, W.H., Hartiala, J., Fan, Y., Wu, Y., Stewart, A.F., Erdmann, J., Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk (2012) Arterioscler Thromb Vasc, 32, pp. 2803-2812; Feig, J.E., Hewing, B., Smith, J.D., Hazen, S.L., Fisher, E.A., High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies (2014) Circ Res, 114, pp. 205-213; Costa, L.G., Giordano, G., Furlong, C.E., Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on (2011) Biochem Pharmacol, 81, pp. 337-344; Camont, L., Lhomme, M., Rached, F., Le Goff, W., Negre-Salvayre, A., Salvayre, R., Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities (2013) Arterioscler Thromb Vasc, 33, pp. 2715-2723; Camont, L., Chapman, M.J., Kontush, A., Biological activities of HDL subpopulations and their relevance to cardiovascular disease (2011) Trends Mol Med, 17, pp. 594-603; Kotani, K., Sakane, N., Sano, Y., Tsuzaki, K., Matsuoka, Y., Egawa, K., Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women (2009) J Clin Biochem Nutr, 45, pp. 329-334; Grubisa, I., Otasevic, P., Dimkovic, N., Nedeljkovic, I., Toljic, B., Vucinic, N., Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis (2013) Srp Arh Celok Lek, 141, pp. 629-633; Lawlor, D.A., Day, I.N., Gaunt, T.R., Hinks, L.J., Briggs, P.J., Kiessling, M., The association of the PON1 q192r polymorphism with coronary heart disease: findings from the British Women's Heart and Health Cohort Study and a meta-analysis (2004) BMC Genet, 5, p. 17; Brophy, V.H., Jarvik, G.P., Richter, R.J., Rozek, L.S., Schellenberg, G.D., Furlong, C.E., Analysis of paraoxonase (PON1) l55m status requires both genotype and phenotype (2000) Pharmacogenetics, 10, pp. 453-460; Kim, D.S., Maden, S.K., Burt, A.A., Ranchalis, J.E., Furlong, C.E., Jarvik, G.P., Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects (2013) Lipids Health Dis, 12, p. 183; Kim, D.S., Burt, A.A., Ranchalis, J.E., Richter, R.J., Marshall, J.K., Nakayama, K.S., Dietary cholesterol increases paraoxonase 1 enzyme activity (2012) J Lipid Res, 53, pp. 2450-2458; Boshtam, M., Razavi, A.E., Pourfarzam, M., Ani, M., Naderi, G.A., Basati, G., Serum paraoxonase 1 activity is associated with fatty acid composition of high density lipoprotein (2013) Dis Markers, 35, pp. 273-280; Arunima, S., Rajamohan, T., Effect of virgin coconut oil enriched diet on the antioxidant status and paraoxonase 1 activity in ameliorating the oxidative stress in rats - a comparative study (2013) Food Funct, 4, pp. 1402-1409; Schrader, C., Rimbach, G., Determinants of paraoxonase 1 status: genes, drugs and nutrition (2011) Curr Med Chem, 18, pp. 5624-5643; Cohen, E., Aviram, M., Khatib, S., Artul, F., Rabin, A., Mannheim, D., Human carotid plaque phosphatidyl choline (PC), specifically interacts with paraoxonase1 (PON1), increases its activity and enhances its uptake by macrophage at the expense of its binding to HDL (2014) Free Radic Biol Med, 76, pp. 14-24; Rosenblat, M., Ward, S., Volkova, N., Hayek, T., Aviram, M., VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies (2012) Biofactors, 38, pp. 292-299; Abu-Saad, K., Murad, H., Lubin, F., Freedman, L.S., Ziv, A., Alpert, G., Jews and Arabs in the same region in Israel exhibit major differences in dietary patterns (2012) J Nutr, 142, pp. 2175-2181; Mackness, B., Durrington, P.N., Boulton, A.J., Hine, D., Mackness, M.I., Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls (2002) Eur J Clin Invest, 32, pp. 259-264; Ostrer, H., Skorecki, K., The population genetics of the Jewish people (2013) Hum Genet, 132, pp. 119-127",Article,Scopus,2-s2.0-84925424571
"Muscogiuri G., Nuzzo V., Gatti A., Zuccoli A., Savastano S., Di Somma C., Pivonello R., Orio F., Colao A.","Hypovitaminosis D: a novel risk factor for coronary heart disease in type 2 diabetes?",2015,"Endocrine",,,,"","",6,,10.1007/s12020-015-0609-7,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928689600&partnerID=40&md5=1290dfa961ae9b3bcb0b1362347c5986","Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli “Federico II”, via S. Pansini 5Naples, Italy; Internal Medicine Unit, San Gennaro HospitalNaples, Italy; Diabetology Unit, San Gennaro HospitalNaples, Italy; Naples, Italy; Department of Endocrinology, University “Parthenope” NaplesNaples, Italy; Endocrinology of Fertile Age, “S. Giovanni di Dio e Ruggi d’Aragona” University Hospital SalernoSalerno, Italy","Muscogiuri, G., Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli “Federico II”, via S. Pansini 5Naples, Italy; Nuzzo, V., Internal Medicine Unit, San Gennaro HospitalNaples, Italy; Gatti, A., Diabetology Unit, San Gennaro HospitalNaples, Italy; Zuccoli, A., Internal Medicine Unit, San Gennaro HospitalNaples, Italy; Savastano, S., Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli “Federico II”, via S. Pansini 5Naples, Italy; Di Somma, C., Naples, Italy; Pivonello, R., Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli “Federico II”, via S. Pansini 5Naples, Italy; Orio, F., Department of Endocrinology, University “Parthenope” NaplesNaples, Italy, Endocrinology of Fertile Age, “S. Giovanni di Dio e Ruggi d’Aragona” University Hospital SalernoSalerno, Italy; Colao, A., Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli “Federico II”, via S. Pansini 5Naples, Italy","Vitamin D (25(OH)D) levels have been associated with cardiovascular disease. Thus, the aim of our study was to investigate the association of 25(OH)D levels with coronary heart disease (CHD) in 698 consecutive type 2 diabetic outpatients. 698 consecutive type 2 diabetic outpatients (25.2 % men, age 66 ± 9 years) and 100 (90 % men, age 65 ± 13 years) age-matched non-diabetic volunteers were enrolled. 25(OH)D assay and the main cardiovascular risk factors were explored. 25(OH)D concentration was 22 ± 10 ng/ml in control subjects and 18.23 ± 10 ng/ml in diabetic patients (p < 0.01). The prevalence of hypovitaminosis D was higher in diabetic patients than in control subjects (90 vs. 83 %, p < 0.01). Diabetic subjects with hypovitaminosis D had higher prevalence of high values of A1C (p < 0.01), BMI (p < 0.01), LDL cholesterol (p < 0.01), triglycerides (p < 0.01), and glycemia (p < 0.01) than their vitamin D-sufficient counterparts. 25(OH)D and HDL cholesterol were lower (p < 0.01), while BMI (p < 0.01), age (p < 0.01), systolic (p < 0.01) and diastolic blood pressure (p < 0.01), diabetes duration (p < 0.01), A1C (p < 0.01), glycemia (p < 0.01), fibrinogen (p < 0.01), triglycerides (p < 0.01), and total (p < 0.01) and LDL cholesterol (p < 0.01) were higher in diabetic subjects with CHD than diabetic subjects without CHD. At the logistic regression analysis, the association of vitamin D with CHD was lost, while sex (p = 0.026), diabetes duration (p = 0.023), and age (p = 0.024) were the most powerful predictors of CHD. The current study demonstrates that 25(OH)D does not have a direct effect on CHD but may have an indirect effect mediated by cardiovascular risk factors such as diabetes duration, age, and sex. © 2015 Springer Science+Business Media New York","Cardiovascular disease; Coronary heart disease; Hypovitaminosis D; Obesity; Type 2 diabetes; Vitamin D",,Article in Press,Scopus,2-s2.0-84928689600
"Rogers T., Lederman R.J.","Interventional CMR: Clinical Applications and Future Directions",2015,"Current Cardiology Reports","17","5",,"","",9,,10.1007/s11886-015-0580-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928319804&partnerID=40&md5=55af073d6dce19e7bc6844a9efeb25eb","Cardiovascular and Pulmonary Branch, Division of Intramural Research, National Heart Lung and Blood Institute, National Institutes of Health, Building 10, Room 2c713Bethesda, MD, United States","Rogers, T., Cardiovascular and Pulmonary Branch, Division of Intramural Research, National Heart Lung and Blood Institute, National Institutes of Health, Building 10, Room 2c713Bethesda, MD, United States; Lederman, R.J., Cardiovascular and Pulmonary Branch, Division of Intramural Research, National Heart Lung and Blood Institute, National Institutes of Health, Building 10, Room 2c713Bethesda, MD, United States","Interventional cardiovascular magnetic resonance (iCMR) promises to enable radiation-free catheterization procedures and to enhance contemporary image guidance for structural heart and electrophysiological interventions. However, clinical translation of exciting pre-clinical interventions has been limited by availability of devices that are safe to use in the magnetic resonance (MR) environment. We discuss challenges and solutions for clinical translation, including MR-conditional and MR-safe device design, and how to configure an interventional suite. We review the recent advances that have already enabled diagnostic MR right heart catheterization and simple electrophysiologic ablation to be performed in humans and explore future clinical applications. © 2015, Springer Science+Business Media New York (outside the USA).","Cardiac electrophysiology; Cardiovascular catheterization; Electrophysiology mapping and ablation; Interventional cardiovascular MRI; MRI catheterization; Real-time MRI; Structural heart disease","de Silva, R., Gutierrez, L.F., Raval, A.N., McVeigh, E.R., Ozturk, C., Lederman, R.J., X-ray fused with magnetic resonance imaging (XFM) to target endomyocardial injections: validation in a swine model of myocardial infarction (2006) Circulation, 114 (22), pp. 2342-2350; Dori, Y., Sarmiento, M., Glatz, A.C., Gillespie, M.J., Jones, V.M., Harris, M.A., X-ray magnetic resonance fusion to internal markers and utility in congenital heart disease catheterization (2011) Circ: Cardiovascular Imaging, 4 (4), pp. 415-424; Faranesh, A.Z., Kellman, P., Ratnayaka, K., Lederman, R.J., Integration of cardiac and respiratory motion into MRI roadmaps fused with x-ray (2013) Med Phys, 40 (3), p. 032302; Abu Hazeem, A.A., Dori, Y., Whitehead, K.K., Harris, M.A., Fogel, M.A., Gillespie, M.J., X-ray magnetic resonance fusion modality may reduce radiation exposure and contrast dose in diagnostic cardiac catheterization of congenital heart disease (2014) Catheter Cardiovasc Interv; Avula, S., Mallucci, C.L., Pizer, B., Garlick, D., Crooks, D., Abernethy, L.J., Intraoperative 3-Tesla MRI in the management of paediatric cranial tumours–initial experience (2012) Pediatr Radiol, 42 (2), pp. 158-167; Ratnayaka, K., Faranesh, A.Z., Hansen, M.S., Stine, A.M., Halabi, M., Barbash, I.M., Real-time MRI-guided right heart catheterization in adults using passive catheters (2013) Eur Heart J, 34 (5), pp. 380-389. , This paper shows that MRI right heart catheterization can be implemented into a clinically-realistic workflow for standard clinical practice; Rogers, T., Ratnayaka, K., Lederman, R.J., MRI catheterization in cardiopulmonary disease (2014) Chest, 145 (1), pp. 30-36; Dukkipati, S.R., Mallozzi, R., Schmidt, E.J., Holmvang, G., d’Avila, A., Guhde, R., Electroanatomic mapping of the left ventricle in a porcine model of chronic myocardial infarction with magnetic resonance-based catheter tracking (2008) Circulation, 118 (8), pp. 853-862; Yutzy, S.R., Duerk, J.L., Pulse sequences and system interfaces for interventional and real-time MRI (2008) J Magn Resonance Imaging: JMRI, 27 (2), pp. 267-275; Pruessmann, K.P., Weiger, M., Scheidegger, M.B., Boesiger, P., SENSE: sensitivity encoding for fast MRI (1999) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 42 (5), pp. 952-962. , COI: 1:STN:280:DC%2BD3c%2FhtFCruw%3D%3D; Kellman, P., Epstein, F.H., McVeigh, E.R., Adaptive sensitivity encoding incorporating temporal filtering (TSENSE) (2001) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 45 (5), pp. 846-852. , COI: 1:STN:280:DC%2BD3MvosVWrtQ%3D%3D; Griswold, M.A., Jakob, P.M., Heidemann, R.M., Nittka, M., Jellus, V., Wang, J., Generalized autocalibrating partially parallel acquisitions (GRAPPA) (2002) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 47 (6), pp. 1202-1210; Johnson, J.N., Hornik, C.P., Li, J.S., Benjamin, D.K., Jr., Yoshizumi, T.T., Reiman, R.E., Cumulative radiation exposure and cancer risk estimation in children with heart disease (2014) Circulation, 130 (2), pp. 161-167; Fratz, S., Chung, T., Greil, G., Samyn, M., Taylor, A., Valsangiacomo Buechel, E., Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease (2013) J Cardiovasc Magn Reson, 15 (1), p. 51; Venneri, L., Rossi, F., Botto, N., Andreassi, M.G., Salcone, N., Emad, A., Cancer risk from professional exposure in staff working in cardiac catheterization laboratory: insights from the National Research Council’s Biological Effects of Ionizing Radiation VII Report (2009) Am Heart J, 157 (1), pp. 118-124; Chambers, C.E., Fetterly, K.A., Holzer, R., Lin, P.J., Blankenship, J.C., Balter, S., Radiation safety program for the cardiac catheterization laboratory (2011) Catheterization Cardiovascular Interv: Off J Soc Cardiac Angiography Interv, 77 (4), pp. 546-556; Barbash, I.M., Saikus, C.E., Faranesh, A.Z., Ratnayaka, K., Kocaturk, O., Chen, M.Y., Direct percutaneous left ventricular access and port closure: pre-clinical feasibility (2011) J Am Coll Cardiol Intv, 4 (12), pp. 1318-1325; Halabi, M., Ratnayaka, K., Faranesh, A.Z., Hansen, M.S., Barbash, I.M., Eckhaus, M.A., Transthoracic delivery of large devices into the left ventricle through the right ventricle and interventricular septum: preclinical feasibility (2013) J Cardiovascular Magn Resonance: Off J Soc Cardiovascular Magn Resonance, 15 (1), p. 10; Ratnayaka, K., Saikus, C.E., Faranesh, A.Z., Bell, J.A., Barbash, I.M., Kocaturk, O., Closed-chest transthoracic magnetic resonance imaging-guided ventricular septal defect closure in swine (2011) J Am Coll Cardiol Intv, 4 (12), pp. 1326-1334; Raval, A.N., Telep, J.D., Guttman, M.A., Ozturk, C., Jones, M., Thompson, R.B., Real-time magnetic resonance imaging-guided stenting of aortic coarctation with commercially available catheter devices in swine (2005) Circulation, 112 (5), pp. 699-706; Raman, V.K., Karmarkar, P.V., Guttman, M.A., Dick, A.J., Peters, D.C., Ozturk, C., Real-time magnetic resonance-guided endovascular repair of experimental abdominal aortic aneurysm in swine (2005) J Am Coll Cardiol, 45 (12), pp. 2069-2077; Eggebrecht, H., Kuhl, H., Kaiser, G.M., Aker, S., Zenge, M.O., Stock, F., Feasibility of real-time magnetic resonance-guided stent-graft placement in a swine model of descending aortic dissection (2006) Eur Heart J, 27 (5), pp. 613-620; Buecker, A., Spuentrup, E., Grabitz, R., Freudenthal, F., Muehler, E., Schaeffter, T., Magnetic resonance-guided placement of atrial septal closure device in animal model of patent foramen ovale (2002) Circulation, 106, pp. 511-515; Rickers, C., Jerosch-Herold, M., Hu, X., Murthy, N., Wang, X., Kong, H., Magnetic resonance image-guided transcatheter closure of atrial septal defects (2003) Circulation, 107 (1), pp. 132-138; Raval, A.N., Karmarkar, P.V., Guttman, M.A., Ozturk, C., Desilva, R., Aviles, R.J., Real-time MRI guided atrial septal puncture and balloon septostomy in swine (2006) Catheterization Cardiovascular Interv: Off J Soc Cardiac Angiography Interv, 67 (4), pp. 637-643; Bucker, A., Neuerburg, J.M., Adam, G.B., Glowinski, A., Schaeffter, T., Rasche, V., Real-time MR guidance for inferior vena cava filter placement in an animal model (2001) J Vascular Interv Radiol: JVIR, 12 (6), pp. 753-756. , COI: 1:STN:280:DC%2BD3Mzhs1Kjsg%3D%3D; Shih, M.C., Rogers, W.J., Bonatti, H., Hagspiel, K.D., Real-time MR-guided retrieval of inferior vena cava filters: an in vitro and animal model study (2011) J Vascular Interv Radiol: JVIR, 22 (6), pp. 843-850; Buecker, A., Neuerburg, J.M., Adam, G.B., Glowinski, A., Schaeffter, T., Rasche, V., Real-time MR fluoroscopy for MR-guided iliac artery stent placement (2000) J Magn Resonance Imaging: JMRI, 12 (4), pp. 616-622. , COI: 1:STN:280:DC%2BD3crgtVGquw%3D%3D; Feng, L., Dumoulin, C.L., Dashnaw, S., Darrow, R.D., Delapaz, R.L., Bishop, P.L., Feasibility of stent placement in carotid arteries with real-time MR imaging guidance in pigs (2005) Radiology, 234 (2), pp. 558-562; Elgort, D.R., Hillenbrand, C.M., Zhang, S., Wong, E.Y., Rafie, S., Lewin, J.S., Image-guided and -monitored renal artery stenting using only MRI (2006) J Magn Resonance Imaging: JMRI, 23 (5), pp. 619-627; Fink, C., Bock, M., Umathum, R., Volz, S., Zuehlsdorff, S., Grobholz, R., Renal embolization: feasibility of magnetic resonance-guidance using active catheter tracking and intraarterial magnetic resonance angiography (2004) Investig Radiol, 39 (2), pp. 111-119; Seppenwoolde, J.H., Bartels, L.W., van der Weide, R., Nijsen, J.F., van het Schip, A.D., Bakker, C.J., Fully MR-guided hepatic artery catheterization for selective drug delivery: a feasibility study in pigs (2006) J Magn Resonance Imaging: JMRI, 23 (2), pp. 123-129; Kuehne, T., Saeed, M., Higgins, C.B., Gleason, K., Krombach, G.A., Weber, O.M., Endovascular stents in pulmonary valve and artery in swine: feasibility study of MR imaging-guided deployment and postinterventional assessment (2003) Radiology, 226 (2), pp. 475-481; Kahlert, P., Parohl, N., Albert, J., Schafer, L., Reinhardt, R., Kaiser, G.M., Real-time magnetic resonance imaging-guided transarterial aortic valve implantation: in vivo evaluation in swine (2012) J Am Coll Cardiol, 59 (2), pp. 192-193; Spuentrup, E., Ruebben, A., Schaeffter, T., Manning, W.J., Gunther, R.W., Buecker, A., Magnetic resonance–guided coronary artery stent placement in a swine model (2002) Circulation, 105 (7), pp. 874-879; Omary, R.A., Green, J.D., Schirf, B.E., Li, Y., Finn, J.P., Li, D., Real-time magnetic resonance imaging-guided coronary catheterization in swine (2003) Circulation, 107 (21), pp. 2656-2659; Unal, O., Li, J., Cheng, W., Yu, H., Strother, C.M., MR-visible coatings for endovascular device visualization (2006) J Magn Resonance Imaging: JMRI, 23 (5), pp. 763-769; Dumoulin, C.L., Souza, S.P., Darrow, R.D., Real-time position monitoring of invasive devices using magnetic resonance (1993) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 29 (3), pp. 411-415. , COI: 1:STN:280:DyaK3s7ps1CktQ%3D%3D; Ladd, M.E., Zimmermann, G.G., Quick, H.H., Debatin, J.F., Boesiger, P., von Schulthess, G.K., Active MR visualization of a vascular guidewire in vivo (1998) J Magn Resonance Imaging: JMRI, 8 (1), pp. 220-225. , COI: 1:STN:280:DyaK1c7lvF2hsg%3D%3D; McKinnon, G.C., Debatin, J.F., Leung, D.A., Wildermuth, S., Holtz, D.J., von Schulthess, G.K., Towards active guidewire visualization in interventional magnetic resonance imaging (1996) Magma, 4 (1), pp. 13-18. , COI: 1:STN:280:DyaK28zntVSmug%3D%3D; Ocali, O., Atalar, E., Intravascular magnetic resonance imaging using a loopless catheter antenna (1997) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 37 (1), pp. 112-118. , COI: 1:STN:280:DyaK2s7jtlansA%3D%3D; Nitz, W., Oppelt, A., Renz, W., Manke, C., Lenhart, M., Link, J., On the heating of linear conductive structures as guide wires and catheters in interventional MRI (2001) J Magn Resonance Imaging: JMRI, 13, pp. 105-114. , COI: 1:STN:280:DC%2BD3M3itlGgsw%3D%3D; Nordbeck, P., Fidler, F., Weiss, I., Warmuth, M., Friedrich, M.T., Ehses, P., Spatial distribution of RF-induced E-fields and implant heating in MRI (2008) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 60 (2), pp. 312-319; Ladd, M.E., Quick, H.H., Reduction of resonant RF heating in intravascular catheters using coaxial chokes (2000) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 43 (4), pp. 615-619. , COI: 1:STN:280:DC%2BD3c3htlGhug%3D%3D; Weiss, S., Vernickel, P., Schaeffter, T., Schulz, V., Gleich, B., Transmission line for improved RF safety of interventional devices (2005) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 54, pp. 182-189; Quick, H.H., Kuehl, H., Kaiser, G., Bosk, S., Debatin, J.F., Ladd, M.E., Inductively coupled stent antennas in MRI (2002) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 48 (5), pp. 781-790; Yeung, C., Susil, R., Atalar, E., RF safety of wires in interventional MRI: using a safety index (2002) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 47, pp. 187-193; Armenean, C., Perrin, E., Armenean, M., Beuf, O., Pilleul, F., Saint-Jalmes, H., RF-induced temperature elevation along metallic wires in clinical magnetic resonance imaging: influence of diameter and length (2004) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med, 52 (5), pp. 1200-1206; Srinivasan, S., Ennis, D.B., Variable flip angle balanced steady-state free precession for lower SAR or higher contrast cardiac cine imaging (2013) Magn Resonance Med: Off J Soc Magn Resonance Med/Soc Magn Resonance Med; Wu, X., Akgun, C., Vaughan, J.T., Andersen, P., Strupp, J., Ugurbil, K., Adapted RF pulse design for SAR reduction in parallel excitation with experimental verification at 9.4 T (2010) J Magn Reson, 205 (1), pp. 161-170. , COI: 1:CAS:528:DC%2BC3cXnsVWjsLs%3D; Tzifa, A., Krombach, G.A., Kramer, N., Kruger, S., Schutte, A., von Walter, M., Magnetic resonance-guided cardiac interventions using magnetic resonance-compatible devices: a preclinical study and first-in-man congenital interventions (2010) Circ Cardiovasc Interv, 3 (6), pp. 585-592; Dick, A.J., Raman, V.K., Raval, A.N., Guttman, M.A., Thompson, R.B., Ozturk, C., Invasive human magnetic resonance imaging during angioplasty: feasibility in a combined XMR suite (2005) Catheterization Cardiovascular Interv: Off J Soc Cardiac Angiography Interv, 64 (3), pp. 265-274; Sonmez, M., Saikus, C.E., Bell, J.A., Franson, D.N., Halabi, M., Faranesh, A.Z., MRI active guidewire with an embedded temperature probe and providing a distinct tip signal to enhance clinical safety (2012) J Cardiovascular Magn Resonance: Off J Soc Cardiovascular Magn Resonance, 14, p. 38; Kocaturk, O., Kim, A.H., Saikus, C.E., Guttman, M.A., Faranesh, A.Z., Ozturk, C., Active two-channel 0.035″ guidewire for interventional cardiovascular MRI (2009) J Magn Resonance Imaging: JMRI, 30 (2), pp. 461-465; Razavi, R., Hill, D.L., Keevil, S.F., Miquel, M.E., Muthurangu, V., Hegde, S., Cardiac catheterisation guided by MRI in children and adults with congenital heart disease (2003) Lancet, 362 (9399), pp. 1877-1882; Kuehne, T., Yilmaz, S., Schulze-Neick, I., Wellnhofer, E., Ewert, P., Nagel, E., Magnetic resonance imaging guided catheterisation for assessment of pulmonary vascular resistance: in vivo validation and clinical application in patients with pulmonary hypertension (2005) Heart, 91 (8), pp. 1064-1069. , COI: 1:STN:280:DC%2BD2MzmtlWnug%3D%3D; Muthurangu, V., Taylor, A., Andriantsimiavona, R., Hegde, S., Miquel, M.E., Tulloh, R., Novel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flow (2004) Circulation, 110 (7), pp. 826-834. , This is a seminal demonstration of the enhanced accuracy of MRI catheterization over conventional indicator-dilution techniques for measuring blood flow required to determine pulmonary vascular resistance; Muthurangu, V., Atkinson, D., Sermesant, M., Miquel, M.E., Hegde, S., Johnson, R., Measurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterization (2005) Am J Phys Heart Circ Phys, 289 (3), pp. 1301-1306. , COI: 1:CAS:528:DC%2BD2MXhtVWktrrM; Nishimura, R.A., Carabello, B.A., Hemodynamics in the cardiac catheterization laboratory of the 21st century (2012) Circulation, 125 (17), pp. 2138-2150; Ohno, Y., Hatabu, H., Murase, K., Higashino, T., Nogami, M., Yoshikawa, T., Primary pulmonary hypertension: 3D dynamic perfusion MRI for quantitative analysis of regional pulmonary perfusion (2007) AJR Am J Roentgenol, 188 (1), pp. 48-56; Blomström Lundqvist, C., Auricchio, A., Brugada, J., Boriani, G., Bremerich, J., Cabrera, J.A., The use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of Cardiovascular Imaging and the European Society of Cardiac Radiology (2013) Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 15 (7), pp. 927-936; Lardo, A.C., McVeigh, E.R., Jumrussirikul, P., Berger, R.D., Calkins, H., Lima, J., Visualization and temporal/spatial characterization of cardiac radiofrequency ablation lesions using magnetic resonance imaging (2000) Circulation, 102 (6), pp. 698-705. , COI: 1:STN:280:DC%2BD3cvhtV2ntw%3D%3D; Dickfeld, T., Kato, R., Zviman, M., Lai, S., Meininger, G., Lardo, A.C., Characterization of radiofrequency ablation lesions with gadolinium-enhanced cardiovascular magnetic resonance imaging (2006) J Am Coll Cardiol, 47 (2), pp. 370-378; Arujuna, A., Karim, R., Caulfield, D., Knowles, B., Rhode, K., Schaeffter, T., Acute pulmonary vein isolation is achieved by a combination of reversible and irreversible atrial injury after catheter ablation: evidence from magnetic resonance imaging (2012) Circ: Arrhythmia Electrophysiol, 5 (4), pp. 691-700; Harrison, J.L., Jensen, H.K., Peel, S.A., Chiribiri, A., Grøndal, A.K., Bloch, L.Ø., Cardiac magnetic resonance and electroanatomical mapping of acute and chronic atrial ablation injury: a histological validation study (2014) Eur Heart J; Celik, H., Ramanan, V., Barry, J., Ghate, S., Leber, V., Oduneye, S., Intrinsic contrast for characterization of acute radiofrequency ablation lesions (2014) Circ Arrhythmia Electrophysiol; Ranjan, R., Kato, R., Zviman, M.M., Dickfeld, T.M., Roguin, A., Berger, R.D., Gaps in the ablation line as a potential cause of recovery from electrical isolation and their visualization using MRI (2011) Circ Arrhythmia Electrophysiol, 4 (3), pp. 279-286; Ranjan, R., Kholmovski, E.G., Blauer, J., Vijayakumar, S., Volland, N.A., Salama, M.E., Identification and acute targeting of gaps in atrial ablation lesion sets using a real-time magnetic resonance imaging system (2012) Circ Arrhythmia Electrophysiol, 5 (6), pp. 1130-1135; Peters, D.C., Wylie, J.V., Hauser, T.H., Nezafat, R., Han, Y., Woo, J.J., Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study (2009) J Am Coll Cardiol Img, 2 (3), pp. 308-316; Hoffmann, B.A., Koops, A., Rostock, T., Mullerleile, K., Steven, D., Karst, R., Interactive real-time mapping and catheter ablation of the cavotricuspid isthmus guided by magnetic resonance imaging in a porcine model (2010) Eur Heart J, 31 (4), pp. 450-456; Ganesan, A.N., Selvanayagam, J.B., Mahajan, R., Grover, S., Nayyar, S., Brooks, A.G., Mapping and ablation of the pulmonary veins and cavo-tricuspid isthmus with a magnetic resonance imaging-compatible externally irrigated ablation catheter and integrated electrophysiology system (2012) Circ Arrhythmia Electrophysiol, 5 (6), pp. 1136-1142; Neizel, M., Kramer, N., Schutte, A., Schnackenburg, B., Kruger, S., Kelm, M., Magnetic resonance imaging of the cardiac venous system and magnetic resonance-guided intubation of the coronary sinus in swine: a feasibility study (2010) Investig Radiol, 45 (8), pp. 502-506; Nazarian, S., Kolandaivelu, A., Zviman, M.M., Meininger, G.R., Kato, R., Susil, R.C., Feasibility of real-time magnetic resonance imaging for catheter guidance in electrophysiology studies (2008) Circulation, 118 (3), pp. 223-229; Eitel, C., Piorkowski, C., Hindricks, G., Gutberlet, M., Electrophysiology study guided by real-time magnetic resonance imaging (2012) Eur Heart J, 33 (15), p. 1975; Grothoff, M., Piorkowski, C., Eitel, C., Gaspar, T., Lehmkuhl, L., Lucke, C., MR imaging-guided electrophysiological ablation studies in humans with passive catheter tracking: initial results (2014) Radiology, 271 (3), pp. 695-702; Krueger, J.J., Ewert, P., Yilmaz, S., Gelernter, D., Peters, B., Pietzner, K., Magnetic resonance imaging-guided balloon angioplasty of coarctation of the aorta: a pilot study (2006) Circulation, 113 (8), pp. 1093-1100; Paetzel, C., Zorger, N., Bachthaler, M., Hamer, O.W., Stehr, A., Feuerbach, S., Magnetic resonance-guided percutaneous angioplasty of femoral and popliteal artery stenoses using real-time imaging and intra-arterial contrast-enhanced magnetic resonance angiography (2005) Investig Radiol, 40 (5), pp. 257-262; Lurz, P., Nordmeyer, J., Muthurangu, V., Khambadkone, S., Derrick, G., Yates, R., Comparison of bare metal stenting and percutaneous pulmonary valve implantation for treatment of right ventricular outflow tract obstruction: use of an x-ray/magnetic resonance hybrid laboratory for acute physiological assessment (2009) Circulation, 119 (23), pp. 2995-3001; White, M.J., Thornton, J.S., Hawkes, D.J., Hill, D.L., Kitchen, N., Mancini, L., Design, operation, and safety of single-room interventional MRI suites: practical experience from two centers (2014) J Magn Resonance Imaging: JMRI; Hoult, D.I., Saunders, J.K., Sutherland, G.R., Sharp, J., Gervin, M., Kolansky, H.G., The engineering of an interventional MRI with a movable 1.5 Tesla magnet (2001) J Magn Resonance Imaging: JMRI, 13 (1), pp. 78-86. , COI: 1:STN:280:DC%2BD3M3itlGnuw%3D%3D; Guttman, M.A., Ozturk, C., Raval, A.N., Raman, V.K., Dick, A.J., DeSilva, R., Interventional cardiovascular procedures guided by real-time MR imaging: an interactive interface using multiple slices, adaptive projection modes and live 3D renderings (2007) J Magn Resonance Imaging: JMRI, 26 (6), pp. 1429-1435; Bennett, M.K., Gilotra, N.A., Harrington, C., Rao, S., Dunn, J.M., Freitag, T.B., Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000–2009 (2013) Circ: Heart Failure, 6 (4), pp. 676-684; Leone, O., Veinot, J.P., Angelini, A., Baandrup, U.T., Basso, C., Berry, G., 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology (2012) Cardiovascular Pathol: Off J Soc Cardiovascular Pathol, 21 (4), pp. 245-274; Hundley, W.G., Bluemke, D.A., Finn, J.P., Flamm, S.D., Fogel, M.A., Friedrich, M.G., ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents (2010) J Am Coll Cardiol, 55 (23), pp. 2614-2662",Review,Scopus,2-s2.0-84928319804
"Bhatia S., Wong N.D., Malik S.","Racial Differences in the Ability of Subclinical Atherosclerosis Testing to Predict CVD",2015,"Current Cardiovascular Risk Reports","9","5",,"","",10,,10.1007/s12170-015-0453-6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925780471&partnerID=40&md5=b9403b3c678d32742b49ce17e2706e42","School of Medicine, University of CaliforniaIrvine, CA, United States; Division of Cardiology, Department of Medicine, University of CaliforniaIrvine, CA, United States","Bhatia, S., School of Medicine, University of CaliforniaIrvine, CA, United States; Wong, N.D., Division of Cardiology, Department of Medicine, University of CaliforniaIrvine, CA, United States; Malik, S., Division of Cardiology, Department of Medicine, University of CaliforniaIrvine, CA, United States","Despite decreases in rates of cardiovascular disease (CVD) nationwide, racial differences in incidence of CVD persist. In fact, the racial disparity in incidence of CVD may only be increasing as CVD rates have been declining unequally in certain ethnicities. As prior risk stratification calculators such as the Framingham Risk Score do not take into account ethnicity, other measures of CVD risk from biomarkers and subclinical measurements of atherosclerosis may be potentially important to help clinicians close the racial disparity in CVD rates. Through measurement of coronary artery calcium, ankle-brachial index, biomarkers such as high-sensitivity C-reactive protein, carotid intima-media thickness, and family history, investigators have improved the prediction of subclinical measurements of atherosclerosis across all races. Yet not all of these tools are equally effective in predicting CVD across ethnicities, as will be discussed in this paper. © 2015, Springer Science+Business Media New York.","Atherosclerosis; Cardiovascular disease; Ethnicity; Race","GBD 2013 Mortality and Causes of Death Collaborators, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) Lancet, 385 (9963), pp. 117-171; Heidenreich, P., Trogdon, J., Khavjou, O., Butler, J., Dracup, K., Ezekowitz, M., Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association (2011) Circulation, 123, pp. 933-944. , PID: 21262990; Safford, M.M., Brown, T.M., Muntner, P.M., Durant, R.W., Glasser, S., Halanych, J.H., Association of race and sex with risk of incident acute coronary heart disease events (2012) JAMA, 308 (17), pp. 1768-1774. , COI: 1:CAS:528:DC%2BC38XhslKisL7M, PID: 23117777; Selvin, E., Erlinger, T.P., Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000 (2004) Circulation, 110 (6), pp. 738-743. , PID: 15262830; Collins, T.C., Petersen, N.J., Suarez-Almazor, M., Ashton, C.M., The prevalence of peripheral arterial disease in a racially diverse population (2003) Arch Intern Med, 163 (12), pp. 1469-1474. , PID: 12824097; Criqui, M.H., Vargas, V., Denenberg, J.O., Ho, E., Allison, M., Langer, R.D., Ethnicity and peripheral arterial disease: the San Diego Population Study (2005) Circulation, 112 (17), pp. 2703-2707. , PID: 16246968; Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association (2014) Circulation, 129 (3), pp. 399-410. , PID: 24446411; Gezmu, T., Schneider, D., Demissie, K., Lin, Y., Gizzi, M.S., Risk factors for acute stroke among South Asians compared to other racial/ethnic groups (2014) PLoS One, 9 (9), p. e108901. , PID: 25268987; Harding, S., Mortality of migrants from the Indian subcontinent to England and Wales: effect of duration of residence (2003) Epidemiology, 14 (3), pp. 287-292. , PID: 12859028; McKeigue, P.M., Miller, G.J., Marmot, M.G., Coronary heart disease in south Asians overseas: a review (1989) J Clin Epidemiol, 42 (7), pp. 597-609. , COI: 1:STN:280:DyaL1MzktFyntQ%3D%3D, PID: 2668448; Bahrami, H., Kronmal, R., Bluemke, D.A., Olson, J., Shea, S., Liu, K., Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis (2008) Arch Intern Med, 168 (19), pp. 2138-2145. , PID: 18955644; Cooper, R., Cutler, J., Desvigne-Nickens, P., Fortmann, S.P., Friedman, L., Havlik, R., Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention (2000) Circulation, 102 (25), pp. 3137-3147. , COI: 1:STN:280:DC%2BD3M%2Fnt1OjtA%3D%3D, PID: 11120707; Goff, D.C., Jr., Lloyd-Jones, D.M., Bennett, G., Coady, S., D’Agostino, R.B., Sr., Gibbons, R., 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) J Am Coll Cardiol, 63, pp. 2935-2959. , PID: 24239921; Otsuka, F., Sakakura, K., Yahagi, K., Joner, M., Virmani, R., Has our understanding of calcification in human coronary atherosclerosis progressed? (2014) Arterioscler Thromb Vasc Biol, 34 (4), pp. 724-736. , COI: 1:CAS:528:DC%2BC2cXks1SjsL8%3D, PID: 24558104; Park, J.K., Kim, J.Y., Kwon, H.M., Kim, T.H., Oh, S.J., Hong, B.K., Multidetector computed tomography for the evaluation of coronary artery disease; the diagnostic accuracy in calcified coronary arteries, comparing with IVUS imaging (2014) Yonsei Med J, 55 (3), pp. 599-605. , PID: 24719125; Kawakubo, M., LaBree, L., Xiang, M., Doherty, T.M., Wong, N.D., Azen, S., Race-ethnic differences in the extent, prevalence, and progression of coronary calcium (2005) Ethn Dis, 15 (2), pp. 198-204. , PID: 15825965; Greenland, P., Alpert, J.S., Beller, G.A., Benjamin, E.J., Budoff, M.J., Fayad, Z.A., American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2010) J Am Coll Cardiol, 56 (25), pp. e50-e103. , PID: 21144964; Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) (2012) Eur Heart J, 33 (13), pp. 1635-1701. , COI: 1:CAS:528:DC%2BC38XhtVeitr3P, PID: 22555213; Pletcher, M.J., Sibley, C.T., Pignone, M., Vittinghoff, E., Greenland, P., Interpretation of the coronary artery calcium score in combination with conventional cardiovascular risk factors: the Multi-Ethnic Study of Atherosclerosis (MESA) (2013) Circulation, 128 (10), pp. 1076-1084. , PID: 23884352; Okwuosa, T.M., Greenland, P., Ning, H., Liu, K., Bild, D.E., Burke, G.L., Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis) potential implications for coronary risk assessment (2011) J Am Coll Cardiol, 57 (18), pp. 1838-1845. , COI: 1:CAS:528:DC%2BC3MXnsFKqurY%3D, PID: 21527159, This study examines the distribution of CAC across FRS strata in the MESA to determine if lower risk persons could benefit from CAC screening; Doherty, T.M., Tang, W., Detrano, R.C., Racial differences in the significance of coronary calcium in asymptomatic black and white subjects with coronary risk factors (1999) J Am Coll Cardiol, 34 (3), pp. 787-794. , COI: 1:CAS:528:DyaK1MXmt12hu7s%3D, PID: 10483961; Newman, A.B., Naydeck, B.L., Whittle, J., Sutton-Tyrrell, K., Edmundowicz, D., Kuller, L.H., Racial differences in coronary artery calcification in older adults (2002) Arterioscler Thromb Vasc Biol, 22 (3), pp. 424-430. , COI: 1:CAS:528:DC%2BD38XitFGhur8%3D, PID: 11884285; Lee, T.C., O’Malley, P.G., Feuerstein, I., Taylor, A.J., The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects (2003) J Am Coll Cardiol, 41 (1), pp. 39-44. , PID: 12570942; Tang, W., Detrano, R.C., Brezden, O.S., Georgiou, D., French, W.J., Wong, N.D., Racial differences in coronary calcium prevalence among high-risk adults (1995) Am J Cardiol, 75 (16), pp. 1088-1091. , COI: 1:STN:280:DyaK2M3ot1Oisw%3D%3D, PID: 7762490; Budoff, M.J., Yang, T.P., Shavelle, R.M., Lamont, D.H., Brundage, B.H., Ethnic differences in coronary atherosclerosis (2002) J Am Coll Cardiol, 39 (3), pp. 408-412. , PID: 11823077; Bild, D.E., Detrano, R., Peterson, D., Guerci, A., Liu, K., Shahar, E., Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA) (2005) Circulation, 111 (10), pp. 1313-1320. , PID: 15769774; Kurian, A.K., Cardarelli, K.M., Racial and ethnic differences in cardiovascular disease risk factors: a systematic review (2007) Ethn Dis, 17 (1), pp. 143-152. , PID: 17274224; Detrano, R., Guerci, A.D., Carr, J.J., Bild, D.E., Burke, G., Folsom, A.R., Coronary calcium as a predictor of coronary events in four racial or ethnic groups (2008) N Engl J Med, 358 (13), pp. 1336-1345. , COI: 1:CAS:528:DC%2BD1cXjvFCgsrk%3D, PID: 18367736, This study found that, regardless of ethnic group, an increase in the coronary calcium score increased the likelihood of a major cardiovascular event; Census Bureu. 2010 census-demographic profile data (2010) 6/14/2011; Hajra, A., Li, Y., Siu, S., Udaltsova, N., Armstrong, M.A., Friedman, G.D., Risk of coronary disease in the South Asian American population (2013) J Am Coll Cardiol, 62 (7), pp. 644-645. , PID: 23770164; Palaniappan, L., Wang, Y., Fortmann, S.P., Coronary heart disease mortality for six ethnic groups in California, 1990–2000 (2004) Ann Epidemiol, 14 (7), pp. 499-506. , PID: 15310526; Kanaya, A.M., Kandula, N.R., Ewing, S.K., Herrington, D., Liu, K., Blaha, M.J., Comparing coronary artery calcium among U.S. South Asians with four racial/ethnic groups: the MASALA and MESA studies (2014) Atherosclerosis, 234 (1), pp. 102-107. , COI: 1:CAS:528:DC%2BC2cXmtVCqtLk%3D, PID: 24632509, This study found that South Asian men have similarly high levels of CAC compared to white men but higher CAC compared to African-Americans, Hispanics, and Chinese Americans. South Asian women had similar CAC levels compared to all women in MESA; Bild, D.E., Bluemke, D.A., Burke, G.L., Detrano, R., Diez Roux, A.V., Folsom, A.R., Multi-ethnic study of atherosclerosis: objectives and design (2002) Am J Epidemiol, 156 (9), pp. 871-881. , PID: 12397006; Koulaouzidis, G., Nicoll, R., Charisopoulou, D., McArthur, T., Jenkins, P.J., Henein, M.Y., Aggressive and diffuse coronary calcification in South Asian angina patients compared to Caucasians with similar risk factors (2013) Int J Cardiol, 167 (6), pp. 2472-2476. , COI: 1:STN:280:DC%2BC38jitlehsQ%3D%3D, PID: 22704877; McClelland, R.L., Nasir, K., Budoff, M., Blumenthal, R.S., Kronmal, R.A., Arterial age as a function of coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]) (2009) Am J Cardiol, 103 (1), pp. 59-63. , COI: 1:CAS:528:DC%2BD1cXhsFajsr%2FI, PID: 19101230; Munir, J.A., Wu, H., Bauer, K., Bindeman, J., Byrd, C., O’Malley, P., Impact of coronary calcium on arterial age and coronary heart disease risk estimation using the MESA arterial age calculator (2010) Atherosclerosis, 211 (2), pp. 467-470. , COI: 1:CAS:528:DC%2BC3cXps1Clsr8%3D, PID: 20378115; Chambless, L.E., Heiss, G., Folsom, A.R., Rosamond, W., Szklo, M., Sharrett, A.R., Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993 (1997) Am J Epidemiol, 146 (6), pp. 483-494. , COI: 1:STN:280:DyaK2svjsFynsA%3D%3D, PID: 9290509; Taylor, A.J., Kent, S.M., Flaherty, P.J., Coyle, L.C., Markwood, T.T., Vernalis, M.N., ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness (2002) Circulation, 106 (16), pp. 2055-2060. , COI: 1:CAS:528:DC%2BD38Xns1Sns7c%3D, PID: 12379573; Chambless, L.E., Folsom, A.R., Davis, V., Sharrett, R., Heiss, G., Sorlie, P., Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987–1998 (2002) Am J Epidemiol, 155 (1), pp. 38-47. , PID: 11772783; Burke, G.L., Evans, G.W., Riley, W.A., Sharrett, A.R., Howard, G., Barnes, R.W., Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study (1995) Stroke, 26 (3), pp. 386-391. , COI: 1:STN:280:DyaK2M7pt12kuw%3D%3D, PID: 7886711; Den Ruijter, H.M., Peters, S.A., Anderson, T.J., Britton, A.R., Dekker, J.M., Eijkemans, M.J., Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis (2012) JAMA, 308 (8), pp. 796-803; Tattersall, M.C., Gassett, A., Korcarz, C.E., Gepner, A.D., Kaufman, J.D., Liu, K.J., Predictors of carotid thickness and plaque progression during a decade: the multi-ethnic study of atherosclerosis (2014) Stroke, 45 (11), pp. 3257-3262. , PID: 25213342, This study found that carotid IMT progressed more slowly in Hispanic and Chinese, when adjusted for traditional CVD factors; Zieske, A.W., Malcom, G.T., Strong, J.P., Natural history and risk factors of atherosclerosis in children and youth: the PDAY study (2002) Pediatr Pathol Mol Med, 21 (2), pp. 213-237. , PID: 11942537, Review; Juonala, M., Magnussen, C.G., Venn, A., Dwyer, T., Burns, T.L., Davis, P.H., Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium (2010) Circulation, 122 (24), pp. 2514-2520. , PID: 21126976; Costanzo, P., Perrone-Filardi, P., Vassallo, E., Paolillo, S., Cesarano, P., Brevetti, G., Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials (2010) J Am Coll Cardiol, 56 (24), pp. 2006-2020. , PID: 21126642; Breton, C.V., Wang, X., Mack, W.J., Berhane, K., Lopez, M., Islam, T.S., Carotid artery intima-media thickness in college students: race/ethnicity matters (2011) Atherosclerosis, 217 (2), pp. 441-446. , COI: 1:CAS:528:DC%2BC3MXps12jtbk%3D, PID: 21679950, This study found that racial differences in cIMT are evident at an early age; Li, S., Chen, W., Srinivasan, S.R., Tang, R., Bond, M.G., Berenson, G.S., Race (black-white) and gender divergences in the relationship of childhood cardiovascular risk factors to carotid artery intima-media thickness in adulthood: the Bogalusa Heart Study (2007) Atherosclerosis, 194 (2), pp. 421-425. , COI: 1:CAS:528:DC%2BD2sXhtFerurnE, PID: 17123535; Ruan, L., Chen, W., Srinivasan, S.R., Sun, M., Wang, H., Toprak, A., Correlates of common carotid artery lumen diameter in black and white younger adults: the Bogalusa Heart Study (2009) Stroke, 40 (3), pp. 702-707. , PID: 19131651; Bennett, P.C., Gill, P.S., Silverman, S., Blann, A.D., Lip, G.Y., Ethnic differences in common carotid intima-media thickness, and the relationship to cardiovascular risk factors and peripheral arterial disease: the Ethnic-Echocardiographic Heart of England Screening Study (2011) QJM, 104 (3), pp. 245-254. , COI: 1:STN:280:DC%2BC3M3gtVSqsQ%3D%3D, PID: 20956456; D’Agostino, R.B., Jr., Burke, G., O’Leary, D., Rewers, M., Selby, J., Savage, P.J., Ethnic differences in carotid wall thickness. The Insulin Resistance Atherosclerosis Study (1996) Stroke, 27 (10), pp. 1744-1749. , PID: 8841322; Manolio, T.A., Arnold, A.M., Post, W., Bertoni, A.G., Schreiner, P.J., Sacco, R.L., Ethnic differences in the relationship of carotid atherosclerosis to coronary calcification: the Multi-Ethnic Study of Atherosclerosis (2008) Atherosclerosis, 197 (1), pp. 132-138. , COI: 1:CAS:528:DC%2BD1cXisVSmu74%3D, PID: 17412347; Järvisalo, M.J., Harmoinen, A., Hakanen, M., Paakkunainen, U., Viikari, J., Hartiala, J., Elevated serum C-reactive protein levels and early arterial changes in healthy children (2002) Arterioscler Thromb Vasc Biol, 22 (8), pp. 1323-1328. , PID: 12171795; Grebe, M.T., Luu, B., Sedding, D., Heidt, M.C., Kemkes-Matthes, B., Schaefer, C.A., Fibrinogen promotes early atherosclerotic changes of the carotid artery in young, healthy adults (2010) J Atheroscler Thromb, 17 (10), pp. 1003-1008. , COI: 1:CAS:528:DC%2BC3MXhvVersrs%3D, PID: 20551578; McDermott, M.M., Guralnik, J.M., Tian, L., Liu, K., Ferrucci, L., Liao, Y., Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study) (2009) J Am Coll Cardiol, 53 (12), pp. 1056-1062. , PID: 19298919; Sikkink, C.J., van Asten, W.N., van’t Hof, M.A., van Langen, H., van der Vliet, J.A., Decreased ankle/brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease (1997) Vasc Med, 2 (3), pp. 169-173. , COI: 1:STN:280:DyaK1c7nvVSgtw%3D%3D, PID: 9546965; Ankle Brachial Index Collaboration, Fowkes, F.G., Murray, G.D., Butcher, I., Heald, C.L., Lee, R.J., Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis (2008) JAMA, 300 (2), pp. 197-208; European Stroke Organisation, Tendera, M., Aboyans, V., Bartelink, M.L., Baumgartner, I., Clément, D., ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC) (2011) Eur Heart J, 32 (22), pp. 2851-2906; Aboyans, V., McClelland, R.L., Allison, M.A., McDermott, M.M., Blumenthal, R.S., Macura, K., Lower extremity peripheral artery disease in the absence of traditional risk factors. The Multi-Ethnic Study of Atherosclerosis (2011) Atherosclerosis, 214 (1), pp. 169-173. , COI: 1:CAS:528:DC%2BC3MXkt1enug%3D%3D, PID: 21067754; Kullo, I.J., Bailey, K.R., Kardia, S.L., Mosley, T.H., Jr., Boerwinkle, E., Turner, S.T., Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study (2003) Vasc Med, 8 (4), pp. 237-242. , PID: 15125483; Weatherley, B.D., Nelson, J.J., Heiss, G., Chambless, L.E., Sharrett, A.R., Nieto, F.J., The association of the ankle-brachial index with incident coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study, 1987–2001 (2007) BMC Cardiovasc Disord, 7, p. 3. , PID: 17227586; Criqui, M.H., McClelland, R.L., McDermott, M.M., Allison, M.A., Blumenthal, R.S., Aboyans, V., The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis) (2010) J Am Coll Cardiol, 56 (18), pp. 1506-1512. , PID: 20951328; Allison, M.A., Criqui, M.H., McClelland, R.L., Scott, J.M., McDermott, M.M., Liu, K., The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA) (2006) J Am Coll Cardiol, 48 (6), pp. 1190-1197. , PID: 16979004; Criqui, M.H., Vargas, V., Denenberg, J.O., Ho, E., Allison, M., Langer, R.D., Ethnicity and peripheral arterial disease: the San Diego Population Study (2005) Circulation, 112 (17), pp. 2703-2707. , PID: 16246968; Ix, J.H., Allison, M.A., Denenberg, J.O., Cushman, M., Criqui, M.H., Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study (2008) J Am Coll Cardiol, 51 (24), pp. 2347-2354. , PID: 18549921; Singh, S., Bailey, K.R., Kullo, I.J., Ethnic differences in ankle brachial index are present in middle-aged individuals without peripheral arterial disease (2013) Int J Cardiol, 162 (3), pp. 228-233. , PID: 21652099, This study’s findings suggested that lower ABI in middle-aged non-Hispanic blacks may not be due to atherosclerotic vascular disease; Sebastianski, M., Makowsky, M.J., Dorgan, M., Tsuyuki, R.T., Paradoxically lower prevalence of peripheral arterial disease in South Asians: a systematic review and meta-analysis (2014) Heart, 100 (2), pp. 100-105. , PID: 23756656, This study found a lower prevalence of PAD in South Asians compared to White Europeans; Meadows, T.A., Bhatt, D.L., Cannon, C.P., Gersh, B.J., Röther, J., Goto, S., Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry (2011) Mayo Clin Proc, 86 (10), pp. 960-967. , PID: 21964173; Wang, T.J., Gona, P., Larson, M.G., Tofler, G.H., Levy, D., Newton-Cheh, C., Multiple biomarkers for the prediction of first major cardiovascular events and death (2006) N Engl J Med, 355 (25), pp. 2631-2639. , COI: 1:CAS:528:DC%2BD28XhtlGhtLvJ, PID: 17182988; Xanthakis, V., Enserro, D.M., Murabito, J.M., Polak, J.F., Wollert, K.C., Januzzi, J.L., Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham offspring study (2014) Circulation, 130 (19), pp. 1676-1683. , COI: 1:CAS:528:DC%2BC2cXhvVyls7vK, PID: 25274000; Sabatine, M.S., Morrow, D.A., de Lemos, J.A., Omland, T., Sloan, S., Jarolim, P., Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease (2012) Circulation, 125 (2), pp. 233-240. , COI: 1:CAS:528:DC%2BC38XotVGjuw%3D%3D, PID: 22179538; Jouni, H., Rodeheffer, R.J., Kullo, I.J., Increased serum N-terminal pro-B-type natriuretic peptide levels in patients with medial arterial calcification and poorly compressible leg arteries (2011) Arterioscler Thromb Vasc Biol, 31 (1), pp. 197-202. , COI: 1:CAS:528:DC%2BC3cXhsFGrurfN, PID: 20947817; Cooke, J.P., Wilson, A.M., Biomarkers of peripheral arterial disease (2010) J Am Coll Cardiol, 55 (19), pp. 2017-2023. , COI: 1:CAS:528:DC%2BC3cXnvVahtrc%3D, PID: 20447524; Murabito, J.M., Keyes, M.J., Guo, C.Y., Keaney, J.F., Jr., Vasan, R.S., D’Agostino, R.B., Sr., Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: the Framingham Offspring Study (2009) Atherosclerosis, 203 (2), pp. 509-514. , COI: 1:CAS:528:DC%2BD1MXjslyitb0%3D, PID: 18701106; Ridker, P.M., Stampfer, M.J., Rifai, N., Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease (2001) JAMA, 285 (19), pp. 2481-2485. , COI: 1:CAS:528:DC%2BD3MXkt1CnsLc%3D, PID: 11368701; Khawaja, F.J., Bailey, K.R., Turner, S.T., Kardia, S.L., Mosley, T.H., Jr., Kullo, I.J., Association of novel risk factors with the ankle brachial index in African American and non-Hispanic white populations (2007) Mayo Clin Proc, 82 (6), pp. 709-716. , PID: 17550751; Wu, M., Rementer, C., Giachelli, C.M., Vascular calcification: an update on mechanisms and challenges in treatment (2013) Calcif Tissue Int, 93 (4), pp. 365-373. , COI: 1:CAS:528:DC%2BC3sXhsFyms7rP, PID: 23456027; Ali, Z., Ellington, A.A., Mosley, T.H., Jr., Kullo, I.J., Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites (2009) Atherosclerosis, 206 (2), pp. 575-580. , COI: 1:CAS:528:DC%2BD1MXht1aju7bK, PID: 19423112; Ye, Z., Ali, Z., Klee, G.G., Mosley, T.H., Jr., Kullo, I.J., Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease (2013) Am J Hypertens, 26 (4), pp. 495-502. , COI: 1:CAS:528:DC%2BC3sXjslKhtbY%3D, PID: 23467205, This study analyzed the associations of 47 biomarkers, representing various pathways of atherosclerosis, with ABI and PAD in African Americans and non-Hispanic Whites; Veeranna, V., Zalawadiya, S.K., Niraj, A., Kumar, A., Ference, B., Afonso, L., Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: results from a multi-ethnic cohort (2013) Int J Cardiol, 166 (2), pp. 487-493. , PID: 22240756, This study found that biomarkers associated with incident CVD events was significantly affected by race; Libby, P., Theroux, P., Pathophysiology of coronary artery disease (2005) Circulation, 111 (25), pp. 3481-3488. , PID: 15983262; Jenny, N.S., Brown, E.R., Detrano, R., Folsom, A.R., Saad, M.F., Shea, S., Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis (2010) Atherosclerosis, 209 (1), pp. 226-229. , COI: 1:CAS:528:DC%2BC3cXis1ensrw%3D, PID: 19766217; Weiner, S.D., Ahmed, H.N., Jin, Z., Cushman, M., Herrington, D.M., Nelson, J.C., Systemic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA) (2014) Heart, 100 (11), pp. 862-866. , PID: 24714919, This study found; Rus, H.G., Vlaicu, R., Niculescu, F., Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall (1996) Atherosclerosis, 127 (2), pp. 263-271. , COI: 1:CAS:528:DyaK28Xnt1Kls7o%3D, PID: 9125317; Celermajer, D.S., Sorensen, K.E., Gooch, V.M., Spiegelhalter, D.J., Miller, O.I., Sullivan, I.D., Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis (1992) Lancet, 340 (8828), pp. 1111-1115. , COI: 1:STN:280:DyaK3s%2FmtFGhuw%3D%3D, PID: 1359209; Ross, R., Atherosclerosis—an inflammatory disease (1999) N Engl J Med, 340 (2), pp. 115-126. , COI: 1:STN:280:DyaK1M%2FptFSqtQ%3D%3D, PID: 9887164; Emerging Risk Factors Collaboration, Erqou, S., Kaptoge, S., Perry, P.L., Di Angelantonio, E., Thompson, A., Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality (2009) JAMA, 302 (4), pp. 412-423; Kamstrup, P.R., Tybjaerg-Hansen, A., Steffensen, R., Nordestgaard, B.G., Genetically elevated lipoprotein(a) and increased risk of myocardial infarction (2009) JAMA, 301 (22), pp. 2331-2339. , COI: 1:CAS:528:DC%2BD1MXntFCms7w%3D, PID: 19509380; Clarke, R., Peden, J.F., Hopewell, J.C., Kyriakou, T., Goel, A., Heath, S.C., Genetic variants associated with Lp(a) lipoprotein level and coronary disease (2009) N Engl J Med, 361 (26), pp. 2518-2528. , COI: 1:CAS:528:DC%2BC3cXls1Gg, PID: 20032323; Guyton, J.R., Dahlen, G.H., Patsch, W., Kautz, J.A., Gotto, A.M., Jr., Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B (1985) Arteriosclerosis, 5 (3), pp. 265-272. , COI: 1:CAS:528:DyaL2MXksFaisL0%3D, PID: 3158297; Parra, H.J., Luyéyé, I., Bouramoué, C., Demarquilly, C., Fruchart, J.C., Black-white differences in serum Lp(a) lipoprotein levels (1987) Clin Chim Acta, 168 (1), pp. 27-31. , COI: 1:STN:280:DyaL1c%2Fislyjuw%3D%3D, PID: 3665103; Virani, S.S., Brautbar, A., Davis, B.C., Nambi, V., Hoogeveen, R.C., Sharrett, A.R., Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study (2012) Circulation, 125 (2), pp. 241-249. , COI: 1:CAS:528:DC%2BC38XotVGisg%3D%3D, PID: 22128224, This study analyzed Lp(a) levels and incident CVD events in African-Americans and Caucasians and provided evidence that Lp(a) should be considered a CVD risk factor in African Americans; Sharma, A., Kasim, M., Joshi, P.H., Qian, Z., Krivitsky, E., Akram, K., Abnormal lipoprotein(a) levels predict coronary artery calcification in Southeast Asians but not in Caucasians: use of noninvasive imaging for evaluation of an emerging risk factor (2011) J Cardiovasc Transl Res, 4 (4), pp. 470-476. , PID: 21484527; Banerjee, D., Wong, E.C., Shin, J., Fortmann, S.P., Palaniappan, L., Racial and ethnic variation in lipoprotein (a) levels among Asian Indian and Chinese patients (2011) J Lipids, 2011, p. 291954. , PID: 21660301; Marenberg, M.E., Risch, N., Berkman, L.F., Floderus, B., de Faire, U., Genetic susceptibility to death from coronary heart disease in a study of twins (1994) N Engl J Med, 330 (15), pp. 1041-1046. , COI: 1:STN:280:DyaK2c7ntlaqtg%3D%3D, PID: 8127331; Lloyd-Jones, D.M., Nam, B.H., D’Agostino, R.B., Sr., Levy, D., Murabito, J.M., Wang, T.J., Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring (2004) JAMA, 291 (18), pp. 2204-2211. , COI: 1:CAS:528:DC%2BD2cXktVGitLg%3D, PID: 15138242; Nasir, K., Budoff, M.J., Wong, N.D., Scheuner, M., Herrington, D., Arnett, D.K., Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA) (2007) Circulation, 116 (6), pp. 619-626. , PID: 17646582; Scheuner, M.T., Setodji, C.M., Pankow, J.S., Blumenthal, R.S., Keeler, E., General Cardiovascular Risk Profile identifies advanced coronary artery calcium and is improved by family history: the multiethnic study of atherosclerosis (2010) Circ Cardiovasc Genet, 3 (1), pp. 97-105. , COI: 1:CAS:528:DC%2BC3cXjslSgtrc%3D, PID: 20160201, This study found that Caucasians demonstrated the most consistent relationship between family history of CHD and incidence and progression of CAC; however, there was no interaction with ethnicity; Solomon, M.D., Tirupsur, A., Hytopoulos, E., Beggs, M., Harrington, D.S., French, C., Clinical utility of a novel coronary heart disease risk-assessment test to further classify intermediate-risk patients (2013) Clin Cardiol, 36 (10), pp. 621-627. , PID: 23929798; Ford, E.S., Giles, W.H., Mokdad, A.H., The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III (2004) J Am Coll Cardiol, 43 (10), pp. 1791-1796. , PID: 15145101; Gill, J.M., Celis-Morales, C.A., Ghouri, N., Physical activity, ethnicity and cardio-metabolic health: does one size fit all? (2014) Atherosclerosis, 232 (2), pp. 319-333. , COI: 1:CAS:528:DC%2BC2cXhsVyktbo%3D, PID: 24468145",Review,Scopus,2-s2.0-84925780471
"Vujic A., Robinson E.L., Ito M., Haider S., Ackers-Johnson M., See K., Methner C., Figg N., Brien P., Roderick H.L., Skepper J., A.Ferguson-Smith, Foo R.S.","Experimental heart failure modelled by the cardiomyocyte-specific loss of an epigenome modifier, DNMT3B",2015,"Journal of Molecular and Cellular Cardiology","82",,,"174","183",,,10.1016/j.yjmcc.2015.03.007,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925432517&partnerID=40&md5=29ddcdb09acbf71b15a72411c6d8ef5f","Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of CambridgeCambridge, United Kingdom; Cardiovascular Research Institute, Centre for Translational Medicine MD6, National University Health System, Singapore; Department of Physiology, Development and Neuroscience, University of CambridgeCambridge, United Kingdom; Centre for Molecular Oncology, Barts Cancer InstituteLondon, United Kingdom; Genome Institute of Singapore, 60 Biopolis Street, Singapore; Clinical Pharmacology Unit, Addenbrooke's Centre for Clinical Investigation Building, University of CambridgeCambridge, United Kingdom; Epigenetics ISP, Babraham InstituteCambridge, United Kingdom","Vujic, A., Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of CambridgeCambridge, United Kingdom, Cardiovascular Research Institute, Centre for Translational Medicine MD6, National University Health System, Singapore; Robinson, E.L., Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of CambridgeCambridge, United Kingdom; Ito, M., Department of Physiology, Development and Neuroscience, University of CambridgeCambridge, United Kingdom; Haider, S., Centre for Molecular Oncology, Barts Cancer InstituteLondon, United Kingdom; Ackers-Johnson, M., Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of CambridgeCambridge, United Kingdom, Cardiovascular Research Institute, Centre for Translational Medicine MD6, National University Health System, Singapore, Genome Institute of Singapore, 60 Biopolis Street, Singapore; See, K., Genome Institute of Singapore, 60 Biopolis Street, Singapore; Methner, C., Clinical Pharmacology Unit, Addenbrooke's Centre for Clinical Investigation Building, University of CambridgeCambridge, United Kingdom; Figg, N., Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of CambridgeCambridge, United Kingdom; Brien, P., Epigenetics ISP, Babraham InstituteCambridge, United Kingdom; Roderick, H.L., Epigenetics ISP, Babraham InstituteCambridge, United Kingdom; Skepper, J., Department of Physiology, Development and Neuroscience, University of CambridgeCambridge, United Kingdom; A.Ferguson-Smith, Department of Physiology, Development and Neuroscience, University of CambridgeCambridge, United Kingdom; Foo, R.S., Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of CambridgeCambridge, United Kingdom, Cardiovascular Research Institute, Centre for Translational Medicine MD6, National University Health System, Singapore, Genome Institute of Singapore, 60 Biopolis Street, Singapore","Differential DNA methylation exists in the epigenome of end-stage failing human hearts but whether it contributes to disease progression is presently unknown. Here, we report that cardiac specific deletion of Dnmt3b, the predominant DNA methyltransferase in adult mouse hearts, leads to an accelerated progression to severe systolic insufficiency and myocardial thinning without a preceding hypertrophic response. This was accompanied by widespread myocardial interstitial fibrosis and myo-sarcomeric disarray. By targeted candidate gene quantitative RT-PCR, we discovered an over-activity of cryptic splice sites in the sarcomeric gene Myh7, resulting in a transcript with 8 exons missing. Moreover, a region of differential methylation overlies the splice site locus in the hearts of the cardiac-specific conditional knockout (CKO) mice. Although abundant and complex forms of alternative splice variants have been reported in diseased hearts and the contribution of each remains to be understood in further detail, our results demonstrate for the first time that a link may exist between alternative splicing and the cardiac epigenome. In particular, this gives the novel evidence whereby the loss of an epigenome modifier promotes the development and progression of heart disease. © 2015 Elsevier Ltd.","Alternative splicing; DNA methylation; Epigenome; Heart failure","(2003) Heart disease and stroke statistics-2003 update, , American Heart Association, Dallas, Tex; Hill, J.A., Olson, E.N., Cardiac plasticity (2008) N Engl J Med, 358 (13), pp. 1370-1380; Hill, J.A., Olson, E.N., (2012) Muscle: fundamental biology and mechanisms of disease, , Academic Press, New York, NY; McNally, E.M., Golbus, J.R., Puckelwartz, M.J., Genetic mutations and mechanisms in dilated cardiomyopathy (2013) J Clin Invest, 123 (1), pp. 19-26; Baccarelli, A., Rienstra, M., Benjamin, E.J., Cardiovascular epigenetics: basic concepts and results from animal and human studies (2010) Circ Cardiovasc Genet, 3 (6), pp. 567-573; Suzuki, M.M., Bird, A., DNA methylation landscapes: provocative insights from epigenomics (2008) Nat Rev Genet, 9 (6), pp. 465-476; Bjornsson, H.T., Sigurdsson, M.I., Fallin, M.D., Irizarry, R.A., Aspelund, T., Cui, H., Intra-individual change over time in DNA methylation with familial clustering (2008) JAMA, 299 (24), pp. 2877-2883; Turunen, M.P., Aavik, E., Yla-Herttuala, S., Epigenetics and atherosclerosis (2009) Biochim Biophys Acta, 1790 (9), pp. 886-891; Zaina, S., Lindholm, M.W., Lund, G., Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia? (2005) J Nutr, 135 (1), pp. 5-8; Bollati, V., Schwartz, J., Wright, R., Litonjua, A., Tarantini, L., Suh, H., Decline in genomic DNA methylation through aging in a cohort of elderly subjects (2009) Mech Ageing Dev, 130 (4), pp. 234-239; Lana, E., Megarbane, A., Tourriere, H., Sarda, P., Lefranc, G., Claustres, M., DNA replication is altered in Immunodeficiency Centromeric instability Facial anomalies (ICF) cells carrying DNMT3B mutations (2012) Eur J Hum Genet, 20 (10), pp. 1044-1050; Okano, M., Bell, D.W., Haber, D.A., Li, E., DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development (1999) Cell, 99 (3), pp. 247-257; Haider, S., Cordeddu, L., Robinson, E., Movassagh, M., Siggens, L., Vujic, A., The landscape of DNA repeat elements in human heart failure (2012) Genome Biol, 13 (10), p. R90; Movassagh, M., Choy, M.K., Knowles, D.A., Cordeddu, L., Haider, S., Down, T., Distinct epigenomic features in end-stage failing human hearts (2011) Circulation, 124 (22), pp. 2411-2422; Lin, H., Yamada, Y., Nguyen, S., Linhart, H., Jackson-Grusby, L., Meissner, A., Suppression of intestinal neoplasia by deletion of Dnmt3b (2006) Mol Cell Biol, 26 (8), pp. 2976-2983; Sohal, D.S., Nghiem, M., Crackower, M.A., Witt, S.A., Kimball, T.R., Tymitz, K.M., Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein (2001) Circ Res, 89 (1), pp. 20-25; Teekakirikul, P., Eminaga, S., Toka, O., Alcalai, R., Wang, L., Wakimoto, H., Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta (2010) J Clin Invest, 120 (10), pp. 3520-3529; Koitabashi, N., Danner, T., Zaiman, A.L., Pinto, Y.M., Rowell, J., Mankowski, J., Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload (2011) J Clin Invest., 121 (6), pp. 2301-2312; Kong, S.W., Hu, Y.W., Ho, J.W., Ikeda, S., Polster, S., John, R., Heart failure-associated changes in RNA splicing of sarcomere genes (2010) Circ Cardiovasc Genet, 3 (2), pp. 138-146; Kalsotra, A., Xiao, X., Ward, A.J., Castle, J.C., Johnson, J.M., Burge, C.B., A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart (2008) Proc Natl Acad Sci U S A, 105 (51), pp. 20333-20338; Kalsotra, A., Wang, K., Li, P.F., Cooper, T.A., MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development (2010) Genes Dev., 24 (7), pp. 653-658; Xu, X., Yang, D., Ding, J.H., Wang, W., Chu, P.H., Dalton, N.D., ASF/SF2-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle (2005) Cell, 120 (1), pp. 59-72; Luco, R.F., Pan, Q., Tominaga, K., Blencowe, B.J., Pereira-Smith, O.M., T, Misteli (2010) Regulation of alternative splicing by histone modifications. Science., 327 (5968), pp. 996-1000; Shukla, S., Kavak, E., Gregory, M., Imashimizu, M., Shutinoski, D., Kashlev, M., CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing (2011) Nature., 479 (7371), pp. 74-79; Hermann, A., Goyal, R., Jeltsch, A., The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites (2004) J Biol Chem, 279 (46), pp. 48350-48359; Brun, M.E., Lana, E., Rivals, I., Lefranc, G., Sarda, P., Claustres, M., Heterochromatic genes undergo epigenetic changes and escape silencing in immunodeficiency, centromeric instability, facial anomalies (ICF) syndrome (2011) PLoS One, 6 (4), p. e19464; Kameda, K., Matsunaga, T., Abe, N., Hanada, H., Ishizaka, H., Ono, H., Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling (2003) Eur Heart J, 24 (24), pp. 2180-2185; Siggens, L., Figg, N., Bennett, M., Foo, R., Nutrient deprivation regulates DNA damage repair in cardiomyocytes via loss of the base-excision repair enzyme OGG1 (2012) FASEB J, 26 (5), pp. 2117-2124; Li, J.M., Gall, N.P., Grieve, D.J., Chen, M., Shah, A.M., Activation of NADPH oxidase during progression of cardiac hypertrophy to failure (2002) Hypertension, 40 (4), pp. 477-484; Lee, J.H., Gao, C., Peng, G., Greer, C., Ren, S., Wang, Y., Xiao, X., Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts (2001) Circ Res., 109 (12), pp. 1332-1341; Bergmann, O., Bhardwaj, R.D., Bernard, S., Zdunek, S., Barnabe-Heider, F., Walsh, S., Evidence for cardiomyocyte renewal in humans (2009) Science, 324 (5923), pp. 98-102",Article,Scopus,2-s2.0-84925432517
"Toklu B., Bangalore S.","Comparison of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention in Patients with Diabetes",2015,"Current Treatment Options in Cardiovascular Medicine","17","5",,"","",13,,10.1007/s11936-015-0377-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925655326&partnerID=40&md5=4fd64ee628b39133519b40d90996d875","New York University School of MedicineNew York, NY, United States; Cardiac Catheterization Laboratory, Cardiovascular Clinical Research Center, The Leon H. Charney Division of Cardiology, New York University School of MedicineNew York, NY, United States","Toklu, B., New York University School of MedicineNew York, NY, United States; Bangalore, S., New York University School of MedicineNew York, NY, United States, Cardiac Catheterization Laboratory, Cardiovascular Clinical Research Center, The Leon H. Charney Division of Cardiology, New York University School of MedicineNew York, NY, United States","The optimal revascularization strategy in patients with diabetes is controversial. The Bypass Angioplasty Revascularization Investigation (BARI) trial, done more than a decade ago, suggested a mortality benefit of coronary artery bypass graft surgery (CABG) when compared with percutaneous coronary intervention (PCI) (with plain old balloon angioplasty) in the subgroup of patients with diabetes. In addition, several observational studies and meta-analyses similarly suggest a benefit of CABG over PCI in patients with diabetes. However, most of these studies compared CABG with PCI using balloon angioplasty, bare metal stents, or first-generation drug-eluting stents. In this review, we critically examine the data for optimal revascularization strategy in patients with diabetes and ask the question whether the currently available data from randomized trials that used outdated stents are applicable to current day practice. © 2015, Springer Science+Business Media New York.","Coronary artery bypass graft; Coronary artery disease; Diabetes mellitus; Drug-eluting stents","Abdallah, M.S., Wang, K., Magnuson, E.A., Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial (2013) JAMA, 310 (15), pp. 1581-1590. , COI: 1:CAS:528:DC%2BC3sXhvVeitrjN, PID: 24129463; AuthorsTask Force, M., Windecker, S., Kolh, P., ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) (2014) Eur Heart J, 35 (37), pp. 2541-2619; Bangalore, S., Kumar, S., Fusaro, M., Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials (2012) BMJ, 345, p. 5170. , PID: 22885395; Bangalore, S., Toklu, B., Amoroso, N., Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis (2013) BMJ, 347, p. 6625. , PID: 24212107, A meta-analysis of 126 randomized controlled comparison trials of all available stents showed that 2nd generation DES, especially CoCr EES, is the most efficacious and safe stent in the current market even when compared to 1st generation DES; Bangalore, S., Toklu, B., Feit, F., Outcomes with coronary artery bypass graft surgery versus percutaneous coronary intervention for patients with diabetes mellitus: can newer generation drug-eluting stents bridge the gap? Circulation (2014) Cardiovasc Interv, 7 (4), pp. 518-525. , A mixed treatment analysis that included 68 randomized controlled trials enrolling 24015 diabetic patients and 71595 patient-years of follow-up revealed that the clinical efficacy gap between CABG and PCI has narrowed with newer generations of PCI modality as CABG was separately compared to POBA to BMS to 1st generation DES. Furthermore, an indirect analysis comparing CABG to 2nd generation DES, especially cobalt-chromium everolimus-eluting stent, showed similar outcomes in death and MI; CABG was associated with numerically increased stroke events whereas PCI with cobalt-chromium everolimus-eluting stent associated with numerically increased repeat revascularization; Banning, A.P., Westaby, S., Morice, M.C., Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents (2010) J Am Coll Cardiol, 55 (11), pp. 1067-1075. , COI: 1:CAS:528:DC%2BC3cXkvVeitbY%3D, PID: 20079596; Bayes-Genis, A., Conover, C.A., Schwartz, R.S., The insulin-like growth factor axis: a review of atherosclerosis and restenosis (2000) Circ Res, 86 (2), pp. 125-130. , COI: 1:CAS:528:DC%2BD3cXht1Cksb0%3D, PID: 10666406; www.tctmd.com/, Beatt KJ, Diabetes, multivessel and LMS disease: treating the whole patient. Transcatheter Cardiovascular Therapeutics 2012. Available from [December 2013]Biondi-Zoccai, G.G., Abbate, A., Liuzzo, G., Biasucci, L.M., Atherothrombosis, inflammation, and diabetes (2003) J Am Coll Cardiol, 41 (7), pp. 1071-1077. , COI: 1:CAS:528:DC%2BD3sXjtlKhu78%3D, PID: 12679203; Booth, J., Clayton, T., Pepper, J., Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS) (2008) Circulation, 118 (4), pp. 381-388. , PID: 18606919; Brar, S.S., Syros, G., Dangas, G., Multivessel disease: percutaneous coronary intervention for classic coronary artery bypass grafting indications (2008) Angiology, 59, pp. 83-88. , PID: 18544582; CABRI Trial Participants, First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation) (1995) Lancet, 346 (8984), pp. 1179-1184; Cohen, D.J., Lavelle, T.A., Van Hout, B., Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial (2012) Catheter Cardiovasc Interv Off J Soc Cardiac Angiography Interv, 79 (2), pp. 198-209; Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. (Mar 6 1993) Lancet 341(8845):573–580Daemen, J., Wenaweser, P., Tsuchida, K., Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study (2007) Lancet, 369 (9562), pp. 667-678. , COI: 1:CAS:528:DC%2BD2sXitFOks7s%3D, PID: 17321312; Danaei, G., Finucane, M.M., Lu, Y., National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants (2011) Lancet, 378 (9785), pp. 31-40. , COI: 1:CAS:528:DC%2BC3MXotlyltbo%3D, PID: 21705069; Dangas, G.D., Farkouh, M.E., Sleeper, L.A., Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial (2014) J Am Coll Cardiol, 64 (12), pp. 1189-1197. , COI: 1:CAS:528:DC%2BC2cXhsFyrt73L, PID: 25236509; De Bruyne, B., Pijls, N.H., Kalesan, B., Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease (2012) N Engl J Med, 367 (11), pp. 991-1001. , PID: 22924638; Farkouh, M.E., Domanski, M., Sleeper, L.A., Strategies for multivessel revascularization in patients with diabetes (2012) N Engl J Med, 367 (25), pp. 2375-2384. , COI: 1:CAS:528:DC%2BC38XhvVyrsr3O, PID: 23121323, Largest of it’s kind, FREEDOM trial, randomized 1900 diabetic patients with multivessel disease to CABG or PCI with 1st generation DES revealing a significant reduction in composite outcome of death, MI or stroke at 5 years in favor of CABG, driven by significantly reduced death and MI rates; Fihn, S.D., Blankenship, J.C., Alexander, K.P., 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons (2014) Circulation, 130 (19), pp. 1749-1767. , PID: 25070666; Fihn, S.D., Gardin, J.M., Abrams, J., 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons (2012) J Am Coll Cardiol, 60 (24), pp. 44-164. , PID: 23182125; Group, B.D.S., Frye, R.L., August, P., A randomized trial of therapies for type 2 diabetes and coronary artery disease (2009) N Engl J Med, 360 (24), pp. 2503-2515; Haller, J.D., Olearchyk, A.S., Cardiology’s 10 greatest discoveries (2002) Tex Heart Inst J/Tex Heart Inst St Luke’s Episcopal Hosp Tex Child Hosp, 29 (4), pp. 342-344; Hannan, E.L., Racz, M.J., McCallister, B.D., A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty (1999) J Am Coll Cardiol, 33 (1), pp. 63-72. , COI: 1:STN:280:DyaK1M7jtFOjuw%3D%3D, PID: 9935010; Hannan, E.L., Racz, M.J., Walford, G., Long-term outcomes of coronary-artery bypass grafting versus stent implantation (2005) N Engl J Med, 352 (21), pp. 2174-2183. , COI: 1:CAS:528:DC%2BD2MXksFOmuro%3D, PID: 15917382; Hannan, E.L., Wu, C., Walford, G., Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease (2008) N Engl J Med, 358 (4), pp. 331-341. , COI: 1:CAS:528:DC%2BD1cXhtFCjsro%3D, PID: 18216353; Henderson, R.A., Pocock, S.J., Sharp, S.J., Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina (1998) Lancet, 352 (9138), pp. 1419-1425. , COI: 1:STN:280:DyaK1M%2FitlWnsw%3D%3D, PID: 9807988; Hillis, L.D., Smith, P.K., Anderson, J.L., 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2012) J Thorac Cardiovasc Surg, 143 (1), pp. 4-34. , PID: 22172748; Hlatky, M.A., Boothroyd, D.B., Melsop, K.A., Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease (2004) Circulation, 110 (14), pp. 1960-1966. , PID: 15451795; Investigators, B., The final 10-year follow-up results from the BARI randomized trial (2007) J Am Coll Cardiol, 49 (15), pp. 1600-1606; Kamalesh, M., Sharp, T.G., Tang, X.C., Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes (2013) J Am Coll Cardiol, 61 (8), pp. 808-816. , PID: 23428214; Kappetein, A.P., Head, S.J., Morice, M.C., Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial (2013) Eur J Cardiothorac Surg, 43 (5), pp. 1006-1013. , PID: 23413014; Kapur, A., Hall, R.J., Malik, I.S., Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial (2010) J Am Coll Cardiol, 55 (5), pp. 432-440. , PID: 20117456; King, S.B., Kosinski, A.S., Guyton, R.A., Lembo, N.J., Weintraub, W.S., Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST) (2000) J Am Coll Cardiol, 35 (5), pp. 1116-1121. , PID: 10758949; King, S.B., Lembo, N.J., Weintraub, W.S., A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST) (1994) N Engl J Med, 331 (16), pp. 1044-1050. , PID: 8090163; Kip, K.E., Faxon, D.P., Detre, K.M., Yeh, W., Kelsey, S.F., Currier, J.W., Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry (1996) Circulation, 94 (8), pp. 1818-1825. , COI: 1:STN:280:DyaK2s%2FislGitA%3D%3D, PID: 8873655; Kurbaan, A.S., Bowker, T.J., Ilsley, C.D., Sigwart, U., Rickards, A.F., Investigators, C., Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode (2001) Am J Cardiol, 87 (8), pp. 947-950. , COI: 1:STN:280:DC%2BD3M3kvFWgsQ%3D%3D, PID: 11305983, A943; Leavitt, B.J., Sheppard, L., Maloney, C., Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery (2004) Circulation, 110, pp. 41-44. , PID: 15364836; Levine, G.N., Bates, E.R., Blankenship, J.C., 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions (2011) J Am Coll Cardiol, 58 (24), pp. 44-122. , PID: 22070834; Lima, E.G., Hueb, W., Garcia, R.M., Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial (2013) Am Heart J, 166 (2), pp. 250-257. , PID: 23895807; Magnuson, E.A., Farkouh, M.E., Fuster, V., Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial (2013) Circulation, 127 (7), pp. 820-831. , PID: 23277307; Morrison, D.A., Sethi, G., Sacks, J., Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the department of veterans affairs cooperative study #385, the angina with extremely serious operative mortality evaluation (AWESOME) (2001) J Am Coll Cardiol, 38 (1), pp. 143-149. , COI: 1:STN:280:DC%2BD3MzpvFCrug%3D%3D, PID: 11451264; O’Gara, P.T., Kushner, F.G., Ascheim, D.D., 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines (2013) Circulation, 127 (4), pp. 362-425. , PID: 23247304; Onuma, Y., Wykrzykowska, J.J., Garg, S., 5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials (2011) JACC Cardiovasc Interv, 4 (3), pp. 317-323. , PID: 21435610; Park, S.J., Kim, Y.H., Park, D.W., Randomized trial of stents versus bypass surgery for left main coronary artery disease (2011) N Engl J Med, 364 (18), pp. 1718-1727. , COI: 1:CAS:528:DC%2BC3MXlvFymtLo%3D, PID: 21463149; Pijls, N.H., Fearon, W.F., Tonino, P.A., Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study (2010) J Am Coll Cardiol, 56 (3), pp. 177-184. , PID: 20537493; Rodriguez, A.E., Baldi, J., Fernandez Pereira, C., Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II) (2005) J Am Coll Cardiol, 46 (4), pp. 582-588. , PID: 16098419; Rodriguez, A., Bernardi, V., Navia, J., ERACI II Investigators, Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results (2001) J Am Coll Cardiol, 37 (1), pp. 51-58. , COI: 1:STN:280:DC%2BD3M%2Fptl2hsA%3D%3D, PID: 11153772; Sarno, G., Lagerqvist, B., Frobert, O., Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR) (2012) Eur Heart J, 33 (5), pp. 606-613. , PID: 22232428; Sedlis, S.P., Morrison, D.A., Lorin, J.D., Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry (2002) J Am Coll Cardiol, 40 (9), pp. 1555-1566. , PID: 12427406; Serruys, P.W., de Jaegere, P., Kiemeneij, F., A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group (1994) N Engl J Med, 331 (8), pp. 489-495. , COI: 1:STN:280:DyaK2czhs1anuw%3D%3D, PID: 8041413; Serruys, P.W., Ong, A.T., van Herwerden, L.A., Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the arterial revascularization therapies study (ARTS) randomized trial (2005) J Am Coll Cardiol, 46 (4), pp. 575-581. , PID: 16098418; Serruys, P.W., Unger, F., Sousa, J.E., Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease (2001) N Engl J Med, 344 (15), pp. 1117-1124. , COI: 1:STN:280:DC%2BD3M3ivVaqsg%3D%3D, PID: 11297702; Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030 (2010) Diabetes Res Clin Pract, 87 (1), pp. 4-14. , COI: 1:STN:280:DC%2BC3c%2Fot1Witg%3D%3D, PID: 19896746; Sianos, G., Morel, M.A., Kappetein, A.P., The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease (2005) EuroIntervention J EuroPCR Collaboration Work Group Interv Cardiol Eur Soc Cardiol, 1 (2), pp. 219-227; Simpfendorfer, C., Belardi, J., Bellamy, G., Galan, K., Franco, I., Hollman, J., Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty (1987) Am J Cardiol, 59 (4), pp. 267-269. , COI: 1:STN:280:DyaL2s7isVGisQ%3D%3D, PID: 2949590; So, S.I., Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial (2002) Lancet, 360 (9338), pp. 965-970; Soares, P.R., Hueb, W.A., Lemos, P.A., Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the medicine, angioplasty, or surgery study (MASS II) (2006) Circulation, 114, pp. 420-424. , PID: 16820611; Tada, T., Kimura, T., Morimoto, T., Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry (2011) Am J Cardiol, 107 (8), pp. 1155-1162. , COI: 1:CAS:528:DC%2BC3MXkt1ahtbs%3D, PID: 21296326; Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease (1996) N Engl J Med, 335 (4), pp. 217-225. , The Bypass Angioplasty Revascularization Investigation (BARI) Investigators; Thourani, V.H., Weintraub, W.S., Stein, B., Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting (1999) Ann Thorac Surg, 67 (4), pp. 1045-1052. , COI: 1:STN:280:DyaK1M3ltF2qtQ%3D%3D, PID: 10320249; Toklu, B., Bangalore, S., Choosing the right coronary stent in the modern era (2014) Curr Cardiol Rep, 16 (4), p. 469. , PID: 24604695; Weintraub, W.S., Mahoney, E.M., Zhang, Z., One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial (2004) Heart, 90 (7), pp. 782-788. , COI: 1:STN:280:DC%2BD2c3pvFyhtw%3D%3D, PID: 15201249; Weintraub, W.S., Mauldin, P.D., Becker, E., Kosinski, A.S., King, S.B., A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the emory angioplasty versus surgery trial (EAST) (1995) Circulation, 92 (10), pp. 2831-2840. , COI: 1:STN:280:DyaK28%2FntFejug%3D%3D, PID: 7586249; Weiss, A.J., Elixhauser, A., Trends in operating room procedures in U.S. hospitals, 2001–2011: Statistical Brief #171 (2006) Healthcare Cost and Utilization Project, , HCUP) Statistical Briefs, Rockville (MD:; Wenaweser, P., Daemen, J., Zwahlen, M., Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study (2008) J Am Coll Cardiol, 52 (14), pp. 1134-1140. , COI: 1:CAS:528:DC%2BD1cXhtFersr7J, PID: 18804739; Whang, W., Bigger, J.T., Jr., Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from the CABG patch trial database. The CABG patch trial investigators and coordinators (2000) J Am Coll Cardiol, 36 (4), pp. 1166-1172. , COI: 1:STN:280:DC%2BD3cvnslSqtA%3D%3D, PID: 11028466; Writing Committee, M., Jneid, H., Anderson, J.L., 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American college of cardiology foundation/American heart association task force on practice guidelines (2012) Circulation, 126 (7), pp. 875-910",Review,Scopus,2-s2.0-84925655326
"Mohammed Abdul K.S., Jovanovic S., Du Q., Sukhodub A., Jovanovic A.","Mild hypoxia in vivo regulates cardioprotective SUR2A: A role for Akt and LDH",2015,"Biochimica et Biophysica Acta - Molecular Basis of Disease","1852","5",,"709","719",,,10.1016/j.bbadis.2015.01.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922389570&partnerID=40&md5=c7a685fbb60cbdd0efcb73c016b39e24","Medical Research Institute, Division of Cardiovascular and Diabetic Medicine, Ninewells Hospital and Medical School, University of DundeeDundee, United Kingdom","Mohammed Abdul, K.S., Medical Research Institute, Division of Cardiovascular and Diabetic Medicine, Ninewells Hospital and Medical School, University of DundeeDundee, United Kingdom; Jovanović, S., Medical Research Institute, Division of Cardiovascular and Diabetic Medicine, Ninewells Hospital and Medical School, University of DundeeDundee, United Kingdom; Du, Q., Medical Research Institute, Division of Cardiovascular and Diabetic Medicine, Ninewells Hospital and Medical School, University of DundeeDundee, United Kingdom; Sukhodub, A., Medical Research Institute, Division of Cardiovascular and Diabetic Medicine, Ninewells Hospital and Medical School, University of DundeeDundee, United Kingdom; Jovanović, A., Medical Research Institute, Division of Cardiovascular and Diabetic Medicine, Ninewells Hospital and Medical School, University of DundeeDundee, United Kingdom","High-altitude residents have lower mortality rates for ischaemic heart disease and this is ascribed to cardiac gene remodelling by chronic hypoxia. SUR2A is a cardioprotective ABC protein serving as a subunit of sarcolemmal ATP-sensitive K+ channels. The purpose of this study was to determine whether SUR2A is regulated by mild hypoxia in vivo and to elucidate the underlying mechanism. Mice were exposed to either 21% (control) or 18% (mild hypoxia) oxygen for 24h. Exposure to 18% oxygen did not affect partial pressure of O2 (PO2) and CO2 (PCO2) in the blood, haematocrit or level of ATP in the heart. However, hypoxia increased myocardial lactate dehydrogenase (LDH) and lactate as well as NAD+ without affecting total NAD. SUR2A levels were significantly increased as well as myocardial resistance to ischaemia-reperfusion. Exposure to 18% oxygen did not phosphorylate extracellular signal regulated kinases (ERK1/2) or AMP activated protein kinase (AMPK), but it phosphorylated protein kinase B (Akt). An inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 (0.2mg/mouse), abolished all observed effects of hypoxia. LDH inhibitors, galloflavin (50μM) and sodium oxamate (80mM) significantly decreased levels of SUR2A in heart embryonic H9c2 cells, while inactive mutant LDH form, gly193-M-LDH increased cellular sensitivity towards stress induced by 2,4-dinitrophenol (10mM). Treatment of H9c2 cells with sodium lactate (30mM) increased intracellular lactate, but did not affect LDH activity or SUR2A levels. We conclude that PI3K/Akt signalling pathway and LDH play a crucial role in increase of cardiac SUR2A induced by in vivo exposure to 18% oxygen. © 2015.","Akt; Heart; Hypoxia; LDH; Oxygen; SUR2A","Burke, M.A., Mutharasan, R.K., Ardehali, H., The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel (2008) Circ. Res., 102, pp. 164-176; Du, Q., Jovanović, S., Clelland, A., Sukhodub, A., Budas, G.R., Phelan, K., Murray-Tait, V., Jovanović, A., Overexpression of SUR2A generates a cardiac phenotype resistant to ischaemia (2006) FASEB J., 20, pp. 1131-1141; Sukhodub, A., Du, Q., Jovanović, S., Jovanović, A., Nicotinamide-rich diet protects the heart against ischaemia-reperfusion in mice: a crucial role for cardiac SUR2A (2010) Pharmacol. Res., 61, pp. 564-570; Sukhodub, A., Sudhir, R., Du, Q., Jovanović, S., Reyes, S., Jovanović, A., Nicotinamide-rich diet improves physical endurance by upregulating SUR2A in the heart (2011) J. Cell. Mol. Med., 15, pp. 1703-1712; Sudhir, R., Sukhodub, A., Du, Q., Jovanović, S., Jovanović, A., Ageing-induced decline in physical endurance in mice is associated with decrease in cardiac SUR2A and increase in cardiac susceptibility to metabolic stress: therapeutic prospects for up-regulation of SUR2A (2011) Biogerontology, 12, pp. 147-155; Ranki, H.J., Budas, G.R., Crawford, R.M., Jovanović, A., Gender-specific difference in cardiac ATP-sensitive K+ channels (2001) J. Am. Coll. Cardiol., 38, pp. 906-915; Jovanović, S., Du, Q., Sukhodub, A., Jovanović, A., M-LDH physically associated with sarcolemmal KATP channels mediates cytoprotection in heart embryonic H9C2 cells (2009) Int. J. Biochem. Cell Biol., 41, pp. 2295-2301; Jovanović, S., Du, Q., Sukhodub, A., Jovanović, A., Dual mechanism of cytoprotection afforded by M-LDH in embryonic heart H9C2 cells (2009) Biochem. Biophys. Acta Mol. Cell. Res., 1793, pp. 1379-1386; Du, Q., Jovanović, S., Sukhodub, A., Jovanović, A., Infection with AV-SUR2A protects H9C2 cells against metabolic stress: a mechanism of SUR2A-mediated cytoprotection independent from the KATP channels activity (2010) Biochem. Biophys. Acta Mol. Cell. Res., 1803, pp. 405-415; Curtis, M.J., Emerging druggable targets for cardiovascular disease (2009) Curr. Opin. Pharmacol., 9, pp. 81-83; Jovanović, A., Jovanović, S., SUR2A targeting for cardioprotection? (2009) Curr. Opin. Pharmacol., 9, pp. 189-193; Jovanović, S., Mohammed Abdul, K.S., Jovanović, A., Cardioprotection afforded by SUR2A: an update (2013) J. Cardiobiol., 1, p. 4; Mortimer, E.A., Monson, R.R., MacMahon, B., Reduction in mortality from coronary heart disease in men residing at high altitude (1977) N. Engl. J. Med., 296, pp. 581-585; Ezzati, M., Horwitz, M.E., Thomas, D.S., Friedman, A.B., Roach, R., Clark, T., Murray, C.J.L., Honigman, B., Altitude, life expectancy and mortality from ischaemic heart disease, stroke, COPD and cancers: national population-based analysis of US counties (2012) J. Epidemiol. Community Health, 66, p. e17; Hurtado, A., Escudero, E., Pando, J., Sharma, S., Johnson, R.J., Cardiovascular and renal effects of chronic exposure to high altitude (2012) Nephrol. Dial. Transplant., 27, pp. iv11-iv16; Faeh, D., Gutzwiller, F., Bopp, M., Lower mortality from coronary heart disease and stroke at higher altitudes in Switzerland (2009) Circulation, 120, pp. 495-501; Tajima, M., Katayose, D., Bessho, M., Isoyama, S., Acute ischaemic preconditioning and chronic hypoxia independently increase myocardial tolerance to ischaemia (1994) Cardiovasc. Res., 28, pp. 312-319; Berger, M.M., Huhn, R., Oei, G.T., Heinen, A., Winzer, A., Bauer, I., Preckel, B., Hollmann, M.W., Hypoxia induces late preconditioning in the rat heart in vivo (2010) Anesthesiology, 113, pp. 1351-1360; Mohammed Abdul, K.S., Jovanovic, S., Du, Q., Sukhodub, A., Jovanovic, A., Upregulation of cardioprotective SUR2A by sub-hypoxic drop in oxygen (2014) Biochem. Biophys. Acta Mol. Cell. Res., 1843, pp. 2424-2431; Crawford, R.M., Jovanović, S., Budas, G.R., Davies, A.M., Lad, H., Wenger, R.H., Robertson, K.A., Jovanović, A., Chronic mild hypoxia protects heart-derived H9c2 cells against acute hypoxia/reoxygenation by regulating expression of the SUR2A subunit of the ATP-sensitive K+ channels (2003) J. Biol. Chem., 278, pp. 31444-31455; Sukhodub, A., Jovanović, S., Du, Q., Budas, G.R., Clelland, A., Shen, M., Sakamoto, K., Jovanović, A., AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K+ channels (2007) J. Cell. Physiol., 210, pp. 224-236; Vlahos, C.J., Matter, W.F., Hui, K.Y., Brown, R.F., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) (1994) J. Biol. Chem., 269, pp. 5241-5248; Essop, M.F., Cardiac metabolic adaptations in response to hypoxia (2007) J. Physiol. Lond., 584, pp. 715-726; Jovanović, S., Jovanović, A., Models of cardioprotection (2007) Drug Discov. Today Dis. Models, 4, pp. 185-190; McClelland, G.B., Brooks, G.A., Changes in MCT 1, MCT 4, and LDH expression are tissue specific in rats after long-term hypobaric hypoxia (2004) J. Appl. Physiol., 92, pp. 1573-1584; Budas, G.R., Sukhodub, A., Alessi, D.R., Jovanovic, A., 3'phosphoinositide-dependent kinase-1 (PDK1) is essential for ischaemic preconditioning of the myocardium (2006) FASEB J., 20, pp. 2556-2558; Hausenloy, D.J., Yellon, D.M., Survival kinases in ischemic preconditioning and postconditioning (2006) Cardiovasc. Res., 70, pp. 240-253; Alvarez-Tejado, M., Naranjo-Suarez, S., Jimenez, C., Carrera, A.C., Landazuri, M.O., del Peso, L., Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells. Protective role in apoptosis (2001) J. Biol. Chem., 276, pp. 22368-22374; Hemmings, B.A., Restuccia, D.F., PI3K-PKB/Akt pathway (2012) Cold Spring Harb. Perspect. Biol., 4, p. a011189; Vadlakonda, L., Dash, A., Pasupuleti, M., Anil Kumar, K., Reddanna, P., The paradox of Akt-mTOR interactions (2013) Front. Oncol., 3, p. 165; Ballantyne, T., Du, Q., Jovanovic, S., Neemo, A., Holmes, R., Shiba, S., Jovanovic, A., Testosterone protects female embryonic heart H9C2 cells against severe metabolic stress by activating estrogen receptors and up-regulating IES SUR2B (2013) Int. J. Biochem. Cell Biol., 45, pp. 283-291; Wilkinson, J.H., Walter, S.J., Oxamate as a differential inhibitor of lactate dehydrogenase isoenzymes (1972) Enzyme, 13, pp. 170-176; Farabegoli, F., Vettraino, M., Manerba, M., Fiume, L., Roberti, M., Di Stefano, G., Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways (2012) Eur. J. Pharm. Sci., 47, pp. 729-738; Fiume, L., Vettriano, M., Carnicelli, D., Arfilli, V., Di Stefano, G., Brigotti, M., Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells (2013) Biochem. Biophys. Res. Commun., 430, pp. 466-469",Article,Scopus,2-s2.0-84922389570
"Mustafa A.H.S., Holroyd E., Butler R., Fraser D., El-Omar M., Nolan J., Mamas M.A.","Transradial Intervention in ST Elevation Myocardial Infarction",2015,"Current Cardiology Reports","17","5",,"","",6,,10.1007/s11886-015-0585-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928350154&partnerID=40&md5=cab578062cef4af5d264e552a65564bd","Manchester Heart Centre, Manchester Royal Infirmary, Central Manchester University Hospitals NHS TrustManchester, United Kingdom; Department of Cardiology, University Hospital North MidlandsStoke-on-Trent, United Kingdom; Keele Cardiovascular Research Group, Institutes of Science and Technology in Medicine and Primary Care, University of KeeleStoke on Trent, United Kingdom","Mustafa, A.H.S., Manchester Heart Centre, Manchester Royal Infirmary, Central Manchester University Hospitals NHS TrustManchester, United Kingdom; Holroyd, E., Department of Cardiology, University Hospital North MidlandsStoke-on-Trent, United Kingdom; Butler, R., Department of Cardiology, University Hospital North MidlandsStoke-on-Trent, United Kingdom; Fraser, D., Manchester Heart Centre, Manchester Royal Infirmary, Central Manchester University Hospitals NHS TrustManchester, United Kingdom; El-Omar, M., Manchester Heart Centre, Manchester Royal Infirmary, Central Manchester University Hospitals NHS TrustManchester, United Kingdom; Nolan, J., Department of Cardiology, University Hospital North MidlandsStoke-on-Trent, United Kingdom, Keele Cardiovascular Research Group, Institutes of Science and Technology in Medicine and Primary Care, University of KeeleStoke on Trent, United Kingdom; Mamas, M.A., Manchester Heart Centre, Manchester Royal Infirmary, Central Manchester University Hospitals NHS TrustManchester, United Kingdom, Keele Cardiovascular Research Group, Institutes of Science and Technology in Medicine and Primary Care, University of KeeleStoke on Trent, United Kingdom","Primary percutaneous coronary intervention (PPCI) in ST elevation myocardial infarction (STEMI) represents the current gold standard reperfusion therapy. Recent advances in antiplatelet and anticoagulant therapy have reduced the risk of ischemic complications and mortality in PPCI although this has been at the expense of major bleeding complications. Access site-related bleeding complications account for up to 50 % of major peri-procedural bleeding complications in PCI. Increasing adoption of the radial artery as the default access site has been shown to markedly reduce such major bleeding complications and mortality in selected patient cohorts. Recent data has suggested that adoption of the transradial access site in STEMI PCI procedures is associated with significant reductions in major bleeding complications and mortality in both national registry data and randomised controlled trials. We provide an overview of this data and discuss the remaining uncertainties around the synergy between access site and contemporary antithrombotic and antiplatelet therapy in such patients. Finally, whilst adoption of the radial artery as the default access site in PPCI has yielded a similar reduction in mortality as observed in the switch from thrombolysis to PPCI in the past, its adoption as a default access site is not universal. We discuss the remaining obstacles and challenges for more widespread adoption of the radial access site as the default access site in PPCI. © 2015, Springer Science+Business Media New York.","Access site; Bleeding; Outcomes; Radial; STEMI","Grines, C., Patel, A., Zijlstra, F., Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials (2003) Am Heart J, 145, pp. 47-57. , COI: 1:STN:280:DC%2BD3s%2FgvVOnsg%3D%3D; Stone, G.W., Witzenbichler, B., Guagliumi, G., Bivalirudin during primary PCI in acute myocardial infarction (2008) N Engl J Med, 358, pp. 2218-2230. , COI: 1:CAS:528:DC%2BD1cXmt1Gju7Y%3D; Stone, G.W., Witzenbichler, B., Guagliumi, G., Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial (2011) Lancet, 377, pp. 2193-2204. , COI: 1:CAS:528:DC%2BC3MXotVejsbo%3D; Kwok, C.R.S., Myint, P., (2014) Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis, , Open Heart: This meta-analysis showed that increase in major bleeding predicts an increase in mortality and MACE; Verheugt, F.W., Steinhubl, S.R., Hamon, M., Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention (2011) J Am Coll Cardiol Intv, 4, pp. 191-197; Mamas, M.A., Ratib, K., Routledge, H., Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials (2012) Heart, 98, pp. 303-311. , COI: 1:CAS:528:DC%2BC38XjvFOmurc%3D, This meta-analysis of eight RCTs showed reduction of mortality, bleeding and access site complications in radial access; Baklanov, D.V., Kaltenbach, L.A., Marso, S.P., The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011) (2013) J Am Coll Cardiol, 61, pp. 420-426. , This analysis from the NCDR registry showed better outcomes in patients treated via the radial route; Kikkert, W.J., Delewi, R., Ouweneel, D.M., Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis (2014) J Am Coll Cardiol Intv, 7, pp. 622-630; Mamas, M.A., Ratib, K., Routledge, H., Influence of arterial access site selection on outcomes in primary percutaneous coronary intervention: are the results of randomized trials achievable in clinical practice? (2013) J Am Coll Cardiol Intv, 6, pp. 698-706. , BCIS registry analysis showed that radial access in STEMI was associated with better outcomes; Rao, S.V., Tremmel, J.A., Gilchrist, I.C., Best practices for transradial angiography and intervention: a consensus statement from the society for cardiovascular angiography and intervention’s transradial working group (2014) Catheter Cardiovasc Interv: Off J Soc Cardiac Angiography Interv, 83, pp. 228-236; Steg, P.G., James, S.K., Gersh, B.J., 2012 ESC STEMI guidelines and reperfusion therapy: evidence-based recommendations, ensuring optimal patient management (2013) Heart, 99, pp. 1156-1157; Hannan, E.L., Farrell, L.S., Walford, G., Utilization of radial artery access for percutaneous coronary intervention for ST-segment elevation myocardial infarction in New York (2014) J Am Coll Cardiol Intv, 7, pp. 276-283; Romagnoli, E., De Vita, M., Burzotta, F., Radial versus femoral approach comparison in percutaneous coronary intervention with intraaortic balloon pump support: the RADIAL PUMP UP registry (2013) Am Heart J, 166, pp. 1019-1026; Fujii, T., Masuda, N., Ijichi, T., Transradial intervention for patients with ST elevation myocardial infarction with or without cardiogenic shock (2014) Catheter Cardiovasc Interv: Off J Soc Cardiac Angiography Interve, 83, pp. 1-7; Mamas, M.A., Anderson, S.G., Ratib, K., Arterial access site utilization in cardiogenic shock in the United Kingdom: is radial access feasible? (2014) Am Heart J, 167, p. 900. , BCIS registry data showing that radial access in cardiogenic shock is associted with lower mortality and bleeding compared to femoral access; Yan, Z.X., Zhou, Y.J., Zhao, Y.X., Safety and feasibility of transradial approach for primary percutaneous coronary intervention in elderly patients with acute myocardial infarction (2008) Chin Med J, 121, pp. 782-786; Rodriguez-Leor, O., Fernandez-Nofrerias, E., Carrillo, X., Results of primary percutaneous coronary intervention in patients ≥75 years treated by the transradial approach (2014) Am J Cardiol, 113, pp. 452-456; Secco, G.G., Marinucci, L., Uguccioni, L., Parisi, R., Uguccioni, S., Fattori, R., Transradial versus transfemoral approach for primary percutaneous coronary interventions in elderly patients (2013) J Invasive Cardiol, 25, pp. 254-256; Mehta, S.R., Jolly, S.S., Cairns, J., Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation (2012) J Am Coll Cardiol, 60, pp. 2490-2499; Romagnoli, E., Biondi-Zoccai, G., Sciahbasi, A., Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (radial versus femoral randomized investigation in ST-elevation acute coronary syndrome) study (2012) J Am Coll Cardiol, 60, pp. 2481-2489; Bernat, I., Horak, D., Stasek, J., ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial: the STEMI-RADIAL trial (2014) J Am Coll Cardiol, 63, pp. 964-972. , This recent RCT comparing radial and femoral access in STEMI showed better outcomes with radial access; Genereux, P., Mehran, R., Palmerini, T., Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial (2011) EuroIntervention : Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 7, pp. 905-916; Chodor, P., Kurek, T., Kowalczuk, A., Radial vs femoral approach with StarClose clip placement for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. RADIAMI II: a prospective, randomised, single centre trial (2011) Kardiol Pol, 69, pp. 763-771; Saito, S., Tanaka, S., Hiroe, Y., Comparative study on transradial approach vs. transfemoral approach in primary stent implantation for patients with acute myocardial infarction: results of the test for myocardial infarction by prospective unicenter randomization for access sites (TEMPURA) trial (2003) Catheter Cardiovasc Interv: Off J Soc Cardiac Angiography Interv, 59, pp. 26-33; Cantor, W.J., Puley, G., Natarajan, M.K., Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial (2005) Am Heart J, 150, pp. 543-549. , COI: 1:CAS:528:DC%2BD2MXhtVWgtrfP; Brasselet, C., Tassan, S., Nazeyrollas, P., Hamon, M., Metz, D., Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: results of the FARMI trial (2007) Heart, 93, pp. 1556-1561. , COI: 1:CAS:528:DC%2BD1cXisl2nsA%3D%3D; Hou, L., Wei, Y.D., Li, W.M., Xu, Y.W., Comparative study on transradial versus transfemoral approach for primary percutaneous coronary intervention in Chinese patients with acute myocardial infarction (2010) Saudi Med J, 31, pp. 158-162; Jolly, S.S., Cairns, J., Niemela, K., Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial (2013) J Am Coll Cardiol Intv, 6, pp. 258-266; Jolly, S.S., Cairns, J., Yusuf, S., Procedural volume and outcomes with radial or femoral access for coronary angiography and intervention (2014) J Am Coll Cardiol, 63, pp. 954-963; Komocsi, A., Aradi, D., Kehl, D., Meta-analysis of randomized trials on access site selection for percutaneous coronary intervention in ST-segment elevation myocardial infarction (2014) Archives Med Sci: AMS, 10, pp. 203-212; Karrowni, W., Vyas, A., Giacomino, B., Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials (2013) J Am Coll Cardiol Intv, 6, pp. 814-823; Chiang, A., Gada, H., Kodali, S.K., Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists (2014) Catheter Cardiovasc Interv: Off J Soc Cardiac Angiography Interv, 83, pp. 721-726; Hess, C.N., Peterson, E.D., Neely, M.L., The learning curve for transradial percutaneous coronary intervention among operators in the United States: a study from the National Cardiovascular Data Registry (2014) Circulation, 129 (22), pp. 2277-2286; Wimmer, N.J., Resnic, F.S., Mauri, L., Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention (2013) J Am Heart Assoc, 2, p. 000174; Mamas, M.A., Anderson, S.G., Carr, M., Baseline bleeding risk and arterial access site practice in relation to procedural outcomes after percutaneous coronary intervention (2014) J Am Coll Cardiol, 64, pp. 1554-1564; Shahzad, A., Kemp, I., Mars, C., Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial (2014) Lancet",Review,Scopus,2-s2.0-84928350154
"Wharton S., Serodio K.J.","Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk",2015,"Current Cardiology Reports","17","5",,"","",9,,10.1007/s11886-015-0590-z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928347829&partnerID=40&md5=568c58c114e07c0d1df475c4edb8623c","Weight Management and Diabetes Management, The Wharton Medical Clinic, 414 Victoria Ave N Suite 14Hamilton, ON, Canada; Department of Health and Kinesiology, York University, 4700 Keele StToronto, ON, Canada","Wharton, S., Weight Management and Diabetes Management, The Wharton Medical Clinic, 414 Victoria Ave N Suite 14Hamilton, ON, Canada, Department of Health and Kinesiology, York University, 4700 Keele StToronto, ON, Canada; Serodio, K.J., Weight Management and Diabetes Management, The Wharton Medical Clinic, 414 Victoria Ave N Suite 14Hamilton, ON, Canada","Since the 1980s, the prevalence of obesity has almost doubled worldwide. Treatments for obesity include lifestyle modification, medications and surgery. Newer anti-obesity medications have been shown to be effective at inducing initial weight management in addition to successful long-term weight maintenance. Historically, weight management medications have been associated with public safety concerns that have resulted in the majority being withdrawn from the market or never receiving medicinal authorization. Recently, several countries have approved some newer generation weight management medications which may be beneficial to combat obesity. These medications have varying effects on cardiometabolic parameters, both positive and potentially negative. This review will outline the mechanisms of action of these medications and their implications for both diabetes and cardiovascular risks. © 2015, The Author(s).","Cardiometabolic risks; Medications; Weight management","http://www.who.int/mediacentre/factsheets/fs311/en/, WHO. Obes. Overweight fact sheet. 2013. Accessed 16 Oct 2014Herouvi, D., Karanasios, E., Karayianni, C., Cardiovascular disease in childhood: the role of obesity (2013) Eur J Pediatr, 172, pp. 721-732; Rueda-Clausen, C.F., Padwal, R.S., Sharma, A.M., New pharmacological approaches for obesity management (2013) Nat Rev Endocrinol, 9, pp. 467-478. , COI: 1:CAS:528:DC%2BC3sXhtFGmsrzM; Carter, R., Mouralidarane, A., Ray, S., Recent advancements in drug treatment of obesity (2012) Clin Med, 12, pp. 456-460; Halford, J.C.G., Pharmacotherapy for obesity (2006) Appetite, 46, pp. 6-10. , COI: 1:CAS:528:DC%2BD28XitFCrsg%3D%3D; Manning, S., Pucci, A., Finer, N., Pharmacotherapy for obesity: novel agents and paradigms (2014) Ther Adv Chronic Dis, 5, pp. 135-148. , COI: 1:CAS:528:DC%2BC2cXhs1OntbvP; Chan, E.W., He, Y., Chui, C.S.L., Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs (2013) Obes Rev, 14, pp. 383-392. , COI: 1:CAS:528:DC%2BC3sXmt1Ohu7s%3D; http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1817249, Orexigen Therapeutics Inc. Orexigen press release 2013—Contrave and Empatic. 2013. 1–5. Accessed 27 Oct 2014FDA. Contrave (naltrexone sr/bupropion SR combination): Advisory Committee Briefing Document. 2010;1–278Kennett, G.A., Clifton, P.G., New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? (2010) Pharmacol Biochem Behav, 97, pp. 63-83. , COI: 1:CAS:528:DC%2BC3cXht1Oms73L; (2014) Guideline on clinical evaluation of medicinal products used in weight control, 4, pp. 1-11; http://www.fda.gov/newsevents/testimony/ucm115044.htm, FDA. Ephedrine alkaloid-containing dietary supplements. 2003. Accessed 2 Oct 2014Andraws, R., Chawla, P., Brown, D.L., Cardiovascular effects of ephedra alkaloids: a comprehensive review (2005) Prog Cardiovasc Dis, 47, pp. 217-225. , COI: 1:CAS:528:DC%2BD2MXos1ams7k%3D; EMA. Press release: the European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. 2008;4–5Padwal, R.S., Majumdar, S.R., Drug treatments for obesity: orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77. , COI: 1:CAS:528:DC%2BD2sXit12itQ%3D%3D; Connolly, H., Crary, J., McGoon, M., Vaulvular heart disease associated with fenfluramine-phentermine (1997) N Engl J Med, 337, pp. 581-588. , COI: 1:CAS:528:DyaK2sXmtVGntLc%3D; Sweeting, A.N., Tabet, E., Caterson, I.D., Management of obesity and cardiometabolic risk—role of phentermine / extended release topiramate (2014) Diabetes Metab Syndr Obes, 12, pp. 35-44; Hainer, V., Hainerová, I.A., Do we need anti-obesity drugs? (2012) Diabetes Metab Res Rev, 28, pp. 8-20; (2010) European Medicines Agency recommends suspension of marketing authorisations for sibutramine, 44, pp. 1-2; Yanovski, S., Yanovski, J.A., Long-term drug treatment for obesity: a systematic and clinical review (2014) JAMA, 311, pp. 74-86. , COI: 1:CAS:528:DC%2BC2cXitF2nurY%3D; Sumithran, P., Proietto, J., Benefit-risk assessment of orlistat in the treatment of obesity (2014) Drug Saf, 37, pp. 597-608. , COI: 1:CAS:528:DC%2BC2cXht1Gks7bE; Torgerson, J., Hauptman, J., Boldrin, M., XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients (2004) Diabetes Care, 27, pp. 155-161. , COI: 1:CAS:528:DC%2BD2cXmvV2jug%3D%3D; Erdmann, J., Lippl, F., Klose, G., Cholesterol lowering effect of dietary weight loss and orlistat treatment—efficacy and limitations (2004) Aliment Pharmacol Ther, 19, pp. 1173-1179. , COI: 1:CAS:528:DC%2BD2cXlsFyiurg%3D; Ransom, T., Goldenberg, R., Mikalachki, A., Reducing the risk of developing diabetes (2013) Can J diabetes, 37, pp. 16-19; Jensen, M.D., Ryan, D.H., Apovian, C.M., 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society (2014) Circulation, 129, pp. 102-138; Apovian, C.M., Aronne, L.J., Bessesen, D.H., Pharmacological management of obesity: an endocrine society clinical practice guideline (2015) J Clin Endocrinol Metab; Allison, D.B., Gadde, K.M., Garvey, W.T., Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) (2012) Obesity (Silver Spring), 20, pp. 330-342. , COI: 1:CAS:528:DC%2BC38XhsFCmsbo%3D; FDA. New Drug Application 22580- VI-0521 QNEXA (phentermine/topiramate). 2012;1–200. This report summarized MACE data and it was determined that there was no significant difference in the risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke between phentermine-topiramate and placeboWoloshin, S., Schwartz, L., The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? (2014) JAMA Intern Med, 174, pp. 615-619; Gadde, K.M., Allison, D.B., Ryan, D.H., Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial (2011) Lancet, 377, pp. 1341-1352. , COI: 1:CAS:528:DC%2BC3MXkvVSqtL4%3D; Garvey, W.T., Ryan, D.H., Look, M., (2012) Two-year sustained weight loss and metabolic benefits with controlled-release phentermine / topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study, 1-3, pp. 297-308; http://ir.vivus.com/releasedetail.cfm?ReleaseID=791927, VIVUS. VIVUS Updates European Filing Strategy for Qsiva. 2013. 1–2. Accessed 2 Oct 2014O’Neil, P.M., Smith, S.R., Weissman, N.J., Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study (2012) Obesity, 20, pp. 1426-1436; Smith, S.R., Weissman, N.J., Anderson, C.M., Multicenter, placebo-controlled trial of lorcaserin for weight management (2010) N Engl J Med, 363, pp. 245-256. , COI: 1:CAS:528:DC%2BC3cXptVOgs74%3D; (2013) Assessment report-Belviq, 44, pp. 1-43; Fidler, M.C., Sanchez, M., Raether, B., A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial (2011) J Clin Endocrinol Metab, 96, pp. 3067-3077. , COI: 1:CAS:528:DC%2BC3MXhtlyitbnO; http://eisai.mediaroom.com/2014-02-24-Eisai-Begins-CAMELLIA-TIMI-61-Long-term-Outcomes-Study-to-Assess-Cardiovascular-and-Metabolic-Effects-of-Lorcaserin-HCI-CIV-in-Overweight-Obese-Patients, Eisai. Eisai Begins CAMELLIA-TIMI 61 LT outcomes study to assess cardiometa effects of lorcaserin HCI CIV in OW and OB pts. 2014;1–5. Accessed 28 Nov 2014http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm, FDA. FDA approves weight-management drug Contrave. 2014;1–4. Accessed 31 Oct 2014. This webpage provided some of the latest breaking news on Contrave FDA Approval. It also provided useful, publically available, information on study results and medication contraindicationsApovian, C.M., Aronne, L., Rubino, D., A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) (2013) Obesity, 21, pp. 935-943. , COI: 1:CAS:528:DC%2BC3sXpvFaksL0%3D; Greenway, F.L., Fujioka, K., Plodkowski, R.A., Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2010) Lancet, 376, pp. 595-605. , COI: 1:CAS:528:DC%2BC3cXhtVGmtbbK; Hollander, P., Gupta, A., Plodkowski, R., Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes (2013) Diabetes Care, 36, pp. 4022-4029. , COI: 1:CAS:528:DC%2BC3sXhvFaksLvM; Wadden, T.A., Foreyt, J.P., Foster, G.D., Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial (2011) Obesity, 19, pp. 110-120. , COI: 1:CAS:528:DC%2BC3cXhs1Wkt7zF; Marre, M., Shaw, J., Brändle, M., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) (2009) Diabet Med, 26, pp. 268-278. , COI: 1:CAS:528:DC%2BD1MXkvVGqur8%3D; Novo Nordisk. Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo. 2014;1–4FDA. Highlight of prescribing information Victoza. 2010;1–23http://www.fda.gov/forpatients/illness/diabetes/ucm408682.htm#collapse3, FDA. Approved diabetes medicines. 2014;1–4. Accessed 29 Oct 2014http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm, FDA. FDA approves weight-management drug Saxenda. 2014. Accessed 16 Mar 2015. This report concisely outlined the FDA approval of Saxendahttp://www.newswire.ca/en/story/1494067/novo-nordisk-receives-health-canada-approval-for-saxenda-liraglutide-for-the-treatment-of-chronic-weight-management#, Novo Nordisk. Novo Nordisk receives Health Canada approval for Saxenda® (liraglutide) for the treatment of chronic weight management. Accessed 13 Mar 2015Novo Nordisk. Novo Nordisk reports 8 % weight loss in phase 3a obesity trial with liraglutide 3 mg. 2013;24–26Astrup, A., Rössner, S., Van Gaal, L., Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study (2009) Lancet, 374, pp. 1606-1616. , COI: 1:CAS:528:DC%2BD1MXhtlyjtLrL; Wadden, T., Hollander, P., Klein, S., Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study (2013) Int J Obes (Lond), 37, pp. 1443-1451. , COI: 1:CAS:528:DC%2BC3sXhslynsr3I, This SCALE trial found numerous positive cardiometabolic effects of liraglutide 3.0 mg and is one of the defining studies used to assess the safety of liraglutide for weight management; Nauck, M., Frid, A., Hermansen, K., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study (2009) Diabetes Care, 32, pp. 84-90. , COI: 1:CAS:528:DC%2BD1MXhs1Ggu7g%3D; Garber, A., Henry, R., Ratner, R., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial (2009) Lancet, 373, pp. 473-481. , COI: 1:CAS:528:DC%2BD1MXhsFKgur0%3D; Zinman, B., Gerich, J., Buse, J., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) (2009) Diabetes Care, 32, pp. 1224-1230. , COI: 1:CAS:528:DC%2BD1MXps1KqsLs%3D; Russell-Jones, D., Vaag, A., Schmitz, O., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial (2009) Diabetologia, 52, pp. 2046-2055. , COI: 1:CAS:528:DC%2BD1MXhtVygtLnE; Marso, S.P., Lindsey, J.B., Stolker, J.M., Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies (2011) Diab Vasc Dis Res, 8, pp. 237-240; George, M., Rajaram, M., Shanmugam, E., New and emerging drug molecules against obesity (2014) J Cardiovasc Pharmacol Ther, 19, pp. 65-76. , COI: 1:CAS:528:DC%2BC2cXjt1antrk%3D; Astrup, A., Madsbad, S., Breum, L., Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (2008) Lancet, 372, pp. 1906-1913. , COI: 1:CAS:528:DC%2BD1cXhsVelurfO; http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1938944, Orexigen Therapeutics Inc. Orexigen receives three month extension of FDA NB32. 2014:1–2. Accessed 15 Oct 2014Jackson, V.M., Price, D.A., Carpino, P.A., Investigational drugs in phase II clinical trials for the treatment of obesity: implications for future development of novel therapies (2014) Expert Opin Investig Drugs, 23, pp. 1055-1066. , COI: 1:CAS:528:DC%2BC2cXhtFeltb%2FK; Gadde, K.M., Yonish, G.M., (2007) Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study, pp. 1227-1230; http://www.orexigen.com/programs/empatic.html, Orexigen Therapeutics Inc. Emaptic. 2014. Accessed 26 Nov 2014. This web page outlined some of the only available data on the effectiveness of Empatic (bupropion-zonisamide slow-release compound) a promising weight management medication undergoing phase III clinical testingRavussin, E., Smith, S.R., Mitchell, J.A., (2009) Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy, 17, pp. 1736-1743; Tam, C.S., Lecoultre, V., Ravussin, E., Novel strategy for the use of leptin for obesity therapy (2011) Expert Opin Biol Ther, 11, pp. 1677-1685. , COI: 1:CAS:528:DC%2BC3MXhsVags77K; http://www.prnewswire.com/news-releases/amylin-pharmaceuticals-announces-positive-results-from-dose-ranging-clinical-study-of-pramlintidemetreleptin-combination-treatment-for-obesity-62158697.html, PR Newswire, source Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity. 2009. Accessed 16 Mar 2014",Review,Scopus,2-s2.0-84928347829
"Han Y., Dorajoo R., Ke T., Ayala B., Chang X., Khor C.-C., van Dam R.M., Yuan J.-M., Koh W.-P., Liu J., Goh D.Y.T., Friedlander Y., Heng C.-K.","Interaction effects between Paraoxonase 1 variants and cigarette smoking on risk of coronary heart disease in a Singaporean Chinese population",2015,"Atherosclerosis","240","1",,"40","45",,,10.1016/j.atherosclerosis.2015.01.042,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923874154&partnerID=40&md5=e048b1d9e679dde5f29830c0e24e7f5c","Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore; Department of Epidemiology, Graduate School of Public Health, University of PittsburghPittsburgh, PA, United States; University of Pittsburgh Cancer InstitutePittsburgh, PA, United States; Duke-NUS Graduate Medical School Singapore, Singapore; School of Public Health and Community Medicine, Hebrew University of Jerusalem, Israel","Han, Y., Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore; Dorajoo, R., Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore; Ke, T., Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore; Ayala, B., Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore, School of Public Health and Community Medicine, Hebrew University of Jerusalem, Israel; Chang, X., Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore; Khor, C.-C., Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore; van Dam, R.M., Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore; Yuan, J.-M., Department of Epidemiology, Graduate School of Public Health, University of PittsburghPittsburgh, PA, United States, University of Pittsburgh Cancer InstitutePittsburgh, PA, United States; Koh, W.-P., Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Duke-NUS Graduate Medical School Singapore, Singapore; Liu, J., Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore; Goh, D.Y.T., Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore; Friedlander, Y., School of Public Health and Community Medicine, Hebrew University of Jerusalem, Israel; Heng, C.-K., Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore","Paraoxonase 1 (PON1) plays an important role in reducing the risk of coronary heart disease (CHD). Smoking is known to reduc. e PON1 activity. We aimed to investigate the effects of interactions between PON1 variants and smoking on CHD in the Singaporean Chinese population. Methods: In a case-control study nested within Singapore Chinese Health Study (N=1914), subjects with and without CHD were classified into never-smokers and ever-smokers (ever smoked at least one cigarette a day for 1 year or longer). Associations at four independent SNPs at the PON1 locus (rs3735590, rs3917550, rs662, rs3917481) with CHD were evaluated using logistic regression, before/after stratification on smoking status. Interactions between smoking and PON1 variants were analyzed with likelihood ratio tests, by including the SNP * smoking interaction term in regression analyses. Results: The T allele at the coding SNP, rs662, was associated with higher risk of CHD in ever-smokers only (OR=1.35, 95% CI 1.08-1.68; adjusted P=0.036). At the miR-SNP, rs3735590, carrying at least one copy of minor allele T was associated with increased risk of CHD in a dominant manner in never-smokers only (OR=1.53, 95% CI 1.11-2.11; adjusted P=0.036). Significant interactions between two PON1 SNPs and smoking in relation to CHD risk were identified (adjusted P=0.012 for rs662; adjusted P=0.044 for rs3735590). These associations remained significant after adjustment for known CHD risk factors and upon correction for multiple tests. Conclusions: Two PON1 SNPs, rs662 and rs3735590, were found to significantly interact with cigarette smoking to modulate the risk of CHD in the Singaporean Chinese population. © 2015 Elsevier Ireland Ltd.","Cigarette smoking; Coronary heart disease; Interaction; MiR-SNP; Paraoxonase 1; Singaporean Chinese; Single nucleotide polymorphism (SNP)","Santulli, G., Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts (2013) JCvD, 1, pp. 1-2; Durrington, P.N., Mackness, B., Mackness, M.I., Paraoxonase and atherosclerosis (2001) Arterioscler. Thromb. Vasc. Biol., 21, pp. 473-480; Bhattacharyya, T., Nicholls, S.J., Topol, E.J., Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk (2008) J.Am. Med. Assoc., 299, pp. 1265-1276; Mackness, M.I., Arrol, S., Durrington, P.N., Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein (1991) FEBS Lett., 286, pp. 152-154; Navab, M., Hama-Levy, S., Van Lenten, B.J., Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio (1997) J.Clin. Investig., 99, pp. 2005-2019; Adkins, S., Gan, K.N., Mody, M., Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes (1993) Am. J. Hum. Genet., 52, pp. 598-608; Humbert, R., Adler, D.A., Disteche, C.M., The molecular basis of the human serum paraoxonase activity polymorphism (1993) Nat. Genet., 3, pp. 73-76; Mackness, M.I., Mackness, B., Durrington, P.N., Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins (1996) Curr. Opin. Lipidol., 7, pp. 69-76; Mackness, B., Mackness, M.I., Arrol, S., Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification (1998) FEBS Lett., 423, pp. 57-60; Mackness, M.I., Arrol, S., Mackness, B., Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation (1997) Lancet, 349, pp. 851-852; Serrato, M., Marian, A.J., Avariant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease (1995) J.Clin. Investig., 96, pp. 3005-3008; Sanghera, D.K., Saha, N., Aston, C.E., Genetic polymorphism of paraoxonase and the risk of coronary heart disease (1997) Arterioscler. Thromb. Vasc. Biol., 17, pp. 1067-1073; James, R.W., Leviev, I., Righetti, A., Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease (2000) Circulation, 101, pp. 2252-2257; Nishio, E., Watanabe, Y., Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols (1997) Biochem. Biophys. Res. Commun., 236, pp. 289-293; Sen-Banerjee, S., Siles, X., Campos, H., Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction (2000) Arterioscler. Thromb. Vasc. Biol., 20, pp. 2120-2126; Agrawal, S., Tripathi, G., Prajnya, R., Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians (2009) Indian J. Med. Sci., 63, pp. 335-344; Hankin, J.H., Stram, D.O., Arakawa, K., Singapore Chinese Health Study: development, validation, and calibration of the quantitative food frequency questionnaire (2001) Nutr. Cancer, 39, pp. 187-195; Buist, A.S., McBurnie, M.A., Vollmer, W.M., International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study (2007) Lancet, 370, pp. 741-750; Chobanian, A.V., Bakris, G.L., Black, H.R., Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (2003) Hypertension, 42, pp. 1206-1252; International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes (2009) Diabetes Care, 32, pp. 1327-1334; Gauderman, W.J., Morrison, J.M., (2006) QUANTO 1.1: a Computer Program for Power and Sample Size Calculations for Genetic-epidemiology Studies, , http://biostats.usc.edu/software, Available from:; Cosin-Aguilar, J., Andres-Conejos, F., Hernandiz-Martinez, A., Effect of smoking on sudden and premature death (1995) J.Cardiovasc Risk, 2, pp. 345-351; Salonen, J.T., Puska, P., Kottke, T.E., Smoking, blood pressure and serum cholesterol as risk factors of acute myocardial infarction and death among men in Eastern Finland (1981) Eur. Heart J., 2, pp. 365-373; Ko, Y.L., Ko, Y.S., Wang, S.M., The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan (1998) Atherosclerosis, 141, pp. 259-264; Wang, X., Fan, Z., Huang, J., Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population (2003) Arterioscler. Thromb. Vasc. Biol., 23, pp. 328-334; Getz, G.S., Reardon, C.A., Paraoxonase, a cardioprotective enzyme: continuing issues (2004) Curr. Opin. Lipidol., 15, pp. 261-267; Hegele, R.A., Brunt, J.H., Connelly, P.W., Apolymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate (1995) Arterioscler. Thromb. Vasc. Biol., 15, pp. 89-95; Herrmann, S.M., Blanc, H., Poirier, O., The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study (1996) Atherosclerosis, 126, pp. 299-303; Sanghera, D.K., Aston, C.E., Saha, N., DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease (1998) Am. J. Hum. Genet., 62, pp. 36-44; Ombres, D., Pannitteri, G., Montali, A., The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients (1998) Arterioscler. Thromb. Vasc. Biol., 18, pp. 1611-1616; Zama, T., Murata, M., Matsubara, Y., A192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese (1997) Arterioscler. Thromb. Vasc. Biol., 17, pp. 3565-3569; Pfohl, M., Koch, M., Enderle, M.D., Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes (1999) Diabetes, 48, pp. 623-627; Odawara, M., Tachi, Y., Yamashita, K., Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus (1997) J.Clin. Endocrinol. Metab., 82, pp. 2257-2260; Liu, M.E., Liao, Y.C., Lin, R.T., Afunctional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis (2013) Atherosclerosis, 228, pp. 161-167; Santulli, G., Coronary heart disease risk factors and mortality (2012) JAMA, 307, pp. 1137-1138; Huen, K., Richter, R., Furlong, C., Validation of PON1 enzyme activity assays for longitudinal studies (2009) Clin. Chim. Acta, 402, pp. 67-74",Article,Scopus,2-s2.0-84923874154
"Rebnord E.W., Pedersen E.R., Strand E., Svingen G.F.T., Meyer K., Schartum-Hansen H., Loland K.H., Seifert R., Ueland P.M., Nilsen D.W.T., Nordrehaug J.E., Nygard O.","Glycated hemoglobin and long-term prognosis in patients with suspected stable angina pectoris without diabetes mellitus: A prospective cohort study",2015,"Atherosclerosis","240","1",,"115","120",,,10.1016/j.atherosclerosis.2015.02.053,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924565958&partnerID=40&md5=710d371d4c796a227aa5bc4005d19a9c","Department of Heart Disease, Haukeland University HospitalBergen, Norway; Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway; BEVITAL, Laboratoriebygget, 9th Floor, Jonas Lies veg 87Bergen, Norway; Laboratory of Clinical Biochemistry, Haukeland University HospitalBergen, Norway; Division of Cardiology, Stavanger University HospitalStavanger, Norway; K. G. Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway","Rebnord, E.W., Department of Heart Disease, Haukeland University HospitalBergen, Norway, Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway; Pedersen, E.R., Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway; Strand, E., Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway; Svingen, G.F.T., Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway; Meyer, K., BEVITAL, Laboratoriebygget, 9th Floor, Jonas Lies veg 87Bergen, Norway; Schartum-Hansen, H., Department of Heart Disease, Haukeland University HospitalBergen, Norway; Løland, K.H., Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway; Seifert, R., Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway; Ueland, P.M., Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway, Laboratory of Clinical Biochemistry, Haukeland University HospitalBergen, Norway; Nilsen, D.W.T., Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway, Division of Cardiology, Stavanger University HospitalStavanger, Norway; Nordrehaug, J.E., Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway, Division of Cardiology, Stavanger University HospitalStavanger, Norway; Nygård, O., Department of Heart Disease, Haukeland University HospitalBergen, Norway, Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway, K. G. Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Mailbox 7804Bergen, Norway","Objective: Associations of glycated hemoglobin A1c (HbA1c) levels to incident coronary and cardiovascular events among non-diabetic patients with coronary artery disease are unclear. We investigated relations of HbA1c to long-term prognosis in such patients. Methods: A prospective cohort of 2519 patients undergoing elective coronary angiography for suspected stable angina pectoris (SAP) was divided into pre-defined categories according to HbA1c (%) levels (<5.0, 5.0-5.6 (reference), 5.7-6.4), and followed for median 4.9 years. The primary end-point was major coronary events (including non-fatal and fatal acute myocardial infarctions, and sudden cardiac death). Secondary end-points were death from cardiovascular disease (CVD) and all-cause mortality. Hazard ratios (HRs) (95% confidence intervals [CIs]) were obtained by Cox regression. Results: Median age at inclusion was 62 years, 73% were males, median HbA1c was 5.6% and random plasma-glucose 5.4mmol/L. After multivariate adjustment, HbA1c levels within the pre-diabetic range were not associated with risk of major coronary events, HR (95% CI): 1.13 (0.79-1.62); P=0.49, death from CVD or all-cause mortality HR (95% CI): 0.95 (0.55-1.66) and 1.04 (0.70-1.53), respectively; P≥0.85. Similarly, there was no significant association between HbA1c values within the lowest category and risk of study outcomes, (P≥0.18). Conclusion: In non-diabetic patients with suspected SAP, there was no overall association between HbA1c levels and prognosis, questioning an independent role of glycemia in the pathogenesis of atherosclerotic complications in these patients. © 2015 The Authors.","Coronary artery disease; Glycated; HbA1c; Hemoglobin A; Mortality; Myocardial infarction; Pre-diabetes","Diagnosis and classification of diabetes mellitus (2013) Diabet. Care, 36 (SUPPL.1), pp. S67-S74; Gerstein, H.C., Islam, S., Anand, S., Almahmeed, W., Damasceno, A., Dans, A., Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study (2010) Diabetologia, 53 (12), pp. 2509-2517; Eskesen, K., Jensen, M.T., Galatius, S., Vestergaard, H., Hildebrandt, P., Marott, J.L., Glycated haemoglobin and the risk of cardiovascular disease, diabetes and all-cause mortality in the Copenhagen City Heart Study (2013) J.Intern. Med., 273 (1), pp. 94-101; Selvin, E., Steffes, M.W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults (2010) N.Engl. J. Med., 362 (9), pp. 800-811; Grundy, S.M., Pre-diabetes, metabolic syndrome, and cardiovascular risk (2012) J.Am. Coll. Cardiol., 59 (7), pp. 635-643; Carson, A.P., Fox, C.S., McGuire, D.K., Levitan, E.B., Laclaustra, M., Mann, D.M., Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes (2010) Circ. Cardiovasc. Qual. Outcomes, 3 (6), pp. 661-667; Khaw, K.T., Wareham, N., Bingham, S., Luben, R., Welch, A., Day, N., Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in norfolk (2004) Ann. Intern. Med., 141 (6), pp. 413-420; Liu, Y., Yang, Y.M., Zhu, J., Tan, H.Q., Liang, Y., Li, J.D., Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis (2011) Cardiovasc. Diabetol., 10, p. 98; Naito, R., Miyauchi, K., Ogita, M., Kasai, T., Kawaguchi, Y., Tsuboi, S., Impact of admission glycemia and glycosylated hemoglobin A1c on long-term clinical outcomes of non-diabetic patients with acute coronary syndrome (2014) J.Cardiol., 63, pp. 106-111; Svingen, G.F., Ueland, P.M., Pedersen, E.K., Schartum-Hansen, H., Seifert, R., Ebbing, M., Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris (2013) Arterioscler. Thromb. Vasc. Biol., 33 (8), pp. 2041-2048; Ebbing, M., Bleie, O., Ueland, P.M., Nordrehaug, J.E., Nilsen, D.W., Vollset, S.E., Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial (2008) J.Am. Med. Assoc., 300 (7), pp. 795-804; Biroccio, A., Urbani, A., Massoud, R., di Ilio, C., Sacchetta, P., Bernardini, S., Aquantitative method for the analysis of glycated and glutathionylated hemoglobin by matrix-assisted laser desorption ionization-time of flight mass spectrometry (2005) Anal. Biochem., 336 (2), pp. 279-288; http://www.bevital.no/, (2015, accessed 22.01.15)Kelleher, B.P., Broin, S.D., Microbiological assay for vitamin B12 performed in 96-well microtitre plates (1991) J.Clin. Pathol., 44 (7), pp. 592-595; Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F., Feldman, H.I., Anew equation to estimate glomerular filtration rate (2009) Ann. Intern. Med., 150 (9), pp. 604-612; Pedersen, E.R., Ueland, T., Seifert, R., Aukrust, P., Schartum-Hansen, H., Ebbing, M., Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris (2010) Atherosclerosis, 212 (2), pp. 644-649; Aggarwal, V., Schneider, A.L., Selvin, E., Low hemoglobin A(1c) in nondiabetic adults: an elevated risk state? (2012) Diabet. Care, 35 (10), pp. 2055-2060; Koenker, R., (2011) Quantile Regression, p. 366. , Cambridge University Press, New York, USA; Hess, K.R., Graphical methods for assessing violations of the proportional hazards assumption in cox regression (1995) Stat. Med., 14 (15), pp. 1707-1723; (2014) R: A Language and Environment for Statistical Computing (Version 3.0.2), , R Foundation for Statistical Computing, Vienna, Austria; Therneau, T., (2012) APackage for Survival Analysis in S. R Package 'survival' Version 2.36-14, , http://CRAN.R-project.org/package=survival, Available from:; Koenker, R., (2012) Quantile Regression. R Package 'quantreg' Version 4.91, , http://CRAN.R-project.org/package=quantreg, Available from:; Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes (2008) N.Engl. J. Med., 359 (15), pp. 1577-1589; Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials (2011) BMJ, 343, p. d4169; Di Angelantonio, E., Gao, P., Khan, H., Butterworth, A.S., Wormser, D., Kaptoge, S., Glycated hemoglobin measurement and prediction of cardiovascular disease (2014) J.Am. Med. Assoc., 311 (12), pp. 1225-1233; Pfister, R., Sharp, S.J., Luben, R., Khaw, K.T., Wareham, N.J., No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population (2011) Diabetologia, 54 (8), pp. 2025-2032; Silbernagel, G., Grammer, T.B., Winkelmann, B.R., Boehm, B.O., Marz, W., Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography (2011) Diabet. Care, 34 (6), pp. 1355-1361; Dawson, A.J., Sathyapalan, T., Atkin, S.L., Kilpatrick, E.S., Biological variation of cardiovascular risk factors in patients with diabetes (2013) Diabet. Med., 30 (10), pp. 1172-1180; Jansen, H., Stolk, R.P., Nolte, I.M., Kema, I.P., Wolffenbuttel, B.H., Snieder, H., Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their interactions in the Lifelines Cohort Study (2013) J.Intern. Med., 273 (3), pp. 283-293; Grimsby, J.L., Porneala, B.C., Vassy, J.L., Yang, Q., Florez, J.C., Dupuis, J., Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. adults: the third National Health and Nutrition Examination Survey (NHANES III) (2012) BMC Med. Genet., 13, p. 30; Ahmad, J., Rafat, D., HbA1c and iron deficiency: a review (2013) Diabet. Metab. Syndr., 7 (2), pp. 118-122; Christman, A.L., Lazo, M., Clark, J.M., Selvin, E., Low glycated hemoglobin and liver disease in the U.S. population (2011) Diabet. Care, 34 (12), pp. 2548-2550; Maki, T., Ikeda, M., Morita, M., Ohnaka, K., Kawate, H., Adachi, M., Relation of cigarette smoking, alcohol use, and coffee consumption to glycated hemoglobin in Japanese men and women (2010) Diabet. Metab. Syndr., 4 (2), pp. 69-73; Di Pino, A., Scicali, R., Calanna, S., Urbano, F., Mantegna, C., Rabuazzo, A.M., Cardiovascular risk profile in subjects with prediabetes and new-onset type 2 diabetes identified by HbA(1c) according to American diabetes association criteria (2014) Diabet. Care, 37 (5), pp. 1447-1453; Perreault, L., Temprosa, M., Mather, K.J., Horton, E., Kitabchi, A., Larkin, M., Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the diabetes prevention program outcomes study (2014) Diabet. Care, 37 (9), pp. 2622-2631; Tabak, A.G., Herder, C., Rathmann, W., Brunner, E.J., Kivimaki, M., Prediabetes: a high-risk state for diabetes development (2012) Lancet, 379 (9833), pp. 2279-2290; DeFronzo, R.A., Abdul-Ghani, M., Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose (2011) Am. J. Cardiol., 108 (3 SUPPL.l.), pp. 3B-24B; Reaven, G., Insulin resistance and coronary heart disease in nondiabetic individuals (2012) Arterioscler. Thromb. Vasc. Biol., 32 (8), pp. 1754-1759; Alexander, C.M., Landsman, P.B., Grundy, S.M., Metabolic syndrome and hyperglycemia: congruence and divergence (2006) Am. J. Cardiol., 98 (7), pp. 982-985; Selvin, E., Lazo, M., Chen, Y., Shen, L., Rubin, J., McEvoy, J.W., Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage (2014) Circulation, 130 (16), pp. 1374-1382; Zheng, J., Ye, P., Luo, L., Xiao, W., Xu, R., Wu, H., Association between blood glucose levels and high-sensitivity cardiac troponin T in an overt cardiovascular disease-free community-based study (2012) Diabet. Res. Clin. Pract., 97 (1), pp. 139-145; Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (2002) N.Engl. J. Med., 346 (6), pp. 393-403; Preiss, D., Lloyd, S.M., Ford, I., McMurray, J.J., Holman, R.R., Welsh, P., Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial (2014) Lancet Diabet. Endocrinol., 2 (2), pp. 116-124; Currie, C.J., Peters, J.R., Tynan, A., Evans, M., Heine, R.J., Bracco, O.L., Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study (2010) Lancet, 375 (9713), pp. 481-489; Rutter, M.K., Low HbA1c and mortality: causation and confounding (2012) Diabetologia, 55 (9), pp. 2307-2311; Selvin, E., Coresh, J., Zhu, H., Folsom, A., Steffes, M.W., Measurement of HbA1c from stored whole blood samples in the atherosclerosis risk in communities study (2010) J.Diabet., 2 (2), pp. 118-124; Selvin, E., Coresh, J., Jordahl, J., Boland, L., Steffes, M.W., Stability of haemoglobin A1c (HbA1c) measurements from frozen whole blood samples stored for over a decade (2005) Diabet. Med., 22 (12), pp. 1726-1730; Chamnan, P., Simmons, R.K., Khaw, K.T., Wareham, N.J., Griffin, S.J., Change in HbA1c over 3 years does not improve the prediction of cardiovascular disease over and above HbA1c measured at a single time point (2013) Diabetologia, 56 (5), pp. 1004-1011; Saukkonen, T., Cederberg, H., Jokelainen, J., Laakso, M., Harkonen, P., Keinanen-Kiukaanniemi, S., Limited overlap between intermediate hyperglycemia as defined by A1C 5.7-6.4%, impaired fasting glucose, and impaired glucose tolerance (2011) Diabet. Care, 34 (10), pp. 2314-2316; Kirk, J.K., D'Agostino, R.B., Bell, R.A., Passmore, L.V., Bonds, D.E., Karter, A.J., Disparities in HbA1c levels between African-American and non-hispanic white adults with diabetes: a meta-analysis (2006) Diabet. Care, 29 (9), pp. 2130-2136",Article,Scopus,2-s2.0-84924565958
"Zhang Q., Bai Y., Yang Z., Tian J., Meng Z.","Effect of sulfur dioxide inhalation on the expression of K<inf>ATP</inf> and L-Ca2+ channels in rat hearts",2015,"Environmental Toxicology and Pharmacology","39","3",,"1132","1138",,,10.1016/j.etap.2015.04.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928159233&partnerID=40&md5=ed96dd11fba058aab394789218d8cb31","Institute of Environmental Medicine and Toxicology, Institute of Environmental Science, Shanxi UniversityTaiyuan, China","Zhang, Q., Institute of Environmental Medicine and Toxicology, Institute of Environmental Science, Shanxi UniversityTaiyuan, China; Bai, Y., Institute of Environmental Medicine and Toxicology, Institute of Environmental Science, Shanxi UniversityTaiyuan, China; Yang, Z., Institute of Environmental Medicine and Toxicology, Institute of Environmental Science, Shanxi UniversityTaiyuan, China; Tian, J., Institute of Environmental Medicine and Toxicology, Institute of Environmental Science, Shanxi UniversityTaiyuan, China; Meng, Z., Institute of Environmental Medicine and Toxicology, Institute of Environmental Science, Shanxi UniversityTaiyuan, China","Epidemiological studies have revealed an association between sulfur dioxide (SO<inf>2</inf>) exposure and cardiovascular diseases. This study is designed to investigate the SO<inf>2</inf> effect on the expression of ATP-sensitive K+ (K<inf>ATP</inf>) channel and L-type calcium (L-Ca2+) channel in rat hearts. The results show that the mRNA and protein levels of the K<inf>ATP</inf> channel subunits Kir6.2 and SUR2A of rat hearts in SO<inf>2</inf> groups were higher than those in control group. SO<inf>2</inf> at 14mg/m3 significantly decreased the expression of the L-Ca2+ channel subunits Ca<inf>v</inf>1.2 and Ca<inf>v</inf>1.3. This suggests that SO<inf>2</inf> can activate the K<inf>ATP</inf> channels by up-regulating the expression of Kir6.2 and SUR2A, while it inhibits the L-Ca2+ channels by down-regulating the expression of Ca<inf>v</inf>1.2 and Ca<inf>v</inf>1.3 in rat hearts. The molecular mechanism of SO<inf>2</inf>-induced negative inotropic effect might be linked to the expression changes of these subunits, which may contribute to the pathogenesis of SO<inf>2</inf>-associated cardiovascular diseases. © 2015 Elsevier B.V.","Cardiovascular diseases; Gene expression; K<inf>ATP</inf> channel; L-Ca2+ channel; Sulfur dioxide","Aguilar-Bryan, L., Bryan, J., Molecular biology of adenosine triphosphate-sensitive potassium channels (1999) Endocr. Rev., 20, pp. 101-135; Backx, P.H., Sulfonylurea receptor expression heterogeneity suggests chamber-specific roles for Sarcolemmal K<inf>ATP</inf> channels in heart (2008) Circ. Res., 103, pp. 1345-1357; Best, J.M., Kamp, T.J., Different subcellular populations of L-type Ca2+ channels exhibit unique regulation and functional roles in cardiomyocytes (2012) J. Mol. Cell. Cardiol., 52, pp. 376-387; Catterall, W.A., Structure and function of voltage gated Ca2+ channels (2000) Annu. Rev. Cell Dev. Biol., 16, pp. 521-555; Du, Z.Q., Meng, Z.Q., Sulfur dioxide derivative modulation of potassium channels in rat ventricular myocytes (2004) Food Chem. Toxicol., 42, pp. 1211-1216; Hong, Y.C., Lee, J.T., Kim, H., Ha, E.H., Schwartz, J., Christiani, D.C., Effects of air pollutants on acute stroke mortality (2002) Environ. Health Perspect., 110, pp. 187-191; Ji, A.J., Savon, S.R., Jakobsen, D.W., Determination of total serum sulfite by HPLC with fluorescence detection (1995) Clin. Chem., 41, pp. 897-903; Kleppisch, T., Nelson, M.T., ATP-sensitive K+ currents in cerebral arterial smooth muscle: pharmacological and hormonal modulation (1995) Am. J. Physiol., 269, pp. H1634-H1640; Li, J.L., Li, R.J., Meng, Z.Q., Sulfur dioxide upregulates the aortic nitric oxide pathway in rats (2010) Eur. J. Pharmacol., 645, pp. 143-150; Meng, Z.Q., Oxidative damage of sulfur dioxide on various organs of mice: sulfur dioxide is a systemic oxidative damage agent (2003) Inhal. Toxicol., 15, pp. 181-195; Meng, Z.Q., Geng, H., Bai, J.L., Yan, G., Blood pressure of rats lowered by sulfur dioxide and its derivatives (2003) Inhal. Toxicol., 15, pp. 951-959; Meng, Z.Q., Liu, Y.X., Cell morphological ultrastructural changes in various organs from mice exposed by inhalation to sulfur dioxide (2007) Inhal. Toxicol., 19, pp. 543-551; Nie, A.F., Meng, Z.Q., Sulfur dioxide derivative modulation of potassium channels in rat ventricular myocytes (2005) Arch. Biochem. Biophys., 442, pp. 187-195; Nie, A.F., Meng, Z.Q., Modulation of L-type calcium current in rat cardiac myocytes by sulfur dioxide derivatives (2006) Food Chem. Toxicol., 44, pp. 355-363; Stipanuk, M.H., Dominy, J.E., Lee, J., Coloso, R.M., Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism (2002) J. Nutr., 136, pp. 1652S-1659S; Yamakage, M., Namiki, A., Calcium channels-basic aspects of their structure, function and gene encoding; anesthetic action on the channels - a review (2002) Can. J. Anaesth., 49, pp. 151-164; Zhang, Q.X., Meng, Z.Q., The vasodilator mechanism of sulfur dioxide on isolated aortic rings of rats: involvement of the K+ and Ca2+ channels (2009) Eur. J. Pharmacol., 602, pp. 117-123; Zhang, Q.X., Meng, Z.Q., The negative inotropic effects of gaseous sulfur dioxide and its derivatives in the isolated perfused rat heart (2012) Environ. Toxicol., 27, pp. 175-184; Zhang, S.Q., Du, J.B., Tian, Y., Geng, B., Tang, C.S., Tang, X.Y., Effects of sulfur dioxide on cardiac function of isolated perfusion heart of rat (2008) Zhonghua Yi Xue Za Zi, 88, pp. 830-834. , (Chinese)",Article,Scopus,2-s2.0-84928159233
"Rischpler C., Paschali A., Anagnostopoulos C., Nekolla S.G.","Cardiac PET for Translational Imaging",2015,"Current Cardiology Reports","17","5",,"","",6,,10.1007/s11886-015-0581-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928340563&partnerID=40&md5=3b15cf37dcc072c514af27d14f867a11","Nuklearmedizinische Klinik der TU MünchenMunchen, Germany; Biomedical Research Foundation Academy of AthensAthens, Greece","Rischpler, C., Nuklearmedizinische Klinik der TU MünchenMunchen, Germany; Paschali, A., Biomedical Research Foundation Academy of AthensAthens, Greece; Anagnostopoulos, C., Biomedical Research Foundation Academy of AthensAthens, Greece; Nekolla, S.G., Nuklearmedizinische Klinik der TU MünchenMunchen, Germany","All along, translational cardiovascular research has been dependent on non-invasive imaging (such as single-photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT), echocardiography, or magnetic resonance imaging (MRI)), as these techniques allow the assessment of surrogate markers in intact living organisms non-invasively. PET offers the advantages of high sensitivity; the capability for longitudinal, quantitative imaging; and that an armamentarium of promising radiotracers is readily available. All commercially available PET scanners are equipped with a CT component, and thus, the often cited disadvantage of a lack of morphologic correlation does not really count anymore. This review aims to give an outline on PET as a promising tool for translational research in cardiology as dedicated preclinical systems with virtually the same imaging features as those used in clinical imaging allows the straightforward concept of “bench to bedside.” © 2015, Springer Science+Business Media New York.","Molecular imaging; PET; PET/CT; Translational research","Chen, I.Y., Wu, J.C., Cardiovascular molecular imaging: focus on clinical translation (2011) Circulation, 123 (4), pp. 425-443. , PID: 21282520, Excellent review on a wide range of biological mechanisms and imaging strategies for a wide range of modalities such as PET, SPECT, MRI, and optical imaging; Martinez-Moller, A., Zikic, D., Botnar, R.M., Bundschuh, R.A., Howe, W., Ziegler, S.I., Dual cardiac-respiratory gated PET: implementation and results from a feasibility study (2007) Eur J Nucl Med Mol Imaging, 34 (9), pp. 1447-1454. , PID: 17318548; Phelps, M.E., Hoffman, E.J., Huang, S.C., Ter-Pogossian, M.M., Effect of positron range on spatial resolution (1975) J Nucl Med:Off Public Soc Nucl Med, 16 (7), pp. 649-652. , COI: 1:CAS:528:DyaE2MXlsFCgtL4%3D; Cheng, A.S., Pegg, T.J., Karamitsos, T.D., Searle, N., Jerosch-Herold, M., Choudhury, R.P., Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla (2007) J Am Coll Cardiol, 49 (25), pp. 2440-2449. , PID: 17599608; Tai, Y.C., Ruangma, A., Rowland, D., Siegel, S., Newport, D.F., Chow, P.L., Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging (2005) J Nucl Med:Off Public Soc Nucl Med, 46 (3), pp. 455-463; Maddahi, J., Packard, R.R., Cardiac PET perfusion tracers: current status and future directions (2014) Semin Nucl Med, 44 (5), pp. 333-343. , PID: 25234078, Overview of established and new flow agents in cardiac PET imaging and their application; Mc Ardle, B.A., Dowsley, T.F., deKemp, R.A., Wells, G.A., Beanlands, R.S., Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease?: a systematic review and meta-analysis (2012) J Am Coll Cardiol, 60 (18), pp. 1828-1837. , PID: 23040573; Yu, M., Nekolla, S.G., Schwaiger, M., Robinson, S.P., The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease (2011) Semin Nucl Med, 41 (4), pp. 305-313. , PID: 21624564, Detailed description of the development of a new PET flow tracer from cells over isolated rodents hearts, in vivo rodents and finally into humans; Huisman, M.C., Higuchi, T., Reder, S., Nekolla, S.G., Poethko, T., Wester, H.J., Initial characterization of an 18F-labeled myocardial perfusion tracer (2008) J Nucl Med:Off Public Soc Nucl Med, 49 (4), pp. 630-636; Higuchi, T., Nekolla, S.G., Huisman, M.M., Reder, S., Poethko, T., Yu, M., A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats (2008) J Nucl Med:Off Public Soc Nucl Med, 49 (10), pp. 1715-1722; Sherif, H.M., Saraste, A., Weidl, E., Weber, A.W., Higuchi, T., Reder, S., Evaluation of a novel (18)F-labeled positron-emission tomography perfusion tracer for the assessment of myocardial infarct size in rats (2009) Circ Cardiovasc Imag, 2 (2), pp. 77-84; Nekolla, S.G., Reder, S., Saraste, A., Higuchi, T., Dzewas, G., Preissel, A., Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model (2009) Circulation, 119 (17), pp. 2333-2342. , COI: 1:STN:280:DC%2BD1MzitVSrsw%3D%3D, PID: 19380625; Maddahi, J., Czernin, J., Lazewatsky, J., Huang, S.C., Dahlbom, M., Schelbert, H., Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest (2011) J Nucl Med:Off Public Soc Nucl Med, 52 (9), pp. 1490-1498. , COI: 1:CAS:528:DC%2BC3MXht1yisrvP; Berman, D.S., Maddahi, J., Tamarappoo, B.K., Czernin, J., Taillefer, R., Udelson, J.E., Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography (2013) J Am Coll Cardiol, 61 (4), pp. 469-477. , COI: 1:CAS:528:DC%2BC38XhvFWhu7jL, PID: 23265345; Madar, I., Ravert, H.T., Du, Y., Hilton, J., Volokh, L., Dannals, R.F., Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium (2006) J Nucl Med:Off Public Soc Nucl Med, 47 (8), pp. 1359-1366. , COI: 1:CAS:528:DC%2BD28XptVajsrg%3D; Ilovich, O., Abourbeh, G., Bocher, M., Freedman, N., Billauer, H., Dotan, S., Structure–activity relationship and preclinical evaluation of carbon-11-labeled ammonium salts as PET–myocardial perfusion imaging agents (2012) Molec Imag Biol:MIB: Off Public Acad Molec Imag, 14 (5), pp. 625-636; Jacobson, O., Abourbeh, G., Tsvirkun, D., Mishani, E., Rat imaging and in vivo stability studies using [11C]-dimethyl-diphenyl ammonium, a candidate agent for PET-myocardial perfusion imaging (2013) Nucl Med Biol, 40 (8), pp. 967-973. , COI: 1:CAS:528:DC%2BC3sXhtlKrtLrP, PID: 23999238; Ghosh, N., Rimoldi, O.E., Beanlands, R.S., Camici, P.G., Assessment of myocardial ischaemia and viability: role of positron emission tomography (2010) Eur Heart J, 31 (24), pp. 2984-2995. , PID: 20965888; Lee, W.W., Marinelli, B., van der Laan, A.M., Sena, B.F., Gorbatov, R., Leuschner, F., PET/MRI of inflammation in myocardial infarction (2012) J Am Coll Cardiol, 59 (2), pp. 153-163. , COI: 1:CAS:528:DC%2BC38XivVejs7Y%3D, PID: 22222080; Schwaiger, M., Hicks, R., The clinical role of metabolic imaging of the heart by positron emission tomography (1991) J Nucl Med:Off Public Soc Nucl Med, 32 (4), pp. 565-578. , COI: 1:STN:280:DyaK3M7ptlOqtQ%3D%3D; Bengel, F.M., Ueberfuhr, P., Ziegler, S.I., Nekolla, S.G., Odaka, K., Reichart, B., Non-invasive assessment of the effect of cardiac sympathetic innervation on metabolism of the human heart (2000) Eur J Nucl Med, 27 (11), pp. 1650-1657. , COI: 1:CAS:528:DC%2BD3cXosVWlsrY%3D, PID: 11105821; Fallavollita, J.A., Heavey, B.M., Luisi, A.J., Jr., Michalek, S.M., Baldwa, S., Mashtare, T.L., Jr., Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy (2014) J Am Coll Cardiol, 63 (2), pp. 141-149. , PID: 24076296; Nguyen, N.T., DeGrado, T.R., Chakraborty, P., Wieland, D.M., Schwaiger, M., Myocardial kinetics of carbon-11-epinephrine in the isolated working rat heart (1997) J Nucl Med:Off Public Soc Nucl Med, 38 (5), pp. 780-785. , COI: 1:CAS:528:DyaK2sXjsVOrsrs%3D; Munch, G., Nguyen, N.T., Nekolla, S., Ziegler, S., Muzik, O., Chakraborty, P., Evaluation of sympathetic nerve terminals with [(11)C]epinephrine and [(11)C]hydroxyephedrine and positron emission tomography (2000) Circulation, 101 (5), pp. 516-523. , COI: 1:CAS:528:DC%2BD3cXhtlajtro%3D, PID: 10662749; Raffel, D.M., Corbett, J.R., del Rosario, R.B., Mukhopadhyay, S.K., Gildersleeve, D.L., Rose, P., Sensitivity of [11C]phenylephrine kinetics to monoamine oxidase activity in normal human heart (1999) J Nucl Med:Off Public Soc Nucl Med, 40 (2), pp. 232-238. , COI: 1:CAS:528:DyaK1MXivVGmu7Y%3D; Raffel, D.M., Corbett, J.R., del Rosario, R.B., Gildersleeve, D.L., Chiao, P.C., Schwaiger, M., Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons (1996) J Nucl Med:Off Public Soc Nucl Med, 37 (12), pp. 1923-1931. , COI: 1:CAS:528:DyaK2sXmtVGrsw%3D%3D; Jacobson, A.F., Senior, R., Cerqueira, M.D., Wong, N.D., Thomas, G.S., Lopez, V.A., Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study (2010) J Am Coll Cardiol, 55 (20), pp. 2212-2221. , PID: 20188504; Yu, M., Bozek, J., Lamoy, M., Guaraldi, M., Silva, P., Kagan, M., Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models (2011) Circ Cardiovasc Imag, 4 (4), pp. 435-443; Sinusas, A.J., Lazewatsky, J., Brunetti, J., Heller, G., Srivastava, A., Liu, Y.H., Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation (2014) J Nucl Med:Off Public Soc Nucl Med, 55 (9), pp. 1445-1451. , COI: 1:CAS:528:DC%2BC2cXhvVSrur3M; Elsinga, P.H., van Waarde, A., Visser, T.J., Vaalburg, W., Visualization of beta-adrenoceptors using PET (1998) Clin Positron Imag:Off J Inst Clin PET, 1 (2), pp. 81-94; Le Guludec, D., Delforge, J., Syrota, A., Desruennes, M., Valette, H., Gandjbakhch, I., In vivo quantification of myocardial muscarinic receptors in heart transplant patients (1994) Circulation, 90 (1), pp. 172-178. , PID: 8025993; Jeong, J.M., Hong, M.K., Chang, Y.S., Lee, Y.S., Kim, Y.J., Cheon, G.J., Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice (2008) J Nucl Med:Off Public Soc Nucl Med, 49 (5), pp. 830-836. , COI: 1:CAS:528:DC%2BD1cXmvVSju7k%3D; Lehner, S., Todica, A., Vanchev, Y., Uebleis, C., Wang, H., Herrler, T., In vivo monitoring of parathyroid hormone treatment after myocardial infarction in mice with [68Ga]annexin A5 and [18F]fluorodeoxyglucose positron emission tomography (2014) Mol Imaging, 13, pp. 1-8",Review,Scopus,2-s2.0-84928340563
"Sahebkar A., Simental-Mendia L.E., Watts G.F., Golledge J.","Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials",2015,"Atherosclerosis","240","1",,"284","296",,,10.1016/j.atherosclerosis.2015.03.016,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925423427&partnerID=40&md5=480cb44f372a2b21a5389ee97a1db607","Biotechnology Research Center, Mashhad University of Medical SciencesMashhad, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western AustraliaPerth, Australia; Biomedical Research Unit, Mexican Social Security InstituteDurango, Mexico; Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western AustraliaPerth, WA, Australia; The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University TownsvilleQLD, Australia; Department of Vascular and Endovascular Surgery, The Townsville HospitalTownsville, QLD, Australia","Sahebkar, A., Biotechnology Research Center, Mashhad University of Medical SciencesMashhad, Iran, Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western AustraliaPerth, Australia; Simental-Mendía, L.E., Biomedical Research Unit, Mexican Social Security InstituteDurango, Mexico; Watts, G.F., Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western AustraliaPerth, WA, Australia; Golledge, J., The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University TownsvilleQLD, Australia, Department of Vascular and Endovascular Surgery, The Townsville HospitalTownsville, QLD, Australia","Objective: The aim of this systematic review was to perform a meta-analysis of randomized controlled trials (RCTs) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 (PAI-1). Methods: Scopus and MEDLINE databases were searched (up to October 15, 2014) to identify RCTs investigating whether fibrates lower plasma PAI-1 concentration or activity. A random-effects model and the generic inverse variance method were used for quantitative data synthesis. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed to assess the impact of potential moderators on the estimated effect sizes. Results: A total of 14 RCTs examining the effects of gemfibrozil (6 trials), bezafibrate (4 trials), and fenofibrate (5 trials) were included. Meta-analysis suggested that fibrate therapy did not significantly reduce plasma PAI-1 concentration (weighed mean difference [WMD]:-11.39ng/mL, 95% CI:-26.64, 3.85, p=0.143) or activity (WMD: 2.02U/mL, 95% CI:-0.87, 4.90, p=0.170). These results remained unchanged after subgroup analysis according to duration of treatment (<12 and ≥12 weeks) and type of fibrate administered (fenofibrate, bezafibrate or gemfibrozil). The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis. Conclusion: This meta-analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1. © 2015.","Coronary heart disease; Fibric acid; Peroxisome proliferator-activated receptor; Plasminogen; Thrombosis","Reiner, Z., Catapano, A.L., ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) Eur. Heart J., 32, pp. 1769-1818; Staels, B., Dallongeville, J., Auwerx, J., Mechanism of action of fibrates on lipid and lipoprotein metabolism (1998) Circulation, 98, pp. 2088-2093; Sahebkar, A., Chew, G., Watts, G.F., Recent advances in pharmacotherapy for hypertriglyceridemia (2014) Prog Lipid Res, 56, pp. 47-66; Ye, J., Kiage, J.N., Arnett, D.K., Short-term effect of fenofibrate on C-reactive protein: a meta-analysis of randomized controlled trials (2011) Diabetol. Metab. Syndr., 3, p. 24; Sahebkar, A., Chew, G.T., Watts, G.F., New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease (2014) Expert Opin. Pharmacother., 15, pp. 493-503; Sahebkar, A., Watts, G.F., Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster (2014) Diabetes Obes. Metab., 16, pp. 780-792; Schonfeld, G., The effects of fibrates on lipoprotein and hemostatic coronary risk factors (1994) Atherosclerosis, 111, pp. 161-174; Heller, F., Harvengt, C., Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects (1983) Eur. J. Clin. Pharmacol., 25, pp. 57-63; Peters, J.M., Hennuyer, N., Staels, B., Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alphadeficient mice (1997) J.Biol. Chem., 272, pp. 27307-27312; Staels, B., Vu-Dac, N., Kosykh, V.A., Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates (1995) J.Clin. Invest., 95, pp. 705-712; Keech, A.C., Mitchell, P., Summanen, P.A., Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial (2007) Lancet, 370, pp. 1687-1697; Rajamani, K., Colman, P.G., Li, L.P., Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial (2009) Lancet, 373, pp. 1780-1788; Loskutoff, D.J., Quigley, J.P., PAI-1, fibrosis, and the elusive provisional fibrin matrix (2000) J.Clin. Invest., 106, pp. 1441-1443; Lijnen, H.R., Pleiotropic functions of plasminogen activator inhibitor-1 (2005) J.Thromb. Haemost., 3, pp. 35-45; Targher, G., Bertolini, L., Scala, L., Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis (2007) Diabetes Care, 30, pp. e31-e32; Gruber, F., Hufnagl, P., Hofer-Warbinek, R., Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression (2003) Blood, 101, pp. 3042-3048; Xanthakis, V., Enserro, D.M., Murabito, J.M., Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the framingham offspring study (2014) Circulation, 130, pp. 1676-1683; Gruzdeva, O., Uchasova, E., Dyleva, Y., Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction (2013) Diabetes Metab. Syndr. Obes., 6, pp. 293-301; Battes, L.C., Akkerhuis, K.M., Cheng, J.M., Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: results from the ATHEROREMO-IVUS study (2014) Int. J. Cardiol., 177, pp. 847-853; Belalcazar, L.M., Ballantyne, C.M., Lang, W., Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study (2011) Arterioscler. Thromb. Vasc. Biol., 31, pp. 1689-1695; Zirlik, A., Ernst, S., Leugers, A., Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes (2009) Thromb. Haemost., 101, pp. 1060-1069; Okopień, B., Haberka, M., Madej, A., Extralipid effects of micronized fenofibrate in dyslipidemic patients (2006) Pharmacol. Rep., 58, pp. 729-735; Nilsson, L., Takemura, T., Eriksson, P., Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells (1999) Arterioscler. Thromb. Vasc. Biol., 19, pp. 1577-1581; Juhan-Vague, I., Alessi, M.C., Vague, P., Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis (1991) Diabetologia, 34, pp. 457-462; Avellone, G., Di Garbo, V., Cordova, R., Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion (1993) Fibrinolysis, 7, pp. 416-421; Andersen, P., Smith, P., Seljeflot, I., Brataker, S., Arnesen, H., Effects of gemfibrozil on lipids and haemostasis after myocardial infarction (1990) Thromb. Haemost., 63, pp. 174-177; Keber, I., Lavre, J., Suc, S., The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates (1994) Fibrinolysis, 8, pp. 57-59; Bröijersen, A., Eriksson, M., Wiman, B., Gemfibrozil treatment of combined hyperlipoproteinemia: no improvement of fibrinolysis despite marked reduction of plasma triglyceride levels (1996) Arterioscler. Thromb. Vasc. Biol., 16, pp. 511-516; Kockx, M., de Maat, M.P.M., Knipscheer, H.C., Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients (1997) Thromb. Haemost., 78, pp. 1167-1172; Moher, D., Liberati, A., Tetzlaff, J., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009) BMJ, 339, p. b2535; Green, S., (2011) Cochrane handbook for systematic reviews of interventions version 5.1. 0, , [updated march 2011], The Cochrane Collaboration; Borenstein, M., Hedges, L., Higgins, J., (2005) Comprehensive Meta-analysis Version 2, , Biostat, Englewood NJ; Sutton, A.J., Abrams, K.R., Jones, D.R., (2000) Methods for Meta-analysis in Medical Research, , John Wiley & Sons, West Sussex; Sahebkar, A., Does PPARγ(2) Gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis (2013) DNA Cell Biol., 32, pp. 188-198; Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis (2014) Phytother. Res., 28, pp. 633-642; Song, F., Altman, D.G., Glenny, A.M., Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses (2003) BMJ, 326, p. 472; Bucher, H.C., Guyatt, G.H., Griffith, L.E., The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials (1997) J.Clin. Epidemiol., 50, pp. 683-691; Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis (2000) Biometrics, 56, pp. 455-463; Durrington, P.N., Mackness, M.I., Bhatnagar, D., Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia (1998) Atherosclerosis, 138, pp. 217-225; O'Neal, D.N., O'Brien, R.C., Timmins, K.L., Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter invitro oxidizability (1998) Diabet. Med., 15, pp. 870-877; Hamsten, A., Syvänne, M., Silveira, A., Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy (2000) Thromb. Haemost., 83, pp. 397-403; Mussoni, L., Mannucci, L., Sirtori, C., Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients (2000) Atherosclerosis, 148, pp. 397-406; Pazzucconi, F., Mannucci, L., Mussoni, L., Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia (1992) Eur. J. Clin. Pharmacol., 43, pp. 219-223; Krysiak, R., Gdula-Dymek, A., Okopień, B., Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients (2011) Pharmacol. Rep., 63, pp. 763-771; Kon Koh, K., Yeal Ahn, J., Hwan Han, S., Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis (2004) Atherosclerosis, 174, pp. 379-383; Okopień, B., Krysiak, R., Herman, Z.S., Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance (2006) J.Clin. Endocrinol. Metab., 91, pp. 1770-1778; Pruski, M., Krysiak, R., Okopien, B., Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia (2009) Diabetes Care, 32, pp. 1421-1424; Krysiak, R., Gdula-Dymek, A., Bachowski, R., Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes (2010) Diabetes Care, 33, pp. 2266-2270; Cortellaro, M., Cofrancesco, E., Boschetti, C., Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment (2000) Thromb. Haemost., 83, pp. 549-553; Genest, J., Nguyen, N.H., Theroux, P., Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state (2000) J.Cardiovasc. Pharmacol., 35, pp. 164-172; Perk, J., De Backer, G., Gohlke, H., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) (2012) Eur. Heart J., 33, pp. 1635-1701; Wiman, B., Hamsten, A., Impaired fibrinolysis and risk of thromboembolism (1991) Prog. Cardiovasc. Dis., 34, pp. 179-192; Corsetti, J.P., Salzman, P., Ryan, D., Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels (2013) PLoS One, 8, p. e68920; Raiko, J.R., Oikonen, M., Wendelin-Saarenhovi, M., Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study (2012) Atherosclerosis, 224, pp. 208-212; Juhan-Vague, I., Vague, P., Alessi, M.C., Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1 (1987) Diabete Metab., 13, pp. 331-336; Mitropoulos, K.A., Miller, G.J., Reeves, B.E.A., Factor VII coagulant activity is strongly associated with plasma concentration of large lipoprotein particles in middle-aged men (1989) Atherosclerosis, 76, pp. 203-208; Fujii, S., Sobel, B.E., Direct effects of gemfibrozil on the fibrinolytic system: diminution of synthesis of plasminogen activator inhibitor type I (1992) Circulation, 85, pp. 1888-1893; Arts, J., Kockx, M., Princen, H.M.G., Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey (1997) Arterioscler. Thromb. Vasc. Biol., 17, pp. 26-32; Chomiki, N., Henry, M., Alessi, M.C., Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls (1994) Thromb. Haemost., 72, pp. 44-53; Alessi, M.C., Peiretti, F., Henry, M., Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease (1997) Diabetes, 46, pp. 860-867; Eriksson, P., Reynisdottir, S., Lönnqvist, F., Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals (1998) Diabetologia, 41, pp. 65-71; Lacut, K., Le Gal, G., Abalain, J.H., Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? (2008) Thromb. Res., 122, pp. 314-319; Lacut, K., Oger, E., Le Gal, G., Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study (2004) Fundam. Clin. Pharmacol., 18, pp. 477-482; Squizzato, A., Galli, M., Romualdi, E., Statins, fibrates, and venous thromboembolism: a meta-analysis (2010) Eur. Heart J., 31, pp. 1248-1256; Herrmann, M., Whiting, M.J., Veillard, A.S., Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study (2012) Clin. Chem. Lab. Med., 50, pp. 2213-2219; Ali, F.Y., Armstrong, P.C., Dhanji, A.R., Antiplatelet actions of statins and fibrates are mediated by PPARs (2009) Arterioscler. Thromb. Vasc. Biol., 29, pp. 706-711; Keech, A., Simes, R.J., Barter, P., Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial (2005) Lancet, 366, pp. 1849-1861; Ginsberg, H.N., Elam, M.B., Effects of combination lipid therapy in type 2 diabetes mellitus (2010) N.Engl. J. Med., 362, pp. 1563-1574; Frick, M.H., Elo, O., Haapa, K., Helsinki Heart Study: primary-prevention trial with gemfi brozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease (1987) N.Engl. J. Med., 317, pp. 1237-1245; Sahebkar, A., Watts, G.F., New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes (2013) Clin. Ther., 35, pp. 1082-1098",Review,Scopus,2-s2.0-84925423427
"Mueller T., Leitner I., Egger M., Haltmayer M., Dieplinger B.","Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases",2015,"Clinica Chimica Acta","445",,,"155","160",,,10.1016/j.cca.2015.03.033,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927138508&partnerID=40&md5=1f469555603ac135aa76488ca98b9541","Department of Laboratory Medicine, Konventhospital Barmherzige BruederLinz, Austria","Mueller, T., Department of Laboratory Medicine, Konventhospital Barmherzige BruederLinz, Austria; Leitner, I., Department of Laboratory Medicine, Konventhospital Barmherzige BruederLinz, Austria; Egger, M., Department of Laboratory Medicine, Konventhospital Barmherzige BruederLinz, Austria; Haltmayer, M., Department of Laboratory Medicine, Konventhospital Barmherzige BruederLinz, Austria; Dieplinger, B., Department of Laboratory Medicine, Konventhospital Barmherzige BruederLinz, Austria","Background: The biomarkers soluble ST2 (sST2), galectin-3, and growth-differentiation factor-15 (GDF-15) provide prognostic information in patients with heart failure (HF). The aim of this study was to evaluate to which extent plasma concentrations of these biomarkers are increased in HF compared with diverse non-cardiac conditions such as infectious disease or chronic kidney disease. Methods: We recruited 15 patients in each of the following clinical categories: HF without co-morbidity, pneumonia without co-morbidity, chronic obstructive pulmonary disease (COPD) without co-morbidity, HF and a co-morbidity of pneumonia, renal disease without co-morbidity, and sepsis. We used 22 healthy individuals as control group. In each of the 112 study participants, we measured plasma concentrations of sST2 (Presage assay), galectin-3 (Abbott assay) and GDF-15 (Roche assay). Results: Compared to controls, the median sST2 concentration was ~. 2.5-fold increased in HF, ~. 3.5-fold in pneumonia, ~. 5.0-fold in COPD, ~. 5.8-fold in HF. +. pneumonia, and ~. 70-fold in sepsis (p. <. 0.001 for all). sST2 was not significantly increased in renal disease. Compared to controls, the median galectin-3 concentration was ~. 1.5-fold increased in HF, ~. 1.4-fold in pneumonia, ~. 2.4-fold in HF. +. pneumonia, ~. 2.5-fold in renal disease, and ~. 2.7-fold in sepsis (p. <. 0.001 for all). Galectin-3 was not significantly increased in COPD. Compared to controls, the median GDF-15 concentration was ~. 4.4-fold increased in HF, ~. 5.4-fold in pneumonia, ~. 2.1-fold in COPD, ~. 8.3-fold in HF. +. pneumonia, ~. 5.1-fold in renal disease, and ~. 27-fold in sepsis (p. <. 0.001). In the 112 study participants, correlation analyses revealed a relatively strong association between galectin-3 and GDF-15 (correlation coefficient, 0.739; p. <. 0.001). Conclusion: Because increased plasma concentrations of sST2, galectin-3, and GDF-15 are not specific for a distinct disease group, the three biomarkers are not useful for diagnostic purposes. The results of our study are novel with respect to sST2, galectin-3 and GDF-15 as markers of inflammatory diseases and should encourage further studies. © 2015.","Cardiac troponin; Galectins; Inflammation; Interleukin-1 receptor family; Natriuretic peptides; Transforming growth factor beta superfamily","Gaggin, H.K., Januzzi, J.L., Biomarkers and diagnostics in HF (1832) Biochim Biophys Acta, 2013, pp. 2442-2450; Schmitter, D., Cotter, G., Voors, A.A., Clinical use of novel biomarkers in heart failure: towards personalized medicine (2014) Heart Fail Rev, 19, pp. 369-381; Pouleur, A.C., Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction? (2015) Clin Chim Acta, 443, pp. 9-16; Yancy, C.W., Jessup, M., Bozkurt, B., American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) J Am Coll Cardiol, 62, pp. e147-e239; Dieplinger, B., Januzzi, J.L., Steinmair, M., Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay (2009) Clin Chim Acta, 409, pp. 33-40; Senni, M., Tribouilloy, C.M., Rodeheffer, R.J., Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991 (1998) Circulation, 98, pp. 2282-2289; Niederman, M.S., Mandell, L.A., Anzueto, A., American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention (2001) Am J Respir Crit Care Med, 163, pp. 1730-1754; Burge, S., Wedzicha, J.A., COPD exacerbations: definitions and classifications (2003) Eur Respir J, 21, pp. 46S-53S; Levey, A.S., Eckardt, K.U., Tsukamoto, Y., Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) (2005) Kidney Int, 67, pp. 2089-2100; American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis (1992) Crit Care Med, 20, pp. 864-874; La'ulu, S.L., Apple, F.S., Murakami, M.M., Ler, R., Roberts, W.L., Straseski, J.A., Performance characteristics of the ARCHITECT galectin-3 assay (2013) Clin Biochem, 46, pp. 119-122; Evaluation of precision performance of clinical chemistry devices; approved guideline (1999) CLSI Document EP5-A, , CLSI, Wayne, PA; Bessière, F., Khenifer, S., Dubourg, J., Durieu, I., Lega, J.C., Prognostic value of troponins in sepsis: a meta-analysis (2013) Intensive Care Med, 39, pp. 1181-1189; Liew, F.Y., Pitman, N.I., McInnes, I.B., Disease-associated functions of IL-33: the new kid in the IL-1 family (2010) Nat Rev Immunol, 10, pp. 103-110; Villarreal, D.O., Weiner, D.B., Interleukin 33: a switch-hitting cytokine (2014) Curr Opin Immunol, 28 C, pp. 102-106; Mueller, T., Jaffe, A.S., Soluble ST2 - analytical considerations (2015) Am J Cardiol, 115 (7 S), pp. 8B-21B; Dieplinger, B., Mueller, T., Soluble ST2 in heart failure (2015) Clin Chim Acta, 443 C, pp. 57-70; Henderson, N.C., Sethi, T., The regulation of inflammation by galectin-3 (2009) Immunol Rev, 230, pp. 160-171; Gao, P., Simpson, J.L., Zhang, J., Gibson, P.G., Galectin-3: its role in asthma and potential as an anti-inflammatory target (2013) Respir Res, 14, p. 136; Song, L., Tang, J.W., Owusu, L., Sun, M.Z., Wu, J., Zhang, J., Galectin-3 in cancer (2014) Clin Chim Acta, 431, pp. 185-191; Ravani, P., Barrett, B.J., Galectin-3 and new-onset CKD: marker or mediator? (2013) J Am Soc Nephrol, 24, pp. 1342-1344; Corre, J., Hébraud, B., Bourin, P., Concise review: growth differentiation factor 15 in pathology: a clinical role? (2013) Stem Cells Transl Med, 2, pp. 946-952; Lindahl, B., The story of growth differentiation factor 15: another piece of the puzzle (2013) Clin Chem, 59, pp. 1550-1552; Mimeault, M., Batra, S.K., Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer (2010) J Cell Physiol, 224, pp. 626-635; Kempf, T., Wollert, K.C., Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome (2013) Crit Care, 17, p. 173; Wollert, K.C., Kempf, T., Growth differentiation factor 15 in heart failure: an update (2012) Curr Heart Fail Rep, 9, pp. 337-345; Unsicker, K., Spittau, B., Krieglstein, K., The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1 (2013) Cytokine Growth Factor Rev, 24, pp. 373-384; Dieplinger, B., Gegenhuber, A., Kaar, G., Poelz, W., Haltmayer, M., Mueller, T., Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department (2010) Clin Biochem, 43, pp. 714-719; Thomsen, R.W., Kasatpibal, N., Riis, A., Nørgaard, M., Sørensen, H.T., The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study (2008) J Gen Intern Med, 23, pp. 1407-1413; Macchia, A., Monte, S., Romero, M., D'Ettorre, A., Tognoni, G., The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure (2007) Eur J Heart Fail, 9, pp. 942-948; Ho, J.E., Mahajan, A., Chen, M.H., Clinical and genetic correlates of growth differentiation factor 15 in the community (2012) Clin Chem, 58, pp. 1582-1591",Article,Scopus,2-s2.0-84927138508
"Kempny A., Diller G.-P., Alonso-Gonzalez R., Uebing A., Rafiq I., Li W., Swan L., Hooper J., Donovan J., Wort S.J., Gatzoulis M.A., Dimopoulos K.","Hypoalbuminaemia predicts outcome in adult patients with congenital heart disease",2015,"Heart","101","9",,"699","705",,,10.1136/heartjnl-2014-306970,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927620771&partnerID=40&md5=bd7b3810a360bfe20a8775a8c02ca3ed","Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom; NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom; National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom; Department of Cardiology and Angiology, Adult Congenital and Valvular Heart Disease Center, University Hospital of MünsterMuenster, Germany; Adult Congenital Heart Centre, Royal Brompton and Harefield NHS Foundation Trust, Sydney StreetLondon, United Kingdom","Kempny, A., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom, Department of Cardiology and Angiology, Adult Congenital and Valvular Heart Disease Center, University Hospital of MünsterMuenster, Germany, Adult Congenital Heart Centre, Royal Brompton and Harefield NHS Foundation Trust, Sydney StreetLondon, United Kingdom; Diller, G.-P., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom, Department of Cardiology and Angiology, Adult Congenital and Valvular Heart Disease Center, University Hospital of MünsterMuenster, Germany; Alonso-Gonzalez, R., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom; Uebing, A., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom; Rafiq, I., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom; Li, W., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom; Swan, L., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom; Hooper, J., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom; Donovan, J., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom; Wort, S.J., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom; Gatzoulis, M.A., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom; Dimopoulos, K., Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton HospitalLondon, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College LondonLondon, United Kingdom, National Heart and Lung Institute, Imperial College School of MedicineLondon, United Kingdom","Background In patients with acquired heart failure, hypoalbuminaemia is associated with increased risk of death. The prevalence of hypoproteinaemia and hypoalbuminaemia and their relation to outcome in adult patients with congenital heart disease (ACHD) remains, however, unknown. Methods Data on patients with ACHD who underwent blood testing in our centre within the last 14 years were collected. The relation between laboratory, clinical or demographic parameters at baseline and mortality was assessed using Cox proportional hazards regression analysis. Results A total of 2886 patients with ACHD were included. Mean age was 33.3 years (23.6-44.7) and 50.1% patients were men. Median plasma albumin concentration was 41.0 g/L (38.0-44.0), whereas hypoalbuminaemia (<35 g/L) was present in 13.9% of patients. The prevalence of hypoalbuminaemia was significantly higher in patients with great complexity ACHD (18.2%) compared with patients with moderate (11.3%) or simple ACHD lesions (12.1%, p<0.001). During a median follow-up of 5.7 years (3.3-9.6), 327 (11.3%) patients died. On univariable Cox regression analysis, hypoalbuminaemia was a strong predictor of outcome (HR 3.37, 95% CI 2.67 to 4.25, p<0.0001). On multivariable Cox regression, after adjusting for age, sodium and creatinine concentration, liver dysfunction, functional class and disease complexity, hypoalbuminaemia remained a significant predictor of death. Conclusions Hypoalbuminaemia is common in patients with ACHD and is associated with a threefold increased risk of risk of death. Hypoalbuminaemia, therefore, should be included in risk-stratification algorithms as it may assist management decisions and timing of interventions in the growing ACHD population.",,"Dimopoulos, K., Diller, G.P., Koltsida, E., Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease (2008) Circulation, 117, pp. 2320-2328; Dimopoulos, K., Diller, G.P., Giannakoulas, G., Anemia in adults with congenital heart disease relates to adverse outcome (2009) J Am Coll Cardiol, 54, pp. 2093-2100; Alonso-Gonzalez, R., Borgia, F., Diller, G.P., Abnormal lung function in adults with congenital heart disease: Prevalence, relation to cardiac anatomy, and association with survival (2013) Circulation, 127, pp. 882-890; Fanali, G., Di Masi, A., Trezza, V., Human serum albumin: From bench to bedside (2012) Mol Aspects Med, 33, pp. 209-290; Ha, C.-E., Bhagavan, N.V., Novel insights into the pleiotropic effects of human serum albumin in health and disease (2013) Biochim Biophys Acta, 1830, pp. 5486-5493; Webb, G.D., Williams, R.G., 32nd Bethesda conference: ""Care of the adult with congenital heart disease ""1 (2001) J Am Coll Cardiol, 37, pp. 1162-1165; (2010) R: A Language and Environment for Statistical Computing, , www.R-project.org, Vienna, Austria: R Foundation for Statistical Computing; Arquès, S., Ambrosi, P., Gélisse, R., Hypoalbuminemia in elderly patients with acute diastolic heart failure (2003) J Am Coll Cardiol, 42, pp. 712-716; Uthamalingam, S., Kandala, J., Daley, M., Serum albumin and mortality in acutely decompensated heart failure (2010) Am Heart J, 160, pp. 1149-1155; Hesse, B., Parving, H.H., Lund-Jacobsen, H., Transcapillary escape rate of albumin and right atrial pressure in chronic congestive heart failure before and after treatment (1976) Circ Res, 39, pp. 358-362; Cullen, S., Shore, D., Redington, A., Characterization of right ventricular diastolic performance after complete repair of tetralogy of Fallot. Restrictive physiology predicts slow postoperative recovery (1995) Circulation, 91, pp. 1782-1789; Senzaki, H., Masutani, S., Ishido, H., Cardiac rest and reserve function in patients with Fontan circulation (2006) J Am Coll Cardiol, 47, pp. 2528-2535; Don, B.R., Kaysen, G., Serum albumin: Relationship to inflammation and nutrition (2004) Semin Dial, 17, pp. 432-437; Sharma, R., Bolger, A.P., Li, W., Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease (2003) Am J Cardiol, 92, pp. 188-193; Chamakou, A.C., Dede, E., Moutafi, A., Neurohormonal and cytokine fluctuations following transcatheter closure for an atrial septal defect (2012) Cytokine, 57, pp. 130-135; Moutafi, A.C., Alissafi, T., Chryssanthopoulos, S., Neurohormones, cytokines, and aortic function in children with repaired coarctation of the aorta (2014) Int J Cardiol, 172, pp. e26-e27; Diller, G.-P., Van Eijl, S., Okonko, D.O., Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension (2008) Circulation, 117, pp. 3020-3030; Scognamiglio, G., Kempny, A., Alonso-Gonzalez, R., Prognostic value of C-reactive protein in patients with Eisenmenger syndrome (2013) Eur Heart J, p. 34; Ballmer, P.E., Causes and mechanisms of hypoalbuminaemia (2001) Clin Nutr, 20, pp. 271-273; Wu, F.M., Ukomadu, C., Odze, R.D., Liver disease in the patient with Fontan circulation (2011) Congenit Heart Dis, 6, pp. 190-201; Hennessey, D.B., Burke, J.P., Ni-Dhonochu, T., Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: A multi-institutional study (2010) Ann Surg, 252, pp. 325-329; Lee, E.-H., Baek, S.-H., Chin, J.-H., Preoperative hypoalbuminemia is a major risk factor for acute kidney injury following off-pump coronary artery bypass surgery (2012) Intensive Care Med, 38, pp. 1478-1486; Ji, Q., Duan, Q., Wang, X., Risk factors for ventilator dependency following coronary artery bypass grafting (2012) Int J Med Sci, 9, pp. 306-310; De La Cruz, K.I., Bakaeen, F.G., Wang, X.L., Hypoalbuminemia and long-term survival after coronary artery bypass: A propensity score analysis (2011) Ann Thorac Surg, 91, pp. 671-675; Quinlan, G.J., Mumby, S., Martin, G.S., Albumin in fluences total plasma antioxidant capacity favorably in patients with acute lung injury (2004) Crit Care Med, 32, pp. 755-759; Quinlan, G.J., Martin, G.S., Evans, T.W., Albumin: Biochemical properties and therapeutic potential (2005) Hepatology, 41, pp. 1211-1219; Konstam, M.A., Colloid osmotic pressure: An under-recognized factor in the clinical syndrome of heart failure (2003) J Am Coll Cardiol, 42, pp. 717-718; Feldt, R.H., Driscoll, D.J., Offord, K.P., Protein-losing enteropathy after the Fontan operation (1996) J Thorac Cardiovasc Surg, 112, pp. 672-680; Mertens, L., Hagler, D.J., Sauer, U., Protein-losing enteropathy after the Fontan operation: An international multicenter study. PLE study group (1998) J Thorac Cardiovasc Surg, 115, pp. 1063-1073",Article,Scopus,2-s2.0-84927620771
"Milano A., Lodder E.M., Bezzina C.R.","TNNI3K in cardiovascular disease and prospects for therapy",2015,"Journal of Molecular and Cellular Cardiology","82",,,"167","173",,,10.1016/j.yjmcc.2015.03.008,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925300943&partnerID=40&md5=dd063b9d39aaefaed06accff1ef2abdd","Department of Clinical and Experimental Cardiology, Academic Medical CentreAmsterdam, Netherlands","Milano, A., Department of Clinical and Experimental Cardiology, Academic Medical CentreAmsterdam, Netherlands; Lodder, E.M., Department of Clinical and Experimental Cardiology, Academic Medical CentreAmsterdam, Netherlands; Bezzina, C.R., Department of Clinical and Experimental Cardiology, Academic Medical CentreAmsterdam, Netherlands","Cardiovascular diseases are an important cause of morbidity and mortality worldwide and the global burden of these diseases continues to grow. Therefore new therapies are urgently needed. The role of protein kinases in disease, including cardiac disease, is long recognized, making kinases important therapeutic targets. We here review the knowledge gathered in the last decade about troponin I-interacting kinase (TNNI3K), a kinase with cardiac-restricted expression that has been implicated in various cardiac phenotypes and diseases including heart failure, cardiomyopathy, ischemia/reperfusion injury and conduction of the cardiac electrical impulse. © 2015 Elsevier Ltd.","Arrhythmia; Heart failure; Ischemia/reperfusion; Kinase; Tnni3k","Fuster, V., Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results (2014) J Am Coll Cardiol, 64, pp. 520-522; Levy, D., Kenchaiah, S., Larson, M.G., Benjamin, E.J., Kupka, M.J., Ho, K.K.L., Long-term trends in the incidence of and survival with heart failure (2002) N Engl J Med, 347, pp. 1397-1402; Heeringa, J., Van Der Kuip, D.A.M., Hofman, A., Kors, J.A., Van Herpen, G., Stricker, B.H.C., Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study (2006) Eur Heart J, 27, pp. 949-953; Anderson, M.E., Higgins, L.S., Schulman, H., Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease (2006) Nat Clin Pract Cardiovasc Med, 3, pp. 437-445; Wheeler, F.C., Tang, H., Marks, O.A., Hadnott, T.N., Chu, P.-L., Mao, L., Tnni3k modifies disease progression in murine models of cardiomyopathy (2009) PLoS Genet, 5, p. e1000647; Wang, X., Wang, J., Su, M., Wang, C., Chen, J., Wang, H., TNNI3K, a cardiac-specific kinase, promotes physiological cardiac hypertrophy in transgenic Mice (2013) PLoS One, 8, p. e58570; Tang, H., Xiao, K., Mao, L., Rockman, H.A., Marchuk, D., Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunction (2013) J Mol Cell Cardiol, 54, pp. 101-111; Lodder, E.M., Scicluna, B.P., Milano, A., Sun, A.Y., Tang, H., Remme, C.A., Dissection of a quantitative trait locus for PR interval duration identifies Tnni3k as a novel modulator of cardiac conduction (2012) PLoS Genet, 8, p. e1003113; Manning, G., Whyte, D.B., Martinez, R., Hunter, T., Sudarsanam, S., The protein kinase complement of the human genome (2002) Science, 298, pp. 1912-1934; Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H., Peterson, J.R., Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity (2011) Nat Biotechnol, 29, pp. 1039-1045; Zhao, Y., Meng, X.-M., Wei, Y.-J., Zhao, X.-W., Liu, D.-Q., Cao, H.-Q., Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin I (2003) J Mol Med (Berl), 81, pp. 297-304; Farrell, C.M., O'Leary, N.A., Harte, R.A., Loveland, J.E., Wilming, L.G., Wallin, C., Current status and new features of the Consensus Coding Sequence database (2014) Nucleic Acids Res, 42, pp. D865-D872; Flicek, P., Ridwan Amode, M., Barrell, D., Beal, K., Billis, K., Brent, S., Ensembl 2014 (2014) Nucleic Acids Res, 42, pp. D749-D755; Prakash, T., Sharma, V.K., Adati, N., Ozawa, R., Kumar, N., Nishida, Y., Expression of conjoined genes: another mechanism for gene regulation in eukaryotes (2010) PLoS One, 5, p. e13284; Vagnozzi, R.J., Gatto, G.J., Kallander, L.S., Hoffman, N.E., Mallilankaraman, K., Ballard, V.L.T., Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart (2013) Sci Transl Med, 5. , 207ra141; Theis, J.L., Zimmermann, M.T., Larsen, B.T., Rybakova, I.N., Long, P.A., Evans, J.M., TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy (2014) Hum Mol Genet; Wang, H., Chen, C., Song, X., Chen, J., Zhen, Y., Sun, K., Mef2c is an essential regulatory element required for unique expression of the cardiac-specific CARK gene (2008) J Cell Mol Med, 12, pp. 304-315; Martin, J.F., Schwarz, J.J., Olson, E.N., Myocyte enhancer factor (MEF) 2C: a tissue-restricted member of the MEF-2 family of transcription factors (1993) Proc Natl Acad Sci U S A, 90, pp. 5282-5286; Sartorelli, V., Huang, J., Hamamori, Y., Kedes, L., Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C (1997) Mol Cell Biol, 17, pp. 1010-1026; Rosenthal, N., Harvey, R.P., (2010) Heart development and regeneration volume II, pp. 1-496; Mosavi, L.K., Cammett, T.J., Desrosiers, D.C., Peng, Z., The ankyrin repeat as molecular architecture for protein recognition (2004) Protein Sci, 13, pp. 1435-1448; Feng, Y., Cao, H.Q., Liu, Z., Ding, J.F., Meng, X.M., Identification of the dual specificity and the functional domains of the cardiac-specific protein kinase TNNI3K (2007) Gen Physiol Biophys, 26, pp. 104-109; Feng, Y., Liu, D.-Q., Wang, Z., Liu, Z., Cao, H.-Q., Wang, L.-Y., AOP-1 interacts with cardiac-specific protein kinase TNNI3K and down-regulates its kinase activity (2007) Biochemistry, 72, pp. 1199-1204; Cardoso, T.C., Ferrari, H.F., Garcia, A.F., Bregano, L.C., Andrade, A.L., Nogueira, A.H., Immunohistochemical approach to the pathogenesis of clinical cases of bovine herpes virus type 5 infections (2010) Diagn Pathol, 5, p. 57; Wang, H., Wang, L., Song, L., Zhang, Y.W., Ye, J., Xu, R.X., TNNI3K is a novel mediator of myofilament function and phosphorylates cardiac troponin I (2013) Br J Med Biol Res, 46, pp. 128-137; Layland, J., Solaro, R.J., Shah, A.M., Regulation of cardiac contractile function by troponin I phosphorylation (2005) Cardiovasc Res, 66, pp. 12-21; Frank, D., Frey, N., Cardiac Z-disc signaling network (2011) J Biol Chem, 286, pp. 9897-9904; Knöll, R., Buyandelger, B., Lab, M., The sarcomeric Z-disc and Z-discopathies (2011) J Biomed Biotechnol, 2011, p. 569628; Scicluna, B.P., Tanck, M.W.T., Remme, C.A., Beekman, L., Coronel, R., Wilde, A.A.M., Quantitative trait loci for electrocardiographic parameters and arrhythmia in the mouse (2011) J Mol Cell Cardiol, 50, pp. 380-389; Aly, M., Wiltshire, S., Chahrour, G., Osti, J.-C.L., Vidal, S.M., Complex genetic control of host susceptibility to coxsackievirus B3-induced myocarditis (2007) Genes Immun, 8, pp. 193-204; Wiltshire, S.A., Leiva-Torres, G.A., Vidal, S.M., Quantitative trait locus analysis, pathway analysis, and consomic mapping show genetic variants of Tnni3k, Fpgt, or H28 control susceptibility to viral myocarditis (2011) J Immunol, 186, pp. 6398-6405; Flint, J., Valdar, W., Shifman, S., Mott, R., Strategies for mapping and cloning quantitative trait genes in rodents (2005) Nat Rev Genet, 6, pp. 271-286; Suzuki, M., Carlson, K.M., Marchuk, D.A.R.H.A, Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy (2002) Circulation, 105, pp. 1824-1829; Wheeler, F.C., Fernandez, L., Carlson, K.M., Wolf, M.J., Rockman, H.A., Marchuk, D.A., QTL mapping in a mouse model of cardiomyopathy reveals an ancestral modifier allele affecting heart function and survival (2005) Mamm Genome, 16, pp. 414-423; Auerbach, S.S., Thomas, R., Shah, R., Xu, H., Vallant, M.K., Nyska, A., Comparative phenotypic assessment of cardiac pathology, physiology, and gene expression in C3H/HeJ, C57BL/6J, and B6C3F1/J mice (2010) Toxicol Pathol, 38, pp. 923-942; Lai, Z., Chen, Y., Feng, L., Meng, X., Feng Ding, J., Wang, L., Overexpression of TNNI3K, a cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and prevents myocardial infarction-induced injury (2008) Am J Physiol Heart Circ Physiol, 295, pp. H708-H716; Cho, M.-C., Rapacciuolo, A., Koch, W.J., Kobayashi, Y., Jones, L.R., Rockman, H.A., Defective-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression (1999) J Biol Chem, 274, pp. 22251-22256; Hausenloy, D.J., Yellon, D.M., Myocardial ischemia-reperfusion injury: a neglected therapeutic target (2013) J Clin Invest, 123, pp. 92-100; Abraham, D.M., Marchuk, D.A., Commentary on cutting edge science (2014) Circ Res, 114, pp. 938-940; Remme, C.A., Verkerk, A.O., Nuyens, D., Ginneken, A.C.G.V., Brunschot, S.V., Belterman, C.N.W., Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD (2006) Circulation, 114, pp. 2584-2594. , [CIRCULATIONAHA.106.653949 [pii]]; Bezzina, C.R., Veldkamp, M.W., Berg, M.P.V.D., Postma, A.V., Rook, M.B., Viersma, J., A single Na(+) channel mutation causing both long-QT and Brugada syndromes (1999) Circ Res, 85, pp. 1206-1213; Remme, C.A., Scicluna, B.P., Verkerk, A.O., Amin, A.S., Brunschot, S.V., Beekman, L., Genetically determined differences in sodium current characteristics modulate conduction disease severity in mice with cardiac sodium channelopathy (2009) Circ Res, 104, pp. 1283-1292. , [CIRCRESAHA.109.194423 [pii]]; Colak, D., Kaya, N., Al-Zahrani, J., Al Bakheet, A., Muiya, P., Andres, E., Left ventricular global transcriptional profiling in human end-stage dilated cardiomyopathy (2009) Genomics, 94, pp. 20-31; Speliotes, E.K., Willer, C.J., Berndt, S.I., Monda, K.L., Thorleifsson, G., Jackson, A.U., Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index (2010) Nat Genet, 42, pp. 937-948; Graff, M., Ngwa, J.S., Workalemahu, T., Homuth, G., Schipf, S., Teumer, A., Genome-wide analysis of BMI in adolescents and young adults reveals additional insight into the effects of genetic loci over the life course (2013) Hum Mol Genet, 22, pp. 3597-3607; Pastuszak, I., GDP-l-fucose pyrophosphorylase (1998) J Biol Chem, 273, pp. 30165-30174; Lal, H., Ahmad, F., Parikh, S., Force, T., Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease (2014) Circ J, 78, pp. 1514-1519",Review,Scopus,2-s2.0-84925300943
"Brandenburg V.M., Schurgers L.J., Kaesler N., Pusche K., van Gorp R.H., Leftheriotis G., Reinartz S., Koos R., Kruger T.","Prevention of vasculopathy by vitamin K supplementation: Can we turn fiction into fact?",2015,"Atherosclerosis","240","1",,"10","16",,,10.1016/j.atherosclerosis.2015.02.040,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923928891&partnerID=40&md5=d490f5d51859358af176d7f688447dbd","Department of Cardiology, University Hospital of the RWTH Aachen, Germany; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht UniversityMaastricht, Netherlands; Department of Nephrology, University Hospital of the RWTH Aachen, Germany; Department of Physiology and Vascular Investigation, Medical School and University Hospital of AngersAngers, France; Department of Radiology, University Hospital of the RWTH Aachen, Germany","Brandenburg, V.M., Department of Cardiology, University Hospital of the RWTH Aachen, Germany; Schurgers, L.J., Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht UniversityMaastricht, Netherlands; Kaesler, N., Department of Nephrology, University Hospital of the RWTH Aachen, Germany; Püsche, K., Department of Cardiology, University Hospital of the RWTH Aachen, Germany; van Gorp, R.H., Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht UniversityMaastricht, Netherlands; Leftheriotis, G., Department of Physiology and Vascular Investigation, Medical School and University Hospital of AngersAngers, France; Reinartz, S., Department of Radiology, University Hospital of the RWTH Aachen, Germany; Koos, R., Department of Cardiology, University Hospital of the RWTH Aachen, Germany; Krüger, T., Department of Nephrology, University Hospital of the RWTH Aachen, Germany","With the discovery that vitamin K-dependent matrix Gla-protein (MGP) is a strong and modifiable factor in the prevention of arterial calcification, vitamin K was put forward as novel treatment option in cardiovascular disease. The vasculoprotective properties of vitamin K are in part based on the ability to improve gamma-glutamylcarboxylation of MGP, which is a prerequisite for MGP as a calcification inhibitor. Data from experimental animal models reveal that high intake of vitamin K can prevent and even reverse vascular calcifications. In addition, clinical data demonstrate that prescription of vitamin K antagonists for long-term oral anticoagulant therapy accelerates vascular calcification. However, controlled data from randomized prospective vitamin K interventional trials are lacking, thereby weakening a general recommendation for supplementation. The present article summarizes our current knowledge on the association between vitamin K and cardiovascular health. Additionally, we focus on an outlook on important ongoing prospective vitamin K intervention studies. These studies address the issues whether vitamin K substitution helps modifying relevant cardiovascular surrogates such as vascular calcification and whether non-vitamin K oral anticoagulants provide an alternative to support cardiovascular health benefits. So research about cardiovascular protection by vitamin K is an evolving field in which we expect a boost of novel and relevant evidence shortly. © 2015 Elsevier Ireland Ltd.","Anticoagulation; Arteriosclerosis; Matrix-gla protein; Vascular calcification; Vitamin K","Krueger, T., Westenfeld, R., Schurgers, L., Brandenburg, V., Coagulation meets calcification: the vitamin K system (2009) Int. J. Artif. Organs, 32 (2), pp. 67-74; Willems, B.A., Vermeer, C., Reutelingsperger, C.P., Schurgers, L.J., The realm of vitamin K dependent proteins: shifting from coagulation toward calcification (2014) Mol. Nutr. Food Res., 58 (8), pp. 1620-1635; Trumbo, P., Yates, A.A., Schlicker, S., Poos, M., Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc (2001) J.Am. Diet. Assoc., 101 (3), pp. 294-301; Inoue, T., Fujita, T., Kishimoto, H., Makino, T., Nakamura, T., Nakamura, T., Sato, T., Yamazaki, K., Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules (2009) J.Bone Min. Metab., 27 (1), pp. 66-75; Luo, G., Ducy, P., McKee, M.D., Pinero, G.J., Loyer, E., Behringer, R.R., Karsenty, G., Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein (1997) Nature, 386 (6620), pp. 78-81; Price, P.A., Faus, S.A., Williamson, M.K., Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves (1998) Arterioscler. Thromb. Vasc. Biol., 18 (9), pp. 1400-1407; Vermeer, C., Vitamin K: the effect on health beyond coagulation - an overview (2012) Food Nutr. Res., p. 56; Murshed, M., Schinke, T., McKee, M.D., Karsenty, G., Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins (2004) J.Cell. Biol., 165 (5), pp. 625-630; Schurgers, L.J., Uitto, J., Reutelingsperger, C.P., Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization (2013) Trends Mol. Med., 19 (4), pp. 217-226; Geleijnse, J.M., Vermeer, C., Grobbee, D.E., Schurgers, L.J., Knapen, M.H., van dM, I., Hofman, A., Witteman, J.C., Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study (2004) J.Nutr., 134 (11), pp. 3100-3105; Juanola-Falgarona, M., Salas-Salvado, J., Martinez-Gonzalez, M.A., Corella, D., Estruch, R., Ros, E., Fito, M., Bullo, M., Dietary intake of vitamin K is inversely associated with mortality risk (2014) J.Nutr., 144 (5), pp. 743-750; Vissers, L.E., Dalmeijer, G.W., Boer, J.M., Monique Verschuren, W.M., van der Schouw, Y.T., Beulens, J.W., Intake of dietary phylloquinone and menaquinones and risk of stroke (2013) J.Am. Heart Assoc., 2 (6), p. e000455; Shea, M.K., Holden, R.M., Vitamin K status and vascular calcification: evidence from observational and clinical studies (2012) Adv. Nutr., 3 (2), pp. 158-165; Erkkila, A.T., Booth, S.L., Vitamin K intake and atherosclerosis (2008) Curr. Opin. Lipidol., 19 (1), pp. 39-42; Gast, G.C., de Roos, N.M., Sluijs, I., Bots, M.L., Beulens, J.W., Geleijnse, J.M., Witteman, J.C., van der Schouw, Y.T., Ahigh menaquinone intake reduces the incidence of coronary heart disease (2009) Nutr. Metab. Cardiovasc. Dis., 19 (7), pp. 504-510; Kruger, T., Oelenberg, S., Kaesler, N., Schurgers, L.J., van de Sandt, A.M., Boor, P., Schlieper, G., Westenfeld, R., Warfarin induces cardiovascular damage in mice (2013) Arterioscler. Thromb. Vasc. Biol., 33 (11), pp. 2618-2624; Li, Q., Guo, H., Chou, D.W., Harrington, D.J., Schurgers, L.J., Terry, S.F., Uitto, J., Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum (2013) Am. J. Pathol., 182 (4), pp. 1139-1150; Schurgers, L.J., Joosen, I.A., Laufer, E.M., Chatrou, M.L., Herfs, M., Winkens, M.H., Westenfeld, R., Reutelingsperger, C.P., Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype (2012) PLoS One, 7 (8), p. e43229; Schurgers, L.J., Spronk, H.M., Skepper, J.N., Hackeng, T.M., Shanahan, C.M., Vermeer, C., Weissberg, P.L., Proudfoot, D., Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification (2007) J.Thromb. Haemost., 5 (12), pp. 2503-2511; Schurgers, L.J., Spronk, H.M., Soute, B.A., Schiffers, P.M., DeMey, J.G., Vermeer, C., Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats (2007) Blood, 109 (7), pp. 2823-2831; Moncada, R.M., Venta, L.A., Venta, E.R., Fareed, J., Walenga, J.M., Messmore, H.L., Tracheal and bronchial cartilaginous rings: warfarin sodium-induced calcification (1992) Radiology, 184 (2), pp. 437-439; Schurgers, L.J., Aebert, H., Vermeer, C., Bultmann, B., Janzen, J., Oral anticoagulant treatment: friend or foe in cardiovascular disease? (2004) Blood, 104 (10), pp. 3231-3232; Weijs, B., Blaauw, Y., Rennenberg, R.J., Schurgers, L.J., Timmermans, C.C., Pison, L., Nieuwlaat, R., Crijns, H.J., Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients (2011) Eur. Heart J., 32 (20), pp. 2555-2562; Koos, R., Mahnken, A.H., Muhlenbruch, G., Brandenburg, V., Pflueger, B., Wildberger, J.E., Kuhl, H.P., Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography (2005) Am. J. Cardiol., 96 (6), pp. 747-749; Lerner, R.G., Aronow, W.S., Sekhri, A., Palaniswamy, C., Ahn, C., Singh, T., Sandhu, R., McClung, J.A., Warfarin use and the risk of valvular calcification (2009) J.Thromb. Haemost., 7 (12), pp. 2023-2027; Brandenburg, V.M., Sinha, S., Specht, P., Ketteler, M., Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder (2014) Pediatr. Nephrol., 29 (12), pp. 2289-2298; Palaniswamy, C., Aronow, W.S., Sekhri, A., Adapa, S., Ahn, C., Singh, T., Malhotra, B., Lerner, R., Warfarin use and prevalence of coronary artery calcification assessed by multislice computed tomography (2014) Am. J. Ther., 21 (3), pp. 148-151; Villines, T.C., O'Malley, P.G., Feuerstein, I.M., Thomas, S., Taylor, A.J., Does prolonged warfarin exposure potentiate coronary calcification in humans? Results of the warfarin and coronary calcification study (2009) Calcif. Tissue Int., 85 (6), pp. 494-500; Schurgers, L.J., Spronk, H.M., Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis (2014) Thromb. Haemost., 112 (5); Schurgers, L.J., Vermeer, C., Differential lipoprotein transport pathways of K-vitamins in healthy subjects (2002) Biochim. Biophys. Acta, 1570 (1), pp. 27-32; Al Rajabi, A., Booth, S.L., Peterson, J.W., Choi, S.W., Suttie, J.W., Shea, M.K., Miao, B., Fu, X., Deuterium-labeled phylloquinone has tissue-specific conversion to menaquinone-4 among Fischer 344 male rats (2012) J.Nutr., 142 (5), pp. 841-845; McCabe, K.M., Booth, S.L., Fu, X., Shobeiri, N., Pang, J.J., Adams, M.A., Holden, R.M., Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease (2013) Kidney Int., 83 (5), pp. 835-844; Nakagawa, K., Hirota, Y., Sawada, N., Yuge, N., Watanabe, M., Uchino, Y., Okuda, N., Okano, T., Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme (2010) Nature, 468 (7320), pp. 117-121; Karl, J.P., Fu, X., Dolnikowski, G.G., Saltzman, E., Booth, S.L., Quantification of phylloquinone and menaquinones in feces, serum, and food by high-performance liquid chromatography-mass spectrometry (2014) J.Chromatogr. B Anal. Technol. Biomed. Life Sci., 963, pp. 128-133; Schlieper, G., Westenfeld, R., Kruger, T., Cranenburg, E.C., Magdeleyns, E.J., Brandenburg, V.M., Djuric, Z., Schurgers, L.J., Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD (2011) J.Am. Soc. Nephrol., 22 (2), pp. 387-395; Caluwe, R., Vandecasteele, S., Van Vlem, B., Vermeer, C., De Vriese, A.S., Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study (2014) Nephrol. Dial. Transplant., 29 (7), pp. 1385-1390; Westenfeld, R., Krueger, T., Schlieper, G., Cranenburg, E.C., Magdeleyns, E.J., Heidenreich, S., Holzmann, S., Schurgers, L.J., Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial (2012) Am. J. Kidney Dis., 59 (2), pp. 186-195; Dalmeijer, G.W., van der Schouw, Y.T., Magdeleyns, E., Ahmed, N., Vermeer, C., Beulens, J.W., The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein (2012) Atherosclerosis, 225 (2), pp. 397-402; Ketteler, M., Rothe, H., Brandenburg, V.M., Westenfeld, R., The K-factor in chronic kidney disease: biomarkers of calcification inhibition and beyond (2014) Nephrol. Dial. Transplant., 29 (7), pp. 1267-1270; Krueger, T., Schlieper, G., Schurgers, L., Cornelis, T., Cozzolino, M., Jacobi, J., Jadoul, M., Floege, J., Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol (2014) Nephrol. Dial. Transplant., 29 (9), pp. 1633-1638; Borissoff, J.I., Spronk, H.M., ten Cate, H., The hemostatic system as a modulator of atherosclerosis (2011) N.Engl. J. Med., 364 (18), pp. 1746-1760; Kakkos, S.K., Kirkilesis, G.I., Tsolakis, I.A., Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials (2014) Eur. J. Vasc. Endovasc. Surg., 48 (5), pp. 565-575; Sardar, P., Chatterjee, S., Chaudhari, S., Lip, G.Y., New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials (2014) J.Am. Geriatr. Soc., 62 (5), pp. 857-864; Gomez-Outes, A., Terleira-Fernandez, A.I., Calvo-Rojas, G., Suarez-Gea, M.L., Vargas-Castrillon, E., Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups (2013) Thrombosis, 2013, p. 640723; Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., Breithardt, G., Califf, R.M., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (2011) N.Engl. J. Med., 365 (10), pp. 883-891; Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., Al Khalidi, H.R., Wallentin, L., Apixaban versus warfarin in patients with atrial fibrillation (2011) N.Engl. J. Med., 365 (11), pp. 981-992; Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Wallentin, L., Dabigatran versus warfarin in patients with atrial fibrillation (2009) N.Engl. J. Med., 361 (12), pp. 1139-1151",Review,Scopus,2-s2.0-84923928891
"Narumi T., Shishido T., Otaki Y., Kadowaki S., Honda Y., Funayama A., Honda S., Hasegawa H., Kinoshita D., Yokoyama M., Nishiyama S., Takahashi H., Arimoto T., Miyamoto T., Watanabe T., Tanaka A., Woo C.-H., Abe J.-I., Takeishi Y., Kubota I.","High-mobility group box 1-mediated heat shock protein beta 1 expression attenuates mitochondrial dysfunction and apoptosis",2015,"Journal of Molecular and Cellular Cardiology","82",,,"1","12",,,10.1016/j.yjmcc.2015.02.018,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924227818&partnerID=40&md5=0d08e7a87c467afbe1952ce893229895","Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Research Institute for Medical Sciences, Yamagata University School of MedicineYamagata, Japan; Department of Pharmacology, College of Medicine, Yeungnam UniversityDaegu, South Korea; Department of Cardiology Division of Internal Medicine, University of Texas MD Anderson Cancer CenterHouston, TX, United States; Department of Cardiology and Hematology, Fukushima Medical UniversityFukushima, Japan","Narumi, T., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Shishido, T., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Otaki, Y., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Kadowaki, S., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Honda, Y., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Funayama, A., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Honda, S., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Hasegawa, H., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Kinoshita, D., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Yokoyama, M., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Nishiyama, S., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Takahashi, H., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Arimoto, T., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Miyamoto, T., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Watanabe, T., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan; Tanaka, A., Research Institute for Medical Sciences, Yamagata University School of MedicineYamagata, Japan; Woo, C.-H., Department of Pharmacology, College of Medicine, Yeungnam UniversityDaegu, South Korea; Abe, J.-I., Department of Cardiology Division of Internal Medicine, University of Texas MD Anderson Cancer CenterHouston, TX, United States; Takeishi, Y., Department of Cardiology and Hematology, Fukushima Medical UniversityFukushima, Japan; Kubota, I., Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of MedicineYamagata, Japan","Aims: Apoptosis of cardiomyocytes is thought to account for doxorubicin cardiotoxicity as it contributes to loss of myocardial tissue and contractile dysfunction. Given that high-mobility group box 1 (HMGB1) is a nuclear DNA-binding protein capable of inhibiting apoptosis, we aimed to clarify the role of HMGB1 in heat shock protein beta 1 (HSPB1) expression during doxorubicin-induced cardiomyopathy. Methods and results: Mitochondrial damage, cardiomyocyte apoptosis, and cardiac dysfunction after doxorubicin administration were significantly attenuated in mice with cardiac-specific overexpression of HMGB1 (HMGB1-Tg) compared with wild type (WT) -mice. HSPB1 levels after doxorubicin administration were significantly higher in HMGB1-Tg mice than in WT mice. Transfection with HMGB1 increased the expression of HSPB1 at both the protein and mRNA levels, and HMGB1 inhibited mitochondrial dysfunction and apoptosis after exposure of cardiomyocytes to doxorubicin. HSPB1 silencing abrogated the inhibitory effect of HMGB1 on cardiomyocyte apoptosis. Doxorubicin increased the binding of HMGB1 to heat shock factor 2 and enhanced heat shock element promoter activity. Moreover, HMGB1 overexpression greatly enhanced heat shock element promoter activity. Silencing of heat shock factor 2 attenuated HMGB1-dependent HSPB1 expression and abrogated the ability of HMGB1 to suppress cleaved caspase-3 accumulation after doxorubicin stimulation. Conclusions: We report the first in vivo and in vitro evidence that cardiac HMGB1 increases HSPB1 expression and attenuates cardiomyocyte apoptosis associated with doxorubicin-induced cardiomyopathy. Cardiac HMGB1 increases HSPB1 expression in cardiomyocytes in a heat shock factor 2-dependent manner. © 2015 .","Apoptosis; Cardiomyopathy; Heart failure; Mitochondria; Molecular biology","Young, R.C., Ozols, R.F., Myers, C.E., The anthracycline antineoplastic drugs (1981) N Engl J Med, 305, pp. 139-153; Carvalho, C., Santos, R.X., Cardoso, S., Correia, S., Oliveira, P.J., Santos, M.S., Doxorubicin: the good, the bad and the ugly effect (2009) Curr Med Chem, 16, pp. 3267-3285; Chatterjee, K., Zhang, J., Honbo, N., Karliner, J.S., Doxorubicin cardiomyopathy (2010) Cardiology, 115, pp. 155-162; Lefrak, E.A., Pitha, J., Rosenheim, S., Gottlieb, J.A., A clinicopathologic analysis of adriamycin cardiotoxicity (1973) Cancer, 32, pp. 302-314; Arola, O.J., Saraste, A., Pulkki, K., Kallajoki, M., Parvinen, M., Voipio-Pulkki, L.M., Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis (2000) Cancer Res, 60, pp. 1789-1792; Yoshida, M., Shiojima, I., Ikeda, H., Komuro, I., Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity (2009) J Mol Cell Cardiol, 47, pp. 698-705; Yan, C., Ding, B., Shishido, T., Woo, C.H., Itoh, S., Jeon, K.I., Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop (2007) Circ Res, 100, pp. 510-519; Nightingale, K., Dimitrov, S., Reeves, R., Wolffe, A.P., Evidence for a shared structural role for HMG1 and linker histones B4 and H1 in organizing chromatin (1996) EMBO J, 15, pp. 548-561; Lange, S.S., Mitchell, D.L., Vasquez, K.M., High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage (2008) Proc Natl Acad Sci U S A, 105, pp. 10320-10325; Calogero, S., Grassi, F., Aguzzi, A., Voigtlander, T., Ferrier, P., Ferrari, S., The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice (1999) Nat Genet, 22, pp. 276-280; Volp, K., Brezniceanu, M.L., Bosser, S., Brabletz, T., Kirchner, T., Gottel, D., Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas (2006) Gut, 55, pp. 234-242; Tang, D., Kang, R., Cheh, C.W., Livesey, K.M., Liang, X., Schapiro, N.E., HMGB1 release and redox regulates autophagy and apoptosis in cancer cells (2010) Oncogene, 29, pp. 5299-5310; Funayama, A., Shishido, T., Netsu, S., Narumi, T., Kadowaki, S., Takahashi, H., Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure (2013) Cardiovasc Res, 99, pp. 657-664; Kitahara, T., Takeishi, Y., Harada, M., Niizeki, T., Suzuki, S., Sasaki, T., High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice (2008) Cardiovasc Res, 80, pp. 40-46; Arrigo, A.P., The cellular ""networking"" of mammalian Hsp27 and its functions in the control of protein folding, redox state and apoptosis (2007) Adv Exp Med Biol, 594, pp. 14-26; Tang, D., Kang, R., Livesey, K.M., Kroemer, G., Billiar, T.R., Van Houten, B., High-mobility group box 1 is essential for mitochondrial quality control (2011) Cell Metab, 13, pp. 701-711; Shishido, T., Woo, C.H., Ding, B., McClain, C., Molina, C.A., Yan, C., Effects of MEK5/ERK5 association on small ubiquitin-related modification of ERK5: implications for diabetic ventricular dysfunction after myocardial infarction (2008) Circ Res, 102, pp. 1416-1425; Le, N.T., Takei, Y., Shishido, T., Woo, C.H., Chang, E., Heo, K.S., P90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction (2012) Circ Res, 110, pp. 536-550; Woo, C.H., Le, N.T., Shishido, T., Chang, E., Lee, H., Heo, K.S., Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-mediated degradation of inducible cAMP early repressor (2010) FASEB J, 24, pp. 4917-4928; Netsu, S., Shishido, T., Kitahara, T., Honda, Y., Funayama, A., Narumi, T., Midkine exacerbates pressure overload-induced cardiac remodeling (2014) Biochem Biophys Res Commun, 443, pp. 205-210; Suzuki, S., Shishido, T., Funayama, A., Netsu, S., Ishino, M., Kitahara, T., Long pentraxin PTX3 exacerbates pressure overload-induced left ventricular dysfunction (2013) PLoS One, 8, p. e53133; Sato-Nishiwaki, M., Aida, Y., Abe, S., Shibata, Y., Kimura, T., Yamauchi, K., Reduced number and morphofunctional change of alveolar macrophages in MafB gene-targeted mice (2013) PLoS One, 8, p. e73963; Di Lisa, F., Blank, P.S., Colonna, R., Gambassi, G., Silverman, H.S., Stern, M.D., Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition (1995) J Physiol, 486, pp. 1-13; Kang, R., Livesey, K.M., Zeh, H.J., Loze, M.T., Tang, D., Metabolic regulation by HMGB1-mediated autophagy and mitophagy (2011) Autophagy, 7, pp. 1256-1258; Wang, X., Dai, Y., Ding, Z., Khaidakov, M., Mercanti, F., Mehta, J.L., Regulation of autophagy and apoptosis in response to angiotensin II in HL-1 cardiomyocytes (2013) Biochem Biophys Res Commun, 440, pp. 696-700; Chauhan, D., Li, G., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance (2003) Blood, 102, pp. 3379-3386; Loukili, N., Rosenblatt-Velin, N., Li, J., Clerc, S., Pacher, P., Feihl, F., Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo (2011) Cardiovasc Res, 89, pp. 586-594; Kim, J.B., Lim, C.M., Yu, Y.M., Lee, J.K., Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain (2008) J Neurosci Res, 86, pp. 1125-1131; Yu, Y., Liu, M., Zhang, L., Cao, Q., Zhang, P., Jiang, H., Heat shock transcription factor 1 inhibits H(2)O(2)-induced cardiomyocyte death through suppression of high-mobility group box 1 (2012) Mol Cell Biochem, 364, pp. 263-269; Green, P.S., Leeuwenburgh, C., Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis (2002) Biochim Biophys Acta, 1588, pp. 94-101; Bianchi, M.E., Beltrame, M., Upwardly mobile proteins. Workshop: the role of HMG proteins in chromatin structure, gene expression and neoplasia (2000) EMBO Rep, 1, pp. 109-114; Pallier, C., Scaffidi, P., Chopineau-Proust, S., Agresti, A., Nordmann, P., Bianchi, M.E., Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes (2003) Mol Biol Cell, 14, pp. 3414-3426; Wilkerson, D.C., Skaggs, H.S., Sarge, K.D., HSF2 binds to the Hsp90, Hsp27, and c-Fos promoters constitutively and modulates their expression (2007) Cell Stress Chaperones, 12, pp. 283-290",Article,Scopus,2-s2.0-84924227818
"Hribal M.L.","A new score to predict recurrent cardiovascular events?",2015,"Atherosclerosis","240","1",,"1","2",,,10.1016/j.atherosclerosis.2015.02.042,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924187455&partnerID=40&md5=fec0ac46224a9b63060e0d88daec889a","Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Viale EuropaCatanzaro, Italy","Hribal, M.L., Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Viale EuropaCatanzaro, Italy",[No abstract available],,"van der Heijden, A.A., Van't Riet, E., Bot, S.D., Cannegieter, S.C., Stehouwer, C.D., Baan, C.A., Dekker, J.M., Nijpels, G., Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn study (2013) Diabetes Care, 36 (11), pp. 3498-3502; Lim, L.S., Haq, N., Mahmood, S., Hoeksema, L., ACPM prevention practice Committee; American college of preventive Medicine. Atherosclerosis cardiovascular disease screening in adults. American college of preventive medicine position statement on preventive practice (2011) Am. J. Prev. Med., 40 (3). , 380e1; Screening for coronary heart disease: recommendation statement (2004) Ann. Inter. Med., 140 (7). , 569e72; Greenland, P., Bonow, R.O., Brundage, B.H., American College of Cardiology Foundation Clinical Consensus Task Force (ACCF/AHA Writing Committee to update the 2000 Expert Consensus Document on electron Bean Computed Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global ca (2007) Circulation, 115 (3), pp. 402-426; (2001) Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), , executive summery. Bethesda MD: NIH; http://www.vascularweb.org/patients/screenings/SVSPositionStatementonVascular%20Screening.html, Society for Vascular Surgery. SVS position statement on vascular screening, Saba, L., Anzidei, M., Sanfilippo, R., Montisci, R., Lucatelli, P., Catalano, C., Passariello, R., Mallarino, G., Imaging of the carotid artery (2012) Atherosclerosis, 220, pp. 294-309; Rizza, S., Copetti, M., Cardellini, M., Menghini, R., Pecchioli, C., Luzi, A., Di Cola, G., Federici, M., Ascore including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis (2015) Atherosclerosis, 239, pp. 459-464; Gooz, M., ADAM-17: the enzyme that does it all (2010) Crit. Rev. Biochem. Mol. Biol., 45 (2), pp. 146-169; Satoh, M., Ishikawa, Y., Itoh, T., Minami, Y., Takahashi, Y., Nakamura, M., The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction (2008) Eur. J. Clin. Invest., 38 (2), pp. 97-105; Müller, A., Krämer, S.D., Meletta, R., Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability (2011) Nucl. Med. Biol., 41 (7), pp. 562-569; Cardellini, M., Menghini, R., Luzi, A., Davato, F., Cardolini, I., D'Alfonso, R., Gentileschi, P., Federici, M., Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness (2011) Diabetes, 60 (12), pp. 3265-3270; Gutwein, P., Abdel-Bakky, M.S., Schramme, A., Doberstein, K., Kämpfer-Kolb, N., Amann, K., Hauser, I.A., Pfeilschifter, J., CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein (2009) Am. J. Pathol., 174 (6), pp. 2061-2072; Ridker, P.M., Rifai, N., Stampfer, M.J., Hennekens, C.H., Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men (2000) Circulation, 101, pp. 1767-1772; (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis (2012) Lancet, 379, pp. 1214-1224; Moreira-Tabaka, H., Peluso, J., Vonesch, J.L., Hentsch, D., Kessler, P., Dumont, S., Muller, C.D., Unlike for human monocytes after LPS activation, release of TNF-α by THP-1 cells is produced by a TACE catalytically different from constitutive TACE (2012) PLoS One, 7 (3), p. e34184; Rizza, S., Copetti, M., Cardellini, M., Porzio, O., Luzi, A., Pecchioli, C., Martelli, E., Federici, M., Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention (2012) Atherosclerosis, 223 (2), pp. 448-453; Ciampi, A., Negassa, A., Lou, Z., Tree-structured prediction for censored survival data and the Cox model (1995) J.Clin. Epidemiol., 48, pp. 675-689; D'Agostino, R.B., Russell, M.W., Huse, D.M., Ellison, R.C., Silbershatz, H., Wilson, P.W., Hartz, S.C., Primary and subsequent coronary risk appraisal: new results from the Framingham study (2000) Am. Heart J., 139 (2), pp. 272-281; Yousuf, O., Mohanty, B., Martin, S., Joshi, P.H., Blaha, M.J., Nasir, K., Blumenthal, R.S., Budoff, M.J., High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? (2013) J.Am. Coll. Cardiol., 5, pp. 397-408; Freitas, W.M., Carvalho, L.S., Moura, F.A., Sposito, A.C., Atherosclerotic disease in octogenarians: a challenge for science and clinical practice (2012) Atherosclerosis, 225. , 281e9",Note,Scopus,2-s2.0-84924187455
"Barannyk O., Oshkai P.","The Influence of the Aortic Root Geometry on Flow Characteristics of a Prosthetic Heart Valve",2015,"Journal of Biomechanical Engineering","137","5", 051005,"","",,,10.1115/1.4029747,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924362842&partnerID=40&md5=74a1a07450be9bbd1daed9329e5b32aa","Department of Mechanical Engineering, University of Victoria, STN CSC, P.O. Box 1700Victoria, BC, Canada","Barannyk, O., Department of Mechanical Engineering, University of Victoria, STN CSC, P.O. Box 1700Victoria, BC, Canada; Oshkai, P., Department of Mechanical Engineering, University of Victoria, STN CSC, P.O. Box 1700Victoria, BC, Canada","In this paper, performance of aortic heart valve prosthesis in different geometries of the aortic root is investigated experimentally. The objective of this investigation is to establish a set of parameters, which are associated with abnormal flow patterns due to the flow through a prosthetic heart valve implanted in the patients that had certain types of valve diseases prior to the valve replacement. Specific valve diseases were classified into two clinical categories and were correlated with the corresponding changes in aortic root geometry while keeping the aortic base diameter fixed. These categories correspond to aortic valve stenosis and aortic valve insufficiency. The control case that corresponds to the aortic root of a patient without valve disease was used as a reference. Experiments were performed at test conditions corresponding to 70 beats/min, 5.5 L/min target cardiac output, and a mean aortic pressure of 100 mmHg. By varying the aortic root geometry, while keeping the diameter of the orifice constant, it was possible to investigate corresponding changes in the levels of Reynolds shear stress and establish the possibility of platelet activation and, as a result of that, the formation of blood clots. Copyright © 2015 by ASME.",,"McDonald, D.A., (1974) Blood Flow in Arteries, , Edward Arnold, London, UK; Iung, B., Baron, G., Butchart, E.G., Delahaye, F., Gohlke-Barwolf, C., Levang, O.W., Tornos, P., Vahanian, A., A Prospective Survey of Patients With Valvular Heart Disease in Europe: The Euro Heart Survey on Valvular Heart Disease (2003) Eur. Heart J., 24 (13), pp. 1231-1243; Yoganathan, A.P., He, Z.M., Jones, S.C., Fluid Mechanics of Heart Valves (2004) Annu. Rev. Biomed. Eng., 6 (1), pp. 331-362; Vongpatanasin, W., Hillis, L.D., Lange, R.A., Medical Progress- Prosthetic Heart Valves (1996) N. Engl. J. Med., 335 (6), pp. 407-416; Yoganathan, A.P., Chandran, K.B., Sotiropoulos, F., Flow in Prosthetic Heart Valves: State-of-the-Art and Future Directions (2005) Ann. Biomed. Eng., 33 (12), pp. 1689-1694; Leverett, L.B., Lynch, E.C., Alfrey, C.P., Hellums, J.D., Red Blood-Cell Damage by Shear-Stress (1972) Biophys. J., 12 (3), pp. 257-273; Lu, P.C., Lai, H.C., Liu, J.S., A Reevaluation and Discussion on the Threshold Limit for Hemolysis in a Turbulent Shear Flow (2001) J. Biomech., 34 (10), pp. 1361-1364; Ge, L., Dasi, L.P., Sotiropoulos, F., Yoganathan, A.P., Characterization of Hemodynamic Forces Induced by Mechanical Heart Valves: Reynolds Vs. Viscous Stresses (2008) Ann. Biomed. Eng., 36 (2), pp. 276-297; Dasi, L.P., Ge, L., Simon, H.A., Sotiropoulos, F., Yoganathan, A.P., Vorticity Dynamics of a Bileaflet Mechanical Heart Valve in an Axisymmetric Aorta (2007) Phys. Fluids, 19 (6), pp. 1-17; ISO, (2010) ISO 14708, Implants for Surgery, Active Implantable Medical Devices; Part 5:2010: Particular Requirements for Circulatory Support Devices; Section 6.106.2.2, Fluid Dynamic Analysis, p. 8; Manning, K.B., Kini, V., Fontaine, A.A., Deutsch, S., Tarbell, J.M., Regurgitant Flow Field Characteristics of the St. Jude Bileaflet Mechanical Heart Valve Under Physiologic Pulsatile Flow Using Particle Image Velocimetry (2003) Artif. Organs, 27 (9), pp. 840-846; Brucker, C., Steinseifer, U., Schroder, W., Reul, H., Unsteady Flow Through a New Mechanical Heart Valve Prosthesis Analysed by Digital Particle Image Velocimetry (2002) Meas. Sci. Technol., 13 (7), pp. 1043-1049; Leo, H.L., Dasi, L.P., Carberry, J., Simon, H.A., Yoganathan, A.P., Fluid Dynamic Assessment of Three Polymeric Heart Valves Using Particle Image Velocimetry (2006) Ann. Biomed. Eng., 34 (6), pp. 936-952; Lim, W.L., Chew, Y.T., Chew, T.C., Low, H.T., Pulsatile Flow Studies of a Porcine Bioprosthetic Aortic Valve In Vitro: PIV Measurements and Shear-Induced Blood Damage (2001) J. Biomech., 34 (11), pp. 1417-1427; Lim, W.L., Chew, Y.T., Chew, T.C., Low, H.T., Particle Image Velocimetry in the Investigation of Flow Past Artificial-Heart Valves (1994) Ann. Biomed. Eng., 22 (3), pp. 307-318; Rabbah, J.-P., Saikrishnan, N., Yoganathan, A.P., A Novel Left Heart Simulator for the Multi-Modality Characterization of Native Mitral Valve Geometry and Fluid Mechanics (2013) Ann. Biomed. Eng., 41 (2), pp. 305-315; Akutsu, T., Fulkuda, T., Saito, J., Time Resolved PIV Ventricular Flow Field Study of Differently Designed Contemporary Bi-Leaflet Mitral Valves (2007) Int. J. Artif. Organs, 30 (8), pp. 732-732; Bluestein, D., Rambod, E., Gharib, M., Vortex Shedding as a Mechanism for Free Emboli Formation in Mechanical Heart Valves (2000) ASME J. Biomech. Eng., 122 (2), pp. 125-134; Dasi, L.P., Sucosky, P., De Zelicourt, D., Sundareswaran, K., Jimenez, J., Yoganathan, A.P., Advances in Cardiovascular Fluid Mechanics: Bench to Bedside (2009) Interdisciplinary Transport Phenomena, , Fluid, Thermal, Biological, Materials, and Space Sciences, New York Academy of Sciences, New York; Marom, G., Haj-Ali, R., Raanani, E., Schaefers, H.-J., Rosenfeld, M., A Fluid-Structure Interaction Model of the Aortic Valve With Coaptation and Compliant Aortic Root (2012) Med. Biol. Eng. Comput., 50 (2), pp. 173-182; Morlacchi, S., Chiastra, C., Cutri, E., Zunino, P., Burzotta, F., Formaggia, L., Dubini, G., Migliavacca, F., Stent Deformation, Physical Stress, and Drug Elution Obtained With Provisional Stenting, Conventional Culotte and Tryton-Based Culotte to Treat Bifurcations: A Virtual Simulation Study (2014) Eurointervention, 9 (12), pp. 1441-1453; Chiastra, C., Morlacchi, S., Pereira, S., Dubini, G., Migliavacca, F., Computational Fluid Dynamics of Stented Coronary Bifurcations Studied With a Hybrid Discretization Method (2012) Eur. J. Mech. B-Fluids, 35, pp. 76-84; Ho, S.Y., Structure and Anatomy of the Aortic Root (2009) Eur. J. Echocardiogr., 10 (1), pp. 3-10; Dotter, C.T., Roberts, D.J., Steinberg, I., Aortic Length- Angiocardiographic Measurements (1950) Circulation, 2 (6), pp. 915-920; Bloomfield, G.S., Gillam, L.D., Hahn, R.T., Kapadia, S., Leipsic, J., Lerakis, S., Tuzcu, M., Douglas, P.S., A Practical Guide to Multimodality Imaging of Transcatheter Aortic Valve Replacement (2012) JACC-Cardiovasc. Imaging, 5 (4), pp. 441-455; Reul, H., Vahlbruch, A., Giersiepen, M., Schmitzrode, T., Hirtz, V., Effert, S., The Geometry of the Aortic Root in Health, at Valve Disease and After Valve-Replacement (1990) J. Biomech., 23 (2), pp. 181-191; Bahlmann, E., Nienaber, C.A., Cramariuc, D., Gohlke-Baerwolf, C., Ray, S., Devereux, R.B., Wachtell, K., Gerdts, E., Aortic Root Geometry in Aortic Stenosis Patients (a Seas Substudy) (2011) Eur. J. Echocardiogr., 12 (8), pp. 585-590; Underwood, M.J., El Khoury, G., Deronck, D., Glineur, D., Dion, R., The Aortic Root: Structure, Function, and Surgical Reconstruction (2000) Heart, 83 (4), pp. 376-380; Cozijnsen, L., Braam, R.L., Waalewijn, R.A., Schepens, M., Loeys, B.L., Van Oosterhout, M.F.M., Barge-Schaapveld, D., Mulder, B.J.M., What Is New in Dilatation of the Ascending Aorta? Review of Current Literature and Practical Advice for the Cardiologist (2011) Circulation, 123 (8), pp. 924-928; Nistri, S., Basso, C., Marzari, C., Mormino, P., Thiene, G., Frequency of Bicuspid Aortic Valve in Young Male Conscripts by Echocardiogram (2005) Am. J. Cardiol., 96 (5), pp. 718-721; Schoen, F.J., Levy, R.J., Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention (2005) Ann. Thorac. Surg., 79 (3), pp. 1072-1080; Yuan, S.M., Lavee, J., Progressive Aortic Dilation After Aortic Valve Replacement (2012) Surg. Pract., 16 (4), pp. 137-141; Boodhwani, M., De Kerchove, L., Glineur, D., Poncelet, A., Rubay, J., Astarci, P., Verhelst, R., El Khoury, G., Repair-Oriented Classification of Aortic Insufficiency: Impact on Surgical Techniques and Clinical Outcomes (2009) J. Thorac. Cardiovasc. Surg., 137 (2), pp. 286-294; Wu, V.C.-C., Kaku, K., Takeuchi, M., Otani, K., Yoshitani, H., Tamura, M., Abe, H., Otsuji, Y., Aortic Root Geometry in Patients With Aortic Stenosis Assessed by Real-Time Three-Dimensional Transesophageal Echocardiography (2014) J. Am. Soc. Echocardiogr., 27 (1), pp. 32-41; Raffel, M., Willert, C.E., Wereley, S.T., Kompenhans, J., (2007) Particle Image Velocimetry: A Practical Guide, , Springer, London, UK; Goncalves, I., Nesbitt, W.S., Yuan, Y.P., Jackson, S.P., Importance of Temporal Flow Gradients and Integrin Alpha(Iib)Beta(3) Mechanotransduction for Shear Activation of Platelets (2005) J. Biol. Chem., 280 (15), pp. 15430-15437; Sallam, A.M., Hwang, N.H.C., Human Red Blood-Cell Hemolysis in a Turbulent Shear-Flow-Contribution of Reynolds Shear Stresses (1984) Biorheology, 21 (6), pp. 783-797; Lansac, E., Di Centa, I., Sleilaty, G., Crozat, E.A., Bouchot, O., Hacini, R., Blin, D., Debauchez, M., An Aortic Ring: From Physiologic Reconstruction of the Root to a Standardized Approach for Aortic Valve Repair (2010) J. Thorac. Cardiovasc. Surg., 140 (6), pp. S28-S35; Myers, P.O., Del Nido, P.J., Emani, S.M., Marx, G.R., Baird, C.W., Valve-Sparing Aortic Root Replacement and Remodeling With Complex Aortic Valve Reconstruction in Children and Young Adults With Moderate or Severe Aortic Regurgitation (2014) J. Thorac. Cardiovasc. Surg., 147 (6), pp. 1768-1774; David, T.E., Armstrong, S., Maganti, M., Colman, J., Bradley, T.J., Long-Term Results of Aortic Valve-Sparing Operations in Patients With Marfan Syndrome (2009) J. Thorac. Cardiovasc. Surg., 138 (4), pp. 859-864; Yacoub, M.H., Gehle, P., Chandrasekaran, V., Birks, E.J., Child, A., Radley-Smith, R., Late Results of a Valve-Preserving Operation in Patients With Aneurysms of the Ascending Aorta and Root (1998) J. Thorac. Cardiovasc. Surg., 115 (5), pp. 1080-1089; Carrel, T., Berdat, P., Pavlovic, M., Sukhanov, S., Englberger, L., Pfammatter, J.P., Surgery of the Dilated Aortic Root and Ascending Aorta in Pediatric Patients: Techniques and Results (2003) Eur. J. Cardio-Thorac. Surg., 24 (2), pp. 249-254; Nataf, P., Lansac, E., Dilation of the Thoracic Aorta: Medical and Surgical Management (2006) Heart, 92 (9), pp. 1345-1352",Article,Scopus,2-s2.0-84924362842
"Swerdlow D.I., Hingorani A.D., Humphries S.E.","Genetic Risk Factors and Mendelian Randomization in Cardiovascular Disease",2015,"Current Cardiology Reports","17","5",,"","",11,,10.1007/s11886-015-0584-x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928319979&partnerID=40&md5=08b5aa8a9a1b04c64adcee2fa8c8e328","Institute of Cardiovascular Science, University College London, 222 Euston RoadLondon, United Kingdom; Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College LondonLondon, United Kingdom","Swerdlow, D.I., Institute of Cardiovascular Science, University College London, 222 Euston RoadLondon, United Kingdom; Hingorani, A.D., Institute of Cardiovascular Science, University College London, 222 Euston RoadLondon, United Kingdom; Humphries, S.E., Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College LondonLondon, United Kingdom","Cardiovascular disease encompasses several diverse pathological states that place a heavy burden on individual and population health. The aetiological basis of many cardiovascular disorders is not fully understood. Growing knowledge of the genetic architecture underlying coronary heart disease, stroke, cardiac arrhythmias and peripheral vascular disease has confirmed some suspected causal pathways in these conditions but also uncovered many previously unknown mechanisms. Here, we consider the contribution of genetics to the understanding of cardiovascular disease risk. We evaluate the utility and relevance of findings from genome-wide association studies and explore the role that Mendelian randomisation has to play in exploiting these. Mendelian randomisation permits robust causal inference in an area of research where this has been hampered by bias and confounding in observational studies. In doing so, it provides evidence for causal processes in cardiovascular disease that could represent novel targets for much-needed new drugs for disease prevention and treatment. © 2015, Springer Science+Business Media New York.","Cardiovascular disease; Causal inference; Genetics; Mendelian randomisation; Risk factors; Risk prediction","Wilson, P.W., D’Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B., Prediction of coronary heart disease using risk factor categories (1998) Circulation, 97, pp. 1837-1847. , COI: 1:STN:280:DyaK1c3msVOjsA%3D%3D; Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., Minhas, R., Sheikh, A., Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2 (2008) BMJ, 336, pp. 1475-1482; Fox, K.A.A., Fitzgerald, G., Puymirat, E., Huang, W., Carruthers, K., Simon, T., Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score (2014) BMJ Open, 4, p. 004425; Brotman, D.J., Walker, E., Lauer, M.S., O’Brien, R.G., In search of fewer independent risk factors (2005) Arch Intern Med, 165, pp. 138-145; Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K.K., Thompson, A., Major lipids, apolipoproteins, and risk of vascular disease (2009) JAMA, 302, pp. 1993-2000; Rapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A.D., Denaxas, S., Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people (2014) Lancet, 383, pp. 1899-1911; Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M.B., Thompson, S.G., Collins, R., C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis (2010) Lancet, 375, pp. 132-140; Danesh, J., Kaptoge, S., Mann, A.G., Sarwar, N., Wood, A., Angleman, S.B., Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review (2008) PLoS Med, 5, p. 78; Seshasai, S.R.K., Kaptoge, S., Thompson, A., Di Angelantonio, E., Gao, P., Diabetes mellitus, fasting glucose, and risk of cause-specific death (2011) N Engl J Med, 364, pp. 829-841; Fruchart, J.-C., Davignon, J., Hermans, M.P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Residual macrovascular risk in 2013: what have we learned? (2014) Cardiovasc Diabetol, 13, p. 26; Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S., Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society (2013) Eur Heart J, 34, pp. 3478-3490. , COI: 1:CAS:528:DC%2BC3sXhvVOqu7vI, Recent European guidance on the clinical management of familial hypercholesterolaemia; Futema, M., Plagnol, V., Li, K., Whittall, R.A., Neil, H.A.W., Seed, M., Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations (2014) J Med Genet, 51, pp. 537-544. , COI: 1:CAS:528:DC%2BC2cXhslaksrzK; Fouchier, S.W., Dallinga-Thie, G.M., Meijers, J.C.M., Zelcer, N., Kastelein, J.J.P., Defesche, J.C., Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia (2014) Circ Res, 115, pp. 552-555. , COI: 1:CAS:528:DC%2BC2cXhsVeqtrzP, Report of a novel locus responsible for causing familial hypercholesterolaemia; Lange, L.A., Hu, Y., Zhang, H., Xue, C., Schmidt, E.M., Tang, Z.-Z., Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol (2014) Am J Hum Genet, 94, pp. 233-245. , COI: 1:CAS:528:DC%2BC2cXitVyqu78%3D, Demonstration of the use of whole-exome sequencing for investigating genetic determinants of atherosclerosis and coronary heart disease; McCarthy, M.I., Abecasis, G.R., Cardon, L.R., Goldstein, D.B., Little, J., Ioannidis, J.P.A., Genome-wide association studies for complex traits: consensus, uncertainty and challenges (2008) Nat Rev Genet, 9, pp. 356-369. , COI: 1:CAS:528:DC%2BD1cXkvVOhs7Y%3D, A guide to the development, application and utility of genome-wide association studies; Jun 30] (2011) Available from:, , www.genome.gov/gwastudies; Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., Assimes, T.L., Thompson, J.R., Large-scale association analysis identifies new risk loci for coronary artery disease (2012) Nat Genet, 45, pp. 25-33. , The largest meta-analysis of genome-wide association studies of coronary heart disease published to date; Willer, C.J., Sanna, S., Jackson, A.U., Scuteri, A., Bonnycastle, L.L., Clarke, R., Newly identified loci that influence lipid concentrations and risk of coronary artery disease (2008) Nat Genet, 40, pp. 161-169. , COI: 1:CAS:528:DC%2BD1cXhtl2rsro%3D; Arsenault, B.J., Boekholdt, S.M., Dubé, M.-P., Rhéaume, E., Wareham, N.J., Khaw, K.-T., Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort (2014) Circ Cardiovasc Genet, 7, pp. 304-310. , COI: 1:CAS:528:DC%2BC2cXht1Smtb7O; Kamstrup, P.R., Tybjaerg-Hansen, A., Steffensen, R., Nordestgaard, B.G., Genetically elevated lipoprotein(a) and increased risk of myocardial infarction (2009) JAMA, 301, pp. 2331-2339. , COI: 1:CAS:528:DC%2BD1MXntFCms7w%3D; Tarasov, K.V., Sanna, S., Scuteri, A., Strait, J.B., Orrù, M., Parsa, A., COL4A1 is associated with arterial stiffness by genome-wide association scan (2009) Circ Cardiovasc Genet, 2, pp. 151-158. , COI: 1:CAS:528:DC%2BD1MXmvVyhtr8%3D; Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann J, Shah T, Sofat R, et al. The interleukin-6 receptor as a potential target for coronary heart disease prevention: evaluation using Mendelian randomisation. Lancet. 2012;2012. A Mendelian randomisation study of the interleukin-6 receptor as a potential therapeutic target in coronary disease, providing evidence that this pathway has a causal role and may hold benefit for disease prevention. Findings were corroborated in a similar study by Sarwar et al., belowSarwar, N., Butterworth, A.S., Freitag, D.F., Gregson, J., Willeit, P., Gorman, D.N., Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies (2012) Lancet, 379, pp. 1205-1213. , A Mendelian randomisation study of the interleukin-6 receptor as a potential therapeutic target in coronary disease, providing evidence that this pathway has a causal role and may hold benefit for disease prevention. Findings were corroborated in a similar study by Swerdlow et al; Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S., Kanoni, S., Discovery and refinement of loci associated with lipid levels (2013) Nat Genet, 45, pp. 1274-1283. , COI: 1:CAS:528:DC%2BC3sXhsFOitb7O; http://www.ncbi.nlm.nih.gov/pubmed/21378990, Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. [Internet]. 2011 [cited 2011 Mar 13]Peden, J.F., Hopewell, J.C., Saleheen, D., Chambers, J.C., Hager, J., Soranzo, N., A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease (2011) Nat Genet, 43, pp. 339-344. , COI: 1:CAS:528:DC%2BC3MXivVSms7s%3D; Johnson, A.D., Hwang, S.-J., Voorman, A., Morrison, A., Peloso, G.M., Hsu, Y.-H., Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study (2013) Circulation, 127, pp. 799-810; Roberts, R., Stewart, A.F.R., 9p21 and the genetic revolution for coronary artery disease (2012) Clin Chem, 58, pp. 104-112. , COI: 1:CAS:528:DC%2BC38XnvFektw%3D%3D; Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk (2011) Nature, 478, pp. 103-109. , A large genome-wide association study reporting common genetic determinants of blood pressure; Speliotes, E.K., Willer, C.J., Berndt, S.I., Monda, K.L., Thorleifsson, G., Jackson, A.U., Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index (2010) Nat Genet, 42, pp. 937-948. , COI: 1:CAS:528:DC%2BC3cXht1KmsL%2FN, A very large genome-wide association study reporting novel genetic determinants of obesity-related traits; Liu, J.Z., Tozzi, F., Waterworth, D.M., Pillai, S.G., Muglia, P., Middleton, L., Meta-analysis and imputation refines the association of 15q25 with smoking quantity (2010) Nat Genet, 42, pp. 436-440. , COI: 1:CAS:528:DC%2BC3cXltFKlsro%3D; Ellinor, P.T., Lunetta, K.L., Albert, C.M., Glazer, N.L., Ritchie, M.D., Smith, A.V., Meta-analysis identifies six new susceptibility loci for atrial fibrillation (2012) Nat Genet, 44, pp. 670-675. , COI: 1:CAS:528:DC%2BC38Xmt1GrsLw%3D; Ellinor, P.T., Lunetta, K.L., Glazer, N.L., Pfeufer, A., Alonso, A., Chung, M.K., Common variants in KCNN3 are associated with lone atrial fibrillation (2010) Nat Genet, 42, pp. 240-244. , COI: 1:CAS:528:DC%2BC3cXit1SmtLk%3D; Butler, A.M., Yin, X., Evans, D.S., Nalls, M.A., Smith, E.N., Tanaka, T., Novel loci associated with PR interval in a genome-wide association study of 10 African American cohorts (2012) Circ Cardiovasc Genet, 5, pp. 639-646. , COI: 1:CAS:528:DC%2BC3sXisVKqur0%3D; Sotoodehnia, N., Isaacs, A., de Bakker, P.I.W., Dörr, M., Newton-Cheh, C., Nolte, I.M., Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction (2010) Nat Genet, 42, pp. 1068-1076. , COI: 1:CAS:528:DC%2BC3cXhsVWmurnM; Ritchie, M.D., Denny, J.C., Zuvich, R.L., Crawford, D.C., Schildcrout, J.S., Bastarache, L., Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk (2013) Circulation, 127, pp. 1377-1385. , COI: 1:CAS:528:DC%2BC3sXltFCgt74%3D; Pfeufer, A., van Noord, C., Marciante, K.D., Arking, D.E., Larson, M.G., Smith, A.V., Genome-wide association study of PR interval (2010) Nat Genet, 42, pp. 153-159. , COI: 1:CAS:528:DC%2BC3cXjsVehsA%3D%3D; Chambers, J.C., Zhao, J., Terracciano, C.M.N., Bezzina, C.R., Zhang, W., Kaba, R., Genetic variation in SCN10A influences cardiac conduction (2010) Nat Genet, 42, pp. 149-152. , COI: 1:CAS:528:DC%2BC3cXjsVegtg%3D%3D; Holm, H., Gudbjartsson, D.F., Arnar, D.O., Thorleifsson, G., Thorgeirsson, G., Stefansdottir, H., Several common variants modulate heart rate, PR interval and QRS duration (2010) Nat Genet, 42, pp. 117-122. , COI: 1:CAS:528:DC%2BC3cXjsVemtQ%3D%3D; Smith, J.G., Avery, C.L., Evans, D.S., Nalls, M.A., Meng, Y.A., Smith, E.N., Impact of ancestry and common genetic variants on QT interval in African Americans (2012) Circ Cardiovasc Genet, 5, pp. 647-655; Chang, K.-C., Barth, A.S., Sasano, T., Kizana, E., Kashiwakura, Y., Zhang, Y., CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart (2008) Proc Natl Acad Sci, 105, pp. 4477-4482. , COI: 1:CAS:528:DC%2BD1cXkt1eiu70%3D; Smith, N.L., Felix, J.F., Morrison, A.C., Demissie, S., Glazer, N.L., Loehr, L.R., Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium (2010) Circ Cardiovasc Genet, 3, pp. 256-266. , COI: 1:CAS:528:DC%2BC3cXpt1aqs78%3D; Villard, E., Perret, C., Gary, F., Proust, C., Dilanian, G., Hengstenberg, C., A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy (2011) Eur Heart J, 32, pp. 1065-1076. , COI: 1:CAS:528:DC%2BC3MXlvVOqtbo%3D; Arnett, D.K., Li, N., Tang, W., Rao, D.C., Devereux, R.B., Claas, S.A., Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study (2009) BMC Med Genet, 10, p. 43; Del Greco, M.F., Pattaro, C., Luchner, A., Pichler, I., Winkler, T., Hicks, A.A., Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster (2011) Hum Mol Genet, 20, pp. 1660-1671; Thanassoulis, G., Campbell, C.Y., Owens, D.S., Smith, J.G., Smith, A.V., Peloso, G.M., Genetic associations with valvular calcification and aortic stenosis (2013) N Engl J Med, 368, pp. 503-512. , COI: 1:CAS:528:DC%2BC3sXitFeltrY%3D; Kamstrup, P.R., Tybjærg-Hansen, A., Nordestgaard, B.G., Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population (2014) J Am Coll Cardiol, 63, pp. 470-477. , COI: 1:CAS:528:DC%2BC2cXhvFGlsLg%3D; Trégouët, D.-A., König, I.R., Erdmann, J., Munteanu, A., Braund, P.S., Hall, A.S., Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease (2009) Nat Genet, 41, pp. 283-285; Dichgans, M., Malik, R., König, I.R., Rosand, J., Clarke, R., Gretarsdottir, S., Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants (2014) Stroke J Cereb Circ, 45, pp. 24-36. , COI: 1:CAS:528:DC%2BC2cXitFymtLs%3D, A valuable comparison between the common genetic determinants of stroke and coronary heart disease highlighting shared aetiological pathways; Traylor, M., Farrall, M., Holliday, E.G., Sudlow, C., Hopewell, J.C., Cheng, Y.-C., Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies (2012) Lancet Neurol, 11, pp. 951-962; Ashton, H.A., Buxton, M.J., Day, N.E., Kim, L.G., Marteau, T.M., Scott, R.A.P., The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial (2002) Lancet, 360, pp. 1531-1539. , COI: 1:STN:280:DC%2BD38not12lsg%3D%3D; Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., A common variant on chromosome 9p21 affects the risk of myocardial infarction (2007) Science, 316, pp. 1491-1493. , COI: 1:CAS:528:DC%2BD2sXmtFSjtro%3D; Helgadottir, A., Thorleifsson, G., Magnusson, K.P., Grétarsdottir, S., Steinthorsdottir, V., Manolescu, A., The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm (2008) Nat Genet, 40, pp. 217-224. , COI: 1:CAS:528:DC%2BD1cXhsVSjsLY%3D; Harrison, S.C., Kalea, A.Z., Holmes, M.V., Agu, O., Humphries, S.E., Genomic research to identify novel pathways in the development of abdominal aortic aneurysm (2012) Cardiol. Res. Pract, 2012, p. 852829; Gretarsdottir, S., Baas, A.F., Thorleifsson, G., Holm, H., den Heijer, M., de Vries, J.-P.P.M., Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm (2010) Nat Genet, 42, pp. 692-697. , COI: 1:CAS:528:DC%2BC3cXos1aitbo%3D; Bown, M.J., Jones, G.T., Harrison, S.C., Wright, B.J., Bumpstead, S., Baas, A.F., Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1 (2011) Am J Hum Genet, 89, pp. 619-627. , COI: 1:CAS:528:DC%2BC3MXhsVKhurfE; Bradley, D.T., Hughes, A.E., Badger, S.A., Jones, G.T., Harrison, S.C., Wright, B.J., A variant in LDLR is associated with abdominal aortic aneurysm (2013) Circ Cardiovasc Genet, 6, pp. 498-504. , COI: 1:CAS:528:DC%2BC3sXhs1Cis7fL; Harrison, S.C., Smith, A.J.P., Jones, G.T., Swerdlow, D.I., Rampuri, R., Bown, M.J., Interleukin-6 receptor pathways in abdominal aortic aneurysm (2012) Eur Heart J, 34, pp. 3707-3716; Hayden, E.C., Technology: the $1,000 genome (2014) Nature, 507, pp. 294-295; Holmes, M.V., Harrison, S., Talmud, P.J., Hingorani, A.D., Humphries, S.E., Utility of genetic determinants of lipids and cardiovascular events in assessing risk (2011) Nat Rev Cardiol, 8, pp. 207-221. , COI: 1:CAS:528:DC%2BC3MXjvVKns74%3D, A comprehensive review of the underlying research and clinical utility of using genetics for predicting cardiovascular disease risk; Ashley, E.A., Butte, A.J., Wheeler, M.T., Chen, R., Klein, T.E., Dewey, F.E., Clinical assessment incorporating a personal genome (2010) Lancet, 375, pp. 1525-1535. , COI: 1:CAS:528:DC%2BC3cXlsVOnt74%3D; Ganna, A., Magnusson, P.K.E., Pedersen, N.L., de Faire, U., Reilly, M., Arnlöv, J., Multilocus genetic risk scores for coronary heart disease prediction (2013) Arterioscler Thromb Vasc Biol, 33, pp. 2267-2272. , COI: 1:CAS:528:DC%2BC3sXht1Oqtr7M; Tikkanen, E., Havulinna, A.S., Palotie, A., Salomaa, V., Ripatti, S., Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease (2013) Arterioscler Thromb Vasc Biol, 33, pp. 2261-2266. , COI: 1:CAS:528:DC%2BC3sXht1OqsbfF; Hughes, M.F., Saarela, O., Stritzke, J., Kee, F., Silander, K., Klopp, N., Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts (2012) PLoS One, 7, p. 40922. , COI: 1:CAS:528:DC%2BC38XhtFamsr3F; Brautbar, A., Pompeii, L.A., Dehghan, A., Ngwa, J.S., Nambi, V., Virani, S.S., A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies (2012) Atherosclerosis, 223, pp. 421-426. , COI: 1:CAS:528:DC%2BC38XhtVWgtb3M; Hernesniemi, J.A., Seppälä, I., Lyytikäinen, L.-P., Mononen, N., Oksala, N., Hutri-Kähönen, N., Genetic profiling using genome-wide significant coronary artery disease risk variants does not improve the prediction of subclinical atherosclerosis: the Cardiovascular Risk in Young Finns Study, the Bogalusa Heart Study and the Health 2000 Survey—a meta-analysis of three independent studies (2012) PLoS One, 7, p. 28931. , COI: 1:CAS:528:DC%2BC38Xit1Cis78%3D; Ripatti, S., Tikkanen, E., Orho-Melander, M., Havulinna, A.S., Silander, K., Sharma, A., A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses (2010) Lancet, 376, pp. 1393-1400. , A clinically focused report of a study investigating the incorporation of genetic information into coronary heart disease risk prediction; Humphries, S.E., Drenos, F., Ken-Dror, G., Talmud, P.J., Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds (2010) Circulation, 121, pp. 2235-2248; Annas, G.J., Elias, S., 23andMe and the FDA (2014) N Engl J Med, 370, pp. 985-988. , COI: 1:CAS:528:DC%2BC2cXkvVyqtL8%3D; Davey Smith, G., Ebrahim, S., Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? (2003) Int J Epidemiol, 32, pp. 1-22. , A guide to the theoretical and practical basis of Mendelian randomisation; Ebrahim, S., Davey Smith, G., Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? (2008) Hum Genet, 123, pp. 15-33. , A review of the role of Mendelian randomisation in overcoming some of the limitations of traditional epidemiology; Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials (2010) Lancet, 376, pp. 1670-1681. , COI: 1:STN:280:DC%2BC3cbmvVGmsQ%3D%3D; Ninomiya, T., Perkovic, V., Turnbull, F., Neal, B., Barzi, F., Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials (2013) BMJ, 347, p. 5680; Myung, S.-K., Ju, W., Cho, B., Oh, S.-W., Park, S.M., Koo, B.-K., Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials (2013) BMJ, 346, p. 10; Hingorani, A., Humphries, S., Nature’s randomised trials (2005) Lancet, 366, pp. 1906-1908. , A concise introduction to the similarities between Mendelian randomisation and the traditional randomised controlled trial; Gregor Mendel’s seminal work on the inheritance of pea plant characteristics. The seminal description of the laws of what has become known as ‘Mendelian’ inheritance (1865) These underly the Mendelian randomisation principle; Linsel-Nitschke, P., Götz, A., Erdmann, J., Braenne, I., Braund, P., Hengstenberg, C., Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease—a Mendelian Randomisation study (2008) PLoS One, 3, p. 2986; Ference, B.A., Julius, S., Mahajan, N., Levy, P.D., Williams, K.A., Flack, J.M., Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension (2014) Hypertension, 63, pp. 1182-1188. , COI: 1:CAS:528:DC%2BC2cXpt1Kruro%3D; Luke, M.M., Kane, J.P., Liu, D.M., Rowland, C.M., Shiffman, D., Cassano, J., A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease (2007) Arterioscler Thromb Vasc Biol, 27, pp. 2030-2036. , COI: 1:CAS:528:DC%2BD2sXpt1Cju7Y%3D; Sarwar, N., Sandhu, M.S., Ricketts, S.L., Butterworth, A.S., Di Angelantonio, E., Boekholdt, S.M., Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies (2010) Lancet, 375, pp. 1634-1639. , COI: 1:CAS:528:DC%2BC3cXlslylu74%3D, A large-scale Mendelian randomisation study implicating triglyceride-mediated aetiological pathways in the development of coronary heart disease; Holmes, M.V., Asselbergs, F.W., Palmer, T.M., Drenos, F., Lanktree, M.B., Nelson, C.P., (2014) Mendelian randomization of blood lipids for coronary heart disease, , Eur Heart J, Report of a study using Mendelian randomisation techniques to investigate the causal contributions of major blood lipid fractions in coronary heart disease:; Do, R., Willer, C.J., Schmidt, E.M., Sengupta, S., Gao, C., Peloso, G.M., Common variants associated with plasma triglycerides and risk for coronary artery disease (2013) Nat Genet, 45, pp. 1345-1352. , COI: 1:CAS:528:DC%2BC3sXhsFOiur%2FN, An innovative Mendelian randomisation study using novel techniques to investigate further the causal contributions of plasma triglycerides in coronary disease; Hafiane, A., Genest, J., HDL, atherosclerosis, and emerging therapies (2013) Cholesterol, 2013, p. 891403. , A review discussing the controversial role of HDL cholesterol in coronary heart disease and the potential utility of pharmacological modulation of HDL-C; Frikke-Schmidt, R., Nordestgaard, B.G., Stene, M.C.A., Sethi, A.A., Remaley, A.T., Schnohr, P., Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease (2008) JAMA, 299, pp. 2524-2532. , COI: 1:CAS:528:DC%2BD1cXmvVyitL8%3D; Haase, C.L., Tybjærg-Hansen, A., Qayyum, A.A., Schou, J., Nordestgaard, B.G., Frikke-Schmidt, R., LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals (2012) J Clin Endocrinol Metab, 97, pp. 248-256. , COI: 1:CAS:528:DC%2BC38XisFOns70%3D; http://www.ncbi.nlm.nih.gov/pubmed/22607825, Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet [Internet]. 2012 [cited 2012 Jun 2]; Available from:. An important Mendelian randomisation study providing evidence that one aspect of HDL cholesterol metabolism appears not to have a causal role in the development of coronary heart diseaseHansson, G.K., Atherosclerosis—an immune disease: the Anitschkov Lecture 2007 (2009) Atherosclerosis, 202, pp. 2-10. , COI: 1:CAS:528:DC%2BD1cXhsFajsb%2FP; Wensley, F., Gao, P., Burgess, S., Kaptoge, S., Di Angelantonio, E., Shah, T., Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data (2011) BMJ, 342, p. 548. , A large collaborative Mendelian randomisation study providing strong evidence against a causal role for C-reactive protein in coronary heart disease; Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst. Rev. Online. 2010;CD008331Holmes, M.V., Lange, L.A., Palmer, T., Lanktree, M.B., North, K.E., Almoguera, B., Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis (2014) Am J Hum Genet, 94, pp. 198-208. , COI: 1:CAS:528:DC%2BC2cXht1KhtL8%3D, An allele score-based Mendelian randomisation study investigating the causal contribution of body mass index—a complex phenotype—in other areas of cardiometabolic disease; Nordestgaard, B.G., Palmer, T.M., Benn, M., Zacho, J., Tybjærg-Hansen, A., Davey Smith, G., The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach (2012) PLoS Med, 9, p. 1001212; Ronksley, P.E., Brien, S.E., Turner, B.J., Mukamal, K.J., Ghali, W.A., Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis (2011) BMJ, 342, p. 671; Holmes, M.V., Dale, C.E., Zuccolo, L., Silverwood, R.J., Guo, Y., Ye, Z., Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data (2014) BMJ, 349, p. 4164. , A landmark genetic investigation of the much-debated causal role of alcohol consumption in a range of cardiometabolic disease phenotypes; Landry, Y., Gies, J.-P., Drugs and their molecular targets: an updated overview (2008) Fundam Clin Pharmacol, 22, pp. 1-18. , COI: 1:CAS:528:DC%2BD1cXis12ktr0%3D; Nicholls, S.J., Cavender, M.A., Kastelein, J.J.P., Schwartz, G., Waters, D.D., Rosenson, R.S., Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial (2012) Cardiovasc Drugs Ther, 26, pp. 71-75. , COI: 1:CAS:528:DC%2BC38XivFOrsr4%3D; Holmes, M.V., Simon, T., Exeter, H.J., Folkersen, L., Asselbergs, F.W., Guardiola, M., Secretory phospholipase A2-IIA and cardiovascular disease: a Mendelian randomization study (2013) J Am Coll Cardiol, 62 (21), pp. 1966-1976. , COI: 1:CAS:528:DC%2BC3sXhslKqsLbO; Nicholls, S.J., Kastelein, J.J.P., Schwartz, G.G., Bash, D., Rosenson, R.S., Cavender, M.A., Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial (2014) JAMA, 311, pp. 252-262. , COI: 1:CAS:528:DC%2BC2cXisVGisrY%3D; Brousseau, M.E., Schaefer, E.J., Wolfe, M.L., Bloedon, L.T., Digenio, A.G., Clark, R.W., Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol (2004) N Engl J Med, 350, pp. 1505-1515. , COI: 1:CAS:528:DC%2BD2cXjtVeqt7Y%3D; Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J.P., Komajda, M., Effects of torcetrapib in patients at high risk for coronary events (2007) N Engl J Med, 357, pp. 2109-2122. , COI: 1:CAS:528:DC%2BD2sXhtlGns7bL; Sofat, R., Hingorani, A.D., Smeeth, L., Humphries, S.E., Talmud, P.J., Cooper, J., Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms (2010) Circulation, 121, pp. 52-62. , COI: 1:CAS:528:DC%2BD1MXhs1WjtrnO, A novel application of Mendelian randomisation for investigating adverse drug effects, providing evidence that the hypertensive effect of torcetrapib therapy was an off-target action of the drug; Sattar, N., Preiss, D., Murray, H.M., Welsh, P., Buckley, B.M., de Craen, A.J., Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (2010) Lancet, 375, pp. 735-742. , COI: 1:CAS:528:DC%2BC3cXisFart74%3D, A large meta-analysis of randomised trials demonstrating the increased risk of new-onset type 2 diabetes with statin treatment; Preiss, D., Seshasai, S.R.K., Welsh, P., Murphy, S.A., Ho, J.E., Waters, D.D., Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis (2011) JAMA, 305, pp. 2556-2564. , COI: 1:CAS:528:DC%2BC3MXotVantLs%3D, Corroboration of the increased diabetes risk with statin therapy, showing that high-intensity statin therapy led to the greatest risk of diabetes; http://linkinghub.elsevier.com/retrieve/pii/S0140673614611831, Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet [Internet]. 2014 [cited 2014 Sep 24]; Available from:. A study using data from randomised trials and Mendelian randomisation to investigate the aetiology of the increased risk of diabetes with statin therapy",Review,Scopus,2-s2.0-84928319979
"Akboga M.K., Canpolat U., Sahinarslan A., Alsancak Y., Nurkoc S., Aras D., Aydogdu S., Abaci A.","Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation",2015,"Atherosclerosis","240","1",,"110","114",,,10.1016/j.atherosclerosis.2015.02.051,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924599499&partnerID=40&md5=d53e8d95e1f971b9d465dacc26755efd","Turkiye Yuksek Ihtisas Education and Research Hospital, Department of CardiologyAnkara, Turkey; Gazi University Medical Faculty, Department of CardiologyAnkara, Turkey","Akboga, M.K., Turkiye Yuksek Ihtisas Education and Research Hospital, Department of CardiologyAnkara, Turkey; Canpolat, U., Turkiye Yuksek Ihtisas Education and Research Hospital, Department of CardiologyAnkara, Turkey; Sahinarslan, A., Gazi University Medical Faculty, Department of CardiologyAnkara, Turkey; Alsancak, Y., Gazi University Medical Faculty, Department of CardiologyAnkara, Turkey; Nurkoc, S., Gazi University Medical Faculty, Department of CardiologyAnkara, Turkey; Aras, D., Turkiye Yuksek Ihtisas Education and Research Hospital, Department of CardiologyAnkara, Turkey; Aydogdu, S., Turkiye Yuksek Ihtisas Education and Research Hospital, Department of CardiologyAnkara, Turkey; Abaci, A., Gazi University Medical Faculty, Department of CardiologyAnkara, Turkey","Objective: Although cardiovascular protective action of bilirubin has been attributed to its antioxidant effect, there was scarce data regarding the anti-inflammatory properties. Herein, we aimed to assess the relationship between serum total bilirubin level and severity of coronary artery disease (CAD) in association with the direct inflammatory marker such as C-reactive protein (CRP), the other indirect markers included in inflammation process such as neutrophil to lymphocyte ratio (NLR) and red cell distribution width (RDW) in patients with stable CAD. Methods: Angiographic data of 1501 patients were analyzed in this retrospective cross-sectional study. Patients were categorized according to Gensini scores as control, mild CAD and severe CAD groups. The association of clinical and laboratory parameters with the severity of CAD were determined by multivariable linear regression analysis. Results: Total bilirubin level in the control group was significantly higher than those of the other groups. After multivariable linear regression analysis total bilirubin [β=-3.131 (-4.481,-1.782), p<0.001] was significantly associated with the severity of CAD. Futhermore, there was a moderate and significant inverse correlation between serum total bilirubin level and the severity of CAD (r=-0.173, p<0.001), CRP (r=-0.112, p<0.001), NLR (r=-0.070, p=0.026) and RDW (r=-0.074, p=0.027). Conclusion: Serum total bilirubin level was independently and inversely associated with the severity of coronary atherosclerosis in patients with stable CAD. In addition, total bilirubin level was inversely correlated with CRP, NLR and RDW. These results suggest that besides its already known effect on the oxidative stress, higher serum total bilirubin level may exhibit an anti-inflammatory effect in the coronary atherosclerotic process. © 2015 Elsevier Ireland Ltd.","Atherosclerosis; Bilirubin; CRP; Inflammation; NLR; RDW","Libby, P., Ridker, P.M., Maseri, A., Inflammation and atherosclerosis (2002) Circulation, 105, pp. 1135-1143; Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease (2005) N.Engl. J. Med., 352, pp. 1685-1695; Witztum, J.L., Berliner, J.A., Oxidized phospholipids and isoprostanes in atherosclerosis (1998) Curr. Opin. Lipidol., 9, pp. 441-448; Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., Witztum, J.L., Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity (1989) N.Engl. J. Med., 320, pp. 915-924; Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N., Ames, B.N., Bilirubin is an antioxidant of possible physiological importance (1987) Science, 235, pp. 1043-1046; Dennery, P.A., McDonagh, A.F., Spitz, D.R., Rodgers, P.A., Stevenson, D.K., Hyperbilirubinemia results in reduced oxidative injury in neonatal gunn rats exposed to hyperoxia (1995) Free Radic. Biol. Med., 19, pp. 395-404; Wu, T.W., Fung, K.P., Wu, J., Yang, C.C., Weisel, R.D., Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins (1996) Biochem. Pharmacol., 51, pp. 859-862; Kang, S.J., Kim, D., Park, H.E., Chung, G.E., Choi, S.H., Choi, S.Y., Elevated serum bilirubin levels are inversely associated with coronary artery atherosclerosis (2013) Atherosclerosis, 230, pp. 242-248; Ghem, C., Sarmento-Leite, R.E., de Quadros, A.S., Rossetto, S., Gottschall, C.A., Serum bilirubin concentration in patients with an established coronary artery disease (2010) Int. Heart J., 51, pp. 86-91; Turfan, M., Duran, M., Poyraz, F., Yayla, C., Akboga, M.K., Sahinarslan, A., Inverse relationship between serum total bilirubin levels and severity of disease in patients with stable coronary artery disease (2013) Coron. Artery Dis., 24, pp. 29-32; Claridge, L.C., Armstrong, M.J., Booth, C., Gill, P.S., Gilbert's syndrome (2011) BMJ, 342, p. d2293; Gensini, G.G., Amore meaningful scoring system for determining the severity of coronary heart disease (1983) Am. J. Cardiol., 51, p. 606; Oishi, Y., Wakatsuki, T., Nishikado, A., Oki, T., Ito, S., Circulating adhesion molecules and severity of coronary atherosclerosis (2000) Coron. Artery Dis., 11, pp. 77-81; Fihn, S.D., Gardin, J.M., Abrams, J., Berra, K., Blankenship, J.C., Dallas, A.P., 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascu (2012) J.Am. Coll. Cardiol., 60, pp. 44-164; Drakopoulou, M., Toutouzas, K., Stefanadi, E., Tsiamis, E., Tousoulis, D., Stefanadis, C., Association of inflammatory markers with angiographic severity and extent of coronary artery disease (2009) Atherosclerosis, 206, pp. 335-339; Witztum, J.L., Steinberg, D., Role of oxidized low density lipoprotein in atherogenesis (1991) J.Clin. Invest., 88, pp. 1785-1792; Neuzil, J., Stocker, R., Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation (1994) J.Biol. Chem., 269, pp. 16712-16729; Schwertner, H.A., Jackson, W.G., Tolan, G., Association of low serum concentration of bilirubin with increased risk of coronary artery disease (1994) Clin. Chem., 40, pp. 18-23; Novotny, L., Vitek, L., Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies (2003) Exp. Biol. Med. (Maywood), 228, pp. 568-571; Gul, M., Uyarel, H., Ergelen, M., Akgul, O., Karaca, G., Turen, S., Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention (2013) Am. J. Cardiol., 111, pp. 166-171; Lin, J.P., O'Donnell, C.J., Schwaiger, J.P., Cupples, L.A., Lingenhel, A., Hunt, S.C., Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the framingham heart study (2006) Circulation, 114, pp. 1476-1481; Sung, K.C., Shin, J., Lim, Y.H., Wild, S.H., Byrne, C.D., Relation of conjugated bilirubin concentrations to the presence of coronary artery calcium (2013) Am. J. Cardiol., 112, pp. 1873-1879; Crisby, M., Kublickiene, K., Henareh, L., Agewall, S., Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease (2009) Heart Vessels, 24, pp. 90-95; Arbel, Y., Finkelstein, A., Halkin, A., Birati, E.Y., Revivo, M., Zuzut, M., Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography (2012) Atherosclerosis, 225, pp. 456-460; Wang, X., Zhang, G., Jiang, X., Zhu, H., Lu, Z., Xu, L., Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies (2014) Atherosclerosis, 234, pp. 206-213; Tonelli, M., Sacks, F., Arnold, M., Moye, L., Davis, B., Pfeffer, M., Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease (2008) Circulation, 117, pp. 163-168. , for the Cholesterol and Recurrent Events (CARE) Trial Investigators; Danesh, J., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease (2004) N.Engl. J. Med., 350, pp. 1387-1397; Tanindi, A., Erkan, A.F., Ekici, B., Alhan, A., Töre, H.F., Neutrophil to lymphocyte ratio is associated with more extensive, severe and complex coronary artery disease and impaired myocardial perfusion (2014) Turk. Kardiyol. Dern. Ars, 42, pp. 125-130; Akboga, M.K., Akyel, A., Sahinarslan, A., Yayla, C., Alsancak, Y., Gokalp, G., Neutrophil to lymphocyte ratio is increased in patients with rheumatic mitral valve stenosis? (2014) Anadolu. Kardiyol. Derg., , (Epub ahead of print); Isik, T., Kurt, M., Ayhan, E., Tanboga, I.H., Ergelen, M., Uyarel, H., The impact of admission red cell distribution width on the development of poor myocardial perfusion after primary percutaneous intervention (2012) Atherosclerosis, 224, pp. 143-149; Tapan, S., Dogru, T., Tasci, I., Ercin, C.N., Ozgurtas, T., Erbil, M.K., Soluble CD40 ligand and soluble P-selectin levels in Gilbert's syndrome: a link to protection against atherosclerosis? (2009) Clin. Biochem., 42, pp. 791-795; Yoshino, S., Hamasaki, S., Ishida, S., Kataoka, T., Yoshikawa, A., Oketani, N., Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients (2011) J.Atheroscler. Thromb., 18, pp. 403-412",Article,Scopus,2-s2.0-84924599499
"Fraineau S., Palii C.G., Allan D.S., Brand M.","Epigenetic regulation of endothelial-cell-mediated vascular repair",2015,"FEBS Journal","282","9",,"1605","1629",,1,10.1111/febs.13183,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928490734&partnerID=40&md5=a8e92a1d779b04a9bba4cb09f7217824","Sprott Center for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research InstituteOttawa, ON, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Canada; Ottawa Institute of Systems Biology, Canada","Fraineau, S., Sprott Center for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research InstituteOttawa, ON, Canada, Department of Cellular and Molecular Medicine, University of Ottawa, Canada, Ottawa Institute of Systems Biology, Canada; Palii, C.G., Sprott Center for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research InstituteOttawa, ON, Canada, Ottawa Institute of Systems Biology, Canada; Allan, D.S., Sprott Center for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research InstituteOttawa, ON, Canada; Brand, M., Sprott Center for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research InstituteOttawa, ON, Canada, Department of Cellular and Molecular Medicine, University of Ottawa, Canada, Ottawa Institute of Systems Biology, Canada","Maintenance of vascular integrity is essential for the prevention of vascular disease and for recovery following cardiovascular, cerebrovascular and peripheral vascular events including limb ischemia, heart attack and stroke. Endothelial stem/progenitor cells have recently gained considerable interest due to their potential use in stem cell therapies to mediate revascularization after ischemic injury. Therefore, there is an urgent need to understand fundamental mechanisms regulating vascular repair in specific cell types to develop new beneficial therapeutic interventions. In this review, we highlight recent studies demonstrating that epigenetic mechanisms (including post-translational modifications of DNA and histones as well as non-coding RNA-mediated processes) play essential roles in the regulation of endothelial stem/progenitor cell functions through modifying chromatin structure. Furthermore, we discuss the potential of using small molecules that modulate the activities of epigenetic enzymes to enhance the vascular repair function of endothelial cells and offer insight on potential strategies that may accelerate clinical applications. Endothelial stem/progenitor cells have gained considerable interest due to their potential use in stem cell therapies to mediate revascularization after ischemic injury. We highlight studies demonstrating that epigenetic mechanisms are essential for endothelial cell functions. Furthermore, we discuss the use of epigenetic drugs to enhance the vascular repair function of endothelial cells and propose potential strategies to accelerate clinical applications. © 2014 FEBS.","DNA methylation; endothelial progenitors; epigenetic drugs; epigenetics; histone acetylation; histone methylation; non-coding RNAs; stem cell therapy; transcription factors; vascular ischemic disease","Rama, P., Matuska, S., Paganoni, G., Spinelli, A., De Luca, M., Pellegrini, G., Limbal stem-cell therapy and long-term corneal regeneration (2010) N Engl J Med, 363, pp. 147-155; Tsubota, K., Satake, Y., Kaido, M., Shinozaki, N., Shimmura, S., Bissen-Miyajima, H., Shimazaki, J., Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation (1999) N Engl J Med, 340, pp. 1697-1703; Schwartz, S.D., Hubschman, J.P., Heilwell, G., Franco-Cardenas, V., Pan, C.K., Ostrick, R.M., Mickunas, E., Lanza, R., Embryonic stem cell trials for macular degeneration: a preliminary report (2012) Lancet, 379, pp. 713-720; Ohnishi, K., Semi, K., Yamamoto, T., Shimizu, M., Tanaka, A., Mitsunaga, K., Okita, K., Maeda, T., Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation (2014) Cell, 156, pp. 663-677; Fadini, G.P., Losordo, D., Dimmeler, S., Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use (2012) Circ Res, 110, pp. 624-637; Shantsila, E., Watson, T., Lip, G.Y., Endothelial progenitor cells in cardiovascular disorders (2007) J Am Coll Cardiol, 49, pp. 741-752; Callum, K., Bradbury, A., ABC of arterial and venous disease: acute limb ischaemia (2000) BMJ, 320, pp. 764-767; Creager, M.A., Kaufman, J.A., Conte, M.S., Clinical practice. Acute limb ischemia (2012) N Engl J Med, 366, pp. 2198-2206; Leeper, N.J., Hunter, A.L., Cooke, J.P., Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells (2010) Circulation, 122, pp. 517-526; Asahara, T., Murohara, T., Sullivan, A., Silver, M., Van Der Zee, R., Li, T., Witzenbichler, B., Isner, J.M., Isolation of putative progenitor endothelial cells for angiogenesis (1997) Science, 275, pp. 964-967; Ingram, D.A., Mead, L.E., Tanaka, H., Meade, V., Fenoglio, A., Mortell, K., Pollok, K., Yoder, M.C., Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood (2004) Blood, 104, pp. 2752-2760; Lin, Y., Weisdorf, D.J., Solovey, A., Hebbel, R.P., Origins of circulating endothelial cells and endothelial outgrowth from blood (2000) J Clin Invest, 105, pp. 71-77; Medina, R.J., O'Neill, C.L., Sweeney, M., Guduric-Fuchs, J., Gardiner, T.A., Simpson, D.A., Stitt, A.W., Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities (2010) BMC Med Genomics, 3, p. 18; Critser, P.J., Yoder, M.C., Endothelial colony-forming cell role in neoangiogenesis and tissue repair (2010) Curr Opin Organ Transplant, 15, pp. 68-72; Lee, S.H., Lee, J.H., Asahara, T., Kim, Y.S., Jeong, H.C., Ahn, Y., Jung, J.S., Kwon, S.M., Genistein promotes endothelial colony-forming cell (ECFC) bioactivities and cardiac regeneration in myocardial infarction (2014) PLoS One, 9; Bouvard, C., Gafsou, B., Dizier, B., Galy-Fauroux, I., Lokajczyk, A., Boisson-Vidal, C., Fischer, A.M., Helley, D., alpha6-integrin subunit plays a major role in the proangiogenic properties of endothelial progenitor cells (2010) Arterioscler Thromb Vasc Biol, 30, pp. 1569-1575; Saif, J., Schwarz, T.M., Chau, D.Y., Henstock, J., Sami, P., Leicht, S.F., Hermann, P.C., Shakesheff, K.M., Combination of injectable multiple growth factor-releasing scaffolds and cell therapy as an advanced modality to enhance tissue neovascularization (2010) Arterioscler Thromb Vasc Biol, 30, pp. 1897-1904; Schwarz, T.M., Leicht, S.F., Radic, T., Rodriguez-Araboalaza, I., Hermann, P.C., Berger, F., Saif, J., Aicher, A., Vascular incorporation of endothelial colony-forming cells is essential for functional recovery of murine ischemic tissue following cell therapy (2012) Arterioscler Thromb Vasc Biol, 32, pp. e13-e21; Palii, C.G., Vulesevic, B., Fraineau, S., Pranckeviciene, E., Griffith, A.J., Chu, A., Faralli, H., Sun, J., Trichostatin A enhances vascular repair by injected human endothelial progenitors through increasing the expression of TAL1-dependent genes (2014) Cell Stem Cell, 14, pp. 644-657; Moubarik, C., Guillet, B., Youssef, B., Codaccioni, J.L., Piercecchi, M.D., Sabatier, F., Lionel, P., Velly, L., Transplanted late outgrowth endothelial progenitor cells as cell therapy product for stroke (2011) Stem Cell Rev, 7, pp. 208-220; Ward, M.R., Stewart, D.J., Kutryk, M.J., Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives (2007) Catheter Cardiovasc Interv, 70, pp. 983-998; Medina, R.J., O'Neill, C.L., Humphreys, M.W., Gardiner, T.A., Stitt, A.W., Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy (2010) Invest Ophthalmol Vis Sci, 51, pp. 5906-5913; Alphonse, R.S., Vadivel, A., Fung, M., Shelley, W.C., Critser, P.J., Ionescu, L., O'Reilly, M., Eaton, F., Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth (2014) Circulation, 129, pp. 2144-2157; Marcelo, K.L., Goldie, L.C., Hirschi, K.K., Regulation of endothelial cell differentiation and specification (2013) Circ Res, 112, pp. 1272-1287; Park, C., Kim, T.M., Malik, A.B., Transcriptional regulation of endothelial cell and vascular development (2013) Circ Res, 112, pp. 1380-1400; De Val, S., Black, B.L., Transcriptional control of endothelial cell development (2009) Dev Cell, 16, pp. 180-195; Kubo, H., Alitalo, K., The bloody fate of endothelial stem cells (2003) Genes Dev, 17, pp. 322-329; De Val, S., Key transcriptional regulators of early vascular development (2011) Arterioscler Thromb Vasc Biol, 31, pp. 1469-1475; Kume, T., Specification of arterial, venous, and lymphatic endothelial cells during embryonic development (2010) Histol Histopathol, 25, pp. 637-646; Rössig, L., Urbich, C., Brühl, T., Dernbach, E., Heeschen, C., Chavakis, E., Sasaki, K., Seeger, F., Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells (2005) J Exp Med, 201, pp. 1825-1835; Song, Y., Li, X., Wang, D., Fu, C., Zhu, Z., Zou, M.H., Zhu, Y., Transcription factor Krüppel-like factor 2 plays a vital role in endothelial colony forming cells differentiation (2013) Cardiovasc Res, 99, pp. 514-524; Li, B., Carey, M., Workman, J.L., The role of chromatin during transcription (2007) Cell, 128, pp. 707-719; Klose, R.J., Zhang, Y., Regulation of histone methylation by demethylimination and demethylation (2007) Nat Rev Mol Cell Biol, 8, pp. 307-318; Kouzarides, T., Chromatin modifications and their function (2007) Cell, 128, pp. 693-705; Cedar, H., Bergman, Y., Linking DNA methylation and histone modification: patterns and paradigms (2009) Nat Rev Genet, 10, pp. 295-304; Rando, O.J., Chang, H.Y., Genome-wide views of chromatin structure (2009) Annu Rev Biochem, 78, pp. 245-271; Fish, J.E., Matouk, C.C., Rachlis, A., Lin, S., Tai, S.C., D'Abreo, C., Marsden, P.A., The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code (2005) J Biol Chem, 280, pp. 24824-24838; Fish, J.E., Marsden, P.A., Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium (2006) Cell Mol Life Sci, 63, pp. 144-162; Fish, J.E., Yan, M.S., Matouk, C.C., St Bernard, R., Ho, J.J., Gavryushova, A., Srivastava, D., Marsden, P.A., Hypoxic repression of endothelial nitric-oxide synthase transcription is coupled with eviction of promoter histones (2010) J Biol Chem, 285, pp. 810-826; Chan, Y., Fish, J.E., D'Abreo, C., Lin, S., Robb, G.B., Teichert, A.M., Karantzoulis-Fegaras, F., Marsden, P.A., The cell-specific expression of endothelial nitric-oxide synthase: a role for DNA methylation (2004) J Biol Chem, 279, pp. 35087-35100; Goretti, E., Wagner, D.R., Devaux, Y., Regulation of endothelial progenitor cell function by micrornas (2013) Minerva Cardioangiol, 61, pp. 591-604; Eken, S.M., Jin, H., Chernogubova, E., Maegdefessel, L., Making sense in antisense: therapeutic potential of noncoding RNAs in diabetes-induced vascular dysfunction (2013) J Diabetes Res, 2013, p. 834727; Division of Cardiology, Role of microRNAs in endothelial progenitor cells: implication for cardiac repair (2014) J Stem Cells, 9, pp. 107-115. , Luxembourg, L.xembourg, C. H., Luxembourg, L.xembourg, Luxembourg, L. o. C. R. P. R. C.-H. L. & Luxembourg, D. o. C. C. H. L; Meng, S., Cao, J.T., Zhang, B., Zhou, Q., Shen, C.X., Wang, C.Q., Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1 (2012) J Mol Cell Cardiol, 53, pp. 64-72; Zhang, J., Zhang, Z., Zhang, D.Y., Zhu, J., Zhang, T., Wang, C., microRNA 126 inhibits the transition of endothelial progenitor cells to mesenchymal cells via the PIK3R2-PI3K/Akt signalling pathway (2013) PLoS One, 8; Meng, S., Cao, J., Zhang, X., Fan, Y., Fang, L., Wang, C., Lv, Z., Li, Y., Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3 (2013) PLoS One, 8; Xu, Q., Meng, S., Liu, B., Li, M.Q., Li, Y., Fang, L., Li, Y.G., MicroRNA-130a regulates autophagy of endothelial progenitor cells through Runx3 (2014) Clin Exp Pharmacol Physiol, 41, pp. 351-357; Zhu, S., Deng, S., Ma, Q., Zhang, T., Jia, C., Zhuo, D., Yang, F., Dykxhoorn, D.M., MicroRNA-10A∗ and MicroRNA-21 modulate endothelial progenitor cell senescence via suppressing high-mobility group A2 (2013) Circ Res, 112, pp. 152-164; Chang, T.Y., Huang, T.S., Wang, H.W., Chang, S.J., Lo, H.H., Chiu, Y.L., Wang, Y.L., Chan, C.H., miRNome traits analysis on endothelial lineage cells discloses biomarker potential circulating microRNAs which affect progenitor activities (2014) BMC Genom, 15, p. 802; Kaikkonen, M.U., Lam, M.T., Glass, C.K., Non-coding RNAs as regulators of gene expression and epigenetics (2011) Cardiovasc Res, 90, pp. 430-440; Robb, G.B., Carson, A.R., Tai, S.C., Fish, J.E., Singh, S., Yamada, T., Scherer, S.W., Marsden, P.A., Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript (2004) J Biol Chem, 279, pp. 37982-37996; Fish, J.E., Matouk, C.C., Yeboah, E., Bevan, S.C., Khan, M., Patil, K., Ohh, M., Marsden, P.A., Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase (2007) J Biol Chem, 282, pp. 15652-15666; Li, K., Blum, Y., Verma, A., Liu, Z., Pramanik, K., Leigh, N.R., Chun, C.Z., Garnaas, M.K., A noncoding antisense RNA in tie-1 locus regulates tie-1 function in vivo (2010) Blood, 115, pp. 133-139; Yan, M.S., Matouk, C.C., Marsden, P.A., Epigenetics of the vascular endothelium (2010) J Appl Physiol (1985), 109, pp. 916-926; Kohli, R.M., Zhang, Y., TET enzymes, TDG and the dynamics of DNA demethylation (2013) Nature, 502, pp. 472-479; Banerjee, S., Bacanamwo, M., DNA methyltransferase inhibition induces mouse embryonic stem cell differentiation into endothelial cells (2010) Exp Cell Res, 316, pp. 172-180; Shirodkar, A.V., St Bernard, R., Gavryushova, A., Kop, A., Knight, B.J., Yan, M.S., Man, H.S., Oettgen, P., A mechanistic role for DNA methylation in endothelial cell (EC)-enriched gene expression: relationship with DNA replication timing (2013) Blood, 121, pp. 3531-3540; Lagarkova, M.A., Volchkov, P.Y., Philonenko, E.S., Kiselev, S.L., Efficient differentiation of hESCs into endothelial cells in vitro is secured by epigenetic changes (2008) Cell Cycle, 7, pp. 2929-2935; Lagarkova, M.A., Shutova, M.V., Bogomazova, A.N., Vassina, E.M., Glazov, E.A., Zhang, P., Rizvanov, A.A., Kiselev, S.L., Induction of pluripotency in human endothelial cells resets epigenetic profile on genome scale (2010) Cell Cycle, 9, pp. 937-946; Ohtani, K., Vlachojannis, G.J., Koyanagi, M., Boeckel, J.N., Urbich, C., Farcas, R., Bonig, H., Dimmeler, S., Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells (2011) Circ Res, 109, pp. 1219-1229; Marks, P.A., Xu, W.S., Histone deacetylase inhibitors: potential in cancer therapy (2009) J Cell Biochem, 107, pp. 600-608; Marks, P.A., Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions (2010) Biochim Biophys Acta, 1799, pp. 717-725; Roth, S.Y., Denu, J.M., Allis, C.D., Histone acetyltransferases (2001) Annu Rev Biochem, 70, pp. 81-120; Smith, B.C., Denu, J.M., Chemical mechanisms of histone lysine and arginine modifications (2009) Biochim Biophys Acta, 1789, pp. 45-57; Kuo, M.H., Allis, C.D., Roles of histone acetyltransferases and deacetylases in gene regulation (1998) BioEssays, 20, pp. 615-626; Gray, S.G., Ekström, T.J., The human histone deacetylase family (2001) Exp Cell Res, 262, pp. 75-83; Guarani, V., Deflorian, G., Franco, C.A., Krüger, M., Phng, L.K., Bentley, K., Toussaint, L., Schmidt, M.H., Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase (2011) Nature, 473, pp. 234-238; Potente, M., Dimmeler, S., Emerging roles of SIRT1 in vascular endothelial homeostasis (2008) Cell Cycle, 7, pp. 2117-2122; De Ruijter, A.J., Van Gennip, A.H., Caron, H.N., Kemp, S., Van Kuilenburg, A.B., Histone deacetylases (HDACs): characterization of the classical HDAC family (2003) Biochem J, 370, pp. 737-749; Bolden, J.E., Peart, M.J., Johnstone, R.W., Anticancer activities of histone deacetylase inhibitors (2006) Nat Rev Drug Discov, 5, pp. 769-784; Lf, C., Fischle, W., Verdin, E., Greene, W.C., Duration of nuclear NF-kappaB action regulated by reversible acetylation (2001) Science, 293, pp. 1653-1657; Crosson, C.E., Mani, S.K., Husain, S., Alsarraf, O., Menick, D.R., Inhibition of histone deacetylase protects the retina from ischemic injury (2010) Invest Ophthalmol Vis Sci, 51, pp. 3639-3645; Zhang, Z., Qin, X., Tong, N., Zhao, X., Gong, Y., Shi, Y., Wu, X., Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation (2012) Exp Eye Res, 94, pp. 98-108; Granger, A., Abdullah, I., Huebner, F., Stout, A., Wang, T., Huebner, T., Epstein, J.A., Gruber, P.J., Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice (2008) FASEB J, 22, pp. 3549-3560; Illi, B., Scopece, A., Nanni, S., Farsetti, A., Morgante, L., Biglioli, P., Capogrossi, M.C., Gaetano, C., Epigenetic histone modification and cardiovascular lineage programming in mouse embryonic stem cells exposed to laminar shear stress (2005) Circ Res, 96, pp. 501-508; Chen, W., Bacanamwo, M., Harrison, D.G., Activation of p300 histone acetyltransferase activity is an early endothelial response to laminar shear stress and is essential for stimulation of endothelial nitric-oxide synthase mRNA transcription (2008) J Biol Chem, 283, pp. 16293-16298; Kaur, H., Chen, S., Xin, X., Chiu, J., Khan, Z.A., Chakrabarti, S., Diabetes-induced extracellular matrix protein expression is mediated by transcription coactivator p300 (2006) Diabetes, 55, pp. 3104-3111; Wei, J.Q., Shehadeh, L.A., Mitrani, J.M., Pessanha, M., Slepak, T.I., Webster, K.A., Bishopric, N.H., Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300 (2008) Circulation, 118, pp. 934-946; Shehadeh, L.A., Sharma, S., Pessanha, M., Wei, J.Q., Liu, J., Yuan, H., Rodrigues, C.O., Bishopric, N.H., MicroRNA-20a constrains p300-driven myocardial angiogenic transcription by direct targeting of p300 (2013) PLoS One, 8; Arany, Z., Huang, L.E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M.A., Bunn, H.F., Livingston, D.M., An essential role for p300/CBP in the cellular response to hypoxia (1996) Proc Natl Acad Sci USA, 93, pp. 12969-12973; Chiu, J.J., Chien, S., Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives (2011) Physiol Rev, 91, pp. 327-387; Hahn, C., Schwartz, M.A., Mechanotransduction in vascular physiology and atherogenesis (2009) Nat Rev Mol Cell Biol, 10, pp. 53-62; Chiu, J.J., Usami, S., Chien, S., Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis (2009) Ann Med, 41, pp. 19-28; Traub, O., Berk, B.C., Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force (1998) Arterioscler Thromb Vasc Biol, 18, pp. 677-685; Lee, D.Y., Lee, C.I., Lin, T.E., Lim, S.H., Zhou, J., Tseng, Y.C., Chien, S., Chiu, J.J., Role of histone deacetylases in transcription factor regulation and cell cycle modulation in endothelial cells in response to disturbed flow (2012) Proc Natl Acad Sci USA, 109, pp. 1967-1972; Gan, Y., Shen, Y.H., Wang, J., Wang, X., Utama, B., Wang, X.L., Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase (2005) J Biol Chem, 280, pp. 16467-16475; Hyndman, K.A., Ho, D.H., Sega, M.F., Pollock, J.S., Histone deacetylase 1 reduces NO production in endothelial cells via lysine deacetylation of NO synthase 3 (2014) Am J Physiol Heart Circ Physiol, 307, p. 5; Nishida, K., Harrison, D.G., Navas, J.P., Fisher, A.A., Dockery, S.P., Uematsu, M., Nerem, R.M., Murphy, T.J., Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase (1992) J Clin Invest, 90, pp. 2092-2096; Fleming, I., Busse, R., Signal transduction of eNOS activation (1999) Cardiovasc Res, 43, pp. 532-541; Zeng, L., Zhang, Y., Chien, S., Liu, X., Shyy, J.Y., The role of p53 deacetylation in p21Waf1 regulation by laminar flow (2003) J Biol Chem, 278, pp. 24594-24599; Pandey, D., Sikka, G., Bergman, Y., Kim, J.H., Ryoo, S., Romer, L., Berkowitz, D., Transcriptional regulation of endothelial arginase 2 by histone deacetylase 2 (2014) Arterioscler Thromb Vasc Biol, 34, pp. 1556-1566; Fan, J., Alsarraf, O., Dahrouj, M., Platt, K.A., Chou, C.J., Rice, D.S., Crosson, C.E., Inhibition of HDAC2 protects the retina from ischemic injury (2013) Invest Ophthalmol Vis Sci, 54, pp. 4072-4080; Xiao, Q., Zeng, L., Zhang, Z., Margariti, A., Ali, Z.A., Channon, K.M., Xu, Q., Hu, Y., Sca-1+ progenitors derived from embryonic stem cells differentiate into endothelial cells capable of vascular repair after arterial injury (2006) Arterioscler Thromb Vasc Biol, 26, pp. 2244-2251; Zeng, L., Xiao, Q., Margariti, A., Zhang, Z., Zampetaki, A., Patel, S., Capogrossi, M.C., Xu, Q., HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells (2006) J Cell Biol, 174, pp. 1059-1069; Zampetaki, A., Zeng, L., Margariti, A., Xiao, Q., Li, H., Zhang, Z., Pepe, A.E., DeFalco, E., Histone deacetylase 3 is critical in endothelial survival and atherosclerosis development in response to disturbed flow (2010) Circulation, 121, pp. 132-142; Zeng, L., Wang, G., Ummarino, D., Margariti, A., Xu, Q., Xiao, Q., Wang, W., Mayr, M., Histone deacetylase 3 unconventional splicing mediates endothelial-to-mesenchymal transition through transforming growth factor β2 (2013) J Biol Chem, 288, pp. 31853-31866; Chang, S., McKinsey, T.A., Zhang, C.L., Richardson, J.A., Hill, J.A., Olson, E.N., Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development (2004) Mol Cell Biol, 24, pp. 8467-8476; Chang, S., Young, B.D., Li, S., Qi, X., Richardson, J.A., Olson, E.N., Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10 (2006) Cell, 126, pp. 321-334; Wang, S., Li, X., Parra, M., Verdin, E., Bassel-Duby, R., Olson, E.N., Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7 (2008) Proc Natl Acad Sci USA, 105, pp. 7738-7743; Sun, X., Wei, L., Chen, Q., Terek, R.M., HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity (2009) J Biol Chem, 284, pp. 21881-21890; Urbich, C., Rössig, L., Kaluza, D., Potente, M., Boeckel, J.N., Knau, A., Diehl, F., Zeiher, A.M., HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells (2009) Blood, 113, pp. 5669-5679; Ha, C.H., Wang, W., Jhun, B.S., Wong, C., Hausser, A., Pfizenmaier, K., McKinsey, T.A., Jin, Z.G., Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis (2008) J Biol Chem, 283, pp. 14590-14599; Kwon, I.S., Wang, W., Xu, S., Jin, Z.G., Histone deacetylase 5 interacts with Krüppel-like factor 2 and inhibits its transcriptional activity in endothelium (2014) Cardiovasc Res, 104, pp. 127-137; Illi, B., Dello Russo, C., Colussi, C., Rosati, J., Pallaoro, M., Spallotta, F., Rotili, D., Martelli, F., Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling (2008) Circ Res, 102, pp. 51-58; Mottet, D., Bellahcène, A., Pirotte, S., Waltregny, D., Deroanne, C., Lamour, V., Lidereau, R., Castronovo, V., Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis (2007) Circ Res, 101, pp. 1237-1246; Turtoi, A., Mottet, D., Matheus, N., Dumont, B., Peixoto, P., Hennequière, V., Deroanne, C., Bellahcène, A., The angiogenesis suppressor gene AKAP12 is under the epigenetic control of HDAC7 in endothelial cells (2012) Angiogenesis, 15, pp. 543-554; Margariti, A., Zampetaki, A., Xiao, Q., Zhou, B., Karamariti, E., Martin, D., Yin, X., Zhang, Z., Histone deacetylase 7 controls endothelial cell growth through modulation of beta-catenin (2010) Circ Res, 106, pp. 1202-1211; Margariti, A., Xiao, Q., Zampetaki, A., Zhang, Z., Li, H., Martin, D., Hu, Y., Xu, Q., Splicing of HDAC7 modulates the SRF-myocardin complex during stem-cell differentiation towards smooth muscle cells (2009) J Cell Sci, 122, pp. 460-470; Ha, C.H., Jhun, B.S., Kao, H.Y., Jin, Z.G., VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis (2008) Arterioscler Thromb Vasc Biol, 28, pp. 1782-1788; Yu, D., Chen, W., Ren, J., Zhang, T., Yang, K., Wu, G., Liu, H., VEGF-PKD1-HDAC7 signaling promotes endothelial progenitor cell migration and tube formation (2014) Microvasc Res, 91, pp. 66-72; Kaluza, D., Kroll, J., Gesierich, S., Manavski, Y., Boeckel, J.N., Doebele, C., Zelent, A., Augustin, H.G., Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells (2013) Arterioscler Thromb Vasc Biol, 33, pp. 533-543; Kaluza, D., Kroll, J., Gesierich, S., Yao, T.P., Boon, R.A., Hergenreider, E., Tjwa, M., Augustin, H.G., Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin (2011) EMBO J, 30, pp. 4142-4156; Potente, M., Ghaeni, L., Baldessari, D., Mostoslavsky, R., Rossig, L., Dequiedt, F., Haendeler, J., Alt, F.W., SIRT1 controls endothelial angiogenic functions during vascular growth (2007) Genes Dev, 21, pp. 2644-2658; Mattagajasingh, I., Kim, C.S., Naqvi, A., Yamamori, T., Hoffman, T.A., Jung, S.B., DeRicco, J., Irani, K., SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase (2007) Proc Natl Acad Sci USA, 104, pp. 14855-14860; Hou, J., Chong, Z.Z., Shang, Y.C., Maiese, K., Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation (2010) Curr Neurovasc Res, 7, pp. 95-112; Zu, Y., Liu, L., Lee, M.Y., Xu, C., Liang, Y., Man, R.Y., Vanhoutte, P.M., Wang, Y., SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells (2010) Circ Res, 106, pp. 1384-1393; Vassallo, P.F., Simoncini, S., Ligi, I., Chateau, A.L., Bachelier, R., Robert, S., Morere, J., Marcelli, M., Accelerated senescence of cord blood endothelial progenitor cells in premature neonates is driven by SIRT1 decreased expression (2014) Blood, 123, pp. 2116-2126; Cloos, P.A., Christensen, J., Agger, K., Helin, K., Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease (2008) Genes Dev, 22, pp. 1115-1140; Zhou, V.W., Goren, A., Bernstein, B.E., Charting histone modifications and the functional organization of mammalian genomes (2011) Nat Rev Genet, 12, pp. 7-18; Calo, E., Wysocka, J., Modification of enhancer chromatin: what, how, and why? (2013) Mol Cell, 49, pp. 825-837; Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B., Plath, K., A bivalent chromatin structure marks key developmental genes in embryonic stem cells (2006) Cell, 125, pp. 315-326; Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S.A., Flynn, R.A., Wysocka, J., A unique chromatin signature uncovers early developmental enhancers in humans (2011) Nature, 470, pp. 279-283; Gifford, C.A., Ziller, M.J., Gu, H., Trapnell, C., Donaghey, J., Tsankov, A., Shalek, A.K., Issner, R., Transcriptional and epigenetic dynamics during specification of human embryonic stem cells (2013) Cell, 153, pp. 1149-1163; Voigt, P., Tee, W.W., Reinberg, D., A double take on bivalent promoters (2013) Genes Dev, 27, pp. 1318-1338; Varier, R.A., Timmers, H.T., Histone lysine methylation and demethylation pathways in cancer (2011) Biochim Biophys Acta, 1815, pp. 75-89; Eissenberg, J.C., Shilatifard, A., Histone H3 lysine 4 (H3K4) methylation in development and differentiation (2010) Dev Biol, 339, pp. 240-249; Ernst, P., Vakoc, C.R., WRAD: enabler of the SET1-family of H3K4 methyltransferases (2012) Brief Funct Genomics, 11, pp. 217-226; Ernst, P., Mabon, M., Davidson, A.J., Zon, L.I., Korsmeyer, S.J., An Mll-dependent Hox program drives hematopoietic progenitor expansion (2004) Curr Biol, 14, pp. 2063-2069; Ernst, P., Fisher, J.K., Avery, W., Wade, S., Foy, D., Korsmeyer, S.J., Definitive hematopoiesis requires the mixed-lineage leukemia gene (2004) Dev Cell, 6, pp. 437-443; Hess, J.L., Yu, B.D., Li, B., Hanson, R., Korsmeyer, S.J., Defects in yolk sac hematopoiesis in Mll-null embryos (1997) Blood, 90, pp. 1799-1806; Diehl, F., Rössig, L., Zeiher, A.M., Dimmeler, S., Urbich, C., The histone methyltransferase MLL is an upstream regulator of endothelial-cell sprout formation (2007) Blood, 109, pp. 1472-1478; Li, Q., Shi, L., Gui, B., Yu, W., Wang, J., Zhang, D., Han, X., Shang, Y., Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14 (2011) Cancer Res, 71, pp. 6899-6908; Pojoga, L.H., Williams, J.S., Yao, T.M., Kumar, A., Raffetto, J.D., Do Nascimento, G.R., Reslan, O.M., Shi, Y., Histone demethylase LSD1 deficiency during high-salt diet is associated with enhanced vascular contraction, altered NO-cGMP relaxation pathway, and hypertension (2011) Am J Physiol Heart Circ Physiol, 301, pp. H1862-H1871; Wang, G.G., Allis, C.D., Chi, P., Chromatin remodeling and cancer. Part I: Covalent histone modifications (2007) Trends Mol Med, 13, pp. 363-372; Black, J.C., Van Rechem, C., Whetstine, J.R., Histone lysine methylation dynamics: establishment, regulation, and biological impact (2012) Mol Cell, 48, pp. 491-507; Snowden, A.W., Gregory, P.D., Case, C.C., Pabo, C.O., Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo (2002) Curr Biol, 12, pp. 2159-2166; Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., Ghosh, D., Otte, A.P., The polycomb group protein EZH2 is involved in progression of prostate cancer (2002) Nature, 419, pp. 624-629; Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Hayes, D.F., EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells (2003) Proc Natl Acad Sci USA, 100, pp. 11606-11611; Tonini, T., D'Andrilli, G., Fucito, A., Gaspa, L., Bagella, L., Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements (2008) J Cell Physiol, 214, pp. 295-300; Richter, G.H., Plehm, S., Fasan, A., Rössler, S., Unland, R., Bennani-Baiti, I.M., Hotfilder, M., Mossbrugger, I., EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation (2009) Proc Natl Acad Sci USA, 106, pp. 5324-5329; Lu, C., Han, H.D., Mangala, L.S., Ali-Fehmi, R., Newton, C.S., Ozbun, L., Armaiz-Pena, G.N., Munkarah, A., Regulation of tumor angiogenesis by EZH2 (2010) Cancer Cell, 18, pp. 185-197; Smits, M., Mir, S.E., Nilsson, R.J., Van Der Stoop, P.M., Niers, J.M., Marquez, V.E., Cloos, J., Noske, D.P., Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2 (2011) PLoS One, 6; Dreger, H., Ludwig, A., Weller, A., Stangl, V., Baumann, G., Meiners, S., Stangl, K., Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells (2012) Hypertension, 60, pp. 1176-1183; Mitic, T., Caporali, A., Floris, I., Meloni, M., Marchetti, M., Urrutia, R., Angelini, G.D., Emanueli, C., EZH2 modulates angiogenesis in vitro and in a mouse model of limb ischemia (2015) Mol Ther, 23, pp. 32-42; Dalgliesh, G.L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Latimer, C., Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes (2010) Nature, 463, pp. 360-363; Agger, K., Cloos, P.A., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., Helin, K., UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development (2007) Nature, 449, pp. 731-734; Zhang, Q.H., Ye, M., Wu, X.Y., Ren, S.X., Zhao, M., Zhao, C.J., Fu, G., Lu, G., Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells (2000) Genome Res, 10, pp. 1546-1560; Hu, M., Sun, X.J., Zhang, Y.L., Kuang, Y., Hu, C.Q., Wu, W.L., Shen, S.H., He, F., Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling (2010) Proc Natl Acad Sci USA, 107, pp. 2956-2961; Khan, C., Pathe, N., Fazal, S., Lister, J., Rossetti, J.M., Azacitidine in the management of patients with myelodysplastic syndromes (2012) Ther Adv Hematol, 3, pp. 355-373; Derissen, E.J., Beijnen, J.H., Schellens, J.H., Concise drug review: azacitidine and decitabine (2013) Oncologist, 18, pp. 619-624; Dhanak, D., Jackson, P., Development and classes of epigenetic drugs for cancer (2014) Biochem Biophys Res Commun, 455, pp. 58-69; Rafehi, H., Balcerczyk, A., Lunke, S., Kaspi, A., Ziemann, M., Kn, H., Okabe, J., Khan, A.W., Vascular histone deacetylation by pharmacological HDAC inhibition (2014) Genome Res, 24, pp. 1271-1284; Iordache, F., Buzila, C., Constantinescu, A., Andrei, E., Maniu, H., Histone deacetylase (HDAC) inhibitors down-regulate endothelial lineage commitment of umbilical cord blood derived endothelial progenitor cells (2012) Int J Mol Sci, 13, pp. 15074-15085; Rössig, L., Li, H., Fisslthaler, B., Urbich, C., Fleming, I., Förstermann, U., Zeiher, A.M., Dimmeler, S., Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis (2002) Circ Res, 91, pp. 837-844; Gan, Y., Shen, Y.H., Utama, B., Wang, J., Coselli, J., Wang, X.L., Dual effects of histone deacetylase inhibition by trichostatin A on endothelial nitric oxide synthase expression in endothelial cells (2006) Biochem Biophys Res Commun, 340, pp. 29-34; Thaler, F., Minucci, S., Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? (2011) Expert Opin Drug Discov, 6, pp. 393-404; Ria, R., Catacchio, I., Berardi, S., De Luisi, A., Caivano, A., Piccoli, C., Ruggieri, V., Nico, B., HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target (2014) Clin Cancer Res, 20, pp. 847-858; Michaelis, M., Michaelis, U.R., Fleming, I., Suhan, T., Cinatl, J., Blaheta, R.A., Hoffmann, K., Nau, H., Valproic acid inhibits angiogenesis in vitro and in vivo (2004) Mol Pharmacol, 65, pp. 520-527; Michaelis, M., Suhan, T., Michaelis, U.R., Beek, K., Rothweiler, F., Tausch, L., Werz, O., Nau, H., Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells (2006) Cell Death Differ, 13, pp. 446-453; Dokmanovic, M., Clarke, C., Marks, P.A., Histone deacetylase inhibitors: overview and perspectives (2007) Mol Cancer Res, 5, pp. 981-989; Lee, M.G., Wynder, C., Schmidt, D.M., McCafferty, D.G., Shiekhattar, R., Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications (2006) Chem Biol, 13, pp. 563-567; Konovalov, S., Garcia-Bassets, I., Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines (2013) J Ovarian Res, 6, p. 75; Schenk, T., Chen, W.C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.U., Mills, K., Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia (2012) Nat Med, 18, pp. 605-611; Shi, L., Cui, S., Engel, J.D., Tanabe, O., Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction (2013) Nat Med, 19, pp. 291-294; Glazer, R.I., Hartman, K.D., Knode, M.C., Richard, M.M., Chiang, P.K., Tseng, C.K., Marquez, V.E., 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60 (1986) Biochem Biophys Res Commun, 135, pp. 688-694; Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P.L., Karuturi, R.K., Yu, Q., Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells (2007) Genes Dev, 21, pp. 1050-1063; Miranda, T.B., Cortez, C.C., Yoo, C.B., Liang, G., Abe, M., Kelly, T.K., Marquez, V.E., Jones, P.A., DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation (2009) Mol Cancer Ther, 8, pp. 1579-1588; McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., Liu, Y., Diaz, E., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations (2012) Nature, 492, pp. 108-112; Verma, S.K., Tian, X., LaFrance, L.V., Duquenne, C., Suarez, D.P., Newlander, K.A., Romeril, S.P., Brackley, J.A., Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 (2012) ACS Med Chem Lett, 3, pp. 1091-1096; Knutson, S.K., Wigle, T.J., Warholic, N.M., Sneeringer, C.J., Allain, C.J., Klaus, C.R., Sacks, J.D., Song, J., A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells (2012) Nat Chem Biol, 8, pp. 890-896; Amatangelo, M.D., Garipov, A., Li, H., Conejo-Garcia, J.R., Speicher, D.W., Zhang, R., Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition (2013) Cell Cycle, 12, pp. 2113-2119; Béguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K.L., Rosen, M., Shen, H., Ezponda, T., EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation (2013) Cancer Cell, 23, pp. 677-692; Mozzetta, C., Pontis, J., Fritsch, L., Robin, P., Portoso, M., Proux, C., Margueron, R., Ait-Si-Ali, S., The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing (2014) Mol Cell, 53, pp. 277-289; Han, H., Yang, X., Pandiyan, K., Liang, G., Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells (2013) PLoS One, 8; Fiskus, W., Sharma, S., Shah, B., Portier, B.P., Devaraj, S.G., Liu, K., Iyer, S.P., Bhalla, K.N., Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells (2014) Leukemia, 28, pp. 2155-2164",Article,Scopus,2-s2.0-84928490734
"Wang J.-W., Gong X.-H., Ding N., Chen X.-F., Sun L., Tang Z., Yu D.-H., Yuan Z.-P., Wang X.-D., Yu J.-M.","The influence of comorbid chronic diseases and physical activity on quality of life in lung cancer survivors",2015,"Supportive Care in Cancer","23","5",,"1383","1389",,,10.1007/s00520-014-2494-7,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926161571&partnerID=40&md5=6fff1cc618de6e38df216668900bf017","School of Public Health, Fudan University, Dong-An RoadShanghai, China; Centre for Research and Action in Public Health, The University of CanberraCanberra, ACT, Australia; College of Clinical Medicine, Anhui Medical UniversityHefei, Anhui Province, China; Shanghai Cancer Rehabilitation Club, 2795 Yang-Gao-Nan RoadShanghai, China; Zhongshan Hospital, Fudan University, 180 Feng-Lin RoadShanghai, China","Wang, J.-W., School of Public Health, Fudan University, Dong-An RoadShanghai, China; Gong, X.-H., School of Public Health, Fudan University, Dong-An RoadShanghai, China; Ding, N., Centre for Research and Action in Public Health, The University of CanberraCanberra, ACT, Australia; Chen, X.-F., School of Public Health, Fudan University, Dong-An RoadShanghai, China; Sun, L., School of Public Health, Fudan University, Dong-An RoadShanghai, China; Tang, Z., School of Public Health, Fudan University, Dong-An RoadShanghai, China; Yu, D.-H., College of Clinical Medicine, Anhui Medical UniversityHefei, Anhui Province, China; Yuan, Z.-P., Shanghai Cancer Rehabilitation Club, 2795 Yang-Gao-Nan RoadShanghai, China; Wang, X.-D., Zhongshan Hospital, Fudan University, 180 Feng-Lin RoadShanghai, China; Yu, J.-M., School of Public Health, Fudan University, Dong-An RoadShanghai, China","Purpose: This study aimed to evaluate the influence of comorbid chronic diseases (CCD) and physical activity (PA) on quality of life (QOL) in lung cancer survivors (LCSs). Methods: The study used a cross-sectional study design. A total of 701 LCSs were recruited from 17 comprehensive cancer rehabilitation clubs in Shanghai, China. Measurements used included the European Organization for Research and Treatment quality of life version 3 questionnaire (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy -General version 4 questionnaire (FACT-G). Independent variables were CCD and PA. Multiple linear regression models were used to control for the effect of sociodemographic characteristic. Results: Subjects with CCD generally reported lower scores for most EORTC QLQ-C30 and FACT-G scales when compared to subjects without CCD, indicating poorer QOL. Subjects with PA generally reported higher scores for most EORTC QLQ-C30 and FACT-G scales when compared to subjects without PA, indicating better QOL. The influences of five times and more PA per week were larger than the influence of less than five times PA per week. Subjects without CCD and with PA generally reported similar scores for most EORTC QLQ-C30 and FACT-G scales when compared to others without CCD and PA. Subjects with CCD and PA generally reported higher scores for most EORTC QLQ-C30 and FACT-G scales when compared to other LCSs with CCD and without PA. Conclusions: CCD have significantly negative influence on QOL. PA has significantly positive influence on QOL among the LCSs with CCD, not among the other LCSs without CCD. © 2014, Springer-Verlag Berlin Heidelberg.","Chronic disease management; Comorbid chronic diseases; Lung cancer survivor; Physical activity; Quality of life","She, J., Yang, P., Hong, Q., Bai, C.X., Lung cancer in China: challenges and interventions (2013) Chest, 143, pp. 1117-1126. , PID: 23546484; (2011) Cancer survival in England: patients diagnosed 2005–2009 and followed up to 2010, , ONS, London:; Claassens, L., van Meerbeeck, J., Coens, C., Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials (2011) J Clin Oncol, 20, pp. 2101-2120; Balduyck, B., Hendriks, J., Lauwers, P., Van Schil, P., Quality of life after lung cancer surgery: a prospective pilot study comparing bronchial sleeve lobectomy with pneumonectomy (2008) J Thorac Oncol, 3, pp. 604-608. , PID: 18520798; Ediebah, D.E., Coens, C., Zikos, E., Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial (2014) Br J Cancer, 110, pp. 2427-2433. , COI: 1:STN:280:DC%2BC2cnkslyksA%3D%3D, PID: 24743709; Janssen-Heijnen, M.L., Schipper, R.M., Razenberg, P.P., Crommelin, M.A., Coebergh, J.W., Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study (1998) Lung Cancer, 21, pp. 105-113. , COI: 1:STN:280:DyaK1M%2FksFSjuw%3D%3D, PID: 9829544; Ogle, K.S., Swanson, G.M., Woods, N., Azzouz, F., Cancer and comorbidity: redefining chronic diseases (2000) Cancer, 88, pp. 653-663. , COI: 1:STN:280:DC%2BD3c7hsFeksA%3D%3D, PID: 10649261; Battafarano, R.J., Piccirillo, J.F., Meyers, B.F., Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer (2002) J Thorac Cardiovasc Surg, 123, pp. 280-287. , PID: 11828287; Tammemagi, C.M., Neslund-Dudas, C., Simoff, M., Kvale, P., Impact of comorbidity on lung cancer survival (2003) Int J Cancer, 103, pp. 792-802. , COI: 1:CAS:528:DC%2BD3sXntVarug%3D%3D, PID: 12516101; Knols, R., Aaronson, N.K., Uebelhart, D., Fransen, J., Aufdemkampe, G., Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials (2005) J Clin Oncol, 23, pp. 3830-3842. , PID: 15923576; Schmitz, K.H., Holtzman, J., Courneya, K.S., Masse, L.C., Duval, S., Kane, R., Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis (2005) Cancer Epidemiol Biomarkers Prev, 14, pp. 1588-1599. , PID: 16030088; Aaronson, N.K., Ahmedzai, S., Bergman, B., The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology (1993) J Nat Cancer Inst, 85, pp. 364-376; Cella, D.F., Tulsky, D.S., Gray, G., The functional assessment of cancer therapy scale: development and validation of the general measure (1993) J Clin Oncol, 11, pp. 570-579. , COI: 1:STN:280:DyaK3s7oslKqsQ%3D%3D, PID: 8445433; Kemmler, G., Holzner, B., Kopp, M., Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (1999) J Clin Oncol, 17, pp. 2932-2940. , COI: 1:STN:280:DC%2BD3c%2FjtVWjsA%3D%3D, PID: 10561373; Holzner, B., Bode, R.K., Hahn, E.A., Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research (2006) Eur J Cancer, 42, pp. 3169-3177. , COI: 1:STN:280:DC%2BD28jhvFyktg%3D%3D, PID: 17045472; Montazeri, A., Hole, D.J., Milroy, R., McEwen, J., Gillis, C.R., Quality of life in lung cancer patients: does socioeconomic status matter? (2003) Health Qual Life Outcomes, 1, p. 19. , PID: 12846929; Jordhøy, M.S., Fayers, P., Loge, J.H., Saltnes, T., Ahlner-Elmqvist, M., Kaasa, S., Quality of life in advanced cancer patients: the impact of sociodemographic and medical characteristics (2001) Br J Cancer, 85, pp. 1478-1485. , PID: 11720432; Seshasai, S.R., Kaptoge, S., Thompson, A., Diabetes mellitus, fasting glucose, and risk of cause-specific death (2011) N Engl J Med, 364, pp. 829-841. , COI: 1:CAS:528:DC%2BC3MXivFSjtrk%3D, PID: 21366474; Tammemagi, C.M., Neslund-Dudas, C., Simoff, M., Kvale, P., Impact of comorbidity on lung cancer survival (2003) Int J Cancer, 103, pp. 792-802. , COI: 1:CAS:528:DC%2BD3sXntVarug%3D%3D, PID: 12516101; Demark-Wahnefried, W., Aziz, N.M., Rowland, J.H., Pinto, B.M., Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer (2005) J Clin Oncol, 23, pp. 5814-5830. , PID: 16043830; Eakin, E.G., Youlden, D.R., Baade, P.D., Health behaviors of cancer survivors: data from an Australian population-based survey (2007) Cancer Causes Control, 18, pp. 881-894. , PID: 17638108; Broderick, J.M., Hussey, J., Kennedy, M.J., O'Donnell, D., Testing the ‘teachable moment’ premise: does physical activity increase in the early survivorship phase? (2014) Support Care Cancer, 22, pp. 989-997. , COI: 1:STN:280:DC%2BC2c3ht1amsw%3D%3D, PID: 24281728; Fisher, E.B., Brownson, C.A., O’Toole, M.L., Shetty, G., Anwuri, V.V., Glasgow, R.E., Ecological approaches to self-management: the case of diabetes (2005) Am J Public Health, 95, pp. 1523-1535. , PID: 16051929; McCorkle, R., Ercolano, E., Lazenby, M., Self-management: enabling and empowering patients living with cancer as a chronic illness (2011) CA Cancer J Clin, 61, pp. 50-62. , PID: 21205833",Article,Scopus,2-s2.0-84926161571
"Cheng T.C., Haisken-DeNew J.P., Yong J.","Cream skimming and hospital transfers in a mixed public-private system",2015,"Social Science and Medicine","132",,,"156","164",,,10.1016/j.socscimed.2015.03.035,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925361840&partnerID=40&md5=263d86958792f6a8fa9cbaadf9606a1d","School of Economics, University of Adelaide, Australia; Melbourne Institute of Applied Economic and Social Research, University of Melbourne, Australia","Cheng, T.C., School of Economics, University of Adelaide, Australia; Haisken-DeNew, J.P., Melbourne Institute of Applied Economic and Social Research, University of Melbourne, Australia; Yong, J., Melbourne Institute of Applied Economic and Social Research, University of Melbourne, Australia","The increasing prominence of the private sector in health care provision has generated considerable interest in understanding its implications on quality and cost. This paper investigates the phenomenon of cream skimming in a mixed public-private hospital setting using the novel approach of analysing hospital transfers. We analyse hospital administrative data of patients with ischemic heart disease from the state of Victoria, Australia. The data set contains approximately 1.77 million admission episodes in 309 hospitals, of which 132 are public hospitals, and 177 private hospitals. We ask if patients transferred between public and private hospitals differ systematically in the severity and complexity of their medical conditions; and if so, whether utilisation also differs. We find that patients with higher disease severity are more likely to be transferred from private to public hospitals whereas the opposite is true for patients transferred to private hospitals. We also find that patients transferred from private to public hospitals stayed longer and cost more than private-to-private transfer patients, after controlling for patients' observed health conditions and personal characteristics. Overall, the evidence is suggestive of the presence of cream skimming in the Victorian hospital system, although we cannot conclusively rule out other mechanisms that might influence hospital transfers. © 2015 Elsevier Ltd.","Australia; Cream skimming; Hospital transfers; Hospital utilisation; Mixed public-private system","(2014) Australian Hospital Statistics 2012-13, , Health services series no. 54. Cat no HSE 145, AIHW, Canberra; Barros, P.P., Olivella, P., Waiting lists and patient selection (2005) J.Econ. Manag. Strategy, 14, pp. 623-646; Barros, P.P., Siciliani, L., Public and private sector interface (2012) Handbook of Health Economics, 2. , Elsevier Science B.V, New York; Barbetta, G.P., Turati, G., Zago, A.M., Behavioral differences between public and private not-for-profit hospitals in the Italian national health service (2007) Health Econ., 16 (1), pp. 75-96; Berta, P., Callea, G., Martini, G., Vittadini, G., The effects of upcoding, cream skimming and readmissions on the Italian hospitals efficiency: a population-based investigation (2010) Econ. Model., 27 (4), pp. 812-821; Biglaiser, G., Ma, C.T., Moonlighting: public service and private practice (2007) RAND J. Econ., 38 (4), pp. 1113-1133; Blackwell, M., Iacus, S., King, G., Porro, G., Cem: coarsened exact matching in Stata (2009) Stata J., 9 (4), pp. 524-546; Brown, L., Barnett, J.R., Is the corporate transformation of hospitals creating a new hybrid health care space? A case study of the impact of co-location of public and private hospitals in Australia (2004) Soc. Sci. & Med., 58, pp. 427-444; Cheng, T.C., Joyce, C.M., Scott, A., An empirical analysis of public and private medical practice in Australia (2013) Health Policy, 111, pp. 43-51; Collyer, F., White, K., (2001) Corporate Control of Health Care in Australia, , The Australia Institute Discussion Paper No. 42; Duggan, M., Hospital ownership and public medical spending (2000) Q.J. Econ., 115 (4), pp. 1343-1373; Eggleston, K., Shen, Y.-C., Lau, J., Schmid, C.H., Chan, J., Hospital ownership and quality of care: what explains the different results in the literature? (2008) Health Econ., 17 (12), pp. 1345-1362; Ellis, R.P., Creaming, skimping and dumping: provider competition on intensive and extensive margins (1998) J.Health Econ., 17, pp. 537-555; Friesner, D.L., Rosenman, R., Do hospitals practice cream skimming? (2009) Health Serv. Manag. Res., 22 (1), pp. 39-49; González, P., On a policy of transferring public patients to private practice (2005) Health Econ., 14, pp. 513-527; Herr, A., Cost and technical efficiency of German hospitals: does ownership matter? (2008) Health Econ., 17 (9), pp. 1057-1071; Iacus, S., King, G., Porro, G., Multivariate matching methods that are monotonic imbalance bounding (2011) J.Am. Stat. Assoc., 106 (493), pp. 345-361; Iacus, S., King, G., Porro, G., Causal inference without balance checking: coarsened exact matching (2012) Polit. Anal., 20 (1), pp. 1-24; Levaggi, R., Montefiori, M., (2003) Horizontal and Vertical Cream Skimming in the Health Care Market, , DISEFIN Working Paper No. 11/2003, University of Genova; Marini, G., Miraldo, M., Jacobs, R., Goddard, M., Giving greater financial independence to hospitals-does it make a difference? The case of English NHS Trusts (2008) Health Econ., 17 (6), pp. 751-775; Siciliani, L., Sivey, P., Street, A., Differences in length of stay between public hospitals, specialised treatment centres and private providers: selection or efficiency (2013) Health Econ., 22 (2), pp. 234-242; Shen, Y.-C., Eggleston, K., Lau, J., Schmid, C.H., Hospital onwership and financial performance: what explains the different empirical literature findings? (2007) Inquiry, 44, pp. 41-68; Street, A., Sivey, P., Mason, A., Miraldo, M., Siciliani, L., Are English treatment centres treating less complex patients (2010) Health Policy, 94 (2), pp. 150-157; Sundararajan, V., Henderson, T., Perry, C., Muggivan, A., Quan, H., Ghali, W.A., New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality (2004) J.Clin. Epidemiol., 57, pp. 1288-1294",Article,Scopus,2-s2.0-84925361840
"Othman A., Saely C.H., Muendlein A., Vonbank A., Drexel H., von Eckardstein A., Hornemann T.","Plasma C20-Sphingolipids predict cardiovascular events independently from conventional cardiovascular risk factors in patients undergoing coronary angiography",2015,"Atherosclerosis","240","1",,"216","221",,,10.1016/j.atherosclerosis.2015.03.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925064463&partnerID=40&md5=b01cf3419fbb368de673ee3057b8af60","Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 100Zurich, Switzerland; Centre for Integrative Human Physiology, University of ZurichZurich, Switzerland; Institute of Experimental and Clinical Pharmacology and Toxicology, University of LübeckLübeck, Germany; Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria; Department of Medicine and Cardiology, Academic Teaching Hospital FeldkirchFeldkirch, Austria; Private University of the Principality of LiechtensteinTriesen, Liechtenstein; Drexel University College of MedicinePhiladelphia, PA, United States","Othman, A., Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 100Zurich, Switzerland, Centre for Integrative Human Physiology, University of ZurichZurich, Switzerland, Institute of Experimental and Clinical Pharmacology and Toxicology, University of LübeckLübeck, Germany; Saely, C.H., Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria, Department of Medicine and Cardiology, Academic Teaching Hospital FeldkirchFeldkirch, Austria, Private University of the Principality of LiechtensteinTriesen, Liechtenstein; Muendlein, A., Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria, Department of Medicine and Cardiology, Academic Teaching Hospital FeldkirchFeldkirch, Austria, Private University of the Principality of LiechtensteinTriesen, Liechtenstein; Vonbank, A., Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria, Department of Medicine and Cardiology, Academic Teaching Hospital FeldkirchFeldkirch, Austria, Private University of the Principality of LiechtensteinTriesen, Liechtenstein; Drexel, H., Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria, Department of Medicine and Cardiology, Academic Teaching Hospital FeldkirchFeldkirch, Austria, Private University of the Principality of LiechtensteinTriesen, Liechtenstein, Drexel University College of MedicinePhiladelphia, PA, United States; von Eckardstein, A., Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 100Zurich, Switzerland, Centre for Integrative Human Physiology, University of ZurichZurich, Switzerland; Hornemann, T., Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 100Zurich, Switzerland, Centre for Integrative Human Physiology, University of ZurichZurich, Switzerland","Aims: Sphingolipids are emerging as novel players in the pathogenesis of atherosclerosis and cardiovascular disease. Serine palmitoyltransferase (SPT) catalyzes the first and rate-limiting step in the de novo synthesis of sphingolipids-the condensation of palmitoyl-CoA and l-Serine. In addition to these canonical substrates, SPT can also metabolize other acyl-CoAs and amino acids, thus generating a variety of atypical sphingoid bases. In this study, we investigated the association of these atypical sphingoid bases with the presence of angiographically characterized coronary artery disease (CAD) as well as their ability to predict the incidence of cardiovascular events. Methods and results: 349 subjects, who underwent coronary angiography for the evaluation of established or suspected stable CAD, were enrolled in the study at baseline and followed up for cardiovascular events over a period of 8 years (median 7.7 years). The sphingoid base profile in the extracted plasma sphingolipids were determined by LC/MS after acid-base hydrolysis. Plasma levels of C18SAdiene were found to be significantly lower in CAD patients at baseline, while levels for C16SA, C16SO, C17SO, C18SA, C18SO, and C19SO and 1-deoxy sphingoid bases were not different. In the prospective analysis C20SO significantly predicted cardiovascular events (standardized adjusted HR=1.20, CI 95% [1.03-1.41]; p=0.022) after adjusting for traditional risk factors, the use of lipid-lowering drugs and angiographically-determined CAD at baseline. Conclusion: Plasma C20SO levels are independent predictive biomarkers for cardiovascular events, even after adjusting for cardiovascular risk factors including coronary stenosis. © 2015 Elsevier Ireland Ltd.","Atypical sphingolipids; C20Sphingosine; Coronary artery disease; Myocardial infarction; Predictive biomarker; Risk factor; Serine-palmitoyltransferase; Stroke","Hornemann, T., Worgall, T.S., Sphingolipids and atherosclerosis (2013) Atherosclerosis, 226, pp. 16-28; Jiang, X.C., Paultre, F., Pearson, T.A., Plasma sphingomyelin level as a risk factor for coronary artery disease (2000) Arterioscler. Thromb. Vasc. Biol., 20, pp. 2614-2618; Nelson, J.C., Jiang, X.C., Tabas, I., Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis (2006) Am. J. Epidemiol., 163, pp. 903-912; Hannun, Y.A., Obeid, L.M., Many ceramides (2011) J.Biol. Chem., 286, pp. 27855-27862; Hornemann, T., Richard, S., Rütti, M.F., Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase (2006) J.Biol. Chem., 281, pp. 37275-37281; Hornemann, T., Penno, A., Rütti, M.F., The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases (2009) J.Biol. Chem., 284, pp. 26322-26330; Illig, T., Gieger, C., Zhai, G., Agenome-wide perspective of genetic variation in human metabolism (2010) Nat. Genet., 42, pp. 137-141; Hicks, A.A., Pramstaller, P.P., Johansson, A., Genetic determinants of circulating sphingolipid concentrations in European populations (2009) PLoS Genet., 5, p. e1000672; Han, G., Gupta, S.D., Gable, K., Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities (2009) Proc. Natl. Acad. Sci. U. S. A., 106, pp. 8186-8191; Harmon, J.M., Bacikova, D., Gable, K., Topological and functional characterization of the ssSPTs, small activating subunits of serine palmitoyltransferase (2013) J.Biol. Chem., 288, pp. 10144-10153; Penno, A., Reilly, M.M., Houlden, H., Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids (2010) J.Biol. Chem., 285, pp. 11178-11187; Zitomer, N.C., Mitchell, T., Voss, K.A., Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals (2009) J.Biol. Chem., 284, pp. 4786-4795; Othman, A., Rutti, M.F., Ernst, D., Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? (2012) Diabetologia, 55, pp. 421-431; Bertea, M., Rutti, M.F., Othman, A., Deoxysphingoid bases as plasma markers in diabetes mellitus (2010) Lipids Health Dis., 9, p. 84; Diabetes mellitus: a major risk factor for cardiovascular disease (1999) Circulation, 100, pp. 1132-1133. , A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association; Drexel, H., Aczel, S., Marte, T., Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? (2005) Diabetes Care, 28, pp. 101-107; Gabir, M.M., Hanson, R.L., Dabelea, D., The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes (2000) Diabetes Care, 23, pp. 1108-1112; A, third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report (2002) Circulation, 106. , 3143-3421; Schlitt, A., Blankenberg, S., Yan, D., Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease (2006) Nutr. Metab. (Lond), 3, p. 5; Yeboah, J., McNamara, C., Jiang, X.C., Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: multi-ethnic study of atherosclerosis (2010) Arterioscler. Thromb. Vasc. Biol., 30, pp. 628-633; Quehenberger, O., Armando, A.M., Brown, A.H., Lipidomics reveals a remarkable diversity of lipids in human plasma (2010) J.Lipid Res., 51, pp. 3299-3305; Hojjati, M.R., Jiang, X.C., Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine (2006) J.Lipid Res., 47, pp. 673-676; Meikle, P.J., Wong, G., Tsorotes, D., Plasma lipidomic analysis of stable and unstable coronary artery disease (2011) Arterioscler. Thromb. Vasc. Biol., 31, pp. 2723-2732; Rosenber, A., Stern, N., Changes in sphingosine and fatty acid components of gangliosides in developing rat and human brain (1966) J.lipid Res., 7. , 122-&; Keranen, A., Fatty-acids and long-chain bases of gangliosides of human gastrointestinal mucosa (1976) Chem. Phys. lipids, 17, pp. 14-21; Merrill, A.H., Wang, E., Wertz, P.W., Differences in the long-chain (Sphingoid) base composition of sphingomyelin from rats Bearing Morris Hepatoma-7777 (1986) Lipids, 21, pp. 529-530; Palestini, P., Masserini, M., Sonnino, S., Changes in the ceramide composition of rat Forebrain gangliosides with age (1990) J.Neurochem., 54, pp. 230-235; Sugiura, Y., Shimma, S., Konishi, Y., Imaging mass spectrometry technology and application on ganglioside study; visualization of age-dependent accumulation of C20-Ganglioside molecular species in the mouse Hippocampus (2008) PLoS One, 3; Chigorno, V., Valsecchi, M., Sonnino, S., Biosynthesis of gangliosides containing C18:1 and C20:1 [3-14C]sphingosine after administrating [1-14C]palmitic acid and [1-14C]stearic acid to rat cerebellar granule cells in culture (1994) Eur. J. Biochem., 221, pp. 1095-1101; Scicchitano, P., Cameli, M., Maiello, M., Nutraceuticals and dyslipidaemia: beyond the common therapeutics (2014) J.Funct. Foods, 6, pp. 11-32",Article,Scopus,2-s2.0-84925064463
"Rein P., Saely C.H., Vonbank A., Fraunberger P., Drexel H.","Is albuminuria a myocardial infarction risk equivalent for atherothrombotic events?",2015,"Atherosclerosis","240","1",,"21","25",,,10.1016/j.atherosclerosis.2015.02.037,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923875749&partnerID=40&md5=bbda751e17f86e7a2a23fc018571f8dd","Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria; Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Austria; Private University of the Principality of LiechtensteinTriesen, Liechtenstein; Medical Central LaboratoriesFeldkirch, Austria; Drexel University College of MedicinePhiladelphia, PA, United States","Rein, P., Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria, Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Austria, Private University of the Principality of LiechtensteinTriesen, Liechtenstein; Saely, C.H., Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria, Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Austria, Private University of the Principality of LiechtensteinTriesen, Liechtenstein; Vonbank, A., Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria, Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Austria, Private University of the Principality of LiechtensteinTriesen, Liechtenstein; Fraunberger, P., Medical Central LaboratoriesFeldkirch, Austria; Drexel, H., Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT)Feldkirch, Austria, Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Austria, Private University of the Principality of LiechtensteinTriesen, Liechtenstein, Drexel University College of MedicinePhiladelphia, PA, United States","People with chronic kidney disease frequently experience cardiovascular events. This study sought to investigate whether the presence of albuminuria displays a vascular risk equivalent to that in patients with prior myocardial infarction. Methods: Albuminuria was defined as a urinary albumin to creatinine ratio of 30μg/mg or greater in 852 consecutive patients undergoing coronary angiography. Prospectively, we recorded vascular events over 3.2±1.2 years. Results: From our patients, 513 (60.2%) had neither albuminuria nor a history of MI, 126 (14.8%) had albuminuria without prior MI, 137 (16.1%) did not have albuminuria but had a history of MI, and 76 (8.9%) had both, albuminuria and prior MI. Compared with the incidence of the composite endpoint among normoalbuminuric patients with no prior MI (11.9%), event rates nearly doubled both in patients with albuminuria without prior MI (24.6%; p=0.003) and in normoalbuminuric patients with a history of prior MI (21.2%; p=0.004) and were highest in patients with both, albuminuria and prior MI (36.8%; p<0.001). Importantly, event rates were not significantly different between patients with albuminuria and no prior history of MI and those with normoalbuminuria but prior MI (p=0.972). Moreover, the event rate in patients with both, albuminuria and history of MI, was significantly higher (p<0.05) than in the two groups exhibiting only one of the two conditions. Conclusion: This is the first study demonstrating that albuminuria is a CAD risk equivalent. Thus, cardiovascular risk factors in albuminuric patients should be treated as aggressively as in patients with prior MI. © 2015 Elsevier Ireland Ltd.","Albumin to creatinine ratio; Albuminuria; Coronary angiography; Coronary artery disease; Myocardial infarction; Prospective","Muntner, P., Hamm, L.L., Kusek, J.W., The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease (2004) Ann. Intern. Med., 140, pp. 9-17; Sarnak, M.J., Cardiovascular complications in chronic kidney disease (2003) Am. J. Kidney Dis., 41, pp. 11-17; Shlipak, M.G., Fried, L.F., Crump, C., Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency (2003) Circulation, 107, pp. 87-92; Go, A.S., Chertow, G.M., Fan, D., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization (2004) N.Engl. J. Med., 351, pp. 1296-1305; Wattanakit, K., Coresh, J., Muntner, P., Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction (2006) J.Am. Coll. Cardiol., 48, pp. 1183-1189; KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease (2011) Kidney Int. Suppl., 2013 (3), pp. 1-150; Reiner, Z., Catapano, A.L., De Backer, G., ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) Eur. Heart J., 32, pp. 1769-1818; Hemmelgarn, B.R., Manns, B.J., Lloyd, A., Relation between kidney function, proteinuria, and adverse outcomes (2010) JAMA, 303, pp. 423-429; Tonelli, M., Muntner, P., Lloyd, A., Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study (2012) Lancet, 380, pp. 807-814; Scanlon, P.J., Faxon, D.P., Audet, A.M., ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions (1999) J.Am. Coll. Cardiol., 33, pp. 1756-1824; Mancia, G., Fagard, R., Narkiewicz, K., 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) Eur. Heart J., 34, pp. 2159-2219; Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation (1998) Diabet. Med., 15, pp. 539-553; Saely, C.H., Koch, L., Schmid, F., Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients (2006) Eur. J. Clin. Invest., 36, pp. 91-97; Levey, A.S., Stevens, L.A., Schmid, C.H., Anew equation to estimate glomerular filtration rate (2009) Ann. Intern. Med., 150, pp. 604-612; Rein, P., Saely, C.H., Muendlein, A., Serial decline of kidney function as a novel biomarker for the progression of atherothrombotic disease (2010) Atherosclerosis, 211, pp. 348-352; Gerstein, H.C., Mann, J.F., Yi, Q., Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals (2001) JAMA, 286, pp. 421-426; Klausen, K., Borch-Johnsen, K., Feldt-Rasmussen, B., Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes (2004) Circulation, 110, pp. 32-35; Matsushita, K., van der, V., Astor, B.C., Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis (2010) Lancet, 375, pp. 2073-2081; Ibsen, H., Wachtell, K., Olsen, M.H., Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study (2004) Kidney Int. Suppl., pp. S56-S58; Arnlov, J., Evans, J.C., Meigs, J.B., Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study (2005) Circulation, 112, pp. 969-975; Hallan, S., Astor, B., Romundstad, S., Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: the HUNT II Study (2007) Arch. Intern. Med., 167, pp. 2490-2496; Rein, P., Saely, C.H., Vonbank, A., Impact of the albumin to creatinine ratio and the coronary artery state on vascular events (2014) Am. J. Cardiol., 113, pp. 1616-1620; de Zeeuw, D., Parving, H.H., Henning, R.H., Microalbuminuria as an early marker for cardiovascular disease (2006) J.Am. Soc. Nephrol., 17, pp. 2100-2105; Bulum, T., Kolaric, B., Duvnjak, L., Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients (2013) J.Endocrinol. Invest., 36, pp. 574-578; Jensen, J.S., Feldt-Rasmussen, B., Strandgaard, S., Arterial hypertension, microalbuminuria, and risk of ischemic heart disease (2000) Hypertension, 35, pp. 898-903; Kang, H.T., Kim, J.K., Kim, J.Y., Independent association of TG/HDL-C with urinary albumin excretion in normotensive subjects in a rural Korean population (2012) Clin. Chim. Acta, 413, pp. 319-324; Schiffrin, E.L., Lipman, M.L., Mann, J.F., Chronic kidney disease: effects on the cardiovascular system (2007) Circulation, 116, pp. 85-97; Gosling, P., Hughes, E.A., Reynolds, T.M., Microalbuminuria is an early response following acute myocardial infarction (1991) Eur. Heart J., 12, pp. 508-513",Article,Scopus,2-s2.0-84923875749
"Nogueira L.G., Frade A.F., Ianni B.M., Laugier L., Pissetti C.W., Cabantous S., Baron M., de Lima Peixoto G., de Melo Borges A., Donadi E., Marin-Neto J.A., Schmidt A., Dias F., Saba B., Wang H.-T.L., Fragata A., Sampaio M., Hirata M.H., Buck P., Mady C., Martinelli M., Lensi M., Siqueira S.F., Pereira A.C., Rodrigues V., Kalil J., Chevillard C., Cunha-Neto E.","Functional IL18 polymorphism and susceptibility to Chronic Chagas Disease",2015,"Cytokine","73","1",,"79","83",,,10.1016/j.cyto.2015.01.037,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924059269&partnerID=40&md5=f42edb363b10bf526d0fb645b34c97a8","Laboratory of Immunology, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Division of Clinical Immunology and Allergy, School of Medicine, University of São PauloSão Paulo, Brazil; Institute for Investigation in Immunology (iii), INCTSão Paulo, Brazil; Myocardiopathies Unit, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Aix-Marseille Université, INSERM, GIMP UMR S906Marseille, France; Laboratory of Immunology, Universidade Federal do Triângulo Mineiro (UFTM), 40 Frei PaulinoUberaba, MG, Brazil; Pacemaker Clinic, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; School of Medicine of Ribeirão Preto (FMRP), University of São PauloSão Paulo, Brazil; Dante Pazzanese Institute of Cardiology and Heart Failure UnitSão Paulo, Brazil","Nogueira, L.G., Laboratory of Immunology, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil, Division of Clinical Immunology and Allergy, School of Medicine, University of São PauloSão Paulo, Brazil, Institute for Investigation in Immunology (iii), INCTSão Paulo, Brazil; Frade, A.F., Laboratory of Immunology, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil, Division of Clinical Immunology and Allergy, School of Medicine, University of São PauloSão Paulo, Brazil, Institute for Investigation in Immunology (iii), INCTSão Paulo, Brazil; Ianni, B.M., Myocardiopathies Unit, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Laugier, L., Aix-Marseille Université, INSERM, GIMP UMR S906Marseille, France; Pissetti, C.W., Laboratory of Immunology, Universidade Federal do Triângulo Mineiro (UFTM), 40 Frei PaulinoUberaba, MG, Brazil; Cabantous, S., Aix-Marseille Université, INSERM, GIMP UMR S906Marseille, France; Baron, M., Laboratory of Immunology, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil, Division of Clinical Immunology and Allergy, School of Medicine, University of São PauloSão Paulo, Brazil, Institute for Investigation in Immunology (iii), INCTSão Paulo, Brazil; de Lima Peixoto, G., Pacemaker Clinic, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; de Melo Borges, A., Laboratory of Immunology, Universidade Federal do Triângulo Mineiro (UFTM), 40 Frei PaulinoUberaba, MG, Brazil; Donadi, E., School of Medicine of Ribeirão Preto (FMRP), University of São PauloSão Paulo, Brazil; Marin-Neto, J.A., School of Medicine of Ribeirão Preto (FMRP), University of São PauloSão Paulo, Brazil; Schmidt, A., School of Medicine of Ribeirão Preto (FMRP), University of São PauloSão Paulo, Brazil; Dias, F., School of Medicine of Ribeirão Preto (FMRP), University of São PauloSão Paulo, Brazil; Saba, B., Dante Pazzanese Institute of Cardiology and Heart Failure UnitSão Paulo, Brazil; Wang, H.-T.L., Dante Pazzanese Institute of Cardiology and Heart Failure UnitSão Paulo, Brazil; Fragata, A., Dante Pazzanese Institute of Cardiology and Heart Failure UnitSão Paulo, Brazil; Sampaio, M., Dante Pazzanese Institute of Cardiology and Heart Failure UnitSão Paulo, Brazil; Hirata, M.H., Dante Pazzanese Institute of Cardiology and Heart Failure UnitSão Paulo, Brazil; Buck, P., Myocardiopathies Unit, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Mady, C., Myocardiopathies Unit, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Martinelli, M., Pacemaker Clinic, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Lensi, M., Pacemaker Clinic, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Siqueira, S.F., Pacemaker Clinic, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Pereira, A.C., Laboratory of Immunology, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil; Rodrigues, V., Laboratory of Immunology, Universidade Federal do Triângulo Mineiro (UFTM), 40 Frei PaulinoUberaba, MG, Brazil; Kalil, J., Laboratory of Immunology, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil, Division of Clinical Immunology and Allergy, School of Medicine, University of São PauloSão Paulo, Brazil, Institute for Investigation in Immunology (iii), INCTSão Paulo, Brazil; Chevillard, C., Aix-Marseille Université, INSERM, GIMP UMR S906Marseille, France; Cunha-Neto, E., Laboratory of Immunology, Heart Institute (InCor), School of Medicine, University of São PauloSão Paulo, Brazil, Division of Clinical Immunology and Allergy, School of Medicine, University of São PauloSão Paulo, Brazil, Institute for Investigation in Immunology (iii), INCTSão Paulo, Brazil","Background: Chronic Chagas Disease cardiomyopathy (CCC), a life-threatening inflammatory dilated cardiomyopathy, affects 30% of the approximately 8 million patients infected by Trypanosoma cruzi, the rest of the infected subjects remaining asymptomatic (ASY). The Th1 T cell-rich myocarditis plays a pivotal role in CCC pathogenesis. Local expression of IL-18 in CCC myocardial tissue has recently been described. IL-18 could potentially amplify the process by inducing increased expression of IFN-γ which in turn can increase the production of IL-18, thereby creating a positive feedback mechanism. In order to assess the contribution of the IL-18 to susceptibility to Chronic Chagas Disease, we investigated the association between a single nucleotide polymorphism (SNP) located in the IL-18 gene with the risk of developing Chagas cardiomyopathy. Methods and results: We analyzed the rs2043055 marker in the IL18 gene in a cohort of Chagas disease cardiomyopathy patients (. n=. 849) and asymptomatic subjects (. n=. 202). We found a significant difference in genotype frequencies among moderate and severe CCC patients with ventricular dysfunction. Conclusions: Our analysis suggests that the IL18 rs2043055 polymorphism- or a SNP in tight linkage disequilibrium with it- may contribute to modulating the Chagas cardiomyopathy outcome. © 2015 Elsevier Ltd.","Cardiomyopathy; Chagas; IL18; Polymorphism; Severity","Schofield, C.J., Jannin, J., Salvatella, R., The future of Chagas disease control (2006) Trends Parasitol, 22 (12), pp. 583-588; Kirchhoff, L.V., Weiss, L.M., Wittner, M., Tanowitz, H.B., Parasitic diseases of the heart (2004) Front Biosci, 9, pp. 706-723; Coura, J.R., Chagas disease: what is known and what is needed - a background article (2007) Mem Inst Oswaldo Cruz, 102, pp. 113-122; Higuchi, M.L., De Morais, C.F., Pereira Barreto, A.C., Lopes, E.A., Stolf, N., Bellotti, G., The role of active myocarditis in the development of heart failure in chronic Chagas' disease: a study based on endomyocardial biopsies (1987) Clin Cardiol, 10 (11), pp. 665-670; Milei, J., Storino, R., Fernandez Alonso, G., Beigelman, R., Vanzulli, S., Ferrans, V.J., Endomyocardial biopsies in chronic chagasic cardiomyopathy. Immunohistochemical and ultrastructural findings (1992) Cardiology, 80 (5-6), pp. 424-437; Higuchi Mde, L., Gutierrez, P.S., Aiello, V.D., Palomino, S., Bocchi, E., Kalil, J., Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process (1993) Virchows Arch A Pathol Anat Histopathol, 423 (3), pp. 157-160; Abel, L.C., Rizzo, L.V., Ianni, B., Albuquerque, F., Bacal, F., Carrara, D., Chronic Chagas' disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection (2001) J Autoimmun, 17 (1), pp. 99-107; Gomes, J.A., Bahia-Oliveira, L.M., Rocha, M.O., Martins-Filho, O.A., Gazzinelli, G., Correa-Oliveira, R., Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response (2003) Infect Immun, 71 (3), pp. 1185-1193; Reis, D.D., Jones, E.M., Tostes, S., Lopes, E.R., Chapadeiro, E., Gazzinelli, G., Expression of major histocompatibility complex antigens and adhesion molecules in hearts of patients with chronic Chagas' disease (1993) Am J Trop Med Hyg, 49 (2), pp. 192-200; Reis, M.M., Higuchi Mde, L., Benvenuti, L.A., Aiello, V.D., Gutierrez, P.S., Bellotti, G., An in situ quantitative immunohistochemical study of cytokines and IL-2R+ in chronic human chagasic myocarditis: correlation with the presence of myocardial Trypanosoma cruzi antigens (1997) Clin Immunol Immunopathol, 83 (2), pp. 165-172; Fonseca, S.G., Reis, M.M., Coelho, V., Nogueira, L.G., Monteiro, S.M., Mairena, E.C., Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy (2007) Scand J Immunol, 66 (2-3), pp. 362-371; Nogueira, L.G., Santos, R.H., Fiorelli, A.I., Mairena, E.C., Benvenuti, L.A., Bocchi, E.A., Myocardial gene expression of T-bet, GATA-3, Ror-gammat, FoxP3, and hallmark cytokines in chronic chagas disease cardiomyopathy: an essentially unopposed TH1-type response (2014) Mediators Inflamm, 2014, p. 914326; Muller, U., Kohler, G., Mossmann, H., Schaub, G.A., Alber, G., Di Santo, J.P., IL-12-independent IFN-gamma production by T cells in experimental Chagas' disease is mediated by IL-18 (2001) J Immunol, 167 (6), pp. 3346-3353; Dinarello, C.A., Fantuzzi, G., Interleukin-18 and host defense against infection (2003) J Infect Dis, 187, pp. S370-S384; Nolan, K.F., Greaves, D.R., Waldmann, H., The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci (1998) Genomics, 51 (1), pp. 161-163; Kruse, S., Kuehr, J., Moseler, M., Kopp, M.V., Kurz, T., Deichmann, K.A., Polymorphisms in the IL18 gene are associated with specific sensitization to common allergens and allergic rhinitis (2003) J Allergy Clin Immunol, 111 (1), pp. 117-122; Thompson, S.R., Humphries, S.E., Interleukin-18 genetics and inflammatory disease susceptibility (2007) Genes Immun, 8 (2), pp. 91-99; Zicker, F., Smith, P.G., Netto, J.C., Oliveira, R.M., Zicker, E.M., Physical activity, opportunity for reinfection, and sibling history of heart disease as risk factors for Chagas' cardiopathy (1990) Am J Trop Med Hyg, 43 (5), pp. 498-505; Llop, E., Rothhammer, F., Acuna, M., Apt, W., HLA antigens in cardiomyopathic Chilean chagasics (1988) Am J Hum Genet, 43 (5), pp. 770-773; Llop, E., Rothhammer, F., Acuna, M., Apt, W., Arribada, A., HLA antigens in Chagas cardiomyopathy: new evidence based on a case-control study (1991) Rev Med Chil, 119 (6), pp. 633-636; Fernandez-Mestre, M.T., Layrisse, Z., Montagnani, S., Acquatella, H., Catalioti, F., Matos, M., Influence of the HLA class II polymorphism in chronic Chagas' disease (1998) Parasite Immunol, 20 (4), pp. 197-203; Layrisse, Z., Fernandez, M.T., Montagnani, S., Matos, M., Balbas, O., Herrera, F., HLA-C(*)03 is a risk factor for cardiomyopathy in Chagas disease (2000) Hum Immunol, 61 (9), pp. 925-929; Deghaide, N.H., Dantas, R.O., Donadi, E.A., HLA class I and II profiles of patients presenting with Chagas' disease (1998) Dig Dis Sci, 43 (2), pp. 246-252; Colorado, I.A., Acquatella, H., Catalioti, F., Fernandez, M.T., Layrisse, Z., HLA class II DRB1, DQB1, DPB1 polymorphism and cardiomyopathy due to Trypanosoma cruzi chronic infection (2000) Hum Immunol, 61 (3), pp. 320-325; Rodriguez-Perez, J.M., Cruz-Robles, D., Hernandez-Pacheco, G., Perez-Hernandez, N., Murguia, L.E., Granados, J., Tumor necrosis factor-alpha promoter polymorphism in Mexican patients with Chagas' disease (2005) Immunol Lett, 98 (1), pp. 97-102; Campelo, V., Dantas, R.O., Simoes, R.T., Mendes-Junior, C.T., Sousa, S.M., Simoes, A.L., TNF microsatellite alleles in Brazilian Chagasic patients (2007) Dig Dis Sci, 52 (12), pp. 3334-3339; Drigo, S.A., Cunha-Neto, E., Ianni, B., Cardoso, M.R., Braga, P.E., Fae, K.C., TNF gene polymorphisms are associated with reduced survival in severe Chagas' disease cardiomyopathy patients (2006) Microbes Infect, 8 (3), pp. 598-603; Beraun, Y., Nieto, A., Collado, M.D., Gonzalez, A., Martin, J., Polymorphisms at tumor necrosis factor (TNF) loci are not associated with Chagas' disease (1998) Tissue Antigens, 52 (1), pp. 81-83; Drigo, S.A., Cunha-Neto, E., Ianni, B., Mady, C., Fae, K.C., Buck, P., Lack of association of tumor necrosis factor-alpha polymorphisms with Chagas disease in Brazilian patients (2007) Immunol Lett, 108 (1), pp. 109-111; Florez, O., Martin, J., Gonzalez, C.I., Interleukin 4, interleukin 4 receptor-alpha and interleukin 10 gene polymorphisms in Chagas disease (2011) Parasite Immunol, 33 (9), pp. 506-511; Cruz-Robles, D., Chavez-Gonzalez, J.P., Cavazos-Quero, M.M., Perez-Mendez, O., Reyes, P.A., Vargas-Alarcon, G., Association between IL-1B and IL-1RN gene polymorphisms and Chagas' disease development susceptibility (2009) Immunol Invest, 38 (3-4), pp. 231-239; Costa, G.C., da Costa Rocha, M.O., Moreira, P.R., Menezes, C.A., Silva, M.R., Gollob, K.J., Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy (2009) J Infect Dis, 199 (3), pp. 451-454; Moreno, M., Silva, E.L., Ramirez, L.E., Palacio, L.G., Rivera, D., Arcos-Burgos, M., Chagas' disease susceptibility/resistance. Linkage disequilibrium analysis suggests epistasis between major histocompatibility complex and interleukin-10 (2004) Tissue Antigens, 64 (1), pp. 18-24; Zafra, G., Morillo, C., Martin, J., Gonzalez, A., Gonzalez, C.I., Polymorphism in the 3' UTR of the IL12B gene is associated with Chagas' disease cardiomyopathy (2007) Microbes Infect, 9 (9), pp. 1049-1052; Ramasawmy, R., Cunha-Neto, E., Fae, K.C., Borba, S.C., Teixeira, P.C., Ferreira, S.C., Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the Toll-like receptor pathway, is associated with lower risk of developing chronic Chagas cardiomyopathy (2009) J Infect Dis, 199 (12), pp. 1838-1845; Ramasawmy, R., Cunha-Neto, E., Fae, K.C., Martello, F.G., Muller, N.G., Cavalcanti, V.L., The monocyte chemoattractant protein-1 gene polymorphism is associated with cardiomyopathy in human chagas disease (2006) Clin Infect Dis, 43 (3), pp. 305-311; Ramasawmy, R., Cunha-Neto, E., Fae, K.C., Muller, N.G., Cavalcanti, V.L., Drigo, S.A., BAT1, a putative anti-inflammatory gene, is associated with chronic Chagas cardiomyopathy (2006) J Infect Dis, 193 (10), pp. 1394-1399; Ramasawmy, R., Fae, K.C., Cunha-Neto, E., Muller, N.G., Cavalcanti, V.L., Ferreira, R.C., Polymorphisms in the gene for lymphotoxin-alpha predispose to chronic Chagas cardiomyopathy (2007) J Infect Dis, 196 (12), pp. 1836-1843; Pissetti, C.W., de Oliveira, R.F., Correia, D., Nascentes, G.A., Llaguno, M.M., Rodrigues, V., Association between the lymphotoxin-alpha gene polymorphism and chagasic cardiopathy (2013) J Interferon Cytokine Res, 33 (3), pp. 130-135; Ramasawmy, R., Fae, K.C., Cunha-Neto, E., Borba, S.C., Ianni, B., Mady, C., Variants in the promoter region of IKBL/NFKBIL1 gene may mark susceptibility to the development of chronic Chagas' cardiomyopathy among Trypanosoma cruzi-infected individuals (2008) Mol Immunol, 45 (1), pp. 283-288; Calzada, J.E., Nieto, A., Beraun, Y., Martin, J., Chemokine receptor CCR5 polymorphisms and Chagas' disease cardiomyopathy (2001) Tissue Antigens, 58 (3), pp. 154-158; Fernandez-Mestre, M.T., Montagnani, S., Layrisse, Z., Is the CCR5-59029-G/G genotype a protective factor for cardiomyopathy in Chagas disease? (2004) Hum Immunol, 65 (7), pp. 725-728; Torres, O.A., Calzada, J.E., Beraun, Y., Morillo, C.A., Gonzalez, C.I., Gonzalez, A., Association of the macrophage migration inhibitory factor -173G/C polymorphism with Chagas disease (2009) Hum Immunol, 70 (7), pp. 543-546; Torres, O.A., Calzada, J.E., Beraun, Y., Morillo, C.A., Gonzalez, A., Gonzalez, C.I., Role of the IFNG+874T/A polymorphism in Chagas disease in a Colombian population (2010) Infect Genet Evol, 10 (5), pp. 682-685; Cunha-Neto, E., Coelho, V., Guilherme, L., Fiorelli, A., Stolf, N., Kalil, J., Autoimmunity in Chagas' disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient (1996) J Clin Invest, 98 (8), pp. 1709-1712; Teixeira, P.C., Frade, A.F., Nogueira, L.G., Kalil, J., Chevillard, C., Cunha-Neto, E., Pathogenesis of Chagas disease cardiomyopathy (2012) World J Clin Infect Dis, 2 (3), pp. 39-53; Vasconcelos, R.H., Montenegro, S.M., Azevedo, E.A., Gomes, Y.M., Morais, C.N., Genetic susceptibility to chronic Chagas disease: an overview of single nucleotide polymorphisms of cytokine genes (2012) Cytokine, 59 (2), pp. 203-208; Cunha-Neto, E., Nogueira, L.G., Teixeira, P.C., Ramasawmy, R., Drigo, S.A., Goldberg, A.C., Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy (2009) Mem Inst Oswaldo Cruz, 104, pp. 252-258; Bilate, A.M., Cunha-Neto, E., Chagas disease cardiomyopathy: current concepts of an old disease (2008) Rev Inst Med Trop Sao Paulo, 50 (2), pp. 67-74; Frade, A.F., Teixeira, P.C., Ianni, B.M., Pissetti, C.W., Saba, B., Wang, L.H., Polymorphism in the alpha cardiac muscle actin 1 gene is associated to susceptibility to chronic inflammatory cardiomyopathy (2013) PLoS ONE, 8 (12), p. e83446; Jorge, M.T., Macedo, T.A., Janones, R.S., Carizzi, D.P., Heredia, R.A., Acha, R.E., Types of arrhythmia among cases of American trypanosomiasis, compared with those in other cardiology patients (2003) Ann Trop Med Parasitol, 97 (2), pp. 139-148; Frade, A.F., Pissetti, C.W., Ianni, B.M., Saba, B., Lin-Wang, H.T., Nogueira, L.G., Genetic susceptibility to Chagas disease cardiomyopathy: involvement of several genes of the innate immunity and chemokine-dependent migration pathways (2013) BMC Infect Dis, 13, p. 587; Cunha-Neto, E., Dzau, V.J., Allen, P.D., Stamatiou, D., Benvenutti, L., Higuchi, M.L., Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy (2005) Am J Pathol, 167 (2), pp. 305-313; Chandrasekar, B., Valente, A.J., Freeman, G.L., Mahimainathan, L., Mummidi, S., Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappaB-dependent PTEN activation (2006) Biochem Biophys Res Commun, 339 (3), pp. 956-963; Reddy, V.S., Harskamp, R.E., van Ginkel, M.W., Calhoon, J., Baisden, C.E., Kim, I.S., Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation (2008) J Cell Physiol, 215 (3), pp. 697-707; Nogueira, L.G., Santos, R.H., Ianni, B.M., Fiorelli, A.I., Mairena, E.C., Benvenuti, L.A., Myocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10 (2012) PLoS Negl Trop Dis, 6 (10), p. e1867",Article,Scopus,2-s2.0-84924059269
"Roysland R., Rosjo H., Hoiseth A.D., Gullestad L., Badr P., Kravdal G., Omland T.","Osteoprotegerin concentrations in patients with suspected reversible myocardial ischemia: Observations from the Akershus Cardiac Examination (ACE) 1 Study",2015,"Cytokine","73","1",,"122","127",,,10.1016/j.cyto.2015.01.020,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924137376&partnerID=40&md5=06fbdca4e02c00cb9ab7d8d57a1bd074","Division of Medicine, Akershus University HospitalLørenskog, Norway; Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, Institute of Clinical Medicine, University of OsloOslo, Norway; Department of Cardiology, Oslo University HospitalRikshospitalet, Norway; Section for Nuclear Medicine and Section for Medical Biochemistry, Division for Diagnostics and Technology, Akershus University HospitalLørenskog, Norway","Røysland, R., Division of Medicine, Akershus University HospitalLørenskog, Norway; Røsjø, H., Division of Medicine, Akershus University HospitalLørenskog, Norway, Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, Institute of Clinical Medicine, University of OsloOslo, Norway; Høiseth, A.D., Division of Medicine, Akershus University HospitalLørenskog, Norway, Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, Institute of Clinical Medicine, University of OsloOslo, Norway; Gullestad, L., Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, Institute of Clinical Medicine, University of OsloOslo, Norway, Department of Cardiology, Oslo University HospitalRikshospitalet, Norway; Badr, P., Division of Medicine, Akershus University HospitalLørenskog, Norway; Kravdal, G., Section for Nuclear Medicine and Section for Medical Biochemistry, Division for Diagnostics and Technology, Akershus University HospitalLørenskog, Norway; Omland, T., Division of Medicine, Akershus University HospitalLørenskog, Norway, Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, Institute of Clinical Medicine, University of OsloOslo, Norway","Increased circulating osteoprotegerin (OPG) levels have been associated with the prevalence and severity of coronary artery disease and the risk of cardiovascular death. OPG is a cytokine of the tumor necrosis factor receptor superfamily and is expressed in various cell types in the body, including osteoblasts, inflammatory cells, vascular smooth muscle cells/endothelial cells and cardiomyocytes. The main sources determining OPG levels in the circulation however, are not well understood, and whether reversible myocardial ischemia influences OPG levels are not known. Accordingly, OPG levels were measured in 198 patients referred for exercise stress testing and myocardial perfusion imaging (MPI). In addition OPG levels were measured in 8 healthy control subjects performing a maximal bicycle stress test. Plasma samples were collected before, immediately after, 1.5. h and 4.5. h after exercise stress testing with MPI. OPG levels at baseline were not different in patient with reversible myocardial ischemia (n= 19) and patients without reversible ischemia (n= 179) (4.7 [3.6-5.5]. pmol/L vs. 4.3 [3.4-5.2]. pmol/L, p= 0.21), and there was an increase in OPG levels immediately after exercise regardless of whether or not the patient had reversible ischemia on MPI (absolute increase: 0.2 [0-0.55]. pmol/L vs. 0.3 [0-0.5]. pmol/L, p= 0.72). OPG levels also increased immediately after stress in the 8 control subjects (3.5 (3.2-3.8). pmol/L at baseline to 3.8 (3.5-4.7), p= 0.008). In conclusion, OPG levels increase acutely during exercise stress testing, but this increase is likely caused by mechanisms other than myocardial ischemia. © 2015 Elsevier Ltd.","Angina; Exercise stress testing; Myocardial ischemia; Myocardial perfusion imaging; Osteoprotegerin","Nakashima, T., Hayashi, M., Takayanagi, H., New insights into osteoclastogenic signaling mechanisms (2012) Trends Endocrinol Metab, 23, pp. 582-590; Venuraju, S.M., Yerramasu, A., Corder, R., Lahiri, A., Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity (2010) J Am Coll Cardiol, 55, pp. 2049-2061; Lieb, W., Gona, P., Larson, M.G., Massaro, J.M., Lipinska, I., Keaney, J.F., Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality (2010) Arterioscler Thromb Vasc Biol, 30, pp. 1849-1854; Vik, A., Mathiesen, E.B., Brox, J., Wilsgaard, T., Njolstad, I., Jorgensen, L., Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study (2011) J Thromb Haemost, 9, pp. 638-644; Omland, T., Ueland, T., Jansson, A.M., Persson, A., Karlsson, T., Smith, C., Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes (2008) J Am Coll Cardiol, 51, pp. 627-633; Roysland, R., Bonaca, M.P., Omland, T., Sabatine, M., Murphy, S.A., Scirica, B.M., Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes (2012) Heart, 98, pp. 786-791; Roysland, R., Masson, S., Omland, T., Milani, V., Bjerre, M., Flyvbjerg, A., Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial (2010) Am Heart J, 160, pp. 286-293; Ueland, T., Dahl, C.P., Kjekshus, J., Hulthe, J., Bohm, M., Mach, F., Osteoprotegerin predicts progression of chronic heart failure: results from CORONA (2011) Circ Heart fail, 4, pp. 145-152; Rosjo, H., Kravdal, G., Hoiseth, A.D., Jorgensen, M., Badr, P., Roysland, R., Troponin I measured by a high-sensitivity assay in patients with suspected reversible myocardial ischemia: data from the Akershus Cardiac Examination (ACE) 1 study (2012) Clin Chem, 58, pp. 1565-1573; Rosjo, H., Tamm, N.N., Kravdal, G., Seferian, K.R., Hoiseth, A.D., Nygard, S., Diagnostic utility of a single-epitope sandwich B-type natriuretic peptide assay in stable coronary artery disease: data from the Akershus Cardiac Examination (ACE) 1 study (2012) Clin Biochem, 45, pp. 1269-1275; Roysland, R., Kravdal, G., Hoiseth, A.D., Nygard, S., Badr, P., Hagve, T.A., Cardiac troponin T levels and exercise stress testing in patients with suspected coronary artery disease: the Akershus Cardiac Examination (ACE) 1 Study (2012) Clin Sci, 122, pp. 599-606; Rosjo, H., Opstad, P.K., Hoff, J.E., Godang, K., Christensen, G., Stridsberg, M., Effect of short- and long-term physical activities on circulating granin protein levels (2013) Regul Pept, 185, pp. 14-19; Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine (1976) Nephron, 16, pp. 31-41; Avignon, A., Sultan, A., Piot, C., Mariano-Goulart, D., Thuan Dit Dieudonne, J.F., Cristol, J.P., Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients (2007) Diabetes Care, 30, pp. 2934-2939; Guzel, S., Seven, A., Kocaoglu, A., Ilk, B., Guzel, E.C., Saracoglu, G.V., Osteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus (2013) Diabetes Vasc Dis Res, 10, pp. 25-31; Poulsen, M.K., Nybo, M., Dahl, J., Hosbond, S., Poulsen, T.S., Johansen, A., Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus (2011) Cardiovasc diabetol, 10, p. 76; Sultan, A., Avignon, A., Galtier, F., Piot, C., Mariano-Goulart, D., Dupuy, A.M., Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients (2008) Diabetes Care, 31, pp. 593-595; Palazzuoli, A., Ascione, R., Gallotta, M., Calabro, A., Gonnelli, S., Quatrini, I., Osteoprotegerin and B-type natriuretic peptide in acute coronary syndromes with preserved systolic function: relation to coronary artery disease extension (2009) Int J Cardiol, 137, pp. 295-298; Zannettino, A.C., Holding, C.A., Diamond, P., Atkins, G.J., Kostakis, P., Farrugia, A., Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor (2005) J Cell Physiol, 204, pp. 714-723; Xiong, Y., Hu, Z., Han, X., Jiang, B., Zhang, R., Zhang, X., Hypertensive stretch regulates endothelial exocytosis of Weibel-Palade bodies through VEGF receptor 2 signaling pathways (2013) Cell Res, pp. 4-5; Rondaij, M.G., Bierings, R., Kragt, A., van Mourik, J.A., Voorberg, J., Dynamics and plasticity of Weibel-Palade bodies in endothelial cells (2006) Arterioscler Thromb Vasc Biol, 26, pp. 1002-1007; Vinholt, P.J., Overgaard, M., Diederichsen, A.C., Mickley, H., Poulsen, T.S., Sand, N.P., An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasma (2013) Thromb Res, 131, pp. 396-400; Helske, S., Kovanen, P.T., Lindstedt, K.A., Salmela, K., Lommi, J., Turto, H., Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload (2007) Eur J Heart Fail, 9, pp. 357-363",Article,Scopus,2-s2.0-84924137376
"Shen L., Chen C., Wei X., Li X., Luo G., Zhang J., Bin J., Huang X., Cao S., Li G., Liao Y.","Overexpression of ankyrin repeat domain 1 enhances cardiomyocyte apoptosis by promoting p53 activation and mitochondrial dysfunction in rodents",2015,"Clinical science (London, England : 1979)","128","10",,"665","678",,,10.1042/CS20140586,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928936459&partnerID=40&md5=39049acd204b4686abd0e3ab8fb00a6c","*State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; †Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China","Shen, L., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Chen, C., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Wei, X., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Li, X., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Luo, G., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Zhang, J., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Bin, J., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Huang, X., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Cao, S., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Li, G., †Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Liao, Y., *State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China","The Ankrd1 (ankyrin repeat domain 1) gene is known to be up-regulated in heart failure and acts as a co-activator of p53, modulating its transcriptional activity, but it remains inconclusive whether this gene promotes or inhibits cell apoptosis. In the present study, we attempted to investigate the role of Ankrd1 on AngII (angiotensin II)- or pressure-overload-induced cardiomyocyte apoptosis. In the failing hearts of mice with pressure overload, the protein expression of Ankrd1-encoded CARP (cardiac ankyrin repeat protein) was significantly increased. In NRCs (neonatal rat cardiomyocytes), AngII increased the expression of Ankrd1 and CARP. In the presence of AngII in NRCs, infection with a recombinant adenovirus containing rat Ankrd1 cDNA (Ad-Ankrd1) enhanced the mitochondrial translocation of Bax and phosphorylated p53, increased mitochondrial permeability and cardiomyocyte apoptosis, and reduced cell viability, whereas these effects were antagonized by silencing of Ankrd1. Intra-myocardial injection of Ad-Ankrd1 in mice with TAC (transverse aortic constriction) markedly exacerbated cardiac dysfunction with an increase in the lung weight/body weight ratio and a decrease in left ventricular fractional shortening. Cardiomyocyte apoptosis and the expression of phosphorylated p53 were also significantly increased in Ad-Ankrd1-infected TAC mice, whereas knockdown of Ankrd1 significantly inhibited the apoptotic signal pathway as well as cardiomyocyte apoptosis in pressure-overload mice. These findings indicate that overexpression of Ankrd1 exacerbates pathological cardiac dysfunction through enhancement of cardiomyocyte apoptosis mediated by the up-regulation of p53.",,,Article,Scopus,2-s2.0-84928936459
"Gao F., Earnest A., Matchar D.B., Campbell M.J., Machin D.","Sample size calculations for the design of cluster randomized trials: A summary of methodology",2015,"Contemporary Clinical Trials","42",,,"41","50",,,10.1016/j.cct.2015.02.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925864280&partnerID=40&md5=b16662a83b9ce552ee3a39fcbafaa687","National Heart Research Institute Singapore, National Heart Centre Singapore, 5 Hospital Drive, Singapore; Center for Quantitative Medicine, Duke-NUS Graduate Medical School, 8 College Road, Singapore; Department of Epidemiology and Preventive Medicine, Monash University, The Alfred Centre, Level 6, 99 Commercial RoadMelbourne, VIC, Australia; Health Services and Systems Research, Duke-NUS Graduate Medical School, 8 College Road, Singapore; Department of Medicine (General Internal Medicine), Duke University Medical Center, 411 W. Chapel Hill Street, Suite 500Durham, NC, United States; Medical Statistics Group, School of Health and Related Research, University of Sheffield, Regents Court, 30 Regent StreetSheffield, United Kingdom; Department of Cancer Studies and Molecular Medicine, Clinical Sciences Building, University of Leicester, Leicester Royal InfirmaryLeicester, United Kingdom","Gao, F., National Heart Research Institute Singapore, National Heart Centre Singapore, 5 Hospital Drive, Singapore, Center for Quantitative Medicine, Duke-NUS Graduate Medical School, 8 College Road, Singapore; Earnest, A., Center for Quantitative Medicine, Duke-NUS Graduate Medical School, 8 College Road, Singapore, Department of Epidemiology and Preventive Medicine, Monash University, The Alfred Centre, Level 6, 99 Commercial RoadMelbourne, VIC, Australia; Matchar, D.B., Health Services and Systems Research, Duke-NUS Graduate Medical School, 8 College Road, Singapore, Department of Medicine (General Internal Medicine), Duke University Medical Center, 411 W. Chapel Hill Street, Suite 500Durham, NC, United States; Campbell, M.J., Medical Statistics Group, School of Health and Related Research, University of Sheffield, Regents Court, 30 Regent StreetSheffield, United Kingdom; Machin, D., Medical Statistics Group, School of Health and Related Research, University of Sheffield, Regents Court, 30 Regent StreetSheffield, United Kingdom, Department of Cancer Studies and Molecular Medicine, Clinical Sciences Building, University of Leicester, Leicester Royal InfirmaryLeicester, United Kingdom","Cluster randomized trial designs are growing in popularity in, for example, cardiovascular medicine research and other clinical areas and parallel statistical developments concerned with the design and analysis of these trials have been stimulated. Nevertheless, reviews suggest that design issues associated with cluster randomized trials are often poorly appreciated and there remain inadequacies in, for example, describing how the trial size is determined and the associated results are presented. In this paper, our aim is to provide pragmatic guidance for researchers on the methods of calculating sample sizes. We focus attention on designs with the primary purpose of comparing two interventions with respect to continuous, binary, ordered categorical, incidence rate and time-to-event outcome variables. Issues of aggregate and non-aggregate cluster trials, adjustment for variation in cluster size and the effect size are detailed. The problem of establishing the anticipated magnitude of between- and within-cluster variation to enable planning values of the intra-cluster correlation coefficient and the coefficient of variation are also described. Illustrative examples of calculations of trial sizes for each endpoint type are included. © 2015 Elsevier Inc.","Cluster randomized trial; Intra-class correlation; Sample size","Etxeberria, A., Pérez, I., Alcorta, I., Emparanza, J.I., Ruiz de Velasco, E., Iglesias, M.T., The CLUES study: a cluster randomized clinical trial for the evaluation of cardiovascular guideline implementation in primary care (2013) BMC Health Serv Res, 13, p. 438; Fretheim, A., Oxman, A.D., Håvelsrud, K., Treweek, S., Kristoffersen, D.T., Bjørndal, A., Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention (2006) PLoS Med, 3 (6), p. e134; Kaczorowski, J., Chambers, L.W., Dolovich, L., Paterson, J.M., Karwalajtys, T., Gierman, T., Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP) (2011) BMJ, 342, p. d442; Martin, R.M., Patel, R., Kramer, M.S., Vilchuck, K., Bogdanovich, N., Sergeichick, N., Effects of promoting longer-term and exclusive breastfeeding on cardiometabolic risk factors at age 11.5years: a cluster-randomized, controlled trial (2014) Circulation, 129, pp. 321-329; Pladevall, M., Brotons, C., Gabriel, R., Arnau, A., Suarez, C., de la Figuera, M., Multi-center cluster-randomized trial of a multi-factorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (The COM99 Study) (2010) Circulation, 122, pp. 1183-1191; Lowrie, R., Mair, F.S., Greenlaw, N., Forsyth, P., Jhund, P.S., McConnachie, A., Pharmacist intervention in primary care to improve outcomes in patients with left ventruicular systolic dysfunction (2012) Eur Heart J, 33, pp. 314-324; Gwadry-Sridhar, F., Guyatt, G., O'Brien, B., Arnold, J.M., Walter, S., Vingilis, E., TEACH: Trial of Education And Compliance in Heart dysfunction chronic disease and heart failure (HF) as an increasing problem (2008) Contemp Clin Trials, 29, pp. 905-918; Donner, A., Klar, N., (2000) Design and analysis of cluster randomization trials in health research, , Arnold, London; Eldridge, S., Kerry, S., (2012) A practical guide to cluster randomised trials in health services research, , Chichester, Wiley-Blackwell; Hayes, R.J., Moulton, L., (2009) Cluster randomised trials, , Chapman and Hall/CRC, Boca Raton; Campbell, M.J., Walters, S.J., (2014) How to design, analyse and report cluster randomized trials in medicine and health related research, , Chichester, Wiley-Blackwell; Campbell, M.J., Challenges of cluster randomised trials (2014) J Comp Eff Res, 3, pp. 271-281; Ivers, N.M., Taljaard, M., Dixon, S., Bennett, C., McRae, A., Taleban, J., Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: review of random sample of 300 trials, 2000-8 (2011) BMJ, 343, p. d5886; Campbell, M.K., Elbourne, D.R., Altman, D.G., CONSORT statement: extension to cluster randomized trials (2004) BMJ, 328, pp. 702-708; Campbell, M.J., Extending CONSORT to include cluster trials (2004) BMJ, 328, pp. 654-655; Machin, D., Campbell, M.J., Tan, S.B., Tan, S.H., (2009) Sample size tables for clinical studies, , Chichester, Wiley-Blackwell; Munro, J.F., Nicholl, J.P., Brazier, J.E., Davey, R., Cochrane, T., Cost effectiveness of a community based exercise programme in over 65year olds: cluster randomised trial (2004) J Epidemiol Community Health, 58, pp. 1004-1010; Adams, G., Gulliford, M.C., Ukoumunne, O.C., Eldridge, S., Chinn, S., Campbell, M.J., Patterns of intra-cluster correlation from primary care research to inform study design and analysis (2004) J Clin Epidemiol, 57, pp. 785-794; Thompson, D.M., Fernald, D.H., Mold, J.W., Intraclass correlation coefficients typical of cluster-randomized studies: estimates from the Robert Wood prescription health projects (2012) Ann Fam Med, 10, pp. 235-240; Van Breukelen, G.J.P., Candel, M.J.J.M., Comments on 'Efficiency loss because of varying cluster size in cluster randomized trials is smaller than literature suggests' (2012) Stat Med, 31, pp. 397-400; Dresser, G.K., Nelson, S.A.E., Mahon, J.L., Zou, G., Vandervoort, M.K., Wong, C.J., Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2) (2013) J Hypertens, 31, pp. 1702-1713; Walters, S.J., Munro, J.F., Brazier, J.E., Using the SF-36 with older adults: a cross-sectional community-based survey (2001) Age Aging, 30, pp. 337-343; Tai, B.C., Machin, D., (2014) Regression methods for medical research, , Chichester, Wiley-Blackwell; Whitehead, J., Sample size calculations for ordered categorical data (1993) Stat Med, 12, pp. 2257-2272; Fayers, P.M., Machin, D., (2015) Quality of life, , Chichester, Wiley-Blackwell; Campbell, M.J., Julious, S.A., Altman, D.G., Sample size for binary, ordered categorical, and continuous outcomes in two group comparisons (1995) BMJ, 311, pp. 1145-1148; Hayes, R.J., Bennett, S., Simple sample size calculations for cluster-randomized trials (1999) Int J Epidemiol, 28, pp. 319-326; Xie, T., Waksman, J., Design and sample size estimation in clinical trials with clustered survival times as the primary endpoint (2003) Stat Med, 22, pp. 2835-2846; Campbell, M.K., Piaggio, G., Elbourne, D.R., Altman, D.G., Consort 2010 statement: extension to cluster randomized trials (2012) BMJ, 345, p. e5661",Article,Scopus,2-s2.0-84925864280
"Zhao W., Zheng X.-L., Zhao S.-P.","Exosome and its roles in cardiovascular diseases",2014,"Heart Failure Reviews","20","3",,"337","348",,,10.1007/s10741-014-9469-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926361672&partnerID=40&md5=59ffbf61918cbc7850123774c564b458","Department of Cardiology, The Second Xiangya Hospital, Central South University, No. 139, People StreetChangsha, Hunan, China; Department of Biochemistry and Molecular Biology, The Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, The University of Calgary, Health Sciences Center, 3330 Hospital Dr NWCalgary, AB, Canada","Zhao, W., Department of Cardiology, The Second Xiangya Hospital, Central South University, No. 139, People StreetChangsha, Hunan, China; Zheng, X.-L., Department of Biochemistry and Molecular Biology, The Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, The University of Calgary, Health Sciences Center, 3330 Hospital Dr NWCalgary, AB, Canada; Zhao, S.-P., Department of Cardiology, The Second Xiangya Hospital, Central South University, No. 139, People StreetChangsha, Hunan, China","Exosomes are nanosized vesicles secreted by cells, which are capable of carrying signaling molecules in the forms of protein, mRNA and miRNA to serve as the platforms for complex intercellular communications. During the past few years, increasing efforts have been devoted to exosome research, and tremendous progress has been made in terms of identifying the molecular composition, elucidating the mechanisms and regulations of biogenesis and characterizing the functions in a variety of physiological and pathological settings including cardiovascular diseases, a leading cause of morbidity and mortality in modern society. This review provides an update on exosome research and summarizes the roles of exosomes in cardiovascular diseases. © 2014, Springer Science+Business Media New York.","Biogenesis; Cardiovascular diseases; Exosome; Intercellular communications","Jhund, P.S., McMurray, J.J., Heart failure after acute myocardial infarction: a lost battle in the war on heart failure? (2008) Circulation, 118 (20), pp. 2019-2021. , PID: 19001032; Malliaras, K., Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction) (2014) J Am Coll Cardiol, 63 (2), pp. 110-122. , PID: 24036024; Ibrahim, A.G., Cheng, K., Marban, E., Exosomes as critical agents of cardiac regeneration triggered by cell therapy (2014) Stem Cell Reports, 2 (5), pp. 606-619. , COI: 1:CAS:528:DC%2BC2cXhtFWisLbM, PID: 24936449; Ratajczak, J., Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication (2006) Leukemia, 20 (9), pp. 1487-1495. , COI: 1:CAS:528:DC%2BD28XosVSjsrk%3D, PID: 16791265; Elmore, S., Apoptosis: a review of programmed cell death (2007) Toxicol Pathol, 35 (4), pp. 495-516. , COI: 1:CAS:528:DC%2BD2sXmtlWmtb4%3D, PID: 17562483; Boulanger, C.M., Microparticles, vascular function and hypertension (2010) Curr Opin Nephrol Hypertens, 19 (2), pp. 177-180. , COI: 1:CAS:528:DC%2BC3cXhs1ynsLs%3D, PID: 20051854; Cocucci, E., Racchetti, G., Meldolesi, J., Shedding microvesicles: artefacts no more (2009) Trends Cell Biol, 19 (2), pp. 43-51. , COI: 1:CAS:528:DC%2BD1MXhs1amt7Y%3D, PID: 19144520; Dignat-George, F., Boulanger, C.M., The many faces of endothelial microparticles (2011) Arterioscler Thromb Vasc Biol, 31 (1), pp. 27-33. , COI: 1:CAS:528:DC%2BC3cXhsFGrur3P, PID: 21160065; Lai, R.C., Exosomes for drug delivery—a novel application for the mesenchymal stem cell (2013) Biotechnol Adv, 31 (5), pp. 543-551. , COI: 1:CAS:528:DC%2BC38XhtlSgtL7M, PID: 22959595; Morel, O., Cellular mechanisms underlying the formation of circulating microparticles (2011) Arterioscler Thromb Vasc Biol, 31 (1), pp. 15-26. , COI: 1:CAS:528:DC%2BC3cXhsFGrur3M, PID: 21160064; Baglio, S.R., Pegtel, D.M., Baldini, N., Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy (2012) Front Physiol, 3, p. 359. , PID: 22973239; Heijnen, H.F., Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules (1999) Blood, 94 (11), pp. 3791-3799. , COI: 1:CAS:528:DyaK1MXnslyktLc%3D, PID: 10572093; Rozmyslowicz, T., Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV (2003) AIDS, 17 (1), pp. 33-42. , COI: 1:CAS:528:DC%2BD38XpsVSrs78%3D, PID: 12478067; Thery, C., Exosomes: secreted vesicles and intercellular communications (2011) F1000 Biol Rep, 2011 (3), p. 15; Chargaff, E., West, R., The biological significance of the thromboplastic protein of blood (1946) J Biol Chem, 166 (1), pp. 189-197. , COI: 1:CAS:528:DyaH2sXhtVehuw%3D%3D, PID: 20273687; Wolf, P., The nature and significance of platelet products in human plasma (1967) Br J Haematol, 13 (3), pp. 269-288. , COI: 1:CAS:528:DyaF2sXksVWmtbg%3D, PID: 6025241; Dalton, A.J., Microvesicles and vesicles of multivesicular bodies versus “virus-like” particles (1975) J Natl Cancer Inst, 54 (5), pp. 1137-1148. , COI: 1:STN:280:DyaE2M7ltlKgtw%3D%3D, PID: 165305; Johnstone, R.M., Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes) (1987) J Biol Chem, 262 (19), pp. 9412-9420. , COI: 1:CAS:528:DyaL2sXksFKmsbo%3D, PID: 3597417; Johnstone, R.M., Bianchini, A., Teng, K., Reticulocyte maturation and exosome release: transferrin receptor containing exosomes shows multiple plasma membrane functions (1989) Blood, 74 (5), pp. 1844-1851. , COI: 1:CAS:528:DyaL1MXlvFaitL0%3D, PID: 2790208; Johnstone, R.M., Exosome formation during maturation of mammalian and avian reticulocytes: evidence that exosome release is a major route for externalization of obsolete membrane proteins (1991) J Cell Physiol, 147 (1), pp. 27-36. , COI: 1:CAS:528:DyaK3MXks12iurg%3D, PID: 2037622; Grdisa, M., Mathew, A., Johnstone, R.M., Expression and loss of the transferrin receptor in growing and differentiating HD3 cells (1993) J Cell Physiol, 155 (2), pp. 349-357. , COI: 1:CAS:528:DyaK3sXks1ymurk%3D, PID: 8482727; Johnstone, R.M., The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins (1992) Biochem Cell Biol, 70 (3-4), pp. 179-190. , COI: 1:CAS:528:DyaK38Xitlant7o%3D, PID: 1515120; Choi, D.S., Proteomics of extracellular vesicles: exosomes and ectosomes. Mass Spectrom Rev (2014) doi:10.1002/mas.21420; Raimondo, F., Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery (2011) Proteomics, 11 (4), pp. 709-720. , COI: 1:CAS:528:DC%2BC3MXhsVSnurk%3D, PID: 21241021; Valadi, H., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells (2007) Nat Cell Biol, 9 (6), pp. 654-659. , COI: 1:CAS:528:DC%2BD2sXmtVSmtb8%3D, PID: 17486113; Hong, B.S., Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells (2009) BMC Genom, 10, p. 556; Skog, J., Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers (2008) Nat Cell Biol, 10 (12), pp. 1470-1476. , COI: 1:CAS:528:DC%2BD1cXhsVentbfI, PID: 19011622; Deregibus, M.C., Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA (2007) Blood, 110 (7), pp. 2440-2448. , COI: 1:CAS:528:DC%2BD2sXhtFCnsbrJ, PID: 17536014; Ratajczak, J., Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery (2006) Leukemia, 20 (5), pp. 847-856. , COI: 1:CAS:528:DC%2BD28XjslOhsbs%3D, PID: 16453000; Kogure, T., Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth (2011) Hepatology, 54 (4), pp. 1237-1248. , COI: 1:CAS:528:DC%2BC3MXht1amtbzF, PID: 21721029; Gibbings, D.J., Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity (2009) Nat Cell Biol, 11 (9), pp. 1143-1149. , COI: 1:CAS:528:DC%2BD1MXhtVKrsbnJ, PID: 19684575; Balaj, L., Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences (2011) Nat Commun, 2, p. 180. , PID: 21285958; Wubbolts, R., Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation (2003) J Biol Chem, 278 (13), pp. 10963-10972. , COI: 1:CAS:528:DC%2BD3sXit1Khu7s%3D, PID: 12519789; Laulagnier, K., Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization (2004) Biochem J, 380, pp. 161-171. , COI: 1:CAS:528:DC%2BD2cXks1yqs7o%3D, PID: 14965343; Subra, C., Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies (2007) Biochimie, 89 (2), pp. 205-212. , COI: 1:CAS:528:DC%2BD2sXhtlaqs7g%3D, PID: 17157973; Escola, J.M., Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes (1998) J Biol Chem, 273 (32), pp. 20121-20127. , COI: 1:CAS:528:DyaK1cXlsVWgsbs%3D, PID: 9685355; Mittelbrunn, M., Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells (2011) Nat Commun, 2, p. 282. , PID: 21505438; Montecalvo, A., Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes (2012) Blood, 119 (3), pp. 756-766. , COI: 1:CAS:528:DC%2BC38Xhs1Kjtb0%3D, PID: 22031862; Henne, W.M., Buchkovich, N.J., Emr, S.D., The ESCRT pathway (2011) Dev Cell, 21 (1), pp. 77-91. , COI: 1:CAS:528:DC%2BC3MXptVSqsr8%3D, PID: 21763610; Hanson, P.I., Shim, S., Merrill, S.A., Cell biology of the ESCRT machinery (2009) Curr Opin Cell Biol, 21 (4), pp. 568-574. , COI: 1:CAS:528:DC%2BD1MXps1CltbY%3D, PID: 19560911; Hurley, J.H., The ESCRT complexes (2010) Crit Rev Biochem Mol Biol, 45 (6), pp. 463-487. , COI: 1:CAS:528:DC%2BC3cXhsVeksbnL, PID: 20653365; Raiborg, C., Stenmark, H., The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins (2009) Nature, 458 (7237), pp. 445-452. , COI: 1:CAS:528:DC%2BD1MXjs1Klurs%3D, PID: 19325624; Thery, C., Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles (2001) J Immunol, 166 (12), pp. 7309-7318. , COI: 1:CAS:528:DC%2BD3MXksVOnu78%3D, PID: 11390481; Mathivanan, S., Simpson, R.J., ExoCarta: a compendium of exosomal proteins and RNA (2009) Proteomics, 9 (21), pp. 4997-5000. , COI: 1:CAS:528:DC%2BD1MXhtleqtbbE, PID: 19810033; Tamai, K., Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein (2010) Biochem Biophys Res Commun, 399 (3), pp. 384-390. , COI: 1:CAS:528:DC%2BC3cXhtV2gur3K, PID: 20673754; Colombo, M., Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles (2013) J Cell Sci, 126, pp. 5553-5565. , COI: 1:CAS:528:DC%2BC2cXhtFyksLY%3D, PID: 24105262; Baietti, M.F., Syndecan-syntenin-ALIX regulates the biogenesis of exosomes (2012) Nat Cell Biol, 14 (7), pp. 677-685. , COI: 1:CAS:528:DC%2BC38XnvVyqtr0%3D, PID: 22660413; Odorizzi, G., The multiple personalities of Alix (2006) J Cell Sci, 119, pp. 3025-3032. , COI: 1:CAS:528:DC%2BD28Xpt1alt7s%3D, PID: 16868030; Stuffers, S., Multivesicular endosome biogenesis in the absence of ESCRTs (2009) Traffic, 10 (7), pp. 925-937. , COI: 1:CAS:528:DC%2BD1MXotFGrsbo%3D, PID: 19490536; Trajkovic, K., Ceramide triggers budding of exosome vesicles into multivesicular endosomes (2008) Science, 319 (5867), pp. 1244-1247. , COI: 1:CAS:528:DC%2BD1cXisVSksLY%3D, PID: 18309083; Yuyama, K., Sphingolipid-modulated exosome secretion promotes clearance of amyloid-beta by microglia (2012) J Biol Chem, 287 (14), pp. 10977-10989. , COI: 1:CAS:528:DC%2BC38XkvVWls7g%3D, PID: 22303002; Kosaka, N., Secretory mechanisms and intercellular transfer of microRNAs in living cells (2010) J Biol Chem, 285 (23), pp. 17442-17452. , COI: 1:CAS:528:DC%2BC3cXmslSnurY%3D, PID: 20353945; Kajimoto, T., Ongoing activation of sphingosine 1-phosphate receptors mediates maturation of exosomal multivesicular endosomes (2013) Nat Commun, 4, p. 2712. , PID: 24231649; Laulagnier, K., PLD2 is enriched on exosomes and its activity is correlated to the release of exosomes (2004) FEBS Lett, 572 (1-3), pp. 11-14. , COI: 1:CAS:528:DC%2BD2cXmsVGhs78%3D, PID: 15304316; Parolini, I., Signal transduction and glycophosphatidylinositol-linked proteins (lyn, lck, CD4, CD45, G proteins, and CD55) selectively localize in Triton-insoluble plasma membrane domains of human leukemic cell lines and normal granulocytes (1996) Blood, 87 (9), pp. 3783-3794. , COI: 1:CAS:528:DyaK28Xis1Sjt7s%3D, PID: 8611704; Salzer, U., Prohaska, R., Stomatin, flotillin-1, and flotillin-2 are major integral proteins of erythrocyte lipid rafts (2001) Blood, 97 (4), pp. 1141-1143. , COI: 1:CAS:528:DC%2BD3MXht1Gis7g%3D, PID: 11159550; Snyers, L., Umlauf, E., Prohaska, R., Oligomeric nature of the integral membrane protein stomatin (1998) J Biol Chem, 273 (27), pp. 17221-17226. , COI: 1:CAS:528:DyaK1cXkt12hu70%3D, PID: 9642292; de Gassart, A., Lipid raft-associated protein sorting in exosomes (2003) Blood, 102 (13), pp. 4336-4344. , PID: 12881314; Fang, Y., Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes (2007) PLoS Biol, 5 (6), p. 158. , PID: 17550307; Vidal, M., Mangeat, P., Hoekstra, D., Aggregation reroutes molecules from a recycling to a vesicle-mediated secretion pathway during reticulocyte maturation (1997) J Cell Sci, 110, pp. 1867-1877. , COI: 1:CAS:528:DyaK2sXlvVaqsbc%3D, PID: 9296387; Zhu, H., Mutation of SIMPLE in Charcot-Marie-Tooth 1C alters production of exosomes (2013) Mol Biol Cell 24(11), 1619-1637, pp. 1-3; Yu, X., Harris, S.L., Levine, A.J., The regulation of exosome secretion: a novel function of the p53 protein (2006) Cancer Res, 66 (9), pp. 4795-4801. , COI: 1:CAS:528:DC%2BD28XjvF2kt74%3D, PID: 16651434; Ghossoub, R., Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2 (2014) Nat Commun, 5, p. 3477. , PID: 24637612; Halkein, J., MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy (2013) J Clin Invest, 123 (5), pp. 2143-2154. , COI: 1:CAS:528:DC%2BC3sXns1Ght7w%3D, PID: 23619365; Hergenreider, E., Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs (2012) Nat Cell Biol, 14 (3), pp. 249-256. , COI: 1:CAS:528:DC%2BC38XitFalu7c%3D, PID: 22327366; Montecalvo, A., Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition (2008) J Immunol, 180 (5), pp. 3081-3090. , COI: 1:CAS:528:DC%2BD1cXit1Oks78%3D, PID: 18292531; Pegtel, D.M., Functional delivery of viral miRNAs via exosomes (2010) Proc Natl Acad Sci USA, 107 (14), pp. 6328-6333. , COI: 1:CAS:528:DC%2BC3cXkslehsLo%3D, PID: 20304794; Nolte-’t Hoen, E.N., Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions (2012) Nucleic Acids Res, 40 (18), pp. 9272-9285. , PID: 22821563; Zhang, Y., Secreted monocytic miR-150 enhances targeted endothelial cell migration (2010) Mol Cell, 39 (1), pp. 133-144. , COI: 1:CAS:528:DC%2BC3cXpsFejs74%3D, PID: 20603081; Pigati, L., Selective release of microRNA species from normal and malignant mammary epithelial cells (2010) PLoS One, 5 (10), p. 13515. , PID: 20976003; Villarroya-Beltri, C., Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs (2013) Nat Commun, 4, p. 2980. , PID: 24356509; Munro, T.P., Mutational analysis of a heterogeneous nuclear ribonucleoprotein A2 response element for RNA trafficking (1999) J Biol Chem, 274 (48), pp. 34389-34395. , COI: 1:CAS:528:DyaK1MXnslOktLs%3D, PID: 10567417; Hoek, K.S., hnRNP A2 selectively binds the cytoplasmic transport sequence of myelin basic protein mRNA (1998) Biochemistry, 37 (19), pp. 7021-7029. , COI: 1:CAS:528:DyaK1cXis12lsbg%3D, PID: 9578590; Levesque, K., Trafficking of HIV-1 RNA is mediated by heterogeneous nuclear ribonucleoprotein A2 expression and impacts on viral assembly (2006) Traffic, 7 (9), pp. 1177-1193. , COI: 1:CAS:528:DC%2BD28XhtVSksLzE, PID: 17004321; Beriault, V., A late role for the association of hnRNP A2 with the HIV-1 hnRNP A2 response elements in genomic RNA, Gag, and Vpr localization (2004) J Biol Chem, 279 (42), pp. 44141-44153. , COI: 1:CAS:528:DC%2BD2cXot1yns7o%3D, PID: 15294897; Filipenko, N.R., Annexin A2 is a novel RNA-binding protein (2004) J Biol Chem, 279 (10), pp. 8723-8731. , COI: 1:CAS:528:DC%2BD2cXhs1OntL4%3D, PID: 14672933; Hollas, H., Annexin A2 recognises a specific region in the 3′-UTR of its cognate messenger RNA (2006) Biochim Biophys Acta, 1763 (11), pp. 1325-1334. , COI: 1:CAS:528:DC%2BD28Xht1CnsLbF, PID: 17045350; Mickleburgh, I., Annexin A2 binds to the localization signal in the 3′ untranslated region of c-myc mRNA (2005) FEBS J, 272 (2), pp. 413-421. , COI: 1:CAS:528:DC%2BD2MXptFeisw%3D%3D, PID: 15654879; Parolini, I., Microenvironmental pH is a key factor for exosome traffic in tumor cells (2009) J Biol Chem, 284 (49), pp. 34211-34222. , COI: 1:CAS:528:DC%2BD1MXhsVymu7fN, PID: 19801663; Hedlund, M., Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells (2011) PLoS One, 6 (2), p. 16899. , COI: 1:CAS:528:DC%2BC3MXjtVyls7s%3D, PID: 21364924; Eldh, M., Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA (2010) PLoS One, 5 (12), p. 15353. , PID: 21179422; King, H.W., Michael, M.Z., Gleadle, J.M., Hypoxic enhancement of exosome release by breast cancer cells (2012) BMC Cancer, 12, p. 421. , COI: 1:CAS:528:DC%2BC3sXitVajsA%3D%3D, PID: 22998595; Raposo, G., Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation (1997) Mol Biol Cell, 8 (12), pp. 2631-2645. , COI: 1:CAS:528:DyaK2sXotVWns7w%3D, PID: 9398681; Savina, A., Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner (2005) Traffic, 6 (2), pp. 131-143. , COI: 1:CAS:528:DC%2BD2MXhtVWmsr4%3D, PID: 15634213; Faure, J., Exosomes are released by cultured cortical neurones (2006) Mol Cell Neurosci, 31 (4), pp. 642-648. , COI: 1:CAS:528:DC%2BD28XjtFOlsbg%3D, PID: 16446100; Blanchard, N., TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex (2002) J Immunol, 168 (7), pp. 3235-3241. , COI: 1:CAS:528:DC%2BD38Xis1ajsLc%3D, PID: 11907077; Malik, Z.A., Cardiac myocyte exosomes: stability, HSP60, and proteomics (2013) Am J Physiol Heart Circ Physiol, 304 (7), pp. 954-965. , COI: 1:CAS:528:DC%2BC3sXnsV2nsrc%3D, PID: 23376832; Genneback, N., Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes. J Extracell Vesicles (2013) doi:10.3402/jev.v2i0.20167; Waldenstrom, A., Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells (2012) PLoS One, 7 (4), p. 34653. , PID: 22506041; Manole, C.G., Experimental acute myocardial infarction: telocytes involvement in neo-angiogenesis (2011) J Cell Mol Med, 15 (11), pp. 2284-2296. , COI: 1:CAS:528:DC%2BC3MXhsFGrurvK, PID: 21895968; Barile, L., Ultrastructural evidence of exosomes secretion by progenitor cells in adult mouse myocardium and adult human cardiospheres (2012) J Biomed Biotechnol, 2012, p. 354605. , PID: 23226938; Stenmark, H., Rab GTPases as coordinators of vesicle traffic (2009) Nat Rev Mol Cell Biol, 10 (8), pp. 513-525. , COI: 1:CAS:528:DC%2BD1MXosFWhsrs%3D, PID: 19603039; Sonnichsen, B., Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11 (2000) J Cell Biol, 149 (4), pp. 901-914. , COI: 1:CAS:528:DC%2BD3cXjtlKns70%3D, PID: 10811830; Hsu, C., Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C (2010) J Cell Biol, 189 (2), pp. 223-232. , COI: 1:CAS:528:DC%2BC3cXlt1Kgsr4%3D, PID: 20404108; Koles, K., Mechanism of evenness interrupted (Evi)-exosome release at synaptic boutons (2012) J Biol Chem, 287 (20), pp. 16820-16834. , COI: 1:CAS:528:DC%2BC38XmvVKnsrw%3D, PID: 22437826; Savina, A., Vidal, M., Colombo, M.I., The exosome pathway in K562 cells is regulated by Rab11 (2002) J Cell Sci, 115, pp. 2505-2515. , COI: 1:CAS:528:DC%2BD38XlsVCqur4%3D, PID: 12045221; Amzallag, N., TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway (2004) J Biol Chem, 279 (44), pp. 46104-46112. , COI: 1:CAS:528:DC%2BD2cXovVCntLc%3D, PID: 15319436; Nazarenko, I., Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation (2010) Cancer Res, 70 (4), pp. 1668-1678. , COI: 1:CAS:528:DC%2BC3cXhvFaktrs%3D, PID: 20124479; Hwang, I., Shen, X., Sprent, J., Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells: distinct roles for CD54 and B7 molecules (2003) Proc Natl Acad Sci USA, 100 (11), pp. 6670-6675. , COI: 1:CAS:528:DC%2BD3sXktlygs7g%3D, PID: 12743365; Morelli, A.E., Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells (2004) Blood, 104 (10), pp. 3257-3266. , COI: 1:CAS:528:DC%2BD2cXhtVWhurrI, PID: 15284116; Miyanishi, M., Identification of Tim4 as a phosphatidylserine receptor (2007) Nature, 450 (7168), pp. 435-439. , COI: 1:CAS:528:DC%2BD2sXhtlajs77P, PID: 17960135; Saunderson, S.C., CD169 mediates the capture of exosomes in spleen and lymph node (2014) Blood, 123 (2), pp. 208-216. , COI: 1:CAS:528:DC%2BC2cXhtV2ks7o%3D, PID: 24255917; Barres, C., Galectin-5 is bound onto the surface of rat reticulocyte exosomes and modulates vesicle uptake by macrophages (2010) Blood, 115 (3), pp. 696-705. , COI: 1:CAS:528:DC%2BC3cXhsFegsbk%3D, PID: 19903899; Svensson, K.J., Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1 (2013) J Biol Chem, 288 (24), pp. 17713-17724. , COI: 1:CAS:528:DC%2BC3sXpsFagtro%3D, PID: 23653359; Gallo, A., The majority of microRNAs detectable in serum and saliva is concentrated in exosomes (2012) PLoS One, 7 (3), p. 30679. , COI: 1:CAS:528:DC%2BC38XktlSktrs%3D, PID: 22427800; Gupta, S., Knowlton, A.A., HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway (2007) Am J Physiol Heart Circ Physiol, 292 (6), pp. 3052-3056. , COI: 1:CAS:528:DC%2BD2sXmvF2ksLw%3D, PID: 17307989; Quaini, F., End-stage cardiac failure in humans is coupled with the induction of proliferating cell nuclear antigen and nuclear mitotic division in ventricular myocytes (1994) Circ Res, 75 (6), pp. 1050-1063. , COI: 1:CAS:528:DyaK2MXitlSjtLc%3D, PID: 7955143; Yu, X., Mechanism of TNF-alpha autocrine effects in hypoxic cardiomyocytes: initiated by hypoxia inducible factor 1alpha, presented by exosomes (2012) J Mol Cell Cardiol, 53 (6), pp. 848-857. , COI: 1:CAS:528:DC%2BC38Xhs1ajt7fI, PID: 23085511; Zhang, X., Hsp20 functions as a novel cardiokine in promoting angiogenesis via activation of VEGFR2 (2012) PLoS One, 7 (3), p. 32765. , COI: 1:CAS:528:DC%2BC38XksFGltbc%3D, PID: 22427880; Kuwabara, Y., Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage (2011) Circ Cardiovasc Genet, 4 (4), pp. 446-454. , COI: 1:CAS:528:DC%2BC3MXhtF2itbfM, PID: 21642241; Cheng, Y., A translational study of urine miRNAs in acute myocardial infarction (2012) J Mol Cell Cardiol, 53 (5), pp. 668-676. , COI: 1:CAS:528:DC%2BC38XhtlSktL7M, PID: 22921780; Aurora, A.B., MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca(2)(+) overload and cell death (2012) J Clin Invest, 122 (4), pp. 1222-1232. , COI: 1:CAS:528:DC%2BC38Xlt1egtb4%3D, PID: 22426211; van Balkom, B.W., Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells (2013) Blood 121(19), 3997-4006, pp. 1-15; Lu, H.Q., Circulating miR-214 is associated with the severity of coronary artery disease (2013) J Geriatr Cardiol, 10 (1), pp. 34-38. , PID: 23610572; Feng, Y., Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22 (2014) PLoS One, 9 (2), p. 88685. , PID: 24558412; Zampetaki, A., Prospective study on circulating MicroRNAs and risk of myocardial infarction (2012) J Am Coll Cardiol, 60 (4), pp. 290-299. , COI: 1:CAS:528:DC%2BC38XhtV2isLjP, PID: 22813605; Rautou, P.E., Microparticles, vascular function, and atherothrombosis (2011) Circ Res, 109 (5), pp. 593-606. , COI: 1:CAS:528:DC%2BC3MXhtVCrt7rE, PID: 21852557; Sahoo, S., Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity (2011) Circ Res, 109 (7), pp. 724-728. , COI: 1:CAS:528:DC%2BC3MXhtFyjt7bM, PID: 21835908; Mocharla, P., AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics (2013) Blood, 121 (1), pp. 226-236. , COI: 1:CAS:528:DC%2BC3sXps1Cisg%3D%3D, PID: 23144172; De Rosa, S., Transcoronary concentration gradients of circulating microRNAs (2011) Circulation, 124 (18), pp. 1936-1944. , PID: 21969012; Chen, J., mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts (2013) Circ Res, 112 (12), pp. 1557-1566. , COI: 1:CAS:528:DC%2BC3sXovVehtr8%3D, PID: 23575307; Huang, Z.P., MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress (2013) Circ Res, 112 (9), pp. 1234-1243. , COI: 1:CAS:528:DC%2BC3sXmsFWrsb8%3D, PID: 23524588; Eulalio, A., Functional screening identifies miRNAs inducing cardiac regeneration (2012) Nature, 492 (7429), pp. 376-381. , COI: 1:CAS:528:DC%2BC38Xhslynu7jO, PID: 23222520; Sayed, D., MicroRNAs play an essential role in the development of cardiac hypertrophy (2007) Circ Res, 100 (3), pp. 416-424. , COI: 1:CAS:528:DC%2BD2sXhsF2ku70%3D, PID: 17234972; Busk, P.K., Cirera, S., MicroRNA profiling in early hypertrophic growth of the left ventricle in rats (2010) Biochem Biophys Res Commun, 396 (4), pp. 989-993. , COI: 1:CAS:528:DC%2BC3cXnsVanu7k%3D, PID: 20470752; Royo, M.B., Comparative effectiveness: the employer perspective (2009) Biotechnol Healthc, 6 (3), pp. 26-29. , PID: 22478774; Wei, C., NF-kappaB mediated miR-26a regulation in cardiac fibrosis (2013) J Cell Physiol, 228 (7), pp. 1433-1442. , COI: 1:CAS:528:DC%2BC3sXktleqsrY%3D, PID: 23254997; Shieh, J.T., Elevated miR-499 levels blunt the cardiac stress response (2011) PLoS One, 6 (5), p. 19481. , COI: 1:CAS:528:DC%2BC3MXmtFKisL0%3D, PID: 21573063; Boon, R.A., MicroRNA-34a regulates cardiac ageing and function (2013) Nature, 495 (7439), pp. 107-110. , COI: 1:CAS:528:DC%2BC3sXjsFCjt7k%3D, PID: 23426265; Fiedler, J., Thum, T., MicroRNAs in myocardial infarction (2013) Arterioscler Thromb Vasc Biol, 33 (2), pp. 201-205. , COI: 1:CAS:528:DC%2BC3sXht1Kksb0%3D, PID: 23325477; Bang, C., Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy (2014) J Clin Invest, 124 (5), pp. 2136-2146. , COI: 1:CAS:528:DC%2BC2cXotVSnsbY%3D, PID: 24743145; Kakkar, R., Lee, R.T., Intramyocardial fibroblast myocyte communication (2010) Circ Res, 106 (1), pp. 47-57. , COI: 1:CAS:528:DC%2BD1MXhs1aqt7nO, PID: 20056945; Timmers, L., Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium (2007) Stem Cell Res, 1 (2), pp. 129-137. , COI: 1:CAS:528:DC%2BD1MXjvVyrtg%3D%3D, PID: 19383393; Lai, R.C., Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury (2010) Stem Cell Res, 4 (3), pp. 214-222. , COI: 1:CAS:528:DC%2BC3cXpsFajs7g%3D, PID: 20138817; Arslan, F., Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3 K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury (2013) Stem Cell Res, 10 (3), pp. 301-312. , COI: 1:CAS:528:DC%2BC3sXlt1Cms7Y%3D, PID: 23399448; Chimenti, I., Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice (2010) Circ Res, 106 (5), pp. 971-980. , COI: 1:CAS:528:DC%2BC3cXjs1arsro%3D, PID: 20110532; Crisostomo, P.R., Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions (2008) Am J Physiol Heart Circ Physiol, 295 (4), pp. 1726-1735. , COI: 1:CAS:528:DC%2BD1cXht1ymurzI, PID: 18723770; Gnecchi, M., Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement (2006) FASEB J, 20 (6), pp. 661-669. , COI: 1:CAS:528:DC%2BD28XjtlensLc%3D, PID: 16581974; Salomon, C., Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis (2013) PLoS One, 8 (7), p. 68451. , COI: 1:CAS:528:DC%2BC3sXhtFOmt7rP, PID: 23861904; Vrijsen, K.R., Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells (2010) J Cell Mol Med, 14 (5), pp. 1064-1070. , COI: 1:CAS:528:DC%2BC3cXpslOlu74%3D, PID: 20465578; Xu, Q., Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease (2012) J Am Coll Cardiol, 59 (23), pp. 2107-2117. , COI: 1:CAS:528:DC%2BC38XnvFOhsb4%3D, PID: 22651868; Jakob, P., Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity (2012) Circulation, 126 (25), pp. 2962-2975. , COI: 1:CAS:528:DC%2BC38XhvVCqsL3J, PID: 23136161; Tano, N., Kim, H.W., Ashraf, M., microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4 (2011) PLoS One, 6 (10), p. 23114. , COI: 1:CAS:528:DC%2BC3MXhsVaksr%2FN, PID: 22039399; Laflamme, M.A., Murry, C.E., Heart regeneration (2011) Nature, 473 (7347), pp. 326-335. , COI: 1:CAS:528:DC%2BC3MXmtlels7c%3D, PID: 21593865; Malliaras, K., Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart (2013) EMBO Mol Med, 5 (2), pp. 191-209. , COI: 1:CAS:528:DC%2BC3sXhvVykt78%3D, PID: 23255322; Asahara, T., Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization (1999) Circ Res, 85 (3), pp. 221-228. , COI: 1:CAS:528:DyaK1MXltFGgs7Y%3D, PID: 10436164; Linke, A., Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function (2005) Proc Natl Acad Sci USA, 102 (25), pp. 8966-8971. , COI: 1:CAS:528:DC%2BD2MXlvF2qu7c%3D, PID: 15951423; Jujo, K., CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction (2010) Proc Natl Acad Sci USA, 107 (24), pp. 11008-11013. , COI: 1:CAS:528:DC%2BC3cXotVGnt7s%3D, PID: 20534467; Barile, L., Bone marrow-derived cells can acquire cardiac stem cells properties in damaged heart (2011) J Cell Mol Med, 15 (1), pp. 63-71. , COI: 1:CAS:528:DC%2BC3MXjs1yks7o%3D, PID: 19912439; Leri, A., Kajstura, J., Anversa, P., Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology (2011) Circ Res, 109 (8), pp. 941-961. , COI: 1:CAS:528:DC%2BC3MXht1eqsrzE, PID: 21960726; Yoon, C.H., Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases (2005) Circulation, 112 (11), pp. 1618-1627. , PID: 16145003; Losordo, D.W., Intramyocardial, autologous CD34+ cell therapy for refractory angina (2011) Circ Res, 109 (4), pp. 428-436. , COI: 1:CAS:528:DC%2BC3MXpslOktr8%3D, PID: 21737787; Bolli, R., Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial (2011) Lancet, 378 (9806), pp. 1847-1857. , PID: 22088800; Chugh, A.R., Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance (2012) Circulation, 126, pp. 54-64. , COI: 1:CAS:528:DC%2BC38XhtlCitbvF, PID: 22965994; Williams, A.R., Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction (2013) Circulation, 127 (2), pp. 213-223. , PID: 23224061; Leistner, D.M., Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy (2011) Clin Res Cardiol, 100 (10), pp. 925-934. , PID: 21633921; Makkar, R.R., Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial (2012) Lancet, 379 (9819), pp. 895-904. , PID: 22336189; Wollert, K.C., Drexler, H., Cell therapy for the treatment of coronary heart disease: a critical appraisal (2010) Nat Rev Cardiol, 7 (4), pp. 204-215. , PID: 20177405; Tongers, J., Losordo, D.W., Landmesser, U., Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges (2011) Eur Heart J, 32 (10), pp. 1197-1206. , COI: 1:CAS:528:DC%2BC3MXmt1yms7k%3D, PID: 21362705; Ratajczak, M.Z., Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies? (2012) Leukemia, 26 (6), pp. 1166-1173. , COI: 1:CAS:528:DC%2BC38Xot1enurs%3D, PID: 22182853; Bearzi, C., Human cardiac stem cells (2007) Proc Natl Acad Sci USA, 104 (35), pp. 14068-14073. , COI: 1:CAS:528:DC%2BD2sXhtVSrtbvN, PID: 17709737; Wyrick, D.L., Smith, S.D., Dassinger, M.S., Surgeon as educator: bedside ultrasound in hypertrophic pyloric stenosis (2014) J Surg Educ, 71 (6), pp. 896-898. , PID: 24931414; Li, T.S., Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells (2012) J Am Coll Cardiol, 59 (10), pp. 942-953. , PID: 22381431; Matar, A.A., Chong, J.J., Stem cell therapy for cardiac dysfunction (2014) SpringerPlus, 3, p. 440. , PID: 25191634; Marban, E., Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells (2014) Mayo Clin Proc, 89 (6), pp. 850-858. , PID: 24943699; Mackie, A.R., Sonic hedgehog-modified human CD34+ cells preserve cardiac function after acute myocardial infarction (2012) Circ Res, 111 (3), pp. 312-321. , COI: 1:CAS:528:DC%2BC38XhtVGhsL7L, PID: 22581926; Lee, C., Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension (2012) Circulation, 126 (22), pp. 2601-2611. , COI: 1:CAS:528:DC%2BC38XhslGjs73I, PID: 23114789; Sahoo, S., Losordo, D.W., Exosomes and cardiac repair after myocardial infarction (2014) Circ Res, 114 (2), pp. 333-344. , COI: 1:CAS:528:DC%2BC2cXhvVSkurg%3D, PID: 24436429; Chen, L., Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury (2013) Biochem Biophys Res Commun, 431 (3), pp. 566-571. , COI: 1:CAS:528:DC%2BC3sXhvFSlsrg%3D, PID: 23318173; Matsumoto, S., Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction (2013) Circ Res, 113 (3), pp. 322-326. , COI: 1:CAS:528:DC%2BC3sXhtFams7bK, PID: 23743335; Gray, W.D., Identification of therapeutic covariant microRNA clusters in hypoxia treated cardiac progenitor cell exosomes using systems biology (2014) Circ Res. pii: CIRCRESAHA, p. 114; Barile, L., Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction (2014) Cardiovasc Res, 103 (4), pp. 530-541. , COI: 1:CAS:528:DC%2BC2cXhsleitbbI, PID: 25016614",Article,Scopus,2-s2.0-84926361672
"Hughes M., Lilleker J.B., Herrick A.L., Chinoy H.","Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: Biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity",2015,"Annals of the Rheumatic Diseases","74","5",,"795","798",,,10.1136/annrheumdis-2014-206812,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926432141&partnerID=40&md5=aac37e405acbe93153a2b8e7575aa645","Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Stott LaneSalford, Manchester, United Kingdom","Hughes, M., Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Stott LaneSalford, Manchester, United Kingdom; Lilleker, J.B., Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Stott LaneSalford, Manchester, United Kingdom; Herrick, A.L., Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Stott LaneSalford, Manchester, United Kingdom; Chinoy, H., Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Stott LaneSalford, Manchester, United Kingdom","Primary cardiac involvement, an under-recognised manifestation of the idiopathic inflammatory myopathies (IIM) and systemic sclerosis (SSc)-spectrum disorders, is associated with significant mortality. Within these two conditions, traditional skeletal muscle enzyme testing may not effectively distinguish between skeletal and cardiac muscle involvement, especially in patients with subclinical cardiac disease. Accurate biomarkers are thus required to screen for cardiac disease, to better inform both therapeutic decision-making and treatment response. The widespread uptake of cardiac troponin testing has revolutionised the management of acute coronary syndromes. While cardiac troponin I (cTnI) appears specific to the myocardium, cardiac troponin T (cTnT) is also expressed by skeletal muscle, including regenerating skeletal muscle tissue. There is increasing interest about the role of cardiac troponins as a putative biomarker of primary cardiac involvement in IIM and SSc-spectrum disorders. Herewith we discuss subclinical cardiac disease in IIM and SSc-spectrum disorders, the respective roles of cTnI and cTnT testing, and the re-expression of cTnT within regenerating skeletal muscle tissue. There remains wide variation in access to cardiac troponin testing nationally and internationally. We propose two pragmatic clinical pathways using cardiac troponins, preferably measuring concomitant cTnT followed by confirmatory (cardiac) cTnI to screen patients for subclinical cardiac disease and/or low-grade skeletal muscle disease activity, and also an agenda for future research.",,"Denbow, C.E., Lie, J.T., Tancredi, R.G., Cardiac involvement in polymyositis: A clinicopathologic study of 20 autopsied patients (1979) Arthritis Rheum, 22, pp. 1088-1092; Steen, V.D., Medsger, T.A., Jr., Severe organ involvement in systemic sclerosis with diffuse scleroderma (2000) Arthritis Rheum, 43, pp. 2437-2444; Lundberg, I.E., The heart in dermatomyositis and polymyositis (2006) Rheumatology (Oxford), 45, pp. iv18-21; Kahan, A., Coghlan, G., McLaughlin, V., Cardiac complications of systemic sclerosis (2009) Rheumatology (Oxford), 48, pp. iii45-8; Tyndall, A.J., Bannert, B., Vonk, M., Causes and risk factors for death in systemic sclerosis: A study from the EULAR scleroderma trials and research (EUSTAR) database (2010) Ann Rheum Dis, 69, pp. 1809-1815; Zhang, L., Wang, G.C., Ma, L., Cardiac involvement in adult polymyositis or dermatomyositis: A systematic review (2012) Clin Cardiol, 35, pp. 686-691; Bulkley, B.H., Ridolfi, R.L., Salyer, W.R., Myocardial lesions of progressive systemic sclerosis: A cause of cardiac dysfunction (1976) Circulation, 53, pp. 483-490; Meune, C., Vignaux, O., Kahan, A., Heart involvement in systemic sclerosis: Evolving concept and diagnostic methodologies (2010) Arch Cardiovasc Dis, 103, pp. 46-52; Lai, Y.T., Dai, Y.S., Yen, M.F., Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: A Taiwanese population-based longitudinal follow-up study (2013) Br J Dermatol, 168, pp. 1054-1059; Man, A., Zhu, Y., Zhang, Y., The risk of cardiovascular disease in systemic sclerosis: A population-based cohort study (2013) Ann Rheum Dis, 72, pp. 1188-1193; Bodor, G.S., Survant, L., Voss, E.M., Cardiac troponin T composition in normal and regenerating human skeletal muscle (1997) Clin Chem, 43, pp. 476-484; Skeik, N., Patel, D.C., A review of troponins in ischemic heart disease and other conditions (2007) Int J Angiol, 16, pp. 53-58; Clause, K.C., Tchao, J., Powell, M.C., Developing cardiac and skeletal muscle share fast-skeletal myosin heavy chain and cardiac troponin-I expression (2012) PLoS One, 7; Adams, J.E., III, Bodor, G.S., Dávila-Román, V.G., Cardiac troponin I: A marker with high specificity for cardiac injury (1993) Circulation, 88, pp. 101-106; Anderson, P.A.W., Malouf, N.N., Oakeley, A.E., Troponin T isoform expression in humans: A comparison among normal and failing adult heart, fetal heart and adult and fetal skeletal muscle (1991) Circ Res, 69, pp. 1226-1233; Erlacher, P., Lercher, A., Falkensammer, J., Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis (2001) Clin Chim Acta, 306, pp. 27-33; Hamm, C.W., Goldmann, B.U., Heeschen, C., Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I (1997) N Engl J Med, 337, pp. 1648-1653; Maynard, S., Menown, I., Adgey, A., Troponin T or troponin I as cardiac markers in ischaemic heart disease (2000) Heart, 83, pp. 371-373; Jeremias, A., Gibson, C.M., Narrative review: Alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded (2005) Ann Intern Med, 142, pp. 786-791; Agewall, S., Giannitsis, E., Jernberg, T., Troponin elevation in coronary vs. Non-coronary disease (2011) Eur Heart J, 32, pp. 404-411; Hamilton, J.S., Sharpe, P.C., Two cases of inflammatory muscle disease presenting with raised serum concentrations of troponin T (2005) J Clin Pathol, 58, pp. 1323-1324; Schwarzmeier, J.D., Hamwi, A., Preisel, M., Positive troponin T without cardiac involvement in inclusion body myositis (2005) Hum Pathol, 36, pp. 917-921; Lindberg, C., Klintberg, L., Oldfors, A., Raised troponin T in inclusion body myositis is common and serum levels are persistent over time (2006) Neuromuscul Disord, 16, pp. 495-497; Aggarwal, R., Lebiedz-Odrobina, D., Sinha, A., Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies (2009) J Rheumatol, 36, pp. 2711-2714; Cox, F.M., Delgado, V., Verschuuren, J.J., The heart in sporadic inclusion body myositis: A study in 51 patients (2010) J Neurol, 257, pp. 447-451; Dinser, R., Frerix, M., Meier, F.M.P., Endocardial and myocardial involvement in systemic sclerosis-is there a relevant inflammatory component? (2013) Joint Bone Spine, 80, pp. 320-323; Vasta, B., Flower, V., Bucciarelli-Ducci, C., Abnormal cardiac enzymes in systemic sclerosis: A report of four patients and review of the literature (2014) Clin Rheumatol, 33, pp. 435-438; Miller, F.W., Rider, L.G., Chung, Y.L., Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies (2001) Rheumatology (Oxford), 40, pp. 1262-1273; Kiely, P.D.W., Bruckner, F.E., Nisbet, J.A., Serum skeletal troponin I in inflammatory muscle disease: Relation to creatine kinase, CKMB and cardiac troponin I (2000) Ann Rheum Dis, 59, pp. 750-751",Review,Scopus,2-s2.0-84926432141
"Heras Canas V., Perez Ramirez M.D., Bermudez Jimenez F., Rojo Martin M.D., Miranda Casas C., Marin Arriaza M., Navarro Mari J.M.","Lactococcus garvieae endocarditis in a native valve identified by MALDI-TOF MS and PCR-based 16s rRNA in Spain: A case report",2015,"New Microbes and New Infections","5",,,"13","15",,,10.1016/j.nmni.2015.02.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928396079&partnerID=40&md5=3dc476b883cfbd6bf20a37f2a63583f3","Department of Microbiology, University Hospital Virgen de las NievesGranada, Spain; Department of Cardiology, University Hospital Virgen de las NievesGranada, Spain; Department of Molecular Biology, University General Hospital Gregorio MarañonMadrid, Spain","Heras Cañas, V., Department of Microbiology, University Hospital Virgen de las NievesGranada, Spain; Pérez Ramirez, M.D., Department of Microbiology, University Hospital Virgen de las NievesGranada, Spain; Bermudez Jiménez, F., Department of Cardiology, University Hospital Virgen de las NievesGranada, Spain; Rojo Martin, M.D., Department of Microbiology, University Hospital Virgen de las NievesGranada, Spain; Miranda Casas, C., Department of Microbiology, University Hospital Virgen de las NievesGranada, Spain; Marin Arriaza, M., Department of Molecular Biology, University General Hospital Gregorio MarañonMadrid, Spain; Navarro Marí, J.M., Department of Microbiology, University Hospital Virgen de las NievesGranada, Spain","Lactococcus garvieae is a Gram-positive, catalase negative coccus arranged in pairs or short chains, well-known as a fish pathogen. We report a case of Infective Endocarditis (IE) by L.garvieae in a native valve from a 68-year-old male with unknown history of contact with raw fish and an extensive history of heart disease. This case highlights the reliability of MALDI-TOF MS compared to conventional methods in the identification of rare microorganisms like this. © 2015 .","Endocarditis; Lactococcus garvieae; MALDI-TOF; Native valve; PCR","Watanabe, Y., Naito, T., Kikuchi, K., Amari, Y., Uehara, Y., Isonuma, H., Infective endocarditis with Lactococcus garvieae in Japan: a case report (2011) JMed Case Rep, 5, p. 356; Facklam, R., Elliott, J.A., Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci (1995) Clin Microbiol Rev, 8, pp. 479-495; James, P.R., Hardman, S.M., Patterson, D.L., Osteomyelitis and possible endocarditis secondary to Lactococcus garvieae: a first case report (2000) Postgrad Med J, 76, pp. 301-303; Mofredj, A., Baraka, D., Kloeti, G., Dumont, J.L., Lactococcus garvieae septicemia with liver abscess in an immunosuppressed patient (2000) Am J Med, 109, pp. 513-514; Aubin, G.G., Bémer, P., Guillouzouic, A., Crémet, L., Touchais, S., Fraquet, N., First report of a hip prosthetic and Joint infection caused by Lactococcus garvieae in a Woman Fishmonger (2011) JClin Microbiol, 49 (5), pp. 2074-2076; Navas, M.E., Hall, G., El Bejjani, D., Acase of endocarditis caused by Lactococcus garvieae and Suggested methods for identification (2013) JClin Microbiol, 51 (6), pp. 1990-1992; Li, W.K., Chen, Y.S., Wann, S.R., Liu, Y.C., Tsai, H.C., Lactococcus garviae endocarditis with initial presentation of acute cerebral infarction in a healthy immunocompetent man (2008) Intern Med, 47 (12), pp. 1143-1146; Russo, G., Iannetta, M., D'Abramo, A., Mascellino, M.T., Annalisa, P., Erario, L., Lactococcus garvieae endocarditis in a patient with colonic diverticulosis: first case report in Italy and review of the literature (2012) New Microbiologica, 35, pp. 495-501; Fihman, V., Raskine, L., Barrou, Z., Kiffel, C., Riahi, J., Berçot, B., Lactococcus garvieae endocarditis: identification by 16s rRNA and sodA sequence analysis (2006) JInfect, 52 (1), pp. 3-6; Vinh, D.C., Nichol, K.A., Rand, F., Embil, J.M., Native-valve bacterial endocarditis caused by Lactococcus garvieae (2006) Diagn Microbiol Infect Dis, 56, pp. 91-94; Elliott, J.A., Collins, M.D., Pigott, N.E., Facklam, R.R., Differentiation of Lactococcus lactis and Lactococcus garvieae from humans by comparison of whole-cell protein patterns (1991) JClin Microbiol, 29, pp. 2731-2734; Texeira, L., Maerquior, V., Vianni, M., Carvalho, M., Fracalanzza, S., Steigerwalt, A., Phenotypic and genotypic characterization of atypical Lactococcus garvieae strains isolated from water buffalos with subclinical mastitis and confirmation of L. garvieae as a senior subjective synonym of Enterococcus seriolicida (1996) JSyst Bacteriol, 46, pp. 664-668; Elliott, J.A., Facklam, R.R., Antimicrobial susceptibilities of Lactococcus lactis and Lactococcus garvieae and a proposed method to discriminate between them (1996) JClin Microbiol, 34, pp. 1296-1298; Ortiz, C., López, J., del Amo, E., Sevilla, T., Elipidio García, P., San Román, J.A., Lactococcus garvieae infective endocarditis: report of 2 cases and Review of the literature (2014) Rev Esp Cardiol, 67 (9), pp. 769-780",Note,Scopus,2-s2.0-84928396079
"Keen L., Turner A.D., Mwendwa D., Callender C., Campbell A.","Depressive symptomatology and respiratory sinus arrhythmia in a non-clinical sample of middle-aged African Americans",2015,"Biological Psychology","108",,,"56","61",,,10.1016/j.biopsycho.2015.03.008,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926430108&partnerID=40&md5=e4ced623441e075ed9f6e3651a2fc766","Virginia State University, Department of PsychologyPetersburg, VA, United States; Center of Excellence on Disparities in HIV and Aging, Rush Alzheimer's Disease CenterChicago, IL, United States; Howard University, Department of PsychologyWashington, DC, United States; Howard University, School of MedicineWashington, DC, United States; National Minority Organ and Tissue Transplant ProgramWashington, DC, United States","Keen, L., Virginia State University, Department of PsychologyPetersburg, VA, United States; Turner, A.D., Center of Excellence on Disparities in HIV and Aging, Rush Alzheimer's Disease CenterChicago, IL, United States; Mwendwa, D., Howard University, Department of PsychologyWashington, DC, United States; Callender, C., Howard University, School of MedicineWashington, DC, United States, National Minority Organ and Tissue Transplant ProgramWashington, DC, United States; Campbell, A., Jr., Howard University, Department of PsychologyWashington, DC, United States","Decreased heart rate variability and depression are both independent risk factors for cardiac mortality in clinical and non-clinical samples. The purpose of the current study is to examine the hypothesis that severity of depressive symptomatology is inversely associated with respiratory sinus arrhythmia (RSA) in a non-clinical sample of African Americans. The sample included 77 African Americans with a mean age of 48.4 (SD. = 11.7). Participants completed the Beck Depression Inventory-II (BDI-II) and a 5-min resting baseline measurement of RSA was collected. The BDI-II total score was positively associated with RSA (β= .334, p= .008). Given the unexpected direction of the association, we separated the BDI-II into cognitive and somatic affective subscales to identify which construct was driving the relationship. The somatic affective, was related to RSA (β= .328, p= .010), but not the cognitive subscale. Given this unexpected positive result, future research should further examine the nature of the relationship between depressive symptomatology and RSA in African Americans, as the relationship may vary based on levels of depressive symptomatology. © 2015 Elsevier B.V.","Cognitive; Depression; Depressive symptomatology; Heart rate variability; Respiratory sinus arrhythmia; Somatic affective","Allen, J., Chambers, A., Towers, D., The many metrics of cardiac chronotropy: A pragmatic primer and a brief comparison of metrics (2007) Journal of Biological Psychology, 74, pp. 243-262; Arnau, R., Meagher, M., Norris, M., Branson, R., Psychometric evaluation of the Beck Depression Inventory-II with primary care medical patients (2001) Health Psychology, 20, pp. 112-119; Barbarin, O., Exploring the inner lives of African American children (1993) Journal of Black Psychology, 19, pp. 478-492; Beck, A., Steer, A., Brown, G., (1996) Manual for the Beck Depression Inventory-II, , Psychological Corporation, San Antonio, TX; Bosch, N., Riese, H., Dietrich, A., Ormel, J., Verhulst, F., Oldehinkel, A., Preadolescents' somatic and cognitive-affective depressive symptoms are differentially related to cardiac autonomic function and cortisol: The TRAILS study (2009) Psychosomatic Medicine, 71, pp. 944-950; Brown, J., O'Keefe, J., Sanders, S., Baker, B., Developmental changes in children's cognition to stressful and painful situations (1986) Journal of Pediatric Psychology, 11 (3), pp. 343-357; Brown, C., Schulberg, H.C., Madonia, M.J., Clinical presentations of major depression by African Americans and whites in primary medical care practice (1996) Journal of Affective Disorders, 41, pp. 181-191; Carney, R., Freedland, K., Stein, P., Skala, J., Hoffman, P., Jaffe, A., Change in heart and heart rate variability during treatment for depression in patients with coronary heart disease (2000) Psychosomatic Medicine, 62, pp. 639-647; Carney, R., Freedland, K., Veith, R., Depression, the autonomic nervous system and coronary heart disease (2000) Psychosomatic Medicine, 67, p. S29; Carney, R., Blumenthal, J., Stein, P., Watkins, L., Catellier, D., Berkman, L., Depression, heart rate variability and acute myocardial infarction (2001) Circulation, 104, pp. 2024-2028; Chambers, A., Allen, J., Vagal tone as an indicator of treatment response in major depression (2002) Psychophysiology, 39, pp. 861-864; Cohen, B., Panguluri, P., Na, B., Whooley, M., Psychological risk factors and the metabolic syndrome in patients with coronary heart disease: Findings from the heart and soul study (2010) Psychiatry Research, 175, pp. 133-137; De Jonge, P., Mangano, D., Whooley, M., Differential association of cognitive and somatic depressive symptoms with heart rate variability in patients with stable coronary heart disease: Findings from the heart and soul study (2007) Psychosomatic Medicine, 69, pp. 735-739; Dobson, K.S., The relationship between anxiety and depression (1985) Clinical Psychology Review, 5, pp. 307-324; Douglas, J., Bakris, G., Epstein, M., Ferdinand, K., Ferrario, C., Flack, J., Management of high blood pressure in African Americans (2003) Archives of Internal Medicine, 163, pp. 323-341; Dunkel, A., Kendel, F., Lehmkuhl, E., Hetzer, R., Regitz-Zagrosek, V., Causal attributions among patients undergoing coronary artery bypass surgery: Gender aspects and relation to depressive symptomatology (2011) Journal of Behavioral Medicine, 34 (5), pp. 351-359; Friedman, B.H., Thayer, J., Autonomic balance revisited: Panic anxiety and heart rate variability (1998) Journal of Psychosomatic Research, 44 (1), pp. 133-151; Glassman, A., Bigger, J., Gaffney, M., Van Zyl, L., Heart rate variability in acute coronary syndrome patients with major depression (2007) Archives of General Psychiatry, 64, pp. 1025-1031; Groot, P., de Geus, E., des Vries, J., (1998) Ambulatory monitoring system (User Manual v1. 2), , Vrije Universiteit, FPP/TD, Amsterdam, The Netherlands; Heron, M., Deaths: Leading causes for 2004 (2007) National Vital Statistics reports, 56, p. 5. , National Vital Statistics; Heron, M., Hoyert, D., Murphy, S., Xu, J., Kochanek, K., Tejada-Verda, B., Deaths: Final data for 2006 (2009) National Vital Statistics reports, 57, p. 14. , National Vital Statistics; Huikuri, H., Raatikainen, M., Moerch-Joergensen, R., Hartikainen, J., Virtanen, V., Boland, J., Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction (2009) European Heart Journal, 30, p. 689; Kemp, A.H., Quintana, D.S., Gray, M.A., Felmingham, K.L., Brown, K., Gatt, J.M., Impact of depression and antidepressant treatment on heart rate variability: A review and meta-analysis (2010) Biological Psychiatry, 67, pp. 1067-1074; Kimayer, L.J., Cultural variations in the clinical presentation of depression and anxiety: Implications for diagnosis and treatment (2001) Journal of Clinical Psychiatry, 62, pp. 22-30; Kinder, L.S., Kamarck, T.W., Baum, A., Orchard, T.J., Depressive symptomatology and coronary heart disease in Type I diabetes mellitus: A study of possible mechanisms (2002) Health Psychology, 21 (6), pp. 542-552; Koelsch, S., Remppis, A., Sammler, D., Jentschke, S., Mietchen, D., Fritz, T., A cardiac signature of emotionality (2007) European Journal of Neuroscience, 26, pp. 3328-3338; Lett, H., Blumenthal, J., Babyak, M., Sherwood, A., Strauman, T., Robins, C., Depression as a risk factor for coronary artery disease: Evidence, mechanism and treatment (2004) Psychosomatic Medicine, 66, pp. 305-315; Licht, C., de Geus, E., Zitman, F., Hoogendijk, W., van Dyck, R., Penninx, B., Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA) (2008) Archives of General Psychiatry, 65, pp. 1358-1367; Masi, C.M., Hawkley, L.C., Rickett, E.M., Cacioppo, J.T., Respiratory sinus arrhythmia and diseases of aging: Obesity, diabetes mellitus, and hypertension (2007) Biological Psychology, 74 (2), pp. 212-223; Miller, B.D., Wood, B.L., Influence of specific emotional states on autonomic reactivity and pulmonary function in asthmatic children (1997) Journal of the American Academy of Child and Adolescent Psychiatry, 36, pp. 669-677; Pizzi, C., Manzoli, L., Mancini, S., Costa, G., Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function (2008) European Heart Journal, 29, pp. 1110-1117; Porges, S., The polyvagal perspective (2007) Biological Psychology, 74, pp. 116-143; Riolo, S., Nguyen, T., Greden, J., King, C., Prevalence of depression by race/ethnicity: Findings from the National Health and Nutrition Examination Survey III (2005) American Journal of Public Health, 95, pp. 998-1000; Rottenberg, J., Wilhelm, F., Gross, J., Gotlib, I., Respiratory sinus arrhythmia as a predictor of outcome in major depressive disorder (2002) Journal of Affective Disorders, 71, pp. 265-272; Rottenberg, J., Chambers, A., Allen, J., Manber, R., Cardiac vagal control in the severity and course of depression: The importance of symptomatic heterogeneity (2007) Journal Affective Disorder, 103 (1), pp. 173-179; Salomon, K., Clift, A., Karlsdottir, M., Rottenberg, J., Major depressive disorder is associated with attenuated cardiovascular reactivity and impaired recovery among those free of cardiovascular disease (2009) Health Psychology, 28, pp. 157-165; Sayar, K., Gulec, H., Gokce, M., Ak, I., Heart rate variability in depressed patients (2002) Bulletin of Clinical Psychopharmacology, 12, pp. 130-133; Siepmann, M., Aykac, V., Unterdorfer, J., Petrowski, K., Mueck-Weymann, M., A pilot study on the effects of heart rate variability biofeedback in patients with depression and in healthy subjects (2008) Applied Psychophysiology Biofeedback, 33, pp. 195-201; Sloan, R., Huang, M., McCreath, H., Sidney, S., Liu, K., Williams, O., Cardiac autonomic control and the effects of age, race, and sex: The Cardia study (2008) Autonomic Neuroscience, 139, pp. 78-85; (2008) SPSS for windows, , SPSS, Inc, Chicago, IL; Suls, J., Bunde, J., Anger, anxiety, and depression as risk factors for cardiovascular disease: The problems and implications of overlapping affective dispositions (2005) Psychological Bulletin, 131 (2), pp. 260-300; Heart rate variability: Standards of measurement, physiological interpretation and clinical use (1996) European Heart Journal, 17, pp. 354-381; Thayer, J., Smith, M., Rossy, L., Sollers, J., Friedman, B., Heart period variability and depressive symptoms: Gender differences (1998) Society of Biological Psychiatry, 44, pp. 304-306; Thayer, J., Lane, R., The role of vagal function in the risk for cardiovascular disease and mortality (2007) Biological Psychology, 74, pp. 224-242; Tyler, A., Gandhi, P.H., The importance of somatic symptoms in depression in primary care (2005) Primary Care Companion Journal of Clinical Psychiatry, 7, pp. 167-176; Vaccarino, V., Lampert, R., Bremner, D., Lee, F., Su, S., Maisano, C., Depressive symptoms and heart rate variability: Evidence for a shared genetic substrate in a study of twins (2008) Psychosomatic Medicine, 70, pp. 628-636; Van der Kooy, K., van Hout, H., van Marwijk, H., de Haan, M., Stehouwe, C., Beekman, A., Differences in heart rate variability between depressed and non-depressed elderly (2006) International Journal of Geriatric Psychiatry, 21, pp. 147-150; Watkins, L., Grossman, P., Krishnan, R., Blumenthal, J., Anxiety reduces baroreflex cardiac control in older adults with major depression (1999) Psychosomatic Medicine, 61, pp. 334-340; Wang, X., Thayer, J., Treiber, F., Sneider, H., Ethnic differences and heritability of heart rate variability in African and European American youth (2005) American Journal of Cardiology, 96, pp. 1166-1172; Wulsin, L., Singal, B., Do depressive symptoms increase the risk for the onset of coronary disease?. A systematic quantitative review (2003) Psychosomatic Medicine, 65, pp. 201-210",Article,Scopus,2-s2.0-84926430108
"Richette P.","Allopurinol and risk of myocardial infarction",2015,"Heart","101","9",,"659","660",,,10.1136/heartjnl-2014-307278,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927623698&partnerID=40&md5=580516daa082d01cc6083fb7f6af552e","Université Paris7, UFRmédicale, Fédérationde RhumatologieParis, Cedex 10, France; INSERM UMR-1132, Hôpital Lariboisière, Université Paris DiderotSorbonne Paris Cité, Paris, France","Richette, P., Université Paris7, UFRmédicale, Fédérationde RhumatologieParis, Cedex 10, France, INSERM UMR-1132, Hôpital Lariboisière, Université Paris DiderotSorbonne Paris Cité, Paris, France",[No abstract available],,"Richette, P., Perez-Ruiz, F., Doherty, M., Improving cardiovascular and renal outcomes in gout: What should we target? (2014) Nat Rev Rheumatol, 10, pp. 654-661; De Abajo, F., Gil, M., Rodríguez, A., Allopurinol use and risk of nonfatal acute myocardial infarction (2015) Heart, 101, pp. 679-685; Neogi, T., George, J., Rekhraj, S., Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal (2012) Arthritis Rheum, 64, pp. 327-338; Higgins, P., Dawson, J., Lees, K.R., Xanthine oxidase inhibition for the treatment of cardiovascular disease: A systematic review and meta-analysis (2012) Cardiovasc Ther, 30, pp. 217-226; Thanassoulis, G., Brophy, J.M., Richard, H., Gout, allopurinol use, and heart failure outcomes (2010) Arch Intern Med, 170, pp. 1358-1364; Rekhraj, S., Gandy, S.J., Szwejkowski, B.R., High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease (2013) J Am Coll Cardiol, 61, pp. 926-932; Noman, A., Ang, D.S., Ogston, S., Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomised, placebo controlled crossover trial (2010) Lancet, 375, pp. 2161-2167; Grimaldi-Bensouda, L., Alperovitch, A., Aubrun, E., Impact of allopurinol on risk of myocardial infarction (2015) Ann Rheum Dis, 74, pp. 836-842",Editorial,Scopus,2-s2.0-84927623698
"Asgari S., Mehrnia A., Moussavi M.","Automatic detection of atrial fibrillation using stationary wavelet transform and support vector machine",2015,"Computers in Biology and Medicine","60",,,"132","142",,,10.1016/j.compbiomed.2015.03.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925676853&partnerID=40&md5=35fed63a1826735e76339630c6f96633","Department of Computer Engineering and Computer Science, California State University, Long Beach, 1250 Bellflower Boulevard-MS 8302Long Beach, CA, United States; Department of Electrical Engineering, University of California, Los Angeles, 56-125B Engineering IV Building, Box 951594Los Angeles, CA, United States; Department of Electrical Engineering, California State University, Long Beach, 1250 Bellflower BoulevardLong Beach, CA, United States","Asgari, S., Department of Computer Engineering and Computer Science, California State University, Long Beach, 1250 Bellflower Boulevard-MS 8302Long Beach, CA, United States; Mehrnia, A., Department of Electrical Engineering, University of California, Los Angeles, 56-125B Engineering IV Building, Box 951594Los Angeles, CA, United States; Moussavi, M., Department of Electrical Engineering, California State University, Long Beach, 1250 Bellflower BoulevardLong Beach, CA, United States","Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia, and a major public health burden associated with significant morbidity and mortality. Automatic detection of AF could substantially help in early diagnosis, management and consequently prevention of the complications associated with chronic AF. In this paper, we propose a novel method for automatic AF detection. Method: Stationary wavelet transform and support vector machine have been employed to detect AF episodes. The proposed method eliminates the need for P-peak or R-Peak detection (a pre-processing step required by many existing algorithms), and hence its performance (sensitivity, specificity) does not depend on the performance of beat detection. The proposed method has been compared with those of the existing methods in terms of various measures including performance, transition time (detection delay associated with transitioning from a non-AF to AF episode), and computation time (using MIT-BIH Atrial Fibrillation database). Results: Results of a stratified 2-fold cross-validation reveals that the area under the Receiver Operative Characteristics (ROC) curve of the proposed method is 99.5%. Moreover, the method maintains its high accuracy regardless of the choice of the parameters[U+05F3] values and even for data segments as short as 10. s. Using the optimal values of the parameters, the method achieves sensitivity and specificity of 97.0% and 97.1%, respectively. Discussion: The proposed AF detection method has high sensitivity and specificity, and holds several interesting properties which make it a suitable choice for practical applications. © 2015 Elsevier Ltd.","Atrial fibrillation; Cardiac arrhythmia; Log-energy entropy; ROC curve analysis; Support vector machine; Wavelet transform","Lainscak, M., Dagres, N., Filippatos, G.S., Anker, S.D., Kremastinos, D.T., Atrial fibrillation in chronic non-cardiac disease: where do we stand? (2008) Int. J. Cardiol., 128, pp. 311-315; Heeringa, J., van der Kuip, D.A., Hofman, A., Kors, J.A., van Herpen, G., Stricker, B.H., Stijnen, T., Witteman, J.C., Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study (2006) Eur. Heart J., 27, pp. 949-953; Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., Singer, D.E., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and risk factors in atrial fibrillation (ATRIA) study (2001) J. Am. Med. Assoc., 285, pp. 2370-2375; Furberg, C.D., Psaty, B.M., Manolio, T.A., Gardin, J.M., Smith, V.E., Rautaharju, P.M., Prevalence of atrial fibrillation in elderly subjects (the cardiovascular health study) (1994) Am. J. Cardiol., 74, pp. 236-241; Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study (1991) Stroke J. Cereb. Circ., 22, pp. 983-988; Benjamin, E.J., Wolf, P.A., D'Agostino, R.B., Silbershatz, H., Kannel, W.B., Levy, D., Impact of atrial fibrillation on the risk of death: the Framingham heart study (1998) Circulation, 98, pp. 946-952; Sanoski, C.A., Clinical, economic, and quality of life impact of atrial fibrillation (2009) J. Manag. Care Pharm., 15, pp. S4-S9; Markides, V., Schilling, R.J., Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment (2003) Heart (Br. Card. Soc.), 89, pp. 939-943; Harris, K., Edwards, D., Mant, J., How can we best detect atrial fibrillation? (2012) J. R. Coll. Physicians Edinb., 42, pp. S5-S22; Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I.C., Rutten, F.H., Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the european society of cardiology (ESC) (2010) Eur. Heart J., 31, pp. 2369-2429; Mehall, J.R., Kohut, R.M., Schneeberger, E.W., Merrill, W.H., Wolf, R.K., Absence of correlation between symptoms and rhythm in symptomatic atrial fibrillation (2007) Ann. Thorac. Surg., 83, pp. 2118-2121; Mant, J., Fitzmaurice, D.A., Hobbs, F.D., Jowett, S., Murray, E.T., Holder, R., Davies, M., Lip, G.Y., Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial (2007) Br. Med. J. (Clin. Res. Ed.), 335, p. 380; Aytemir, K., Aksoyek, S., Yildirir, A., Ozer, N., Oto, A., Prediction of atrial fibrillation recurrence after cardioversion by P wave signal-averaged electrocardiography (1999) Int. J. Cardiol., 70, pp. 15-21; Slocum, J., Sahakian, A., Swiryn, S., Diagnosis of atrial fibrillation from surface electrocardiograms based on computer-detected atrial activity (1992) J. Electrocardiol., 25, pp. 1-8; Clavier, L., Boucher, J.M., Lepage, R., Blanc, J.J., Cornily, J.C., Automatic P-wave analysis of patients prone to atrial fibrillation (2002) Med. Biol. Eng. Comput., 40, pp. 63-71; Dotsinsky, I., Atrial wave detection algorithm for discovery of some rhythm abnormalities (2007) Physiol. Meas., 28, pp. 595-610; Moody, G.B., Mark, R.G., A new method for detecting atrial fibrillation using R-R intervals (1983) Comput. Cardiol., pp. 227-230; Tateno, K., Glass, L., Automatic detection of atrial fibrillation using the coefficient of variation and density histograms of RR and deltaRR intervals (2001) Med. Biol. Eng. Comput., 39, pp. 664-671; Sarkar, S., Ritscher, D., Mehra, R., A detector for a chronic implantable atrial tachyarrhythmia monitor (2008) IEEE Trans. Bio-Med. Eng., 55, pp. 1219-1224; Dash, S., Chon, K.H., Lu, S., Raeder, E.A., Automatic real time detection of atrial fibrillation (2009) Ann. Biomed. Eng., 37, pp. 1701-1709; Lee, J., Nam, Y., McManus, D.D., Chon, K.H., Time-varying coherence function for atrial fibrillation detection (2013) IEEE Trans. Bio-Med. Eng., 60, pp. 2783-2793; Couceiro, R., Carvalho, P., Henriques, J., Antunes, M., Harris, M., Habetha, J., Detection of atrial fibrillation using model-based ECG analysis (2008) Proceedings of the 19th International Conference on Pattern Recognition, pp. 1-5. , in: ICPR 2008, 2008; Babaeizadeh, S., Gregg, R.E., Helfenbein, E.D., Lindauer, J.M., Zhou, S.H., Improvements in atrial fibrillation detection for real-time monitoring (2009) J. Electrocardiol., 42, pp. 522-526; Jiang, K., Huang, C., Ye, S.M., Chen, H., High accuracy in automatic detection of atrial fibrillation for Holter monitoring (2012) J. Zhejiang Univ. Sci. B, 13, pp. 751-756; Larburu, N., Lopetegi, T., Romero, I., Comparative study of algorithms for atrial fibrillation detection (2011) Comput. Cardiol., pp. 265-268; Huang, C., Ye, S., Chen, H., Li, D., He, F., Tu, Y., A novel method for detection of the transition between atrial fibrillation and sinus rhythm (2011) IEEE Trans. Bio-Med. Eng., 58, pp. 1113-1119; Gomes, P.R., Soares, F.O., Correia, J.H., Lima, C.S., ECG Data-Acquisition and classification system by using wavelet-domain Hidden Markov Models (2010) Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2010, pp. 4670-4673; Addison, P.S., Wavelet transforms and the ECG: a review (2005) Physiol. Meas., 26, pp. R155-R199; Weng, B., Wang, J.J., Michaud, F., Blanco-Velasco, M., Atrial fibrillation detection using stationary wavelet transform analysis (2008) Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2008, pp. 1128-1131; Alcaraz, R., Vaya, C., Cervigon, R., Sanchez, C., Rieta, J.J., Wavelet sample entropy: a new approach to predict termination of atrial fibrillation (2006) Comput. Cardiol., 2006, pp. 597-600; Shaoyu, Q., Ping, Z., Wavelet and wavelet packet transform analysis in the ECG signals of atrial fibrillation (2007) Proceedings of the Complex Medical Engineering, pp. 1766-1769. , CME 2007, IEEE/ICME International Conference on, 2007; Karatsiolis, S., Schizas, C.N., Region based support vector machine algorithm for medical diagnosis on Pima Indian Diabetes dataset (2012) Proceedings of the 2012 IEEE 12th International Conference on, Bioinformatics & Bioengineering (BIBE), pp. 139-144; El-Naqa, I., Yang, Y., Wernick, M.N., Galatsanos, N.P., Nishikawa, R.M., A support vector machine approach for detection of microcalcifications (2002) Med. Imaging IEEE Trans., 21, pp. 1552-1563; Gao, S., Li, H., Breast cancer diagnosis based on support vector machine (2012) Proceeedings of the Uncertainty Reasoning and Knowledge Engineering (URKE), pp. 240-243. , 2nd International Conference on, IEEE, 2012; Campbell, C., Kernel methods: a survey of current techniques (2002) Neurocomputing, 48, pp. 63-84; Cristianini, N., Shawe-Taylor, J., (2000) An Introduction to Support Vector Machines and Other Kernel-Based Learning Methods, , Cambridge university press, Cambridge, United Kingdom; Boser, B.E., Guyon, I.M., Vapnik, V.N., A training algorithm for optimal margin classifiers (1992) Proceedings of the fifth annual workshop on Computational learning theory, ACM, pp. 144-152; Goldberger, A.L., Amaral, L.A., Glass, L., Hausdorff, J.M., Ivanov, P.C., Mark, R.G., Mietus, J.E., Stanley, H.E., PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals (2000) Circulation, 101, pp. E215-E220; Stridh, M., Sornmo, L., Meurling, C.J., Olsson, S.B., Sequential characterization of atrial tachyarrhythmias based on ECG time-frequency analysis (2004) IEEE Trans. Bio-Med. Eng., 51, pp. 100-114; Kim, D.-S., Lee, J.-S., Propagation and attenuation characteristics of various ground vibrations (2000) Soil Dyn. Earthq. Eng., 19, pp. 115-126; Pan, J., Tompkins, W.J., A real-time QRS detection algorithm (1985) Biomed. Eng. IEEE Trans., pp. 230-236",Article,Scopus,2-s2.0-84925676853
"Lau E., Foody J.A.M.","Secondary prevention of heart disease in women: Gaps in care/gaps in knowledge—where do we need to focus our attention",2015,"Current Cardiovascular Risk Reports","9","5",,"1","10",,,10.1007/s12170-015-0452-7,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928318485&partnerID=40&md5=ee4fa48e9c865bcf9911acfb8f071269","Department of Medicine, Brigham and Women’s Hospital, 75 Francis Street, PB-136Boston, MA, United States; Harvard Medical SchoolBoston, MA, United States; Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 75 Francis Street, PB-136Boston, MA, United States","Lau, E., Department of Medicine, Brigham and Women’s Hospital, 75 Francis Street, PB-136Boston, MA, United States; Foody, J.A.M., Harvard Medical SchoolBoston, MA, United States, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 75 Francis Street, PB-136Boston, MA, United States","Cardiovascular disease (CVD) is the leading cause of death in women in the USA, and yet, CVD is consistently underestimated and undertreated in women. Awareness of this gender gap is growing, but still persists. Women with existing CVD are a particularly vulnerable and neglected population. Better understanding of the secondary prevention of CVD is sorely needed. Women are underrepresented in all CVD trials and sex-specific research is lacking. Consequently, the present guidelines for the secondary prevention of CVD in women are largely derived from studies performed in men. Albeit imperfect, these guidelines are less frequently applied to female patients. CVD outcomes are consistently worse in women than men, highlighting the need to address this gender disparity. We review the current guidelines and data on the secondary prevention of CVD in women and outline areas in need of further investigation and intervention. © 2015, Springer Science+Business Media New York.","Cardiovascular disease; Coronary artery disease; Secondary prevention; Women","Mosca, L., Barrett-Connor, E., Wenger, N.K., Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes (2011) Circulation, 124 (19), pp. 2145-2154. , PID: 22064958, This review presents sex/gender differences in the burden of CVD and explores how clinical trials can be used to provide recommendations for CVD prevention in women; Vaccarino, V., Parsons, L., Every, N.R., Barron, H.V., Krumholz, H.M., Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants (1999) N Engl J Med, 341 (4), pp. 217-225. , COI: 1:STN:280:DyaK1MzivVCqsA%3D%3D, PID: 10413733; Mulcahy, R., Hickey, N., Maurer, B., Coronary heart disease in women. Study of risk factors in 100 patients less than 60 years of age (1967) Circulation, 36 (4), pp. 577-586. , COI: 1:STN:280:DyaF2s3lt1SgsA%3D%3D, PID: 6072095; Gulati, M., Shaw, L.J., Bairey Merz, C.N., Myocardial ischemia in women: lessons from the NHLBI WISE study (2012) Clin Cardiol, 35 (3), pp. 141-148. , PID: 22389117, This review highlights the major findings from the WISE study which introduced the idea of a “female” pattern of ischemic heart disease. Although women are more likely to experience myocardial ischemia and death, they have less obstructive coronary disease; Clayton, J.A., Collins, F.S., Policy: NIH to balance sex in cell and animal studies (2014) Nature, 509 (7500), pp. 282-283. , PID: 24834516, This policy statement announces that NIH is dedicated to ensuring that sex is balanced in all funded preclinical research; Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) Circulation, 129 (25 Suppl 2), pp. S1-S45. , PID: 24222016, The American College of Cardiology/American Heart Association task force presents guidelines for the management of hyperlipidemia for primary and secondary prevention of CVD in adult patients; Mosca, L., Benjamin, E.J., Berra, K., Bezanson, J.L., Dolor, R.J., Lloyd-Jones, D.M., Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association (2011) Circulation, 123 (11), pp. 1243-1262. , PID: 21325087, The American Heart Association task force presents evidence-based guidelines for the primary and secondary prevention of CVD in women; Kritchevsky, D., Dietary protein, cholesterol and atherosclerosis: a review of the early history (1995) J Nutr, 125 (3 Suppl), pp. 589s-593. , COI: 1:CAS:528:DyaK2MXktFGmurs%3D, PID: 7884538; Bowen, D.J., Henderson, M.M., Iverson, D., Burrows, E., Henry, H., Foreyt, J., Reducing dietary fat: understanding the success of the women’s health trial (1994) Cancer Prev Int, 1 (1), pp. 21-30; Krummel, D.A., Koffman, D.M., Bronner, Y., Davis, J., Greenlund, K., Tessaro, I., Cardiovascular health interventions in women: what works? (2001) J Womens Health Gend Based Med, 10 (2), pp. 117-136. , COI: 1:STN:280:DC%2BD3M7mslOrtA%3D%3D, PID: 11268297; Zhang, Y., Cardiovascular diseases in American women (2010) Nutr Metab Cardiovasc Dis NMCD, 20 (6), pp. 386-393. , COI: 1:STN:280:DC%2BC3cjgvVSitQ%3D%3D; Owens, J.F., Matthews, K.A., Wing, R.R., Kuller, L.H., Physical activity and cardiovascular risk: a cross-sectional study of middle-aged premenopausal women (1990) Prev Med, 19 (2), pp. 147-157. , COI: 1:STN:280:DyaK3c3psFCmtQ%3D%3D, PID: 2359739; Nies, M.A., Vollman, M., Cook, T., African-American women’s experiences with physical activity in their daily lives (1999) Public Health Nurs (Boston, Mass), 16 (1), pp. 23-31. , COI: 1:STN:280:DyaK1M7nsVerug%3D%3D; Banks-Wallace, J., Conn, V., Interventions to promote physical activity among African American women (2002) Public Health Nurs (Boston, Mass), 19 (5), pp. 321-335; Agaku, I.T., King, B.A., Dube, S.R., Current cigarette smoking among adults—United States, 2005–2012 (2014) MMWR Morb Mortal Wkly Rep, 63 (2), pp. 29-34. , PID: 24430098; Mackay, J., Amos, A., Women and tobacco (2003) Respirology (Carlton, Vic), 8 (2), pp. 123-130; Melloni, C., Berger, J.S., Wang, T.Y., Gunes, F., Stebbins, A., Pieper, K.S., Representation of women in randomized clinical trials of cardiovascular disease prevention (2010) Circ Cardiovasc Qual Outcomes, 3 (2), pp. 135-142. , PID: 20160159; Kannel, W.B., Castelli, W.P., Gordon, T., McNamara, P.M., Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study (1971) Ann Intern Med, 74 (1), pp. 1-12. , COI: 1:STN:280:DyaE3M%2FnvVCrtg%3D%3D, PID: 5539274; Austin, M.A., Hokanson, J.E., Edwards, K.L., Hypertriglyceridemia as a cardiovascular risk factor (1998) Am J Cardiol, 81 (4a), pp. 7b-12. , COI: 1:STN:280:DyaK1c7os1SjsA%3D%3D, PID: 9526807; Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R., III, Leiter, L.A., Linz, P., Effects of combination lipid therapy in type 2 diabetes mellitus (2010) The New England Journal of Medicine, 362 (17), pp. 1563-1574; Howard, B.V., Cowan, L.D., Go, O., Welty, T.K., Robbins, D.C., Lee, E.T., Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The strong heart study (1998) Diabetes Care, 21 (8), pp. 1258-1265. , COI: 1:STN:280:DyaK1czmslyjtQ%3D%3D, PID: 9702430; Koerbel, G., Korytkowski, M., Coronary heart disease in women with diabetes (2003) Diabetes Spectr, 16 (3), pp. 148-153; Hu, F.B., Stampfer, M.J., Haffner, S.M., Solomon, C.G., Willett, W.C., Manson, J.E., Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes (2002) Diabetes Care, 25 (7), pp. 1129-1134. , PID: 12087009; Mente, A., Yusuf, S., Islam, S., McQueen, M.J., Tanomsup, S., Onen, C.L., Metabolic syndrome and risk of acute myocardial infarction a case–control study of 26,903 subjects from 52 countries (2010) J Am Coll Cardiol, 55 (21), pp. 2390-2398. , PID: 20488312; Gitt A, Bramlage P, Towae F, Papp A, Deeg E, Senges J, Zeymer U, Zahn R, Fleischmann H, Boehler S, et al. Newly diagnosed diabetes and prediabetes in patients after acute myocardial infarction predicts adverse outcomes during a three-year follow-up: results of the sweetheart registry. J Am Coll Cardiol. 2013; 61(10_S)James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) (2014) JAMA, 311 (5), pp. 507-520. , COI: 1:CAS:528:DC%2BC2cXis1aktr8%3D, PID: 24352797, The Joint National Committee 8 presents their updated evidence based guidelines for the management of high blood pressure in adults; Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Heart disease and stroke statistics—2014 update: a report from the American Heart Association (2014) Circulation, 129 (3), pp. e28-e292. , PID: 24352519; Hertz, R.P., Unger, A.N., Cornell, J.A., Saunders, E., Racial disparities in hypertension prevalence, awareness, and management (2005) Arch Intern Med, 165 (18), pp. 2098-2104. , PID: 16216999; Pimenta, E., Hypertension in women (2012) Hypertens Res Off J Jpn Soc Hypertens, 35 (2), pp. 148-152. , COI: 1:CAS:528:DC%2BC38XhvVGjsLc%3D; Hsia, J., Margolis, K.L., Eaton, C.B., Wenger, N.K., Allison, M., Wu, L., Prehypertension and cardiovascular disease risk in the women’s health initiative (2007) Circulation, 115 (7), pp. 855-860. , PID: 17309936; August, P., Oparil, S., Hypertension in women (1999) J Clin Endocrinol Metab, 84 (6), pp. 1862-1866. , COI: 1:CAS:528:DyaK1MXjs1Oitbc%3D, PID: 10372676; Os, I., Oparil, S., Gerdts, E., Hoieggen, A., Essential hypertension in women (2004) Blood Press, 13 (5), pp. 272-278. , PID: 15545149; Os, I., Bratland, B., Dahlof, B., Gisholt, K., Syvertsen, J.O., Tretli, S., Female preponderance for lisinopril-induced cough in hypertension (1994) Am J Hypertens, 7 (11), pp. 1012-1015. , COI: 1:STN:280:DyaK2M7ltFamtQ%3D%3D, PID: 7848615; Neaton, J.D., Grimm, R.H., Jr., Prineas, R.J., Stamler, J., Grandits, G.A., Elmer, P.J., Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group (1993) JAMA, 270 (6), pp. 713-724. , COI: 1:STN:280:DyaK3szivFOmtg%3D%3D, PID: 8336373; Lichtman, J.H., Froelicher, E.S., Blumenthal, J.A., Carney, R.M., Doering, L.V., Frasure-Smith, N., Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association (2014) Circulation, 129 (12), pp. 1350-1369. , PID: 24566200, The American Heart Association recognizes depression as an independent risk factor for cardiovascular disease; Smith, S.C., Jr., Benjamin, E.J., Bonow, R.O., Braun, L.T., Creager, M.A., Franklin, B.A., AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation (2011) Circulation, 124 (22), pp. 2458-2473. , PID: 22052934; Nemeroff, C.B., Knight, D.L., Franks, J., Craighead, W.E., Krishnan, K.R., Further studies on platelet serotonin transporter binding in depression (1994) Am J Psychiatry, 151 (11), pp. 1623-1625. , COI: 1:STN:280:DyaK2M%2FjtVSgsA%3D%3D, PID: 7943450; Berkman, L.F., Blumenthal, J., Burg, M., Carney, R.M., Catellier, D., Cowan, M.J., Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial (2003) JAMA, 289 (23), pp. 3106-3116. , PID: 12813116; Huang, C.J., Hsieh, M.H., Hou, W.H., Liu, J.C., Jeng, C., Tsai, P.S., Depression, antidepressants, and the risk of coronary heart disease: a population-based cohort study (2013) Int J Cardiol, 168 (5), pp. 4711-4716. , PID: 23948112; Kannel, W.B., Hjortland, M.C., McNamara, P.M., Gordon, T., Menopause and risk of cardiovascular disease: the Framingham study (1976) Ann Intern Med, 85 (4), pp. 447-452. , COI: 1:STN:280:DyaE2s%2FitVWrtw%3D%3D, PID: 970770; Mendelsohn, M.E., Karas, R.H., The protective effects of estrogen on the cardiovascular system (1999) N Engl J Med, 340 (23), pp. 1801-1811. , COI: 1:CAS:528:DyaK1MXjvFKrtbg%3D, PID: 10362825; Vaidya, D., Becker, D.M., Bittner, V., Mathias, R.A., Ouyang, P., Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data (2011) BMJ (Clin Res Ed), 343, p. d5170; Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group (1998) JAMA, 280 (7), pp. 605-613. , COI: 1:CAS:528:DyaK1cXlslGqsLY%3D, PID: 9718051; Harman, S.M., Brinton, E.A., Cedars, M., Lobo, R., Manson, J.E., Merriam, G.R., KEEPS: The kronos early estrogen prevention study (2005) Climacteric J Int Menopause Soc, 8 (1), pp. 3-12. , COI: 1:STN:280:DC%2BD2M7nt1GktA%3D%3D; Mosca, L., Hammond, G., Mochari-Greenberger, H., Towfighi, A., Albert, M.A., Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey (2013) Circulation, 127 (11), pp. 1254-1263. , PID: 23429926, This study showed that awareness of heart disease in women has been growing over the last 15 years, but significant gaps still remain; Mosca, L., Ferris, A., Fabunmi, R., Robertson, R.M., Tracking women’s awareness of heart disease: an American Heart Association national study (2004) Circulation, 109 (5), pp. 573-579. , PID: 14761901; Yancy, C.W., Wang, T.Y., Ventura, H.O., Pina, I.L., Vijayaraghavan, K., Ferdinand, K.C., The coalition to reduce racial and ethnic disparities in cardiovascular disease outcomes (credo): why credo matters to cardiologists (2011) J Am Coll Cardiol, 57 (3), pp. 245-252. , PID: 21232662, This report outlines the mission and efforts of the American College of Cardiology's Coalition to Reduce Racial Ethnic Disparities in Cardiovascular Disease Outcomes (credo) to help improve delivery of care and heatlh outcomes of diverse patient populations; Freemantle, N., Cleland, J., Young, P., Mason, J., Harrison, J., Beta blockade after myocardial infarction: systematic review and meta regression analysis (1999) BMJ (Clin Res Ed), 318 (7200), pp. 1730-1737. , COI: 1:STN:280:DyaK1MzhtVOhuw%3D%3D; Cho, L., Hoogwerf, B., Huang, J., Brennan, D.M., Hazen, S.L., Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study (2008) J Womens Health (2002), 17 (4), pp. 515-521; Daly, C., Clemens, F., Lopez Sendon, J.L., Tavazzi, L., Boersma, E., Danchin, N., Gender differences in the management and clinical outcome of stable angina (2006) Circulation, 113 (4), pp. 490-498. , PID: 16449728; Butler, J., Arbogast, P.G., BeLue, R., Daugherty, J., Jain, M.K., Ray, W.A., Outpatient adherence to beta-blocker therapy after acute myocardial infarction (2002) J Am Coll Cardiol, 40 (9), pp. 1589-1595. , PID: 12427410; Crane, P.B., Oles, K.S., Kennedy-Malone, L., Beta-blocker medication usage in older women after myocardial infarction (2006) J Am Acad Nurse Pract, 18 (10), pp. 463-470. , PID: 16999711; Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators (2000) N Engl J Med, 342 (3), pp. 145-153. , COI: 1:STN:280:DC%2BD3c%2Fpt1emug%3D%3D, PID: 10639539; Savarese, G., Costanzo, P., Cleland, J.G., Vassallo, E., Ruggiero, D., Rosano, G., A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure (2013) J Am Coll Cardiol, 61 (2), pp. 131-142. , COI: 1:CAS:528:DC%2BC38XhvFWhu7zP, PID: 23219304; Reibis, R.K., Bestehorn, K., Pittrow, D., Jannowitz, C., Wegscheider, K., Voller, H., Elevated risk profile of women in secondary prevention of coronary artery disease: a 6-year survey of 117,913 patients (2009) J Womens Health (2002), 18 (8), pp. 1123-1131; Brown, N.J., Vaughan, D.E., Angiotensin-converting enzyme inhibitors (1998) Circulation, 97 (14), pp. 1411-1420. , COI: 1:CAS:528:DyaK1cXis1KqtLs%3D, PID: 9577953; Cooke, C.E., Fatodu, H., Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization (2006) J Manag Care Pharm JMCP, 12 (8), pp. 649-655; Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (1998) N Engl J Med, 339, pp. 1349-1357; Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M., Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial (2002) Lancet, 360 (9346), pp. 1623-1630. , COI: 1:CAS:528:DC%2BD38XovFegt7o%3D, PID: 12457784; Gutierrez, J., Ramirez, G., Rundek, T., Sacco, R.L., Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis (2012) Arch Intern Med, 172 (12), pp. 909-919. , COI: 1:CAS:528:DC%2BC38XhtFGjt77K, PID: 22732744; Koopman, C., Vaartjes, I., Heintjes, E.M., Spiering, W., van Dis, I., Herings, R.M., Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010 (2013) Eur Heart J, 34 (41), pp. 3198-3205. , COI: 1:CAS:528:DC%2BC3sXhslaksbfL, PID: 24046432, This review outlines the age-specific and gender-specific trends in primary prevention, secondary prevention, and in-hospital treatment of coronary heart disase from 1998-2010; Arnold, S.V., Spertus, J.A., Tang, F., Krumholz, H.M., Borden, W.B., Farmer, S.A., Statin use in outpatients with obstructive coronary artery disease (2011) Circulation, 124 (22), pp. 2405-2410. , COI: 1:CAS:528:DC%2BC3MXhsFCisLzI, PID: 22064595; Golomb, B.A., Evans, M.A., Dimsdale, J.E., White, H.L., Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial (2012) Arch Intern Med, 172 (15), pp. 1180-1182. , PID: 22688574; Kostis, W.J., Cheng, J.Q., Dobrzynski, J.M., Cabrera, J., Kostis, J.B., Meta-analysis of statin effects in women versus men (2012) J Am Coll Cardiol, 59 (6), pp. 572-582. , COI: 1:CAS:528:DC%2BC38XhvVCjtrs%3D, PID: 22300691, This meta-analysis examines the sex-specific differences in efficacy and safety of statin therapy for the prevention and treatment of coronary heart disease; Johansen, K.L., Increased diabetes mellitus risk with statin use: comment on “statin use and risk of diabetes mellitus in postmenopausal women in the women’s health initiative (2012) Arch Intern Med, 172 (2), p. 152. , PID: 22231613; Undela, K., Srikanth, V., Bansal, D., Statin use and risk of breast cancer: a meta-analysis of observational studies (2012) Breast Cancer Res Treat, 135 (1), pp. 261-269. , COI: 1:CAS:528:DC%2BC38XhtFOkurbM, PID: 22806241; Stein, E.A., Mellis, S., Yancopoulos, G.D., Stahl, N., Logan, D., Smith, W.B., Effect of a monoclonal antibody to PCSK9 on LDL cholesterol (2012) N Engl J Med, 366 (12), pp. 1108-1118. , COI: 1:CAS:528:DC%2BC38XktlCqtLY%3D, PID: 22435370, This study presents three phase I studies of a monoclonal antibody to PCSK9, a novel agent for the treatment of hyperlipidemia; Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R.S., Watts, G.F., Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab (2014) J Am Coll Cardiol, 63 (23), pp. 2541-2548. , COI: 1:CAS:528:DC%2BC2cXpslCrtbY%3D, PID: 24694531, This study is a randomized controlled study that compares subcutaneous evoloumab, an anti-PCKS9 inhibitor, to oral ezetimibe in patients with hyperlipidema who were unable to tolerate effective statin doses; Robinson, J.G., Nedergaard, B.S., Rogers, W.J., Fialkow, J., Neutel, J.M., Ramstad, D., Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial (2014) JAMA, 311 (18), pp. 1870-1882. , PID: 24825642, This study presents a randomized controlled study that evalutes the efficcy and safety of evolocumab, an anti-PCSK9 antibody, when used with a moderate- or high-intensity statin for the treatment of hyperlipidemia; Mayne, J., Raymond, A., Chaplin, A., Cousins, M., Kaefer, N., Gyamera-Acheampong, C., Plasma PCSK9 levels correlate with cholesterol in men but not in women (2007) Biochem Biophys Res Commun, 361 (2), pp. 451-456. , COI: 1:CAS:528:DC%2BD2sXosF2jsLY%3D, PID: 17645871; Keech, A., Simes, R.J., Barter, P., Best, J., Scott, R., Taskinen, M.R., Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial (2005) Lancet, 366 (9500), pp. 1849-1861. , COI: 1:STN:280:DC%2BD2MnjtVCnsg%3D%3D, PID: 16310551; Ginsberg, H.N., The ACCORD (Action to Control Cardiovascular Risk in Diabetes) lipid trial: what we learn from subgroup analyses (2011) Diabetes Care, 34, pp. S107-S108. , PID: 21525439; Keene, D., Price, C., Shun-Shin, M.J., Francis, D.P., Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients (2014) BMJ (Clin Res Ed), 349, p. g4379; Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J., Komajda, M., Effects of torcetrapib in patients at high risk for coronary events (2007) N Engl J Med, 357 (21), pp. 2109-2122. , COI: 1:CAS:528:DC%2BD2sXhtlGns7bL, PID: 17984165; Nissen, S.E., Tardif, J.C., Nicholls, S.J., Revkin, J.H., Shear, C.L., Duggan, W.T., Effect of torcetrapib on the progression of coronary atherosclerosis (2007) N Engl J Med, 356 (13), pp. 1304-1316. , COI: 1:CAS:528:DC%2BD2sXjsFGnsrY%3D, PID: 17387129; Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J., Effects of dalcetrapib in patients with a recent acute coronary syndrome (2012) N Engl J Med, 367 (22), pp. 2089-2099. , COI: 1:CAS:528:DC%2BC38XhslyltrvK, PID: 23126252; Luscher, T.F., Taddei, S., Kaski, J.C., Jukema, J.W., Kallend, D., Munzel, T., Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial (2012) Eur Heart J, 33 (7), pp. 857-865. , PID: 22345126; Gotto, A.M., Jr., Cannon, C.P., Li, X.S., Vaidya, S., Kher, U., Brinton, E.A., Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease (2014) Am J Cardiol, 113 (1), pp. 76-83. , COI: 1:CAS:528:DC%2BC3sXhslajsLzN, PID: 24188894; Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients (2002) BMJ, 324, pp. 71-86; Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials (2009) Lancet, 373 (9678), pp. 1849-1860. , PID: 19482214, This meta-analysis examined the use of aspirin for primary prevention of myocardial infarction (MI), stroke, or vascular death; Becker, D.M., Segal, J., Vaidya, D., Yanek, L.R., Herrera-Galeano, J.E., Bray, P.F., Sex differences in platelet reactivity and response to low-dose aspirin therapy (2006) JAMA, 295 (12), pp. 1420-1427. , COI: 1:CAS:528:DC%2BD28Xislehu74%3D, PID: 16551714, This meta-analysis examines the serious vascular events and major bleeds in long-term aspirin use versus control; Sam, C., Massaro, J.M., D’Agostino, R.B., Sr., Levy, D., Lambert, J.W., Wolf, P.A., Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study) (2004) Am J Cardiol, 94 (7), pp. 947-951. , COI: 1:CAS:528:DC%2BD2cXotFCmsbo%3D, PID: 15464686; Marrugat, J., Sala, J., Masia, R., Pavesi, M., Sanz, G., Valle, V., Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempo de Espera (1998) JAMA, 280 (16), pp. 1405-1409. , COI: 1:STN:280:DyaK1M%2FhsFKiug%3D%3D, PID: 9800999; Rivera, C.M., Song, J., Copeland, L., Buirge, C., Ory, M., McNeal, C.J., Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women (2012) J Womens Health (2002), 21 (4), pp. 379-387. , This study evaluates self-reported aspirin use in women for primary and secondary prevention of CVD from 2004 to 2009; Maree, A.O., Fitzgerald, D.J., Variable platelet response to aspirin and clopidogrel in atherothrombotic disease (2007) Circulation, 115 (16), pp. 2196-2207. , PID: 17452618; Berger, J.S., Bhatt, D.L., Cannon, C.P., Chen, Z., Jiang, L., Jones, J.B., The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis (2009) J Am Coll Cardiol, 54 (21), pp. 1935-1945. , COI: 1:CAS:528:DC%2BD1MXhs1Slur7E, PID: 19909874; Wiviott, S.D., Braunwald, E., McCabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Prasugrel versus clopidogrel in patients with acute coronary syndromes (2007) N Engl J Med, 357 (20), pp. 2001-2015. , COI: 1:CAS:528:DC%2BD2sXhtlWis7rN, PID: 17982182; Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C., Ticagrelor versus clopidogrel in patients with acute coronary syndromes (2009) N Engl J Med, 361 (11), pp. 1045-1057. , COI: 1:CAS:528:DC%2BD1MXhtFaltL%2FJ, PID: 19717846; Husted, S., James, S.K., Bach, R.G., Becker, R.C., Budaj, A., Heras, M., The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial (2014) Eur Heart J, 35 (23), pp. 1541-1550. , COI: 1:CAS:528:DC%2BC2cXhtVaks7bO, PID: 24682844; Morrow, D.A., Braunwald, E., Bonaca, M.P., Ameriso, S.F., Dalby, A.J., Fish, M.P., Vorapaxar in the secondary prevention of atherothrombotic events (2012) N Engl J Med, 366 (15), pp. 1404-1413. , COI: 1:CAS:528:DC%2BC38XlslOrsLk%3D, PID: 22443427; Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, Thompson DR, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2011;(7):Cd001800. This systematic review examines the effectiveness of exercise-based cardiac rehabilittion on mortality, morbidity, and health-related quality of life of patients with CHDTaylor, R.S., Brown, A., Ebrahim, S., Jolliffe, J., Noorani, H., Rees, K., Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials (2004) Am J Med, 116 (10), pp. 682-692. , PID: 15121495; Jackson, L., Leclerc, J., Erskine, Y., Linden, W., Getting the most out of cardiac rehabilitation: a review of referral and adherence predictors (2005) Heart, 91 (1), pp. 10-14. , COI: 1:STN:280:DC%2BD2cnivV2gug%3D%3D, PID: 15604322; Wenger, N.K., Speroff, L., Packard, B., Cardiovascular health and disease in women (1993) N Engl J Med, 329 (4), pp. 247-256. , COI: 1:STN:280:DyaK3szgt1yiug%3D%3D, PID: 8316269; Allen, J.K., Scott, L.B., Stewart, K.J., Young, D.R., Disparities in women’s referral to and enrollment in outpatient cardiac rehabilitation (2004) J Gen Intern Med, 19 (7), pp. 747-753. , PID: 15209588; Mosca, L., Linfante, A.H., Benjamin, E.J., Berra, K., Hayes, S.N., Walsh, B.W., National study of physician awareness and adherence to cardiovascular disease prevention guidelines (2005) Circulation, 111 (4), pp. 499-510. , PID: 15687140; Beckie, T.M., Beckstead, J.W., Predicting cardiac rehabilitation attendance in a gender-tailored randomized clinical trial (2010) J Cardiopulm Rehabil Prev, 30 (3), pp. 147-156. , PID: 20216324; Beckie, T.M., Beckstead, J.W., Schocken, D.D., Evans, M.E., Fletcher, G.F., The effects of a tailored cardiac rehabilitation program on depressive symptoms in women: a randomized clinical trial (2011) Int J Nurs Stud, 48 (1), pp. 3-12. , PID: 20615504; Grodstein, F., Stampfer, M., The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women (1995) Prog Cardiovasc Dis, 38 (3), pp. 199-210. , COI: 1:CAS:528:DyaK28Xot1entQ%3D%3D, PID: 7494882; Schierbeck, L.L., Rejnmark, L., Tofteng, C.L., Stilgren, L., Eiken, P., Mosekilde, L., Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial (2012) BMJ (Clin Res Ed), 345, p. e6409",Review,Scopus,2-s2.0-84928318485
"Haralambos K., Whatley S.D., Edwards R., Gingell R., Townsend D., Ashfield-Watt P., Lansberg P., Datta D.B.N., McDowell I.F.W.","Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales",2015,"Atherosclerosis","240","1",,"190","196",,,10.1016/j.atherosclerosis.2015.03.003,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924965687&partnerID=40&md5=a1fabc909bc4cb2d1364d01213c4c6b4","Wales Heart Research Institute, Cardiff University School of Medicine, University Hospital of WalesCardiff, United Kingdom; Wales FH Service c/o Cardiff, Vale University Health Board, United Kingdom; CTMM-TraIT Center for Translational Molecular Medicine, High Tech Campus 84AG Eindhoven, Netherlands","Haralambos, K., Wales Heart Research Institute, Cardiff University School of Medicine, University Hospital of WalesCardiff, United Kingdom; Whatley, S.D., Wales FH Service c/o Cardiff, Vale University Health Board, United Kingdom; Edwards, R., Wales FH Service c/o Cardiff, Vale University Health Board, United Kingdom; Gingell, R., Wales FH Service c/o Cardiff, Vale University Health Board, United Kingdom; Townsend, D., Wales FH Service c/o Cardiff, Vale University Health Board, United Kingdom; Ashfield-Watt, P., Wales Heart Research Institute, Cardiff University School of Medicine, University Hospital of WalesCardiff, United Kingdom; Lansberg, P., CTMM-TraIT Center for Translational Molecular Medicine, High Tech Campus 84AG Eindhoven, Netherlands; Datta, D.B.N., Wales FH Service c/o Cardiff, Vale University Health Board, United Kingdom; McDowell, I.F.W., Wales Heart Research Institute, Cardiff University School of Medicine, University Hospital of WalesCardiff, United Kingdom","Familial Hypercholesterolaemia (FH) is caused by mutations in genes of the Low Density Lipoprotein (LDL) receptor pathway. A definitive diagnosis of FH can be made by the demonstration of a pathogenic mutation. The Wales FH service has developed scoring criteria to guide selection of patients for DNA testing, for those referred to clinics with hypercholesterolaemia. The criteria are based on a modification of the Dutch Lipid Clinic scoring criteria and utilise a combination of lipid values, physical signs, personal and family history of premature cardiovascular disease. They are intended to provide clinical guidance and enable resources to be targeted in a cost effective manner. Methods: 623 patients who presented to lipid clinics across Wales had DNA testing following application of these criteria. Results: The proportion of patients with a pathogenic mutation ranged from 4% in those scoring 5 or less up to 85% in those scoring 15 or more. LDL-cholesterol was the strongest discriminatory factor. Scores gained from physical signs, family history, coronary heart disease, and triglycerides also showed a gradient in mutation pick-up rate according to the score. Conclusion: These criteria provide a useful tool to guide selection of patients for DNA testing when applied by health professionals who have clinical experience of FH. © 2015 Elsevier Ireland Ltd.","Cholesterol; Criteria; Diagnosis; Familial hypercholesterolaemia; Genetics","Goldstein, J.L., Hobbs, H.H., Brown, M.S., Familial hypercholesterolaemia (1995) The Metabolic Basis of Inherited Disease, pp. 1981-2030. , McGraw Hill, New York, C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.); Lansberg, P.J., Tuzgöl, S., van de Ree, M.A., Defesche, J.C., Kastelein, J.J., Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands (2000) Ned. Tijdschr. Geneeskd., 144, pp. 1437-1440; Benn, M., Watts, G.F., Tybjaerg-Hansen, A., Nordestgaard, B.G., Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication (2012) J.Clin. Endocrinol. Metab., 97, pp. 3956-3964; Sjouke, B., Kusters, D.M., Kindt, I., Besseling, J., Defesche, J.C., Sijbrands, E.J., Roeters van Lennep, J.E., Hovingh, G.K., Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome (2014) Eur. Heart J., , First published online 28 Feb 2014; Stone, N.J., Levy, R.I., Fredrickson, D.S., Verter, J., Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia (1974) Circulation, 49, pp. 476-488; Datta, B.N., McDowell, I.F.W., Rees, A., Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia (2010) Curr. Opin. Lipidol., 21, pp. 366-371; (2008) National Institute of Health and Clinical Excellence Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: Identification and Management of Adults and Children with Familial Hypercholesterolaemia, , (Clinical Guideline 71); (2011) Elucigene FH20 and LIPOchip for the Diagnosis of Familial Hypercholesterolaemia (NICE Diagnostics Guidance 2); Sharma, P., Boyers, D., Boachie, C., Stewart, F., Miedzybrodzka, Z., Simpson, W., Kilonzo, M., Mowatt, G., Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation (2012) Health Technol. Assess., 17 (17); McDowell, I., Watson, M., Townsend, D., Featherstone, K., Parham, K., Whatley, S., An evaluation of DNA diagnostics for familial hypercholesterolaemia including a study of personal and family implications [abstract] (2007) Atherosclerosis, 194, p. 282; Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group (1991) BMJ, 303, pp. 893-896; (1999) Familial Hypercholesterolemia - Report of a Second WHO Consultation, , World Health Organization, Geneva, Switzerland, (WHO publication no.WHO/HGN/FH/CONS/99.2); Defesche, J.C., Familial hypercholesterolaemia (2000) Lipids and Vascular Disease, pp. 65-76. , Martin Dunitz, London, D.J. Betteridge (Ed.); Williams, R.R., Hunt, S.C., Schumacher, M.C., Hegele, R.A., Leppert, M.F., Ludwig, E.H., Hopkins, P.N., Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics (1993) Am. J. Cardiol., 72, pp. 171-176; Damgaard, D., Larsen, M.L., Nissen, P.H., Jensen, J.M., Jensen, H.K., Soerensen, V.R., Jensen, L.G., Faergeman, O., The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population (2005) Atherosclerosis, 180 (1), pp. 155-160; Clarke, R.E., Padayachee, S.T., Preston, R., McMahon, Z., Gordon, M., Graham, C., Crook, M.A.W., Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia (2013) Heart, 99 (3), pp. 175-180; Civeira, F., Ros, E., Jarauta, E., Plana, N., Zambon, D., Puzo, J., Martinez de Esteban, J.P., Pocovi, M., Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia (2008) Am. J. Cardiol., 102 (9), pp. 1187-1193; Huijgen, R., Hutten, B.A., Kindt, I., Vissers, M.N., Kastelein, J.J., Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH (2012) Circ. Cardiovasc. Genet., 5 (3), pp. 354-359; Harada-Shiba, M., Arai, H., Okamura, T., Yokote, K., Oikawa, S., Nohara, A., Okada, T., Yamashita, S., Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan (2012) J.Atheroscler. Thromb., 19 (11), pp. 1019-1026; Wallis, Y., Payne, S., McAnulty, C., Bodmer, D., Sistermans, E., Robertson, K., Moore, D., Devereau, A., (2013) Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Medicine, , (Approved September 2013), Association for Clinical Genetic Science (ACGS), Dutch Society of Clinical Laboratory Specialists (VKGL); Holm, S., Asimple sequentially rejective multiple test procedure (1979) Scand. J. Stat., 6 (2), pp. 65-70; Mallett, S., Halligan, S., Thompson, M., Collins, G.S., Altman, D.G., Interpreting diagnostic accuracy studies for patient care (2012) BMJ, 2, pp. 345-399; Humphries, S.E., Cranston, T., Allen, M., Middleton-Price, H., Fernandez, M.C., Senior, V., Hawe, E., Wierzbicki, A.S., Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing (2006) J.Mol. Med., 84, pp. 203-214; Naoumova, R.P., Tosi, I., Patel, D., Neuwirth, C., Horswell, S.D., Marais, A.D., van Heyningen, C., Soutar, A.K., Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response (2005) Arterioscler. Thromb. Vasc. Biol., 25, pp. 2654-2660; Palacios, L., Grandoso, L., Cuevas, N., Olano-Martín, E., Martinez, A., Tejedor, D., Stef, M., Molecular characterization of familial hypercholesterolemia in Spain (2012) Atherosclerosis, 221, pp. 137-142; Civeira, F., Jarauta, E., Cenarro, A., García-Otín, A.L., Tejedor, D., Zambón, D., Mallen, M., Pocoví, M., Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting (2008) J.Am. Coll. Cardiol., 52 (19), pp. 1546-1553; Oostweveer, D.M., Versmissen, J., Yazdanpanah, M., Hamza, T.H., Sijbrands, E.J.G., Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis (2009) Atherosclerosis, 207 (2), pp. 311-317; Bertolini, S., Pisciotta, L., Rabacchi, C., Cefalù, A.B., Noto, D., Fasano, T., Signori, A., Calandra, S., Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy (2013) Atherosclerosis, 227, pp. 342-348; Bhatnagar, D., Diagnosis and screening for familial hypercholesterolaemia: finding the patients, finding the genes (2006) Ann. Clin. Biochem., 43, pp. 441-456; Winder, A.F., Jolleys, J.C., Day, L.B., Butowski, P.F., Corneal arcus, case finding and definition of individual clinical risk in heterozygous familial hypercholesterolaemia (1998) Clin. Genet., 54 (6), pp. 497-502; Talmud, P.J., Shah, S., Whittall, F.M., Howard, P., Cooper, J.A., Harrison, S.C., Li, K., Humphries, S.E., Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study (2013) Lancet, 381 (9874), pp. 1293-1301; Starr, B., Hadfield, G., Hutten, B.A., Lansberg, P.J., Leren, T.P., Damgaard, D.H., Neil, A.W., Humphries, S.E., Development of sensitive and specific age- and gender specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing (2008) Clin. Chem. Lab. Med., 46 (6), pp. 791-803; Koivisto, P.V., Koivisto, U.M., Miettinen, T.A., Kontula, K., Diagnosis of heterozygous familial hypercholesterolemia DNA analysis complements clinical examination and analysis of serum lipid levels (1992) Arterioscler. Thromb. Vasc. Biol., 12, pp. 584-592; Leren, T.P., Manshaus, T., Skovholt, U., Skodje, T., Nossen, I.E., Teie, C., Sørensen, S., Bakken, K.S., Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program (2004) Semin. Vasc. Med., 4 (1), pp. 75-85; (2013) Guidelines for the Diagnosis and Management of FH, , http://www.csanz.edu.au/wp-content/uploads/2013/12/Familial_Hypercholesterolemia_2013.pdf, The Cardiac Society of Australia and New Zealand",Article,Scopus,2-s2.0-84924965687
"Xu Y., Xie Y., Shao X., Ni Z., Mou S.","L-FABP: A novel biomarker of kidney disease",2015,"Clinica Chimica Acta","445",,,"85","90",,,10.1016/j.cca.2015.03.017,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925944212&partnerID=40&md5=dc23e0b3f04ad89a5426bab268883dd7","Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, China","Xu, Y., Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, China; Xie, Y., Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, China; Shao, X., Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, China; Ni, Z., Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, China; Mou, S., Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, China","Human liver-type fatty acid-binding protein (hL-FABP), which is found in both the normal and the diseased human kidney, has been observed to bind free fatty acids. Recently, the predictive and prognostic value of L-FABP in kidney diseases has attracted considerable attention. Numerous studies have demonstrated that L-FABP is a promising biomarker of several kidney diseases, and it has also been shown to attenuate renal injury. We performed a literature review regarding the ability of L-FABP to identify patients at risk of developing kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD) and to protect the kidneys in the course of kidney disease. © 2015 Elsevier B.V.","Acute kidney injury; Chronic kidney disease; Fatty acid; Liver-type fatty acid-binding protein","McMahon, G.M., Waikar, S.S., Biomarkers in nephrology: Core Curriculum 2013 (2013) Am J Kidney Dis, 62 (1), pp. 165-178; Waikar, S.S., Betensky, R.A., Bonventre, J.V., Creatinine as the gold standard for kidney injury biomarker studies? (2009) Nephrol Dial Transplant, 24 (11), pp. 3263-3265; Wasung, M.E., Chawla, L.S., Madero, M., Biomarkers of renal function, which and when? (2014) Clin Chim Acta, 438, pp. 350-357; Ockner, R.K., Manning, J.A., Poppenhausen, R.B., Ho, W.K., A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues (1972) Science, 177 (43), pp. 56-58; Kamijo-Ikemori, A., Sugaya, T., Matsui, K., Yokoyama, T., Kimura, K., Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice (2011) Nephrol (Carlton), 16 (6), pp. 539-544; Yang, J., Choi, H.M., Seo, M.Y., Lee, J.Y., Kim, K., Jun, H., Urine liver-type fatty acid-binding protein predicts graft outcome up to 2years after kidney transplantation (2014) Transplant Proc, 46 (2), pp. 376-380; Parr, S.K., Clark, A.J., Bian, A., Shintani, A.K., Wickersham, N.E., Ware, L.B., Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury (2015) Kidney Int, 87 (3), pp. 640-648; Belcher, J.M., Garcia-Tsao, G., Sanyal, A.J., Thiessen-Philbrook, H., Peixoto, A.J., Perazella, M.A., Urinary biomarkers and progression of AKI in patients with cirrhosis (2014) Clin J Am Soc Nephrol, 9 (11), pp. 1857-1867; Yamamoto, T., Noiri, E., Ono, Y., Doi, K., Negishi, K., Kamijo, A., Renal L-type fatty acid binding protein in acute ischemic injury (2007) J Am Soc Nephrol, 18 (11), pp. 2894-2902; Chmurzyńska, A., The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism (2006) J Appl Genet, 47 (1), pp. 39-48; Rebecca, L.S., Dennis, R.P., The human fatty acid-binding protein family: evolutionary divergences and functions (2011) Hum Genom, 5 (3), pp. 170-191; Michael, D.S., Digestion and absorption of dietary triglycerides (2014) The gastrointestinal system: gastrointestinal, nutritional and hepatobiliary physiology, pp. 160-178. , E-Publishing Inc, New York, P.S. Leung (Ed.); Sharma, A., Yogavel, M., Sharma, A., Utility of anion and cation combinations for phasing of protein structures (2012) J Struct Funct Genom, 13 (3), pp. 135-143; Cai, J., Lucke, C., Chen, Z., Qiao, Y., Klimtchuk, E., Hamilton, J.A., Solution structure and backbone dynamics of human liver fatty acid binding protein: fatty acid binding revisited (2012) Biophys J, 102 (11), pp. 2585-2594; Huang, H., McIntosh, A.L., Martin, G.G., Landrock, K.K., Landrock, D., Gupta, S., Structural and functional interaction of fatty acids with human liver fatty acid-binding protein (L-FABP) T94A variant (2014) FEBS J, 281 (9), pp. 2266-2283; David, A., Sweetser, R.O.H., Jeffrey, I., Gordon. The metabolic significance of mammalian fatty-acid binding proteins: abundant proteins in search of a function (1987) Annu Rev Nutr, 7, pp. 337-359; Petrescu, A.D., McIntosh, A.L., Storey, S.M., Huang, H., Martin, G.G., Landrock, D., High glucose potentiates L-FABP mediated fibrate induction of PPARalpha in mouse hepatocytes (2013) Biochim Biophys Acta, 1831 (8), pp. 1412-1425; Wolfrum, C., Borrmann, C.M., Borchers, T., Spener, F., Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus (2001) Proc Natl Acad Sci U S A, 98 (5), pp. 2323-2328; Ek-Von Mentzer, B.A., Zhang, F., Hamilton, J.A., Binding of 13-HODE and 15-HETE to phospholipid bilayers, albumin, and intracellular fatty acid binding proteins. Implications for transmembrane and intracellular transport and for protection from lipid peroxidation (2001) J Biol Chem, 276 (19), pp. 15575-15580; Wang, G., Gong, Y., Anderson, J., Sun, D., Minuk, G., Roberts, M.S., Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells (2005) Hepatology, 42 (4), pp. 871-879; Fan, W., Chen, K., Zheng, G., Wang, W., Teng, A., Liu, A., Role of liver fatty acid binding protein in hepatocellular injury: effect of CrPic treatment (2013) J Inorg Biochem, 124, pp. 46-53; Wang, G., Chen, Q.M., Minuk, G.Y., Gong, Y., Burczynski, F.J., Enhanced expression of cytosolic fatty acid binding protein and fatty acid uptake during liver regeneration in rats (2004) Mol Cell Biochem, 262 (1-2), pp. 41-49; Rajaraman, G., Burczynski, F.J., Effect of dexamethasone, 2-bromopalmitate and clofibrate on L-FABP mediated hepatoma proliferation (2004) J Pharm Pharmacol, 56 (9), pp. 1155-1161; Chertow, G.M., Burdick, E., Honour, M., Bonventre, J.V., Bates, D.W., Acute kidney injury, mortality, length of stay, and costs in hospitalized patients (2005) J Am Soc Nephrol, 16 (11), pp. 3365-3370; Uchino, S., Acute renal failure in critically ill patients: a multinational, multicenter study (2005) JAMA, 294, pp. 813-818; Tanaka, T., Noiri, E., Yamamoto, T., Sugaya, T., Negishi, K., Maeda, R., Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury (2008) Nephron Exp Nephrol, 108 (1), pp. 19-26; Siew, E.D., Ware, L.B., Ikizler, T.A., Biological markers of acute kidney injury (2011) J Am Soc Nephrol, 22 (5), pp. 810-820; Parikh, C.R., Butrymowicz, I., Yu, A., Chinchilli, V.M., Park, M., Hsu, C.Y., Urine stability studies for novel biomarkers of acute kidney injury (2014) Am J Kidney Dis, 63 (4), pp. 567-572; Basile, D.P., Leonard, E.C., Beal, A.G., Schleuter, D., Friedrich, J., Persistent oxidative stress following renal ischemia-reperfusion injury increases ANG II hemodynamic and fibrotic activity (2012) Am J Physiol Renal Physiol, 302 (11), pp. 1494-1502; Abd El-Hamid, A.M., Noha, N.L., Comparative study on the protective role of vitamin C and L-arginine in experimental renal ischemia reperfusion in adult rats (2014) Int J Phys Pathophysiol Pharmacol, 6 (3), pp. 153-165; Kwiecien, S., Jasons, K., Magierowski, M., Sliwowski, Z., Pajdo, R., Brzozowski, B., Lipid peroxidation, reactive oxygen species and antioxidatie factors in the pathogenesis of gastric mucosal lesions and mechanism of protection against oxidative stress-indued gastric injury (2014) J Physiol Pharmacol, 65 (5), pp. 613-622; Iguchi, N., Uchiyama, A., Ueta, K., Sawa, Y., Fujino, Y., Neutrophil gelatinase-associated lipocalin and liver-type fatty acid-binding protein as biomarkers for acute kidney injury after organ transplantation (2014) J Anesth; Yalavarthy, R., Edelstein, C.L., Teitelbaum, I., Acute renal failure and chronic kidney disease following liver transplantation (2007) Hemodial Int, 11 (3), pp. S7-S12; Kawai, A., Kusaka, M., Kitagawa, F., Ishii, J., Fukami, N., Maruyama, T., Serum liver-type fatty acid-binding protein predicts recovery of graft function after kidney transplantation from donors after cardiac death (2014) Clin Transpl, 28 (6), pp. 749-754; Portilla, D., Dent, C., Sugaya, T., Nagothu, K.K., Kundi, I., Moore, P., Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery (2008) Kidney Int, 73 (4), pp. 465-472; Matsui, K., Kamijo-Ikemori, A., Sugaya, T., Yasuda, T., Kimura, K., Usefulness of urinary biomarkers in early detection of acute kidney injury after cardiac surgery in adults (2012) Circ J, 76 (1), pp. 213-220; Coca, S.G., Garg, A.X., Thiessen-Philbrook, H., Koyner, J.L., Patel, U.D., Krumholz, H.M., Urinary biomarkers of AKI and mortality 3years after cardiac surgery (2014) J Am Soc Nephrol, 25 (5), pp. 1063-1071; Krawczeski, C.D., Goldstein, S.L., Woo, J.G., Wang, Y., Piyaphanee, N., Ma, Q., Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass (2011) J Am Coll Cardiol, 58 (22), pp. 2301-2309; Parikh, C.R.1., Thiessen-Philbrook, H., Garg, A.X., Kadiyala, D., Shlipak, M.G., Koyner, J.L., Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery (2013) Clin J Am Soc Nephrol, 8 (7), pp. 1079-1088; Peco-Antić, A., Ivanišević, I., Vulićević, I., Kotur-Stevuljević, J., Ilić, S., Ivanišević, J., Biomarkers of acute kidney injury in pediatric cardiac surgery (2013) Clin Biochem, 46 (13-14), pp. 1244-1251; Andreucci, M., Faga, T., Pisani, A., Sabbatini, M., Michael, A., Acute kidney injury by radiographic contrast media: pathogenesis and prevention (2014) Biomed Res Int, 2014, p. 362725; Curtis, L.M., Agarwal, A., HOpe for contrast-induced acute kidney injury (2007) Kidney Int, 72 (8), pp. 907-909; Stacul, F., van der Molen, A.J., Reimer, P., Webb, J.A., Thomsen, H.S., Morcos, S.K., Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines (2011) Eur Radiol, 21 (12), pp. 2527-2541; Nakamura, T., Sugaya, T., Node, K., Ueda, Y., Koide, H., Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy (2006) Am J Kidney Dis, 47 (3), pp. 439-444; Spector, A.A., Fatty acid binding to plasma albumin (1975) J Lipid Res, 16 (3), pp. 165-179; Hamilton, J.A., Era, S., Bhamidipati, S.P., Reed, R.G., Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin (1991) Proc Natl Acad Sci U S A, 88, pp. 2051-2054; Jin, K., Norris, K., Vaziri, N.D., Dysregulation of hepatic fatty acid metabolism in chronic kidney disease (2013) Nephrol Dial Transplant, 28 (2), pp. 313-320; Zuo, N., Suzuki, Y., Sugaya, T., Osaki, K., Kanaguchi, Y., Wang, L., Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy (2011) Nephrol Dial Transplant, 26 (7), pp. 2127-2137; Sasaki, H., Kamijo-Ikemori, A., Sugaya, T., Yamashita, K., Yokoyama, T., Koike, J., Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy (2009) Nephron Clin Pract, 112 (3), pp. c148-c156; Kamijo-Ikemori, A., Sugaya, T., Sekizuka, A., Hirata, K., Kimura, K., Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice (2009) Nephrol Dial Transplant, 24 (3), pp. 788-800; Kamijo, A., Kimura, K., Sugaya, T., Yamanouchi, M., Hikawa, A., Hirano, N., Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease (2004) J Lab Clin Med, 143, pp. 23-30; Ichikawa, D., Kamijo-Ikemori, A., Sugaya, T., Shibagaki, Y., Yasuda, T., Katayama, K., Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation (2014) Am J Physiol Renal Physiol, 306 (6), pp. F655-F663; Kamijo-Ikemori, A., Sugaya, T., Ichikawa, D., Hoshino, S., Matsui, K., Yokoyama, T., Urinary liver type fatty acid binding protein in diabetic nephropathy (2013) Clin Chim Acta, 424, pp. 104-108; Panduru, N.M., Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes (2013) Diabetes Care, 36 (7), pp. 2077-2083; Kamijo, A., Sugaya, T., Hikawa, A., Yamanouchi, M., Hirata, Y., Ishimitsu, T., Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial (2005) J Lab Clin Med, 145 (3), pp. 125-133; Mou, S., Wang, Q., Li, J., Shi, B., Ni, Z., Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis (2012) Clin Chim Acta, 413 (1-2), pp. 187-191; Pisani, A., Riccio, E., Andreucci, M., Faga, T., Ashour, M., Di Nuzzi, A., Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy (2013) Biomed Res Int, 2013; Kanaguchi, Y., Suzuki, Y., Osaki, K., Sugaya, T., Horikoshi, S., Tomino, Y., Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis (2011) Nephrol Dial Transplant, 26 (11), pp. 3465-3473; Schroeder, F., Petrescu, A.D., Huang, H., Atshaves, B.P., McIntosh, A.L., Martin, G.G., Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription (2008) Lipids, 43 (1), pp. 1-17; Susantitaphong, P., Siribamrungwong, M., Doi, K., Noiri, E., Terrin, N., Jaber, B.L., Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis (2013) Am J Kidney Dis, 61 (3), pp. 430-439; Shao, X.H., Tian, L., Xu, W.J., Zhang, Z., Wang, C., Qi, C., Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis (2014) PLoS ONE, 9 (1), p. e84131; Xue, W., Xie, Y.Y., Wang, Q., Xu, W.J., Mou, S., Ni, Z.H., Diagnostic performance of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for acute kidney injury in an obstructive nephropathy patient (2014) Nephrol (Carlton), 19 (4), pp. 186-194; Xie, Y.Y., Xue, W., Shao, X.H., Che, X.J., Xu, W.J., Ni, Z.H., Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes (2014) PLoS ONE, 9 (11), p. e112865; Xie, Y.Y., Xu, W.J., Wang, Q., Shao, X.H., Ni, Z.H., Mou, S., Urinary excretion of liver-type FABP as a new clinical marker for the progression of obstructive nephropathy (2014) Biomark Med, 8 (4), pp. 543-556; Manabe, K., Kamihata, H., Motohiro, M., Senoo, T., Yoshida, S., Iwasaka, T., Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury (2011) Eur J Clin Investig, 42 (5), pp. 557-563",Review,Scopus,2-s2.0-84925944212
"El-Khuffash A., James A.T., Cleary A., Semberova J., Franklin O., Miletin J.","Late medical therapy of patent ductus arteriosus using intravenous paracetamol",2015,"Archives of Disease in Childhood: Fetal and Neonatal Edition","100","3",,"F253","F256",,,10.1136/archdischild-2014-307930,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927672297&partnerID=40&md5=47bf24126846a7fdfd382f5346020b52","Department of Neonatology, Rotunda Hospital, Parnell StreetDublin, Ireland; School of Medicine, Royal College of Surgeons in IrelandDublin, Ireland; Coombe Women and Infants University HospitalDublin, Ireland; Institute for the Care of Mother and ChildPrague, Czech Republic; Department of Paediatric Cardiology, Our Lady's Children's Hospital CrumlinDublin, Ireland; UCD School of Medicine and Medical SciencesDublin, Ireland","El-Khuffash, A., Department of Neonatology, Rotunda Hospital, Parnell StreetDublin, Ireland, School of Medicine, Royal College of Surgeons in IrelandDublin, Ireland; James, A.T., Department of Neonatology, Rotunda Hospital, Parnell StreetDublin, Ireland; Cleary, A., Department of Neonatology, Rotunda Hospital, Parnell StreetDublin, Ireland; Semberova, J., Coombe Women and Infants University HospitalDublin, Ireland, Institute for the Care of Mother and ChildPrague, Czech Republic; Franklin, O., Department of Paediatric Cardiology, Our Lady's Children's Hospital CrumlinDublin, Ireland; Miletin, J., Coombe Women and Infants University HospitalDublin, Ireland, Institute for the Care of Mother and ChildPrague, Czech Republic, UCD School of Medicine and Medical SciencesDublin, Ireland","Objective To investigate the effect of late treatment with intravenous paracetamol on patent ductus arteriosus (PDA) closure prior to possible PDA ligation. Methods A retrospective review of infants with a haemodynamically significant PDA, considered for PDA ligation and treated with intravenous paracetamol prior to possible ligation. Results Thirty six infants with a median gestation of 26.1 weeks received paracetamol at a median age of 27 days. Paracetamol was associated with immediate closure in nine (25%) infants. There was no response to paracetamol treatment in four (11%) infants who subsequently underwent a PDA ligation. In 23 (64%) infants, the PDA constricted and all but one of this group demonstrated complete PDA closure prior to discharge. Conclusions There may be a role for intravenous paracetamol in late closure of infants with a significant PDA to avoid ligation. The use of paracetamol for late treatment of PDA should be systematically evaluated.",,"Mirea, L., Sankaran, K., Seshia, M., Treatment of patent ductus arteriosus and neonatal mortality/morbidities: Adjustment for treatment selection bias (2012) J Pediatr, 161, pp. 689-694; Weisz, D.E., More, K., McNamara, P.J., PDA ligation and health outcomes: A meta-analysis (2014) Pediatrics, 133, pp. 1024-e1046; El-Khuffash, A.F., Jain, A., McNamara, P.J., Ligation of the patent ductus arteriosus in preterm infants: Understanding the physiology (2013) J Pediatr, 162, pp. 1100-1106; El-Khuffash, A., Jain, A., Corcoran, D., Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: Evidence from human and murine studies (2014) Pediatr Res, 76, pp. 238-244; James, A.T., Corcoran, J.D., Jain, A., Assessment of myocardial performance in preterm infants less than 29 weeks gestation during the transitional period (2014) Early Hum Dev, 90, pp. 829-835; Oncel, M.Y., Yurttutan, S., Degirmencioglu, H., Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants (2013) Neonatology, 103, pp. 166-169; Oncel, M.Y., Yurttutan, S., Erdeve, O., Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: A randomized controlled trial (2014) J Pediatr, 164, pp. 510-514",Article,Scopus,2-s2.0-84927672297
"Tham J.C., le Roux C.W., Docherty N.G.","Cardiovascular, Renal and Overall Health Outcomes After Bariatric Surgery",2015,"Current Cardiology Reports","17","5",,"","",8,,10.1007/s11886-015-0588-6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928339025&partnerID=40&md5=47eea20295246bb9e2ff33135c9785fb","Musgrove Park HospitalTaunton, United Kingdom; Diabetes Complications Research Centre, Conway Institute, School of Medicine and Medical Sciences, University College DublinDublin, Ireland; Gastrosurgical Laboratory, University of GothenburgGothenburg, Sweden; Division of Investigative Science, Imperial College LondonLondon, United Kingdom","Tham, J.C., Musgrove Park HospitalTaunton, United Kingdom; le Roux, C.W., Diabetes Complications Research Centre, Conway Institute, School of Medicine and Medical Sciences, University College DublinDublin, Ireland, Gastrosurgical Laboratory, University of GothenburgGothenburg, Sweden, Division of Investigative Science, Imperial College LondonLondon, United Kingdom; Docherty, N.G., Diabetes Complications Research Centre, Conway Institute, School of Medicine and Medical Sciences, University College DublinDublin, Ireland","Obesity is associated with significant increases in morbidity and mortality secondary, in part, to the increased burden of cardiovascular and renal diseases. Currently, bariatric surgery represents an important component of intensive approaches to the treatment of chronic and complex obesity. The efficacy of bariatric surgery extends beyond its ability to support significant and sustainable reductions in bodyweight to improvements in metabolic and cardiovascular health which are proposed to occur, in part, via weight loss-independent physiological changes. This report summarises the concept of cardiovascular and renal diseases as important constituent aspects of obese morbidity that contribute to overall impairments in health and lifespan. It furthermore describes the key features of bariatric surgical interventions, the evidence base for their beneficial effect on cardiovascular and renal diseases, and lastly provides some perspectives on the mechanisms involved. © 2015, Springer Science+Business Media New York.","Bariatric; Cardiovascular; Health outcomes; Obesity; Renal; Surgery","Padwal, R.S., Pajewski, N.M., Allison, D.B., Sharma, A.M., Using the Edmonton Obesity Staging System to predict mortality in a population-representative cohort of people with overweight and obesity (2011) CMAJ, 183 (14), pp. 1059-1066. , The authors described a method of classifying obese patients according to co-morbidities instead of BMI which better stratifies the potential benefit achievable from bariatric surgery; Afkarian, M., Sachs, M.C., Kestenbaum, B., Hirsch, I.B., Tuttle, K.R., Himmelfarb, J., Kidney disease and increased mortality risk in type 2 diabetes (2013) J Am Soc Nephrol, 24 (2), pp. 302-308. , COI: 1:CAS:528:DC%2BC3sXivFejtr4%3D; Kushner, R.F., Ryan, D.H., Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews (2014) JAMA, 312 (9), pp. 943-952. , COI: 1:CAS:528:DC%2BC2cXhs12jt7jF; Christiansen, T., Bruun, J.M., Madsen, E.L., Richelsen, B., Weight loss maintenance in severely obese adults after an intensive lifestyle intervention: 2- to 4-year follow-up (2007) Obesity (Silver Spring), 15 (2), pp. 413-420; Wing, R.R., Bolin, P., Brancati, F.L., Bray, G.A., Clark, J.M., Coday, M., Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes (2013) N Engl J Med, 369 (2), pp. 145-154. , COI: 1:CAS:528:DC%2BC3sXht1emtL3E, Part of the Look AHEAD research group that scrutinised the possible management of obesity with lifestyle intervention but found that cardiovascular outcomes were no different when compared to control subjects; Group, L.A.R., Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial (2014) Lancet Diabetes Endocrinol, 2 (10), pp. 801-809; Schauer, P.R., Burguera, B., Ikramuddin, S., Cottam, D., Gourash, W., Hamad, G., Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus (2003) Ann Surg, 238 (4), pp. 467-484. , discussion 84–5; Schauer, P.R., Bhatt, D.L., Kirwan, J.P., Wolski, K., Brethauer, S.A., Navaneethan, S.D., Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes (2014) N Engl J Med, 370 (21), pp. 2002-2013. , The authors describe a landmark study that compared bariatric surgery with medical therapy against medical therapy alone in the management of type 2 diabetes mellitus instead of the traditional surgery versus medical treatment. The message portrayed from the study proposes surgery as an adjunct to medical therapy in the treatment of obese patients; Carlsson, L.M., Romeo, S., Jacobson, P., Burza, M.A., Maglio, C., Sjöholm, K., (2014) The incidence of albuminuria after bariatric surgery and usual care in Swedish obese subjects (SOS): a prospective controlled intervention trial. Int J Obes, , Lond: The study shows the reversal of kidney damage as a result of bariatric surgery in the long-term; Carlsson, L.M., Peltonen, M., Ahlin, S., Anveden, Å., Bouchard, C., Carlsson, B., Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects (2012) N Engl J Med, 367 (8), pp. 695-704. , COI: 1:CAS:528:DC%2BC38XhtlSlt7%2FN; Delling, L., Karason, K., Olbers, T., Sjöström, D., Wahlstrand, B., Carlsson, B., Feasibility of bariatric surgery as a strategy for secondary prevention in cardiovascular disease: a report from the Swedish obese subjects trial (2010) J Obes; Hallersund, P., Sjöström, L., Olbers, T., Lönroth, H., Jacobson, P., Wallenius, V., Gastric bypass surgery is followed by lowered blood pressure and increased diuresis—long term results from the Swedish Obese Subjects (SOS) study (2012) PLoS One, 7 (11), p. 49696. , COI: 1:CAS:528:DC%2BC38XhvVyju77K; Sjöström, L., Lindroos, A.K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery (2004) N Engl J Med, 351 (26), pp. 2683-2693; Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C.D., Karason, K., Wedel, H., Bariatric surgery and long-term cardiovascular events (2012) JAMA, 307 (1), pp. 56-65. , The authors revealed that cardiovascular adverse events are more likely in patients with a high baseline insulin level instead of a high BMI; suggesting that management should focus on patients with poorly controlled diabetes and maintenance of good glycaemic control is vital; Sjöström, L., Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery (2013) J Intern Med, 273 (3), pp. 219-234; Sjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, Å., Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications (2014) JAMA, 311 (22), pp. 2297-2304. , This study is landmark study with very long-term follow-up that showed a high rate of type 2 diabetes mellitus remission and reduction in macrovascular and microvascular complications; Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Bariatric surgery versus conventional medical therapy for type 2 diabetes (2012) N Engl J Med; Flum, D.R., Belle, S.H., King, W.C., Wahed, A.S., Berk, P., Chapman, W., Perioperative safety in the longitudinal assessment of bariatric surgery (2009) N Engl J Med, 361 (5), pp. 445-454; Courcoulas, A.P., Christian, N.J., Belle, S.H., Berk, P.D., Flum, D.R., Garcia, L., Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity (2013) JAMA, 310 (22), pp. 2416-2425. , COI: 1:CAS:528:DC%2BC2cXosFGhtQ%3D%3D, This study showed that weight loss outcomes fall into different distinct patterns, suggesting possible different aetiology of obesity and response to bariatric surgery; O’Brien, P.E., Dixon, J.B., Brown, W., Schachter, L.M., Chapman, L., Burn, A.J., The laparoscopic adjustable gastric band (Lap-Band): a prospective study of medium-term effects on weight, health and quality of life (2002) Obes Surg, 12 (5), pp. 652-660; Sjöström, L., Narbro, K., Sjöström, C.D., Karason, K., Larsson, B., Wedel, H., Effects of bariatric surgery on mortality in Swedish obese subjects (2007) N Engl J Med, 357 (8), pp. 741-752; Puzziferri, N., Roshek, T.B., Mayo, H.G., Gallagher, R., Belle, S.H., Livingston, E.H., Long-term follow-up after bariatric surgery: a systematic review (2014) JAMA, 312 (9), pp. 934-942. , COI: 1:CAS:528:DC%2BC2cXhs12jt7nP; Sultan, S., Gupta, D., Parikh, M., Youn, H., Kurian, M., Fielding, G., Five-year outcomes of patients with type 2 diabetes who underwent laparoscopic adjustable gastric banding (2010) Surg Obes Relat Dis, 6 (4), pp. 373-376; Committee, A.C.I., Updated position statement on sleeve gastrectomy as a bariatric procedure (2012) Surg Obes Relat Dis, 8 (3), pp. 21-26; Rosenthal, R.J., Diaz, A.A., Arvidsson, D., Baker, R.S., Basso, N., Bellanger, D., International sleeve gastrectomy expert panel consensus statement: best practice guidelines based on experience of >12,000 cases (2012) Surg Obes Relat Dis, 8 (1), pp. 8-19; Trastulli, S., Desiderio, J., Guarino, S., Cirocchi, R., Scalercio, V., Noya, G., Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials (2013) Surg Obes Relat Dis, 9 (5), pp. 816-829; Gill, R.S., Birch, D.W., Shi, X., Sharma, A.M., Karmali, S., Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review (2010) Surg Obes Relat Dis, 6 (6), pp. 707-713; Higa, K.D., Boone, K.B., Ho, T., Davies, O.G., Laparoscopic Roux-en-Y gastric bypass for morbid obesity: technique and preliminary results of our first 400 patients (2000) Arch Surg, 135 (9), pp. 1029-1033. , COI: 1:STN:280:DC%2BD3cvmtF2luw%3D%3D, discussion 33–4; Dillemans, B., Sakran, N., Van Cauwenberge, S., Sablon, T., Defoort, B., Van Dessel, E., Standardization of the fully stapled laparoscopic Roux-en-Y gastric bypass for obesity reduces early immediate postoperative morbidity and mortality: a single center study on 2606 patients (2009) Obes Surg, 19 (10), pp. 1355-1364; Jacobsen, H.J., Bergland, A., Raeder, J., Gislason, H.G., High-volume bariatric surgery in a single center: safety, quality, cost-efficacy and teaching aspects in 2,000 consecutive cases (2012) Obes Surg, 22 (1), pp. 158-166. , COI: 1:STN:280:DC%2BC387jvF2qtg%3D%3D; Hutter, M.M., Schirmer, B.D., Jones, D.B., Ko, C.Y., Cohen, M.E., Merkow, R.P., First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass (2011) Ann Surg, 254 (3), pp. 410-420. , discussion 20–2; Birkmeyer, N.J., Dimick, J.B., Share, D., Hawasli, A., English, W.J., Genaw, J., Hospital complication rates with bariatric surgery in Michigan (2010) JAMA, 304 (4), pp. 435-442. , COI: 1:CAS:528:DC%2BC3cXpslGitLY%3D; DeMaria, E.J., Murr, M., Byrne, T.K., Blackstone, R., Grant, J.P., Budak, A., Validation of the obesity surgery mortality risk score in a multicenter study proves it stratifies mortality risk in patients undergoing gastric bypass for morbid obesity (2007) Ann Surg, 246 (4), pp. 578-582. , discussion 83–4; Poirier, P., Alpert, M.A., Fleisher, L.A., Thompson, P.D., Sugerman, H.J., Burke, L.E., Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association (2009) Circulation, 120 (1), pp. 86-95; Poirier, P., Cornier, M.A., Mazzone, T., Stiles, S., Cummings, S., Klein, S., Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association (2011) Circulation, 123 (15), pp. 1683-1701; Turgeon, N.A., Perez, S., Mondestin, M., Davis, S.S., Lin, E., Tata, S., The impact of renal function on outcomes of bariatric surgery (2012) J Am Soc Nephrol, 23 (5), pp. 885-894; Frisch, A., Chandra, P., Smiley, D., Peng, L., Rizzo, M., Gatcliffe, C., Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery (2010) Diabetes Care, 33 (8), pp. 1783-1788. , COI: 1:CAS:528:DC%2BC3cXhtFahs7jK; Oster, G., Thompson, D., Edelsberg, J., Bird, A.P., Colditz, G.A., Lifetime health and economic benefits of weight loss among obese persons (1999) Am J Public Health, 89 (10), pp. 1536-1542. , COI: 1:STN:280:DyaK1MvktFGjtQ%3D%3D; Pi-Sunyer, F.X., Short-term medical benefits and adverse effects of weight loss (1993) Ann Intern Med, 119 (7), pp. 722-726. , COI: 1:STN:280:DyaK3szntVyhug%3D%3D; Liu, R.C., Sabnis, A.A., Forsyth, C., Chand, B., The effects of acute preoperative weight loss on laparoscopic Roux-en-Y gastric bypass (2005) Obes Surg, 15 (10), pp. 1396-1402; Zerrweck, C., Maunoury, V., Caiazzo, R., Branche, J., Dezfoulian, G., Bulois, P., (2012), Preoperative weight loss with intragastric balloon decreases the risk of significant adverse outcomes of laparoscopic gastric bypass in super-super obese patients, Obes Surg:Adams, T.D., Pendleton, R.C., Strong, M.B., Kolotkin, R.L., Walker, J.M., Litwin, S.E., Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese (2010) Obesity (Silver Spring), 18 (1), pp. 121-130; Karlsson, J., Taft, C., Rydén, A., Sjöström, L., Sullivan, M., Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study (2007) Int J Obes (Lond), 31 (8), pp. 1248-1261. , COI: 1:STN:280:DC%2BD2svivFahuw%3D%3D; Adams, T.D., Gress, R.E., Smith, S.C., Halverson, R.C., Simper, S.C., Rosamond, W.D., Long-term mortality after gastric bypass surgery (2007) N Engl J Med, 357 (8), pp. 753-761. , COI: 1:CAS:528:DC%2BD2sXpsF2iu7k%3D; Serés, L., Lopez-Ayerbe, J., Coll, R., Rodriguez, O., Vila, J., Formiguera, X., Increased exercise capacity after surgically induced weight loss in morbid obesity (2006) Obesity (Silver Spring), 14 (2), pp. 273-279; Valezi, A.C., Machado, V.H., Morphofunctional evaluation of the heart of obese patients before and after bariatric surgery (2011) Obes Surg, 21 (11), pp. 1693-1697; Haller, H., Epidermiology and associated risk factors of hyperlipoproteinemia (1977) Z Gesamte Inn Med, 32 (8), pp. 124-128. , COI: 1:STN:280:DyaE2s3jvVSlsA%3D%3D; The lean patient with type 2 diabetes: characteristics and therapy challenge (2007) Int J Clin Pract Suppl, pp. 1533-1539; Fenske, W.K., Dubb, S., Bueter, M., Seyfried, F., Patel, K., Tam, F.W., (2012) Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study, , Surg Obes Relat Dis, The authors described the effects of bariatric surgery on the metabolic syndrome whereby the hallmark mild chronic inflammatory response in obesity is diminished in the post-operative setting:; Schauer, P.R., Kashyap, S.R., Wolski, K., Brethauer, S.A., Kirwan, J.P., Pothier, C.E., Bariatric surgery versus intensive medical therapy in obese patients with diabetes (2012) N Engl J Med; Ikramuddin, S., Korner, J., Lee, W.J., Connett, J.E., Inabnet, W.B., Billington, C.J., Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial (2013) JAMA, 309 (21), pp. 2240-2249. , COI: 1:CAS:528:DC%2BC3sXhtFalsbrN; de Vries, A.P., Ruggenenti, P., Ruan, X.Z., Praga, M., Cruzado, J.M., Bajema, I.M., Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease (2014) Lancet Diabetes Endocrinol, 2 (5), pp. 417-426; Lieske, J.C., Collazo-Clavell, M.L., Sarr, M.G., Rule, A.D., Bergstralh, E.J., Kumar, R., Gastric bypass surgery and measured and estimated GFR in women (2014) Am J Kidney Dis, 64 (4), pp. 663-665; Peterli, R., Steinert, R.E., Woelnerhanssen, B., Peters, T., Christoffel-Courtin, C., Gass, M., Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial (2012) Obes Surg, 22 (5), pp. 740-748; Pournaras, D.J., Osborne, A., Hawkins, S.C., Vincent, R.P., Mahon, D., Ewings, P., Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes (2010) Ann Surg, 252 (6), pp. 966-971; Vallon, V., Docherty, N.G., Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4 (2014) Exp Physiol, 99 (9), pp. 1140-1145. , COI: 1:CAS:528:DC%2BC2cXhsFeltrzP, The authors discuss the effects of glucagon-like peptide 1 on renal function and suggest the possible mechanism of improvements in renal function as a result on glucagon-like peptide receptor stimulation; Docherty, N.G., le Roux, C.W., Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease (2014) Exp Physiol, 99 (9), pp. 1146-1153; Miras, A.D., Chuah, L.L., Lascaratos, G., Faruq, S., Mohite, A.A., Shah, P.R., Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes (2012) Diabetes Care, 35 (12), p. 81",Review,Scopus,2-s2.0-84928339025
"Naeije R.","Assessment of Right Ventricular Function in Pulmonary Hypertension",2015,"Current Hypertension Reports","17","5",,"","",8,,10.1007/s11906-015-0546-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926283151&partnerID=40&md5=9262620d4c2555847ad37086e727ebb4","Department of Cardiology, Erasme University Hospital, 808, Lennik roadBrussels, Belgium","Naeije, R., Department of Cardiology, Erasme University Hospital, 808, Lennik roadBrussels, Belgium","Right ventricular function is a major determinant of symptomatology and prognosis in severe pulmonary hypertension. The diagnosis of right heart failure rests on a clinical approach with invasive and noninvasive measurements. Magnetic resonance and echocardiographic imaging of the right ventricle is of prognostic relevance. The gold standard of right ventricular function is the ratio of end-systolic to arterial elastances determined from synchronized volume and pressure measurements. Pressure measurements can be obtained during a right heart catheterization and volume measurements by integration of Doppler pulmonary flow-velocity, magnetic resonance imaging, or, more recently, three-dimensional echocardiography. Imaging also informs about regional function and derived estimates of dyssynchrony and asynchrony. Modern imaging with 3D echocardiography and magnetic resonance aims at improved assessment of regional function and right ventriculo-arterial coupling to assist in the evaluation and prognostication of severe pulmonary hypertension. © 2015, Springer Science+Business Media New York.","Afterload; Arterial elastance; Echocardiography; End-systolic elastance; Magnetic resonance imaging; Pulmonary hypertension; Right ventricular function; Right ventriculo-arterial coupling; Time constant","Vonk-Noordegraaf, A., Haddad, F., Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology (2013) J Am Coll Cardiol, 62, pp. 22-33. , PID: 24355638, Report of the working group on the right ventricle at the world symposium on pulmonary hypertension; Hoeper, M.M., Bogaard, H.J., Condliffe, R., Definitions and diagnosis of pulmonary hypertension (2013) J Am Coll Cardiol, 62, pp. 45-50; Hoeper, M.M., Barbera, J.A., Channink, R.N., Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension (2009) J Am Coll Cardiol, 54, pp. 85-96. , PID: 19555862; Naeije, R., D’Alto, M., Forfia, P.R., (2014) Clinical and research measurements techniques of the pulmonary circulation, , The present and the future, Progr Cardiovasc Dis:; Fuster, V., Steele, P.M., Edwards, W.D., Gersh, B.J., McGoon, M.D., Frye, R.L., Primary pulmonary hypertension: natural history and the importance of thrombosis (1984) Circulation, 70, pp. 580-587. , COI: 1:STN:280:DyaL2M%2Fgt1aitQ%3D%3D, PID: 6148159; D’Alonzo, G.E., Barst, R.J., Ayres, S.M., Survival in patients with primary pulmonary hypertension. Results from a national prospective registry (1991) Ann Intern Med, 115, pp. 343-349. , PID: 1863023; Sandoval, J., Bauerle, O., Palomar, A., Survival in primary pulmonary hypertension. Validation of a prognostic equation (1994) Circulation, 89, pp. 1733-1744. , COI: 1:STN:280:DyaK2c7pvFOguw%3D%3D, PID: 8149539; McLaughlin, V.V., Shillington, A., Rich, S., Survival in primary pulmonary hypertension: the impact of epoprostenol therapy (2002) Circulation, 106 (12), pp. 1477-1482. , COI: 1:CAS:528:DC%2BD38XntVKksb0%3D, PID: 12234951; Sitbon, O., Humbert, M., Nunes, H., Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival (2002) J Am Coll Cardiol, 40, pp. 780-788. , COI: 1:CAS:528:DC%2BD38XntVKjsr0%3D, PID: 12204511; Humbert, M., Sitbon, O., Chaouat, A., Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era (2010) Circulation, 122, pp. 156-163. , PID: 20585011; Benza, R.L., Miller, D.P., Gomberg-Maitland, M., Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL) (2010) Circulation, 122, pp. 164-172. , PID: 20585012; Raymond, R.J., Hinderliter, A.L., Willis, P.W., Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension (2002) J Am Coll Cardiol, 39, pp. 1214-1219. , PID: 11923049; Bustamante-Labarta, M., Perrone, S., De La Fuente, R.L., Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension (2002) J Am Soc Echocardiogr, 15, pp. 1160-1164. , PID: 12411899; Forfia, P.R., Fisher, M.R., Mathai, S.C., Tricuspid annular displacement predicts survival in pulmonary hypertension (2006) Am J Respir Crit Care Med, 174, pp. 1034-1041. , PID: 16888289; Utsunomiya, H., Nakatani, S., Nishihira, M., Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension (2009) J Am Soc Echocardiogr, 22, pp. 1368-1374. , PID: 19944957; Ghio, S., Klersy, C., Magrini, G., Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension (2010) Int J Cardiol, 140, pp. 272-278. , PID: 19070379; Sachdev, A., Villarraga, H.R., Frantz, R.P., Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension (2011) Chest, 139, pp. 1299-1309. , PID: 21148241; Brierre, G., Blot-Souletie, N., Degano, B., New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension (2010) Eur J Echocardiogr, 11, pp. 516-522. , PID: 20185528; Ghio, S., Pazzano, A.S., Klersy, C., Clinical and prognostic relevance of echocardiographic evaluation of right ventricular geometry in patients with idiopathic pulmonary arterial hypertension (2011) Am J Cardiol, 107, pp. 628-632. , PID: 21184990; Haeck, M.L., Scherptong, R.W., Marsan, N.A., Prognostic value of right ventricular longitudinal peak systolic strain in patients with pulmonary hypertension (2012) Circ Cardiovasc Imaging, 5, pp. 628-636. , PID: 22875884; Fine, N.M., Chen, L., Basztiansen, P.M., Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension (2013) Circ Cardiovasc Imaging, 6, pp. 711-721. , PID: 23811750; Ernande, L., Cottin, V., Leroux, P.Y., Right isovolumic contraction velocity predicts survival in pulmonary hypertension (2013) J Am Soc Echocardiogr, 26, pp. 297-306. , PID: 23265440; Ameloot, K., Palmers, P.J., Vandebruane, A., Clinical value of echocardiographic Doppler-derived right ventricular dp/dt in patients with pulmonary arterial hypertension (2014) Eur Heart J Cardiovasc Imaging, 15, pp. 1411-1419. , PID: 25201651; Smith, B.C., Dobson, G., Dawson, D., Charalampopoulos, A., Grapsa, J., Nihoyannopoulos, P., Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension (2014) J Am Coll Cardiol, 64, pp. 41-51. , PID: 24998127; Yeo, T.C., Dujardin, K.S., Tei, C., Mahoney, D.W., McGoon, M.D., Seward, J.B., Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension (1998) Am J Cardiol, 81, pp. 1157-1161. , COI: 1:STN:280:DyaK1c3ms1Sqtw%3D%3D, PID: 9605059; Grünig, E., Tiede, H., Enyimayew, E.O., Assessment and prognostic relevance of right ventricular contractile reserve in patients with pulmonary arterial hypertension (2013) Circulation, 128, pp. 2005-2015. , PID: 24056689; van Wolferen, S.A., Marcus, J.T., Boonstra, A., Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension (2007) Eur Heart J, 28, pp. 1250-1257. , PID: 17242010; Moledina, S., Pandya, B., Bartsota, M., Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension (2013) Circ Cardiovasc Imaging, 6, pp. 407-414. , PID: 23572488; Yamada, Y., Okuda, S., Kataoka, M., Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy (2012) Circ J, 76, pp. 1737-1743. , COI: 1:CAS:528:DC%2BC38XhtFOktr3I, PID: 22498565; van de Veerdonk, M.C., Kind, T., Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy (2011) J Am Coll Cardiol, 58, pp. 2511-2519. , PID: 22133851; Swift, A.J., Rajaram, S., Campbell, M.J., Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension (2014) Circ Cardiovasc Imaging, 7, pp. 100-106. , PID: 24275955; Freed, B.H., Gomberg-Maitland, M., Chandra, S., Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension (2012) J Cardiovasc Magn Reson, 14, p. 11. , PID: 22296860; Eysmann, S.B., Palevsky, H.I., Reichek, N., Hackney, K., Doughlas, P.S., Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension (1989) Circulation, 80, pp. 353-360. , COI: 1:STN:280:DyaL1MzisVensg%3D%3D, PID: 2752562; Tei, C., Dujardin, K.S., Hodge, D.O., Doppler echocardiographic index for assessment of global right ventricular function (1996) J Am Soc Echocardiogr, 9, pp. 838-847. , COI: 1:STN:280:DyaK2s%2FpvVOksQ%3D%3D, PID: 8943444; Swift, A.J., Rajaram, S., Capener, D., LGE Patterns in pulmonary hypertension do not impact overall mortality (2014) JACC Cardiovasc Imaging, 7, pp. 1209-1217. , PID: 25496540; Macchia, A., Monte, S., Pellegrini, F., Depression worsens outcomes in elderly patients with heart failure: an analysis of 48,117 patients in a community setting (2008) Eur J Heart Fail, 10, pp. 714-721. , PID: 18565789; Naeije, R., Brimioulle, S., Dewachter, C., Biomechanics of the right ventricle (2014) Pulm Circ, 4, pp. 395-406. , PID: 25621153, Updated understanding of right ventricular function; Vonk-Noordegraaf, A., Westerhof, N., Describing right ventricular function (2013) Eur Respir J, 41, pp. 1419-1423. , PID: 23314901, Updated concise review on how to measure right ventricular function; Saouti, N., Westerhof, N., Helderman, F., Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure (2010) Am J Respir Crit Care Med, 182, pp. 1315-1320. , PID: 20622041; Mahapatra, S., Mahapatra, S., Nishimura, R.A., Oh, J.K., McGoon, M.D., The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension (2006) J Am Soc Echocardiogr, 19, pp. 1045-1050. , PID: 16880101; Gan, C.T., Lankhaar, J.W., Westerhof, N., Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension (2007) Chest, 132, pp. 1906-1912. , PID: 17989161; Pagnamenta, A., Dewachter, C., McEntee, K., Fesler, P., Brimioulle, S., Naeije, R., Early right ventriculo-arterial uncoupling in borderline pulmonary hypertension on experimental heart failure (2010) J Appl Physiol, 109, pp. 1080-1085. , PID: 20689091; Pellegrini, P., Rossi, A., Pasotti, M., Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure (2014) Chest, 145, pp. 1064-1074. , PID: 24356904; Ghio, S., Gavazzi, A., Campana, C., Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure (2001) J Am Coll Cardiol, 37, pp. 183-188. , COI: 1:STN:280:DC%2BD3M%2Fptlyrtw%3D%3D, PID: 11153735; Maughan, W.L., Shoukas, A.A., Sagawa, K., Weisfeldt, M.L., Instantaneous pressure-volume relationship of the canine right ventricle (1979) Circ Res, 44, pp. 309-315. , COI: 1:STN:280:DyaE1M7gsFOksg%3D%3D, PID: 761311; Brimioulle, S., Wauthy, P., Ewalenko, P., Single-beat estimation of right ventricular end-systolic pressure-volume relationship (2003) Am J Physiol Heart Circ Physiol, 284, pp. 1625-1630. , COI: 1:CAS:528:DC%2BD3sXjvFGrt7o%3D, PID: 12531727; Kerbaul, F., Brimioulle, S., Rondelet, B., Dewachter, C., Hubloue, I., Naeije, R., How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension (2007) Am J Respir Crit Care Med, 175, pp. 846-850. , COI: 1:CAS:528:DC%2BD2sXltlOnu7o%3D, PID: 17272784; De Man, F.S., Handoko, M.L., van Ballegoij, L.L., Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension (2012) Circ Heart Fail, 5, pp. 97-105. , PID: 22157723; Kuehne, T., Yilmaz, S., Steendijk, P., Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension (2004) Circulation, 110, pp. 2010-2016. , PID: 15451801, First report on gold standard measurements of right ventricular function by the pressure-volume approach in sevee pulmonary hypertension; Tedford, R.J., Mudd, J.O., Girgis, R.E., Right ventricular dysfunction in systemic sclerosis associated pulmonary arterial hypertension (2013) Circ Heart Fail, 6, pp. 953-963. , COI: 1:CAS:528:DC%2BC3sXhslCqu7zO, PID: 23797369; Overbeek, M.J., Lankhaar, J.W., Westerhof, N., Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension (2008) Eur Respir J, 31, pp. 1160-1166. , COI: 1:STN:280:DC%2BD1czkvVansg%3D%3D, PID: 18216049; Wauthy, P., Naeije, R., Brimioulle, S., Left and right ventriculo-arterial coupling in a patient with congenitally corrected transposition (2005) Cardiol Young, 15, pp. 647-649. , PID: 16297261; McCabe, C., White, P.A., Hoole, S.P., Right ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary artery: a pressure-volume study using the conductance catheter (2014) J Appl Physiol, 116, pp. 355-363. , PID: 24356516; Sanz, J., García-Alvarez, A., Fernández-Friera, L., Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study (2012) Heart, 98, pp. 238-243. , PID: 21917658; Trip, P., Kind, T., van de Veerdonk, M.C., Accurate assessment of load-independent right ventricular systolic function in patients with pulmonary hypertension (2013) J Heart Lung Transplant, 32, pp. 50-55. , PID: 23164535; Vanderpool, R.R., Pinsky, M.R., Naeije, R., Right ventricular-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension (2015) Heart, 101, pp. 37-43. , PID: 25214501, First report on prognostic impact of comprehensive measurements of right ventriculo-arterial coupling in severe pulmonary hypertension; Rain, S., Handoko, M.L., Trip, P., Right ventricular diastolic impairment in patients with pulmonary arterial hypertension (2013) Circulation, 128, pp. 2016-2025. , COI: 1:CAS:528:DC%2BC3sXhslSmtrbO, PID: 24056688; D’Alto, M., Romeo, E., Argiento, P., Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension (2015) J Am Soc Echocardiogr, 28, pp. 108-115. , PID: 25441329; Opotowsky, A.R., Ojeda, J., Rogers, F., A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension (2012) Circ Cardiovasc Imaging, 5, pp. 765-775. , PID: 22914595; Lopez-Candales, A., Dohi, K., Rajagopalan, N., Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class (2005) Cardiovasc Ultrasound, 3, p. 23. , PID: 16129028; Meris, A., Faletra, F., Conca, C., Timing and magnitude of regional right ventricular function: a speckle tracking derived strain study of normal subjects and patients with right ventricular dysfunction (2010) J Am Soc Echocardiogr, 23, pp. 823-831. , PID: 20646910; Marcus, J.T., Gan, C.T., Zwanenburg, J.J., Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling (2008) J Am Coll Cardiol, 51, pp. 750-757. , PID: 18279740; Guazzi, M., Bandera, F., Pelissero, G., A tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis (2013) Am J Physiol Heart Circ Physiol, 305, pp. 1373-1381. , COI: 1:CAS:528:DC%2BC3sXhvFKhtbbP, PID: 23997100; Vogel, M., Schmidt, M.R., Christiansen, S.B., Validation of myocardial acceleration during isovolumic contraction as a novel non-invasive index of right ventricular contractility (2002) Circulation, 105, pp. 1693-1699. , PID: 11940549; Sharma, T., Lau, E.M., Choudhary, P., Dobutamine stress for evaluation of right ventricular reserve in pulmonary arterial hypertension (2014) Eur Respir J, 45 (3), pp. 700-708; Guihaire, J., Haddad, F., Noly, P.E., Right ventricular reserve in a piglet model of chronic pulmonary hypertension (2014) Eur Respir J, 45 (3), pp. 709-717; Naeije, R., The 6-min walk distance in pulmonary arterial hypertension: “Je t’aime, moi non plus (2010) Chest, 137, pp. 1258-1260. , PID: 20525647, Brief review on the physiologic meaning of exercise tests in severe pulmonary hypertension",Review,Scopus,2-s2.0-84926283151
"Kang Y.H., Park M.-G., Noh K.-H., Park H.R., Lee H.W., Son S.M., Park K.-P.","Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels areassociated with acute ischemic stroke severity",2015,"Atherosclerosis","240","1",,"228","233",,,10.1016/j.atherosclerosis.2015.03.028,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925063904&partnerID=40&md5=077b9adc1ac28f4be53c5f60fefb244b","Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Yangsan HospitalYangsan, South Korea; Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of MedicineYangsan, South Korea; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan HospitalYangsan, South Korea","Kang, Y.H., Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Yangsan HospitalYangsan, South Korea, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan HospitalYangsan, South Korea; Park, M.-G., Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of MedicineYangsan, South Korea, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan HospitalYangsan, South Korea; Noh, K.-H., Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of MedicineYangsan, South Korea, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan HospitalYangsan, South Korea; Park, H.R., Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of MedicineYangsan, South Korea, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan HospitalYangsan, South Korea; Lee, H.W., Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Yangsan HospitalYangsan, South Korea, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan HospitalYangsan, South Korea; Son, S.M., Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Yangsan HospitalYangsan, South Korea, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan HospitalYangsan, South Korea; Park, K.-P., Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of MedicineYangsan, South Korea, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan HospitalYangsan, South Korea","Background: TNF-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor receptor superfamily and its serum level is known to be closely associated with future cardiovascular events and prognosis of various cardiovascular diseases. We investigated whether serum TRAIL levels are associated with the severity of acute ischemic stroke and specific stroke subtype. Methods: We used an enzyme-linked immunosorbent assay to measure the serum TRAIL levels of 293 patients with acute ischemic stroke within 7 days of onset. Stroke subtype was classified as large artery atherosclerosis, cardioembolism, small vessel occlusion and other determined etiology. We used National Institute of Health Stroke Scale (NIHSS) score of first hospital day and stroke volume on diffusion-weighted imaging within 7 days of stroke onset for measuring the severity of acute ischemic stroke. Results: The level of serum TRAIL showed significant negative correlations with NIHSS score and stroke volume. Serum TRAIL levels significantly decreased as the tertile of NIHSS score and stroke volume increased. The relative risk of patients with serum TRAIL<64.0pg/mL for the presence of highest tertile of NIHSS score was significantly increased (adjusted OR [95%CI]; 7.07 [3.64-13.74]). Regarding stroke volume, the relative risk of patients with serum TRAIL<71.5pg/mL for the presence of highest tertile of stroke volume was also significantly increased (adjusted OR [95%CI]; 2.81 [1.61-4.92]). There are no significant differences of serum TRAIL level among stroke subtypes. Conclusions: Low serum TRAIL levels were significantly associated with the acute ischemic stroke severity. This finding suggests that serum TRAIL might also have a role in acute ischemic stroke as well as other cardiovascular diseases. © 2015 Elsevier Ireland Ltd.","Acute ischemic stroke; Cerebral infarction; TRAIL","Manzo, F., Nebbioso, A., Miceli, M., Conte, M., De Bellis, F., Carafa, V., TNF-related apoptosis-inducing ligand: signalling of a ""smart"" molecule (2009) Int. J. Biochem. Cell Biol., 41, pp. 460-466; Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Nicholl, J.K., Identification and characterization of a new member of the TNF family that induces apoptosis (1995) Immunity, 3, pp. 673-682; Secchiero, P., Gonelli, A., Carnevale, E., Milani, D., Pandolfi, A., Zella, D., TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways (2003) Circulation, 107, pp. 2250-2256; Zauli, G., Pandolfi, A., Gonelli, A., Di Pietro, R., Guarnieri, S., Ciabattoni, G., Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells (2003) Circ. Res., 92, pp. 732-740; Secchiero, P., Candido, R., Corallini, F., Zacchigna, S., Toffoli, B., Rimondi, E., Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice (2006) Circulation, 114, pp. 1522-1530; Niessner, A., Hohensinner, P.J., Rychli, K., Neuhold, S., Zorn, G., Richter, B., Prognostic value of apoptosis markers in advanced heart failure patients (2008) Eur. Heart J., 30, pp. 789-796; Volpato, S., Ferrucci, L., Secchiero, P., Corallini, F., Zuliani, G., Fellin, R., Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults (2011) Atherosclerosis, 215, pp. 452-458; Schoppet, M., Sattler, A.M., Schaefer, J.R., Hofbauer, L.C., Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis (2006) Atherosclerosis, 184, pp. 446-447; Michowitz, Y., Goldstein, E., Roth, A., Afek, A., Abashidze, A., Ben Gal, Y., The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis (2005) J.Am. Coll. Cardiol., 45, pp. 1018-1024; Osmancik, P., Teringova, E., Tousek, P., Paulu, P., Widimsky, P., Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients (2013) PLoS One, 8, p. e53860; Adams, H.P., Bendixen, B.H., Kappelle, L.J., Biller, J., Love, B.B., Gordon, D.L., Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke Treatment (1993) Stroke, 24, pp. 35-41; Kasner, S.E., Clinical interpretation and use of stroke scales (2006) Lancet Neurol., 5, pp. 603-612; Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC) (2007) J.Hypertens., 25, pp. 1105-1187; Standards of medical care in diabetes-2014 (2014) Diabetes Care, 37, pp. S14-S80; Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of Cardiology/American heart association task force on practice Guidelines (2014) J.Am. Coll. Cardiol., 63, pp. 2889-2934; Kischkel, F.C., Lawrence, D.A., Chuntharapai, A., Schow, P., Kim, K.J., Ashkenazi, A., Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5 (2000) Immunity, 12, pp. 611-620; Sprick, M.R., Weigand, M.A., Rieser, E., Rauch, C.T., Juo, P., Blenis, J., FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 (2000) Immunity, 12, pp. 599-609; Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand invivo (1999) Nat. Med., 5, pp. 157-163; Li, J.H., Kirkiles-Smith, N.C., McNiff, J.M., Pober, J.S., TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells (2003) J.Immunol., 171, pp. 1526-1533; Secchiero, P., TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release (2005) Blood, 105, pp. 3413-3419; Frankel, M.R., Morgenstern, L.B., Kwiatkowski, T., Lu, M., Tilley, B.C., Broderick, J.P., Predicting prognosis after stroke: a placebo group analysis from the national Institute of neurological disorders and stroke rt-PA stroke Trial (2000) Neurology, 55, pp. 952-959; Schlegel, D.J., Tanne, D., Demchuk, A.M., Levine, S.R., Kasner, S.E., Multicenter rt-PA stroke survey Group. Prediction of hospital disposition after thrombolysis for acute ischemic stroke using the national institutes of health stroke Scale (2004) Arch. Neurol., 61, pp. 1061-1064; Secchiero, P., Corallini, F., Ceconi, C., Parrinello, G., Volpato, S., Ferrari, R., Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction (2009) PLoS One, 4, p. e4442",Article,Scopus,2-s2.0-84925063904
"Freak-Poli R., Mirza S.S., Franco O.H., Arfan Ikram M., Hofman A., Tiemeier H.","Positive affect is not associated with incidence of cardiovascular disease: A population-based study of older persons",2015,"Preventive Medicine","74",,,"14","20",,,10.1016/j.ypmed.2015.01.032,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923355082&partnerID=40&md5=66296e6392f4d6e1408b58101819d9f8","Department of Epidemiology, Erasmus Medical CentreRotterdam, Netherlands; Department of Epidemiology and Preventive Medicine, Monash UniversityMelbourne, Australia; Department of Neurology, Erasmus Medical CentreRotterdam, Netherlands; Department of Radiology, Erasmus Medical CentreRotterdam, Netherlands; Department of Child and Adolescent Psychiatry, Erasmus Medical Centre, Netherlands; Department of Psychiatry, Erasmus Medical Centre, Netherlands","Freak-Poli, R., Department of Epidemiology, Erasmus Medical CentreRotterdam, Netherlands, Department of Epidemiology and Preventive Medicine, Monash UniversityMelbourne, Australia; Mirza, S.S., Department of Epidemiology, Erasmus Medical CentreRotterdam, Netherlands; Franco, O.H., Department of Epidemiology, Erasmus Medical CentreRotterdam, Netherlands; Arfan Ikram, M., Department of Epidemiology, Erasmus Medical CentreRotterdam, Netherlands, Department of Neurology, Erasmus Medical CentreRotterdam, Netherlands, Department of Radiology, Erasmus Medical CentreRotterdam, Netherlands; Hofman, A., Department of Epidemiology, Erasmus Medical CentreRotterdam, Netherlands; Tiemeier, H., Department of Epidemiology, Erasmus Medical CentreRotterdam, Netherlands, Department of Child and Adolescent Psychiatry, Erasmus Medical Centre, Netherlands, Department of Psychiatry, Erasmus Medical Centre, Netherlands","Introduction: The relationship between positive psychological well-being (PPWB) and cardiovascular disease (CVD) is inconsistent across different CVD outcomes and for different PPWB constructs, such as positive affect. In addition, the relationship between PPWB and CVD as a composite measure is rarely assessed. Objective: To assess whether positive affect is protective of incident CVD. Method: Positive affect was assessed in two cohorts between 1993 and 2001 in Rotterdam using relevant questions from the Center for Epidemiological Studies Depression (CES-D) scale and the Hospital Anxiety and Depression Scale (HADS; in a sub-sample) in 6349 non-demented, CVD-free, consenting adults, aged 55. +. years. Composite CVD was defined as stroke, heart failure and coronary heart disease, which were continuously monitored through medical records until 1st April 2010. Results: There were 1480 (23.3%) first time CVD events during follow-up (11.9. ±. 2.8 SD. years, 58,416. person-years). Positive affect was not associated with incident CVD (CES-D HR: 1.00 per point, 95% CI: 0.98-1.02; HADS HR: 0.98, 95% CI: 0.92-1.05). Stratification by age or sex and assessment of separate CVD outcome did not change results. Conclusion: In this large, population-based study, there was no association between positive affect and twelve-year incident CVD in older adults who were free of diagnosed CVD at baseline. © 2015 Elsevier Inc.","Cardiovascular disease; Coronary heart disease; Happiness; Heart failure; Positive affect; Stroke; Well-being","Bhattacharyya, M.R., Whitehead, D.L., Rakhit, R., Steptoe, A., Depressed mood, positive affect, and heart rate variability in patients with suspected coronary artery disease (2008) Psychosom. Med., 70, pp. 1020-1027; Boehm, J.K., Kubzansky, L.D., The heart's content: the association between positive psychological well-being and cardiovascular health (2012) Psychol. Bull., 138, pp. 655-691; Bos, M.J., Linden, T., Koudstaal, P.J., Hofman, A., Skoog, I., Breteler, M.M., Tiemeier, H., Depressive symptoms and risk of stroke: the Rotterdam Study (2008) J. Neurol. Neurosurg. Psychiatry, 79, pp. 997-1001; Clayton, D., Hill, M., (1993) Statistical Models in Epidemiology, p. 273. , Oxford University Press, Oxford, New York; Davidson, K.W., Mostofsky, E., Whang, W., Don't worry, be happy: positive affect and reduced 10-year incident coronary heart disease: the Canadian Nova Scotia Health Survey (2010) Eur. Heart J., 31, pp. 1065-1070; Denollet, J., Pedersen, S.S., Daemen, J., de Jaegere, P., Serruys, P.W., van Domburg, R.T., Reduced positive affect (anhedonia) predicts major clinical events following implantation of coronary-artery stents (2008) J. Intern. Med., 263, pp. 203-211; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state. A practical method for grading the cognitive state of patients for the clinician (1975) J. Psychiatr. Res., 12, pp. 189-198; Fries, J.F., Spitz, P.W., Young, D.Y., The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales (1982) J. Rheumatol., 9, pp. 789-793; Gerdtham, U., Johannesson, M., The relationship between happiness, health, and socioeconomic factors: results based on Swedish microdata (2001) J. Socio-Econ., 30, pp. 553-557; Goldston, K., Baillie, A.J., Depression and coronary heart disease: a review of the epidemiological evidence, explanatory mechanisms and management approaches (2008) Clin. Psychol. Rev., 28, pp. 288-306; Greenland, S., Finkle, W.D., A critical look at methods for handling missing covariates in epidemiologic regression analyses (1995) Am. J. Epidemiol., 142, pp. 1255-1264; Hawkins, M.A., Callahan, C.M., Stump, T.E., Stewart, J.C., Depressive symptom clusters as predictors of incident coronary artery disease: a 15-year prospective study (2014) Psychosom. Med., 76, pp. 38-43; Herrmann, C., International experiences with the hospital anxiety and depression scale-a review of validation data and clinical results (1997) J. Psychosom. Res., 42, pp. 17-41; Korn, E.L., Graubard, B.I., Midthune, D., Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale (1997) Am. J. Epidemiol., 145, pp. 72-80; Krijthe, B.P., Walter, S., Newson, R.S., Hofman, A., Hunink, M.G., Tiemeier, H., Is positive affect associated with survival? A population-based study of elderly persons (2011) Am. J. Epidemiol., 173, pp. 1298-1307; Lamers, S.M., Bolier, L., Westerhof, G.J., Smit, F., Bohlmeijer, E.T., The impact of emotional well-being on long-term recovery and survival in physical illness: a meta-analysis (2012) J. Behav. Med., 35, pp. 538-547; Lawton, M.P., Brody, E.M., Assessment of older people: self-maintaining and instrumental activities of daily living (1969) Gerontologist, 9, pp. 179-186; Leening, M.J., Kavousi, M., Heeringa, J., van Rooij, F.J., Verkroost-van Heemst, J., Deckers, J.W., Mattace-Raso, F.U., Hofman, A., Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study (2012) Eur. J. Epidemiol., 27, pp. 173-185; Leening, M.J., Ferket, B.S., Steyerberg, E.W., Kavousi, M., Deckers, J.W., Nieboer, D., Heeringa, J., Hofman, A., Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study (2014) BMJ, 349, p. g5992; Levine, G.N., Keaney, J.F., Vita, J.A., Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms (1995) N. Engl. J. Med., 332, pp. 512-521; Maldonado, G., Greenland, S., Simulation study of confounder-selection strategies (1993) Am. J. Epidemiol., 138, pp. 923-936; Mickey, R.M., Greenland, S., The impact of confounder selection criteria on effect estimation (1989) Am. J. Epidemiol., 129, pp. 125-137; Nabi, H., Kivimaki, M., De Vogli, R., Marmot, M.G., Singh-Manoux, A., Positive and negative affect and risk of coronary heart disease: Whitehall II prospective cohort study (2008) BMJ, 337, p. a118; (2011) Divided We Stand: Why Inequality Keeps Rising, , OECD Publishing; Oishi, S., Kesebir, S., Diener, E., Income inequality and happiness (2011) Psychol. Sci., 22, pp. 1095-1100; Olson, T.R., Presniak, M.D., MacGregor, M.W., Reevaluating positive affect in the Center for Epidemiologic Studies-Depression scale (2010) Psychiatry Res., 178, pp. 545-549; Organization for Economic Cooperation and Development (OECD), OECD Better Life Index. OECDOstir, G.V., Markides, K.S., Peek, M.K., Goodwin, J.S., The association between emotional well-being and the incidence of stroke in older adults (2001) Psychosom. Med., 63, pp. 210-215; Pan, A., Sun, Q., Okereke, O.I., Rexrode, K.M., Hu, F.B., Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review (2011) JAMA, 306, pp. 1241-1249; The CES-D Scale: a self-report depression scale for research in the general population (1977) Appl. Psychol. Meas., 1, pp. 385-401. , Radloff; Rozanski, A., Kubzansky, L.D., Psychologic functioning and physical health: a paradigm of flexibility (2005) Psychosom. Med., 67, pp. S47-S53; Rugulies, R., Depression as a predictor for coronary heart disease. a review and meta-analysis (2002) Am. J. Prev. Med., 23, pp. 51-61; Ryff, C.D., Dienberg Love, G., Urry, H.L., Muller, D., Rosenkranz, M.A., Friedman, E.M., Davidson, R.J., Singer, B., Psychological well-being and ill-being: do they have distinct or mirrored biological correlates? (2006) Psychother. Psychosom., 75, pp. 85-95; Seligman, M.E., Steen, T.A., Park, N., Peterson, C., Positive psychology progress: empirical validation of interventions (2005) Am. Psychol., 60, pp. 410-421; Stack, S., Eshleman, J., Marital status and happiness: a 17-nation study (1998) J. Marriage Fam., 60, pp. 527-536; (2013) StataCorp Stata(R) 13.1 Statistics/Data Analysis, , StataCorp, Texas, USA; Steptoe, A., O'Donnell, K., Marmot, M., Wardle, J., Positive affect, psychological well-being, and good sleep (2008) J. Psychosom. Res., 64, pp. 409-415; Strong, D.R., Kahler, C.W., Leventhal, A.M., Abrantes, A.M., Lloyd-Richardson, E., Niaura, R., Brown, R.A., Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment (2009) Nicotine Tob. Res., 11, pp. 1142-1153; (2012) World Happiness Report, , Columbia University, J. Helliwell, R. Layard, J. Sachs (Eds.); (2013) The 2013 Legatum Prosperity Index, , The Legatum Institute Foundation; Veenhoven, R., (2014) World Database of Happiness, , Erasmus University Rotterdam, The Netherlands; (2011) Global Atlas on Cardiovascular Disease Prevention and Control, , WHO, Geneva, S. Mendis, P. Puska, B. Norrving (Eds.); Yanek, L.R., Kral, B.G., Moy, T.F., Vaidya, D., Lazo, M., Becker, L.C., Becker, D.M., Effect of positive well-being on incidence of symptomatic coronary artery disease (2013) Am. J. Cardiol., 112, pp. 1120-1125; Zigmond, A.S., Snaith, R.P., The hospital anxiety and depression scale (1983) Acta Psychiatr. Scand., 67, pp. 361-370",Article,Scopus,2-s2.0-84923355082
"Chowdhury R., Alam D.S., Fakir I.I., Adnan S.D., Naheed A., Tasmin I., Monower M.M., Hossain F., Hossain F.M., Rahman M.M., Afrin S., Roy A.K., Akter M., Sume S.A., Biswas A.K., Pennells L., Surendran P., Young R.D., Spackman S.A., Hasan K., Harshfield E., Sheikh N., Houghton R., Saleheen D., Howson J.M.M., Butterworth A.S., Cardiology Research Group, Raqib R., Majumder A.A.S., Danesh J., Di Angelantonio E.","The Bangladesh Risk of Acute Vascular Events (BRAVE) Study: objectives and design",2015,"European Journal of Epidemiology",,,,"","",11,,10.1007/s10654-015-0037-2,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928665752&partnerID=40&md5=3db9e8c3bb7917a6c55c2e9d430ae4d6","Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; National Institute of Cardiovascular DiseaseDhaka, Bangladesh; Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphia, PA, United States; Wellcome Trust Sanger Institute, HinxtonCambridge, United Kingdom","Chowdhury, R., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Alam, D.S., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Fakir, I.I., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Adnan, S.D., National Institute of Cardiovascular DiseaseDhaka, Bangladesh; Naheed, A., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Tasmin, I., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Monower, M.M., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Hossain, F., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Hossain, F.M., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Rahman, M.M., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Afrin, S., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Roy, A.K., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Akter, M., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Sume, S.A., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Biswas, A.K., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Pennells, L., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Surendran, P., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Young, R.D., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Spackman, S.A., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Hasan, K., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Harshfield, E., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Sheikh, N., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Houghton, R., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Saleheen, D., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphia, PA, United States; Howson, J.M.M., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Butterworth, A.S., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom; Cardiology Research Group, National Institute of Cardiovascular DiseaseDhaka, Bangladesh; Raqib, R., Chronic Non-communicable Disease Unit, International Centre for Diarrhoeal Disease ResearchDhaka, Bangladesh; Majumder, A.A.S., National Institute of Cardiovascular DiseaseDhaka, Bangladesh; Danesh, J., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom, Wellcome Trust Sanger Institute, HinxtonCambridge, United Kingdom; Di Angelantonio, E., Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of CambridgeCambridge, United Kingdom","During recent decades, Bangladesh has experienced a rapid epidemiological transition from communicable to non-communicable diseases. Coronary heart disease (CHD), with myocardial infarction (MI) as its main manifestation, is a major cause of death in the country. However, there is limited reliable evidence about its determinants in this population. The Bangladesh Risk of Acute Vascular Events (BRAVE) study is an epidemiological bioresource established to examine environmental, genetic, lifestyle and biochemical determinants of CHD among the Bangladeshi population. By early 2015, the ongoing BRAVE study had recruited over 5000 confirmed first-ever MI cases, and over 5000 controls “frequency-matched” by age and sex. For each participant, information has been recorded on demographic factors, lifestyle, socioeconomic, clinical, and anthropometric characteristics. A 12-lead electrocardiogram has been recorded. Biological samples have been collected and stored, including extracted DNA, plasma, serum and whole blood. Additionally, for the 3000 cases and 3000 controls initially recruited, genotyping has been done using the CardioMetabochip+ and the Exome+ arrays. The mean age (standard deviation) of MI cases is 53 (10) years, with 88 % of cases being male and 46 % aged 50 years or younger. The median interval between reported onset of symptoms and hospital admission is 5 h. Initial analyses indicate that Bangladeshis are genetically distinct from major non-South Asian ethnicities, as well as distinct from other South Asian ethnicities. The BRAVE study is well-placed to serve as a powerful resource to investigate current and future hypotheses relating to environmental, biochemical and genetic causes of CHD in an important but under-studied South Asian population. © 2015 The Author(s)","Arsenic; Bangladesh; BRAVE; Cardiovascular disease; Coronary heart disease; Genetics; Myocardial infarction; Non-communicable diseases; Risk factors; South Asia",,Article in Press,Scopus,2-s2.0-84928665752
"Cloonan L., Fitzpatrick K.M., Kanakis A.S., Furie K.L., Rosand J., Rost N.S.","Metabolic determinants of white matter hyperintensity burden in patients with ischemic stroke",2015,"Atherosclerosis","240","1",,"149","153",,,10.1016/j.atherosclerosis.2015.02.052,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925002557&partnerID=40&md5=8e57951f755fd1b950987c514bb7755f","J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General HospitalBoston, MA, United States; Center for Human Genetic Research, Massachusetts General HospitalBoston, MA, United States; Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Massachusetts General HospitalBoston, MA, United States; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, 110 Lockwood St., Suite 324Providence, RI, United States","Cloonan, L., J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General HospitalBoston, MA, United States; Fitzpatrick, K.M., J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General HospitalBoston, MA, United States; Kanakis, A.S., J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General HospitalBoston, MA, United States; Furie, K.L., J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General HospitalBoston, MA, United States, Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, 110 Lockwood St., Suite 324Providence, RI, United States; Rosand, J., J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General HospitalBoston, MA, United States, Center for Human Genetic Research, Massachusetts General HospitalBoston, MA, United States, Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Massachusetts General HospitalBoston, MA, United States; Rost, N.S., J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General HospitalBoston, MA, United States, Center for Human Genetic Research, Massachusetts General HospitalBoston, MA, United States","Objective: Increasing white matter hyperintensity (WMH) burden is linked to risk of stroke and poor post-stroke outcomes. While the biology of WMH remains ill-defined, several lines of evidence implicate endothelial dysfunction. In this study, we sought to assess the association between metabolic markers of endothelial dysfunction and WMH severity in patients with acute ischemic stroke (AIS). Methods: In this retrospective study, consecutive subjects, ≥18 years of age, admitted to our ED with AIS, brain MRI, and blood homocysteine (Hcy) and hemoglobin A1c (HgbA1c) measurements were eligible for this analysis. WMH volume (WMHV) was quantified using a validated semi-automated algorithm and log-transformed for linear regression analyses. Results: There were 809 AIS subjects included (mean age 65.57±14.7, median WMHV 6.25cm3 (IQR 2.8-13.1)). In univariate analysis, age, female gender, race, ethnicity, systolic blood pressure, history of hypertension, atrial fibrillation, coronary artery disease, prior stroke, and current alcohol and tobacco use (all p&lt;0.05), as well as Hcy (p&lt;0.0001) and HgbA1c levels (p=0.0005) were associated with WMHV. However, only Hcy (β=0.11, p=0.003) and HgbA1c levels (β=0.1, p=0.008) independently predicted WMHV in the multivariate model, along with age (β=0.03, p&lt;0.0001), race (β=0.39, p=0.01), ethnicity (β=-0.11, p=0.03), and current alcohol use (β=0.26, p=0.002). Conclusions: Elevated levels of Hcy and HgbA1c have been previously linked to endothelial dysfunction related to oxidative stress. The association between Hcy and HgbA1c and WMH burden in AIS suggests that the degree of endothelial dysfunction may be greater in patients with increased WMHV, and may in part explain the relationship between WMHV and poor post-stroke outcomes. © 2015 Elsevier Ireland Ltd.","Acute ischemic stroke; Blood biomarkers; Endothelial dysfunction; Hyperglycemia; Hyperhomocysteinemia; Small vessel disease; White matter hyperintensity","Schmidt, R., Fazekas, F., Kleinert, G., Magnetic resonance imaging signal hyperintensities in the deep and subcortical white matter. A comparative study between stroke patients and normal volunteers (1992) Arch. Neurol., 49 (8), pp. 825-827; Debette, S., Markus, H.S., The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis (2010) BMJ, 341, p. c3666; Kuller, L.H., Longstreth, W.T., Arnold, A.M., Bernick, C., Bryan, R.N., Beauchamp, N.J., White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke (2004) Stroke, 35 (8), pp. 1821-1825; Jeerakathil, T., Wolf, P.A., Beiser, A., Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study (2004) Stroke, 35 (8), pp. 1857-1861; Han, J.H., Wong, K.S., Wang, Y.Y., Fu, J.H., Ding, D., Hong, Z., Plasma level of sICAM-1 is associated with the extent of white matter lesion among asymptomatic elderly subjects (2009) Clin. Neurol. Neurosurg., 111, pp. 847-851; Rost, N.S., Rahman, R., Sonni, S., Determinants of white matter hyperintensity volume in patients with acute ischemic stroke (2010) J.Stroke Cerebrovasc. Dis., 19 (3), pp. 230-235; Hirase, T., Node, K., Endothelial dysfunction as a cellular mechanism for vascular failure (2012) Am. J. Physiol. Heart Circ. Physiol., 302 (3), pp. H499-H505; Liu, D.S., Gao, W., Liang, E.S., Effects of allicin on hyperhomocysteinemia-induced experimental vascular endothelial dysfunction (2013) Eur. J. Pharmacol., 714 (1-3), pp. 163-169; Leung, S.B., Zhang, H., Lau, C.W., Huang, Y., Lin, Z., Salidroside improves homocysteine-induced endothelial dysfunction by reducing oxidative stress (2013) Evid. Based Complement. Altern. Med., 2013, p. 679635; Eringa, E.C., Serne, E.H., Meijer, R.I., Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes (2013) Rev. Endocr. Metab. Disord., 14, pp. 39-48; Verma, S., Buchanan, M., Anderson, T., Endothelial function testing as a biomarker of vascular disease (2003) Circulation, 108, pp. 2054-2059; El Oudi, M., Bouguerra, C., Aouni, Z., Homocysteine and inflammatory biomarkers plasma levels, and severity of acute coronary syndrome (2011) Ann. Biol. Clin. Paris., 69 (2), pp. 175-180; Lorbeer, R., Empen, K., Dörr, M., Arndt, M., Association between glycosylated haemoglobin A(1c) and endothelial function in an adult non-diabetic population (2011) Atherosclerosis, 217 (2), pp. 358-363. , http://www.ncbi.nlm.nih.gov/pubmed/21570686; Cé, G.V., Rohde, L.E., da Silva, A.M., Endothelial dysfunction is related to poor glycemic control in adolescents with type 1 diabetes under 5 years of disease: evidence of metabolic memory (2011) J.Clin. Endocrinol. Metab., 96 (5), pp. 1493-1499; Rost, N.S., Rahman, R.M., Biffi, A., White matter hyperintensity volume is increased in small vessel stroke subtypes (2010) Neurology, 75 (19), pp. 1670-1677; Topakian, R., Barrick, T.R., Howe, F.A., Markus, H.S., Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis (2010) J.Neurol. Neurosurg. Psychiatr., 81 (2), pp. 192-197; Wardlaw, J.M., Sandercock, P.A.G., Dennis, M.S., Starr, J., Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? (2003) Stroke, 34 (3), pp. 806-812; Wardlaw, J.M., Farrall, A., Armitage, P.A., Changes in background blood-brain barrier integrity between lacunar and cortical ischemic stroke subtypes (2008) Stroke, 39 (4), pp. 1327-1332; Wardlaw, J.M., Doubal, F.N., Valdes-Hernandez, M., Blood-brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease (2013) Stroke, 44 (2), pp. 525-527; Hassan, A., Hunt, B.J., O'Sullivan, M., Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis (2003) Brain, 126, pp. 424-432; Symons, J.D., Abel, E.D., Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide (2013) Rev. Endocr. Metab. Disord., 14 (1), pp. 59-68; Jakubowski, K., The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease (2008) J.Physiol. Pharmacol., 59 (SUPPL.9), pp. 155-167; Böger, R.H., Bode-Böger, S.M., Sydow, K., Heistad, D.D., Lentz, S.R., Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia (2000) Arterioscler. Thromb. Vasc. Biol., 20, pp. 1557-1564; Chen, S., Li, N., Deb-Chatterji, M., Asymmetric dimethyarginine as marker and mediator in ischemic stroke (2012) Int. J. Mol. Sci., 13, pp. 15983-16004; Hoth, K.F., Tate, D.F., Poppas, A., Endothelial function and white matter hyperintensities in older adults with cardiovascular disease (2007) Stroke, 38, pp. 308-312; Vallance, P., Leone, A., Calver, A., Collier, J., Moncada, S., Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis (1992) J.Cardiovasc. Pharmacol., 20 (SUPPL.12), pp. S60-S62; Bai, Y., Sun, L., Du, L., Association of circulating levels of asymmetric dimethylarginine (ADMA) with carotid intima-media thickness: evidence from 6188 participants (2013) Ageing Res. Rev., 12, pp. 699-707; Singh, A.S., Atam, V., Chaudhary, S.C., Relation of glycated hemoglobin with carotid atherosclerosis in ischemic stroke patients: an observational study in Indian population (2013) Ann. Indian Acad. Neurol., 16, pp. 185-189; Jimenez-Conde, J., Biffi, A., Rahman, R., Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke (2010) Stroke, 41, pp. 437-442; Pantoni, L., Garcia, J.H., Pathogenesis of leukoaraiosis: a review (1997) Stroke, 28, pp. 652-659; Fein, G., Shimotsu, R., Di Sclafani, V., Barakos, J., Harper, C., Increased white matter signal hyperintensities in long-term abstinent alcoholics compared to non-alcoholic controls (2009) Alcohol Clin. Exp. Res., 33, pp. 70-78; Mukamal, K.J., Longstreth, W.T., Mittleman, M.A., Crum, R.M., Siscovick, D.S., Alcohol consumption and subclinical findings on magnetic resonance imaging of the brain in older adults: the Cardiovascular Health Study (2001) Stroke, 32, pp. 1939-1946. , http://www.ncbi.nlm.nih.gov/pubmed/11546878; Collins, M.A., Neafsey, E.J., Mukamal, K.J., Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies (2009) Alcohol Clin. Exp. Res., 33, pp. 206-209; Papamichael, C., Karatzis, E., Karatzi, K., Red wine's antioxidants counteract acute endothelial dysfunction caused by cigarette smoking in healthy nonsmokers (2004) Am. Heart J., 147, p. E5; Haorah, J., Knipe, B., Leibhart, J., Ghorpade, A., Persidsky, Y., Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction (2005) J.Leukoc. Biol., 78, pp. 1223-1232; Toda, N., Ayajiki, K., Vascular actions of nitric oxide as affected by exposure to alcohol (2010) Alcohol Alcohol, 45, pp. 347-355; Collins, M.A., Neafsey, E.J., Neuroinflammatory pathways in binge alcohol-induced neuronal degeneration: oxidative stress cascade involving aquaporin, brain edema, and phospholipase A2 activation (2012) Neurotox. Res., 21, pp. 70-78; Yeh, M.Y., Burnham, E.L., Moss, M., Brown, L.A., Chronic alcoholism alters systemic and pulmonary glutathione redox status (2007) Am. J. Respir. Crit. Care Med., 176, pp. 270-276; Tiwari, V., Chopra, K., Resveratrol abrogates alcohol-induced cognitive deficits by attenuating oxidative-nitrosative stress and inflammatory cascade in the adult rat brain (2013) Neurochem. Int., 62, pp. 861-869; Wright, C.B., Paik, M.C., Brown, T.R., Total homocysteine is associated with white matter hyperintensity volume: the northern Manhattan study (2005) Stroke, 36, pp. 1207-1211; Kissela, B., Lindsell, C.J., Kleindorfer, D., Clinical prediction of functional outcome after ischemic stroke: the surprising importance of periventricular white matter disease and race (2009) Stroke, 40, pp. 530-536; Brickman, A.M., Schupf, N., Manly, J.J., Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan (2008) Arch. Neurol., 65, pp. 1053-1061; Eikelboom, J.W., Hankey, G.J., Anand, S.S., Lofthouse, E., Staples, N., Baker, R.I., Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke (2003) Stroke, 31, pp. 1069-1075; Kwon, H.M., Lee, Y.S., Bae, H.J., Kang, D.W., Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke (2014) Stroke, 45, pp. 871-873; Chaiworapongsa, T., Chaemsaithong, P., Yeo, L., Romero, R., Pre-eclampsia part 1: current understanding of its pathophysiology (2014) Nat. Rev. Nephrol., 10 (8), pp. 466-480; Zhang, C., Meng, Y., Liu, Q., Injury to the endothelial surface layer induces glomerular hyperfiltration rats with early-stage diabetes (2014) J.Diabetes Res., 2014, p. 953740",Article,Scopus,2-s2.0-84925002557
"Keating G.M.","Ferric carboxymaltose: A guide to its use in iron deficiency",2015,"Drugs and Therapy Perspectives","31","5",,"143","149",,,10.1007/s40267-015-0203-3,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928331314&partnerID=40&md5=8657f5f3c111adcdff7eb117c3f42ced","Springer, Private Bag 65901, Mairangi BayAuckland, New Zealand","Keating, G.M., Springer, Private Bag 65901, Mairangi BayAuckland, New Zealand","Ferric carboxymaltose (Ferinject®, Injectafer®) is an important intravenous iron preparation option for the treatment of iron deficiency. A single high dose [up to 750 mg (USA) or 1000 mg (EU) of iron] can be administered intravenously in a short time frame (15 min). Thus, fewer doses of ferric carboxymaltose may be needed to replenish iron stores relative to some other intravenous iron preparations. Ferric carboxymaltose improved self-reported patient global assessment, New York Heart Association functional class and exercise capacity in patients with chronic heart failure and iron deficiency in the FAIR-HF and CONFIRM-HF trials. In other trials, ferric carboxymaltose replenished iron stores and corrected anaemia in various populations with iron-deficiency anaemia, including patients with chronic kidney disease, inflammatory bowel disease or heavy uterine bleeding, postpartum iron-deficiency anaemia and perioperative anaemia. Intravenous ferric carboxymaltose was generally well tolerated, with a very low risk of hypersensitivity reactions. In general, it was better tolerated than oral ferrous sulfate, mainly reflecting a lower incidence of gastrointestinal adverse effects. The higher acquisition cost of ferric carboxymaltose was offset by lower costs for other items, with the potential for cost savings. © 2015, Springer International Publishing Switzerland.",,"Goddard, A.F., James, M.W., McIntyre, A.S., Guidelines for the management of iron deficiency anaemia (2011) Gut., 60 (10), pp. 1309-1316. , COI: 1:CAS:528:DC%2BC3MXhtlCgurfF, PID: 21561874; Gasche, C., Berstad, A., Befrits, R., Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases (2007) Inflamm Bowel Dis., 13 (12), pp. 1545-1553. , PID: 17985376; Breymann, C., Bian, X.-M., Blanco-Capito, L.R., Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region (2011) J Perinat Med., 39 (2), pp. 113-121. , PID: 21070128; (2012) Kidney Int Suppl, 2 (4), pp. 279-335; Anker, S.D., Comin Colet, J., Filippatos, G., Ferric carboxymaltose in patients with heart failure and iron deficiency (2009) N Engl J Med., 361 (25), pp. 2436-2448. , COI: 1:CAS:528:DC%2BD1MXhsFKisr7K, PID: 19920054; Ponikowski, P., van Veldhuisen, D.J., Comin-Colet, J., Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency (2014) Eur Heart J.; Herrera, C., Robles, V., Navarro, E., Iron deficiency in the absence of anemia affects the perception of health-related quality of life in IBD patients in remission [abstract no. P124] (2015) J Crohns Colitis, 9, pp. S138-S139; http://www.medicines.org.uk, Vifor Pharma UK Limited. Ferinject (ferric carboxymaltose): UK summary of product characteristics. 2013. Accessed 29 Jan 2015http://www.fda.gov, American Regent Inc. Injectafer® (ferric carboxymaltose injection): US prescribing information. 2013. Accessed 29 Jan 2015Keating, G.M., Ferric carboxymaltose: a review of its use in iron deficiency (2015) Drugs., 75 (1), pp. 101-127. , PID: 25428711; Geisser, P., The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations (2009) Port J Nephrol Hypert., 23 (1), pp. 11-16; Funk, F., Ryle, P., Canclini, C., The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose (2010) Arzneimittelforschung., 60 (6a), pp. 345-353. , COI: 1:CAS:528:DC%2BC3cXpslyjtbo%3D, PID: 20648926; Macdougall, I.C., Bock, A.H., Carrera, F., FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia (2014) Nephrol Dial Transplant., 29 (11), pp. 2075-2084. , PID: 24891437; Qunibi, W.Y., Martinez, C., Smith, M., A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients (2011) Nephrol Dial Transplant., 26 (5), pp. 1599-1607. , COI: 1:CAS:528:DC%2BC3MXlsFKns7k%3D, PID: 20929915; Onken, J.E., Bregman, D.B., Harrington, R.A., Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial (2014) Nephrol Dial Transplant., 29 (4), pp. 833-842. , COI: 1:CAS:528:DC%2BC2cXlsFOgtbg%3D, PID: 23963731; Schaefer, R.M., Khasabov, N.N., Todorov, N.G., The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia [abstract no. MP375] (2008) 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; Charytan, C., Bernardo, M.V., Koch, T.A., Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study (2013) Nephrol Dial Transplant., 28 (4), pp. 953-964. , COI: 1:CAS:528:DC%2BC3sXlsV2qsLo%3D, PID: 23222534; Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846–53.e1–2Kulnigg, S., Stoinov, S., Simanenkov, V., A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT®) randomized controlled trial (2008) Am J Gastroenterol., 103 (5), pp. 1182-1192. , COI: 1:CAS:528:DC%2BD1cXntFCrsrw%3D, PID: 18371137; Evstatiev, R., Alexeeva, O., Bokemeyer, B., Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease (2013) Clin Gastroenterol Hepatol., 11 (3), pp. 269-277. , COI: 1:CAS:528:DC%2BC3sXhtFKisbs%3D, PID: 23078888; Breymann, C., Gliga, F., Bejenariu, C., Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia (2008) Int J Gynaecol Obstet., 101 (1), pp. 67-73. , COI: 1:CAS:528:DC%2BD1cXjtlSqs7c%3D, PID: 18234203; Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435.e1–7Van Wyck, D.B., Martens, M.G., Seid, M.H., Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial (2007) Obstet Gynecol., 110 (2), pp. 267-278. , PID: 17666600; Van Wyck, D.B., Mangione, A., Morrison, J., Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial (2009) Transfusion (Paris)., 49 (12), pp. 2719-2728; Favrat, B., Balck, K., Breymann, C., Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women: PREFER a randomized, placebo-controlled study (2014) PLoS One., 9 (4), p. e94217. , PID: 24751822; Bisbe, E., Moltó, L., Arroyo, R., Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty (2014) Br J Anaesth., 113 (3), pp. 402-409. , COI: 1:STN:280:DC%2BC2cnotlygtw%3D%3D, PID: 24780615; Bager, P., Dahlerup, J.F., Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage—a placebo-controlled study (2014) Aliment Pharmacol Ther., 39 (2), pp. 176-187. , COI: 1:CAS:528:DC%2BC3sXhvFOjsLnM, PID: 24251969; Filippatos, G., Farmakis, D., Colet, J.C., Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial (2013) Eur J Heart Fail., 15 (11), pp. 1267-1276. , COI: 1:CAS:528:DC%2BC3sXhs1yrsrnL, PID: 23787722; Comin-Colet, J., Lainscak, M., Dickstein, K., The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study (2013) Eur Heart J., 34 (1), pp. 30-38. , COI: 1:CAS:528:DC%2BC3sXotl2muw%3D%3D, PID: 22297124; Ponikowski, P., Filippatos, G., Colet, J.C., The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study (2015) Eur J Heart Fail., 17 (3), pp. 329-339. , COI: 1:CAS:528:DC%2BC2MXjvFygur8%3D, PID: 25683972; Froessler, B., Collingwood, J., Hodyl, N.A., Intravenous ferric carboxymaltose for anaemia in pregnancy (2014) BMC Pregnancy Childbirth., 14, p. 115. , PID: 24667031; Shander, A., Javidroozi, M., Perelman, S., From bloodless surgery to patient blood management (2012) Mt Sinai J Med., 79 (1), pp. 56-65. , PID: 22238039; Hedenus, M., Karlsson, T., Ludwig, H., Intravenous ferric carboxymaltose as sole anemia therapy in patients with lymphoid malignancies, chemotherapy-induced anemia and functional iron deficiency [abstract] (2013) Blood, 122 (21), p. 3439; Kulnigg-Dabsch, S., Evstatiev, R., Dejaco, C., Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia (2012) PLoS One., 7 (4), p. e34520. , COI: 1:CAS:528:DC%2BC38XlvFCjtrk%3D, PID: 22506024; Kulnigg-Dabsch, S., Schmid, W., Howaldt, S., Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled ThromboVIT trial (2013) Inflamm Bowel Dis., 19 (8), pp. 1609-1616. , PID: 23644823; Barkun, A.N., Bardou, M., Kuipers, E.J., International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding (2010) Ann Intern Med., 152 (2), pp. 101-113. , PID: 20083829; Hussain, I., Bhoyroo, J., Butcher, A., Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia (2013) Anemia., 2013, p. 169107. , PID: 24069536; http://www.ema.europa.eu, European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. 2013. Accessed 6 Mar 2015Blazevic, A., Hunze, J., Boots, J.M.M., Severe hypophosphataemia after intravenous iron administration (2014) Neth J Med., 72 (1), pp. 49-53. , COI: 1:CAS:528:DC%2BC2cXksFSisLs%3D, PID: 24457442; Christoph, P., Schuller, C., Studer, H., Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose (2012) J Perinat Med., 40 (5), pp. 469-474. , COI: 1:CAS:528:DC%2BC38XhvVKgsLjL, PID: 22945271; Data on file, Vifor Inc, 2014Wilson, P.D., Hutchings, A., Jeans, A., An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic (2013) J Med Econ., 16 (1), pp. 108-114. , PID: 22989163; Fragoulakis, V., Kourlaba, G., Goumenos, D., Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece (2012) Clinicoeconom Out Res., 4, pp. 127-134; Calvet, X., Ruíz, M.A., Dosal, A., Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency (2012) PLoS One., 7 (9), p. e45604. , COI: 1:CAS:528:DC%2BC38XhsVelsb%2FK, PID: 23029129; Bager, P., Dahlerup, J.F., The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective (2010) J Crohns Colitis., 4 (4), pp. 427-430. , PID: 21122539; Gutzwiller, F.S., Schwenkglenks, M., Blank, P.R., Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK (2012) Eur J Heart Fail., 14 (7), pp. 782-790. , COI: 1:CAS:528:DC%2BC38XpsVaitbo%3D, PID: 22689292; Blank, P.R., Schwenkglenks, M., Szucs, T.D., Cost-effectiveness of ferric carboxymaltose in patients with chronic heart failure: an analysis from the FAIR-HF trial [abstract no. P1437] (2010) Eur Heart J., 31, p. 225; Lim, E.-A., Sohn, H.-S., Lee, H., Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea (2014) Cost Eff Resour Alloc., 12, p. 19. , PID: 25278814; Comin-Colet, J., Rubio-Rodriguez, D., Rubio-Terres, C., A cost-effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain (2015) Rev Esp Cardiol (Engl Ed)., , PID: 25649970",Article,Scopus,2-s2.0-84928331314
"Li F.-F., Sun R., Xue S., Qian P., Yan H.-X., Zhang W.-F., Sun Z.-M., Zhang H.-K., Wang Y.-Q.","Pulse signal analysis of patients with coronary heart diseases using Hilbert-Huang transformation and time-domain method",2015,"Chinese Journal of Integrative Medicine","21","5",,"355","360",,,10.1007/s11655-015-2173-7,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928819517&partnerID=40&md5=9505f64c577e702e7a8d8488642f5d18","Syndrome Laboratory of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai, China; Department of Engineering Mechanics, Shanghai Jiaotong UniversityShanghai, China; Department of Cardiothoracic Surgery, Renji Hospital Affiliated to Medicine School of Shanghai Jiaotong UniversityShanghai, China","Li, F.-F., Syndrome Laboratory of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai, China; Sun, R., Department of Engineering Mechanics, Shanghai Jiaotong UniversityShanghai, China; Xue, S., Department of Cardiothoracic Surgery, Renji Hospital Affiliated to Medicine School of Shanghai Jiaotong UniversityShanghai, China; Qian, P., Syndrome Laboratory of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai, China; Yan, H.-X., Syndrome Laboratory of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai, China; Zhang, W.-F., Syndrome Laboratory of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai, China; Sun, Z.-M., Syndrome Laboratory of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai, China; Zhang, H.-K., Syndrome Laboratory of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai, China; Wang, Y.-Q., Syndrome Laboratory of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai, China","Objective: To explore characteristic of pulse signal to distinguish patients with coronary heart diseases (CHD) from patients without CHD and healthy adults, and accordingly evaluate the potential role of pulse signal to diagnosis CHD.Methods: Totally 407 patients enrolled from 4 collaborating medical centers were assigned to a CHD group (205 patients) and a non-CHD group (202 patients). The healthy control group (62 adults) enrolled from Shanghai University of Traditional Chinese Medicine. Pulse signals were collected using the synchronous multiplex pulse signal acquisition system. The pulse signals were analyzed and extracted using Hilbert-Huang transformation (HHT) and time-domain, respectively. The time-domain parameters of pulse signal were processed by the analysis of variance (SNK test).Results: Special patterns in the CHD group pulse signal were found in this study: (1) time-domain parameters of pulse signal, h<inf>1</inf>, h<inf>3</inf>, h<inf>4</inf>, h<inf>3</inf>/h<inf>1</inf>, t<inf>s</inf>, t<inf>4</inf>/t were increased and w was wider; (2) 44% of C<inf>2</inf> waves in HHT were chaotic and disordered and 72% of C waves were exhibited irregularly with average amplitude over 10 g-forces, which were all significantly different from controls.Conclusion: Characteristic wave and time-domain parameters of pulse signal were extracted using HHT and time-domain which could be served as a non-invasive approach for assessing patients with CHD. © 2015, Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg.","coronary heart diseases; Hilbert-Huang transformation; pulse signal; time domain","Cai, K.B., Cao, D., Duan, Y.Z., Luo, D.C., Liu, Z.X., Feature extraction and recognition technique for human pulse signals (2011) J Chongqing Univ (Chin), 34, pp. 119-123; Wang, Y., Xu, M., Ying, M., A wavelet multi-distinguishing analysis method of pulse signal (2011) J Beijing Instit Graph Communic (Chin), 19 (6), pp. 42-46. , COI: 1:CAS:528:DC%2BC3MXht1Gktb%2FL; Yan, H.X., Qin, K.R., Wang, Y.Q., Li, F.F., Run, F.Y., Hong, Y.J., Research of the EEMD method to pulse analysis of traditional Chinese medicine based on different amplitudes of the added white noise (2011) J Biomed Engineer (Chin), 28, pp. 22-26; Guo, R., Wang, Y.Q., Yan, J.J., Yan, H.X., Yang, Y.C., Study of traditional Chinese medicine pulse signals in patients with coronary heart disease based on recurrence quantification analysis (2011) J Chin Integr Med (Chin), 9, pp. 1226-1233; Li, F.F., Wang, Y.Q., Yao, D., Yan, H.X., Qian, P., Relationship between pulse graph traits and coronary artery stenosis, and ultrasound cardiograph (2008) World Sci Technol-Moderniz Tradit Chin Med Mater Med (Chin), 10, pp. 53-59; Liu, Z.R., Li, X.X., Study on analysis of pulse (1983) China Sci (B ed; Chin), 2, pp. 131-138; Fei, Z.F., Observation of pulse in fever patients caused by exogeneous pathogens (1985) Shanghai J Tradit Chin Med (Chin), 2, p. 40; Zhang, J.R., Usage of linear theory of pulse ferry on pulse in CHD (1986) China Med Biologic Engineer (Chin), 5, p. 175; Huang, N.E., Shen, Z., Long, S.R., Wu, M.C., Shih, H.H., Zheng, Q., The empirical mode decomposition and the Hilbert spectrum for nonlinear and non-stationary time series analysis (1998) Proc R Soc Lond A, 454, pp. 903-995; Huang, N.E., Shen, Z., Long, S.R., A new view of nonlinear water waves: the Hilbert spectrum (1999) Ann Rev Fluid Mech, 31, pp. 417-457; Liu, F.B., Lang, J.Y., Zhao, L., Fang, J.Q., Leung, K.F., Lin, L.Z., Development of health status scale of traditional Chinese medicine (TCM-HSS) (2008) J Sun Yat-Sen Univ (Med Sci; Chin), 29, pp. 332-336. , COI: 1:CAS:528:DC%2BD1MXjsF2itr4%3D; Denomination and diagnostic criteria for ischemic heart disease (1981) Chin J Cardiol (Chin), 9, pp. 75-76; Fei, Z.F., (2003) Modern Chinese pulse diagnosis, , People’s Health Publishing House, Beijing:",Article,Scopus,2-s2.0-84928819517
"Elboudwarej O., Wei J., Siegel R.","Diagnosis of an aortic valvular lesion",2015,"Heart","101","9",,"","",,,10.1136/heartjnl-2014-306723,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927588941&partnerID=40&md5=9ce1b55438c16eb2571672f69d40b3b7","Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly BlvdLos Angeles, CA, United States","Elboudwarej, O., Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly BlvdLos Angeles, CA, United States; Wei, J., Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly BlvdLos Angeles, CA, United States; Siegel, R., Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly BlvdLos Angeles, CA, United States",[No abstract available],,"Asopa, S., Patel, A., Khan, O.A., Non-bacterial thrombotic endocarditis (2007) Eur J Cardiothorac Surg, 32, pp. 696-701; Dutta, T., Karas, M.G., Segal, A.Z., Yield of transesophageal echocardiography for nonbacterial thrombotic endocarditis and other cardiac sources of embolism in cancer patients with cerebral ischemia (2006) Am J Cardiol, 97, pp. 894-898; El-Shami, K., Griffiths, E., Streiff, M., Nonbacterial thrombotic endocarditis in cancer patients:Pathogenesis, diagnosis, and treatment (2007) Oncologist, 12, pp. 518-523; Steiner, I., Nonbacterial thrombotic endocarditis - A study of 171 case reports (1993) Cesk Patol, 29, pp. 58-60; Whitlock, R.P., Sun, J.C., Fremes, S.E., Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2012) Chest, 141 (2), p. e576S. , Suppl",Note,Scopus,2-s2.0-84927588941
"Weiss J.N., Garfinkel A., Karagueuzian H.S., Nguyen T.P., Olcese R., Chen P.-S., Qu Z.","Perspective: A dynamics-based classification of ventricular arrhythmias",2015,"Journal of Molecular and Cellular Cardiology","82",,,"136","152",,,10.1016/j.yjmcc.2015.02.017,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925127686&partnerID=40&md5=c2f4be3ba07ab90ec4632c0d88a387d9","UCLA Cardiovascular Research Laboratory, Department of Medicine (Cardiology), UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Department of Physiology, UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Department of Integrative Biology and Physiology, UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Department of Anesthesiology, UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Krannert Institute of Cardiology and Department of Medicine (Cardiology), Indiana University School of MedicineIndianapolis, IN, United States","Weiss, J.N., UCLA Cardiovascular Research Laboratory, Department of Medicine (Cardiology), UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States, Department of Physiology, UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Garfinkel, A., UCLA Cardiovascular Research Laboratory, Department of Medicine (Cardiology), UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States, Department of Integrative Biology and Physiology, UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Karagueuzian, H.S., UCLA Cardiovascular Research Laboratory, Department of Medicine (Cardiology), UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Nguyen, T.P., UCLA Cardiovascular Research Laboratory, Department of Medicine (Cardiology), UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Olcese, R., Department of Physiology, UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States, Department of Anesthesiology, UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States; Chen, P.-S., Krannert Institute of Cardiology and Department of Medicine (Cardiology), Indiana University School of MedicineIndianapolis, IN, United States; Qu, Z., UCLA Cardiovascular Research Laboratory, Department of Medicine (Cardiology), UCLA and the David Geffen School of Medicine at UCLALos Angeles, CA, United States","Despite key advances in the clinical management of life-threatening ventricular arrhythmias, culminating with the development of implantable cardioverter-defibrillators and catheter ablation techniques, pharmacologic/biologic therapeutics have lagged behind. The fundamental issue is that biological targets are molecular factors. Diseases, however, represent emergent properties at the scale of the organism that result from dynamic interactions between multiple constantly changing molecular factors. For a pharmacologic/biologic therapy to be effective, it must target the dynamic processes that underlie the disease. Here we propose a classification of ventricular arrhythmias that is based on our current understanding of the dynamics occurring at the subcellular, cellular, tissue and organism scales, which cause arrhythmias by simultaneously generating arrhythmia triggers and exacerbating tissue vulnerability. The goal is to create a framework that systematically links these key dynamic factors together with fixed factors (structural and electrophysiological heterogeneity) synergistically promoting electrical dispersion and increased arrhythmia risk to molecular factors that can serve as biological targets. We classify ventricular arrhythmias into three primary dynamic categories related generally to unstable Ca cycling, reduced repolarization, and excess repolarization, respectively. The clinical syndromes, arrhythmia mechanisms, dynamic factors and what is known about their molecular counterparts are discussed. Based on this framework, we propose a computational-experimental strategy for exploring the links between molecular factors, fixed factors and dynamic factors that underlie life-threatening ventricular arrhythmias. The ultimate objective is to facilitate drug development by creating an in silico platform to evaluate and predict comprehensively how molecular interventions affect not only a single targeted arrhythmia, but all primary arrhythmia dynamics categories as well as normal cardiac excitation-contraction coupling. © 2015 Elsevier Ltd.","Ca signaling; Fibrillation; Nonlinear dynamics; Reentry; Repolarization reserve; Sudden cardiac death","Hoffman, B.F., Rosen, M.R., Cellular mechanisms for cardiac arrhythmias (1981) Circ Res, 49, pp. 1-15; Rosen, M.R., Mechanisms for arrhythmias (1988) Am J Cardiol, 61, pp. 2A-8A; Jalife, J., Ventricular fibrillation: mechanisms of initiation and maintenance (2000) Ann Rev Physiol, 62, pp. 25-50; Keating, M.T., Sanguinetti, M.C., Molecular and cellular mechanisms of cardiac arrhythmias (2001) Cell, 104, pp. 569-580; Rubart, M., Zipes, D.P., Mechanisms of sudden cardiac death (2005) J Clin Invest, 115, pp. 2305-2315; Qu, Z., Weiss, J.N., Mechanisms of ventricular arrhythmias: from molecular fluctuations to electrical turbulence (2015) Ann Rev Physiol, 77. , [in press]; Echt, D.S., Liebson, P.R., Mitchell, L.B., Peters, R.W., Obias-Manno, D., Barker, A.H., Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial (1991) N Engl J Med, 324, pp. 781-788; Waldo, A.L., Camm, A.J., deRuyter, H., Friedman, P.L., MacNeil, D.J., Pauls, J.F., Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol (1996) Lancet, 348, pp. 7-12; Myerburg, R.J., Mitrani, R., Interian, A., Castellanos, A., Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact (1998) Circulation, 97, pp. 1514-1521; Bardy, G.H., Lee, K.L., Mark, D.B., Poole, J.E., Packer, D.L., Boineau, R., Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (2005) N Engl J Med, 352, pp. 225-237; Fonarow, G.C., Yancy, C.W., Hernandez, A.F., Peterson, E.D., Spertus, J.A., Heidenreich, P.A., Potential impact of optimal implementation of evidence-based heart failure therapies on mortality (2011) Am Heart J, 161, pp. 1024-1030; Qu, Z., Hu, G., Garfinkel, A., Weiss, J.N., Nonlinear and stochastic dynamics in the heart (2014) Phys Rep, 543, pp. 61-162; Sarkar, A.X., Sobie, E.A., Regression analysis for constraining free parameters in electrophysiological models of cardiac cells (2010) PLoS Comput Biol, 6, p. e1000914; Britton, O.J., Bueno-Orovio, A., Van Ammel, K., Lu, H.R., Towart, R., Gallacher, D.J., Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology (2013) Proc Natl Acad Sci U S A, 110, pp. E2098-E2105; Sato, D., Xie, L.H., Sovari, A.A., Tran, D.X., Morita, N., Xie, F., Synchronization of chaotic early afterdepolarizations in the genesis of cardiac arrhythmias (2009) Proc Natl Acad Sci U S A, 106, pp. 2983-2988; Gyorke, S., Molecular basis of catecholaminergic polymorphic ventricular tachycardia (2009) Heart Rhythm, 6, pp. 123-129; Mohamed, U., Napolitano, C., Priori, S.G., Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia (2007) J Cardiovasc Electrophysiol, 18, pp. 791-797; Swaminathan, P.D., Purohit, A., Hund, T.J., Anderson, M.E., Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias (2012) Circ Res, 110, pp. 1661-1677; Tomaselli, G.F., Zipes, D.P., What causes sudden death in heart failure? (2004) Circ Res, 95, pp. 754-763; Cerrone, M., Noujaim, S.F., Tolkacheva, E.G., Talkachou, A., O'Connell, R., Berenfeld, O., Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia (2007) Circ Res, 101, pp. 1039-1048; Katra, R.P., Laurita, K.R., Cellular mechanism of calcium-mediated triggered activity in the heart (2005) Circ Res, 96, pp. 535-542; Xie, Y., Sato, D., Garfinkel, A., Qu, Z., Weiss, J.N., So little source, so much sink: requirements for afterdepolarizations to propagate in tissue (2010) Biophys J, 99, pp. 1408-1415; Fujiwara, K., Tanaka, H., Mani, H., Nakagami, T., Takamatsu, T., Burst emergence of intracellular Ca waves evokes arrhythmogenic oscillatory depolarization via the Na-Ca exchanger: simultaneous confocal recording of membrane potential and intracellular Ca in the heart (2008) Circ Res, 103, pp. 509-518; Wasserstrom, J.A., Shiferaw, Y., Chen, W., Ramakrishna, S., Patel, H., Kelly, J.E., Variability in timing of spontaneous calcium release in the intact rat heart is determined by the time course of sarcoplasmic reticulum calcium load (2010) Circ Res, 107, pp. 1117-1126; de Jong, S., van Veen, T.A.B., van Rijen, H.V.M., de Bakker, J.M.T., Fibrosis and cardiac arrhythmias (2011) J Cardiovasc Pharmacol, 57, pp. 630-810; Nguyen, T.P., Qu, Z., Weiss, J.N., Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils (2014) J Mol Cell Cardiol, 70, pp. 83-91; Kummer, J.L., Nair, R., Krishnan, S.C., Images in cardiovascular medicine. Bidirectional ventricular tachycardia caused by digitalis toxicity (2006) Circulation, 113, pp. e156-e157; Valent, S., Kelly, P., Images in clinical medicine. Digoxin-induced bidirectional ventricular tachycardia (1997) N Engl J Med, 336, p. 550; Baher, A.A., Uy, M., Xie, F., Garfinkel, A., Qu, Z., Weiss, J.N., Bidirectional ventricular tachycardia: ping pong in the His-Purkinje system (2011) Heart Rhythm, 8, pp. 599-605; de Lange, E., Garfinkel, A., Weiss, J.N., Qu, Z., Delayed afterdepolarizations provide the trigger and substrate for reentrant arrhythmias in cardiac tissue: a modeling study (2011) Heart Rhythm, 8, p. S325; Rosen, M.R., Wit, A.L., Hoffman, B.F., Electrophysiology and pharmacology of cardiac arrhythmias. IV. Cardiac antiarrhythmic and toxic effects of digitalis (1975) Am Heart J, 89, pp. 391-399; Weiss, J.N., Karma, A., Shiferaw, Y., Chen, P.S., Garfinkel, A., Qu, Z., From pulsus to pulseless: the saga of cardiac alternans (2006) Circ Res, 98, pp. 1244-1253; Qu, Z., Garfinkel, A., Chen, P.S., Weiss, J.N., Mechanisms of discordant alternans and induction of reentry in simulated cardiac tissue (2000) Circulation, 102, pp. 1664-1670; Watanabe, M.A., Fenton, F.H., Evans, S.J., Hastings, H.M., Karma, A., Mechanisms for discordant alternans (2001) J Cardiovasc Electrophysiol, 12, pp. 196-206; Pastore, J.M., Girouard, S.D., Laurita, K.R., Akar, F.G., Rosenbaum, D.S., Mechanism linking T-wave alternans to the genesis of cardiac fibrillation (1999) Circulation, 99, pp. 1385-1394; Rosenbaum, D.S., Jackson, L.E., Smith, J.M., Garan, H., Ruskin, J.N., Cohen, R.J., Electrical alternans and vulnerability to ventricular arrhythmias (1994) N Engl J Med, 330, pp. 235-241; Wilson, L.D., Jeyaraj, D., Wan, X., Hoeker, G.S., Said, T.H., Gittinger, M., Heart failure enhances susceptibility to arrhythmogenic cardiac alternans (2009) Heart Rhythm, 6, pp. 251-259; Wasserstrom, J.A., Sharma, R., Kapur, S., Kelly, J.E., Kadish, A.H., Balke, C.W., Multiple defects in intracellular calcium cycling in whole failing rat heart (2009) Circulation: heart failure, 2, pp. 223-232; Weiss, J.N., Nivala, M., Garfinkel, A., Qu, Z., Alternans and arrhythmias: from cell to heart (2011) Circ Res, 108, pp. 98-112; Bassani, J.W., Yuan, W., Bers, D.M., Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes (1995) Am J Physiol, 268, pp. C1313-C1319; Shannon, T.R., Ginsburg, K.S., Bers, D.M., Potentiation of fractional sarcoplasmic reticulum calcium release by total and free intra-sarcoplasmic reticulum calcium concentration (2000) Biophys J, 78, pp. 334-343; Diaz, M.E., O'Neill, S.C., Eisner, D.A., Sarcoplasmic reticulum calcium content fluctuation is the key to cardiac alternans (2004) Circ Res, 94, pp. 650-656; Picht, E., Desantiago, J., Blatter, L.A., Bers, D.M., Cardiac alternans do not rely on diastolic sarcoplasmic reticulum calcium content fluctuations (2006) Circ Res, 99, pp. 740-748; Shiferaw, Y., Sato, D., Karma, A., Coupled dynamics of voltage and calcium in paced cardiac cells (2005) Phys Rev E Stat Nonlin Soft Matter Phys, 71, p. 021903; Diaz, M.E., Eisner, D.A., O'Neill, S.C., Depressed ryanodine receptor activity increases variability and duration of the systolic Ca transient in rat ventricular myocytes (2002) Circ Res, 91, pp. 585-593; Gaeta, S.A., Bub, G., Abbott, G.W., Christini, D.J., Dynamical mechanism for subcellular alternans in cardiac myocytes (2009) Circ Res, 105, pp. 335-342; Nolasco, J.B., Dahlen, R.W., A graphic method for the study of alternation in cardiac action potentials (1968) J Appl Physiol, 25, pp. 191-196; Tolkacheva, E.G., Schaeffer, D.G., Gauthier, D.J., Krassowska, W., Condition for alternans and stability of the 1:1 response pattern in a ""memory"" model of paced cardiac dynamics (2003) Phys Rev E Stat Nonlin Soft Matter Phys, 67, p. 031904; Cao, J.M., Qu, Z., Kim, Y.H., Wu, T.J., Garfinkel, A., Weiss, J.N., Spatiotemporal heterogeneity in the induction of ventricular fibrillation by rapid pacing: importance of cardiac restitution properties (1999) Circ Res, 84, pp. 1318-1331; Qu, Z., Karagueuzian, H.S., Garfinkel, A., Weiss, J.N., Effects of Na channel and cell coupling abnormalities on vulnerability to reentry: a simulation study (2004) Am J Physiol Heart Circ Physiol, 286, pp. H1310-H1321; Qu, Z., Xie, Y., Garfinkel, A., Weiss, J.N., T-wave Alternans and arrhythmogenesis in cardiac diseases (2010) Front Physiol, 1; Qu, Z., Nivala, M., Weiss, J.N., Calcium alternans in cardiac myocytes: order from disorder (2013) J Mol Cell Cardiol, 58, pp. 100-109; Maruyama, M., Joung, B., Tang, L., Shinohara, T., On, Y.K., Han, S., Diastolic intracellular calcium-membrane voltage coupling gain and postshock arrhythmias: role of purkinje fibers and triggered activity (2010) Circ Res, 106, pp. 399-408; Pogwizd, S.M., Schlotthauer, K., Li, L., Yuan, W., Bers, D.M., Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness (2001) Circ Res, 88, pp. 1159-1167; Karma, A., Spiral breakup in model equations of action potential propagation in cardiac tissue (1993) Phys Rev Lett, 71, pp. 1103-1106; Saitoh, H., Bailey, J.C., Surawicz, B., Alternans of action potential duration after abrupt shortening of cycle length: differences between dog Purkinje and ventricular muscle fibers (1988) Circ Res, 62, pp. 1027-1040; Rovetti, R., Cui, X., Garfinkel, A., Weiss, J.N., Qu, Z., Spark-induced sparks as a mechanism of intracellular calcium alternans in cardiac myocytes (2010) Circ Res, 106, pp. 1582-1591; Mahajan, A., Sato, D., Shiferaw, Y., Baher, A., Xie, L.-H., Peralta, R., Modifying L-type calcium current kinetics: consequences for cardiac excitation and arrhythmia dynamics (2008) Biophys J, 94, pp. 411-423; Pu, J., Balser, J.R., Boyden, P.A., Lidocaine action on Na currents in ventricular myocytes from the epicardial border zone of the infarcted heart (1998) Circ Res, 83, pp. 431-440; Joyner, R.W., Ramza, B.M., Osaka, T., Tan, R.C., Cellular mechanisms of delayed recovery of excitability in ventricular tissue (1991) Am J Physiol, 260, pp. H225-H233; Pu, J., Boyden, P.A., Alterations of Na currents in myocytes from epicardial border zone of the infarcted heart. A possible ionic mechanism for reduced excitability and postrepolarization refractoriness (1997) Circ Res, 81, pp. 110-119; Roden, D.M., Taking the ""idio"" out of ""idiosyncratic"": predicting Torsades de Pointes (1998) Pacing Clin Electrophysiol, 21, pp. 1029-1034; Roden, D.M., Long QT, syndrome: reduced repolarization reserve and the genetic link (2006) J Int Med, 259, pp. 59-69; Nattel, S., Maguy, A., Le Bouter, S., Yeh, Y.-H., Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation (2007) Physiol Rev, 87, pp. 425-456; January, C.T., Moscucci, A., Cellular mechanisms of early afterdepolarizations (1992) Ann N Y Acad Sci, 644, pp. 23-32; Weiss, J.N., Garfinkel, A., Karagueuzian, H.S., Chen, P.S., Qu, Z., Early afterdepolarizations and cardiac arrhythmias (2010) Heart Rhythm, 7, pp. 1891-1899; Chang, M.G., Sato, D., de Lange, E., Lee, J.H., Karagueuzian, H.S., Garfinkel, A., Bi-stable wave propagation and early afterdepolarization-mediated cardiac arrhythmias (2012) Heart Rhythm, 9, pp. 115-122; Choi, B.R., Burton, F., Salama, G., Cytosolic Ca triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome (2002) J Physiol, 543, pp. 615-631; Zhao, Z., Wen, H., Fefelova, N., Allen, C., Baba, A., Matsuda, T., Revisiting the ionic mechanisms of early afterdepolarizations in cardiomyocytes: predominant by Ca waves or Ca currents? (2012) Am J Physiol Heart Circ Physiol, 302, pp. H1636-H1644; Volders, P.G., Vos, M.A., Szabo, B., Sipido, K.R., de Groot, S.H., Gorgels, A.P., Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts (2000) Cardiovasc Res, 46, pp. 376-392; Clancy, C.E., Rudy, Y., Na channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism (2002) Circulation, 105, pp. 1208-1213; Luo, C.H., Rudy, Y., A dynamic model of the cardiac ventricular action potential.2. Afterdepolarizations, triggered activity, and potentiation (1994) Circ Res, 74, pp. 1097-1113; Tran, D.X., Sato, D., Yochelis, A., Weiss, J.N., Garfinkel, A., Qu, Z., Bifurcation and chaos in a model of cardiac early afterdepolarizations (2009) Phys Rev Lett, 102, p. 258103; Channell, P., Cymbalyuk, G., Shilnikov, A., Origin of bursting through homoclinic spike adding in a neuron model (2007) Phys Rev Lett, 98, p. 134101; Shilnikov, A., Cymbalyuk, G., Transition between tonic spiking and bursting in a neuron model via the blue-sky catastrophe (2005) Phys Rev Lett, 94, p. 048101; Hondeghem, L.M., Dujardin, K., De Clerck, F., Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia (2001) Cardiovasc Res, 50, pp. 345-353; Zhao, Z., Xie, Y., Wen, H., Xiao, D., Allen, C., Fefelova, N., Role of the transient outward potassium current in the genesis of early afterdepolarizations in cardiac cells (2012) Cardiovasc Res, 95, pp. 308-316; Nguyen, T.P., Xie, Y., Garfinkel, A., Qu, Z., Weiss, J.N., Arrhythmogenic consequences of myofibroblast-myocyte coupling (2012) Cardiovasc Res, 93, pp. 242-251; Gadsby, D.C., Cranefield, P.F., Two levels of resting potential in cardiac Purkinje fibers (1977) J Gen Physiol, 70, pp. 725-746; Kim, T.Y., Kunitomo, Y., Pfeiffer, Z., Patel, D., Hwang, J., Harrison, K., Complex excitation dynamics underlie polymorphic ventricular tachycardia in a transgenic rabbit model of long QT syndrome type 1 (2015) Heart Rhythm, 12, pp. 220-228; Chang, M.G., de Lange, E., Calmettes, G., Garfinkel, A., Qu, Z., Weiss, J.N., Pro- and antiarrhythmic effects of ATP-sensitive potassium current activation on reentry during early afterdepolarization-mediated arrhythmias (2013) Heart Rhythm, 10, pp. 575-582; Maruyama, M., Lin, S.F., Xie, Y., Chua, S.K., Joung, B., Han, S., Genesis of phase 3 early afterdepolarizations and triggered activity in acquired long-QT syndrome (2011) Circ Arrhythm Electrophysiol, 4, pp. 103-111; Zareba, W., Moss, A.J., le Cessie, S., Hall, W.J., T wave alternans in idiopathic long QT syndrome (1994) J Am Coll Cardiol, 23, pp. 1541-1546; Qu, Z., Xie, L.H., Olcese, R., Karagueuzian, H.S., Chen, P.S., Garfinkel, A., Early afterdepolarizations in cardiac myocytes: beyond reduced repolarization reserve (2013) Cardiovasc Res, 99, pp. 6-15; Bennett, P.B., Yazawa, K., Makita, N., George, A.L., Molecular mechanism for an inherited cardiac arrhythmia (1995) Nature, 376, pp. 683-685; Wagner, S., Dybkova, N., Rasenack, E.C., Jacobshagen, C., Fabritz, L., Kirchhof, P., Ca/calmodulin-dependent protein kinase II regulates cardiac Na channels (2006) J Clin Invest, 116, pp. 3127-3138; Yang, T., Chun, Y.W., Stroud, D.M., Mosley, J.D., Knollmann, B.C., Hong, C.C., Screening for acute IKr block is insufficient to detect Torsades de Pointes liability: role of late sodium current (2014) Circulation, 130, pp. 224-234; Wagner, S., Ruff, H.M., Weber, S.L., Bellmann, S., Sowa, T., Schulte, T., Reactive oxygen species-activated Ca/calmodulin kinase IIdelta is required for late INa augmentation leading to cellular Na and Ca overload (2011) Circ Res, 108, pp. 555-565; Hale, S.L., Shryock, J.C., Belardinelli, L., Sweeney, M., Kloner, R.A., Late sodium current inhibition as a new cardioprotective approach (2008) J Mol Cell Cardiol, 44, pp. 954-967; Morita, N., Lee, J.H., Xie, Y., Sovari, A., Qu, Z., Weiss, J.N., Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine (2011) J Am Coll Cardiol, 57, pp. 366-375; Wu, L., Shryock, J.C., Song, Y., Li, Y., Antzelevitch, C., Belardinelli, L., Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome (2004) J Pharmacol Exp Ther, 310, pp. 599-605; Hennessey, J.A., Boczek, N.J., Jiang, Y.H., Miller, J.D., Patrick, W., Pfeiffer, R., A CACNA1C variant associated with reduced voltage-dependent inactivation, increased CaV1.2 channel window current, and arrhythmogenesis (2014) PLoS One, 9, p. e106982; Madhvani, R.V., Xie, Y., Pantazis, A., Garfinkel, A., Qu, Z., Weiss, J.N., Shaping a new Ca conductance to suppress early afterdepolarizations in cardiac myocytes (2011) J Physiol, 589, pp. 6081-6092; Colecraft, H.M., Alseikhan, B., Takahashi, S.X., Chaudhuri, D., Mittman, S., Yegnasubramanian, V., Novel functional properties of Ca channel beta subunits revealed by their expression in adult rat heart cells (2002) J Physiol, 541, pp. 435-452; Morita, N., Sovari, A.A., Xie, Y., Fishbein, M.C., Mandel, W.J., Garfinkel, A., Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress (2009) Am J Physiol Heart Circ Physiol, 297, pp. H1594-H1605; Giudicessi, J.R., Ackerman, M.J., Potassium-channel mutations and cardiac arrhythmias-diagnosis and therapy (2012) Nat Rev Cardiol, 9, pp. 319-332; Antzelevitch, C., Yan, G.X., J wave syndromes (2010) Heart Rhythm, 7, pp. 549-558; Lukas, A., Antzelevitch, C., Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia (1996) Cardiovasc Res, 32, pp. 593-603; Lukas, A., Antzelevitch, C., Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia. Role of the transient outward current (1993) Circulation, 88, pp. 2903-2915; Hoogendijk, M.G., Opthof, T., Postema, P.G., Wilde, A.A., de Bakker, J.M., Coronel, R., The Brugada ECG pattern: a marker of channelopathy, structural heart disease, or neither? Toward a unifying mechanism of the Brugada syndrome (2010) Circ Arrhythm Electrophysiol, 3, pp. 283-290; Jeyaraj, D., Wilson, L.D., Zhong, J., Flask, C., Saffitz, J.E., Deschenes, I., Mechanoelectrical feedback as novel mechanism of cardiac electrical remodeling (2007) Circulation, 115, pp. 3145-3155; Burashnikov, A., Antzelevitch, C., Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity (2003) Circulation, 107, pp. 2355-2360; Chua, S.K., Chang, P.C., Maruyama, M., Turker, I., Shinohara, T., Shen, M.J., Small-conductance calcium-activated potassium channel and recurrent ventricular fibrillation in failing rabbit ventricles (2011) Circ Res, 108, pp. 971-979; Maoz, A., Christini, D.J., Krogh-Madsen, T., Dependence of phase-2 reentry and repolarization dispersion on epicardial and transmural ionic heterogeneity: a simulation study (2014) Europace, 16, pp. 458-465; Maoz, A., Krogh-Madsen, T., Christini, D.J., Instability in action potential morphology underlies phase 2 reentry: a mathematical modeling study (2009) Heart Rhythm, 6, pp. 813-822; Dong, M., Sun, X., Prinz, A.A., Wang, H.S., Effect of simulated Ito on guinea pig and canine ventricular action potential morphology (2006) Am J Physiol Heart Circ Physiol, 291, pp. H631-H637; Greenstein, J.L., Wu, R., Po, S., Tomaselli, G.F., Winslow, R.L., Role of the calcium-independent transient outward current Ito1 in shaping action potential morphology and duration (2000) Circ Res, 87, pp. 1026-1033; Miyoshi, S., Mitamura, H., Fujikura, K., Fukuda, Y., Tanimoto, K., Hagiwara, Y., A mathematical model of phase 2 reentry: role of L-type Ca current (2003) Am J Physiol Heart Circ Physiol, 284, pp. H1285-H1294; Hsieh, Y.C., Chang, P.C., Hsueh, C.H., Lee, Y.S., Shen, C., Weiss, J.N., Apamin-sensitive potassium current modulates action potential duration restitution and arrhythmogenesis of failing rabbit ventricles (2013) Circ Arrhythm Electrophysiol, 6, pp. 410-418; Chi, K.R., Revolution dawning in cardiotoxicity testing (2013) Nat Rev Drug Discov, 12, pp. 565-567; Moreno, J.D., Zhu, Z.I., Yang, P.C., Bankston, J.R., Jeng, M.T., Kang, C., A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms (2011) Sci Transl Med, 3. , 98ra83; Moreno, J.D., Yang, P.C., Bankston, J.R., Grandi, E., Bers, D.M., Kass, R.S., Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening (2013) Circ Res, 113, pp. e50-e61; Tenenbaum, J.B., Vd, S., Langford, J.C., A global geometric framework for nonlinear dimensionality reduction (2000) Science, 290, pp. 2319-2323; Piccini, J.P., Hammill, B.G., Sinner, M.F., Jensen, P.N., Hernandez, A.F., Heckbert, S.R., Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007 (2012) Circ Cardiovasc Qual Outcomes, 5, pp. 85-93; Calkins, H., Catheter ablation to maintain sinus rhythm (2012) Circulation, 125, pp. 1439-1445; Cappato, R., Calkins, H., Chen, S.A., Davies, W., Iesaka, Y., Kalman, J., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation (2010) Circ Arrhythm Electrophysiol, 3, pp. 32-38; Song, Y., Shryock, J.C., Belardinelli, L., An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes (2008) Am J Physiol Heart Circ Physiol, 294, pp. H2031-H2039; Hiromoto, K., Shimizu, H., Furukawa, Y., Kanemori, T., Mine, T., Masuyama, T., Discordant repolarization alternans-induced atrial fibrillation is suppressed by verapamil (2005) Circ J, 69, pp. 1368-1373; Atienza, F., Martins, R.P., Jalife, J., Translational research in atrial fibrillation: a quest for mechanistically based diagnosis and therapy (2012) Circ Arrhythm Electrophysiol, 5, pp. 1207-1215; Wijffels, M., Kirchhof, C., Dorland, R., Allessie, M.A., Atrial fibrillation begets atrial fibrillation - a study in awake chronically instrumented goats (1995) Circulation, 92, pp. 1954-1968",Review,Scopus,2-s2.0-84925127686
"Huang X., Zou L., Yu X., Chen M., Guo R., Cai H., Yao D., Xu X., Chen Y., Ding C., Cai X., Wang L.","Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway",2015,"Journal of Molecular and Cellular Cardiology","82",,,"153","166",,,10.1016/j.yjmcc.2015.03.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925038281&partnerID=40&md5=5bbbbb6c26022cfe1349cc8d60999b23","Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China","Huang, X., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Zou, L., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Yu, X., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Chen, M., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Guo, R., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Cai, H., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Yao, D., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Xu, X., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Chen, Y., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Ding, C., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Cai, X., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China; Wang, L., Division of Pulmonary Medicine First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and LungWenzhou, Zhejiang, China","Pulmonary arterial hypertension (PAH) is characterized by pulmonary arterial remodeling mainly due to excess cellular proliferation and apoptosis resistance of pulmonary arterial smooth muscle cells (PASMCs). Salidroside, an active ingredient isolated from Rhodiola rosea is proposed to exert protective effects against PAH. However, the function of salidroside in PAH has not been investigated systematically and the underlying mechanisms are not clear. To investigate the effects of salidroside on PAH, the mice in chronic hypoxia model of PAH were given by an increasing concentration of salidroside (0, 16mg/kg, 32mg/kg, and 64mg/kg). After salidroside treatment, the chronic hypoxia-induced right ventricular hypertrophy and pulmonary arterial remodeling were attenuated, suggesting a protective role played by salidroside in PAH. To explore the potential mechanisms, the apoptosis of PASMCs after salidroside treatment under hypoxia conditions were determined in vivo and in vitro, and also the mitochondria-dependent apoptosis factors, Bax, Bcl-2, cytochrome C, and caspase 9 were examined. The results revealed that salidroside reversed hypoxia-induced cell apoptosis resistance at least partially via a mitochondria-dependent pathway. In addition, salidroside upregulated the expression of adenosine A2a receptor (A2aR) in lung tissues of mice and in PASMCs in vitro after hypoxia exposure. Combined the evidence above, we conclude that salidroside can attenuate chronic hypoxia-induced PAH by promoting PASMCs apoptosis via an A2aR related mitochondria dependent pathway. © 2015.","Adenosine A2a receptor; Apoptosis; Chronic hypoxia; Pulmonary arterial hypertension; Salidroside","Jeffery, T.K., Wanstall, J.C., Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension (2001) Pharmacol Ther, 92, pp. 1-20; Humbert, M., Morrell, N.W., Archer, S.L., Stenmark, K.R., MacLean, M.R., Lang, I.M., Cellular and molecular pathobiology of pulmonary arterial hypertension (2004) J Am Coll Cardiol, 43, pp. 13S-24S; Chin, K.M., Rubin, L.J., Pulmonary arterial hypertension (2008) J Am Coll Cardiol, 51, pp. 1527-1538; Humbert, M., Sitbon, O., Simonneau, G., Treatment of pulmonary arterial hypertension (2004) N Engl J Med, 351, pp. 1425-1436; Pietra, G.G., Capron, F., Stewart, S., Leone, O., Humbert, M., Robbins, I.M., Pathologic assessment of vasculopathies in pulmonary hypertension (2004) J Am Coll Cardiol, 43, pp. 25S-32S; Tuder, R.M., Abman, S.H., Braun, T., Capron, F., Stevens, T., Thistlethwaite, P.A., Development and pathology of pulmonary hypertension (2009) J Am Coll Cardiol, 54, pp. S3-S9; Yuan, J.X., Rubin, L.J., Pathogenesis of pulmonary arterial hypertension: the need for multiple hits (2005) Circulation, 111, pp. 534-538; Shimizu, S., Matsuoka, Y., Shinohara, Y., Yoneda, Y., Tsujimoto, Y., Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells (2001) J Cell Biol, 152, pp. 237-250; Allan, L.A., Clarke, P.R., Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation (2009) FEBS J, 276, pp. 6063-6073; Hu, H.L., Zhang, Z.X., Chen, C.S., Cai, C., Zhao, J.P., Wang, X., Effects of mitochondrial potassium channel and membrane potential on hypoxic human pulmonary artery smooth muscle cells (2010) Am J Respir Cell Mol Biol, 42, pp. 661-666; Archer, S.L., Fang, Y.H., Ryan, J.J., Piao, L., Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension (2013) Pulm circ, 3, pp. 144-152; Paulin, R., Michelakis, E.D., The metabolic theory of pulmonary arterial hypertension (2014) Circ Res, 115, pp. 148-164; Bishopric, N.H., Andreka, P., Slepak, T., Webster, K.A., Molecular mechanisms of apoptosis in the cardiac myocyte (2001) Curr Opin Pharmacol, 1, pp. 141-150; Tsujimoto, Y., Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? (1998) Genes Cells, 3, pp. 697-707; Gross, A., McDonnell, J.M., Korsmeyer, S.J., BCL-2 family members and the mitochondria in apoptosis (1999) Genes Dev, 13, pp. 1899-1911; Salakou, S., Kardamakis, D., Tsamandas, A.C., Zolota, V., Apostolakis, E., Tzelepi, V., Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis (2007) In Vivo, 21, pp. 123-132; McMurtry, M.S., Bonnet, S., Wu, X., Dyck, J.R., Haromy, A., Hashimoto, K., Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis (2004) Circ Res, 95, pp. 830-840; Panossian, A., Wagner, H., Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration (2005) Phytother Res, 19, pp. 819-838; Guan, S., Feng, H., Song, B., Guo, W., Xiong, Y., Huang, G., Salidroside attenuates LPS-induced pro-inflammatory cytokine responses and improves survival in murine endotoxemia (2011) Int Immunopharmacol, 11, pp. 2194-2199; Qu, Z.Q., Zhou, Y., Zeng, Y.S., Lin, Y.K., Li, Y., Zhong, Z.Q., Protective effects of a Rhodiola crenulata extract and salidroside on hippocampal neurogenesis against streptozotocin-induced neural injury in the rat (2012) PLoS One, 7, p. e29641; Darbinyan, V., Kteyan, A., Panossian, A., Gabrielian, E., Wikman, G., Wagner, H., Rhodiola rosea in stress induced fatigue-a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty (2000) Phytomedicine, 7, pp. 365-371; Ming, D.S., Hillhouse, B.J., Guns, E.S., Eberding, A., Xie, S., Vimalanathan, S., Bioactive compounds from Rhodiola rosea (Crassulaceae) (2005) Phytother. Res, 19, pp. 740-743; Xing, S., Yang, X., Li, W., Bian, F., Wu, D., Chi, J., Salidroside stimulates mitochondrial biogenesis and protects against H(2)O(2)-induced endothelial dysfunction (2014) Oxid Med Cell Longev, 2014, p. 904834; Chen, C., Tang, Y., Deng, W., Huang, C., Wu, T., Salidroside blocks the proliferation of pulmonary artery smooth muscle cells induced by platelet derived growth factor BB (2014) Mol Med Rep, 10, pp. 917-922; Mandegar, M., Fung, Y.C., Huang, W., Remillard, C.V., Rubin, L.J., Yuan, J.X., Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension (2004) Microvasc Res, 68, pp. 75-103; Xu, M.H., Gong, Y.S., Su, M.S., Dai, Z.Y., Dai, S.S., Bao, S.Z., Absence of the adenosine A2A receptor confers pulmonary arterial hypertension and increased pulmonary vascular remodeling in mice (2011) J Vasc Res, 48, pp. 171-183; Schermuly, R.T., Ghofrani, H.A., Wilkins, M.R., Grimminger, F., Mechanisms of disease: pulmonary arterial hypertension (2011) Nat Rev Cardiol, 8, pp. 443-455; Majka, S., Burnham, E., Stenmark, K.R., Cell-based therapies in pulmonary hypertension: who, what, and when? (2011) Am J Physiol Lung Cell Mol Physiol, 301, pp. L9-L11; Archer, S.L., Weir, E.K., Wilkins, M.R., Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies (2010) Circulation, 121, pp. 2045-2066; Muller, C.E., Scior, T., Adenosine receptors and their modulators (1993) Pharm Acta Helv, 68, pp. 77-111; Saadjian, A.Y., Paganelli, F., Gaubert, M.L., Levy, S., Guieu, R.P., Adenosine plasma concentration in pulmonary hypertension (1999) Cardiovasc Res, 43, pp. 228-236; Dubey, R.K., Gillespie, D.G., Mi, Z., Suzuki, F., Jackson, E.K., Smooth muscle cell-derived adenosine inhibits cell growth (1996) Hypertension, 27, pp. 766-773; Soleimani, M., Katebi, M., Alizadeh, A., Mohammadzadeh, F., Mehdizadeh, M., The role of the A2A receptor in cell apoptosis caused by MDMA (2012) Cell J, 14, pp. 231-236; Bruzzese, L., Fromonot, J., By, Y., Durand-Gorde, J.M., Condo, J., Kipson, N., NF-kappaB enhances hypoxia-driven T-cell immunosuppression via upregulation of adenosine A(2A) receptors (2014) Cell Signal, 26, pp. 1060-1067; Yang, J., Zheng, X., Haugen, F., Dare, E., Lovdahl, C., Schulte, G., Adenosine increases LPS-induced nuclear factor kappa B activation in smooth muscle cells via an intracellular mechanism and modulates it via actions on adenosine receptors (2014) Acta Physiol, 210, pp. 590-599",Article,Scopus,2-s2.0-84925038281
"Krishnaswamy P.S., Egom E.E., Moghtadaei M., Jansen H.J., Azer J., Bogachev O., Mackasey M., Robbins C., Rose R.A.","Altered parasympathetic nervous system regulation of the sinoatrial node in Akita diabetic mice",2015,"Journal of Molecular and Cellular Cardiology","82",,,"125","135",,,10.1016/j.yjmcc.2015.02.024,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925136782&partnerID=40&md5=fe9e75189cdbe0679eb0fc618ce6a569","Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; School of Biomedical Engineering, Faculty of Medicine, Dalhousie UniversityHalifax, NS, Canada","Krishnaswamy, P.S., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; Egom, E.E., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; Moghtadaei, M., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; Jansen, H.J., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; Azer, J., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; Bogachev, O., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; Mackasey, M., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; Robbins, C., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada; Rose, R.A., Department of Physiology and Biophysics, Dalhousie UniversityHalifax, NS, Canada, School of Biomedical Engineering, Faculty of Medicine, Dalhousie UniversityHalifax, NS, Canada","Cardiovascular autonomic neuropathy (CAN) is a serious complication of diabetes mellitus that impairs autonomic regulation of heart rate (HR). This has been attributed to damage to the nerves that modulate spontaneous pacemaker activity in the sinoatrial node (SAN). Our objective was to test the hypothesis that impaired parasympathetic regulation of HR in diabetes is due to reduced responsiveness of the SAN to parasympathetic agonists. We used the Akita mouse model of type 1 diabetes to study the effects of the parasympathetic agonist carbachol (CCh) on SAN function using intracardiac programmed stimulation, high resolution optical mapping and patch-clamping of SAN myocytes. CCh decreased HR by 30% and increased corrected SAN recovery time (cSNRT) by 123% in wildtype mice. In contrast, CCh only decreased HR by 12%, and only increased cSNRT by 37% in Akita mice. These alterations were due to smaller effects of CCh on SAN electrical conduction and spontaneous action potential firing in isolated SAN myocytes. Voltage clamp experiments demonstrate that the acetylcholine-activated K+ current (IKACh) is reduced in Akita SAN myocytes due to enhanced desensitization and faster deactivation kinetics. These IKACh alterations were normalized by treating Akita SAN myocytes with PI(3,4,5)P3 or an inhibitor of regulator of G-protein signaling 4 (RGS4). There was no difference in the effects of CCh on the hyperpolarization-activated current (If) between wildtype and Akita mice. Our study demonstrates that Akita diabetic mice demonstrate impaired parasympathetic regulation of HR and SAN function due to reduced responses of the SAN to parasympathetic agonists. Our experiments demonstrate a key role for insulin-dependent phosphoinositide 3-kinase (PI3K) signaling in the parasympathetic dysfunction seen in the SAN in diabetes. © 2015 Elsevier Ltd.","Diabetes mellitus; Insulin signaling; Ion channels; Parasympathetic nervous system; Sinoatrial node","Vinik, A.I., Ziegler, D., Diabetic cardiovascular autonomic neuropathy (2007) Circulation, 115, pp. 387-397; Weston, P.J., Gill, G.V., Is undetected autonomic dysfunction responsible for sudden death in Type 1 diabetes mellitus? The 'dead in bed' syndrome revisited (1999) Diabet Med, 16, pp. 626-631; Maser, R.E., Mitchell, B.D., Vinik, A.I., Freeman, R., The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis (2003) Diabetes Care, 26, pp. 1895-1901; Mangoni, M.E., Nargeot, J., Genesis and regulation of the heart automaticity (2008) Physiol Rev, 88, pp. 919-982; Irisawa, H., Brown, H.F., Giles, W., Cardiac pacemaking in the sinoatrial node (1993) Physiol Rev, 73, pp. 197-227; DiFrancesco, D., Pacemaker mechanisms in cardiac tissue (1993) Annu Rev Physiol, 55, pp. 455-472; Lakatta, E.G., Maltsev, V.A., Vinogradova, T.M., A coupled SYSTEM of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker (2010) Circ Res, 106, pp. 659-673; Gehrmann, J., Meister, M., Maguire, C.T., Martins, D.C., Hammer, P.E., Neer, E.J., Impaired parasympathetic heart rate control in mice with a reduction of functional G protein betagamma-subunits (2002) Am J Physiol Heart Circ Physiol, 282, pp. H445-H456; Wickman, K., Nemec, J., Gendler, S.J., Clapham, D.E., Abnormal heart rate regulation in GIRK4 knockout mice (1998) Neuron, 20, pp. 103-114; Mesirca, P., Marger, L., Toyoda, F., Rizzetto, R., Audoubert, M., Dubel, S., The G-protein-gated K+ channel, IKACh, is required for regulation of pacemaker activity and recovery of resting heart rate after sympathetic stimulation (2013) J Gen Physiol, 142, pp. 113-126; Choate, J.K., Feldman, R., Neuronal control of heart rate in isolated mouse atria (2003) Am J Physiol Heart Circ Physiol, 285, pp. H1340-H1346; Yoshioka, M., Kayo, T., Ikeda, T., Koizumi, A., A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice (1997) Diabetes, 46, pp. 887-894; Kayo, T., Koizumi, A., Mapping of murine diabetogenic gene mody on chromosome 7 at D7Mit258 and its involvement in pancreatic islet and beta cell development during the perinatal period (1998) J Clin Invest, 101, pp. 2112-2118; Hsueh, W., Abel, E.D., Breslow, J.L., Maeda, N., Davis, R.C., Fisher, E.A., Recipes for creating animal models of diabetic cardiovascular disease (2007) Circ Res, 100, pp. 1415-1427; Egom, E.E., Vella, K., Hua, R., Jansen, H.J., Moghtadaei, M., Polina, I., Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C (2015) J Physiol, 593, pp. 1127-1146; Azer, J., Hua, R., Krishnaswamy, P.S., Rose, R.A., Effects of natriuretic peptides on electrical conduction in the sinoatrial node and atrial myocardium of the heart (2014) J Physiol, 592, pp. 1025-1045; Springer, J., Azer, J., Hua, R., Robbins, C., Adamczyk, A., McBoyle, S., The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors (2012) J Mol Cell Cardiol, 52, pp. 1122-1134; Azer, J., Hua, R., Vella, K., Rose, R.A., Natriuretic peptides regulate heart rate and sinoatrial node function by activating multiple natriuretic peptide receptors (2012) J Mol Cell Cardiol, 53, pp. 715-724; Hua, R., Adamczyk, A., Robbins, C., Ray, G., Rose, R.A., Distinct patterns of constitutive phosphodiesterase activity in mouse sinoatrial node and atrial myocardium (2012) PLoS One, 7, p. e47652; Bugger, H., Boudina, S., Hu, X.X., Tuinei, J., Zaha, V.G., Theobald, H.A., Type 1 diabetic Akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3 (2008) Diabetes, 57, pp. 2924-2932; Park, H.J., Zhang, Y., Du, C., Welzig, C.M., Madias, C., Aronovitz, M.J., Role of SREBP-1 in the development of parasympathetic dysfunction in the hearts of type 1 diabetic Akita mice (2009) Circ Res, 105, pp. 287-294; Basu, R., Oudit, G.Y., Wang, X., Zhang, L., Ussher, J.R., Lopaschuk, G.D., Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function (2009) Am J Physiol Heart Circ Physiol, 297, pp. H2096-H2108; Narula, O.S., Samet, P., Javier, R.P., Significance of the sinus-node recovery time (1972) Circulation, 45, pp. 140-158; Chadda, K.D., Banka, V.S., Bodenheimer, M.M., Helfant, R.H., Corrected sinus node recovery time. Experimental physiologic and pathologic determinants (1975) Circulation, 51, pp. 797-801; Luo, M., Guan, X., Luczak, E.D., Lang, D., Kutschke, W., Gao, Z., Diabetes increases mortality after myocardial infarction by oxidizing CaMKII (2013) J Clin Invest, 123, pp. 1262-1274; Fedorov, V.V., Hucker, W.J., Dobrzynski, H., Rosenshtraukh, L.V., Efimov, I.R., Postganglionic nerve stimulation induces temporal inhibition of excitability in rabbit sinoatrial node (2006) Am J Physiol Heart Circ Physiol, 291, pp. H612-H623; Glukhov, A.V., Fedorov, V.V., Anderson, M.E., Mohler, P.J., Efimov, I.R., Functional anatomy of the murine sinus node: high-resolution optical mapping of ankyrin-B heterozygous mice (2010) Am J Physiol Heart Circ Physiol, 299, pp. H482-H491; Bleeker, W.K., Mackaay, A.J., Masson-Pevet, M., Bouman, L.N., Becker, A.E., Functional and morphological organization of the rabbit sinus node (1980) Circ Res, 46, pp. 11-22; Verheijck, E.E., van Kempen, M.J., Veereschild, M., Lurvink, J., Jongsma, H.J., Bouman, L.N., Electrophysiological features of the mouse sinoatrial node in relation to connexin distribution (2001) Cardiovasc Res, 52, pp. 40-50; Lomax, A.E., Rose, R.A., Giles, W.R., Electrophysiological evidence for a gradient of G protein-gated K+ current in adult mouse atria (2003) Br J Pharmacol, 140, pp. 576-584; Cifelli, C., Rose, R.A., Zhang, H., Voigtlaender-Bolz, J., Bolz, S.S., Backx, P.H., RGS4 regulates parasympathetic signaling and heart rate control in the sinoatrial node (2008) Circ Res, 103, pp. 527-535; Oudit, G.Y., Sun, H., Kerfant, B.G., Crackower, M.A., Penninger, J.M., Backx, P.H., The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease (2004) J Mol Cell Cardiol, 37, pp. 449-471; Ishii, M., Inanobe, A., Kurachi, Y., PIP3 inhibition of RGS protein and its reversal by Ca2+/calmodulin mediate voltage-dependent control of the G protein cycle in a cardiac K+ channel (2002) Proc Natl Acad Sci U S A, 99, pp. 4325-4330; Popov, S.G., Krishna, U.M., Falck, J.R., Wilkie, T.M., Ca2+/Calmodulin reverses phosphatidylinositol 3,4, 5-trisphosphate-dependent inhibition of regulators of G protein-signaling GTPase-activating protein activity (2000) J Biol Chem, 275, pp. 18962-18968; Roman, D.L., Talbot, J.N., Roof, R.A., Sunahara, R.K., Traynor, J.R., Neubig, R.R., Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay (2007) Mol Pharmacol, 71, pp. 169-175; Roman, D.L., Blazer, L.L., Monroy, C.A., Neubig, R.R., Allosteric inhibition of the regulator of G protein signaling-Galpha protein-protein interaction by CCG-4986 (2010) Mol Pharmacol, 78, pp. 360-365; Thackeray, J.T., Beanlands, R.S., Dasilva, J.N., Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging (2012) Am J Nucl Med Mol Imaging, 2, pp. 314-334; Vinogradova, T.M., Fedorov, V.V., Yuzyuk, T.N., Zaitsev, A.V., Rosenshtraukh, L.V., Local cholinergic suppression of pacemaker activity in the rabbit sinoatrial node (1998) J Cardiovasc Pharmacol, 32, pp. 413-424; Fedorov, V.V., Glukhov, A.V., Chang, R., Conduction barriers and pathways of the sinoatrial pacemaker complex: their role in normal rhythm and atrial arrhythmias (2012) Am J Physiol Heart Circ Physiol, 302, pp. H1773-H1783; Wolf, R.M., Glynn, P., Hashemi, S., Zarei, K., Mitchell, C.C., Anderson, M.E., Atrial fibrillation and sinus node dysfunction in human ankyrin-B syndrome: a computational analysis (2013) Am J Physiol Heart Circ Physiol, 304, pp. H1253-H1266; Watson, N., Linder, M.E., Druey, K.M., Kehrl, J.H., Blumer, K.J., RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits (1996) Nature, 383, pp. 172-175; Wieland, T., Mittmann, C., Regulators of G-protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system (2003) Pharmacol Ther, 97, pp. 95-115; Fu, Y., Huang, X., Zhong, H., Mortensen, R.M., D'Alecy, L.G., Neubig, R.R., Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects (2006) Circ Res, 98, pp. 659-666; Fu, Y., Huang, X., Piao, L., Lopatin, A.N., Neubig, R.R., Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block (2007) Am J Physiol Heart Circ Physiol, 292, pp. H2532-H2539; Doupnik, C.A., Davidson, N., Lester, H.A., Kofuji, P., RGS proteins reconstitute the rapid gating kinetics of gbetagamma-activated inwardly rectifying K+ channels (1997) Proc Natl Acad Sci U S A, 94, pp. 10461-10466; Zhang, Q., Pacheco, M.A., Doupnik, C.A., Gating properties of GIRK channels activated by Galpha(o)- and Galpha(i)-coupled muscarinic m2 receptors in Xenopus oocytes: the role of receptor precoupling in RGS modulation (2002) J Physiol, 545, pp. 355-373; Neubig, R.R., And the winner is. RGS4! (2008) Circ Res, 103, pp. 444-446; Lu, Z., Jiang, Y.P., Xu, X.H., Ballou, L.M., Cohen, I.S., Lin, R.Z., Decreased L-type Ca2+ current in cardiac myocytes of type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling (2007) Diabetes, 56, pp. 2780-2789; Abel, E.D., Insulin signaling in heart muscle: lessons from genetically engineered mouse models (2004) Curr Hypertens Rep, 6, pp. 416-423; Zhang, Y., Welzig, C.M., Picard, K.L., Du, C., Wang, B., Pan, J.Q., Glycogen synthase kinase-3beta inhibition ameliorates cardiac parasympathetic dysfunction in type 1 diabetic Akita mice (2014) Diabetes, 63, pp. 2097-2113",Article,Scopus,2-s2.0-84925136782
"Levy R.J.","Carbon monoxide pollution and neurodevelopment: A public health concern",2015,"Neurotoxicology and Teratology","49",,,"31","40",,,10.1016/j.ntt.2015.03.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925329299&partnerID=40&md5=4bc09ae4a2786197e97eb31b607838e1","Department of Anesthesiology, Columbia University Medical Center, 622 W. 168th StreetNew York, NY, United States","Levy, R.J., Department of Anesthesiology, Columbia University Medical Center, 622 W. 168th StreetNew York, NY, United States","Although an association between air pollution and adverse systemic health effects has been known for years, the effect of pollutants on neurodevelopment has been underappreciated. Recent evidence suggests a possible link between air pollution and neurocognitive impairment and behavioral disorders in children, however, the exact nature of this relationship remains poorly understood. Infants and children are uniquely vulnerable due to the potential for exposure in both the fetal and postnatal environments during critical periods in development. Carbon monoxide (CO), a common component of indoor and outdoor air pollution, can cross the placenta to gain access to the fetal circulation and the developing brain. Thus, CO is of particular interest as a known neurotoxin and a potential public health threat. Here we review overt CO toxicity and the policies regulating CO exposure, detail the evidence suggesting a potential link between CO-associated ambient air pollution, tobacco smoke, and learning and behavioral abnormalities in children, describe the effects of subclinical CO exposure on the brain during development, and provide mechanistic insight into a potential connection between CO exposure and neurodevelopmental outcome. CO can disrupt a number of critical processes in the developing brain, providing a better understanding of how this specific neurotoxin may impair neurodevelopment. However, further investigation is needed to better define the effects of perinatal CO exposure on the immature brain. Current policies regarding CO standards were established based on evidence of cardiovascular risk in adults with pre-existing comorbidities. Thus, recent and emerging data highlighted in this review regarding CO exposure in the fetus and developing child may be important to consider when the standards and guidelines are evaluated and revised in the future. © 2015 Elsevier Inc.","Air pollution; Autism; Brain; Carbon monoxide; Development; Toxicity","Adams, K.F., Koch, G., Chatterjee, B., Goldstein, G.M., O'Neil, J.J., Bromberg, P.A., Acute elevation of blood carboxyhemoglobin to 6% impairs exercise performance and aggravates symptoms in patients with ischemic heart disease (1988) J Am Coll Cardiol, 12, pp. 900-909; Alehan, F., Erol, I., Onay, O.S., Cerebral palsy due to nonlethal maternal carbon monoxide intoxication (2007) Birth Defects Res A Clin Mol Teratol, 79, pp. 614-616; Allen, J.L., Liu, X., Weston, D., Prince, L., Oberdörster, G., Finkelstein, J.N., Developmental exposure to concentrated ambient ultrafine particulate matter air pollution in mice results in persistent and sex-dependent behavioral neurotoxicity and glial activation (2014) Toxicol Sci, 140, pp. 160-178; Allred, E.N., Bleecker, E.R., Chaitman, B.R., Dahms, T.E., Gottlieb, S.O., Hackney, J.D., Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease (1989) N Engl J Med, 321, pp. 1426-1432; Allred, E.N., Bleecker, E.R., Chaitman, B.R., Dahms, T.E., Gottlieb, S.O., Hackney, J.D., Effects of carbon monoxide on myocardial ischemia (1991) Environ Health Perspect, 91, pp. 89-132; Anderson, E.W., Andelman, R.J., Strauch, J.M., Fortuin, N.J., Knelson, J.H., Effect of low-level carbon monoxide exposure on onset and duration of angina pectoris. A study in ten patients with ischemic heart disease (1973) Ann Intern Med, 79, pp. 46-50; Aronow, W.S., Isbell, M.W., Carbon monoxide effect on exercise-induced angina pectoris (1973) Ann Intern Med, 79, pp. 392-395; What is autism?, , http://www.autismspeaks.org/what-autism, [Online] Available at:, [Accessed on May 27, 2014]; Baker, M.D., Henretig, F.M., Ludwig, S., Carboxyhemoglobin levels in children with nonspecific flu-like symptoms (1988) J Pediatr, 113, pp. 501-504; Bauer, I., Pannen, B.H., Bench-to-bedside review: carbon monoxide-from mitochondrial poisoning to therapeutic use (2009) Crit Care, 13, p. 220; Becerra, T.A., Wilhelm, M., Olsen, J., Cockburn, M., Ritz, B., Ambient air pollution and autism in Los Angeles county, California (2013) Environ Health Perspect, 121, pp. 380-386; Benagiano, V., Lorusso, L., Coluccia, A., Tarullo, A., Flace, P., Girolamo, F., Glutamic acid decarboxylase and GABA immunoreactivities in the cerebellar cortex of adult rat after prenatal exposure to a low concentration of carbon monoxide (2005) Neuroscience, 135, pp. 897-905; Bissonnette, J.M., Wickham, W.K., Placental diffusing capacity for carbon monoxide in unanesthetized guinea pigs (1977) Respir Physiol, 31, pp. 161-168; Bissonnette, J.M., Wickham, W.K., Drummond, W.H., Placental diffusing capacities at varied carbon monoxide tensions (1977) J Clin Invest, 59, pp. 1038-1044; Block, M.L., Elder, A., Auten, R.L., Bilbo, S.D., Chen, H., Chen, J.C., The outdoor air pollution and brain health workshop (2012) Neurotoxicology, 33, pp. 972-984; Bolton, J.L., Huff, N.C., Smith, S.H., Mason, S.N., Foster, W.M., Auten, R.L., Maternal stress and effects of prenatal air pollution on offspring mental health outcomes in mice (2013) Environ Health Perspect, 121, pp. 1075-1082; Brown, S.D., Piantadosi, C.A., In vivo binding of carbon monoxide to cytochrome c oxidase in rat brain (1990) J Appl Physiol, 68, pp. 604-610; Carratù, M.R., Cagiano, R., Desantis, S., Labate, M., Tattoli, M., Trabace, L., Prenatal exposure to low levels of carbon monoxide alters sciatic nerve myelination in rat offspring (2000) Life Sci, 67, pp. 1759-1772; Carter, A.M., Placental oxygen transfer and the oxygen supply to the fetus (1999) Fetal Matern Med, 11, pp. 151-161; Autism spectrum disorder, , http://www.cdc.gov/ncbddd/autism/data.html, [Online] Available at:, [Accessed on May 27, 2014]; Unintentional poisoning deaths-United States 1999-2004 (2007) MMWR Morb Mortal Wkly Rep, 56, pp. 93-96; Nonfatal, unintentional, non-fire-related carbon monoxide exposures-United States, 2004-2006 (2008) MMWR Morb Mortal Wkly Rep, 57, pp. 896-899; Chan, W.Y., Lorke, D.E., Tiu, S.C., Yew, D.T., Proliferation and apoptosis in the developing human neocortex (2002) Anat Rec, 267, pp. 261-276; Cheng, Y., Thomas, A., Mardini, F., Bianchi, S.L., Tang, J.X., Peng, J., Neurodevelopmental consequences of sub-clinical carbon monoxide exposure in newborn mice (2012) PLoS One, 7, p. e32029; Daher, N., Saleh, R., Jaroudi, E., Sheheitli, H., Badr, T., Sepetdjian, E., Comparison of carcinogen, carbon monoxide, and ultrafine particle emissions from narghile waterpipe and cigarette smoking: sidestream smoke measurements and assessment of second-hand smoke emission factors (2010) Atmos Environ, 44, pp. 8-14; De Salvia, M.A., Cagiano, R., Carratù, M.R., Di Giovanni, V., Trabace, L., Cuomo, V., Irreversible impairment of active avoidance behavior in rats prenatally exposed to mild concentrations of carbon monoxide (1995) Psychopharmacology (Berl), 122, pp. 66-71; Dix-Cooper, L., Eskenazi, B., Romero, C., Balmes, J., Smith, K.R., Neurodevelopmental performance among school age children in rural Guatemala is associated with prenatal and postnatal exposure to carbon monoxide, a marker for exposure to woodsmoke (2012) Neurotoxicology, 33, pp. 246-254; Eissenberg, T., Shihadeh, A., Waterpipe tobacco and cigarette smoking: direct comparison of toxicant exposure (2009) Am J Prev Med, 37, pp. 518-523; Fechter, L.D., Neurotoxicity of prenatal carbon monoxide exposure (1987) Res Rep Health Eff Inst, 12, pp. 3-22; Fechter, L.D., Annau, Z., Prenatal carbon monoxide exposure alters behavioral development (1980) Neurobehav Toxicol, 2, pp. 7-11; Fechter, L.D., Karpa, M.D., Proctor, B., Lee, A.G., Storm, J.E., Disruption of neostriatal development in rats following perinatal exposure to mild, but chronic carbon monoxide (1987) Neurotoxicol Teratol, 9, pp. 277-281; Fechter, L.D., Young, J.S., Carlisle, L., Potentiation of noise induced threshold shifts and hair cell loss by carbon monoxide (1988) Hear Res, 34, pp. 39-47; Foster, M., Goodwin, S.R., Williams, C., Loeffler, J., Recurrent acute life-threatening events and lactic acidosis caused by chronic carbon monoxide poisoning in an infant (1999) Pediatrics, 104, p. e34; Giustino, A., Cagiano, R., Carratù, M.R., Cassano, T., Tattoli, M., Cuomo, V., Prenatal exposure to low concentrations of carbon monoxide alters habituation and non-spatial working memory in rat offspring (1999) Brain Res, 844, pp. 201-205; Gomez, C., Berlin, I., Marquis, P., Delcroix, M., Expired air carbon monoxide concentration in mothers and their spouses above 5ppm is associated with decreased fetal growth (2005) Prev Med, 40, pp. 10-15; Gorman, D., Drewry, A., Huang, Y.L., Sames, C., The clinical toxicology of carbon monoxide (2003) Toxicology, 187, pp. 25-38; Grandjean, P., Landrigan, P.J., Developmental neurotoxicity of industrial chemicals (2006) Lancet, 368, pp. 2167-2178; Greingor, J.L., Tosi, J.M., Ruhlmann, S., Aussedat, M., Acute carbon monoxide intoxication during pregnancy. One case report and review of the literature (2001) Emerg Med J, 18, pp. 399-401; Gül, I., Karapinar, H., Yarlioglues, M., Ozdogru, I., Kaya, M.G., Yilmaz, A., Acute effects of passive smoking on endothelial function (2011) Angiology, 62, pp. 245-247; Ha, E.H., Hong, Y.C., Lee, B.E., Woo, B.H., Schwartz, J., Christiani, D.C., Is air pollution a risk factor for low birth weight in Seoul? (2001) Epidemiology, 12, pp. 643-648; Hakem, R., Hakem, A., Duncan, G.S., Henderson, J.T., Woo, M., Soengas, M.S., Differential requirement for caspase 9 in apoptotic pathways in vivo (1998) Cell, 94, pp. 339-352; Hampson, N.B., Norkool, D.M., Carbon monoxide poisoning in children riding in the back of pickup trucks (1992) JAMA, 267, pp. 538-540; Hampson, N.B., Piantadosi, C.A., Thom, S.R., Weaver, L.K., Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning (2012) Am J Respir Crit Care Med, 186, pp. 1095-1101; Hauck, H., Neuberger, M., Carbon monoxide uptake and the resulting carboxyhemoglobin in man (1984) Eur J Appl Physiol Occup Physiol, 53, pp. 186-190; Hegaard, H.K., Kjaergaard, H., Moller, L.F., Wachmann, H., Ottesen, B., The effect of environmental tobacco smoke during pregnancy on birth weight (2006) Acta Obstet Gynecol Scand, 85, pp. 675-681; Herbert, M.R., Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders (2010) Curr Opin Neurol, 23, pp. 103-110; Herrmann, M., King, K., Weitzman, M., Prenatal tobacco smoke and postnatal secondhand smoke exposure and child neurodevelopment (2008) Curr Opin Pediatr, 20, pp. 184-190; Higgins, S., Smoking in pregnancy (2002) Curr Opin Obstet Gynecol, 14, pp. 145-151; Hofhuis, W., de Jongste, J.C., Merkus, P.J., Adverse health effects of prenatal and postnatal tobacco smoke exposure on children (2003) Arch Dis Child, 88, pp. 1086-1090; Iheagwara, K.N., Thom, S.R., Deutschman, C.S., Levy, R.J., Myocardial cytochrome oxidase activity is decreased following carbon monoxide exposure (2007) Biochim Biophys Acta, 1772, pp. 1112-1116; Iqbal, S., Clower, J.H., Hernandez, S.A., Damon, S.A., Yip, F.Y., A review of disaster-related carbon monoxide poisoning: surveillance, epidemiology, and opportunities for prevention (2012) Am J Public Health, 102, pp. 1957-1963; Iqbal, S., Law, H.Z., Clower, J.H., Yip, F.Y., Elixhauser, A., Hospital burden of unintentional carbon monoxide poisoning in the United States, 2007 (2012) Am J Emerg Med, 30, pp. 657-664; Jain, K.K., Carbon monoxide and other tissue poisons (2009) Textbook of hyperbaric medicine, pp. 111-133. , Hogrefe Publishing, Cambridge, MA, K.K. Jain (Ed.); Jiang, Y., de Bruin, A., Caldas, H., Fangusaro, J., Hayes, J., Conway, E.M., Essential role for survivin in early brain development (2005) J Neurosci, 25, pp. 6962-6970; Jo, W.K., Oh, J.W., Dong, J.I., Evaluation of exposure to carbon monoxide associated with passive smoking (2004) Environ Res, 94, pp. 309-318; Jung, C.R., Lin, Y.T., Hwang, B.F., Air pollution and newly diagnostic autism spectrum disorders: a population-based cohort study in Taiwan (2013) PLoS One, 8, p. e75510; Kao, L.W., Nañagas, K.A., Carbon monoxide poisoning (2004) Emerg Med Clin North Am, 22, pp. 985-1018; Kao, L.W., Nañagas, K.A., Carbon monoxide poisoning (2005) Med Clin N Am, 89, pp. 1161-1194; Kapetanaki, S.M., Silkstone, G., Husu, I., Liebl, U., Wilson, M.T., Vos, M.H., Interaction of carbon monoxide with the apoptosis-inducing cytochrome c-cardiolipin complex (2009) Biochemistry, 48, pp. 1613-1619; Kleinman, M.T., Davidson, D.M., Vandagriff, R.B., Caiozzo, V.J., Whittenberger, J.L., Effects of short-term exposure to carbon monoxide in subjects with coronary artery disease (1989) Arch Environ Health, 44, pp. 361-369; Kleinman, M.T., Leaf, D.A., Kelly, E., Caiozzo, V., Osann, K., O'Niell, T., Urban angina in the mountains: effects of carbon monoxide and mild hypoxemia on subjects with chronic stable angina (1998) Arch Environ Health, 53, pp. 388-397; Kuida, K., Zheng, T.S., Na, S., Kuan, C., Yang, D., Karasuyama, H., Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice (1996) Nature, 384, pp. 368-372; La Fauci, G., Weiser, G., Steiner, I.P., Shavit, I., Carbon monoxide poisoning in narghile (water pipe) tobacco smokers (2012) CJEM, 14, pp. 57-59; Li, M., Cui, Z., Niu, Y., Liu, B., Fan, W., Yu, D., Synaptogenesis in the developing mouse visual cortex (2010) Brain Res Bull, 81, pp. 107-113; Lindbohm, M.L., Sallmen, M., Taskinen, H., Effects of exposure to environmental tobacco smoke on reproductive health (2002) Scand J Work Environ Health, 28, pp. 84-96; Lindley, A., Becker, S., Gray, R., Herman, A., Effect of continuing or stopping smoking during pregnancy on infant birth weight, crown-heel length, head circumference, ponderal index, and brain: body weight ratio (2000) Am J Epidemiol, 152, pp. 219-225; Liu, S., Knewski, D., Shi, Y., Chen, Y., Burnett, R.T., Association between gaseous ambient air pollutants and adverse pregnancy outcomes in Vancouver, British Columbia (2003) Environ Health Perspect, 111, pp. 1773-1778; Longo, L.D., Carbon monoxide in the pregnant mother and fetus and its exchange across the placenta (1970) Ann N Y Acad Sci, 174, pp. 312-341; Lopez, I., Acuna, D., Webber, D.S., Korsak, R.A., Edmond, J., Mild carbon monoxide exposure diminishes selectively the integrity of the cochlea of the developing rat (2003) J Neurosci Res, 74, pp. 666-675; Maisonet, M., Bush, T.J., Correa, A., Jaakkola, J.J., Relation between ambient air pollution and low birth weight in the northeastern United States (2001) Environ Health Perspect, 109, pp. 351-356; Martinasek, M.P., Ward, K.D., Calvanese, A.V., Change in carbon monoxide exposure among waterpipe bar patrons (2014) Nicotine Tob Res, 16, pp. 1014-1019; McGregor, H.P., Westcott, K., Walker, D.W., The effect of prenatal exposure to carbon monoxide on breathing and growth of the newborn guinea pig (1998) Pediatr Res, 43, pp. 126-131; Misek, R., Patte, C., Carbon monoxide toxicity after lighting coals at a hookah bar (2014) J Med Toxicol, 10, pp. 295-298; Morris, R.D., Naumova, E.N., Munasinghe, R.L., Ambient air pollution and hospitalization for congestive heart failure among elderly people in seven large US cities (1995) Am J Public Health, 85, pp. 1361-1365; Mustafic, H., Jabre, P., Caussin, C., Murad, M.H., Escolano, S., Tafflet, M., Main air pollutants and myocardial infarction: a systematic review and meta-analysis (2012) JAMA, 307, pp. 713-721; Olney, J.W., Young, C., Wozniak, D.F., Ikonomidou, C., Jevtovic-Todorovic, V., Anesthesia-induced developmental neuroapoptosis. Does it happen in humans? (2004) Anesthesiology, 101, pp. 273-275; Patel, P., Sun, L., Update on neonatal anesthetic neurotoxicity: insight into molecular mechanisms and relevance to humans (2009) Anesthesiology, 110, pp. 703-708; Pelham, T.W., Holt, L.E., Moss, M.A., Exposure to carbon monoxide and nitrogen dioxide in enclosed ice arenas (2002) Occup Environ Med, 59, pp. 224-233; Pfeiffer, B.E., Huber, K.M., The state of synapses in fragile X syndrome (2009) Neuroscientist, 15, pp. 549-567; Raub, J., Carbon monoxide (1999) Environmental health criteria, 213. , http://whqlibdoc.who.int/ehc/WHO_EHC_213.pdf, World Health Organization, [Online, Available at. Accessed May 27, 2014]; Raub, J.A., Benignus, V.A., Carbon monoxide and the nervous system (2002) Neurosci Biobehav Rev, 26, pp. 925-940; Raub, J.A., Mathieu-Nolf, M., Hampson, N.B., Thom, S.R., Carbon monoxide poisoning a public health perspective (2000) Toxicology, 145, pp. 1-14; Rauh, V.A., Horton, M.K., Miller, R.L., Whyatt, R.M., Perera, F., Neonatology and the environment: impact of early exposure to airborne environmental toxicants on infant and child neurodevelopment (2010) Neoreviews, 11, pp. 363-369; Rice, D., Barone, S., Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models (2000) Environ Health Perspect, 108, pp. 511-533; Ritz, B., Yu, F., The effect of ambient carbon monoxide on low birth weight among children born in Southern California between 1989 and 1993 (1999) Environ Health Perspect, 107, pp. 17-25; Ritz, B., Yu, F., Chapa, G., Fruin, S., Effect of air pollution on preterm birth among children born in Southern California between 1989 and 1993 (2000) Epidemiology, 11, pp. 502-511; Ritz, B., Wilhelm, M., Zhao, Y., Air pollution and infant death in Southern California, 1989-2000 (2006) Pediatrics, 118, pp. 493-502; Rizzi, S., Ori, C., Jevtovic-Todorovic, V., Timing versus duration: determinants of anesthesia-induced developmental apoptosis in the young mammalian brain (2010) Ann N Y Acad Sci, 1199, pp. 43-51; Roberts, A.L., Lyall, K., Hart, J.E., Laden, F., Just, A.C., Bobb, J.F., Perinatal air pollutant exposures and autism spectrum disorder in the children of Nurses' Health Study II participants (2013) Environ Health Perspect, 121, pp. 978-984; Rosenberg, R.E., Daniels, A.M., Law, J.K., Law, P.A., Kaufmann, W.E., Trends in autism spectrum disorder diagnoses: 1994-2007 (2009) J Autism Dev Disord, 39, pp. 1099-1111; Roza, S.J., Verburg, B.O., Jaddoe, V.W., Hofman, A., Mackenbach, J.P., Steegers, E.A., Effects of maternal smoking in pregnancy on prenatal brain development. The Generation R Study (2007) Eur J Neurosci, 25, pp. 611-617; Salam, M.T., Millstein, J., Li, Y.F., Lurmann, F.W., Margolis, H.G., Gilliland, F.D., Birth outcomes and prenatal exposure to ozone, carbon monoxide, and particulate matter: results from the children's health study (2005) Environ Health Perspect, 113, pp. 1638-1644; Sanno, H., Shen, X., Kuru, N., Bormuth, I., Bobsin, K., Gardner, H.A., Control of postnatal apoptosis in the neocortex by RhoA-subfamily GTPases determines neuronal density (2010) J Neurosci, 30, pp. 4221-4231; Sheps, D.S., Adams, K.F., Bromberg, P.A., Goldstein, G.M., O'Neil, J.J., Horstman, D., Lack of effect of low levels of carboxyhemoglobin on cardiovascular function in patients with ischemic heart disease (1987) Arch Environ Health, 42, pp. 108-116; Smithline, H.A., Ward, K.R., Chiulli, D.A., Blake, H.C., Rivers, E.P., Whole body oxygen consumption and critical oxygen delivery in response to prolonged and severe carbon monoxide poisoning (2003) Resuscitation, 56, pp. 97-104; Stockard-Sullivan, J.E., Korsak, R.A., Webber, D.S., Edmond, J., Mild carbon monoxide exposure and auditory function in the developing rat (2003) J Neurosci Res, 74, pp. 644-654; Tomaszewski, C., Carbon monoxide (2002) Goldfrank's toxicologic emergencies, pp. 1478-1497. , McGraw-Hill, New York, L.R. Goldfrank, N.E. Flomenbaum, N.A. Lewin (Eds.); Carbon monoxide, , http://www.epa.gov/airquality/carbonmonoxide/, [Online]. Available at:, [Accessed May 27, 2014]; Vanderhaeghen, P., Cheng, H.J., Guidance molecules in axon pruning and cell death (2010) Cold Spring Harb Perspect Biol, 2, p. a001859; Vecino, E., Hernández, M., García, M., Cell death in the developing vertebrate retina (2004) Int J Dev Biol, 48, pp. 965-974; Vik, T., Jacobsen, G., Vatten, L., Bakketeig, L., Pre and postnatal growth in children of women who smoked in pregnancy (1996) Early Hum Dev, 45, pp. 245-255; Volk, H.E., Hertz-Picciotto, I., Delwiche, L., Lurmann, F., McConnell, R., Residential proximity to freeways and autism in the CHARGE study (2011) Environ Health Perspect, 119, pp. 873-877; Volk, H.E., Lurmann, F., Penfold, B., Hertz-Picciotto, I., McConnell, R., Traffic-related air pollution, particulate matter, and autism (2013) JAMA Psychiatry, 70, pp. 71-77; von Rappard, J., Schönenberger, M., Bärlocher, L., Carbon monoxide poisoning following use of a water pipe/hookah (2014) Dtsch Arztebl Int, 111, pp. 674-679; Vrijheid, M., Martinez, D., Aguilera, I., Bustamante, M., Ballester, F., Estarlich, M., Indoor air pollution from gas cooking and infant neurodevelopment (2012) Epidemiology, 23, pp. 23-32; Wang, L., Pinkerton, K.E., Air pollutant effects on fetal and early postnatal development (2007) Birth Defects Res C Embryo Today, 81, pp. 144-154; Wang, W., Li, J., Chang, Y., Xie, X., Ren, J., Wang, X., Effects of immune reaction in rats after acute carbon monoxide poisoning (2011) Undersea Hyperb Med, 38, pp. 239-246; Webber, D.S., Korsak, R.A., Sininger, L.K., Sampogna, S.L., Edmond, J., Mild carbon monoxide exposure impairs the developing auditory system of the rat (2003) J Neurosci Res, 74, pp. 655-665; Winter, P.M., Miller, J.N., Carbon monoxide poisoning (1976) JAMA, 236, p. 1502; Wisborg, K., Kesmodel, U., Henriksen, T.B., Olsen, S.F., Secher, N.J., Exposure to tobacco smoke in utero and the risk of stillbirth and death in the first year of life (2001) Am J Epidemiol, 154, pp. 322-327; Young, J.S., Upchurch, M.B., Kaufman, M.J., Fechter, L.D., Carbon monoxide exposure potentiates high-frequency auditory threshold shifts induced by noise (1987) Hear Res, 26, pp. 37-43; Zhou, S., Weitzman, M., Vilcassim, R., Wilson, J., Legrand, N., Saunders, E., Air quality in New York City hookah bars (2014) Tob Control, , [Epub ahead of print]",Review,Scopus,2-s2.0-84925329299
"Nigro P., Perrucci G.L., Gowran A., Zanobini M., Capogrossi M.C., Pompilio G.","C-kit+ cells: The tell-tale heart of cardiac regeneration?",2015,"Cellular and Molecular Life Sciences","72","9",,"1725","1740",,,10.1007/s00018-014-1832-8,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928501284&partnerID=40&md5=334d9f6f923de8e8ebca44f83c7cbb69","Laboratory of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Via Parea 4Milan, Italy; Department of Clinical and Community Sciences, University of Milan, Via Festa del Perdono 7Milan, Italy; Department of Cardiovascular Surgery, Centro Cardiologico Monzino-IRCCS, Via Parea 4Milan, Italy; Laboratory of Vascular Pathology, Istituto Dermopatico dell'Immacolata-IRCCS, Via Monti di Creta 104Rome, Italy","Nigro, P., Laboratory of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Via Parea 4Milan, Italy; Perrucci, G.L., Department of Clinical and Community Sciences, University of Milan, Via Festa del Perdono 7Milan, Italy; Gowran, A., Laboratory of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Via Parea 4Milan, Italy; Zanobini, M., Department of Cardiovascular Surgery, Centro Cardiologico Monzino-IRCCS, Via Parea 4Milan, Italy; Capogrossi, M.C., Laboratory of Vascular Pathology, Istituto Dermopatico dell'Immacolata-IRCCS, Via Monti di Creta 104Rome, Italy; Pompilio, G., Laboratory of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Via Parea 4Milan, Italy, Department of Clinical and Community Sciences, University of Milan, Via Festa del Perdono 7Milan, Italy, Department of Cardiovascular Surgery, Centro Cardiologico Monzino-IRCCS, Via Parea 4Milan, Italy","Cardiovascular disease is the leading cause of morbidity and mortality in the developed world. Although ongoing therapeutic strategies ameliorate symptoms and prolong life for patients with cardiovascular diseases, they do not solve the critical issue related to the loss of cardiac tissue. Accordingly, stem/progenitor cell therapy has emerged as a paramount approach for cardiac repair and regeneration. In this regard, c-kit+ cells have animated much interest and controversy. These cells are self-renewing, clonogenic, and multipotent and display a noteworthy potential to differentiate into all cardiovascular lineages. However, their functional contribution to cardiomyocyte turnover is one of the centrally debated issues concerning their regenerative potential. Regardless, plentiful preclinical and clinical studies have been conducted which provide evidence for the capacity of c-kit+ cells to improve cardiac function. The purpose of this review is to give a comprehensive, impartial, critical description and evaluation of the literature on c-kit+ cells from bench to bedside in order to address their true potential, benefits and controversies. © 2015 Springer Basel.","c-kit+ cells; Cardiovascular disease; Cell therapy; Myocardial regeneration","Abdel-Latif, A., Bolli, R., Tleyjeh, I.M., Montori, V.M., Perin, E.C., Hornung, C.A., Zuba-Surma, E.K., Dawn, B., Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis (2007) Arch Intern Med, 167, pp. 989-997. , 17533201; Ale, A., Siebenhaar, F., Kosanke, K., Aichler, M., Radrich, K., Heydrich, S., Schiemann, M., Wildgruber, M., Cardioprotective c-kit(+) bone marrow cells attenuate apoptosis after acute myocardial infarction in mice - In vivo assessment with fluorescence molecular imaging (2013) Theranostics, 3, pp. 903-913. , 3841340; Amir, G., Ma, X., Reddy, V.M., Hanley, F.L., Reinhartz, O., Ramamoorthy, C., Riemer, R.K., Dynamics of human myocardial progenitor cell populations in the neonatal period (2008) Ann Thorac Surg, 86, pp. 1311-1319. , 18805183; Angert, D., Berretta, R.M., Kubo, H., Zhang, H., Chen, X., Wang, W., Ogorek, B., Houser, S.R., Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells (2011) Circ Res, 108, pp. 1226-1237. , 3322670; Barile, L., Chimenti, I., Gaetani, R., Forte, E., Miraldi, F., Frati, G., Messina, E., Giacomello, A., Cardiac stem cells: Isolation, expansion and experimental use for myocardial regeneration (2007) Nat Clin Pract Cardiovasc Med, 4, pp. 9-S14; Bearzi, C., Rota, M., Hosoda, T., Tillmanns, J., Nascimbene, A., De Angelis, A., Yasuzawa-Amano, S., Anversa, P., Human cardiac stem cells (2007) Proc Natl Acad Sci USA, 104, pp. 14068-14073. , 1955818; Beltrami, A.P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., Kasahara, H., Anversa, P., Adult cardiac stem cells are multipotent and support myocardial regeneration (2003) Cell, 114, pp. 763-776; Bergmann, O., Bhardwaj, R.D., Bernard, S., Zdunek, S., Barnabe-Heider, F., Walsh, S., Zupicich, J., Frisen, J., Evidence for cardiomyocyte renewal in humans (2009) Science, 324, pp. 98-102. , 2991140; Besmer, P., Murphy, J.E., George, P.C., Qiu, F.H., Bergold, P.J., Lederman, L., Snyder, Jr.H.W., Hardy, W.D., A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family (1986) Nature, 320, pp. 415-421; Bianco, P., Riminucci, M., Gronthos, S., Robey, P.G., Bone marrow stromal stem cells: Nature, biology, and potential applications (2001) Stem Cells, 19, pp. 180-192; Blume-Jensen, P., Claesson-Welsh, L., Siegbahn, A., Zsebo, K.M., Westermark, B., Heldin, C.H., Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis (1991) EMBO J, 10, pp. 4121-4128. , 453162 1:CAS:528:DyaK38Xkt1ersrs%3D 1721869; Blume-Jensen, P., Ronnstrand, L., Gout, I., Waterfield, M.D., Heldin, C.H., Modulation of kit/stem cell factor receptor-induced signaling by protein kinase C (1994) J Biol Chem, 269, pp. 21793-21802. , 7520444; Bolli, R., Chugh, A.R., D'Amario, D., Loughran, J.H., Stoddard, M.F., Ikram, S., Beache, G.M., Anversa, P., Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial (2011) Lancet, 378, pp. 1847-1857. , 3614010; Bolli, R., Tang, X.L., Sanganalmath, S.K., Rimoldi, O., Mosna, F., Abdel-Latif, A., Jneid, H., Kajstura, J., Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy (2013) Circulation, 128, pp. 122-131; Bollini, S., Smart, N., Riley, P.R., Resident cardiac progenitor cells: At the heart of regeneration (2011) J Mol Cell Cardiol, 50, pp. 296-303; Boni, A., Urbanek, K., Nascimbene, A., Hosoda, T., Zheng, H., Delucchi, F., Amano, K., Leri, A., Notch1 regulates the fate of cardiac progenitor cells (2008) Proc Natl Acad Sci USA, 105, pp. 15529-15534. , 2563067; Bu, L., Jiang, X., Martin-Puig, S., Caron, L., Zhu, S., Shao, Y., Roberts, D.J., Chien, K.R., Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages (2009) Nature, 460, pp. 113-117; Cencioni, C., Melchionna, R., Straino, S., Romani, M., Cappuzzello, C., Annese, V., Wu, J.C., Capogrossi, M.C., Ex vivo acidic preconditioning enhances bone marrow ckit+ cell therapeutic potential via increased CXCR4 expression (2012) Eur Heart J; Chen, Z., Pan, X., Yao, Y., Yan, F., Chen, L., Huang, R., Ma, G., Epigenetic regulation of cardiac progenitor cells marker c-kit by stromal cell derived factor-1alpha (2013) PLoS One, 8, p. 69134. , 3722185; Chen, Z., Pan, X., Yao, Y., Yan, F., Chen, L., Huang, R., Ma, G., Regulation of c-kit+ progenitor cells by stromal cell derived factor-1alpha in adult murine heart (2014) Heart Lung Circ, 23, pp. 75-81; Cheng, K., Malliaras, K., Li, T.S., Sun, B., Houde, C., Galang, G., Smith, J., Marban, E., Magnetic enhancement of cell retention, engraftment, and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion (2012) Cell Transplant, 21, pp. 1121-1135. , 4323149; Chugh, A.R., Beache, G.M., Loughran, J.H., Mewton, N., Elmore, J.B., Kajstura, J., Pappas, P., Bolli, R., Administration of cardiac stem cells in patients with ischemic cardiomyopathy: The SCIPIO trial: Surgical aspects and interim analysis of myocardial function and viability by magnetic resonance (2012) Circulation, 126, pp. 54-S64. , 3448934; Copeland, N.G., Gilbert, D.J., Cho, B.C., Donovan, P.J., Jenkins, N.A., Cosman, D., Anderson, D., Williams, D.E., Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles (1990) Cell, 63, pp. 175-183. , 1698554 (0092-8674(90)90298-S); Cottage, C.T., Neidig, L., Sundararaman, B., Din, S., Joyo, A.Y., Bailey, B., Gude, N., Sussman, M.A., Increased mitotic rate coincident with transient telomere lengthening resulting from pim-1 overexpression in cardiac progenitor cells (2012) Stem Cells, 30, pp. 2512-2522. , 3479348; Czechowicz, A., Kraft, D., Weissman, I.L., Bhattacharya, D., Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches (2007) Science, 318, pp. 1296-1299. , 2527021; D'Amario, D., Fiorini, C., Campbell, P.M., Goichberg, P., Sanada, F., Zheng, H., Hosoda, T., Anversa, P., Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies (2011) Circ Res, 108, pp. 857-861. , 3074470; Dawn, B., Stein, A.B., Urbanek, K., Rota, M., Whang, B., Rastaldo, R., Torella, D., Bolli, R., Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function (2005) Proc Natl Acad Sci USA, 102, pp. 3766-3771. , 553298; De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., Ferreira-Martins, J., Anversa, P., Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function (2010) Circulation, 121, pp. 276-292. , 2810713; De Falco, E., Porcelli, D., Torella, A.R., Straino, S., Iachininoto, M.G., Orlandi, A., Truffa, S., Pesce, M., SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells (2004) Blood, 104, pp. 3472-3482. , 15284120; Deb, A., Wang, S., Skelding, K.A., Miller, D., Simper, D., Caplice, N.M., Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients (2003) Circulation, 107, pp. 1247-1249. , 12628942; Dey, D., Han, L., Bauer, M., Sanada, F., Oikonomopoulos, A., Hosoda, T., Unno, K., Wu, J.C., Dissecting the molecular relationship among various cardiogenic progenitor cells (2013) Circ Res, 112, pp. 1253-1262. , 3657513; Di Filippo, C., Luongo, M., Marfella, R., Ferraraccio, F., Lettieri, B., Capuano, A., Rossi, F., D'Amico, M., Oxygen/ozone protects the heart from acute myocardial infarction through local increase of eNOS activity and endothelial progenitor cells recruitment (2010) Naunyn Schmiedebergs Arch Pharmacol, 382, pp. 287-291; Di Meglio, F., Castaldo, C., Nurzynska, D., Romano, V., Miraglia, R., Bancone, C., Langella, G., Montagnani, S., Epithelial-mesenchymal transition of epicardial mesothelium is a source of cardiac CD117-positive stem cells in adult human heart (2010) J Mol Cell Cardiol, 49, pp. 719-727. , 20566360; Dimmeler, S., Leri, A., Aging and disease as modifiers of efficacy of cell therapy (2008) Circ Res, 102, pp. 1319-1330. , 2728476; Ellison, G.M., Torella, D., Dellegrottaglie, S., Perez-Martinez, C., Perez De Prado, A., Vicinanza, C., Purushothaman, S., Nadal-Ginard, B., Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart (2011) J Am Coll Cardiol, 58, pp. 977-986; Ellison, G.M., Vicinanza, C., Smith, A.J., Aquila, I., Leone, A., Waring, C.D., Henning, B.J., Nadal-Ginard, B., Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair (2013) Cell, 154, pp. 827-842; Fazel, S., Cimini, M., Chen, L., Li, S., Angoulvant, D., Fedak, P., Verma, S., Li, R.K., Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines (2006) J Clin Invest, 116, pp. 1865-1877. , 1483161; Filippo, C.D., Perretti, M., Rossi, F., Ferraraccio, F., Motterlini, R., D'Amico, M., Acute myocardial infarction in streptozotocin-induced hyperglycaemic rats: Protection by a carbon monoxide-releasing molecule (CORM-3) (2012) Naunyn Schmiedebergs Arch Pharmacol, 385, pp. 137-144. , 22038495; Fischer, K.M., Cottage, C.T., Wu, W., Din, S., Gude, N.A., Avitabile, D., Quijada, P., Sussman, M.A., Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase (2009) Circulation, 120, pp. 2077-2087. , 2787902; Fransioli, J., Bailey, B., Gude, N.A., Cottage, C.T., Muraski, J.A., Emmanuel, G., Wu, W., Sussman, M.A., Evolution of the c-kit-positive cell response to pathological challenge in the myocardium (2008) Stem Cells, 26, pp. 1315-1324. , 4037162; Gambini, E., Pesce, M., Persico, L., Bassetti, B., Gambini, A., Alamanni, F., Agrifoglio, M., Pompilio, G., Patient profile modulates cardiac c-kit(+) progenitor cell availability and amplification potential (2012) Transl Res, 160, pp. 363-373; Gambini, E., Pompilio, G., Biondi, A., Alamanni, F., Capogrossi, M.C., Agrifoglio, M., Pesce, M., C-kit+ cardiac progenitors exhibit mesenchymal markers and preferential cardiovascular commitment (2011) Cardiovasc Res, 89, pp. 362-373; Gersh, B.J., Sliwa, K., Mayosi, B.M., Yusuf, S., Novel therapeutic concepts: The epidemic of cardiovascular disease in the developing world: Global implications (2010) Eur Heart J, 31, pp. 642-648. , 20176800; Gorbunov, N., Petrovski, G., Gurusamy, N., Ray, D., Do Kim, H., Das, D.K., Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells (2012) J Cell Mol Med, 16, pp. 174-184. , 3823103; Grazia, T.J., Plenter, R.J., Lepper, H.M., Victorino, F., Miyamoto, S.D., Crossno, Jr.J.T., Pietra, B.A., Zamora, M.R., Prolongation of cardiac allograft survival by a novel population of autologous CD117+ bone marrow-derived progenitor cells (2011) Am J Transplant, 11, pp. 34-44. , 3059253; Hausenloy, D.J., Tsang, A., Mocanu, M.M., Yellon, D.M., Ischemic preconditioning protects by activating prosurvival kinases at reperfusion (2005) Am J Physiol Heart Circ Physiol, 288, pp. 971-H976; He, J.Q., Vu, D.M., Hunt, G., Chugh, A., Bhatnagar, A., Bolli, R., Human cardiac stem cells isolated from atrial appendages stably express c-kit (2011) PLoS One, 6, p. 27719. , 3225366; He, X.Z., Wang, H.Y., Shen, Y., Zhong, Q.H., Fang, S.X., Peng, W.J., Xue, J.F., Cardiomyocyte progenitors in a canine pulmonary vein model of persistent atrial fibrillation (2012) J Cardiol, 60, pp. 242-247. , 22704544; Heger, K., Seidler, B., Vahl, J.C., Schwartz, C., Kober, M., Klein, S., Voehringer, D., Schmidt-Supprian, M., CreER(T2) expression from within the c-kit gene locus allows efficient inducible gene targeting in and ablation of mast cells (2014) Eur J Immunol, 44, pp. 296-306; Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N.R., Crystal, R.G., Rafii, S., Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand (2002) Cell, 109, pp. 625-637. , 2826110 1:CAS:528:DC%2BD38XksVGgs7w%3D 12062105 (S0092867402007547); Heissig, B., Werb, Z., Rafii, S., Hattori, K., Role of c-kit/kit ligand signaling in regulating vasculogenesis (2003) Thromb Haemost, 90, pp. 570-576; Hesse, M., Fleischmann, B.K., Kotlikoff, M.I., Concise review: The role of c-kit expressing cells in heart repair at the neonatal and adult stage (2014) Stem Cells, 32, pp. 1701-1712; Hou, X., Appleby, N., Fuentes, T., Longo, L.D., Bailey, L.L., Hasaniya, N., Kearns-Jonker, M., Isolation, characterization, and spatial distribution of cardiac progenitor cells in the sheep heart (2012) J Clin Exp Cardiolog, S6; Hu, X., Sun, A., Xie, X., Huang, Z., Jia, J., Yao, R., Ge, J., Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats (2013) J Cardiovasc Pharmacol Ther, 18, pp. 162-176; Huang, C., Zhang, X., Ramil, J.M., Rikka, S., Kim, L., Lee, Y., Gude, N.A., Gustafsson, A.B., Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice (2010) Circulation, 121, pp. 675-683. , 2834271; Huang, E., Nocka, K., Beier, D.R., Chu, T.Y., Buck, J., Lahm, H.W., Wellner, D., Besmer, P., The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus (1990) Cell, 63, pp. 225-233. , 1698557 (0092-8674(90)90303-V); Huizinga, J.D., Thuneberg, L., Kluppel, M., Malysz, J., Mikkelsen, H.B., Bernstein, A., W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity (1995) Nature, 373, pp. 347-349; Ikuta, K., Weissman, I.L., Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation (1992) Proc Natl Acad Sci USA, 89, pp. 1502-1506. , 48479 1:CAS:528:DyaK38Xhs1Ojsb4%3D 1371359; Ishikawa, K., Fish, K., Aguero, J., Yaniz-Galende, E., Jeong, D., Kho, C., Tilemann, L., Hajjar, R.J., Stem cell factor gene transfer improves cardiac function after myocardial infarction in swine (2014) Circ Heart Fail, , 25342737; Itzhaki-Alfia, A., Leor, J., Raanani, E., Sternik, L., Spiegelstein, D., Netser, S., Holbova, R., Barbash, I.M., Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells (2009) Circulation, 120, pp. 2559-2566. , 19996019; Jesty, S.A., Steffey, M.A., Lee, F.K., Breitbach, M., Hesse, M., Reining, S., Lee, J.C., Kotlikoff, M.I., C-kit+ precursors support postinfarction myogenesis in the neonatal, but not adult, heart (2012) Proc Natl Acad Sci USA, 109, pp. 13380-13385. , 3421216; Kaminski, A., Ma, N., Donndorf, P., Lindenblatt, N., Feldmeier, G., Ong, L.L., Furlani, D., Steinhoff, G., Endothelial NOS is required for SDF-1alpha/CXCR4-mediated peripheral endothelial adhesion of c-kit+ bone marrow stem cells (2008) Lab Invest, 88, pp. 58-69; Klein, S., Seidler, B., Kettenberger, A., Sibaev, A., Rohn, M., Feil, R., Allescher, H.D., Saur, D., Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity (2013) Nat Commun, 4, p. 1630. , 23535651; Koike, T., Hirai, K., Morita, Y., Nozawa, Y., Stem cell factor-induced signal transduction in rat mast cells. Activation of phospholipase D but not phosphoinositide-specific phospholipase C in c-kit receptor stimulation (1993) J Immunol, 151, pp. 359-366. , 7686941; Kwon, C., Cheng, P., King, I.N., Andersen, P., Shenje, L., Nigam, V., Srivastava, D., Notch post-translationally regulates beta-catenin protein in stem and progenitor cells (2011) Nat Cell Biol, 13, pp. 1244-1251. , 3187850; Kwon, C., Qian, L., Cheng, P., Nigam, V., Arnold, J., Srivastava, D., A regulatory pathway involving Notch1/beta-catenin/Isl1 determines cardiac progenitor cell fate (2009) Nat Cell Biol, 11, pp. 951-957. , 2748816; Laflamme, M.A., Gold, J., Xu, C., Hassanipour, M., Rosler, E., Police, S., Muskheli, V., Murry, C.E., Formation of human myocardium in the rat heart from human embryonic stem cells (2005) Am J Pathol, 167, pp. 663-671. , 1698736; Lagostena, L., Avitabile, D., De Falco, E., Orlandi, A., Grassi, F., Iachininoto, M.G., Ragone, G., Capogrossi, M.C., Electrophysiological properties of mouse bone marrow c-kit+ cells co-cultured onto neonatal cardiac myocytes (2005) Cardiovasc Res, 66, pp. 482-492; Lemmon, M.A., Pinchasi, D., Zhou, M., Lax, I., Schlessinger, J., Kit receptor dimerization is driven by bivalent binding of stem cell factor (1997) J Biol Chem, 272, pp. 6311-6317. , 9045650; Lennartsson, J., Blume-Jensen, P., Hermanson, M., Ponten, E., Carlberg, M., Ronnstrand, L., Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction (1999) Oncogene, 18, pp. 5546-5553; Lennartsson, J., Ronnstrand, L., Stem cell factor receptor/c-kit: From basic science to clinical implications (2012) Physiol Rev, 92, pp. 1619-1649; Leri, A., Kajstura, J., Anversa, P., Cardiac stem cells and mechanisms of myocardial regeneration (2005) Physiol Rev, 85, pp. 1373-1416; Leri, A., Kajstura, J., Anversa, P., Role of cardiac stem cells in cardiac pathophysiology: A paradigm shift in human myocardial biology (2011) Circ Res, 109, pp. 941-961. , 3299091; Lev, S., Givol, D., Yarden, Y., Interkinase domain of kit contains the binding site for phosphatidylinositol 3 kinase (1992) Proc Natl Acad Sci USA, 89, pp. 678-682. , 48302 1:CAS:528:DyaK38XnvVylsw%3D%3D 1370584; Li, M., Naqvi, N., Yahiro, E., Liu, K., Powell, P.C., Bradley, W.E., Martin, D.I., Husain, A., C-kit is required for cardiomyocyte terminal differentiation (2008) Circ Res, 102, pp. 677-685. , 2763373; Li, Q., Guo, Y., Ou, Q., Chen, N., Wu, W.J., Yuan, F., O'Brien, E., Bolli, R., Intracoronary administration of cardiac stem cells in mice: A new, improved technique for cell therapy in murine models (2011) Basic Res Cardiol, 106, pp. 849-864. , 3640450; Li, T.S., Cheng, K., Lee, S.T., Matsushita, S., Davis, D., Malliaras, K., Zhang, Y., Marban, E., Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair (2010) Stem Cells, 28, pp. 2088-2098. , 3405979; Li, T.S., Kubo, M., Ueda, K., Murakami, M., Mikamo, A., Hamano, K., Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure (2010) J Thorac Cardiovasc Surg, 139, pp. 459-465. , 19748631; Limana, F., Esposito, G., D'Arcangelo, D., Di Carlo, A., Romani, S., Melillo, G., Mangoni, A., Capogrossi, M.C., HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3 (2011) PLoS One, 6, p. 19845. , 3120764; Limana, F., Esposito, G., Fasanaro, P., Foglio, E., Arcelli, D., Voellenkle, C., Di Carlo, A., Capogrossi, M.C., Transcriptional profiling of HMGB1-induced myocardial repair identifies a key role for Notch signaling (2013) Mol Ther, 21, pp. 1841-1851. , 3808142; Limana, F., Germani, A., Zacheo, A., Kajstura, J., Di Carlo, A., Borsellino, G., Leoni, O., Capogrossi, M.C., Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac c-kit+ cell proliferation and differentiation (2005) Circ Res, 97, pp. 73-e83; Limana, F., Zacheo, A., Mocini, D., Mangoni, A., Borsellino, G., Diamantini, A., De Mori, R., Capogrossi, M.C., Identification of myocardial and vascular precursor cells in human and mouse epicardium (2007) Circ Res, 101, pp. 1255-1265; Linke, A., Muller, P., Nurzynska, D., Casarsa, C., Torella, D., Nascimbene, A., Castaldo, C., Anversa, P., Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function (2005) Proc Natl Acad Sci USA, 102, pp. 8966-8971. , 1157041; Makkar, R.R., Smith, R.R., Cheng, K., Malliaras, K., Thomson, L.E., Berman, D., Czer, L.S., Marban, E., Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial (2012) Lancet, 379, pp. 895-904. , 4326004; Manova, K., Bachvarova, R.F., Huang, E.J., Sanchez, S., Pronovost, S.M., Velazquez, E., McGuire, B., Besmer, P., C-kit receptor and ligand expression in postnatal development of the mouse cerebellum suggests a function for c-kit in inhibitory interneurons (1992) J Neurosci, 12, pp. 4663-4676. , 1281492; Mathur, A., Martin, J.F., Stem cells and repair of the heart (2004) Lancet, 364, pp. 183-192; Matsuda, T., Miyagawa, S., Fukushima, S., Kitagawa-Sakakida, S., Akimaru, H., Horii-Komatsu, M., Kawamoto, A., Sawa, Y., Human cardiac stem cells with reduced notch signaling show enhanced therapeutic potential in a rat acute infarction model (2013) Circ J, 78, pp. 222-231. , 24107361 (DN/JST.JSTAGE/circj/CJ-13-0534); Mishra, R., Vijayan, K., Colletti, E.J., Harrington, D.A., Matthiesen, T.S., Simpson, D., Goh, S.K., Kaushal, S., Characterization and functionality of cardiac progenitor cells in congenital heart patients (2011) Circulation, 123, pp. 364-373. , 3320857; Miyamoto, S., Kawaguchi, N., Ellison, G.M., Matsuoka, R., Shin'Oka, T., Kurosawa, H., Characterization of long-term cultured c-kit+ cardiac stem cells derived from adult rat hearts (2010) Stem Cells Dev, 19, pp. 105-116; Mohsin, S., Khan, M., Nguyen, J., Alkatib, M., Siddiqi, S., Hariharan, N., Wallach, K., Sussman, M.A., Rejuvenation of human cardiac progenitor cells with Pim-1 kinase (2013) Circ Res, 113, pp. 1169-1179. , 3999968; Molkentin, J.D., Letter by Molkentin regarding article, ""the absence of evidence is not evidence of absence: The pitfalls of Cre Knock-Ins in the c-Kit Locus"" (2014) Circ Res, 115, pp. 21-e23; Molkentin, J.D., Houser, S.R., Are resident c-kit+ cardiac stem cells really all that are needed to mend a broken heart? (2013) Circ Res, 113, pp. 1037-1039; Molkentin, J.D., House, S.R., Response to Torella et al. (2014) Circ Res, 114, p. 27; Moscoso, I., Tejados, N., Barreiro, O., Sepulveda, P., Izarra, A., Calvo, E., Dorronsoro, A., Bernad, A., Podocalyxin-like protein 1 is a relevant marker for human c-kit cardiac stem cells (2013) J Tissue Eng Regen Med, , 23897803; Muller-Ehmsen, J., Krausgrill, B., Burst, V., Schenk, K., Neisen, U.C., Fries, J.W., Fleischmann, B.K., Schwinger, R.H., Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction (2006) J Mol Cell Cardiol, 41, pp. 876-884. , 16973174; Murry, C.E., Soonpaa, M.H., Reinecke, H., Nakajima, H., Nakajima, H.O., Rubart, M., Pasumarthi, K.B., Field, L.J., Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts (2004) Nature, 428, pp. 664-668; Nadal-Ginard, B., Ellison, G.M., Torella, D., Absence of evidence is not evidence of absence: Pitfalls of cre knock-ins in the c-Kit locus (2014) Circ Res, 115, pp. 415-418; Nadal-Ginard, B., Ellison, G.M., Torella, D., Response to Molkentin's Letter to the Editor Regarding Article, ""the Absence of Evidence is Not Evidence of Absence: The Pitfalls of Cre Knock-Ins in the c-kit Locus"" (2014) Circ Res, 115, pp. 38-e39; Papayannopoulou, T., Priestley, G.V., Nakamoto, B., Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway (1998) Blood, 91, pp. 2231-2239. , 9516120; Penicka, M., Widimsky, P., Kobylka, P., Kozak, T., Lang, O., Images in cardiovascular medicine. Early tissue distribution of bone marrow mononuclear cells after transcoronary transplantation in a patient with acute myocardial infarction (2005) Circulation, 112, pp. 63-e65. , 16043651; Philo, J.S., Wen, J., Wypych, J., Schwartz, M.G., Mendiaz, E.A., Langley, K.E., Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, Kit (1996) J Biol Chem, 271, pp. 6895-6902. , 8636116; Porrello, E.R., Mahmoud, A.I., Simpson, E., Hill, J.A., Richardson, J.A., Olson, E.N., Sadek, H.A., Transient regenerative potential of the neonatal mouse heart (2011) Science, 331, pp. 1078-1080. , 3099478; Potten, C.S., Loeffler, M., Stem cells: Attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt (1990) Development, 110, pp. 1001-1020. , 2100251; Quaini, F., Urbanek, K., Beltrami, A.P., Finato, N., Beltrami, C.A., Nadal-Ginard, B., Kajstura, J., Anversa, P., Chimerism of the transplanted heart (2002) N Engl J Med, 346, pp. 5-15. , 11777997; Quijada, P., Toko, H., Fischer, K.M., Bailey, B., Reilly, P., Hunt, K.D., Gude, N.A., Sussman, M.A., Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells (2012) Circ Res, 111, pp. 77-86. , 3398618; Rota, M., Kajstura, J., Hosoda, T., Bearzi, C., Vitale, S., Esposito, G., Iaffaldano, G., Anversa, P., Bone marrow cells adopt the cardiomyogenic fate in vivo (2007) Proc Natl Acad Sci USA, 104, pp. 17783-17788. , 2077031; Rota, M., Lecapitaine, N., Hosoda, T., Boni, A., De Angelis, A., Padin-Iruegas, M.E., Esposito, G., Kajstura, J., Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene (2006) Circ Res, 99, pp. 42-52; Rota, M., Padin-Iruegas, M.E., Misao, Y., De Angelis, A., Maestroni, S., Ferreira-Martins, J., Fiumana, E., Kajstura, J., Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function (2008) Circ Res, 103, pp. 107-116. , 2747796; Sanada, F., Kim, J., Czarna, A., Chan, N.Y., Signore, S., Ogorek, B., Isobe, K., Leri, A., C-kit-positive cardiac stem cells nested in hypoxic niches are activated by stem cell factor reversing the aging myopathy (2014) Circ Res, 114, pp. 41-55. , 3959163; Sandlow, J.I., Feng, H.L., Cohen, M.B., Sandra, A., Expression of c-kit and its ligand, stem cell factor, in normal and subfertile human testicular tissue (1996) J Androl, 17, pp. 403-408. , 8889703; Sandstedt, J., Jonsson, M., Kajic, K., Sandstedt, M., Lindahl, A., Dellgren, G., Jeppsson, A., Asp, J., Left atrium of the human adult heart contains a population of side population cells (2012) Basic Res Cardiol, 107, p. 255. , 22361742; Sanganalmath, S.K., Bolli, R., Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions (2013) Circ Res, 113, pp. 810-834. , 3892665; Sato, H., Shiraishi, I., Takamatsu, T., Hamaoka, K., Detection of TUNEL-positive cardiomyocytes and c-kit-positive progenitor cells in children with congenital heart disease (2007) J Mol Cell Cardiol, 43, pp. 254-261; Scherschel, J.A., Soonpaa, M.H., Srour, E.F., Field, L.J., Rubart, M., Adult bone marrow-derived cells do not acquire functional attributes of cardiomyocytes when transplanted into peri-infarct myocardium (2008) Mol Ther, 16, pp. 1129-1137. , 2574931; Senyo, S.E., Steinhauser, M.L., Pizzimenti, C.L., Yang, V.K., Cai, L., Wang, M., Wu, T.D., Lee, R.T., Mammalian heart renewal by pre-existing cardiomyocytes (2013) Nature, 493, pp. 433-436. , 3548046; Simpson, D.L., Mishra, R., Sharma, S., Goh, S.K., Deshmukh, S., Kaushal, S., A strong regenerative ability of cardiac stem cells derived from neonatal hearts (2012) Circulation, 126, pp. 46-S53; Singla, D.K., Abdelli, L.S., Embryonic stem cells and released factors stimulate c-kit/FLK-1 progenitor cells and promote neovascularization in doxorubicin-induced cardiomyopathy (2014) Cell Transplant; Smith, A.J., Lewis, F.C., Aquila, I., Waring, C.D., Nocera, A., Agosti, V., Nadal-Ginard, B., Ellison, G.M., Isolation and characterization of resident endogenous c-kit+ cardiac stem cells from the adult mouse and rat heart (2014) Nat Protoc, 9, pp. 1662-1681; Smits, A.M., Van Laake, L.W., Den Ouden, K., Schreurs, C., Szuhai, K., Van Echteld, C.J., Mummery, C.L., Goumans, M.J., Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium (2009) Cardiovasc Res, 83, pp. 527-535; Song, D., Li, Y., Cao, J., Han, Z., Gao, L., Xu, Z., Yin, Z., Wang, C., Effect of iron deficiency on c-kit(+) cardiac stem cells in vitro (2013) PLoS One, 8, p. 65721. , 3677875; Sukhacheva, T.V., Chudinovskikh, Y.A., Eremeeva, M.V., Serov, R.A., Samsonova, M.V., Chernyaev, A.L., Kim, A.I., Bockeria, L.A., Resident cardiomyocyte precursor stem cells in the myocardium of infants of the first two years of life with tetralogy of Fallot (2012) Bull Exp Biol Med, 154, pp. 158-162. , 23330114; Tallini, Y.N., Greene, K.S., Craven, M., Spealman, A., Breitbach, M., Smith, J., Fisher, P.J., Kotlikoff, M.I., C-kit expression identifies cardiovascular precursors in the neonatal heart (2009) Proc Natl Acad Sci USA, 106, pp. 1808-1813. , 2644119; Tan, J.C., Nocka, K., Ray, P., Traktman, P., Besmer, P., The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase (1990) Science, 247, pp. 209-212. , 1688471; Tang, X.L., Rokosh, G., Sanganalmath, S.K., Yuan, F., Sato, H., Mu, J., Dai, S., Bolli, R., Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction (2010) Circulation, 121, pp. 293-305. , 2814341; Tang, Y.L., Zhu, W., Cheng, M., Chen, L., Zhang, J., Sun, T., Kishore, R., Qin, G., Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression (2009) Circ Res, 104, pp. 1209-1216. , 2756190; Taylor, D.A., Atkins, B.Z., Hungspreugs, P., Jones, T.R., Reedy, M.C., Hutcheson, K.A., Glower, D.D., Kraus, W.E., Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation (1998) Nat Med, 4, pp. 929-933. , 9701245; Tillmanns, J., Rota, M., Hosoda, T., Misao, Y., Esposito, G., Gonzalez, A., Vitale, S., Anversa, P., Formation of large coronary arteries by cardiac progenitor cells (2008) Proc Natl Acad Sci USA, 105, pp. 1668-1673. , 2234202; Toko, H., Hariharan, N., Konstandin, M.H., Ormachea, L., McGregor, M., Gude, N.A., Sundararaman, B., Sussman, M.A., Differential regulation of cellular senescence and differentiation by prolyl isomerase Pin1 in cardiac progenitor cells (2014) J Biol Chem, 289, pp. 5348-5356. , 3937613; Torella, D., Ellison, G.M., Karakikes, I., Nadal-Ginard, B., Resident cardiac stem cells (2007) Cell Mol Life Sci, 64, pp. 661-673; Torella, D., Ellison, G.M., Nadal-Ginard, B., Adult c-kit(pos) cardiac stem cells fulfill Koch's postulates as causal agents for cardiac regeneration (2014) Circ Res, 114, pp. 24-e26; Trieselmann, N.Z., Soboloff, J., Berger, S.A., Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation (2003) Cell Mol Life Sci, 60, pp. 759-766. , 12785722; Urbanek, K., Cabral-Da-Silva, M.C., Ide-Iwata, N., Maestroni, S., Delucchi, F., Zheng, H., Ferreira-Martins, J., Leri, A., Inhibition of notch1-dependent cardiomyogenesis leads to a dilated myopathy in the neonatal heart (2010) Circ Res, 107, pp. 429-441. , 2919068; Urbanek, K., Cesselli, D., Rota, M., Nascimbene, A., De Angelis, A., Hosoda, T., Bearzi, C., Leri, A., Stem cell niches in the adult mouse heart (2006) Proc Natl Acad Sci USA, 103, pp. 9226-9231. , 1474010; Urbanek, K., Torella, D., Sheikh, F., De Angelis, A., Nurzynska, D., Silvestri, F., Beltrami, C.A., Anversa, P., Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure (2005) Proc Natl Acad Sci USA, 102, pp. 8692-8697. , 1150816; Van Berlo, J.H., Kanisicak, O., Maillet, M., Vagnozzi, R.J., Karch, J., Lin, S.C., Middleton, R.C., Molkentin, J.D., C-kit+ cells minimally contribute cardiomyocytes to the heart (2014) Nature, 509, pp. 337-341. , 4127035; Van Vliet, P., Roccio, M., Smits, A.M., Van Oorschot, A.A., Metz, C.H., Van Veen, T.A., Sluijter, J.P., Goumans, M.J., Progenitor cells isolated from the human heart: A potential cell source for regenerative therapy (2008) Neth Heart J, 16, pp. 163-169. , 2431168 18566670; Verduci, L., Loparco, G., Pozzoli, O., Pompilio, G., Capogrossi, M.C., Identification of Kita (c-kit) positive cells in the heart of adult zebrafish (2014) Int J Cardiol, 175, pp. 204-205. , 24820757; Waskow, C., Paul, S., Haller, C., Gassmann, M., Rodewald, H.R., Viable c-kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis (2002) Immunity, 17, pp. 277-288. , 12354381 (S1074761302003862); Wichmann, C., Quagliano-Lo Coco, I., Yildiz, O., Chen-Wichmann, L., Weber, H., Syzonenko, T., Doring, C., Grez, M., Activating c-kit mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors (2014) Leukemia, , 4320295; Williams, D.E., Eisenman, J., Baird, A., Rauch, C., Van Ness, K., March, C.J., Park, L.S., Boswell, H.S., Identification of a ligand for the c-kit proto-oncogene (1990) Cell, 63, pp. 167-174. , 1698553 (0092-8674(90)90297-R); Xiang, F.L., Lu, X., Liu, Y., Feng, Q., Cardiomyocyte-specific overexpression of human stem cell factor protects against myocardial ischemia and reperfusion injury (2013) Int J Cardiol, 168, pp. 3486-3494. , 23680593; Yan, F., Yao, Y., Chen, L., Li, Y., Sheng, Z., Ma, G., Hypoxic preconditioning improves survival of cardiac progenitor cells: Role of stromal cell derived factor-1alpha-CXCR4 axis (2012) PLoS One, 7, p. 37948. , 3399836; Yarden, Y., Kuang, W.J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T.J., Chen, E., Ullrich, A., Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand (1987) EMBO J, 6, pp. 3341-3351. , 553789 1:CAS:528:DyaL1cXhtVOhtLs%3D 2448137; Yousef, M., Schannwell, C.M., Kostering, M., Zeus, T., Brehm, M., Strauer, B.E., The BALANCE Study: Clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction (2009) J Am Coll Cardiol, 53, pp. 2262-2269. , 19520249; Zakharova, L., Nural-Guvener, H., Nimlos, J., Popovic, S., Gaballa, M.A., Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-kit+ cells (2013) J Am Heart Assoc, 2, p. 000317. , 3835238; Zhang, G., Nakamura, Y., Wang, X., Hu, Q., Suggs, L.J., Zhang, J., Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart (2007) Tissue Eng, 13, pp. 2063-2071; Zhang, J., Wang, J., Study on Panax notoginseng mobilizing marrow stem cells efferens efficiency of acute myocardial infarction in rats (2009) Zhongguo Zhong Yao Za Zhi, 34, pp. 893-895. , 19623990; Zhang, L., Chen, B., Zhao, Y., Dubielecka, P.M., Wei, L., Qin, G.J., Chin, Y.E., Zhao, T.C., Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts (2012) J Biol Chem, 287, pp. 39338-39348. , 3501087; Zhang, L., Qin, X., Zhao, Y., Fast, L., Zhuang, S., Liu, P., Cheng, G., Zhao, T.C., Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis (2012) J Pharmacol Exp Ther, 341, pp. 285-293. , 3310703; Zhang, Y., Li, T.S., Lee, S.T., Wawrowsky, K.A., Cheng, K., Galang, G., Malliaras, K., Marban, E., Dedifferentiation and proliferation of mammalian cardiomyocytes (2010) PLoS One, 5, p. 12559. , 2933247; Zhang, Y.H., Zhang, G.W., Gu, T.X., Li-Ling, J., Wen, T., Zhao, Y., Wang, C., Liu, B., Exogenous basic fibroblast growth factor promotes cardiac stem cell-mediated myocardial regeneration after miniswine acute myocardial infarction (2011) Coron Artery Dis, 22, pp. 279-285. , 21422919; Zhang, Y.Y., Li, G., Che, H., Sun, H.Y., Li, X., Au, W.K., Xiao, G.S., Li, G.R., Characterization of functional ion channels in human cardiac c-kit+ progenitor cells (2014) Basic Res Cardiol, 109, p. 407. , 24691761; Zsebo, K.M., Williams, D.A., Geissler, E.N., Broudy, V.C., Martin, F.H., Atkins, H.L., Hsu, R.Y., Murdock, D.C., Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor (1990) Cell, 63, pp. 213-224. , 1698556 (0092-8674(90)90302-U)",Review,Scopus,2-s2.0-84928501284
"Thorpy M.J.","Update on Therapy for Narcolepsy",2015,"Current Treatment Options in Neurology","17","5",,"","",12,,10.1007/s11940-015-0347-4,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927594973&partnerID=40&md5=b9c90ae094d9e95aa6d508b1e442e5d7","Sleep–Wake Disorders Center, Montefiore Medical CenterBronx, NY, United States; Albert Einstein College of Medicine, 111 East 210thSt. Bronx, NY, United States","Thorpy, M.J., Sleep–Wake Disorders Center, Montefiore Medical CenterBronx, NY, United States, Albert Einstein College of Medicine, 111 East 210thSt. Bronx, NY, United States","Narcolepsy is a severe, incurable, neurological disorder that is treated by pharmacological management of its symptoms. The main symptoms are excessive daytime sleepiness (EDS) and cataplexy, although addition symptoms that may require treatment include sleep paralysis, hypnagogic hallucinations, and disturbed nocturnal sleep. Sodium oxybate and modafinil/armodafinil are the first-line treatments for EDS, and sodium oxybate for cataplexy. Sodium oxybate treats all the symptoms of narcolepsy, whereas modafinil is effective for EDS only. Alternative medications for EDS include methylphenidate or amphetamines such as dextroamphetamine, lisdexamfetamine, methamphetamine, or combination amphetamine salts. Non-FDA approved medications for cataplexy include norepinephrine reuptake inhibitors such as venlafaxine or atomoxetine. Combination therapy can be more effective for sleepiness such as sodium oxybate and modafinil/armodafinil. Medication for narcolepsy is generally well tolerated and usually required life-long although does not eliminate all symptoms of narcolepsy. © 2015, Springer Science+Business Media New York.","Amphetamine; Armodafinil; Cataplexy; Dextroamphetamine; Hypocretin; Lisdexamfetamine; Methamphetamine; Methylphenidate; Modafinil; Narcolepsy; Sleepiness; Sodium oxybate; Treatment; Venlafaxine","Majid, H., Hirshkowitz, M., Therapeutics of narcolepsy (2010) Sleep Med Clin, 5, pp. 659-673; Ohayon, M.M., Epidemiology of narcolepsy (2007) Narcolepsy and hypersomnia, pp. 125-132. , Bassetti C, Billiard M, Mignot E, (eds), Informa Healthcare, New York:; Nishino, S., Ripley, B., Overeem, S., Nevsimalova, S., Lammers, G.J., Vankova, J., Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy (2001) Ann Neurol, 50, pp. 381-388. , COI: 1:CAS:528:DC%2BD3MXntFalt7s%3D, PID: 11558795; Faraco, J., Lin, L., Kornum, B.R., Kenny, E.E., Trynka, G., Einen, M., ImmunoChip study implicates antigen presentation to T cells in narcolepsy (2013) PLoS Genet, 9, p. e1003270. , COI: 1:CAS:528:DC%2BC3sXkt1WltrY%3D, PID: 23459209; American Academy of Sleep Medicine, (2014) International classification of sleep disorders—third edition (ICSD-3), , American Academy of Sleep Medicine, Rochester:; Narcolepsy fact sheet (2014) February, p. 16. , http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm#241213201; Roth, T., Dauvilliers, Y., Mignot, E., Montplaisir, J., Paul, J., Swick, T., Disrupted nighttime sleep in narcolepsy (2013) J Clin Sleep Med, 9, pp. 955-965. , PID: 23997709, A comprehensive article describing in detail the clinical and polysomnographic features of disturbed sleep in narcolepsy; Leu-Semenescu, S., De Cock, V.C., Le Masson, V.D., Debs, R., Lavault, S., Roze, E., Hallucinations in narcolepsy with and without cataplexy: contrasts with Parkinson’s disease (2011) Sleep Med, 12, pp. 497-504. , PID: 21486708, A detailed look at REM sleep dream phenomena in patients with narcolepsy; Wamsley, E., Donjacour, C.E., Scammell, T.E., Lammers, G.J., Stickgold, R., Delusional confusion of dreaming and reality in narcolepsy (2014) Sleep, 37, pp. 419-422. , PID: 24501437; Pisko, J., Pastorek, L., Buskova, J., Sonka, K., Nevsimalova, S., Nightmares in narcolepsy: underinvestigated symptom? (2014) Sleep Med, 15 (8), pp. 967-972. , PID: 24796285; Nightingale, S., Orgill, J.C., Ebrahim, I.O., de Lacy, S.F., Agrawal, S., Williams, A.J., The association between narcolepsy and REM behavior disorder (RBD) (2005) Sleep Med, 6, pp. 253-258. , COI: 1:STN:280:DC%2BD2M3itFGgtg%3D%3D, PID: 15854856; Frauscher, B., Ehrmann, L., Mitterling, T., Gabelia, D., Gschliesser, V., Brandauer, E., Delayed diagnosis, range of severity and multiple sleep comorbidities: a clinical and polysomnographic analysis of 100 patients of the Innsbruck narcolepsy cohort (2013) J Clin Sleep Med, 9, pp. 805-812. , PID: 23946711; Carter, L.P., Acebo, C., Kim, A., Patients’ journey to a narcolepsy diagnosis: a physician survey and retrospective chart review (2014) Postgrad Med, 126, pp. 216-224. , PID: 24918805; Dauvilliers, Y., Montplaisir, J., Molinari, N., Carlander, B., Ondze, B., Besset, A., Age at onset of narcolepsy in two large populations of patients in France and Quebec (2001) Neurology, 57, pp. 2029-2033. , COI: 1:STN:280:DC%2BD3Mnpt1Kjuw%3D%3D, PID: 11739821; Okun, M.L., Lin, L., Pelin, Z., Hong, S., Mignot, E., Clinical aspects of narcolepsy–cataplexy across ethnic groups (2002) Sleep, 25, pp. 27-35. , PID: 11833858; Thorpy, M.J., Krieger, A.C., Delayed diagnosis of narcolepsy: characterization and impact (2014) Sleep Med, 15, pp. 502-507. , PID: 24780133, A comprehensive evaluation of the evidence and reasons for the delay in diagnosis of narcolepsy; Pizza, F., Franceschini, C., Peltola, H., Vandi, S., Finotti, E., Ingravallo, F., Clinical and polysomnographic course of childhood narcolepsy with cataplexy (2013) Brain, 136, pp. 3787-3795. , PID: 24142146; Billiard, M., Bassetti, C., Dauvilliers, Y., Dolenc-Groselj, L., Lammers, G.J., Mayer, G., EFNS guidelines on management of narcolepsy (2006) Eur J Neurol, 13, pp. 1035-1048. , COI: 1:STN:280:DC%2BD28rmt1Sgsw%3D%3D, PID: 16987156; Morgenthaler, T.I., Kapur, V.K., Brown, T., Swick, T.J., Alessi, C., Aurora, R.N., Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin (2007) Sleep, 30, pp. 1705-1711. , PID: 18246980; Jazz Pharmaceuticals (2014) Xyrem (sodium oxybate) oral solution [prescribing information]; Nittur, N., Konofal, E., Dauvilliers, Y., Franco, P., Leu-Semenescu, S., Cock, V.C., Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review (2013) Sleep Med, 14, pp. 30-36. , PID: 23036267; Dauvilliers, Y., Bassetti, C., Lammers, G.J., Arnulf, I., Mayer, G., Rodenbeck, A., Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial (2013) Lancet Neurol, 12, pp. 1068-1075. , COI: 1:CAS:528:DC%2BC3sXhsFyrsbjF, PID: 24107292; Black J, Swick T, Feldman N, Doekel Jr R, Khayrallah M, Bream G, et al. Efficacy and safety of oral ADX-N05 for the treatment of excessive daytime sleepiness in adults with narcolepsy: results of a randomized, double-blind, placebo-controlled trial [abstract]. Presented at: 28th Annual Meeting of the Associated Professional Sleep Societies (SLEEP); May 31–June 4, 2014; Minneapolis, MN. 2014. Abstract LBA4Bogan, R.K., Feldman, N.T., Lankford, D.A., Khayrallah, M.A., A double-blind placebo-controlled randomized crossover study of the efficacy and safety of ADX-N05 for the treatment of excessive daytime sleepiness in adult subjects with narcolepsy [abstract] (2013) Sleep, 36, p. A257; Arias-Carrion, O., Murillo-Rodriguez, E., Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats (2014) PLoS One, 9, p. e95342. , PID: 24736646; Weinhold, S.L., Seeck-Hirschner, M., Nowak, A., Hallschmid, M., Goder, R., Baier, P.C., The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy (2014) Behav Brain Res, 262, pp. 8-13. , COI: 1:CAS:528:DC%2BC2cXisFehsbY%3D, PID: 24406723; Kantor, S., Mochizuki, T., Lops, S.N., Ko, B., Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice (2013) Sleep, 36 (8), pp. 1129-1138. , PID: 23904672; Thorpy, M.J., Dauvilliers, Y., Clinical and practical considerations in the pharmacologic management of narcolepsy (2015) Sleep Med, 16 (1), pp. 9-18. , PID: 25458251, A comprehensive evaluation of clinically relevant recommendations for making treatment decisions in narcolepsy; Cephalon (2010) Provigil (modafinil) tablets [prescribing information]; Cephalon (2010) Nuvigil (armodafinil) tablets [prescribing information]; Wang, Y.G., Swick, T.J., Carter, L.P., Thorpy, M.J., Benowitz, N.L., Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion (2009) J Clin Sleep Med, 5, pp. 365-371. , COI: 1:CAS:528:DC%2BD1MXht1agtLfL, PID: 19968016, A review of the post marketing information available of the safety of sodium oxybate; Poryazova, R., Tartarotti, S., Khatami, R., Baumann, C.R., Valko, P., Kallweit, U., Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience (2011) Eur Neurol, 65, pp. 175-182. , COI: 1:CAS:528:DC%2BC3MXjslKrs7s%3D, PID: 21389728; Zvosec, D.L., Smith, S.W., Porrata, T., Strobl, A.Q., Dyer, J.E., Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma (2011) Am J Emerg Med, 29, pp. 319-332. , PID: 20825811; Feldman, N.T., Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing (2010) Sleep Breath, 14, pp. 77-79. , PID: 19626356; Husain, A.M., Ristanovic, R.K., Bogan, R.K., Weight loss in narcolepsy patients treated with sodium oxybate (2009) Sleep Med, 10, pp. 661-663. , PID: 19014899; Black, J., Houghton, W.C., Sodium oxybate improves excessive daytime sleepiness in narcolepsy (2006) Sleep, 29, pp. 939-946. , PID: 16895262; Auger, R.R., Goodman, S.H., Silber, M.H., Krahn, L.E., Pankratz, V.S., Slocumb, N.L., Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study (2005) Sleep, 28, pp. 667-672. , PID: 16477952; Bayard, S., Langenier, M.C., Dauvilliers, Y., Effect of psychostimulants on impulsivity and risk taking in narcolepsy with cataplexy (2013) Sleep, 36, pp. 1335-1340. , PID: 23997366; Bayard, S., Dauvilliers, Y.A., Reward-based behaviors and emotional processing in human with narcolepsy–cataplexy (2013) Front Behav Neurosci, 7, p. 50. , PID: 23734110; Tsujino, N., Sakurai, T., Role of orexin in modulating arousal, feeding, and motivation (2013) Front Behav Neurosci, 7, p. 28. , COI: 1:CAS:528:DC%2BC3sXht1ajur3J, PID: 23616752; Vitiello, B., Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function (2008) Child Adolesc Psychiatr Clin N Am, 17, pp. 459-474. , PID: 18295156; Vignatelli L, D’Alessandro R, Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database Syst Rev 2008:CD003724Frey, J., Darbonne, C., Fluoxetine suppresses human cataplexy: a pilot study (1994) Neurology, 44, pp. 707-709. , COI: 1:STN:280:DyaK2c3hsl2jsQ%3D%3D, PID: 8164831; Izzi, F., Placidi, F., Marciani, M.G., Zannino, S., Torelli, F., Corte, F., Effective treatment of narcolepsy-cataplexy with duloxetine: a report of three cases [letter] (2009) Sleep Med, 10, pp. 153-154. , COI: 1:STN:280:DC%2BD1M%2Fns1Clug%3D%3D, PID: 18226953; Moller, L.R., Ostergaard, J.R., Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations (2009) J Child Adolesc Psychopharmacol, 19, pp. 197-201. , PID: 19364297; Ju, Y.E., Larson-Prior, L., Duntley, S., Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants (2011) Sleep Med, 12, pp. 278-283. , PID: 21317035; (2010) Prescrire Int, 19, pp. 164-165; Martinez-Rodriguez, J., Iranzo, A., Santamaria, J., Genis, D., Molins, A., Silva, Y., Status cataplecticus induced by abrupt withdrawal of clomipramine (2002) Neurologia, 17, pp. 113-116. , PID: 11864561, (article in Spanish); Schwartz, J.R., Nelson, M.T., Schwartz, E.R., Hughes, R.J., Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness (2004) Clin Neuropharmacol, 27, pp. 74-79. , COI: 1:CAS:528:DC%2BD2cXks1Sgtr0%3D, PID: 15252267; Mignot, E.J., A practical guide to the therapy of narcolepsy and hypersomnia syndromes (2012) Neurotherapeutics, 9, pp. 739-752. , PID: 23065655, A recent analysis of medications used in the treatment of narcolepsy; Vendrame, M., Havaligi, N., Matadeen-Ali, C., Adams, R., Kothare, S.V., Narcolepsy in children: a single-center clinical experience (2008) Pediatr Neurol, 38, pp. 314-320. , PID: 18410846; Aran, A., Einen, M., Lin, L., Plazzi, G., Nishino, S., Mignot, E., Clinical and therapeutic aspects of childhood narcolepsy–cataplexy: a retrospective study of 51 children (2010) Sleep, 33, pp. 1457-1464. , PID: 21102987; Lecendreux, M., Bruni, O., Franco, P., Gringras, P., Konofal, E., Nevsimalova, S., Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy (2012) J Sleep Res, 21, pp. 481-483. , PID: 22283810; Society American Geriatrics Society, Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults (2012) J Am Geriatr Soc, 60, pp. 616-631; Thorpy, M., Zhao, C.G., Dauvilliers, Y., Management of narcolepsy during pregnancy (2013) Sleep Med, 14, pp. 367-376. , PID: 23433999, A comprehensive assessment of the information regarding narcolepsy medications and pregnancy; Maurovich-Horvat, E., Kemlink, D., Hogl, B., Frauscher, B., Ehrmann, L., Geisler, P., Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies (2013) J Sleep Res, 22, pp. 496-512. , PID: 23560595",Review,Scopus,2-s2.0-84927594973
"Sala-Vila A., Estruch R., Ros E.","New Insights into the Role of Nutrition in CVD Prevention",2015,"Current Cardiology Reports","17","5",,"","",11,,10.1007/s11886-015-0583-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928325289&partnerID=40&md5=958e71fde799c4c92714f36dccb5f76a","Lipid Clinic, Endocrinology and Nutrition Service, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, C. Villarroel 170Barcelona, Spain; Ciber Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII)Barcelona, Spain; Department of Internal Medicine, IDIBAPS, Hospital Clinic, C. Villarroel 170Barcelona, Spain; Lipid Clinic, Endocrinology and Nutrition Service, (IDIBAPS) Hospital Clínic, C. Villarroel 170Barcelona, Spain","Sala-Vila, A., Lipid Clinic, Endocrinology and Nutrition Service, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, C. Villarroel 170Barcelona, Spain, Ciber Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII)Barcelona, Spain; Estruch, R., Ciber Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII)Barcelona, Spain, Department of Internal Medicine, IDIBAPS, Hospital Clinic, C. Villarroel 170Barcelona, Spain; Ros, E., Lipid Clinic, Endocrinology and Nutrition Service, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, C. Villarroel 170Barcelona, Spain, Ciber Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII)Barcelona, Spain, Lipid Clinic, Endocrinology and Nutrition Service, (IDIBAPS) Hospital Clínic, C. Villarroel 170Barcelona, Spain","Nutrition plays an increasingly significant role in lifestyle strategies for cardiovascular prevention. Foods and dietary patterns that encompass specific foods and beverages and their combinations, with synergies among their components, are the subject of much epidemiologic and clinical research in relation to health issues, including cardiovascular disease. Foods with the highest evidence for beneficial effects on cardiovascular outcomes (mainly fatal and nonfatal coronary artery disease and stroke) and intermediate risk markers (principally cholesterol and blood pressure) are fruits and vegetables, legumes, nuts, whole grains, dairy products, fish, and alcohol consumed in moderation. Epidemiologic and clinical trial evidence on cardiovascular health issues is reviewed for these foods and for the dietary pattern with the highest probability of a causal link with cardiovascular protection, namely the Mediterranean diet. When pertinent, mechanisms of protection derived from specific nutrients in foods are also examined. The explosion of knowledge in cardioprotective foods and diets needs to be translated to the public, as dietary quality is still far from optimal in large segments of the population. © 2015, Springer Science+Business Media New York.","Alcohol; Cardiovascular disease; Dairy products; Diet; Dietary patterns; Fish; Fruits and vegetables; Legumes; Mediterranean diet; Nuts; Seeds; Whole grains","Stampfer, M.J., Hu, F.B., Manson, J.E., Rimm, E.B., Willett, W.C., Primary prevention of coronary heart disease in women through diet and lifestyle (2000) N Engl J Med, 343 (1), pp. 16-22. , COI: 1:STN:280:DC%2BD3czisVOmuw%3D%3D; Yusuf, S., Hawken, S., Ôunpuu, S., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study (2004) Lancet, 364 (9438), pp. 937-952; Chiuve, S.E., Rexrode, K.M., Spiegelman, D., Logroscino, G., Manson, J.E., Rimm, E.B., Primary prevention of stroke by healthy lifestyle (2008) Circulation, 118 (9), pp. 947-954; Åkesson, A., Larsson, S.C., Discacciati, A., Wolk, A., Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study (2014) J Am Coll Cardiol, 64 (13), pp. 1299-1306; Perk, J., De Backer, G., Gohlke, H., Joint European Societies’ guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) Eur Heart J, 33 (13), pp. 1635-1701. , COI: 1:CAS:528:DC%2BC38XhtVeitr3P; Eckel, R.H., Jakicic, J.M., Ard, J.D., 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (2014) J Am Coll Cardiol, 63 (25), pp. 2960-2984. , Erratum in: J Am Coll Cardiol. 2014;63(25 Pt B):3027–8; Lichtenstein, A.H., Appel, L.J., Brands, M., Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee (2006) Circulation, 114 (1), pp. 82-96. , Erratum in: Circulation. 2006;114(23):e629. Circulation. 2006;114(1):e27; Mozaffarian, D., Appel, L.J., Van Horn, L., Components of a cardioprotective diet: new insights (2011) Circulation, 123 (24), pp. 2870-2891; Salas-Salvadó, J., Martinez-González, M.A., Bulló, M., Ros, E., The role of diet in the prevention of type 2 diabetes (2011) Nutr Metab Cardiovasc Dis, 21, pp. 32-48; Hu, F.B., Dietary pattern analysis: a new direction in nutritional epidemiology (2002) Curr Opin Lipidol, 13 (1), pp. 3-9. , COI: 1:CAS:528:DC%2BD38XitV2ms7k%3D; Jacobs, D.R., Jr., Gross, M.D., Tapsell, L.C., Food synergy: an operational concept for understanding nutrition (2009) Am J Clin Nutr, 89 (5), pp. 1543-1548. , COI: 1:CAS:528:DC%2BD1MXlt1Okt7Y%3D; Cahill, L.E., Chiuve, S.E., Mekary, R.A., Jensen, M.K., Flint, A.J., Hu, F.B., Prospective study of breakfast eating and incident coronary heart disease in a cohort of male US health professionals (2013) Circulation, 128 (4), pp. 337-343; Paul, L., Diet, nutrition and telomere length (2011) J Nutr Biochem, 22 (10), pp. 895-901. , COI: 1:CAS:528:DC%2BC3MXht1ansLrP; Power, S.E., O’Toole, P.W., Stanton, C., Ross, R.P., Fitzgerald, G.F., Intestinal microbiota, diet and health (2014) Br J Nutr, 111 (3), pp. 387-402. , COI: 1:CAS:528:DC%2BC2cXitVaqs7k%3D; Corella, D., Ordovas, J.M., Nutrigenomics in cardiovascular medicine (2009) Circ Cardiovasc Genet, 2 (6), pp. 637-651. , COI: 1:CAS:528:DC%2BC3cXotVSntA%3D%3D; Johnson, R.K., Appel, L.J., Brands, M., Dietary sugars intake and cardiovascular health. A scientific statement from the American Heart Association (2009) Circulation, 120 (11), pp. 1011-1020. , COI: 1:CAS:528:DC%2BD1MXht1WntbbP; Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90. Erratum in: N Engl J Med. 2014;370(9):886. This is a landmark trial of nutritional intervention for primary cardiovascular prevention. Nearly 7500 individuals at high risk were randomized to two Mediterranean diets, supplemented with either extra-virgin olive oil or mixed nuts, versus advice on a low-fat diet. After intervention for 5 years, there was a 30% reduction in CVD events in the two Mediterranean diet groupsDauchet, L., Amouyel, P., Hercberg, S., Dallongeville, J., Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies (2006) J Nutr, 136 (10), pp. 2588-2593. , COI: 1:CAS:528:DC%2BD28XhtVGmu7vI; Larsson, S.C., Virtamo, J., Wolk, A., Total and specific fruit and vegetable consumption and risk of stroke: a prospective study (2013) Atherosclerosis, 227 (1), pp. 147-152. , COI: 1:CAS:528:DC%2BC3sXltVWgtw%3D%3D; Leenders, M., Boshuizen, H.C., Ferrari, P., Fruit and vegetable intake and cause-specific mortality in the EPIC study (2014) Eur J Epidemiol, 29 (9), pp. 639-652. , COI: 1:CAS:528:DC%2BC2cXhsVCisb7M; Consumption of berries, fruits and vegetables and mortality among 10,000 Norwegian men followed for four decades (2014) Eur J Nutr; Hu, D., Huang, J., Wang, Y., Zhang, D., Qu, Y., Fruits and vegetables consumption and risk of stroke: a meta-analysis of prospective cohort studies (2014) Stroke, 45 (6), pp. 1613-1619. , COI: 1:CAS:528:DC%2BC2cXovFGks78%3D; Wang, X., Ouyang, Y., Liu, J., Zhu, M., Zhao, G., Bao, W., Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose–response meta-analysis of prospective cohort studies (2014) BMJ, 349, p. 4490; Ley, S.H., Hamdy, O., Mohan, V., Hu, F.B., Prevention and management of type 2 diabetes: dietary components and nutritional strategies (2014) Lancet, 383 (9933), pp. 1999-2007. , COI: 1:CAS:528:DC%2BC2cXpslCrsb4%3D, Comprehensive review that summarizes the results of all relevant meta-analyses of prospective studies and RCTs focused on dietary factors, glycemic control, and diabetes risk; Muraki, I., Imamura, F., Manson, J.E., Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies (2013) BMJ, 347, p. 5001. , Erratum in: BMJ. 2013;347:f6935; Ledoux, T.A., Hingle, M.D., Baranowski, T., Relationship of fruit and vegetable intake with adiposity: a systematic review (2011) Obes Rev, 12 (5), pp. 143-150. , COI: 1:STN:280:DC%2BC3MvktlCrtQ%3D%3D; Vergnaud, A.C., Norat, T., Romaguera, D., Fruit and vegetable consumption and prospective weight change in participants of the European Prospective Investigation into Cancer and Nutrition-Physical Activity, Nutrition, Alcohol, Cessation of Smoking, Eating Out of Home, and Obesity study (2012) Am J Clin Nutr, 95 (1), pp. 184-193. , COI: 1:CAS:528:DC%2BC38XjtVeqtQ%3D%3D; Appel, L.J., Moore, T.J., Obarzanek, E., A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group (1997) N Engl J Med, 336 (16), pp. 1117-1124. , COI: 1:STN:280:DyaK2s3jvVOmsA%3D%3D; Ros, E., Hu, F.B., Consumption of plant seeds and cardiovascular health: epidemiological and clinical trial evidence (2013) Circulation, 128 (5), pp. 553-565. , Comprehensive review of the main characteristics of widely consumed seeds (grains, legumes, nuts, cocoa, and coffee), with detailed description of composition, heart health effects and mechanisms thereof; Afshin, A., Micha, R., Khatibzadeh, S., Mozaffarian, D., Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis (2014) Am J Clin Nutr, 100 (1), pp. 278-288. , COI: 1:CAS:528:DC%2BC2cXhtFWht7bP; Mattei, J., Hu, F.B., Campos, H., A higher ratio of beans to white rice is associated with lower cardiometabolic risk factors in Costa Rican adults (2011) Am J Clin Nutr, 94, pp. 869-876. , COI: 1:CAS:528:DC%2BC3MXhtFSqu7jL; Papanikolaou, Y., Fulgoni, V.L., III, Bean consumption is associated with greater nutrient intake, reduced systolic blood pressure, lower body weight, and a smaller waist circumference in adults: results from the National Health and Nutrition Examination Survey 1999–2002 (2008) J Am Coll Nutr, 2008, pp. 569-576; Bazzano, L.A., Thompson, A.M., Tees, M.T., Nguyen, C., Winham, D.M., Non-soy legume consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials (2011) Nutr Metab Cardiovasc Dis, 21 (2), pp. 94-103. , COI: 1:CAS:528:DC%2BC3MXhslKqtL0%3D; Anderson, J.W., Major, A.W., Pulses and lipaemia, short- and long-term effect: potential in the prevention of cardiovascular disease (2002) Brit J Nutr, 88, pp. 263-271. , COI: 1:CAS:528:DC%2BD3sXhtVajsLo%3D; Sievenpiper, J.L., Kendall, C.W., Esfahani, A., Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes (2009) Diabetologia, 52 (8), pp. 1479-1495. , COI: 1:STN:280:DC%2BD1MvotVyruw%3D%3D; Jayalath, V.H., de Souza, R.J., Sievenpiper, J.L., Effect of dietary pulses on blood pressure: a systematic review and meta-analysis of controlled feeding trials (2014) Am J Hypertens, 27 (1), pp. 56-64; Ros, E., Health benefits of nut consumption (2010) Nutrients, 2 (7), pp. 652-682. , COI: 1:CAS:528:DC%2BC3cXos12msrY%3D; Luo, C., Zhang, Y., Ding, Y., Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis (2014) Am J Clin Nutr, 100 (1), pp. 256-269. , COI: 1:CAS:528:DC%2BC2cXhtFWht7bN, Comprehensive meta-analysis of prospective cohort studies relating nut consumption to various CVD outcomes and total and cause-specific mortality; Zhou, D., Yu, H., He, F., Nut consumption in relation to cardiovascular disease risk and type 2 diabetes: a systematic review and meta-analysis of prospective studies (2014) Am J Clin Nutr, 100 (1), pp. 270-277. , COI: 1:CAS:528:DC%2BC2cXhtFWht7bO; Sabaté, J., Oda, K., Ros, E., Nut consumption and blood lipids: a pooled analysis of 25 intervention trials (2010) Arch Intern Med, 170 (9), pp. 821-827; Meschia, J.F., Bushnell, C., Boden-Albala, B., Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association (2014) Stroke, 45 (12), pp. 3754-3832; Bes-Rastrollo, M., Wedick, N.M., Martínez-González, M.A., Li, T.Y., Sampson, L., Hu, F.B., Prospective study of nut consumption, long-term weight change, and obesity risk in women (2009) Am J Clin Nutr, 89 (6), pp. 1913-1919. , COI: 1:CAS:528:DC%2BD1MXms1ejtrs%3D; Ibarrola-Jurado, N., Bulló, M., Guasch-Ferré, M., PREDIMED Study Investigators. Cross-sectional assessment of nut consumption and obesity, metabolic syndrome and other cardiometabolic risk factors: the PREDIMED study (2013) PLoS One, 8 (2), p. 57367. , COI: 1:CAS:528:DC%2BC3sXjvV2gsbw%3D; Salas-Salvadó, J., Fernández-Ballart, J., Ros, E., Effect of the Mediterranean diet supplemented with nuts on metabolic syndrome status. One-year results of the PREDIMED randomized trial (2008) Arch Intern Med, 168 (22), pp. 2449-2458; Babio, N., Toledo, E., Estruch, R., Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial (2014) CMAJ, 186 (17), pp. 649-657; Flores-Mateo, G., Rojas-Rueda, D., Basora, J., Ros, E., Salas-Salvadó, J., Nut intake and adiposity: meta-analysis of clinical trials (2013) Am J Clin Nutr, 97 (6), pp. 1346-1355. , COI: 1:CAS:528:DC%2BC3sXoslyqtLk%3D; Lillioja, S., Neal, A.L., Tapsell, L., Jacobs, D.R., Jr., Whole grains, type 2 diabetes, coronary heart disease, and hypertension: links to the aleurone preferred over indigestible fiber (2013) Biofactors, 39 (3), pp. 242-258. , COI: 1:CAS:528:DC%2BC3sXhtVajsLjM, Insightful review with emphasis on the myriad healthy components of the bran fraction of cereal grains. Also reviews prospective studies of whole grain consumption and CAD outcomes; Hu, E.A., Pan, A., Malik, V., Sun, Q., White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review (2012) BMJ, 344, p. 1454; Ye, E.Q., Chacko, S.A., Chou, E.L., Kugizaki, M., Liu, S., Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain (2012) J Nutr, 142 (7), pp. 1304-1313. , COI: 1:CAS:528:DC%2BC38XpsFWmur0%3D, Erratum in J Nutr. 2013;143(9):1524; Whitehead, A., Beck, E.J., Tosh, S., Wolever, T.M., Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials (2014) Am J Clin Nutr, 100 (6), pp. 1413-1421. , COI: 1:CAS:528:DC%2BC2cXitVelurfF; Ferruzzi, M.G., Jonnalagadda, S.S., Liu, S., Developing a standard definition of whole-grain foods for dietary recommendations: summary report of a multidisciplinary expert roundtable discussion (2014) Adv Nutr, 5 (2), pp. 164-176. , COI: 1:CAS:528:DC%2BC2cXosFCktLY%3D; Gibson, R.A., Makrides, M., Smithers, L.G., Voevodin, M., Sinclair, A.J., The effect of dairy foods on CHD: a systematic review of prospective cohort studies (2009) Br J Nutr, 102 (9), pp. 1267-1275. , COI: 1:CAS:528:DC%2BD1MXhsVyrtL%2FF; Soedamah-Muthu, S.S., Ding, E.L., Al-Delaimy, W.K., Hu, F.B., Engberink, M.F., Willett, W.C., Milk and dairy consumption and incidence of cardiovascular diseases and all-cause mortality: dose–response meta-analysis of prospective cohort studies (2011) Am J Clin Nutr, 93 (1), pp. 158-171. , COI: 1:CAS:528:DC%2BC3MXls1CrsA%3D%3D; Siri-Tarino, P.W., Sun, Q., Hu, F.B., Krauss, R.M., Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease (2010) Am J Clin Nutr, 91 (3), pp. 535-546. , COI: 1:CAS:528:DC%2BC3cXisFyntLk%3D; Chowdhury, R., Warnakula, S., Kunutsor, S., Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis (2014) Ann Intern Med, 160 (6), pp. 398-406; German, J.B., Gibson, R.A., Krauss, R.M., A reappraisal of the impact of dairy foods and milk fat on cardiovascular disease risk (2009) Eur J Nutr, 48 (4), pp. 191-203. , COI: 1:CAS:528:DC%2BD1MXntF2hu74%3D; Chrysant, S.G., Chrysant, G.S., An update on the cardiovascular pleiotropic effects of milk and milk products (2013) J Clin Hypertens (Greenwich), 15 (7), pp. 503-510; Fekete, A.A., Givens, D.I., Lovegrove, J.A., The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies (2013) Nutr Res Rev, 26 (2), pp. 177-190. , COI: 1:CAS:528:DC%2BC3sXhvVShtL7L; Tong, X., Dong, J.Y., Wu, Z.W., Li, W., Qin, L.Q., Dairy consumption and risk of type 2 diabetes mellitus: a meta-analysis of cohort studies (2011) Eur J Clin Nutr, 65 (9), pp. 1027-1031. , COI: 1:STN:280:DC%2BC3MfhsVGltA%3D%3D; Hjerpsted, J., Leedo, E., Tholstrup, T., Cheese intake in large amounts lowers LDL-cholesterol concentrations compared with butter intake of equal fat content (2011) Am J Clin Nutr, 94 (6), pp. 1479-1484. , COI: 1:CAS:528:DC%2BC3MXhsFKls7%2FI; De Caterina, R., N-3 fatty acids in cardiovascular disease (2011) N Engl J Med, 364 (25), pp. 2439-2450; McLennan, P.L., Cardiac physiology and clinical efficacy of dietary fish oil clarified through cellular mechanisms of omega-3 polyunsaturated fatty acids (2014) Eur J Appl Physiol, 114 (7), pp. 1333-1356. , COI: 1:CAS:528:DC%2BC2cXls1egsLo%3D; Kris-Etherton, P.M., Harris, W.S., Appel, L.J., Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association (2003) Arterioscler Thromb Vasc Biol, 23 (2), pp. 151-152. , COI: 1:CAS:528:DC%2BD3sXjtVOmsrw%3D; Xun, P., Qin, B., Song, Y., Fish consumption and risk of stroke and its subtypes: accumulative evidence from a meta-analysis of prospective cohort studies (2012) Eur J Clin Nutr, 66 (1), pp. 1199-1207. , COI: 1:STN:280:DC%2BC3s%2FitV2gsQ%3D%3D; Chowdhury, R., Stevens, S., Gorman, D., Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis (2012) BMJ, 345, p. 6698; Zheng, J., Huang, T., Yu, Y., Hu, X., Yang, B., Li, D., Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies (2012) Public Health Nutr, 15 (4), pp. 725-737; Leung Yinko, S.S., Stark, K.D., Thanassoulis, G., Pilote, L., Fish consumption and acute coronary syndrome: a meta-analysis (2014) Am J Med, 127 (9), pp. 848-857; Wu, J.H., Micha, R., Imamura, F., Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis (2012) Br J Nutr, 107, pp. 214-227. , COI: 1:CAS:528:DC%2BC38XntFOhtLo%3D; Harris, W.S., Are n-3 fatty acids still cardioprotective? (2013) Curr Opin Clin Nutr Metab Care, 16 (2), pp. 141-149. , COI: 1:CAS:528:DC%2BC3sXit1egtb8%3D; Barceló-Coblijn, G., Murphy, E.J., Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels (2009) Prog Lipid Res, 48 (6), pp. 355-374; Pan, A., Chen, M., Chowdhury, R., α-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis (2012) Am J Clin Nutr, 96 (6), pp. 1262-1273. , COI: 1:CAS:528:DC%2BC38XhslylsbnF, This systematic review and meta-analysis of both dietary and biomarker studies suggests that increasing exposure to dietary ALA is associated with a moderately lower risk of CVD; Deckelbaum, R.J., Calder, P.C., Harris, W.S., Conclusions and recommendations from the symposium, Heart Healthy Omega-3s for Food: Stearidonic Acid (SDA) as a Sustainable Choice (2011) J Nutr, 142 (3), pp. 641-643; Lim, S.S., Vos, T., Flaxman, A.D., Danei, G., Shibuya, K., Adair-Rohani, H., A comparative risk assessment of burden disease and injury attributable to 67 risk factors and risk factors clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) Lancet, 380 (9859), pp. 2224-2260; Chiva-Blanch, G., Arranz, S., Lamuela-Raventos, R.M., Estruch, R., Effects of wine, alcohol and polyphenols on cardiovascular disease risk factors: evidences from human studies (2013) Alcohol Alcohol, 48 (3), pp. 270-277. , COI: 1:CAS:528:DC%2BC3sXntV2jtbo%3D; Ronksley, P.E., Brien, S.E., Turner, B.J., Mukamal, K.J., Ghali, W.A., Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis (2011) BMJ, 342, p. 671; Roerecke, M., Rehm, J., Alcohol consumption, drinking patterns, and ischemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers (2014) BMC Med, 12, p. 182; Baliunas, D.O., Taylor, B.J., Irving, H., Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis (2009) Diabetes Care, 32 (11), pp. 2123-2132. , COI: 1:CAS:528:DC%2BD1MXhsVOgtrbE; Sayon-Orea, C., Martinez-Gonzalez, M.A., Bes-Rastrollo, M., Alcohol consumption and body weight: a systematic review (2011) Nutr Rev, 69 (8), pp. 419-431; Brien, S.E., Ronksley, P.E., Turner, B.J., Mukamal, K.J., Ghali, W.A., Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies (2011) BMJ, 342, p. 636; Costanzo, S., Di Castelnuovo, A., Donati, M.B., Iacoviello, L., de Gaetano, G., Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis (2011) Eur J Epidemiol, 26 (11), pp. 833-850; Britton, K.A., Gaziano, J.M., Sesso, H.D., Djoussé, L., Relation of alcohol consumption and coronary heart disease in hypertensive male physicians (from the Physicians’ Health Study) (2009) Am J Cardiol, 104 (7), pp. 932-935. , COI: 1:CAS:528:DC%2BD1MXhtFKnsbfM; Rosenbloom, J.I., Mukamal, K.J., Frost, L.E., Mittleman, M.A., Alcohol consumption patterns, beverage type, and long-term mortality among women survivors of acute myocardial infarction (2012) Am J Cardiol, 109 (2), pp. 147-152; Chiva-Blanch, G., Urpi-Sardá, M., Ros, E., Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication (2012) Circ Res, 111 (8), pp. 1065-1068. , COI: 1:CAS:528:DC%2BC38XhsVWmt77F, Clinical trial demonstrating that beneficial effects of red wine on blood pressure and plasma nitric oxide are attributable to polyphenols rather than alcohol; Estruch, R., Sacanella, E., Mota, F., Consumption of red wine, but not gin, decreases erythrocyte superoxide dismutase activity: a randomised cross-over trial (2011) Nutr Metab Cardiovasc Dis, 21 (1), pp. 46-53. , COI: 1:CAS:528:DC%2BC3MXhtVWntL4%3D; Covas, M.I., Gambert, P., Fitó, M., de la Torre, R., Wine and oxidative stress: up-to-date evidence of the effects of moderate wine consumption on oxidative damage in humans (2010) Atherosclerosis, 208 (2), pp. 297-304. , COI: 1:CAS:528:DC%2BC3cXhtlyru74%3D; Chiva-Blanch, G., Urpi-Sarda, M., Llorach, R., Rotches-Ribalta, M., Guillén, M., Casas, R., Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial (2012) Am J Clin Nutr, 95 (2), pp. 326-334. , COI: 1:CAS:528:DC%2BC38XhsFyht7g%3D; Micha, R., Wallace, S.K., Mozaffarian, D., Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis (2010) Circulation, 121, pp. 2271-2283; Pan, A., Sun, Q., Bernstein, A.M., Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis (2011) Am J Clin Nutr, 94 (4), pp. 1088-1096. , COI: 1:CAS:528:DC%2BC3MXht1OgurvM; Rohrmann, S., Overvad, K., Bueno-de-Mesquita, H.B., Meat consumption and mortality—results from the European Prospective Investigation into Cancer and Nutrition (2013) BMC Med, 11, p. 63; Micha, R., Michas, G., Lajous, M., Mozaffarian, D., Processing of meats and cardiovascular risk: time to focus on preservatives (2013) BMC Med, 11, p. 136. , COI: 1:CAS:528:DC%2BC3sXhtVams73J; Li, D., Siriamornpun, S., Wahlqvist, M.L., Mann, N.J., Sinclair, A.J., Lean meat and heart health (2005) Asia Pac J Clin Nutr, 14 (2), pp. 113-119. , COI: 1:CAS:528:DC%2BD2MXlsFeisrw%3D; Fraser, G.E., Vegetarian diets: what do we know of their effects on common chronic diseases? (2009) Am J Clin Nutr, 89 (5), pp. 1607-1612. , COI: 1:CAS:528:DC%2BD1MXlt1OktLk%3D, Erratum in: Am J Clin Nutr. 2009;90(1):248; Salehi-Abargouei, A., Maghsoudi, Z., Shirani, F., Azadbakht, L., Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal and nonfatal cardiovascular diseases-incidence: a systematic review and meta-analysis on observational prospective studies (2013) Nutrition, 29 (4), pp. 611-618; Chiuve, S.E., Fung, T.T., Rimm, E.B., Alternative dietary indices both strongly predict risk of chronic disease (2012) J Nutr, 142 (6), pp. 1009-1018. , COI: 1:CAS:528:DC%2BC38XhtVert7nL; Bach-Faig, A., Berry, E.M., Lairon, D., Mediterranean diet pyramid today science and cultural updates (2011) Public Health Nutr, 14 (12A), pp. 2274-2284; Howard, B.V., Van Horn, L., Hsia, J., Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial (2006) JAMA, 295 (6), pp. 655-666. , COI: 1:CAS:528:DC%2BD28XhtF2rsrY%3D; Wing, R.R., Bolin, P., Brancati, F.L., Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes (2013) N Engl J Med, 369 (2), pp. 145-154. , Erratum in: N Engl J Med. 2014;370(19):1866; Whayne, T.F., Jr., Ischemic heart disease and the Mediterranean diet (2014) Curr Cardiol Rep, 16 (6), p. 491; Ruiz-Canela, M., Estruch, R., Corella, D., Salas-Salvadó, J., Martínez-González, M.A., Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial (2014) JAMA, 311 (4), pp. 415-417. , COI: 1:CAS:528:DC%2BC2cXitlyjurc%3D; Martínez-González, M.Á., Toledo, E., Arós, F., Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevención con Dieta Mediterránea) trial (2014) Circulation, 130 (1), pp. 18-26; Salas-Salvadó, J., Bulló, M., Estruch, R., Ros, E., Covas, M.I., Ibarrola-Jurado, N., Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial (2014) Ann Intern Med, 160 (1), pp. 1-10; Domenech, M., Roman, P., Lapetra, J., Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial (2014) Hypertension, 64 (1), pp. 69-76. , COI: 1:CAS:528:DC%2BC2cXpsFKns7w%3D; Sala-Vila, A., Romero-Mamani, E.S., Gilabert, R., Changes in ultrasound-assessed carotid intima-media thickness and plaque with a Mediterranean diet: a substudy of the PREDIMED trial (2014) Arterioscler Thromb Vasc Biol, 34 (2), pp. 439-445. , COI: 1:CAS:528:DC%2BC2cXotVylsw%3D%3D; Wang, D.D., Leung, C.W., Li, Y., Ding, E.L., Chiuve, S.E., Hu, F.B., Trends in dietary quality among adults in the United States, 1999 through 2010 (2014) JAMA Intern Med, 174 (10), pp. 1587-1595; Li, S., Chiuve, S.E., Flint, A., Better diet quality and decreased mortality among myocardial infarction survivors (2013) JAMA Intern Med, 173 (19), pp. 1808-1818",Review,Scopus,2-s2.0-84928325289
"Aguero J., Ishikawa K., Fish K.M., Hammoudi N., Hadri L., Garcia-Alvarez A., Ibanez B., Fuster V., Hajjar R.J., Leopold J.A.","Combination proximal pulmonary artery coiling and distal embolization induces chronic elevations in pulmonary artery pressure in swine",2015,"PLoS ONE","10","4", e0124526,"","",,,10.1371/journal.pone.0124526,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928791912&partnerID=40&md5=363aa7a7a0a08bae1297451197de9388","Cardiovascular Research Center, Icahn School of Medicine at Mount SinaiNew York, NY, United States; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Epidemiology, Atherothrombosis and Imaging DepartmentMadrid, Spain; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount SinaiNew York, NY, United States; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical SchoolBoston, MA, United States","Aguero, J., Cardiovascular Research Center, Icahn School of Medicine at Mount SinaiNew York, NY, United States, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Epidemiology, Atherothrombosis and Imaging DepartmentMadrid, Spain; Ishikawa, K., Cardiovascular Research Center, Icahn School of Medicine at Mount SinaiNew York, NY, United States; Fish, K.M., Cardiovascular Research Center, Icahn School of Medicine at Mount SinaiNew York, NY, United States; Hammoudi, N., Cardiovascular Research Center, Icahn School of Medicine at Mount SinaiNew York, NY, United States; Hadri, L., Cardiovascular Research Center, Icahn School of Medicine at Mount SinaiNew York, NY, United States; Garcia-Alvarez, A., Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Epidemiology, Atherothrombosis and Imaging DepartmentMadrid, Spain; Ibanez, B., Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Epidemiology, Atherothrombosis and Imaging DepartmentMadrid, Spain; Fuster, V., Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Epidemiology, Atherothrombosis and Imaging DepartmentMadrid, Spain, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount SinaiNew York, NY, United States; Hajjar, R.J., Cardiovascular Research Center, Icahn School of Medicine at Mount SinaiNew York, NY, United States; Leopold, J.A., Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical SchoolBoston, MA, United States","Pulmonary hypertension (PH) is associated with aberrant vascular remodeling and right ventricular (RV) dysfunction that contribute to early mortality. Large animal models that recapitulate human PH are essential for mechanistic studies and evaluating novel therapies; however, these models are not readily accessible to the field owing to the need for advanced surgical techniques or hypoxia. In this study, we present a novel swine model that develops cardiopulmonary hemodynamics and structural changes characteristic of chronic PH. This percutaneous model was created in swine (n=6) by combining distal embolization of dextran beads with selective coiling of the lobar pulmonary arteries (2 procedures per lung over 4 weeks). As controls, findings from this model were compared with those from a standard weekly distal embolization model (n=6) and sham animals (n=4). Survival with the combined embolization model was 100%. At 8 weeks after the index procedure, combined embolization procedure animals had increased mean pulmonary artery pressure (mPA) and pulmonary vascular resistance (PVR) compared to the controls with no effect on left heart or systemic pressures. RV remodeling and RV dysfunction were also present with a decrease in the RV ejection fraction, increase in the myocardial performance index, impaired longitudinal function, as well as cardiomyocyte hypertrophy, and interstitial fibrosis, which were not present in the controls. Pulmonary vascular remodeling occurred in both embolization models, although only the combination embolization model had a decrease in pulmonary capacitance. Taken together, these cardiopulmonary hemodynamic and structural findings identify the novel combination embolization swine model as a valuable tool for future studies of chronic PH. © 2015 Aguero et al.",,"Champion, H.C., Michelakis, E.D., Hassoun, P.M., Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: State of the art and clinical and research implications (2009) Circulation, 120, pp. 992-1007. , PMID: 19752350; Pietra, G.G., Capron, F., Stewart, S., Leone, O., Humbert, M., Robbins, I.M., Pathologic assessment of vasculopathies in pulmonary hypertension (2004) J Am Coll Cardiol, 43, pp. 25S-32S. , PMID: 15194175; Stenmark, K.R., Meyrick, B., Galie, N., Mooi, W.J., McMurtry, I.F., Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure (2009) Am J Physiol Lung Cell Mol Physiol, 297, pp. L1013-L1032. , PMID: 19748998; Rondelet, B., Kerbaul, F., Motte, S., Van Beneden, R., Remmelink, M., Brimioulle, S., Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension (2003) Circulation, 107, pp. 1329-1335. , PMID: 12628956; Silove, E.D., Tavernor, W.D., Berry, C.L., Reactive pulmonary arterial hypertension after pulmonary venous constriction in the calf (1972) Cardiovasc Res, 6, pp. 36-44. , PMID: 5014277; Pereda, D., Garcia-Alvarez, A., Sanchez-Quintana, D., Nuno, M., Fernandez-Friera, L., Fernandez-Jimenez, R., Swine model of chronic postcapillary pulmonary hypertension with right ventricular remodeling: Long-term characterization by cardiac catheterization, magnetic resonance, and pathology (2014) J Cardiovasc Transl Res, 7, pp. 494-506. , PMID: 24771313; Shelub, I., Van Grondelle, A., McCullough, R., Hofmeister, S., Reeves, J.T., A model of embolic chronic pulmonary hypertension in the dog (1984) J Appl Physiol Respir Environ Exerc Physiol, 56, pp. 810-815. , PMID: 6706785; Perkett, E.A., Davidson, J.M., Meyrick, B., Sequence of structural changes and elastin peptide release during vascular remodelling in sheep with chronic pulmonary hypertension induced by air embolization (1991) Am J Pathol, 139, pp. 1319-1332. , PMID: 1836307; Weimann, J., Zink, W., Schnabel, P.A., Jakob, H., Gebhard, M.M., Martin, E., Selective vasodilation by nitric oxide inhalation during sustained pulmonary hypertension following recurrent microembolism in pigs (1999) J Crit Care, 14, pp. 133-140. , PMID: 10527251; Kim, H., Yung, G.L., Marsh, J.J., Konopka, R.G., Pedersen, C.A., Chiles, P.G., Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension (2000) Eur Respir J, 15, pp. 640-648. , PMID: 10780753; Pohlmann, J.R., Akay, B., Camboni, D., Koch, K.L., Mervak, B.M., Cook, K.E., A low mortality model of chronic pulmonary hypertension in sheep (2012) J Surg Res, 175, pp. 44-48. , PMID: 21529838; Sato, H., Hall, C.M., Griffith, G.W., Johnson, K.F., McGillicuddy, J.W., Bartlett, R.H., Large animal model of chronic pulmonary hypertension (2008) ASAIO J, 54, pp. 396-400. , PMID: 18645357; Mercier, O., Tivane, A., Dorfmuller, P., De Perrot, M., Raoux, F., Decante, B., Piglet model of chronic pulmonary hypertension (2013) Pulm Circ, 3, pp. 908-915. , PMID: 25006407; Kelley, K.W., Curtis, S.E., Marzan, G.T., Karara, H.M., Anderson, C.R., Body surface area of female swine (1973) J Anim Sci, 36, pp. 927-930. , PMID: 4703721; Zhou, X., Wang, D., Castro, C.Y., Hawkins, H., Lynch, J.E., Liu, X., A pulmonary hypertension model induced by continuous pulmonary air embolization (2011) J Surg Res, 170, pp. e11-e16. , PMID: 21696769; Garcia-Alvarez, A., Fernandez-Friera, L., Garcia-Ruiz, J.M., Nuno-Ayala, M., Pereda, D., Fernandez-Jimenez, R., Noninvasive monitoring of serial changes in pulmonary vascular resistance and acute vasodilator testing using cardiac magnetic resonance (2013) J Am Coll Cardiol, 62, pp. 1621-1631. , PMID: 23954344; Burrowes, K.S., Clark, A.R., Tawhai, M.H., Blood flow redistribution and ventilation-perfusion mismatch during embolic pulmonary arterial occlusion (2011) Pulm Circ, 1, pp. 365-376. , PMID: 22140626; Song, J.K., Eskridge, J.M., Chung, E.C., Blake, L.C., Elliott, J.P., Finch, L., Preoperative embolization of cerebral arteriovenous malformations with silk sutures: Analysis and clinical correlation of complications revealed on computerized tomography scanning (2000) J Neurosurg, 92, pp. 955-960. , PMID: 10839255; Zeng, G.Q., Liu, R., Liao, H.X., Zhang, X.F., Qian, Y.X., Liu, B.H., Single intraperitoneal injection of monocrotaline as a novel large animal model of chronic pulmonary hypertension in Tibet minipigs (2013) PLoS One, 8, p. e78965. , PMID: 24244396; Stenmark, K.R., McMurtry, I.F., Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: A time for reappraisal? (2005) Circ Res, 97, pp. 95-98. , PMID: 16037575; Bauer, N.R., Moore, T.M., McMurtry, I.F., Rodent models of PAH: Are we there yet? (2007) Am J Physiol Lung Cell Mol Physiol, 293, pp. L580-L582. , PMID: 17660327; Gomez-Arroyo, J.G., Farkas, L., Alhussaini, A.A., Farkas, D., Kraskauskas, D., Voelkel, N.F., The monocrotaline model of pulmonary hypertension in perspective (2012) Am J Physiol Lung Cell Mol Physiol, 302, pp. L363-L369. , PMID: 21964406; Guihaire, J., Haddad, F., Boulate, D., Decante, B., Denault, A.Y., Wu, J., Non-invasive indices of right ventricular function are markers of ventricular-arterial coupling rather than ventricular contractility: Insights from a porcine model of chronic pressure overload (2013) Eur Heart J Cardiovasc Imaging, 14, pp. 1140-1149. , PMID: 23677917; Mahapatra, S., Nishimura, R.A., Sorajja, P., Cha, S., McGoon, M.D., Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension (2006) J Am Coll Cardiol, 47, pp. 799-803. , PMID: 16487848; Stevens, G.R., Garcia-Alvarez, A., Sahni, S., Garcia, M.J., Fuster, V., Sanz, J., RV dysfunction in pulmonary hypertension is independently related to pulmonary artery stiffness (2012) JACC Cardiovasc Imaging, 5, pp. 378-387. , PMID: 22498327",Article,Scopus,2-s2.0-84928791912
"Sahlin E., Sirotkina M., Marnerides A., Iwarsson E., Papadogiannakis N.","Fetal calcifications are associated with chromosomal abnormalities",2015,"PLoS ONE","10","4", e0123343,"","",,,10.1371/journal.pone.0123343,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928813759&partnerID=40&md5=02ce5e2083ac4cb38521d02c89a5d49c","Department of Molecular Medicine, Surgery and Center for Molecular Medicine, Karolinska University HospitalStockholm, Sweden; Department of Pathology, Karolinska University Hospital, Huddinge and Karolinska InstitutetStockholm, Sweden","Sahlin, E., Department of Molecular Medicine, Surgery and Center for Molecular Medicine, Karolinska University HospitalStockholm, Sweden; Sirotkina, M., Department of Pathology, Karolinska University Hospital, Huddinge and Karolinska InstitutetStockholm, Sweden; Marnerides, A., Department of Pathology, Karolinska University Hospital, Huddinge and Karolinska InstitutetStockholm, Sweden; Iwarsson, E., Department of Molecular Medicine, Surgery and Center for Molecular Medicine, Karolinska University HospitalStockholm, Sweden; Papadogiannakis, N., Department of Pathology, Karolinska University Hospital, Huddinge and Karolinska InstitutetStockholm, Sweden","Objective: The biological importance of calcifications occasionally noted in fetal tissues (mainly liver) at autopsy or ultrasound is largely unexplored. Previous reports hint at an association to infection, circulatory compromise, malformations or chromosomal abnormalities. To identify factors associated with calcifications, we have performed a case-control study on the largest cohort of fetuses with calcifications described thus far. Methods: One-hundred and fifty-one fetuses with calcifications and 302 matched controls were selected from the archives of the Department of Pathology, Karolinska University Hospital. Chromosome analysis by karyotyping or quantitative fluorescence-polymerase chain reaction was performed. Autopsy and placenta reports were scrutinized for presence of malformations and signs of infection. Results: Calcifications were mainly located in the liver, but also in heart, bowel, and other tissues. Fetuses with calcifications showed a significantly higher proportion of chromosomal abnormalities than controls; 50% vs. 20% (p<0.001). The most frequent aberrations among cases included trisomy 21 (33%), trisomy 18 (22%), and monosomy X (18%). A similar distribution was seen among controls. When comparing cases and controls with chromosomal abnormalities, the cases had a significantly higher prevalence of malformations (95% vs. 77%, p=0.004). Analyzed the other way around, cases with malformations had a significantly higher proportion of chromosomal abnormalities compared with controls, (66% vs. 31%, p<0.001). Conclusion: The presence of fetal calcifications is associated with high risk of chromosomal abnormality in combination with malformations. Identification of a calcification together with a malformation at autopsy more than doubles the probability of detecting a chromosomal abnormality, compared with identification of a malformation only. We propose that identification of a fetal tissue calcification at autopsy, and potentially also at ultrasound examination, should infer special attention towards co-existence of malformations, as this would be a strong indicator for a chromosomal abnormality. © 2015 Sahlin et al.",,"Slotnick, R.N., Abuhamad, A.Z., Prognostic Implications of Fetal Echogenic Bowel (1996) Lancet, 347, pp. 85-87. , PMID: 8538346; Kidron, D., Sharony, R., Fetal Liver Calcifications: An Autopsy Study (2012) Virchows Arch, 460, pp. 399-406. , PMID: 22391985; Hawass, N.D., El Badawi, M.G., Fatani, J.A., Al-Meshari, A., Makanjoula, D., Edress, Y.B., Foetal Hepatic Calcification (1990) Pediatr Radiol, 20, pp. 528-535. , PMID: 2216588; Pata, O., Gunduz, N.M., Unlu, C., Isolated Fetal Liver Calcifications (2012) J Turk Ger Gynecol Assoc, 13, pp. 67-69. , PMID: 24627679; Bronshtein, M., Blazer, S., Prenatal Diagnosis of Liver Calcifications (1995) Obstet Gynecol, 86, pp. 739-743. , PMID: 7566840; Koopman, E., Wladimiroff, J.W., Fetal Intrahepatic Hyperechogenic Foci: Prenatal Ultrasound Diagnosis and Outcome (1998) Prenat Diagn, 18, pp. 339-342. , PMID: 9602479; Achiron, R., Seidman, D.S., Afek, A., Malinger, G., Lipitz, S., Mashiach, S., Prenatal Ultrasonographic Diagnosis of Fetal Hepatic Hyperechogenicities: Clinical Significance and Implications for Management (1996) Ultrasound Obstet Gynecol, 7, pp. 251-255. , PMID: 8726876; Avni, E.F., Rypens, F., Donner, C., Cuvelliez, P., Rodesch, F., Hepatic Cysts and Hyperechogenicities: Perinatal Assessment and Unifying Theory on Their Origin (1994) Pediatr Radiol, 24, pp. 569-572. , PMID: 7724278; Simchen, M.J., Toi, A., Bona, M., Alkazaleh, F., Ryan, G., Chitayat, D., Fetal Hepatic Calcifications: Prenatal Diagnosis and Outcome (2002) Am J Obstet Gynecol, 187, pp. 1617-1622. , PMID: 12501073; Stein, B., Bromley, B., Michlewitz, H., Miller, W.A., Benacerraf, B.R., Fetal Liver Calcifications: Sonographic Appearance and Postnatal Outcome (1995) Radiology, 197, pp. 489-492. , PMID: 7480699; Kogutt, M.S., Hepatic Calcifications Presumably Due to Congenital Syphilis (1991) AJR Am J Roentgenol, 156, pp. 634-635. , PMID: 1899768; Yamashita, Y., Iwanaga, R., Goto, A., Kaneko, S., Yamashita, F., Waseda, N., Congenital Cytomegalovirus Infection Associated with Fetal Ascites and Intrahepatic Calcifications (1989) Acta Paediatr Scand, 78, pp. 965-967. , PMID: 2557722; Nguyen, D.L., Leonard, J.C., Ischemic Hepatic Necrosis: A Cause of Fetal Liver Calcification (1986) AJR Am J Roentgenol, 147, pp. 596-597. , PMID: 3526847; Satge, D., Gasser, B., Geneix, A., Malet, P., Stoll, C., Hepatic Calcifications in a Fetus with Trisomy 9 That Underwent Cordocentesis (1994) Prenat Diagn, 14, pp. 303-306. , PMID: 8066041; Tennstedt, C., Chaoui, R., Vogel, M., Goldner, B., Dietel, M., Pathologic Correlation of Sonographic Echogenic Foci in the Fetal Heart (2000) Prenat Diagn, 20, pp. 287-292. , PMID: 10740200; Roberts, D.J., Genest, D., Cardiac Histologic Pathology Characteristic of Trisomies 13 and 21 (1992) Hum Pathol, 23, pp. 1130-1140. , PMID: 1398642; Mann, K., Donaghue, C., Fox, S.P., Docherty, Z., Ogilvie, C.M., Strategies for the Rapid Prenatal Diagnosis of Chromosome Aneuploidy (2004) Eur J Hum Genet, 12, pp. 907-915. , PMID: 15292918; Donaghue, C., Roberts, A., Mann, K., Ogilvie, C.M., Development and Targeted Application of a Rapid Qf-Pcr Test for Sex Chromosome Imbalance (2003) Prenat Diagn, 23, pp. 201-210. , PMID: 12627420; Suzumori, N., Sugiura-Ogasawara, M., Genetic Factors as a Cause of Miscarriage (2010) Curr Med Chem, 17, pp. 3431-3437. , PMID: 20712563; Kovacs, C.S., Bone Development in the Fetus and Neonate: Role of the Calciotropic Hormones (2011) Curr Osteoporos Rep, 9, pp. 274-283. , PMID: 21904825",Article,Scopus,2-s2.0-84928813759
"Lee W.-C.","Excess relative risk as an effect measure in case-control studies of rare diseases",2015,"PLoS ONE","10","4", e0121141,"","",,,10.1371/journal.pone.0121141,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928682538&partnerID=40&md5=0878b333498176700f78b489f0c2fc7d","Research Center for Genes, Environment and Human Health, Institute of Epidemiology and Preventive Medicine, National Taiwan UniversityTaipei, Taiwan","Lee, W.-C., Research Center for Genes, Environment and Human Health, Institute of Epidemiology and Preventive Medicine, National Taiwan UniversityTaipei, Taiwan","Epidemiologists often use ratio-type indices (rate ratio, risk ratio and odds ratio) to quantify the association between exposure and disease. By comparison, less attention has been paid to effect measures on a difference scale (excess rate or excess risk). The excess relative risk (ERR) used primarily by radiation epidemiologists is of peculiar interest here, in that it involves both difference and ratio operations. The ERR index (but not the difference-type indices) is estimable in case-control studies. Using the theory of sufficient component cause model, the author shows that when there is no mechanistic interaction (no synergism in the sufficient cause sense) between the exposure under study and the stratifying variable, the ERR index (but not the ratio-type indices) in a rare-disease case-control setting should remain constant across strata and can therefore be regarded as a common effect parameter. By exploiting this homogeneity property, the related attributable fraction indices can also be estimated with greater precision. The author demonstrates the methodology (SAS codes provided) using a case-control dataset, and shows that ERR preserves the logical properties of the ratio-type indices. In light of the many desirable properties of the ERR index, the author advocates its use as an effect measure in case-control studies of rare diseases. © 2015 Wen-Chung Lee.",,"Rothman, K.J., Greenland, S., Lash, T.L., (2008) Modern Epidemiology, 3rd Ed., , Philadelphia: Lippincott; Hogue, C.J.R., Gaylor, D.W., Schulz, K.F., Estimators of relative risk for case-control studies (1983) Am J Epidemiol, 118, pp. 396-407. , PMID: 6613982; Breslow, N.E., Day, N.E., The Analysis of Case-Control Studies (1980) Statistical Methods in Cancer Research, 1. , Lyon: International Agency for Research on Cancer PMID: 7379018; Thompson, D.E., Mabuchi, K., Ron, E., Soda, M., Tokunaga, M., Ochikubo, S., Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987 (1994) Radiat Res, 137, pp. s17-s67. , PMID: 8127952; Preston, D.L., Ron, E., Tokuoka, S., Funamoto, S., Nishi, N., Soda, M., Solid cancer incidence in atomic bomb survivors: 1958-1998 (2007) Radiat Res, 168, pp. 1-64. , PMID: 17722996; Richardson, D.B., A simple approach for fitting linear relative rate models in SAS (2008) Am J Epidemiol, 168, pp. 1333-1338. , PMID: 18953061; Langholz, B., Richardson, D.B., Fitting general relative risk models for survival time and matched case-control analysis (2010) Am J Epidemiol, 171, pp. 377-1283. , PMID: 20044379; Suissa, S., Relative excess risk: An alternative measure of comparative risk (1999) Am J Epidemiol, 150, pp. 279-282. , PMID: 10430232; VanderWeele, T.J., Robins, J.M., The identification of synergism in the sufficient-component cause framework (2007) Epidemiology, 18, pp. 329-339. , PMID: 17435441; VanderWeele, T.J., Robins, J.M., Empirical and counterfactual conditions for sufficient cause interactions (2008) Biometrika, 95, pp. 49-61; VanderWeele, T.J., Sufficient cause interactions and statistical interactions (2009) Epidemiology, 20, pp. 6-13. , PMID: 19234396; Lee, W.C., Assessing causal mechanistic interactions: A peril ratio index of synergy based on multiplicativity (2013) PLoS ONE, 8, p. e67424. , PMID: 23826299; Lee, W.C., Estimation of a common effect parameter from follow-up data when there is no mechanistic interaction (2014) PLoS ONE, 9, p. e86374. , PMID: 24466062; Shapiro, S., Slone, D., Rosenberg, L., Kaufman, D.W., Stolley, P.D., Miettinen, O.S., Oral-contraceptive use in relation to myocardial infarction (1979) Lancet, 1, pp. 743-747. , PMID: 85989; Schlesselman, J.J., (1982) Case-Control Studies: Design, Conduct, Analysis, , Oxford: Oxford University Press",Article,Scopus,2-s2.0-84928682538
"Elder R.W., George R.P., McCabe N.M., Rodriguez Iii F.H., Book W.M., Mahle W.T., Kirk A.D.","Immunologic Aging in Adults with Congenital Heart Disease: Does Infant Sternotomy Matter?",2015,"Pediatric Cardiology",,,,"","",6,,10.1007/s00246-015-1174-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928595299&partnerID=40&md5=3baec6215c4953b33cd208a938aeaeb3","Section of Pediatric Cardiology, Department of Pediatrics and Internal Medicine, Yale University School of Medicine, 333 Cedar Street, 3 LCI, PO Box 208064New Haven, CT, United States; Department of Pediatric Nephrology, Emory University School of Medicine, 1405 Clifton Road, NEAtlanta, GA, United States; Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, NEAtlanta, GA, United States; Division of Pediatric Cardiology, Sibley Heart Center, Children’s Healthcare of Atlanta, Emory University School of Medicine, 1405 Clifton Road, NEAtlanta, GA, United States; Division of Cardiology, Department of Internal Medicine, Emory University School of Medicine, 1365 Clifton Road, NE, Suite A2447Atlanta, GA, United States; Department of Surgery, Duke University School of Medicine, DUMC 3704Durham, NC, United States","Elder, R.W., Section of Pediatric Cardiology, Department of Pediatrics and Internal Medicine, Yale University School of Medicine, 333 Cedar Street, 3 LCI, PO Box 208064New Haven, CT, United States; George, R.P., Department of Pediatric Nephrology, Emory University School of Medicine, 1405 Clifton Road, NEAtlanta, GA, United States; McCabe, N.M., Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, NEAtlanta, GA, United States; Rodriguez Iii, F.H., Division of Pediatric Cardiology, Sibley Heart Center, Children’s Healthcare of Atlanta, Emory University School of Medicine, 1405 Clifton Road, NEAtlanta, GA, United States; Book, W.M., Division of Cardiology, Department of Internal Medicine, Emory University School of Medicine, 1365 Clifton Road, NE, Suite A2447Atlanta, GA, United States; Mahle, W.T., Division of Pediatric Cardiology, Sibley Heart Center, Children’s Healthcare of Atlanta, Emory University School of Medicine, 1405 Clifton Road, NEAtlanta, GA, United States; Kirk, A.D., Department of Surgery, Duke University School of Medicine, DUMC 3704Durham, NC, United States","Thymectomy is performed routinely in infants undergoing cardiothoracic surgery. Children post-sternotomy have decreased numbers of T lymphocytes, although the mechanisms involved and long-term consequences of this have not been defined. We hypothesized that lymphopenia in patients with adult congenital heart disease (ACHD) would be reflective of premature T cell maturation and exhaustion. Adults with ACHD who had sternotomy to repair congenital heart disease as infants (<1 year) and age-matched ACHD patients without prior sternotomy were studied using polychromatic flow cytometry interrogating markers of lymphocyte maturation, exhaustion and senescence. Group differences were analyzed using Mann–Whitney U and Fisher’s exact tests. Eighteen ACHD patients aged 21–40 years participated: 10 cases and 8 controls. Median age at sternotomy for cases was 52 days. Cases and controls were matched for age (28.9 vs. 29.1 years; p = 0.83), gender (p = 0.15) and race (p = 0.62) and had similar case complexity. Cases had a lower mean percentage of cytotoxic CD8 lymphocytes compared to controls (26.8 vs. 33.9 %; p = 0.016), with fewer naive, undifferentiated CD8 T cells (31.0 vs. 53.6 %; p = 0.027). CD8 cells expressing PD1, a marker of immune exhaustion, trended higher in cases versus controls (25.6 vs. 19.0 %; p = 0.083). Mean percentage of CD4 cells was higher in cases versus controls (65.6 vs. 59.6 %; p = 0.027), without differences in CD4 T cell maturation subtype. In summary, ACHD patients who undergo sternotomy as infants exhibit differences in T lymphocyte composition compared to ACHD controls, suggesting accelerated immunologic exhaustion. Investigation is warranted to assess the progressive nature and clinical impact of this immune phenotypic change. © 2015 Springer Science+Business Media New York","Adult congenital heart disease; Congenital heart disease; Immune function; Surgery; Thymectomy",,Article in Press,Scopus,2-s2.0-84928595299
"Ou X.-H., Li M.-L., Liu R., Fan X.-R., Mao L., Fan X.-H., Yang Y., Zeng X.-R.","Remodeling of K<inf>v</inf>1.5 channel in right atria from Han Chinese patients with atrial fibrillation",2015,"Medical Science Monitor","21",,,"1207","1213",,,10.12659/MSM.893533,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928709508&partnerID=40&md5=130d017ac2e57114630307033f157f0f","Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China","Ou, X.-H., Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China; Li, M.-L., Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China; Liu, R., Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China; Fan, X.-R., Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China; Mao, L., Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China; Fan, X.-H., Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China; Yang, Y., Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China; Zeng, X.-R., Institute of Cardiovascular Research, Luzhou Medical CollegeLuzhou, Sichuan, China","Background: The incidence of atrial fibrillation (AF) in rheumatic heart diseases (RHD) is very high and increases with age. Occurrence and maintenance of AF are very complicated process accompanied by many different mechanisms. Ion-channel remodeling, including the voltage-gated potassium channel K<inf>v</inf>1.5, plays an important role in the pathophysiology of AF. However, the changes of K<inf>v</inf>1.5 channel expression in Han Chinese patients with RHD and AF remain poorly understood. The aim of the present study was to investigate whether the K<inf>V</inf>1.5 channels of the right atria may be altered with RHD, age, and sex to contribute to AF. Material/Methods: Right atrial appendages were obtained from 20 patients with normal cardiac functions who had undergone surgery, and 26 patients with AF. Subjects were picked from 4 groups: adult and aged patients in normal sinus rhythm (SR) and AF. Patients were divided into non-RHD and RHD groups or men and women groups in normal SR and AF, respectively. The expression of K<inf>v</inf>1.5 protein and messenger RNA (mRNA) were measured using Western blotting and polymerase chain reaction (PCR) method, respectively. Results: Compared with the SR group, the expression of K<inf>v</inf>1.5 protein decreased significantly in the AF group. However, neither K<inf>v</inf>1.5 protein nor KCNA5 mRNA had significant differences in adult and aged groups, non-RHD and RHD group, and men and women group of AF. Conclusions: The expression of K<inf>v</inf>1.5 channel protein changes with AF but not with age, RHD, and sex in AF. © Med Sci Monit.","Aging; Atrial fibrillation; Kv 1.5 potassium channel; Rheumatic heart disease; Sex","Heeringa, J., Van Der Kuip, D.A., Hofman, A., Prevalence, incidence and lifetime risk of atrial fibrillation: The rotterdam study (2006) Eur Heart J, 27, pp. 949-953; Nattel, S., Burstein, B., Dobrev, D., Atrial remodeling and atrial fibrillation: Mechanisms and implications (2008) Circ Arrhythm Electrophysiol, 1 (1), pp. 62-73; Allessie, M., Ausma, J., Schotten, U., Electrical, contractile and structural remodeling during atrial fibrillation (2002) Cardiovasc Res, 54, pp. 230-246; Brundel, B.J., Van Gelder, I.C., Henning, R.H., Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation (2001) Circulation, 103, pp. 684-690; Bosch, R.F., Zeng, X., Grammer, J.B., Ionic mechanisms of electrical remodeling in human atrial fibrillation (1999) Cardiovasc Res, 44, pp. 121-131; Grammer, J.B., Bosch, R.F., Kuhlkamp, V., Seipel, L., Molecular remodeling of kv4.3 potassium channels in human atrial fibrillation (2000) J Cardiovasc Electrophysiol, 11, pp. 626-633; Lai, L.P., Su, M.J., Lin, J.L., Changes in the mrna levels of delayed rectifier potassium channels in human atrial fibrillation (1999) Cardiology, 92, pp. 248-255; Van Wagoner, D.R., Pond, A.L., McCarthy, P.M., Outward k+ current densities and K<inf>v</inf>1.5 expression are reduced in chronic human atrial fibrillation (1997) Circ Res, 80, pp. 772-781; January, C.T., Wann, L.S., Alpert JS et al: 2014 aha/acc/hrs guideline for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society (2014) Circulation, 130, pp. 2071-2104; Schiller, N.B., Shah, P.M., Crawford, M., Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms (1989) J am Soc Echocardiogr, 2 (5), pp. 358-367; Tamkun, M.M., Knoth, K.M., Walbridge, J.A., Molecular cloning and characterization of two voltage-gated k+ channel cdnas from human ventricle (1991) FASEB J, 5, pp. 331-337; Van Wagoner, D.R., Pond, A.L., McCarthy, P.M., Outward k+ current densities and K<inf>v</inf>1.5 expression are reduced in chronic human atrial fibrillation (1997) Circ Res, 80, pp. 772-781; Brundel, B.J., Van Gelder, I.C., Henning, R.H., Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: Differential regulation of protein and mrna levels for k+ channels (2001) J am Coll Cardiol, 37 (3), pp. 926-932; Billman, G.E., Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks k(V)1.5 channels, for the potential treatment of atrial fibrillation (2010) Curr Opin Investig Drugs, 11, pp. 1048-1058; Lau, C.P., Tse, H.F., Siu, C.W., Gbadebo, D., Atrial electrical and structural remodeling: Implications for racial differences in atrial fibrillation (2012) J Cardiovasc Electrophysiol, 23, pp. S36-S40; Gao, M., Wang, J., Wang, Z., An altered expression of genes involved in the regulation of ion channels in atrial myocytes is correlated with the risk of atrial fibrillation in patients with heart failure (2013) Exp Ther Med, 5, pp. 1239-1243; Voigt, N., Heijman, J., Wang, Q., Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation (2014) Circulation, 129, pp. 145-156; Slagsvold, K.H., Johnsen, A.B., Rognmo, O., Comparison of left versus right atrial myocardium in patients with sinus rhythm or atrial fibrillation – an assessment of mitochondrial function and microrna expression (2014) Physiol Rep, 2 (8), pp. e12124; Trovato, G.M., Pace, P., Cangemi, E., Gender, lifestyles, illness perception and stress in stable atrial fibrillation (2012) Clin Ther, 163, pp. 281-286; Xu, G.J., Gan, T.Y., Tang, B.P., Age-related changes in cellular electrophysiology and calcium handling for atrial fibrillation (2013) J Cell Mol Med, 17, pp. 1109-1118; Dun, W., Boyden, P.A., Aged atria: Electrical remodeling conducive to atrial fibrillation (2009) J Interv Card Electrophysiol, 25, pp. 9-18",Article,Scopus,2-s2.0-84928709508
"Amanullah M.M., Hamid M., Hanif H.M., Muzaffar M., Siddiqui M.T., Adhi F., Ahmad K., Khan S., Hasan Z.","Effect of steroids on inflammatory markers and clinical parameters in congenital open heart surgery: a randomised controlled trial",2015,"Cardiology in the Young",,,,"","",10,,10.1017/S1047951115000566,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928599255&partnerID=40&md5=01399e36dc766e80d3108bb74c019782","Department of Surgery, AKUH, Karachi, Pakistan; Department of Cardiac Anaesthesia, AKUH, Karachi, Pakistan; Medical College, Agha Khan University, AKUH, Karachi, Pakistan; Department of Pathology and Microbiology, AKUH, Karachi, Pakistan","Amanullah, M.M., Department of Surgery, AKUH, Karachi, Pakistan; Hamid, M., Department of Cardiac Anaesthesia, AKUH, Karachi, Pakistan; Hanif, H.M., Department of Surgery, AKUH, Karachi, Pakistan; Muzaffar, M., Department of Surgery, AKUH, Karachi, Pakistan; Siddiqui, M.T., Department of Surgery, AKUH, Karachi, Pakistan; Adhi, F., Department of Surgery, AKUH, Karachi, Pakistan; Ahmad, K., Department of Surgery, AKUH, Karachi, Pakistan; Khan, S., Medical College, Agha Khan University, AKUH, Karachi, Pakistan; Hasan, Z., Department of Pathology and Microbiology, AKUH, Karachi, Pakistan","Background: Cardiopulmonary bypass is associated with systemic inflammatory response. Steroids suppress this response, although the therapeutic evidence remains controversial. We hypothesised that intravenous steroids in children undergoing open-heart surgery would decrease inflammation leading to better early post-operative outcomes. We conducted a randomised controlled trial to evaluate the trends in the levels of immunomodulators and their effects on clinical parameters. Objective: To assess the effects of intravenous steroids on early post-operative inflammatory markers and clinical parameters in children undergoing open-heart surgery. Materials and methods: A randomised controlled trial involving 152 patients, from one month up to 18 years of age, who underwent open-heart surgery for congenital heart disease from April 2010–2012 was carried out. Patients were randomised and administered either three scheduled intravenous pulse doses of dexamethasone (1 mg/kg) or placebo. Blood samples were drawn at four time intervals and serum levels of inflammatory cytokines – Interleukin-6, 8, 10, 18, and tumour necrosis factor-alpha – were measured. Clinical parameters were also assessed. Results: Blood cytokine levels were compared between the dexamethasone (n=65) and placebo (n=64) groups. Interleukin-6 levels were lower at 6 and 24 hours post-operatively (p<0.001), and Interleukin-10 levels were higher 6 hours post-operatively (p<0.001) in the steroid group. Interleukin-8, 18, and tumour necrosis factor-alpha levels did not differ between the groups at any time intervals. The clinical parameters were similar in both the groups. Conclusion: Dexamethasone caused quantitative suppression of Interleukin-6 and increased Interleukin-10 activation, contributing to reduced immunopathology, but it did not translate into clinical benefit in the short term. © Cambridge University Press 2015","Cardiopulmonary bypass; congenital heart disease; inflammatory markers; steroids",,Article in Press,Scopus,2-s2.0-84928599255
"Charach G., Rubalsky O., Charach L., Rabinovich A., Argov O., Rogowski O., George J.","Internal thoracic impedance - A useful method for expedient detection and convenient monitoring of pleural effusion",2015,"PLoS ONE","10","4", e0122576,"","",,,10.1371/journal.pone.0122576,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928685127&partnerID=40&md5=f5d0b152cd29944890288052fcec0380","Department of Internal Medicine C, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv, Israel; Cardiology Department Kaplan Medical Center, Hebrew University Medical CenterJerusalem, Israel","Charach, G., Department of Internal Medicine C, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv, Israel; Rubalsky, O., Department of Internal Medicine C, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv, Israel; Charach, L., Department of Internal Medicine C, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv, Israel; Rabinovich, A., Department of Internal Medicine C, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv, Israel; Argov, O., Department of Internal Medicine C, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv, Israel; Rogowski, O., Department of Internal Medicine C, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv, Israel; George, J., Department of Internal Medicine C, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv, Israel, Cardiology Department Kaplan Medical Center, Hebrew University Medical CenterJerusalem, Israel","Measurement of internal thoracic impedance (ITI) is sensitive and accurate in detecting acute pulmonary edema even at its preclinical stage. We evaluated the suitability of the highly sensitive and noninvasive RS-207 monitor for detecting pleural effusion and for demonstrating increased ITI during its resolution. This prospective controlled study was performed in a single department of internal medicine of a university-affiliated hospital between 2012-2013. One-hundred patients aged 25-96 years were included, of whom 50 had bilateral or right pleural effusion of any etiology (study group) and 50 had no pleural effusion (controls). ITI, the main component of which is lung impedance, was continuously measured by the RS-207 monitor. The predictive value of ITI monitoring was determined by 8 measurements taken every 8 hours. Pleural effusion was diagnosed according to well-accepted clinical and roentgenological criteria. During treatment, the ITI of the study group increased from 32.9±4.2 ohm to 42.8±3.8 ohm (p<0.0001) compared to non-significant changes in the control group (59.6±6.6 ohm, p = 0.24). Prominent changes were observed in the respiratory rate of the study group: there was a decrease from 31.2± 4.0 to 19.5±2.4 ohm (35.2%) compared to no change for the controls, and a mean increase from 83.6±5.3%-92.5±1.6% (13.2%) in O2 saturation compared to 94.2±1.7% for the controls. Determination of ITI for the detection and monitoring of treatment of patients with pleural effusion enables earlier diagnosis and more effective therapy, and can prevent hospitalization and serious complications, such as respiratory distress, and the need for mechanical ventilation. Trial Registration: The study is registered at ClinicalTrials.gov NCT01601444. © 2015 Charach et al.",,"Luepker, R.V., Michael, J.R., Warbasse, J.R., Transthoracic electrical impedance: Quantitative evaluation of non-invasive measure of thoracic fluid volume (1973) Am Heart J, 85, pp. 83-93. , PMID: 4734144; Fein, A., Grossman, R.F., Jones, G., Goodman, P.C., Murray, J.F., Evaluation of transthoracic electrical impedance in the diagnosis of pulmonary edema (1979) Circulation, 60, pp. 1156-1160. , PMID: 487548; Saunders, C.E., The use of transthoracic electrical bio impedance in assessing thoracic fluid status in emergency department patients (1988) Am J Emerg Med, 6, pp. 337-340. , PMID: 3390250; Spinale, F.G., Reines, H.D., Cook, M.C., Crawford, F.A., Noninvasive estimation of extravascular lung water (1989) J Surg Res, 47, pp. 535-540. , PMID: 2685470; Zellner, J.L., Spinale, F.G., Crawford, F.A., Bioimpedance: A novel method for the determination of extravascular lung water (1990) J Surg Res, 48, pp. 454-459. , PMID: 2112668; Campbell, J.H., Harris, N.D., Zhang, F., Morice, A.H., Brown, B.H., Detection of changes in intrathoracic fluid in man using electrical impedance tomography (1994) Clin Sci (Lond), 87, pp. 97-101. , PMID: 8062525; Newell, J.C., Edis, P.M., Ren, X., Larson-Wiseman, J.L., Danyleiko, M.D., Assessment of acute pulmonary edema in dogs by electrical impedance imaging (1996) IEEE Trans Biomed Eng, 43, pp. 133-138. , PMID: 8682524; Charach, G., Shochat, M., Rabinovich, A., Ayzenberg, O., George, J., Charach, L., Preventive treatment of alveolar pulmonary edema of cardiogenic origin (2012) J Geriatr Cardiol, 9, pp. 321-327. , PMID: 23341835; Yu, C.-M., Wang, L., Chau, E., Chan, R.H., Kong, S.L., Tang, M.O., Intrathoracic impedance monitoring in patients with heart failure (2005) Circulation, 112, pp. 841-848. , PMID: 16061743; Kubicek, W.G., Patterson, R.P., Witsoe, D.A., Impedance cardiography as a noninvasive method of monitoring cardiac function and other parameters of the cardiovascular system Ann NY Acad Sci International Conference of Bioelectrical Impedance, 1970, 170, pp. 724-731. , Art. 2; Anderson, F.A., Impedance plethysmography (1980) Encyclopedia of Medical Devices and Instrumentation., pp. 1632-1643. , Edited by Webster JG. New York: Wiley-Inter Science Publication, Wiley and Sons; Rabinovich, P., Shochat, M., Zeldin, V., Milman, O., Method and device for stable impedance plethysmography (1998), US Patent May 12Shochat, M., Shotan, A., Blondheim, D.S., Kazatsker, M., Dahan, I., Asif, A., Usefulness of lung impedance-guided pre-emptive therapy to prevent pulmonary edema during ST-elevation myocardial infarction and to improve long-term outcomes (2012) Am J Cardiol, 110, pp. 190-196. , PMID: 22482863; Quaglietti, S.E., Atwood, J.E., Ackerman, L., Froelicher, V., Management of the patient with congestive heart failure using outpatient, home, and palliative care (2000) Prog Cardiovasc Dis, 43, pp. 259-274. , PMID: 11153512; Charach, G., Rabinovich, P., Grosskopf, I., Weintraub, M., Transthoracic monitoring of the impedance of the right lung in patients with cardiogenic pulmonary edema (2001) Crit Care Med, 29, pp. 1137-1144. , PMID: 11395588; Shochat, M., Meisel, S., Rabinovich, P., Peled, B., Monitoring of the internal thoracic impedance: A novel method to detect pulmonary edema before appearance of clinical signs Supp. J Am Col Cardiol 52ndAnnual Scientific Session. 2003, pp. 1206-1273; Shochat, M., Meisel, S., Rabinovich, P., Peled, B., Shotan, A., A new method for detecting cardiogenic pulmonary edema before appearance of clinical signs and for the evaluation of treatment efficacy Supp. J Am Coll Cardiol 53nd Annual Scientific Session 2004, 43, pp. 1154-1196. , PMID: 15063422; Shochat, M., Charach, G., Frimerman, A., Rabinovich, P., Shotan, A., Meisel, S., Internal thoracic impedance monitoring: A new prospect in acute heart failure (2004) Eur Heart J, 25; Shochat, M., Kazatzker, M., Charach, G., Fremerman, A., Rabinovich, P., Shotan, A., Internal thoracic impedance monitoring: A new tool for the early diagnosis and treatment of acute heart failure (2005) Eur J Heart Fail, 4; Shochat, M., Charach, G., Meyler, S., Kazatzker, M., Mosseri, M., Frimerman, A., Internal thoracic impedance monitoring: A novel method for the early detection of cardiogenic pulmonary congestion at the pre-clinical stage (2006) Cardiovasc Revasc Med, 7, pp. 41-45. , PMID: 16513522; Shochat, M., Charach, G., Meyler, S., Meisel, S., Weintraub, M., Mengeritsky, G., Mosseri, M., Rabinovich, P., Prediction of cardiogenic pulmonary edema onset by monitoring right lung impedance (2006) Intensive Care Med, 32, pp. 1214-1221. , PMID: 16775717",Article,Scopus,2-s2.0-84928685127
"Guo J., Shi X., Yang W., Gong S., Zhao Q., Wang L., He J., Shi X., Sun X., Liu J.","Exercise physiology and pulmonary hemodynamic abnormality in PH patients with exercise induced venous-to-systemic shunt",2015,"PLoS ONE","10","4", e0121690,"","",,,10.1371/journal.pone.0121690,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928719890&partnerID=40&md5=4838b035d9938c9cef533c0cba4e1b57","Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Heart-Lung Function Testing Center, Chinese Academy of Medical Sciences, Peking Union Medical CollegeBeijing, China","Guo, J., Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Shi, X., Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Yang, W., Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Gong, S., Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Zhao, Q., Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Wang, L., Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; He, J., Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Shi, X., Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China; Sun, X., Heart-Lung Function Testing Center, Chinese Academy of Medical Sciences, Peking Union Medical CollegeBeijing, China; Liu, J., Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China, Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai, China","Objectives: To identify the pulmonary hypertension (PH) patients who develop an exercise induced venous-to-systemic shunt (EIS) by performing the cardiopulmonary exercise test (CPET), analyse the changes of CPET measurements during exercise and compare the exercise physiology and resting pulmonary hemodynamics between shunt-PH and no-shunt-PH patients. Methods: Retrospectively, resting pulmonary function test (PFT), right heart catheterization (RHC), and CPET for clinical evaluation of 104 PH patients were studied. Results: Considering all 104 PH patients by three investigators, 37 were early EIS+, 61 were EIS-, 3 were late EIS+, and 3 others were placed in the discordant group. PeakVO<inf>2</inf>, AT and OUES were all reduced in the shunt-PH patients compared with the no-shunt-PH subjects, whereas VE/VCO<inf>2</inf> slope and the lowest VE/VCO<inf>2</inf> increased. Besides, the changes and the response characteristics of the key CPET parameters at the beginning of exercise in the shunt group were notably different from those of the no shunt one. At cardiac catheterization, the shunt patients had significantly increased mean pulmonary artery pressure (mPAP), mean right atrial pressure (mRAP) and pulmonary vascular resistance (PVR), reduced cardiac output (CO) and cardiac index (CI) compared with the no shunt ones (P<0.05). Resting CO was significantly correlated with exercise parameters of AT (r = 0.527, P<0.001), OUES (r = 0.410, P<0.001) and Peak VO<inf>2</inf> (r = 0.405, P<0.001). PVR was significantly, but weakly, correlated with the above mentioned CPET parameters. In Conclusions: CPET may allow a non-invasive method for detecting an EIS and assessing the severity of the disease in PH patients. © 2015 Guo et al.",,"Rubin, L.J., Current concepts: Primary pulmonary hypertension (1997) N Engl J Med, 336, pp. 111-117. , PMID: 8988890; D'Alonzo, G.E., Barst, R.J., Ayres, S.M., Bergofsky, E.H., Brundage, B.H., Detre, K.M., Survival in patients with primary pulmonary hypertension: Results from a national prospective registry (1991) Ann Intern Med, 115, pp. 343-349. , PMID: 1863023; Opitz, C.F., Wensel, R., Winkler, J., Halank, M., Bruch, L., Kleber, F.X., Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension (2005) Eur Heart J, 26, pp. 1895-1902. , PMID: 15888496; Sietsema, K.E., Cooper, D.M., Perloff, J.K., Child, J.S., Rosove, M.H., Wasserman, K., Control of ventilation during exercise in patients with central venous-to-systemic arterial shunts (1988) J Appl Physiol, 64, pp. 234-242. , PMID: 3356640; Sun, X.-G., Hansen, J.E., Oudiz, R.J., Wasserman, K., Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension (2002) Circulation, 105, pp. 54-60. , PMID: 11772876; Moorthy, S.S., Losasso, A.M., Patency of the foramen ovale in the critically ill patient (1974) Anesthesiology, 41, pp. 405-407. , PMID: 4606888; Hagen, P.T., Scholz, D.G., Edwards, W.D., Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts (1984) Mayo Clin Proc, 59, pp. 17-20. , PMID: 6694427; Oudiz, R.J., Middle, R., Hovanesyan, A., Sun, X.G., Roveran, G., Hansen, J.E., Usefulness of right-to-left shunting and poor exercise gas exchange for predicting prognosis in patients with pulmonary arterial hypertension (2010) Am J Cardiol, 105 (8), pp. 1186-1191. , PMID: 20381675; Yasunobu, Y., Oudiz, R.J., Sun, X.G., Hansen, J.E., Wasseeman, K., End-tidal Pco2 abnormality and exercise limitation in patients with primary pulmonary hypertension (2005) Chest, 127, pp. 1637-1646. , PMID: 15888840; Oudiz, R.J., Roveran, G., Hansen, J.E., Sun, X.G., Wasserman, K., Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension (2007) Eur J Heart Fail, 9, pp. 917-921. , PMID: 17707133; Simonneau, G., Gatzoulis, M.A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Updated clinical classification of pulmonary hypertension (2013) J Am Coll Cardiol, 62 (25), pp. D34-D41. , Dec 24 PMID: 24355639; American Thoracic Society, Guidelines for the six-minute walk test. ATS statement (2002) Am J Respir Crit Care Med, p. 166; Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R.O., Burgos, F., Casaburi, R., Interpretative strategies for lung function tests (2005) Eur Respir J, 26, pp. 948-968. , PMID: 16264058; Zheng, J., Zhong, N., Normative values of pulmonary function testing in Chinese adults (2002) Chin Med J, 115, pp. 50-54. , PMID: 11930658; American Thoracic Society, American College of Chest Physicians, ATS/ACCP statement on cardiopulmonary exercise testing (2003) Am J Respir Crit Care Med, 167, pp. 211-277. , PMID: 12524257; Sue, D.Y., Wasserman, K., Impact of integrative cardiopulmonary exercise testing on clinical decision making (1991) Chest, 99, pp. 981-992. , PMID: 2009806; Beaver, W.L., Wasserman, K., Whipp, B.J., A new method for detecting anaerobic threshold by gas exchange (1986) J Appl Physiol, 60, pp. 2020-2027. , PMID: 3087938; Sun, X.G., Hansen, J.E., Garatachea, N., Storer, T.W., Wasserman, K., Ventilatory efficiency during exercise in healthy subjects (2002) Am J Respir Crit Care Med, 166 (11), pp. 1443-1448. , Dec 1 PMID: 12450934; Baba, R., Nagashima, M., Goto, M., Nagano, Y., Yokota, M., Tauchi, N., Oxygen uptake efficiency slope: A new index of cardiorespiratory functional reserve derived from the relation between 25 oxygen uptake and minute ventilation during incremental exercise (1996) J Am Coll Cardiol, 28, pp. 1567-1572. , PMID: 8917273; Ting, H., Sun, X.G., Chuang, M.L., Lewis, D.A., Hansen, J.E., Wasserman, K., A noninvasive assessment of pulmonary perfusion abnormality in patients with primary pulmonary hypertension (2000) Chest, 119, pp. 824-832; Sun, X.G., Hansen, J.E., Oudiz, R.J., Wasserman, K., Exercise pathophysiology in patients with primary pulmonary hypertension (2001) Circulation, 104, pp. 429-435. , PMID: 11468205; Sun, X.G., Hansen, J.E., Sringer, W.W., Oxygen uptake efficiency plateau best predicts early death in heart failure (2012) Chest, 141 (5), pp. 1284-1294. , PMID: 22030802; Guazzi, M., Myers, J., Arena, R., Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure (2005) J Am Coll Cardiol, 46, pp. 1883-1890. , PMID: 16286176; Arena, R., Myers, J., Guazzi, M., The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: An evidence-based review (2008) Heart Fail Rev, 13, pp. 245-269. , PMID: 17987381; Reindl, I., Werneck, K.-D., Opitz, C., Impaired ventilatory efficiency in chronic heart failure: 14 possible role of pulmonary vasoconstriction (1998) Am Heart J, 136, pp. 778-785. , PMID: 9812071; Mortara, A., La Rovere, M.T., Pinna, G.D., Arterial baroreflex modulation of heart rate in chronic heart failure: Clinical and hemodynamic correlates and prognostic implications (1997) Circulation, 96, pp. 3450-3458. , PMID: 9396441; Ponikowski, P., Anker, S.D., Chua, T.P., Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy (1997) Am J Cardiol, 79, pp. 1645-1650. , PMID: 9202356; Davies, L.C., Wensel, R., Georgiadou, P., Cicoira, M., Coats, A.J., Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: Oxygen uptake efficiency slope (2006) Eur Heart J, 27, pp. 684-690. , PMID: 16338939; Sun, X.G., Hansen, J.E., Sringer, W.W., Oxygen uptake efficiency plateau best predicts early death in heart failure (2012) Chest, 141, pp. 1284-1294. , PMID: 22030802; Sun, X.G., Hansen, J.E., Sringer, W.W., Oxygen uptake efficiency plateau: Physiology and reference values (2012) Eur J Appl Physiol, 112, pp. 919-928. , PMID: 21695524; Rich, S., Lam, W., Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension (1983) Am J Cardiol, 51, pp. 1560-1561. , PMID: 6189385; Barst, R.J., Role of atrial septostomy in the treatment of pulmonary vascular disease (2000) Thorax, 55, pp. 95-96. , PMID: 10639523; Wensel, R., Opitz, C.F., Ewert, R., Bruch, L., Kleber, F.X., Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension (2000) Circulation, 101, pp. 2388-2392. , PMID: 10821815; Rhodes, J., Barst, R.J., Garofano, R.P., Thoele, D.G., Gersony, W.M., Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension (1991) J Am Coll Cardiol, 18, pp. 1738-1744. , PMID: 1960322; Groepenhoff, H., Vonk-Noordegraaf, A., Boonstra, A., Spreeuwenberg, M.D., Postmus, P.E., Bogaard, H.J., Exercise testing to estimate survival in pulmonary hypertension (2008) Med Sci Sports Exerc, 40, pp. 1725-1732. , PMID: 18799981; Fleg, J.L., Pina, I.L., Balady, G.J., Chaitman, B.R., Fletcher, B., Lavie, C., Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association (2000) Circulation, 102, pp. 1591-1597. , PMID: 11004153; Lynch, J.J., Schuchard, G.H., Gross, C.M., Wann, L.S., Prevalence of right-to-left atrial shunting in a healthy population: Detection by Valsalva maneuver contrast echocardiography (1984) Am J Cardiol, 53, pp. 1478-1480. , PMID: 6720602; Lechat, P., Mas, J.L., Lascault, G., Loron, P., Theard, M., Klimczac, M., Prevalence of patent foramen ovalein patients with stroke (1988) N Engl J Med, 318, pp. 1148-1152. , PMID: 3362165; De Belder, M.A., Tourikis, L., Leech, G., Camm, A.J., Risk of patent foramen ovale for thromboembolic events in all age groups (1992) Am J Cardiol, 69, pp. 1316-1320. , PMID: 1585866",Article,Scopus,2-s2.0-84928719890
"Chen G.M., Yu Z.H., Nie X.J., Li Z., Sun Z.W., Weng Z.F., Yang Y.Y., Chen S.L., Wang C.F., Zheng S.R., Luo Y.Y., Lu Y.T., Cao H.Q., Zhan H.X.","Plasma exchange parameter selection and safety observation of children with severe ricinism",2015,"Genetics and Molecular Research","14","2",,"4169","4176",,,10.4238/2015.April.27.32,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928592433&partnerID=40&md5=37419428c83b8062aab9afff4b83e9f2","Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China","Chen, G.M., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Yu, Z.H., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Nie, X.J., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Li, Z., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Sun, Z.W., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Weng, Z.F., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Yang, Y.Y., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Chen, S.L., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Wang, C.F., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Zheng, S.R., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Luo, Y.Y., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Lu, Y.T., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Cao, H.Q., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China; Zhan, H.X., Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University, Affliated Dongfang Hospital of Xiamen UniversityFuzhou, China","The aim of this study was to investigate the selection of plasma exchange (PE) parameters and the safety of children with severe ricinism. The PE parameters and heparin dosage in 7 children with severe ricinism were recorded, and changes in the patients’ vital signs and coagulation function were monitored before and after PE. All patients successfully completed PE. The speed of blood fow was 50-80 mL/min, speed of exchange fow was 600-800 mL/h, and isolating rate of blood plasma was 12.5-19.05%. Transmembrane pressure was stable at approximately 100 mmHg, and venous pressure was stable at approximately 95 mmHg. The frst dose of heparin was 0.39 ± 0.04 mg/ kg, and the maintaining heparin dose was 0.40 ± 0.05 to 0.22 ± 0.03 mg·kg-1·h-1. During the PE process, mean arterial pressure, heart rate, respiratory rate, and pulse oxygen saturation were steady. After PE, the activated partial thromboplastin time and thrombin time prolonged to 2-3 times greater than that before PE. However, no bleeding tendency was seen. For children with severe ricinism, the choice of PE to eliminate the toxin from blood, tissues, and organs was safe and effective. © FUNPEC-RP.","PE parameters; Plasma exchange (PE); Rescue treatment; Ricinism; Ricinus communis","Assiri, A.S., Ricin poisoning causing death after ingestion of herbal medicine (2012) Ann. Saudi Med, 32, pp. 315-317; Audi, J., Belson, M., Patel, M., Schier, J., Ricin poisoning: A comprehensive review (2005) JAMA, 294, pp. 2342-2351; Balint, G.A., Ricin: The toxic protein of castor oil seeds (1974) Toxicology, 2, pp. 77-102; Basic-Jukic, N., Kes, P., Glavas-Boras, S., Brunetta, B., Complications of therapeutic plasma exchange: Experience with 4857 treatments (2005) Ther. Apher. Dial, 9, pp. 391-395; Brandon, D.L., Korn, A.M., Yang, L.L., Detection of ricin contamination in liquid egg by electrochemiluminescence immunosorbent assay (2012) J. Food Sci, 77, pp. T83-T88; Buonocore, C., Alipour, M., Omri, A., Pucaj, K., Treatment of ricin A-chain-induced hepatotoxicity with liposome-encapsulated N-acetylcysteine (2011) J. Drug Target, 19, pp. 821-829; Challoner, K.R., McCarron, M.M., Castor bean intoxication (1990) Ann. Emerg. Med, 19, pp. 1177-1183; Erkurt, M.A., Kuku, I., Kaya, E., Ozgen, U., Therapeutic plasma-exchange in hematologic disease: Results from a single center in Eastern Anatolia (2013) Transfus. Apher. Sci, 48, pp. 335-339; Hu, W.G., Yin, J., Chau, D., Negrych, L.M., Humanization and characterization of an anti-ricin neutralization monoclonal antibody (2012) Plos One, 7; Inoue, D., Togami, K., Shimoike, N., Tamura, R., Early diagnosis and successful treatment of catastrophic antiphospholipid syndrome complicated by multiple organ failure (2010) Nihon Rinsho Meneki Gakkai Kaishi, 33, pp. 24-30; Kaya, E., Keklik, M., Sencan, M., Yilmaz, M., Therapeutic plasma exchange in patients with neurological diseases: Multicenter retrospective analysis (2013) Transfus. Apher. Sci, 48, pp. 349-352; Lim, H., Kim, H.J., Cho, Y.S., A case of ricin poisoning following ingestion of (2009) Korean Castor Bean. Emerg. Med. J, 26, pp. 301-302; McGuckin, S., Westwood, J.P., Webster, H., Collier, D., Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: A single institution experience (2014) Vox Sang, 106, pp. 161-166; Musshoff, F., Madea, B., Ricin poisoning and forensic toxicology (2009) Drug Test. Anal, 1, pp. 184-191; Nakae, H., Igarashi, T., Tajimi, K., Selective plasma exchange with dialysis in patients with acute liver failure (2012) Ther. Apher. Dial, 16, pp. 467-471; Naumnik, B., Pawlak, K., Myśliwiec, M., Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: A cross-over study (2009) Thromb. Res, 123, pp. 631-636; Qiu, H.M., Zheng, S.C., Wan, W.G., Zou, H.J., Meta-analysis of the effectiveness of plasma exchange in treatment of severe and acute organophosphate poisoning (2011) Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, 29, pp. 779-781; Qu, L., Kiss, J.E., Dargo, G., Carcillo, J.A., Outcomes of previously healthy pediatric patients with fulminant sepsis-induced multisystem organ failure receiving therapeutic plasma exchange (2011) J. Clin. Apher, 26, pp. 208-213; Roche, J.K., Stone, M.K., Gross, L.K., Lindner, M., Post-exposure targeting of specifc epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model (2008) Lab. Invest, 88, pp. 1178-1191; Schutt, R.C., Ronco, C., Rosner, M.H., The role of therapeutic plasma exchange in poisonings and intoxications (2012) Semin. Dial, 25, pp. 201-206; Shen, J.I., Winkelmayer, W.C., Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis (2012) Am. J. Kidney Dis, 60, pp. 473-486; Stenbøg, P., Busk, T., Larsen, F.S., Effcacy of liver assisting in patients with hepatic encephalopathy with special focus on plasma exchange (2013) Metab. Brain Dis, 28, pp. 333-335",Article,Scopus,2-s2.0-84928592433
"Gleason R.L., Caulk A.W., Seifu D., Parker I., Vidakovic B., Getenet H., Assefa G., Amogne W.","Current efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia",2015,"PLoS ONE","10","4", e0117125,"","",,,10.1371/journal.pone.0117125,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928670685&partnerID=40&md5=e56fcc7a570f851275c6547a2fb03838","George W. Woodruff School of Mechanical Engineering, Georgia Institute of TechnologyAtlanta, GA, United States; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of TechnologyAtlanta, GA, United States; Petit Institute for Bioengineering and Bioscience, Georgia Institute of TechnologyAtlanta, GA, United States; Department of Biochemistry, Medical Faculty, Addis Ababa UniversityAddis Ababa, Ethiopia; Department of Internal Medicine, Medical Faculty, Addis Ababa UniversityAddis Ababa, Ethiopia; Department of Radiology, Medical Faculty, Addis Ababa UniversityAddis Ababa, Ethiopia","Gleason, R.L., Jr., George W. Woodruff School of Mechanical Engineering, Georgia Institute of TechnologyAtlanta, GA, United States, Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of TechnologyAtlanta, GA, United States, Petit Institute for Bioengineering and Bioscience, Georgia Institute of TechnologyAtlanta, GA, United States; Caulk, A.W., George W. Woodruff School of Mechanical Engineering, Georgia Institute of TechnologyAtlanta, GA, United States; Seifu, D., Department of Biochemistry, Medical Faculty, Addis Ababa UniversityAddis Ababa, Ethiopia; Parker, I., Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of TechnologyAtlanta, GA, United States; Vidakovic, B., Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of TechnologyAtlanta, GA, United States; Getenet, H., Department of Internal Medicine, Medical Faculty, Addis Ababa UniversityAddis Ababa, Ethiopia; Assefa, G., Department of Radiology, Medical Faculty, Addis Ababa UniversityAddis Ababa, Ethiopia; Amogne, W., Department of Internal Medicine, Medical Faculty, Addis Ababa UniversityAddis Ababa, Ethiopia","Background: HIV patients on antiretroviral therapy have shown elevated incidence of dyslipidemia, lipodystrophy, and cardiovascular disease (CVD). Most studies, however, focus on cohorts from developed countries, with less data available for these co-morbidities in Ethiopia and sub-Saharan Africa. Methods: Adult HIV-negative (n = 36), treatment naïve (n = 51), efavirenz (EFV)-treated ( n = 91), nevirapine (NVP)-treated (n = 95), or ritonavir-boosted lopinavir (LPV/r)-treated (n=44) subjects were recruited from Black Lion Hospital in Addis Ababa, Ethiopia. Aortic pressure, augmentation pressure, and pulse wave velocity (PWV) were measured via applanation tonometry and carotid intima-media thickness (cIMT) and carotid arterial stiffness, and brachial artery flow-mediated dilation (FMD) were measured via non-invasive ultrasound. Body mass index, waist-to-hip circumference ratio (WHR), skinfold thickness, and self-reported fat redistribution were used to quantify lipodystrophy. CD4+ cell count, plasma HIV RNA levels, fasting glucose, total-, HDL-, and LDL-cholesterol, triglycerides, hsCRP, sVCAM-1, sICAM-1, leptin and complete blood count were measured. Results: PWV and normalized cIMT were elevate and FMD impaired in EFV- and LPV/r-treated subjects compared to NVP-treated subjects; normalized cIMT was also elevated and FMD impaired in the EFV- and LPV/r-treated subjects compared to treatment-naïve subjects. cIMT was not statistically different across groups. Treated subjects exhibited elevated markers of dyslipidemia, inflammation, and lipodystrophy. PWV was associated with age, current EFV and LPV/r used, heart rate, blood pressure, triglycerides, LDL, and hsCRP, FMD with age, HIV duration, WHR, and glucose, and cIMT with age, current EFV use, skinfold thickness, and blood pressure. Conclusions: Current EFV- or LPV/r-treatment, but not NVP-treatment, correlated with elevated markers of atherosclerosis, which may involve mechanisms distinct from traditional risk factors. © 2015 Gleason et al.",,"Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G., Chisholm, D., Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study (1999) Lancet, 353, pp. 2093-2099. , PMID: 10382692; Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., Costagliola, D., Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men (2003) AIDS, 17, pp. 2479-2486. , PMID: 14600519; Friis-Moller, N., Sabin, C., Weber, R., D'Arminio Monforte, A., El-Sadr, W., Combination antiretroviral therapy and the risk of myocardial infarction (2003) New England Journal of Medicine, 349, pp. 1993-2003. , PMID: 14627784; Maggi, P., Lillo, A., Perilli, F., Maserati, R., Chirianni, A., Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: A comparative study (2004) AIDS, 18, pp. 1023-1028. , PMID: 15096805; Sevastianova, K., Sutinen, J., Westerbacka, J., Ristola, M., Yki-Jarvinen, H., Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy (2005) Antivir Ther, 10, pp. 925-935. , PMID: 16430198; Van Vonderen, M., Hassink, E., Van Agtmael, M., Stehouwer, C., Danner, S., Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy (2009) Journal of Infectious Diseases, 199, pp. 1186-1194. , PMID: 19275490; Hsue, P., Lo, J., Franklin, A., Bolger, A., Martin, J., Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection (2004) Circulation, 109, pp. 1603-1608. , PMID: 15023877; Stein, J., Klein, M., Bellehumeur, J., McBride, P., Wiebe, D., Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction (2001) Circulation, 104, pp. 257-262. , PMID: 11457741; Shankar, S., Dube, M., Gorski, J., Klaunig, J., Steinberg, H., Indinavir impairs endothelial function in healthy HIV-negative men (2005) American Heart Journal, 150, p. 933. , PMID: 16290967; Fontas, E., Van Leth, F., Sabin, C., Friis-Moller, N., Rickenbach, M., Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? (2004) Journal of Infectious Diseases, 189, pp. 1056-1074. , PMID: 14999610; Hsue, P.Y., Hunt, P.W., Wu, Y., Schnell, A., Ho, J.E., Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients (2009) AIDS, 23, pp. 2021-2027. , PMID: 19542863; UNAIDS, (2012) Report on the Global AIDS Epidemic; Van Wijk, J.P., De Koning, E.J., Cabezas, M.C., Joven, J., Op't Roodt J, Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients (2006) Journal of the American College of Cardiology, 47, pp. 1117-1123. , PMID: 16545639; Johnsen, S., Dolan, S.E., Fitch, K.V., Kanter, J.R., Hemphill, L.C., Carotid intimal medial thickness in human immunodeficiency virus-infected women: Effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome (2006) Journal of Clinical Endocrinology and Metabolism, 91, pp. 4916-4924. , PMID: 17003092; Stein, J.H., Klein, M.A., Bellehumeur, J.L., McBride, P.E., Wiebe, D.A., Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction (2001) Circulation, 104, pp. 257-262. , PMID: 11457741; Shankar, S.S., Dube, M.P., Gorski, J.C., Klaunig, J.E., Steinberg, H.O., Indinavir impairs endothelial function in healthy HIV-negative men (2005) American Heart Journal, 150, p. 933. , PMID: 16290967; Blanco, J.J., Garcia, I.S., Cerezo, J.G., De Rivera, J.M., Anaya, P.M., Endothelial function in HIV-infected patients with low or mild cardiovascular risk (2006) Journal of Antimicrobial Chemotherapy, 58, pp. 133-139. , PMID: 16702174; Fisher, S.D., Miller, T.L., Lipshultz, S.E., Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis (2006) Atherosclerosis, 185, pp. 1-11. , PMID: 16297390; Friis-Moller, N., Weber, R., Reiss, P., Thiebaut, R., Kirk, O., Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study (2003) AIDS, 17, pp. 1179-1193. , PMID: 12819520; Worm, S.W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study (2010) Journal of Infectious Diseases, 201, pp. 318-330. , PMID: 20039804; Currier, J.S., Kendall, M.A., Henry, W.K., Alston-Smith, B., Torriani, F.J., Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults (2007) AIDS, 21, pp. 1137-1145. , PMID: 17502724; Currier, J.S., Kendall, M.A., Zackin, R., Henry, W.K., Alston-Smith, B., Carotid artery intima-media thickness and HIV infection: Traditional risk factors overshadow impact of protease inhibitor exposure (2005) AIDS, 19, pp. 927-933. , PMID: 15905673; Grubb, J.R., Dejam, A., Voell, J., Blackwelder, W.C., Sklar, P.A., Lopinavir-ritonavir: Effects on endothelial cell function in healthy subjects (2006) Journal of Infectious Diseases, 193, pp. 1516-1519. , PMID: 16652279; Nolan, D., Watts, G.F., Herrmann, S.E., French, M.A., John, M., Endothelial function in HIV-infected patients receiving protease inhibitor therapy: Does immune competence affect cardiovascular risk? (2003) QJM, 96, pp. 825-832. , PMID: 14566037; Solages, A., Vita, J.A., Thornton, D.J., Murray, J., Heeren, T., Endothelial function in HIV-infected persons (2006) Clinical Infectious Diseases, 42, pp. 1325-1332. , PMID: 16586393; Arnet, D., Evans, G., Riley, W., Arterial stiffness: A new cardiovascular risk factor? (1994) American Journal of Epidemiology, 140, pp. 669-682. , PMID: 7942769; Kaplan, R.C., Sinclair, E., Landay, A.L., Lurain, N., Sharrett, A.R., T cell activation predicts carotid artery stiffness among HIV-infected women (2011) Atherosclerosis; Seaberg, E.C., Benning, L., Sharrett, A.R., Lazar, J.M., Hodis, H.N., Association between human immunodeficiency virus infection and stiffness of the common carotid artery (2010) Stroke, 41, pp. 2163-2170. , PMID: 20798374; Hansen, L., Parker, I., Roberts, L.M., Sutliff, R., Platt, M., Azidothymidine (AZT) leads to arterial stiffening and intima-media thickening in mice (2013) Journal of Biomechanics, , In Press; Van Vonderen, M., Smulders, Y., Stehouwer, C., Danner, S., Gundy, C., Carotid intima-media thickness and arterial stiffness in HIV-infected patients: The role of HIV, antiretroviral therapy, and lipodystrophy (2009) Journal of Acquired Immune Deficiency Syndromes, 50, pp. 153-161. , PMID: 19131894; Yeboah, J., Folsom, A.R., Burke, G.L., Johnson, C., Polak, J.F., Predictive value of brachial flowmediated dilation for incident cardiovascular events in a population-based study: The multi-ethnic study of atherosclerosis (2009) Circulation, 120, pp. 502-509. , PMID: 19635967; Oliviero, U., Bonadies, G., Apuzzi, V., Foggia, M., Bosso, G., Human immunodeficiency virus per se exerts atherogenic effects (2009) Atherosclerosis, 204, pp. 586-589. , PMID: 19084229; Torriani, F., Komarow, L., Parker, R., Cotter, B., Currier, J., Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s (2008) Journal of the American College of Cardiology, 52, pp. 569-576. , PMID: 18687253; Gupta, S.K., Shen, C., Moe, S.M., Kamendulis, L.M., Goldman, M., Worsening endothelial function with efavirenz compared to protease inhibitors: A 12-month prospective study (2012) PloS One, 7, p. e45716. , PMID: 23029197; Masiá, M., Padilla, S., García, N., Jarrin, I., Bernal, E., Endothelial function is impaired in HIV-infected patients with lipodystrophy (2010) Antiviral Therapy, 15, pp. 101-110. , PMID: 20167996; Chironi, G., Escaut, L., Gariepy, J., Cogny, A., Teicher, E., Brief report: Carotid intima-media thickness in heavily pretreated HIV-infected patients (2003) Journal of Acquired Immune Deficiency Syndromes, 32, pp. 490-493. , PMID: 12679699; Mercie, P., Thiebaut, R., Aurillac-Lavignolle, V., Pellegrin, J., Yvorra-Vives, M., Carotid intimamedia thickness is slightly increased over time in HIV-1-infected patients (2005) HIV Med, 6, pp. 380-387. , PMID: 16268819; Lorenz, M., Stephan, C., Harmjanz, A., Staszewski, S., Buehler, A., Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis (2008) Atherosclerosis, 196, pp. 720-726. , PMID: 17275008; Hsue, P., Hunt, P., Schnell, A., Kalapus, S., Hoh, R., Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis (2009) AIDS, 23, pp. 1059-1067. , PMID: 19390417; Mangili, A., Polak, J.F., Quach, L.A., Gerrior, J., Wanke, C.A., Markers of atherosclerosis and inflammation and mortality in patients with HIV infection (2011) Atherosclerosis, 214, pp. 468-473. , PMID: 21130995; Kaplan, R.C., Sinclair, E., Landay, A.L., Lurain, N., Sharrett, A.R., T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women (2011) The Journal of Infectious Diseases, 203, pp. 452-463. , PMID: 21220772; Longenecker, C., Funderburg, N., Jiang, Y., Debanne, S., Storer, N., Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals (2013) HIV Med; Ross, A.C., O'Riordan, M.A., Storer, N., Dogra, V., McComsey, G.A., Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children (2010) Atherosclerosis, 211, pp. 492-498. , PMID: 20471650; Falcone, E.L., Mangili, A., Skinner, S., Alam, A., Polak, J.F., Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV (2011) Antiviral Therapy, 16, pp. 1-8. , PMID: 21311103; Kline, E.R., Sutliff, R.L., The role of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction (2008) J Investig Med, 56, pp. 752-769. , PMID: 18525451; Hansen, L., Parker, I., Roberts, L.M., Sutliff, R.L., Platt, M.O., Azidothymidine (AZT) leads to arterial stiffening and intima-media thickening in mice (2013) J Biomech, 46, pp. 1540-1547. , PMID: 23623314; Sutliff, R., Dikalov, S., Weiss, D., Parker, J., Raidel, S., Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide (2002) American Journal of Physiology: Heart and Circulatory Physiology, 283, pp. H2363-H2370. , PMID: 12388299; Choi, A.I., Vittinghoff, E., Deeks, S.G., Weekley, C.C., Li, Y., Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons (2011) AIDS, 25, pp. 1289-1298. , PMID: 21516027; Kowalska, J.D., Kirk, O., Mocroft, A., Hoj, L., Friis-Moller, N., Implementing the number needed to harm in clinical practice: Risk of myocardial infarction in HIV-1-infected patients treated with abacavir (2010) HIV Medicine, 11, pp. 200-208. , PMID: 19863618; Worm, S.W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study (2010) The Journal of Infectious Diseases, 201, pp. 318-330. , PMID: 20039804; Lundgren, J., Neuhaus, J., Babiker, A., Cooper, D., Duprez, D., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients (2008) AIDS, 22, pp. F17-F24. , PMID: 18753925; Ribaudo, H.J., Benson, C.A., Zheng, Y., Koletar, S.L., Collier, A.C., No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-term results from ACTG A5001/ALLRT (2011) Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 52, pp. 929-940; Hsue, P.Y., Hunt, P.W., Wu, Y., Schnell, A., Ho, J.E., Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients (2009) AIDS, 23, pp. 2021-2027. , PMID: 19542863; Sutliff, R.L., Dikalov, S., Weiss, D., Parker, J., Raidel, S., Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide (2002) American Journal of Physiology: Heart and Circulatory Physiology, 283, pp. H2363-H2370. , PMID: 12388299; Hansen, L., Kennedy, I., Sutliff, R., Platt, M., Gleason, R., AZT Induces Intima-Medial Thickening, Endothelial Dysfunction, and Arterial Stiffening in Mice, , In Preparation; El-Sadr, W.M., Lundgren, J.D., Neaton, J.D., Gordin, F., Abrams, D., CD4+ count-guided interruption of antiretroviral treatment (2006) New England Journal of Medicine, 355, pp. 2283-2296. , PMID: 17135583; Oliviero, U., Bonadies, G., Apuzzi, V., Foggia, M., Bosso, G., Human immunodeficiency virus per se exerts atherogenic effects (2009) Atherosclerosis, 204, pp. 586-589. , PMID: 19084229; Hsue, P.Y., Hunt, P.W., Schnell, A., Kalapus, S.C., Hoh, R., Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis (2009) AIDS, 23, pp. 1059-1067. , PMID: 19390417; Joshi, V.V., Pawel, B., Connor, E., Sharer, L., Oleske, J.M., Arteriopathy in children with acquired immune deficiency syndrome (1987) Pediatr Pathol, 7, pp. 261-275. , PMID: 3684808; Perez-Atayde, A.R., Kearney, D.I., Bricker, J.T., Colan, S.D., Easley, K.A., Cardiac, aortic, and pulmonary arteriopathy in HIV-infected children: The Prospective P2C2 HIV Multicenter Study (2004) Pediatric and Developmental Pathology: The Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 7, pp. 61-70; Paton, P., Tabib, A., Loire, R., Tete, R., Coronary artery lesions and human immunodeficiency virus infection (1993) Res Virol, 144, pp. 225-231. , PMID: 8356344; Maniker, A.H., Hunt, C.D., Cerebral aneurysm in the HIV patient: A report of six cases (1996) Surg Neurol, 46, pp. 49-54. , PMID: 8677489; Blum, A., Hadas, V., Burke, M., Yust, I., Kessler, A., Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction (2005) Clin Cardiol, 28, pp. 149-153. , PMID: 15813624; Bonnet, D., Aggoun, Y., Szezepanski, I., Bellal, N., Blanche, S., Arterial stiffness and endothelial dysfunction in HIV-infected children (2004) AIDS, 18, pp. 1037-1041. , PMID: 15096807; Lorenz, M.W., Stephan, C., Harmjanz, A., Staszewski, S., Buehler, A., Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis (2007) Atherosclerosis; Buchacz, K., Weidle, P., Moore, D., Were, W., Mermin, J., Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda (2008) Journal of Acquired Immune Deficiency Syndromes, 47, pp. 304-311. , PMID: 18398971; Charakida, M., Donald, A., Green, H., Storry, C., Early structural and functional changes of the vasculature in HIV-infected children (2005) Circulation; Estrada, V., Portilla, J., Dyslipidemia related to antiretroviral therapy (2011) AIDS Reviews, 13, pp. 49-56. , PMID: 21412389; Loonam, C.R., Mullen, A., Nutrition and the HIV-associated lipodystrophy syndrome (2012) Nutrition Research Reviews, 25, pp. 267-287. , PMID: 23174511; Ridker, P.M., Rifai, N., Rose, L., Buring, J.E., Cook, N.R., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events (2002) The New England Journal of Medicine, 347, pp. 1557-1565. , PMID: 12432042; Ballantyne, C.M., Hoogeveen, R.C., Bang, H., Coresh, J., Folsom, A.R., Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middleaged men and women in the Atherosclerosis Risk in Communities (ARIC) study (2005) Archives of Internal Medicine, 165, pp. 2479-2484. , PMID: 16314544; Rost, N.S., Wolf, P.A., Kase, C.S., Kelly-Hayes, M., Silbershatz, H., Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham study (2001) Stroke; a Journal of Cerebral Circulation, 32, pp. 2575-2579. , PMID: 11692019; Dolan, S.E., Hadigan, C., Killilea, K.M., Sullivan, M.P., Hemphill, L., Increased cardiovascular disease risk indices in HIV-infected women (1999) Journal of Acquired Immune Deficiency Syndromes, 39, pp. 44-54. , PMID: 15851913; Masia, M., Bernal, E., Padilla, S., Graells, M.L., Jarrin, I., The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients (2007) Atherosclerosis, 195, pp. 167-171. , PMID: 17049532; Ross, A.C., Armentrout, R., O'Riordan, M.A., Storer, N., Rizk, N., Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy (2008) Journal of Acquired Immune Deficiency Syndromes, 49, pp. 499-506. , PMID: 18989230; Kristoffersen, U., Kofoed, K., Kronborg, G., Giger, A., Kjaer, A., Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy (2009) HIV Med, 10, pp. 79-87. , PMID: 19200170; Lichtner, M., Cuomo, M., Rossi, R., Strano, S., Massetti, A., Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment (2009) Atherosclerosis, 204, pp. e1-e3. , PMID: 19185298; Neuhaus, J., Jacobs, D.R., Baker, J.V., Calmy, A., Duprez, D., Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection (2010) The Journal of Infectious Diseases, 201, pp. 1788-1795. , PMID: 20446848; Miller, T.L., Somarriba, G., Orav, E.J., Mendez, A.J., Neri, D., Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1 (1999) Journal of Acquired Immune Deficiency Syndromes, 55, pp. 182-188. , PMID: 20531209; Baker, J., Ayenew, W., Quick, H., Hullsiek, K., Tracy, R., High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection (2010) Journal of Infectious Diseases, 201, pp. 285-292. , PMID: 19954384; Calmy, A., Gayet-Ageron, A., Montecucco, F., Nguyen, A., Mach, F., HIV increases markers of cardiovascular risk: Results from a randomized, treatment interruption trial (2009) AIDS, 23, pp. 929-939. , PMID: 19425222; Galkina, E., Ley, K., Vascular adhesion molecules in atherosclerosis (2007) Arteriosclerosis, Thrombosis, and Vascular Biology, 27, pp. 2292-2301. , PMID: 17673705; Gattegno, L., Bentata-Peyssare, M., Gronowski, S., Chaouche, K., Ferriere, F., Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) and of vascular cell adhesion molecule 1 (VCAM-1) in HIV-1 infection (1995) Cell Adhesion and Communication, 3, pp. 179-185. , PMID: 8846020; Mastroianni, C.M., Lichtner, M., Mengoni, F., Agostino, C., Ettorre, G., Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients (2000) Clinical Immunology (Orlando, Fla), 95, pp. 212-217. , PMID: 10866128; Matarese, G., Mantzoros, C., La Cava, A., Leptin and adipocytokines: Bridging the gap between immunity and atherosclerosis (2007) Current Pharmaceutical Design, 13, pp. 3676-3680. , PMID: 18220805; Takemura, Y., Walsh, K., Ouchi, N., Adiponectin and cardiovascular inflammatory responses (2007) Current Atherosclerosis Reports, 9, pp. 238-243. , PMID: 18241619; Gougeon, M.L., Penicaud, L., Fromenty, B., Leclercq, P., Viard, J.P., Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations (2004) Antiviral Therapy, 9, pp. 161-177. , PMID: 15134178",Article,Scopus,2-s2.0-84928670685
"Hastings K.G., Jose P.O., Kapphahn K.I., Frank A.T.H., Goldstein B.A., Thompson C.A., Eggleston K., Cullen M.R., Palaniappan L.P.","Leading causes of death among Asian American subgroups (2003-2011)",2015,"PLoS ONE","10","4", e0124341,"","",,,10.1371/journal.pone.0124341,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928533422&partnerID=40&md5=430cdc80a621fa515a666816d856f8d6","Stanford University School of Medicine, Division of General Medical DisciplinesStanford, CA, United States; Sutter Health Medical Foundation, Department of CardiologyDavis, CA, United States; Columbia University School of NursingNew York, NY, United States; Palo Alto Medical Foundation Research InstitutePalo Alto, CA, United States; Stanford University, Shorenstein Asia-Pacific Research CenterStanford, CA, United States","Hastings, K.G., Stanford University School of Medicine, Division of General Medical DisciplinesStanford, CA, United States; Jose, P.O., Sutter Health Medical Foundation, Department of CardiologyDavis, CA, United States; Kapphahn, K.I., Stanford University School of Medicine, Division of General Medical DisciplinesStanford, CA, United States; Frank, A.T.H., Columbia University School of NursingNew York, NY, United States; Goldstein, B.A., Stanford University School of Medicine, Division of General Medical DisciplinesStanford, CA, United States; Thompson, C.A., Palo Alto Medical Foundation Research InstitutePalo Alto, CA, United States; Eggleston, K., Stanford University, Shorenstein Asia-Pacific Research CenterStanford, CA, United States; Cullen, M.R., Stanford University School of Medicine, Division of General Medical DisciplinesStanford, CA, United States; Palaniappan, L.P., Stanford University School of Medicine, Division of General Medical DisciplinesStanford, CA, United States","Background: Our current understanding of Asian American mortality patterns has been distorted by the historical aggregation of diverse Asian subgroups on death certificates, masking important differences in the leading causes of death across subgroups. In this analysis, we aim to fill an important knowledge gap in Asian American health by reporting leading causes of mortality by disaggregated Asian American subgroups. Methods and Findings: We examined national mortality records for the six largest Asian subgroups (Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese) and non-Hispanic Whites (NHWs) from 2003-2011, and ranked the leading causes of death. We calculated all-cause and causespecific age-adjusted rates, temporal trends with annual percent changes, and rate ratios by race/ethnicity and sex. Rankings revealed that as an aggregated group, cancer was the leading cause of death for Asian Americans. When disaggregated, there was notable heterogeneity. Among women, cancer was the leading cause of death for every group except Asian Indians. In men, cancer was the leading cause of death among Chinese, Korean, and Vietnamese men, while heart disease was the leading cause of death among Asian Indians, Filipino and Japanese men. The proportion of death due to heart disease for Asian Indian males was nearly double that of cancer (31% vs. 18%). Temporal trends showed increased mortality of cancer and diabetes in Asian Indians and Vietnamese; increased stroke mortality in Asian Indians; increased suicide mortality in Koreans; and increased mortality from Alzheimer's disease for all racial/ethnic groups from 2003-2011. All-cause rate ratios revealed that overall mortality is lower in Asian Americans compared to NHWs. Conclusions: Our findings show heterogeneity in the leading causes of death among Asian American subgroups. Additional research should focus on culturally competent and cost-effective approaches to prevent and treat specific diseases among these growing diverse populations. © 2015 Hastings et al.",,"U.S. Census Bureau, (2012) Table 4. Projections of the Population by Sex, Race, and Hispanic Origin for the United States: 2015 to 2060, , Washington, D.C.: U.S. Census Bureau; U.S. Census Bureau, (2011) American Community Survey 1-Year Estimates; Palaniappan, L.P., Araneta, M.R., Assimes, T.L., Barrett-Connor, E.L., Carnethon, M.R., Criqui, M.H., Call to action: Cardiovascular disease in Asian Americans: A science advisory from the American Heart Association (2010) Circulation, 122 (12), pp. 1242-1252. , PMID: 20733105; Kim, G., Chiriboga, D.A., Jang, Y., Lee, S., Huang, C.H., Parmelee, P., Health status of older Asian Americans in California (2010) J Am Geriatr Soc, 58 (10), pp. 2003-2008. , PMID: 20929469; Keppel, K.G., Pearcy, J.N., Heron, M.P., Is there progress toward eliminating racial/ethnic disparities in the leading causes of death? (2010) Public Health Rep, 125 (5), pp. 689-697. , PMID: 20873285; Heron, M., Deaths: Leading causes for 2010. National vital statistics reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics (2013) National Vital Statistics System, 62 (6), pp. 1-97; Holland, A.T., Palaniappan, L.P., Problems with the collection and interpretation of asian-american health data: Omission, aggregation, and extrapolation (2012) Ann Epidemiol, 22 (6), pp. 397-405. , PMID: 22625997; U.S. White House Office of the Press Secretary, (2009) Executive Order: Increasing Participation of Asian Americans, , October 14, Report No; Palaniappan, L., Wang, Y., Fortmann, S.P., Coronary heart disease mortality for six ethnic groups in California, 1990-2000 (2004) Ann Epidemiol, 14 (7), pp. 499-506. , PMID: 15310526; Wild, S.H., Laws, A., Fortmann, S.P., Varady, A.N., Byrne, C.D., Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990 (1995) Ann Epidemiol, 5 (6), pp. 432-439. , PMID: 8680605; Miller, B.A., Chu, K.C., Hankey, B.F., Ries, L.A., Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S (2008) Cancer Causes Control, 19 (3), pp. 227-256. , PMID: 18066673; U.S. White House Office of the Press Secretary, (2009) Executive Order: Increasing Participation of Asian Americans; Narayan, K.M., Aviles-Santa, L., Oza-Frank, R., Pandey, M., Curb, J.D., McNeely, M., Report of a National Heart, Lung, And Blood Institute Workshop: Heterogeneity in cardiometabolic risk in Asian Americans In the U.S. Opportunities for research (2010) J Am Coll Cardiol, 55 (10), pp. 966-973. , PMID: 20202512; National Center for Health Statistics CfDCaP, (2001) Report to Evaluate to U.S. Standard Certificates; Murphy, S.L., Xu, J., Kochanek, M.A., Deaths: Final Data for 2010 (2013) National Vital Statistics Reports, 61 (4), p. 118; Hoyert, D.L., Xu, J., Deaths: Preliminary data for 2011. National vital statistics reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics (2012) National Vital Statistics System, 61 (6), pp. 1-51; Hoyert, D.L., Kung, H.C., Asian or Pacific Islander mortality, selected states, 1992 (1997) Mon Vital Stat Rep, 46 (1), pp. 1-63. , PMID: 9404389; Cullen, M.R., Cummins, C., Fuchs, V.R., Geographic and racial variation in premature mortality in the U.S.: Analyzing the disparities (2012) PLoS One, 7 (4), p. e32930. , PMID: 22529892; Winkleby, M.A., Cubbin, C., Influence of individual and neighbourhood socioeconomic status on mortality among black, Mexican-American, and white women and men in the United States (2003) J Epidemiol Community Health, 57 (6), pp. 444-452. , PMID: 12775792; Sohn, L., The health and health status of older Korean Americans at the 100-year anniversary of Korean immigration (2004) J Cross Cult Gerontol, 19 (3), pp. 203-219. , PMID: 15243198; Palaniappan, L., Mukherjea, A., Holland, A., Ivey, S.L., Leading causes of mortality of Asian Indians in California (2010) Ethn Dis, 20 (1), pp. 53-57. , PMID: 20178183; Ye, J., Rust, G., Baltrus, P., Daniels, E., Cardiovascular risk factors among Asian Americans: Results from a National Health Survey (2009) Ann Epidemiol, 19 (10), pp. 718-723. , PMID: 19560369; Muir, C.S., Coronary heart disease in seven racial groups in Singapore (1960) Br Heart J, 22, pp. 45-53. , PMID: 14425054; McKeigue, P.M., Miller, G.J., Marmot, M.G., Coronary heart disease in south Asians overseas: A review (1989) J Clin Epidemiol, 42 (7), pp. 597-609. , PMID: 2668448; Balarajan, R., Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales (1991) BMJ, 302 (6776), pp. 560-564. , PMID: 2021718; Klatsky, A.L., Tekawa, I., Armstrong, M.A., Sidney, S., The risk of hospitalization for ischemic heart disease among Asian Americans in northern California (1994) Am J Public Health, 84 (10), pp. 1672-1675. , PMID: 7943495; Jose, P.O., Frank, A.T., Kapphahn, K.I., Goldstein, B.A., Eggleston, K., Hastings, K.G., Cardiovascular disease mortality in Asian Americans (2014) J Am Coll Cardiol, 64 (23), pp. 2486-2494. , PMID: 25500233; Ursua, R.A., Islam, N.S., Aguilar, D.E., Wyatt, L.C., Tandon, S.D., Abesamis-Mendoza, N., Predictors of hypertension among Filipino immigrants in the Northeast US (2013) J Community Health, 38 (5), pp. 847-855. , PMID: 23553685; Klatsky, A.L., Armstrong, M.A., Cardiovascular risk factors among Asian Americans living in northern California (1991) Am J Public Health, 81 (11), pp. 1423-1428. , PMID: 1951798; Klatsky, A.L., Tekawa, I.S., Armstrong, M.A., Cardiovascular risk factors among Asian Americans (1996) Public Health Rep, 111, pp. 62-64. , PMID: 8898779; Moran, A., Diez Roux, A.V., Jackson, S.A., Kramer, H., Manolio, T.A., Shrager, S., Acculturation is associated with hypertension in a multiethnic sample (2007) Am J Hypertens, 20 (4), pp. 354-363. , PMID: 17386340; Agency for Healthcare Research and Quality, (2008) Disparities in Health Care Quality among Racial and Ethnic Minority Groups: Findings from the National Healthcare Quality and Disparities Reports; Wang, E.J., Wong, E.C., Dixit, A.A., Fortmann, S.P., Linde, R.B., Palaniappan, L.P., Type 2 diabetes: Identifying high risk Asian American subgroups in a clinical population (2011) Diabetes Res Clin Pract, 93 (2), pp. 248-254. , PMID: 21665315; Haiman, C.A., Stram, D.O., Wilkens, L.R., Pike, M.C., Kolonel, L.N., Henderson, B.E., Ethnic and racial differences in the smoking-related risk of lung cancer (2006) N Engl J Med, 354 (4), pp. 333-342. , PMID: 16436765; Chae, D.G., Gavin, A.R., Takeuchi, D.T., Smoking prevalence among Asian Americans: Findings from the National Latino and Asian American Study (NLAAS) (2006) Public Health Rep, 121 (6), pp. 775-863. , PMID: 17278414; Khang, Y.H., Lynch, J.W., Kaplan, G.A., Impact of economic crisis on cause-specific mortality in South Korea (2005) International Journal of Epidemiology, 34 (6), pp. 1291-1301. , PMID: 16338946; Watts, J., Suicide rate rises as South Korea's economy falters (1998) Lancet, 352, p. 1365. , PMID: 9802287; Kim, S.Y.K.M., Kawachi, I., Cho, Y., Comparative epidemiology of suicide in South Korea and Japan: Effects of age, gender and suicide methods (2011) Crisis, 32 (1), pp. 5-14. , PMID: 21371965; McCracken, M., Olsen, M., Chen, M.S., Jr., Jemal, A., Thun, M., Cokkinides, V., Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities (2007) CA: A Cancer Journal for Clinicians, 57 (4), pp. 190-205; Gomez, S.L., Noone, A.M., Lichtensztajn, D.Y., Scoppa, S., Gibson, J.T., Liu, L., Cancer incidence trends among Asian American populations in the United States, 1990-2008 (2013) Journal of the National Cancer Institute, 105 (15), pp. 1096-1110. , PMID: 23878350; Lee, S., Chen, L., Jung, M.Y., Baezconde-Garbanati, L., Juon, H.S., Acculturation and cancer screening among asian americans: Role of health insurance and having a regular physician (2014) Journal of Community Health, 39 (2), pp. 201-212. , PMID: 24002493; Lee, H.Y., Ju, E., Vang, P.D., Lundquist, M., Breast and cervical cancer screening disparity among Asian American women: Does race/ethnicity matter[corrected]? (2010) Journal of Women's Health, 19 (10), pp. 1877-1884. , PMID: 20831437; Shahidi, N.C., Homayoon, B., Cheung, W.Y., Factors associated with suboptimal colorectal cancer screening in US immigrants (2013) American Journal of Clinical Oncology, 36 (4), pp. 381-387. , PMID: 22643567; Thompson, C.A., Gomez, S.L., Chan, A., Chan, J.K., McClellan, S.R., Chung, S., Patient and provider characteristics associated with colorectal, breast, and cervical cancer screening among Asian Americans (2014) Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of PreventiveOncology, 23 (11), pp. 2208-2217; Chang, E.T., Yang, J., Alfaro-Velcamp, T., So, S.K., Glaser, S.L., Gomez, S.L., Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians (2010) Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of PreventiveOncology, 19 (12), pp. 3106-3118; Immigration and Nationality Act. Section 212(a), 221(d)Wong, J.S., Port, F.K., Hulbert-Shearon, T.E., Carroll, C.E., Wolfe, R.A., Agodoa, L.Y., Survival advantage in Asian American end-stage renal disease patients (1999) Kidney International, 55 (6), pp. 2515-2523. , PMID: 10354301; Ku, L., Matani, S., Left Out: Immigrants' access to health care and insurance (2001) Health Affairs, 20 (1), pp. 247-256. , PMID: 11194848; Derose, Kp.E.J., Lurie, N., Immigrants and health care: Sources of vulnerability (2007) Health Affairs, 26 (5), pp. 1258-1268. , PMID: 17848435; Qureshi Ai, A.M., Rahim, B., Kahn, S., Khan, N., Suri, M.F., Paradoxical increase in stroke mortality among Asian Indians in the United States (2014) Journal of Vascular and Interventional Neurology, 7 (1), pp. 1-4. , PMID: 24920980; Weintraub, W.S., Daniels, S.R., Burke, L.E., Franklin, B.A., Goff, D.C., Jr., Hayman, L.L., Value of primordial and primary prevention for cardiovascular disease: A policy statement from the American Heart Association (2011) Circulation, 124, pp. 967-990. , PMID: 21788592; Marmot, M.G., Syme, S.L., Acculturation and coronary heart disease in Japanese-Americans (1976) Am J Epidemiol, 104 (3), pp. 225-247. , PMID: 961690; Taylor, V.M., Yasui, Y., Tu, S.P., Neuhouser, M.L., Li, L., Woodall, E., Heart disease prevention among Chinese immigrants (2007) J Community Health, 32 (5), pp. 299-310. , PMID: 17922202; Benfante, R., Studies of cardiovascular disease and cause-specific mortality trends in Japanese-American men living in Hawaii and risk factor comparisons with other Japanese populations in the Pacific region: A review (1992) Hum Biol, 64 (6), pp. 791-805. , PMID: 1427739; Arias, E., Eschbach, K., Schauman, W.S., Backlund, E.L., Sorlie, P.D., The Hispanic Mortality Advantage and Ethnic Misclassification on US Death Certificates (2010) American Journal of Public Health, 100, pp. S171-S177. , PMID: 19762677; Arias, E., Schauman, W.S., Eschbach, K., Sorlie, P.D., Backlund, E., The validity of race and Hispanic origin reporting on death certificates in the United States Vital and Health Statistics Series 2, Data Evaluation and Methods Research, 2008 (148), pp. 1-23; Rosenberg, H.M., Maurer, J.D., Sorlie, P.D., Johnson, N.J., MacDorman, M.F., Hoyert, D.L., Quality of death rates by race and Hispanic origin: A summary of current research, 1999 Vital and Health Statistics Series 2, Data Evaluation and Methods Research, 1999 (128), pp. 1-13; Sorlie, P.D., Rogot, E., Johnson, N.J., Validity of demographic characteristics on the death certificate (1992) Epidemiology (Cambridge, Mass), 3 (2), pp. 181-184. , PMID: 1576225; Choi, B.C., Hanley, A.J., Holowaty, E.J., Dale, D., Use of surnames to identify individuals of Chinese ancestry (1993) American Journal of Epidemiology, 138 (9), pp. 723-734. , PMID: 8237987; Lauderdale, D.S., Kestenbaum, B., Asian American ethnic identification by surname Population Res Policy Rev, 2000 (19), pp. 283-300; National Research Council (US) Panel on Race E, and Health in Later Life, Bulatao, R.A., Anderson, N.B., (2004) Understanding Racial and Ethnic Differences in Health in Late Life: A Research Agenda",Article,Scopus,2-s2.0-84928533422
"Loconte D.C., Grossi V., Bozzao C., Forte G., Bagnulo R., Stella A., Lastella P., Cutrone M., Benedicenti F., Susca F.C., Patruno M., Varvara D., Germani A., Chessa L., Laforgia N., Tenconi R., Simone C., Resta N.","Molecular and functional characterization of three different postzygotic mutations in PIK3CA-related overgrowth spectrum (PROS) patients: Effects on PI3K/AKT/mTOR signaling and sensitivity to PIK3 inhibitors",2015,"PLoS ONE","10","4", e0123092,"","",,,10.1371/journal.pone.0123092,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928538996&partnerID=40&md5=98b9a30e890124d444f9bd4d4d92eec3","Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; National Cancer Institute, IRCCS Oncologico Giovanni Paolo IIBari, Italy; Department of Clinical and Molecular Medicine, Sapienza University of RomeRome, Italy; Cancer Genetics Laboratory, IRCCS S. de BellisCastellana Grotte, Italy; Center for Rare Diseases-Internal Medicine C. Frugoni, University Hospital of BariBari, Italy; US Dermatologia Pediatrica, Ospedale dell'Angelo Ulss 12 MestreVenezia, Italy; Genetic Counseling Service, Department of Pediatrics, Regional Hospital of BolzanoBolzano, Italy; Neonatology and NICU Section, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; University of PadovaPadova, Italy","Loconte, D.C., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; Grossi, V., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy, National Cancer Institute, IRCCS Oncologico Giovanni Paolo IIBari, Italy; Bozzao, C., Department of Clinical and Molecular Medicine, Sapienza University of RomeRome, Italy; Forte, G., Cancer Genetics Laboratory, IRCCS S. de BellisCastellana Grotte, Italy; Bagnulo, R., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; Stella, A., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; Lastella, P., Center for Rare Diseases-Internal Medicine C. Frugoni, University Hospital of BariBari, Italy; Cutrone, M., US Dermatologia Pediatrica, Ospedale dell'Angelo Ulss 12 MestreVenezia, Italy; Benedicenti, F., Genetic Counseling Service, Department of Pediatrics, Regional Hospital of BolzanoBolzano, Italy; Susca, F.C., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; Patruno, M., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; Varvara, D., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; Germani, A., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; Chessa, L., Department of Clinical and Molecular Medicine, Sapienza University of RomeRome, Italy; Laforgia, N., Neonatology and NICU Section, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy; Tenconi, R., University of PadovaPadova, Italy; Simone, C., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy, National Cancer Institute, IRCCS Oncologico Giovanni Paolo IIBari, Italy; Resta, N., Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari 'Aldo Moro'Bari, Italy","Background: PIK3CA-related overgrowth spectrum (PROS) include a group of disorders that affect only the terminal portion of a limb, such as type I macrodactyly, and conditions like fibroadipose overgrowth (FAO), megalencephaly-capillary malformation (MCAP) syndrome, congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combinedtype vascular malformations, epidermal nevi, skeletal and spinal anomalies (CLOVES) syndrome and Hemihyperplasia Multiple Lipomatosis (HHML). Heterozygous postzygotic PIK3CA mutations are frequently identified in these syndromes, while timing and tissue specificity of the mutational event are likely responsible for the extreme phenotypic variability observed. Methods: We carried out a combination of Sanger sequencing and targeted deep sequencing of genes involved in the PI3K/AKT/mTOR pathway in three patients (1 MCAP and 2 FAO) to identify causative mutations, and performed immunoblot analyses to assay the phosphorylation status of AKT and P70S6K in affected dermal fibroblasts. In addition, we evaluated their ability to grow in the absence of serum and their response to the PI3K inhibitors wortmannin and LY294002 in vitro. Results and Conclusion: Our data indicate that patients ' cells showed constitutive activation of the PI3K/Akt pathway. Of note, PI3K pharmacological blockade resulted in a significant reduction of the proliferation rate in culture, suggesting that inhibition of PI3K might prove beneficial in future therapies for PROS patients. © 2015 Loconte et al.",,"Moore, C.A., Toriello, H.V., Abuelo, D.N., Curry, C.J., Hall, B.D., Higgins, J.V., Macrocephaly-cutis marmoratatelangiectaticacongenita: A distinct disorder with developmental delay and connective tissue abnormalities (1997) Am J Med Genet, 70, pp. 67-73. , PMID: 9129744; Rivière, J.B., Mirzaa, G.M., O'Roak, B.J., Beddaoui, M., Alcantara, D., Conway, R.L., De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes (2012) Nat Genet, 44, pp. 934-940. , PMID: 22729224; Mirzaa, G.M., Parry, D.A., Fry, A.E., Giamanco, K.A., Schwartzentruber, J., Vanstone, M., De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome (2014) Nat Genet, 46, pp. 510-515. , PMID: 24705253; Kurek, K.C., Luks, V.L., Ayturk, U.M., Alomari, A.I., Fishman, S.J., Spencer, S.A., Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome (2012) Am J Hum Genet, 90, pp. 1108-1115. , PMID: 22658544; Biesecker, L.G., Peters, K.F., Darling, T.N., Choyke, P., Hill, S., Schimke, N., Clinical differentiation between Proteus syndrome and hemihyperplasia: Description of a distinct form of hemihyperplasia (1998) Am J Med Genet, 79, pp. 311-318. , PMID: 9781913; Lindhurst, M.J., Parker, V.E., Payne, F., Sapp, J.C., Rudge, S., Harris, J., Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA (2012) Nat Genet, 44, pp. 928-933. , PMID: 22729222; Keppler-Noreuil, K.M., Rios, J.J., Parker, V.E.R., Semple, R.K., Lindhurst, M.J., Sapp, J.C., PIK3CA-Related Overgrowth Spectrum (PROS): Diagnostic and Testing Eligibility Criteria, Differential Diagnosis, and Evaluation (2014) Am J Med Genet Part A, 167 A, pp. 287-295. , PMID: 25557259; Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., High frequency of mutations of the PIK3CA gene in human cancers (2004) Science, 304, p. 554. , PMID: 15016963; Kang, S., Bader, A.G., Vogt, P.K., Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic (2005) Proc Natl Acad Sci U S A, 102, pp. 802-807. , PMID: 15647370; Dalle Pezze, P., Sonntag, A.G., Thien, A., Prentzell, M.T., Gödel, M., Fischer, S., A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation (2012) Sci Signaling, 5 (217), p. ra25. , 27 PMID: 22457331; Gan, X., Wang, J., Su, B., Wu, D., Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate (2011) J Biol Chem, 286, pp. 10998-11002. , PMID: 21310961; Keppler-Noreuil, K.M., Sapp, J.C., Lindhurst, M.J., Parker, V.E., Blumhorst, C., Darling, T., Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum (2014) Am J Med Genet A, 164, pp. 1713-1733; Rios, J.J., Paria, N., Burns, D.K., Israel, B.A., Cornelia, R., Wise, C.A., Somatic gain of function in PIK3CA in patients with macrodactily (2013) Hum Mol Genet, 22, pp. 444-451. , PMID: 23100325; Boscolo, E., Coma, S., Luks, V.L., Greene, A.K., Klagsbrun, M., Warman, M.L., AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation (2014) Angiogenesis, , Nov 26. [Epub ahead of print]; Osborn, A.J., Dickie, P., Neilson, D.E., Glaser, K., Lynch, K.A., Gupta, A., Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations (2015) Hum Mol Genet, 24, pp. 926-933. , PMID: 25292196; Biesecker, L., The challenges of Proteus syndrome: Diagnosis and management (2006) Eur J Hum Genet, 14, pp. 1151-1157. , PMID: 16883308; Tosi, L.L., Sapp, J.C., Allen, E.S., O'Keefe, R.J., Biesecker, L.G., Assessment and management of the orthopedic and other complications of Proteus syndrome (2011) J Child Orthop, 5, pp. 319-327. , PMID: 23024722; Chen, Y., Wang, B.C., Xiao, Y., PI3K: A potential therapeutic target for cancer (2012) J Cell Physiol, 227, pp. 2818-2821. , PMID: 21938729",Article,Scopus,2-s2.0-84928538996
"Fauchier L., Greenlaw N., Ferrari R., Ford I., Fox K.M., Tardif J.-C., Tendera M., Steg Ph.G., Sokn F.J., Reid C., Lang I., Van Den Branden F., Cesar L.M., Mattos M.A., Luqman Hj.N., Goudev A., Dorian P., Hu D., Widimsky P., Hassager C., Danchin N., Kaab S., Vardas P., Sulaiman K.J., Al Mahmeed W., Al Suwaidi J., Al Rashdan I., Abdulkader F., Merkely B., Kaul U., Daly K., Tavazzi L., Jang Y., Erglis A., Laucevicius A., Jamaluddin A.N., Gamba M.A., Tulevski I.I., Stepinska J., Morais J., Macarie C., Oganov R., Shalnova S., Al-Zaibag M., Hou M.K., Kamensky G., Fras Z., Kanic V., Naidoo D.P., Zamorano J.L., Rickli H., Jaussi A., Sriratanasathavorn C., Kalra P., Lutai M., Oleksandr, Nguyen L.V., Henry R.","Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International clarify registry",2015,"PLoS ONE","10","4", e0125164,"","",,,10.1371/journal.pone.0125164,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928555753&partnerID=40&md5=43434cbee315dfb7051e43a16b9e3559","Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Université François RabelaisTours, France; Robertson Centre, University of GlasgowGlasgow, United Kingdom; Department of Cardiology, University Hospital of Ferrara, Maria Cecilia HospitalCotignola, Italy; NHLI Imperial College, ICMS, Royal Brompton HospitalLondon, United Kingdom; Montreal Heart Institute, Université de MontrealMontreal, Canada; Medical University of SilesiaKatowice, Poland; Université Paris-Diderot, Sorbonne-Paris CitéParis, France; INSERM U-1148Paris, France; Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de ParisParis, France; Argentina; Australia; Austria; Belgium; Brazil; Brunei Darussalam; Bulgaria; Canada; China; Czech Republic; Denmark; France; Germany; Greece; Oman; United Arab Emirates; Qatar; Kuwait; Bahrain; Hungary; India; Ireland; Italy; South Korea; Latvia; Lithuania; Malaysia; Mexico; Netherlands; Poland; Portugal; Romania; Russian Federation; Saudi Arabia; Singapore; Slovakia; Slovenia; South Africa; Spain; Switzerland; Thailand; United Kingdom; Ukraine; Viet Nam; West Indies, United Kingdom","Fauchier, L., Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Université François RabelaisTours, France; Greenlaw, N., Robertson Centre, University of GlasgowGlasgow, United Kingdom; Ferrari, R., Department of Cardiology, University Hospital of Ferrara, Maria Cecilia HospitalCotignola, Italy, Italy; Ford, I., Robertson Centre, University of GlasgowGlasgow, United Kingdom; Fox, K.M., NHLI Imperial College, ICMS, Royal Brompton HospitalLondon, United Kingdom; Tardif, J.-C., Montreal Heart Institute, Université de MontrealMontreal, Canada; Tendera, M., Medical University of SilesiaKatowice, Poland; Steg, Ph.G., NHLI Imperial College, ICMS, Royal Brompton HospitalLondon, United Kingdom, Université Paris-Diderot, Sorbonne-Paris CitéParis, France, INSERM U-1148Paris, France, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de ParisParis, France; Sokn, F.J., Argentina; Reid, C., Australia; Lang, I., Austria; Van Den Branden, F., Belgium; César, L.M., Brazil; Mattos, M.A., Brazil; Luqman, Hj.N., Brunei Darussalam; Goudev, A., Bulgaria; Dorian, P., Canada; Hu, D., China; Widimsky, P., Czech Republic; Hassager, C., Denmark; Danchin, N., France; Kääb, S., Germany; Vardas, P., Greece; Sulaiman, K.J., Oman; Al Mahmeed, W., United Arab Emirates; Al Suwaidi, J., Qatar; Al Rashdan, I., Kuwait; Abdulkader, F., Bahrain; Merkely, B., Hungary; Kaul, U., India; Daly, K., Ireland; Tavazzi, L., Italy; Jang, Y., South Korea; Erglis, A., Latvia; Laucevičius, A., Lithuania; Jamaluddin, A.N., Malaysia; Gamba, M.A., Mexico; Tulevski, I.I., Netherlands; Stępińska, J., Poland; Morais, J., Portugal; Macarie, C., Romania; Oganov, R., Russian Federation; Shalnova, S., Russian Federation; Al-Zaibag, M., Saudi Arabia; Hou, M.K., Singapore; Kamensky, G., Slovakia; Fras, Z., Slovenia; Kanič, V., Slovenia; Naidoo, D.P., South Africa; Zamorano, J.L., Spain; Rickli, H., Switzerland; Jaussi, A., Switzerland; Sriratanasathavorn, C., Thailand; Kalra, P., United Kingdom; Lutai, M., Ukraine; Oleksandr, Ukraine; Nguyen, L.V., Viet Nam; Henry, R., West Indies, United Kingdom","Background: Few data are available regarding the use of antithrombotic strategies in coronary artery disease patients with atrial fibrillation (AF) in everyday practice. We sought to describe the prevalence of AF and its antithrombotic management in a contemporary population of patients with stable coronary artery disease. Methods and Findings: CLARIFY is an international, prospective, longitudinal registry of outpatients with stable coronary artery disease, defined as prior (≥12 months) myocardial infarction, revascularization procedure, coronary stenosis >50%, or chest pain associated with evidence of myocardial ischemia. Overall, 33,428 patients were screened, of whom 32,954 had data available for analysis at baseline; of these 2,229 (6.7%) had a history of AF. Median (interquartile range) CHA<inf>2</inf>DS<inf>2</inf>-VASc score was 4 (3, 5). Oral anticoagulation alone was used in 25.7%, antiplatelet therapy alone in 52.8% (single 41.8%, dual 11.0%), and both in 21.5%. OAC use was independently associated with permanent AF (p<0.001), CHA<inf>2</inf>DS<inf>2</inf>-VASc score (p=0.006), pacemaker (p<0.001), stroke (p=0.04), absence of angina (p=0.004), decreased left ventricular ejection fraction (p<0.001), increased waist circumference (p=0.005), and longer history of coronary artery disease (p=0.008). History of percutaneous coronary intervention (p=0.004) and no/partial reimbursement for cardiovascular medication (p=0.01, p<0.001, respectively) were associated with reduced oral anticoagulant use. Conclusions: In this contemporary cohort of patients with stable coronary artery disease and AF, most of whom are theoretical candidates for anticoagulation, oral anticoagulants were used in only 47.2%. Half of the patients received antiplatelet therapy alone and one-fifth received both antiplatelets and oral anticoagulants. Efforts are needed to improve adherence to guidelines in these patients. Trial Registration: ISRCTN registry of clinical trials: ISRCTN43070564. © 2015 Fauchier et al.",,"European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Eur Heart J, 31, pp. 2369-2429. , PMID: 20802247; European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Guidelines on myocardial revascularization (2010) Eur Heart J, 31, pp. 2501-2555. , PMID: 20802248; Sorensen, R., Hansen, M.L., Abildstrom, S.Z., Hvelplund, A., Andersson, C., Jorgensen, C., Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data (2009) Lancet, 374, pp. 1967-1974. , PMID: 20006130; Steg, P.G., Greenlaw, N., Tardif, J.C., Tendera, M., Ford, I., Kaab, S., Women and men with stable coronary artery disease have similar clinical outcomes: Insights from the international prospective CLARIFY registry (2012) Eur Heart J, 33, pp. 2831-2840. , PMID: 22922505; Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation (2010) Chest, 137, pp. 263-272. , PMID: 19762550; Pisters, R., Lane, D.A., Nieuwlaat, R., De Vos, C.B., Crijns, H.J., Lip, G.Y., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey (2010) Chest, 138, pp. 1093-1100. , PMID: 20299623; Goto, S., Bhatt, D.L., Rother, J., Alberts, M., Hill, M.D., Ikeda, Y., Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis (2008) Am Heart J, 156, pp. 855-863+863 e852. , PMID: 19061698; Ruiz-Nodar, J.M., Marin, F., Hurtado, J.A., Valencia, J., Pinar, E., Pineda, J., Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis (2008) J Am Coll Cardiol, 51, pp. 818-825. , PMID: 18294566; Rubboli, A., Kovacic, J.C., Mehran, R., Lip, G.Y., Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: Successfully navigating the treatment options (2011) Chest, 139, pp. 981-987. , PMID: 21540213; Gao, F., Zhou, Y.J., Wang, Z.J., Shen, H., Liu, X.L., Nie, B., Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation (2010) Circ J, 74, pp. 701-708. , PMID: 20208381; Zhao, H.J., Zheng, Z.T., Wang, Z.H., Li, S.H., Zhang, Y., Zhong, M., ""Triple therapy"" rather than ""triple threat"": A meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment (2011) Chest, 139, pp. 260-270. , PMID: 21285053; Dewilde, W.J., Oirbans, T., Verheugt, F.W., Kelder, J.C., De Smet, B.J., Herrman, J.P., Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial (2013) Lancet, 381, pp. 1107-1115. , PMID: 23415013; Aguilar, E., Garcia-Diaz, A.M., Sanchez Munoz-Torrero, J.F., Alvarez, L.R., Piedecausa, M., Arnedo, G., Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation (2012) Thromb Res, 130, pp. 390-395. , PMID: 22658293; Patrono, C., Andreotti, F., Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: Striking the right balance between efficacy and safety (2013) Circulation, 128, pp. 684-686. , PMID: 23861513; Nieuwlaat, R., Olsson, S.B., Lip, G.Y., Camm, A.J., Breithardt, G., Capucci, A., Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation (2007) Am Heart J, 153, pp. 1006-1012. , PMID: 17540203; Waldo, A.L., Becker, R.C., Tapson, V.F., Colgan, K.J., Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation (2005) J Am Coll Cardiol, 46, pp. 1729-1736. , PMID: 16256877; Gorin, L., Fauchier, L., Nonin, E., Charbonnier, B., Babuty, D., Lip, G.Y., Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: Implications of undertreatment and overtreatment in real-life clinical practice (2011) Chest, 140, pp. 911-917. , the Loire Valley Atrial Fibrillation Project PMID: 21436246; Lip, G.Y., Zarifis, J., Watson, R.D., Beevers, D.G., Physician variation in the management of patients with atrial fibrillation (1996) Heart, 75, pp. 200-205. , PMID: 8673762; Man-Son-Hing, M., Laupacis, A., Anticoagulant-related bleeding in older persons with atrial fibrillation: Physicians' fears often unfounded (2003) Arch Intern Med, 163, pp. 1580-1586. , PMID: 12860581; Peterson, G.M., Boom, K., Jackson, S.L., Vial, J.H., Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: Identifying barriers to stroke prevention (2002) Intern Med J, 32, pp. 15-23. , PMID: 11783668; De Caterina, R., Connolly, S.J., Pogue, J., Chrolavicius, S., Budaj, A., Morais, J., Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: Insights from ACTIVE-W (2010) Eur Heart J, 31, pp. 2133-2140. , PMID: 20685676; Lip, G.Y., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, K.J., Cuisset, T., Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting (2010) Thromb Haemost, 103, pp. 13-28. , PMID: 20062939; Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial (2006) Lancet, 367, pp. 1903-1912. , PMID: 16765759; Faxon, D.P., Eikelboom, J.W., Berger, P.B., Holmes, D.R., Bhatt, D.L., Moliterno, D.J., Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective (2011) Thromb Haemost, 106, pp. 572-584. , PMID: 21785808; Huber, K., Airaksinen, K.J., Cuisset, T., Marin, F., Rubboli, A., Lip, G.Y., Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe (2011) Thromb Haemost, 106, pp. 569-571. , PMID: 21909592; McFadden, E.P., Stabile, E., Regar, E., Cheneau, E., Ong, A.T., Kinnaird, T., Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy (2004) Lancet, 364, pp. 1519-1521. , PMID: 15500897; January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cleveland, J.C., Jr., Cigarroa, J.E., AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society (2014) J Am Coll Cardiol, , 2014; De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper (2012) J Am Coll Cardiol, 59, pp. 1413-1425. , PMID: 22497820; Hohnloser, S.H., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial (2012) Circulation, 125, pp. 669-676. , PMID: 22215856",Article,Scopus,2-s2.0-84928555753
"Battaggia A., Donzelli A., Font M., Molteni D., Galvano A.","Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials",2015,"PLoS ONE","10","4", e0124587,"","",,,10.1371/journal.pone.0124587,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928536415&partnerID=40&md5=8baa16a883a352ecec0791377e6a3f89","Infofarma Unità Locale Socio Sanitaria 20Verona, Italy; Azienda Sanitaria Locale di MilanoMilan, Italy; University of MilanMilan, Italy; University of PalermoPalermo, Italy","Battaggia, A., Infofarma Unità Locale Socio Sanitaria 20Verona, Italy; Donzelli, A., Azienda Sanitaria Locale di MilanoMilan, Italy; Font, M., Infofarma Unità Locale Socio Sanitaria 20Verona, Italy; Molteni, D., University of MilanMilan, Italy; Galvano, A., University of PalermoPalermo, Italy","Background: Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity outcomes. Methods and Findings: We searched for RCT on Ezetimibe using MEDLINE, CCTR, EMBASE, ClinicalTrials.gov databases up to December 2013, Merck and Novartis online registers, and personal communications. Two authors independently selected trials fulfilling these criteria: RCTs comparing Ezetimibe±statin or another lipid-lowering drug against placebo, or against the same lipid-lowering drug at the same dosage, with a follow-up at least 24 weeks and one or more of these outcomes: all-cause mortality, cardiovascular (CV) mortality, stroke, myocardial infarction (MI), cancer, serious adverse events (SAEs); we assessed the risk of bias using the Cochrane checklist. We extracted the data for major clinical events as a dichotomous measure, with the patient the unit of analysis. Pooled analysis was done with random and fixed effect based models. Trials comparing Ezetimibe plus a lipid-lowering drug against the same lipidlowering drug representing the net effect of Ezetimibe, showed a nonsignificant tendency toward damage for cancer, MI, stroke and SAEs. Ezetimibe+simvastatin vs. simvastatin alone showed a stronger tendency towards a higher risk for all-cause death (2.52; 0.65-9.74), CV death (3.04; 0.48-19.21), non-CV death (3.03; 0.12-73.50), MI (1.91; 0.42-8.70), stroke (2.38; 0.46-12.35), cancer (RR 11.11; 0.62-198.29), and SAEs (1.45; 0.95-2.23). Limitations include small numbers of events and inadequate power of the pooling. Trials comparing Ezetimibe+simvastatin vs placebo showed non-significant effects: MI (0.81; 0.66-1.00 p = 0.051), all-cause death (1.02; 0.95-1.09), CV death (0.91; 0.80-1.04), non-CV death (108; 0.99-1.18), stroke (0.86; 0.72-1.04), cancer (1.18; 0.80-1.74), SAEs (1.01; 0.96-1.06). Conclusions: Ezetimibe±simvastatin had inconsistent effects on important outcomes. No firm conclusions are possible, but findings indicative of damage suggest much more selective use of Ezetimibe±simvastatin. © 2015, Public Library of Science. All rights reserved.",,"Kastelein, J.J., Akdim, F., Stroes, E.S., Zwinderman, A.H., Bots, M.L., Stalenhoef, A.F., Simvastatin with or without ezetimibe in familial hypercholesterolemia (2008) N Engl J Med., 358, pp. 1431-1443. , PMID: 18376000; Kastelein, J.J., Akdim, F., Stroes, E.S., Zwinderman, A.H., Bots, M.L., Stalenhoef, A.F., Simvastatin with or without ezetimibe in familial hypercholesterolemia (2008) N Engl J Med., 358, pp. 1431-1443. , PMID: 18376000; Rossebø, A.B., Pedersen, T.R., Boman, K., Brudi, P., Chambers, J.B., Egstrup, K., Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (2008) N Engl J Med., 359, pp. 1343-1356. , PMID: 18765433; Taylor, A.J., Villines, T.C., Stanek, E.J., Devine, P.J., Griffen, L., Miller, M., Extended-release niacin or ezetimibe and carotid intima-media thickness (2009) NEngl J Med., 361, pp. 2113-2122. , PMID: 19915217; Todd, C., Villines, T.D., Stanek, E.J., Devine, P.J., Turco, M., Miller, M., The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis). Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration (2010) J Am Coll Cardiol., 55, pp. 2721-2726. , PMID: 20399059; Howard, B.V., Roman, M.J., Devereux, R.B., Fleg, J.L., Galloway, J.M., Henderson, J.A., Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: The SANDS randomized trial (2008) JAMA, 299, pp. 1678-1689. , PMID: 18398080; Fleg, J.L., Mete, M., Howard, B.V., Umans, J.G., Roman, M.J., Ratner, R.E., Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) trial (2008) J Am Coll Cardiol., 52, pp. 2198-2205. , PMID: 19095139; Landray, M., Baigent, C., Leaper, C., Adu, D., Altmann, P., Armitage, J., The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD (2006) Am J Kidney Dis., 47, pp. 385-395. , PMID: 16490616; Mascitelli, L., Pezzetta, F., Goldstein, M.R., Role of Ezetimibe in the Prevention of Cardiovascular Disease: Absence of Evidence (2010) Arch Med Res., 41, pp. 649-650. , PMID: 21199735; Baigent, C., Landray, M.J., Reith, C., Emberson, J., Wheeler, D.C., Tomson, C., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial (2001) Lancet., 377, pp. 2181-2192; Therapeutics Initiative. Do statins have a role in primary prevention? An update (2010) Therapeutics Letter., 77, pp. 1-2; Wood, L., Egger, M., Gluud, L.L., Schulz, K.F., Juni, P., Altman, D.G., Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study (2008) BMJ, 336, pp. 601-605. , PMID: 18316340; Savovic, J., Jones, H.E., Altman, D.G., Harris, R.J., Juni, P., Pildal, J., Influence of reported study design characteristics on intervention effect estimates from RCTs (2012) Ann Intern Med., 157, pp. 429-438. , PMID: 22945832; Strippoli, G.M.F., Navaneethan, S.D., Johnson, D.W., Perkovic, V., Pellegrini, F., Nicolucci, A., Effects of statins in patients with chronic kidney disease: Metaanalysis and metaregression of randomized controlled trials. Cochrane Renal Group (2008) BMJ, 336, pp. 645-658. , PMID: 18299289; http://dailymed.nlm.nih.gov/dailymed/about.cfm, Available Accessed 2015 March 20Higgins, J.P.T., Green, S., (2011) Cochrane Handbook for Systematic Reviews of Interventions, , http://www.cochrane.org/handbook, Wiley-Blackwell H/B Cochrane Community (beta) website Available Accessed 2015 March 20; Borenstein, M., Hedges, L.V., Higgins, J.P.T., Rothstein, H.R., (2008) Introduction to Meta-Analysis, , Wiley March; Peters, J.L., Sutton, A.J., Jones, D.R., Abrams, K.R., Rushton, L., Comparison of Two Methods to Detect Publication Bias in Meta-analysis (2006) JAMA, 295, pp. 676-680. , PMID: 16467236; Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in metaanalysis detected by a simple, graphical test (1997) BMJ, 315, pp. 629-634. , PMID: 9310563; Crowther, M.J., Hinchliffe, S.R., Donald, A., Sutton, A.J., Simulation-based sample size calculation for designing new clinical trials and diagnostic test accuracy studies to update an existing meta-analysis (2013) The Stata Journal., 13, pp. 451-473; Higgins, J.P.T., White, I.R., Wood, M.A., Imputation methods for missing outcome data in meta-analysis of clinical trials (2008) Clinical Trials., 5, pp. 225-239. , PMID: 18559412; Arimura, T., Miura, S., Ike, A., Sugihara, M., Iwata, A., Nishikawa, H., Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina (2012) J Cardiol., 60, pp. 111-118. , PMID: 22542530; Kouvelos, G.N., Arnaoutoglou, E.M., Matsagkas, M.I., Kostara, C., Gartzonika, C., Bairaktari, E.T., Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: Results of a pilot study (2013) J Cardiovasc Pharmacol Ther., 18, pp. 5-12. , PMID: 22573476; Ballantyne, C.M., Lipka, L.J., Sager, P.T., Strony, J., Alizadeh, J., Suresh, R., Longterm safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia (2004) Int J Clin Pract., 58, pp. 653-658. , PMID: 15311720; West, A.M., Anderson, J.D., Meyer, C.H., Epstein, F.H., Wang, H., Hagspiel, K.D., The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline (2011) Atherosclerosis., 218, pp. 156-162. , PMID: 21570685; McKenney, J.M., Farnier, M., Lo, K.W., Bays, H.E., Perevozkaya, I., Carlson, G., Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia (2006) J Am Coll Cardiol., 47, pp. 1584-1587. , PMID: 16630994; Rayner, B.L., Byrne, M.J., Van Zyl Smit, R., A Prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with Simvastatin and diet, versus diet alone (1996) Clin Nephrol., 46, pp. 219-224. , PMID: 8905205; Walker, R.J., Sutherland, W.H., Walker, H.L., MaMahon, S., Robson, R.A., Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT study Collaborative Group (1997) Nephrol Dial Transplant., 12, pp. 87-92. , PMID: 9027779; Collins, R., Armitage, J., Parish, S., Sleigh, P., Peto, R., MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial (2003) Lancet., 361, pp. 2005-2016. , PMID: 12814710; Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J.P., Komajda, M., Effects of torcetrapib in patients at high risk for coronary events (2007) N Engl J Med., 357, pp. 2109-2122. , PMID: 17984165; Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J., Effects of dalcetrapib in patients with a recent acute coronary syndrome (2012) N Engl J Med., 367, pp. 2089-2099. , PMID: 23126252; Teo, K.K., Goldstein, L.B., Chaitman, B.R., Grant, S., Weintraub, W.S., Anderson, D.C., Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease. The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) Trial (2013) Stroke., 44, pp. 2688-2693. , PMID: 23881958; Peto, R., Emberson, J., Landray, M., Baigent, C., Collins, R., Clare, R., Analyses of cancer data from three ezetimibe trials (2008) N Engl J Med., 359, pp. 1357-1366. , PMID: 18765432; Doggrel, S.A., The ezetimibe controversy-can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? (2012) Expert Opin Pharmacother., 13, pp. 1469-1480. , PMID: 22725704",Article,Scopus,2-s2.0-84928536415
"Zhou T., Chen X., Li Z., Li L.","Relationship between serum bilirubin and left ventricular hypertrophy in patients with essential hypertension",2015,"PLoS ONE","10","4", e0125275,"","",,,10.1371/journal.pone.0125275,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928562859&partnerID=40&md5=7151221c2cf3771e6a73ad84d0173cec","Department of Cardiology, Southern Medical UniversityGuangzhou, Guangdong Province, China; Xiangya Nursing School, Central South UniversityChangsha, Hunan Province, China; Nursing Department, Southern Medical UniverstiyGuangzhou, Guangdong Province, China; Department of Epidemiology and Health Statistics, School of Public Health, Central South UniversityChangsha, Hunan Province, China; Department of Nursing, Xiangya Medical School, Central South UniversityChangsha, Hunan Province, China","Zhou, T., Department of Cardiology, Southern Medical UniversityGuangzhou, Guangdong Province, China; Chen, X., Xiangya Nursing School, Central South UniversityChangsha, Hunan Province, China, Nursing Department, Southern Medical UniverstiyGuangzhou, Guangdong Province, China; Li, Z., Department of Epidemiology and Health Statistics, School of Public Health, Central South UniversityChangsha, Hunan Province, China; Li, L., Department of Nursing, Xiangya Medical School, Central South UniversityChangsha, Hunan Province, China","Background: Prospective studies have found low bilirubin levels were an important predictive factor of cardiovascular events. However, few have yet investigated possible association between serum bilirubin level and LVH in essential hypertension. The aim of the present study was to evaluate the relationship between serum bilirubin levels with LVH in newly diagnosed hypertension patients. Methods: The present study evaluated the relationship between serum total bilirubin level and left ventricle hypertrophy (LVH) in newly diagnosed hypertensive patients with a sample size of 344. We divided subjects into LVH group (n=138) and non-LVH group (n=206). Physical examination, laboratory tests and echocardiography were conducted. The multivariate logistic regression model was used to verify the independent association between RDW and LVH. Results: Our results found that patients with LVH had lower bilirubin levels than non-LVH ones. Stepwise multiple linear regression analysis showed total bilirubin level (B=-0.017, P=0.008) was negatively associated with left ventricle mass index (LVMI) even adjusting for some confounders. The multiples logistic regression found total bilirubin level was independently related with of LVH, as a protective factors (OR=0.91, P =0.010). Conclusion: As a routine and quick laboratory examination index, serum bilirubin may be treated as novel marker for evaluating LVH risk in hypertensive patients. Cohort study with larger sample size are needed. © 2015 Zhou et al.",,"Muntner, P., Krousel-Wood, M., Hyre, A.D., Stanley, E., Cushman, W.C., Cutler, J.A., Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines (2009) Hypertension, 53, pp. 617-623. , PMID: 19221214; 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension (2013) J Hypertens, 31, pp. 1925-1938. , PMID: 24107724; Van Den Hoogen, P.C.W., Feskens, E.J.M., Nagelkerke, N.J.D., Menotti, A., Kromhout, D., The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world (2000) N. Engl. J. Med, 342, pp. 1-8. , Seven Countries Study Research Group. PMID: 10620642; Verdecchia, P., Reboldi, G., Angeli, F., Trimarco, B., Mancia, G., Pogue, J., Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease (2015) Hypertension, 65, pp. 108-114. , PMID: 25331850; Faraco, G., Iadecola, C., Hypertension: A harbinger of stroke and dementia (2013) Hypertension, 62, pp. 810-817. , PMID: 23980072; Subramaniam, A., Shanmugam, M.K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma (2013) Biochim Biophys Acta, 1835, pp. 46-60. , PMID: 23103770; Sah N, D.Y., Gür, M., Elbasan, Z., Kalkan, G.Y., Ozdoʇru, I., Kivrak, A., Myocardial performance index and aortic dispensability in patients with different left ventricle geometry in newly diagnosed essential hypertension (2013) Blood Press, 22, pp. 329-335. , PMID: 23550550; Levy, D., Murabito, J.M., Anderson, K.M., Christiansen, J.C., Castelli, W.P., Echocardiographic left ventricular hypertrophy: Clinical characteristics. The Framingham Heart Study (1992) Clin Exp Hypertens, 14, pp. 85-97. , PMID: 1531786; Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N., Ames, B.N., Bilirubin is an antioxidant of possible physiological importance (1987) Science, 235, pp. 1043-1046. , PMID: 3029864; Vitek, L., The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases (2012) Front Pharmacol, 3, p. 55. , PMID: 22493581; Kimm, H., Yun, J., Jo, J., Jee, S., Low serum bilirubin level as an independent predictor of stroke incidence: A prospective study in Korean men and women (2009) Stroke, 40, pp. 3422-3427. , PMID: 19713538; Perlstein, T., Pande, R., Beckman, J., Creager, M., Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004 (2008) Arteriosclerosis, Thrombosis, and Vascular Biology., 28, pp. 166-172. , PMID: 17975120; Hopkins, P.N., Wu, L.L., Hunt, S.C., James, B.C., Vincent, G.M., Williams, R.R., Higher Serum Bilirubin Is Associated With Decreased Risk for Early Familial Coronary Artery Disease (1996) Arteriosclerosis, Thrombosis, and Vascular Biology, 16, pp. 250-255. , PMID: 8620339; Horsfall, L., Nazareth, I., Petersen, I., Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort (2012) Circulation, 126, pp. 2556-2564. , PMID: 23110860; (2001) Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis, , New York, NY: Springer; Kawamura, K., Ishikawa, K., Wada, Y., Kimura, S., Matsumoto, H., Kohro, T., Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction (2005) Arterioscler Thromb Vasc Biol, 25, pp. 155-160. , PMID: 15499042; IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000 (2001) Am J Kidney Dis, 37, pp. S182-S238. , PMID: 11229970; Lang, R.M., Badano, L.P., Mor-Avi, V., Afilalo, J., Armstrong, A., Erannde, L., Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging (2015) J Am Soc Echocardiogr, 28, pp. 1-39. , PMID: 25559473; Porter, T.R., Abdelmoneim, S., Belcik, J.T., McCulloch, M.L., Mulvagh, S.L., Olson, J.J., Guidelines for the cardiac sonographer in the performance of contrast echocardiography: A focused update from the American Society of Echocardiography (2014) J Am Soc Echocardiogr, 27, pp. 797-810. , PMID: 25085408; Varis, J.P., Puukka, P.J., Karanko, H.M., Jula, A.M., Risk assessment of echocardiographic left ventricular hypertrophy with electrocardiography, bodymass index and blood pressure (2014) Blood Press, 23, pp. 39-46. , PMID: 23772751; Leoncini, G., Viazzi, F., Parodi, D., Ratto, E., Vettoretti, S., Vaccaro, V., Creatinine clearance and signs of end-organ damage in primary hypertension (2004) J Hum Hypertens, 18, pp. 511-516. , PMID: 15002001; Ndisang, J.F., Jadhav, A., Upregulating the heme oxygenase system suppresses left ventricular hypertrophy in adult spontaneously hypertensive rats for 3 months (2009) J Card Fail, 15, pp. 616-628. , PMID: 19700139; Ayaz, T., Durakoglugil, M.E., Kocaman, S.A., Durakoglugil, T., Erdogan, T., Sahin, S.B., Bilirubin Level is Associated with Left Ventricular Hypertrophy Independent of Blood Pressure in Previously Untreated Hypertensive Patients (2014) Korean Circ J, 44, pp. 336-343. , PMID: 25278987; Tiribelli, C., Ostrow, J.D., The molecular basis of bilirubin encephalopathy and toxicity: Report of an EASL Single Topic Conference (2005) J Hepatol, 43, pp. 156-156. , PMID: 15921815; Mayer, M., Association of serum bilirubin concentration with risk of coronary artery disease (2000) Clin Chem, 46, pp. 1723-1727. , PMID: 11067805; Kawamoto, R., Ninomiya, D., Hasegawa, Y., Kasai, Y., Kusunoki, T., Ohtsuka, N., Mildly Elevated Serum Bilirubin Levels Are Negatively Associated with Carotid Atherosclerosis among Elderly Persons (2014) PLoS One, 9, p. e114281. , PMID: 25479598; Abbasi, A., Deetman, P.E., Corpeleijn, E., Gansevoort, R.T., Gans, R.O., Hillege, H.L., Bilirubin as a potential causal factor in type 2 diabetes risk: A Mendelian randomization study (2014) Diabetes, 64, pp. 1459-1469. , PMID: 25368098; Song, Y.S., Koo, B.K., Cho, N.H., Moon, M.K., Effect of low serum total bilirubin levels (</ = 0.32 mg/dl) on risk of coronary artery disease in patients with metabolic syndrome (2014) Am J Cardiol, 114, pp. 1695-1700. , PMID: 25288499; Parfenova, H., Leffler, C.W., Basuroy, S., Liu, J., Fedinec, A.L., Antioxidant roles of heme oxygenase, carbon monoxide, and bilirubin in cerebral circulation during seizures (2012) J Cereb Blood Flow Metab, 32, pp. 1024-1034. , PMID: 22354150; Kotani, K., Tsuzaki, K., Sakane, N., The relationship between gamma-glutamyltransferase (GGT), bilirubin (Bil) and small dense low-density lipoprotein (sdLDL) in asymptomatic subjects attending a clinic for screening dyslipidaemias (2014) Ann Acad Med Singapore, 43, pp. 216-219. , PMID: 24833073; Vitek, L., Jirsa, M., Brodanova, M., Kalab, M., Marecek, Z., Danzig, V., Gilbert syndrome and ischemic heart disease: A protective effect of elevated bilirubin levels (2002) Atherosclerosis, 160, pp. 449-456. , PMID: 11849670; Mayer, M., Association of serum bilirubin concentration with risk of coronary artery disease (2000) Clin Chem, 46, pp. 1723-1727. , PMID: 11067805; Vitek, L., The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases (2012) Front Pharmacol, 3, p. 55. , PMID: 22493581; Lippi, G., Targher, G., Further insights on the relationship between bilirubin and C-reactive protein (2012) Clin Chem Lab Med, 50, pp. 2229-2230. , PMID: 23093262",Article,Scopus,2-s2.0-84928562859
"Michaud K., Grabherr S., Faouzi M., Grimm J., Doenz F., Mangin P.","Pathomorphological and CT-angiographical characteristics of coronary atherosclerotic plaques in cases of sudden cardiac death",2015,"International Journal of Legal Medicine",,,,"","",11,,10.1007/s00414-015-1191-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928324056&partnerID=40&md5=12f489f5920fab8b15abed8e7d9239f4","University Center of Legal MedicineLausanne, Switzerland; Institute of Social and Preventive MedicineLausanne, Switzerland; Departement of Diagnostic and Intervential RadiologyLausanne, Switzerland","Michaud, K., University Center of Legal MedicineLausanne, Switzerland; Grabherr, S., University Center of Legal MedicineLausanne, Switzerland; Faouzi, M., Institute of Social and Preventive MedicineLausanne, Switzerland; Grimm, J., University Center of Legal MedicineLausanne, Switzerland, Departement of Diagnostic and Intervential RadiologyLausanne, Switzerland; Doenz, F., Departement of Diagnostic and Intervential RadiologyLausanne, Switzerland; Mangin, P., University Center of Legal MedicineLausanne, Switzerland","The goal of this study was to assess the localization and types of thrombosed plaques in cases of sudden cardiac death attributed to coronary artery disease and to evaluate possible correlations with body mass index (BMI) and increased heart weight. This retrospective study was performed on forensic cases for which the cause of death was attributed to coronary artery disease. A complete autopsy and a multi-phase postmortem computed tomography (CT) angiography (MPMCTA) were performed in all cases. Eighty-five cases were selected (mean age, 55.18 ± 11.04 years; 72 men and 13 women). MPMCTA performed prior to autopsy enabled an evaluation of coronary artery perfusion before dissection of the body and helped therefore to guide sampling for histology. An acute coronary thrombosis was found in 57 cases, which included plaque erosion in 26 cases (mean age, 46.73 ± 8.33 years) and rupture or intra-plaque hemorrhage in 31 cases (mean age, 58.23 ± 10.62 years). Erosions were most frequently found in the left anterior descending artery (61.5 %), while only 35.48 % of ruptures were observed in this artery. Chronic coronary pathology was considered as the main cause of death in 28 cases (mean age, 59.64 ± 9.47 years). Sixty-two of the cases (72.94 %) had a BMI in the overweight category (BMI ≥25), with the highest mean BMI in patients with chronic coronary pathology without acute thrombosis found at autopsy. The heart weight was above the predicted reference values in 52 cases (61.18 %). Our results are in accordance with previously published studies on the spatial distribution of vulnerable plaques. We observed a higher percentage of eroded plaques than previously reported. Patients with coronary erosions were significantly younger than those with plaque rupture or those without an acute coronary thrombosis (p values <0.0001). BMI and heart weight were significantly higher for cases without thrombosis in comparison with those with plaque rupture (p values 0.028 and 0.003, respectively). Our results indicating that increased BMI and overweight hearts are associated with chronic ischemic heart disease are compatible with clinical studies. Performing more postmortem studies on forensic autopsies, including modern radiological examinations with MPMCTA, can enhance the detection of vulnerable plaques in living patients and prevent sudden cardiac death. © 2015 Springer-Verlag Berlin Heidelberg","Coronary artery; Ischemic heart disease; MPMCTA; Postmortem CT angiography; Sudden cardiac death",,Article in Press,Scopus,2-s2.0-84928324056
"Paccou J., Edwards M.H., Ward K.A., Jameson K.A., Moss C.L., Harvey N.C., Dennison E.M., Cooper C.","Ischemic heart disease is associated with lower cortical volumetric bone mineral density of distal radius",2015,"Osteoporosis International",,,,"","",9,,10.1007/s00198-015-3132-z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928332686&partnerID=40&md5=f11939b7b56bca405ace5c7274d7b521","MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General HospitalSouthampton, United Kingdom; Department of Rheumatology, Lille University Hospital, Lille 2Lille cedex, France; MRC Human Nutrition Research, Elsie Widdowson Laboratory, 120 Fulbourn RoadCambridge, United Kingdom; Victoria UniversityWellington, New Zealand; NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of OxfordOxford, United Kingdom; NIHR Nutrition Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Trust, Southampton General HospitalSouthampton, United Kingdom","Paccou, J., MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General HospitalSouthampton, United Kingdom, Department of Rheumatology, Lille University Hospital, Lille 2Lille cedex, France; Edwards, M.H., MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General HospitalSouthampton, United Kingdom; Ward, K.A., MRC Human Nutrition Research, Elsie Widdowson Laboratory, 120 Fulbourn RoadCambridge, United Kingdom; Jameson, K.A., MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General HospitalSouthampton, United Kingdom; Moss, C.L., MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General HospitalSouthampton, United Kingdom; Harvey, N.C., MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General HospitalSouthampton, United Kingdom; Dennison, E.M., MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General HospitalSouthampton, United Kingdom, Victoria UniversityWellington, New Zealand; Cooper, C., MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General HospitalSouthampton, United Kingdom, NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of OxfordOxford, United Kingdom, NIHR Nutrition Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Trust, Southampton General HospitalSouthampton, United Kingdom","Summary: In this study, high-resolution peripheral quantitative computed tomography (HR-pQCT) was used to investigate geometric, volumetric and microstructural parameters at the distal radius and at the distal tibia in participants with ischaemic heart disease. We found that, compared with participants without ischaemic heart disease, they had substantially lower cortical volumetric bone mineral density (BMD) at the distal radius. Introduction: HR-pQCT captures novel aspects of bone geometry and volumetric bone mineral density (vBMD) and offers the ability to measure bone microarchitecture, but data relating measures obtained from this technique in patients with ischemic heart disease (IHD) are lacking. Methods: Here, we report an analysis from the Hertfordshire Cohort Study, where we were able to study associations between measures obtained from HR-pQCT of distal radius and distal tibia in 350 participants (184 men and 166 women) aged 71.5–80.5 years with or without IHD (e.g. heart attack, angina or heart failure; n = 75 and n = 275, respectively). Results: Analyses for all participants (men and women together) revealed that cortical vBMD (Ct.vBMD) was lower (p < 0.001) and cortical thickness (Ct.th) was not different (p = 0.519), whereas cortical porosity (Ct.Po) was higher (p = 0.016) in participants with IHD at the distal radius. Moreover, trabecular microarchitectural parameters were not significantly different in patients with IHD (p > 0.05 for all). Adjustment for a priori confounders (age, gender, body mass index, smoking status, alcohol consumption, high blood pressure and diabetes mellitus) did not materially affect the relationship described for Ct.vBMD (p = 0.002), but differences in Ct.Po were attenuated. Analyses in men alone revealed that only Ct.vBMD was lower at the distal radius in participants with IHD with and without adjustment for a priori confounders (p = 0.0002 and p = 0.004, respectively), whereas no statistical differences were found in women, although patterns of differences were similar in both sexes. Moreover, no association was found between IHD and bone parameters at the distal tibia either in men or women. Conclusions: We have demonstrated that IHD is associated with lower Ct.vBMD of the distal radius. © 2015 International Osteoporosis Foundation and National Osteoporosis Foundation","Cortical porosity; Cortical volumetric bone mineral density; High-resolution peripheral quantitative computed tomography; Ischemic heart disease; Vascular calcification",,Article in Press,Scopus,2-s2.0-84928332686
"Corona G., Giuliani C., Verbalis J.G., Forti G., Maggi M., Peri A.","Hyponatremia improvement is associated with a reduced risk of mortality: Evidence from a meta-analysis",2015,"PLoS ONE","10","4", e0124105,"","",,,10.1371/journal.pone.0124105,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928408851&partnerID=40&md5=871f5eef903cc9779fba2a4ccbc9e61f","Endocrinology Unit, Maggiore-Bellaria HospitalBologna, Italy; Endocrine Unit, University of Florence, Careggi HospitalFlorence, Italy; Division of Endocrinology and Metabolism, Georgetown UniversityWashington, DC, United States; Andrology Unit, University of Florence, Careggi HospitalFlorence, Italy","Corona, G., Endocrinology Unit, Maggiore-Bellaria HospitalBologna, Italy; Giuliani, C., Endocrine Unit, University of Florence, Careggi HospitalFlorence, Italy; Verbalis, J.G., Division of Endocrinology and Metabolism, Georgetown UniversityWashington, DC, United States; Forti, G., Endocrine Unit, University of Florence, Careggi HospitalFlorence, Italy; Maggi, M., Andrology Unit, University of Florence, Careggi HospitalFlorence, Italy; Peri, A., Endocrine Unit, University of Florence, Careggi HospitalFlorence, Italy","Background: Hyponatremia is the most common electrolyte disorder and it is associated with increased morbidity and mortality. However, there is no clear demonstration that the improvement of serum sodium concentration ([Na+]) counteracts the increased risk of mortality associated with hyponatremia. Thus, we performed a meta-analysis that included the published studies that addressed the effect of hyponatremia improvement on mortality. Methods and Findings: A Medline, Embase and Cochrane search was performed to retrieve all English-language studies of human subjects published up to June 30th 2014, using the following words: ""hyponatremia"", ""hyponatraemia"", ""mortality"", ""morbidity "" and ""sodium"". Fifteen studies satisfied inclusion criteria encompassing a total of 13,816 patients. The identification of relevant abstracts, the selection of studies and the subsequent data extraction were performed independently by two of the authors, and conflicts resolved by a third investigator. Across all fifteen studies, any improvement of hyponatremia was associated with a reduced risk of overall mortality (OR=0.57[0.40-0.81]). The association was even stronger when only those studies (n=8) reporting a threshold for serum [Na+] improvement to > 130 mmol/L were considered (OR=0.51[0.31-0.86]). The reduced mortality rate persisted at follow-up (OR=0.55 [0.36-0.84] at 12 months). Meta-regression analyses showed that the reduced mortality associated with hyponatremia improvement was more evident in older subjects and in those with lower serum [Na+] at enrollment. Conclusions:This meta-analysis documents for the first time that improvement in serum [Na+] in hyponatremic patients is associated with a reduction of overall mortality. © 2015 Corona et al.",,"Upadhyay, A., Jaber, B.L., Madias, N.E., Incidence and prevalence of hyponatremia (2006) Am J Med, 119, pp. 30-35. , PMID: 16431179; Hoorn, E.J., Lindemans, J., Zietse, R., Development of severe hyponatremia in hospitalized patients: Treatment-related risk factors and inadequate management (2006) Nephrol Dial Transplant, 28, pp. 70-76; Gill, G., Huda, B., Boyd, A., Skagen, K., Wile, D., Watson, I., Characteristics and mortality of severe hyponatremia - A hospital-based study (2006) Clin Endocrinol (Oxf), 65, pp. 246-249. , PMID: 16886968; Renneboog, B., Musch, W., Vandemergel, X., Manto, M.U., Decaux, G., Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits (2006) Am J Med, 119, pp. 71.e1-71.e8; Gankam, K.F., Andres, C., Sattar, L., Decaux, G., Mild hyponatremia and risk of fracture in the ambulatory elderly (2008) QJM, 101, pp. 583-588. , PMID: 18477645; Kinsella, S., Moran, S., Sullivan, M.O., Molloy, M.G., Eustace, J.A., Hyponatremia independent of osteoporosis is associated with fracture occurrence (2010) Clin J Am Soc Nephrol, 5, pp. 275-280. , PMID: 20056759; Verbalis, J.G., Barsony, J., Sugimura, Y., Tian, Y., Adams, D.J., Carter, E.A., Hyponatremia-induced osteoporosis (2010) J Bone Miner Res, 25, pp. 554-563. , PMID: 19751154; Barsony, J., Sugimura, Y., Verbalis, J.G., Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss (2010) J Biol Chem, 286, pp. 10864-10875. , PMID: 21135109; Barsony, J., Manigrasso, M.B., Xu, Q., Tam, H., Verbalis, J.G., Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats (2012) Age (Dordr), 35, pp. 271-288; Benvenuti, S., Deledda, C., Luciani, P., Modi, G., Bossio, A., Giuliani, C., Low extracellular sodium causes neuronal distress independently of reduced osmolality in an experimental model of chronic hyponatremia (2013) Neuromolecular Med, 15, pp. 493-503. , PMID: 23695860; Wald, R., Jaber, B.L., Price, L.L., Impact of hospital-associated hyponatremia on selected outcomes (2010) Arch Intern Med, 170, pp. 294-302. , PMID: 20142578; Zilberberg, M.D., Exuzides, A., Spalding, J., Foreman, A., Jones, A.G., Colby, C., Hyponatremia and hospital outcomes among patients with pneumonia: A retrospective cohort study (2008) BMC Pulm Med, 8, p. 16. , PMID: 18710521; Klein, L., O'Connor, C.M., Leimberger, J.D., Gattis-Stough, W., Piña, I.L., Felker, G.M., Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study (2005) Circulation, 111, pp. 2454-2460. , PMID: 15867182; Waikar, S.S., Mount, D.B., Curhan, G.C., Mortality after hospitalization with mild, moderate, and severe hyponatremia (2009) Am J Med, 122, pp. 857-865. , PMID: 19699382; Kim, W.R., Biggins, S.W., Kremers, W.K., Wiesner, R.H., Kamath, P.S., Benson, J.T., Hyponatremia and mortality among patients on the liver-transplant waiting list (2008) N Engl J Med, 359, pp. 1018-1026. , PMID: 18768945; Terzian, C., Frye, E.B., Piotrowski, Z.H., Admission hyponatremia in the elderly: Factors influencing prognosis (1994) J Gen Intern Med, 9, pp. 89-91. , PMID: 8164083; Corona, G., Giuliani, C., Parenti, G., Norello, D., Verbalis, J.G., Forti, G., Moderate hyponatremia is associated with increased risk of mortality: Evidence from a meta-analysis (2013) PLoS One, 8, p. e80451. , PMID: 24367479; Konstam, M.A., Gheorghiade, M., Burnett, J.C., Jr., Maggioni, A.P., Swedberg, K., Udelson, J.E., Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial (2007) JAMA, 297, pp. 1319-1331. , PMID: 17384437; Hauptman, P.J., Burnett, J., Gheorghiade, M., Grinfeld, L., Konstam, M.A., Kostic, D., Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan (2013) J Card Fail, 19, pp. 390-397. , PMID: 23743487; Madan, V.D., Novak, E., Rich, M.W., Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia (2011) Circ Heart Fail, 4, pp. 637-643. , PMID: 21673193; Lee, S.E., Choi, D.J., Yoon, C.H., Oh, I.Y., Jeon, E.S., Kim, J.J., Improvement of hyponatraemia during hospitalization for acute heart failure is not associated with improvement of prognosis: An analysis from the Korean Heart Failure (KorHF) registry (2012) Heart, 98, pp. 1798-1804. , PMID: 23125248; Higgins, J.P.T., Green, S., (2008) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1, , www.cochrane-handbook.org, The Cochrane Collaboration. Available; Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias (1994) Biometrics, 50, pp. 1088-1101. , PMID: 7786990; Egger, M., Davey, S.G., Schneider, M., Bias in meta-analysis detected by a simple, graphical test (1997) BMJ, 315, pp. 629-634. , PMID: 9310563; Licata, G., Di Pasquale, P., Parrinello, G., Cardinale, A., Scandurra, A., Follone, G., Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: Long-term effects (2003) Am Heart J, 145, pp. 459-466. , PMID: 12660669; Gheorghiade, M., Rossi, J.S., Cotts, W., Shin, D.D., Hellkamp, A.S., Piña, I.L., Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial (2007) Arch Intern Med, 167, pp. 1998-2005. , PMID: 17923601; Rossi, J., Bayram, M., Udelson, J.E., Lloyd-Jones, D., Adams, K.F., Oconnor, C.M., Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: Insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial (2007) Acute Card Care, 9, pp. 82-86. , PMID: 17573581; Hackworth, W.A., Heuman, D.M., Sanyal, A.J., Fisher, R.A., Sterling, R.K., Luketic, V.A., Effect of hyponatraemia on outcomes following orthotopic liver transplantation (2009) Liver Int, 29, pp. 1071-1077. , PMID: 19302181; Rusinaru, D., Buiciuc, O., Leborgne, L., Slama, M., Massy, Z., Tribouilloy, A., Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction (2009) Am J Cardiol, 103, pp. 405-410. , PMID: 19166698; Hansen, O., Sørensen, P., Hansen, K.H., The occurrence of hyponatremia in SCLC and the influence on prognosis: A retrospective study of 453 patients treated in a single institution in a 10-year period (2010) Lung Cancer, 68, pp. 111-114. , PMID: 19535164; Vaishya, R., Kaur, J., Seema, Chopra, S., Jaswal, S., Mortality predictors in severe hyponatraemia in emergency inpatients (2012) J Indian Med Assoc, 110, pp. 94-97. , PMID: 23029842; Ng, A.C., Chow, V., Yong, A.S., Chung, T., Kritharides, L., Fluctuation of serum sodium and its impact on short and long-term mortality following acute pulmonary embolism (2013) PLoS One, 8, p. e61966. , PMID: 23620796; Qureshi, W., Hassan, S., Khalid, F., Almahmoud, M.F., Shah, B., Tashman, R., Outcomes of correcting hyponatremia in patients with myocardial infarction (2013) Clin Res Cardiol, 102, pp. 637-644. , PMID: 23653254; Darmon, M., Pichon, M., Schwebel, C., Ruckly, S., Adrie, C., Influence of early dysnatremia correction on survival of critically ill patients (2014) Shock, 41, pp. 394-399. , PMID: 24667611; Nzerue, C.M., Baffoe-Bonnie, H., You, W., Falana, B., Dai, S., Predictors of outcome in hospitalized patients with severe hyponatremia (2003) J Natl Med Assoc, 95, pp. 335-343. , PMID: 12793790; Doshi, S.M., Shah, P., Lei, X., Lahoti, A., Salahudeen, A.K., Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes (2012) Am J Kidney Dis, 59, pp. 222-228. , PMID: 22001181; Lee, J., Kim, D.K., Lee, J.W., Oh, K.H., Oh, Y.K., Han, J.S., Rapid correction rate of hyponatremia as an independent risk factor for neurological complication following liver transplantation (2013) Tohoku J Exp Med, 229, pp. 97-105. , PMID: 23303272; Huda, M.S., Boyd, A., Skagen, K., Wile, D., Van Heyningen, C., Watson, I., Investigation and management of severe hyponatraemia in a hospital setting (2006) Postgrad Med J, 82, pp. 216-219. , PMID: 16517805; Giuliani, C., Cangioli, M., Beck-Peccoz, P., Faustini-Fustini, M., Fiaccadori, E., Peri, A., Awareness and management of hyponatraemia: The Italian Hyponatraemia Survey (2013) J Endocrinol Invest, 36, pp. 693-698. , PMID: 23558469; Konstam, M.A., Udelson, J.E., Hyponatraemia and vasopressin in heart failure: Markers or mediators? (2009) Eur J Heart Fail, 13, pp. 242-244; Peri, A., Pirozzi, N., Parenti, G., Festuccia, F., Menè, P., Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) (2010) J Endocrinol Invest, 33, pp. 671-682. , PMID: 20935451; Peri, A., Clinical review: The use of vaptans in clinical endocrinology (2013) J Clin Endocrinol Metab, 98, pp. 1321-1332. , PMID: 23401044; Verbalis, J.G., Goldsmith, S.R., Greenberg, A., Korzelius, C., Schrier, R.W., Sterns, R.H., Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations (2013) Am J Med, 12, pp. S1-S42",Article,Scopus,2-s2.0-84928408851
"Klink T., Heverhagen J.T.","Images in clinical medicine. Mitral annular calcification",2015,"The New England journal of medicine","372","17",,"e23","",,,10.1056/NEJMicm1404772,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928698344&partnerID=40&md5=e89b13f8d0456c89317753facb0cfb8c","Inselspital-Bern University Hospital, Bern, Switzerland klink_t1@ukw.de","Klink, T., Inselspital-Bern University Hospital, Bern, Switzerland klink_t1@ukw.de; Heverhagen, J.T., Inselspital-Bern University Hospital, Bern, Switzerland klink_t1@ukw.de",[No abstract available],,,Article,Scopus,2-s2.0-84928698344
"Dulfer K., Bossers S.S.M., Utens E.M.W.J., Duppen N., Kuipers I.M., Kapusta L., van Iperen G., Schokking M., ten Harkel A.D.J., Takken T., Helbing W.A.","Does functional health status predict health-related quality of life in children after Fontan operation?",2015,"Cardiology in the Young",,,,"","",10,,10.1017/S1047951115000426,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928254328&partnerID=40&md5=1a8370097d5f38437a94aff275d7d89d","Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Centre–Sophia Children’s Hospital, Rotterdam, the Netherlands; Department of Paediatrics, Division of Cardiology, Erasmus Medical Centre – Sophia Children’s Hospital, Rotterdam, the Netherlands; Department of Paediatrics, Division of Cardiology, Academic Medical Centre, Amsterdam, the Netherlands; Department of Paediatrics, Division of Cardiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; Department of Paediatrics, Pediatric Cardiology Unit, Tel-Aviv Sourasky Medical Centre, Tel Aviv, Israel; Department of Paediatrics, Division of Cardiology, University Medical Centre Utrecht – Wilhelmina Children’s Hospital, Utrecht, the Netherlands; Department of Paediatrics, Division of Cardiology, Leiden University Medical Centre, Leiden, the Netherlands; Child Development and Exercise Centre, University Medical Centre Utrecht – Wilhelmina Children’s Hospital, Utrecht, the Netherlands","Dulfer, K., Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Centre–Sophia Children’s Hospital, Rotterdam, the Netherlands; Bossers, S.S.M., Department of Paediatrics, Division of Cardiology, Erasmus Medical Centre – Sophia Children’s Hospital, Rotterdam, the Netherlands; Utens, E.M.W.J., Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Centre–Sophia Children’s Hospital, Rotterdam, the Netherlands; Duppen, N., Department of Paediatrics, Division of Cardiology, Erasmus Medical Centre – Sophia Children’s Hospital, Rotterdam, the Netherlands; Kuipers, I.M., Department of Paediatrics, Division of Cardiology, Academic Medical Centre, Amsterdam, the Netherlands; Kapusta, L., Department of Paediatrics, Division of Cardiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, Department of Paediatrics, Pediatric Cardiology Unit, Tel-Aviv Sourasky Medical Centre, Tel Aviv, Israel; van Iperen, G., Department of Paediatrics, Division of Cardiology, University Medical Centre Utrecht – Wilhelmina Children’s Hospital, Utrecht, the Netherlands; Schokking, M., Department of Paediatrics, Division of Cardiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; ten Harkel, A.D.J., Department of Paediatrics, Division of Cardiology, Leiden University Medical Centre, Leiden, the Netherlands; Takken, T., Child Development and Exercise Centre, University Medical Centre Utrecht – Wilhelmina Children’s Hospital, Utrecht, the Netherlands; Helbing, W.A., Department of Paediatrics, Division of Cardiology, Erasmus Medical Centre – Sophia Children’s Hospital, Rotterdam, the Netherlands","Purpose: It is important to identify those children with a Fontan circulation who are at risk for impaired health-related quality of life. We aimed to determine the predictive value of functional health status – medical history and present medical status – on both physical and psychosocial domains of health-related quality of life, as reported by patients themselves and their parents. Methods: We carried out a prospective cross-sectional multi-centre study in Fontan patients aged between 8 and 15, who had undergone staged completion of total cavopulmonary connection according to a current technique before the age of 7 years. Functional health status was assessed as medical history – that is, age at Fontan, type of Fontan, ventricular dominance, and number of cardiac surgical procedures – and present medical status – assessed with magnetic resonance imaging, exercise testing, and rhythm assessment. Health-related quality of life was assessed with The TNO/AZL Child Questionnaire Child Form and Parent Form. Results: In multivariate prediction models, several medical history variables, such as more operations post-Fontan completion, lower age at Fontan completion, and dominant right ventricle, and present medical status variables, such as smaller end-diastolic volume, a higher score for ventilatory efficiency, and the presence of sinus node dysfunction, predicted worse outcomes on several parent-reported and self-reported physical as well as psychosocial health-related quality of life domains. Conclusions: Medical history and worse present medical status not only predicted worse physical parent-reported and self-reported health-related quality of life but also worse psychosocial health-related quality of life and subjective cognitive functioning. These findings will help in identifying patients who are at risk for developing impaired health-related quality of life. © Cambridge University Press 2015","congenital heart disease; Fontan circulation; quality of life",,Article in Press,Scopus,2-s2.0-84928254328
"Kayani S., Ahmad M., Sultana S., Khan Shinwari Z., Zafar M., Yaseen G., Hussain M., Bibi T.","Ethnobotany of medicinal plants among the communities of Alpine and Sub-alpine regions of Pakistan",2015,"Journal of Ethnopharmacology","164",,,"186","202",,,10.1016/j.jep.2015.02.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923667243&partnerID=40&md5=f47a671744483645380fbbed0459ed6b","Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Department of Biotechnology, Quaid-i-Azam UniversityIslamabad, Pakistan; Botany Department, Hazara UniversityMansehra, Pakistan; Department of Plant Sciences, Sardar Bahadur Khan Womens UniversityQuetta, Pakistan","Kayani, S., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Ahmad, M., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Sultana, S., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Khan Shinwari, Z., Department of Biotechnology, Quaid-i-Azam UniversityIslamabad, Pakistan; Zafar, M., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Yaseen, G., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan; Hussain, M., Botany Department, Hazara UniversityMansehra, Pakistan; Bibi, T., Department of Plant Sciences, Quaid-i-Azam UniversityIslamabad, Pakistan, Department of Plant Sciences, Sardar Bahadur Khan Womens UniversityQuetta, Pakistan","Ethno-pharmacological relevance To best of our knowledge it is first quantitative ethno-botanical study from Alpine and Sub-alpine, Western Himalaya of Pakistan. The study aims to report, compare the uses and highlight the ethno-botanical significance of medicinal plants for treatment of various diseases. Methods A total of 290 (278 males and 12 females) informants including 14 Local Traditional Healers (LTHs) were interviewed. Information was collected using semi-structured interviews, analyzed and compared by quantitative ethno-botanical indices such as Informant Consensus Factor (ICF), Relative frequency of citation (RFC), use value (UV), Fidelity Level (FL) and Jaccard index (JI). Results A total of 125 plant species (Gymnosperms 7 species, Monocotyledons 2 and 116 Di-cotyledons) belonging to 41 families are collected, identified and ethno-botanically assessed. The most dominant family is Ranunculaceae (20 species) followed by Rosaceae (14 species). In diseases treated, gastrointestinal tract (GIT) diseases have highest proportion (27.5%) followed by respiratory diseases (20%) in the mountain communities. The most dominant life form of plants used is herbs (78%) followed by shrubs (19%) while the most commonly used plant parts are leaves (44 reports) followed by underground part, the roots (37 reports). The highest ICF (0.68) is found for ear, nose and eye disease category followed by respiratory disorders (0.46). There are 15 medicinal plants having 100% FL. Use value (UV) and Relative frequency of citation (RFC) range from 0.03 to 0.53 and 0.04 to 0.23 respectively. In comparison, maximum similarity index is found in the studies with JI 19.52 followed by 17.39. Similarity percentage of plant uses range from 1.69% to 19.52% while dissimilarity percentage varies from 0% to 20%. Conclusions The Alpine and Sub-alpine regions of Pakistan are rich in medicinal plants and still need more research exploration. On the other hand, ethno-botanical knowledge in study areas is decreasing day by day due to high emigration rates resulting from after effects of wars during the last few decades. Historically developed ethno-botanical heritage should be preserved and promoted on global level for analyzing phytochemical, pharmaceutical and other biological activities for future drug discovery. © 2015 Elsevier Ireland Ltd. All rights reserved.","Alpine-Subalpine regions; Ethno-botanical indices; Ethnobotany; Pakistan","Acharya, R., Ethnobotanical study of medicinal plants of Resunga hill used by Magar community of Badagaun VDC, Gulmi district, Nepal (2012) Scientific World, 10, pp. 54-65; Adzu, B., Amos, S., Amizan, M.B., Gamaniel, K., Evaluation of the antidiarrhoeal effects of Zizyphus spina-christi stem bark in rats (2003) Acta Tropica, 87, pp. 245-250; Ahmad, M., Sultana, S., Hadi, S.F., Hadda, T.B., Rashid, S., Zafar, M., Khan, M.A., Yaseen, G., An ethnobotanical study of medicinal plants in high mountainous region of Chail valley (District Swat-Pakistan) (2014) Journal of Ethnobiology and Ethnomedicine, 10, p. 36; Akhtar, N., Rashid, A., Murad, W., Bergmeier, E., Diversity and use of ethno-medicinal plants in the region of Swat, North Pakistan (2013) Journal of Ethnobiology and Ethnomedicine, 9 (1), p. 25; Ali, S.I., Significance of flora with special reference to Pakistan (2008) Pakistan Journal of Botany, 40 (3), pp. 967-971; Altundag, E., Ozturk, M., Ethnomedicinal studies on the plant resources of east Anatolia, Turkey (2011) Procedia-Social and Behavioral Sciences, 19, pp. 756-777; Balick, M.J., Cox, P.A., (1996) Plants, People and Culture: The Science of Ethnobotany, p. 228. , Scientific American Library New York; Balick, M.J., Elisabetsky, E., Laird, S.A., (1996) Medicinal Resources of the Tropical Forest: Biodiversity and Its Importance to Human Health, , Columbia University Press New York; Bannerman, R.H., Burton, J., Wen-Chieh, C., (1983) TM and Health Care Coverage: A Reader for Health Administrators and Practitioners, 1983, pp. 318-327. , World Health Organization; Bano, A., Ahmad, M., Hadda, T.B., Saboor, A., Sultana, S., Zafar, M., Khan, M.P.Z., Ashraf, M.A., Quantitative ethnomedicinal study of plants used in the Skardu valley at high altitude of Karakoram-Himalayan range, Pakistan (2014) Journal of Ethnobiology and Ethnomedicine, 10 (1), p. 43; Bano, A., Ahmad, M., Zafar, M., Sultana, S., Rashid, S., Khan, M.A., Ethnomedicinal knowledge of the most commonly used plants from Deosai Plateau, Western Himalayas, Gilgit Baltistan, Pakistan (2014) Journal of Ethnopharmacology, 155, pp. 1046-1052; Basualdo, I., Zardini, E.M., Ortiz, M., Medicinal plants of Paraguay underground organs: II (1995) Economic Botany, 49, pp. 387-394; Bennett, B., Prance, G., Introduced plants in the indigenous pharmacopoeia of Northern South America (2000) Economic Botany, 54, pp. 90-102; Bhat, J.A., Kumar, M., Bussmann, R.W., Ecological status and traditional knowledge of medicinal plants in Kedarnath Wildlife Sanctuary of Garhwal Himalaya, India (2013) Journal of Ethnobiology and Ethnomedicine, 9; Bruni, A., Ballero, M., Poli, F., Quantitative ethnopharmacological study of the Campidano Valley and Urzulei district, Sardinia, Italy (1997) Journal of Ethnopharmacology, 57 (2), pp. 97-124; Caniago, I., Siebert, S.F., Medicinal plant ecology, knowledge and conservation in Kalimantan, Indonesia (1998) Economic Botany, 52, pp. 229-250; Chaudhary, N.I., Schnapp, A., Park, J.E., Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model (2006) American Journal of Respiratory and Critical Care Medicine, 173 (7), pp. 769-776; Chen, G., Yang, M., Song, Y., Lu, Z., Zhang, J., Huang, H., Guo, D.A., Comparative analysis on microbial and rat metabolism of ginsenoside Rb1 by high-performance liquid chromatography coupled with tandem mass spectrometry (2008) Biomedical Chromatography, 22 (7), pp. 779-785; Comerford, S.C., Medicinal plants of two Mayan healers from SanAndres, Peten, Guatemala (1996) Economic Botany, 50, pp. 327-336; Cornara, L., La Rocca, A., Terrizzano, L., Dente, F., Mariotti, M.G., Ethnobotanical and phytomedical knowledge in the North-Western Ligurian Alps (2014) Journal of Ethnopharmacology, 155, pp. 463-484; Cox, P.A., Will tribal knowledge survive the millennium? (2000) Science Ernst, 287, pp. 44-45; De-La-Cruz, H., Vilcapoma, G., Zevallos, P.A., Ethnobotanical study of medicinal plants used by the Andean people of Canta, Lima, Peru (2007) Journal of Ethnopharmacology, 111, pp. 284-294; Dhillion, S.S., Svarstad, H., Amundsen, C., Bugge, H.C., Bio prospecting: Effects on environment and development (2002) AMBIO, 31 (6), pp. 491-493; Edwards, S., Nebel, S., Heinrich, M., Questionnaire surveys: Methodological and epistemological problems for field-based ethnopharmacologists (2005) Journal of Ethnopharmacology, 100 (1), pp. 30-36; Farnsworth, N.R., Soejarto, D.D., Global importance of medicinal plants (1991) The Conservation of Medicinal Plants, pp. 25-51. , O. Akerele, V. Heywood, H. Synge, Cambridge University Press Cambridge UK; Figueiredo, G.M., Leitao-Filho, H.F., Begossi, A., Ethnobotany of Atlantic forest coastal communities diversity of plant uses in Gamboa (Itacuruçá Island, Brazil) (1993) Human Ecology, 21 (4), pp. 419-430; Flaster, T., Ethnobotanical approaches to the discovery of bioactive compounds (1996) Progress in New Crops. In: Proceedings of the Third National Symposium, pp. 561-565. , ASHS Press, Alexandria; Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A., Goldgar, D.E., Risks of cancer in BRCA1-mutation carriers (1994) The Lancet, 343 (8899), pp. 692-695; Frei, B., Baltisberger, M., Sticher, O., Heinrich, M., Medical ethnobotany of the Zapotecs of the Isthmus-Sierra (Oaxaca, Mexico) documentation and assessment of indigenous uses (1998) Journal of Ethnopharmacology, 62, pp. 149-165; Friedman, J., Yaniv, Z., Dafni, A., Palewitch, D., A preliminary classification of the healing potential of medicinal plants, based on a rational analysis of an ethnopharmological field survey among Bedouins in the Negev desert, Israel (1986) Journal of Ethnopharmacology, 16, pp. 275-287; Gairola, S., Sharma, J., Bedi, Y.S., A cross-cultural analysis of Jammu, Kashmir and Ladakh (India) medicinal plant use (2014) Journal of Ethnopharmacology, 155 (2), pp. 925-986; Ghimire, S.K., Gimenez, O., Pradel, R., McKey, D., Aumeeruddy, T.Y., Demographic variation and population viabilityina threatened Himalayan medicinal and aromatic herb Nardostachys grandiflora matrix modeling of harvesting effects in two contrasting habitats (2008) Journal of Applied Ecology, 45, pp. 41-51; Ghorbani, A., Langenberger, G., Feng, L., Sauerborn, J., Ethnobotanical study of medicinal plants utilised by Hani ethnicity in Naban river watershed national nature reserve, Yunnan, China (2011) Journal of Ethnopharmacology, 134 (3), pp. 651-667; Giday, M., Asfaw, Z., Elmqvist, T., Woldu, Z., An ethnobotanical study of medicinal plants used by the Zay people in Ethiopia (2003) Journal of Ethnopharmacology, 85 (1), pp. 43-52; Gonza, T.M.R., Casares, P.M., Sanchez, R.C.P., Ramiro, G.J.M., Molero, M.J., Pieroni, A., Giusti, M.E., Eljorhig, S., Medicinal plants in the Mediterranean area: Synthesis of the results of the project RUBIA (2008) Journal of Ethnopharmacology, 116, pp. 341-357; Gottlieb, O.R., Ethnopharmacology versus chemosystematics in the search for biologically active principles in plants (1982) Journal of Ethnopharmacology, 6 (2), pp. 227-238; Hamayun, M., Khan, M.A., Begum, S., Marketing of medicinal plants of Utror-Gabral valleys, Swat, Pakistan (2003) Ethnobotanical Leaflets, 1, p. 13; Hammond, G.B., Fernandez, I.D., Villegas, L.F., Vaisberg, A.J., A survey of traditional medicinal plants from the Callejon de Huaylas, Department of Ancash, Peru (1998) Journal of Ethnopharmacology, 61, pp. 17-30; Han, J., Ye, M., Guo, H., Yang, M., Wang, B.R., Guo, D.A., Analysis of multiple constituents in a Chinese herbal preparation Shuang-Huang-Lian oral liquid by HPLC-DAD-ESI-MS (2007) Journal of Pharmaceutical and Biomedical Analysis, 44 (2), pp. 430-438; Heinrich, M., Ankil, A., Frei, B., Wiemann, C., Stricher, V., Medicinal plants in Mexico: Healers consensus and cultural importance (1998) Social Science and Medicine, 47, pp. 1859-1871; Heinrich, M., Edwards, S., Moerman, D.E., Leonti, M., Ethnopharmacological field studies: A critical assessment of their conceptual basis and methods (2009) Journal of Ethnopharmacology, 124 (1), pp. 1-17; Heinrich, M., Gibbons, S., Ethnopharmacology in drug discovery: An analysis of its role and potential contribution (2001) Journal of Pharmacy and Pharmacology, 53 (4), pp. 425-432; Heinrich, M., Kufer, J., Leonti, M., Pardo-De-Santayana, M., Ethnobotany and ethnopharmacology - Interdisciplinary links with the historical sciences (2006) Journal of Ethnopharmacology, 107 (2), pp. 157-160; Houghton, P.J., Manby, J., Medicinal plants of the Mapuche (1985) Journal of Ethnopharmacology, 13 (1), pp. 89-103; Jain, S.K., Rao, R.R., (1977) A Handbook of Field and Herbarium Methods, , Today and Tomorrow Printers and Publishers New Delhi; Jain, S.K., Saklani, A., Observations on the ethnobotany of the tons valley region in the Uttarkashi District of the Northwest Himalaya, India (1991) Mountain Research and Development, 11, pp. 157-161; Jarić, S., Popović, Z., Mačukanović-Jocić, M., Djurdjević, L., Mijatović, M., Karadžić, B., Mitrović, M., Pavlović, P., An ethnobotanical study on the usage of wild medicinal herbs from Kopaonik Mountain (Central Serbia) (2007) Journal of Ethnopharmacology, 111, pp. 160-175; Johnston, M., Colquhoun, A., Preliminary ethnobotanical survey of Kurupukari: An Amerindian settlement of Central Guyana (1996) Economic Botany, 50, pp. 182-194; Joshi, A.R., Joshi, K., Indigenous knowledge and uses of medicinal plants by local communities of the Kali Gandanki Watershed Area, Nepal (2000) Journal of Ethnopharmacology, 73, pp. 175-183; Kayani, S., Ahmad, M., Zafar, M., Sultana, S., Khan, M.P.Z., Ashraf, M.A., Yaseen, G., Ethnobotanical uses of medicinal plants for respiratory disorders among the inhabitants of Gallies, Abbottabad, Northern Pakistan (2014) Journal of Ethnopharmacology, 156, pp. 47-60; Khan, S.W., Khatoon, S., Ethnobotanical studies on useful trees and shrubs of Haramosh and Bugrote Valleys in Gilgit Northern areas of Pakistan (2007) Pakistan Journal of Botany, 39 (3), pp. 699-710; Kunwar, R.M., Nepal, B.K., Kshhetri, H.B., Rai, S.K., Bussmann, R.W., (2006) Journal of Ethnobiology and Ethnomedicine, 2, p. 27; Ladio, A., Lozada, M., Weigandt, M., Comparison of traditional wild plant knowledge between aboriginal communities inhabiting arid and forest environments in Patagonia, Argentina (2007) Journal of Arid Environments, 69 (4), pp. 695-715; Leonti, M., The future is written: Impact of scripts on the cognition, selection, knowledge and transmission of medicinal plant use and its implications for ethnobotany and ethnopharmacology (2011) Journal of Ethnopharmacology, 134 (3), pp. 542-555; Leonti, M., Casu, L., Sanna, F., Bonsignore, L., A comparison of medicinal plant use in Sardinia and Sicily - Ve material medicare visited (2009) Journal of Ethnopharmacology, 121, pp. 255-267; Leonti, M., Sticher, O., Heinrich, M., Medicinal plants of the Popoluca, México: Organoleptic properties as indigenous selection criteria (2002) Journal of Ethnopharmacology, 81 (3), pp. 307-315; Leonti, M., Sticher, O., Heinrich, M., Antiquity of medicinal plant usage in two Macro-Mayan ethnic groups (Mexico) (2003) Journal of Ethnopharmacology, 88, pp. 119-124; Lewington, A., (1990) Plant for People, , Oxford University Press New York, USA; Lin, J., Puckree, T., Mvelase, T.P., Anti-diarrhoeal evaluation of some medicinal plants used by Zulu traditional healers (2002) Journal of Ethnopharmacology, 79 (1), pp. 53-56; Liu, R., Sun, J., Bi, K., Guo, D.A., Identification and determination of major flavonoids in rat serum by HPLC-UV and HPLC-MS methods following oral administration of Dalbergia odorifera extract (2005) Journal of Chromatography, 829 (1), pp. 35-44; Macia, M.J., Garcia, E., Vidaurre, P.J., An ethnobotanical survey of medicinal plants commercialized in the markets of la Paz and El Alto, Bolivia (2005) Journal of Ethnopharmacology, 97, pp. 337-350; Madikizela, B., Ndhlala, A.R., Finnie, J.F., Van Staden, J., Ethnopharmacological study of plants from Pondoland used against diarrhoea (2012) Journal of Ethnopharmacology, 141 (1), pp. 61-71; Malik, A.H., Khuroo, A.A., Dar, G.H., Khan, Z.S., Ethnomedicinal uses of some plants in the Kashmir Himalaya (2011) Indian Journal of Traditional Knowledge, 10, pp. 362-366; Manandhar, N.P., A survey of medicinal plants of Jajarkot district, Nepal (1995) Journal of Ethnopharmacology, 48 (1), pp. 1-6; Manandhar, N.P., Native phytotherapy among the Raute tribes of Dadeldhura district, Nepal (1998) Journal of Ethnopharmacology, 60 (3), pp. 199-206; Manandhar, N.P., Medicinal plants used by Chepang tribes of Makawanpur district, Nepal (1989) Fitoterapia, 60, pp. 61-68; Manandhar, N.P., Folklore medicine of Chitwan district, Nepal (1990) Ethnobotany, 2, pp. 31-38; Manandhar, N.P., Traditional phytotherapy of Danuwar tribes of Kamlakhonj in Sindhuli district, Nepal (1990) Fitoterapia, 61, pp. 325-331; Manandhar, N.P., Folklore medicine of Dhading district, Nepal (1992) Fitoterapia, 63, pp. 163-177; Manandhar, N.P., An ethnobotanical survey of herbal drugs of Kaski district, Nepal (1994) Fitoterapia, 65, pp. 7-13; Matu, N.E., Staden, J.V., Antibacterial and anti-inflammatory activities of some plants used for medicinal purposes in Kenya (2003) Journal of Ethnopharmacology, 87, pp. 35-41; Menković, N., Šavikin, K., Tasić, S., Zdunić, G., Stešević, D., Milosavljević, S., Vincek, D., Ethnobotanical study on traditional uses of wild medicinal plants in Prokletije mountains (Montenegro) (2011) Journal of Ethnopharmacology, 133 (1), pp. 97-107; Milliken, W., Albert, B., Gomez, G.G., (1999) Yanomani: A Forest People, , Kew: Royal Botanic Gardens Kew viii; Milliken, W., Albert, D., The use of medicinal plants by the Yanomami Indians of Brazil (1996) Economic Botany, 50, pp. 10-25; Moerman, D., (1998) Native American Ethnobotany, , Portland Timber Press Oregon, Portland; Moore, P.D., Trials in bad taste (1994) Nature, 370, pp. 410-411; Mshigeni, K.E., Seaweeds in medicine and pharmacy: A global perspective (1990) Proceedings of An International Conference of Experts from Developing Countries on Traditional Medicinal Plants, pp. 125-132. , Mshigeni, K.E. (Ed.) The United Republic of Tanzania, Ministry of Health, Dares Salaam University Press; Mukherjee, P.K., Nema, N.K., Venkatesh, P., Debnath, P.K., Changing scenario for promotion and development of Ayurveda-way forward (2012) Journal of Ethnopharmacology, 143 (2), pp. 424-434; Mukherjee, P.K., Wahile, A., Integrated approaches towards drug development from Ayurveda and other Indian system of medicines (2006) Journal of Ethnopharmacology, 103 (1), pp. 25-35; Mustafa, B., Hajdari, A., Krasniqi, F., Hoxha, E., Ademi, H., Quave, C.L., Pieroni, A., Medical ethnobotany of the Albanian Alps in Kosovo (2012) Journal of Ethnobiology and Ethnomedicine, 8; Mustafa, A.K., Sikka, G., Gazi, S.K., Steppan, J., Jung, S.M., Bhunia, A.K., Snyder, S.H., Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels (2011) Circulation Research, 109 (11), pp. 1259-1268; Pandey, M.R., Use of medicinal plants in traditional Tibetan therapy system in upper Mustang, Nepal (2006) Our Nature, 4, pp. 69-82; Phillips, O., Gentry, A.H., Reynel, C., Wilkin, P., Durand, B.C., Quantitative ethnobotany and Amazonian conservation (1994) Conservation Biology, 8, pp. 225-248; Pie, S.J., Manadhar, N.P., Source of some local medicines in the Himalayan regions (1987) Himalayan Ecosystems, pp. 77-112; Pieroni, A., Sabine Nebel, S., Quave, C.B., Harald Münz, C., Heinrich, M., Ethnopharmacology of liakra: Traditional weedy vegetables of the Arbëreshë of the Vulture area in southern Italy (2002) Journal of Ethnopharmacology, 81, pp. 165-185; Pieroni, A., Local plant resources in the ethnobotany of Theth, a village in the Northern Albanian Alps (2008) Genetic Resources and Crop Evolution, 55 (8), pp. 1197-1214; Pieroni, A., Quave, C.L., Traditional pharmacopoeias and medicines among Albanians and Italians in southern Italy A comparison (2005) Journal of Ethnopharmacology, 101 (13), pp. 258-270; Plotkin, M.J., The outlook for new agriculture and industrial products from the tropics (1988) Biodiversity, pp. 106-116. , E.O. Wilson, National Academy Press Washington, DC; Plotkin, M.J., Famolare, L., Conclusions and recommendations (1992) Sustainable Harvest and Marketing of Rain Forest Products, pp. 310-313. , M.J. Plotkin, L. Famolare, Island Press Washington, DC; Rajaei, P., Mohamadi, N., Ethnobotanical study of medicinal plants of Hezar Mountain allocated in south east of Iran (2012) Iranian Journal of Pharmaceutical Research (IJPR), 11, p. 1153; Rani, S., Rana, J., Jeelani, S., Gupta, R., Kumari, S., Ethnobotanical notes on 30 medicinal polypetalous plants of district Kangra of Himachal Pradesh (2013) Journal of Medicinal Plant Research, 7, pp. 1362-1369; Rigat, M., Garnatje, T., Vallès, J., Plant biodiversity in Pyrenean homegardens (Catalonia, Iberian peninsula): Current state of a mountain agroecosystem (2011) Acta Botanica Gallica, 158, pp. 525-551; Robinson, T., Metabolism and function of alkaloids in plants (1974) Science, 184, pp. 430-435; Rokaya, M.B., Münzbergová, Z., Timsina, B., Ethnobotanical study of medicinal plants from the Humla district of western Nepal (2010) Journal of Ethnopharmacology, 130, pp. 485-504; Sargin, S.A., Akçicek, E., Selvi, S., An ethnobotanical study of medicinal plants used by the local people of Alaşehir (Manisa) in Turkey (2013) Journal of Ethnopharmacology, 150, pp. 860-874; Sargin, M., Uygur-Bayramiçli, O., Sargin, H., Orbay, E., Yayla, A., Association of nonalcoholic fatty liver disease with insulin resistance: Is OGTT indicated in nonalcoholic fatty liver disease (2003) Journal of Clinical Gastroenterology, 37 (5), pp. 399-402; Schlage, C., Mabula, C., Mahunnah, R.L.A., Heinrich, M., Medicinal plants of the Washambaa (Tanzania): Documentation and ethnopharmacological evaluation (2000) Journal of Plant Biology, 2, pp. 83-92; Schmeda-Hirschmann, G., Rodriguez, J., Astudillo, L., Gastroprotective activity of the diterpene solidagenone and its derivatives on experimentally induced gastric lesions in mice (2002) Journal of Ethnopharmacology, 81 (1), pp. 111-115; Shinwari, Z.K., Gilani, S.S., Sustainable harvest of medicinal plants at Bulashbar Nullah, Astore (Northern Pakistan) (2003) Journal of Ethnopharmacology, 84, pp. 289-298; Shrestha, P.M., Dhillion, S.S., Medicinal plant diversity and use in the highlands of Dolakha district, Nepal (2003) Journal of Ethnopharmacology, 86 (1), pp. 81-96; Singh, M.P., Malla, S.B., Rajbhandari, S.B., Manandhar, A., Medicinal plants of Nepal retrospects and prospects (1979) Economic Botany, 33, pp. 185-193; Srithi, K., Balslev, H., Wangpaka, P., Srisanga, P., Trisonthi, C., Medicinal plant knowledge and its erosion among the Mien (Yao) in northern Thailand (2009) Journal of Ethnopharmacology, 123 (2), pp. 335-342; Street, R.A., Stirk, W.A., Van Staden, J., South African traditional medicinal plant trade - Challenges in regulating quality, safety and efficacy (2008) Journal of Ethnopharmacology, 119 (3), pp. 705-710; Svarstad, H., Dhillion, S.S., Responding to bioprospecting rejectionor regulation? (2000) Responding to Bioprospecting: From Plants in the South to Medicines in North, pp. 9-15. , H. Svarstad, S.S. Dhillion, Spartacus Forlag Oslo; Tabuti, J., Dhillion, S.S., Lye, K., Traditional medicine in Bulamogi County, Uganda: Its practitioners, uses and viability (2003) Journal of Ethnopharmacology, 85, pp. 119-129; Taylor, J.L.S., Van Staden, J., COX-1 inhibitory activity in extracts from Eucomis LHerit. Species (2001) Journal of Ethnopharmacology, 75 (2), pp. 257-265; Taylor, R.S., Manandhar, N.P., Towers, G.H., Screening of selected medicinal plants of Nepal for antimicrobial activities (1995) Journal of Ethnopharmacology, 46, pp. 153-159; Thakur, S., Sarkar, B., Cholia, R.P., Gautam, N., Dhiman, M., Mantha, A.K., APE1/Ref-1 as an emerging therapeutic target for various human diseases phytochemical modulation of its functions (2014) Experimental and Molecular Medicine, 46 (7), p. e106; Trotter, I.I.R.T., Logan, M.H., Informant consensus: A new approach for identifying potentially effective medicinal plants (1986) Plants in Indigenous Medicine and Diet: Biobehavioral Approaches, , Redgrave Publishing Company, Bedford Hills, NY; Turner, W.R., Tjørve, E., Scale dependence in species area relationships (2005) Ecography, 28 (6), pp. 721-730; Ugulu, I., Baslar, S., Yorek, N., Dogan, Y., The investigation and quantitative ethnobotanical evaluation of medicinal plants used around Izmir Province, Turkey (2009) Journal of Medicinal Plants Research, 3, pp. 345-367; Uprety, Y., Asselin, H., Boon, E.K., Yadav, S., Shrestha, K.K., Indigenous use and bio-efficacy of medicinal plants in the Rasuwa District, Central Nepal (2010) Journal of Ethnobiology and Ethnomedicine, 6, p. 3; Verpoorte, R., Choi, Y.H., Kim, H.K., Ethnopharmacology and systems biology: A perfect holistic match (2005) Journal of Ethnopharmacology, 100 (1), pp. 53-56; Verpoorte, R., Contin, A., Memelink, J., Biotechnology for the production of plant secondary metabolites (2002) Phytochemistry Reviews, 1 (1), pp. 13-25; Verpoorte, R., Van Der Heijden, R., Ten Hoopen, H.J.G., Memelink, J., Metabolic engineering of plant secondary metabolite pathways for the production of fine chemicals (1999) Biotechnology Letters, 21 (6), pp. 467-479; Vitalini, S., Iriti, M., Puricelli, C., Ciuchi, D., Segale, A., Fico, G., Traditional knowledge on medicinal and food plants used in ValSan Giacomo (Sondrio, Italy) an alpine ethnobotanical study (2013) Journal of Ethnopharmacology, 145, pp. 517-529; Wolda, H., (1981) Similarity Indices, Sample Size and Diversity, 50 (3), pp. 296-302. , Oecologia 50 3 1981 296 302; Yesilada, E., Küpeli, E., Clematis vitalba L. Aerial part exhibits potent anti-inflammatory, antinociceptive and antipyretic effects (2007) Journal of Ethnopharmacology, 110 (3), pp. 504-515; Zhang, J.L., Cui, M., He, Y., Yu, H.L., Guo, D.A., Chemical fingerprint and metabolic fingerprint analysis of Danshen injection by HPLC-UV and HPLC-MS methods (2005) Journal of Pharmaceutical and Biomedical Analysis, 36 (5), pp. 1029-1035",Article,Scopus,2-s2.0-84923667243
"Matza L.S., Stewart K.D., Gandra S.R., Delio P.R., Fenster B.E., Davies E.W., Jordan J.B., Lothgren M., Feeny D.H.","Acute and chronic impact of cardiovascular events on health state utilities Utilization, expenditure, economics and financing systems",2015,"BMC Health Services Research","15","1", 173,"","",,,10.1186/s12913-015-0772-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928338072&partnerID=40&md5=5a1a14196c7c1daa0dbe03ff416a2b58","Outcomes Research, Evidera, 7101 Wisconsin Avenue, Suite 1400Bethesda, MD, United States; Global Health Economics, Amgen Inc., One Amgen Center DriveThousand Oaks, CA, United States; Neurology Associates of Santa Barbara, 219 Nogales Avenue, Suite FSanta Barbara, CA, United States; Division of Cardiology, National Jewish Health, 1400 Jackson StreetDenver, CO, United States; Outcomes Research, Evidera, Metro Building, 6th Floor No. 1 ButterwickLondon, United Kingdom; Global Health Economics, Amgen (Europe), Dammstrasse 23 P.O. Box 1557Zug, Switzerland; Department of Economics, McMaster UniversityHamilton, ON, Canada","Matza, L.S., Outcomes Research, Evidera, 7101 Wisconsin Avenue, Suite 1400Bethesda, MD, United States; Stewart, K.D., Outcomes Research, Evidera, 7101 Wisconsin Avenue, Suite 1400Bethesda, MD, United States; Gandra, S.R., Global Health Economics, Amgen Inc., One Amgen Center DriveThousand Oaks, CA, United States; Delio, P.R., Neurology Associates of Santa Barbara, 219 Nogales Avenue, Suite FSanta Barbara, CA, United States; Fenster, B.E., Division of Cardiology, National Jewish Health, 1400 Jackson StreetDenver, CO, United States; Davies, E.W., Outcomes Research, Evidera, Metro Building, 6th Floor No. 1 ButterwickLondon, United Kingdom; Jordan, J.B., Outcomes Research, Evidera, 7101 Wisconsin Avenue, Suite 1400Bethesda, MD, United States; Lothgren, M., Global Health Economics, Amgen (Europe), Dammstrasse 23 P.O. Box 1557Zug, Switzerland; Feeny, D.H., Department of Economics, McMaster UniversityHamilton, ON, Canada","Background: Cost-utility models are frequently used to compare treatments intended to prevent or delay the onset of cardiovascular events. Most published utilities represent post-event health states without incorporating the disutility of the event or reporting the time between the event and utility assessment. Therefore, this study estimated health state utilities representing cardiovascular conditions while distinguishing between acute impact including the cardiovascular event and the chronic post-event impact. Methods: Health states were drafted and refined based on literature review, clinician interviews, and a pilot study. Three cardiovascular conditions were described: stroke, acute coronary syndrome (ACS), and heart failure. One-year acute health states represented the event and its immediate impact, and post-event health states represented chronic impact. UK general population respondents valued the health states in time trade-off tasks with time horizons of one year for acute states and ten years for chronic states. Results: A total of 200 participants completed interviews (55% female; mean age = 46.6 y). Among acute health states, stroke had the lowest utility (0.33), followed by heart failure (0.60) and ACS (0.67). Utility scores for chronic health states followed the same pattern: stroke (0.52), heart failure (0.57), and ACS (0.82). For stroke and ACS, acute utilities were significantly lower than chronic post-event utilities (difference = 0.20 and 0.15, respectively; both p ;< 0.0001). Conclusions: Results add to previously published utilities for cardiovascular events by distinguishing between chronic post-event health states and acute health states that include the event and its immediate impact. Findings suggest that acute versus chronic impact should be considered when selecting scores for use in cost-utility models. Thus, the current utilities provide a unique option that may be used to represent the acute and chronic impact of cardiovascular conditions in economic models comparing treatments that may delay or prevent the onset of cardiovascular events. © 2015 Matza et al.; licensee BioMed Central.","Acute coronary syndrome; Cardiovascular disease; Cost-utility; Heart failure; Stroke; Time trade-off; Utility","Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Heart disease and stroke statistics-2014 update: A report from the American Heart Association (2014) Circulation, 129 (3), pp. e28-e292. , 24352519; Nichols, M., Townsend, N., Luengo-Fernandez, R., Leal, J., Gray, A., Scarborough, P., (2012) European Cardiovascular Disease Statistics, p. 125. , 2012 European Heart Network, European Society of Cardiology September Brussels, Belgium, Sophia Antipolis, France; Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Benjamin, E.J., Berry, J.D., Borden, W.B., Heart disease and stroke statistics-2012 update: A report from the American Heart Association (2012) Circulation, 125 (1), pp. e2-e220. , 22179539; World Health Organization (WHO), (2011) Global Status Report on Noncommunicable Diseases 2010, p. 161. , Geneva, Switzerland WHO Library; Achar, S.A., Kundu, S., Norcross, W.A., Diagnosis of acute coronary syndrome (2005) Am Fam Physician, 72 (1), pp. 119-126. , 16035692; Alpert, J.S., Thygesen, K., Antman, E., Bassand, J.P., Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction (2000) J Am Coll Cardiol, 36 (3), pp. 959-969. , 1:STN:280:DC%2BD3cvlvV2luw%3D%3D 10987628; Hamm, C.W., Bassand, J.P., Agewall, S., Bax, J., Boersma, E., Bueno, H., ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) (2011) Eur Heart J, 32 (23), pp. 2999-3054. , 21873419; (2012) National Clinical Guideline for Stroke. 4th ed., p. 208. , London: Royal College of Physicians; National Clinical Guideline Centre, Stroke rehabilitation: Long term rehabilitation after stroke (2013) Clinical Guideline 162 Methods, Evidence and Recommendations, p. 573. , London, UK: NCGC; Pearn, J., O'Connor, R.J., Community stroke rehabilitation helps patients return to work (2013) Practitioner, 257 (1764), pp. 23-27+22-23. , 24383153; Pinsky, J.I., Jette, A.M., Branch, L.G., Kannel, W.B., Feinleib, M., The Framingham disability study: Relationship of various coronary heart disease manifestations to disability in older persons living in the community (1990) Am J Public Health, 80 (11), pp. 1363-1368. , 1404890 1:STN:280:DyaK3M%2Flt1ShtA%3D%3D 2240306; Leal, J., Luengo-Fernandez, R., Gray, A., Petersen, S., Rayner, M., Economic burden of cardiovascular diseases in the enlarged European Union (2006) Eur Heart J, 27 (13), pp. 1610-1619. , 16495286; Luengo-Fernandez, R., Leal, J., Gray, A., Petersen, S., Rayner, M., Cost of cardiovascular diseases in the United Kingdom (2006) Heart, 92 (10), pp. 1384-1389. , 1861058 1:STN:280:DC%2BD28rkvVWnsA%3D%3D 16702172; Law, M.R., Wald, N.J., Rudnicka, A.R., Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis (2003) BMJ, 326 (7404), p. 1423. , 162260 1:CAS:528:DC%2BD3sXlvFCjsLY%3D 12829554; Mihos, C.G., Pineda, A.M., Santana, O., Cardiovascular effects of statins, beyond lipid-lowering properties (2014) Pharmacol Res, 88, pp. 12-19. , 1:CAS:528:DC%2BC2cXkslehtbw%3D 24631782; Wilt, T.J., Bloomfield, H.E., MacDonald, R., Nelson, D., Rutks, I., Ho, M., Effectiveness of statin therapy in adults with coronary heart disease (2004) Arch Intern Med, 164 (13), pp. 1427-1436. , 1:CAS:528:DC%2BD2cXmsVKqsb0%3D 15249352; Noto, D., Cefalu, A.B., Averna, M.R., Beyond statins: New lipid lowering strategies to reduce cardiovascular risk (2014) Curr Atheroscler Rep, 16 (6), p. 414. , 24777633; Raal, F.J., Giugliano, R.P., Sabatine, M.S., Koren, M.J., Langslet, G., Bays, H., Reduction in Lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of more than 1,300 patients in 4 phase II trials (2014) J Am Coll Cardiol, 63 (13), pp. 1278-1288. , 1:CAS:528:DC%2BC2cXltl2msbo%3D 24509273; Stein, E.A., Giugliano, R.P., Koren, M.J., Raal, F.J., Roth, E.M., Weiss, R., Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: Pooled analysis of 1359 patients in four phase 2 trials (2014) Eur Heart J, 35 (33), pp. 2249-2259. , 1:CAS:528:DC%2BC2cXhslCht7nO 24598985; Ara, R., Tumur, I., Pandor, A., Duenas, A., Williams, R., Wilkinson, A., Ezetimibe for the treatment of hypercholesterolaemia: A systematic review and economic evaluation (2008) Health Technol Assess, 12 (21), pp. 1-212; Coyle, D., Coyle, K., Cameron, C., Lee, K., Kelly, S., Steiner, S., Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation (2013) Value Health, 16 (4), pp. 498-506. , 23796283; Kamel, H., Hegde, M., Johnson, D.R., Gage, B.F., Johnston, S.C., Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke (2010) Stroke, 41 (7), pp. 1514-1520. , 20508188; MacDonald, G.P., Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein (2010) J Am Osteopath Assoc, 110 (8), pp. 427-436. , 20805548; Brazier, J.R., Ratcliffe, J., Salomon, J.A., Tsuchiya, A., (2007) Measuring and Valuing Health Benefits for Economic Evaluation, , New York: Oxford University Press; Feeny, D., Preference-based measures: Utility and quality-adjusted life years (2005) Assessing Quality of Life in Clinical Trials. 2nd ed., pp. 405-431. , Fayers R. Hays (eds) New York: Oxford University Press; Torrance, G.W., Measurement of health state utilities for economic appraisal (1986) J Health Econ, 5 (1), pp. 1-30. , 1:STN:280:DyaL283otVOltQ%3D%3D 10311607; Smith, D.W., Davies, E.W., Wissinger, E., Huelin, R., Matza, L.S., Chung, K., A systematic literature review of cardiovascular event utilities (2013) Expert Rev Pharmacoecon Outcomes Res, 13 (6), pp. 767-790. , 24175732; Sullivan, P.W., Ghushchyan, V., Preference-based EQ-5D index scores for chronic conditions in the United States (2006) Med Decis Making, 26 (4), pp. 410-420. , 2634296 16855129; Sullivan, P.W., Slejko, J.F., Sculpher, M.J., Ghushchyan, V., Catalogue of EQ-5D scores for the United Kingdom (2011) Med Decis Making, 31 (6), pp. 800-804. , 21422468; Van Exel, N.J., Op Reimer, W.J.S., Koopmanschap, M.A., Assessment of post-stroke quality of life in cost-effectiveness studies: The usefulness of the Barthel Index and the EuroQoL-5D (2004) Qual Life Res, 13 (2), pp. 427-433. , 15085915; Lindgren, P., Glader, E.L., Jonsson, B., Utility loss and indirect costs after stroke in Sweden (2008) Eur J Cardiovasc Prev Rehabil, 15 (2), pp. 230-233. , 18391653; Olsson, B.G., Sunnerhagen, K.S., Effects of day hospital rehabilitation after stroke (2006) J Stroke Cerebrovasc Dis, 15 (3), pp. 106-113. , 17904061; Chaiyawat, P., Kulkantrakorn, K., Effectiveness of home rehabilitation program for ischemic stroke upon disability and quality of life: A randomized controlled trial (2012) Clin Neurol Neurosurg, 114 (7), pp. 866-870. , 22321758; Darlington, A.S., Dippel, D.W., Ribbers, G.M., Van Balen, R., Passchier, J., Busschbach, J.J., Coping strategies as determinants of quality of life in stroke patients: A longitudinal study (2007) Cerebrovasc Dis, 23 (5-6), pp. 401-407. , 17406109; Leeds, L., Meara, J., Hobson, P., The impact of discharge to a care home on longer term stroke outcomes (2004) Clin Rehabil, 18 (8), pp. 924-928. , 15609848; Olsson, B.G., Sunnerhagen, K.S., Functional and cognitive capacity and health-related quality of life 2 years after day hospital rehabilitation for stroke: A prospective study (2007) J Stroke Cerebrovasc Dis, 16 (5), pp. 208-215; Lacey, E.A., Musgrave, R.J., Freeman, J.V., Tod, A.M., Scott, P., Psychological morbidity after myocardial infarction in an area of deprivation in the UK: Evaluation of a self-help package (2004) Eur J Cardiovasc Nurs, 3 (3), pp. 219-224. , 15350231; Euro Heart Survey on Coronary Revascularization, Lenzen, M.J., Op Reimer, W.J.S., Pedersen, S.S., Boersma, E., Maier, W., The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: A report from the Euro Heart Survey on Coronary Revascularisation (2007) Heart, 93 (3), pp. 339-344. , 1861429 16980515; Glasziou, P.P., Bromwich, S., Simes, R.J., Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial (1994) Med J Aust, 161 (9), pp. 532-536. , 7968752 1:STN:280:DyaK2M%2FlvVCnug%3D%3D; Buck, D., Jacoby, A., Massey, A., Ford, G., Evaluation of measures used to assess quality of life after stroke (2000) Stroke, 31 (8), pp. 2004-2010. , 1:STN:280:DC%2BD3cvhsFynsA%3D%3D 10926971; Price, C.I., Curless, R.H., Rodgers, H., Can stroke patients use visual analogue scales? (1999) Stroke, 30 (7), pp. 1357-1361. , 1:STN:280:DyaK1MzhvFSqug%3D%3D 10390307; Sneeuw, K.C., Aaronson, N.K., De Haan, R.J., Limburg, M., Assessing quality of life after stroke: The value and limitations of proxy ratings (1997) Stroke, 28 (8), pp. 1541-1549. , 1:STN:280:DyaK2svgs1artw%3D%3D 9259746; Steg, P.G., Dabbous, O.H., Feldman, L.J., Cohen-Solal, A., Aumont, M.C., Lopez-Sendon, J., Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE) (2004) Circulation, 109 (4), pp. 494-499. , 14744970; Hobbs, F.D., Kenkre, J.E., Roalfe, A.K., Davis, R.C., Hare, R., Davies, M.K., Impact of heart failure and left ventricular systolic dysfunction on quality of life: A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population (2002) Eur Heart J, 23 (23), pp. 1867-1876. , 1:STN:280:DC%2BD38noslKnsA%3D%3D 12445536; National Clinical Guideline Centre, (2010) Chronic Heart Failure: The Management of Chronic Heart Failure in Adults in Primary and Secondary Care, p. 211. , London: NCGC; Grech, E.D., Ramsdale, D.R., Acute coronary syndrome: Unstable angina and non-ST segment elevation myocardial infarction (2003) BMJ, 326 (7401), pp. 1259-1261. , 1126130 12791748; Arnesen, T., Trommald, M., Are QALYs based on time trade-off comparable?-A systematic review of TTO methodologies (2005) Health Econ, 14 (1), pp. 39-53. , 15386674; Dolan, P., Modeling valuations for EuroQol health states (1997) Med Care, 35 (11), pp. 1095-1108. , 1:STN:280:DyaK1c%2FjtlKrtg%3D%3D 9366889; Dolan, P., Gudex, C., Kind, P., Williams, A., The time trade-off method: Results from a general population study (1996) Health Econ, 5 (2), pp. 141-154. , 1:STN:280:DyaK28zhtVWjtg%3D%3D 8733106; Hürny, C., Van Wegberg, B., Bacchi, M., Bernhard, J., Thurlimann, B., Real, O., Subjective health estimations (SHE) in patients with advanced breast cancer: An adapted utility concept for clinical trials (1998) Br J Cancer, 77 (6), pp. 985-991. , 9528845; Matza, L.S., Chung, K., Van Brunt, K., Brazier, J.E., Braun, A., Currie, B., Health state utilities for skeletal-related events secondary to bone metastases (2014) Eur J Health Econ, 15 (1), pp. 7-18. , 3889679 23355121; Stevenson, L.W., Hellkamp, A.S., Leier, C.V., Sopko, G., Koelling, T., Warnica, J.W., Changing preferences for survival after hospitalization with advanced heart failure (2008) J Am Coll Cardiol, 52 (21), pp. 1702-1708. , 2763302 19007689; Chen, C.L., Kuppermann, M., Caughey, A.B., Zane, L.T., A community-based study of acne-related health preferences in adolescents (2008) Arch Dermatol, 144 (8), pp. 988-994. , 18711070; Guest, J.F., Naik, N., Sladkevicius, E., Coombs, J., Gray, E.J., Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom (2012) Leuk Lymphoma, 53 (5), pp. 928-933. , 21988666; Khanna, D., Ahmed, M., Furst, D.E., Ginsburg, S.S., Park, G.S., Hornung, R., Health values of patients with systemic sclerosis (2007) Arthritis Rheum, 57 (1), pp. 86-93. , 17266070; Saw, S.M., Gazzard, G., Gomezperalta, C., Au Eong, K.G., Seah, S., Utility assessment among cataract surgery patients (2005) J Cataract Refract Surg, 31 (4), pp. 785-791. , 15899457; Schmitt, J., Meurer, M., Klon, M., Frick, K.D., Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: A population-based study (2008) Br J Dermatol, 158 (2), pp. 351-359. , 1:STN:280:DC%2BD1c%2FmtFWlsQ%3D%3D 18070214; Rowen, D., Brazier, J., Tsuchiya, A., Young, T., Ibbotson, R., It's all in the name, or is it? The impact of labeling on health state values (2012) Med Decis Making, 32 (1), pp. 31-40. , 21685376; Brazier, J., Czoski-Murray, C., Roberts, J., Brown, M., Symonds, T., Kelleher, C., Estimation of a preference-based index from a condition-specific measure: The King's Health Questionnaire (2008) Med Decis Making, 28 (1), pp. 113-126. , 17641139; CADTH (Canadian Agency for Drugs and Technologies in Health), (2006) Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd Ed., , Ottawa: Canadian Agency for Drugs and Technologies in Health; NICE (National Institute for Health and Clinical Excellence), (2013) Process and Methods Guides: Guide to the Methods of Technology Appraisal 2013, p. 93. , http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf, London, UK: NICE; (2013) Guidelines for Preparing Submissions to PBAC, Version 4.4, p. 344. , Canberra, Australia: Australian Government Department of Health, PBAC; Rowen, D., Brazier, J., Health utility measurement (2011) The Oxford Handbook of Health Economics, pp. 788-813. , Glied S, Smith P, editors. New York: Oxford University Press; Furlong, W., Feeny, D.H., Torrance, G.W., Barr, R., Horsman, J., (1990) Guide to Design and Development of Health-state Utility Instrumentation, pp. 90-99. , Hamilton, ON: McMaster University; Tengs, T.O., Yu, M., Luistro, E., Health-related quality of life after stroke a comprehensive review (2001) Stroke, 32 (4), pp. 964-972. , 1:STN:280:DC%2BD3M3ivVyqtA%3D%3D 11283398; Kuppermann, M., Shiboski, S., Feeny, D., Elkin, E.P., Washington, A.E., Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis (1997) Med Decis Making, 17 (1), pp. 42-55. , 1:STN:280:DyaK2s7kslantw%3D%3D 8994150; MacKeigan, L.D., O'Brien, B.J., Oh, P.I., Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes (1999) Med Decis Making, 19 (2), pp. 113-121. , 1:STN:280:DyaK1M3ks1Wjtg%3D%3D 10231073",Article,Scopus,2-s2.0-84928338072
"Zheng H., Li Y., Xie N., Huang J.L., Xu H.F., Luo M.","Decreased levels of soluble receptor for advanced glycation end-products in aortic valve calcification patients",2015,"Genetics and Molecular Research","14","2",,"3775","3783",,,10.4238/2015.April.22.6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928129056&partnerID=40&md5=3f558cf1b6fe6e5dd89275b00164d9de","Geriatrics Department, Tongji Hospital Affiliated to Tongji UniversityShanghai, China; Heart Failure Department, Shanghai East Hospital Affiliated to Tongji UniversityShanghai, China; Cardiology Department, Tongji Hospital Affiliated to Tongji UniversityShanghai, China","Zheng, H., Geriatrics Department, Tongji Hospital Affiliated to Tongji UniversityShanghai, China; Li, Y., Heart Failure Department, Shanghai East Hospital Affiliated to Tongji UniversityShanghai, China; Xie, N., Geriatrics Department, Tongji Hospital Affiliated to Tongji UniversityShanghai, China; Huang, J.L., Geriatrics Department, Tongji Hospital Affiliated to Tongji UniversityShanghai, China; Xu, H.F., Cardiology Department, Tongji Hospital Affiliated to Tongji UniversityShanghai, China; Luo, M., Geriatrics Department, Tongji Hospital Affiliated to Tongji UniversityShanghai, China","The soluble receptor for advanced glycation end-products (sRAGE) shows a close relationship with atherosclerosis. The goal of this study was to compare the levels of sRAGE in patients with and without aortic valve calcification and to investigate the relationship between them. After transthoracic echocardiographic examination, 120 male patients with aortic valve calcification and 120 age-matched male controls without aortic valve calcification were included in our study. sRAGE levels were compared between groups. The prevalence of diabetes mellitus and coronary artery disease were significantly higher in the aortic valve calcification group than in the control group (63.3 versus 45%, P = 0.01, and 65 versus 51.7%, P < 0.01, respectively). The levels of sRAGE were lower in the aortic valve calcification group than in the control group (203.8 ± 34.6 versus 324.7 ± 41.6 pg/mL, P < 0.01). In multivariate analysis, age, coronary artery disease, and sRAGE levels were independent predictors of aortic valve calcification. Our study demonstrates that sRAGE, which was proven to be a potential marker of atherosclerosis, might have a role in the development of aortic valve calcification. © FUNPEC-RP.","Aortic valve calcification; Atherosclerosis; Soluble receptor for advanced glycation end-products","Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation (1998) Diabet. Med, 15, pp. 539-553; Allison, M.A., Cheung, P., Criqui, M.H., Langer, R.D., Mitral and aortic annular calcification are highly associated with systemic calcified atherosclerosis (2006) Circulation, 113, pp. 861-866; American College of Cardiology Foundation Appropriate Use Criteria Task Force, ACCF/ASE/AHA/ASNC/HFSA/ HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians (2012) J. Am Coll. Cardiol, 57, pp. 1126-1166. , American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology; Basta, G., Corciu, A.I., Vianello, A., Del Turco, S., Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis (2010) Atherosclerosis, 210, pp. 614-618; Baumgartner, H., Hung, J., Bermejo, J., Chambers, J.B., Echocardiographic assessment of valve stenosis: EAE/ ASE recommendations for clinical practice (2009) J. Am. Soc. Echocardiogr, 22, pp. 1-23; Bhatnagar, D., Soran, H., Durrington, P.N., Hypercholesterolaemia and its management (2008) BMJ, 337, pp. a993; Bonow, R.O., Carabello, B.A., Chatterjee, K., de Leon, A.C., 2008 Focused update incorporated into the ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons (2008) J. Am. Coll. Cardiol, 52, pp. 1-142; Boon, A., Cheriex, E., Lodder, J., Kessels, F., Cardiac valve calcification: Characteristics of patients with calcification of the mitral annulus or aortic valve (1997) Heart, 78, pp. 472-474; Cecil, D.L., Terkeltaub, R.A., Arterial calcification is driven by RAGE in Enpp1-/-mice (2011) J. Vasc. Res, 48, pp. 227-235; Donnan, G.A., Fisher, M., McLeod, M., Davis, S.M., Stroke (2008) Lancet, 371, pp. 1612-1623; Drolet, M.C., Roussel, E., Deshaies, Y., Couet, J., A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice (2006) J. Am. Coll. Cardiol, 47, pp. 850-855; Falcone, C., Emanuele, E., D'Angelo, A., Buzzi, M.P., Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men (2005) Arterioscler. Thromb. Vasc. Biol, 25, pp. 1032-1037; Helske, S., Kupari, M., Lindstedt, K.A., Kovanen, P.T., Aortic valve stenosis: An active atheroinflammatory process (2007) Curr. Opin. Lipidol, 18, pp. 483-491; Latsios, G., Tousoulis, D., Androulakis, E., Papageorgiou, N., Monitoring calcific aortic valve disease: The role of biomarkers (2012) Curr. Med. Chem, 19, pp. 2548-2554; Li, F., Cai, Z., Chen, F., Shi, X., Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products (2012) Basic Res. Cardiol, 107, p. 306; Lin, L., Park, S., Lakatta, E.G., RAGE signaling in inflammation and arterial aging (2009) Front. Biosci, 14, pp. 1403-1413; Lindsey, J.B., de Lemos, J.A., Cipollone, F., Ayers, C.R., Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: Observations from the Dallas Heart Study (2009) Diabetes Care, 32, pp. 1218-1220; Maillard-Lefebvre, H., Boulanger, E., Daroux, M., Gaxatte, C., Soluble receptor for advanced glycation end products: A new biomarker in diagnosis and prognosis of chronic inflammatory diseases (2009) Rheumatology, 48, pp. 1190-1196; Mak, G.S., Truong, Q.A., Cardiac CT: Imaging of and Through Cardiac Devices (2012) Curr. Cardiovasc. Imaging Rep, 5, pp. 328-336; Prasad, Y., Bhalodkar, N.C., Aortic sclerosis-a marker of coronary atherosclerosis (2004) Clin. Cardiol, 27, pp. 671-673; Rajamannan, N.M., Mechanisms of aortic valve calcification: the LDL-density-radius theory: A translation from cell signaling to physiology (2010) Am. J. Physiol. Heart Circ. Physiol, 298, pp. H5-H15; Rajamannan, N.M., Subramaniam, M., Caira, F., Stock, S.R., Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway (2005) Circulation, 112, pp. 1229-1234; Sashida, Y., Rodriguez, C.J., Boden-Albala, B., Jin, Z., Ethnic differences in aortic valve thickness and related clinical factors (2010) Am. Heart J, 159, pp. 698-704; Scanlon, P.J., Faxon, D.P., Audet, A.M., Carabello, B., ACC/AHA guidelines for coronary angiography: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions (1999) Circulation, 99, pp. 2345-2357; Stewart, B.F., Siscovick, D., Lind, B.K., Gardin, J.M., Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study (1997) J. Am. Coll. Cardiol, 29, pp. 630-634; Vahanian, A., Baumgartner, H., Bax, J., Butchart, E., Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (2007) Eur. Heart J, 28, pp. 230-268; Vazzana, N., Santilli, F., Cuccurullo, C., Davì, G., Soluble forms of RAGE in internal medicine (2009) Intern. Emerg. Med, 4, pp. 389-401; Wautier, M.P., Chappey, O., Corda, S., Stern, D.M., Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE (2001) Am. J. Physiol. Endocrinol. Metab, 280, pp. E685-E694",Article,Scopus,2-s2.0-84928129056
"Nicoll R., Howard J.M., Henein M.Y.","A review of the effect of diet on cardiovascular calcification",2015,"International Journal of Molecular Sciences","16","4",,"8861","8883",,,10.3390/ijms16048861,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928138827&partnerID=40&md5=cda067485c7157cda9bf9cf11e9d1ab5","Department of Public Health and Clinical Medicine and Heart Centre, Umea UniversityUmea, Sweden; Acumen LabTiverton, Devon, United Kingdom","Nicoll, R., Department of Public Health and Clinical Medicine and Heart Centre, Umea UniversityUmea, Sweden; Howard, J.M., Acumen LabTiverton, Devon, United Kingdom; Henein, M.Y., Department of Public Health and Clinical Medicine and Heart Centre, Umea UniversityUmea, Sweden","Cardiovascular (CV) calcification is known as sub-clinical atherosclerosis and is recognised as a predictor of CV events and mortality. As yet there is no treatment for CV calcification and conventional CV risk factors are not consistently correlated, leaving clinicians uncertain as to optimum management for these patients. For this reason, a review of studies investigating diet and serum levels of macro- and micronutrients was carried out. Although there were few human studies of macronutrients, nevertheless transfats and simple sugars should be avoided, while long chain ω-3 fats from oily fish may be protective. Among the micronutrients, an intake of 800 μg/day calcium was beneficial in those without renal disease or hyperparathyroidism, while inorganic phosphorus from food preservatives and colas may induce calcification. A high intake of magnesium (≥380 mg/day) and phylloquinone (500 μg/day) proved protective, as did a serum 25(OH)D concentration of ≥75 nmol/L. Although oxidative damage appears to be a cause of CV calcification, the antioxidant vitamins proved to be largely ineffective, while supplementation of α-tocopherol may induce calcification. Nevertheless other antioxidant compounds (epigallocatechin gallate from green tea and resveratrol from red wine) were protective. Finally, a homocysteine concentration >12 μmol/L was predictive of CV calcification, although a plasma folate concentration of >39.4 nmol/L could both lower homocysteine and protect against calcification. In terms of a dietary programme, these recommendations indicate avoiding sugar and the transfats and preservatives found in processed foods and drinks and adopting a diet high in oily fish and vegetables. The micronutrients magnesium and vitamin K may be worthy of further investigation as a treatment option for CV calcification. © 2015 by the authors. licensee MDPI, Basel, Switzerland.","Antioxidants; Cardiovascular calcification; Coronary calcification; Diet; Homocysteine; Minerals; Transfats; Vitamins; ω-3 fats","Nicoll, R., Henein, M., Arterial and valvular calcification: A systemic diffuse disease (2013) ICF J, 1, pp. 19-24; Nicoll, R., Henein, M.Y., Arterial calcification: Friend or foe? Int (2013) J. Cardiol., 167, pp. 322-327; Rennenberg, R.J.M.W., Kessels, A.G.H., Schurgers, J.L., van Engelshoven, J.M.A., de Leeuw, P.W., Kroon, A.A., Vascular calcification as a marker of increased cardiovascular risk: A meta-analysis (2009) Vasc. Health Risk Manag, 5, pp. 185-197; Detrano, R., Guerci, A.D., Carr, J.J., Bild, D.E., Burke, G., Folsom, A.R., Liu, K., Bluemke, D.A., Coronary calcium as a predictor of coronary events in four racial or ethnic groups (2008) N. Engl. J. Med, 358, pp. 1336-1345; Nicoll, R., Henein, M., Extensive coronary calcification: A clinically unrecognised condition (2010) Curr. Vasc. Pharmacol, 8, pp. 701-705; Peters, S.A., Bakker, M., den Ruijter, H.M., Bots, M.L., Added value of CAC in risk stratification for cardiovascular events: A systematic review (2012) Eur. J. Clin. Investig, 42, pp. 110-116; Möhlenkamp, S., Lehmann, N., Greenland, P., Moebus, S., Kälsch, H., Schmermund, A., Dragano, N., Mann, K., Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy (2011) Atherosclerosis, 215, pp. 229-236; Shanahan, C.M., Cary, N.R., Metcalfe, J.C., Weissberg, P.L., High espression of genes for calcification-regulating proteins in human atherosclerotic plaque (1994) J. Clin. Investig, 93, pp. 2393-2402; Schmid, K., McSharry, W.O., Pameijer, C.H., Binette, J.P., Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta (1980) Atherosclerosis, 37, pp. 199-210; Min, H., Morony, S., Sarosi, I., Dunstan, C.R., Capparelli, C., Scully, S., Van, G., Lacey, D.L., Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis (2000) J. Exp. Med, 192, pp. 463-474; Lomashvili, K., Garg, P., O'Neill, W.C., Chemical and hormonal determinants of vascular calcification in vitro (2006) Kidney Int, 69, pp. 1464-1470; Henein, M., Owen, A., Statins moderate coronary atheroma but not coronary calcification: Results from meta-analyses (2010) Scand. Cardiovasc. J, 44, p. 3; Rossebø, A.B., Pedersen, T.R., Boman, K., Brudi, P., Chambers, J.B., Egstrup, K., Gerdts, E., Kesäniemi, Y.A., Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (2008) N. Engl. J. Med, 359, pp. 1343-1356; Jensky, N.E., Criqui, M.H., Wright, M.C., Wassel, C.L., Brody, S.A., Allison, M.A., Blood pressure and vascular calcification (2010) Hypertension, 55, pp. 990-997; Pletcher, M.J., Sibley, C.T., Pignone, M., Vittinghoff, E., Greenland, P., Interpretation of the coronary artery calcium score in combination with conventional cardiovascular risk factors: The Multi-Ethnic Study of Atherosclerosis (MESA) (2013) Circulation, 128, pp. 1076-1084; Park, H.A., Lee, J.S., Kuller, L.H., Relationship between premenopausal dietary intake and postmenopausal subclinical atherosclerosis (2006) Atherosclerosis, 186, pp. 420-427; Snell-Bergeon, J.K., Chartier-Logan, C., Maahs, D.M., Ogden, L.G., Hokanson, J.E., Kinney, G.L., Eckel, R.H., Rewers, M., Adults with type 1 diabetes eat a high-fat atherogenic diet that is associated with coronary artery calcium (2009) Diabetologia, 52, pp. 801-809; Son, Y.K., Lee, S.M., Kim, S.E., Kim, K.H., Lee, S.Y., Bae, H.R., Han, J.Y., An, W.S., Association between vascular calcification scores on plain radiographs and fatty acid contents of erythrocyte membrane in hemodialysis patients (2012) J. Ren. Nutr, 22, pp. 58-66; He, K., Liu, K., Daviglus, M.L., Mayer-Davis, E., Jenny, N.S., Jiang, R., Ouyang, P., Wu, C., Intakes of long-chain n-3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosis (2008) Am. J. Clin. Nutr, 88, pp. 1111-1118; Sekikawa, A., Curb, J.D., Ueshima, H., Lee, S.Y., Bae, H.R., Han, J.Y., Park, Y., An, W.S., Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men (2008) J. Am. Coll. Cardiol, 52, pp. 417-424; Sekikawa, A., Miura, K., Lee, S., Fujiyoshi, A., Edmundowicz, D., Kadowaki, T., Long chain n-3 polyunsaturated fatty acids and incidence rate of coronary artery calcification in Japanese men in Japan and white men in the USA: Population based prospective cohort study (2014) Heart, 100, pp. 569-573; Ueeda, M., Doumei, T., Takaya, Y., Shinohata, R., Katayama, Y., Ohnishi, N., Takaishi, A., Kusachi, S., Serum n-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction (2008) Circ. J, 72, pp. 1836-1843; Heine-Bröring, R.C., Brouwer, I.A., Proença, R.V., van Rooij, F.J., Hofman, A., Oudkerk, M., Witteman, J.C., Geleijnse, J.M., Intake of fish and marine n-3 fatty acids in relatio.n to coronary calcification: The Rotterdam Study (2010) Am. J. Clin. Nutr, 91, pp. 1317-1323; Drolet, M.C., Couet, J., Arsenault, M., Development of aortic valve sclerosis or stenosis in rabbits: Role of cholesterol and calcium (2008) J. Heart Valve Dis, 17, pp. 381-387; Birt, D.F., Pour, P.M., Interaction of dietary fat and protein in spontaneous diseases of Syrian golden hamsters (1985) J. Natl. Cancer Inst, 75, pp. 127-133; Burgess, N.A., Reynolds, T.M., Williams, N., Pathy, A., Smith, S., Evaluation of four animal models of intrarenal calcium deposition and assessment of the influence of dietary supplementation with essential fatty acids on calcification (1995) Urol. Res, 23, pp. 239-242; Kanai, S., Uto, K., Honda, K., Hagiwara, N., Oda, H., Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats (2011) Atherosclerosis, 215, pp. 43-51; Schlemmer, C.K., Coetzer, H., Claassen, N., Kruger, M.C., Rademeyer, C., van Jaarsveld, L., Smuts, C.M., Ectopic calcification of rat aortas and kidneys is reduced with n-3 fatty acid supplementation (1998) Prostaglandins Leukot Essent Fatty Acids, 59, pp. 221-227; Kummerow, F.A., Zhou, Q., Mahfouz, M.M., Effect of trans fatty acids on calcium influx into human arterial endothelial cells (1999) Am. J. Clin. Nutr, 70, pp. 832-838; Abedin, M., Lim, J., Tang, T.B., Park, D., Demer, L.L., Tintut, Y., n-3 Fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-γ pathways (2006) Circ. Res, 98, pp. 727-729; Lutsey, P.L., Jacobs, D.R., Jr., Kori, S., Mayer-Davis, E., Shea, S., Steffen, L.M., Szklo, M., Tracy, R., Whole grain intake and its cross-sectional association with obesity, insulin resistance, inflammation, diabetes and subclinical CVD: The MESA Study (2007) Br. J. Nutr, 98, pp. 397-405; Danielsen, R., Sigvaldason, H., Thorgeirsson, G., Sigfússon, N., Predominance of aortic calcification as an atherosclerotic manifestation in women: The Reykjavik Study (1996) J. Clin. Epidemiol, 49, pp. 383-387; Van Gils, M.J., Bodde, M.C., Cremers, L.G., Dippel, D.W., van der Lugt, A., Determinants of calcification growth in atherosclerotic carotid arteries: A serial multi-detector CT angiography study (2013) Atherosclerosis, 227, pp. 95-99; Meigs, J.B., Larson, M.G., D'Agostino, R.B., Levy, D., Clouse, M.E., Nathan, D.M., Wilson, P.W., O'Donnell, C.J., Coronary artery calcification in type 2 diabetes and insulin resistance: The framingham offspring study (2002) Diabetes Care, 25, pp. 1313-1319; Kronmal, R.A., McClelland, R.L., Detrano, R., Shea, S., Lima, J.A., Cushman, M., Bild, D.E., Burke, G.L., Risk factors for the progression of coronary artery calcification in asymptomatic subjects: Results from the Multi-Ethnic Study of Atherosclerosis (MESA) (2007) Circulation, 115, pp. 2722-2730; Barascuk, N., Ganz, M., Nielsen, M., Register, T.C., Rasmussen, L.M., Karsdal, M.A., Christiansen, C., Abdominal aortic calcification quantified by the Morphological Atherosclerotic Calcification Distribution (MACD) index is associated with features of the metabolic syndrome (2011) BMC Cardiovasc. Disord, 11, p. 75; Schauer, I.E., Snell-Bergeon, J.K., Bergman, B.C., Maahs, D.M., Kretowski, A., Eckel, R.H., Rewers, M., Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study (2011) Diabetes, 60, pp. 306-314; Moebus, S., Stang, A., Möhlenkamp, S., Dragano, N., Schmermund, A., Slomiany, U., Hoffmann, B., Mann, K., Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort-Results of the Heinz Nixdorf Recall Study (2009) Diabetologia, 52, pp. 81-89; Tanaka, M., Fukui, M., Tomiyasu, K., Akabame, S., Nakano, K., Hasegawa, G., Oda, Y., Nakamura, N., U-shaped relationship between insulin level and coronary artery calcification (CAC) (2010) J. Atheroscler. Thromb, 17, pp. 1033-1040; Liu, F., Zhong, H., Liang, J.Y., Fu, P., Luo, Z.J., Zhou, L., Gou, R., Huang, J., Effect of high glucose levels on the calcification of vascular smooth muscle cells by inducing osteoblastic differentiation and intracellular calcium deposition via BMP-2/Cbfα-1 pathway (2010) J. Zhejiang Univ. Sci. B, 11, pp. 905-911; Zhou, Y.B., Zhang, J., Cai, Y., Teng, X., Duan, X.H., Song, J.Q., Du, J., Qi, Y.F., Insulin resistance induces medial artery calcification in fructose-fed rats (2012) Exp. Biol. Med. (Maywood), 237, pp. 50-57; Chonan, O., Takahashi, R., Yasui, H., Watanuki, M., Effects of β-1-4 linked galactooligosaccharides on use of magnesium and calcification of the kidney and heart in rats fed excess dietary phosphorus and calcium (1996) Biosci. Biotechnol. Biochem, 60, pp. 1735-1737; Sterck, J.G., Ritskes-Hoitinga, J., Beynen, A.C., Inhibitory effect of high protein intake on nephrocalcinosis in female rats (1992) Br. J. Nutr, 67, pp. 223-233; Gigliotti, J.C., Smith, A.L., Jaczynski, J., Tou, J.C., Consumption of krill protein concentrate prevents early renal injury and nephrocalcinosis in female Sprague-Dawley rats (2011) Urol. Res, 39, pp. 59-67; Wen, S.F., Huang, T.P., Moorthy, A.V., Effects of low-protein diet on experimental diabetic neuropathy in the rat (1985) J. Lab. Clin. Med, 106, pp. 589-597; Brown, E.M., Role of the calcium-sensing receptor in extracellular calcium homeostasis (2013) Best Pract. Res. Clin. Endocrinol. Metab, 27, pp. 333-343; Wang, T.K., Bolland, M.J., van Pelt, N.C., Horne, A.M., Mason, B.H., Ames, R.W., Grey, A.B., Reid, I.R., Relationships between vascular calcification, calcium metabolism, bone density, and fractures (2010) J. Bone Miner Res, 25, pp. 2777-2785; Samelson, E.J., Booth, S.L., Fox, C.S., Tucker, K.L., Wang, T.J., Hoffmann, U., Cupples, L.A., Kiel, D.P., Calcium intake is not associated with increased coronary artery calcification: The Framingham Study (2012) Am. J. Clin. Nutr, 96, pp. 1274-1280; Spence, L.A., Weaver, C.M., Calcium intake, vascular calcification, and vascular disease (2013) Nutr. Rev, 71, pp. 15-22; Kim, J.H., Yoon, J.W., Kim, K.W., Lee, E.J., Lee, W., Cho, S.H., Shin, C.S., Increased dietary calcium intake is not associated with coronary artery calcification (2012) Int. J. Cardiol, 157, pp. 429-431; Kwak, S.M., Kim, J.S., Choi, Y., Chang, Y., Kwon, M.J., Jung, J.G., Jeong, C., Shin, H., Dietary intake of calcium and phosphorus and serum concentration in relation to the risk of coronary artery calcification in asymptomatic adults (2014) Arterioscler. Thromb. Vasc. Biol, 34, pp. 1763-1769; Raffield, L.M., Agarwal, S., Cox, A.J., Hsu, F.C., Carr, J.J., Freedman, B.I., Xu, J., Vitolins, M.Z., Cross-sectional analysis of calcium intake for associations with vascular calcification and mortality in individuals with type 2 diabetes from the Diabetes Heart Study (2014) Am. J. Clin. Nutr, 100, pp. 1029-1035; Agata, U., Park, J.H., Hattori, S., Iimura, Y., Ezawa, I., Akimoto, T., Omi, N., The effect of different amounts of calcium intake on bone metabolism and arterial calcification in ovariectomised rats (2013) J. Nutr. Sci. Vitaminol. (Tokyo), 59, pp. 29-36; Hsu, H.H., Culley, N.C., Effects of dietary calcium on atherosclerosis, aortic calcification, and icterus in rabbits fed a supplemental cholesterol diet (2006) Lipids Health Dis, 5, p. 16; Moe, S.M., Chen, N.X., Newman, C.L., Gattone, V.H., II, Organ, J.M., Chen, X., Allen, M.R., A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD (2014) J. Bone Miner. Res, 29, pp. 902-910; Cancela, A.L., Santos, R.D., Titan, S.M., Goldenstein, P.T., Rochitte, C.E., Lemos, P.A., dos Reis, L.M., Moysés, R.M., Phosphorus is associated with coronary artery disease in patients with preserved renal function (2012) PLo S ONE, 7; Linefsky, J.P., O'Brien, K.D., Katz, R., de Boer, I.H., Barasch, E., Jenny, N.S., Siscovick, D.S., Kestenbaum, B., Association of serum phosphate levels with aortic valve sclerosis and annular calcification: The cardiovascular health study (2011) J. Am. Coll. Cardiol, 58, pp. 291-297; Shin, S., Kim, K.J., Chang, H.J., Cho, I., Kim, Y.J., Choi, B.W., Rhee, Y., Shim, C.Y., Impact of serum calcium and phosphate on coronary atherosclerosis detected by cardiac computed tomography (2012) Eur. Heart J, 33, pp. 2873-2881; Civitelli, R., Ziambaras, K., Calcium and phosphate homeostasis: Concerted interplay of new regulators (2011) J. Endocrinol. Investig, 34, pp. 3-7; Calvo, M.S., Uribarri, J., Public Health impact of dietary phosphorus excess on bone and cardiovascular health in the general population (2013) Am. J. Clin. Nutr; Linefsky, J.P., O'Brien, K.D., Sachs, M., Katz, R., Eng, J., Michos, E.D., Budoff, M.J., Kestenbaum, B., Serum phosphate is associated with aortic valve calcification in the Multi-ethnic Study of Atherosclerosis (MESA) (2014) Atherosclerosis, 233, pp. 331-337; McCarty, M.F., Di Nicolantonio, J.J., Bioavailable dietary phosphate, a mediator of cardiovascular disease, may be decreased with plant-based diets, phosphate binders, niacin, and avoidance of phosphate additives (2014) Nutrition, 30, pp. 739-747; Tuttle, K.R., Short, R.A., Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function (2009) Clin. J. Am. Soc. Nephrol, 4, pp. 1968-1973; Figueiredo, C.P., Rajamannan, N.M., Lopes, J.B., Caparbo, V.F., Takayama, L., Kuroishi, M.E., Oliveira, I.S., Bonfá, E., Serum phosphate and hip bone mineral density as additional factors for high vascular calcification scores in a community-dwelling: The São Paulo Ageing & Health Study (SPAH) (2013) Bone, 52, pp. 354-359; Razzaque, M.S., Phosphate toxicity and vascular mineralization (2013) Contrib. Nephrol, 180, pp. 74-85; Nishizawa, Y., Jono, S., Ishimura, E., Shioi, A., Hyperphosphatemia and vascular calcification in end-stage renal disease (2005) J. Ren. Nutr, 15, pp. 178-182; Yamada, S., Tokumoto, M., Tatsumoto, N., Taniguchi, M., Noguchi, H., Nakano, T., Masutani, K., Kitazono, T., Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia (2014) Am. J. Physiol. Ren. Physiol, 306, pp. F1418-F1428; Louvet, L., Buchel, J., Steppan, S., Passlick-Deetjen, J., Massy, Z.A., Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells (2014) Nephrol. Dial Transplant, 28, pp. 869-878; Bonjour, J.P., Gue'guen, L., Palacios, C., Shearer, M.J., Weaver, C.M., Minerals and vitamins in bone health: The potential value of dietary enhancement (2009) Br. J. Nutr, 101, pp. 1581-1596; Hruby, A., O'Donnell, C.J., Jacques, P.F., Meigs, J.B., Hoffmann, U., McKeown, N.M., Magnesium intake is inversely associated with coronary artery calcification: The framingham heart study (2014) JACC Cardiovasc. Imaging, 7, pp. 59-69; Ishimura, E., Okuno, S., Kitatani, K., Tsuchida, T., Yamakawa, T., Shioi, A., Inaba, M., Nishizawa, Y., Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients (2007) Clin. Nephrol, 68, pp. 222-227; Meema, H.E., Oreopoulos, D.G., Rapoport, A., Serum magnesium level and arterial calcification in end-stage renal disease (1987) Kidney Int, 32, pp. 388-394; Tzanakis, I., Virvidakis, K., Tsomi, A., Mantakas, E., Girousis, N., Karefyllakis, N., Papadaki, A., Mountokalakis, T., Intra-and extracellular magnesium levels and atheromatosis in haemodialysis patients (2004) Magnes. Res, 17, pp. 102-108; Salem, S., Bruck, H., Bahlmann, F.H., Peter, M., Passlick-Deetjen, J., Kretschmer, A., Steppan, S., Nierhaus, M., Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification (2012) Am. J. Nephrol, 35, pp. 31-39; Planells, E., Llopis, J., Perán, F., Aranda, P., Changes in tissue calcium and phosphorus content and plasma concentrations of parathyroid hormone and calcitonin after long-term magnesium deficiency in rats (1995) J. Am. Coll. Nutr, 14, pp. 292-298; Pen, J.X., Li, L., Wang, X., Zhang, Y.H., Li, X.F., Wu, S.Y., The effect of the magnesium supplementation on vascular calcification in rats (2012) Zhongguo Ying Yong Sheng Li Xue Za Zhi, 28, pp. 20-23; Nagase, N., Saijo, Y., Nitta, H., Tamura, Y., Orino, S., Akaike, Y., Mori, H., Myocardial disorders caused by magnesium deficiency in diabetic KK mice (1989) Magnesium, 8, pp. 307-315; Adamczyk, A., Stolarz-Skrzypek, K., Wesołowska, A., Czarnecka, D., Vitamin D and vitamin D receptor activators in treatment of hypertension and cardiovascular disease (2014) Cardiovasc. Hematol. Disord. Drug Targets, 14, pp. 34-44; Turner, A.G., Hanrath, M.A., Morris, H.A., Atkins, G.J., Anderson, P.H., The local production of 1,25(OH)2D3 promotes osteoblast and osteocyte maturation (2013) J. Steroid Biochem. Mol. Biol, 144, pp. 114-118; Leiben, L., Masuyama, R., Torrekens, S., van Looveren, R., Schrooten, J., Baatsen, P., Lafage-Proust, M.-H., Bonewald, L.F., Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralisation (2012) J. Clin. Investig, 122, pp. 1803-1815; Kang, Y.H., Jin, J.S., Yi, D.W., Son, S.M., Bone morphogenetic protein-7 inhibits vascular calcification induced by high vitamin D in mice (2010) Tohoku J. Exp. Med, 221, pp. 299-307; Tang, F.T., Chen, S.R., Wu, X.Q., Wang, T.Q., Chen, J.W., Li, J., Bao, L.P., Liu, P.Q., Hypercholesterolemia accelerates vascular calcification induced by excessive vitamin D via oxidative stress (2006) Calcif. Tissue Int, 79, pp. 326-339; Ellam, T., Hameed, A., Ul Haque, R., Muthana, M., Wilkie, M., Francis, S.E., Chico, T.J., Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein e knockout mice (2014) PLo S ONE, 9; Schmidt, N., Brandsch, C., Kühne, H., Thiele, A., Hirche, F., Stangl, G.I., Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice (2012) PLo S ONE, 7; Schmidt, N., Brandsch, C., Schutkowski, A., Hirche, F., Stangl, G.I., Dietary vitamin D inadequacy accelerates calcification and osteoblast-like cell formation in the vascular system of LDL receptor knockout and wild-type mice (2014) J. Nutr, 144, pp. 638-646; Michos, E.D., Streeten, E.A., Ryan, K.A., Rampersaud, E., Peyser, P.A., Bielak, L.F., Shuldiner, A.R., Post, W., Serum 25-hydroxyvitamin d levels are not associated with subclinical vascular disease or C-reactive protein in the old order amish (2009) Calcif. Tissue Int, 84, pp. 195-202; Walker, M.D., Cong, E., Kepley, A., di Tullio, M.R., Rundek, T., Homma, S., Lee, J.A., Zhang, C., Association between serum 25-hydroxyvitamin d level and subclinical cardiovascular disease in primary hyperparathyroidism (2014) J. Clin. Endocrinol. Metab, 99, pp. 671-680; De Boer, I.H., Kestenbaum, B., Shoben, A.B., Michos, E.D., Sarnak, M.J., Siscovick, D.S., 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification (2009) J. Am. Soc. Nephrol, 20, pp. 1805-1812; García-Canton, C., Bosch, E., Ramírez, A., Gonzalez, Y., Auyanet, I., Guerra, R., Perez, M.A., Lago, M., Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5 (2011) Nephrol. Dial.Transplant, 26, pp. 2250-2256; Lee, S.Y., Kim, H.Y., Gu, S.W., Kim, H.J., Yang, D.H., 25-hydroxyvitamin D levels and vascular calcification in predialysis and dialysis patients with chronic kidney disease (2012) Kidney Blood Press Res, 35, pp. 349-354; Young, K.A., Snell-Bergeon, J.K., Naik, R.G., Hokanson, J.E., Tarullo, D., Gottlieb, P.A., Garg, S.K., Rewers, M., Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes (2011) Diabetes Care, 34, pp. 454-458; Dishmon, D.A., Dotson, J.L., Munir, A., Nelson, M.D., Bhattacharya, S.K.D., Cruz, I.A., Davis, R.C., Weber, K.T., Hypovitaminosis D and valvular calcification in patients with dilated cardiomyopathy (2009) Am. J. Med. Sci, 337, pp. 312-316; Arad, Y., Spadaro, L.A., Roth, M., Scordo, J., Goodman, K., Sherman, S., Lerner, G., Guerci, A.D., Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications. An electron beam computed tomography study (1998) Coron. Artery Dis, 9, pp. 513-518; Watson, K.E., Abrolat, M.L., Malone, L.L., Hoeg, J.M., Doherty, T., Detrano, R., Demer, L.L., Active serum vitamin D levels are inversely correlated with coronary calcification (1997) Circulation, 96, pp. 1755-1760; Yokoyama, K., Study on vascular calcification in patients on continuous ambulatory peritoneal dialysis (CAPD): Special reference to active vitamin D (VD) treatment (1993) Nihon Jinzo Gakkai Shi, 35, pp. 1171-1180; Allison, M.A., Carr, J.J., Langer, R.D., Cochrane, B.B., Hendrix, S.L., Hsia, J., Hunt, J.R., Robinson, J.G., Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative (2010) Menopause, 17, pp. 683-691; Hsia, J., Heiss, G., Ren, H., Allison, M., Dolan, N.C., Greenland, P., Heckbert, S.R., Sidney, S., Calcium/vitamin D supplementation and cardiovascular events (2007) Circulation, 115, pp. 846-854; Pearson, D.A., Bone health and osteoporosis: The role of vitamin K and potential antagonism by anticoagulants (2007) Nutr. Clin. Pract, 22, pp. 517-544; Palaniswamy, C., Aronow, W.S., Sekhri, A., Adapa, S., Ahn, C., Singh, T., Malhotra, B., Lerner, R., Warfarin use and prevalence of coronary artery calcification assessed by multislice computed tomography (2012) Am. J. Ther, 21, pp. 148-151; Schurgers, L.J., Joosen, I.A., Laufer, E.M., Chatrou, M.L., Herfs, M., Winkens, M.H., Westenfeld, R., Shanahan, C.M., Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype (2012) PLo S ONE, 7; Lerner, R.G., Aronow, W.S., Sekhri, A., Palaniswamy, C., Ahn, C., Singh, T., Sandhu, R., McClung, J.A., Warfarin use and the risk of valvular calcification (2009) J. Thromb. Haemost, 7, pp. 2023-2027; Fusaro, M., Tripepi, G., Noale, M., Plebani, M., Zaninotto, M., Piccoli, A., Naso, A., Avolio, M., Prevalence of vertebral fractures, vascular calcifications, and mortality in warfarin treated hemodialysis patients (2013) Curr. Vasc. Pharmacol; Beulens, J.W., Bots, M.L., Atsma, F., Bartelink, M.L., Prokop, M., Geleijnse, J.M., Witteman, J.C., van der Schouw, Y.T., High dietary menaquinone intake is associated with reduced coronary calcification (2009) Atherosclerosis, 203, pp. 489-493; Geleijnse, J.M., Vermeer, C., Grobbee, D.E., Schurgers, L.J., Knapen, M.H., van der Meer, I.M., Hofman, A., Witteman, J.C., Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study (2004) J. Nutr, 134, pp. 3100-3105; Shea, M.K., Booth, S.L., Miller, M.E., Burke, G.L., Chen, H., Cushman, M., Tracy, R.P., Kritchevsky, S.B., Association between circulating vitamin K1 and coronary calcium progression in community-dwelling adults: The Multi-Ethnic Study of Atherosclerosis (2013) Am. J. Clin. Nutr, 98, pp. 197-208; Fusaro, M., Noale, M., Viola, V., Galli, F., Tripepi, G., Vajente, N., Plebani, M., Miotto, D., Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study (2012) J. Bone Miner. Res, 27, pp. 2271-2278; Dalmeijer, G.W., van der Schouw, Y.T., Vermeer, C., Magdeleyns, E.J., Schurgers, L.J., Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women (2013) J. Nutr. Biochem, 24, pp. 624-628; Dalmeijer, G.W., van der Schouw, Y.T., Booth, S.L., de Jong, P.A., Beulens, J.W., Phylloquinone concentrations and the risk of vascular calcification in healthy women (2014) Arterioscler. Thromb. Vasc. Biol, 34, pp. 1587-1590; Pilkey, R.M., Morton, A.R., Boffa, M.B., Noordhof, C., Day, A.G., Su, Y., Miller, L.M., Booth, S.L., Subclinical vitamin K deficiency in hemodialysis patients (2007) Am. J. Kidney Dis, 49, pp. 432-439; Shea, M.K., O'Donnell, C.J., Hoffmann, U., Dallal, G.E., Dawson-Hughes, B., Ordovas, J.M., Price, P.A., Booth, S.L., Vitamin K supplementation and progression of coronary artery calcium in older men and women (2009) Am. J. Clin. Nutr, 89, pp. 1799-1807; McCabe, K.M., Booth, S.L., Fu, X., Shobeiri, N., Pang, J.J., Adams, M.A., Holden, R.M., Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease (2013) Kidney Int, 83, pp. 835-844; Schurgers, L.J., Spronk, H.M., Skepper, J.N., Hackeng, T.M., Shanahan, C.M., Vermeer, C., Weissberg, P.L., Proudfoot, D., Post-translational modifications regulate matrix Gla protein function: Importance for inhibition of vascular smooth muscle cell calcification (2007) J. Thromb. Haemost, 5, pp. 2503-2511; Spronk, H.M., Soute, B.A., Schurgers, L.J., Thijssen, H.H., de Mey, J.G., Vermeer, C., Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats (2003) J. Vasc. Res, 40, pp. 531-537; Cranenburg, E.C., Brandenburg, V.M., Vermeer, C., Stenger, M., Mühlenbruch, G., Mahnken, A.H., Gladziwa, U., Schurgers, L.J., Uncarboxylated matrix Gla protein (uc MGP) is associated with coronary artery calcification in haemodialysis patients (2009) Thromb. Haemost, 101, pp. 359-366; Liabeuf, S., Olivier, B., Vemeer, C., Theuwissen, E., Magdeleyns, E., Aubert, C.E., Brazier, M., Massy, Z.A., Vascular calcification in patients with type 2 diabetes: The involvement of matrix Gla protein (2014) Cardiovasc. Diabetol, 13, p. 85; Shea, M.K., O'Donnell, C.J., Vermeer, C., Magdeleyns, E.J., Crosier, M.D., Gundberg, C.M., Ordovas, J.M., Booth, S.L., Circulating uncarboxylated matrix Gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults (2011) J. Nutr, 141, pp. 1529-1534; Hirasaka, N., Liang, X.M., Mune, M., Atherosclerosis and vascular calcification in hemodialysis patients (2004) Clin. Calcium, 14, pp. 85-90; Chavan, S.N., More, U., Mulgund, S., Saxena, V., Sontakke, A.N., Effect of supplementation of vitamin C and E on oxidative stress in osteoporosis (2007) Indian J. Clin. Biochem, 22, pp. 101-105; Ahmadi, N., Tsimikas, S., Hajsadeghi, F., Saeed, A., Nabavi, V., Bevinal, M.A., Kadakia, J., Budoff, M.J., Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium (2010) Am. J. Cardiol, 105, pp. 459-466; Watanabe, K., Ohara, M., Suzuki, T., Ouchi, M., Suzuki, K., Hashimoto, M., Saigusa, T., Oba, K., Aortic arch calcification detectable on chest X-ray films is associated with plasma diacron-reactive oxygen metabolites in patients with type 2 diabetes but without cardiovascular disease (2013) J. Nippon. Med. Sch, 80, pp. 410-419; Liberman, M., Bassi, E., Martinatti, M.K., Lario, F.C., Wosniak, J., Pomerantzeff, P.M., Laurindo, F.R., Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification (2008) Atheroscler. Thromb. Vasc. Biol, 28, pp. 463-470; Muteliefu, G., Enomoto, A., Niwa, T., Indoxyl sulfate promotes proliferation of human aortic smooth muscle cells by inducing oxidative stress (2009) J. Ren. Nutr, 19, pp. 29-32; Mody, N., Parhami, F., Sarafian, T.A., Demer, L.L., Oxidative stress modulates osteoblastic differentiation of vascular and bone cells (2001) Free Radic. Biol. Med, 31, pp. 509-519; Valabhji, J., McColl, A.J., Richmond, W., Schachter, M., Rubens, M.B., Elkeles, R.S., Total antioxidant status and coronary artery calcification in type 1 diabetes (2001) Diabetes Care, 24, pp. 1608-1613; Conaway, H.H., Henning, P., Lerner, U.H., Vitamin A metabolism, action and role in skeletal homeostasis (2013) Endocr. Rev, 34, pp. 766-797; Hatzigeorgiou, C., Taylor, A.J., Feuerstein, I.M., Bautista, L., O'Malley, P.G., Antioxidant vitamin intake and subclinical coronary atherosclerosis (2006) Prev. Cardiol, 9, pp. 75-81; Huang, G., Wang, D., Khan, U.I., Zeb, I., Manson, J.E., Miller, V., Hodis, H.N., Harman, S.M., Associations between retinol-binding protein 4 and cardiometabolic risk factors and subclinical atherosclerosis in recently postmenopausal women: Cross-sectional analyses from the KEEPS Study (2012) Cardiovasc. Diabetol, 11, p. 52; Huk, D.J., Hammond, H.L., Kegechika, H., Lincoln, J., Increased dietary intake of vitamin A promotes aortic valve calcification in vivo. Arterioscler (2013) Thromb. Vasc. Biol., 33, pp. 285-293; McQuillan, B.M., Hung, J., Beilby, J.P., Nido, M., Thompson, P.L., Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS) (2001) J. Am. Coll. Cardiol, 38, pp. 1788-1794; Klipstein-Grobusch, K., Launer, L.J., Geleijnse, J.M., Boeing, H., Hofman, A., Witteman, J.C., Serum carotenoids and atherosclerosis. The Rotterdam Study (2000) Atherosclerosis, 148, pp. 49-56; Nieves, J.W., Osteoporosis: The role of micronutrients (2005) Am. J. Clin. Nutr, 81, pp. 1232S-1239S; Arad, Y., Spadaro, L.A., Roth, M., Newstein, D., Guerci, A.D., Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: The St. Francis Heart Study randomized clinical trial (2005) J. Am. Coll. Cardiol, 46, pp. 166-172; Takata, T., Ikeda, M., Kodama, H., Kitagawa, N., Treatment of pseudoxanthoma elasticum with tocopherol acetate and ascorbic acid (2007) Pediatr. Dermatol, 24, pp. 424-425; Vasudev, S.C., Chandy, T., Sharma, C.P., Glutaraldehyde treated bovine pericardium: Changes in calcification due to vitamins and platelet inhibitors (1997) Artif. Organs, 21, pp. 1007-1013; Aggarwal, B.B., Sundaram, C., Prasad, S., Kannappan, R., Tocotrienols, the vitamin E of the 21st century: Its potential against cancer and other chronic diseases (2010) Biochem. Pharmacol, 80, pp. 1613-1631; Naina Mohamed, I., Borhanuddin, B., Shuid, A.N., Mohd Fozi, N.F., Vitamin E and bone structural changes: An evidence-based review (2012) Evid. Based Complement. Alternat. Med, 2012, p. 250584; Vogt, M.T., San Valentin, R., Forrest, K.Y., Nevitt, M.C., Cauley, J.A., Bone mineral density and aortic calcification: The Study of Osteoporotic Fractures (1997) J. Am. Geriatr. Soc, 45, pp. 140-145; Van Woudenbergh, G.J., Vliegenthart, R., van Rooij, F.J., Hofman, A., Oudkerk, M., Witteman, J.C., Geleijnse, J.M., Coffee consumption and coronary calcification: The Rotterdam Coronary Calcification Study (2008) Arterioscler. Thromb. Vasc. Biol, 28, pp. 1018-1023; Rehman, H., Krishnasamy, Y., Haque, K., Thurman, R.G., Lemasters, J.J., Schnellmann, R.G., Zhong, Z., Green tea polyphenols stimulate mitochondrial biogenesis and improve renal function after chronic cyclosporin a treatment in rats (2013) PLo S ONE, 38; Beazley, K.E., Lima, F., Borras, T., Nurminskaya, M., Attenuation of chondrogenic transformation in vascular smooth muscle by dietary quercetin in the MGP-deficient mouse model (2013) PLo S ONE, 8; Liu, Y., Liu, W., Sun, G., Wei, X., Yi, D., Calcification resistance of procyanidin-treated decellularized porcine aortic valves in vivo. Heart Surg (2009) Forum., 12, pp. E24-E29; Peng, C.C., Hsieh, C.L., Ker, Y.B., Wang, H.Y., Chen, K.C., Peng, R.Y., Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney disease (2012) Mol. Nutr. Food Res, 56, pp. 1541-1558; Nicoll, R., Henein, M.Y., Alcohol and the heart (2011) Alcohol. Clin. Exp. Res, 35, pp. 1737-1738; Vliegenthart, R., Oei, H.H., van den Elzen, A.P., van Rooij, F.J., Hofman, A., Oudkerk, M., Witteman, J.C., Alcohol consumption and coronary calcification in general population (2004) Arch. Intern. Med, 164, pp. 2355-2660; Tomayko, E.J., Cachia, A.J., Chung, H.R., Wilund, K.R., Resveratrol supplementation reduces aortic atherosclerosis and calcification and attenuates loss of aerobic capacity in a mouse model of uremia (2014) J. Med. Food, 17, pp. 278-283; Kim, H.S., Shin, H.I., Lim, H.S., Lee, T.Y., Lee, K., Jeong, D., α-Lipoic acid attenuates coxsackievirus B3-induced ectopic calcification in heart, pancreas, and lung (2013) Biochem. Biophys. Res. Commun, 432, pp. 378-383; Bassi, E., Liberman, M., Martinatti, M.K., Bortolotto, L.A., Leurindo, F.R., Lipoic acid, but not tempol, preserves vascular compliance and decreases medial calcification in a model of elastocalcinosis (2014) Braz. J. Med. Biol. Res, 47, pp. 119-127; Ivanovski, O., Nikolov, I.G., Drueke, B.T., Massy, A.Z., Atherosclerosis and vascular calcification in uraemia-A new experimental model (2007) Prilozi, 28, pp. 11-24; Muteliefu, G., Shimizu, H., Enomoto, A., Nishijima, F., Takahashi, M., Niwa, T., Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21 and prelamin A through oxidative stress (2012) Am. J. Physiol. Cell Physiol, 303, pp. C126-C134; Nakahara, T., Sato, H., Shimizu, T., Tanaka, T., Matsui, H., Kawai-Kowase, K., Sato, M., Kurabayashi, M., Fibroblast growth factor-2 induces osteogenic differentiation through a Runx2 activation in vascular smooth muscle cells (2010) Biochem. Biophys. Res. Commun, 394, pp. 243-248; Stanger, O., Herrmann, W., Pietrzik, K., Fowler, B., Geisel, J., Dierkes, J., Weger, M., DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): Consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: Guidelines and recommendations (2003) Clin. Chem. Lab. Med, 41, pp. 1392-1403; Clarke, R., Halsey, J., Lewington, S., Lonn, E., Armitage, J., Manson, J.E., Bønaa, K.H., Jamison, R., Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37,485 individuals (2010) Arch. Intern. Med, 170, pp. 1622-1631; Clarke, R., Lowering blood homocysteine with folic acid-based supplements: Meta-analysis of randomised trials (2000) Indian Heart J, 52, pp. S59-S64; Homocysteine Lowering Trialists' Collaboration., Dose-dependent effects of folic acid on blood concentrations of homocysteine: A meta-analysis of the randomized trials (2005) Am. J. Clin. Nutr, 82, pp. 806-812; Ebbing, M., Bønaa, K.H., Arnesen, E., Ueland, P.M., Nordrehaug, J.E., Rasmussen, K., Njølstad, I., Tverdal, A., Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials (2010) J. Intern. Med, 268, pp. 367-382; Sarwar, A.B., Sarwar, A., Rosen, B.D., Nasir, K., Measuring subclinical atherosclerosis: Is homocysteine relevant? Clin (2007) Chem. Lab. Med., 45, pp. 1667-1677; Kim, B.J., Kim, B.S., Kang, J.H., Plasma homocysteine and coronary artery calcification in Korean men (2014) Eur. J. Prev. Cardiol, 22, pp. 478-485; Sun, Q., Jia, X., Gao, J., Mou, W., Tong, H., Wen, X., Tian, Y., Association of serum homocysteine levels with the severity and calcification of coronary atherosclerotic plaques detected by coronary CT angiography (2014) Int. Angiol, 33, pp. 316-323; Van Campenhout, A., Moran, C.S., Parr, A., Clancy, P., Rush, C., Jakubowski, H., Golledge, J., Role of homocysteine in aortic calcification and osteogenic cell differentiation (2009) Atherosclerosis, 202, pp. 557-566; Bozbas, H., Yildirir, A., Atar, I., Pirat, B., Eroglu, S., Aydinalp, A., Ozin, B., Muderrisoglu, H., Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification (2007) J. Heart Valve Dis, 16, pp. 387-393; Held, C., Sumner, G., Sheridan, P., McQueen, M., Smith, S., Dagenais, G., Yusuf, S., Lonn, E., Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: Baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART) (2008) Vasc. Med, 13, pp. 245-253; Rasouli, M.L., Nasir, K., Blumenthal, R.S., Park, R., Aziz, D.C., Budoff, M.J., Plasma homocysteine predicts progression of atherosclerosis (2005) Atherosclerosis, 181, pp. 159-165; Russo, D., Corrao, S., Miranda, I., Ruocco, C., Manzi, S., Elefante, R., Brancaccio, D., Andreucci, V.E., Progression of coronary artery calcification in predialysis patients (2007) Am. J. Nephrol, 27, pp. 152-158; He, J., Reilly, M., Yang, W., Chen, J., Go, A.S., Lash, J.P., Rahman, M., Kanthety, R., Risk factors for coronary artery calcium among patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study) (2012) Am. J. Cardiol, 110, pp. 1735-1741; Petrović, D., Obrenović, R., Stojimirović, B., Risk factors for aortic valve calcification in patients on regular hemodialysis (2009) Int. J. Artif. Organs, 32, pp. 173-179; Hodis, H.N., Mack, W.J., Dustin, L., Mahrer, P.R., Azen, S.P., Detrano, R., Selhub, J., Liu, C.H., High-dose B vitamin supplementation and progression of subclinical atherosclerosis: A randomized controlled trial (2009) Stroke, 40, pp. 730-736; Budoff, M.J., Ahmadi, N., Gul, K.M., Liu, S.T., Flores, F.R., Tiano, J., Takasu, J., Tsimikas, S., Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: A randomized clinical trial (2009) Prev. Med, 49, pp. 101-107; Ahmadi, N., Nabavi, V., Hajsadeghi, F., Zeb, I., Flores, F., Ebrahimi, R., Budoff, M., Aged garlic extract with supplement is associated with increase in brown adipose, decrease in white adipose tissue and predict lack of progression in coronary atherosclerosis (2013) Int. J. Cardiol, 168, pp. 2310-2314; Demer, L.L., Vascular calcification and osteoporosis: Inflammatory responses to oxidised lipids (2002) Int. J. Epidemiol, 31, pp. 737-741; Maziere, C., Salle, V., Gomila, C., Maziere, J.C., Oxidised low density lipoprotein increases RANKL level in human vascular cells. Involvement of oxidative stress (2013) Biochem. Biophys. Res. Commun, 440, pp. 295-299; Hofbauer, L.C., Brueck, C.C., Shanahan, C.M., Schoppet, M., Dobnig, H., Vascular calcification and osteoporosis-From clinical observation towards molecular understanding (2007) Osteoporos. Int, 18, pp. 251-259; Anagnostis, P., Karagiannis, A., Kakafika, A.I., Tziomalos, K., Athyros, V.G., Mikhailidis, D.P., Atherosclerosis and osteoporosis: Age-dependent degenerative processes or related entities? (2009) Osteoporosis Int, 20, pp. 197-207; Fukami, K., Yamagishi, S.I., Okuda, S., Role of AGEs-RAGE system in cardiovascular disease (2013) Curr. Pharm. Des, 20, pp. 2395-2402; Wang, Y., Zhang, Z.Y., Chen, X.Q., Wang, X., Cao, H., Liu, S.W., Advanced glycation end products promote human aortic smooth muscle cell calcification in vitro via activating NF-κ B and down-regulating IGF1R expression (2013) Acta Pharmacol. Sin, 34, pp. 480-486; Wei, Q., Ren, X., Jiang, Y., Jin, H., Liu, N., Li, J., Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress (2013) BMC Cardiovasc. Disord, 13, p. 13; Tanikawa, T., Okada, Y., Tanikawa, R., Tanaka, Y., Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK (2009) J. Vasc. Res, 46, pp. 572-580; Chang, L., Zhao, J., Xu, J., Jiang, W., Tang, C.S., Qi, Y.F., Effects of taurine and homocysteine on calcium homeostasis and hydrogen peroxide and superoxide anions in rat myocardial mitochondria (2004) Clin. Exp. Pharmacol. Physiol, 31, pp. 237-243; Zhang, X., Li, H., Jin, H., Ebin, Z., Brodsky, S., Goligorsky, M.S., Effects of homocysteine on endothelial nitric oxide production (2000) Am. J. Physiol. Renal. Physiol, 279, pp. F671-F678; Yang, Y., Yu, F., Li, J.X., Tang, C.S., Li, C.Y., Promoting effect of hyperhomocysteinemia on vascular calcification in rats (2004) Zhongguo Ying Yong Sheng Li Xue Za Zhi, 20, pp. 333-336; Vervoort, L.M., Ronden, J.E., Thijssen, H.H., The potent antioxidant activity of the vitamin K cycle in microsomal lipid peroxidation (1999) Biochem. Pharmacol, 54, pp. 871-876; Hiruma, Y., Nakahama, K., Fujita, H., Morita, I., Vitamin K2 and geranylgeraniol, its side chain component, inhibited osteoclast formation in a different manner (2004) Biochem. Biophys. Res. Commun, 314, pp. 24-30",Review,Scopus,2-s2.0-84928138827
"He D.-K., Zhang Y.-F., Liang Y., Ye S.-X., Wang C., Kang B., Wang Z.-N.","Risk factors for embolism in cardiac myxoma: A retrospective analysis",2015,"Medical Science Monitor","21",,,"1146","1154",,,10.12659/MSM.893855,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928501003&partnerID=40&md5=fb68fee87a0ae8531f4e44d3746d5bf5","Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China; Department of Cardiothoracic Surgery, Fuzhou General HospitalFuzhou, Fujian, China; Department of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical UniversityShanghai, China","He, D.-K., Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China; Zhang, Y.-F., Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China; Liang, Y., Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China; Ye, S.-X., Department of Cardiothoracic Surgery, Fuzhou General HospitalFuzhou, Fujian, China; Wang, C., Department of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical UniversityShanghai, China; Kang, B., Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China; Wang, Z.-N., Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China","Background: Myxomas are the most common primary heart tumors and are closely associated with embolic events. Cardiac myxomas typically arise from the interatrial septum at the border of the fossa ovalis in the left atrium. Any other location is considered atypical. Embolism, one of the complications of myxoma, is associated with high morbidity and mortality. The aim of this study was to investigate the risk factors for embolism in patients with cardiac myxoma. Material/Methods: In this retrospective study, a cohort of 162 patients with cardiac myxomas was surgically treated between January 1998 and June 2014 at 3 cardiac centers in China. Preoperative data, including platelet count, sex, age, and the tumor (size, location, surface, and attachment), were compared between embolic and non-embolic groups of patients. Results: No significant differences in vascular risk factors were seen between the 2 groups. However, the percentage of higher platelet count (>300×109/L) and mean platelet volume in the embolic group were significantly higher than in the non-embolic group (P=0.0356, and 0.0113, respectively). Irregular surface and atypical location of the myxomas were also independently associated with increased risk of embolic complications. Conclusions: Tumor location, macroscopic appearance, mean platelet volume, and high platelet count are strong risk factors for embolic events in patients with cardiac myxomas. © Med Sci Monit, 2015.","Embolism; Heart Neoplasms; Myxoma","Butany, J., Nair, V., Naseemuddin, A., Cardiac tumours: Diagnosis and management (2005) Lancet Oncol, 6 (4), pp. 219-228; Bjessmo, S., Ivert, T., Cardiac myxoma: 40 years’ experience in 63 patients (1997) Ann Thorac Surg, 63 (3), pp. 697-700; Yuan, S.M., Glandular cardiac myxoma: Case report with literature review (2014) Folia Morphol, 73 (3), pp. 374-382; Dell’Amore, A., Albertini, A., Lamarra, M., Twenty years experience in oncologic surgery for primary cardiac tumors (2013) G Chir, 34 (4), pp. 106-111; Garatti, A., Nano, G., Canziani, A., Surgical excision of cardiac myxomas: Twenty years experience at a single institution (2012) Ann Thorac Surg, 93 (3), pp. 825-831; Patil, N.P., Dutta, N., Satyarthy, S., Cardiac myxomas: Experience over one decade (2011) J Card Surg, 26 (4), pp. 355-359; Lee, S.J., Kim, J.H., Na, C.Y., Oh, S.S., Eleven years’ experience with Korean cardiac myxoma patients: Focus on embolic complications (2012) Cerebrovasc Dis, 33 (5), pp. 471-479; Sivakumar, K., Singhi, A., Mohanraj, A., Ezhilan, J., Tumor embolism from a right atrial myxoma leads to acute right heart failure after surgery and atrial septal patch dehiscence J am Coll Cardiol, 63 (23), 2014p. , 2579; Vaideeswar, P., Gupta, R., Mishra, P., Atypical cardiac myxomas: A clinic pathologic analysis and their comparison to 64 typical myxomas (2012) Cardiovasc Pathol, 21 (3), pp. 180-187; Acebo, E., Val-Bernal, J.F., Gomez-Roman, J.J., Revuelta, J.M., Clinicopathologic study and DNA analysis of 37 cardiac myxomas: A 28-year experience (2003) Chest, 123 (5), pp. 1379-1385; Pinede, L., Duhaut, P., Loire, R., Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases (2001) Medicine (Baltimore), 80 (3), pp. 159-172; Reynen, K., Cardiac myxomas (1995) N Engl J Med, 333 (24), pp. 1610-1617; Obrenovic-Kircanski, B., Mikic, A., Parapid, B., A 30-year-single-center experience in atrial myxomas: From presentation to treatment and prognosis (2013) Thorac Cardiovasc Surg, 61 (6), pp. 530-536; Blondeau, P., Primary cardiac tumors - French studies of 533 cases (1990) Thorac Cardiovasc Surg, 38, pp. 192-195; Li, Q., Shang, H., Zhou, D., Repeated embolism and multiple aneurysms: Central nervous system manifestations of cardiac myxoma (2008) Eur J Neurol, 15 (12), pp. 112-113; Riedl, J., Pabinger, I., Ay, C., Platelets in cancer and thrombosis (2014) Hamostaseologie, 34 (1), pp. 54-62; Connolly, G.C., Phipps, R.P., Francis, C.W., Platelets and cancer-associated thrombosis (2014) Semin Oncol, 41 (3), pp. 302-310; Smith, N.M., Pathansali, R., Bath, P.M., Platelets and stroke (1999) Vasc Med, 4 (3), pp. 165-172; Martin, J.F., Trowbridge, E.A., Salmon, G., Plumb, J., The biological significance of platelet volume: Its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration (1983) Thromb Res, 32 (5), pp. 443-460; Lin, J.N., Lai, C.H., Lu, L.F., Lin, H.H., Fever of unknown origin from a left atrial myxoma: An immunologic basis and cytokine association (2011) South Med J, 104 (5), pp. 360-362; Smith, M., Chaudhry, M.A., Lozano, P., Humphrey, M.B., Cardiac myxoma induced paraneoplastic syndromes: A review of the literature (2012) Eur J Intern Med, 23 (8), pp. 669-673; Graham, H.V., Vonhartitzsch, B., Medina, J.R., Infected atrial myxoma (1976) Am J Cardiol, 38 (5), pp. 658-661; Dias, R.R., Fernandes, F., Ramires, F.J., Mortality and embolic potential of cardiac tumors (2014) Arq Bras Cardiol, 103 (1), pp. 13-18",Article,Scopus,2-s2.0-84928501003
"Alosco M.L., Hayes S.M.","Structural brain alterations in heart failure: a review of the literature and implications for risk of Alzheimer’s disease",2015,"Heart Failure Reviews",,,,"","",11,,10.1007/s10741-015-9488-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928150276&partnerID=40&md5=b65b5044363f665d903c4bb251d20e1b","Memory Disorders Research Center, VA Boston Healthcare System and Boston University School of MedicineBoston, MA, United States; Department of Psychological Sciences, Kent State UniversityKent, OH, United States; Neuroimaging Research for Veterans Center, VA Boston Healthcare SystemBoston, MA, United States","Alosco, M.L., Memory Disorders Research Center, VA Boston Healthcare System and Boston University School of MedicineBoston, MA, United States, Department of Psychological Sciences, Kent State UniversityKent, OH, United States; Hayes, S.M., Memory Disorders Research Center, VA Boston Healthcare System and Boston University School of MedicineBoston, MA, United States, Neuroimaging Research for Veterans Center, VA Boston Healthcare SystemBoston, MA, United States","Cardiovascular disease is a recognized contributor to the pathogenesis of Alzheimer’s disease (AD). Heart failure (HF) is a cardiovascular subtype that can be used to model the contribution of cardiovascular disease to AD. Neuroimaging research indicates that HF patients exhibit a diverse range of structural brain alterations and epidemiological studies suggest HF may be an important risk factor for AD. The neural alterations observed in HF may overlap with those observed in AD and contribute to increased risk of AD in HF patients. To examine this possibility, we reviewed structural MRI studies in persons with HF. We examined subcortical brain regions affected in the early stages of AD (medial temporal lobes), as well as cortical alterations that typically occur in the later stages of AD. Our review indicates that patients with HF exhibit greater neural atrophy and white matter microstructural alterations of nearly every region of the Papez circuit (e.g., hippocampus, cingulate gyrus, thalamus, mammillary bodies, and fornix), as well-significant alterations in cortical and cerebellar regions. Based on animal research and past work in AD patients, the mechanisms for structural brain changes in HF may stem from reductions in cerebral blood flow subsequent to cardiac deficiency. This review supports the hypothesis that HF may contribute to AD risk via widespread structural brain changes, including many of the same regions affected by AD. Case-controlled prospective neuroimaging studies with long-term follow-ups are needed to clarify the risk of AD in HF and elucidate the neural underpinnings of AD risk in HF. © 2015 Springer Science+Business Media New York (outside the USA)","Alzheimer’s disease; Cerebrovascular disease; DTI; Heart failure; Medial temporal lobe; MRI",,Article in Press,Scopus,2-s2.0-84928150276
"Liu J., Li M., Lu H., Qiao W., Xi D., Luo T.T., Xiong H., Guo Z.","Effects of probucol on restenosis after percutaneous coronary intervention a systematic review and meta-analysis",2015,"PLoS ONE","10","4", e0124021,"","",,,10.1371/journal.pone.0124021,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928571271&partnerID=40&md5=cdd49d78bf6a145aa613c2dde35f9378","Division of Cardiology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China; Department of Gastroenterology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China","Liu, J., Division of Cardiology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China; Li, M., Division of Cardiology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China; Lu, H., Division of Cardiology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China; Qiao, W., Department of Gastroenterology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China; Xi, D., Division of Cardiology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China; Luo, T.T., Division of Cardiology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China; Xiong, H., Division of Cardiology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China; Guo, Z., Division of Cardiology, Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China","Background: Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent-implantation is controversial. So this meta-analysis was conducted to investigate the association between probucol and late restenosis. Methods: Articles were assessed by four trained investigators, with divergences resolved by consensus. PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trials were searched for pertinent studies. Inclusion criteria were random allocated to treatment and a comparison of probucol-treated patients and control patients (not treated with lipid-lowering drug) undergoing PCI. Results: Fifteen studies with 859 subjects were analyzed. Major outcome, binary angiographic restenosis defined as >50% stenosis upon follow-up angiography, was significantly decreased with probucol treatment (RR = 0.59 [0.43, 0.80] among vessels, P = 0.0007; and RR = 0.52 [0.40, 0.68] among patients, P<0.00001). Probucol also increased the minimal luminal diameter (SMD = 0.45 [0.30, 0.61], P< 0.00001) and decreased late loss upon follow-up after 6 months (SMD = -0.41 [-0.60, -0.22], P<0.0001). Moreover, there was a significantly lower incidence of major adverse cardiac events (MACE) in the probucol group than control group (RR = 0.69 [0.51, 0.93], P = 0.01). Conclusion: Probucol is more than a lipid-lowering drug. It is also effective in reducing the risk of restenosis and incidence of MACE after PCI. © 2015 Liu et al.",,"Fanelli, C., Aronoff, R., Restenosis following coronary angioplasty (1990) Am Heart J, 119, pp. 357-368; Califf, R.M., Fortin, D.F., Frid, D.J., Harlan, W.R., 3rd, Ohman, E.M., Bengtson, J.R., Restenosis after coronary angioplasty: An overview (1991) J Am Coll Cardiol, 17, pp. 2B-13B; Serruys, P.W., De Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease (1994) N Engl J Med, 331, pp. 489-495. , Benestent Study Group PMID: 8041413; Fischman, D.L., Leon, M.B., Baim, D.S., Schatz, R.A., Savage, M.P., Penn, I., A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators (1994) N Engl J Med, 331, pp. 496-501. , PMID: 8041414; Mintz, G.S., Popma, J.J., Pichard, A.D., Kent, K.M., Satler, L.F., Wong, C., Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study (1996) Circulation, 94, pp. 35-43; Pratt, R.E., Dzau, V.J., Pharmacological strategies to prevent restenosis: Lessons learned from blockade of the renin-angiotensin system (1996) Circulation, 93, pp. 848-852. , PMID: 8598073; Grewe, P.H., Deneke, T., Machraoui, A., Barmeyer, J., Muller, K.M., Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen (2000) J Am Coll Cardiol, 35, pp. 157-163; Hoffmann, R., Mintz, G.S., Dussaillant, G.R., Popma, J.J., Pichard, A.D., Satler, L.F., Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study (1996) Circulation, 94, pp. 1247-1254. , PMID: 8822976; Schneider, J.E., Berk, B.C., Gravanis, M.B., Santoian, E.C., Cipolla, G.D., Tarazona, N., Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis (1993) Circulation, 88, pp. 628-637. , PMID: 8339427; Ferns, G.A., Forster, L., Stewart-Lee, A., Nourooz-Zadeh, J., Anggard, E.E., Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit (1993) Atherosclerosis, 100, pp. 171-181. , PMID: 8357349; Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (2009) J Clin Epidemiol, 62, pp. 1006-1012. , PMID: 19631508; Bradburn, M.J., Deeks, J.J., Berlin, J.A., Russell Localio, A., Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events (2007) Stat Med, 26, pp. 53-77. , PMID: 16596572; Thompson, S.G., Sharp, S.J., Explaining heterogeneity in meta-analysis: A comparison of methods (1999) Stat Med, 18, pp. 2693-2708. , PMID: 10521860; Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses (2003) BMJ, 327, pp. 557-560. , PMID: 12958120; Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test (1997) BMJ, 315, pp. 629-634. , PMID: 9310563; Setsuda, M., Inden, M., Hiraoka, N., Okamoto, S., Tanaka, H., Okinaka, T., Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty (1993) Clin Ther, 15, pp. 374-382. , PMID: 8519045; Watanabe, K., Sekiya, M., Ikeda, S., Miyagawa, M., Hashida, K., Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty (1996) American Heart Journal, 132, pp. 23-29. , PMID: 8701872; Tardif, J.C., Cote, G., Lesperance, J., Bourassa, M., Lambert, J., Doucet, S., Probucol and multivitamins in the prevention of restenosis after coronary angioplasty (1997) N Engl J Med, 337, pp. 365-372. , Multivitamins and Probucol Study Group; Yokoi, H., Daida, H., Kuwabara, Y., Nishikawa, H., Takatsu, F., Tomihara, H., Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial (PART) (1997) J Am Coll Cardiol, 30, pp. 855-862; Sekiya, M., Funada, J., Watanabe, K., Miyagawa, M., Akutsu, H., Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis (1998) American Journal of Cardiology, 82, pp. 144-147; Kim, M.H., Cha, K.S., Han, J.Y., Kim, H.J., Kim, J.S., Effect of antioxidant probucol for preventing stent restenosis (2002) Catheter Cardiovasc Interv, 57, pp. 424-428. , PMID: 12455074; Tardif, J.C., Gregoire, J., Schwartz, L., Title, L., Laramee, L., Reeves, F., Effects of AGI-1067 and probucol after percutaneous coronary interventions (2003) Circulation, 107, pp. 552-558. , PMID: 12566365; Wakeyama, T., Ogawa, H., Iida, H., Takaki, A., Iwami, T., Mochizuki, M., Effects of candesartan and probucol on restenosis after coronary stenting: Results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial (2003) Circ J, 67, pp. 519-524. , PMID: 12808270; Kaminnyi, A.I., Lankin, V.Z., Samko, A.N., Sozykin, A.L., Provatorov, S.I., Konovalova, G.G., Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplasty (2005) Bull Exp Biol Med, 139, pp. 183-185. , PMID: 16027801; Nunes, G.L., Abizaid, A.C., Theodoro, M.P., Brito, F.S., Jr., Caixeta, A., Da Silva, L.F., Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: A randomized study (2006) Am Heart J, 152, pp. 914.e911-914.e917. , PMID: 17070157; Kuntz, R.E., Baim, D.S., Defining coronary restenosis. Newer clinical and angiographic paradigms (1993) Circulation, 88, pp. 1310-1323. , PMID: 8353892; Dussaillant, G.R., Mintz, G.S., Pichard, A.D., Kent, K.M., Satler, L.F., Popma, J.J., Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis (1995) J Am Coll Cardiol, 26, pp. 720-724; Moreno, R., Fernandez, C., Alfonso, F., Hernandez, R., Perez-Vizcayno, M.J., Escaned, J., Coronary stenting versus balloon angioplasty in small vessels: A meta-analysis from 11 randomized studies (2004) J Am Coll Cardiol, 43, pp. 1964-1972; Lau, A.K., Leichtweis, S.B., Hume, P., Mashima, R., Hou, J.Y., Chaufour, X., Probucol promotes functional reendothelialization in balloon-injured rabbit aortas (2003) Circulation, 107, pp. 2031-2036. , PMID: 12681995; Wu, B.J., Kathir, K., Witting, P.K., Beck, K., Choy, K., Li, C., Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging (2006) J Exp Med, 203, pp. 1117-1127. , PMID: 16606673; Deng, Y.M., Wu, B.J., Witting, P.K., Stocker, R., Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1 (2004) Circulation, 110, pp. 1855-1860; Keaney, J.F., Jr., Xu, A., Cunningham, D., Jackson, T., Frei, B., Vita, J.A., Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation (1995) J Clin Invest, 95, pp. 2520-2529. , PMID: 7769097; Tagawa, T., Urabe, Y., Kimura, Y., Suzuki, S., Ono, H., Takeda, K., Long-term treatment with probucol improves endothelial function in patients with coronary artery disease (2004) Hypertens Res, 27, pp. 311-318. , PMID: 15198477; Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST) (2002) J Am Coll Cardiol, 39, pp. 610-616; Drash, A.L., Rudert, W.A., Borquaye, S., Wang, R., Lieberman, I., Effect of probucol on development of diabetes mellitus in BB rats (1988) Am J Cardiol, 62, pp. 27B-30B. , PMID: 3394650; Gorogawa, S., Kajimoto, Y., Umayahara, Y., Kaneto, H., Watada, H., Kuroda, A., Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes (2002) Diabetes Res Clin Pract, 57, pp. 1-10; Reinoehl, J., Frankovich, D., Machado, C., Kawasaki, R., Baga, J.J., Pires, L.A., Probucol-associated tachyarrhythmic events and QT prolongation: Importance of gender (1996) Am Heart J, 131, pp. 1184-1191. , PMID: 8644599; Tan, Y., Liu, T.R., Hu, S.W., Tian, D., Li, C., Zhong, J.K., Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions (2014) PLoS One, 9, p. e94264. , PMID: 24736723; Guo, Z.G., Li, C., Zhong, J.K., Tu, Y., Xie, D., Laboratory investigation of dysfunctional HDL (2012) Chem Phys Lipids, 165, pp. 32-37. , PMID: 22064068; Zhong, J.K., Guo, Z.G., Li, C., Wang, Z.K., Lai, W.Y., Tu, Y., Probucol alleviates atherosclerosis and improves high density lipoprotein function (2011) Lipids Health Dis, 10, p. 210. , PMID: 22078494; Franceschini, G., Sirtori, M., Vaccarino, V., Gianfranceschi, G., Rezzonico, L., Chiesa, G., Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer (1989) Arteriosclerosis, 9, pp. 462-469. , PMID: 2751476; Yamamoto, S., Tanigawa, H., Li, X., Komaru, Y., Billheimer, J.T., Rader, D.J., Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport (2011) Circulation, 124, pp. 1382-1390. , PMID: 21859969; Li, S., Liang, J., Niimi, M., Bilal Waqar, A., Kang, D., Koike, T., Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits (2014) J Atheroscler Thromb, 21, pp. 648-658. , PMID: 24584175; Li, J.F., Chen, S., Feng, J.D., Zhang, M.Y., Liu, X.X., Probucol via inhibition of NHE1 attenuates LPS-accelerated atherosclerosis and promotes plaque stability in vivo (2014) Exp Mol Pathol, 96, pp. 250-256. , PMID: 24594116; Sundell, C.L., Somers, P.K., Meng, C.Q., Hoong, L.K., Suen, K.L., Hill, R.R., AGI-1067: A multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent (2003) J Pharmacol Exp Ther, 305, pp. 1116-1123. , PMID: 12626663; Kunsch, C., Luchoomun, J., Grey, J.Y., Olliff, L.K., Saint, L.B., Arrendale, R.F., Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: A novel antioxidant and anti-inflammatory agent (2004) J Pharmacol Exp Ther, 308, pp. 820-829. , PMID: 14617690; Tardif, J.C., McMurray, J.J., Klug, E., Small, R., Schumi, J., Choi, J., Effects of succinobucol (AGI-1067) after an acute coronary syndrome: A randomised, double-blind, placebo-controlled trial (2008) Lancet, 371, pp. 1761-1768. , PMID: 18502300; Byrne, R.A., Mehilli, J., Iijima, R., Schulz, S., Pache, J., Seyfarth, M., A polymer-free dual drug-eluting stent in patients with coronary artery disease: A randomized trial vs. polymer-based drug-eluting stents (2009) Eur Heart J, 30, pp. 923-931. , PMID: 19240066; Massberg, S., Byrne, R.A., Kastrati, A., Schulz, S., Pache, J., Hausleiter, J., Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: The Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial (2011) Circulation, 124, pp. 624-632. , PMID: 21768546; Mak, K.H., Belli, G., Ellis, S.G., Moliterno, D.J., Subacute stent thrombosis: Evolving issues and current concepts (1996) J Am Coll Cardiol, 27, pp. 494-503. , PMID: 8557927; Rodes, J., Cote, G., Lesperance, J., Bourassa, M.G., Doucet, S., Bilodeau, L., Prevention of restenosis after angioplasty in small coronary arteries with probucol (1998) Circulation, 97, pp. 429-436. , PMID: 9490236; Daida, H., Kuwabara, Y., Yokoi, H., Nishikawa, H., Takatsu, F., Nakata, Y., Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]) (2000) Am J Cardiol, 86, pp. 550-552+A559. , PMID: 11009277; Kasai, T., Miyauchi, K., Kubota, N., Kajimoto, K., Amano, A., Daida, H., Probucol therapy improves long-term (>10-year) survival after complete revascularization: A propensity analysis (2012) Atherosclerosis, 220, pp. 463-469. , PMID: 22024277",Article,Scopus,2-s2.0-84928571271
"Seo K., Kitazawa T., Yoshino Y., Koga I., Ota Y.","Characteristics of serum endocan levels in infection",2015,"PLoS ONE","10","4", e0123358,"","",,,10.1371/journal.pone.0123358,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928473362&partnerID=40&md5=8723f3538be18a8a74e2a536b367e0a4","Department of Internal Medicine, Teikyo UniversityTokyo, Japan","Seo, K., Department of Internal Medicine, Teikyo UniversityTokyo, Japan; Kitazawa, T., Department of Internal Medicine, Teikyo UniversityTokyo, Japan; Yoshino, Y., Department of Internal Medicine, Teikyo UniversityTokyo, Japan; Koga, I., Department of Internal Medicine, Teikyo UniversityTokyo, Japan; Ota, Y., Department of Internal Medicine, Teikyo UniversityTokyo, Japan","Objectives: Endocan is a newly recognized biomarker of sepsis. However, there have been no studies of the trends in endocan levels during infection and their associations with other clinical factors. The aim of this study was to assess the time course of endocan levels and the associations of endocan with clinical factors during infection by comparison with other biomarkers. Methods: Serum samples and blood cultures were obtained from patients who were diagnosed with infection from June 2013 to March 2014. Serum endocan, C-reactive protein (CRP), and procalcitonin (PCT) levels during four periods during infection were measured (day 0, day 1-2, day 3-5, and day 6-10). Results: A total of 78 patients were enrolled in this study. The median endocan level decreased by only 23% during infection, whereas both serum CRP and PCT levels decreased by more than 80%. Endocan levels were correlated to neither CRP levels nor PCT levels in each period. Endocan levels at day 0 in patients with bacteremia were higher than those without bacteremia (1.09 ng/mL vs 0.82 ng/mL, P=0.002), but neither CRP levels nor PCT levels at day 0 were different between the two groups. Areas under the receiver operator characteristic (ROC) curves of endocan, CRP, and PCT at day 0 were 0.662, 0.343, and 0.563, respectively. Positive blood cultures tended to be related to high endocan levels, but not significantly (odds ratio: 4.24, 95% CI: 0.99-10.34, P=0.05). Conclusions: In bacteremic cases, serum endocan levels in bacteremia tended to be higher than in non-bacteremic cases. Although endocan level was not identified as a prognostic factor of bacteremia, further prospective study concerning the relationship between serum endocan level and bacteremia would be needed. © 2015 Seo et al.",,"Mathevon, T., Souweine, B., Traore, O., Aublet, B., Caillaud, D., ICU-acquired nosocomial infection: Impact of delay of adequate antibiotic treatment (2002) Scand J Infect Dis, 34, pp. 831-835. , PMID: 12578154; Bates, D.W., Sands, K., Miller, E., Lanken, P.N., Hibberd, P.L., Graman, P.S., Predicting bacteremia in patients with sepsis syndrome (1997) J Infect Dis, 176, pp. 1538-1551. , Academic Medical Center Consortium Sepsis Project Working Group. PMID: 9395366; Luzzani, A., Polati, E., Dorizzi, R., Rungatscher, A., Pavan, R., Merlini, A., Comparison of procalcitonin and C-reactive protein as markers of sepsis (2003) Crit Care Med, 31, pp. 1737-1741. , PMID: 12794413; Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M., Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock (2012) Crit Care Med, 41, pp. 580-637. , PMID: 23353941; Bechard, D., Gentina, T., Delehedde, M., Scherpereel, A., Lyon, M., Aumercier, M., Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity (2001) J Biol Chem, 276, pp. 48341-48349. , PMID: 11590178; Maurage, C.A., Adam, E., Mineo, J.F., Sarrazin, S., Debunne, M., Siminski, R.M., Endocan expression and localization in human glioblastomas (2009) J Neuropathol Exp Neurol, 68, pp. 633-641. , PMID: 19458546; Grigoriu, B.D., Depontieu, F., Scherpereel, A., Gourcerol, D., Devos, P., Ouatas, T., Endocan expression and relationship with survival in human non-small cell lung cancer (2006) Clin Cancer Res, 12, pp. 4575-4582. , PMID: 16899604; Chen, L.Y., Liu, X., Wang, S.L., Qin, C.Y., Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion J Int Med Res, 38, pp. 498-510. , PMID: 20515564; Kim, J.H., Park, M.Y., Kim, C.N., Kim, K.H., Kang, H.B., Kim, K.D., Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1alpha in human colon carcinoma: Impact of ESM-1 on prognosis and its correlation with clinicopathological features Oncol Rep, 28, pp. 1701-1708. , PMID: 22948784; Leroy, X., Aubert, S., Zini, L., Franquet, H., Kervoaze, G., Villers, A., Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma Histopathology, 56, pp. 180-187. , PMID: 20102396; Roudnicky, F., Poyet, C., Wild, P., Krampitz, S., Negrini, F., Huggenberger, R., Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis Cancer Res, 73, pp. 1097-1106. , PMID: 23243026; El Behery, M.M., Seksaka, M.A., Ibrahiem, M.A., Saleh, H.S., El Alfy, Y., Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer Arch Gynecol Obstet, 288, pp. 1371-1376. , PMID: 23708323; Bechard, D., Meignin, V., Scherpereel, A., Oudin, S., Kervoaze, G., Bertheau, P., Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies (2000) J Vasc Res, 37, pp. 417-425. , PMID: 11025405; Lassalle, P., Molet, S., Janin, A., Heyden, J.V., Tavernier, J., Fiers, W., ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines (1996) J Biol Chem, 271, pp. 20458-20464. , PMID: 8702785; Scherpereel, A., Depontieu, F., Grigoriu, B., Cavestri, B., Tsicopoulos, A., Gentina, T., Endocan, a new endothelial marker in human sepsis (2006) Crit Care Med, 34, pp. 532-537. , PMID: 16424738; Hohn, A., Schroeder, S., Gehrt, A., Bernhardt, K., Bein, B., Wegscheider, K., Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock BMC Infect Dis, 13, p. 158. , PMID: 23547790; Hatfield, K.J., Lassalle, P., Leiva, R.A., Lindas, R., Wendelboe, O., Bruserud, O., Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia Hematology, 16, pp. 351-356. , PMID: 22183069; Voiosu, T., Balanescu, P., Bengus, A., Voiosu, A., Baicus, C.R., Barbu, M., Serum endocan levels are increased in patients with inflammatory bowel disease Clin Lab, 60, pp. 505-510. , PMID: 24697130; Mikkelsen, M.E., Shah, C.V., Scherpereel, A., Lanken, P.N., Lassalle, P., Bellamy, S.L., Lower serum endocan levels are associated with the development of acute lung injury after major trauma J Crit Care, 27, pp. 522e511-527e511; Tang, L., Zhao, Y., Wang, D., Deng, W., Li, C., Li, Q., Endocan levels in peripheral blood predict outcomes of acute respiratory distress syndrome (2014) Mediators Inflamm, p. 625180. , PMID: 25132734; Su, Y.H., Shu, K.H., Hu, C.P., Cheng, C.H., Wu, M.J., Yu, T.M., Serum Endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients Transplant Proc, 46, pp. 323-327. , PMID: 24655954; Hurlimann, J., Thorbecke, G.J., Hochwald, G.M., The liver as the site of C-reactive protein formation (1966) J Exp Med, 123, pp. 365-378. , PMID: 4379352; Meisner, M., Pathobiochemistry and clinical use of procalcitonin (2002) Clin Chim Acta, 323, pp. 17-29. , PMID: 12135804; Liaudat, S., Dayer, E., Praz, G., Bille, J., Troillet, N., Usefulness of procalcitonin serum level for the diagnosis of bacteremia (2001) Eur J Clin Microbiol Infect Dis, 20, pp. 524-527. , PMID: 11681430; Hoenigl, M., Raggam, R.B., Wagner, J., Prueller, F., Grisold, A.J., Leitner, E., Procalcitonin fails to predict bacteremia in SIRS patients: A cohort study Int J Clin Pract; Sarrazin, S., Adam, E., Lyon, M., Depontieu, F., Motte, V., Landolfi, C., Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy (2006) Biochim Biophys Acta, 1765, pp. 25-37. , PMID: 16168566; Lee, W., Ku, S.K., Kim, S.W., Bae, J.S., Endocan elicits severe vascular inflammatory responses in vitro and in vivo J Cell Physiol, 229, pp. 620-630. , PMID: 24446198; Trinchet, J.C., Hornstein, M., Jupeau, A., Beaugrand, M., Hecht, Y., Ferrier, J.P., Do latent bacteremia and endotoxinemia exist in cirrhotics? A study of 48 patients (1983) Gastroenterol Clin Biol, 7, pp. 518-522. , PMID: 6873564",Article,Scopus,2-s2.0-84928473362
"Tang W.-H., Wang C.-P., Chung F.-M., Huang L.L.H., Yu T.-H., Hung W.-C., Lu L.-F., Chen P.-Y., Luo C.-H., Lee K.-T., Lee Y.-J., Lai W.-T.","Uremic retention solute indoxyl sulfate level Is associated with prolonged QTc interval in early CKD patients",2015,"PLoS ONE","10","4", e0119545,"","",,,10.1371/journal.pone.0119545,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928540960&partnerID=40&md5=4c6be06905256a596e376f0441b27ef6","Graduate Institute of Medicine, Collage of Medicine, Kaohsiung Medical UniversityKaohsiung, Taiwan; Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University HospitalKaohsiung, Taiwan; Division of Cardiology, Department of Internal Medicine, I-Shou UniversityKaohsiung, Taiwan; Institute of Biotechnology, National Cheng Kung UniversityTainan, Taiwan; Division of Cardiac Surgery, Department of Surgery, IShou UniversityKaohsiung, Taiwan; Institute of Electric Engineering, National Cheng-Kung UniversityTainan, Taiwan; Lee's Endocrinologic ClinicPingtung, Taiwan","Tang, W.-H., Graduate Institute of Medicine, Collage of Medicine, Kaohsiung Medical UniversityKaohsiung, Taiwan, Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University HospitalKaohsiung, Taiwan; Wang, C.-P., Division of Cardiology, Department of Internal Medicine, I-Shou UniversityKaohsiung, Taiwan; Chung, F.-M., Division of Cardiology, Department of Internal Medicine, I-Shou UniversityKaohsiung, Taiwan; Huang, L.L.H., Institute of Biotechnology, National Cheng Kung UniversityTainan, Taiwan; Yu, T.-H., Division of Cardiology, Department of Internal Medicine, I-Shou UniversityKaohsiung, Taiwan; Hung, W.-C., Division of Cardiology, Department of Internal Medicine, I-Shou UniversityKaohsiung, Taiwan; Lu, L.-F., Division of Cardiac Surgery, Department of Surgery, IShou UniversityKaohsiung, Taiwan; Chen, P.-Y., Institute of Electric Engineering, National Cheng-Kung UniversityTainan, Taiwan; Luo, C.-H., Institute of Electric Engineering, National Cheng-Kung UniversityTainan, Taiwan; Lee, K.-T., Graduate Institute of Medicine, Collage of Medicine, Kaohsiung Medical UniversityKaohsiung, Taiwan, Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University HospitalKaohsiung, Taiwan; Lee, Y.-J., Lee's Endocrinologic ClinicPingtung, Taiwan; Lai, W.-T., Graduate Institute of Medicine, Collage of Medicine, Kaohsiung Medical UniversityKaohsiung, Taiwan, Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University HospitalKaohsiung, Taiwan","Total mortality and sudden cardiac death is highly prevalent in patients with chronic kidney disease (CKD). In CKD patients, the protein-bound uremic retention solute indoxyl sulfate (IS) is independently associated with cardiovascular disease. However, the underlying mechanisms of this association have yet to be elucidated. The relationship between IS and cardiac electrocardiographic parameters was investigated in a prospective observational study among early CKD patients. IS arrhythmogenic effect was evaluated by in vitro cardiomyocyte electrophysiological study and mathematical computer simulation. In a cohort of 100 early CKD patients, patients with corrected QT (QTc) prolongation had higher IS levels. Furthermore, serum IS level was independently associated with prolonged QTc interval. In vitro, the delay rectifier potassium current (IK) was found to be significantly decreased after the treatment of IS in a dose-dependent manner. The modulation of IS to the IK was through the regulation of the major potassium ion channel protein Kv 2.1 phosphorylation. In a computer simulation, the decrease of IK by IS could prolong the action potential duration (APD) and induce early afterdepolarization, which is known to be a trigger mechanism of lethal ventricular arrhythmias. In conclusion, serum IS level is independently associated with the prolonged QTc interval in early CKD patients. IS down-regulated I<inf>K</inf> channel protein phosphorylation and the I<inf>K</inf> current activity that in turn increased the cardiomyocyte APD and QTc interval in vitro and in the computer ORd model. These findings suggest that IS may play a role in the development of arrhythmogenesis in CKD patients. © 2015 Tang et al.",,"Genovesi, S., Rossi, E., Nava, M., Riva, H., De Franceschi, S., Fabbrini, P., A case series of chronic haemodialysis patients: Mortality, sudden death, and QT interval (2013) Europace, 15, pp. 1025-1033. , PMID: 23284142; Straus, S.M., Kors, J.A., De Bruin, M.L., Van Der Hooft, C.S., Hofman, A., Heeringa, J., Prolonged QTc interval and risk of sudden cardiac death in a population of older adults (2006) J Am Coll Cardiol, 47, pp. 362-367. , PMID: 16412861; Shamseddin, M.K., Parfrey, P.S., Sudden cardiac death in chronic kidney disease: Epidemiology and prevention (2011) Nat Rev Nephrol, 7, pp. 145-154. , PMID: 21283136; Hoffman, B.F., Guo, S.D., Feinmark, S.J., Arrhythmias caused by platelet activating factor (1996) J Cardiovasc Electrophysiol, 7, pp. 120-133. , PMID: 8853022; Hoffman, B.F., Feinmark, S.J., Guo, S.D., Electrophysiologic effects of interactions between activated canine neutrophils and cardiac myocytes (1997) J Cardiovasc Electrophysiol, 8, pp. 679-687. , PMID: 9209969; Aoyama, I., Shimokata, K., Niwa, T., An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats (2002) Nephron, 92, pp. 635-651. , PMID: 12372949; Motojima, M., Hosokawa, A., Yamato, H., Muraki, T., Yoshioka, T., Uremic toxins of organic anions upregulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells (2003) Kidney Int, 63, pp. 1671-1680. , PMID: 12675842; Lee, C.T., Kuo, C.C., Chen, Y.M., Hsu, C.Y., Lee, W.C., Tsai, Y.C., Factors associated with blood concentrations of indoxyl sulfate and p-cresol in patients undergoing peritoneal dialysis (2010) Perit Dial Int, 30, pp. 456-463. , PMID: 20338972; Ito, S., Higuchi, Y., Yagi, Y., Nishijima, F., Yamato, H., Ishii, H., Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease (2013) J Leukoc Biol, 93, pp. 837-845. , PMID: 23362306; Chiu, C.A., Lu, L.F., Yu, T.H., Hung, W.C., Chung, F.M., Tsai, I.T., Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy (2010) Rev Diabet Stud, 7, pp. 275-284. , PMID: 21713315; Hsu, C.C., Lu, Y.C., Chiu, C.A., Yu, T.H., Hung, W.C., Wang, C.P., Levels of indoxyl sulfate are associated with severity of coronary atherosclerosis (2013) Clin Invest Med, 36, pp. E42-E49. , PMID: 23374599; Noble, D., Tsien, R.W., Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibres (1969) J Physiol, 200, pp. 205-231. , PMID: 5761944; Carmeliet, E., K + channels and control of ventricular repolarization in the heart (1993) Fundam Clin Pharmacol, 7, pp. 19-28. , PMID: 8458599; Nattel, S., Maguy, A., Le Bouter, S., Yeh, Y.H., Arrhythmogenic ion-channel remodeling in the heart: Heart failure, myocardial infarction, and atrial fibrillation (2007) Physiol Rev, 87, pp. 425-456. , PMID: 17429037; Kannankeril, P., Roden, D.M., Darbar, D., Drug-induced long QT syndrome (2010) Pharmacol Rev, 62, pp. 760-781. , PMID: 21079043; Levey, A.S., Coresh, J., Greene, T., Stevens, L.A., Zhang, Y.L., Hendriksen, S., Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate (2006) Ann Intern Med, 145, pp. 247-254. , PMID: 16908915; Wang, C.P., Lu, L.F., Yu, T.H., Hung, W.C., Chiu, C.A., Chung, F.M., Associations among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events (2013) J Nephrol, 26, pp. 111-118. , PMID: 22460182; Wang, C.P., Lu, L.F., Yu, T.H., Hung, W.C., Chiu, C.A., Chung, F.M., Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure (2010) Atherosclerosis, 211, pp. 579-583. , PMID: 20427046; Magnani, J.W., Wang, N., Nelson, K.P., Connelly, S., Deo, R., Rodondi, N., Electrocardiographic PR interval and adverse outcomes in older adults: The Health, Aging, and Body Composition study (2013) Circ Arrhythm Electrophysiol, 6, pp. 84-90. , PMID: 23243193; Malik, M., Hnatkova, K., Batchvarov, V., Gang, Y., Smetana, P., Camm, A.J., Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation (2004) Pacing Clin Electrophysiol, 27, pp. 1659-1669. , PMID: 15613131; Salvi, V., Karnad, D.R., Panicker, G.K., Natekar, M., Hingorani, P., Kerkar, V., Comparison of 5 methods of QT interval measurements on electrocardiograms from a thorough QT/QTc study: Effect on assay sensitivity and categorical outliers (2011) J Electrocardiol, 44, pp. 96-104. , PMID: 21238976; Rautaharju, P.M., Surawicz, B., Gettes, L.S., Bailey, J.J., Childers, R., Deal, B.J., AHA/ACCF/ HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U waves, and the QT interval: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society (2009) J Am Coll Cardiol, 53, pp. 982-991. , Endorsed by the International Society for Computerized Electrocardiology PMID: 19281931; Wang, W., Hino, N., Yamasaki, H., Aoki, T., Ochi, R., KV2.1 K+ channels underlie major voltage-gated K+ outward current in H9c2 myoblasts (2002) Jpn J Physiol, 52, pp. 507-514. , PMID: 12617756; Lekawanvijit, S., Adrahtas, A., Kelly, D.J., Kompa, A.R., Wang, B.H., Krum, H., Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? (2010) Eur Heart J, 31, pp. 1771-1779. , PMID: 20047993; Meijers, B.K., Van Kerckhoven, S., Verbeke, K., Dehaen, W., Vanrenterghem, Y., Hoylaerts, M.F., The uremic retention solute p-cresyl sulfate and markers of endothelial damage (2009) Am J Kidney Dis, 54, pp. 891-901. , PMID: 19615803; Murakoshi, H., Shi, G., Scannevin, R.H., Trimmer, J.S., Phosphorylation of the Kv2.1 K+ channel alters voltage-dependent activation (1997) Mol Pharmacol, 52, pp. 821-828. , PMID: 9351973; Ito, T., Nuriya, M., Yasui, M., Regulation of Kv2.1 phosphorylation in an animal model of anoxia (2010) Neurobiol Dis, 38, pp. 85-91. , PMID: 20079839; Hamill, O.P., Marty, A., Neher, E., Sakmann, B., Sigworth, F.J., Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches (1981) Pflugers Arch, 391, pp. 85-100. , PMID: 6270629; Lee, K.T., Tang, P.W., Tsai, W.C., Liu, I.H., Yen, H.W., Voon, W.C., Differential effects of central and peripheral fat tissues on the delayed rectifier k outward currents in cardiac myocytes (2013) Cardiology, 125, pp. 118-124. , PMID: 23711914; O'Hara, T., Virag, L., Varro, A., Rudy, Y., Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation (2011) PLoS Comput Biol, 7, p. e1002061. , PMID: 21637795; Zagotta, W.N., Hoshi, T., Aldrich, R.W., Shaker potassium channel gating. III: Evaluation of kinetic models for activation (1994) J Gen Physiol, 103, pp. 321-362. , PMID: 8189208; Gima, K., Rudy, Y., Ionic current basis of electrocardiographic waveforms: A model study (2002) Circ Res, 90, pp. 889-896. , PMID: 11988490; Rush, S., Larsen, H., A practical algorithm for solving dynamic membrane equations (1978) IEEE Trans Biomed Eng, 25, pp. 389-392. , PMID: 689699; Covic, A., Diaconita, M., Gusbeth-Tatomir, P., Covic, M., Botezan, A., Ungureanu, G., Haemodialysis increases QT(c) interval but not QT(c) dispersion in ESRD patients without manifest cardiac disease (2002) Nephrol Dial Transplant, 17, pp. 2170-2177. , PMID: 12454229; Ronco, C., Haapio, M., House, A.A., Anavekar, N., Bellomo, R., Cardiorenal syndrome (2008) J Am Coll Cardiol, 52, pp. 1527-1539. , PMID: 19007588; Faure, V., Dou, L., Sabatier, F., Cerini, C., Sampol, J., Berland, Y., Elevation of circulating endothelial microparticles in patients with chronic renal failure (2006) J Thromb Haemost, 4, pp. 566-573. , PMID: 16405517; Yamamoto, H., Tsuruoka, S., Ioka, T., Ando, H., Ito, C., Akimoto, T., Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells (2006) Kidney Int, 69, pp. 1780-1785. , PMID: 16612331; Peng, Y.S., Lin, Y.T., Chen, Y., Hung, K.Y., Wang, S.M., Effects of indoxyl sulfate on adherens junctions of endothelial cells and the underlying signaling mechanism (2012) J Cell Biochem, 113, pp. 1034-1043. , PMID: 22213462; Barreto, F.C., Barreto, D.V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients (2009) Clin J Am Soc Nephrol, 4, pp. 1551-1558. , PMID: 19696217; Wu, I.W., Hsu, K.H., Lee, C.C., Sun, C.Y., Hsu, H.J., Tsai, C.J., p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease (2011) Nephrol Dial Transplant, 26, pp. 938-947. , PMID: 20884620; Atoh, K., Itoh, H., Haneda, M., Serum indoxyl sulfate levels in patients with diabetic nephropathy: Relation to renal function (2009) Diabetes Res Clin Pract, 83, pp. 220-226. , PMID: 19027976; National Kidney Foundation, K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification (2002) Am J Kidney Dis, 39, pp. S1-S266. , PMID: 11904577; Zhang, T., Yong, S.L., Drinko, J.K., Popović, Z.B., Shryock, J.C., Belardinelli, L., LQTS mutation N1325S in cardiac sodium channel gene SCN5A causes cardiomyocyte apoptosis, cardiac fibrosis and contractile dysfunction in mice (2011) Int J Cardiol, 147, pp. 239-245. , PMID: 19762097; Quan, X.Q., Bai, R., Liu, N., Chen, B.D., Zhang, C.T., Increasing gap junction coupling reduces transmural dispersion of repolarization and prevents torsade de pointes in rabbit LQT3 model (2007) J Cardiovasc Electrophysiol, 18, pp. 1184-1189. , PMID: 17711442; Rosenberger, D., Gargoum, R., Tyagi, N., Metreveli, N., Sen, U., Maldonado, C., Homocysteine enriched diet leads to prolonged QT interval and reduced left ventricular performance in telemetric monitored mice (2011) Nutr Metab Cardiovasc Dis, 21, pp. 492-498. , PMID: 20227264; Peng, Y.S., Lin, Y.T., Wang, S.D., Hung, K.Y., Chen, Y., Wang, S.M., P-cresol induces disruption of cardiomyocyte adherens junctions (2013) Toxicology, 306, pp. 176-184. , PMID: 23466501; Song, M.Y., Hong, C., Bae, S.H., So, I., Park, K.S., Dynamic modulation of the kv2.1 channel by SRC-dependent tyrosine phosphorylation (2012) J Proteome Res, 11, pp. 1018-1026. , PMID: 22106938; Park, K.S., Mohapatra, D.P., Misonou, H., Trimmer, J.S., Graded regulation of the Kv2.1 potassium channel by variable phosphorylation (2006) Science, 313, pp. 976-979. , PMID: 16917065; Walsh, K.B., Zhang, J., Neonatal rat cardiac fibroblasts express three types of voltage-gated K+ channels: Regulation of a transient outward current by protein kinase C (2008) Am J Physiol Heart Circ Physiol, 294, pp. H1010-H1017. , PMID: 18156198; Inoguchi, T., Sonta, T., Tsubouchi, H., Etoh, T., Kakimoto, M., Sonoda, N., Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: Role of vascular NAD(P)H oxidase (2003) J Am Soc Nephrol, 14, pp. S227-S232. , PMID: 12874436; Cain, B.S., Meldrum, D.R., Harken, A.H., Protein kinase C in normal and pathologic myocardial states (1999) J Surg Res, 81, pp. 249-259. , PMID: 9927548; Enomoto, A., Takeda, M., Tojo, A., Sekine, T., Cha, S.H., Khamdang, S., Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity (2002) J Am Soc Nephrol, 13, pp. 1711-1720. , PMID: 12089366; Zhang, Q., Hong, M., Duan, P., Pan, Z., Ma, J., You, G., Organic anion transporter OAT1 undergoes constitutive and protein kinase C-regulated trafficking through a dynamin- and clathrin-dependent pathway (2008) J Biol Chem, 283, pp. 32570-32579. , PMID: 18818201; Jourde-Chiche, N., Dou, L., Cerini, C., Dignat-George, F., Vanholder, R., Brunet, P., Protein-bound toxins-update 2009 (2009) Semin Dial, 22, pp. 334-339. , PMID: 19708977; Neirynck, N., Vanholder, R., Schepers, E., Eloot, S., Pletinck, A., Glorieux, G., An update on uremic toxins (2013) Int Urol Nephrol, 45, pp. 139-150. , PMID: 22893494; Lekawanvijit, S., Kompa, A.R., Manabe, M., Wang, B.H., Langham, R.G., Nishijima, F., Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate (2012) PLoS One, 7, p. e41281. , PMID: 22829936; Vanholder, R., De Smet, R., Glorieux, G., Argilés, A., Baurmeister, U., Brunet, P., Review on uremic toxins: Classification, concentration, and interindividual variability (2003) Kidney Int, 63, pp. 1934-1943. , PMID: 12675874",Article,Scopus,2-s2.0-84928540960
"Yamada A., Shiraishi Y., Miura H., Hashem H.M.O., Tsuboko Y., Yamagishi M., Yambe T.","Development of a thermodynamic control system for the Fontan circulation pulsation device using shape memory alloy fibers",2015,"Journal of Artificial Organs",,,,"","",7,,10.1007/s10047-015-0827-z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928138923&partnerID=40&md5=7768ecb4d91f69f483be4c09e7c605ea","Graduate School of Biomedical Engineering, Tohoku UniversitySendai, Japan; Department of Medical Engineering and Cardiology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo-machi 4-1, Aoba-kuSendai, Japan; Graduate School of Medicine, Tohoku UniversitySendai, Japan; Pediatric Cardiovascular Surgery, Kyoto Prefectural University of MedicineKyoto, Japan","Yamada, A., Graduate School of Biomedical Engineering, Tohoku UniversitySendai, Japan, Department of Medical Engineering and Cardiology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo-machi 4-1, Aoba-kuSendai, Japan; Shiraishi, Y., Department of Medical Engineering and Cardiology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo-machi 4-1, Aoba-kuSendai, Japan; Miura, H., Department of Medical Engineering and Cardiology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo-machi 4-1, Aoba-kuSendai, Japan; Hashem, H.M.O., Graduate School of Medicine, Tohoku UniversitySendai, Japan; Tsuboko, Y., Graduate School of Biomedical Engineering, Tohoku UniversitySendai, Japan; Yamagishi, M., Pediatric Cardiovascular Surgery, Kyoto Prefectural University of MedicineKyoto, Japan; Yambe, T., Graduate School of Biomedical Engineering, Tohoku UniversitySendai, Japan, Department of Medical Engineering and Cardiology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo-machi 4-1, Aoba-kuSendai, Japan","The Fontan procedure is one of the common surgical treatments for circulatory reconstruction in pediatric patients with congenital heart disease. In Fontan circulation, low pulsatility may induce localized lung ischemia and may impair the development of pulmonary peripheral endothelial cells. To promote pulmonary circulation in Fontan circulation, we have been developing a pediatric pulmonary circulatory pulsation device using shape memory alloy fibers attached from the outside of total cavopulmonary connection. In this study, we developed a new thermal control system for the device and examined its functions. We mounted on the device 16 fibers connected in parallel around an ePTFE graft circumferentially. To provide optimized contraction, we designed the new thermal control system. The system consisted of a thermistor, a pressure sensor, and a regulator that was controlled by the adaptive thermodynamic transfer functions. We monitored the parameters and calculated heat transfer function as well as pressure distribution on the graft surface. Then we examined and compared the dynamic contractile pressure and changes in surface temperature. As a result, by the application of the control based on the new feedback system analysis, the circumferential contractile pressure increased by 35 %. The adaptive thermodynamic regulation was useful for the selection of alternative thresholds of the surface temperature of the graft. The system could achieve effective contraction for the pulsatile flow generation by the device. © 2015 The Japanese Society for Artificial Organs","Congenital heart disease; Fontan circulation; Shape memory alloy fiber",,Article in Press,Scopus,2-s2.0-84928138923
"Kerst G., Moysich A., Ho S.Y., Apitz C., Latus H., Schranz D.","Transcatheter Closure of Perimembranous Ventricular Septal Defects with Left Ventricular to Right Atrial Shunt",2015,"Pediatric Cardiology",,,,"","",7,,10.1007/s00246-015-1170-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928128260&partnerID=40&md5=5089cf7859dd2fa2aa2c966cde512fd7","Department of Pediatric Cardiology, Pediatric Heart Center Giessen, University Children’s Hospital, Feulgenstr. 10-12Giessen, Germany; Cardiac Morphology Unit, Royal Brompton Hospital, Imperial College LondonLondon, United Kingdom","Kerst, G., Department of Pediatric Cardiology, Pediatric Heart Center Giessen, University Children’s Hospital, Feulgenstr. 10-12Giessen, Germany; Moysich, A., Department of Pediatric Cardiology, Pediatric Heart Center Giessen, University Children’s Hospital, Feulgenstr. 10-12Giessen, Germany; Ho, S.Y., Cardiac Morphology Unit, Royal Brompton Hospital, Imperial College LondonLondon, United Kingdom; Apitz, C., Department of Pediatric Cardiology, Pediatric Heart Center Giessen, University Children’s Hospital, Feulgenstr. 10-12Giessen, Germany; Latus, H., Department of Pediatric Cardiology, Pediatric Heart Center Giessen, University Children’s Hospital, Feulgenstr. 10-12Giessen, Germany; Schranz, D., Department of Pediatric Cardiology, Pediatric Heart Center Giessen, University Children’s Hospital, Feulgenstr. 10-12Giessen, Germany","During the development of so-called aneurysmal transformation of perimembranous ventricular septal defects (pmVSD), tricuspid valve (TV) morphology and function may be altered resulting in left ventricular (LV) to right atrial (RA) shunting. The feasibility and outcome of interventional closure of these pmVSD has not been investigated so far. Interventional closure of pmVSD associated with mild to moderate LV-to-RA shunt was performed in four patients (aged 6.5–12.5 years). pmVSD were closed under fluoroscopic guidance by establishing an arteriovenous wire loop via a femoral artery and advancing the delivery sheath from a femoral vein. Before device release (or withdrawal if necessary), residual shunting across the device and TV valve function was investigated by transthoracic echocardiography and LV angiography. pmVSD sizes of 4, 5.5, 8 and 8.5 mm were closed with a 4/4 and 6/6 Amplatzer duct occluder II and an 8- and 10-mm Amplatzer muscular VSD occluder device, respectively. There were no or only minor residual postinterventional LV-to-RA shunts. No atrioventricular blocks were observed during a mean follow-up of 12.5 months (range 6.5–17 months). Transthoracic echocardiography indicated that the elimination of the VSD jet pushing the antero-superior TV leaflet open is the key mechanism for LV-to-RA shunt reduction after transcatheter pmVSD closure. Interventional closure in pmVSD associated with mild to moderate indirect LV-to-RA shunting is feasible and results in significant reduction in or elimination of LV-to-RA shunting. © 2015 Springer Science+Business Media New York","Congenital heart disease; Gerbode defect; Interventional cardiology; Perimembranous ventricular septal defect",,Article in Press,Scopus,2-s2.0-84928128260
"Lubas A., Ryczek R., Kade G., Niemczyk S.","Renal perfusion index reflects cardiac systolic function in chronic cardio-renal syndrome",2015,"Medical Science Monitor","21",,,"1089","1096",,,10.12659/MSM.892630,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928156301&partnerID=40&md5=f4544bce7f8966470ed9eef7589ed96d","Department of Internal Diseases, Nephrology and Dialysis, Military Institute of MedicineWarsaw, Poland; Department of Cardiology and Internal Medicine, Military Institute of MedicineWarsaw, Poland","Lubas, A., Department of Internal Diseases, Nephrology and Dialysis, Military Institute of MedicineWarsaw, Poland; Ryczek, R., Department of Cardiology and Internal Medicine, Military Institute of MedicineWarsaw, Poland; Kade, G., Department of Internal Diseases, Nephrology and Dialysis, Military Institute of MedicineWarsaw, Poland; Niemczyk, S., Department of Internal Diseases, Nephrology and Dialysis, Military Institute of MedicineWarsaw, Poland","Background: Cardiac dysfunction can modify renal perfusion, which is crucial to maintain sufficient kidney tissue oxygenation. Renal cortex perfusion assessed by dynamic ultrasound method is related both to renal function and cardiac hemodynamics. The aim of the study was to test the hypothesis that Renal Perfusion Index (RPI) can more closely reflect cardiac hemodynamics and differentiate etiology of chronic cardio-renal syndrome. Material/Methods: Twenty-four patients with hypertension and chronic kidney disease (CKD) at 2–4 stage (12 with hypertensive nephropathy and 12 with CKD prior to hypertension) were enrolled in the study. Blood tests, 24-h ABPM, echocardiography, and ultrasonography with estimation of Total renal Cortical Perfusion intensity and Renal Perfusion Index (RPI) were performed. Results: In the group of all patients, RPI correlated with left ventricular stoke volume (LVSV), and cardiac index, but not with markers of renal function. In multiple stepwise regression analysis CKD-EPI<inf>(Cys-Cr)</inf> (b=–0.360), LVSV (b=0.924) and MAP (b=0.376) together independently influenced RPI (R2=0.74; p<0.0001). RPI<0.567 allowed for the identification of patients with chronic cardio-renal syndrome with sensitivity of 41.7% and specificity of 83.3%. Conclusions: Renal perfusion index relates more strongly to cardiac output than to renal function, and could be helpful in recognizing chronic cardio-renal syndrome. Applicability of RPI in diagnosing early abnormalities in the cardiorenal axis requires further investigation. © Med Sci Monit.","Cardio-renal syndrome; Chronic; Hypertension; Perfusion imaging; Renal; Renal insufficiency","McCullough, P.A., Kellum, J.A., Haase, M., Pathophysiology of the cardiorenal syndromes: Executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI) (2013) Contrib Nephrol, 182, pp. 82-98; Singh, P., Ricksten, S.E., Bragadottir, G., Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease (2013) Clin Exp Pharm and Physiology, 40, pp. 138-147; Sinkeler, S.J., Damman, K., Van Veldhuisen, D.J., A re-appraisal of volume status and renal function impairment in chronic heart failure: Combined effects of pre-renal failure and venous congestion on renal function (2012) Heart Failure Rev, 17, pp. 263-270; Tumlin, J.A., Costanzo, M.R., Chawla, L.S., Cardiorenal syndrome type 4: Insights on clinical presentation and pathophysiology from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI) (2013) Contrib Nephrol, 182, pp. 158-173; Scholbach, T., Scholbach, J., Can we measure renal tissue perfusion by ultrasound? (2009) J Med Ultrasound, 17, pp. 9-16; Lubas, A., Kade, G., Niemczyk, S., Renal resistive index as a marker of vascular damage in cardiovascular diseases (2013) Int Urol Nephrol, 46, pp. 395-402; Hanamura, K., Tojo, A., Kinugasa, S., The resistive index is a marker of renal function, pathology, prognosis, and responsiveness to steroid therapy in chronic kidney disease patients (2012) Int J Nephrol, , 139565; Lubas, A., Zelichowski, G., Próchnicka, A., Renal autoregulation in medical therapy of renovascular hypertension (2010) Arch Med Sci, 6, pp. 912-918; Lubas, A., Zelichowski, G., Próchnicka, A., Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension (2010) Arch Med Sci, 6, pp. 533-538; Levey, A.S., Stevens, L.A., Schmid, C.H., A new equation to estimate glomerular filtration rate (2009) Ann Intern Med, 60412, p. 150. , [published erratum appears in Ann Intern Med, 2011; 155: 408]; Scholbach, T., Dimos, I., Scholbach, J., A new method of color Doppler perfusion measurement via dynamic sonographic signal quantification in renal parenchyma (2004) Nephron Physiol, 96, pp. 99-104; Lubas, A., Ryczek, R., Kade, G., Impact of Cardiovascular Organ Damage on Cortical Renal Perfusion in Patients with Chronic Renal Failure (2013) Biomed Res Int, p. 137868; Sahn, D.J., Demaria, A., Kisslo, J., Weyman, A., Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements (1978) Circulation, 58, pp. 1072-1083; Devereux, R.B., Alonso, D.R., Lutas, E.M., Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings (1986) Am J Cardiol, 57, pp. 450-458; Bidani, A.K., Polichnowski, A.J., Loutzenhiser, R., Griffin, K.A., Renal microvascular dysfunction, hypertension and CKD progression (2013) Curr Opin Nephrol Hypertens, 22, pp. 1-9; Guglin, M., Rivero, A., Matar, F., Garcia, M., Renal dysfunction in heart failure is due to congestion but not low output (2011) Clin Cardiol, 34, pp. 113-116; Scholbach, T., Girelli, E., Scholbach, J., Dynamic tissue perfusion measurement: A novel tool in follow-up of renal transplants (2005) Transplantation, 79, pp. 1711-1716; Hwang, E.A., Kim, H.S., Ha, E., Mun, K.C., Apoptosis in endothelial cells by cyclosporine (2012) Transplant Proc, 44, pp. 982-984; Zarjou, A., Guo, L., Sanders, P.W., A reproducible mouse model of chronic allograft nephropathy with vasculopathy (2012) Kidney Int, 82, pp. 1231-1235; Przybylowski, P., Malyszko, J., Malyszko, J., Immunosuppressive regimen and prevalence of chronic kidney disease in orthotopic heart transplant recipients (2010) Med Sci Monit, 16 (11), pp. CR563-CR566; Libório, A.B., Uchia, R.S., Aragao, A.P., Importance of anemia in the chronic Cardiorenal syndrome: Effects on renal function after heart transplantation (2012) Med Sci Monit, 18 (10), pp. CR611-CR616",Article,Scopus,2-s2.0-84928156301
"Lopez-Perez A., Sebastian R., Ferrero J.M.","Three-dimensional cardiac computational modelling: METHODS, features and applications",2015,"BioMedical Engineering Online","14","1", 35,"","",,,10.1186/s12938-015-0033-5,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928897378&partnerID=40&md5=7a2df8d28da23aec3c89189f9ad14b92","Universitat Politècnica de València, Centre for Research and Innovation in Bioengineering (Ci2B)València, Spain; Universitat de València, Computational Multiscale Physiology Lab (CoMMLab)València, Spain","Lopez-Perez, A., Universitat Politècnica de València, Centre for Research and Innovation in Bioengineering (Ci2B)València, Spain; Sebastian, R., Universitat de València, Computational Multiscale Physiology Lab (CoMMLab)València, Spain; Ferrero, J.M., Universitat Politècnica de València, Centre for Research and Innovation in Bioengineering (Ci2B)València, Spain","The combination of computational models and biophysical simulations can help to interpret an array of experimental data and contribute to the understanding, diagnosis and treatment of complex diseases such as cardiac arrhythmias. For this reason, three-dimensional (3D) cardiac computational modelling is currently a rising field of research. The advance of medical imaging technology over the last decades has allowed the evolution from generic to patient-specific 3D cardiac models that faithfully represent the anatomy and different cardiac features of a given alive subject. Here we analyse sixty representative 3D cardiac computational models developed and published during the last fifty years, describing their information sources, features, development methods and online availability. This paper also reviews the necessary components to build a 3D computational model of the heart aimed at biophysical simulation, paying especial attention to cardiac electrophysiology (EP), and the existing approaches to incorporate those components. We assess the challenges associated to the different steps of the building process, from the processing of raw clinical or biological data to the final application, including image segmentation, inclusion of substructures and meshing among others. We briefly outline the personalisation approaches that are currently available in 3D cardiac computational modelling. Finally, we present examples of several specific applications, mainly related to cardiac EP simulation and model-based image analysis, showing the potential usefulness of 3D cardiac computational modelling into clinical environments as a tool to aid in the prevention, diagnosis and treatment of cardiac diseases. © 2015. Lopez-Perez et al.","Biophysical simulation; Cardiac conduction system (CCS); Cardiac image segmentation; Cardiac modelling; Computational modelling; Fibre orientation; Patient-specific modelling; Personalisation; Three-dimensional (3D) modelling","Koushanpour, E., Collings, W., Validation and dynamic applications of an ellipsoid model of the left ventricle (1966) J Appl Physiol, 21, pp. 1655-1661; Ghista, D., Sandler, H., An analytic elastic-viscoelastic model for the shape and the forces in the left ventricle (1969) J Biomech, 2, pp. 35-47; Janz, R.F., Grimm, A.F., Finite-Element Model for the Mechanical Behavior of the Left Ventricle: prediction of deformation in the potassium-arrested rat heart (1972) Circ Res, 30, pp. 244-252; Broek, J.H.J.M., Broek, M.H.L.M., Application of an ellipsoidal heart model in studying left ventricular contractions (1980) J Biomech, 13, pp. 493-503; Colli Franzone, P., Guerri, L., Pennacchio, M., Taccardi, B., Spread of excitation in 3-D models of the anisotropic cardiac tissue. II. Effects of fiber architecture and ventricular geometry (1998) Math Biosci, 147, pp. 131-171; Kerckhoffs, R.C.P., Bovendeerd, P.H.M., Kotte, J.C.S., Prinzen, F.W., Smits, K., Arts, T., Homogeneity of cardiac contraction despite physiological asynchrony of depolarization: a model study (2003) Ann Biomed Eng, 31, pp. 536-547; Sermesant, M., Moireau, P., Camara, O., Sainte-Marie, J., Andriantsimiavona, R., Cimrman, R., Cardiac function estimation from MRI using a heart model and data assimilation: advances and difficulties (2006) Med Image Anal, 10, pp. 642-656; Okajima, M., Fujino, T., Kobayashi, T., Yamada, K., Computer simulation of the propagation process in excitation of the ventricles (1968) Circ Res, 23, pp. 203-211; Horan, L.G., Hand, R.C., Johnson, J.C., Sridharan, M.R., Rankin, T.B., Flowers, N.C., A theoretical examination of ventricular repolarization and the secondary T wave (1978) Circ Res, 42, pp. 750-757; Miller, W.T., Geselowitz, D.B., Simulation studies of the electrocardiogram. I. The normal heart (1978) Circ Res, 43, pp. 301-315; Vetter, F.J., McCulloch, A.D., Three-dimensional analysis of regional cardiac function: a model of rabbit ventricular anatomy (1998) Prog Biophys Mol Biol, 69, pp. 157-183; Nielsen, P.M.F., LeGrice, I.J., Smaill, B.H., Hunter, P.J., Mathematical model of geometry and fibrous structure of the heart (1991) Am J Physiol Heart Circ Physiol, 260, pp. H1365-H1378; Stevens, C., Remme, E., LeGrice, I., Hunter, P., Ventricular mechanics in diastole: material parameter sensitivity (2003) J Biomech, 36, pp. 737-748; Aoki, M., Okamoto, Y., Musha, T., Harumi, K.I., Three-dimensional simulation of the ventricular depolarization and repolarization processes and body surface potentials: normal heart and bundle branch block (1987) IEEE Trans Biomed Eng, 34, pp. 454-462; Thakor, N.V., Eisenman, L.N., Three-dimensional computer model of the heart: fibrillation induced by extrastimulation (1989) Comput Biomed Res, 22, pp. 532-545; Freudenberg, J., Schiemann, T., Tiede, U., Höhne, K.H., Simulation of cardiac excitation patterns in a three-dimensional anatomical heart atlas (2000) Comput Biol Med, 30, pp. 191-205; Trunk, P., Mocnik, J., Trobec, R., Gersak, B., 3D heart model for computer simulations in cardiac surgery (2007) Comput Biol Med, 37, pp. 1398-1403; Siregar, P., Sinteff, J.P., Julen, N., Beux, P., An interactive 3D anisotropic cellular automata model of the heart (1998) Comput Biomed Res, 31, pp. 323-347; Harrild, D.M., Henriquez, C.S., A computer model of normal conduction in the human atria (2000) Circ Res, 87, pp. e25-36; Bodin, O.N., Kuz'min, A.V., Synthesis of a realistic model of the surface of the heart (2006) Biomed Eng (NY), 40, pp. 280-283; Ruiz-Villa, C.A., Tobón, C., Rodríguez, J.F., Ferrero, J.M., Hornero, F., Saíz, J., Influence of atrial dilatation in the generation of re-entries caused by ectopic activity in the left atrium (2009) Comput Cardiol, 36, pp. 457-460; Blanc, O., Virag, N., Vesin, J.M., Kappenberger, L., A computer model of human atria with reasonable computation load and realistic anatomical properties (2001) IEEE Trans Biomed Eng, 48, pp. 1229-1237; Zemlin, C.W., Herzel, H., Ho, S.Y., Panfilov, A.V., A realistic and efficient model of excitation propagation in the human atria (2001) Comput Simul Exp Assess Card Electrophysiol. Arkmonk, pp. 29-34. , Virag N, Kappenberger L, Blanc O, editors New York: Futura Publishing Company, Inc; Seemann, G., Höper, C., Sachse, F.B., Dössel, O., Holden, A.V., Zhang, H., Heterogeneous three-dimensional anatomical and electrophysiological model of human atria (2006) Philos Trans R Soc A Math Phys Eng Sci, 364, pp. 1465-1481; Zhao, J., Butters, T.D., Zhang, H., LeGrice, I.J., Sands, G.B., Smaill, B.H., Image-based model of atrial anatomy and electrical activation: a computational platform for investigating atrial arrhythmia (2013) IEEE Trans Med Imaging, 32, pp. 18-27; Creswell, L.L., Wyers, S.G., Pirolo, J.S., Perman, W.H., Vannier, M.W., Pasque, M.K., Mathematical modeling of the heart using magnetic resonance imaging (1992) IEEE Trans Med Imaging, 11, pp. 581-589; Lorange, M., Gulrajani, R.M., A computer heart model incorporating anisotropic propagation: I. Model construction and simulation of normal activation (1993) J Electrocardiol, 26, pp. 245-261; Winslow, R.L., Scollan, D.F., Holmes, A., Yung, C.K., Zhang, J., Jafri, M.S., Electrophysiological modeling of cardiac ventricular function: from cell to organ (2000) Annu Rev Biomed Eng, 2, pp. 119-155; Virag, N., Jacquemet, V., Henriquez, C.S., Zozor, S., Blanc, O., Vesin, J.M., Study of atrial arrhythmias in a computer model based on magnetic resonance images of human atria (2002) Chaos, 12, pp. 754-763; Helm, P.A., Tseng, H.J., Younes, L., McVeigh, E.R., Winslow, R.L., Ex vivo 3D diffusion tensor imaging and quantification of cardiac laminar structure (2005) Magn Reson Med, 54, pp. 850-859; Arevalo, H.J., Helm, P.A., Trayanova, N.A., Development of a model of the infarcted canine heart that predicts arrhythmia generation from specific cardiac geometry and scar distribution (2008) Comput Cardiol, 35, pp. 497-500; Plotkowiak, M., Rodriguez, B., Plank, G., Schneider, J.E., Gavaghan, D., Kohl, P., High performance computer simulations of cardiac electrical function based on high resolution MRI datasets (2008) Int Conf Comput Sci 2008, pp. 571-580. , LNCS 5101. Berlin Heidelberg: Springer-Verlag; Heidenreich, E.A., Ferrero, J.M., Doblaré, M., Rodríguez, J.F., Adaptive macro finite elements for the numerical solution of monodomain equations in cardiac electrophysiology (2010) Ann Biomed Eng, 38, pp. 2331-2345; Gurev, V., Lee, T., Constantino, J., Arevalo, H., Trayanova, N.A., Models of cardiac electromechanics based on individual hearts imaging data: Image-based electromechanical models of the heart (2011) Biomech Model Mechanobiol, 10, pp. 295-306; Deng, D., Jiao, P., Ye, X., Xia, L., An image-based model of the whole human heart with detailed anatomical structure and fiber orientation (2012) Comput Math Methods Med, 2012, p. 16; Aslanidi, O.V., Nikolaidou, T., Zhao, J., Smaill, B.H., Gilbert, S.H., Holden, A.V., Application of micro-computed tomography with iodine staining to cardiac imaging, segmentation, and computational model development (2013) IEEE Trans Med Imaging, 32, pp. 8-17; Haddad, R., Clarysse, P., Orkisz, M., Croisille, P., Revel, D., Magnin, I.E., A realistic anthropomorphic numerical model of the beating heart (2005) Funct Imaging Model Heart 2005, pp. 384-393. , LNCS 3504. Berlin Heidelberg: Springer-Verlag; Appleton, B., Wei, Q., Liu, N., Xia, L., Crozier, S., Liu, F., An electrical heart model incorporating real geometry and motion (2006) 27th Annu Int Conf Eng Med Biol Soc (IEEE-EMBS 2005), pp. 345-348. , Shanghai, China: IEEE; Niederer, S., Rhode, K., Razavi, R., Smith, N., An electrical heart model incorporating real geometry and motion (2009) 27th Annu Int Conf Eng Med Biol Soc (IEEE-EMBS 2005), pp. 348-356. , Shanghai, China: IEEE; Yang, G., Toumoulin, C., Coatrieux, J.L., Shu, H., Luo, L., Boulmier, D., A 3D static heart model from a MSCT data set (2006) 27th Annu Int Conf IEEE Eng Med Biol Soc (IEEE-EMBS 2005), pp. 5499-5502. , Shangai, China: IEEE; Romero, D., Sebastian, R., Bijnens, B.H., Zimmerman, V., Boyle, P.M., Vigmond, E.J., Effects of the purkinje system and cardiac geometry on biventricular pacing: a model study (2010) Ann Biomed Eng, 38, pp. 1388-1398; Lorenzo-Valdés, M., Sanchez-Ortiz, G.I., Mohiaddin, R., Rueckert, D., Atlas-based segmentation and tracking of 3D cardiac MR images using non-rigid registration (2002) Med Image Comput Comput Assist Interv 2002, pp. 642-650. , LNCS 2488. Berlin Heidelberg: Springer-Verlag; Ordas, S., Oubel, E., Sebastian, R., Frangi, A.F., Computational anatomy atlas of the heart (2007) 5th Int Symp Image Signal Process Anal (ISPA 2007), pp. 338-342. , Istanbul, Turkey: IEEE; Burton, R.A.B., Plank, G., Schneider, J.E., Grau, V., Ahammer, H., Keeling, S.L., Three-dimensional models of individual cardiac histoanatomy: tools and challenges (2006) Ann N Y Acad Sci, 1080, pp. 301-319; Plank, G., Burton, R.A.B., Hales, P., Bishop, M., Mansoori, T., Bernabeu, M.O., Generation of histo-anatomically representative models of the individual heart: tools and application (2009) Philos Trans R Soc A Math Phys Eng Sci, 367, pp. 2257-2292; Bishop, M.J., Plank, G., Burton, R.A.B., Schneider, J.E., Gavaghan, D.J., Grau, V., Development of an anatomically detailed MRI-derived rabbit ventricular model and assessment of its impact on simulations of electrophysiological function (2010) Am J Physiol - Heart Circ Physiol, 298, pp. H699-718; Ecabert, O., Peters, J., Schramm, H., Lorenz, C., Berg, J., Walker, M.J., Automatic model-based segmentation of the heart in CT images (2008) IEEE Trans Med Imaging, 27, pp. 1189-1201; Ecabert, O., Peters, J., Walker, M.J., Ivanc, T., Lorenz, C., Berg, J., Segmentation of the heart and great vessels in CT images using a model-based adaptation framework (2011) Med Image Anal, 15, pp. 863-876; Schulte, R.F., Sands, G.B., Sachse, F.B., Dössel, O., Pullan, A.J., Creation of a human heart model and its customisation using ultrasound images (2001) Biomed Tech Eng, 46, pp. 26-28; Wenk, J.F., Zhang, Z., Cheng, G., Malhotra, D., Acevedo-Bolton, G., Burger, M., First finite element model of the left ventricle with mitral valve: insights into ischemic mitral regurgitation (2010) Ann Thorac Surg, 89, pp. 1546-1553; Frangi, A.F., Rueckert, D., Schnabel, J.A., Niessen, W.J., Automatic construction of multiple-object three-dimensional statistical shape models: application to cardiac modeling (2002) IEEE Trans Med Imaging, 21, pp. 1151-1166; Hoogendoorn, C., Duchateau, N., Sánchez-Quintana, D., Whitmarsh, T., Sukno, F.M., Craene, M., A high-resolution atlas and statistical model of the human heart from multislice CT (2013) IEEE Trans Med Imaging, 32, pp. 28-44; Vadakkumpadan, F., Rantner, L.J., Tice, B., Boyle, P., Prassl, A.J., Vigmond, E., Image-based models of cardiac structure with applications in arrhythmia and defibrillation studies (2009) J Electrocardiol, 42, p. 157; Perperidis, D., Mohiaddin, R., Rueckert, D., Construction of a 4D statistical atlas of the cardiac anatomy and its use in classification (2005) Med Image Comput Comput Interv 2005, pp. 402-410. , LNCS 3750. Berlin Heidelberg: Springer-Verlag; Lötjönen, J., Kivistö, S., Koikkalainen, J., Smutek, D., Lauerma, K., Statistical shape model of atria, ventricles and epicardium from short- and long-axis MR images (2004) Med Image Anal, 8, pp. 371-386; Lorenz, C., Berg, J., A comprehensive shape model of the heart (2006) Med Image Anal, 10, pp. 657-670; Mansoori, T., Plank, G., Burton, R., Schneider, J., Khol, P., Gavaghan, D., An iterative method for registration of high-resolution cardiac histoanatomical and MRI images (2007) 4th IEEE Int Symp Biomed Imaging: From Nano to Macro (ISBI 2007), pp. 572-575. , Arlington, VA (USA): IEEE; Gibb, M., Burton, R.A.B., Bollensdorff, C., Afonso, C., Mansoori, T., Schotten, U., Resolving the three-dimensional histology of the heart (2012) Comput Methods Syst Biol - Lect Notes Comput Sci 7605, pp. 2-16. , Berlin Heidelberg: Springer; Burton, R.A.B., Lee, P., Casero, R., Garny, A., Siedlecka, U., Schneider, J.E., Three-dimensional histology: tools and application to quantitative assessment of cell-type distribution in rabbit heart (2014) Europace, 16, pp. 86-95; Niederer, S.A., Shetty, A.K., Plank, G., Bostock, J., Razavi, R., Smith, N.P., Biophysical modeling to simulate the response to multisite left ventricular stimulation using a quadripolar pacing lead (2012) Pacing Clin Electrophysiol, 35, pp. 204-214; Weese, J., Groth, A., Nickisch, H., Barschdorf, H., Weber, F.M., Velut, J., Generating anatomical models of the heart and the aorta from medical images for personalized physiological simulations (2013) Med Biol Eng Comput, 51, pp. 1209-1219; Gibb, M., Bishop, M., Burton, R., Kohl, P., Grau, V., Plank, G., The role of blood vessels in rabbit propagation dynamics and cardiac arrhythmias (2009) Funct Imaging Model Heart - FIMH 2009, pp. 268-276. , LNCS 5528. Berlin Heidelberg: Springer; Prassl, A.J., Kickinger, F., Ahammer, H., Grau, V., Schneider, J.E., Hofer, E., Automatically generated, anatomically accurate meshes for cardiac electrophysiology problems (2009) IEEE Trans Biomed Eng, 56, pp. 1318-1330; Dux-Santoy, L., Sebastian, R., Felix-Rodriguez, J., Ferrero, J.M., Saiz, J., Interaction of specialized cardiac conduction system with antiarrhythmic drugs: a simulation study (2011) IEEE Trans Biomed Eng, 58, pp. 3475-3478; Lamata, P., Niederer, S., Nordsletten, D., Barber, D.C., Roy, I., Hose, D.R., An accurate, fast and robust method to generate patient-specific cubic Hermite meshes (2011) Med Image Anal, 15, pp. 801-813; Pathmanathan, P., Cooper, J., Fletcher, A., Mirams, G., Murray, P., Osborne, J., A computational study of discrete mechanical tissue models (2009) Phys Biol, 6, p. 036001; Niederer, S.A., Kerfoot, E., Benson, A.P., Bernabeu, M.O., Bernus, O., Bradley, C., Verification of cardiac tissue electrophysiology simulators using an N-version benchmark (2011) Philos Trans R Soc A Math Phys Eng Sci, 369, pp. 4331-4351; Tusscher, K.H.W.J., Panfilov, A.V., Cell model for efficient simulation of wave propagation in human ventricular tissue under normal and pathological conditions (2006) Phys Med Biol, 51, pp. 6141-6156; LeGrice, I., Smaill, B., Chai, L., Edgar, S., Gavin, J., Hunter, P., Laminar structure of the heart: ventricular myocyte arrangement and connective tissue architecture in the dog (1995) Am J Physiol Heart Circ Physiol, 269, pp. H571-H582; Anderson, R.H., Smerup, M., Sanchez-Quintana, D., Loukas, M., Lunkenheimer, P.P., The three-dimensional arrangement of the myocytes in the ventricular walls (2009) Clin Anat, 22, pp. 64-76; Clerc, L., Directional differences of impulse spread in trabecular muscle from mammalian heart (1976) J Physiol, 255, pp. 335-346; Streeter, D.D., Spotnitz, H.M., Patel, D.P., Ross, J., Sonnenblick, E.H., Fiber orientation in the canine left ventricle during diastole and systole (1969) Circ Res, 24, pp. 339-347; Scollan, D., Holmes, A., Winslow, R., Forder, J., Histological validation of myocardial microstructure obtained from diffusion tensor magnetic resonance imaging (1998) Am J Physiol Heart Circ Physiol, 275, pp. H2308-H2318; Hsu, E.W., Muzikant, A.L., Matulevicius, S.A., Penland, R.C., Henriquez, C.S., Magnetic resonance myocardial fiber-orientation mapping with direct histological correlation (1998) Am J Physiol Heart Circ Physiol, 274, pp. H1627-H1634; Holmes, A.A., Scollan, D.F., Winslow, R.L., Direct histological validation of diffusion tensor MRI in formaldehyde-fixed myocardium (2000) Magn Reson Med, 44, pp. 157-161; Sermesant, M., Forest, C., Pennec, X., Delingette, H., Ayache, N., Deformable biomechanical models: application to 4D cardiac image analysis (2003) Med Image Anal, 7, pp. 475-488; Peyrat, J.M., Sermesant, M., Pennec, X., Delingette, H., Xu, C., McVeigh, E.R., A computational framework for the statistical analysis of cardiac diffusion tensors: application to a small database of canine hearts (2007) IEEE Trans Med Imaging, 26, pp. 1500-1514; Toussaint, N., Sermesant, M., Stoeck, C.T., Kozerke, S., Batchelor, P.G., In vivo human 3D cardiac fibre architecture: reconstruction using curvilinear interpolation of diffusion tensor images (2010) Med Image Comput Comput Assist Interv, 13, pp. 418-425; Toussaint, N., Stoeck, C.T., Schaeffter, T., Kozerke, S., Sermesant, M., Batchelor, P.G., In vivo human cardiac fibre architecture estimation using shape-based diffusion tensor processing (2013) Med Image Anal, 17, pp. 1243-1255; Bishop, M.J., Hales, P., Plank, G., Gavaghan, D.J., Scheider, J., Grau, V., Comparison of rule-based and DTMRI-derived fibre architecture in a whole rat ventricular computational model (2009) Funct Imaging Model Heart 2009, pp. 87-96. , LNCS 5528. Berlin Heidelberg: Springer-Verlag; Bayer, J.D., Blake, R.C., Plank, G., Trayanova, N.A., A novel rule-based algorithm for assigning myocardial fiber orientation to computational heart models (2012) Ann Biomed Eng, 40, pp. 2243-2254; Dobrzynski, H., Anderson, R.H., Atkinson, A., Borbas, Z., D'Souza, A., Fraser, J.F., Structure, function and clinical relevance of the cardiac conduction system, including the atrioventricular ring and outflow tract tissues (2013) Pharmacol Ther, 139, pp. 260-288; Tranum-Jensen, J., Wilde, A.A., Vermeulen, J.T., Janse, M.J., Morphology of electrophysiologically identified junctions between Purkinje fibers and ventricular muscle in rabbit and pig hearts (1991) Circ Res, 69, pp. 429-437; Boyle, P.M., Deo, M., Plank, G., Vigmond, E.J., Purkinje-mediated effects in the response of quiescent ventricles to defibrillation shocks (2010) Ann Biomed Eng, 38, pp. 456-468; Behradfar, E., Nygren, A., Vigmond, E.J., The role of Purkinje-myocardial coupling during ventricular arrhythmia: a modeling study (2014) PLoS One, 9; DiFrancesco, D., Noble, D., A model of cardiac electrical activity incorporating ionic pumps and concentration changes (1985) Philos Trans R Soc B Biol Sci, 307, pp. 353-398; Stewart, P., Aslanidi, O.V., Noble, D., Noble, P.J., Boyett, M.R., Zhang, H., Mathematical models of the electrical action potential of Purkinje fibre cells (2009) Philos Trans R Soc A Math Phys Eng Sci, 367, pp. 2225-2255; Li, P., Rudy, Y., A model of canine purkinje cell electrophysiology and Ca(2+) cycling: rate dependence, triggered activity, and comparison to ventricular myocytes (2011) Circ Res, 109, pp. 71-79; Chinchapatnam, P., Rhode, K.S., Ginks, M., Mansi, T., Peyrat, J.M., Lambiase, P., Estimation of volumetric myocardial apparent conductivity from endocardial electro-anatomical mapping (2009) 31st Annu Int Conf IEEE Eng Med Biol Soc (EMBC 2009), pp. 2907-2910. , Minneapolis, MN (USA): IEEE; Durrer, D., Dam, R.T., Freud, G.E., Janse, M.J., Meijler, F.L., Arzbaecher, R.C., Total excitation of the isolated human heart (1970) Circulation, 41, pp. 899-912; Pollard, A.E., Barr, R.C., Computer simulations of activation in an anatomically based model of the human ventricular conduction system (1991) IEEE Trans Biomed Eng, 38, pp. 982-996; Abboud, S., Berenfeld, O., Sadeh, D., Simulation of high-resolution QRS complex using a ventricular model with a fractal conduction system. Effects of ischemia on high-frequency QRS potentials (1991) Circ Res, 68, pp. 1751-1760; Sebastian, R., Zimmerman, V., Romero, D., Sanchez-Quintana, D., Frangi, A.F., Characterization and modeling of the peripheral cardiac conduction system (2013) IEEE Trans Med Imaging, 32, pp. 45-55; Bordas, R., Gillow, K., Lou, Q., Efimov, I.R., Gavaghan, D., Kohl, P., Rabbit-specific ventricular model of cardiac electrophysiological function including specialized conduction system (2011) Prog Biophys Mol Biol, 107, pp. 90-100; Stephenson, R.S., Boyett, M.R., Hart, G., Nikolaidou, T., Cai, X., Corno, A.F., Contrast enhanced micro-computed tomography resolves the 3-dimensional morphology of the cardiac conduction system in mammalian hearts (2012) PLoS One, 7; Berenfeld, O., Jalife, J., Purkinje-Muscle reentry as a mechanism of polymorphic ventricular arrhythmias in a 3-dimensional model of the ventricles (1998) Circ Res, 82, pp. 1063-1077; Azzouzi, A., Coudière, Y., Turpault, R., Zemzemi, N., A mathematical model of the Purkinje-muscle junctions (2011) Math Biosci Eng MBE, 8, pp. 915-930; Dux-Santoy, L., Sebastian, R., Rodriguez, J.F., Ferrero, J.M., Modeling the different sections of the cardiac conduction system to obtain realistic electrocardiograms (2013) 35th Annu Int Conf IEEE Eng Med Biol Soc (EMBC 2013), pp. 6846-6849. , Osaka, Japan: IEEE; Cardenes, R., Sebastian, R., Berruezo, A., Camara, O., Inverse estimation of ventricular Purkinje tree pathways from sequences of depolarization (2014) Comput Cardiol, 41, pp. 677-680. , Cambridge, Massachusetts (USA): IEEE; Palamara, S., Vergara, C., Catanzariti, D., Faggiano, E., Pangrazzi, C., Centonze, M., Computational generation of the Purkinje network driven by clinical measurements: the case of pathological propagations (2014) Int J Numer Method Biomed Eng, 30, pp. 1558-1577; Moe, G.K., Rheinboldt, W.C., Abildskov, J.A., A computer model of atrial fibrillation (1964) Am Heart J, 67, pp. 200-220; Hodgkin, A.L., Huxley, A.F., A quantitative description of membrane current and its application to conduction and excitation in nerve (1952) J Physiol, 117, pp. 500-544; Fink, M., Niederer, S.A., Cherry, E.M., Fenton, F.H., Koivumäki, J.T., Seemann, G., Cardiac cell modelling: Observations from the heart of the cardiac physiome project (2011) Prog Biophys Mol Biol, 104, pp. 2-21; Rudy, Y., Silva, J.R., Computational biology in the study of cardiac ion channels and cell electrophysiology (2006) Q Rev Biophys, 39, pp. 57-116; Sakmann, B., Neher, E., Patch clamp techniques for studying ionic channels in excitable membranes (1984) Annu Rev Physiol, 41, pp. 455-472; Maleckar, M.M., Greenstein, J.L., Giles, W.R., Trayanova, N.A., K+ current changes account for the rate dependence of the action potential in the human atrial myocyte (2009) Am J Physiol Heart Circ Physiol, 297, pp. H1398-H1410; O'Hara, T., Virág, L., Varró, A., Rudy, Y., Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation (2011) PLoS Comput Biol, 7; Roberts, B.N., Yang, P.C., Behrens, S.B., Moreno, J.D., Clancy, C.E., Computational approaches to understand cardiac electrophysiology and arrhythmias (2012) Am J Physiol Heart Circ Physiol, 303, pp. H766-H783; Liu, D.W., Gintant, G.A., Antzelevitch, C., Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle (1993) Circ Res, 72, pp. 671-687; Szentadrassy, N., Banyasz, T., Biro, T., Szabo, G., Toth, B.I., Magyar, J., Apico-basal inhomogeneity in distribution of ion channels in canine and human ventricular myocardium (2005) Cardiovasc Res, 65, pp. 851-860; Volders, P.G., Sipido, K.R., Carmeliet, E., Spätjens, R.L., Wellens, H.J., Vos, M.A., Repolarizing K+ currents ITO1 and IKs are larger in right than left canine ventricular midmyocardium (1999) Circulation, 99, pp. 206-210; Tobón, C., Rodríguez, J.F., Ferrero, J.M., Hornero, F., Saiz, J., Dominant frequency and organization index maps in a realistic three-dimensional computational model of atrial fibrillation (2012) Europace, 14, pp. v25-32; Tobón, C., Ruiz-Villa, C.A., Heidenreich, E., Romero, L., Hornero, F., Saiz, J., A three-dimensional human atrial model with fiber orientation. Electrograms and arrhythmic activation patterns relationship (2013) PLoS One, 8; Roth, B.J., The electrical potential produced by a strand of cardiac muscle: a bidomain analysis (1988) Ann Biomed Eng, 16, pp. 609-637; FitzHugh, R., Impulses and physiological states in theoretical models of nerve membrane (1961) Biophys J, 1, pp. 445-466; Aliev, R.R., Panfilov, A.V., Modeling of heart excitation patterns caused by a local inhomogeneity (1996) J Theor Biol, 181, pp. 33-40; Mitchell, C.C., Schaeffer, D.G., A two-current model for the dynamics of cardiac membrane (2003) Bull Math Biol, 65, pp. 767-793; Fenton, F., Karma, A., Vortex dynamics in three-dimensional continuous myocardium with fiber rotation: filament instability and fibrillation (1998) Chaos, 8, pp. 20-47; Bueno-Orovio, A., Cherry, E.M., Fenton, F.H., Minimal model for human ventricular action potentials in tissue (2008) J Theor Biol, 253, pp. 544-560; Colli Franzone, P., Guerri, L., Rovida, S., Wavefront propagation in an activation model of the anisotropic cardiac tissue: asymptotic analysis and numerical simulations (1990) J Math Biol, 28, pp. 121-176; Keener, J.P., An eikonal-curvature equation for action potential propagation in myocardium (1991) J Math Biol, 29, pp. 629-651; Relan, J., Chinchapatnam, P., Sermesant, M., Rhode, K., Ginks, M., Delingette, H., Coupled personalization of cardiac electrophysiology models for prediction of ischaemic ventricular tachycardia (2011) Interface Focus, 1, pp. 396-407; Camara, O., Sermesant, M., Lamata, P., Wang, L., Pop, M., Relan, J., Inter-model consistency and complementarity: Learning from ex-vivo imaging and electrophysiological data towards an integrated understanding of cardiac physiology (2011) Prog Biophys Mol Biol, 107, pp. 122-133; Rice, J.J., Wang, F., Bers, D.M., Tombe, P.P., Approximate model of cooperative activation and crossbridge cycling in cardiac muscle using ordinary differential equations (2008) Biophys J, 95, pp. 2368-2390; Mullins, P.D., Bondarenko, V.E., A mathematical model of the mouse ventricular myocyte contraction (2013) PLoS One, 8, p. e63141; Trayanova, N.A., Rice, J.J., Cardiac electromechanical models: from cell to organ (2011) Front Physiol, 2, p. 43; Williams, G.S.B., Smith, G.D., Sobie, E.A., Jafri, M.S., Models of cardiac excitation-contraction coupling in ventricular myocytes (2010) Math Biosci, 226, pp. 1-15; Jafri, M.S., Models of excitation-contraction coupling in cardiac ventricular myocytes (2012) Bioinforma Drug Discov Methods Mol Biol, 910, pp. 309-335. , New York: Springer Science + Business Media; Pfeiffer, E.R., Tangney, J.R., Omens, J.H., McCulloch, A.D., Biomechanics of cardiac electromechanical coupling and mechanoelectric feedback (2014) J Biomech Eng, 136, pp. 0210071-02100711; Quinn, T.A., Kohl, P., Ravens, U., Cardiac mechano-electric coupling research: fifty years of progress and scientific innovation (2014) Prog Biophys Mol Biol, 115, pp. 71-75; Craelius, W., Chen, V., El-Sherif, N., Stretch activated ion channels in ventricular myocytes (1988) Biosci Rep, 8, pp. 407-414; Kohl, P., Hunter, P., Noble, D., Stretch-induced changes in heart rate and rhythm: clinical observations, experiments and mathematical models (1999) Prog Biophys Mol Biol, 71, pp. 91-138; Kohl, P., Sachs, F., Franz, M.R., Cardiac Mechano-Electric Feedback and Arrhytmias: From Pipette to Patient (2005), Philadelphia: Elsevier Health SciencesCabo, C., Boyden, P.A., Electrical remodeling of the epicardial border zone in the canine infarcted heart: a computational analysis (2003) Am J Physiol Heart Circ Physiol, 284, pp. H372-H384; Clancy, C.E., Rudy, Y., Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death (2001) Cardiovasc Res, 50, pp. 301-313; Marks, A.R., Calcium cycling proteins and heart failure: mechanisms and therapeutics (2013) J Clin Invest, 123, pp. 46-52; Hansen, D.E., Craig, C.S., Hondeghem, L.M., Stretch-induced arrhythmias in the isolated canine ventricle. Evidence for the importance of mechanoelectrical feedback (1990) Circulation, 81, pp. 1094-1105; Wang, Z., Taylor, L.K., Denney, W.D., Hansen, D.E., Initiation of ventricular extrasystoles by myocardial stretch in chronically dilated and failing canine left ventricle (1994) Circulation, 90, pp. 2022-2031; Trayanova, N.A., Constantino, J., Gurev, V., Models of stretch-activated ventricular arrhythmias (2010) J Electrocardiol, 43, pp. 476-485; Reumann, M., Farina, D., Miri, R., Lurz, S., Osswald, B., Dössel, O., Computer model for the optimization of AV and VV delay in cardiac resynchronization therapy (2007) Med Biol Eng Comput, 45, pp. 845-854; Wu, M.-T., Tseng, W.-Y.I., Su, M.-Y.M., Liu, C.-P., Chiou, K.-R., Wedeen, V.J., Reese, T.G., Diffusion tensor magnetic resonance imaging mapping the fiber architecture remodeling in human myocardium after infarction: correlation with viability and wall motion (2006) Circulation, 114, pp. 1036-1045; Rutherford, S.L., Trew, M.L., Sands, G.B., LeGrice, I.J., Smaill, B.H., High-resolution 3-dimensional reconstruction of the infarct border zone: impact of structural remodeling on electrical activation (2012) Circ Res, 111, pp. 301-311; Ashikaga, H., Arevalo, H., Vadakkumpadan, F., Blake, R.C., Bayer, J.D., Nazarian, S., Feasibility of image-based simulation to estimate ablation target in human ventricular arrhythmia (2013) Heart Rhythm, 10, pp. 1109-1116; Martos, R., Baugh, J., Ledwidge, M., O'Loughlin, C., Conlon, C., Patle, A., Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction (2007) Circulation, 115, pp. 888-895; Tusscher, K.H.W.J., Panfilov, A.V., Influence of diffuse fibrosis on wave propagation in human ventricular tissue (2007) Europace, 9, pp. vi38-45; Kim, R.J., Fieno, D.S., Parrish, T.B., Harris, K., Chen, E.L., Simonetti, O., Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function (1999) Circulation, 100, pp. 1992-2002; Sebastian, R., Zimmerman, V., Sukno, F., Bijnens, B.H., Frangi, A.F., Cardiac modelling for pathophysiology research and clinical applications. The need for an automated pipeline (2010) World Congr Med Phys Biomed Eng 2009, pp. 2207-2210. , Berlin Heidelberg: Springer; Heidenreich, E.A., Gaspar, F.J., Ferrero, J.M., Rodríguez, J.F., Compact schemes for anisotropic reaction-diffusion equations with adaptive time step (2010) Int J Numer Methods Eng, 82, pp. 1022-1043; Mewton, N., Liu, C.Y., Croisille, P., Bluemke, D., Lima, J.A.C., Assessment of myocardial fibrosis with cardiovascular magnetic resonance (2011) J Am Coll Cardiol, 57, pp. 891-903; Dass, S., Suttie, J.J., Piechnik, S.K., Ferreira, V.M., Holloway, C.J., Banerjee, R., Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy (2012) Circ Cardiovasc Imaging, 5, pp. 726-733; Krueger, M.W., Seemann, G., Rhode, K., Keller, D.U.J., Schilling, C., Arujuna, A., Personalization of atrial anatomy and electrophysiology as a basis for clinical modeling of radio-frequency ablation of atrial fibrillation (2013) IEEE Trans Med Imaging, 32, pp. 73-84; Krueger, M.W., Schulze, W.H.W., Rhode, K.S., Razavi, R., Seemann, G., Dössel, O., Towards personalized clinical in-silico modeling of atrial anatomy and electrophysiology (2013) Med Biol Eng Comput, 51, pp. 1251-1260; Sermesant, M., Peyrat, J.-M., Chinchapatnam, P., Billet, F., Mansi, T., Rhode, K., Toward patient-specific myocardial models of the heart (2008) Heart Fail Clin, 4, pp. 289-301; Konukoglu, E., Relan, J., Cilingir, U., Menze, B.H., Chinchapatnam, P., Jadidi, A., Efficient probabilistic model personalization integrating uncertainty on data and parameters: Application to eikonal-diffusion models in cardiac electrophysiology (2011) Prog Biophys Mol Biol, 107, pp. 134-146; Lambiase, P.D., Rinaldi, A., Hauck, J., Mobb, M., Gill, J.S., Bucknall, C.A., Non-contact left ventricular endocardial mapping in cardiac resynchronisation therapy (2004) Heart, 90, pp. 44-51; Perez-David, E., Arenal, A., Rubio-Guivernau, J.L., Castillo, R., Atea, L., Arbelo, E., Noninvasive identification of ventricular tachycardia-related conducting channels using contrast-enhanced magnetic resonance imaging in patients with chronic myocardial infarction: comparison of signal intensity scar mapping and endocardial voltage mappin (2011) J Am Coll Cardiol, 57, pp. 184-194; Fernández-Armenta, J., Berruezo, A., Andreu, D., Camara, O., Silva, E., Serra, L., Three-dimensional architecture of scar and conducting channels based on high resolution ce-CMR: insights for ventricular tachycardia ablation (2013) Circ Arrhythm Electrophysiol, 6, pp. 528-537; Petitjean, C., Dacher, J.N., A review of segmentation methods in short axis cardiac MR images (2011) Med Image Anal, 15, pp. 169-184; Frangi, A.F., Niessen, W.J., Viergever, M.A., Three-dimensional modeling for functional analysis of cardiac images: a review (2001) IEEE Trans Med Imaging, 20, pp. 2-25; Sermesant, M., Delingette, H., Ayache, N., An electromechanical model of the heart for image analysis and simulation (2006) IEEE Trans Med Imaging, 25, pp. 612-625; Mitchell, S., Lelieveldt, B., Geest, R., Bosch, J., Reiber, J., Sonka, M., Segmentation of cardiac MR images: An active appearance model approach (2000) Proc SPIE 3979, Med Imaging 2000: Image Process, pp. 224-234. , Hanson KM, editor, San Diego, CA (USA): SPIE Digital Library; Mitchell, S.C., Bosch, J.G., Lelieveldt, B.P.F., Geest, R.J., Reiber, J.H.C., Sonka, M., 3-D active appearance models: segmentation of cardiac MR and ultrasound images (2002) IEEE Trans Med Imaging, 21, pp. 1167-1178; Ordas, S., Boisrobert, L., Huguet, M., Frangi, A.F., Active shape models with invariant optimal features (IOF-ASM) application to cardiac MRI segmentation (2003) Comput Cardiol, 30, pp. 633-636. , Thessaloniki, Greece: IEEE; Young, A.A., Frangi, A.F., Computational cardiac atlases: from patient to population and back (2009) Exp Physiol, 94, pp. 578-596; Fonseca, C.G., Backhaus, M., Bluemke, D.A., Britten, R.D., Chung, J.D.O., Cowan, B.R., The Cardiac Atlas Project - an imaging database for computational modeling and statistical atlases of the heart (2011) Bioinformatics, 27, pp. 2288-2295; Janse, M.J., Kleber, A.G., Electrophysiological changes and ventricular arrhythmias in the early phase of regional myocardial ischemia (1981) Circ Res, 49, pp. 1069-1081; Ferrero, J.M., Trenor, B., Romero, L., Multiscale computational analysis of the bioelectric consequences of myocardial ischaemia and infarction (2014) Europace, 16, pp. 405-415; Ferrero, J.M., Sáiz, J., Ferrero, J.M., Thakor, N.V., Simulation of action potentials from metabolically impaired cardiac myocytes: role of ATP-sensitive K+ current (1996) Circ Res, 79, pp. 208-221; Ferrero, J.M., Trénor, B., Rodríguez, B., Sáiz, J., Electrical activity and reentry during acute regional myocardial ischemia: insights from simulations (2003) Int J Bifurc Chaos, 13, pp. 3703-3715; Shaw, R.M., Rudy, Y., Electrophysiologic effects of acute myocardial ischemia: a theoretical study of altered cell excitability and action potential duration (1997) Cardiovasc Res, 35, pp. 256-272; Trénor, B., Romero, L., Ferrero, J.M., Sáiz, J., Moltó, G., Alonso, J.M., Vulnerability to reentry in a regionally ischemic tissue: a simulation study (2007) Ann Biomed Eng, 35, pp. 1756-1770; Tice, B.M., Rodríguez, B., Eason, J., Trayanova, N., Mechanistic investigation into the arrhythmogenic role of transmural heterogeneities in regional ischaemia phase 1A (2007) Europace, 9, pp. vi46-58; Romero, L., Trénor, B., Alonso, J.M., Tobón, C., Saiz, J., Ferrero, J.M., The relative role of refractoriness and source-sink relationship in reentry generation during simulated acute ischemia (2009) Ann Biomed Eng, 37, pp. 1560-1571; Heidenreich, E.A., Ferrero, J.M., Rodríguez, J.F., Modeling the human heart under acute ischemia (2012) Patient-Specific Comput Model, 5, pp. 81-103. , Calvo Lopez B, Peña E, editors, Netherlands: Dordrecht: Springer; Rodríguez, B., Tice, B.M., Eason, J.C., Aguel, F., Ferrero, J.M., Trayanova, N., Effect of acute global ischemia on the upper limit of vulnerability: a simulation study (2004) Am J Physiol Heart Circ Physiol, 286, pp. H2078-H2088; Lazzara, R., Scherlag, B.J., Electrophysiologic basis for arrhythmias in ischemic heart disease (1984) Am J Cardiol, 53, pp. B1-7; Vigmond, E., Vadakkumpadan, F., Gurev, V., Arevalo, H., Deo, M., Plank, G., Towards predictive modelling of the electrophysiology of the heart (2009) Exp Physiol, 94, pp. 563-577; Rantner, L.J., Arevalo, H.J., Constantino, J.L., Efimov, I.R., Plank, G., Trayanova, N.A., Three-dimensional mechanisms of increased vulnerability to electric shocks in myocardial infarction: altered virtual electrode polarizations and conduction delay in the peri-infarct zone (2012) J Physiol, 590, pp. 4537-4551; Pop, M., Sermesant, M., Mansi, T., Crystal, E., Ghate, S., Peyrat, J.M., Correspondence between simple 3-D MRI-based computer models and in-vivo EP measurements in swine with chronic infarctions (2011) IEEE Trans Biomed Eng, 58, pp. 3483-3486; Ng, J., Jacobson, J.T., Ng, J.K., Gordon, D., Lee, D.C., Carr, J.C., Virtual electrophysiological study in a 3-dimensional cardiac magnetic resonance imaging model of porcine myocardial infarction (2012) J Am Coll Cardiol, 60, pp. 423-430; Arevalo, H., Plank, G., Helm, P., Halperin, H., Trayanova, N., Tachycardia in post-infarction hearts: insights from 3D image-based ventricular models (2013) PLoS One, 8; Kerckhoffs, R.C.P., Neal, M.L., Gu, Q., Bassingthwaighte, J.B., Omens, J.H., McCulloch, A.D., Coupling of a 3D finite element model of cardiac ventricular mechanics to lumped systems models of the systemic and pulmonic circulation (2007) Ann Biomed Eng, 35, pp. 1-18; Kerckhoffs, R.C.P., Campbell, S.G., Flaim, S.N., Howard, E.J., Sierra-Aguado, J., Mulligan, L.J., Multi-scale modeling of excitation-contraction coupling in the normal and failing heart (2009) Annu Int Conf IEEE Eng Med Biol Soc, 2009, pp. 4281-4282; Sermesant, M., Chabiniok, R., Chinchapatnam, P., Mansi, T., Billet, F., Moireau, P., Patient-specific electromechanical models of the heart for the prediction of pacing acute effects in CRT: a preliminary clinical validation (2012) Med Image Anal, 16, pp. 201-215; Vinson, C.A., Gibson, D.G., Yettram, A.L., Analysis of left ventricular behaviour in diastole by means of finite element method (1979) Br Heart J, 41, pp. 60-67; Yamaki, M., Kubota, I., Tomoike, H., Simulation of late potentials and arrhythmias by use of a three-dimensional heart model: casuality of peri-infarctional slow conduction in ventricular fibrillation (1999) J Electrocardiol, 32, pp. 115-121; Kerfoot, E., Lamata, P., Niederer, S., Hose, R., Spaan, J., Smith, N., Share and enjoy: anatomical models database - generating and sharing cardiovascular model data using web services (2013) Med Biol Eng Comput, 51, pp. 1181-1190",Review,Scopus,2-s2.0-84928897378
"Yang Y., Jiang Z., Ding F.","One-stage surgical treatment for Cantrell syndrome without repairing the left ventricular diverticulum: a case report",2015,"Cardiology in the Young",,,,"","",3,,10.1017/S104795111500030X,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927943820&partnerID=40&md5=183f2b585ec63b2ecb019f9e3ea97923","Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China","Yang, Y., Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Jiang, Z., Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Ding, F., Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China","Cantrell syndrome includes the defects of the heart, pericardium, diaphragm, abdominal wall, and sternum. The operative mortality is usually high. We report here a one-stage surgical correction in a case of Cantrell syndrome with left ventricular diverticulum. © Cambridge University Press 2015","Congenital heart disease; echocardiography; surgical treatment",,Article in Press,Scopus,2-s2.0-84927943820
"Tsai J., Grant A.M., Beckman M.G., Grosse S.D., Yusuf H.R., Richardson L.C.","Determinants of venous thromboembolism among hospitalizations of US adults: A multilevel analysis",2015,"PLoS ONE","10","4", e0123842,"","",,,10.1371/journal.pone.0123842,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928251681&partnerID=40&md5=59dbaa4912240dda2a8a10cf07c96edc","Division of Blood Disorders, National Center on Birth Defects, Developmental Disabilities Centers for Disease Control and PreventionAtlanta, GA, United States","Tsai, J., Division of Blood Disorders, National Center on Birth Defects, Developmental Disabilities Centers for Disease Control and PreventionAtlanta, GA, United States; Grant, A.M., Division of Blood Disorders, National Center on Birth Defects, Developmental Disabilities Centers for Disease Control and PreventionAtlanta, GA, United States; Beckman, M.G., Division of Blood Disorders, National Center on Birth Defects, Developmental Disabilities Centers for Disease Control and PreventionAtlanta, GA, United States; Grosse, S.D., Division of Blood Disorders, National Center on Birth Defects, Developmental Disabilities Centers for Disease Control and PreventionAtlanta, GA, United States; Yusuf, H.R., Division of Blood Disorders, National Center on Birth Defects, Developmental Disabilities Centers for Disease Control and PreventionAtlanta, GA, United States; Richardson, L.C., Division of Blood Disorders, National Center on Birth Defects, Developmental Disabilities Centers for Disease Control and PreventionAtlanta, GA, United States","Background: Venous thromboembolism (VTE) is a significant clinical and public health concern. We evaluated a variety of multilevel factors - demographics, clinical and insurance status, preexisting comorbid conditions, and hospital characteristics - for VTE diagnosis among hospitalizations of US adults. Methods: We generated adjusted odds ratios with 95% confidence intervals (CIs) and determined sources of outcome variation by conducting multilevel logistic regression analysis of data from the 2011 Nationwide Inpatient Sample that included 6,710,066 hospitalizations of US adults nested within 1,039 hospitals. Results: Among hospitalizations of adults, age, sex, race or ethnicity, total days of hospital stay, status of health insurance, and operating room procedure were important determinants of VTE diagnosis; each of the following preexisting comorbid conditions - acquired immune deficiency syndrome, anemia, arthritis, congestive heart failure, coagulopathy, hypertension, lymphoma, metastatic cancer, other neurological disorders, obesity, paralysis, pulmonary circulation disorders, renal failure, solid tumor without metastasis, and weight loss - was associated independently with 1.04 (95% CI: 1.02-1.06) to 2.91 (95% CI: 2.81-3.00) times increased likelihood of VTE diagnosis than among hospitalizations of adults without any of these corresponding conditions. The presence of 2 or more of such conditions was associated a 180%-450% increased likelihood of a VTE diagnosis. Hospitalizations of adults who were treated in urban hospitals were associated with a 14%-15% increased likelihood of having a VTE diagnosis than those treated in rural hospitals. Approximately 7.4% of the total variation in VTE diagnosis occurred between hospitals. Conclusion: The presence of certain comorbidities and hospital contextual factors is associated with significantly elevated likelihood of VTE diagnosis among hospitalizations of adults. The findings of this study underscore the importance of clinical risk assessment and adherence to evidence-based clinical practice guidelines in preventing VTE, as well as the need to evaluate potential contextual factors that might modify the risk of VTE among hospitalized patients. © 2015, Public Library of Science. All rights reserved.",,"DHHS, (2008) The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism, , http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf, Office of the Surgeon General. U.S. Department of Health & Human Services. Washington, DC. Availabe URL (accessed August 8, 2011); Tapson, V.F., Decousus, H., Pini, M., Chong, B.H., Froehlich, J.B., Monreal, M., Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism (2007) Chest, 132 (3), pp. 936-945. , Sep; PMID: 17573514; Ruppert, A., Steinle, T., Lees, M., Economic burden of venous thromboembolism: A systematic review (2011) Journal of Medical Economics, 14 (1), pp. 65-74. , PMID: 21222564; Tsai, J., Abe, K., Boulet, S.L., Beckman, M.G., Hooper, W.C., Grant, A.M., Predictive accuracy of 29-comorbidity index for in-hospital deaths in US adult hospitalizations with a diagnosis of venous thromboembolism (2013) PLOS ONE, 8 (7), p. e70061. , PMID: 23922902; Tsai, J., Grant, A.M., Soucie, J.M., Helwig, A., Yusuf, H.R., Boulet, S.L., Clustering Patterns of Comorbidities Associated with In-Hospital Death in Hospitalizations of US Adults with Venous Thromboembolism (2013) International Journal of Medical Sciences, 10 (10), pp. 1352-1360. , PMID: 23983596; Heit, J.A., Melton, L.J., 3rd, Lohse, C.M., Petterson, T.M., Silverstein, M.D., Mohr, D.N., Incidence of venous thromboembolism in hospitalized patients vs community residents (2001) Mayo Clinic Proceedings Mayo Clinic, 76 (11), pp. 1102-1110. , [Comparative Study Research Support, U.S. Gov't, P.H.S.] Nov PMID: 11702898; Spencer, F.A., Lessard, D., Emery, C., Reed, G., Goldberg, R.J., Venous thromboembolism in the outpatient setting (2007) Arch Intern Med, 167 (14), pp. 1471-1475. , [Research Support, N.I.H., Extramural] Jul 23 PMID: 17646600; White, R.H., Identifying risk factors for venous thromboembolism (2012) Circulation, 125 (17), pp. 2051-2053. , [Comment Editorial] May 1 PMID: 22474263; Wolberg, A.S., Aleman, M.M., Leiderman, K., Machlus, K.R., Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited (2012) Anesthesia and Analgesia, 114 (2), pp. 275-285. , Feb PMID: 22104070; Chandra, D., Parisini, E., Mozaffarian, D., Meta-analysis: Travel and risk for venous thromboembolism (2009) Ann Intern Med, 151 (3), pp. 180-190. , Aug 4 PMID: 19581633; Maynard, G.A., Stein, J., Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective Quality Improvement (2010) AHRQ Publication, , Prepared by the Society of Hospital Medicine. No. 08-0075. Rockville, MD. AHRQ. August; American College of Chest Physicians Antithrombotic T, Guyatt, G.H., Akl, E.A., Crowther, M., Gutterman, D.D., Schuunemann, H.J., Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2012) Chest, 141 (2), pp. 7S-47S. , Feb PMID: 22315257; Qaseem, A., Chou, R., Humphrey, L.L., Starkey, M., Shekelle, P., Venous thromboembolism prophylaxis in hospitalized patients: A clinical practice guideline from the American College of Physicians (2011) Ann Intern Med, 155 (9), pp. 625-632. , Nov 1 PMID: 22041951; Vogeli, C., Kang, R., Landrum, M., Hasnain Wynia, R., Weissman, J., Quality of care provided to individual patients in US hospitals: Results from an analysis of national Hospital Quality Alliance data (2009) Medical Care, 47 (5), pp. 591-599. , PMID: 19365292; Foster, D., Zrull, L., Chenoweth, J., Hospital Performance Differences by Ownership. Research Brief (2013) 100 Top Hospitals: Study Overview, 20th Edition, , Ann Arbor, MI. Truven Health Analytics; Houchens, R., Chu, B., Steiner, C., Hierarchical modeling using HCUP data (2007) HCUP Methods Series Report, , http://www.hcup-us.ahrq.gov/reports/methods.jsp\, Online. January 10, 2007 Available Last accessed: June 14, 2013; Huseynova, K., Xiong, W., Ray, J.G., Ahmed, N., Nathens, A.B., Venous Thromboembolism as a Marker of Quality of Care in Trauma (2009) Journal of the American College of Surgeons, 208 (4), pp. 547-552.e1. , 4 PMID: 19476788; (2013) Overview of the Nationwide Inpatient Sample (NIS), , http://www.hcup-us.ahrq.gov/nisoverview.jsp, Agency for Healthcare Research and Quality (AHRQ). Rockville, MD. URL accessed on 8/2/2013; (2011) Introduction to the HCUP Nationwide Inpatient Sample (NIS), , http://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2011.pdf, Healthcare Cost and Utilization Project (HCUP) Agency for Healthcare Research and Quality (AHRQ). Rockville, MD. URL accessed on 8/2/2013 PMID: 22514803; Elixhauser, A., Steiner, C., Harris, D.R., Coffey, R.M., Comorbidity measures for use with administrative data (1998) Med Care, 36 (1), pp. 8-27. , Jan PMID: 9431328; (2012) Comorbidity Software, Version 3.7, , http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp, Agency for Healthcare Research and Quality (AHRQ). Rockville, MD. URL accessed on 3/22/2012; (2012) Procedure Classes 2012, , http://www.hcup-us.ahrq.gov/toolssoftware/procedure/procedure.jsp, Agency for Healthcare Research and Quality (AHRQ). Rockville, MD. URL accessed on 7/12/2012; (2012) Major Operating Room Procedure Indicator, , http://www.hcup-us.ahrq.gov/db/vars/orproc/nisnote.jsp, Agency for Healthcare Research and Quality (AHRQ). Rockville, MD. URL accessed on 7/12/2012; Snijders, T.A.B., Bosker, R., (2011) Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling. Second Ed, , SAGE Publications Ltd; Carle, A.C., Fitting multilevel models in complex survey data with design weights: Recommendations (2009) BMC Med Res Methodol, 9, p. 49. , PMID: 19602263; Keenan, C.R., White, R.H., The effects of race/ethnicity and sex on the risk of venous thromboembolism (2007) Current Opinion in Pulmonary Medicine, 13 (5), pp. 377-383. , Sep PMID: 17940480; Yusuf, H.R., Reyes, N., Zhang, Q.C., Okoroh, E.M., Siddiqi, A.E., Tsai, J., Hospitalizations of Adults > = 60 Years of Age With Venous Thromboembolism (2013) Clin Appl Thromb Hemost, , Jun 27; Piazza, G., Seddighzadeh, A., Goldhaber, S.Z., Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: Prophylaxis omitted more often and pulmonary embolism more frequent (2007) Chest, 132 (2), pp. 554-561. , Aug PMID: 17573518; Kaboli, P.J., Brenner, A., Dunn, A.S., Prevention of venous thromboembolism in medical and surgical patients (2005) Cleveland Clinic Journal of Medicine, 72, pp. S7-S13. , Apr PMID: 15853174; Streiff, M.B., Lau, B.D., Thromboprophylaxis in nonsurgical patients (2012) Hematology Am Soc Hematol Educ Program, 2012, pp. 631-637. , PMID: 23233645; Cohen, A.T., Alikhan, R., Arcelus, J.I., Bergmann, J.F., Haas, S., Merli, G.J., Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients (2005) Thromb Haemost, 94 (4), pp. 750-759. , Oct PMID: 16270626; Dean, S.M., Abraham, W., Venous thromboembolic disease in congestive heart failure (2010) Congestive Heart Failure, 16 (4), pp. 164-169. , Jul-Aug PMID: 20662869; Lyman, G.H., Venous thromboembolism in the patient with cancer: Focus on burden of disease and benefits of thromboprophylaxis (2011) Cancer, 117 (7), pp. 1334-1349. , Apr 1 PMID: 21425133; Lopes, A.A., Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hypertension (2006) Cardiovascular & Hematological Agents in Medicinal Chemistry, 4 (1), pp. 53-59. , Jan; Ageno, W., Becattini, C., Brighton, T., Selby, R., Kamphuisen, P.W., Cardiovascular risk factors and venous thromboembolism: A meta-analysis (2008) Circulation, 117 (1), pp. 93-102. , Jan 1 PMID: 18086925; Kim, S.C., Schneeweiss, S., Liu, J., Solomon, D.H., Risk of venous thromboembolism in patients with rheumatoid arthritis (2013) Arthritis Care & Research, 65 (10), pp. 1600-1607. , Oct; Tveit, D.P., Hypolite, I.O., Hshieh, P., Cruess, D., Agodoa, L.Y., Welch, P.G., Chronic dialysis patients have high risk for pulmonary embolism (2002) American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 39 (5), pp. 1011-1017. , May PMID: 11979344; Heit, J.A., Silverstein, M.D., Mohr, D.N., Petterson, T.M., O'Fallon, W.M., Melton, L.J., 3rd, Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study (2000) Arch Intern Med, 160 (6), pp. 809-815. , Mar 27 PMID: 10737280; Dabbagh, O., Oza, A., Prakash, S., Sunna, R., Saettele, T.M., Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease (2010) Chest, 137 (5), pp. 1145-1149. , May PMID: 20040609; Bibas, M., Biava, G., Antinori, A., HIV-Associated Venous Thromboembolism (2011) Mediterranean Journal of Hematology and Infectious Diseases, 3 (1), p. e2011030. , PMID: 21869916; Franchini, M., Targher, G., Montagnana, M., Lippi, G., Iron and thrombosis (2008) Annals of Hematology, 87 (3), pp. 167-173. , Mar PMID: 18066546; Sundstrom, A., Seaman, H., Kieler, H., Alfredsson, L., The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: A case-control study using the General Practice Research Database (2009) BJOG, 116 (1), pp. 91-97. , Jan PMID: 19016686; Wattanakit, K., Cushman, M., Stehman-Breen, C., Heckbert, S.R., Folsom, A.R., Chronic kidney disease increases risk for venous thromboembolism (2008) Journal of the American Society of Nephrology: JASN, 19 (1), pp. 135-140. , Jan PMID: 18032796; Folsom, A.R., Boland, L.L., Cushman, M., Heckbert, S.R., Rosamond, W.D., Walston, J.D., Frailty and risk of venous thromboembolism in older adults (2007) The Journals of Gerontology Series A, Biological Sciences and Medical Sciences, 62 (1), pp. 79-82. , Jan PMID: 17301042; Valderas, J.M., Starfield, B., Sibbald, B., Salisbury, C., Roland, M., Defining comorbidity: Implications for understanding health and health services (2009) Annals of Family Medicine, 7 (4), pp. 357-363. , [Research Support, Non-U.S. Gov't Review] Jul-Aug PMID: 19597174; Pickett, K.E., Pearl, M., Multilevel analyses of neighbourhood socioeconomic context and health outcomes: A critical review (2001) J Epidemiol Community Health, 55 (2), pp. 111-122. , Feb PMID: 11154250; Papanikolaou, P.N., Christidi, G.D., Ioannidis, J.P., Patient outcomes with teaching versus nonteaching healthcare: A systematic review (2006) PLoS Med, 3 (9), p. e341. , Sep PMID: 16968119; Thornlow, D., Stukenborg, G., The association between hospital characteristics and rates of preventable complications and adverse events (2006) Medical Care, 44 (3), pp. 265-269. , PMID: 16501398; Sarrazin, M.S., Rosenthal, G.E., Finding pure and simple truths with administrative data (2012) JAMA, 307 (13), pp. 1433-1435. , [Comment Editorial] Apr 4 PMID: 22474208; Duncan, C., Jones, K., Moon, G., Context, composition and heterogeneity: Using multilevel models in health research (1998) Soc Sci Med, 46 (1), pp. 97-117. , Jan PMID: 9464672",Article,Scopus,2-s2.0-84928251681
"Wasilewski J., Roleder M., Niedziela J., Nowakowski A., Osadnik T., Glowacki J., Mirota K., Polonski L.","The Role of Septal Perforators and “Myocardial Bridging Effect” in Atherosclerotic Plaque Distribution in the Coronary Artery Disease",2015,"Polish Journal of Radiology","80","1",,"195","201",,,10.12659/PJR.893227,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928159925&partnerID=40&md5=dfae918554a454d3eef43fd38f606178","3rd Department of Cardiology, Medical University of Silesia, Silesian Center for Heart DiseasesZabrze, Poland; Department of Mechanical Engineering, University of SheffieldSheffield, United Kingdom; Department of Diagnostic Imaging, Medical University of Silesia, Silesian Center for Heart DiseasesZabrze, Poland; Department of Mechanical Engineering Fundamentals, University of Bielsko-BiałaBielsko-Biała, Poland","Wasilewski, J., 3rd Department of Cardiology, Medical University of Silesia, Silesian Center for Heart DiseasesZabrze, Poland; Roleder, M., 3rd Department of Cardiology, Medical University of Silesia, Silesian Center for Heart DiseasesZabrze, Poland; Niedziela, J., 3rd Department of Cardiology, Medical University of Silesia, Silesian Center for Heart DiseasesZabrze, Poland; Nowakowski, A., Department of Mechanical Engineering, University of SheffieldSheffield, United Kingdom; Osadnik, T., 3rd Department of Cardiology, Medical University of Silesia, Silesian Center for Heart DiseasesZabrze, Poland; Głowacki, J., Department of Diagnostic Imaging, Medical University of Silesia, Silesian Center for Heart DiseasesZabrze, Poland; Mirota, K., Department of Mechanical Engineering Fundamentals, University of Bielsko-BiałaBielsko-Biała, Poland; Poloński, L., 3rd Department of Cardiology, Medical University of Silesia, Silesian Center for Heart DiseasesZabrze, Poland","The distribution of atherosclerotic plaque burden in the human coronary arteries is not uniform. Plaques are located mostly in the left anterior descending artery (LAD), then in the right coronary artery (RCA), circumflex branch (LCx) and the left main coronary artery (LM) in a decreasing order of frequency. In the LAD and LCx, plaques tend to cluster within the proximal segment, while in the RCA their distribution is more uniform. Several factors have been involved in this phenomenon, particularly flow patterns in the left and right coronary artery. Nevertheless, it does not explain the difference in lesion frequency between the LAD and the LCx as these are both parts of the left coronary artery. Branching points are considered to be the risk points of atherosclerosis. In the LCx, the number of side branches is lower than in the LAD or RCA and there are no septal perforators with intramuscular courses like in the proximal third of the LAD and the posterior descending artery (PDA). We hypothesized that septal branches generate disturbed flow in the LAD and PDA in a similar fashion to the myocardial bridge (myocardial bridging effect). This coronary architecture determines the non-uniform plaque distribution in coronary arteries and LAD predisposition to plaque formation. © Pol J Radiol.","Atherosclerosis; Haemodynamics; Myocardial bridge; Septal Branch","Montenegro, M.R., Eggen, D.A., Topography of atherosclerosis in the coronary arteries (1968) Lab Invest, 18 (5), pp. 586-593; Ackerman, R.F., Dry, T.J., Edwards, J.E., Relationship of Various Factors to the Degree of Coronary Atherosclerosis in Women (1950) Circulation, 1 (6), pp. 1345-1354; White, N.K., Edwards, J.E., Dry, T.J., The Relationship of the Degree of Coronary Atherosclerosis with Age, in Men (1950) Circulation, 1 (4), pp. 645-654; Schmermund, A., Baumgart, D., Möhlenkamp, S., Natural history and topographic pattern of progression of coronary calcification in symptomatic patients: An electron-beam CT study (2001) Arterioscler Thromb Vasc Biol, 21 (3), pp. 421-426; Tuzcu, E.M., Kapadia, S.R., Tutar, E., High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound (2001) Circulation, 103 (22), pp. 2705-2710; Halon, D.A., Sapoznikov, D., Lewis, B.S., Gotsman, M.S., Localization of lesions in the coronary circulation (1983) Am J Cardiol, 52 (8), pp. 921-926; Giannoglou, G.D., Antoniadis, A.P., Chatzizisis, Y.S., Louridas, G.E., Difference in the topography of atherosclerosis in the left versus right coronary artery in patients referred for coronary angiography (2010) BMC Cardiovasc Disord, 10, p. 26; O’Rourke, R.A., Brundage, B.H., Froelicher, V.F., American College of Cardiology/American Heart Association Expert Consensus Document on Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease: Committee Members (2000) Circulation, 102 (1), pp. 126-140; Lee, S., Choi, E.-K., Chang, H.-J., Subclinical coronary artery disease as detected by coronary computed tomography angiography in an asymptomatic population (2010) Korean Circ J, 40 (9), pp. 434-441; Lai, H.M., Holtzman, D., Aronow, W.S., Association of coronary artery calcium with severity of myocardial ischemia in left anterior descending, left circumflex, and right coronary artery territories (2012) Clin Cardiol, 35 (1), pp. 61-63; Enrico, B., Suranyi, P., Thilo, C., Coronary artery plaque formation at coronary CT angiography: Morphological analysis and relationship to hemodynamics (2009) Eur Radiol, 19 (4), pp. 837-844; Erciyes, D., Şener, M., Duran, C., Segmental distribution of calcium scores in the coronary arteries (2012) Arch Turk Soc Cardiol, 40, pp. 671-680; Wasilewski, J., Niedziela, J., Nowakowski, A., The Distribution of Coronary Artery Atherosclerosis Burden. The Impact of Septal Perforators on Plaque Localization at the Left Anterior Descending Artery; The Effect of Myocardial Bridging (2014) Am J Cardiol, 113 (7). , S19. [OP-064] 10th International Congress of Update in Cardiology and Cardiovascular Surgery, Antalaya [Turkey] 13–16.03.2014, abstracts; Golinvaux, N., Maehara, A., Mintz, G.S., An intravascular ultrasound appraisal of atherosclerotic plaque distribution in diseased coronary arteries (2012) Am Heart J, 163 (4), pp. 624-631; Hong, M.K., Mintz, G.S., Cheol, W.L., The site of plaque rupture in native coronary arteries: A three-vessel intravascular ultrasound analysis (2005) J am Coll Cardiol, 46 (2), pp. 261-265; Cheruvu, P.K., Finn, A.V., Gardner, C., Frequency and Distribution of Thin-Cap Fibroatheroma and Ruptured Plaques in Human Coronary Arteries. A Pathologic Study (2007) J am Coll Cardiol, 50 (10), pp. 940-949; Li, Y.-S., Haga, J.H., Chien, S., Molecular basis of the effects of shear stress on vascular endothelial cells (2005) J Biomech, 38 (10), pp. 1949-1971; Lehoux, S., Castier, Y., Tedgui, A., Molecular mechanisms of the vascular responses to haemodynamic forces (2006) J Intern Med, 259 (4), pp. 381-392; Gimbrone, M.A., Topper, J.N., Nagel, T., Endothelial dysfunction, hemodynamic forces, and atherogenesis (2000) Ann N Y Acad Sci, 902, pp. 230-239. , discussion 239–40; Malek, A.M., Alper, S.L., Izumo, S., Hemodynamic shear stress and its role in atherosclerosis (1999) JAMA, 282 (21), pp. 2035-2042; Cunningham, K.S., Gotlieb, A.I., The role of shear stress in the pathogenesis of atherosclerosis (2005) Lab Invest, 85 (1), pp. 9-23; Resnick, N., Yahav, H., Shay-Salit, A., Fluid shear stress and the vascular endothelium: For better and for worse (2003) Prog Biophys Mol Biol, 81, pp. 177-199; Chiu, J.-J., Chien, S., Effects of disturbed flow on vascular endothelium: Pathophysiological basis and clinical perspectives (2011) Physiol Rev, 91 (1), pp. 327-387; Demer, L.L., Watson, K.E., Bostrom, K., Mechanism of calcification in atherosclerosis (1994) Trends Cardiovasc Med, 4, pp. 45-49; Doherty, T.M., Asotra, K., Fitzpatrick, L.A., Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads (2003) Proc Natl Acad Sci USA, 100 (20); Liu, L., Yuan, W., Wang, J., Mechanisms for osteogenic differentiation of human mesenchymal stem cells induced by fluid shear stress (2010) Biomech Model Mechanobiol, 9, pp. 659-670; Sorescu, G.P., Song, H., Tressel, S.L., Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase (2004) Circ Res, 95, pp. 773-779; Stone, P.H., Coskun, A.U., Yeghiazarians, Y., Prediction of sites of coronary atherosclerosis progression: In vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behavior (2003) Curr Opin Cardiol, 18 (6), pp. 458-470; Chatzizisis, Y.S., Giannoglou, G.D., Parcharidis, G.E., Louridas, G.E., Is left coronary system more susceptible to atherosclerosis than right? A pathophysiological insight (2007) Int J Cardiol, 116 (1), pp. 7-13; Chatzizisis, Y.S., Giannoglou, G.D., Pulsatile flow: A critical modulator of the natural history of atherosclerosis (2006) Med Hypotheses, 67 (2), pp. 338-340; Alegria, J.R., Herrmann, J., Holmes, D.R., Myocardial bridging (2005) Eur Heart J, 26 (12), pp. 1159-1168; Mohlenkamp, S., Update on Myocardial Bridging (2002) Circulation, 106 (20), pp. 2616-2622; Nakanishi, R., Rajani, R., Ishikawa, Y., Myocardial bridging on coronary cta: An innocent bystander or a culprit in myocardial infarction? (2012) J Cardiovasc Comput Tomogr, 6 (1), pp. 3-13; Czekajska-Chehab, E., Staśkiewicz, G., Orzechowski, P., Drop, A., Multiple myocardial bridges of coronary arteries in ECG-gated MSCT (2010) Pol J Radiol, 75 (1), pp. 154-155; Ishikawa, Y., Akasaka, Y., Ito, K., Significance of anatomical properties of myocardial bridge on atherosclerosis evolution in the left anterior descending coronary artery (2006) Atherosclerosis, 186 (2), pp. 380-389; Ishii, T., Asuwa, N., Masuda, S., Ishikawa, Y., The effects of a myocardial bridge on coronary atherosclerosis and ischaemia (1998) J Pathol, 185, pp. 4-9; Lee, S.S., Wu, T.L., The role of the mural coronary artery in prevention of coronary atherosclerosis (1972) Arch Pathol, 93 (1), pp. 32-35; Ge, J., Erbel, R., Rupprecht, H.J., Comparison of intravascular ultrasound and angiography in the assessment of myocardial bridging (1994) Circulation, 89, pp. 1725-1732; Nakaura, T., Nagayoshi, Y., Awai, K., Myocardial bridging is associated with coronary atherosclerosis in the segment proximal to the site of bridging (2013) J Cardiol, 63 (2), pp. 134-139; Klues, H.G., Schwarz, E.R., Vom Dahl, J., Disturbed intracoronary hemodynamics in myocardial bridging: Early normalization by intracoronary stent placement (1997) Circulation, 96, pp. 2905-2913; Robicsek, F., Thubrikar, M.J., The freedom from atherosclerosis of intramyocardial coronary arteries: Reduction of mural stress – a key factor (1994) Eur J Cardiothorac Surg, 8, pp. 228-235; Ge, J., Jeremias, A., Rupp, A., New signs characteristic of myocardial bridging demonstrated by intracoronary ultrasound and Doppler (1999) Eur Heart J, 20, pp. 1707-1716; Haga, J.H., Li, Y.-S., Chien, S., Molecular basis of the effects of mechanical stretch on vascular smooth muscle cells (2007) J Biomech, 40, pp. 947-960; Chatzizisis, Y.S., Giannoglou, G.D., Myocardial bridges spared from atherosclerosis: Overview of the underlying mechanisms (2009) Can J Cardiol, 25 (4), pp. 219-222; Soulis, J.V., Giannoglou, G.D., Chatzizisis, Y.S., Spatial and phasic oscillation of non-Newtonian wall shear stress in human left coronary artery bifurcation: An insight to atherogenesis (2006) Coron Artery Dis, 17, pp. 351-358; Thubrikar, M.J., Robicsek, F., Pressure-induced arterial wall stress and atherosclerosis (1995) Ann Thorac Surg, 59 (6), pp. 1594-1603; Levin, D.C., (1988) Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, pp. 268-310; Topaz, O., Disciascio, G., Vetrovec, G.W., Septal perforator arteries: From angiographic-morphologic characteristics to related revascularization options (1992) Am Heart J, 124 (3), pp. 810-815; James, T.N., Burch, G.E., Blood Supply of the Human Interventricular Septum (1958) Circulation, 17 (3), pp. 391-396; Possatti, L.L., Ramos, H.F., Rodrigues, H., Musso, F., Anatomical study of the anterior intraventricular septal branches and their relationschip with the blood supply of the septomarginal trabercula (2005) Braz J Morphol Sci, 22, pp. 169-174; Bream, P.R., Jones, J.M., Elliott, L.P., The anomalous septal perforating artery. Its origin from the first diagonal, first marginal, or circumflex artery (1981) Radiology, 138, pp. 301-307; Bream, P.R., Souza, A.S., Elliott, L.P., Right superior septal perforator artery: Its angiographic description and clinical significance (1979) Am J Roentgenol, 133 (1), pp. 67-73; Von Lüdinghausen, M., Ohmachi, N., Right superior septal artery with “normal” right coronary and ectopic “early” aortic origin: A contribution to the vascular supply of the interventricular septum of the human heart (2001) Clin Anat, 14 (5), pp. 312-319; Takeguchi, T., Ibukuro, K., Fukuda, H., Anatomy of right superior septal artery demonstrated on the coronary CT scan (2012) Acta Radiol, 53, pp. 23-27; Balghith, M.A., Schoenhagen, P., Foody, J.M., Atherosclerotic plaque distribution in the left anterior descending coronary artery as assessed by intravascular ultrasound (2003) Am J Cardiol, 91 (4), pp. 443-445; Watanabe, N., Akasaka, T., Yamaura, Y., Intramyocardial coronary flow characteristics in patients with hypertrophic cardiomyopathy: Non-invasive assessment by transthoracic Doppler echocardiography (2003) Heart, 89 (6), pp. 657-658; Navarro-Lopez, F., Soler, J., Magriña, J., Systolic compression of coronary artery in hypertrophic cardiomyopathy (1986) Int J Cardiol, 12, pp. 309-320; Kostis, J.B., Moreyra, A.E., Natarajan, N., The pathophysiology and diverse etiology of septal perforator compression (1979) Circulation, 59, pp. 913-919; Kenny, A., Wisbey, C.R., Shapiro, L.M., Profiles of coronary blood flow velocity in patients with aortic stenosis and the effect of valve replacement: A transthoracic echocardiographic study (1994) Br Heart J, 71 (1), pp. 57-62; Yoshikawa, J., Akasaka, T., Yoshida, K., Takagi, T., Systolic coronary flow reversal and abnormal diastolic flow patterns in patients with aortic stenosis: Assessment with an intracoronary Doppler catheter (1993) J am Soc Echocardiogr, 6 (5), pp. 516-524; Altunkan, S., Erdogan, N., Altin, L., Budoff, M.J., Relation of coronary artery calcium to left ventricular mass and geometry in patients with essential hypertension (2003) Blood Press Monit, 8, pp. 9-15; Gardin, J.M., Iribarren, C., Detrano, R.C., Relation of echocardiographic left ventricular mass, geometry and wall stress, and left atrial dimension to coronary calcium in young adults (The CARDIA study) (2005) Am J Cardiol, 95, pp. 626-629; Levin, D.C., Beckmann, C.F., Garnic, J.D., Frequency and clinical significance of failure to visualize the conus artery during coronary arteriography (1981) Circulation, 63, pp. 833-837; Koşar, P., Ergun, E., Oztürk, C., Koşar, U., Anatomic variations and anomalies of the coronary arteries: 64-slice CT angiographic appearance (2009) Diagn Interv Radiol, 15, pp. 275-283; Pejković, B., Krajnc, I., Erhuber, F., Kosutić, D., Anatomical aspects of the arterial blood supply to the sinoatrial and atrioventricular nodes of the human heart (2008) J Int Med Res, 36 (4), pp. 691-698; Fioranelli, M., Gonnella, C., (2009) Clinical Anatomy of the Coronary Circulation, (Springer), pp. 1-11. , Milano: , Milan; Nerantzis, C.E., Gribizi, J.E., Margaris, N.G., Posterior right diagonal artery (1994) Anat Rec, 238, pp. 528-532; Margaris, N.G., Kostopoulos, K.G., Nerantzis, C.E., Posterior right diagonal artery. An angiographic study (1997) Angiology, 48, pp. 673-677",Article,Scopus,2-s2.0-84928159925
"Sarkis E.","Penile and generalised calciphylaxis in peritoneal dialysis",2015,"BMJ Case Reports","2015",, 209153,"","",,,10.1136/bcr-2014-209153,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928318942&partnerID=40&md5=5841e1a4b4237cc9394f53aaced6fe1a","Department of Internal Medicine, Cooper Medical CenterCamden, NJ, United States","Sarkis, E., Department of Internal Medicine, Cooper Medical CenterCamden, NJ, United States","This is a rare case of penile and generalised calciphylaxis. We describe the case of a patient admitted to our hospital for septic shock and necrotic skin findings, end-stage renal disease on peritoneal dialysis. Skin findings turned out to be calciphyactic lesions. The patient was taken to the operating room for penile debridement and started on antibiotics. He was treated with sodium thiosulfate and switched to haemodialysis. Calciphylaxis is a rare disease in which the treatment is basically supportive. Further studies are needed to identify the risk factors, mechanisms of disease and treatment modalities. Copyright © 2015 BMJ Publishing Group. All rights reserved.",,"Sandhu, G., Casares, P., Ranade, A., Acute calciphylaxis precipitated by the initiation of hemodialysis (2013) Clin Nephrol, 80, pp. 301-305; Adrogué, H.J., Frazier, M.R., Zeluff, B., Systemic calciphylaxis revisited (1981) Am J Nephrol, 1, pp. 177-183; Janigan, D.T., Hirsch, D.J., Klassen, G.A., Calcified subcutaneous arterioles with infarcts of the subcutis and skin (""calciphylaxis"") in chronic renal failure (2000) Am J Kidney Dis, 35, pp. 588-597; Mazhar, A.R., Johnson, R.J., Gillen, D., Risk factors and mortality associated with calciphylaxis in end-stage renal disease (2001) Kidney Int, 60, pp. 324-332; Coates, T., Kirkland, G.S., Dymock, R.B., Cutaneous necrosis from calcific uremic arteriolopathy (1998) Am J Kidney Dis, 32, pp. 384-391; New, N., Mohandas, J., John, G.T., Calcific uremic arteriolopathy in peritoneal dialysis populations (2011) Int J Nephrol; Nigwekar, S.U., Wolf, M., Sterns, R.H., Calciphylaxis from nonuremic causes: A systematic review (2008) Clin J Am Soc Nephrol, 3, pp. 1139-1143; Nigwekar, S.U., Brunelli, S.M., Meade, D., Sodium thiosulfate therapy for calcific uremic arteriolopathy (2013) Clin J Am Soc Nephrol, 8, pp. 1162-1170; Zitt, E., König, M., Vychytil, A., Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients (2013) Nephrol Dial Transplant, 28, pp. 1232-1240; Yatzidis, H., Successful sodium thiosulphate treatment for recurrent calcium urolithiasis (1985) Clin Nephrol, 23, pp. 63-67; Hayden, M.R., Tyagi, S.C., Kolb, L., Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: The emerging role of sodium thiosulfate (2005) Cardiovasc Diabetol, 4, p. 4; Akai, A., Okamoto, H., Shigematsu, K., Revascularization surgery for penile calciphylaxis (2013) J Vasc Surg, 58 (6), pp. 1665-1667; O'Neil, B., Southwick, A.W., Three cases of penile calciphylaxis: Diagnosis, treatment strategies, and the role of sodium thiosulfate (2012) Urology, 80, pp. 5-8; Bhatty, T.A., Riaz, K., Calciphylaxis mimicking penile gangrene: A case report (2009) Scienti ficWorldJournal, 9, pp. 1355-1359; García Morúa, A., Gutiérrez García, J.D., Arrambide Gutiérrez, J.G., Penile calciphylaxis: 5-year experience and literature review (2009) Actas Urol Esp, 33, pp. 1019-1023. , (Urology Service, Hospital Universitario Dr. José E. González, Monterrey, Nuevo León, Mexico); Sandhu, G., Gini, M.B., Ranade, A., Penile calciphylaxis: A life-threatening condition successfully treated with sodium thiosulfate (2012) Am J Ther, 19, pp. e66-e68",Article,Scopus,2-s2.0-84928318942
"Byrd J.C., Furman R.R., Coutre S.E., Burger J.A., Blum K.A., Coleman M., Wierda W.G., Jones J.A., Zhao W., Heerema N.A., Johnson A.J., Shaw Y., Bilotti E., Zhou C., James D.F., O'Brien S.","Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib",2015,"Blood","125","16",,"2497","2506",,1,10.1182/blood-2014-10-606038,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927732048&partnerID=40&md5=d804bb6ba49e17d4a4193cf3664af6e9","Ohio State UniversityColumbus, OH, United States; Weill Cornell Medical CollegeNew York, NY, United States; Stanford Cancer Center, Stanford University, School of MedicineStanford, CA, United States; University of Texas, MD Anderson Cancer CenterHouston, TX, United States; Pharmacyclics, Inc.Sunnyvale, CA, United States","Byrd, J.C., Ohio State UniversityColumbus, OH, United States; Furman, R.R., Weill Cornell Medical CollegeNew York, NY, United States; Coutre, S.E., Stanford Cancer Center, Stanford University, School of MedicineStanford, CA, United States; Burger, J.A., University of Texas, MD Anderson Cancer CenterHouston, TX, United States; Blum, K.A., Ohio State UniversityColumbus, OH, United States; Coleman, M., Weill Cornell Medical CollegeNew York, NY, United States; Wierda, W.G., University of Texas, MD Anderson Cancer CenterHouston, TX, United States; Jones, J.A., Ohio State UniversityColumbus, OH, United States; Zhao, W., Ohio State UniversityColumbus, OH, United States; Heerema, N.A., Ohio State UniversityColumbus, OH, United States; Johnson, A.J., Ohio State UniversityColumbus, OH, United States; Shaw, Y., Pharmacyclics, Inc.Sunnyvale, CA, United States; Bilotti, E., Pharmacyclics, Inc.Sunnyvale, CA, United States; Zhou, C., Pharmacyclics, Inc.Sunnyvale, CA, United States; James, D.F., Pharmacyclics, Inc.Sunnyvale, CA, United States; O'Brien, S., University of Texas, MD Anderson Cancer CenterHouston, TX, United States","Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL). The durable responses observed with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period. We report on median 3-year follow-up of 132 patients with symptomatic treatment-naïve and relapsed/refractory CLL or small lymphocytic lymphoma. Longer treatment with ibrutinib was associated with improvement in response quality over time and durable remissions. Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections. Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease. Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 year and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better. Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse. © 2015 by The American Society of Hematology.",,"Hallek, M., Cheson, B.D., Catovsky, D., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines (2008) Blood, 111 (12), pp. 5446-5456; Döhner, H., Stilgenbauer, S., Benner, A., Genomic aberrations and survival in chronic lymphocytic leukemia (2000) N Engl J Med, 343 (26), pp. 1910-1916; Lozanski, G., Ruppert, A.S., Heerema, N.A., Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: A Cancer and Leukemia Group B study (2012) Leuk Lymphoma, 53 (9), pp. 1743-1748; Austen, B., Skowronska, A., Baker, C., Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion (2007) J Clin Oncol, 25 (34), pp. 5448-5457; Wang, L., Lawrence, M.S., Wan, Y., SF3B1 and other novel cancer genes in chronic lymphocytic leukemia (2011) N Engl J Med, 365 (26), pp. 2497-2506; Zenz, T., Eichhorst, B., Busch, R., TP53 mutation and survival in chronic lymphocytic leukemia (2010) J Clin Oncol, 28 (29), pp. 4473-4479; Puente, X.S., Pinyol, M., Quesada, V., Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia (2011) Nature, 475 (7354), pp. 101-105; Messina, M., Del Giudice, I., Khiabanian, H., Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness (2014) Blood, 123 (15), pp. 2378-2388; Byrd, J.C., Gribben, J.G., Peterson, B.L., Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy (2006) J Clin Oncol, 24 (3), pp. 437-443; Hallek, M., Fischer, K., Fingerle-Rowson, G., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial (2010) Lancet, 376 (9747), pp. 1164-1174; Goede, V., Fischer, K., Busch, R., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions (2014) N Engl J Med, 370 (12), pp. 1101-1110; Hillmen, P., Robak, T., Janssens, A., Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): Results of the phase III study complement 1 (OMB110911) 55th American Society of Hematology Annual Meeting and Exposition. December 7-10, 2013. New Orleans, LA, , [abstract]. Paper presented at; Tam, C.S., O'Brien, S., Wierda, W., Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia (2008) Blood, 112 (4), pp. 975-980; Woyach, J.A., Ruppert, A.S., Heerema, N.A., Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712 (2011) J Clin Oncol, 29 (10), pp. 1349-1355; Gribben, J.G., Hosing, C., Maloney, D.G., Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia (2011) Biol Blood Marrow Transplant, 17 (1), pp. S63-S70; Druker, B.J., Talpaz, M., Resta, D.J., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia (2001) N Engl J Med, 344 (14), pp. 1031-1037; O'Brien, S.G., Guilhot, F., Larson, R.A., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2003) N Engl J Med, 348 (11), pp. 994-1004; Hillmen, P., Using the biology of chronic lymphocytic leukemia to choose treatment (2011) Hematology Am Soc Hematol Educ Program, 2011, pp. 104-109; Herman, S.E.M., Gordon, A.L., Hertlein, E., Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 (2011) Blood, 117 (23), pp. 6287-6296; Ponader, S., Chen, S.-S., Buggy, J.J., The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo (2012) Blood, 119 (5), pp. 1182-1189; Honigberg, L.A., Smith, A.M., Sirisawad, M., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy (2010) Proc Natl Acad Sci USA, 107 (29), pp. 13075-13080; Buchner, M., Fuchs, S., Prinz, G., Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia (2009) Cancer Res, 69 (13), pp. 5424-5432; Herman, S.E.M., Gordon, A.L., Wagner, A.J., Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals (2010) Blood, 116 (12), pp. 2078-2088; Hoellenriegel, J., Meadows, S.A., Sivina, M., The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia (2011) Blood, 118 (13), pp. 3603-3612; Advani, R.H., Buggy, J.J., Sharman, J.P., Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies (2013) J Clin Oncol, 31 (1), pp. 88-94; Byrd, J.C., Furman, R.R., Coutre, S.E., Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia (2013) N Engl J Med, 369 (1), pp. 32-42; O'Brien, S., Furman, R.R., Coutre, S.E., Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial (2014) Lancet Oncol, 15 (1), pp. 48-58; Byrd, J.C., Brown, J.R., O'Brien, S., Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia (2014) N Engl J Med, 371 (3), pp. 213-223; Pharmacyclics, Inc., (2015) IMBRUVICA® (Ibrutinib), , [package insert]. Sunnyvale, CA: Pharmacyclics, Inc; International Harmonization Project on Lymphoma, Cheson, B.D., Pfistner, B., Juweid, M.E., Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25 (5), pp. 579-586; Byrd, J.C., McGrail, L.H., Hospenthal, D.R., Howard, R.S., Dow, N.A., Diehl, L.F., Herpes virus infections occur frequently following treatment with fludarabine: Results of a prospective natural history study (1999) Br J Haematol, 105 (2), pp. 445-447; Smith, D.D., Goldstein, L., Cheng, M., Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib (2015) Ann Hematol, 94 (2), pp. 249-256; Woyach, J.A., Smucker, K., Smith, L.L., Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy (2014) Blood, 123 (12), pp. 1810-1817; Pettitt, A.R., Jackson, R., Carruthers, S., Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the national cancer research institute CLL206 trial (2012) J Clin Oncol, 30 (14), pp. 1647-1655; Hillmen, P., Skotnicki, A.B., Robak, T., Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia (2007) J Clin Oncol, 25 (35), pp. 5616-5623; Stephens, D.M., Ruppert, A.S., Jones, J.A., Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del (17p13.1) karyotype at a single center (2014) Leukemia, 28 (6), pp. 1365-1368; Friedberg, J.W., Sharman, J., Sweetenham, J., Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia (2010) Blood, 115 (13), pp. 2578-2585; Brown, J.R., Byrd, J.C., Coutre, S.E., Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia (2014) Blood, 123 (22), pp. 3390-3397; Non-Hodgkin's Lymphomas, V3, , www.nccn.org, Available at Accessed July 31, 2014; Cheson, B.D., Byrd, J.C., Rai, K.R., Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia (2012) J Clin Oncol, 30 (23), pp. 2820-2822; Dubovsky, J.A., Beckwith, K.A., Natarajan, G., Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes (2013) Blood, 122 (15), pp. 2539-2549; Farooqui, M., Aue, G., Valdez, J., Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p 55th American Society of Hematology Annual Meeting and Exposition. December 7-10, 2013. New Orleans, LA, , [abstract]. Paper presented at; Woyach, J.A., Furman, R.R., Liu, T.-M., Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib (2014) N Engl J Med, 370 (24), pp. 2286-2294",Article,Scopus,2-s2.0-84927732048
"Wan K., Zhao J., Huang H., Zhang Q., Chen X., Zeng Z., Zhang L., Chen Y.","The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization",2015,"PLoS ONE","10","4", e0123521,"","",,,10.1371/journal.pone.0123521,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928150206&partnerID=40&md5=2d765acbedc11cb9646e41b6b3b58c29","Department of Cardiology, West China Hospital, Sichuan UniversityChengdu, Sichuan Province, China; Division of Cardiology, People's Hospital of Sichuan ProvinceChengdu, Sichuan, China","Wan, K., Department of Cardiology, West China Hospital, Sichuan UniversityChengdu, Sichuan Province, China; Zhao, J., Department of Cardiology, West China Hospital, Sichuan UniversityChengdu, Sichuan Province, China; Huang, H., Division of Cardiology, People's Hospital of Sichuan ProvinceChengdu, Sichuan, China; Zhang, Q., Department of Cardiology, West China Hospital, Sichuan UniversityChengdu, Sichuan Province, China; Chen, X., Department of Cardiology, West China Hospital, Sichuan UniversityChengdu, Sichuan Province, China; Zeng, Z., Department of Cardiology, West China Hospital, Sichuan UniversityChengdu, Sichuan Province, China; Zhang, L., Department of Cardiology, West China Hospital, Sichuan UniversityChengdu, Sichuan Province, China; Chen, Y., Department of Cardiology, West China Hospital, Sichuan UniversityChengdu, Sichuan Province, China","Aims: High triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) are cardiovascular risk factors. A positive correlation between elevated TG/HDL-C ratio and all-cause mortality and cardiovascular events exists in women. However, utility of TG to HDL-C ratio for prediction is unknown among acute coronary syndrome (ACS). Methods: Fasting lipid profiles, detailed demographic data, and clinical data were obtained at baseline from 416 patients with ACS after coronary revascularization. Subjects were stratified into three levels of TG/HDL-C. We constructed multivariate Cox-proportional hazard models for all-cause mortality over a median follow-up of 3 years using log TG to HDL-C ratio as a predictor variable and analyzing traditional cardiovascular risk factors. We constructed a logistic regression model for major adverse cardiovascular events (MACEs) to prove that the TG/HDL-C ratio is a risk factor. Results: The subject's mean age was 64 ± 11 years; 54.5% were hypertensive, 21.8% diabetic, and 61.0% current or prior smokers. TG/HDL-C ratio ranged from 0.27 to 14.33. During the follow-up period, there were 43 deaths. In multivariate Cox models after adjusting for age, smoking, hypertension, diabetes, and severity of angiographic coronary disease, patients in the highest tertile of ACS had a 5.32-fold increased risk of mortality compared with the lowest tertile. After adjusting for conventional coronary heart disease risk factors by the logistic regression model, the TG/HDL-C ratio was associated with MACEs. Conclusion: The TG to HDL-C ratio is a powerful independent predictor of all-cause mortality and is a risk factor of cardiovascular events. © 2015 Wan et al.",,"Fuster, V., Kelly, B.B., Vedanthan, R., Global cardiovascular health: Urgent need for an intersectoral approach (2011) J Am Coll Cardiol, 58, pp. 1208-1210. , PMID: 21903051; Neil, H.A., Cooper, J., Betteridge, D.J., Capps, N., McDowell, I.F., Durrington, P.N., All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study (2010) Atherosclerosis, 211, pp. 618-623. , PMID: 20356595; Ballantyne, C.M., Olsson, A.G., Cook, T.J., Mercuri, M.F., Pedersen, T.R., Kjekshus, J., Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S (2001) Circulation, 104, pp. 3046-3051. , PMID: 11748098; Winkler, L., Schlag, B., Ostermann, G., Dargel, R., Apolipoproteins as risk indicators of ischemic heart disease (1989) Przegl Lek, 46, pp. 595-598. , PMID: 2587787; Thomas, G.S., Cromwell, W.C., Ali, S., Chin, W., Flaim, J.D., Davidson, M., Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: A randomized, double-blind, placebo-controlled trial (2013) J Am Coll Cardiol, 62, pp. 2178-2184. , PMID: 24013058; Bhalodkar, N.C., Blum, S., Enas, E.A., Accuracy of the ratio of triglycerides to high-density lipoprotein cholesterol for predicting low-density lipoprotein cholesterol particle sizes, phenotype B, and particle concentrations among Asian Indians (2006) Am J Cardiol, 97, pp. 1007-1009. , PMID: 16563906; Hanak, V., Munoz, J., Teague, J., Stanley, A., Jr., Bittner, V., Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B (2004) Am J Cardiol., 94, pp. 219-222. , PMID: 15246907; Gaziano, J.M., Hennekens, C.H., O'Donnell, C.J., Breslow, J.L., Buring, J.E., Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction (1997) Circulation, 96, pp. 2520-2525. , PMID: 9355888; Hadaegh, F., Khalili, D., Ghasemi, A., Tohidi, M., Sheikholeslami, F., Azizi, F., Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men (2009) Nutr Metab Cardiovasc Dis, 19, pp. 401-408. , PMID: 19091534; Bittner, V., Johnson, B.D., Zineh, I., Rogers, W.J., Vido, D., Marroquin, O.C., The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: A report from the Women's Ischemia Syndrome Evaluation (WISE) (2009) Am Heart J, 157, pp. 548-555. , PMID: 19249427; Gensini, G.G., A more meaningful scoring system for determining the severity of coronary heart disease (1983) Am J Cardiol, 51, p. 606. , PMID: 6823874; Maruyama, C., Imamura, K., Teramoto, T., Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia (2003) J Atheroscler Thromb, 10, pp. 186-191. , PMID: 14564088; Dobiasova, M., Frohlich, J., The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)) (2001) Clin Biochem, 34, pp. 583-588. , PMID: 11738396; Giannini, C., Santoro, N., Caprio, S., Kim, G., Lartaud, D., Shaw, M., The triglyceride-to-HDL cholesterol ratio: Association with insulin resistance in obese youths of different ethnic backgrounds (2011) Diabetes Care, 34, pp. 1869-1874. , PMID: 21730284; Pacifico, L., Bonci, E., Andreoli, G., Romaggioli, S., Di Miscio, R., Lombardo, C.V., Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents (2014) Nutr Metab Cardiovasc Dis, 24, pp. 737-743. , PMID: 24656140; Cordero, A., Laclaustra, M., Leon, M., Casasnovas, J.A., Grima, A., Luengo, E., Comparison of serum lipid values in subjects with and without the metabolic syndrome (2008) Am J Cardiol, 102, pp. 424-428. , PMID: 18678299; Wakabayashi, I., Alcohol intake and triglycerides/high-density lipoprotein cholesterol ratio in men with hypertension (2013) Am J Hypertens, 26, pp. 888-895. , PMID: 23519165; Brehm, A., Pfeiler, G., Pacini, G., Vierhapper, H., Roden, M., Relationship between serum lipoprotein ratios and insulin resistance in obesity (2004) Clin Chem, 50, pp. 2316-2322. , PMID: 15459091; Hermans, M.P., Ahn, S.A., Rousseau, M.F., log(TG)/HDL-C is related to both residual cardiometabolic risk and beta-cell function loss in type 2 diabetes males (2010) Cardiovasc Diabetol, 9, p. 88. , PMID: 21156040; Sumner, A.E., Harman, J.L., Buxbaum, S.G., Miller, B.V., 3rd, Tambay, A.V., Wyatt, S.B., The triglyceride/high-density lipoprotein cholesterol ratio fails to predict insulin resistance in African-American women: An analysis of Jackson Heart Study (2010) Metab Syndr Relat Disord, 8, pp. 511-514. , PMID: 20715971; Urbina, E.M., Khoury, P.R., McCoy, C.E., Dolan, L.M., Daniels, S.R., Kimball, T.R., Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults (2013) Pediatrics, 131, pp. e1082-e1090. , PMID: 23460684; Hermans, M.P., Ahn, S.A., Rousseau, M.F., The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females (2012) Lipids Health Dis, 11, p. 132. , PMID: 23046637; Shimizu, Y., Nakazato, M., Sekita, T., Kadota, K., Yamasaki, H., Takamura, N., Association of arterial stiffness and diabetes with triglycerides-to-HDL cholesterol ratio for Japanese men: The Nagasaki Islands Study (2013) Atherosclerosis, 228, pp. 491-495. , PMID: 23601500; De Giorgis, T., Marcovecchio, M.L., Di Giovanni, I., Giannini, C., Chiavaroli, V., Chiarelli, F., Triglycerides-to-HDL ratio as a new marker of endothelial dysfunction in obese prepubertal children (2014) Eur J Endocrinol, 170, pp. 173-180. , PMID: 24165018; Maki, K.C., Davidson, M.H., Dicklin, M.R., Bell, M., Witchger, M., Feinstein, S.B., Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease (2011) J Clin Lipidol, 5, pp. 141-151. , PMID: 21600518; Da Luz, P.L., Favarato, D., Faria-Neto, J.R., Jr., Lemos, P., Chagas, A.C., High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease (2008) Clinics (Sao Paulo), 63, pp. 427-432. , PMID: 18719750; St-Pierre, A.C., Cantin, B., Dagenais, G.R., Mauriege, P., Despres, J.P., Lamarche, B., The triglyceride/high-density lipoprotein cholesterol ratio, the small dense low-density lipoprotein phenotype, and ischemic heart disease risk (2004) Metab Syndr Relat Disord, 2, pp. 57-64. , PMID: 18370677; DeGoma, E.M., Leeper, N.J., Heidenreich, P.A., Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol (2008) J Am Coll Cardiol, 51, pp. 49-55. , PMID: 18174036; Barter, P., Gotto, A.M., LaRosa, J.C., Maroni, J., Szarek, M., Grundy, S.M., HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events (2007) N Engl J Med, 357, pp. 1301-1310. , PMID: 17898099",Article,Scopus,2-s2.0-84928150206
"Chiba T., Sato Y., Suzuki S., Umegaki K.","Concomitant use of dietary supplements and medicines in patients due to miscommunication with physicians in Japan",2015,"Nutrients","7","4",,"2947","2960",,,10.3390/nu7042947,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927940996&partnerID=40&md5=a390cd9fd0009eb259ea42182c9f828b","Information Center, National Institute of Health and Nutrition, 1-23-1 ToyamaShinjuku-ku, Tokyo, Japan","Chiba, T., Information Center, National Institute of Health and Nutrition, 1-23-1 ToyamaShinjuku-ku, Tokyo, Japan; Sato, Y., Information Center, National Institute of Health and Nutrition, 1-23-1 ToyamaShinjuku-ku, Tokyo, Japan; Suzuki, S., Information Center, National Institute of Health and Nutrition, 1-23-1 ToyamaShinjuku-ku, Tokyo, Japan; Umegaki, K., Information Center, National Institute of Health and Nutrition, 1-23-1 ToyamaShinjuku-ku, Tokyo, Japan","We previously reported that some patients used dietary supplements with their medication without consulting with physicians. Dietary supplements and medicines may interact with each other when used concomitantly, resulting in health problems. An Internet survey was conducted on 2109 people who concomitantly took dietary supplements and medicines in order to address dietary supplement usage in people who regularly take medicines in Japan. A total of 1508 patients (two admitted patients and 1506 ambulatory patients) and 601 non-patients, who were not consulting with physicians, participated in this study. Purpose for dietary supplement use was different among ages. Dietary supplements were used to treat diseases in 4.0% of non-patients and 11.9% of patients, while 10.8% of patients used dietary supplements to treat the same diseases as their medication. However, 70.3% of patients did not declare dietary supplement use to their physicians or pharmacists because they considered the concomitant use of dietary supplements and medicines to be safe. A total of 8.4% of all subjects realized the potential for adverse effects associated with dietary supplements. The incidence of adverse events was higher in patients who used dietary supplements to treat their disease. Communication between patients and physicians is important for avoiding the adverse effects associated with the concomitant use of dietary supplements and medicines. © 2015, by the authors; licensee MDPI, Basel, Switzerland.","Adverse effects; Dietary supplements; Medication; Patients; Treatment of diseases","Bailey, R.L., Gahche, J.J., Miller, P.E., Thomas, P.R., Dwyer, J.T., Why US adults use dietary supplements (2013) JAMA Intern. Med, 173, pp. 355-361; Ishihara, J., Sobue, T., Yamamoto, S., Sasaki, S., Akabane, M., Tsugane, S., Validity and reproducibility of a self-administered questionnaire to determine dietary supplement users among Japanese (2001) Eur. J. Clin. Nutr, 55, pp. 360-365; Ishihara, J., Sobue, T., Yamamoto, S., Sasaki, S., Tsugane, S., Demographics, lifestyles, health characteristics, and dietary intake among dietary supplement users in Japan (2003) Int. J. Epidemiol, 32, pp. 546-553; Hirayama, F., Lee, A.H., Binns, C.W., Watanabe, F., Ogawa, T., Dietary supplementation by older adults in Japan (2008) Asia Pac. J. Clin. Nutr, 17, pp. 280-284; Lyle, B.J., Mares-Perlman, J.A., Klein, B.E., Klein, R., Greger, J.L., Supplement users differ from nonusers in demographic, lifestyle, dietary and health characteristics (1998) J. Nutr, 128, pp. 2355-2362; Messerer, M., Johansson, S.E., Wolk, A., Sociodemographic and health behaviour factors among dietary supplement and natural remedy users (2001) Eur. J. Clin. Nutr, 55, pp. 1104-1110; Block, G., Jensen, C.D., Norkus, E.P., Dalvi, T.B., Wong, L.G., McManus, J.F., Hudes, M.L., Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: A cross-sectional study (2007) Nutr. J, 6; Wu, C.H., Wang, C.C., Kennedy, J., Changes in herb and dietary supplement use in the U.S. adult population: A comparison of the 2002 and 2007 national health interview surveys (2011) Clin. Ther, 33, pp. 1749-1758; Yamada, K., Sato-Mito, N., Nagata, J., Umegaki, K., Health claim evidence requirements in Japan (2008) J. Nutr, 138, pp. 1192S-1198S; Ohama, H., Ikeda, H., Moriyama, H., Health foods and foods with health claims in Japan (2006) Toxicology, 221, pp. 95-111; Teschke, R., Wolff, A., Frenzel, C., Schulze, J., Eickhoff, A., Herbal hepatotoxicity: A tabular compilation of reported cases (2012) Liver Int, 32, pp. 1543-1556; Bjelakovic, G., Gluud, L.L., Nikolova, D., Bjelakovic, M., Nagorni, A., Gluud, C., Antioxidant supplements for liver diseases (2011) Cochrane Database Syst. Rev, 3; Pilkington, K., Boshnakova, A., Complementary medicine and safety: A systematic investigation of design and reporting of systematic reviews (2012) Complement Ther. Med, 20, pp. 73-82; Young, C., Oladipo, O., Frasier, S., Putko, R., Chronister, S., Marovich, M., Hemorrhagic stroke in young healthy male following use of sports supplement Jack3d (2012) Mil. Med, 177, pp. 1450-1454; Archer, J.R., Dargan, P.I., Lostia, A.M., van der Walt, J., Henderson, K., Drake, N., Sharma, S., Kicman, A.T., Running an unknown risk: A marathon death associated with the use of 1,3-dimethylamylamine (DMAA) (2015) Drug Test Anal; Pawar, R.S., Tamta, H., Ma, J., Krynitsky, A.J., Grundel, E., Wamer, W.G., Rader, J.I., Updates on chemical and biological research on botanical ingredients in dietary supplements (2013) Anal. Bioanal. Chem, 405, pp. 4373-4384; Cohen, P.A., DMAA as a dietary supplement ingredient (2012) Arch. Intern. Med, 172, pp. 1038-1039; Cohen, P.A., Maller, G., DeSouza, R., Neal-Kababick, J., Presence of banned drugs in dietary supplements following FDA recalls (2014) JAMA, 312, pp. 1691-1693; Chiba, T., Sato, Y., Nakanishi, T., Yokotani, K., Suzuki, S., Umegaki, K., Inappropriate usage of dietary supplements in patients by miscommunication with physicians in Japan (2014) Nutrients, 6, pp. 5392-5404; Hyodo, I., Amano, N., Eguchi, K., Narabayashi, M., Imanishi, J., Hirai, M., Nakano, T., Takashima, S., Nationwide survey on complementary and alternative medicine in cancer patients in Japan (2005) J. Clin. Oncol, 23, pp. 2645-2654; Klafke, N., Eliott, J.A., Wittert, G.A., Olver, I.N., Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services (2012) Ann. Oncol, 23, pp. 1571-1578; Paul, M., Davey, B., Senf, B., Stoll, C., Munstedt, K., Mucke, R., Micke, O., Hubner, J., Patients with advanced cancer and their usage of complementary and alternative medicine (2013) J. Cancer Res. Clin. Oncol, 139, pp. 1515-1522; Singendonk, M., Kaspers, G.J., Naafs-Wilstra, M., Meeteren, A.S., Loeffen, J., Vlieger, A., High prevalence of complementary and alternative medicine use in the dutch pediatric oncology population: A multicenter survey (2013) Eur. J. Pediatr, 172, pp. 31-37; Frenkel, M., Sierpina, V., The use of dietary supplements in oncology (2014) Curr. Oncol. Rep, 16; Sadovsky, R., Collins, N., Tighe, A.P., Brunton, S.A., Safeer, R., Patient use of dietary supplements: A clinician's perspective (2008) Curr. Med. Res. Opin, 24, pp. 1209-1216; Messina, B.A., Herbal supplements: Facts and myths-Talking to your patients about herbal supplements (2006) J. Perianesth. Nurs, 21, pp. 268-278; Kemper, K.J., Gardiner, P., Gobble, J., Woods, C., Expertise about herbs and dietary supplements among diverse health professionals (2006) BMC Complement. Altern. Med, 6; Ashar, B.H., Rice, T.N., Sisson, S.D., Physicians' understanding of the regulation of dietary supplements (2007) Arch. Intern. Med, 167, pp. 966-969; Park, S.Y., Murphy, S.P., Martin, C.L., Kolonel, L.N., Nutrient intake from multivitamin/mineral supplements is similar among users from five ethnic groups: The multiethnic cohort study (2008) J. Am. Diet. Assoc, 108, pp. 529-533; Velicer, C.M., Ulrich, C.M., Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review (2008) J. Clin. Oncol, 26, pp. 665-673; Li, J.Y., Taylor, P.R., Li, B., Dawsey, S., Wang, G.Q., Ershow, A.G., Guo, W., Shen, Q., Nutrition intervention trials in Linxian, China: Multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia (1993) J. Natl. Cancer Inst, 85, pp. 1492-1498; Qiao, Y.L., Dawsey, S.M., Kamangar, F., Fan, J.H., Abnet, C.C., Sun, X.D., Johnson, L.L., Yu, B., Total and cancer mortality after supplementation with vitamins and minerals: Follow-up of the Linxian General Population Nutrition Intervention Trial (2009) J. Natl. Cancer Inst, 101, pp. 507-518; Hara, A., Sasazuki, S., Inoue, M., Shimazu, T., Iwasaki, M., Sawada, N., Yamaji, T., Tsugane, S., Use of vitamin supplements and risk of total cancer and cardiovascular disease among the Japanese general population: A population-based survey (2011) BMC Public Health, 11; Alexander, D.D., Weed, D.L., Chang, E.T., Miller, P.E., Mohamed, M.A., Elkayam, L., A systematic review of multivitamin-multimineral use and cardiovascular disease and cancer incidence and total mortality (2013) J. Am. Coll. Nutr, 32, pp. 339-354; Ikuyama, S., Imamura-Takase, E., Tokunaga, S., Oribe, M., Nishimura, J., Sixty percent of patients with rheumatoid arthritis in Japan have used dietary supplements or health foods (2009) Mod. Rheumatol, 19, pp. 253-259; Madabushi, R., Frank, B., Drewelow, B., Derendorf, H., Butterweck, V., Hyperforin in St. John's wort drug interactions (2006) Eur. J. Clin. Pharmacol, 62, pp. 225-233; Izzo, A.A., Ernst, E., Interactions between herbal medicines and prescribed drugs: An updated systematic review (2009) Drugs, 69, pp. 1777-1798; Shord, S.S., Shah, K., Lukose, A., Drug-botanical interactions: A review of the laboratory, animal, and human data for 8 common botanicals (2009) Integr. Cancer Ther, 8, pp. 208-227; Hermann, R., von Richter, O., Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions (2012) Planta Med, 78, pp. 1458-1477; Yokotani, K., Chiba, T., Sato, Y., Taki, Y., Yamada, S., Shinozuka, K., Murata, M., Umegaki, K., Hepatic cytochrome p450 mediates interaction between warfarin and Coleus forskohlii extract in vivo and in vitro (2012) J. Pharm. Pharmacol, 64, pp. 1793-1801; Virgona, N., Yokotani, K., Yamazaki, Y., Shimura, F., Chiba, T., Taki, Y., Yamada, S., Umegaki, K., Coleus forskohlii extract induces hepatic cytochrome p450 enzymes in mice (2012) Food Chem. Toxicol, 50, pp. 750-755; Muto, S., Fujita, K., Yamazaki, Y., Kamataki, T., Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome p450 (2001) Mutat Res, 479, pp. 197-206; Bamba, Y., Yun, Y.S., Kunugi, A., Inoue, H., Compounds isolated from Curcuma aromatica Salisb. Inhibit human p450 enzymes (2011) J. Nat. Med, 65, pp. 583-587; Nakajima, M., Itoh, M., Yamanaka, H., Fukami, T., Tokudome, S., Yamamoto, Y., Yamamoto, H., Yokoi, T., Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6 (2006) J. Clin. Pharmacol, 46, pp. 337-344; Chen, Y., Xiao, P., Ou-Yang, D.S., Fan, L., Guo, D., Wang, Y.N., Han, Y., Huang, Y.F., Simultaneous action of the flavonoid quercetin on cytochrome p450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers (2009) Clin. Exp. Pharmacol. Physiol, 36, pp. 828-833; Kimura, Y., Ito, H., Ohnishi, R., Hatano, T., Inhibitory effects of polyphenols on human cytochrome p450 3A4 and 2C9 activity (2010) Food Chem. Toxicol, 48, pp. 429-435; Detampel, P., Beck, M., Krahenbuhl, S., Huwyler, J., Drug interaction potential of resveratrol (2012) Drug Metab. Rev, 44, pp. 253-265; Mehta, D.H., Gardiner, P.M., Phillips, R.S., McCarthy, E.P., Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions (2008) J. Altern. Complement. Med, 14, pp. 1263-1269; Samuels, N., Zisk-Rony, R.Y., Zevin, S., Becker, E.L., Yinnon, A.M., Oberbaum, M., Use of non-vitamin, non-mineral (NVNM) supplements by hospitalized internal medicine patients and doctor-patient communication (2012) Patient Educ. Couns, 89, pp. 392-398; Binkowska-Bury, M., Januszewicz, P., Wolan, M., Sobolewski, M., Krauze, M., Fijalek, Z.E., Counterfeit medicines in Poland: Opinions of primary healthcare physicians, nurses and lay persons (2013) J. Clin. Nurs, 22, pp. 559-568; Cellini, M., Attipoe, S., Seales, P., Gray, R., Ward, A., Stephens, M., Deuster, P.A., Dietary supplements: Physician knowledge and adverse event reporting (2013) Med. Sci. Sports Exerc, 45, pp. 23-28; Gardiner, P., Sadikova, E., Filippelli, A.C., White, L.F., Jack, B.W., Medical reconciliation of dietary supplements: Don't ask, don't tell (2015) Patient Educ. Couns, 98, pp. 512-517",Article,Scopus,2-s2.0-84927940996
"Jin X.J., Tahk S.-J., Yang H.-M., Lim H.-S., Yoon M.-H., Choi S.-Y., Choi B.-J., Hwang G.-S., Seo K.-W., Shin J.-S., Lee Y.-H., Choi Y.-W., Park S.-J., Park J.-S., Shin J.-H.","The relationship between intravascular ultrasound-derived percent total atheroma volume and fractional flow reserve in the intermediate stenosis of proximal or middle left anterior descending coronary artery",2015,"International Journal of Cardiology","185",,,"56","61",,,10.1016/j.ijcard.2015.03.048,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928248490&partnerID=40&md5=c960730e2f1341178988e812a0a4f972","Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea","Jin, X.J., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Tahk, S.-J., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Yang, H.-M., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Lim, H.-S., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Yoon, M.-H., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Choi, S.-Y., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Choi, B.-J., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Hwang, G.-S., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Seo, K.-W., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Shin, J.-S., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Lee, Y.-H., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Choi, Y.-W., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Park, S.-J., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Park, J.-S., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea; Shin, J.-H., Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-RoYeongtong-gu, Suwon, South Korea","Background It remains undefined whether the atherosclerotic disease extent of the conductive vessel (expressed as intravascular ultrasound [IVUS]-derived percent total atheroma volume [%TAV]), correlates with functional severity of intermediate stenosis of left anterior descending artery (LAD). Methods An IVUS study and fractional flow reserve (FFR) measurements performed in 130 patients with coronary angiographic intermediate stenosis of proximal or middle LAD. %TAV was calculated as the percentage of total vessel volume occupied by total atheroma volume on IVUS. Results A significant correlation was observed between %TAV and FFR (r = - 0.71, p < 0.001). Minimal lumen area (MLA) correlated moderately with FFR (r = 0.54, p < 0.001). The independent predictors of FFR < 0.8 were %TAV (odds ratio [OR]: 1.29, 95% confidence interval [CI] = 1.18-1.40, p < 0.001) and MLA (OR: 0.37, 95% CI = 0.16-0.85, p = 0.019). A receiver-operating characteristic curve suggested %TAV ≥ 39.0% (sensitivity 85%, specificity 83% and area under curve [AUC] = 0.90) and MLA ≤ 2.6 mm2 (sensitivity 72%, specificity 70% and AUC = 0.75) as the best cut-off values for FFR < 0.8. Forty-eight point five (48.5%) of total studied lesions (63/130) showed %TAV ≥ 39.0%. Eighty-four point four (84.4%) of lesions (38/45) with %TAV ≥ 39.0% and MLA ≤ 2.6 mm2, and 72.2% of lesions (13/18) with %TAV ≥ 39.0% and MLA > 2.6 mm2, FFR was less than 0.8. Conclusions Volumetric quantification of the atherosclerotic disease extent of the coronary artery, expressed as IVUS-derived %TAV, showed a strong correlation with FFR. Not only the segmental luminal narrowing but also the total plaque burden of conductive artery are major determinants for the presence of myocardial ischemia in intermediate stenosis of LAD. © 2014 Published by Elsevier Ireland Ltd.","Fractional flow reserve; Intravascular ultrasound; Percent total atheroma volume","De Bruyne, B., Hersbach, F., Pijls, N.H., Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but ""normal"" coronary angiography (2001) Circulation, 104, pp. 2401-2406; Koo, B.K., Yang, H.M., Doh, J.H., Optimal intravascular ultrasound criteria and their accuracy for defining the functional significance of intermediate coronary stenosis of different locations (2011) JACC Cardiovasc. Interv., 4, pp. 803-811; Kang, S.J., Lee, J.Y., Ahn, J.M., Validation of intravascular ultrasound-derived parameters with fractional flow reserve for assessment of coronary stenosis severity (2011) Circ. Cardiovasc. Interv., 4, pp. 65-71; Ben-Dor, I., Torquson, R., Gaglia, Jr.M.A., Correlation between fractional flow reserve and intravascular ultrasound lumen area in intermediate coronary artery stenosis (2011) EuroIntervention, 7, pp. 225-233; Kang, S.J., Ahn, J.M., Song, H., Usefulness of minimal luminal coronary area determined by intravascular ultrasound to predict functional significance in stable and unstable angina pectoris (2012) Am. J. Cardiol., 109, pp. 947-953; Waksman, R., Legutko, J., Singh, J., FIRST: Fractional flow reserve and intravascular ultrasound relationship study (2013) J. Am. Coll. Cardiol., 61, pp. 917-923; Magni, V., Chieffo, A., Colombo, A., Evaluation of intermediate coronary stenosis with intravascular ultrasound and fractional flow reserve: Its use and abuse (2009) Catheter. Cardiovasc. Interv., 73, pp. 441-448; Nam, C.W., Yoon, H.J., Cho, Y.K., Outcomes of percutaneous coronary intervention in intermediate coronary artery disease (2010) JACC Cardiovasc. Interv., 3, pp. 812-817; Mintz, G.S., Nissen, S.E., Anderson, W.D., American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS): A report of the American College of Cardiology Task Force on Clinical Expert consensus Documents (2001) J. Am. Coll. Cardiol., 37, pp. 1478-1492; Mintz, G.S., Kovach, J.A., Javier, S.P., Mechanisms of lumen enlargement after excimer laser coronary angioplasty: An intravascular ultrasound study (1995) Circulation, 92, pp. 3408-3414; Gonzalo, N., Escaned, J., Alfonso, F., Morphometric assessment of coronary stenosis relevance with optical coherence tomography: A comparison with fractional flow reserve and intravascular ultrasound (2012) J. Am. Coll. Cardiol., 59, pp. 1080-1089; Nicholls, S.J., Sipahi, I., Schoenhagen, P., Intravascular ultrasound assessment of novel antiatherosclerotic therapies: Rationale and design of the Acyl-CoA: Cholesterol acyltransferase intravascular atherosclerosis treatment evaluation (ACTIV-ATE) study (2006) Am. Heart J., 152, pp. 67-74; Yamagishi, M., Hosokawa, H., Saito, S., Coronary disease morphology and distribution determined by quantitative angiography and intravascular ultrasound: Re-evaluation in a cooperative multicenter intravascular ultrasound study (COMIUS) (2002) Jpn. Circ. J., 66, pp. 735-740; Yoon, M.H., Tahk, S.J., Yang, H.M., Comparison of the intracoronary continuous infusion method using a microcatheter and the intravenous continuous adenosine infusion method for inducing maximal hyperemia for fractional flow reserve measurement (2009) Am. Heart J., 157, pp. 1050-1056; Glagov, S., Weisenberg, E., Zarins, C.K., Stankunavicius, R., Koletitis, G.J., Compensatory enlargement of human atherosclerotic coronary arteries (1987) N. Engl. J. Med., 316, pp. 1371-1375; Nissen, S.E., Gurley, J.C., Grines, C.L., Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease (1991) Circulation, 84, pp. 1087-1099; Mintz, G.S., Painter, J.A., Pichard, A.D., Atherosclerosis in angiographically ""normal"" coronary artery reference segments: An intravascular ultrasound study with. Clinical correlations (1995) J. Am. Coll. Cardiol., 25, pp. 1479-1485",Article,Scopus,2-s2.0-84928248490
"Apiyasawat S., Tangcharoen T., Wisaratapong T., Yamwong S., Wiboonpolprasert S., Sritara P.","CHA<inf>2</inf>DS<inf>2</inf>-VASc scores predict mortality after hospitalization for atrial fibrillation",2015,"International Journal of Cardiology","185",,,"293","296",,,10.1016/j.ijcard.2015.03.180,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928264152&partnerID=40&md5=aeaaa6a8a1e9c593cb4648d8aebecbcb","Division of Cardiology, Department of Medicine, Ramathibodi Hospital, Rama VI RoadRatchathewi, Bangkok, Thailand; Ministry of Public HealthBangkok, Thailand","Apiyasawat, S., Division of Cardiology, Department of Medicine, Ramathibodi Hospital, Rama VI RoadRatchathewi, Bangkok, Thailand; Tangcharoen, T., Division of Cardiology, Department of Medicine, Ramathibodi Hospital, Rama VI RoadRatchathewi, Bangkok, Thailand; Wisaratapong, T., Division of Cardiology, Department of Medicine, Ramathibodi Hospital, Rama VI RoadRatchathewi, Bangkok, Thailand; Yamwong, S., Division of Cardiology, Department of Medicine, Ramathibodi Hospital, Rama VI RoadRatchathewi, Bangkok, Thailand; Wiboonpolprasert, S., Ministry of Public HealthBangkok, Thailand; Sritara, P., Division of Cardiology, Department of Medicine, Ramathibodi Hospital, Rama VI RoadRatchathewi, Bangkok, Thailand","Objective The outcome of patients hospitalized for atrial fibrillation (AF) is relatively poor. We sought to determine the mortality rate and predictors of mortality following hospitalization for AF and to evaluate whether the CHA<inf>2</inf>DS<inf>2</inf>-VASc score was a predictor of mortality. Methods We examined the national database of Thailand residents who registered for government provided health insurance in 2005 and reviewed patient records from 2005 to 2010 to determine all-cause mortality. A total of 8981 patients (mean age, 65 years; 42% male) were admitted to the hospital with a diagnosis of AF. Data on demographics and comorbidities were retrieved from the database. The CHA<inf>2</inf>DS<inf>2</inf>-VASc score was calculated for each patient. Results The hospitalization rate for AF was 15.5 per 100,000 person-years. The two most common comorbidities were hypertension (N = 1638, 18.2%) and diabetes (N = 1349, 15.0%). The average CHA<inf>2</inf>DS<inf>2</inf>-VASc score for all patients was 1.8. By the 72-month follow-up (average 46 months), 3948 patients (44.0%) had died. The CHA<inf>2</inf>DS<inf>2</inf>-VASc score was directly related to the mortality rate (P log-rank < 0.0001). Multivariate analysis showed that a CHA<inf>2</inf>DS<inf>2</inf>-VASc score ≥ 6 (hazard ratio [HR] 2.2, 95% confidence interval [CI], 1.4-3.7, P = 0.002) and the presence of chronic kidney disease (HR 2.0, 95% CI 1.7-2.4, P < 0.0001) were the strongest predictors of death. Conclusion The outcome after hospitalization for AF is relatively poor. The CHA<inf>2</inf>DS<inf>2</inf>-VASc score is an independent prognostic marker of poor outcomes following hospitalization for AF. © 2015 Elsevier Ireland Ltd. All rights reserved.","Atrial fibrillation; CHA<inf>2</inf>DS<inf>2</inf>-VASc; Hospitalization; Mortality","Miyasaka, Y., Barnes, M.E., Gersh, B.J., Cha, S.S., Bailey, K.R., Abhayaratna, W.P., Seward, J.B., Tsang, T.S., Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence (2006) Circulation, 114 (2), pp. 119-125; Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., Singer, D.E., Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study (2001) JAMA, 285 (18), pp. 2370-2375; Benjamin, E.J., Wolf, P.A., D'Agostino, R.B., Silbershatz, H., Kannel, W.B., Levy, D., Impact of atrial fibrillation on the risk of death: The Framingham Heart Study (1998) Circulation, 98 (10), pp. 946-952; Wattigney, W.A., Mensah, G.A., Croft, J.B., Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: Implications for primary prevention (2003) Circulation, 108 (6), pp. 711-716; Frost, L., Vestergaard, P., Mosekilde, L., Mortensen, L.S., Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999 (2005) Int. J. Cardiol., 103 (1), pp. 78-84; Stewart, S., Macintyre, K., Chalmers, J.W., Boyd, J., Finlayson, A., Redpath, A., Pell, J.P., McMurray, J.J., Trends in case-fatality in 22968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995 (2002) Int. J. Cardiol., 82 (3), pp. 229-236; Miyasaka, Y., Barnes, M.E., Bailey, K.R., Cha, S.S., Gersh, B.J., Seward, J.B., Tsang, T.S., Mortality trends in patients diagnosed with first atrial fibrillation: A 21-year community-based study (2007) J. Am. Coll. Cardiol., 49 (9), pp. 986-992; Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I.C., Rutten, F.H., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Eur. Heart J., 31 (19), pp. 2369-2429. , European Heart Rhythm Association, European Association For Cardio-Thoracic Surgery; January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cleveland, J.C., Jr., Cigarroa, J.E., Conti, J.B., Yancy, C.W., AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society (2014) Circulation, 130 (23), pp. 2071-2104; Ntaios, G., Lip, G.Y., Makaritsis, K., Papavasileiou, V., Vemmou, A., Koroboki, E., Savvari, P., Vemmos, K., CHADS<inf>2</inf>, CHA<inf>2</inf>S<inf>2</inf>DS<inf>2</inf>-VASc, and long-term stroke outcome in patients without atrial fibrillation (2013) Neurology, 80 (11), pp. 1009-1017; Paoletti Perini, A., Bartolini, S., Pieragnoli, P., Ricciardi, G., Perrotta, L., Valleggi, A., Vergaro, G., Padeletti, L., CHADS<inf>2</inf> and CHA<inf>2</inf>DS<inf>2</inf>-VASc score to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy (2014) Europace, 16 (1), pp. 71-80; Naccarelli, G.V., Panaccio, M.P., Cummins, G., Tu, N., CHADS<inf>2</inf> and CHA<inf>2</inf>DS<inf>2</inf>-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients (2012) Am. J. Cardiol., 109 (10), pp. 1526-1533; Department Of Provincial Administration, (2006) Population from Registration Record by Age Group and Sex, Whole Kingdom: 2005, , (Thailand, Print); Olsson, L.G., Swedberg, K., Lappas, G., Stewart, S., Rosengren, A., Trends in mortality after first hospitalization with atrial fibrillation diagnosis in Sweden 1987 to 2006 (2013) Int. J. Cardiol., 170 (1), pp. 75-80; (2009) OECD Factbook 2009: Economic, Environmental and Social Statistics, , OECD, OECD Publishing; Nakagawa, K., Hirai, T., Takashima, S., Fukuda, N., Ohara, K., Sasahara, E., Taguchi, Y., Inoue, H., Chronic kidney disease and CHADS<inf>2</inf> score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation (2011) Am. J. Cardiol., 107 (6), pp. 912-916; Zimmerman, D., Sood, M.M., Rigatto, C., Holden, R.M., Hiremath, S., Clase, C.M., Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis (2012) Nephrol. Dial. Transplant., 27 (10), pp. 3816-3822",Article,Scopus,2-s2.0-84928264152
"Savastano S., De Servi S., Oltrona Visconti L., Raimondi M.","The Pavia Cardiac Arrest REgistry - Pavia CARE. It's time for Cardiologists to be engaged in cardiac arrest",2015,"International Journal of Cardiology","185",,,"93","94",,,10.1016/j.ijcard.2015.03.124,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928484990&partnerID=40&md5=d83ae0ac13f25540fb3f808a5bdd57c7","Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, piazzale GolgiPavia, Italy; Intensive Cardiac Care Unit, Fondazione IRCCS Policlinico San MatteoPavia, Italy; AAT 118 Pavia, Fondazione IRCCS Policlinico San MatteoPavia, Italy","Savastano, S., Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, piazzale GolgiPavia, Italy; De Servi, S., Intensive Cardiac Care Unit, Fondazione IRCCS Policlinico San MatteoPavia, Italy; Oltrona Visconti, L., Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, piazzale GolgiPavia, Italy; Raimondi, M., AAT 118 Pavia, Fondazione IRCCS Policlinico San MatteoPavia, Italy",[No abstract available],"Cardiac arrest; Neurological outcome; Registry; Sudden death; Survival","Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T.B., Flegal, K., Ford, E., Hong, Y., Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2009) Circulation, 119, pp. e21-e181; Del Vecchio, M., Padeletti, L., Cardiac sudden death in Italy. Dimensions, perceptions, policies and economic/financial impact (2008) G. Ital. Cardiol. (Rome), 9 (11), pp. 5S-23S; Savastano, S., Klersy, C., Raimondi, M., Langord, K., Vanni, V., Rordorf, R., Vicentini, A., Visconti, L.O., Positive trend in survival to hospitaldischarge after out-of-hospital cardiac arrest: A quantitative review of theliterature (2014) J. Cardiovasc. Med., 15, pp. 609-615; Gräsner, J.T., Herlitz, J., Koster, R.W., Rosell-Ortiz, F., Stamatakis, L., Bossaert, L., Quality management in resuscitation - Towards a European cardiac arrest registry(EuReCa) (2011) Resuscitation, 82 (8), pp. 989-994; Ristagno, G., Semeraro, F., Radeschi, G., Pellis, T., Gordini, G., Ferro, S., Cerchiari, E., The ""italian Registry of Cardiac Arrest - RIAC"", a National achievement to portrait the Italian reality and to contribute to the wider European vision by ""euReCa"" (2014) Resuscitation, 85 (12), pp. e193-e194; Capucci, A., Aschieri, D., Piepoli, M.F., Tripling survival from sudden cardiac arrest via early defibrillation without traditional education in cardiopulmonary resuscitation (2002) Circulation, 106, pp. 1065-1070; Cappato, R., Curnis, A., Marzollo, P., Prospective assessment of integrating the existing emergency medical system with automated external defibrillators fully operated by volunteers and laypersons for out-of-hospital cardiac arrest: The Brescia Early Defibrillation Study (BEDS) (2006) Eur. Heart J., 27, pp. 553-561; Casaccia, M., Bertello, F., Sicuro, M., Out-of-hospital cardiac arrest in an experimental model of the management of cardiologic emergencies in a metropolitan area (1995) G. Ital. Cardiol., 25, pp. 127-137; D'Este, F., Busetto, L., Russo, G., Extrahospital cardiac arrest: The experience of Mestre Emergency Service (1998) G. Ital. Cardiol., 28, pp. 678-686; Fabbri, A., Marchesini, G., Spada, M., Monitoring intervention programmes for out-of-hospital cardiac arrest in a mixed urban and rural setting (2006) Resuscitation, 71, pp. 180-187; Kette, F., Pellis, T., Increased survival despite a reduction in out-of-hospital ventricular fibrillation in north-east Italy (2007) Resuscitation, 72, pp. 52-58; Citerio, G., Buquicchio, I., Rossi, G.P., Prospective performance evaluation of emergency medical services for cardiac arrest in Lombardia: Is something moving forward? (2006) Eur. J. Emerg. Med., 13, pp. 192-196; Terranova, P., Valli, P., Severgnini, B., Early outcomes of out-of-hospital cardiac arrest after early defibrillation: A 24 months retrospective analysis (2006) Indian Pacing Electrophysiol. J., 6, pp. 194-201; Taglieri, N., Saia, F., Lanzillotti, V., Impact of a territorial ST-segment elevation myocardial infarction network on prognosis of patients with out-of-hospital cardiac arrest (2011) Acute Card. Care, 13, pp. 143-147",Letter,Scopus,2-s2.0-84928484990
"Ganapathy A.V., Monjazeb S., Ganapathy K.S., Shanoon F., Razavi M.","""asymptomatic"" persistent or permanent atrial fibrillation: A misnomer in selected patients",2015,"International Journal of Cardiology","185",,,"112","113",,,10.1016/j.ijcard.2015.03.122,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928231026&partnerID=40&md5=697ba6cf5a956c5de58bd42e365c0174","School of Medicine, Baylor College of Medicine, 1 Baylor PlazaHouston, TX, United States; School of Medicine, University of Texas Medical Branch, 301 University BoulevardGalveston, TX, United States; Center for Arrhythmia Research and Innovation, Texas Heart Institute, 6770 Bertner AvenueHouston, TX, United States","Ganapathy, A.V., School of Medicine, Baylor College of Medicine, 1 Baylor PlazaHouston, TX, United States, Center for Arrhythmia Research and Innovation, Texas Heart Institute, 6770 Bertner AvenueHouston, TX, United States; Monjazeb, S., School of Medicine, University of Texas Medical Branch, 301 University BoulevardGalveston, TX, United States; Ganapathy, K.S., Center for Arrhythmia Research and Innovation, Texas Heart Institute, 6770 Bertner AvenueHouston, TX, United States; Shanoon, F., Center for Arrhythmia Research and Innovation, Texas Heart Institute, 6770 Bertner AvenueHouston, TX, United States; Razavi, M., Center for Arrhythmia Research and Innovation, Texas Heart Institute, 6770 Bertner AvenueHouston, TX, United States",[No abstract available],"Arrhythmia; Atrial fibrillation; Cardioversion","Colilla, S., Crow, A., Petkun, W., Singer, D.E., Simon, T., Liu, X., Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. Adult population (2013) Am. J. Cardiol., 112 (8), pp. 1142-1147; Rho, R.W., Page, R.L., Asymptomatic atrial fibrillation (2005) Prog. Cardiovasc. Dis., 48 (2), pp. 79-87; Benjamin, E.J., Levy, D., Vaziri, S.M., D'Agostino, R.B., Belanger, A.J., Wolf, P.A., Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study (1994) JAMA, 271 (11), pp. 840-844; Furberg, C.D., Psaty, B.M., Manolio, T.A., Gardin, J.M., Smith, V.E., Rautaharju, P.M., Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study) (1994) Am. J. Cardiol., 74 (3), pp. 236-241; Kerr, C., Boone, J., Connolly, S., Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation (1996) Eur. Heart J., 17, pp. 48-51; Blackshear, J.L., Pearce, L.A., Hart, R.G., Aortic plaque in atrial fibrillation: Prevalence, predictors, and thromboembolic implications (1999) Stroke, 30 (4), pp. 834-840; Friberg, L., Engdahl, J., Frykman, V., Svennberg, E., Levin, L.A., Rosenqvist, M., Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP) (2013) Europace, 15 (1), pp. 135-140; January, C.T., Wann, L.S., Alpert, J.S., 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society (2014) J. Am. Coll. Cardiol., 64 (21), pp. e1-e76; Wann, L.S., Curtis, A.B., January, C.T., 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) Circulation, 123 (1), pp. 104-123; Groenveld, H.F., Crijns, H.J., Van Den Berg, M.P., The effect of rate control on quality of life in patients with permanent atrial fibrillation: Data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study (2011) J. Am. Coll. Cardiol., 58 (17), pp. 1795-1803",Letter,Scopus,2-s2.0-84928231026
"Xi Y., Honeywell C., Zhang D., Schwartzentruber J., Beaulieu C.L., Tetreault M., Hartley T., Marton J., Vidal S.M., Majewski J., Aravind L., Gollob M., Boycott K.M., Gow R.M.","Whole exome sequencing identifies the TNNI3K gene as a cause of familial conduction system disease and congenital junctional ectopic tachycardia",2015,"International Journal of Cardiology","185",,,"114","116",,,10.1016/j.ijcard.2015.03.130,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928252599&partnerID=40&md5=70b22015e84518632bb8721578ea35cb","Children's Hospital of Eastern Ontario Research Institute, University of OttawaOttawa, ON, Canada; Department of Pediatrics, Children's Hospital of Eastern OntarioOttawa, ON, Canada; National Center for Biotechnology Information, National Library of Medicine, National Institutes of HealthBethesda, MD, United States; McGill University, Genome Quebec Innovation CentreMontreal, QC, Canada; Department of Human Genetics, McGill UniversityMontreal, QC, Canada; Toronto General Hospital, Department of Cardiology, University of TorontoToronto, ON, Canada","Xi, Y., Children's Hospital of Eastern Ontario Research Institute, University of OttawaOttawa, ON, Canada; Honeywell, C., Department of Pediatrics, Children's Hospital of Eastern OntarioOttawa, ON, Canada; Zhang, D., National Center for Biotechnology Information, National Library of Medicine, National Institutes of HealthBethesda, MD, United States; Schwartzentruber, J., McGill University, Genome Quebec Innovation CentreMontreal, QC, Canada; Beaulieu, C.L., Department of Pediatrics, Children's Hospital of Eastern OntarioOttawa, ON, Canada; Tetreault, M., McGill University, Genome Quebec Innovation CentreMontreal, QC, Canada, Department of Human Genetics, McGill UniversityMontreal, QC, Canada; Hartley, T., Department of Pediatrics, Children's Hospital of Eastern OntarioOttawa, ON, Canada; Marton, J., Department of Human Genetics, McGill UniversityMontreal, QC, Canada; Vidal, S.M., Department of Human Genetics, McGill UniversityMontreal, QC, Canada; Majewski, J., McGill University, Genome Quebec Innovation CentreMontreal, QC, Canada, Department of Human Genetics, McGill UniversityMontreal, QC, Canada; Aravind, L., National Center for Biotechnology Information, National Library of Medicine, National Institutes of HealthBethesda, MD, United States; Gollob, M., Toronto General Hospital, Department of Cardiology, University of TorontoToronto, ON, Canada; Boycott, K.M., Children's Hospital of Eastern Ontario Research Institute, University of OttawaOttawa, ON, Canada, Department of Pediatrics, Children's Hospital of Eastern OntarioOttawa, ON, Canada; Gow, R.M., Department of Pediatrics, Children's Hospital of Eastern OntarioOttawa, ON, Canada",[No abstract available],"Exome sequencing; Junctional ectopic tachycardia; TNNI3K","Henneveld, H., Hutter, P., Bink-Boelkens, M., Junctional ectopic tachycardia evolving into complete heart block (1998) Heart, 80, pp. 627-628; Villain, E., Vetter, V.L., Garcia, J.M., Evolving concepts in the management of congenital junctional ectopic tachycardia. A multicenter study (1990) Circulation, 81, pp. 1544-1549; Srour, M., Putorti, M.L., Schwartzentruber, J., Mutations in riboflavin transporter present with severe sensory loss and deafness in childhood (2014) Muscle Nerve, 50, pp. 775-779; Theis, J.L., Zimmermann, M.T., Larsen, B.T., TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy (2014) Hum. Mol. Genet., 23, pp. 5793-5804; Lai, Z.F., Chen, Y.Z., Evidence, hypotheses and significance of MAP kinase TNNI3K interacting with its partners (2012) World J. Hypertens., 2, pp. 22-28; Wheeler, F.C., Tang, H., Marks, O.A., Tnni3k modifies disease progression in murine models of cardiomyopathy (2009) PLoS Genet., 5, p. e1000647; Lodder, E.M., Scicluna, B.P., Milano, A., Dissection of a quantitative trait locus for PR interval duration identifies Tnni3k as a novel modulator of cardiac conduction (2012) PLoS Genet., 8, p. e1003113; Azam, M., Seeliger, M.A., Gray, N.S., Activation of tyrosine kinases by mutation of the gatekeeper threonine (2008) Nat. Struct. Mol. Biol., 15, pp. 1109-1118; Eyers, P.A., Craxton, M., Morrice, N., Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution (1998) Chem. Biol., 5, pp. 321-328; Joseph, R.E., Andreotti, A.H., Controlling the activity of the Tec kinase Itk by mutation of the phenylalanine gatekeeper residue (2011) Biochemistry, 50, pp. 221-229",Letter,Scopus,2-s2.0-84928252599
"Buturak A., Norgaz T., Gorgulu S.","Brivudine induced coronary vasospasm as a manifestation of Kounis syndrome: First report",2015,"International Journal of Cardiology","185",,,"4","6",,,10.1016/j.ijcard.2015.03.082,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928485392&partnerID=40&md5=ede613f3071ebf70ae218da4c3a61f79","Acibadem Universitesi, Kerem Aydinlar Kampüsü, Kayidaʇi Cad. No: 32Istanbul, Turkey","Buturak, A., Acibadem Universitesi, Kerem Aydinlar Kampüsü, Kayidaʇi Cad. No: 32Istanbul, Turkey; Norgaz, T., Acibadem Universitesi, Kerem Aydinlar Kampüsü, Kayidaʇi Cad. No: 32Istanbul, Turkey; Gorgulu, S., Acibadem Universitesi, Kerem Aydinlar Kampüsü, Kayidaʇi Cad. No: 32Istanbul, Turkey",[No abstract available],"Brivudine; Kounis; Vasospasm","Terlemez, S., Eryilmaz, U., Tokgöz, Y., Uysal, P., Coşan, A., Kounis syndrome caused by metronidazole - A case of 14 year-old boy (2015) Int. J. Cardiol., 20, pp. 222-224; McGlinchey, P.G., Webb, S.T., Campbell, N.P., 5-Fluorouracil-induced cardiotoxicity mimicking myocardial infarction: A case report (2001) BMC Cardiovasc. Disord., 1, p. 3; Kounis, N.G., Zavras, G.M., Histamine-induced coronary artery spasm: The concept of allergic angina (1991) Br. J. Clin. Pract., 45, pp. 121-128; Bani, D., Nistri, S., Mannaioni, P.F., Masini, E., Cardiac anaphylaxis: Pathophysiology and therapeutic perspectives (2006) Curr. Allergy Asthma Rep., 6, pp. 14-19; Genovese, A., Spadaro, G., Highlights in cardiovascular effects of histamine and H1-receptor antagonists (1997) Allergy, 52, pp. 67-68; Kounis, N.G., Mazarakis, A., Tsigkas, G., Giannopoulos, S., Goudevenos, J., Kounis syndrome: A new twist on an old disease (2011) Futur. Cardiol., 7, pp. 805-824; Biteker, M., A new classification of Kounis syndrome (2010) Int. J. Cardiol., 145, p. 553; Gázquez, V., Dalmau, G., Gaig, P., Gómez, C., Navarro, S., Mercé, J., (2010) J. Investig. Allergol. Clin. Immunol., 20, pp. 162-165; Rodrigues, M.C., Coelho, D., Granja, C., Drugs that may provoke Kounis syndrome (2013) Braz. J. Anesthesiol., 63, pp. 426-428",Letter,Scopus,2-s2.0-84928485392
"Kisaka T., Rossiter H.B., Wasserman K., Kihara Y.","Exercise oscillatory ventilation: Ventilation-perfusion abnormality in heart failure",2015,"International Journal of Cardiology","185",,,"55","",,,10.1016/j.ijcard.2015.03.123,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928487215&partnerID=40&md5=dfe8cd19148f3febb9ba362e9b9f53be","Division of Respiratory and Critical Care, Physiology and Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, UCLA School of MedicineTorrance, CA, United States; Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health SciencesHiroshima, Japan; CDCRC-Building, 1124 West Carson StreetTorrance, CA, United States; 1124 West Carson Street, RB-2Torrance, CA, United States; 3 1-2-3 KasumiMinami-ku, Hiroshima, Japan","Kisaka, T., Division of Respiratory and Critical Care, Physiology and Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, UCLA School of MedicineTorrance, CA, United States, Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health SciencesHiroshima, Japan, 1124 West Carson Street, RB-2Torrance, CA, United States; Rossiter, H.B., Division of Respiratory and Critical Care, Physiology and Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, UCLA School of MedicineTorrance, CA, United States, CDCRC-Building, 1124 West Carson StreetTorrance, CA, United States; Wasserman, K., Division of Respiratory and Critical Care, Physiology and Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, UCLA School of MedicineTorrance, CA, United States, 1124 West Carson Street, RB-2Torrance, CA, United States; Kihara, Y., Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health SciencesHiroshima, Japan, 3 1-2-3 KasumiMinami-ku, Hiroshima, Japan",[No abstract available],"Exercise oscillatory ventilation; Heart failure; Periodic breathing","Cornelis, J., Taeymans, J., Hens, W., Beckers, P., Vrints, C., Vissers, D., Prognostic respiratory parameters in heart failure patients with and without exercise oscillatory ventilation - A systematic review and descriptive meta-analysis (2015) Int. J. Cardiol., 182, pp. 476-486; Matsuki, R., Kisaka, T., Ozono, R., Kinoshita, H., Sada, Y., Oda, N., Characteristics of patients with severe heart failure exhibiting exercise oscillatory ventilation (2013) Clin. Exp. Hypertens., 35, pp. 267-272; Arena, R., Guazzi, M., Cahalin, L.P., Myers, J., Revisiting cardiopulmonary exercise testing applications in heart failure: Aligning evidence with clinical practice (2014) Exerc. Sport Sci. Rev., 42, pp. 153-160; Tomita, Y., Kasai, T., Kisaka, T., Rossiter, H.B., Kihara, Y., Wasserman, K., Altered breathing syndrome in heart failure: Newer insights and treatment options (2015) Curr. Heart Fail. Rep., 12, pp. 158-165",Letter,Scopus,2-s2.0-84928487215
"Canpolat U.","Isolation of the Pandorra's box and end of the evils in left atrium",2015,"International Journal of Cardiology","185",,,"7","8",,,10.1016/j.ijcard.2015.03.109,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928473621&partnerID=40&md5=17d7054c706a523841a51e8fa3a81376","Cardiology Clinic, Türkiye Yüksek Ihtisas Training and Research HospitalAnkara, Turkey","Canpolat, U., Cardiology Clinic, Türkiye Yüksek Ihtisas Training and Research HospitalAnkara, Turkey",[No abstract available],"Ablation; Atrial fibrillation; Posterior wall","Kim, J.S., Shin, S.Y., Na, J.O., Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation?: A prospective randomized clinical trial (2014) Int. J. Cardiol., 181 C, pp. 277-283; Calkins, H., Kuck, K.H., Cappato, R., 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation (2012) Heart Rhythm., 9, pp. 632-696. , Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); And in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society; Mandapati, R., Skanes, A., Chen, J., Berenfeld, O., Jalife, J., Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart (2000) Circulation, 101, pp. 194-199; Huang, J.L., Tai, C.T., Lin, Y.J., The mechanisms of an increased dominant frequency in the left atrial posterior wall during atrial fibrillation in acute atrial dilatation (2006) J. Cardiovasc. Electrophysiol., 17, pp. 178-188; Kalifa, J., Tanaka, K., Zaitsev, A.V., Mechanisms of wave fractionation at boundaries of high-frequency excitation in the posterior left atrium of the isolated sheep heart during atrial fibrillation (2006) Circulation, 113, pp. 626-633; Canpolat, U., Oto, A., Hazirolan, T., A prospective DE-MRI study evaluating the role of TGF-beta1 in left atrial fibrosis and Implications for outcomes of cryoballoon-based catheter ablation: New Insights into primary fibrotic atriocardiomyopathy (2015) J. Cardiovasc. Electrophysiol., 26, pp. 251-259; Segerson, N.M., Daccarett, M., Badger, T.J., Magnetic resonance imaging-confirmed ablative debulking of the left atrial posterior wall and septum for treatment of persistent atrial fibrillation: Rationale and initial experience (2010) J. Cardiovasc. Electrophysiol., 21, pp. 126-132; Tamborero, D., Mont, L., Berruezo, A., Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein ablation for atrial fibrillation: A prospective randomized study (2009) Circ. Arrhythm. Electrophysiol., 2, pp. 35-40; D'Ascenzo, F., Corleto, A., Biondi-Zoccai, G., Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: A meta-analysis (2013) Int. J. Cardiol., 167, pp. 1984-1989",Letter,Scopus,2-s2.0-84928473621
"Udo E.O., Van Hemel N.M., Zuithoff N.P.A., Doevendans P.A., Moons K.G.M.","Risk of heart failure- and cardiac death gradually increases with more right ventricular pacing",2015,"International Journal of Cardiology","185",,,"95","100",,,10.1016/j.ijcard.2015.03.053,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928412188&partnerID=40&md5=18530808123aac26c03ddc9f9c94f15c","Department of Cardiology, UMC Utrecht, the Netherlands, Heidelberglaan 100Utrecht, Netherlands; Julius Center for Health Sciences and Primary Care, UMC Utrecht, the Netherlands, Universiteitsweg 100Utrecht, Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO box 85500Utrecht, Netherlands","Udo, E.O., Department of Cardiology, UMC Utrecht, the Netherlands, Heidelberglaan 100Utrecht, Netherlands, Julius Center for Health Sciences and Primary Care, UMC Utrecht, the Netherlands, Universiteitsweg 100Utrecht, Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO box 85500Utrecht, Netherlands; Van Hemel, N.M., Department of Cardiology, UMC Utrecht, the Netherlands, Heidelberglaan 100Utrecht, Netherlands; Zuithoff, N.P.A., Julius Center for Health Sciences and Primary Care, UMC Utrecht, the Netherlands, Universiteitsweg 100Utrecht, Netherlands; Doevendans, P.A., Department of Cardiology, UMC Utrecht, the Netherlands, Heidelberglaan 100Utrecht, Netherlands; Moons, K.G.M., Julius Center for Health Sciences and Primary Care, UMC Utrecht, the Netherlands, Universiteitsweg 100Utrecht, Netherlands","Background Right ventricular pacing (RVP) is associated with an increased risk of heart failure (HF) events. However, the extent and shape of this association is hardly assessed. Objective We quantified whether the undesired effects of RVP are confirmed in an unselected population of first bradycardia pacemaker recipients. Furthermore, we studied the shape of the association between RVP and HF death and cardiac death. Methods Cumulative percentage RVP (%RVP) was measured in 1395 patients. Using multivariable Cox regression analysis with %RVP as time-dependant co-variate we evaluated the association between %RVP and HF- and cardiac death, both unadjusted and adjusted for confounders, including age, gender, pacemaker-indication, cardiac disease, HF at baseline, diabetes, hypertension, atrio-ventricular synchrony, usage of beta-blocking drugs, anti-arrhythmic medication, HF medication, and prior atrial fibrillation/flutter. Non-linear associations were evaluated with restricted cubic splines. Results During a mean follow-up of 5.8 (SD 1.1) years 104 HF deaths and 144 cardiac deaths were observed. %RVP was significantly associated with HF- and cardiac death in both unadjusted (p < 0.001 and p < 0.001, respectively) and adjusted analyses (p = 0.046 and p = 0.009, respectively). Our results show a linear association between %RVP and HF- and cardiac death. We observed a constant increase of 8% risk of HF death per 10% increase in RVP. A model incorporating various non-linear transformations of %RVP using restrictive cubic splines showed no improved model fit over linear associations. Conclusion This long-term, prospective study observed a significant, though linear association between %RVP and risk of HF death and/or cardiac death in unselected bradycardia pacing recipients. © 2015 Elsevier Ireland Ltd. All rights reserved.","Heart failure; Pacemaker; Survival","Vassallo, J.A., Cassidy, D.M., Miller, J.M., Buxton, A.E., Marchlinski, F.E., Josephson, M.E., Left ventricular endocardial activation during right ventricular pacing: Effect of underlying heart disease (1986) J. Am. Coll. Cardiol., 7, pp. 1228-1233; Nielsen, J.C., Kristensen, L., Andersen, H.R., Mortensen, P.T., Pedersen, O.L., Pedersen, A.K., A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: Echocardiographic and clinical outcome (2003) J. Am. Coll. Cardiol., 42, pp. 614-623; Leclercq, C., Gras, D., Le Helloco, A., Nicol, L., Mabo, P., Daubert, C., Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing (1995) Am. Heart J., 129, pp. 1133-1141; Rosenqvist, M., Isaaz, K., Botvinick, E.H., Relative importance of activation sequence compared to atrioventricular synchrony in left ventricular function (1991) Am. J. Cardiol., 67, pp. 148-156; Olshansky, B., Day, J.D., Lerew, D.R., Brown, S., Stolen, K.Q., Eliminating right ventricular pacing may not be best for patients requiring implantable cardioverter-defibrillators (2007) Heart Rhythm., 4, pp. 886-891. , INTRINSIC RV Study Investigators; Wilkoff, B.L., Cook, J.R., Epstein, A.E., Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial (2002) JAMA, 288, pp. 3115-3123; Kachboura, S., Ben Halima, A., Fersi, I., Marrakchi, S., Zouaoui, W., Kammoun, I., Assessment of heart failure and left ventricular systolic dysfunction after cardiac pacing in patients with preserved left ventricular systolic function (2008) Ann. Cardiol. Angeiol. (Paris), 57, pp. 29-36; Freudenberger, R.S., Wilson, A.C., Lawrence-Nelson, J., Hare, J.M., Kostis, J.B., Myocardial Infarction Data Acquisition System Study Group (MIDAS 9). Permanent pacing is a risk factor for the development of heart failure (2005) Am. J. Cardiol., 95, pp. 671-674; Milasinovic, G., Tscheliessnigg, K., Boehmer, A., Percent ventricular pacing with managed ventricular pacing mode in standard pacemaker population (2008) Europace, 10, pp. 151-155; Sanfins, V., Alves, A., Rodrigues, B., RIVER: Portuguese registry to monitor unnecessary right ventricular pacing (2010) Rev. Port. Cardiol., 29, pp. 581-589; Gillis, A.M., Purerfellner, H., Israel, C.W., Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block (2006) Pacing Clin. Electrophysiol., 29, pp. 697-705; Olshansky, B., Day, J., McGuire, M., Hahn, S., Brown, S., Lerew, D.R., Reduction of right ventricular pacing in patients with dual-chamber ICDs (2006) Pacing Clin. Electrophysiol., 29, pp. 237-243; Tse, H.F., Wong, K.K., Siu, C.W., Zhang, X.H., Ho, W.Y., Lau, C.P., Upgrading pacemaker patients with right ventricular apical pacing to right ventricular septal pacing improves left ventricular performance and functional capacity (2009) J. Cardiovasc. Electrophysiol., 20, pp. 901-905; Mond, H.G., Vlay, S.C., Pacing the right ventricular septum: Time to abandon apical pacing (2010) Pacing Clin. Electrophysiol., 33, pp. 1293-1297; Tse, H.F., Yu, C., Wong, K.K., Functional abnormalities in patients with permanent right ventricular pacing: The effect of sites of electrical stimulation (2002) J. Am. Coll. Cardiol., 40, pp. 1451-1458; Riahi, S., Nielsen, J.C., Hjortshøj, S., Heart failure in patients with sick sinus syndrome treated with single lead atrial or dual-chamber pacing: No association with pacing mode or right ventricular pacing site (2012) Europace, 14, pp. 1475-1482; Shalganov, T.N., Paprika, D., Vatasescu, R., Mid-term echocardiographic follow up of left ventricular function with permanent right ventricular pacing in pediatric patients with and without structural heart disease (2007) Cardiovasc. Ultrasound, 5, p. 13; Sagar, S., Shen, W.K., Asirvatham, S.J., Effect of long-term right ventricular pacing in young adults with structurally normal heart (2010) Circulation, 121, pp. 1698-1705; Sweeney, M.O., Hellkamp, A.S., Ellenbogen, K.A., Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction (2003) Circulation, 107, pp. 2932-2937; Mazza, A., Bendini, M.G., Leggio, M., Incidence and predictors of heart failure hospitalization and death in permanent pacemaker patients: A single-centre experience over medium-term follow-up (2013) Europace, 15 (9), pp. 1267-1272; Vatasescu, R., Shalganov, T., Paprika, D., Evolution of left ventricular function in paediatric patients with permanent right ventricular pacing for isolated congenital heart block: A medium term follow-up (2007) Europace, 9, pp. 228-232; Sharma, A.D., Rizo-Patron, C., Hallstrom, A.P., Percent right ventricular pacing predicts outcomes in the DAVID trial (2005) Heart Rhythm., 2, pp. 830-834; Van Eck, J.W., Van Hemel, N.M., Grobbee, D.E., Buskens, E., Moons, K.G., FOLLOWPACE study: A prospective study on the cost-effectiveness of routine follow-up visits in patients with a pacemaker (2006) Europace, 8, pp. 60-64; Gregoratos, G., Abrams, J., Epstein, A.E., ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) (2002) J. Cardiovasc. Electrophysiol., 13, pp. 1183-1199; Harrell, F.E., (2001) Regression Modeling Strategies with Applications to Linear Models, Logistic Regression and Survival Analysis, , Springer Verlag New York; Harrell, Jr.F.E., Lee, K.L., Mark, D.B., Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors (1996) Stat. Med., 15, pp. 361-387; Stevens, J.P., (1996) Applied Multivariate Statistics for the Social Sciences, , Erlbaum Mahwah, NJ; Zannad, F., Stough, W.G., Pitt, B., Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: The need for a consensus definition (2008) Eur. Heart J., 29, pp. 413-421; Barsheshet, A., Moss, A.J., McNitt, S., Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator (2011) Heart Rhythm., 8, pp. 212-218; Steinberg, J.S., Fischer, A., Wang, P., The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II (2005) J. Cardiovasc. Electrophysiol., 16, pp. 359-365; Hayes, J.J., Sharma, A.D., Love, J.C., Abnormal conduction increases risk of adverse outcomes from right ventricular pacing (2006) J. Am. Coll. Cardiol., 48, pp. 1628-1633; Smit, M.D., Van Dessel, P.F., Nieuwland, W., Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients (2006) Heart Rhythm., 3, pp. 1397-1403; Stockburger, M., Celebi, O., Krebs, A., Right ventricular pacing is associated with impaired overall survival, but not with an increased incidence of ventricular tachyarrhythmias in routine cardioverter/defibrillator recipients with reservedly programmed pacing (2009) Europace, 11, pp. 924-930; Chen, S., Yin, Y., Lan, X., Paced QRS duration as a predictor for clinical heart failure events during right ventricular apical pacing in patients with idiopathic complete atrioventricular block: Results from an observational cohort study (PREDICT-HF) (2013) Eur. J. Heart Fail., 15, pp. 352-359; Elkayam, L.U., Koehler, J.L., Sheldon, T.J., Glotzer, T.V., Rosenthal, L.S., Lamas, G.A., The influence of atrial and ventricular pacing on the incidence of atrial fibrillation: A meta-analysis (2011) Pacing Clin. Electrophysiol., 34, pp. 1593-1599; Lamas, G.A., Lee, K.L., Sweeney, M.O., Ventricular pacing or dual-chamber pacing for sinus-node dysfunction (2002) N. Engl. J. Med., 346, pp. 1854-1862",Article,Scopus,2-s2.0-84928412188
"Tarin J.J., Garcia-Perez M.A., Hamatani T., Cano A.","Infertility etiologies are genetically and clinically linked with other diseases in single meta-diseases",2015,"Reproductive Biology and Endocrinology","13","1", 31,"","",,,10.1186/s12958-015-0029-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928016060&partnerID=40&md5=09e8f13a0d690a845678448b20a08ff0","University of Valencia, Department of Functional Biology and Physical Anthropology, Faculty of Biological SciencesBurjassot Valencia, Spain; University of Valencia, Department of Genetics, Faculty of Biological SciencesBurjassot Valencia, Spain; Research Unit-INCLIVA, Hospital Clínico de ValenciaValencia, Spain; Keio University School of Medicine, Department of Obstetrics and GynecologyTokyo, Japan; University of Valencia, Department of Pediatrics, Obstetrics and Gynecology, Faculty of MedicineValencia, Spain; University Clinic Hospital, Service of Obstetrics and GynecologyValencia, Spain","Tarín, J.J., University of Valencia, Department of Functional Biology and Physical Anthropology, Faculty of Biological SciencesBurjassot Valencia, Spain; García-Pérez, M.A., University of Valencia, Department of Genetics, Faculty of Biological SciencesBurjassot Valencia, Spain, Research Unit-INCLIVA, Hospital Clínico de ValenciaValencia, Spain; Hamatani, T., Keio University School of Medicine, Department of Obstetrics and GynecologyTokyo, Japan; Cano, A., University of Valencia, Department of Pediatrics, Obstetrics and Gynecology, Faculty of MedicineValencia, Spain, University Clinic Hospital, Service of Obstetrics and GynecologyValencia, Spain","The present review aims to ascertain whether different infertility etiologies share particular genes and/or molecular pathways with other pathologies and are associated with distinct and particular risks of later-life morbidity and mortality. In order to reach this aim, we use two different sources of information: (1) a public web server named DiseaseConnect (http://disease-connect.org ) focused on the analysis of common genes and molecular mechanisms shared by diseases by integrating comprehensive omics and literature data; and (2) a literature search directed to find clinical comorbid relationships of infertility etiologies with only those diseases appearing after infertility is manifested. This literature search is performed because DiseaseConnect web server does not discriminate between pathologies emerging before, concomitantly or after infertility is manifested. Data show that different infertility etiologies not only share particular genes and/or molecular pathways with other pathologies but they have distinct clinical relationships with other diseases appearing after infertility is manifested. In particular, (1) testicular and high-grade prostate cancer in male infertility; (2) non-fatal stroke and endometrial cancer, and likely non-fatal coronary heart disease and ovarian cancer in polycystic ovary syndrome; (3) osteoporosis, psychosexual dysfunction, mood disorders and dementia in premature ovarian failure; (4) breast and ovarian cancer in carriers of BRCA1/2 mutations in diminished ovarian reserve; (5) clear cell and endometrioid histologic subtypes of invasive ovarian cancer, and likely low-grade serous invasive ovarian cancer, melanoma and non-Hodgkin lymphoma in endometriosis; and (6) endometrial and ovarian cancer in idiopathic infertility. The present data endorse the principle that the occurrence of a disease (in our case infertility) is non-random in the population and suggest that different infertility etiologies are genetically and clinically linked with other diseases in single meta-diseases. This finding opens new insights for clinicians and reproductive biologists to treat infertility problems using a phenomic approach instead of considering infertility as an isolated and exclusive disease of the reproductive system/hypothalamic-pituitary-gonadal axis. In agreement with a previous validation analysis of the utility of DiseaseConnect web server, the present study does not show a univocal correspondence between common gene expression and clinical comorbid relationship. Further work is needed to untangle the potential genetic, epigenetic and phenotypic relationships that may be present among different infertility etiologies, morbid conditions and physical/cognitive traits. © Tarín et al.; licensee BioMed Central.","Cancer; Disease; Gene expression; Molecular pathways; Phenomics","https://uts.nlm.nih.gov/home.html, Unified Medical Language System (UMLS) metathesaurus. Accessed October 27, 2014Thoma, M.E., McLain, A.C., Louis, J.F., King, R.B., Trumble, A.C., Sundaram, R., Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach (2013) Fertil Steril, 99, pp. 1324-1331; Tarín, J.J., García-Pérez, M.A., Cano, A., Assisted reproductive technology results: why are live-birth percentages so low? (2014) Mol Reprod Dev, 81, pp. 568-583; Liu, C.C., Tseng, Y.T., Li, W., Wu, C.Y., Mayzus, I., Rzhetsky, A., DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections (2014) Nucleic Acids Res, 42, pp. W137-W146; http://disease-connect.org, Accessed October 23, 2014Oti, M., Huynen, M.A., Brunner, H.G., Phenome connections (2008) Trends Genet, 24, pp. 103-106; Tomao, F., Lo Russo, G., Spinelli, G.P., Stati, V., Prete, A.A., Prinzi, N., Fertility drugs, reproductive strategies and ovarian cancer risk (2014) J Ovarian Res, 7, p. 51; Rizzuto, I., Behrens, R.F., Smith, L.A., Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility (2013) Cochrane Database Syst Rev, 8; Schüler, S., Ponnath, M., Engel, J., Ortmann, O., Ovarian epithelial tumors and reproductive factors: a systematic review (2013) Arch Gynecol Obstet, 287, pp. 1187-1204; Zreik, T.G., Mazloom, A., Chen, Y., Vannucci, M., Pinnix, C.C., Fulton, S., Fertility drugs and the risk of breast cancer: a meta-analysis and review (2010) Breast Cancer Res Treat, 124, pp. 13-26; Siristatidis, C., Sergentanis, T.N., Kanavidis, P., Trivella, M., Sotiraki, M., Mavromatis, I., Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer-a systematic review and meta-analysis (2013) Hum Reprod Update, 19, pp. 105-123; Sergentanis, T.N., Diamantaras, A.A., Perlepe, C., Kanavidis, P., Skalkidou, A., Petridou, E.T., IVF and breast cancer: a systematic review and meta-analysis (2014) Hum Reprod Update, 2, pp. 106-123; http://www.cdc.gov/art/reports/2012/fertility-clinic.html, Assisted Reproductive Technology, Fertility Clinic Success Rates Report; 2012. Accessed October 1, 2014http://www.genome.jp/kegg/pathway.html, pathway database.Accessed October 23, 2014Hotaling, J.M., Walsh, T.J., Male infertility: a risk factor for testicular cancer (2009) Nat Rev Urol, 6, pp. 550-556; Peng, X., Zeng, X., Peng, S., Deng, D., Zhang, J., The association risk of male subfertility and testicular cancer: a systematic review (2009) PLoS One, 4; Walsh, T.J., Male reproductive health and prostate cancer risk (2011) Curr Opin Urol, 21, pp. 506-513; Eisenberg, M.L., Li, S., Behr, B., Cullen, M.R., Galusha, D., Lamb, D.J., Semen quality, infertility and mortality in the USA (2014) Hum Reprod, 29, pp. 1567-1574; Belloc, S., Cohen-Bacrie, M., Amar, E., Izard, V., Benkhalifa, M., Dalléac, A., High body mass index has a deleterious effect on semen parameters except morphology: results from a large cohort study (2014) Fertil Steril, 102, pp. 1268-1273; Omu, A.E., Sperm parameters: paradigmatic index of good health and longevity (2013) Med Princ Pract, 22, pp. 30-42; Sermondade, N., Faure, C., Fezeu, L., Shayeb, A.G., Bonde, J.P., Jensen, T.K., BMI in relation to sperm count: an updated systematic review and collaborative meta-analysis (2013) Hum Reprod Update, 19, pp. 221-231; Eisenberg, M.L., Kim, S., Chen, Z., Sundaram, R., Schisterman, E.F., Buck Louis, G.M., The relationship between male BMI and waist circumference on semen quality: data from the LIFE study (2014) Hum Reprod, 29, pp. 193-200; Li, Y., Lin, H., Li, Y., Cao, J., Association between socio-psycho-behavioral factors and male semen quality: systematic review and meta-analyses (2011) Fertil Steril, 95, pp. 116-123; Ely, J.J., Inadequate levels of essential nutrients in developed nations as a risk factor for disease: a review (2003) Rev Environ Health, 18, pp. 111-129; Leon, D.A., Shkolnikov, V.M., McKee, M., Alcohol and Russian mortality: a continuing crisis (2009) Addiction, 104, pp. 1630-1636; Pilgrim, J.L., Woodford, N., Drummer, O.H., Cocaine in sudden and unexpected death: a review of 49 post-mortem cases (2013) Forensic Sci Int, 227, pp. 52-59; Rizzuto, D., Fratiglioni, L., Lifestyle factors related to mortality and survival: a mini-review (2014) Gerontology, 60, pp. 327-335; Povey, A.C., Clyma, J.A., McNamee, R., Moore, H.D., Baillie, H., Pacey, A.A., Modifiable and non-modifiable risk factors for poor semen quality: a case-referent study (2012) Hum Reprod, 27, pp. 2799-2806; Pacey, A.A., Povey, A.C., Clyma, J.A., McNamee, R., Moore, H.D., Baillie, H., Modifiable and non-modifiable risk factors for poor sperm morphology (2014) Hum Reprod, 29, pp. 1629-1636; Permuth-Wey, J., Besharat, A., Sellers, T.A., Epidemiology of ovarian cancer: an update (2014) Advances in Diagnosis and Management of Ovarian Cancer, pp. 1-21. , Farghaly SA, editor. New York: Springer Science & Business Media; Parikh, N.I., Cnattingius, S., Mittleman, M.A., Ludvigsson, J.F., Ingelsson, E., Subfertility and risk of later life maternal cardiovascular disease (2012) Hum Reprod, 27, pp. 568-575; Venn, A., Hemminki, E., Watson, L., Bruinsma, F., Healy, D., Mortality in a cohort of IVF patients (2001) Hum Reprod, 16, pp. 2691-2696; Braat, D.D., Schutte, J.M., Bernardus, R.E., Mooij, T.M., Leeuwen, F.E., Maternal death related to IVF in the Netherlands 1984-2008 (2010) Hum Reprod, 25, pp. 1782-1786; Westerlund, E., Brandt, L., Hovatta, O., Wallén, H., Ekbom, A., Henriksson, P., Incidence of hypertension, stroke, coronary heart disease, and diabetes in women who have delivered after in vitro fertilization: a population-based cohort study from Sweden (2014) Fertil Steril, 102, pp. 1096-1102; Udell, J.A., Lu, H., Redelmeier, D.A., Long-term cardiovascular risk in women prescribed fertility therapy (2013) J Am Coll Cardiol, 62, pp. 1704-1712; Yli-Kuha, A.N., Gissler, M., Klemetti, R., Luoto, R., Hemminki, E., Cancer morbidity in a cohort of 9175 Finnish women treated for infertility (2012) Hum Reprod, 27, pp. 1149-1155; Calogero, A.E., Calabrò, V., Catanuso, M., Condorelli, R.A., Vignera, S., Understanding polycystic ovarian syndrome pathogenesis: an updated of its genetic aspects (2011) J Endocrinol Invest, 34, pp. 630-644; Teede, H., Deeks, A., Moran, L., Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan (2010) BMC Med, 8, p. 41; Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) (2004) Hum Reprod, 19, pp. 41-47; http://mips.helmholtz-muenchen.de/genre/proj/corum/index.html, Accessed October 28, 2014Kar, S., Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: a prospective study of PCOS women (2013) J Hum Reprod Sci, 6, pp. 194-200; Anderson, S.A., Barry, J.A., Hardiman, P.J., Risk of coronary heart disease and risk of stroke in women with polycystic ovary syndrome: A systematic review and meta-analysis (2014) Int J Cardiol, 176, pp. 486-487; Vink, J.M., Sadrzadeh, S., Lambalk, C.B., Boomsma, D.I., Heritability of polycystic ovary syndrome in a Dutch twin-family study (2006) J Clin Endocrinol Metab, 91, pp. 2100-2104; Hunter, A., Vimplis, S., Sharma, A., Eid, N., Atiomo, W., To determine whether first-degree male relatives of women with polycystic ovary syndrome are at higher risk of developing cardiovascular disease and type II diabetes mellitus (2007) J Obstet Gynaecol, 27, pp. 591-596; Davies, M.J., Marino, J.L., Willson, K.J., March, W.A., Moore, V.M., Intergenerational associations of chronic disease and polycystic ovary syndrome (2011) PLoS One, 6; Louwers, Y.V., Roest-Schalken, M.E., Kleefstra, N., Roeters van Lennep, J., Berg, M., Fauser, B.C., Excess mortality in mothers of patients with polycystic ovary syndrome (2014) Hum Reprod, 29, pp. 1780-1786; Savaris, R.F., Groll, J.M., Young, S.L., DeMayo, F.J., Jeong, J.W., Hamilton, A.E., Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles (2011) J Clin Endocrinol Metab, 96, pp. 1737-1746; Ali, A.T., Risk factors for endometrial cancer (2013) Ceska Gynekol, 78, pp. 448-459; Chittenden, B.G., Fullerton, G., Maheshwari, A., Bhattacharya, S., Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review (2009) Reprod Biomed Online, 19, pp. 398-405; Barry, J.A., Azizia, M.M., Hardiman, P.J., Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis (2014) Hum Reprod Update, 20, pp. 748-758; Ali, A.T., Reproductive factors and the risk of endometrial cancer (2014) Int J Gynecol Cancer, 24, pp. 384-393; Housman, E., Reynolds, R.V., Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations (2014) J Am Acad Dermatol, 71, p. 847. , e1-e10; Daan, N.M., Louwers, Y.V., Koster, M.P., Eijkemans, M.J., de Rijke, Y.B., Lentjes, E.W., Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? (2014) Fertil Steril, 102, pp. 1444-1451; Lambrinoudaki, I., Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome (2011) Maturitas, 68, pp. 13-16; Silva, C.A., Yamakami, L.Y., Aikawa, N.E., Araujo, D.B., Carvalho, J.F., Bonfá, E., Autoimmune primary ovarian insufficiency (2014) Autoimmun Rev, 13, pp. 427-430; Nelson, L.M., Clinical practice. Primary ovarian insufficiency (2009) N Engl J Med, 360, pp. 606-614; Maclaran, K., Horner, E., Panay, N., Premature ovarian failure: long-term sequelae (2010) Menopause Int, 16, pp. 38-41; Cox, L., Liu, J.H., Primary ovarian insufficiency: an update (2014) Int J Womens Health, 6, pp. 235-243; Shuster, L.T., Rhodes, D.J., Gostout, B.S., Grossardt, B.R., Rocca, W.A., Premature menopause or early menopause: long-term health consequences (2010) Maturitas, 65, pp. 161-166; Li, S., Rosenberg, L., Wise, L.A., Boggs, D.A., LaValley, M., Palmer, J.R., Age at natural menopause in relation to all-cause and cause-specific mortality in a follow-up study of US black women (2013) Maturitas, 75, pp. 246-252; Shah, D., Nagarajan, N., Premature menopause - Meeting the needs (2014) Post Reprod Health, 20, pp. 62-68; Mahendru, A.A., Morris, E., Cardiovascular disease in menopause: does the obstetric history have any bearing? (2013) Menopause Int, 19, pp. 115-120; Scott, E.L., Zhang, Q.G., Vadlamudi, R.K., Brann, D.W., Premature menopause and risk of neurological disease: basic mechanisms and clinical implications (2014) Mol Cell Endocrinol, 389, pp. 2-6; Atwood, C.S., Bowen, R.L., The reproductive-cell cycle theory of aging: an update (2011) Exp Gerontol, 46, pp. 100-107; Greene, A.D., Patounakis, G., Segars, J.H., Genetic associations with diminished ovarian reserve: a systematic review of the literature (2014) J Assist Reprod Genet, 31, pp. 935-946; http://sart.org/find_frm.html, 2012 National Clinic Summary Report.. Accessed October 3, 2014Richardson, M.C., Guo, M., Fauser, B.C., Macklon, N.S., Environmental and developmental origins of ovarian reserve (2014) Hum Reprod Update, 20, pp. 353-369; Gleicher, N., Kim, A., Weghofer, A., Kushnir, V.A., Shohat-Tal, A., Lazzaroni, E., Hypoandrogenism in association with diminished functional ovarian reserve (2013) Hum Reprod, 28, pp. 1084-1091; Verit, F.F., Keskin, S., Omer, B., Yalcinkaya, S., Sakar, N., Is there any relationship between cardiovascular risk markers and young women with diminished ovarian reserve? (2014) Gynecol Endocrinol, 30, pp. 697-700; Titus, S., Li, F., Stobezki, R., Akula, K., Unsal, E., Jeong, K., Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans (2013) Sci Transl Med, 5. , 172ra21; Wang, E.T., Pisarska, M.D., Bresee, C., Ida Chen, Y.D., Lester, J., Afshar, Y., BRCA1 germline mutations may be associated with reduced ovarian reserve (2014) Fertil Steril, 102, pp. 1723-1728; Brohet, R.M., Velthuizen, M.E., Hogervorst, F.B., Meijers-Heijboer, H.E., Seynaeve, C., Collée, M.J., HEBON Resource. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (2014) J Med Genet, 51, pp. 98-107; Mersch, J., Jackson, M.A., Park, M., Nebgen, D., Peterson, S.K., Singletary, C., Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian (2015) Cancer, 121, pp. 269-275; Oktay, K., Kim, J.Y., Barad, D., Babayev, S.N., Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks (2010) J Clin Oncol, 28, pp. 240-244; Rzepka-Górska, I., Tarnowski, B., Chudecka-Głaz, A., Górski, B., Zielińska, D., Tołoczko-Grabarek, A., Premature menopause in patients with BRCA1 gene mutation (2006) Breast Cancer Res Treat, 100, pp. 59-63; Finch, A., Valentini, A., Greenblatt, E., Lynch, H.T., Ghadirian, P., Armel, S., Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation (2013) Fertil Steril, 99, pp. 1724-1728; Lin, W.T., Beattie, M., Chen, L.M., Oktay, K., Crawford, S.L., Gold, E.B., Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California (2013) Cancer, 119, pp. 1652-1659; Collins, I.M., Milne, R.L., McLachlan, S.A., Friedlander, M., Hickey, M., Weideman, P.C., Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (2013) J Clin Oncol, 31, pp. 3920-3925; Oktay, K., Moy, F., Titus, S., Stobezki, R., Turan, V., Dickler, M., Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations (2014) J Clin Oncol, 32, pp. 1093-1094; Batt, R.E., Martin, D.C., Odunsi, K., Endometriosis of the retrocervical septum is proposed to replace the anatomically incorrect term endometriosis of the rectovaginal septum (2014) Hum Reprod, 29, pp. 2603-2605; Munksgaard, P.S., Blaakaer, J., The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data (2011) Gynecol Oncol, 123, pp. 157-163; Pavlidou, A., Vlahos, N.F., Endometriosis and ovarian cancer: clinical and molecular aspects (2014) Minerva Endocrinol, 39, pp. 155-165; Nezhat, F.R., Pejovic, T., Reis, F.M., Guo, S.W., The link between endometriosis and ovarian cancer: clinical implications (2014) Int J Gynecol Cancer, 24, pp. 623-628; Vlahos, N.F., Economopoulos, K.P., Fotiou, S., Endometriosis, in vitro fertilization and the risk of gynaecological malignancies, including ovarian and breast cancer (2010) Best Pract Res Clin Obstet Gynaecol, 24, pp. 39-50; Kim, H.S., Kim, T.H., Chung, H.H., Song, Y.S., Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis (2014) Br J Cancer, 110, pp. 1878-1890; Hu, X., Zhou, Y., Feng, Q., Wang, R., Su, L., Long, J., Association of endometriosis risk and genetic polymorphisms involving biosynthesis of sex steroids and their receptors: an updating meta-analysis (2012) Eur J Obstet Gynecol Reprod Biol, 164, pp. 1-9; Forte, A., Cipollaro, M., Galderisi, U., Genetic, epigenetic and stem cell alterations in endometriosis: new insights and potential therapeutic perspectives (2014) Clin Sci (Lond), 126, pp. 123-138; Rahmioglu, N., Nyholt, D.R., Morris, A.P., Missmer, S.A., Montgomery, G.W., Zondervan, K.T., Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets (2014) Hum Reprod Update, 20, pp. 702-716; Worley, M.J., Welch, W.R., Berkowitz, R.S., Ng, S.W., Endometriosis-associated ovarian cancer: a review of pathogenesis (2013) Int J Mol Sci, 14, pp. 5367-5379; Siufi Neto, J., Kho, R.M., Siufi, D.F., Baracat, E.C., Anderson, K.S., Abrão, M.S., Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer (2014) J Minim Invasive Gynecol, 21, pp. 55-63; Cetin, I., Cozzi, V., Antonazzo, P., Infertility as a cancer risk factor - a review (2008) Placenta, 29, pp. 169-177; Pearce, C.L., Templeman, C., Rossing, M.A., Lee, A., Near, A.M., Webb, P.M., Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies (2012) Lancet Oncol, 13, pp. 385-394; Heidemann, L.N., Hartwell, D., Heidemann, C.H., Jochumsen, K.M., The relation between endometriosis and ovarian cancer - a review (2014) Acta Obstet Gynecol Scand, 93, pp. 20-31; Venn, A., Watson, L., Bruinsma, F., Giles, G., Healy, D., Risk of cancer after use of fertility drugs with in-vitro fertilisation (1999) Lancet, 354, pp. 1586-1590; Ness, R.B., Cramer, D.W., Goodman, M.T., Kjaer, S.K., Mallin, K., Mosgaard, B.J., Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies (2002) Am J Epidemiol, 155, pp. 217-224; Venn, A., Healy, D., McLachlan, R., Cancer risks associated with the diagnosis of infertility (2003) Best Pract Res Clin Obstet Gynaecol, 17, pp. 343-367; G, S., A, B., Kamath, A., Shivaprakash, P., Adhikari, P., Up, R., Acanthosis nigricans in PCOS patients and its relation with type 2 diabetes mellitus and body mass at a tertiary care hospital in Southern India (2013) J Clin Diagn Res, 7, pp. 317-319; Xie, J., Kvaskoff, M., Li, Y., Zhang, M., Qureshi, A.A., Missmer, S.A., Severe teenage acne and risk of endometriosis (2014) Hum Reprod, 29, pp. 2592-2599; Shah, D.K., Correia, K.F., Vitonis, A.F., Missmer, S.A., Body size and endometriosis: results from 20 years of follow-up within the Nurses' Health Study II prospective cohort (2013) Hum Reprod, 28, pp. 1783-1792; Vercellini, P., Buggio, L., Somigliana, E., Barbara, G., Viganò, P., Fedele, L., Attractiveness of women with rectovaginal endometriosis: a case-control study (2013) Fertil Steril, 99, pp. 212-218; Vercellini, P., Buggio, L., Somigliana, E., Dridi, D., Marchese, M.A., Viganò, P., 'Behind blue eyes': the association between eye colour and deep infiltrating endometriosis (2014) Hum Reprod, 29, pp. 2171-2175; Buggio, L., Vercellini, P., Somigliana, E., Viganò, P., Frattaruolo, M.P., Fedele, L., ""You are so beautiful"": behind women's attractiveness towards the biology of reproduction: a narrative review (2012) Gynecol Endocrinol, 28, pp. 753-757; Atkinson, J., Pipitone, R.N., Sorokowska, A., Sorokowski, P., Mberira, M., Bartels, A., Voice and handgrip strength predict reproductive success in a group of indigenous African females (2012) PLoS One, 7; Arden, R., Gottfredson, L.S., Miller, G., Pierce, A., Intelligence and semen quality are positively correlated (2009) Intelligence, 37, pp. 277-282; Soler, C., Kekäläinen, J., Núñez, M., Sancho, M., Álvarez, J.G., Núñez, J., Male facial attractiveness and masculinity may provide sex- and culture-independent cues to semen quality (2014) J Evol Biol, 27, pp. 1930-1938; Peters, M., Rhodes, G., Simmons, L.W., Does attractiveness in men provide clues to semen quality? (2008) J Evol Biol, 21, pp. 572-579",Editorial,Scopus,2-s2.0-84928016060
"Yang Y., Fan Y., Li J., Liu B., Shao Y., Cao H., Wang J., Zou R., Zhang Q., Hu X.","Serum uric acid as a predictor for cardiovascular and all-cause mortality in women versus men",2015,"International Journal of Cardiology","185",,,"125","128",,,10.1016/j.ijcard.2015.03.121,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928266592&partnerID=40&md5=9cd395a5dd33aa691099fae270332080","Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China","Yang, Y., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Fan, Y., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Li, J., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Liu, B., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Shao, Y., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Cao, H., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Wang, J., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Zou, R., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Zhang, Q., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China; Hu, X., Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical UniversityShenyang, China",[No abstract available],"Gender difference; Meta-analysis; Mortality; Serum uric acid","Fang, J., Alderman, M.H., Serum uric acid and cardiovascular mortality the NHANES i epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey (2000) JAMA, 283, pp. 2404-2410; Freedman, D.S., Williamson, D.F., Gunter, E.W., Byers, T., Relation of serum uric acid to mortality and ischemic heart disease. The NHANES i Epidemiologic Follow-up Study (1995) Am. J. Epidemiol., 141, pp. 637-644; Culleton, B.F., Larson, M.G., Kannel, W.B., Levy, D., Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study (1999) Ann. Intern. Med., 131, pp. 7-13; Chen, J.H., Chuang, S.Y., Chen, H.J., Yeh, W.T., Pan, W.H., Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: A Chinese cohort study (2009) Arthritis Rheum., 61, pp. 225-232; Juraschek, S.P., Tunstall-Pedoe, H., Woodward, M., Serum uric acid and the risk of mortality during 23 years follow-up in the Scottish Heart Health Extended Cohort Study (2014) Atherosclerosis, 233, pp. 623-629; Sakata, K., Hashimoto, T., Ueshima, H., Okayama, A., Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged (2001) Eur. J. Epidemiol., 17, pp. 461-468; Hu, P., Seeman, T.E., Harris, T.B., Reuben, D.B., Is serum uric acid level associated with all-cause mortality in high-functioning older persons: MacArthur studies of successful aging? (2001) J. Am. Geriatr. Soc., 49, pp. 1679-1684; Liese, A.D., Hense, H.W., Lowel, H., Doring, A., Tietze, M., Keil, U., Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases (1999) Epidemiology, 10, pp. 391-397; Jee, S.H., Lee, S.Y., Kim, M.T., Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men (2004) Eur. J. Cardiovasc. Prev. Rehabil., 11, pp. 185-191; Niskanen, L.K., Laaksonen, D.E., Nyyssonen, K., Alfthan, G., Lakka, H.M., Lakka, T.A., Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study (2004) Arch. Intern. Med., 164, pp. 1546-1551; Meisinger, C., Koenig, W., Baumert, J., Doring, A., Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: The MONICA/KORA cohort study (2008) Arterioscler. Thromb. Vasc. Biol., 28, pp. 1186-1192; Wang, Y., Xu, Y., Hu, D., Guo, X., Zhao, D., Li, J., Joint association of ankle-brachial index and serum uric acid on the outcomes of six-year all-cause mortality and cardiovascular mortality in Chinese patients (2012) Int. J. Cardiol., 158, pp. 144-145; Zhao, G., Huang, L., Song, M., Song, Y., Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: A meta-analysis of prospective studies (2013) Atherosclerosis, 231, pp. 61-68; Wells, G., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., The Newcastle-Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-analyses, , http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, (accessed May 6, 2014); Rodrigues, S.L., Baldo, M.P., Capingana, P., Magalhaes, P., Dantas, E.M., Molina Mdel, C., Gender distribution of serum uric acid and cardiovascular risk factors: Population based study (2012) Arq. Bras. Cardiol., 98, pp. 13-21; Adamopoulos, D., Vlassopoulos, C., Seitanides, B., Contoyiannis, P., Vassilopoulos, P., The relationship of sex steroids to uric acid levels in plasma and urine (1977) Acta Endocrinol. (Copenh), 85, pp. 198-208",Letter,Scopus,2-s2.0-84928266592
"Canpolat U., Aytemir K., Ozer N., Oto A.","Relationship between the epicardial fat thickness and total atrial conduction time in patients with lone paroxysmal atrial fibrillation",2015,"International Journal of Cardiology","185",,,"106","108",,,10.1016/j.ijcard.2015.03.091,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928266314&partnerID=40&md5=9ee55741fe1641fbae0eb96076424cc2","Department of Cardiology, Hacettepe University, Faculty of MedicineSihhiye, Ankara, Turkey","Canpolat, U., Department of Cardiology, Hacettepe University, Faculty of MedicineSihhiye, Ankara, Turkey; Aytemir, K., Department of Cardiology, Hacettepe University, Faculty of MedicineSihhiye, Ankara, Turkey; Özer, N., Department of Cardiology, Hacettepe University, Faculty of MedicineSihhiye, Ankara, Turkey; Oto, A., Department of Cardiology, Hacettepe University, Faculty of MedicineSihhiye, Ankara, Turkey",[No abstract available],"Atrial conduction time; Atrial fibrillation; Epicardial fat; Remodeling","Lin, Y.K., Chen, Y.J., Chen, S.A., Potential atrial arrhythmogenicity of adipocytes: Implications for the genesis of atrial fibrillation (2010) Med. Hypotheses, 74, pp. 1026-1029; Friedrichs, K., Klinke, A., Baldus, S., Inflammatory pathways underlying atrial fibrillation (2011) Trends Mol. Med., 17, pp. 556-563; Merckx, K.L., De Vos, C.B., Palmans, A., Atrial activation time determined by transthoracic Doppler tissue imaging can be used as an estimate of the total duration of atrial electrical activation (2005) J. Am. Soc. Echocardiogr. Off. Publ. Am. Soc. Echocardiogr., 18, pp. 940-944; Mazurek, T., Zhang, L., Zalewski, A., Human epicardial adipose tissue is a source of inflammatory mediators (2003) Circulation, 108, pp. 2460-2466; Yorgun, H., Canpolat, U., Aytemir, K., Association of epicardial and peri-atrial adiposity with the presence and severity of non-valvular atrial fibrillation (2015) Int. J. Cardiovasc. Imaging, 31, pp. 649-657; Al Chekakie, M.O., Welles, C.C., Metoyer, R., Pericardial fat is independently associated with human atrial fibrillation (2010) J. Am. Coll. Cardiol., 56, pp. 784-788; Camm, A.J., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Eur. Heart J., 31, pp. 2369-2429. , European Heart Rhythm A, European Association For Cardio-Thoracic S; Allessie, M., Ausma, J., Schotten, U., Electrical, contractile and structural remodeling during atrial fibrillation (2002) Cardiovasc. Res., 54, pp. 230-246; Canpolat, U., Oto, A., Hazirolan, T., A prospective DE-MRI study evaluating the role of TGF-beta1 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: New insights into primary fibrotic atriocardiomyopathy (2015) J. Cardiovasc. Electrophysiol., 26, pp. 251-259; Chao, T.F., Lai, Y.H., Yun, C.H., The association between atrium electromechanical interval and pericardial fat (2014) PLoS One, 9, p. e97472",Letter,Scopus,2-s2.0-84928266314
"Chung J.-H., Ann S.H., Koo B.-K., Nam C.-W., Doh J.-H., Singh G.B., Kim H.I., Shin E.-S.","Assessment of stent edge dissections by fractional flow reserve",2015,"International Journal of Cardiology","185",,,"29","33",,,10.1016/j.ijcard.2015.03.043,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928264558&partnerID=40&md5=1bcb58ec09b508d6d16d736c383d08e4","Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, 290-3 Jeonha-dongDong-gu, Ulsan, South Korea; Department of Internal Medicine and Cardiovascular Center, Seoul National University HospitalSeoul, South Korea; Department of Internal Medicine, Keimyung University College of Medicine, Dongsan Medical CenterDaegu, South Korea; Division of Cardiology, Inje University, Ilsan Paik Hospital, South Korea; Suntech Research CenterSeoul, South Korea","Chung, J.-H., Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, 290-3 Jeonha-dongDong-gu, Ulsan, South Korea; Ann, S.H., Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, 290-3 Jeonha-dongDong-gu, Ulsan, South Korea; Koo, B.-K., Department of Internal Medicine and Cardiovascular Center, Seoul National University HospitalSeoul, South Korea; Nam, C.-W., Department of Internal Medicine, Keimyung University College of Medicine, Dongsan Medical CenterDaegu, South Korea; Doh, J.-H., Division of Cardiology, Inje University, Ilsan Paik Hospital, South Korea; Singh, G.B., Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, 290-3 Jeonha-dongDong-gu, Ulsan, South Korea; Kim, H.I., Suntech Research CenterSeoul, South Korea; Shin, E.-S., Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, 290-3 Jeonha-dongDong-gu, Ulsan, South Korea","Backgrounds Edge dissections after intervention have been studied with imaging techniques, however, functional assessment has not been studied yet. We investigated the relationship between fractional flow reserve (FFR) and the angiographic type of stent edge dissections and tried to assess the use of FFR-guided management for edge dissection. Methods 51 edge dissections assessed by FFR were included in this prospective observational study. FFR was measured for each type of edge dissection and compared with quantitative coronary angiographic findings. Clinical outcomes were evaluated based on FFR measurements. Results Edge dissections were classified as type A (47.1%; 24/51), type B (41.2%; 21/51), type C (2.0%; 1/51) and type D (9.8%; 5/51). Mean FFR in type A dissection was 0.87 ± 0.09, in type B 0.86 ± 0.07, in type C 0.72 and in type D 0.57 ± 0.08. All type C and D dissections (6/51) had FFR ≤ 0.8 and were treated with additional stents. Among the 45 type A and B dissections, 8 had a FFR ≤ 0.8 (17.8%), and 50% received additional stenting. All dissections with FFR > 0.8 were left untreated except one long dissection case. There was no death, myocardial infarction or target lesion revascularization during hospitalization or the follow-up period (median 152 days; IQR 42-352 days). Conclusions FFR correlates well with an angiographic type of edge dissection. Angiographic findings are sufficient for deciding the treatment of severe dissections such as types C and D, while FFR-guided management may be safe and effective for mild edge dissections such as types A and B. © 2015 Elsevier Ireland Ltd. All rights reserved.","Drug eluting stent; Fractional flow reserve; Stent edge dissection","Sheris, S.J., Canos, M.R., Weissman, N.J., Natural history of intravascular ultrasound-detected edge dissections from coronary stent deployment (2000) Am. Heart J., 139, pp. 59-63; Ann, S.H., Lim, K.H., De Jin, C., Shin, E.S., (2015) Multi-modality Imaging for Stent Edge Assessment, 30, pp. 162-168; Chamie, D., Bezerra, H.G., Attizzani, G.F., Yamamoto, H., Kanaya, T., Stefano, G.T., Incidence, predictors, morphological characteristics, and clinical outcomes of stent edge dissections detected by optical coherence tomography (2013) J. Am. Coll. Cardiol. Intv., 6, pp. 800-813; Hong, M.K., Park, S.W., Lee, N.H., Nah, D.Y., Lee, C.W., Kang, D.H., Long-term outcomes of minor dissection at the edge of stents detected with intravascular ultrasound (2000) Am. J. Cardiol., 86, pp. 791-795. , (a9); Honye, J., Mahon, D.J., Jain, A., White, C.J., Ramee, S.R., Wallis, J.B., Morphological effects of coronary balloon angioplasty in vivo assessed by intravascular ultrasound imaging (1992) Circulation, 85, pp. 1012-1025; Radu, M.D., Raber, L., Heo, J., Gogas, B.D., Jorgensen, E., Kelbaek, H., Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation (2014) EuroIntervention, 9, pp. 1085-1094; Liu, X., Tsujita, K., Maehara, A., Mintz, G.S., Weisz, G., Dangas, G.D., Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation (2009) J. Am. Coll. Cardiol. Intv., 2, pp. 997-1004; Pijls, N.H., Van Schaardenburgh, P., Manoharan, G., Boersma, E., Bech, J.W., Van'T Veer, M., Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study (2007) J. Am. Coll. Cardiol., 49, pp. 2105-2111; Ishii, H., Kataoka, T., Kobayashi, Y., Tsumori, T., Takeshita, H., Matsumoto, R., Utility of myocardial fractional flow reserve for prediction of restenosis following sirolimus-eluting stent implantation (2011) Heart Vessel., 26, pp. 572-581; Yamashita, J., Tanaka, N., Fujita, H., Akasaka, T., Takayama, T., Oikawa, Y., Usefulness of functional assessment in the treatment of patients with moderate angiographic paclitaxel-eluting stent restenosis (2013) Circ. J., 77, pp. 1180-1185; Nam, C.W., Hur, S.H., Cho, Y.K., Park, H.S., Yoon, H.J., Kim, H., Relation of fractional flow reserve after drug-eluting stent implantation to one-year outcomes (2011) Am. J. Cardiol., 107, pp. 1763-1767; Huber, M.S., Mooney, J.F., Madison, J., Mooney, M.R., Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty (1991) Am. J. Cardiol., 68, pp. 467-471; Rogers, J.H., Lasala, J.M., Coronary artery dissection and perforation complicating percutaneous coronary intervention (2004) J. Invasive Cardiol., 16, pp. 493-499; Jang, H.J., Koo, B.K., Lee, H.S., Park, J.B., Kim, J.H., Seo, M.K., Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory (2013) Eur. Heart J., 34, pp. 2055-2062; Koo, B.K., Yang, H.M., Doh, J.H., Choe, H., Lee, S.Y., Yoon, C.H., Optimal intravascular ultrasound criteria and their accuracy for defining the functional significance of intermediate coronary stenoses of different locations (2011) J. Am. Coll. Cardiol. Intv., 4, pp. 803-811; Park, S.J., Kang, S.J., Ahn, J.M., Shim, E.B., Kim, Y.T., Yun, S.C., Visual-functional mismatch between coronary angiography and fractional flow reserve (2012) J. Am. Coll. Cardiol. Intv., 5, pp. 1029-1036; Koo, B.K., The present and future of fractional flow reserve (2014) Circ. J., 78, pp. 1048-1054",Article,Scopus,2-s2.0-84928264558
"Zhang Z., Li G., Liu T.","Psoriasis and risk of atrial fibrillation",2015,"International Journal of Cardiology","185",,,"301","303",,,10.1016/j.ijcard.2015.03.149,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928250095&partnerID=40&md5=7836ace53c84486bb2d9b0fc24ab32c9","Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical UniversityTianjin, China","Zhang, Z., Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical UniversityTianjin, China; Li, G., Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical UniversityTianjin, China; Liu, T., Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical UniversityTianjin, China",[No abstract available],"Atrial fibrillation; Psoriasis; Risk","Kurd, S.K., Gelfand, J.M., The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004 (2009) J. Am. Acad. Dermatol., 60, pp. 218-224; Gelfand, J.M., Weinstein, R., Porter, S.B., Neimann, A.L., Berlin, J.A., Margolis, D.J., Prevalence and treatment of psoriasis in the United Kingdom: A population-based study (2005) Arch. Dermatol., 141, pp. 1537-1541; Farber, E.M., Nall, M.L., The natural history of psoriasis in 5,600 patients (1974) Dermatologica, 148, pp. 1-18; Mehta, N.N., Yu, Y., Pinnelas, R., Krishnamoorthy, P., Shin, D.B., Troxel, A.B., Gelfand, J.M., Attributable risk estimate of severe psoriasis on major cardiovascular events (2011) Am. J. Med., 124, pp. 775e1-775e6; Ahlehoff, O., Gislason, G.H., Charlot, M., Jorgensen, C.H., Lindhardsen, J., Olesen, J.B., Abildstrom, S.Z., Hansen, P.R., Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study (2011) J. Intern. Med., 270, pp. 147-157; Mehta, N.N., Azfar, R.S., Shin, D.B., Neimann, A.L., Troxel, A.B., Gelfand, J.M., Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database (2010) Eur. Heart J., 31, pp. 1000-1006; Prodanovich, S., Kirsner, R.S., Kravetz, J.D., Ma, F., Martinez, L., Federman, D.G., Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality (2009) Arch. Dermatol., 145, pp. 700-703; Gelfand, J.M., Dommasch, E.D., Shin, D.B., Azfar, R.S., Kurd, S.K., Wang, X., Troxel, A.B., The risk of stroke in patients with psoriasis (2009) J. Investig. Dermatol., 129, pp. 2411-2418; Brauchli, Y.B., Jick, S.S., Miret, M., Meier, C.R., Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: An inception cohort study with a nested case-control analysis (2009) Br. J. Dermatol., 160, pp. 1048-1056; Friedewald, V.E., Cather, J.C., Gelfand, J.M., Gordon, K.B., Gibbons, G.H., Grundy, S.M., Jarratt, M.T., Roberts, W.C., AJC editor's consensus: Psoriasis and coronary artery disease (2008) Am. J. Cardiol., 102, pp. 1631-1643; Gelfand, J.M., Neimann, A.L., Shin, D.B., Wang, X., Margolis, D.J., Troxel, A.B., Risk of myocardial infarction in patients with psoriasis (2006) JAMA, 296, pp. 1735-1741; Mosca, S., Gargiulo, P., Balato, N., Di Costanzo, L., Parente, A., Paolillo, S., Ayala, F., Perrone-Filardi, P., Ischemic cardiovascular involvement in psoriasis: A systematic review (2014) Int. J. Cardiol., 178, pp. 191-199; Kannel, W.B., Benjamin, E.J., Status of the epidemiology of atrial fibrillation (2008) Med. Clin. N. Am., 92, pp. 17-40; Liu, T., Li, G., Psoriasis, inflammation, and atrial fibrillation (2008) Am. J. Cardiol., 102, p. 647; Ahlehoff, O., Gislason, G.H., Jorgensen, C.H., Lindhardsen, J., Charlot, M., Olesen, J.B., Abildstrom, S.Z., Hansen, P.R., Psoriasis and risk of atrial fibrillation and ischaemic stroke: A Danish Nationwide Cohort Study (2012) Eur. Heart J., 33, pp. 2054-2064; Bang, C.N., Okin, P.M., Kober, L., Wachtell, K., Gottlieb, A.B., Devereux, R.B., Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The Losartan Intervention for Endpoint study (2014) J. Hypertens., 32, pp. 667-672; Armstrong, A.W., Azizi, S., Wu, J., Harskamp, C.T., Farrow, J., Johnson, M.A., Klem, K., Armstrong, E.J., Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation (2013) Arch. Dermatol. Res., 305, pp. 891-897; Dilaveris, P.E., Gialafos, E.J., Andrikopoulos, G.K., Richter, D.J., Papanikolaou, V., Poralis, K., Gialafos, J.E., Clinical and electrocardiographic predictors of recurrent atrial fibrillation (2000) Pacing Clin. Electrophysiol., 23, pp. 352-358; Dilaveris, P.E., Gialafos, E.J., Sideris, S.K., Theopistou, A.M., Andrikopoulos, G.K., Kyriakidis, M., Gialafos, J.E., Toutouzas, P.K., Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation (1998) Am. Heart J., 135, pp. 733-738; Centurion, O.A., Clinical implications of the P wave duration and dispersion: Relationship between atrial conduction defects and abnormally prolonged and fractionated atrial endocardial electrograms (2009) Int. J. Cardiol., 134, pp. 6-8; Ozer, N., Aytemir, K., Atalar, E., Sade, E., Aksoyek, S., Ovunc, K., Acyl, T., Kes, S., P wave dispersion in hypertensive patients with paroxysmal atrial fibrillation (2000) Pacing Clin. Electrophysiol., 23, pp. 1859-1862; Cui, Q.Q., Zhang, W., Wang, H., Sun, X., Wang, R., Yang, H.Y., Meng, X.Q., Wang, H., Assessment of atrial electromechanical coupling and influential factors in nonrheumatic paroxysmal atrial fibrillation (2008) Clin. Cardiol., 31, pp. 74-78; Omi, W., Nagai, H., Takamura, M., Okura, S., Okajima, M., Furusho, H., Maruyama, M., Kaneko, S., Doppler tissue analysis of atrial electromechanical coupling in paroxysmal atrial fibrillation (2005) J. Am. Soc. Echocardiogr., 18, pp. 39-44; Yildiz, A., Ucmak, D., Oylumlu, M., Akkurt, M.Z., Yuksel, M., Akil, M.A., Acet, H., Bilik, M.Z., Assessment of atrial electromechanical delay and P-wave dispersion in patients with psoriasis (2014) Echocardiography, 31, pp. 1071-1076; Aksan, G., Nar, G., Soylu, K., Inci, S., Yuksel, S., Ocal, H.S., Yuksel, E.P., Gulel, O., Assessment of atrial electromechanical delay and left atrial mechanical functions in patients with psoriasis vulgaris (2014) Echocardiography; Simsek, H., Sahin, M., Akyol, A., Akdag, S., Ozkol, H.U., Gumrukcuoglu, H.A., Gunes, Y., Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients (2013) Scientific World Journal, 2013, p. 901215; Bacaksiz, A., Erdogan, E., Tasal, A., Vatankulu, M.A., Kul, S., Sevgili, E., Ertas, G., Uysal, O., Electrocardiographic P-wave characteristics in patients with psoriasis vulgaris (2013) Ups. J. Med. Sci., 118, pp. 35-41; Liu, T., Li, L., Korantzopoulos, P., Goudevenos, J.A., Li, G., Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation (2008) Am. J. Cardiol., 101, pp. 1749-1752; Liu, T., Li, G., Li, L., Korantzopoulos, P., Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis (2007) J. Am. Coll. Cardiol., 49, pp. 1642-1648; Friedewald, V.J., Cather, J.C., Gordon, K.B., Kavanaugh, A., Ridker, P.M., Roberts, W.C., The editor's roundtable: Psoriasis, inflammation, and coronary artery disease (2008) Am. J. Cardiol., 101, pp. 1119-1126; Kremers, H.M., McEvoy, M.T., Dann, F.J., Gabriel, S.E., Heart disease in psoriasis (2007) J. Am. Acad. Dermatol., 57, pp. 347-354; Kim, Y.M., Guzik, T.J., Zhang, Y.H., Zhang, M.H., Kattach, H., Ratnatunga, C., Pillai, R., Casadei, B., A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation (2005) Circ. Res., 97, pp. 629-636; Korantzopoulos, P., Kolettis, T.M., Galaris, D., Goudevenos, J.A., The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation (2007) Int. J. Cardiol., 115, pp. 135-143; Liu, T., Korantzopoulos, P., Li, L., Li, G., Preventive effects of rosuvastatin on atrial fibrillation: A meta-analysis of randomized controlled trials (2013) Int. J. Cardiol., 167, pp. 3058-3060; Liu, T., Li, L., Korantzopoulos, P., Liu, E., Li, G., Statin use and development of atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials and observational studies (2008) Int. J. Cardiol., 126, pp. 160-170; Mosiewicz, J., Pietrzak, A., Chodorowska, G., Trojnar, M., Szepietowski, J., Reich, K., Rizzo, M., Rational for statin use in psoriatic patients (2013) Arch. Dermatol. Res., 305, pp. 467-472",Letter,Scopus,2-s2.0-84928250095
"Wang J., Gu C., Gao M., Yu W., Li H., Zhang F., Yu Y.","Comparison of the incidence of postoperative neurologic complications after on-pump versus off-pump coronary artery bypass grafting in high-risk patients: A meta-analysis of 11 studies",2015,"International Journal of Cardiology","185",,,"195","197",,,10.1016/j.ijcard.2015.03.115,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928237563&partnerID=40&md5=d489a13aea0eab2acc140de37bc92dbb","Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical UniversityBeijing, China","Wang, J., Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical UniversityBeijing, China; Gu, C., Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical UniversityBeijing, China; Gao, M., Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical UniversityBeijing, China; Yu, W., Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical UniversityBeijing, China; Li, H., Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical UniversityBeijing, China; Zhang, F., Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical UniversityBeijing, China; Yu, Y., Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical UniversityBeijing, China",[No abstract available],"Meta-analysis; Off-pump CABG; On-pump CABG; Postoperative neurologic complications","Puskas, J.D., Winston, A.D., Wright, C.E., Stroke after coronary artery operation: Incidence, correlates, outcome, and cost (2000) Ann. Thorac. Surg., 69, pp. 1053-1056; Farkouh, M.E., Domanski, M., Sleeper, L.A., Strategies for multivessel revascularization in patients with diabetes (2012) N. Engl. J. Med., 367, pp. 2375-2384; Al-Ruzzeh, S., George, S., Bustami, M., Effect of off-pump coronary artery bypass surgery on clinical, angiographic, neurocognitive, and quality of life outcomes: Randomised controlled trial (2006) BMJ, 332, p. 1365; Nathoe, H.M., Van Dijk, D., Jansen, E.W., A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients (2003) N. Engl. J. Med., 348, pp. 394-402; Kuss, O., Von Salviati, B., Borgermann, J., Off-pump versus on-pump coronary artery bypass grafting: A systematic review and meta-analysis of propensity score analyses (2010) J. Thorac. Cardiovasc. Surg., 140, pp. 829-835. , (35 e1-13); Moller, C.H., Perko, M.J., Lund, J.T., No major differences in 30-day outcomes in high-risk patients randomized to off-pump versus on-pump coronary bypass surgery: The best bypass surgery trial (2010) Circulation, 121, pp. 498-504; Marui, A., Okabayashi, H., Komiya, T., Benefits of off-pump coronary artery bypass grafting in high-risk patients (2012) Circulation, 126, pp. S151-S157; Yokoyama, T., Baumgartner, F.J., Gheissari, A., Off-pump versus on-pump coronary bypass in high-risk subgroups (2000) Ann. Thorac. Surg., 70, pp. 1546-1550; Chamberlain, M.H., Ascione, R., Reeves, B.C., Evaluation of the effectiveness of off-pump coronary artery bypass grafting in high-risk patients: An observational study (2002) Ann. Thorac. Surg., 73, pp. 1866-1873; Al-Ruzzeh, S., Nakamura, K., Athanasiou, T., Does off-pump coronary artery bypass (OPCAB) surgery improve the outcome in high-risk patients? A comparative study of 1398 high-risk patients (2003) Eur. J. Cardiothorac. Surg., 23, pp. 50-55; Chukwuemeka, A., Weisel, A., Maganti, M., Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: A propensity score analysis (2005) Ann. Thorac. Surg., 80, pp. 2148-2153; Lahtinen, J., Biancari, F., Rimpilainen, J., Off-pump versus on-pump coronary artery bypass surgery in high-risk patients (EuroSCORE >/= 6) (2007) Thorac. Cardiovasc. Surg., 55, pp. 13-18; Baba, T., Goto, T., Maekawa, K., Early neuropsychological dysfunction in elderly high-risk patients after on-pump and off-pump coronary bypass surgery (2007) J. Anesth., 21, pp. 452-458; Meco, M., Biraghi, T., Panisi, P., Aortocoronary bypass grafting in high-risk patients over 75 years. Propensity score analysis of on versus off-pump, early and midterm results (2007) J. Cardiovasc. Surg., 48, pp. 339-347; Moller, C.H., Perko, M.J., Lund, J.T., Three-year follow-up in a subset of high-risk patients randomly assigned to off-pump versus on-pump coronary artery bypass surgery: The Best Bypass Surgery trial (2011) Heart, 97, pp. 907-913; Lemma, M.G., Coscioni, E., Tritto, F.P., On-pump versus off-pump coronary artery bypass surgery in high-risk patients: Operative results of a prospective randomized trial (on-off study) (2012) J. Thorac. Cardiovasc. Surg., 143, pp. 625-631; Ji, Q., Mei, Y., Wang, X., Ding, W., On-pump versus off-pump coronary artery bypass surgery in high-risk patients (2014) Int. Heart J., 55, pp. 484-488; Kilo, J., Czerny, M., Gorlitzer, M., Cardiopulmonary bypass affects cognitive brain function after coronary artery bypass grafting (2001) Ann. Thorac. Surg., 72, pp. 1926-1932; Van Diepen, S., Vavalle, J.P., Newby, L.K., The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction (2013) Crit. Care Med., 41, pp. 2080-2087; Van Dijk, D., Jansen, E.W., Hijman, R., Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery: A randomized trial (2002) JAMA, 287, pp. 1405-1412; Zamvar, V., Williams, D., Hall, J., Assessment of neurocognitive impairment after off-pump and on-pump techniques for coronary artery bypass graft surgery: Prospective randomised controlled trial (2002) BMJ, 325, pp. 1268-1272",Letter,Scopus,2-s2.0-84928237563
